PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Giannelli, G; FalkMarzillier, J; Schiraldi, O; StetlerStevenson, WG; Quaranta, V				Giannelli, G; FalkMarzillier, J; Schiraldi, O; StetlerStevenson, WG; Quaranta, V			Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5	SCIENCE			English	Article							EXTRACELLULAR-MATRIX; TISSUE INHIBITOR; IV COLLAGENASE; KERATINOCYTES; CARCINOMAS; ACTIVATION; ADHESION; COMPLEX	Structural changes in the extracellular matrix are necessary for cell migration during tissue remodeling and tumor invasion. Specific cleavage of laminin-5 (Ln-5) by matrix metalloprotease-2 (MMP2) was shown to induce migration of breast epithelial cells. MMP2 cleaved the Ln-5 gamma 2 subunit at residue 587, exposing a putative cryptic promigratory site on Ln-5 that triggers cell motility. This altered form of Ln-5 is found in tumors and in tissues undergoing remodeling, but not in quiescent tissues. Cleavage of Ln-5 by MMP2 and the resulting activation of the Ln-5 cryptic site may provide new targets for modulation of tumor cell invasion and tissue remodeling.	SCRIPPS RES INST, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; UNIV BARI, INST MED CLIN 2, I-70124 BARI, ITALY; NCI, PATHOL LAB, BETHESDA, MD 20892 USA	Scripps Research Institute; Universita degli Studi di Bari Aldo Moro; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Stetler-Stevenson, William G/H-6956-2012; giannelli, gianluigi/A-8169-2012; Quaranta, Vito/G-6512-2016; Stetler-Stevenson, William/AAE-3501-2020	Stetler-Stevenson, William G/0000-0002-5500-5808; Quaranta, Vito/0000-0001-7491-8672; Stetler-Stevenson, William/0000-0002-5500-5808	NCI NIH HHS [CA47858] Funding Source: Medline; NIDCR NIH HHS [DE10063] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047858] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010063] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AUMAILLEY M, 1990, FEBS LETT, V262, P82, DOI 10.1016/0014-5793(90)80159-G; Baker SE, 1996, J CELL SCI, V109, P2509; Basbaum CB, 1996, CURR OPIN CELL BIOL, V8, P731, DOI 10.1016/S0955-0674(96)80116-5; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BIRKEDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728, DOI 10.1016/0955-0674(95)80116-2; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; BURDSAL CA, 1991, DEV BIOL, V144, P327, DOI 10.1016/0012-1606(91)90425-3; BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; CALOF AL, 1994, NEURON, V13, P117, DOI 10.1016/0896-6273(94)90463-4; CALOF AL, 1996, NATURE, V383, P441; Chen Wen-Tien, 1992, Current Opinion in Cell Biology, V4, P802; FRIDMAN R, 1993, BIOCHEM J, V289, P411, DOI 10.1042/bj2890411; GAILIT J, 1994, CURR OPIN CELL BIOL, V6, P717, DOI 10.1016/0955-0674(94)90099-X; Giannelli G, 1996, LAB INVEST, V74, P1091; GIANNELLI G, UNPUB; HORMIA M, 1995, J INVEST DERMATOL, V105, P557, DOI 10.1111/1523-1747.ep12323451; ITOH Y, 1995, BIOCHEM J, V308, P645, DOI 10.1042/bj3080645; KARECLA PI, 1994, CELL ADHES COMMUN, V2, P309, DOI 10.3109/15419069409014206; KOHN EC, 1995, CANCER RES, V55, P1856; LANGHOFER M, 1993, J CELL SCI, V105, P753; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LAURIE GW, 1982, J CELL BIOL, V95, P340, DOI 10.1083/jcb.95.1.340; MARINKOVICH MP, 1992, J BIOL CHEM, V267, P17900; MIYAZAKI K, 1993, P NATL ACAD SCI USA, V90, P11767, DOI 10.1073/pnas.90.24.11767; MONTEAGUDO C, 1990, AM J PATHOL, V136, P585; Pelletier AJ, 1996, J BIOL CHEM, V271, P1364, DOI 10.1074/jbc.271.3.1364; Plopper G, 1996, J CELL SCI, V109, P1965; PYKE C, 1995, CANCER RES, V55, P4132; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SOULE HD, 1990, CANCER RES, V50, P6075; WANG X, 1994, CANCER RES, V54, P4726; WILHELM SM, 1989, J BIOL CHEM, V264, P17213	32	997	1020	2	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 11	1997	277	5323					225	228		10.1126/science.277.5323.225	http://dx.doi.org/10.1126/science.277.5323.225			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK418	9211848				2022-12-01	WOS:A1997XK41800041
J	Wang, B; Kuspa, A				Wang, B; Kuspa, A			Dictyostelium development in the absence of cAMP	SCIENCE			English	Article							DEPENDENT PROTEIN-KINASE; 3-DIMENSIONAL SCROLL WAVES; ADENYLATE-CYCLASE ACTIVITY; GENE-EXPRESSION; CELL-DIFFERENTIATION; PHOSPHODIESTERASE GENE; SIGNAL-TRANSDUCTION; EXTRACELLULAR CAMP; CATALYTIC SUBUNIT; DISCOIDEUM	Adenosine 3',5'-monophosphate (cAMP) and cAMP-dependent protein kinase (PKA) are regulators of development in many organisms. Dictyostelium uses cAMP as an extracellular chemoattractant and as an intracellular signal for differentiation. Cells that are mutant in adenylyl cyclase do not develop. Moderate expression of the catalytic subunit of PKA in adenylyl cyclase-null cells led to near-normal development without detectable accumulation of cAMP. These results suggest that all intracellular cAMP signaling is effected through PKA and that signals other than extracellular cAMP coordinate morphogenesis in Dictyostelium.	BAYLOR COLL MED,DEPT BIOCHEM,HOUSTON,TX 77030	Baylor College of Medicine				Kuspa, Adam/0000-0002-9156-149X	NIGMS NIH HHS [R01 GM052359] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052359] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABE K, 1983, DEV BIOL, V95, P200, DOI 10.1016/0012-1606(83)90018-0; ABE K, 1983, J GEN MICROBIOL, V129, P1623; ANJARD C, 1992, DEVELOPMENT, V115, P785; BONNER JT, 1952, AM NAT, V86, P79, DOI 10.1086/281707; BONNER JT, 1959, P NATL ACAD SCI USA, V45, P379, DOI 10.1073/pnas.45.3.379; BRETSCHNEIDER T, 1995, P NATL ACAD SCI USA, V92, P4387, DOI 10.1073/pnas.92.10.4387; DEVREOTES P, 1987, METHOD CELL BIOL, V28, P299; Dormann D, 1996, DEVELOPMENT, V122, P761; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; DYNES JL, 1989, P NATL ACAD SCI USA, V86, P7966, DOI 10.1073/pnas.86.20.7966; FIRTEL RA, 1995, GENE DEV, V9, P1427, DOI 10.1101/gad.9.12.1427; FOSNAUGH KL, 1989, NUCLEIC ACIDS RES, V17, P9489, DOI 10.1093/nar/17.22.9489; FRANKE J, 1987, DEV BIOL, V124, P504, DOI 10.1016/0012-1606(87)90503-3; GERISCH G, 1985, COLD SPRING HARB SYM, V50, P813, DOI 10.1101/SQB.1985.050.01.099; Hammerschmidt M, 1996, GENE DEV, V10, P647, DOI 10.1101/gad.10.6.647; HARWOOD AJ, 1992, DEV BIOL, V149, P90, DOI 10.1016/0012-1606(92)90266-J; HARWOOD AJ, 1992, CELL, V69, P615, DOI 10.1016/0092-8674(92)90225-2; HOPPER NA, 1993, DEVELOPMENT, V119, P147; KENCHT DA, 1986, MOL CELL BIOL, V6, P3973; KLEIN C, 1976, FEBS LETT, V68, P125, DOI 10.1016/0014-5793(76)80419-X; KLEIN PS, 1988, SCIENCE, V241, P1467, DOI 10.1126/science.3047871; LACOMBE ML, 1986, J BIOL CHEM, V261, P6811; LEPAGE T, 1995, NATURE, V373, P711, DOI 10.1038/373711a0; Levine H, 1996, P NATL ACAD SCI USA, V93, P6382, DOI 10.1073/pnas.93.13.6382; Loomis WF, 1996, MICROBIOL REV, V60, P135, DOI 10.1128/MMBR.60.1.135-150.1996; MANN SKO, 1993, DEVELOPMENT, V119, P135; MANN SKO, 1994, P NATL ACAD SCI USA, V91, P10561, DOI 10.1073/pnas.91.22.10561; Mann SKO, 1997, DEV BIOL, V183, P208, DOI 10.1006/dbio.1996.8499; MANN SKO, 1992, P NATL ACAD SCI USA, V89, P10701, DOI 10.1073/pnas.89.22.10701; MANSTEIN DJ, 1995, GENE, V162, P129, DOI 10.1016/0378-1119(95)00351-6; MCROBBIE SJ, 1988, DEVELOPMENT, V104, P275; NELLEN W, 1987, METHOD CELL BIOL, V28, P67; PAN DJ, 1995, CELL, V80, P543, DOI 10.1016/0092-8674(95)90508-1; Parent CA, 1996, ANNU REV BIOCHEM, V65, P411; PART D, 1985, CELL DIFFER DEV, V17, P221, DOI 10.1016/0045-6039(85)90496-8; PETERS DJM, 1991, P NATL ACAD SCI USA, V88, P9219, DOI 10.1073/pnas.88.20.9219; PITT GS, 1992, CELL, V69, P305, DOI 10.1016/0092-8674(92)90411-5; PITT GS, 1993, GENE DEV, V7, P2172, DOI 10.1101/gad.7.11.2172; RAPER KENNETH B., 1940, JOUR ELISHA MITCHELL SCI SOC, V56, P241; Reymond CD, 1995, EXPERIENTIA, V51, P1166, DOI 10.1007/BF01944734; RICHARDSON DL, 1991, DEV BIOL, V144, P269, DOI 10.1016/0012-1606(91)90421-X; Rietdorf J, 1996, DEV BIOL, V177, P427, DOI 10.1006/dbio.1996.0175; ROOS W, 1977, NATURE, V266, P259, DOI 10.1038/266259a0; SCHAAP P, 1986, CELL, V45, P137, DOI 10.1016/0092-8674(86)90545-3; SCHULKES C, 1995, FEBS LETT, V368, P381, DOI 10.1016/0014-5793(95)00676-Z; SHAULSKY G, 1995, GENE DEV, V9, P1111, DOI 10.1101/gad.9.9.1111; SIEGERT F, 1992, P NATL ACAD SCI USA, V89, P6433, DOI 10.1073/pnas.89.14.6433; SIEGERT F, 1995, CURR BIOL, V5, P937, DOI 10.1016/S0960-9822(95)00184-9; SIMON MN, 1992, NATURE, V356, P171, DOI 10.1038/356171a0; Soede RDM, 1996, DEV BIOL, V177, P152, DOI 10.1006/dbio.1996.0152; STERNFELD J, 1981, DIFFERENTIATION, V20, P10, DOI 10.1111/j.1432-0436.1981.tb01150.x; STERNFELD J, 1982, DEV BIOL, V93, P111, DOI 10.1016/0012-1606(82)90244-5; STRUTT DI, 1995, NATURE, V373, P705, DOI 10.1038/373705a0; SUSSMAN M, 1987, METHOD CELL BIOL, V28, P9; TOMCHIK KJ, 1981, SCIENCE, V212, P443, DOI 10.1126/science.6259734; TRAYNOR D, 1992, P NATL ACAD SCI USA, V89, P8303, DOI 10.1073/pnas.89.17.8303; VanHaastert PJM, 1995, EXPERIENTIA, V51, P1144; WALLRAFF E, 1984, J GEN MICROBIOL, V130, P2103; Wang B., UNPUB; WEIJER CJ, 1987, METHOD CELL BIOL, V28, P449; WILLIAMS JG, 1989, CELL, V59, P1157, DOI 10.1016/0092-8674(89)90771-X; WU L, 1995, DEV BIOL, V171, P149, DOI 10.1006/dbio.1995.1267	62	87	87	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 11	1997	277	5323					251	254		10.1126/science.277.5323.251	http://dx.doi.org/10.1126/science.277.5323.251			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK418	9211856				2022-12-01	WOS:A1997XK41800049
J	Chuang, HH; Jan, YN; Jan, LY				Chuang, HH; Jan, YN; Jan, LY			Regulation of IRK3 inward rectifier K+ channel by m1 acetylcholine receptor and intracellular magnesium	CELL			English	Article							BETA-GAMMA-SUBUNITS; NUCLEUS ACCUMBENS NEURONS; RAT SYMPATHETIC NEURONS; M-CURRENT INHIBITION; POTASSIUM CHANNEL; MUSCARINIC RECEPTOR; CALCIUM CURRENT; SUBSTANCE-P; CARDIAC MYOCYTES; ATRIAL MYOCYTES	Inward rectifier K+ channels control the cell's membrane potential and neuronal excitability. We report that the IRK3 but not the IRK1 inward rectifier K+ channel activity is inhibited by mi muscarinic acetylcholine receptor. This m1 modulation cannot be accounted for by protein kinase C, Ca2+, or channel phosphorylation, but can be mimicked by Mg2+. Based on quantitative analyses of IRK3 and two different IRK1 mutant channels bestowed with sensitivity to m1 modulation, we suggest that the resting Mg2+ level causes chronic inhibition of IRK3 channels, and m1 receptor stimulation may lead to an increase of cytoplasmic Mg2+ concentration and further channel inhibition, due to the ability of Mg2+ to lead these channels into a prolonged inactivated state.	UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT BIOCHEM,SAN FRANCISCO,CA 94143	Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco				Jan, Yuh Nung/0000-0003-1367-6299; Jan, Lily/0000-0003-3938-8498				AGUS ZS, 1991, ANNU REV PHYSIOL, V53, P299, DOI 10.1146/annurev.physiol.53.1.299; BRAUN AP, 1992, PFLUG ARCH EUR J PHY, V421, P431, DOI 10.1007/BF00370253; CAULFIELD MP, 1993, PHARMACOL THERAPEUT, V58, P319, DOI 10.1016/0163-7258(93)90027-B; CAULFIELD MP, 1994, J PHYSIOL-LONDON, V477, P415, DOI 10.1113/jphysiol.1994.sp020203; CECH SY, 1980, MOL CELL BIOCHEM, V33, P67; Collins A, 1996, J NEUROSCI, V16, P1; COLLINS A, 1992, J PHYSIOL-LONDON, V454, P27, DOI 10.1113/jphysiol.1992.sp019253; CROWFROF.PJ, 1971, J PHYSIOL-LONDON, V219, P443, DOI 10.1113/jphysiol.1971.sp009671; DIFRANCESCO D, 1980, PFLUG ARCH EUR J PHY, V387, P83, DOI 10.1007/BF00584257; Dukes ID, 1996, DIABETES, V45, P845, DOI 10.2337/diabetes.45.7.845; EGAN TM, 1986, NATURE, V319, P405, DOI 10.1038/319405a0; ELLIOTT DA, 1974, J BIOL CHEM, V249, P3985; ERDOS JJ, 1983, J PHYSIOL-LONDON, V337, P351, DOI 10.1113/jphysiol.1983.sp014628; FAKLER B, 1995, CELL, V80, P149, DOI 10.1016/0092-8674(95)90459-X; FICKER E, 1994, SCIENCE, V266, P1068, DOI 10.1126/science.7973666; FLATMAN PW, 1991, ANNU REV PHYSIOL, V53, P259, DOI 10.1146/annurev.ph.53.030191.001355; GOLDIN AL, 1992, METHOD ENZYMOL, V207, P266; GRUBBS RD, 1986, J BIOL CHEM, V261, P2550; GUPTA RK, 1984, ANNU REV BIOPHYS BIO, V13, P221; HARTZELL HC, 1989, J GEN PHYSIOL, V94, P745, DOI 10.1085/jgp.94.4.745; Hille B., 1992, IONIC CHANNELS EXCIT; HUANG CL, 1995, NEURON, V15, P1133, DOI 10.1016/0896-6273(95)90101-9; HUANG XY, 1993, CELL, V75, P1145, DOI 10.1016/0092-8674(93)90324-J; INOUE M, 1988, J PHYSIOL-LONDON, V407, P177, DOI 10.1113/jphysiol.1988.sp017409; JONES S, 1995, NEURON, V14, P399, DOI 10.1016/0896-6273(95)90295-3; KOFUJI P, 1995, P NATL ACAD SCI USA, V92, P6542, DOI 10.1073/pnas.92.14.6542; KRAPIVINSKY G, 1995, J BIOL CHEM, V270, P29059, DOI 10.1074/jbc.270.49.29059; KUNKEL MT, 1995, CELL, V83, P443, DOI 10.1016/0092-8674(95)90122-1; KURACHI Y, 1986, PFLUG ARCH EUR J PHY, V407, P264, DOI 10.1007/BF00585301; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LOPATIN AN, 1994, NATURE, V372, P366, DOI 10.1038/372366a0; Marrion NV, 1996, NEURON, V16, P163, DOI 10.1016/S0896-6273(00)80033-1; MATSUDA H, 1987, NATURE, V325, P156, DOI 10.1038/325156a0; MCLACHLAN EM, 1989, J PHYSIOL-LONDON, V415, P109, DOI 10.1113/jphysiol.1989.sp017714; MORISHIGE KI, 1994, FEBS LETT, V346, P251, DOI 10.1016/0014-5793(94)00483-8; MURPHY E, 1991, ANNU REV PHYSIOL, V53, P273, DOI 10.1146/annurev.physiol.53.1.273; NAKAJIMA Y, 1988, P NATL ACAD SCI USA, V85, P3643, DOI 10.1073/pnas.85.10.3643; NOBLE D, 1984, J PHYSIOL-LONDON, V353, P1; NORTH RA, 1989, J PHYSIOL-LONDON, V417, P1; NORTH RA, 1987, P NATL ACAD SCI USA, V84, P5487, DOI 10.1073/pnas.84.15.5487; OH U, 1995, J MEMBRANE BIOL, V147, P241; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; PERIER F, 1994, P NATL ACAD SCI USA, V91, P6240, DOI 10.1073/pnas.91.13.6240; RANE SG, 1989, NEURON, V3, P239, DOI 10.1016/0896-6273(89)90037-8; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; RIJKERS GT, 1993, BIOCHEM J, V289, P373, DOI 10.1042/bj2890373; ROBBINS J, 1993, J PHYSIOL-LONDON, V469, P153, DOI 10.1113/jphysiol.1993.sp019809; SAKMANN B, 1983, NATURE, V303, P250, DOI 10.1038/303250a0; SATO R, 1995, J MEMBRANE BIOL, V148, P185; Selyanko AA, 1996, NEURON, V16, P151, DOI 10.1016/S0896-6273(00)80032-X; SHEN KZ, 1992, J PHYSIOL-LONDON, V455, P471, DOI 10.1113/jphysiol.1992.sp019312; Sodickson DL, 1996, J NEUROSCI, V16, P6374; SOEJIMA M, 1984, PFLUG ARCH EUR J PHY, V400, P424, DOI 10.1007/BF00587544; STANFIELD PR, 1994, J PHYSIOL-LONDON, V478, P1; STANFIELD PR, 1985, NATURE, V315, P498, DOI 10.1038/315498a0; STANFIELD PR, 1994, J PHYSIOL-LONDON, V475, P1; STOREY KB, 1992, ANAL BIOCHEM, V201, P119; TAKANO K, 1995, NEURON, V14, P999, DOI 10.1016/0896-6273(95)90338-0; UCHIMURA N, 1990, J PHYSIOL-LONDON, V422, P369, DOI 10.1113/jphysiol.1990.sp017989; VANDENBERG CA, 1987, P NATL ACAD SCI USA, V84, P2560, DOI 10.1073/pnas.84.8.2560; VELIMIROVIC BM, 1995, P NATL ACAD SCI USA, V92, P1590, DOI 10.1073/pnas.92.5.1590; Wang HS, 1996, J PHYSIOL-LONDON, V492, P467, DOI 10.1113/jphysiol.1996.sp021322; WHITE RE, 1988, SCIENCE, V239, P778, DOI 10.1126/science.2448878; WHITE RE, 1989, BIOCHEM PHARMACOL, V38, P859, DOI 10.1016/0006-2952(89)90272-4; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0; YAMADA M, 1994, BIOCHEM BIOPH RES CO, V200, P1484, DOI 10.1006/bbrc.1994.1618; YANG J, 1995, NEURON, V14, P1047, DOI 10.1016/0896-6273(95)90343-7	67	51	55	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 27	1997	89	7					1121	1132		10.1016/S0092-8674(00)80299-8	http://dx.doi.org/10.1016/S0092-8674(00)80299-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XG830	9215634	Bronze			2022-12-01	WOS:A1997XG83000016
J	Edwards, DA; Hanes, J; Caponetti, G; Hrkach, J; BenJebria, A; Eskew, ML; Mintzes, J; Deaver, D; Lotan, N; Langer, R				Edwards, DA; Hanes, J; Caponetti, G; Hrkach, J; BenJebria, A; Eskew, ML; Mintzes, J; Deaver, D; Lotan, N; Langer, R			Large porous particles for pulmonary drug delivery	SCIENCE			English	Article							LEUPROLIDE ACETATE; SIZE; PHAGOCYTOSIS; AEROSOL; BIOAVAILABILITY; INTRATRACHEAL; MICROSPHERES; DEPOSITION; PROTEINS; PEPTIDE	A new type of inhalation aerosol, characterized by particles of small mass density and large size, permitted the highly efficient delivery of inhaled therapeutics into the systemic circulation. Particles with mass densities less than 0.4 gram per cubic centimeter and mean diameters exceeding 5 micrometers were inspired deep into the lungs and escaped the lungs' natural clearance mechanisms until the inhaled particles delivered their therapeutic payload. Inhalation of large porous insulin particles resulted in elevated systemic levels of insulin and suppressed systemic glucose levels for 96 hours, whereas small nonporous insulin particles had this effect for only 4 hours. High systemic bioavailability of testosterone was also achieved by inhalation delivery of porous particles with a mean diameter (20 micrometers) approximately 10 times that of conventional inhaled therapeutic particles.	MIT,DEPT CHEM ENGN,CAMBRIDGE,MA 02139; UNIV PARMA,DEPT PHARM,I-43100 PARMA,ITALY; PENN STATE UNIV,FENSKE LAB,UNIVERSITY PK,PA 16802; PENN STATE UNIV,DEPT ANIM SCI,UNIVERSITY PK,PA 16802; TECHNION ISRAEL INST TECHNOL,DEPT BIOMED ENGN,IL-32000 HAIFA,ISRAEL	Massachusetts Institute of Technology (MIT); University of Parma; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Technion Israel Institute of Technology	Edwards, DA (corresponding author), PENN STATE UNIV,DEPT CHEM ENGN,204 FENSKE LAB,UNIVERSITY PK,PA 16802, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U54HD029125] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026698] Funding Source: NIH RePORTER; NICHD NIH HHS [HD29125] Funding Source: Medline; NIGMS NIH HHS [GM26698] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADJEI A, 1990, PHARMACEUT RES, V7, P565, DOI 10.1023/A:1015853824722; ADJEI A, 1994, INT J PHARM, V107, P57, DOI 10.1016/0378-5173(94)90302-6; BRAIN JD, 1985, RETICULOENDOTHELIAL, P315; COHEN S, 1991, PHARMACEUT RES, V8, P713, DOI 10.1023/A:1015841715384; COLTHORPE P, 1992, PHARMACEUT RES, V9, P764, DOI 10.1023/A:1015851521551; EDWARDS DA, 1995, J AEROSOL SCI, V26, P293, DOI 10.1016/0021-8502(94)00101-4; Einarsson O, 1995, ANN NY ACAD SCI, V762, P89; French DL, 1996, J AEROSOL SCI, V27, P769, DOI 10.1016/0021-8502(96)00021-3; Ganderton, 1992, GENERATION RESPIRABL; Gennaro AR., 1995, REMINGTON SCI PRACTI, V19th; GONDA I, 1992, TOPICS IN PHARMACEUTICAL SCIENCES 1991, P95; GONDA I, 1990, CRIT REV THER DRUG, V6, P4273; HEYDER J, 1986, J AEROSOL SCI, V17, P811, DOI 10.1016/0021-8502(86)90035-2; HRKACH JS, 1995, MACROMOLECULES, V28, P4736, DOI 10.1021/ma00117a055; Jeyanthi R, 1996, J CONTROL RELEASE, V38, P235, DOI 10.1016/0168-3659(95)00125-5; KAWAGUCHI H, 1986, BIOMATERIALS, V7, P61, DOI 10.1016/0142-9612(86)90091-8; KOMADA F, 1994, J PHARM SCI, V83, P863, DOI 10.1002/jps.2600830621; KRENIS LJ, 1961, P SOC EXP BIOL MED, V107, P748; LANGER R, 1990, SCIENCE, V249, P1527, DOI 10.1126/science.2218494; LECORRE P, 1994, INT J PHARM, V107, P41, DOI 10.1016/0378-5173(94)90300-X; Li WI, 1996, J AEROSOL SCI, V27, P1269, DOI 10.1016/0021-8502(96)00046-8; LIU FY, 1993, PHARMACEUT RES, V10, P228, DOI 10.1023/A:1018934810512; NIVEN RW, 1995, CRIT REV THER DRUG, V12, P151, DOI 10.1615/CritRevTherDrugCarrierSyst.v12.i2-3.20; PATTON JS, 1992, ADV DRUG DELIVER REV, V8, P179, DOI 10.1016/0169-409X(92)90002-8; PAVIA D, 1984, AEROSOLS LUNG CLIN E, P200; RUDT S, 1992, J CONTROL RELEASE, V22, P263, DOI 10.1016/0168-3659(92)90101-V; Sacchetti M., 1996, INHALATION AEROSOLS, P337; SMITH SJ, 1996, INHALATION AEROSOLS, P233; TOM JW, 1991, J AEROSOL SCI, V22, P555, DOI 10.1016/0021-8502(91)90013-8; VIDGREN MT, 1987, INT J PHARM, V35, P139, DOI 10.1016/0378-5173(87)90082-2; WARHEIT DB, 1993, MICROSC RES TECHNIQ, V26, P412, DOI 10.1002/jemt.1070260509	31	934	1023	8	231	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 20	1997	276	5320					1868	1871		10.1126/science.276.5320.1868	http://dx.doi.org/10.1126/science.276.5320.1868			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XF103	9188534				2022-12-01	WOS:A1997XF10300051
J	Vidal, RA; Bahr, D; Baragiola, RA; Peters, M				Vidal, RA; Bahr, D; Baragiola, RA; Peters, M			Oxygen on Ganymede: Laboratory studies	SCIENCE			English	Article							AMORPHOUS WATER ICE; GALILEAN SATELLITES; ASTROPHYSICAL IMPLICATIONS; ION-BOMBARDMENT; SUBLIMATION; ATMOSPHERE; EUROPA; PHOTODESORPTION; CALLISTO; EJECTION	To test proposals for the origin of oxygen absorption bands in the visible reflectance spectrum of Ganymede, the reflectance of condensed films of pure oxygen (O-2) and O-2-water mixtures and the evolution of O-2 from the films as a function of temperature were determined, Absorption band shapes and positions for oxygen at 26 kelvin were similar to those reported for Ganymede, whereas those for the mixtures were slightly shifted. The band intensity dropped by more than two orders of magnitude when the ice mixture was warmed to 100 keivin, although about 20 percent of the O-2 remained trapped in the ice, which suggested that at these temperatures O-2 molecules dissolve in the ice rather than aggregate in clusters or bubbles. The experiments suggest that the absorption bands in Ganymede's spectrum were not produced in the relatively warm surface of the satellite but in a much colder source. Solid O-2 may exist in a cold subsurface layer or in an atmospheric haze.	UNIV VIRGINIA,LAB ATOM & SURFACE PHYS,CHARLOTTESVILLE,VA 22901; TEIKYO UNIV,SCH MED,PHYS LAB,HACHIOJI,TOKYO 192,JAPAN	University of Virginia; Teikyo University				Vidal, Ricardo/0000-0001-7082-9787				BARNUN A, 1987, PHYS REV B, V35, P2427, DOI 10.1103/PhysRevB.35.2427; BARNUN A, 1985, SURF SCI, V150, P143, DOI 10.1016/0039-6028(85)90215-8; BLAKE D, 1991, SCIENCE, V254, P548, DOI 10.1126/science.11538372; BROADFOOT AL, 1979, SCIENCE, V204, P979, DOI 10.1126/science.204.4396.979; BURATTI BJ, 1991, ICARUS, V92, P312, DOI 10.1016/0019-1035(91)90054-W; CALVIN W, UNPUB; Calvin WM, 1996, GEOPHYS RES LETT, V23, P673, DOI 10.1029/96GL00450; CARLSON RW, 1973, SCIENCE, V182, P53, DOI 10.1126/science.182.4107.53; CLARK RN, 1980, ICARUS, V44, P388, DOI 10.1016/0019-1035(80)90033-0; DEPATER I, 1984, ICARUS, V57, P93, DOI 10.1016/0019-1035(84)90011-3; DIANOVKLOKOV VI, 1962, OPT SPECTROSC, V13, P109; DOWELL LG, 1960, NATURE, V188, P1144, DOI 10.1038/1881144a0; GREENBLATT GD, 1990, J GEOPHYS RES-ATMOS, V95, P18577, DOI 10.1029/JD095iD11p18577; Grun E, 1996, NATURE, V381, P395, DOI 10.1038/381395a0; Gurnett DA, 1996, NATURE, V384, P535, DOI 10.1038/384535a0; HALL DT, 1995, NATURE, V373, P677, DOI 10.1038/373677a0; HANSEN OL, 1973, ICARUS, V18, P237, DOI 10.1016/0019-1035(73)90208-X; JENNISKENS P, 1994, SCIENCE, V265, P753, DOI 10.1126/science.11539186; JOHNSON RE, 1997, ASTROPHYS J LETT, V480, P1; Kivelson MG, 1996, NATURE, V384, P537, DOI 10.1038/384537a0; LANDAU A, 1962, SPECTROCHIM ACTA, V18, P1; MATSON DL, 1989, ICARUS, V77, P67, DOI 10.1016/0019-1035(89)90007-9; MATSON DL, 1983, J GEOPHYS RES-SPACE, V88, P4771, DOI 10.1029/JA088iA06p04771; MAYER E, 1986, NATURE, V319, P298, DOI 10.1038/319298a0; Mishchenko MI, 1996, J QUANT SPECTROSC RA, V56, P673, DOI 10.1016/S0022-4073(96)00117-3; MORENO MA, 1991, ICARUS, V93, P63, DOI 10.1016/0019-1035(91)90164-O; MORRISON D, 1973, ICARUS, V18, P224, DOI 10.1016/0019-1035(73)90207-8; Noll KS, 1996, SCIENCE, V273, P341, DOI 10.1126/science.273.5273.341; Orton GS, 1996, SCIENCE, V274, P389, DOI 10.1126/science.274.5286.389; REIMANN CT, 1984, SURF SCI, V147, P227, DOI 10.1016/0039-6028(84)90177-8; SACK NJ, 1993, PHYS REV B, V48, P9973, DOI 10.1103/PhysRevB.48.9973; SACK NJ, 1991, J GEOPHYS RES-PLANET, V96, P17535, DOI 10.1029/91JE01681; SHI M, 1995, NUCL INSTRUM METH B, V96, P524, DOI 10.1016/0168-583X(95)00249-9; SPENCER JR, 1995, J GEOPHYS RES-PLANET, V100, P19049, DOI 10.1029/95JE01503; Urquhart ML, 1996, J GEOPHYS RES-PLANET, V101, P21169, DOI 10.1029/96JE02239; WESTLEY MS, 1995, PLANET SPACE SCI, V43, P1311, DOI 10.1016/0032-0633(95)00088-M; WESTLEY MS, 1995, NATURE, V373, P405, DOI 10.1038/373405a0; WONG MC, 1995, ICARUS, V115, P109, DOI 10.1006/icar.1995.1082; YUNG YL, 1977, ICARUS, V30, P97, DOI 10.1016/0019-1035(77)90124-5; [No title captured]; [No title captured]	41	55	55	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 20	1997	276	5320					1839	1842		10.1126/science.276.5320.1839	http://dx.doi.org/10.1126/science.276.5320.1839			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XF103	9188525				2022-12-01	WOS:A1997XF10300042
J	Taddei, F; Radman, M; MaynardSmith, J; Toupance, B; Gouyon, PH; Godelle, B				Taddei, F; Radman, M; MaynardSmith, J; Toupance, B; Gouyon, PH; Godelle, B			Role of mutator alleles in adaptive evolution	NATURE			English	Article							ESCHERICHIA-COLI; POPULATIONS; STRAINS; COMPETITION; ADAPTATION; SELECTION	Because most newly arising mutations are neutral or deleterious, it has been argued(1-3) that the mutation rate has evolved to be as low as possible, limited only by the cost of error-avoidance and error-correction mechanisms, But up to one per cent of natural bacterial isolates are 'mutator' clones that have high mutation rates(4-6). We consider here whether high mutation rates might play an important role in adaptive evolution, Models of large, asexual, clonal populations adapting to a new environment show that strong mutator genes (such as those that increase mutation rates by 1,000-fold) can accelerate adaptation, even if the mutator gene remains at a very low frequency (for example, 10(-5)), Less potent mutators (10 to 100-fold increase) can become fixed in a fraction of finite populations, The parameters of the model have been set to values typical for Escherichia coli cultures, which behave in a manner similar to the model in long-term adaptation experiments(7).	UNIV SUSSEX,SCH BIOL SCI,MICROBIAL GENET GRP,BRIGHTON BN1 9QG,E SUSSEX,ENGLAND; UNIV PARIS 11,CNRS,LAB EVOLUT & SYSTEMAT,F-91405 ORSAY,FRANCE; INST NATL AGRON PARIS GRIGNON,F-75005 PARIS,FRANCE; ECOLE NATL GENIE RURAL EAUX & FORETS,F-75732 PARIS,FRANCE	University of Sussex; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; AgroParisTech; UDICE-French Research Universities; Universite Paris Saclay	Taddei, F (corresponding author), UNIV PARIS 07,INST JACQUES MONOD,CNRS,LAB MUTAGENESE,2 PL JUSSIEU,F-75251 PARIS,FRANCE.		Gouyon, Pierre-Henri/A-9603-2013; Radman, Miroslav/HDM-5955-2022	Radman, Miroslav/0000-0002-7034-4365; Radman, Miroslav/0000-0003-0216-3148; TOUPANCE, Bruno/0000-0002-8244-1824				CHAO L, 1983, NATURE, V303, P633, DOI 10.1038/303633a0; CHAO L, 1983, EVOLUTION, V37, P125, DOI 10.1111/j.1558-5646.1983.tb05521.x; DAVID JL, 1993, HEREDITY, V71, P642, DOI 10.1038/hdy.1993.189; DRAKE JW, 1991, P NATL ACAD SCI USA, V88, P7160, DOI 10.1073/pnas.88.16.7160; GROSS MD, 1981, MUTAT RES, V91, P107, DOI 10.1016/0165-7992(81)90081-6; Haraguchi Y, 1996, J THEOR BIOL, V183, P121, DOI 10.1006/jtbi.1996.9999; HARTL DL, 1984, ANNU REV GENET, V18, P31, DOI 10.1146/annurev.ge.18.120184.000335; ISHII K, 1989, GENETICS, V121, P163; JYSSUM K., 1960, ACTA PATHOL ET MICROBIOL SCAND, V48, P113; KIMURA M, 1967, GENET RES, V9, P23, DOI 10.1017/S0016672300010284; LeClerc JE, 1996, SCIENCE, V274, P1208, DOI 10.1126/science.274.5290.1208; LEIGH EG, 1973, GENETICS, V73, P1; LEIGH EG, 1970, AM NAT, V104, P301, DOI 10.1086/282663; LENSKI RE, 1991, AM NAT, V138, P1315, DOI 10.1086/285289; LENSKI RE, 1994, P NATL ACAD SCI USA, V91, P6808, DOI 10.1073/pnas.91.15.6808; LIBERMAN U, 1986, THEOR POPUL BIOL, V30, P125, DOI 10.1016/0040-5809(86)90028-6; Magnasco MO, 1996, PHYS LETT A, V221, P287, DOI 10.1016/0375-9601(96)00599-3; Mao EF, 1997, J BACTERIOL, V179, P417, DOI 10.1128/jb.179.2.417-422.1997; Matic I, 1996, TRENDS MICROBIOL, V4, P69, DOI 10.1016/0966-842X(96)81514-9; MAYNARDSMITH J, 1993, P NATIONAL ACADEMY S, V90, P4384; MOXON ER, 1994, CURR BIOL, V4, P24, DOI 10.1016/S0960-9822(00)00005-1; NINIO J, 1991, GENETICS, V129, P957; PECK JR, 1994, GENETICS, V137, P597; Sniegowski PD, 1997, NATURE, V387, P703, DOI 10.1038/42701; TADDEI F, IN PRESS ENV STRESS; Tomlinson IPM, 1996, P NATL ACAD SCI USA, V93, P14800, DOI 10.1073/pnas.93.25.14800; TROBNER W, 1984, MOL GEN GENET, V198, P175, DOI 10.1007/BF00328719; TROBNER W, 1981, Z ALLG MIKROBIOL, V21, P347, DOI 10.1002/jobm.3630210412; TROBNER W, 1985, NATURWISSENSCHAFTEN, V72, P377, DOI 10.1007/BF00410603; Van Valen L., 1973, EVOL THEORY, V1, P1, DOI DOI 10.1038/344864A0	30	535	545	0	79	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 12	1997	387	6634					700	702		10.1038/42696	http://dx.doi.org/10.1038/42696			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XD869	9192893	Bronze			2022-12-01	WOS:A1997XD86900052
J	Krumholz, HM; Murillo, JE; Chen, J; Vaccarino, V; Radford, MJ; Ellerbeck, EF; Wang, Y				Krumholz, HM; Murillo, JE; Chen, J; Vaccarino, V; Radford, MJ; Ellerbeck, EF; Wang, Y			Thrombolytic therapy for eligible elderly patients with acute myocardial infarction	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							WORCESTER-HEART-ATTACK; AGE; MORTALITY	Objective.-To determine the correlates of thrombolytic therapy use in a population-based sample of elderly patients hospitalized with acute myocardial infarction who were eligible for the therapy on presentation. Design.-Retrospective cohort study using data from medical charts and administrative files. Setting.-All acute care, nongovernmental hospitals in Connecticut. Patients.-A cohort of 3093 patients aged 65 years and older with a discharge diagnosis of acute myocardial infarction covered by Medicare from May 1992 to May 1993. Results.-Among the 753 patients with ST-segment elevation of 1 mm or more in at least 2 contiguous leads, left bundle branch block not known to be old, and no absolute contraindications to thrombolytic therapy who were not referred for direct angioplasty or bypass surgery, 419 patients (56%) did not receive thrombolytic therapy. The strongest predictors of not receiving thrombolytic therapy included advanced age, absence of chest pain, presentation more than 6 hours after the onset of symptoms, left bundle branch block, total ST-segment elevation of 6 mm or less, presence of Q waves, ST-segment elevation in only 2 leads, and altered mental status. Physicians documented why they did not administer thrombolytic therapy in 19% of the charts, Delay in presentation and increased age were the most common reasons cited, Among the subset of 261 patients who presented with chest pain and within 6 hours of symptoms, 197 (75%) received thrombolytic therapy. Conclusions.-Many eligible and ideal patients for thrombolytic therapy are not treated. Physicians are less likely to use thrombolytic therapy in eligible patients with characteristics associated with an increased risk of bleeding, lower-risk infarction, less certain diagnosis, less certain efficacy, or altered mental status, These findings suggest that the lack of treatment represents a clinical judgment rather than an inadvertent omission. in some cases, such as the lower use of thrombolytic therapy with older age, these judgments are not consistent with the published literature and may represent opportunities to improve care.	YALE UNIV, SCH MED, DEPT MED, SECT CARDIOVASC MED, NEW HAVEN, CT 06520 USA; YALE UNIV, SCH MED, DEPT EPIDEMIOL & PUBL HLTH, SECT CHRON DIS EPIDEMIOL, NEW HAVEN, CT 06520 USA; YALE NEW HAVEN MED CTR, CTR OUTCOMES RES & EVALUAT, NEW HAVEN, CT 06504 USA; CONNECTICUT PEER REVIEW ORG, MIDDLETOWN, CT USA; UNIV CONNECTICUT, SCH MED, DEPT MED, DIV CARDIOL, FARMINGTON, CT USA; HLTH CARE FINANCING ADM, KANSAS CITY, MO USA	Yale University; Yale University; Yale University; University of Connecticut			, Harlan/AAI-2875-2020; Ellerbeck, Edward/I-8438-2014	Ellerbeck, Edward/0000-0002-7774-2729; Radford, Martha/0000-0001-7503-9557				APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; Arnold AER, 1995, EUR HEART J, V16, P1502, DOI 10.1093/oxfordjournals.eurheartj.a060770; BAYER AJ, 1986, J AM GERIATR SOC, V34, P263, DOI 10.1111/j.1532-5415.1986.tb04221.x; COX DA, 1994, AM J CARDIOL, V73, P729, DOI 10.1016/0002-9149(94)90872-9; ELLERBECK EF, 1995, JAMA-J AM MED ASSOC, V273, P1509, DOI 10.1001/jama.273.19.1509; FURBERG CD, 1992, AM J CARDIOL, V69, P1329, DOI 10.1016/0002-9149(92)91231-R; GOLDBERG RJ, 1989, AM HEART J, V117, P543, DOI 10.1016/0002-8703(89)90727-8; *GRP IT STUD STREP, 1986, LANCET, V1, P397; GUNNAR RM, 1990, J AM COLL CARDIOL, V16, P249, DOI 10.1016/0735-1097(90)90575-A; Gurwitz Jerry H., 1994, Archives of Internal Medicine, V154, P2202, DOI 10.1001/archinte.154.19.2202; Gurwitz JH, 1996, ANN INTERN MED, V124, P283, DOI 10.7326/0003-4819-124-3-199602010-00001; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Hosmer DW, 2000, APPL LOGISTIC REGRES, V2nd; *ISIS I COLL GROUP, 1988, LANCET, V2, P849; KRUMHOLZ HM, 1994, J AM GERIATR SOC, V42, P127, DOI 10.1111/j.1532-5415.1994.tb04938.x; KRUMHOLZ HM, 1992, NEW ENGL J MED, V327, P7, DOI 10.1056/NEJM199207023270102; LANDWEHR JM, 1984, J AM STAT ASSOC, V79, P61, DOI 10.2307/2288334; PFEFFER MA, 1991, JAMA-J AM MED ASSOC, V266, P528, DOI 10.1001/jama.266.4.528; Ryan TJ, 1996, J AM COLL CARDIOL, V28, P1328; Sgarbossa EB, 1996, NEW ENGL J MED, V334, P481, DOI 10.1056/NEJM199602223340801; *US DEP HHS, 1988, INT CLASS DIS 9 REV; Vorchheimer David A., 1996, Journal of the American College of Cardiology, V27, p389A; WEAVER WD, 1991, J AM COLL CARDIOL, V18, P657, DOI 10.1016/0735-1097(91)90784-7	23	144	147	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 4	1997	277	21					1683	1688		10.1001/jama.277.21.1683	http://dx.doi.org/10.1001/jama.277.21.1683			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XB088	9169894				2022-12-01	WOS:A1997XB08800028
J	Komori, T; Yagi, H; Nomura, S; Yamaguchi, A; Sasaki, K; Deguchi, K; Shimizu, Y; Bronson, RT; Gao, YH; Inada, M; Sato, M; Okamoto, R; Kitamura, Y; Yoshiki, S; Kishimoto, T				Komori, T; Yagi, H; Nomura, S; Yamaguchi, A; Sasaki, K; Deguchi, K; Shimizu, Y; Bronson, RT; Gao, YH; Inada, M; Sato, M; Okamoto, R; Kitamura, Y; Yoshiki, S; Kishimoto, T			Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts	CELL			English	Article							COLONY-STIMULATING FACTOR; ACUTE MYELOID-LEUKEMIA; IN-SITU HYBRIDIZATION; TRANSCRIPTION FACTOR; ALKALINE-PHOSPHATASE; INSITU HYBRIDIZATION; MESSENGER-RNA; RUNT DOMAIN; DEVELOPMENTAL EXPRESSION; SPARC OSTEONECTIN	A transcription factor, Cbfa1, which belongs to the rent-domain gene family, is expressed restrictively in fetal development. To elucidate the function of Cbfa1, we generated mice with a mutated Cbfa1 locus. Mice with a homozygous mutation in Cbfa1 died just after birth without breathing. Examination of their skeletal systems showed a complete lack of ossification. Although immature osteoblasts, which expressed alkaline phophatase weakly but not Osteopontin and Osteocalcin, and a few immature osteoclasts appeared at the perichondrial region, neither vascular nor mesenchymal cell invasion was observed in the cartilage. Therefore, our data suggest that both intramembranous and endochondral ossification were completely blocked, owing to the maturational arrest of osteoblasts in the mutant mice, and demonstrate that Cbfa1 plays an essential role in osteogenesis.	OSAKA UNIV,SCH MED,DEPT PATHOL,SUITA,OSAKA 565,JAPAN; SHOWA UNIV,SCH DENS,DEPT ORAL PATHOL,SHINAGAWA KU,TOKYO 142,JAPAN; TUFTS UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02111; TUFTS UNIV,SCH VET MED,BOSTON,MA 02111; OSAKA CITY UNIV,SCH MED,DEPT ANAT 1,ABENO KU,OSAKA 545,JAPAN	Osaka University; Showa University; Tufts University; Tufts University; Osaka Metropolitan University	Komori, T (corresponding author), OSAKA UNIV,SCH MED,DEPT MED 3,2-2 YAMADAOKA,SUITA,OSAKA 565,JAPAN.		Kishimoto, Tadamitsu/C-8470-2009	Yagi, Hideshi/0000-0002-8506-8965				Aubin Jane E., 1993, P1; BAE SC, 1993, ONCOGENE, V8, P809; BAE SC, 1995, GENE, V159, P245, DOI 10.1016/0378-1119(95)00060-J; Banerjee C, 1996, P NATL ACAD SCI USA, V93, P4968, DOI 10.1073/pnas.93.10.4968; BRONCKERS ALJJ, 1987, BONE MINER, V2, P361; CAMERON S, 1994, BLOOD, V83, P2851, DOI 10.1182/blood.V83.10.2851.2851; CHEN J, 1991, HISTOCHEM J, V23, P281, DOI 10.1007/BF01045047; COPRAY JCVM, 1989, J ANAT, V162, P43; Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0; Frank R, 1995, ONCOGENE, V11, P2667; FRANZEN A, 1989, MATRIX, V9, P261, DOI 10.1016/S0934-8832(89)80001-0; Geoffroy V, 1995, J BIOL CHEM, V270, P30973, DOI 10.1074/jbc.270.52.30973; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; HALE JE, 1988, J BIOL CHEM, V263, P5820; HALLBERG B, 1992, NUCLEIC ACIDS RES, V20, P6495, DOI 10.1093/nar/20.24.6495; HIRAKAWA K, 1994, J BONE MINER RES, V9, P1551; HIROTA S, 1994, CELL TISSUE RES, V277, P27, DOI 10.1007/BF00303077; HSIANG YHH, 1993, J IMMUNOL, V150, P3905; IBARAKI K, 1992, J BONE MINER RES, V7, P743; IKEDA T, 1992, J HISTOCHEM CYTOCHEM, V40, P1079, DOI 10.1177/40.8.1619274; JARVIS JL, 1974, AM J ROENTGENOL, V121, P5, DOI 10.2214/ajr.121.1.5; KAMACHI Y, 1990, J VIROL, V64, P4808, DOI 10.1128/JVI.64.10.4808-4819.1990; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; KODAMA H, 1991, J EXP MED, V173, P269, DOI 10.1084/jem.173.1.269; KODAMA H, 1991, J EXP MED, V173, P1291, DOI 10.1084/jem.173.5.1291; KOMORI T, 1993, SCIENCE, V261, P1171, DOI 10.1126/science.8356451; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; MALAVAL L, 1994, J CELL PHYSIOL, V158, P555, DOI 10.1002/jcp.1041580322; MARK MP, 1988, DIFFERENTIATION, V37, P123, DOI 10.1111/j.1432-0436.1988.tb00804.x; MERRIMAN HL, 1995, BIOCHEMISTRY-US, V34, P13125, DOI 10.1021/bi00040a025; MIYAUCHI A, 1991, J BIOL CHEM, V266, P20369; MIYAZAKI Y, 1990, J BIOL CHEM, V265, P14432; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; Mundlos S, 1996, ANN NY ACAD SCI, V785, P301, DOI 10.1111/j.1749-6632.1996.tb56290.x; MUNDLOS S, 1995, HUM MOL GENET, V4, P71, DOI 10.1093/hmg/4.1.71; NODA M, 1987, J BONE MINER RES, V2, P161; NOMURA S, 1993, ACTA HISTOCHEM CYTOC, V26, P303, DOI 10.1267/ahc.26.303; NOMURA S, 1988, J CELL BIOL, V106, P441, DOI 10.1083/jcb.106.2.441; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; PROSSER HM, 1992, P NATL ACAD SCI USA, V89, P9934, DOI 10.1073/pnas.89.20.9934; REDONDO JM, 1992, MOL CELL BIOL, V12, P4817, DOI 10.1128/MCB.12.11.4817; REINHOLT FP, 1990, P NATL ACAD SCI USA, V87, P4473, DOI 10.1073/pnas.87.12.4473; RODAN GA, 1988, CIBA F SYMP, V136, P78; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; SATAKE M, 1995, MOL CELL BIOL, V15, P1662; SIMEONE A, 1995, DEV DYNAM, V203, P61, DOI 10.1002/aja.1002030107; SOMERMAN MJ, 1987, J BONE MINER RES, V2, P259; STEIN GS, 1993, ENDOCR REV, V14, P424, DOI 10.1210/er.14.4.424; TAKAHASHI A, 1995, BLOOD, V86, P607, DOI 10.1182/blood.V86.2.607.bloodjournal862607; TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P2600, DOI 10.1210/endo-123-5-2600; TANAKA S, 1993, J CLIN INVEST, V91, P257, DOI 10.1172/JCI116179; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WANG SW, 1992, MOL CELL BIOL, V12, P89, DOI 10.1128/MCB.12.1.89; WARGNIER A, 1995, P NATL ACAD SCI USA, V92, P6930, DOI 10.1073/pnas.92.15.6930; WEINREB M, 1990, J BONE MINER RES, V5, P831; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085	65	3437	3590	4	157	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 30	1997	89	5					755	764		10.1016/S0092-8674(00)80258-5	http://dx.doi.org/10.1016/S0092-8674(00)80258-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XB925	9182763	Bronze			2022-12-01	WOS:A1997XB92500012
J	Dietrich, FS; Mulligan, J; Hennessy, K; Yelton, MA; Allen, E; Araujo, R; Aviles, E; Berno, A; Brennan, T; Carpenter, J; Chen, E; Cherry, JM; Chung, E; Duncan, M; Guzman, E; Hartzell, G; HunickeSmith, S; Hyman, RW; Kayser, A; Komp, C; Lashkari, D; Lew, H; Lin, D; Mosedale, D; Nakahara, K; Namath, A; Norgren, R; Oefner, P; Oh, C; Petel, FX; Roberts, D; Sehl, P; Schramm, S; Shogren, T; Smith, V; Taylor, P; Wei, Y; Botstein, D; Davis, RW				Dietrich, FS; Mulligan, J; Hennessy, K; Yelton, MA; Allen, E; Araujo, R; Aviles, E; Berno, A; Brennan, T; Carpenter, J; Chen, E; Cherry, JM; Chung, E; Duncan, M; Guzman, E; Hartzell, G; HunickeSmith, S; Hyman, RW; Kayser, A; Komp, C; Lashkari, D; Lew, H; Lin, D; Mosedale, D; Nakahara, K; Namath, A; Norgren, R; Oefner, P; Oh, C; Petel, FX; Roberts, D; Sehl, P; Schramm, S; Shogren, T; Smith, V; Taylor, P; Wei, Y; Botstein, D; Davis, RW			The nucleotide sequence of Saccharomyces cerevisiae chromosome V	NATURE			English	Article							PHYSICAL MAPS; GENE; YEAST	Here we report the sequence of 569,202 base pairs of Saccharomyces cerevisiae chromosome V. Analysis of the sequence revealed a centromere, two telomeres and 271 open reading frames (ORFs) plus 13 tRNAs and four small nuclear RNAs. There are two Ty1 transposable elements, each of which contains an ORF (included in the count of 271). Of the ORFs, 78 (29%) are new, 81 (30%) have potential homologues in the public databases, and 112 (41%) are previously characterized yeast genes.	STANFORD DNA SEQUENCING & TECHNOL CTR,PALO ALTO,CA 94304; STANFORD UNIV,SCH MED,DEPT BIOCHEM,PALO ALTO,CA 94305; STANFORD UNIV,SCH MED,DEPT GENET,PALO ALTO,CA 94305	Stanford University; Stanford University; Stanford University			Tuluc, Petronel/C-2527-2011; Oh, Chulmin/ABB-6024-2021	Cherry, J. Michael/0000-0001-9163-5180	NHGRI NIH HHS [P01 HG000205-11, P01 HG000205] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P01HG000205] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; FLEER R, 1987, MOL CELL BIOL, V7, P1180, DOI 10.1128/MCB.7.3.1180; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; GLEESON TJ, 1991, COMPUT APPL BIOSCI, V7, P398; LASHKARI DA, 1995, P NATL ACAD SCI USA, V92, P7912, DOI 10.1073/pnas.92.17.7912; LOUIS EJ, 1994, GENETICS, V136, P789; LOUIS EJ, 1992, GENETICS, V131, P559; MORTIMER RK, 1992, YEAST, V8, P817, DOI 10.1002/yea.320081002; Oefner PJ, 1996, NUCLEIC ACIDS RES, V24, P3879, DOI 10.1093/nar/24.20.3879; OLSON MV, 1986, P NATL ACAD SCI USA, V83, P7826, DOI 10.1073/pnas.83.20.7826; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RILES L, 1993, GENETICS, V134, P81; SMITH TF, 1985, NUCLEIC ACIDS RES, V13, P645, DOI 10.1093/nar/13.2.645; STILES JI, 1981, J MOL BIOL, V148, P331, DOI 10.1016/0022-2836(81)90179-0; WEBER E, 1990, MOL MICROBIOL, V4, P585, DOI 10.1111/j.1365-2958.1990.tb00627.x	16	37	368	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 29	1997	387	6632		S			78	81		10.1038/387s078	http://dx.doi.org/10.1038/387s078			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XB546	9169868				2022-12-01	WOS:A1997XB54600008
J	Nalbantoglu, J; TiradoSantiago, G; Lahsaini, A; Poirier, J; Goncalves, O; Verge, A; Momoli, F; Welner, SA; Massicotte, G; Julien, JP; Shapiro, ML				Nalbantoglu, J; TiradoSantiago, G; Lahsaini, A; Poirier, J; Goncalves, O; Verge, A; Momoli, F; Welner, SA; Massicotte, G; Julien, JP; Shapiro, ML			Impaired learning and LTP in mice expressing the carboxy terminus of the Alzheimer amyloid precursor protein	NATURE			English	Article							BETA-PROTEIN; TRANSGENIC MICE; WATER-MAZE; DISEASE; NEURONS; DERIVATIVES; HIPPOCAMPUS; CHANNELS; PEPTIDE; CELLS	Proteolytic processing of amyloid precursor protein (APP) through an endosomal/lysosomal pathway generates carboxyterminal polypeptides that contain an intact beta-amyloid domain(1-3). Cleavage by as-yet unidentified proteases releases the beta-amyloid peptide in soluble form(4-6). In Alzheimer's disease, aggregated beta-amyloid is deposited in extracellular neuritic plaques. Although most of the molecular mechanisms involving beta-amyloid and APP in the aetiology of Alzheimer's disease are still unclear, changes in APP metabolism maybe important in the pathogenesis of the disease, Here we show that transgenic mice expressing the amyloidogenic carboxy-terminal 104 amino acids of APP develop, with ageing, extracellular beta-amyloid immunoreactivity, increased gliosis and microglial reactivity, as well as cell loss in the CA1 region of the hippocampus. Adult transgenic mice demonstrate spatial-learning deficits in the Morris water maze and in maintenance of long-term potentiation (LTP). Our results indicate that alterations in the processing of APP may have considerable physiological effects on synaptic plasticity.	MCGILL UNIV,DEPT PSYCHOL,MONTREAL,PQ H3A 2B4,CANADA; MCGILL UNIV,DEPT PSYCHIAT,MONTREAL,PQ H3A 2B4,CANADA; MCGILL UNIV,MCGILL CTR STUDIES AGING,MONTREAL,PQ H3A 2B4,CANADA; MONTREAL NEUROL HOSP & INST,MONTREAL,PQ H3A 2B4,CANADA; UNIV QUEBEC,TROIS RIVIERES,PQ G9A 5H7,CANADA; MONTREAL GEN HOSP,CTR NEUROSCI,MONTREAL,PQ H3G 1A4,CANADA	McGill University; McGill University; McGill University; McGill University; University of Quebec; University of Quebec Trois Rivieres; McGill University	Nalbantoglu, J (corresponding author), MCGILL UNIV,DEPT NEUROL & NEUROSURG,MONTREAL,PQ H3A 2B4,CANADA.							ARISPE N, 1993, P NATL ACAD SCI USA, V90, P567, DOI 10.1073/pnas.90.2.567; Bear Mark F., 1994, Current Opinion in Neurobiology, V4, P389, DOI 10.1016/0959-4388(94)90101-5; BEAUDET L, 1992, GENE, V116, P205, DOI 10.1016/0378-1119(92)90517-S; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; ElKhoury J, 1996, NATURE, V382, P716; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; ETCHEBERRIGARAY R, 1994, SCIENCE, V264, P276, DOI 10.1126/science.8146663; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; HYMAN BT, 1992, PROG CLIN BIOL RES, V379, P123; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KOLB B, 1983, BEHAV NEUROSCI, V97, P13, DOI 10.1037/0735-7044.97.1.13; LeBlanc A, 1995, J NEUROSCI, V15, P7837; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; MEANEY MJ, 1988, SCIENCE, V239, P766, DOI 10.1126/science.3340858; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; QUON D, 1991, NATURE, V352, P239, DOI 10.1038/352239a0; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SKELTON RW, 1992, HIPPOCAMPUS, V2, P73, DOI 10.1002/hipo.450020110; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; YANKNER BA, 1989, SCIENCE, V245, P417, DOI 10.1126/science.2474201; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531; YOSHIKAWA K, 1992, NATURE, V359, P64, DOI 10.1038/359064a0	30	295	311	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 29	1997	387	6632					500	505		10.1038/387500a0	http://dx.doi.org/10.1038/387500a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XB479	9168112				2022-12-01	WOS:A1997XB47900048
J	Law, C; Marcaccio, M; Tam, P; Heddle, N; Kelton, JG				Law, C; Marcaccio, M; Tam, P; Heddle, N; Kelton, JG			High-dose intravenous immune globulin and the response to splenectomy in patients with idiopathic thrombocytopenic purpura	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							THERAPEUTIC EXPERIENCE; GAMMA-GLOBULIN	Background High-dose intravenous immune globulin produces a temporary rise in the platelet count in patients with idiopathic thrombocytopenic purpura. Splenectomy may also be effective, but it is not possible to predict which patients will have a good response. We hypothesized that the response to intravenous immune globulin predicts the response to splenectomy. Methods We studied retrospectively 30 patients with idiopathic thrombocytopenic purpura who had first been treated with immune globulin and then undergone splenectomy. The responses to the two treatments were classified on the basis of the platelet count as poor (< 50,000 per cubic millimeter), good (50,000 to 150,000 per cubic millimeter), or excellent (> 150,000 per cubic millimeter). Results All nine patients who had poor responses to intravenous immune globulin also had poor responses to splenectomy at one year. Of the 21 patients with good or excellent responses to intravenous immune globulin, 19 had good or excellent responses to splenectomy. Conclusions Patients with idiopathic thrombocytopenic purpura who have good or excellent responses to intravenous immune globulin are likely to have good or excellent responses to splenectomy, whereas patients who have poor responses to intravenous immune globulin are unlikely to have good or excellent responses to splenectomy. (C) 1997, Massachusetts Medical Society.	MCMASTER UNIV, MED CTR, DEPT PATHOL, HAMILTON, ON L8N 3Z5, CANADA; MCMASTER UNIV, MED CTR, DEPT MED, HAMILTON, ON L8N 3Z5, CANADA; MCMASTER UNIV, MED CTR, DEPT SURG, HAMILTON, ON L8N 3Z5, CANADA; HAMILTON HLTH SCI CORP, HAMILTON, ON, CANADA	McMaster University; McMaster University; McMaster University; McMaster University								BENYEHUDA D, 1994, ACTA HAEMATOL-BASEL, V91, P1; BRENNAN MF, 1975, AM J SURG, V129, P490, DOI 10.1016/0002-9610(75)90197-X; BUSSEL JB, 1983, BLOOD, V62, P480; BUSSEL JB, 1984, BRIT J HAEMATOL, V56, P1, DOI 10.1111/j.1365-2141.1984.tb01266.x; BUSSEL JB, 1990, HEMATOL ONCOL CLIN N, V4, P179, DOI 10.1016/S0889-8588(18)30512-4; COON WW, 1987, SURG GYNECOL OBSTET, V164, P225; FABRIS F, 1989, ACTA HAEMATOL-BASEL, V81, P28; FEHR J, 1982, NEW ENGL J MED, V306, P1254, DOI 10.1056/NEJM198205273062102; FENAUX P, 1989, EUR J HAEMATOL, V42, P259; George JN, 1996, BLOOD, V88, P3, DOI 10.1182/blood.V88.1.3.3; GEORGE JN, 1994, NEW ENGL J MED, V331, P1207, DOI 10.1056/NEJM199411033311807; Hashizume M, 1996, SURG LAPAROSC ENDOSC, V6, P129, DOI 10.1097/00019509-199604000-00008; JACOBS P, 1986, Q J MED, V58, P153; JULIA A, 1990, BRIT J HAEMATOL, V76, P250, DOI 10.1111/j.1365-2141.1990.tb07880.x; KELTON JG, 1985, BLOOD, V66, P490; KELTON JG, 1985, CURRENT CONCEPTS TRA, P51; KONRADSEN HB, 1991, ACTA PAEDIATR SCAND, V80, P423, DOI 10.1111/j.1651-2227.1991.tb11877.x; NAJEAN Y, 1991, BRIT J HAEMATOL, V79, P271, DOI 10.1111/j.1365-2141.1991.tb04532.x; PIZZUTO J, 1984, BLOOD, V64, P1179; SIEGEL RS, 1989, AM J HEMATOL, V30, P206, DOI 10.1002/ajh.2830300404	20	98	100	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 22	1997	336	21					1494	1498		10.1056/NEJM199705223362104	http://dx.doi.org/10.1056/NEJM199705223362104			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WZ767	9154768	Bronze			2022-12-01	WOS:A1997WZ76700004
J	Trofa, AF; DeFraites, RF; Smoak, BL; KanesaThasan, N; King, AD; Burrous, JM; MacArthy, PO; Rossi, C; Hoke, CH				Trofa, AF; DeFraites, RF; Smoak, BL; KanesaThasan, N; King, AD; Burrous, JM; MacArthy, PO; Rossi, C; Hoke, CH			Dengue fever in US military personnel in Haiti	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DISEASE; VIRUS	Objective.-To describe clinical manifestations and public health implications of an outbreak of dengue fever (DF) during Operation Uphold Democracy, Haiti, 1994. Design.-Consecutive sample, Setting.-Military combat support hospital, Port-au-Prince, Haiti, Patients.-A total of 101 US military personnel with acute febrile illnesses, Interventions.-A disease surveillance team collected clinical and epidemiologic data from US military clinics throughout Haiti, Febrile patients admitted to the combat support hospital were evaluated with standardized clinical and laboratory procedures, The surveillance team followed patients daily, Main Outcome Measures.-Arbovirus isolation and specific antibody determination and symptoms and physical findings, Results.-Febrile illnesses accounted for 103 (25%) of the 406 combat support hospital admissions during the first 8 weeks of deployment. Ail patients with febrile illness recovered. A total of 30 patients had DF; no patient had evidence of infection with malaria, Dengue virus serotypes 1,2, and 4 were isolated from 22 patients, and 8 patients developed IgM antibody to dengue virus, Patients with DF could not be distinguished from other febrile patients on clinical grounds alone, No arboviruses other than dengue were identified. Conclusions.-Active surveillance, with clinical and laboratory evaluation directed by an epidemiologic team, led to the timely recognition of an outbreak of febrile illness among US troops in Haiti, Viral isolation and serological studies were essential in confirming DF, During the surveillance period, DF accounted for at least 30% of the febrile illnesses among hospitalized US troops, Dengue fever is a significant threat to military personnel and civilian travelers in Haiti and has the potential for introduction to and transmission in the United States.	WALTER REED ARMY INST RES, DIV PREVENT MED, WASHINGTON, DC USA; WALTER REED ARMY INST RES, DIV COMMUNICABLE DIS & IMMUNOL, WASHINGTON, DC USA; USA, MED RES INST INFECT DIS, DEPT APPL DIAGNOST, FREDERICK, MD USA	United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR)								Bakker, 1996, J Travel Med, V3, P204, DOI 10.1111/j.1708-8305.1996.tb00747.x; *CDCP, 1994, MMWR-MORBID MORTAL W, V43, P845; *CDCP, 1995, MMWR-MORBID MORTAL W, V44, P353; EHRENKRANZ NJ, 1971, NEW ENGL J MED, V285, P1460, DOI 10.1056/NEJM197112232852606; GAMBEL JM, 1996, MIL REV, V76, P51; GUBLER DJ, 1993, INFECT AGENT DIS, V2, P383; GUBLER DJ, 1989, AM J TROP MED HYG, V40, P571, DOI 10.4269/ajtmh.1989.40.571; HENCHAL EA, 1982, AM J TROP MED HYG, V31, P830, DOI 10.4269/ajtmh.1982.31.830; HYAMS KC, 1993, MIL MED, V158, P729, DOI 10.1093/milmed/158.11.729; HYAMS KC, 1986, AM J TROP MED HYG, V35, P860, DOI 10.4269/ajtmh.1986.35.860; INNIS BL, 1989, AM J TROP MED HYG, V40, P418, DOI 10.4269/ajtmh.1989.40.418; MONATH T, 1984, HUNTERS TROPICAL MED, P143; MORENS DM, 1994, CLIN INFECT DIS, V19, P500, DOI 10.1093/clinids/19.3.500; NEWTON JA, 1994, JAMA-J AM MED ASSOC, V272, P397, DOI 10.1001/jama.272.5.397; Rigau-Perez Jose G., 1994, Morbidity and Mortality Weekly Report, V43, P7; Schwartz E, 1996, AM J MED, V101, P516, DOI 10.1016/S0002-9343(96)00278-1; SHARP TW, 1995, AM J TROP MED HYG, V53, P89, DOI 10.4269/ajtmh.1995.53.89; TESH RB, 1979, AM J TROP MED HYG, V28, P1053, DOI 10.4269/ajtmh.1979.28.1053; *USD INC, 1990, EP INF VERS 5 WORD P; VENTURA AK, 1976, J INFECT DIS, V134, P436, DOI 10.1093/infdis/134.5.436; Wallace MR, 1996, AM J MED, V100, P49, DOI 10.1016/S0002-9343(96)90011-X; *WHO, 1994, WEEKLY EPIDEMIOL REC, V69, P177	22	55	59	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 21	1997	277	19					1546	1548		10.1001/jama.277.19.1546	http://dx.doi.org/10.1001/jama.277.19.1546			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WY969	9153369				2022-12-01	WOS:A1997WY96900033
J	Brearley, AJ				Brearley, AJ			Disordered biopyriboles, amphibole, and talc in the allende meteorite: Products of nebular or parent body aqueous alteration?	SCIENCE			English	Article							CARBONACEOUS CHONDRITE; PHYLLOSILICATES; MINERALOGY; MATRIX; RIMS	Transmission electron microscope observations of the Allende carbonaceous chondrite provided evidence of widespread hydrous phases replacing enstatite in chondrules. Calcic amphibole and talc occur in thin (less than 0.3 micrometer) crosscutting veins and as alteration products of primary chondrule glass in contraction cracks within the enstatite, In addition, talc and disordered biopyriboles were found replacing enstatite grains along cracks and fractures. Although rare hydrous phases have been reported in calcium- and aluminum-rich inclusions in the Allende meteorite, these observations suggest that aqueous fluids played a much more significant role in the mineralogical and geochemical evolution of Allende than has previously been thought.			Brearley, AJ (corresponding author), UNIV NEW MEXICO, INST METEORIT, DEPT EARTH & PLANETARY SCI, ALBUQUERQUE, NM 87131 USA.			Brearley, Adrian/0000-0002-7364-8815				BARBER DJ, 1985, CLAY MINER, V20, P415, DOI 10.1180/claymin.1985.020.4.01; BERMAN RG, 1988, J PETROL, V29, P445, DOI 10.1093/petrology/29.2.445; BERMAN RG, 1991, CAN MINERAL, V29, P833; BREARLEY AJ, 1996, LUNAR PLANET SCI, V27, P161; BUNCH TE, 1980, GEOCHIM COSMOCHIM AC, V44, P1543, DOI 10.1016/0016-7037(80)90118-0; CHERNOSKY JV, 1982, CAN MINERAL, V20, P19; CLARKE RS, 1970, SMITHSON CONTRIB EAR, V5, P53; Grossman J. N., 1988, METEORITES EARLY SOL, P619; HASHIMOTO A, 1987, GEOCHIM COSMOCHIM AC, V51, P1685, DOI 10.1016/0016-7037(87)90348-6; Housley R. M., 1983, CHONDRULES THEIR ORI, P145; HUA X, 1988, GEOCHIM COSMOCHIM AC, V52, P1389, DOI 10.1016/0016-7037(88)90210-4; IKEDA Y, 1993, GEOCHIM COSMOCHIM AC, V57, P439, DOI 10.1016/0016-7037(93)90442-Y; KELLER LP, 1991, SCIENCE, V252, P946, DOI 10.1126/science.252.5008.946; KELLER LP, 1990, GEOCHIM COSMOCHIM AC, V54, P1155, DOI 10.1016/0016-7037(90)90446-R; KIMURA K, 1995, P NAT I POL RES S AN, V8, P123; Kimura M., 1996, METEORIT PLANET SCI, V31, pA70; KOJIMA T, 1993, METEORITICS, V28, P649, DOI 10.1111/j.1945-5100.1993.tb00636.x; Kojima T, 1996, GEOCHIM COSMOCHIM AC, V60, P2651, DOI 10.1016/0016-7037(96)00116-0; Krot AN, 1997, METEORIT PLANET SCI, V32, P31, DOI 10.1111/j.1945-5100.1997.tb01238.x; KROT AN, 1995, METEORITICS, V30, P738; MacPherson G.J., 1988, METEORITES EARLY SOL, P746; PECK JA, 1987, GEOCHIM COSMOCHIM AC, V51, P1503, DOI 10.1016/0016-7037(87)90332-2; TOMEOKA K, 1982, NATURE, V299, P326, DOI 10.1038/299326a0; TOMEOKA K, 1990, GEOCHIM COSMOCHIM AC, V54, P1787; VEBLEN DR, 1979, AM MINERAL, V64, P687; VEBLEN DR, 1980, AM MINERAL, V65, P599; WEINBRUCH S, 1990, METEORITICS, V25, P115, DOI 10.1111/j.1945-5100.1990.tb00983.x; YASUDA M, 1983, PHYS CHEM MINER, V9, P192, DOI 10.1007/BF00311954; ZOLENSKY M, 1993, GEOCHIM COSMOCHIM AC, V57, P3123, DOI 10.1016/0016-7037(93)90298-B; [No title captured]	30	75	75	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 16	1997	276	5315					1103	1105		10.1126/science.276.5315.1103	http://dx.doi.org/10.1126/science.276.5315.1103			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WZ225	9148802				2022-12-01	WOS:A1997WZ22500041
J	Duan, XQ; Gimble, FS; Quiocho, FA				Duan, XQ; Gimble, FS; Quiocho, FA			Crystal structure of PI-Scel, a homing endonuclease with protein splicing activity	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; DNA-BINDING; RESTRICTION ENDONUCLEASES; ADENOSINE-TRIPHOSPHATASE; ANOMALOUS DIFFRACTION; SECONDARY STRUCTURE; CATALYTIC SUBUNIT; INTRON SEQUENCES; GENE; RECOGNITION	PI-Scel is a bifunctional yeast protein that propagates its mobile gene by catalyzing protein splicing and site specific DNA double-strand cleavage. Here, we report the 2.4 Angstrom crystal structure of the PI-Scel protein. The structure is composed of two separate domains (I and II) with novel folds and different functions. Domain I, which is elongated and formed largely from seven beta sheets, harbors the N and C termini residues and two His residues that are implicated in protein splicing. Domain II, which is compact and is primarily composed of two similar alpha/beta motifs related by local twofold symmetry, contains the putative nuclease active site with a cluster of two acidic residues and one basic residue commonly found in restriction endonucleases. This report presents prototypic structures of domains with single endonuclease and protein splicing active sites.	BAYLOR COLL MED,STRUCT & COMPUTAT BIOL & MOL BIOPHYS PROGRAM,HOUSTON,TX 77030; BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT BIOCHEM,HOUSTON,TX 77030; TEXAS A&M UNIV,DEPT BIOCHEM & BIOPHYS,HOUSTON,TX 77030; TEXAS A&M UNIV,CTR MACROMOL DESIGN INST BIOSCI & TECHNOL,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; Texas A&M University System; Texas A&M University System			Wood, David W/B-2992-2012		NIGMS NIH HHS [R29 GM50815, GM08280] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008280, R29GM050815] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGGARWAL AK, 1995, CURR OPIN STRUC BIOL, V5, P11, DOI 10.1016/0959-440X(95)80004-K; BALDWIN GS, 1995, BIOCHEMISTRY-US, V34, P705, DOI 10.1021/bi00002a038; BELFORT M, 1989, TRENDS GENET, V5, P209, DOI 10.1016/0168-9525(89)90083-8; BREMER MCD, 1992, NUCLEIC ACIDS RES, V20, P5484, DOI 10.1093/nar/20.20.5484; BRUNGER AT, 1992, J APPL CRYSTALLOGR, V24, P958; CHENG XD, 1994, EMBO J, V13, P3927, DOI 10.1002/j.1460-2075.1994.tb06708.x; Chong SR, 1996, J BIOL CHEM, V271, P22159, DOI 10.1074/jbc.271.36.22159; COOPER AA, 1993, EMBO J, V12, P2575, DOI 10.1002/j.1460-2075.1993.tb05913.x; COOPER AA, 1995, TRENDS BIOCHEM SCI, V20, P351, DOI 10.1016/S0968-0004(00)89075-1; Cowtan K., 1994, JT CCP4 ESF EACBM NE, V31, P34; Gimble FS, 1996, J MOL BIOL, V263, P163, DOI 10.1006/jmbi.1996.0567; GIMBLE FS, 1995, J BIOL CHEM, V270, P5849, DOI 10.1074/jbc.270.11.5849; GIMBLE FS, 1992, NATURE, V357, P301, DOI 10.1038/357301a0; GIMBLE FS, 1993, J BIOL CHEM, V268, P21844; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HENKE RM, 1995, EMBO J, V14, P5094, DOI 10.1002/j.1460-2075.1995.tb00191.x; HENSGENS LAM, 1983, CELL, V32, P379, DOI 10.1016/0092-8674(83)90457-9; HIRATA R, 1992, BIOCHEM BIOPH RES CO, V188, P40, DOI 10.1016/0006-291X(92)92347-Z; HIRATA R, 1990, J BIOL CHEM, V265, P6726; HODGES RA, 1992, NUCLEIC ACIDS RES, V20, P6153, DOI 10.1093/nar/20.23.6153; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KANE PM, 1990, SCIENCE, V250, P651, DOI 10.1126/science.2146742; KOSTREWA D, 1995, BIOCHEMISTRY-US, V34, P683, DOI 10.1021/bi00002a036; LAMBOWITZ AM, 1989, CELL, V56, P323, DOI 10.1016/0092-8674(89)90232-8; LAWSKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P282; LOIZOS N, 1994, P NATL ACAD SCI USA, V91, P11983, DOI 10.1073/pnas.91.25.11983; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; LykkeAndersen J, 1996, NUCLEIC ACIDS RES, V24, P3982, DOI 10.1093/nar/24.20.3982; MICHEL F, 1982, BIOCHIMIE, V64, P867, DOI 10.1016/S0300-9084(82)80349-0; MUELLER JE, 1993, NUCLEASES, P111; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perler FB, 1997, NUCLEIC ACIDS RES, V25, P1087, DOI 10.1093/nar/25.6.1087; PIETROKOVSKI S, 1994, PROTEIN SCI, V3, P2340, DOI 10.1002/pro.5560031218; RAUMANN BE, 1994, NATURE, V367, P754, DOI 10.1038/367754a0; READ RJ, 1986, ACTA CRYSTALLOGR A, V47, P110; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; SCHLEIF R, 1988, SCIENCE, V241, P1182, DOI 10.1126/science.2842864; SHELDRICK GM, 1991, ISOMORPHOUS REPLACEM; SKOWRON P, 1993, GENE, V125, P1, DOI 10.1016/0378-1119(93)90738-O; SOMERS WS, 1992, NATURE, V367, P754; VIPOND IB, 1995, BIOCHEMISTRY-US, V34, P697, DOI 10.1021/bi00002a037; WARING RB, 1982, P NATL ACAD SCI-BIOL, V79, P6332, DOI 10.1073/pnas.79.20.6332; WAUGH DS, 1993, P NATL ACAD SCI USA, V90, P9596, DOI 10.1073/pnas.90.20.9596; Wende W, 1996, NUCLEIC ACIDS RES, V24, P4123, DOI 10.1093/nar/24.21.4123; [No title captured]	48	234	259	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 16	1997	89	4					555	564		10.1016/S0092-8674(00)80237-8	http://dx.doi.org/10.1016/S0092-8674(00)80237-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WZ323	9160747	Bronze			2022-12-01	WOS:A1997WZ32300009
J	Zhang, FM; Basinski, MB; Beals, JM; Briggs, SL; Churgay, LM; Clawson, DK; DiMarchi, RD; Furman, TC; Hale, JE; Hsiung, HM; Schoner, BE; Smith, DP; Zhang, XY; Wery, JP; Schevitz, RW				Zhang, FM; Basinski, MB; Beals, JM; Briggs, SL; Churgay, LM; Clawson, DK; DiMarchi, RD; Furman, TC; Hale, JE; Hsiung, HM; Schoner, BE; Smith, DP; Zhang, XY; Wery, JP; Schevitz, RW			Crystal structure of the obese protein leptin-E100	NATURE			English	Article							RECEPTOR; GENE; MICE	Mutations in the obese gene (OB) or in the gene encoding the OB receptor(OB-R) result in obesity, infertility and diabetes in a variety of mouse phenotypes(1-7). The demonstration that OB protein (also known as leptin) can normalize body weight in ob/ob mice has generated enormous interests(8-11). Most human obesity does not appear to result from a mutant form of leptin: rather, serum leptin concentrations are increased and there is an apparent inability to transport it to the central nervous system (CNS)(12). Injection of leptin into the CNS of overfed rodents resistant to peripheral administration was found to induce biological activity(13). Consequently, for the leptin to act as a weight-lowering hormone in human obesity, it appears that appropriate concentrations must be present in the CNS. This places a premium on understanding the structure of the hormone in order to design more potent and selective agonists, Here we report the crystal structure at 2.4 Angstrom resolution of a human mutant OB protein (leptin-E100) that has comparable biological activity to wild type but which crystallizes more readily. The structure reveals a four-helix bundle similar to that of the long-chain helical cytokine family(14).			Zhang, FM (corresponding author), ELI LILLY & CO,LILLY RES LABS,ENDOCRINE RES DIV,RES TECHNOL & PROT,INDIANAPOLIS,IN 46285, USA.							Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BRUNGER AT, 1993, XPLOR VERSION 3 1 SY; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Caro JF, 1996, LANCET, V348, P159, DOI 10.1016/S0140-6736(96)03173-X; Chehab FF, 1997, SCIENCE, V275, P88, DOI 10.1126/science.275.5296.88; Cioffi JA, 1996, NAT MED, V2, P585, DOI 10.1038/nm0596-585; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Ghilardi N, 1996, P NATL ACAD SCI USA, V93, P6231, DOI 10.1073/pnas.93.13.6231; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HEEK MV, 1997, J CLIN INVEST, V99, P385; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HILL CP, 1993, P NATL ACAD SCI USA, V90, P5176; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; MADEJ T, 1995, FEBS LETT, V373, P18; MCDONALD NQ, 1995, EMBO J, V14, P2689, DOI 10.1002/j.1460-2075.1995.tb07269.x; OTWINOWSKI Z, 1993, P CCP4 STUD WEEK, P29; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; ROBINSON RC, 1994, CELL, V77, P1101, DOI 10.1016/0092-8674(94)90449-9; ROZWARSKI DA, 1994, STRUCTURE, V2, P159, DOI 10.1016/S0969-2126(00)00018-6; SPRANG SR, 1993, CURR OPIN STRUC BIOL, V3, P815, DOI 10.1016/0959-440X(93)90144-A; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Vaisse C, 1996, NAT GENET, V14, P95, DOI 10.1038/ng0996-95; Xu GY, 1996, J BIOMOL NMR, V8, P123; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	29	513	567	2	45	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 8	1997	387	6629					206	209		10.1038/387206a0	http://dx.doi.org/10.1038/387206a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WX945	9144295				2022-12-01	WOS:A1997WX94500061
J	Sweet, RL; Landers, DV				Sweet, RL; Landers, DV			Pelvic inflammatory disease in HIV-positive women	LANCET			English	Editorial Material							IMMUNODEFICIENCY-VIRUS INFECTION				Sweet, RL (corresponding author), UNIV PITTSBURGH,SCH MED,DEPT OBSTET GYNECOL & REPROD SCI,PITTSBURGH,PA 15213, USA.							Barbosa C, 1997, OBSTET GYNECOL, V89, P65, DOI 10.1016/S0029-7844(96)00387-0; HOEGSBERG B, 1990, AM J OBSTET GYNECOL, V163, P1135, DOI 10.1016/0002-9378(90)90671-S; KAMENGA MC, 1995, AM J OBSTET GYNECOL, V172, P919, DOI 10.1016/0002-9378(95)90022-5; KORN AP, 1993, OBSTET GYNECOL, V82, P765; KORN AP, 1996, PELVIC INFLAMMATORY; LEGA M, 1991, AIDS S1, V5, pS55	6	2	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 3	1997	349	9061					1265	1266		10.1016/S0140-6736(05)62501-9	http://dx.doi.org/10.1016/S0140-6736(05)62501-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW899	9142056				2022-12-01	WOS:A1997WW89900003
J	Enerback, S; Jacobsson, A; Simpson, EM; Guerra, C; Yamashita, H; Harper, ME; Kozak, LP				Enerback, S; Jacobsson, A; Simpson, EM; Guerra, C; Yamashita, H; Harper, ME; Kozak, LP			Mice lacking mitochondrial uncoupling protein are cold-sensitive but not obese	NATURE			English	Article							BROWN ADIPOSE-TISSUE; INDUCED THERMOGENESIS; TARGETED DISRUPTION; ENERGY-EXPENDITURE; TRANSGENIC MICE; MESSENGER-RNAS; BLOOD-FLOW; FAT; RATS; GENE	The mitochondrial uncoupling protein (UCP) in the mitochondrial inner membrane of mammalian brown adipose tissue generates heat by uncoupling oxidative phosphorylation(1). This process protects against cold(2) and regulates energy balance(3). Manipulation of thermogenesis could be an effective strategy against obesity(4-9). Here we determine the role of UCP in the regulation of body mass by targeted inactivation of the gene encoding it. We find that UCP-deficient mice consume less oxygen after treatment with. a beta 3-adrenergic-receptor agonist and that they are sensitive to cold, indicating that their thermo-regulation is defective. However this deficiency caused neither hyperphagia nos obesity in mice fed on either a standard or a high-ibt diet, We propose that the loss of UCP may be compensated by UCP2, a newly discovered homologue of UCP; this gene is ubiquitously expressed and is induced in the brown fat of UCP-deficient mice.	JACKSON LAB, BAR HARBOR, ME 04609 USA; UNIV OTTAWA, FAC MED, DEPT BIOCHEM, OTTAWA, ON K1H 9M5, CANADA	Jackson Laboratory; University of Ottawa			Guerra, Carmen/K-5852-2014; Simpson, Elizabeth/H-1183-2012	Yamashita, Hitoshi/0000-0002-5785-5208; Guerra, Carmen/0000-0002-3891-046X; Simpson, Elizabeth/0000-0002-0654-4303; Harper, Mary-Ellen/0000-0003-3864-5886				BERNLOHR DA, 1984, P NATL ACAD SCI-BIOL, V81, P5468, DOI 10.1073/pnas.81.17.5468; BILLINGTON CJ, 1994, AM J PHYSIOL, V266, pR1765, DOI 10.1152/ajpregu.1994.266.6.R1765; CANNON B, 1977, FEBS LETT, V76, P284, DOI 10.1016/0014-5793(77)80169-5; CHAMPIGNY O, 1991, P NATL ACAD SCI USA, V88, P10774, DOI 10.1073/pnas.88.23.10774; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cummings DE, 1996, NATURE, V382, P622, DOI 10.1038/382622a0; DERMAN E, 1981, CELL, V23, P731, DOI 10.1016/0092-8674(81)90436-0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOSTER DO, 1979, CAN J PHYSIOL PHARM, V57, P257, DOI 10.1139/y79-039; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; Hamann A, 1996, ENDOCRINOLOGY, V137, P21, DOI 10.1210/en.137.1.21; HIMMSHAGEN J, 1994, AM J PHYSIOL, V266, pR1371, DOI 10.1152/ajpregu.1994.266.4.R1371; HOLLOWAY BR, 1991, BRIT J PHARMACOL, V104, P97, DOI 10.1111/j.1476-5381.1991.tb12391.x; Kopecky J, 1995, J CLIN INVEST, V96, P2914, DOI 10.1172/JCI118363; Koza RA, 1996, ARCH BIOCHEM BIOPHYS, V336, P97, DOI 10.1006/abbi.1996.0536; KOZAK LP, 1983, P NATL ACAD SCI-BIOL, V80, P3020, DOI 10.1073/pnas.80.10.3020; KOZAK LP, 1991, GENE DEV, V5, P2256, DOI 10.1101/gad.5.12a.2256; KOZAK LP, 1988, J BIOL CHEM, V263, P12274; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lean M. E. J., 1986, BROWN ADIPOSE TISSUE, P339; LEIBEL RL, 1995, NEW ENGL J MED, V332, P621, DOI 10.1056/NEJM199503093321001; LOWELL BB, 1993, NATURE, V366, P740, DOI 10.1038/366740a0; MA SWY, 1986, CAN J PHYSIOL PHARM, V64, P1252, DOI 10.1139/y86-211; Melnyk A, 1997, AM J PHYSIOL-REG I, V272, pR1088, DOI 10.1152/ajpregu.1997.272.4.R1088; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; ROTHWELL NJ, 1979, NATURE, V281, P31, DOI 10.1038/281031a0; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SUSULIC VS, 1995, J BIOL CHEM, V270, P29483, DOI 10.1074/jbc.270.49.29483; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; Thomas SA, 1997, NATURE, V387, P94, DOI 10.1038/387094a0; ZEVIANI M, 1988, GENE, V65, P1, DOI 10.1016/0378-1119(88)90411-8	31	1030	1059	0	44	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 1	1997	387	6628					90	94		10.1038/387090a0	http://dx.doi.org/10.1038/387090a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WW758	9139827				2022-12-01	WOS:A1997WW75800053
J	Braun, BR; Johnson, AD				Braun, BR; Johnson, AD			Control of filament formation in Candida albicans by the transcriptional repressor TUP1	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; YEAST; GROWTH; TRANSFORMATION; MORPHOGENESIS; ALPHA-2	The pathogenic yeast Candida albicans regulates its cellular morphology in response to environmental conditions. Ellipsoidal, single cells (blastospores) predominate in rich media, whereas filaments composed of elongated cells that are attached end-to-end form in response to starvation, serum, and other conditions. The TUP1 gene, which encodes a general transcriptional repressor in Saccharomyces cerevisiae, was isolated from C. albicans and disrupted. The resulting tup1 mutant strain of C. albicans grew exclusively as filaments under all conditions tested. TUP1 was epistatic to the transcriptional activator CPH1, previously found to promote filamentous growth. The results suggest a model where TUP1 represses genes responsible for initiating filamentous growth and this repression is lifted under inducing environmental conditions.			Braun, BR (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL & IMMUNOL, 513 PARNASSUS AVE, SAN FRANCISCO, CA 94143 USA.				NIGMS NIH HHS [GM37049] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037049] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		DUDLEY MN, 1990, PHARMACOTHERAPY, V10, P133; Edmondson DG, 1996, GENE DEV, V10, P1247, DOI 10.1101/gad.10.10.1247; FIDEL PL, UNPUB; FONZI WA, 1993, GENETICS, V134, P717; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; GIMENO GJ, 1992, CELL, V68, P14077; GOW NAR, 1984, SABOURAUDIA, V22, P137; HILL J, 1991, NUCLEIC ACIDS RES, V19, P5791, DOI 10.1093/nar/19.20.5791; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; Kohler JR, 1996, P NATL ACAD SCI USA, V93, P13223, DOI 10.1073/pnas.93.23.13223; KOMACHI K, 1994, GENE DEV, V8, P2857, DOI 10.1101/gad.8.23.2857; KRON SJ, 1995, CURR OPIN CELL BIOL, V7, P845, DOI 10.1016/0955-0674(95)80069-7; LEBERER E, 1996, P NATL ACAD SCI US, V93; LEMONTT JF, 1980, GENETICS, V94, P899; LIU HP, 1994, SCIENCE, V266, P1723, DOI 10.1126/science.7992058; McGinnis M.R., 1980, LAB HDB MED MYCOLOGY; MERSONDAVIES LA, 1989, J GEN MICROBIOL, V135, P3143; Odds F, 1988, CANDIDA CANDIDOSIS; Odds F. C., 1994, ASM News (Washington), V60, P313; ODDS FC, 1985, CRC CR REV MICROBIOL, V12, P45, DOI 10.3109/10408418509104425; OHAMA T, 1993, NUCLEIC ACIDS RES, V21, P4039, DOI 10.1093/nar/21.17.4039; ROBERTS RL, 1994, GENE DEV, V8, P2974, DOI 10.1101/gad.8.24.2974; Rubin R. H., 1993, European Journal of Clinical Microbiology and Infectious Diseases, V12, pS42; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; TZAMARIAS D, 1994, NATURE, V369, P758, DOI 10.1038/369758a0; WAHI M, 1995, GENETICS, V140, P79; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WILLIAMS FE, 1990, MOL CELL BIOL, V10, P6500, DOI 10.1128/MCB.10.12.6500; WRIGHT RM, 1993, CURR GENET, V23, P388, DOI 10.1007/BF00312623	30	443	453	2	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 4	1997	277	5322					105	109		10.1126/science.277.5322.105	http://dx.doi.org/10.1126/science.277.5322.105			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XJ418	9204892				2022-12-01	WOS:A1997XJ41800050
J	Xia, D; Yu, CA; Kim, H; Xian, JZ; Kachurin, AM; Zhang, L; Yu, L; Deisenhofer, J				Xia, D; Yu, CA; Kim, H; Xian, JZ; Kachurin, AM; Zhang, L; Yu, L; Deisenhofer, J			Crystal structure of the cytochrome bc(1) complex from bovine heart mitochondria	SCIENCE			English	Article							AMINO-ACID SEQUENCE; C REDUCTASE COMPLEX; UBIQUINONE-BINDING-PROTEIN; ELECTRON-TRANSPORT CHAIN; RAT-LIVER MITOCHONDRIA; PROTONMOTIVE Q-CYCLE; IRON SULFUR PROTEIN; BEEF-HEART; BC1 COMPLEX; RHODOBACTER-SPHAEROIDES	On the basis of x-ray diffraction data to a resolution of 2.9 angstroms, atomic models of most protein components of the bovine cytochrome bc(1) complex were built, including core 1, core 2, cytochrome b, subunit 6 subunit 7, a carboxyl-terminal fragment of cytochrome c(1), and an amino-terminal fragment of the iron-sulfur protein. The positions of the four iron centers within the be, complex and the binding sites of the two specific respiratory inhibitors antimycin A and myxothiazol were identified. The membrane-spanning region of each bc(1) complex monomer consists of 13 transmembrane helices, eight of which belong to cytochrome b. Closely interacting monomers are arranged as symmetric dimers and form cavities through which the inhibitor binding pockets can be accessed. The proteins core 1 and core 2 are structurally similar to each other and consist of two domains of roughly equal size and identical folding topology.	UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA; OKLAHOMA STATE UNIV, DEPT BIOCHEM & MOL BIOL, STILLWATER, OK 74078 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Oklahoma State University System; Oklahoma State University - Stillwater					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030721, R37GM030721] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 30721] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akiba T, 1996, NAT STRUCT BIOL, V3, P553, DOI 10.1038/nsb0696-553; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; BERRY EA, 1992, J MOL BIOL, V224, P1161, DOI 10.1016/0022-2836(92)90476-Z; BERRY EA, 1995, ACTA CRYSTALLOGR D, V51, P235, DOI 10.1107/S0907444994010486; BORCHART U, 1986, FEBS LETT, V200, P81, DOI 10.1016/0014-5793(86)80515-4; BORCHART U, 1985, FEBS LETT, V191, P125, DOI 10.1016/0014-5793(85)81007-3; BRAND MD, 1976, J BIOL CHEM, V251, P5670; BRANDT U, 1994, CRIT REV BIOCHEM MOL, V29, P165, DOI 10.3109/10409239409086800; Brasseur G, 1996, BBA-BIOENERGETICS, V1275, P61, DOI 10.1016/0005-2728(96)00051-5; BRAUN HP, 1995, TRENDS BIOCHEM SCI, V20, P171, DOI 10.1016/S0968-0004(00)88999-9; BRAUN HP, 1992, EMBO J, V11, P3219, DOI 10.1002/j.1460-2075.1992.tb05399.x; COCCO T, 1991, EUR J BIOCHEM, V195, P731, DOI 10.1111/j.1432-1033.1991.tb15760.x; Cowtan KD, 1996, ACTA CRYSTALLOGR D, V52, P43, DOI 10.1107/S090744499500761X; *DAR LAB, 1979, CCP4 SERC UK COLL CO; DEGLIESPOSTI M, 1993, BIOCHIM BIOPHYS ACTA, V1143, P243, DOI 10.1016/0005-2728(93)90197-N; DENG K, UNPUB; Ding H, 1995, BIOCHEMISTRY-US, V34, P15979, DOI 10.1021/bi00049a012; DIRAGO JP, 1988, J BIOL CHEM, V263, P12564; ERECINSKA M, 1972, P NATL ACAD SCI USA, V69, P50, DOI 10.1073/pnas.69.1.50; Ernster, 1987, CYTOCHROME SYSTEMS M, P617; GENCIC S, 1991, EUR J BIOCHEM, V199, P123, DOI 10.1111/j.1432-1033.1991.tb16099.x; GENNIS RB, 1993, J BIOENERG BIOMEMBR, V25, P195, DOI 10.1007/BF00762582; Glaser E, 1996, BBA-BIOENERGETICS, V1275, P33, DOI 10.1016/0005-2728(96)00046-1; GLASER E, 1994, FEBS LETT, V346, P83, DOI 10.1016/0014-5793(94)00312-2; GLASER EG, 1984, BIOCHIM BIOPHYS ACTA, V766, P322, DOI 10.1016/0005-2728(84)90248-2; GONZALEZHALPHEN D, 1988, BIOCHEMISTRY-US, V27, P7021, DOI 10.1021/bi00418a053; GREEN DW, 1954, PROC R SOC LON SER-A, V225, P287, DOI 10.1098/rspa.1954.0203; HATEFI Y, 1962, J BIOL CHEM, V237, P1681; HENDRICKSON WA, 1988, PROTEINS, V4, P77, DOI 10.1002/prot.340040202; Holm L, 1996, SCIENCE, V273, P595, DOI 10.1126/science.273.5275.595; Iwata S, 1996, STRUCTURE, V4, P567, DOI 10.1016/S0969-2126(96)00062-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAWAMOTO M, 1994, J MOL BIOL, V244, P238, DOI 10.1006/jmbi.1994.1722; KUBOTA T, 1991, J MOL BIOL, V221, P379, DOI 10.1016/0022-2836(91)80059-4; LEE JW, 1995, J MOL BIOL, V252, P15, DOI 10.1006/jmbi.1994.0470; LEONARD K, 1981, J MOL BIOL, V149, P259, DOI 10.1016/0022-2836(81)90301-6; MIKI T, 1994, J BIOL CHEM, V269, P1827; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; MITCHELL R, 1986, BIOCHIM BIOPHYS ACTA, V849, P229, DOI 10.1016/0005-2728(86)90029-0; MUSATOV A, 1994, BIOCHEMISTRY-US, V33, P13005, DOI 10.1021/bi00248a009; NALECZ MJ, 1985, ARCH BIOCHEM BIOPHYS, V236, P619; OHNISHI T, 1989, J BIOL CHEM, V264, P735; OHNISHI T, 1980, J BIOL CHEM, V255, P3278; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PACES V, 1993, P NATL ACAD SCI USA, V90, P5355, DOI 10.1073/pnas.90.11.5355; RAWLINGS ND, 1991, BIOCHEM J, V275, P389, DOI 10.1042/bj2750389; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; ROBERTSON DE, 1988, BIOCHIM BIOPHYS ACTA, V935, P273, DOI 10.1016/0005-2728(88)90223-X; SALERNO JC, 1990, BIOCHEMISTRY-US, V29, P6987, DOI 10.1021/bi00482a006; SCHAGGER H, 1987, FEBS LETT, V219, P161, DOI 10.1016/0014-5793(87)81210-3; SCHAGGER H, 1985, FEBS LETT, V190, P89, DOI 10.1016/0014-5793(85)80434-8; SCHAGGER H, 1986, METHOD ENZYMOL, V126, P224; Tolkatchev D, 1996, J BIOL CHEM, V271, P12356, DOI 10.1074/jbc.271.21.12356; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; TRUMPOWER BL, 1994, ANNU REV BIOCHEM, V63, P675, DOI 10.1146/annurev.bi.63.070194.003331; TSAI AL, 1983, J BIOL CHEM, V258, P2122; USUI S, 1990, BIOCHEM BIOPH RES CO, V167, P575, DOI 10.1016/0006-291X(90)92063-6; VONJAGOW G, 1986, J BIOENERG BIOMEMBR, V18, P157, DOI 10.1007/BF00743462; WAKABAYASHI S, 1985, J BIOL CHEM, V260, P337; WAKABAYASHI S, 1982, J BIOCHEM, V91, P2077, DOI 10.1093/oxfordjournals.jbchem.a133901; WEST IC, 1986, BIOCHIM BIOPHYS ACTA, V849, P236, DOI 10.1016/0005-2728(86)90030-7; WIDGER WR, 1984, P NATL ACAD SCI-BIOL, V81, P674, DOI 10.1073/pnas.81.3.674; WIKSTROM MK, 1972, BIOCHIM BIOPHYS ACTA, V283, P403, DOI 10.1016/0005-2728(72)90258-7; YU CA, 1994, J MOL BIOL, V243, P802, DOI 10.1016/0022-2836(94)90051-5; Yu CA, 1996, BBA-BIOENERGETICS, V1275, P47, DOI 10.1016/0005-2728(96)00049-7; YU CA, 1978, BIOCHEM BIOPH RES CO, V82, P1070, DOI 10.1016/0006-291X(78)90296-6; YU L, 1995, J BIOL CHEM, V270, P25634, DOI 10.1074/jbc.270.43.25634; YUE WH, 1991, BIOCHEMISTRY-US, V30, P2303, DOI 10.1021/bi00223a002; YUN CH, 1991, BIOCHEMISTRY-US, V30, P6747, DOI 10.1021/bi00241a017	69	868	901	1	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 4	1997	277	5322					60	66		10.1126/science.277.5322.60	http://dx.doi.org/10.1126/science.277.5322.60			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XJ418	9204897				2022-12-01	WOS:A1997XJ41800037
J	Linet, MS; Hatch, EE; Kleinerman, RA; Robison, LL; Kaune, WT; Friedman, DR; Severson, RK; Haines, CM; Hartsock, CT; Niwa, S; Wacholder, S; Tarone, RE				Linet, MS; Hatch, EE; Kleinerman, RA; Robison, LL; Kaune, WT; Friedman, DR; Severson, RK; Haines, CM; Hartsock, CT; Niwa, S; Wacholder, S; Tarone, RE			Residential exposure to magnetic fields and acute lymphoblastic leukemia in children	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ELECTRICAL WIRING CONFIGURATIONS; CHILDHOOD-CANCER; SELECTION BIAS; POWER-LINES; WIRE CODES; RISK	Background Previous studies found associations between childhood leukemia and surrogate indicators of exposure to magnetic fields (the power-line classification scheme known as ''wire coding''), but not between childhood leukemia and measurements of 60-Hz residential magnetic fields. Methods We enrolled 638 children with acute lymphoblastic leukemia (ALL) who were under 15 years of age and were registered with the Children's Cancer Group and 620 controls in a study of residential exposure to magnetic fields generated by nearby power lines. In the subjects' current and former homes, data collectors blinded to the subjects' health status measured magnetic fields for 24 hours in each child's bedroom and for 30 seconds in three or four other rooms and outside the front door. A computer algorithm assigned wire-code categories, based on the distance and configuration of nearby power lines, to the subjects' main residences (for 416 case patients and 416 controls) and to those where the family had lived during the mother's pregnancy with the subject (for 230 case patients and 230 controls). Results The risk of childhood ALL was not linked to summary time-weighted average residential magnetic-field levels, categorized according to a priori criteria. The odds ratio for ALL was 1.24 (95 percent confidence interval, 0.86 to 1.79) at exposures of 0.200 mu T or greater as compared with less than 0.065 mu T. The risk of ALL was not increased among children whose main residences were in the highest wire-code category (odds ratio as compared with the lowest category, 0.88; 95 percent confidence interval, 0.48 to 1.63). Furthermore, the risk was not significantly associated with either residential magnetic-field levels or the wire codes of the homes mothers resided in when pregnant with the subjects. Conclusions Our results provide little evidence that living in homes characterized by high measured time-weighted average magnetic-field levels or by the highest wire-code category increases the risk of ALL in children. (C) 1997, Massachusetts Medical Society.	CHILDRENS CANC GRP,ARCADIA,CA; UNIV MINNESOTA,SCH MED,DIV PEDIAT EPIDEMIOL & CLIN RES,MINNEAPOLIS,MN 55455; EM FACTORS,RICHLAND,WA; WESTAT CORP,ROCKVILLE,MD; INFORMAT MANAGEMENT SERV INC,ROCKVILLE,MD	University of Minnesota System; University of Minnesota Twin Cities; Westat; Information Management Services, Inc.	Linet, MS (corresponding author), NCI,DIV CANC EPIDEMIOL & GENET,EXECUT PLAZA N,SUITE 408,BETHESDA,MD 20892, USA.		Robison, Leslie/N-8122-2018	Hatch, Elizabeth/0000-0001-7901-3928; Kleinerman, Ruth/0000-0001-7415-2478	NCI NIH HHS [R01 CA48051] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA048051] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARNES F, 1989, BIOELECTROMAGNETICS, V10, P13, DOI 10.1002/bem.2250100103; Breslow NE., 1980, IARC SCI PUBL, V32, P122; *COMM POSS EFF EL, 1996, POSS HLTH EFF EXP RE, P113; DOVAN T, 1993, BIOELECTROMAGNETICS, V14, P145, DOI 10.1002/bem.2250140207; FEYCHTING M, 1993, AM J EPIDEMIOL, V138, P467, DOI 10.1093/oxfordjournals.aje.a116881; Friedman DR, 1996, EPIDEMIOLOGY, V7, P151, DOI 10.1097/00001648-199603000-00008; FULTON JP, 1980, AM J EPIDEMIOL, V111, P292, DOI 10.1093/oxfordjournals.aje.a112899; GURNEY JG, 1995, EPIDEMIOLOGY, V6, P31, DOI 10.1097/00001648-199501000-00007; *HIGH VOLT TRANSM, 1993, SURV RES MAGN FIELD, V1; JONES TL, 1993, J CLIN EPIDEMIOL, V46, P545, DOI 10.1016/0895-4356(93)90127-M; KAUNE WT, 1994, BIOELECTROMAGNETICS, V15, P33, DOI 10.1002/bem.2250150108; KAUNE WT, 1987, BIOELECTROMAGNETICS, V8, P315, DOI 10.1002/bem.2250080402; KAUNE WT, 1994, BIOELECTROMAGNETICS, V15, P275, DOI 10.1002/bem.2250150402; KLEINERMAN RA, IN PRESS EPIDEMIOLOG; LONDON S, 1993, AM J EPIDEMIOL, V137, P381; LONDON SJ, 1991, AM J EPIDEMIOL, V134, P923, DOI 10.1093/oxfordjournals.aje.a116176; *NAT RAD PROT BOAR, 1992, DOC NRPB, V3, P54; *OAK RIDG ASS U PA, 1992, PUBL OAK RID ASS U P, pR1; OLSEN JH, 1993, BRIT MED J, V307, P891, DOI 10.1136/bmj.307.6909.891; POOLE C, 1991, CANCER CAUSE CONTROL, V2, P267, DOI 10.1007/BF00052144; Robison L L, 1987, Prog Clin Biol Res, V246, P19; ROBISON LL, 1984, AM J EPIDEMIOL, V120, P164, DOI 10.1093/oxfordjournals.aje.a113866; SAVITZ DA, 1988, AM J EPIDEMIOL, V128, P21, DOI 10.1093/oxfordjournals.aje.a114943; SAVITZ DA, 1989, EPIDEMIOL REV, V11, P59, DOI 10.1093/oxfordjournals.epirev.a036045; Tenforde T. S., 1996, P185; TOMENIUS L, 1986, BIOELECTROMAGNETICS, V7, P191, DOI 10.1002/bem.2250070209; Tynes T, 1997, AM J EPIDEMIOL, V145, P219, DOI 10.1093/oxfordjournals.aje.a009094; VERKASALO PK, 1993, BRIT MED J, V307, P895, DOI 10.1136/bmj.307.6909.895; WACHOLDER S, 1992, AM J EPIDEMIOL, V135, P1029, DOI 10.1093/oxfordjournals.aje.a116397; WERTHEIMER N, 1979, AM J EPIDEMIOL, V109, P273, DOI 10.1093/oxfordjournals.aje.a112681; WERTHEIMER N, 1982, INT J EPIDEMIOL, V11, P345, DOI 10.1093/ije/11.4.345	31	309	319	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 3	1997	337	1					1	7		10.1056/NEJM199707033370101	http://dx.doi.org/10.1056/NEJM199707033370101			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XH186	9203424				2022-12-01	WOS:A1997XH18600001
J	Ligterink, W; Kroj, T; zurNieden, U; Hirt, H; Scheel, D				Ligterink, W; Kroj, T; zurNieden, U; Hirt, H; Scheel, D			Receptor-mediated activation of a MAP kinase in pathogen defense of plants	SCIENCE			English	Article							FUNGAL ELICITOR; EXTRACELLULAR GLYCOPROTEIN; PHYTOPHTHORA-MEGASPERMA; NUCLEAR-LOCALIZATION; PARSLEY CELLS; PHOSPHORYLATION; PROTOPLASTS; TRANSIENT; PATHWAYS	Parsley cells recognize the fungal plant pathogen Phytophthora sojae through a plasma membrane receptor. A pathogen-derived oligopeptide elicitor binds to this receptor and thereby stimulates a multicomponent defense response through sequential activation of ion channels and an oxidative burst. An elicitor-responsive mitogen-activated protein (MAP) kinase was identified that acts downstream of the ion channels but independently or upstream of the oxidative burst. Upon receptor-mediated activation, the MAP kinase is translocated to the nucleus where it might interact with transcription factors that induce expression of defense genes.	UNIV VIENNA,INST MICROBIOL & GENET,VIENNA BIOCTR,A-1030 VIENNA,AUSTRIA; INST PLANT BIOCHEM,D-06120 HALLE,GERMANY	University of Vienna; Vienna Biocenter (VBC); Leibniz Institut fur Pflanzenbiochemie			Ligterink, Wilco/C-8103-2009; Hirt, Heribert/A-2061-2013	Ligterink, Wilco/0000-0002-0228-169X; 				Bogre L, 1996, NATURE, V383, P489, DOI 10.1038/383489a0; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; DANGL JL, 1987, EMBO J, V6, P2551, DOI 10.1002/j.1460-2075.1987.tb02543.x; DIETRICH A, 1990, J BIOL CHEM, V265, P6360; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; Hirt H, 1997, TRENDS PLANT SCI, V2, P11, DOI 10.1016/S1360-1385(96)10048-0; Jabs T, 1997, P NATL ACAD SCI USA, V94, P4800, DOI 10.1073/pnas.94.9.4800; Jonak C, 1996, P NATL ACAD SCI USA, V93, P11274, DOI 10.1073/pnas.93.20.11274; Kombrink E, 1995, ADV BOT RES, V21, P1; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; LIGTERINK W, UNPUB; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; Mehdy MC, 1996, PHYSIOL PLANTARUM, V98, P365, DOI 10.1034/j.1399-3054.1996.980219.x; Mizoguchi T, 1997, TRENDS BIOTECHNOL, V15, P15, DOI 10.1016/S0167-7799(96)10074-3; Mizoguchi T, 1996, P NATL ACAD SCI USA, V93, P765, DOI 10.1073/pnas.93.2.765; MIZOGUCHI T, 1994, PLANT J, V5, P111, DOI 10.1046/j.1365-313X.1994.5010111.x; NURNBERGER T, 1994, CELL, V78, P449, DOI 10.1016/0092-8674(94)90423-5; PARKER JE, 1991, MOL PLANT MICROBE IN, V4, P19, DOI 10.1094/MPMI-4-019; Rushton PJ, 1996, EMBO J, V15, P5690, DOI 10.1002/j.1460-2075.1996.tb00953.x; SACKS W, 1995, MOL GEN GENET, V246, P45, DOI 10.1007/BF00290132; Sambrook J, 1989, MOL CLONING LAB MANU, V1-3; SANGHERA JS, 1992, MOL BIOL CELL, V3, P775, DOI 10.1091/mbc.3.7.775; SCHEEL D, 1986, RECOGNITION MICROBE, P325; SCHMELZER E, 1989, PLANT CELL, V1, P993, DOI 10.1105/tpc.1.10.993; SEO S, 1995, SCIENCE, V270, P1988, DOI 10.1126/science.270.5244.1988; SOMSSICH IE, 1989, PLANT MOL BIOL, V12, P227, DOI 10.1007/BF00020507; SUZUKI K, 1995, PLANT CELL, V7, P639, DOI 10.1105/tpc.7.5.639; VANLAMMEREN AAM, 1985, PLANTA, V165, P1, DOI 10.1007/BF00392205; ZIMMERMANN S, 1997, P NATL ACAD SCI USA, V94, P275	30	299	326	1	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 27	1997	276	5321					2054	2057		10.1126/science.276.5321.2054	http://dx.doi.org/10.1126/science.276.5321.2054			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XG748	9197271				2022-12-01	WOS:A1997XG74800069
J	Yang, XL; KhosraviFar, R; Chang, HY; Baltimore, D				Yang, XL; KhosraviFar, R; Chang, HY; Baltimore, D			Daxx, a novel Fas-binding protein that activates JNK and apoptosis	CELL			English	Article							C-JUN; TNF RECEPTOR; DEATH DOMAIN; CELL-DEATH; ANTIGEN; INTERACTS; KINASE	The Fas cell surface receptor induces apoptosis upon receptor oligomerization. We have identified a novel signaling protein, termed Daxx, that binds specifically to the Fas death domain. Overexpression of Daxx enhances Fas-mediated apoptosis and activates the Jun N-terminal kinase (JMK) pathway. A C-terminal portion of Daxx interacts with the Fas death domain, while a different region activates both JNK and apoptosis. The Fas-binding domain of Daxx is a dominant-negative inhibitor of both Fas-induced apoptosis and JMK activation, while the FADD death domain partially inhibits death but not JNK activation. The Daxx apoptotic pathway is sensitive to both Bcl-2 and dominant-negative JNK pathway components and acts cooperatively with the FADD pathway. Thus, Daxx and FADD define two distinct apoptotic pathways downstream of Fas.			Yang, XL (corresponding author), MIT,DEPT BIOL,77 MASSACHUSETTS AVE,CAMBRIDGE,MA 02139, USA.		Khosravi-Far, Roya/C-3789-2008		NATIONAL CANCER INSTITUTE [R01CA051462] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA051462-17, CA51462] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abbas AK, 1996, CELL, V84, P655, DOI 10.1016/S0092-8674(00)81042-9; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BROWN PH, 1994, ONCOGENE, V9, P791; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; Goillot E, 1997, P NATL ACAD SCI USA, V94, P3302, DOI 10.1073/pnas.94.7.3302; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HSU H, 1996, CELL, V84, P290; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Huang BH, 1996, NATURE, V384, P638, DOI 10.1038/384638a0; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1993, J IMMUNOL, V151, P621; JOHNSON NL, 1996, J BIOL CHEM, V271, P3299; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Lacronique V, 1996, NAT MED, V2, P80, DOI 10.1038/nm0196-80; Latinis KM, 1996, BLOOD, V87, P871, DOI 10.1182/blood.V87.3.871.bloodjournal873871; Lenczowski JM, 1997, MOL CELL BIOL, V17, P170, DOI 10.1128/MCB.17.1.170; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; Rathmell JC, 1996, CELL, V87, P319, DOI 10.1016/S0092-8674(00)81349-5; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YANG XL, 1994, EMBO J, V13, P5878, DOI 10.1002/j.1460-2075.1994.tb06933.x	44	803	856	3	22	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 27	1997	89	7					1067	1076		10.1016/S0092-8674(00)80294-9	http://dx.doi.org/10.1016/S0092-8674(00)80294-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XG830	9215629	Green Accepted, Bronze			2022-12-01	WOS:A1997XG83000011
J	Beamer, LJ; Carroll, SF; Eisenberg, D				Beamer, LJ; Carroll, SF; Eisenberg, D			Crystal structure of human BPI and two bound phospholipids at 2.4 angstrom resolution	SCIENCE			English	Article							ESTER TRANSFER PROTEIN; PERMEABILITY-INCREASING PROTEIN; LIPOPOLYSACCHARIDE-BINDING-PROTEIN; MESSENGER-RNA; TISSUE DISTRIBUTION; MOLECULAR-CLONING; AMINO-ACIDS; FRAGMENT; SEQUENCE; CDNA	Bactericidal/permeability-increasing protein (BPI), a potent antimicrobial protein of 456 residues, binds to and neutralizes lipopolysaccharides from the outer membrane of Gram-negative bacteria. At a resolution of 2.4 angstroms, the crystal structure of human BPI shows a boomerang-shaped molecule formed by two similar domains. Two apolar pockets on the concave surface of the boomerang each bind a molecule of phosphatidylcholine, primarily by interacting with their acyl chains; this suggests that the pockets may also bind the acyl chains of lipopolysaccharide. As a model for the related plasma lipid transfer proteins, BPI illuminates a mechanism of lipid transfer for this protein family.	UNIV CALIF LOS ANGELES,INST MOL BIOL,LAB STRUCT BIOL & MOL MED,LOS ANGELES,CA 90095; XOMA CORP,BERKELEY,CA 94710	University of California System; University of California Los Angeles					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM031299] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31299] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrahamson SL, 1997, J BIOL CHEM, V272, P2149; AGELLON LB, 1990, BIOCHEMISTRY-US, V29, P1372, DOI 10.1021/bi00458a004; ALBERS JJ, 1995, BBA-LIPID LIPID MET, V1258, P27, DOI 10.1016/0005-2760(95)00091-P; Alexandrov NN, 1996, PROTEINS, V25, P354, DOI 10.1002/(SICI)1097-0134(199607)25:3<354::AID-PROT7>3.3.CO;2-W; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BANASZAK L, 1994, ADV PROTEIN CHEM, V45, P89; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; Capodici C, 1996, J IMMUNOL, V156, P4789; COHEN GH, 1986, J MOL BIOL, V190, P593; COLOVOS C, 1993, PROTEIN SCI, V2, P1511, DOI 10.1002/pro.5560020916; CONNOLLY ML, 1985, J AM CHEM SOC, V107, P1118, DOI 10.1021/ja00291a006; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; DAY JR, 1994, J BIOL CHEM, V269, P9388; DRAYNA D, 1987, NATURE, V327, P632, DOI 10.1038/327632a0; ELSBACH P, 1995, INFECT AGENT DIS, V4, P102; Fischer D, 1995, PROTEIN ENG, V8, P981, DOI 10.1093/protein/8.10.981; GAZZANOSANTORO H, 1995, INFECT IMMUN, V63, P2201, DOI 10.1128/IAI.63.6.2201-2205.1995; GRAY PW, 1989, J BIOL CHEM, V264, P9505; HEUMANN D, 1994, SCI AM SCI MED, V1, P28; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HOESS A, 1993, EMBO J, V12, P3351, DOI 10.1002/j.1460-2075.1993.tb06008.x; HOLM L, 1996, NUCLEIC ACIDS RES, V25, P341; Horwitz AH, 1996, PROTEIN EXPRES PURIF, V8, P28, DOI 10.1006/prep.1996.0071; JIANG XC, 1991, J BIOL CHEM, V266, P4631; JIANG XC, 1995, BIOCHEMISTRY-US, V34, P7258, DOI 10.1021/bi00021a042; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leesong M, 1996, STRUCTURE, V4, P253, DOI 10.1016/S0969-2126(96)00030-5; LEONG SR, 1990, NUCLEIC ACIDS RES, V18, P3052, DOI 10.1093/nar/18.10.3052; LITTLE RG, 1994, J BIOL CHEM, V269, P1865; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NAGASHIMA M, 1988, J LIPID RES, V29, P1643; OHLENDORF DH, 1983, J MOL BIOL, V169, P757, DOI 10.1016/S0022-2836(83)80169-7; OOI CE, 1987, J BIOL CHEM, V262, P14891; OOI CE, 1991, J EXP MED, V174, P649, DOI 10.1084/jem.174.3.649; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; PAPE ME, 1991, ARTERIOSCLER THROMB, V11, P1759, DOI 10.1161/01.ATV.11.6.1759; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; REEKE GN, 1975, J BIOL CHEM, V250, P1525; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; SU GL, 1994, J IMMUNOL, V153, P743; TALL A, 1995, ANNU REV BIOCHEM, V64, P235; TAYLOR AH, 1995, J BIOL CHEM, V270, P17934, DOI 10.1074/jbc.270.30.17934; VONDERMOHLEN MAM, 1995, J INFECT DIS, V172, P144, DOI 10.1093/infdis/172.1.144; WANG S, 1992, J BIOL CHEM, V267, P17487	49	307	340	3	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 20	1997	276	5320					1861	1864		10.1126/science.276.5320.1861	http://dx.doi.org/10.1126/science.276.5320.1861			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XF103	9188532				2022-12-01	WOS:A1997XF10300049
J	Umemori, H; Inoue, T; Kume, S; Sekiyama, N; Nagao, M; Itoh, H; Nakanishi, S; Mikoshiba, K; Yamamoto, T				Umemori, H; Inoue, T; Kume, S; Sekiyama, N; Nagao, M; Itoh, H; Nakanishi, S; Mikoshiba, K; Yamamoto, T			Activation of the G protein Gq/11 through tyrosine phosphorylation of the alpha subunit	SCIENCE			English	Article							METABOTROPIC GLUTAMATE-RECEPTOR; SIGNAL-TRANSDUCTION; KINASES; CELLS; INHIBITORS; EXPRESSION; MGLUR1; SYSTEM; FYN	Various receptors coupled to the heterotrimeric guanine nucleotide-binding protein Gq/11 stimulate formation of inositol-1,4,5-trisphosphate (IP3). Activation of these receptors also induces protein tyrosine phosphorylation. Formation of IP3 in response to stimulated receptors that couple to Gq/11 was blocked by protein tyrosine kinase inhibitors. These inhibitors appeared to act before activation of Gq/11. Moreover, stimulation of receptors coupled to Gq/11 induced phosphorylation on a tyrosine residue (Tyr(356)) Of the G alpha(q/11) subunit, and this tyrosine phosphorylation event was essential for Gq/11 activation. Tyrosine phosphorylation of G alpha(q/11) induced changes in its interaction with receptors. Therefore, tyrosine phosphorylation of G alpha(q/11) appears to regulate the activation of Gq/11 protein.	UNIV TOKYO,INST MED SCI,DEPT MOL NEUROBIOL,TOKYO 108,JAPAN; KYOTO UNIV,FAC MED,DEPT SCI BIOL,KYOTO 606,JAPAN; TOKYO INST TECHNOL,FAC BIOSCI & BIOTECHNOL,DEPT SCI BIOL,YOKOHAMA,KANAGAWA 226,JAPAN	University of Tokyo; Kyoto University; Tokyo Institute of Technology	Umemori, H (corresponding author), UNIV TOKYO,INST MED SCI,DEPT ONCOL,TOKYO 108,JAPAN.		Kume, Shoen/M-4356-2016; Mikoshiba, Katsuhiko/N-7943-2015; Inoue, Takafumi/AAM-9533-2020	Kume, Shoen/0000-0002-4292-205X; Inoue, Takafumi/0000-0002-2728-0060; Umemori, Hisashi/0000-0001-7198-2062				ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ARAMORI I, 1992, NEURON, V8, P757, DOI 10.1016/0896-6273(92)90096-V; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BLUML K, 1994, J BIOL CHEM, V269, P18870; BOURNE HR, 1995, NATURE, V376, P727, DOI 10.1038/376727a0; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; FUKUDA K, 1988, NATURE, V335, P355, DOI 10.1038/335355a0; FUSAKI N, 1994, INT IMMUNOL, V6, P1245, DOI 10.1093/intimm/6.8.1245; GAZIT A, 1991, J MED CHEM, V34, P1896, DOI 10.1021/jm00110a022; Hamm HE, 1996, CURR OPIN CELL BIOL, V8, P189, DOI 10.1016/S0955-0674(96)80065-2; HAUSDORFF WP, 1992, P NATL ACAD SCI USA, V89, P5720, DOI 10.1073/pnas.89.13.5720; ILLIC D, 1995, NATURE, V377, P539; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; LEEBLUNDBERG LMF, 1991, J BIOL CHEM, V266, P7746; Liu WW, 1996, P NATL ACAD SCI USA, V93, P8258, DOI 10.1073/pnas.93.16.8258; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MELDRUM E, 1991, BIOCHIM BIOPHYS ACTA, V1092, P49, DOI 10.1016/0167-4889(91)90177-Y; MOYERS JS, 1995, BIOCHEM J, V305, P411, DOI 10.1042/bj3050411; NAKAMURA F, 1995, J BIOL CHEM, V270, P6246, DOI 10.1074/jbc.270.11.6246; NAKAMURA K, 1994, J PHYSIOL-LONDON, V474, P35, DOI 10.1113/jphysiol.1994.sp020000; NAKANISHI S, 1994, NEURON, V13, P1031, DOI 10.1016/0896-6273(94)90043-4; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; OKUMA Y, 1992, J BIOL CHEM, V267, P14826; SHIGEMOTO R, 1994, NEURON, V12, P1245, DOI 10.1016/0896-6273(94)90441-3; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; UMEMORI H, 1992, MOL BRAIN RES, V16, P303, DOI 10.1016/0169-328X(92)90239-8; UMEMORI H, 1994, NATURE, V367, P572, DOI 10.1038/367572a0; UMEMORI H, UNPUB; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P	34	117	117	1	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 20	1997	276	5320					1878	1881		10.1126/science.276.5320.1878	http://dx.doi.org/10.1126/science.276.5320.1878			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XF103	9188537				2022-12-01	WOS:A1997XF10300054
J	Wilson, DS				Wilson, DS			Evolution - Human groups as units of selection	SCIENCE			English	Editorial Material											Wilson, DS (corresponding author), SUNY BINGHAMTON,DEPT BIOL SCI,BINGHAMTON,NY 13902, USA.							Boehm C, 1997, AM NAT, V150, pS100, DOI 10.1086/286052; WILSON DS, 1997, AM NAT S, V150	2	26	26	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 20	1997	276	5320					1816	1817		10.1126/science.276.5320.1816	http://dx.doi.org/10.1126/science.276.5320.1816			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XF103	9206841				2022-12-01	WOS:A1997XF10300033
J	delaFuente, JM; RamirezRodriguez, V; CabreraPonce, JL; HerreraEstrella, L				delaFuente, JM; RamirezRodriguez, V; CabreraPonce, JL; HerreraEstrella, L			Aluminum tolerance in transgenic plants by alteration of citrate synthesis	SCIENCE			English	Article							TRITICUM-AESTIVUM L; SORGHUM GENOTYPES; ROOT APICES; TOXICITY; ACID; GROWTH	Aluminum when in soluble form, as found in acidic soils that comprise about 40 percent of the world's arable land, is toxic to many crops. Organic acid excretion has been correlated with aluminum tolerance in higher plants. Overproduction of citrate was shown to result in aluminum tolerance in transgenic tobacco (Nicotiana tabacum) and papaya (Carica papaya) plants.	CINVESTAV IPN,DEPT INGN GENET,UNIDAD IRAPUATO,IRAPUATO 36500,GUANAJUATO,MEXICO	CINVESTAV - Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional			Herrera-Estrella, Luis/ABC-7431-2020; Estrella, Luis R Herrera/G-7351-2011; PONCE, JOSE LUIS CABRERA/H-3051-2012; Herrera-Estrella, Luis/AAL-2472-2020	Estrella, Luis R Herrera/0000-0001-7936-3856; Herrera-Estrella, Luis/0000-0001-7936-3856; CABRERA PONCE, JOSE LUIS/0000-0002-6142-1963				BALIGAR VC, 1989, PLANT SOIL, V116, P257, DOI 10.1007/BF02214555; BALIGAR VC, 1993, PLANT SOIL, V150, P271, DOI 10.1007/BF00013024; BARTLETT RJ, 1972, PLANT SOIL, V37, P419, DOI 10.1007/BF02139985; CABRERAPONCE JL, 1995, PLANT CELL REP, V15, P1, DOI 10.1007/BF01690242; DELAFUENTE JM, UNPUB; DELHAIZE E, 1993, PLANT PHYSIOL, V103, P695, DOI 10.1104/pp.103.3.695; DELHAIZE E, 1995, PLANT PHYSIOL, V107, P315, DOI 10.1104/pp.107.2.315; DELHAIZE E, 1993, PLANT PHYSIOL, V103, P685, DOI 10.1104/pp.103.3.685; DONALD LJ, 1989, J BACTERIOL, V171, P5542, DOI 10.1128/jb.171.10.5542-5550.1989; FOY CD, 1978, ANNU REV PLANT PHYS, V29, P511, DOI 10.1146/annurev.pp.29.060178.002455; Herrera-Estrella L., 1988, PLANT MOL BIOL PRACT, P131; HUE NV, 1986, SOIL SCI SOC AM J, V50, P28, DOI 10.2136/sssaj1986.03615995005000010006x; KOCHIAN VL, 1995, PLANT MOL BIOL, V46, P237; MIYASAKA SC, 1991, PLANT PHYSIOL, V96, P737, DOI 10.1104/pp.96.3.737; OWNBY J D, 1989, Journal of Plant Physiology, V135, P588; PARROT WA, 1990, CROP SCI, V30, P387, DOI 10.2135/cropsci1990.0011183X003000020030x; PELLET DM, 1995, PLANTA, V196, P788, DOI 10.1007/BF01106775; PICHA DH, 1985, J AGR FOOD CHEM, V33, P743, DOI 10.1021/jf00064a045; POLLE E, 1978, CROP SCI, V30, P389; RYAN PR, 1993, J EXP BOT, V44, P437, DOI 10.1093/jxb/44.2.437; RYAN PR, 1995, PLANTA, V196, P103, DOI 10.1007/BF00193223; Srere P.A., 1969, METHODS ENZYM, V1, P3, DOI [10.1016/0076-6879(69)13005-0, DOI 10.1016/0076-6879(69)13005-0]; TAIZ L, 1995, PLANT PHYSIOL, V108, P29	23	344	371	0	59	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 6	1997	276	5318					1566	1568		10.1126/science.276.5318.1566	http://dx.doi.org/10.1126/science.276.5318.1566			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XC701	9171061				2022-12-01	WOS:A1997XC70100044
J	Robertson, NP; ORiordan, JI; Chataway, J; Kingsley, DPE; Miller, DH; Clayton, D; Compston, DAS				Robertson, NP; ORiordan, JI; Chataway, J; Kingsley, DPE; Miller, DH; Clayton, D; Compston, DAS			Offspring recurrence rates and clinical characteristics of conjugal multiple sclerosis	LANCET			English	Article							EAST-ANGLIA; MRI; CONSANGUINITY; DISTRICT; CRITERIA; TWINS	Background There has been no previous systematic study of conjugal multiple sclerosis. This study of conjugal pairs with complex traits investigated disease transmissibility and the genetic contribution to frequency and clinical course. Methods We studied 45 conjugal pairs concordant for multiple sclerosis from 58 pairs recorded in a national register of familial disease. 86 offspring of the 45 pairs were individually assessed for clinical evidence of neurological disease; those over age 16 underwent cranial resonance imaging. Clinical features were in 33 pairs in whom neither member had symptoms before they met. Findings Of the 86 offspring, five (6%) bad clinically definite multiple sclerosis. A further five children had either characteristic imaging abnormalities or clinical symptoms consistent with demyelination, but did not meet the criteria for clinically definite disease. There was no evidence of clinical concordance, clustering at year of onset, or distortion of the expected pattern of age of onset in the second affected spouse from 33 pairs. The crude recurrence in children of conjugal pairs (1 in 17) is significantly higher than previously reported population-based risks for offspring of single affected parents (1 in 200). Interpretation Taken with the low prevalence of multiple sclerosis in the spouses of affected individuals, and the lack of concordance for age at onset in these families, the disparity in crude recurrence between children of conjugal pairs and those of single affected parents shows that the recurrence risk in children is determined by genetic factors inherited from both parents.	INST NEUROL,MR RES UNIT,LONDON WC1N 3BG,ENGLAND; MRC,CAMBRIDGE CTR BRAIN REPAIR,CAMBRIDGE,ENGLAND; INST PUBL HLTH,MRC,BIOSTAT UNIT,CAMBRIDGE,ENGLAND	University of London; University College London; University of Cambridge; MRC Biostatistics Unit; University of Cambridge	Robertson, NP (corresponding author), UNIV CAMBRIDGE,ADDENBROOKES HOSP,NEUROL UNIT,CAMBRIDGE CB2 2QQ,ENGLAND.			O'Riordan, Jonathan/0000-0001-6774-2488				Agresti A, 1992, Stat Methods Med Res, V1, P201, DOI 10.1177/096228029200100205; Allison RS, 1954, ULSTER MED J      S2, V23, P5; BINZER M, 1994, J NEUROL NEUROSUR PS, V57, P497, DOI 10.1136/jnnp.57.4.497; *CAMBR COUNT COUNC, 1992, POP FOR 1989 2001; CENDROWSKI WS, 1966, J NEUROL SCI, V3, P349, DOI 10.1016/0022-510X(66)90012-8; CONFAVREUX C, 1992, J NEUROL NEUROSUR PS, V55, P671, DOI 10.1136/jnnp.55.8.671; Constantinescu C S, 1995, Mult Scler, V1, P170; EBERS GC, 1986, NEW ENGL J MED, V315, P1638, DOI 10.1056/NEJM198612253152603; EBERS GC, 1995, NATURE, V377, P150, DOI 10.1038/377150a0; EDAN G, 1991, REV NEUROL, V147, P595; FAZEKAS F, 1989, EUR NEUROL, V29, P164, DOI 10.1159/000116401; FINELLI PF, 1991, NEUROLOGY, V441, P1320; FREDRIKSON S, 1992, NEUROLOGY, V42, P577, DOI 10.1212/WNL.42.3.577; GILBERT GJ, 1971, NEUROLOGY, V21, P1169, DOI 10.1212/WNL.21.11.1169; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; LYNCH SG, 1990, NEUROLOGY, V40, P900, DOI 10.1212/WNL.40.6.900; McAlpine D., 1955, MULT SCLER J; MUMFORD CJ, 1992, J NEUROL NEUROSUR PS, V55, P877, DOI 10.1136/jnnp.55.10.877; MUMFORD CJ, 1994, NEUROLOGY, V44, P5; OFFENBACHER H, 1993, NEUROLOGY, V43, P905, DOI 10.1212/WNL.43.5.905; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; ROBERTS DF, 1991, GENET EPIDEMIOL, V8, P147, DOI 10.1002/gepi.1370080302; ROBERTSON N, 1995, J NEUROL NEUROSUR PS, V59, P71, DOI 10.1136/jnnp.59.1.71; Robertson NP, 1996, BRAIN, V119, P449, DOI 10.1093/brain/119.2.449; ROBERTSON NP, 1996, J EPIDEMIOL COMMUNIT, V50, P1; Sadovnick AD, 1996, LANCET, V347, P1728, DOI 10.1016/S0140-6736(96)90807-7; SADOVNICK AD, 1982, LANCET, V1, P1068; SCHAPIRA K, 1963, BRAIN, V86, P315, DOI 10.1093/brain/86.2.315; SWINGLER RJ, 1988, J NEUROL NEUROSUR PS, V51, P1520, DOI 10.1136/jnnp.51.12.1520; THORPE JW, 1994, J NEUROL NEUROSUR PS, V57, P491, DOI 10.1136/jnnp.57.4.491; TIENARI PJ, 1992, J NEUROL NEUROSUR PS, V55, P883, DOI 10.1136/jnnp.55.10.883	31	79	80	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 31	1997	349	9065					1587	1590		10.1016/S0140-6736(96)07317-5	http://dx.doi.org/10.1016/S0140-6736(96)07317-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XB673	9174560				2022-12-01	WOS:A1997XB67300009
J	Kouhara, H; Hadari, YR; SpivakKroizman, T; Schilling, J; BarSagi, D; Lax, I; Schlessinger, J				Kouhara, H; Hadari, YR; SpivakKroizman, T; Schilling, J; BarSagi, D; Lax, I; Schlessinger, J			A lipid-anchored Grb2-binding protein that links FGF-receptor activation to the Ras/MAPK signaling pathway	CELL			English	Article							GROWTH-FACTOR RECEPTOR; INSULIN-RECEPTOR; TYROSINE KINASES; POINT MUTATION; SH3 DOMAINS; PC12 CELLS; DIFFERENTIATION; GRB2; TRANSDUCTION; MITOGENESIS	Activation of the Ras/MAPK signaling cascade is essential for growth factor-induced cell proliferation and differentiation. In this report, we describe the purification, cloning, and characterization of a novel protein, designated FRS2, that is tyrosine phosphorylated and binds to Grb2/Sos in response to FGF or NGF stimulation. We find that FRS2 is myristylated and that this modification is essential for membrane localization, tyrosine phosphorylation, Grb2/Sos recruitment, and MAPK activation. FRS2 functions as a lipid-anchored docking protein that targets signaling molecules to the plasma membrane in response to FGF stimulation to link receptor activation with the MAPK and other signaling pathways essential for cell growth and differentiation. Finally, we demonstrate that FRS2 is closely related and probably indentical to SNT, the long-sought target of FGF and NGF receptors.	SUGEN INC,REDWOOD CITY,CA 94063; SUNY STONY BROOK,DEPT MICROBIOL & MOL GENET,STONY BROOK,NY 11794	State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook	Kouhara, H (corresponding author), NYU,MED CTR,DEPT PHARMACOL,500 1ST AVE,NEW YORK,NY 10016, USA.			Bar-Sagi, Dafna/0000-0003-2597-8948				BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; Borg JP, 1996, MOL CELL BIOL, V16, P6229; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Goh KC, 1996, J BIOL CHEM, V271, P5832, DOI 10.1074/jbc.271.10.5832; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; INGLESE J, 1992, J BIOL CHEM, V267, P1422; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MILLIGAN G, 1995, TRENDS BIOCHEM SCI, V20, P181, DOI 10.1016/S0968-0004(00)89004-0; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; ONEILL TJ, 1994, MOL CELL BIOL, V14, P8433; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; VIHINEN M, 1995, BIOCHEMISTRY-US, V34, P1475, DOI 10.1021/bi00005a002	29	704	718	0	32	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 30	1997	89	5					693	702		10.1016/S0092-8674(00)80252-4	http://dx.doi.org/10.1016/S0092-8674(00)80252-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XB925	9182757	hybrid			2022-12-01	WOS:A1997XB92500006
J	Bell, CC; Han, VZ; Sugawara, Y; Grant, K				Bell, CC; Han, VZ; Sugawara, Y; Grant, K			Synaptic plasticity in a cerebellum-like structure depends on temporal order	NATURE			English	Article							LONG-TERM DEPRESSION; PURKINJE-CELL; IN-VITRO; POTENTIATION; SYNAPSES; FISH; CA1	Cerebellum-like structures in fish appear to act as adaptive sensory processors, in which learned predictions about sensory input are generated and subtracted from actual sensory input, allowing unpredicted inputs to stand out(1-3). Pairing sensory input with centrally originating predictive signals, such as corollary discharge signals linked to motor commands, results in neural responses to the predictive signals alone that are 'negative images' of the previously paired sensory responses, Adding these 'negative images' to actual sensory inputs minimizes the neural response to predictable sensory features, At the cellular level, sensory input is relayed to the basal region of Purkinje-like cells, whereas predictive signals are relayed by parallel fibres to the apical dendrites of the same cells(4). The generation of negative images could be explained by plasticity at parallel fibre synapses(5-7). We show here that such plasticity exists in the electrosensory lobe of mormyrid electric fish and that it has the necessary properties for such a model: it is reversible, anti-hebbian (excitatory postsynaptic potentials (EPSPs) are depressed after pairing with a postsynaptic spike) and tightly dependent on the sequence of pre- and postsynaptic events, with depression occurring only if the postsynaptic spike follows EPSP onset within 60 ms.	CNRS,INST ALFRED FESSARD,F-91190 GIF SUR YVETTE,FRANCE; TEIKYO UNIV,SCH MED,DEPT PHYSIOL,ITABASHI KU,TOKYO 173,JAPAN	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Teikyo University	Bell, CC (corresponding author), GOOD SAMARITAN HOSP,RS DOW NEUROL SCI INST,1120 NW 20TH AVE,PORTLAND,OR 97209, USA.							BASTIAN J, 1995, J COMP PHYSIOL A, V176, P63; BELL C, 1993, P NATL ACAD SCI USA, V9, P4560; BELL C, IN PRESS BRAIN BEHAV; BELL CC, 1981, SCIENCE, V214, P450, DOI 10.1126/science.7291985; CHEN C, 1995, LEARN MEMORY, V2, P185, DOI 10.1101/lm.2.3-4.185; DEBANNE D, 1994, P NATL ACAD SCI USA, V91, P1148, DOI 10.1073/pnas.91.3.1148; EKEROT CF, 1989, NEUROSCI RES, V6, P264, DOI 10.1016/0168-0102(89)90065-5; Grant K, 1996, J COMP NEUROL, V375, P18; GUSTAFSSON B, 1987, J NEUROSCI, V7, P774; HASHEMZADEHGARGARI H, 1991, NEUROSCI LETT, V126, P37, DOI 10.1016/0304-3940(91)90365-Z; HEBB DO, 1949, ORG BEHAVIOR; HIRANO T, 1991, SYNAPSE, V7, P321, DOI 10.1002/syn.890070408; HUERTA P, 1991, NEUROSCI LETT, V126, P37; HUERTA PT, 1995, NEURON, V15, P1053, DOI 10.1016/0896-6273(95)90094-2; ITO M, 1989, ANNU REV NEUROSCI, V12, P85, DOI 10.1146/annurev.neuro.12.1.85; Markram H, 1997, SCIENCE, V275, P213, DOI 10.1126/science.275.5297.213; Meek J, 1996, J COMP NEUROL, V375, P43, DOI 10.1002/(SICI)1096-9861(19961104)375:1<43::AID-CNE3>3.0.CO;2-O; Montgomery J. C., 1995, AUDIT NEUROSCI, P207; MONTGOMERY JC, 1994, NEUROSCI LETT, V174, P145, DOI 10.1016/0304-3940(94)90007-8; NELSON ME, 1995, J COMP PHYSIOL A, V177, P723; SAKURAI M, 1987, J PHYSIOL-LONDON, V394, P463, DOI 10.1113/jphysiol.1987.sp016881	21	420	429	1	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 15	1997	387	6630					278	281		10.1038/387278a0	http://dx.doi.org/10.1038/387278a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WZ167	9153391				2022-12-01	WOS:A1997WZ16700051
J	Burns, CM; Chu, H; Rueter, SM; Hutchinson, LK; Canton, H; SandersBush, E; Emeson, RB				Burns, CM; Chu, H; Rueter, SM; Hutchinson, LK; Canton, H; SandersBush, E; Emeson, RB			Regulation of serotonin-2C receptor G-protein coupling by RNA editing	NATURE			English	Article							CA2+ PERMEABILITY; IN-VITRO; ADENOSINE; CHANNELS; DETERMINANTS; INHIBITION; INVITRO	The neurotransmitter serotonin (5-hydroxytryptamine, 5-HT) elicits a wide array of physiological effects by binding to several receptor subtypes. The 5-HT2 family of receptors belongs to a large group of seven-transmembrane-spanning G-protein-coupled receptors and includes three receptor subtypes (5-HT2A, 5-HT2B and 5-HT2C) which are linked to phospholipase C, promoting the hydrolysis of membrane phospholipids and a subsequent increase in the intracellular levels of inositol phosphates and diacylglycerol(1). Here we show that transcripts encoding the 2C subtype of serotonin receptor (5-HT2CR) undergo RNA editing events in which genomically encoded adenosine residues are converted to inosines by the action of double-stranded RNA adenosine deaminase(s). Sequence analysis of complementary DNA isolates from dissected brain regions have indicated the tissue-specific expression of seven major 5-HT2C receptor isoforms encoded by eleven distinct RNA species. Editing of J-HT2CR messenger RNAs alters the amino-acid coding potential of the predicted second intracellular loop of the receptor and can lead to a 10-15-fold reduction in the efficacy of the interaction between receptors and their G proteins. These observations indicate that RNA editing is a new mechanism for regulating serotonergic signal transduction and suggest that this post-transcriptional modification may be critical for modulating the different cellular functions that are mediated by other members of the G-protein-coupled receptor superfamily.	VANDERBILT UNIV, SCH MED, DEPT PHARMACOL, NASHVILLE, TN 37232 USA	Vanderbilt University				Emeson, Ronald/0000-0002-4585-1648				ARTENS EJ, 1979, RECEPTORS, P33; AUSUBEL EM, 1989, CURRENT PROTOCOLS MO; BARKER EL, 1994, J BIOL CHEM, V269, P11687; BASS BL, 1993, RNA WORLD, P383; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; EGEBJERG J, 1993, P NATL ACAD SCI USA, V90, P755, DOI 10.1073/pnas.90.2.755; Gomeza J, 1996, J BIOL CHEM, V271, P2199, DOI 10.1074/jbc.271.4.2199; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; Herb A, 1996, P NATL ACAD SCI USA, V93, P1875, DOI 10.1073/pnas.93.5.1875; HIGUCHI M, 1993, CELL, V75, P1361, DOI 10.1016/0092-8674(93)90622-W; HOYER D, 1994, PHARMACOL REV, V46, P157; JULIUS D, 1988, SCIENCE, V241, P558, DOI 10.1126/science.3399891; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KOHLER M, 1993, NEURON, V10, P491, DOI 10.1016/0896-6273(93)90336-P; LEONHARDT S, 1992, MOL PHARMACOL, V42, P328; LOMELI H, 1994, SCIENCE, V266, P1709, DOI 10.1126/science.7992055; Maas S, 1996, J BIOL CHEM, V271, P12221, DOI 10.1074/jbc.271.21.12221; Melcher T, 1996, NATURE, V379, P460, DOI 10.1038/379460a0; MELLER E, 1991, J PHARMACOL EXP THER, V257, P668; MORO O, 1993, J BIOL CHEM, V268, P22273; OCONNELL MA, 1995, MOL CELL BIOL, V15, P1389; Polson AG, 1996, NATURE, V380, P454; ROSS EM, 1995, RECENT PROG HORM RES, V50, P207; RUETER SM, 1995, SCIENCE, V267, P1491, DOI 10.1126/science.7878468; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; WESTPHAL RS, 1995, MOL PHARMACOL, V48, P200; WESTPHAL RS, 1994, MOL PHARMACOL, V46, P937; YANG JH, 1995, NATURE, V374, P77, DOI 10.1038/374077a0; YU L, 1991, MOL BRAIN RES, V11, P143, DOI 10.1016/0169-328X(91)90116-F; ZUKER M, 1989, METHOD ENZYMOL, V180, P262	30	855	882	1	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 15	1997	387	6630					303	308		10.1038/387303a0	http://dx.doi.org/10.1038/387303a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WZ167	9153397				2022-12-01	WOS:A1997WZ16700058
J	Lan, RS; Lo, SK; Chuang, ML; Yang, CT; Tsao, TCY; Lee, CH				Lan, RS; Lo, SK; Chuang, ML; Yang, CT; Tsao, TCY; Lee, CH			Elastance of the pleural space: A predictor for the outcome of pleurodesis in patients with malignant pleural effusion	ANNALS OF INTERNAL MEDICINE			English	Article						pleurodesis; pleural effusion, malignant; bleomycin; thoracostomy; elastance	TETRACYCLINE PLEURODESIS; INTRACAVITARY BLEOMYCIN; LOW GLUCOSE; MANAGEMENT; PH; ROTATION; FLUID; TERM	Background: In patients who have malignant pleural effusion, it is difficult to diagnose trapped lung before thoracoscopy, thoracostomy, and drainage of the effusion. Predicting the outcome of pleurodesis in patients who have malignant pleural effusion without trapped lung is also difficult. Objective: To investigate the factors that may be useful in diagnosing trapped lung and predicting the outcome of pleurodesis. Design: Prospective cohort study. Setting: University medical center. Patients: 65 patients with symptomatic malignant pleural effusion. Intervention: A chest tube was inserted for drainage of the effusion, and pleurodesis was done using bleomycin as the sclerosant. Measurements: The pH and glucose levels of the effusion and the elastance of the pleural space (defined as the decline in pleural fluid pressure in cm H2O after removal of 500 mt of effusion) were measured. The outcome of pleurodesis was evaluated 1 month after the chest tube was removed. Results: Patients with an elastance of 19 cm H2O or more had a higher incidence of trapped lung (11 of 14 patients) than did those with an elastance less than 19 cm H2O (3 of 51 patients) (P < 0.001). None of the 14 patients with an elastance of 19 cm H2O or more and none of the 14 patients with a trapped lung had successful pleurodesis. Forty-two of 43 patients with an elastance less than 19 cm H2O who did not have a trapped lung had successful pleurodesis. Elastance seemed to be the best predictor for trapped lung and outcome of pleurodesis, although outcome was also correlated with pH and glucose levels of the effusion. Low-dose bleomycin (30 mg) is as effective as the usual dose of bleomycin (60 mg) for pleurodesis. Conclusion: In patients with symptomatic malignant pleural effusion, measurement of the elastance of the pleural space is a simple and effective method for the diagnosis of trapped lung and prediction of the outcome of chemical pleurodesis with bleomycin.	DEAKIN UNIV, BURWOOD, VIC 3125, AUSTRALIA	Deakin University	Lan, RS (corresponding author), CHANG GUNG MEM HOSP, DEPT CHEST MED, 199 TUNG HWA N RD, TAIPEI 10591, TAIWAN.			LO, Sing Kai/0000-0001-8401-1759; Yang, Cheng-Ta/0000-0003-1846-1027				AELONY Y, 1995, CHEST S, V108, pS111; CHERNOW B, 1977, AM J MED, V63, P695, DOI 10.1016/0002-9343(77)90154-1; DRYZER SR, 1993, CHEST, V104, P1763, DOI 10.1378/chest.104.6.1763; GOOD JT, 1978, CHEST, V74, P602, DOI 10.1378/chest.74.5.602a; GOOD JT, 1985, AM REV RESPIR DIS, V131, P737; HAUSHEER FH, 1985, SEMIN ONCOL, V12, P54; LIGHT RW, 1980, AM REV RESPIR DIS, V121, P799; LIGHT RW, 1995, PLEURAL DISEASES; Moffett M J, 1992, Semin Oncol, V19, P59; OSTROWSKI MJ, 1982, CANCER TREAT REP, V66, P1903; OSTROWSKI MJ, 1986, CANCER, V57, P721, DOI 10.1002/1097-0142(19860215)57:4<721::AID-CNCR2820570407>3.0.CO;2-5; PALADINE W, 1976, CANCER, V38, P1903, DOI 10.1002/1097-0142(197611)38:5<1903::AID-CNCR2820380506>3.0.CO;2-A; RODRIGUEZPANADE.F, 1990, EUR RESP J S10, V3, pS247; RODRIGUEZPANADERO F, 1989, AM REV RESPIR DIS, V139, P663, DOI 10.1164/ajrccm/139.3.663; RUCKDESCHEL JC, 1995, SEMIN ONCOL, V22, P58; RUCKDESCHEL JC, 1992, MALIGNANT PLEURAL EF; SAHN SA, 1985, CLIN CHEST MED, V6, P113; SAHN SA, 1988, ANN INTERN MED, V108, P345, DOI 10.7326/0003-4819-108-3-345; SANCHEZARMENGOL A, 1993, CHEST, V104, P1482, DOI 10.1378/chest.104.5.1482; VARGAS FS, 1994, CHEST, V106, P1246, DOI 10.1378/chest.106.4.1246; VILLANUEVA AG, 1994, THORAX, V49, P23, DOI 10.1136/thx.49.1.23; WALKERRENARD PB, 1994, ANN INTERN MED, V120, P56, DOI 10.7326/0003-4819-120-1-199401010-00010	22	91	94	1	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1997	126	10					768	+		10.7326/0003-4819-126-10-199705150-00003	http://dx.doi.org/10.7326/0003-4819-126-10-199705150-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WZ823	9148649				2022-12-01	WOS:A1997WZ82300005
J	Struewing, JP; Hartge, P; Wacholder, S; Baker, SM; Berlin, M; McAdams, M; Timmerman, MM; Brody, LC; Tucker, MA				Struewing, JP; Hartge, P; Wacholder, S; Baker, SM; Berlin, M; McAdams, M; Timmerman, MM; Brody, LC; Tucker, MA			The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BREAST-CANCER; OVARIAN-CANCER; SUSCEPTIBILITY GENE; FAMILIES; CARRIERS; WOMEN	Background Carriers of germ-line mutations in BRCA1 and BRCA2 from families at high risk for cancer have been estimated to have an 85 percent risk of breast cancer. Since the combined frequency of BRCA1 and BRCA2 mutations exceeds 2 percent among Ashkenazi Jews, we were able to estimate the risk of cancer in a large group of Jewish men and women from the Washington, D.C., area. Methods We collected blood samples from 5318 Jewish subjects who had filled out epidemiologic questionnaires. Carriers of the 185delAG and 5382insC mutations in BRCA1 and the 6174delT mutation in BRCA2 were identified with assays based on the polymerase chain reaction. We estimated the risks of breast and other cancers by comparing the cancer histories of relatives of carriers of the mutations and noncarriers. Results One hundred twenty carriers of a BRCA1 or BRCA2 mutation were identified. By the age of 70, the estimated risk of breast cancer among carriers was 56 percent (95 percent confidence interval, 40 to 73 percent); of ovarian cancer, 16 percent (95 percent confidence interval, 6 to 28 percent); and of prostate cancer, 16 percent (95 percent confidence interval, 4 to 30 percent). There were no significant differences in the risk of breast cancer between carriers of BRCA1 mutations and carriers of BRCA2 mutations, and the incidence of colon cancer among the relatives of carriers was not elevated. Conclusions Over 2 percent of Ashkenazi Jews carry mutations in BRCA1 or BRCA2 that confer increased risks of breast, ovarian, and prostate cancer. The risks of breast cancer may be overestimated, but they fall well below previous estimates based on subjects from high-risk families. (C) 1997, Massachusetts Medical Society.	NATL CANC INST,DIV CANC EPIDEMIOL & GENET,NIH,BETHESDA,MD; NATL HUMAN GENOME RES INST,LAB GENE TRANSFER,NIH,BETHESDA,MD; WESTAT CORP,ROCKVILLE,MD; IMS INC,SILVER SPRING,MD	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Westat			Struewing, Jeffery P/C-3221-2008; Struewing, Jeffery P/I-7502-2013; Tucker, Margaret A/B-4297-2015	Struewing, Jeffery P/0000-0002-4848-3334; 				Berman DB, 1996, AM J HUM GENET, V58, P1166; BRINTON LA, 1995, J NATL CANCER I, V87, P827, DOI 10.1093/jnci/87.11.827; Couch FJ, 1996, HUM MUTAT, V8, P8, DOI 10.1002/humu.1380080102; Couch FJ, 1996, NAT GENET, V13, P123, DOI 10.1038/ng0596-123; EASTON DF, 1995, AM J HUM GENET, V56, P265; EASTON DF, 1993, AM J HUM GENET, V52, P678; Egan KM, 1996, LANCET, V347, P1645, DOI 10.1016/S0140-6736(96)91485-3; FEUER EJ, 1993, J NATL CANCER I, V85, P892, DOI 10.1093/jnci/85.11.892; FitzGerald MG, 1996, NEW ENGL J MED, V334, P143, DOI 10.1056/NEJM199601183340302; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; Gayther SA, 1997, NAT GENET, V15, P103, DOI 10.1038/ng0197-103; GAYTHER SA, 1995, NAT GENET, V11, P428, DOI 10.1038/ng1295-428; HARTGE P, 1989, AM J OBSTET GYNECOL, V161, P10, DOI 10.1016/0002-9378(89)90221-4; Hubbard R, 1996, NEW ENGL J MED, V334, P1192, DOI 10.1056/NEJM199605023341812; Langston AA, 1996, NEW ENGL J MED, V334, P137, DOI 10.1056/NEJM199601183340301; Lapham EV, 1996, SCIENCE, V274, P621, DOI 10.1126/science.274.5287.621; LERMAN C, 1994, ARCH INTERN MED, V154, P609, DOI 10.1001/archinte.154.6.609; Muto MG, 1996, CANCER RES, V56, P1250; Neuhausen S, 1996, NAT GENET, V13, P126, DOI 10.1038/ng0596-126; Oddoux C, 1996, NAT GENET, V14, P188, DOI 10.1038/ng1096-188; Offit K, 1996, LANCET, V347, P1643, DOI 10.1016/S0140-6736(96)91484-1; Phelan CM, 1996, NAT GENET, V13, P120, DOI 10.1038/ng0596-120; Roa BB, 1996, NAT GENET, V14, P185, DOI 10.1038/ng1096-185; Rothenberg KH, 1995, J LAW MED ETHICS, V23, P312, DOI 10.1111/j.1748-720X.1995.tb01373.x; SOMMER SS, 1992, BIOTECHNIQUES, V12, P82; STRUEWING JP, 1995, AM J HUM GENET, V57, P1; STRUEWING JP, 1995, NAT GENET, V11, P198, DOI 10.1038/ng1095-198; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; Thorlacius S, 1996, NAT GENET, V13, P117, DOI 10.1038/ng0596-117; TONIN P, 1995, J MED GENET, V32, P982, DOI 10.1136/jmg.32.12.982; TONIN P, 1995, AM J HUM GENET, V57, P189; Tonin P, 1996, NAT MED, V2, P1179, DOI 10.1038/nm1196-1179; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0	34	1672	1706	0	61	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 15	1997	336	20					1401	1408		10.1056/NEJM199705153362001	http://dx.doi.org/10.1056/NEJM199705153362001			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WY577	9145676	Bronze			2022-12-01	WOS:A1997WY57700001
J	Mohammadi, M; McMahon, G; Sun, L; Tang, C; Hirth, P; Yeh, BK; Hubbard, SR; Schlessinger, J				Mohammadi, M; McMahon, G; Sun, L; Tang, C; Hirth, P; Yeh, BK; Hubbard, SR; Schlessinger, J			Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors	SCIENCE			English	Article							BREAST-CARCINOMA CELLS; SIGNAL TRANSDUCTION; HUMAN ASTROCYTOMAS; INSULIN-RECEPTOR; CROUZON-SYNDROME; POINT MUTATION; FGF FAMILY; EXPRESSION; CANCER; GENES	A new class of protein tyrosine kinase inhibitors was identified that is based on an oxindole core (indolinones). Two compounds from this class inhibited the kinase activity of fibroblast growth factor receptor 1 (FGFR1) and showed differential specificity toward other receptor tyrosine kinases. Crystal structures of the tyrosine kinase domain of FGFR1 in complex with the two compounds were determined. The oxindole occupies the site in which the adenine of adenosine triphosphate binds, whereas the moieties that extend from the oxindole contact residues in the hinge region between the two kinase lobes. The more specific inhibitor of FGFR1 induces a conformational change in the nucleotide-binding loop. This structural information will facilitate the design of new inhibitors for use in the treatment of cancer and other diseases in which cell signaling by tyrosine kinases plays a crucial role in disease pathogenesis.	NYU,MED CTR,SKIRBALL INST BIOMOL MED,NEW YORK,NY 10016; NYU,MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016; SUGEN,REDWOOD CITY,CA 94063	New York University; New York University			Mohammadi, Moosa/ABA-6745-2020; kasaei, fahime/T-7197-2018	Mohammadi, Moosa/0000-0003-2434-9437; Hubbard, Stevan/0000-0002-2707-9383				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ADNANE J, 1991, ONCOGENE, V6, P659; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; Brem H., 1993, ONCOGENES TUMOR SUPP, P211; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; deAzevedo WF, 1996, P NATL ACAD SCI USA, V93, P2735, DOI 10.1073/pnas.93.7.2735; Engh RA, 1996, J BIOL CHEM, V271, P26157, DOI 10.1074/jbc.271.42.26157; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; HUBBARD SR, UNPUB; Isakoff SJ, 1996, J BIOL CHEM, V271, P3959; JAAKKOLA S, 1993, INT J CANCER, V54, P374; JACQUEMIER J, 1994, INT J CANCER, V59, P373, DOI 10.1002/ijc.2910590314; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KLAGSBRUN M, 1989, ARTERIOSCLEROSIS, V9, P269, DOI 10.1161/01.ATV.9.3.269; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; LEUNG HY, 1994, INT J CANCER, V59, P667, DOI 10.1002/ijc.2910590515; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LI JJ, 1993, CANCER-AM CANCER SOC, V72, P2253, DOI 10.1002/1097-0142(19931001)72:7<2253::AID-CNCR2820720732>3.0.CO;2-4; LUQMANI YA, 1995, INT J CANCER, V64, P274, DOI 10.1002/ijc.2910640411; LYALL RM, 1989, J BIOL CHEM, V264, P14503; MALKIN MG, 1996, P AM M AM SOC CLIN O, V15, pA1573; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MCLESKEY SW, 1994, CANCER RES, V54, P523; MCMAHON G, UNPUB; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; MOLLER NPH, 1995, J BIOL CHEM, V270, P23126, DOI 10.1074/jbc.270.39.23126; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MORRISON RS, 1994, J NEURO-ONCOL, V18, P207, DOI 10.1007/BF01328955; Myoken Y, 1996, INT J CANCER, V65, P650, DOI 10.1002/(SICI)1097-0215(19960301)65:5<650::AID-IJC15>3.0.CO;2-B; Naski MC, 1996, NAT GENET, V13, P233, DOI 10.1038/ng0696-233; NEILSON KM, 1995, J BIOL CHEM, V270, P26037, DOI 10.1074/jbc.270.44.26037; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PENAULTLLORCA F, 1995, INT J CANCER, V61, P170, DOI 10.1002/ijc.2910610205; REARDON W, 1994, NAT GENET, V8, P98, DOI 10.1038/ng0994-98; ROUSSEAU F, 1994, NATURE, V371, P252, DOI 10.1038/371252a0; SCHULZEGAHMEN U, 1995, PROTEINS, V22, P378, DOI 10.1002/prot.340220408; SHIANG R, 1994, CELL, V78, P335, DOI 10.1016/0092-8674(94)90302-6; STORY MT, 1995, WORLD J UROL, V13, P297; TAVORMINA PL, 1995, NAT GENET, V9, P321, DOI 10.1038/ng0395-321; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; THEILLET C, 1993, GENE CHROMOSOME CANC, V7, P219, DOI 10.1002/gcc.2870070407; THOMAS KA, 1982, P NATL ACAD SCI-BIOL, V79, P4843, DOI 10.1073/pnas.79.16.4843; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WARE JL, 1993, CANCER METAST REV, V12, P287, DOI 10.1007/BF00665959; Webster MK, 1996, EMBO J, V15, P520, DOI 10.1002/j.1460-2075.1996.tb00384.x; Webster MK, 1996, MOL CELL BIOL, V16, P4081; Xu RM, 1996, P NATL ACAD SCI USA, V93, P6308, DOI 10.1073/pnas.93.13.6308; YAMAGUCHI F, 1994, P NATL ACAD SCI USA, V91, P484, DOI 10.1073/pnas.91.2.484	54	986	1083	0	71	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 9	1997	276	5314					955	960		10.1126/science.276.5314.955	http://dx.doi.org/10.1126/science.276.5314.955			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WY792	9139660				2022-12-01	WOS:A1997WY79200050
J	Wright, BA; Lombardino, LJ; King, WM; Puranik, CS; Leonard, CM; Merzenich, MM				Wright, BA; Lombardino, LJ; King, WM; Puranik, CS; Leonard, CM; Merzenich, MM			Deficits in auditory temporal and spectral resolution in language-impaired children	NATURE			English	Article							PERCEPTION	Between 3 and 6 per cent of children who are otherwise unimpaired have extreme difficulties producing and understanding spoken language(1). This disorder is typically labelled specific language impairment. Children diagnosed with specific language impairment often have accompanying reading difficulties (dyslexia)(2), but not all children with reading difficulties have specific language impairment(3). Some researchers claim that language impairment arises from failures specific to language or cognitive processing(4-6). Others hold that language impairment results from a more elemental problem that makes affected children unable to hear the acoustic distinctions among successive brief sounds in speech(7-11). Here we report the results of psychophysical tests employing simple tones and noises showing that children with specific language impairment have severe auditory perceptual deficits for brief but not long tones in particular sound contexts. Our data support the view that language difficulties result from problems in auditory perception, and provide further information about the nature of these perceptual problems that should contribute to improving the diagnosis and treatment of language impairment and related disorders.	UNIV FLORIDA,DEPT COMMUN PROC & DISORDERS,GAINESVILLE,FL 32611; UNIV FLORIDA,DEPT NEUROSCI,GAINESVILLE,FL 32611; UNIV FLORIDA,INST BRAIN,GAINESVILLE,FL 32611	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Wright, BA (corresponding author), UNIV CALIF SAN FRANCISCO,WM KECK AUTOIMMUNE DIS CTR,BOX 0732,SAN FRANCISCO,CA 94143, USA.							AARON PG, 1988, ANN DYSLEXIA, V36, P33; ARAM DM, 1975, J SPEECH HEAR RES, V18, P229, DOI 10.1044/jshr.1802.229; BRADLEY L, 1978, NATURE, V271, P746, DOI 10.1038/271746a0; Brown L., 1990, TEST NONVERBAL INTEL; CARLYON RP, 1989, HEARING RES, V41, P223, DOI 10.1016/0378-5955(89)90014-2; CATTS HW, 1993, J SPEECH HEAR RES, V36, P948, DOI 10.1044/jshr.3605.948; ELLIOTT LL, 1989, J SPEECH HEAR RES, V32, P112, DOI 10.1044/jshr.3201.112; Farmer ME, 1995, PSYCHON B REV, V2, P460, DOI 10.3758/BF03210983; FASTL H, 1976, ACUSTICA, V36, P317; FRUMKIN B, 1980, NEUROPSYCHOLOGIA, V18, P443, DOI 10.1016/0028-3932(80)90147-5; GAUGER LM, IN PRESS J SPEECH HE; GREEN DM, 1990, J ACOUST SOC AM, V87, P2662, DOI 10.1121/1.399058; Kraus N, 1996, SCIENCE, V273, P971, DOI 10.1126/science.273.5277.971; LUBERT N, 1981, J SPEECH HEAR DISORD, V46, P3, DOI 10.1044/jshd.4601.03; Merzenich MM, 1996, SCIENCE, V271, P77, DOI 10.1126/science.271.5245.77; MOORE BCJ, 1987, J ACOUST SOC AM, V81, P1873, DOI 10.1121/1.394751; Patterson R.D., 1986, FREQUENCY SELECTIVIT, P123; PATTERSON RD, 1982, J ACOUST SOC AM, V72, P1788, DOI 10.1121/1.388652; Semel EM, 1987, CLIN EVALUATION LANG; SODERQUIST D R, 1981, Journal of Auditory Research, V21, P227; StuddertKennedy M, 1995, PSYCHON B REV, V2, P508, DOI 10.3758/BF03210986; Tallal P, 1996, SCIENCE, V271, P81, DOI 10.1126/science.271.5245.81; TALLAL P, 1973, NATURE, V241, P468, DOI 10.1038/241468a0; VELLUTINO FR, 1977, J LEARN DISABIL, V10, P375, DOI 10.1177/002221947701000614; WAGENAAR WA, 1969, PSYCHOL BULL, V72, P384, DOI 10.1037/h0028329; 1988, P NATL C LEARN DIS B	26	383	394	0	46	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 8	1997	387	6629					176	178		10.1038/387176a0	http://dx.doi.org/10.1038/387176a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	WX945	9144287				2022-12-01	WOS:A1997WX94500053
J	Ward, W; Alvarado, L; Rawlings, ND; Engel, JC; Franklin, C; McKerrow, JH				Ward, W; Alvarado, L; Rawlings, ND; Engel, JC; Franklin, C; McKerrow, JH			A primitive enzyme for a primitive cell: The protease required for excystation of Giardia	CELL			English	Article							CATHEPSIN-B; CYSTEINE PROTEASE; CRYSTAL-STRUCTURE; ACID-PHOSPHATASE; LAMBLIA; LOCALIZATION; TROPHOZOITES; PROTEINASE; MURIS; PURIFICATION	Protozoan parasites of the genus Giardia are one of the earliest lineages of eukaryotic cells. To initiate infection, trophozoites emerge from a cyst in the host. Excystation is blocked by specific cysteine protease inhibitors. Using a biotinylated inhibitor, the target protease was identified and its corresponding gene cloned. The protease was localized to vesicles that release their contents just prior to excystation. The Giardia protease is the earliest known branch of the cathepsin B family. Its phylogeny confirms that the cathepsin B lineage evolved in primitive eukaryotic cells, prior to the divergence of plant and animal kingdoms, and underscores the diversity of cellular functions that this enzyme family facilitates.	IMSS,CMNSXX1,UNIDAD INVEST MED ENFERMEDADES INFECCIOSAS & PARA,MEXICO CITY 06725,DF,MEXICO; BABRAHAM INST,PEPTIDASE LAB,DEPT IMMUNOL,CAMBRIDGE CB2 4AT,ENGLAND; VET AFFAIRS MED CTR,SAN FRANCISCO,CA 94121	Instituto Mexicano del Seguro Social; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Ward, W (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94143, USA.		Rawlings, Neil/M-5566-2013; Rawlings, Neil D./I-4867-2012	Rawlings, Neil/0000-0001-5557-7665; 	NIAID NIH HHS [AI35707] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI035707] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAM RD, 1991, MICROBIOL REV, V55, P706, DOI 10.1128/MMBR.55.4.706-732.1991; Ausubel F. M., 1994, CURRENT PROTOCOLS MO; BERTI PJ, 1995, J MOL BIOL, V246, P373; CHUNG YB, 1995, J PARASITOL, V81, P137, DOI 10.2307/3283911; COGGINS JR, 1986, EXP PARASITOL, V61, P219, DOI 10.1016/0014-4894(86)90155-4; EAKIN AE, 1990, MOL BIOCHEM PARASIT, V39, P1, DOI 10.1016/0166-6851(90)90002-4; EAKIN AE, 1992, J BIOL CHEM, V267, P7411; ELLIOTT E, 1996, SERIES PERSPECTIVES, P12; FARTHING MJG, 1992, J MED MICROBIOL, V37, P1, DOI 10.1099/00222615-37-1-1; FEELY DE, 1991, J PARASITOL, V77, P441, DOI 10.2307/3283133; FEELY DE, 1987, J PROTOZOOL, V34, P80, DOI 10.1111/j.1550-7408.1987.tb03137.x; Feisenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; FRIEND DS, 1966, J CELL BIOL, V29, P317, DOI 10.1083/jcb.29.2.317; *GEN COMP GROUP, 1994, PROGR MAN WISC SEQ A; GILLIN FD, 1991, PARASITOL TODAY, V7, P113, DOI 10.1016/0169-4758(91)90169-O; Gillin FD, 1996, ANNU REV MICROBIOL, V50, P679, DOI 10.1146/annurev.micro.50.1.679; HARE DF, 1989, EXP PARASITOL, V68, P168, DOI 10.1016/0014-4894(89)90094-5; HASNAIN S, 1992, BIOL CHEM H-S, V373, P413, DOI 10.1515/bchm3.1992.373.2.413; JOSHUATOR L, 1995, SCIENCE, V269, P945, DOI 10.1126/science.7638617; KANE AV, 1991, J PARASITOL, V77, P974, DOI 10.2307/3282752; KAPPUS KD, 1994, AM J TROP MED HYG, V50, P705, DOI 10.4269/ajtmh.1994.50.705; KEISTER DB, 1983, T ROY SOC TROP MED H, V77, P487, DOI 10.1016/0035-9203(83)90120-7; KURATA S, 1992, EUR J BIOCHEM, V204, P911, DOI 10.1111/j.1432-1033.1992.tb16711.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECHEVALLIER MW, 1991, APPL ENVIRON MICROB, V57, P2617, DOI 10.1128/AEM.57.9.2617-2621.1991; LEIPE DD, 1993, MOL BIOCHEM PARASIT, V59, P41, DOI 10.1016/0166-6851(93)90005-I; LEVINE WC, 1990, MMWR-MORBID MORTAL W, V89, P1; LINDMARK DG, 1988, EXP PARASITOL, V65, P141, DOI 10.1016/0014-4894(88)90116-6; MANIATIS T, 1987, MOL CLONING; MANNING P, 1992, J PROTOZOOL, V89, P290; MEESTER FD, 1990, INFECT IMMUN, V58, P1396; MUSIL D, 1991, EMBO J, V10, P2321, DOI 10.1002/j.1460-2075.1991.tb07771.x; PARENTI DM, 1989, J INFECT DIS, V160, P1076, DOI 10.1093/infdis/160.6.1076; PEATTIE DA, 1990, PARASITOL TODAY, V6, P52, DOI 10.1016/0169-4758(90)90070-K; QUICK R, 1992, J INFECT DIS, V166, P673, DOI 10.1093/infdis/166.3.673; RASNICK D, 1985, ANAL BIOCHEM, V149, P461, DOI 10.1016/0003-2697(85)90598-6; RAWLINGS ND, 1994, METHOD ENZYMOL, V244, P461; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SIDDALL ME, 1992, J PROTOZOOL, V39, P361, DOI 10.1111/j.1550-7408.1992.tb01465.x; SMITH PD, 1982, INFECT IMMUN, V36, P714, DOI 10.1128/IAI.36.2.714-719.1982; SOGIN ML, 1989, SCIENCE, V243, P75, DOI 10.1126/science.2911720; Sullivan PB, 1990, ARCH DIS CHILD, V65, P304; VIDAL MFC, 1991, J CLIN MICROBIOL, V29, P636, DOI 10.1128/JCM.29.3.636-637.1991; WANG AL, 1986, MOL BIOCHEM PARASIT, V21, P269, DOI 10.1016/0166-6851(86)90132-5; Wasilewski MM, 1996, MOL BIOCHEM PARASIT, V81, P179, DOI 10.1016/0166-6851(96)02703-X; WERRIES E, 1991, J PROTOZOOL, V38, P378, DOI 10.1111/j.1550-7408.1991.tb01374.x	46	120	125	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 2	1997	89	3					437	444		10.1016/S0092-8674(00)80224-X	http://dx.doi.org/10.1016/S0092-8674(00)80224-X			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WX899	9150143	Bronze			2022-12-01	WOS:A1997WX89900014
J	Sainz, J; VanTornout, JM; Loro, ML; Sayre, J; Roe, TF; Gilsanz, V				Sainz, J; VanTornout, JM; Loro, ML; Sayre, J; Roe, TF; Gilsanz, V			Vitamin D-receptor gene polymorphisms and bone density in prepubertal American girls of Mexican descent	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PREMENOPAUSAL WOMEN; OSTEOPOROSIS; ALLELES; MASS; PUBERTY; VIEW	Background Bone mass is under strong genetic control, and recent studies in adults have suggested that allelic differences in the gene for the vitamin D receptor may account for inherited variability in bone mass. We studied the relations of the vitamin D-receptor genotype to skeletal development and variation in the size, volume, and density of bone in children. Methods We identified three allelic variants of the vitamin D-receptor gene using the polymerase chain reaction and three restriction enzymes (Apal, Bsml, and Taql) in 100 normal prepubertal American girls of Mexican descent. We then determined the relations of the different vitamin D-receptor genotypes (AA, Aa, aa, BE, Bb, bb, TT, Tt, and tt) to the cross-sectional area, cortical area, and cortical bone density of the femoral shaft and the cross-sectional area and density of the lumbar vertebrae. Results The vitamin D-receptor genotype was associated with femoral and vertebral bone density. Girls with aa and bb genotypes had 2 to 3 percent higher femoral bone density (P=0.008 and P=0.04, respectively) and 8 to 10 percent higher vertebral bone density (P=0.01 and P=0.03, respectively) than girls with AA and BE genotypes. There was no association between the cross-sectional area of the vertebrae or the cross-sectional or cortical area of the femur and the vitamin D-receptor genotype. The chronologic age, bone age, height, weight, body-surface area, and body-mass index did not differ significantly among girls with different vitamin D-receptor genotypes. Conclusions Vitamin D-receptor gene alleles predict the density of femoral and vertebral bone in prepubertal American girls of Mexican descent. (C) 1997, Massachusetts Medical Society.	CHILDRENS HOSP LOS ANGELES, DEPT RADIOL, LOS ANGELES, CA 90027 USA; CHILDRENS HOSP LOS ANGELES, DEPT PEDIAT, LOS ANGELES, CA 90027 USA; UNIV CALIF LOS ANGELES, DEPT BIOSTAT, SCH MED, LOS ANGELES, CA USA	Children's Hospital Los Angeles; Children's Hospital Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NCI NIH HHS [1K11 CA61870 02] Funding Source: Medline; NIAMS NIH HHS [R01-AR4-1853-01A1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K11CA061870] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041853] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BARGERLUX MJ, 1995, CALCIFIED TISSUE INT, V57, P161, DOI 10.1007/BF00298438; BEHRMAN RE, 1987, NELSON TXB PEDIAT, P24; BONJOUR JP, 1991, J CLIN ENDOCR METAB, V73, P555, DOI 10.1210/jcem-73-3-555; CANN CE, 1991, EXPANDING ROLE MED P, P250; CARTER DR, 1992, J BONE MINER RES, V7, P137; CHRISTIAN JC, 1989, AM J HUM GENET, V44, P429; Cooper GS, 1996, J BONE MINER RES, V11, P1841; Dawson-Hughes Bess, 1995, P335; DAWSONHUGHES B, 1995, J CLIN ENDOCR METAB, V80, P3657, DOI 10.1210/jc.80.12.3657; DYSON ED, 1970, NATURE, V225, P957, DOI 10.1038/225957a0; EISMAN JA, 1995, J BONE MINER RES, V10, P1289; FLEET JC, 1995, J BONE MINER RES, V10, P985; GARNERO P, 1995, J BONE MINER RES, V10, P1283; Genant HK, 1996, J BONE MINER RES, V11, P707; GILSANZ V, 1991, NEW ENGL J MED, V325, P1597, DOI 10.1056/NEJM199112053252302; GILSANZ V, 1994, RADIOLOGY, V190, P673, DOI 10.1148/radiology.190.3.8115609; GONG JK, 1964, ANAT REC, V149, P325, DOI 10.1002/ar.1091490303; Greulich WW, 1950, RADIOGRAPHIC ATLAS S; Hangartner TN, 1996, J BONE MINER RES, V11, P1518, DOI 10.1002/jbmr.5650111019; HOWARD G, 1995, J CLIN ENDOCR METAB, V80, P2800, DOI 10.1210/jc.80.9.2800; HUSTMYER FG, 1994, J CLIN INVEST, V94, P2130, DOI 10.1172/JCI117568; KALENDER WA, 1992, OSTEOPOROSIS INT, V2, P82, DOI 10.1007/BF01623841; Matkovic V, 1996, J CLIN ENDOCR METAB, V81, P2013, DOI 10.1210/jc.81.6.2013; MELHUS H, 1994, LANCET, V344, P949, DOI 10.1016/S0140-6736(94)92297-7; MORRISON NA, 1994, NATURE, V367, P284, DOI 10.1038/367284a0; MORRISON NA, 1992, P NATL ACAD SCI USA, V89, P6665, DOI 10.1073/pnas.89.15.6665; Need AG, 1996, EUR J CLIN INVEST, V26, P793, DOI 10.1046/j.1365-2362.1996.2080554.x; PEACOCK M, 1995, J BONE MINER RES, V10, P1294; RIGGS BL, 1986, NEW ENGL J MED, V314, P1676, DOI 10.1056/NEJM198606263142605; SAMBROOK PN, 1994, BRIT J RHEUMATOL, V33, P1007; SEEMAN E, 1989, NEW ENGL J MED, V320, P554, DOI 10.1056/NEJM198903023200903; SHOHAT T, 1995, HUM HERED, V45, P150, DOI 10.1159/000154276; Terwilliger J., 1994, HDB HUMAN GENETIC LI; Viitanen AM, 1996, CALCIFIED TISSUE INT, V59, P231, DOI 10.1007/s002239900113; [No title captured]	35	238	251	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 10	1997	337	2					77	82		10.1056/NEJM199707103370202	http://dx.doi.org/10.1056/NEJM199707103370202			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XJ822	9211676				2022-12-01	WOS:A1997XJ82200002
J	Manuelidis, L; Fritch, W; Xi, YG				Manuelidis, L; Fritch, W; Xi, YG			Evolution of a strain of CJD that induces BSE-like plaques	SCIENCE			English	Article								Bovine spongiform encephalopathy (BSE) has become a public health issue because a recently evolved BSE agent has infected people, yielding an unusual form of Creutzfeld-Jakob disease (CJD). A new CJD agent that provokes similar amyloid plaques and cerebellar pathology was serially propagated. First-passage rats showed obvious clinical signs and activated microglia but had negligible PrP-res (the more protease-resistant form of host PrP) or cerebellar lesions. Microglia and astrocytes may participate in strain selection because the agent evolved, stabilized, and reproducibly provoked BSE-like disease in subsequent passages. Early vacuolar change involving activated microglia and astrocytes preceded significant PrP-res accumulation by more than 50 days. These studies reveal several inflammatory host reactions to an exogenous agent.			Manuelidis, L (corresponding author), YALE UNIV,SCH MED,SECT NEUROPATHOL,310 CEDAR ST,NEW HAVEN,CT 06510, USA.				NINDS NIH HHS [NS34569, NS12674] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS034569, R01NS012674] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))			0	119	121	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 4	1997	277	5322					94	98		10.1126/science.277.5322.94	http://dx.doi.org/10.1126/science.277.5322.94			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XJ418	9204907				2022-12-01	WOS:A1997XJ41800047
J	Ogas, J; Cheng, JC; Sung, ZR; Somerville, C				Ogas, J; Cheng, JC; Sung, ZR; Somerville, C			Cellular differentiation regulated by gibberellin in the Arabidopsis thaliana pickle mutant	SCIENCE			English	Article							LYCOPERSICON-ESCULENTUM MILL; GENE FAMILY; GA1 LOCUS; WILD-TYPE; PLANT; GROWTH; TRANSFORMATION; ROOTS; SITES; ACID	The plant growth regulator gibberellin (GA) has a profound effect on shoot development and promotes developmental transitions such as flowering. Little is known about any analogous effect GA might have on root development. In a screen for mutants, Arabidopsis plants carrying a mutation designated pickle (pkl) were isolated in which the primary root meristem retained characteristics of embryonic tissue. Expression of this aberrant differentiation state was suppressed by GA. Root tissue from plants carrying the pkl mutation spontaneously regenerated new embryos and plants.	UNIV CALIF BERKELEY,DEPT PLANT BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley	Ogas, J (corresponding author), CARNEGIE INST WASHINGTON,DEPT PLANT BIOL,290 PANAMA ST,STANFORD,CA 94305, USA.		Somerville, Christopher R/A-4048-2009	Somerville, Christopher R/0000-0003-4647-0094; Ogas, Joe/0000-0002-1332-7729; Sung, Zinmay/0000-0003-0478-9144				BALUSKA F, 1993, PLANTA, V191, P149, DOI 10.1007/BF00199744; BARLOW PW, 1991, J EXP BOT, V42, P339, DOI 10.1093/jxb/42.3.339; BELL CJ, 1994, GENOMICS, V19, P137, DOI 10.1006/geno.1994.1023; BRUNDRETT MC, 1991, BIOTECH HISTOCHEM, V66, P111, DOI 10.3109/10520299109110562; Chien JC, 1996, PLANT PHYSIOL, V111, P1321, DOI 10.1104/pp.111.4.1321; FAY JM, 1991, ECON BOT, V45, P16, DOI 10.1007/BF02860046; FINKELSTEIN RR, 1994, ARABIDOPSIS, P523; GUERCHE P, 1990, PLANT CELL, V2, P469, DOI 10.1105/tpc.2.5.469; IZUMI K, 1985, PLANT CELL PHYSIOL, V26, P821; KOORNNEEF M, 1985, PHYSIOL PLANTARUM, V65, P33, DOI 10.1111/j.1399-3054.1985.tb02355.x; KOORNNEEF M, 1983, GENET RES, V41, P57, DOI 10.1017/S0016672300021066; KREBBERS E, 1988, PLANT PHYSIOL, V87, P859, DOI 10.1104/pp.87.4.859; LEMIEUX B, 1990, THEOR APPL GENET, V80, P234, DOI 10.1007/BF00224392; MARTON L, 1991, PLANT CELL REP, V10, P235, DOI 10.1007/BF00232565; MCCLINTON RS, IN PRESS PLANTA; METZ AM, 1992, GENE, V120, P313, DOI 10.1016/0378-1119(92)90112-3; MORRIS PC, 1994, ARABIDOPSIS, P173; NAKIELSKI J, 1995, PLANTA, V196, P30, DOI 10.1007/BF00193214; OHLROGGE JB, 1991, BIOCHIM BIOPHYS ACTA, V1082, P1, DOI 10.1016/0005-2760(91)90294-R; Okamuro JK, 1996, P NATL ACAD SCI USA, V93, P13831, DOI 10.1073/pnas.93.24.13831; PATTON DA, 1990, AM J BOT, V77, P653, DOI 10.2307/2444811; PENG JR, 1993, PLANT CELL, V5, P351, DOI 10.1105/tpc.5.3.351; Ross JHE, 1996, PLANT J, V9, P625, DOI 10.1046/j.1365-313X.1996.9050625.x; SUN TP, 1992, PLANT CELL, V4, P119, DOI 10.1105/tpc.4.2.119; SUN TP, 1994, PLANT CELL, V6, P1509, DOI 10.1105/tpc.6.10.1509; TRAAS J, 1995, PLANT J, V7, P785, DOI 10.1046/j.1365-313X.1995.07050785.x; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; VANROOIJEN GJH, 1992, PLANT MOL BIOL, V18, P1177, DOI 10.1007/BF00047721; VERWOERD TC, 1989, NUCLEIC ACIDS RES, V17, P2362, DOI 10.1093/nar/17.6.2362	29	247	276	1	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 4	1997	277	5322					91	94		10.1126/science.277.5322.91	http://dx.doi.org/10.1126/science.277.5322.91			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XJ418	9204906				2022-12-01	WOS:A1997XJ41800046
J	Ji, GY; Beavis, R; Novick, RP				Ji, GY; Beavis, R; Novick, RP			Bacterial interference caused by autoinducing peptide variants	SCIENCE			English	Article							GENE REGULATOR AGR; DELTA-LYSIN GENE; STAPHYLOCOCCUS-AUREUS; HLD; RNA	The synthesis of virulence factors and other extracellular proteins by Staphylococcus aureus is globally controlled by the agr locus, which encodes a two-component signaling pathway whose activating ligand is an agr-encoded autoinducing peptide. The cognate peptides produced by some strains inhibit the expression of agr in other strains, and the amino acid sequences of peptide and receptor are markedly different between such strains, suggesting a hypervariability-generating mechanism. Cross-inhibition of gene expression represents a type of bacterial interference that could be correlated with the ability of one strain to exclude others from infection or colonization sites, or both.	NYU MED CTR, SKIRBALL INST BIOMOLEC MED, NEW YORK, NY 10016 USA	New York University				Novick, richard/0000-0003-4418-7893	NIAID NIH HHS [R01-AI30138] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030138] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARC MC, 1986, CAN J MICROBIOL, V32, P751, DOI 10.1139/m86-136; BEAVIS R, UNPUB; HAVARSTEIN LS, 1995, MOL MICROBIOL, V16, P229, DOI 10.1111/j.1365-2958.1995.tb02295.x; HICKS J, 1979, NATURE, V282, P478, DOI 10.1038/282478a0; HILLENKAMP F, 1991, ANAL CHEM, V63, pA1193; HOLM SE, 1983, SCAND J INFECT DIS, P73; JANZON L, 1989, MOL GEN GENET, V219, P480, DOI 10.1007/BF00259623; JANZON L, 1990, EMBO J, V9, P1391, DOI 10.1002/j.1460-2075.1990.tb08254.x; JI G, UNPUB; Ji GY, 1995, P NATL ACAD SCI USA, V92, P12055, DOI 10.1073/pnas.92.26.12055; KORNBLUM J, 1990, MOL BIOL STAPHYLOCOC, pCH28; LINA G, UNPUB; MORFELDT E, 1995, EMBO J, V14, P4569, DOI 10.1002/j.1460-2075.1995.tb00136.x; MURPHY GL, 1988, BIOESSAYS, V9, P7, DOI 10.1002/bies.950090103; NOBLE WC, 1980, BRIT J EXP PATHOL, V61, P339; NOVICK RP, 1995, MOL GEN GENET, V248, P446, DOI 10.1007/BF02191645; NOVICK RP, 1993, EMBO J, V12, P3967, DOI 10.1002/j.1460-2075.1993.tb06074.x; PEDRAZA A, UNPUB; PENG HL, 1988, J BACTERIOL, V170, P4365, DOI 10.1128/jb.170.9.4365-4372.1988; SHINEFIE.HR, 1974, ANN NY ACAD SCI, V236, P444, DOI 10.1111/j.1749-6632.1974.tb41509.x; WILSKE B, 1992, RES MICROBIOL, V143, P583, DOI 10.1016/0923-2508(92)90116-6; WILSON KH, 1983, J INFECT DIS, V147, P733, DOI 10.1093/infdis/147.4.733; Wolz C, 1996, INFECT IMMUN, V64, P3142, DOI 10.1128/IAI.64.8.3142-3147.1996	23	576	604	4	58	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 27	1997	276	5321					2027	2030		10.1126/science.276.5321.2027	http://dx.doi.org/10.1126/science.276.5321.2027			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XG748	9197262				2022-12-01	WOS:A1997XG74800060
J	Maraskovsky, E; OReilly, LA; Teepe, M; Corcoran, LM; Peschon, JJ; Strasser, A				Maraskovsky, E; OReilly, LA; Teepe, M; Corcoran, LM; Peschon, JJ; Strasser, A			Bcl-2 can rescue T lymphocyte development in interleukin-7 receptor-deficient mice but not in mutant rag-1(-/-) mice	CELL			English	Article							NEGATIVE SELECTION; TRANSGENIC MICE; B-CELLS; THYMOCYTE DEVELOPMENT; RAG-1-DEFICIENT MICE; V(D)J REARRANGEMENT; POSITIVE SELECTION; CONTROL POINTS; GROWTH-FACTOR; GAMMA-CHAIN	Signals from cytokine and antigen receptors play crucial roles during lymphocyte development. Mice lacking interleukin-7 receptor are lymphopenic, due to a defect in cell expansion at an early stage of differentiation, and the few mature T cells that develop in IL-7R(-/-) animals are functionally impaired. Both defects were rescued completely by overexpression of the anti-apoptosis protein Bcl-2. T cell progenitors lacking antigen receptor molecules are also blocked in differentiation and die, presumably because they fail to receive a positive signal via their pre-T cell receptor. Surprisingly, Bcl-2 did not promote survival or differentiation of T cells in rag-1(-/-) mice. These results provide evidence that blocking apoptosis is the essential function of IL-7R during differentiation and activation of T lymphocytes and that pre-TCR signaling blocks a pathway to apoptosis that is insensitive to Bcl-2.	IMMUNEX RES & DEV CORP,DEPT MOL IMMUNOL,SEATTLE,WA 98101; IMMUNEX RES & DEV CORP,DEPT CELLULAR IMMUNOL,SEATTLE,WA 98101		Maraskovsky, E (corresponding author), ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,PARKVILLE,VIC 3050,AUSTRALIA.		Corcoran, Lynn M/C-9316-2013; Strasser, Andreas/C-7581-2013	Strasser, Andreas/0000-0002-5020-4891				CAO XQ, 1995, IMMUNITY, V2, P223, DOI 10.1016/1074-7613(95)90047-0; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; EGERTON M, 1990, INT IMMUNOL, V2, P501, DOI 10.1093/intimm/2.6.501; FEHLING HJ, 1995, NATURE, V375, P795, DOI 10.1038/375795a0; FISHER AG, 1995, INT IMMUNOL, V7, P415, DOI 10.1093/intimm/7.3.415; Forster I, 1989, Int Immunol, V1, P321, DOI 10.1093/intimm/1.4.321; FULCHER DA, 1994, J EXP MED, V179, P125, DOI 10.1084/jem.179.1.125; GODFREY DI, 1992, J IMMUNOL, V149, P2281; GODFREY DI, 1993, IMMUNOL TODAY, V14, P547, DOI 10.1016/0167-5699(93)90186-O; GOODWIN RG, 1989, P NATL ACAD SCI USA, V86, P302, DOI 10.1073/pnas.86.1.302; GRABSTEIN KH, 1993, J EXP MED, V178, P257, DOI 10.1084/jem.178.1.257; GROETTRUP M, 1993, CELL, V75, P283, DOI 10.1016/0092-8674(93)80070-U; KONDO M, 1994, SCIENCE, V263, P1453, DOI 10.1126/science.8128231; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; LINETTE GP, 1994, IMMUNITY, V1, P197, DOI 10.1016/1074-7613(94)90098-1; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; MACKAREHTSCHIAN K, 1995, IMMUNITY, V3, P147, DOI 10.1016/1074-7613(95)90167-1; Maraskovsky E, 1996, J IMMUNOL, V157, P5315; Mazel S, 1996, J EXP MED, V183, P2219, DOI 10.1084/jem.183.5.2219; MEMON SA, 1995, J IMMUNOL, V155, P4644; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MOLLINA TJ, 1992, NATURE, V357, P161; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; MORRISSEY PJ, 1991, J IMMUNOL, V147, P561; MORRISSEY PJ, 1989, J EXP MED, V169, P707, DOI 10.1084/jem.169.3.707; MUEGGE K, 1993, SCIENCE, V261, P93, DOI 10.1126/science.7686307; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; Murray R, 1989, Int Immunol, V1, P526, DOI 10.1093/intimm/1.5.526; NAMEN AE, 1988, NATURE, V333, P571, DOI 10.1038/333571a0; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; NOSAKA T, 1995, SCIENCE, V270, P800, DOI 10.1126/science.270.5237.800; NOSSAL GJV, 1994, CELL, V76, P229, DOI 10.1016/0092-8674(94)90331-X; OReilly LA, 1996, EMBO J, V15, P6979, DOI 10.1002/j.1460-2075.1996.tb01090.x; PENIT C, 1995, J IMMUNOL, V154, P5103; PESCHON JJ, 1994, J EXP MED, V180, P1955, DOI 10.1084/jem.180.5.1955; PETRIE HT, 1993, J EXP MED, V178, P615, DOI 10.1084/jem.178.2.615; PHILPOTT KL, 1992, SCIENCE, V256, P1448, DOI 10.1126/science.1604321; Raff MC, 1996, CELL, V86, P173, DOI 10.1016/S0092-8674(00)80087-2; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; RICH BE, 1993, J EXP MED, V177, P305, DOI 10.1084/jem.177.2.305; RODEWALD HR, 1995, IMMUNITY, V3, P313, DOI 10.1016/1074-7613(95)90116-7; ROLINK A, 1993, J EXP MED, V178, P1263, DOI 10.1084/jem.178.4.1263; SAMARIDIS J, 1991, EUR J IMMUNOL, V21, P453, DOI 10.1002/eji.1830210230; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; Shortman K, 1996, ANNU REV IMMUNOL, V14, P29, DOI 10.1146/annurev.immunol.14.1.29; SPANOPOULOU E, 1994, GENE DEV, V8, P1030, DOI 10.1101/gad.8.9.1030; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; STRASSER A, 1994, NATURE, V368, P457, DOI 10.1038/368457a0; STRASSER A, 1994, P NATL ACAD SCI USA, V91, P1376, DOI 10.1073/pnas.91.4.1376; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; SUDO T, 1993, P NATL ACAD SCI USA, V90, P9125, DOI 10.1073/pnas.90.19.9125; SURH CD, 1994, NATURE, V372, P100, DOI 10.1038/372100a0; VANHAESEBROECK B, 1993, ONCOGENE, V8, P1075; VEIS DJ, 1993, J IMMUNOL, V151, P2546; VONBOEHMER H, 1994, CELL, V76, P219, DOI 10.1016/0092-8674(94)90330-1; VONFREEDENJEFFRY U, 1995, J EXP MED, V181, P1519, DOI 10.1084/jem.181.4.1519; Young F, 1997, IMMUNITY, V6, P23, DOI 10.1016/S1074-7613(00)80239-3	59	426	427	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 27	1997	89	7					1011	1019		10.1016/S0092-8674(00)80289-5	http://dx.doi.org/10.1016/S0092-8674(00)80289-5			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XG830	9215624	Bronze			2022-12-01	WOS:A1997XG83000006
J	Hoffman, DA; Magee, JC; Colbert, CM; Johnston, D				Hoffman, DA; Magee, JC; Colbert, CM; Johnston, D			K+ channel regulation of signal propagation in dendrites of hippocampal pyramidal neurons	NATURE			English	Article							ACTION-POTENTIALS; CELL DENDRITES; IN-VITRO; CA1; CONDUCTANCE; MODULATION; AMPLIFICATION; INACTIVATION; INTEGRATION; ACTIVATION	Pyramidal neurons receive tens of thousands of synaptic inputs on their dendrites. The dendrites dynamically after the strengths of these synapses and coordinate them to produce an output in ways that are not well understood. surprisingly, there turns out to be a very high density of transient A-type potassium ion channels in dendrites of hippocampal CA1 pyramidal neurons. These channels prevent initiation of an action potential in the dendrites, limit the back-propagation of action potentials into the dendrites, and reduce excitatory synaptic events. The channels act to prevent large, rapid dendritic depolarizations, thereby regulating orthograde and retrograde propagation of dendritic potentials.	BAYLOR COLL MED,DEPT NEUROSCI,HOUSTON,TX 77030	Baylor College of Medicine			Hoffman, Dax A/E-5155-2011	Hoffman, Dax A/0000-0001-6999-2157				Alonso G, 1997, NEUROSCIENCE, V77, P617; ANDREASEN M, 1995, J PHYSIOL-LONDON, V483, P421, DOI 10.1113/jphysiol.1995.sp020595; CALLAWAY JC, 1995, J NEUROPHYSIOL, V74, P1395, DOI 10.1152/jn.1995.74.4.1395; CHEN QX, 1991, J NEUROSCI, V11, P337; Christie BR, 1996, LEARN MEMORY, V3, P160, DOI 10.1101/lm.3.2-3.160; Colbert CM, 1996, J NEUROSCI, V16, P6676; COVARRUBIAS M, 1994, NEURON, V13, P1403, DOI 10.1016/0896-6273(94)90425-1; GAGE PW, 1992, TRENDS NEUROSCI, V15, P46, DOI 10.1016/0166-2236(92)90025-4; HALLIWELL JV, 1986, P NATL ACAD SCI USA, V83, P493, DOI 10.1073/pnas.83.2.493; Helmchen F, 1996, BIOPHYS J, V70, P1069, DOI 10.1016/S0006-3495(96)79653-4; Hines M, 1993, NEURAL SYSTEMS ANAL, P127; HOUNSGAARD J, 1988, J PHYSIOL-LONDON, V402, P731, DOI 10.1113/jphysiol.1988.sp017231; JAFFE DB, 1995, NATURE, V374, P1395; Johnston D, 1996, BIOPHYS J, V70, P1095, DOI 10.1016/S0006-3495(96)79674-1; Johnston D, 1996, ANNU REV NEUROSCI, V19, P165, DOI 10.1146/annurev.ne.19.030196.001121; KLEE R, 1995, J NEUROPHYSIOL, V74, P1982, DOI 10.1152/jn.1995.74.5.1982; Lipowsky R, 1996, J NEUROPHYSIOL, V76, P2181, DOI 10.1152/jn.1996.76.4.2181; MAGEE JC, 1995, J PHYSIOL-LONDON, V487, P67, DOI 10.1113/jphysiol.1995.sp020862; Magee JC, 1996, J NEUROPHYSIOL, V76, P3460, DOI 10.1152/jn.1996.76.5.3460; MAGEE JC, 1995, SCIENCE, V268, P301, DOI 10.1126/science.7716525; Magee JC, 1997, SCIENCE, V275, P209, DOI 10.1126/science.275.5297.209; Mainen ZF, 1995, NEURON, V15, P1427, DOI 10.1016/0896-6273(95)90020-9; MALETICSAVATIC M, 1995, J NEUROSCI, V15, P3840; Markram H, 1996, NATURE, V382, P807, DOI 10.1038/382807a0; NICOLL A, 1993, J PHYSIOL-LONDON, V468, P693, DOI 10.1113/jphysiol.1993.sp019795; Rapp M, 1996, P NATL ACAD SCI USA, V93, P11985, DOI 10.1073/pnas.93.21.11985; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; RUDY B, 1988, NEUROSCIENCE, V25, P729, DOI 10.1016/0306-4522(88)90033-4; SCHWINDT PC, 1995, J NEUROPHYSIOL, V74, P2220, DOI 10.1152/jn.1995.74.5.2220; SEGAL M, 1984, J NEUROSCI, V4, P604; SEGAL M, 1984, J NEUROPHYSIOL, V51, P1409, DOI 10.1152/jn.1984.51.6.1409; SERIDIO P, 1994, J NEUROPHYSIOL, V72, P1516; SHENG M, 1992, NEURON, V9, P271, DOI 10.1016/0896-6273(92)90166-B; SOLC CK, 1987, SCIENCE, V236, P1094, DOI 10.1126/science.2437657; SPRUSTON N, 1995, SCIENCE, V268, P297, DOI 10.1126/science.7716524; STORM JF, 1988, NATURE, V336, P379, DOI 10.1038/336379a0; STUART G, 1995, NEURON, V15, P1065, DOI 10.1016/0896-6273(95)90095-0; STUART GJ, 1994, NATURE, V367, P69, DOI 10.1038/367069a0; TALUKDER G, 1995, J NEUROPHYSIOL, V73, P73, DOI 10.1152/jn.1995.73.1.73; Tsubokawa H, 1996, J NEUROPHYSIOL, V76, P2896, DOI 10.1152/jn.1996.76.5.2896; TURNER RW, 1991, J NEUROSCI, V11, P2270; WU RL, 1992, J NEUROSCI, V12, P2235; YUSTE R, 1995, NATURE, V375, P682, DOI 10.1038/375682a0; Yuste R, 1996, NEURON, V16, P701, DOI 10.1016/S0896-6273(00)80091-4	44	1043	1088	0	47	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 26	1997	387	6636					869	875		10.1038/43119	http://dx.doi.org/10.1038/43119			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XG416	9202119	Bronze			2022-12-01	WOS:A1997XG41600041
J	Grodstein, F; Stampfer, MJ; Colditz, GA; Willett, WC; Manson, JE; Joffe, M; Rosner, B; Fuchs, C; Hankinson, SE; Hunter, DJ; Hennekens, CH; Speizer, FE				Grodstein, F; Stampfer, MJ; Colditz, GA; Willett, WC; Manson, JE; Joffe, M; Rosner, B; Fuchs, C; Hankinson, SE; Hunter, DJ; Hennekens, CH; Speizer, FE			Postmenopausal hormone therapy and mortality	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ESTROGEN REPLACEMENT THERAPY; FOLLOW-UP; WOMEN; DISEASE; CANCER; RISK	Background Postmenopausal hormone therapy has both benefits and hazards, including decreased risks of osteoporosis and cardiovascular disease and an increased risk of breast cancer. Methods We examined the relation between the use of postmenopausal hormones and mortality among participants in the Nurses' Health Study, who were 30 to 55 years of age at base line in 1976. Data were collected by biennial questionnaires beginning in 1976 and continuing th rough 1992. We documented 3637 deaths from 1976 to 1994. Each participant who died was matched with 10 controls alive at the time of her death. For each death, we defined the subject's hormone status according to the last biennial questionnaire before her death or before the diagnosis of the fatal disease; this reduced bias caused by the discontinuation of hormone use between the time of diagnosis of a potentially fatal disease and death. Results After adjustment for confounding variables, current hormone users had a lower risk-of death (relative risk, 0.63; 95 percent confidence interval, 0.56 to 0.70) than subjects who had never taken hormones; however, the apparent benefit decreased with long-term use (relative risk, 0.80; 0.67 to 0.96, after 10 or more years) because of an increase in mortality from breast cancer among long-term hormone users. Current hormone users with coronary risk factors (69 percent of the women) had the largest reduction in mortality (relative risk, 0.51; 95 percent confidence interval, 0.45 to 0.57), with substantially less benefit for those at low risk (13 percent of the women; relative risk, 0.89; 95 percent confidence interval, 0.62 to 1.28). Conclusions On average, mortality among women who use postmenopausal hormones is lower than among nonusers; however, the survival benefit diminishes with longer duration of use and is lower for women at low risk for coronary disease. (C)1997, Massachusetts Medical Society.	BRIGHAM & WOMENS HOSP,DIV PREVENT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT AMBULATORY CARE & PREVENT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Grodstein, F (corresponding author), BRIGHAM & WOMENS HOSP,CHANNING LAB,181 LONGWOOD AVE,BOSTON,MA 02115, USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NATIONAL CANCER INSTITUTE [R37CA040356, R01CA040356] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034594] Funding Source: NIH RePORTER; NCI NIH HHS [CA 40356] Funding Source: Medline; NHLBI NIH HHS [HL 34594] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARRETTCONNOR E, 1991, ANN INTERN MED, V115, P455, DOI 10.7326/0003-4819-115-6-455; BUSH TL, 1983, JAMA-J AM MED ASSOC, V249, P903, DOI 10.1001/jama.249.7.903; CALLE EE, 1995, J NATL CANCER I, V87, P517, DOI 10.1093/jnci/87.7.517; CAULEY JA, 1990, AM J OBSTET GYNECOL, V163, P1438, DOI 10.1016/0002-9378(90)90602-4; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; COLDITZ GA, 1995, NEW ENGL J MED, V333, P1357; CRIQUI MH, 1988, AM J EPIDEMIOL, V128, P606, DOI 10.1093/oxfordjournals.aje.a115008; Ettinger B, 1996, OBSTET GYNECOL, V87, P6, DOI 10.1016/0029-7844(95)00358-4; FOLSOM AR, 1995, AM J PUBLIC HEALTH, V85, P1128, DOI 10.2105/AJPH.85.8_Pt_1.1128; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; Grodstein F, 1996, AM J EPIDEMIOL, V143, P979; GRODSTEIN F, 1995, PROG CARDIOVASC DIS, V38, P199, DOI 10.1016/S0033-0620(95)80012-3; Grodstein F., 1996, American Journal of Epidemiology, V143, pS63; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; Grodstein F, 1996, NEW ENGL J MED, V335, P1406; HENDERSON BE, 1991, ARCH INTERN MED, V151, P75, DOI 10.1001/archinte.151.1.75; Hosmer DW, 2000, APPL LOGISTIC REGRES, V2nd; *NAT CTR HLTH STAT, 1967, DHEW PUBL, V1693; PETITTI DB, 1987, OBSTET GYNECOL, V70, P289; POSTHUMA WFM, 1994, BRIT MED J, V308, P1268; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; STURGEON SR, 1995, EPIDEMIOLOGY, V6, P227, DOI 10.1097/00001648-199505000-00006; VANDENBROUCKE JP, 1995, EPIDEMIOLOGY, V6, P207; WILLETT W, 1983, AM J EPIDEMIOL, V117, P651, DOI 10.1093/oxfordjournals.aje.a113598	24	981	994	0	12	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 19	1997	336	25					1769	1775		10.1056/NEJM199706193362501	http://dx.doi.org/10.1056/NEJM199706193362501			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XE485	9187066	Bronze			2022-12-01	WOS:A1997XE48500001
J	Sabri, O; Erkwoh, R; Schreckenberger, M; Owega, A; Sass, H; Buell, U				Sabri, O; Erkwoh, R; Schreckenberger, M; Owega, A; Sass, H; Buell, U			Correlation of positive symptoms exclusively to hyperperfusion or hypoperfusion of cerebral cortex in never-treated schizophrenics	LANCET			English	Article							EMISSION COMPUTED-TOMOGRAPHY; NEUROLEPTIC-NAIVE PATIENTS; BLOOD-FLOW; GLUCOSE-METABOLISM; SPECT; HYPOFRONTALITY; QUANTIFICATION; PATTERNS	Background Studies of schizophrenia by single photon emission computed tomography (SPECT) and positron emission tomography (PET) have shown both regional cerebral hyperperfusion and hypoperfusion. The aim of this study was to examine the inter-relations between regional cerebral blood flow (rCBF), psychopathology, and effects of neuroleptic therapy. Methods 24 never-treated patients with acute schizophrenia were examined with hexamethyl-propyleneamine-oxime brain SPECT and assessed psychopathologically according to the positive and negative syndrome scale; they were studied again after neuroleptic treatment and psychopathological remission. rCBF values that deviated from those of 20 controls by more than 2 SD were regarded as abnormal. Findings Both hyperperfused and hypoperfused patterns were found among schizophrenia patients during acute illness. The seven positive symptoms on the symptom scale showed different correlations with rCBF, formal thought disorders and grandiosity correlated positively (and strongly) with bifrontal and bitemporal rCBF; delusions, hallucinations, and distrust correlated negatively (and strongly) with cingulate, left thalamic, left frontal, and left temporal rCBF. Stereotyped ideas as a negative symptom correlated negatively (and strongly) with left frontal, cingulate, left temporal, and left parietal rCBF, After neuroleptic treatment (and reduction of positive symptoms), only negative symptoms correlated exclusively with bifrontal, bitemporal, cingulate, basal ganglia, and thalamic hypoperfusion, Interpretation Different positive symptoms are accompanied by different rCBF values-some related to hyperperfusion, others to hypoperfusion. This finding may help to explain observed inconsistencies of perfusion patterns in drug-naive schizophrenics.	RHEIN WESTFAL TH AACHEN,DEPT PSYCHIAT,D-52057 AACHEN,GERMANY	RWTH Aachen University	Sabri, O (corresponding author), RHEIN WESTFAL TH AACHEN,DEPT NUCL MED,PAUWELSSTR 30,D-52057 AACHEN,GERMANY.			Sabri, Osama/0000-0002-6425-3504				ANDREASEN NC, 1992, ARCH GEN PSYCHIAT, V49, P943; Association AP, 1987, DIAGNOSTIC STAT MANU; BRODIE JD, 1984, ANN NEUROL, V15, P166; CATAFAU AM, 1994, J NUCL MED, V35, P935; CHANG LT, 1978, IEEE T NUCL SCI, V25, P638, DOI 10.1109/TNS.1978.4329385; COSTA DC, 1986, NUCL MED COMMUN, V7, P647; EBMEIER KP, 1993, BIOL PSYCHIAT, V33, P487, DOI 10.1016/0006-3223(93)90002-U; FLURY B, 1983, ANGEW MULTIVARIATE S, P135; HOLM S, 1979, SCAND J STAT, V6, P65; KAISER HJ, 1994, NUKLEARMED, V33, P123; KAY SR, 1987, SCHIZOPHRENIA BULL, V13, P261, DOI 10.1093/schbul/13.2.261; KOJIMA A, 1989, J NUCL MED, V30, P508; Kretschmann H. J., 1991, KLINISCHE NEUROANATO; LEWIS SW, 1992, PSYCHOL MED, V22, P27, DOI 10.1017/S0033291700032694; LIDDLE PF, 1992, BRIT J PSYCHIAT, V160, P179, DOI 10.1192/bjp.160.2.179; Mellers JDC, 1996, ACTA PSYCHIAT SCAND, V93, P92, DOI 10.1111/j.1600-0447.1996.tb09808.x; PAULMAN RG, 1990, BIOL PSYCHIAT, V27, P377, DOI 10.1016/0006-3223(90)90549-H; SABRI O, 1995, NUKLEARMED-NUCL MED, V34, P50; SHEPPARD G, 1983, LANCET, V2, P1448, DOI 10.1016/S0140-6736(83)90798-5; SYED GMS, 1992, NUCL MED COMMUN, V13, P811, DOI 10.1097/00006231-199211000-00007; SYED GMS, 1992, NUCL MED COMMUN, V13, P879, DOI 10.1097/00006231-199212000-00005; SZECHTMAN H, 1988, ARCH GEN PSYCHIAT, V45, P523; TALAIRACIN J, 1967, ATLAS ANATOMIE STERE; VOLKOW ND, 1986, J NEUROL NEUROSUR PS, V49, P1199, DOI 10.1136/jnnp.49.10.1199; WIESEL FA, 1987, ACTA PSYCHIAT SCAND, V76, P628, DOI 10.1111/j.1600-0447.1987.tb02933.x; WOLKIN A, 1985, AM J PSYCHIAT, V142, P564; WOLKIN A, 1992, ARCH GEN PSYCHIAT, V49, P959	27	146	150	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 14	1997	349	9067					1735	1739		10.1016/S0140-6736(96)08380-8	http://dx.doi.org/10.1016/S0140-6736(96)08380-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XE065	9193384				2022-12-01	WOS:A1997XE06500011
J	Fox, CA; EhrenhoferMurray, AE; Loo, S; Rine, J				Fox, CA; EhrenhoferMurray, AE; Loo, S; Rine, J			The origin recognition complex, SIR1, and the S phase requirement for silencing	SCIENCE			English	Article							MATING-TYPE LOCUS; SACCHAROMYCES-CEREVISIAE; DNA-REPLICATION; CELL-CYCLE; TRANSCRIPTIONAL ACTIVATION; SHUTTLE VECTORS; GENE-EXPRESSION; YEAST SILENCER; REPRESSION; PROTEINS	Silencing of transcription in Saccharomyces cerevisiae has several links to DNA replication, including a role for the origin recognition complex (ORC), the DNA replication initiator, in both processes. In addition, the establishment of silencing at the HML and HMR loci requires cells to pass through the S phase of the cell cycle. Passage through S phase was required for silencing of HMR even under conditions in which ORC itself was no longer required. The requirement for ORC in silencing of HMR could be bypassed by tethering the Sir1 protein to the HMR-E silencer. However, ORC had a Sir1-independent role in transcriptional silencing at telomeres. Thus, the role of ORC in silencing was separable from its role in initiation, and the role of S phase in silencing was independent of replication initiation at the silencers.	UNIV CALIF BERKELEY, DEPT MOL & CELL BIOL, DIV GENET, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM031105, R01GM031105] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31105] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM J, 1984, J MOL BIOL, V176, P307, DOI 10.1016/0022-2836(84)90492-3; AMMERER G, 1983, METHOD ENZYMOL, V101, P192; APARICIO OM, 1994, GENE DEV, V8, P1133, DOI 10.1101/gad.8.10.1133; APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; AXELROD A, 1991, MOL CELL BIOL, V11, P1080, DOI 10.1128/MCB.11.2.1080; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1995, CELL, V83, P563, DOI 10.1016/0092-8674(95)90096-9; BRAND AH, 1987, CELL, V51, P709, DOI 10.1016/0092-8674(87)90094-8; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; CHEREST H, 1987, MOL GEN GENET, V210, P307, DOI 10.1007/BF00325699; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHIEN CT, 1993, CELL, V75, P531, DOI 10.1016/0092-8674(93)90387-6; CORMACK BP, 1993, SCIENCE, V262, P244, DOI 10.1126/science.8211143; DUBEY DD, 1991, MOL CELL BIOL, V11, P5346, DOI 10.1128/MCB.11.10.5346; FELDMAN JB, 1984, J MOL BIOL, V178, P815, DOI 10.1016/0022-2836(84)90313-9; FELICI F, 1989, MOL CELL BIOL, V9, P3260, DOI 10.1128/MCB.9.8.3260; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; FOX C, UNPUB; FOX CA, 1995, GENE DEV, V9, P911, DOI 10.1101/gad.9.8.911; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; HARTWELL LH, 1976, J MOL BIOL, V104, P803, DOI 10.1016/0022-2836(76)90183-2; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; HENDERSON DS, 1994, EMBO J, V13, P1450, DOI 10.1002/j.1460-2075.1994.tb06399.x; JACOBS CW, 1988, J CELL BIOL, V107, P1409, DOI 10.1083/jcb.107.4.1409; KIMMERLY W, 1988, EMBO J, V7, P2241, DOI 10.1002/j.1460-2075.1988.tb03064.x; Loo S, 1995, ANNU REV CELL DEV BI, V11, P519, DOI 10.1146/annurev.cellbio.11.1.519; LOO S, 1995, MOL BIOL CELL, V6, P741, DOI 10.1091/mbc.6.6.741; MCNALLY FJ, 1991, MOL CELL BIOL, V11, P5648, DOI 10.1128/MCB.11.11.5648; MICKLEM G, 1993, NATURE, V366, P87, DOI 10.1038/366087a0; MILLER AM, 1984, NATURE, V312, P247, DOI 10.1038/312247a0; PALLADINO F, 1993, CELL, V75, P543, DOI 10.1016/0092-8674(93)90388-7; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RIVIER D, UNPUB; RIVIER DH, 1992, SCIENCE, V256, P659, DOI 10.1126/science.1585179; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SCHENA M, 1991, METHOD ENZYMOL, V194, P389; SIKORSKI RS, 1989, GENETICS, V122, P19; Triolo T, 1996, NATURE, V381, P251, DOI 10.1038/381251a0; ZHU JG, 1992, MOL CELL BIOL, V12, P4733, DOI 10.1128/MCB.12.10.4733	42	137	138	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 6	1997	276	5318					1547	1551		10.1126/science.276.5318.1547	http://dx.doi.org/10.1126/science.276.5318.1547			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XC701	9171055				2022-12-01	WOS:A1997XC70100038
J	Das, A; Gilbert, CD				Das, A; Gilbert, CD			Distortions of visuotopic map match orientation singularities in primary visual cortex	NATURE			English	Article							MONKEY STRIATE CORTEX; FUNCTIONAL ARCHITECTURE; INTRINSIC SIGNALS; DYNAMIC CHANGES; FIELD SIZE; ORGANIZATION	The map of orientation columns in primary visual cortex (V1) is known to show strong local distortions, with a generally smooth progression of orientation preference across extended regions of cortex, interrupted by sharp jumps (fractures) and point singularities(1-4). The map of visual space on V1, in contrast, has been assumed to be locally smooth and isotropic. We find, on the contrary, that the map of visual space on cat V1 shows strong and systematic local distortions in register with inhomogeneities in the orientation map, with the rate of receptive field movement across cortex being largely proportional to the local rate of change of orientation. This suggests possible systematic local variations in the functional connectivity of short-range lateral connections that underlie local cortical processing.	ROCKEFELLER UNIV,NEW YORK,NY 10021	Rockefeller University								[Anonymous], 1941, AM J OPHTHALMOL, DOI [10.1016/S0002-9394(41)91363-6, DOI 10.1016/S0002-9394(41)91363-6]; BLASDEL GG, 1986, NATURE, V321, P579, DOI 10.1038/321579a0; BONHOEFFER T, 1991, NATURE, V353, P429, DOI 10.1038/353429a0; DANIEL PM, 1961, J PHYSIOL-LONDON, V159, P203, DOI 10.1113/jphysiol.1961.sp006803; DAS A, 1995, J NEUROPHYSIOL, V74, P779, DOI 10.1152/jn.1995.74.2.779; DURBIN R, 1990, NATURE, V343, P644, DOI 10.1038/343644a0; FROSTIG RD, 1990, P NATL ACAD SCI USA, V87, P6082, DOI 10.1073/pnas.87.16.6082; GRINVALD A, 1986, NATURE, V324, P361, DOI 10.1038/324361a0; HUBEL DH, 1974, J COMP NEUROL, V158, P295, DOI 10.1002/cne.901580305; HUBEL DH, 1974, J COMP NEUROL, V158, P267, DOI 10.1002/cne.901580304; MOTTER BC, 1993, J NEUROPHYSIOL, V70, P909, DOI 10.1152/jn.1993.70.3.909; PETTET MW, 1992, P NATL ACAD SCI USA, V89, P8366, DOI 10.1073/pnas.89.17.8366; TSO DY, 1990, SCIENCE, V249, P417, DOI 10.1126/science.2165630	13	99	99	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 5	1997	387	6633					594	598		10.1038/42461	http://dx.doi.org/10.1038/42461			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XC522	9177346				2022-12-01	WOS:A1997XC52200054
J	Bashaw, GJ; Baker, BS				Bashaw, GJ; Baker, BS			The regulation of the Drosophila msl-2 gene reveals a function for Sex-lethal in translational control	CELL			English	Article							DOSAGE COMPENSATION; TRANSFORMER GENE; X-CHROMOSOMES; RNA-BINDING; IN-VIVO; MELANOGASTER; PROTEIN; EXPRESSION; DIFFERENTIATION; LOCALIZATION	In Drosophila, dosage compensation occurs by increasing the transcription of the single male X chromosome. Four trans-acting factors encoded by the male-specific lethal genes are required for this process. Dosage compensation is restricted to males by the splicing regulator Sex-lethal, which functions to prevent the production of the MSL-2 protein in females by an unknown mechanism. In this report, we provide evidence that Sex-lethal acts synergistically through sequences in both the 5' and 3' untranslated regions of MSL-2 to mediate repression. We also provide evidence that the repression of MSL-2 is directly regulated by Sex-lethal at the level of translation.			Bashaw, GJ (corresponding author), STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305, USA.							BAKER BS, 1994, ANNU REV GENET, V28, P491, DOI 10.1146/annurev.ge.28.120194.002423; BASHAW GJ, 1995, DEVELOPMENT, V121, P3245; BELL LR, 1991, CELL, V65, P229, DOI 10.1016/0092-8674(91)90157-T; BERK AJ, 1978, CELL, V14, P695, DOI 10.1016/0092-8674(78)90252-0; BOGGS RT, 1987, CELL, V50, P739, DOI 10.1016/0092-8674(87)90332-1; Bone JR, 1996, GENETICS, V144, P705; BOPP D, 1991, GENE DEV, V5, P403, DOI 10.1101/gad.5.3.403; CLINE TW, 1993, TRENDS GENET, V9, P385, DOI 10.1016/0168-9525(93)90138-8; Cline TW, 1996, ANNU REV GENET, V30, P637, DOI 10.1146/annurev.genet.30.1.637; CURTIS D, 1995, CELL, V81, P171, DOI 10.1016/0092-8674(95)90325-9; DECKER CJ, 1995, CURR OPIN CELL BIOL, V7, P386, DOI 10.1016/0955-0674(95)80094-8; Dubnau J, 1996, NATURE, V379, P694, DOI 10.1038/379694a0; Franke A, 1996, DEVELOPMENT, V122, P2751; GORMAN M, 1995, DEVELOPMENT, V121, P463; GORMAN M, 1993, CELL, V72, P39, DOI 10.1016/0092-8674(93)90048-U; HILFIKER A, 1994, EMBO J, V13, P3542, DOI 10.1002/j.1460-2075.1994.tb06661.x; HINNEBUSCH AG, 1994, TRENDS BIOCHEM SCI, V19, P409, DOI 10.1016/0968-0004(94)90089-2; JONES FE, 1995, J VIROL, V69, P4863, DOI 10.1128/JVI.69.8.4863-4871.1995; KELLEY RL, 1995, CELL, V81, P867, DOI 10.1016/0092-8674(95)90007-1; KELLEY RL, 1995, SCIENCE, V270, P1607, DOI 10.1126/science.270.5242.1607; LUCCHESI JC, 1987, ADV GENET, V24, P371, DOI 10.1016/S0065-2660(08)60013-9; Marin I, 1996, NATURE, V383, P160, DOI 10.1038/383160a0; NAGOSHI RN, 1988, CELL, V53, P229, DOI 10.1016/0092-8674(88)90384-4; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; RiveraPomar R, 1996, NATURE, V379, P746, DOI 10.1038/379746a0; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; RYNER LC, 1991, GENE DEV, V5, P2071, DOI 10.1101/gad.5.11.2071; Sambrook J., 1989, MOL CLONING LAB MANU; SAMUELS ME, 1994, MOL CELL BIOL, V14, P4975, DOI 10.1128/MCB.14.7.4975; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; Smibert CA, 1996, GENE DEV, V10, P2600, DOI 10.1101/gad.10.20.2600; Sokal R., 1981, BIOMETRY; SOSNOWSKI BA, 1989, CELL, V58, P449, DOI 10.1016/0092-8674(89)90426-1; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; WANG JW, 1994, GENE DEV, V8, P2072, DOI 10.1101/gad.8.17.2072; ZHOU SB, 1995, EMBO J, V14, P2884, DOI 10.1002/j.1460-2075.1995.tb07288.x	38	166	170	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 30	1997	89	5					789	798		10.1016/S0092-8674(00)80262-7	http://dx.doi.org/10.1016/S0092-8674(00)80262-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XB925	9182767	Bronze			2022-12-01	WOS:A1997XB92500016
J	Reif, B; Hennig, M; Griesinger, C				Reif, B; Hennig, M; Griesinger, C			Direct measurement of angles between bond vectors in high-resolution NMR	SCIENCE			English	Article							CHEMICAL-SHIFT TENSORS; LARGER PROTEINS; EXCHANGE SPECTROSCOPY; BACKBONE DYNAMICS; C-13; N-15; RELAXATION; MACROMOLECULES; CALMODULIN; SPECTRA	Angles between two interatomic vectors are measured for structure elucidation in solution nuclear magnetic resonance (NMR). The angles can be determined directly by using the effects of dipole-dipole cross-correlated relaxation of double-quantum and zero-quantum coherences. The measured rates can be directly related to the angular geometry without need for calibration of a Karplus-type curve, as is the case for scalar coupling measurements, and depend only on the rotational correlation time of the molecule as an empirical parameter. This makes the determination of torsional angles independent from the measurement of coupling constants. The two interatomic vectors can in principle be arbitrarily far apart. The method was demonstrated on the measurement of the peptide backbone angle psi in the protein rhodniin, which is difficult to determine in solution by NMR spectroscopy.	UNIV FRANKFURT, INST ORGAN CHEM, D-60439 FRANKFURT, GERMANY	Goethe University Frankfurt				Reif, Bernd/0000-0001-7368-7198				ABRAGAM A, 1961, PRINCIPLES NUCLEAR M; BARBATO G, 1992, BIOCHEMISTRY-US, V31, P5269, DOI 10.1021/bi00138a005; BATEY RT, 1992, NUCLEIC ACIDS RES, V20, P4515, DOI 10.1093/nar/20.17.4515; BAX A, 1991, Journal of Biomolecular NMR, V1, P99, DOI 10.1007/BF01874573; BLOEMBERGEN N, 1948, PHYS REV, V73, P679, DOI 10.1103/PhysRev.73.679; BRUSCHWEILER R, 1989, J AM CHEM SOC, V111, P8034; Cavanagh J., 1996, PROTEIN NMR SPECTROS; CLORE GM, 1991, BIOCHEMISTRY-US, V30, P12, DOI 10.1021/bi00215a002; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P7387, DOI 10.1021/bi00484a006; CLORE GM, 1991, SCIENCE, V252, P1390, DOI 10.1126/science.2047852; DABBAGH G, 1994, MACROMOLECULES, V27, P6183, DOI 10.1021/ma00099a038; DUNCAN TM, 1990, COMPILATION CHEM SHI; EMSLEY L, 1989, J MAGN RESON, V82, P211, DOI 10.1016/0022-2364(89)90185-6; EMSLEY L, 1990, CHEM PHYS LETT, V165, P469, DOI 10.1016/0009-2614(90)87025-M; Feng X, 1996, CHEM PHYS LETT, V257, P314, DOI 10.1016/0009-2614(96)00558-1; FU RQ, 1995, CHEM PHYS LETT, V245, P415, DOI 10.1016/0009-2614(95)01037-A; GRIESINGER C, 1987, J AM CHEM SOC, V109, P7227, DOI 10.1021/ja00257a074; GRIESINGER C, 1987, J MAGN RESON, V73, P574, DOI 10.1016/0022-2364(87)90027-8; HARTZELL CJ, 1987, J AM CHEM SOC, V109, P5966, DOI 10.1021/ja00254a012; IKURA M, 1990, BIOCHEMISTRY-US, V29, P4659, DOI 10.1021/bi00471a022; IKURA M, 1990, J AM CHEM SOC, V112, P9020, DOI 10.1021/ja00180a080; JANES N, 1983, J MAGN RESON, V54, P111, DOI 10.1016/0022-2364(83)90150-6; KARPLUS M, 1959, J CHEM PHYS, V30, P11, DOI 10.1063/1.1729860; KARPLUS M, 1963, J AM CHEM SOC, V85, P2870, DOI 10.1021/ja00901a059; KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003; KAY LE, 1990, SCIENCE, V249, P411, DOI 10.1126/science.2377896; LINDER M, 1980, J CHEM PHYS, V73, P4959, DOI 10.1063/1.439973; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; LUMSDEN MD, 1994, J AM CHEM SOC, V116, P1403, DOI 10.1021/ja00083a028; MADI Z, 1989, WTEST PROGRAM PACKAG; Maurer M. T., UNPUB; MICHNICKA MJ, 1993, BIOCHEMISTRY-US, V32, P395, DOI 10.1021/bi00053a002; NIKONOWICZ EP, 1992, NUCLEIC ACIDS RES, V20, P4507, DOI 10.1093/nar/20.17.4507; OH BH, 1988, SCIENCE, V240, P908, DOI 10.1126/science.3129784; OSCHKINAT H, 1988, NATURE, V332, P374, DOI 10.1038/332374a0; Phan IQH, 1996, J BIOMOL NMR, V8, P369, DOI 10.1007/BF00228140; QUANT S, 1994, THL, V36, P6649; Schmidt-Rohr K, 1996, J AM CHEM SOC, V118, P7601, DOI 10.1021/ja9605782; Schmidt-Rohr K, 1996, MACROMOLECULES, V29, P3975, DOI 10.1021/ma9517106; Smith LJ, 1996, J MOL BIOL, V255, P494, DOI 10.1006/jmbi.1996.0041; SOLOMON I, 1955, PHYS REV, V99, P559, DOI 10.1103/PhysRev.99.559; SOLOMON I, 1956, J CHEM PHYS, V25, P261, DOI 10.1063/1.1742867; Tjandra N, 1996, J AM CHEM SOC, V118, P6264, DOI 10.1021/ja960106n; TJANDRA N, 1995, EUR J BIOCHEM, V230, P1014, DOI 10.1111/j.1432-1033.1995.tb20650.x; Tjandra N, 1996, J AM CHEM SOC, V118, P6986, DOI 10.1021/ja960510m; TOLMAN JR, 1995, P NATL ACAD SCI USA, V92, P9279, DOI 10.1073/pnas.92.20.9279; VANDELOCHT A, 1995, EMBO J, V14, P5149, DOI 10.1002/j.1460-2075.1995.tb00199.x; WANG AC, 1995, J AM CHEM SOC, V117, P1810, DOI 10.1021/ja00111a021; Werbelow L.G., 1977, ADV MAGN RESON, V9, P189, DOI 10.1016/b978-0-12-025509-2.50008-7; WOESSNER DE, 1962, J CHEM PHYS, V36, P1, DOI 10.1063/1.1732274; WOESSNER DE, 1962, J CHEM PHYS, V37, P647, DOI 10.1063/1.1701390; Wuthrich K., 1986, NMR PROTEINS NUCL AC; ZUIDERWEG ERP, 1991, J AM CHEM SOC, V113, P370, DOI 10.1021/ja00001a060	53	265	267	0	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 23	1997	276	5316					1230	1233		10.1126/science.276.5316.1230	http://dx.doi.org/10.1126/science.276.5316.1230			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XA497	9157875				2022-12-01	WOS:A1997XA49700034
J	Weldon, M				Weldon, M			A useful collagenous colitis registry	LANCET			English	Editorial Material							DIARRHEA				Weldon, M (corresponding author), ST GEORGE HOSP,SCH MED,DIV GASTROENTEROL ENDOCRINOL & METAB,CRANMER TERRACE,LONDON SW17 0RE,ENGLAND.							CARPENTER HA, 1992, DIGEST DIS SCI, V37, P1903, DOI 10.1007/BF01308086; Halaby IA, 1996, DIS COLON RECTUM, V39, P573, DOI 10.1007/BF02058714; JARNEROT G, 1995, GASTROENTEROLOGY, V109, P449, DOI 10.1016/0016-5085(95)90332-1; LEWIS FW, 1991, DIGEST DIS SCI, V36, P1161, DOI 10.1007/BF01297466; LINDSTROM CG, 1976, PATHOL EUR, V11, P87; RASKMADSEN J, 1983, DIGEST DIS SCI, V28, P1141, DOI 10.1007/BF01295815; TYSK BJ, 1996, GUT, V39, P846	7	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 17	1997	349	9063					1410	1411		10.1016/S0140-6736(05)63720-8	http://dx.doi.org/10.1016/S0140-6736(05)63720-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WZ765	9164312				2022-12-01	WOS:A1997WZ76500005
J	Hamman, BD; Chen, JC; Johnson, EE; Johnson, AE				Hamman, BD; Chen, JC; Johnson, EE; Johnson, AE			The aqueous pore through the translocon has a diameter of 40-60 angstrom during cotranslational protein translocation at the ER membrane	CELL			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; NICOTINAMIDE ADENINE-DINUCLEOTIDE; SOLUTION CONFORMATIONAL DYNAMICS; NUCLEAR MAGNETIC-RESONANCE; SIGNAL-SEQUENCE; 3-DIMENSIONAL STRUCTURE; PYRIDINE DINUCLEOTIDES; PHOTOCROSS-LINKING; COMPLEX; TUNNEL	Eukaryotic secretory proteins are cotranslationally translocated through the endoplasmic reticulum (ER) membrane via aqueous pores that span the lipid bilayer. Fluorescent probes were incorporated into nascent secretory proteins using modified Lys-tRNAs, and the resulting nascent chains were sealed off from the cytosol in fully assembled translocation intermediates. Fluorescence quenching agents of different sizes were then introduced into the ER lumen in order to determine which were small enough to enter the pore and to quench the fluorescence of probes inside the ribosome and/or the pore. These accessibility studies showed that the aqueous pore in a functioning translocon is 40-60 Angstrom in diameter, making it the largest hole observed to date in a membrane that must maintain a permeability barrier.	TEXAS A&M UNIV, DEPT MED BIOCHEM & GENET, COLLEGE STN, TX 77843 USA; TEXAS A&M UNIV, DEPT CHEM, COLLEGE STN, TX 77843 USA; TEXAS A&M UNIV, DEPT BIOCHEM & BIOPHYS, COLLEGE STN, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station			Johnson, Arthur E/G-3457-2012		NIGMS NIH HHS [GM 26494] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026494] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; Andrews DW, 1996, TRENDS BIOCHEM SCI, V21, P365; Bell CE, 1996, BIOCHEMISTRY-US, V35, P1137, DOI 10.1021/bi9520848; BLOBEL G, 1970, J CELL BIOL, V45, P130, DOI 10.1083/jcb.45.1.130; Borel AC, 1996, CELL, V85, P379, DOI 10.1016/S0092-8674(00)81116-2; CHATTOPADHYAY SK, 1983, J AM CHEM SOC, V105, P6205, DOI 10.1021/ja00358a002; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; Do H, 1996, CELL, V85, P369, DOI 10.1016/S0092-8674(00)81115-0; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; Hanein D, 1996, CELL, V87, P721, DOI 10.1016/S0092-8674(00)81391-4; Harlow E LD, 1988, ANTIBODIES LAB MANUA, V1st; HEDGE RS, 1996, CELL, V85, P217; HERRON JN, 1989, PROTEINS, V5, P271, DOI 10.1002/prot.340050404; HIGH S, 1993, J BIOL CHEM, V268, P26745; Johnson AE, 1995, COLD SPRING HARB SYM, V60, P71, DOI 10.1101/SQB.1995.060.01.010; KRIEG UC, 1989, J CELL BIOL, V109, P2033, DOI 10.1083/jcb.109.5.2033; Lakowicz J. R., 2006, PRINCIPLES FLUORESCE, DOI 10.1007/978-0-387-46312-4; Li M, 1996, P NATL ACAD SCI USA, V93, P6902, DOI 10.1073/pnas.93.14.6902; MALKIN LI, 1967, J MOL BIOL, V26, P329, DOI 10.1016/0022-2836(67)90301-4; McCracken AA, 1996, J CELL BIOL, V132, P291, DOI 10.1083/jcb.132.3.291; NICCHITTA CV, 1993, CELL, V73, P989, DOI 10.1016/0092-8674(93)90276-V; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; SHAW AS, 1988, P NATL ACAD SCI USA, V85, P7592, DOI 10.1073/pnas.85.20.7592; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cellbio.10.1.87; WIERTZ EJH, 1996, CELL, V84, P669; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Wilkinson BM, 1996, J BIOL CHEM, V271, P25590, DOI 10.1074/jbc.271.41.25590; WILSON IA, 1991, METHOD ENZYMOL, V203, P153; WOLIN SL, 1988, EMBO J, V7, P3559, DOI 10.1002/j.1460-2075.1988.tb03233.x; ZENS AP, 1975, J AM CHEM SOC, V97, P2850, DOI 10.1021/ja00843a040; ZENS AP, 1976, J AM CHEM SOC, V98, P7559, DOI 10.1021/ja00440a019; [No title captured]	37	233	238	0	6	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 16	1997	89	4					535	544		10.1016/S0092-8674(00)80235-4	http://dx.doi.org/10.1016/S0092-8674(00)80235-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WZ323	9160745	Bronze			2022-12-01	WOS:A1997WZ32300007
J	Kellermayer, MSZ; Smith, SB; Granzier, HL; Bustamante, C				Kellermayer, MSZ; Smith, SB; Granzier, HL; Bustamante, C			Folding-unfolding transitions in single titin molecules characterized with laser tweezers	SCIENCE			English	Article							SKELETAL-MUSCLE; STRIATED-MUSCLE; SARCOMERE-LENGTH; PASSIVE TENSION; CARDIAC-MUSCLE; ELASTICITY; FILAMENTS; PROTEIN; FIBRONECTIN; CONNECTIN	Titin, a giant filamentous polypeptide, is believed to play a fundamental role in maintaining sarcomeric structural integrity and developing what is known as passive force in muscle. Measurements of the force required to stretch a single molecule revealed that titin behaves as a highly nonlinear entropic spring. The molecule unfolds in a high-force transition beginning at 20 to 30 piconewtons and refolds in a low-force transition at similar to 2.5 piconewtons. A fraction of the molecule (5 to 40 percent) remains permanently unfolded, behaving as a wormlike chain with a persistence length (a measure of the chain's bending rigidity) of 20 angstroms. Force hysteresis arises from a difference between the unfolding and refolding kinetics of the molecule relative to the stretch and release rates in the experiments, respectively. Scaling the molecular data up to sarcomeric dimensions reproduced many features of the passive force versus extension curve of muscle fibers.	WASHINGTON STATE UNIV,DEPT VET COMPARAT ANAT PHARMACOL & PHYSIOL,PULLMAN,WA 99164; UNIV OREGON,HOWARD HUGHES MED INST,INST MOL BIOL,EUGENE,OR 97403	Washington State University; Howard Hughes Medical Institute; University of Oregon					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR042652] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM032543, R01GM032543] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-42652] Funding Source: Medline; NIGMS NIH HHS [GM-32543] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUSTAMANTE C, 1994, SCIENCE, V265, P1599, DOI 10.1126/science.8079175; ERICKSON HP, 1994, P NATL ACAD SCI USA, V91, P10114, DOI 10.1073/pnas.91.21.10114; FRITZ JD, 1993, COMP BIOCHEM PHYS B, V105, P357, DOI 10.1016/0305-0491(93)90241-V; FURST DO, 1988, J CELL BIOL, V106, P1563, DOI 10.1083/jcb.106.5.1563; GOTO Y, 1982, J MOL BIOL, V156, P911, DOI 10.1016/0022-2836(82)90147-4; GRANZIER HL, 1995, BIOPHYS J, V68, P1027, DOI 10.1016/S0006-3495(95)80278-X; GRANZIER HLM, 1993, BIOPHYS J, V65, P2141, DOI 10.1016/S0006-3495(93)81262-1; GRANZIER HLM, 1991, AM J PHYSIOL, V260, pC1060, DOI 10.1152/ajpcell.1991.260.5.C1060; HIGUCHI H, 1993, BIOPHYS J, V65, P1906, DOI 10.1016/S0006-3495(93)81261-X; HOROWITS R, 1987, J CELL BIOL, V105, P2217, DOI 10.1083/jcb.105.5.2217; HOROWITS R, 1986, NATURE, V323, P160, DOI 10.1038/323160a0; KIEFHABER T, 1992, J MOL BIOL, V224, P217, DOI 10.1016/0022-2836(92)90585-8; KRATKY O, 1949, RECL TRAV CHIM PAY B, V68, P1106; Kuhn W, 1942, KOLLOID Z, V101, P248, DOI 10.1007/BF01793684; LABEIT S, 1992, EMBO J, V11, P1711, DOI 10.1002/j.1460-2075.1992.tb05222.x; LABEIT S, 1995, SCIENCE, V270, P293, DOI 10.1126/science.270.5234.293; LABEIT S, 1990, NATURE, V345, P273, DOI 10.1038/345273a0; Linke WA, 1996, J MOL BIOL, V261, P62, DOI 10.1006/jmbi.1996.0441; MAIN AL, 1992, CELL, V71, P671, DOI 10.1016/0092-8674(92)90600-H; Marko JF, 1995, MACROMOLECULES, V28, P8759, DOI 10.1021/ma00130a008; MARUYAMA K, 1994, BIOPHYS CHEM, V50, P73, DOI 10.1016/0301-4622(94)85021-6; NAVE R, 1989, J CELL BIOL, V109, P2177, DOI 10.1083/jcb.109.5.2177; PAN KM, 1994, BIOCHEMISTRY-US, V33, P8255, DOI 10.1021/bi00193a012; Plaxco KW, 1996, P NATL ACAD SCI USA, V93, P10703, DOI 10.1073/pnas.93.20.10703; Smith SB, 1996, SCIENCE, V271, P795, DOI 10.1126/science.271.5250.795; SMITH SS, UNPUB; SOTERIOU A, 1993, P ROY SOC B-BIOL SCI, V254, P83, DOI 10.1098/rspb.1993.0130; TRINICK J, 1984, J MOL BIOL, V180, P331, DOI 10.1016/S0022-2836(84)80007-8; TROMBITAS K, 1993, J MUSCLE RES CELL M, V14, P416, DOI 10.1007/BF00121293; Tskhovrebova L, 1997, J MOL BIOL, V265, P100, DOI 10.1006/jmbi.1996.0717; WANG K, 1984, P NATL ACAD SCI-BIOL, V81, P3685, DOI 10.1073/pnas.81.12.3685; Wang K, 1985, Cell Muscle Motil, V6, P315	32	975	1001	1	144	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 16	1997	276	5315					1112	1116		10.1126/science.276.5315.1112	http://dx.doi.org/10.1126/science.276.5315.1112			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WZ225	9148805				2022-12-01	WOS:A1997WZ22500044
J	Zheng, WP; Flavell, RA				Zheng, WP; Flavell, RA			The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells	CELL			English	Article							MURINE IL-4 GENE; TYROSINE PHOSPHORYLATION; MESSENGER-RNAS; DIFFERENTIATION; INTERLEUKIN-4; PROMOTER; MICE; ACTIVATION; INHIBITION; DISRUPTION	CD4 T cells potentiate the inflammatory or humoral immune response through the action of Th1 and Th2 cells, respectively. The molecular basis of the differentiation of these cells from naive T cell precursors is, however, unclear. We found that GATA-3 was selectively expressed in Th2 cells. GATA-3 is expressed at a high level in naive, freshly activated T cells and Th2 lineage cells, but subsides to a minimal level in Th1 lineage cells as naive cells commit to their Th subset. Antisense GATA-3 inhibited the expression of all Th2 cytokine genes in the Th2 clone D10. GATA-3 directly activated an IL-4 promoter-luciferase reporter gene in M12 cells. In transgenic mice, elevated GATA-3 in CD4 T cells caused Th2 cytokine gene expression in developing Th1 cells. Thus, GATA-3 is necessary and sufficient for Th2 cytokine gene expression.	YALE UNIV,SCH MED,HOWARD HUGHES MED INST,IMMUNOBIOL SECT,NEW HAVEN,CT 06520	Howard Hughes Medical Institute; Yale University								Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; ABEHSIRAAMAR O, 1992, J IMMUNOL, V148, P3820; BACON CM, 1995, P NATL ACAD SCI USA, V92, P7307, DOI 10.1073/pnas.92.16.7307; CROFT M, 1995, J IMMUNOL, V154, P4269; DAVYDOV IV, 1995, J IMMUNOL, V155, P5273; GEORGE KM, 1994, DEVELOPMENT, V120, P2673; GREPIN C, 1995, MOL CELL BIOL, V15, P4095; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; Hattori N, 1996, J EXP MED, V184, P1137, DOI 10.1084/jem.184.3.1137; HO IC, 1991, EMBO J, V10, P1187, DOI 10.1002/j.1460-2075.1991.tb08059.x; Ho IC, 1996, CELL, V85, P973, DOI 10.1016/S0092-8674(00)81299-4; Hodge MR, 1996, SCIENCE, V274, P1903, DOI 10.1126/science.274.5294.1903; HODGE MR, 1995, J IMMUNOL, V154, P6397; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; JACOBSON NG, 1995, J EXP MED, V181, P1755, DOI 10.1084/jem.181.5.1755; KAMOGAWA Y, 1993, CELL, V75, P985, DOI 10.1016/0092-8674(93)90542-X; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; Kaplan MH, 1996, NATURE, V382, P174, DOI 10.1038/382174a0; KAYE J, 1983, J EXP MED, V158, P836, DOI 10.1084/jem.158.3.836; KILLEEN N, 1993, EMBO J, V12, P1547, DOI 10.1002/j.1460-2075.1993.tb05798.x; KLEIN SC, 1995, APMIS, V103, P345, DOI 10.1111/j.1699-0463.1995.tb01118.x; KO LJ, 1991, MOL CELL BIOL, V11, P2778, DOI 10.1128/MCB.11.5.2778; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; Lederer JA, 1996, J EXP MED, V184, P397, DOI 10.1084/jem.184.2.397; LEE HJ, 1994, J ALLERGY CLIN IMMUN, V94, P594, DOI 10.1016/0091-6749(94)90135-X; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; Magram J, 1996, IMMUNITY, V4, P471, DOI 10.1016/S1074-7613(00)80413-6; Mosmann TR, 1996, IMMUNOL TODAY, V17, P138, DOI 10.1016/0167-5699(96)80606-2; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; Nakamura T, 1997, J IMMUNOL, V158, P1085; NESS SA, 1994, CURR OPIN GENET DEV, V4, P718, DOI 10.1016/0959-437X(94)90139-T; PANDOLFI PP, 1995, NAT GENET, V11, P40, DOI 10.1038/ng0995-40; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; RAO A, 1991, CRIT REV IMMUNOL, V10, P495; REINER SL, 1994, J IMMUNOL METHODS, V175, P275, DOI 10.1016/0022-1759(94)90370-0; Rincon M, 1997, MOL CELL BIOL, V17, P1522, DOI 10.1128/MCB.17.3.1522; Rincon M, 1997, J EXP MED, V185, P461, DOI 10.1084/jem.185.3.461; Rincon Mercedes, 1997, Genes and Function, V1, P51; ROCKEN M, 1992, J IMMUNOL, V148, P1031; ROMAGNANI S, 1994, ANNU REV IMMUNOL, V12, P227, DOI 10.1146/annurev.iy.12.040194.001303; ROMAGNANI S, 1991, IMMUNOL TODAY, V12, P256, DOI 10.1016/0167-5699(91)90120-I; ROONEY JW, 1995, IMMUNITY, V2, P473, DOI 10.1016/1074-7613(95)90028-4; SCHINDLER C, 1994, EMBO J, V13, P1350, DOI 10.1002/j.1460-2075.1994.tb06388.x; SCOTT LM, 1992, BLOOD, V80, P1725; SEDER RA, 1992, J EXP MED, V176, P1091, DOI 10.1084/jem.176.4.1091; SEDER RA, 1993, P NATL ACAD SCI USA, V90, P10188, DOI 10.1073/pnas.90.21.10188; SZABO SJ, 1995, IMMUNITY, V2, P665, DOI 10.1016/1074-7613(95)90011-X; Thierfelder WE, 1996, NATURE, V382, P171, DOI 10.1038/382171a0; Ting CN, 1996, NATURE, V384, P474, DOI 10.1038/384474a0; TODD MD, 1993, J EXP MED, V177, P1663, DOI 10.1084/jem.177.6.1663; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650	54	1819	1915	3	44	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 16	1997	89	4					587	596		10.1016/S0092-8674(00)80240-8	http://dx.doi.org/10.1016/S0092-8674(00)80240-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WZ323	9160750	hybrid			2022-12-01	WOS:A1997WZ32300012
J	Krainer, M; SilvaArrieta, S; FitzGerald, MG; Shimada, A; Ishioka, C; Kanamaru, R; MacDonald, DJ; Unsal, H; Finkelstein, DM; Bowcock, A; Isselbacher, KJ; Haber, DA				Krainer, M; SilvaArrieta, S; FitzGerald, MG; Shimada, A; Ishioka, C; Kanamaru, R; MacDonald, DJ; Unsal, H; Finkelstein, DM; Bowcock, A; Isselbacher, KJ; Haber, DA			Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OVARIAN-CANCER; SUSCEPTIBILITY GENE; FAMILIAL BREAST; MUTATIONS; LINKAGE	Background Germ-line mutations in the BRCA1 and BRCA2 genes predispose women to breast cancer. BRCA1 mutations are found in approximately 12 percent of women with breast cancer of early onset, and the specific mutation causing a deletion of adenine and guanine (185delAG), which is present in 1 percent of the Ashkenazi Jewish population, contributes to 21 percent of breast cancers among young Jewish women. The contribution of BRCA2 mutations to breast cancer of early onset is unknown. Methods Lymphocyte specimens from 73 women with breast cancer diagnosed by the age of 32 were studied for heterozygous mutations of BRCA2 by a complementary-DNA-based protein-truncation assay, followed by automated nucleotide sequencing, In addition, specimens from 39 Jewish women with breast cancer diagnosed by the age of 40 were tested for specific mutations by an allele-specific polymerase chain reaction. Results Definite BRCA2 mutations were found in 2 of the 73 women with early-onset breast cancer (2.7 percent; 95 percent confidence interval, 0.4 to 9.6 percent), suggesting that BRCA2 is associated with fewer cases than BRCA1 (P = 0.03). The specific BRCA2 mutation causing a deletion of thymine (6174delT), which is found in 1.3 percent of the Ashkenazi Jewish population, was observed in 1 of the 39 young Jewish women with breast cancer (2.6 percent; 95 percent confidence interval, 0.09 to 13.5 percent), indicating that it has a small role as a risk factor for early-onset breast cancer. Among young women with breast cancer, there are BRCA2 mutations that cause truncation of the extreme C terminus of the protein and that may be functionally silent, along with definite truncating mutations. Conclusions Germ-line mutations in BRCA2 contribute to fewer cases of breast cancer among young women than do mutations in BRCA1. Carriers of BRCA2 mutations may have a smaller increase in the risk of early-onset breast cancer. (C) 1997, Massachusetts Medical Society.	MASSACHUSETTS GEN HOSP,CTR CANC,GENET MOL LAB,CHARLESTOWN,MA 02129; CTR CANC RISK ANAL,CHARLESTOWN,MA; MASSACHUSETTS GEN HOSP,DIV BIOSTAT,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,DIV HEMATOL ONCOL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA; TOHOKU UNIV,DEPT CLIN ONCOL,SENDAI,MIYAGI 980,JAPAN; UNIV TEXAS,SW MED CTR,DIV PEDIAT HEMATOL ONCOL,DALLAS,TX	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Tohoku University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Bowcock, Anne/0000-0001-8691-9090; Krainer, Michael/0000-0002-7011-4957	NCI NIH HHS [CA60650] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060650] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Berman DB, 1996, AM J HUM GENET, V58, P1166; CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; CLAUS EB, 1991, AM J HUM GENET, V48, P232; Couch FJ, 1996, NAT GENET, V13, P123, DOI 10.1038/ng0596-123; EASTON DF, 1993, AM J HUM GENET, V52, P678; FitzGerald MG, 1996, NEW ENGL J MED, V334, P143, DOI 10.1056/NEJM199601183340302; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; Ishioka C, 1997, P NATL ACAD SCI USA, V94, P2449, DOI 10.1073/pnas.94.6.2449; Langston AA, 1996, NEW ENGL J MED, V334, P137, DOI 10.1056/NEJM199601183340301; Mazoyer S, 1996, NAT GENET, V14, P253, DOI 10.1038/ng1196-253; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Muto MG, 1996, CANCER RES, V56, P1250; Neuhausen S, 1996, NAT GENET, V13, P126, DOI 10.1038/ng0596-126; Oddoux C, 1996, NAT GENET, V14, P188, DOI 10.1038/ng1096-188; Offit K, 1996, LANCET, V347, P1643, DOI 10.1016/S0140-6736(96)91484-1; Phelan CM, 1996, NAT GENET, V13, P120, DOI 10.1038/ng0596-120; Ries L, 1994, NIH PUBLICATION, V94-2789; Roa BB, 1996, NAT GENET, V14, P185, DOI 10.1038/ng1096-185; ROWELL S, 1994, AM J HUM GENET, V55, P861; SHATTUCKEIDENS D, 1995, JAMA-J AM MED ASSOC, V273, P535, DOI 10.1001/jama.273.7.535; SIMARD J, 1994, NAT GENET, V8, P392, DOI 10.1038/ng1294-392; STRUEWING JP, 1995, NAT GENET, V11, P198, DOI 10.1038/ng1095-198; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; Tonin P, 1996, NAT MED, V2, P1179, DOI 10.1038/nm1196-1179; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0	28	170	176	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 15	1997	336	20					1416	1421		10.1056/NEJM199705153362003	http://dx.doi.org/10.1056/NEJM199705153362003			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WY577	9145678				2022-12-01	WOS:A1997WY57700003
J	Manzanares, M; Cordes, S; Kwan, CT; Sham, MH; Barsh, GS; Krumlauf, R				Manzanares, M; Cordes, S; Kwan, CT; Sham, MH; Barsh, GS; Krumlauf, R			Segmental regulation of Hoxb-3 by kreisler	NATURE			English	Article							GENE-EXPRESSION; 2 RHOMBOMERES; ETS DOMAIN; HINDBRAIN; MUTANT; MOUSE; JUN; FOS; PROTOONCOGENES; KROX-20	Hox genes control regional identity during segmentation of the vertebrate hindbrain into rhombomeres(1-3). Here we use transgenic analysis to investigate the upstream mechanisms for regulation of Hoxb-3 in rhombomere(r)5. We identified enhancers from the mouse and chick genes sufficient for r5-restricted expression. Sequence comparisons revealed two blocks of similarity (of 19 and 45 base pairs), which each contain in vitro binding sites for the kreisler protein (Kmrl1), a Maf/b-Zip protein expressed in r5 and r6 (ref. 4). Both sites are required for r5 activity, suggesting that Hoxb-3 is a direct target of kreisler. Multimers of the 19-base-pair (bp) block recreate a Krml1-like pattern in r5/r6, but the 45-bp block mediates expression only in r5. Therefore elements within the 45-bp block restrict the response to Krml1. We identified additional sequences that contain an Ets-related activation site, required for both the activation and restriction to r5. These studies demonstrate that Krml1 directly activates expression of Hoxb-3 in r5 in combination with an Ets-related activation site, and suggest that kreisler plays a primary role in regulating segmental identity through Hox genes.	NATL INST MED RES, MRC, DIV DEV NEUROBIOL, LONDON NW7 1AA, ENGLAND; STANFORD UNIV, MED CTR, BECKMAN CTR MOL & GENET MED, DEPT PEDIAT, STANFORD, CA 94305 USA; STANFORD UNIV, MED CTR, BECKMAN CTR MOL & GENET MED, DEPT GENET, STANFORD, CA 94305 USA; STANFORD UNIV, MED CTR, BECKMAN CTR MOL & GENET MED, HOWARD HUGHES MED INST, STANFORD, CA 94305 USA; UNIV HONG KONG, DEPT BIOCHEM, HONG KONG, HONG KONG	MRC National Institute for Medical Research; Stanford University; Stanford University; Howard Hughes Medical Institute; Stanford University; University of Hong Kong			Manzanares, Miguel/E-1702-2015; Cordes, Sabine P/A-5423-2012; Krumlauf, Robb/AAH-5012-2019; Manzanares, Miguel/AAZ-8305-2021; Sham, Mai Har/AAX-3781-2020; Sham, Mai Har/C-4387-2009	Manzanares, Miguel/0000-0003-4849-2836; Krumlauf, Robb/0000-0001-9102-7927; Manzanares, Miguel/0000-0003-4849-2836; Sham, Mai Har/0000-0003-1179-7839; 				CARPENTER EM, 1993, DEVELOPMENT, V118, P1063; CORDES SP, 1994, CELL, V79, P1025, DOI 10.1016/0092-8674(94)90033-7; DEOL MS, 1964, J EMBRYOL EXP MORPH, V12, P475; DOLLE P, 1993, P NATL ACAD SCI USA, V90, P7666, DOI 10.1073/pnas.90.16.7666; FROHMAN MA, 1993, DEVELOPMENT, V117, P925; Goddard JM, 1996, DEVELOPMENT, V122, P3217; HUNT P, 1991, NATURE, V353, P861, DOI 10.1038/353861a0; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581; Lumsden A, 1996, SCIENCE, V274, P1109, DOI 10.1126/science.274.5290.1109; MARK M, 1993, DEVELOPMENT, V119, P319; MAROULAKOU IG, 1994, ONCOGENE, V9, P1551; MCKAY I, IN PRESS EUR J NEURO; MCKAY IJ, 1994, DEVELOPMENT, V120, P2199; Nonchev S, 1996, P NATL ACAD SCI USA, V93, P9339, DOI 10.1073/pnas.93.18.9339; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; SCHNEIDERMAUNOURY S, 1993, CELL, V75, P1199, DOI 10.1016/0092-8674(93)90329-O; SHAM MH, 1992, EMBO J, V11, P1825, DOI 10.1002/j.1460-2075.1992.tb05234.x; Shore P, 1996, MOL CELL BIOL, V16, P3338; Sieweke MH, 1996, CELL, V85, P49, DOI 10.1016/S0092-8674(00)81081-8; Studer M, 1996, NATURE, V384, P630, DOI 10.1038/384630a0; SWIATEK PJ, 1993, GENE DEV, V7, P2071, DOI 10.1101/gad.7.11.2071; TREIER M, 1995, CELL, V83, P753, DOI 10.1016/0092-8674(95)90188-4; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WHITING J, 1991, GENE DEV, V5, P2048, DOI 10.1101/gad.5.11.2048; YEE SP, 1993, GENE DEV, V7, P1277, DOI 10.1101/gad.7.7a.1277	26	126	127	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 8	1997	387	6629					191	195		10.1038/387191a0	http://dx.doi.org/10.1038/387191a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WX945	9144291				2022-12-01	WOS:A1997WX94500057
J	Nichols, BJ; Ungermann, C; Pelham, HRB; Wickner, WT; Haas, A				Nichols, BJ; Ungermann, C; Pelham, HRB; Wickner, WT; Haas, A			Homotypic vacuolar fusion mediated by t- and v-SNAREs	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; SECRETORY PATHWAY; IN-VITRO; VESICULAR TRANSPORT; PROTEIN; YEAST; INHERITANCE; GENE; ENDOCYTOSIS; RECEPTOR	Membrane fusion is necessary both in the eukaryotic secretory pathway and for the inheritance of organelles during the cell cycle. In the secretory pathway, heterotypic fusion takes place between small transport vesicles and organelles. It requires N-ethylmaleimide-sensitive fusion protein (NSF/Sec18p), soluble NSF attachment proteins (SNAPs/Sec17p) and SNAP receptors (SNAREs). SNAREs are integral membrane proteins (v-SNAREs on vesicles, t-SNAREs on the target organelles) and are thought to provide specificity to the fusion process(1-5). It has been suggested that Sec17p and Sec18p bind to v-SNARE/t-SNARE complexes and mediate the membrane fusion event(1-3). Homotypic fusion of yeast vacuoles also requires Sec17p and Sec18p (ref, 6), but in vitro they are needed only to 'prime' the vacuoles, not for subsequent docking or fusion(7,8). It has been unclear whether these reactions involve SNAREs that are similar to those previously identified in heterotypic fusion systems and, hence, whether the actions of Sec18p/NSF and Sec17p/alpha SNAP in these systems can be compared, Here we identify typical v- and t-SNAREs on the yeast vacuolar membrane, Although both are normally present, vacuoles containing only the v-SNARE can fuse with those containing only the t-SNARE. Vacuoles containing neither SNARE cannot fuse with those containing both, demonstrating that docking is mediated by cognate SNAREs on the two organelle membranes. Even when t- and v-SNAREs are on separate membranes, Sec17p and Sec18p act at the priming stage. Their action is not required at the point of assembly of the SNARE complex, nor for the fusion event itself.	MRC,MOL BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND; DARTMOUTH COLL,SCH MED,DEPT BIOCHEM,HANOVER,NH 03755	MRC Laboratory Molecular Biology; Dartmouth College								AALTO MK, 1993, EMBO J, V12, P4095, DOI 10.1002/j.1460-2075.1993.tb06093.x; BANFIELD DK, 1994, J CELL BIOL, V127, P357, DOI 10.1083/jcb.127.2.357; Becherer KA, 1996, MOL BIOL CELL, V7, P579, DOI 10.1091/mbc.7.4.579; CONRADT B, 1994, J CELL BIOL, V126, P99, DOI 10.1083/jcb.126.1.99; DASCHER C, 1994, J BIOL CHEM, V269, P29363; HAAS A, 1994, J CELL BIOL, V126, P87, DOI 10.1083/jcb.126.1.87; HAAS A, 1995, EMBO J, V14, P5258, DOI 10.1002/j.1460-2075.1995.tb00210.x; Haas A, 1996, EMBO J, V15, P3296, DOI 10.1002/j.1460-2075.1996.tb00694.x; Haas Albert, 1995, Methods in Cell Science, V17, P283, DOI 10.1007/BF00986234; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; KILMARTIN JV, 1984, J CELL BIOL, V98, P922, DOI 10.1083/jcb.98.3.922; Lewis MJ, 1996, CELL, V85, P205, DOI 10.1016/S0092-8674(00)81097-1; Mayer A, 1997, J CELL BIOL, V136, P307, DOI 10.1083/jcb.136.2.307; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; PROTOPOPOV V, 1993, CELL, V74, P855, DOI 10.1016/0092-8674(93)90465-3; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SEMENZA JC, 1990, CELL, V61, P1349, DOI 10.1016/0092-8674(90)90698-E; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Steel GJ, 1996, EMBO J, V15, P745, DOI 10.1002/j.1460-2075.1996.tb00410.x; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WADA Y, 1992, J BIOL CHEM, V267, P18671; WALCHSOLIMENA C, 1995, J CELL BIOL, V128, P637, DOI 10.1083/jcb.128.4.637; WICHMANN H, 1992, CELL, V71, P1131, DOI 10.1016/S0092-8674(05)80062-5; Xu ZY, 1997, J CELL BIOL, V136, P299, DOI 10.1083/jcb.136.2.299; YOSHIDA A, 1992, J BIOL CHEM, V267, P24925	29	385	390	0	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 8	1997	387	6629					199	202		10.1038/387199a0	http://dx.doi.org/10.1038/387199a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WX945	9144293				2022-12-01	WOS:A1997WX94500059
J	Coppolino, MG; Woodside, MJ; Demaurex, N; Grinstein, S; StArnaud, R; Dedhar, S				Coppolino, MG; Woodside, MJ; Demaurex, N; Grinstein, S; StArnaud, R; Dedhar, S			Calreticulin is essential for integrin-mediated calcium signalling and cell adhesion	NATURE			English	Article							GENE-EXPRESSION; MODULATION; INCREASES; RECEPTOR; BINDING; ANTIGEN	Integrins are important mediators of cell adhesion to extracellular ligands and can transduce biochemical signals both into and out of cells(1,2). The cytoplasmic domains of integrins interact with several structural and signalling proteins and consequently participate in the regulation of cell shape, motility, growth and differentiation(3). It has been shown that calreticulin associates with the cytoplasmic domains of integrin a-subunits and that this interaction can influence integrin-mediated cell adhesion to extracellular matrix(4,5). We have now developed calreticulin-deficient embryonic stem (ES) cells and isolated embryonic fibroblasts from calreticulin mutant mice. We find that in both cell types integrin-mediated adhesion is severely impaired, although integrin expression is unaltered. Expression of recombinant calreticulin in double knockout ES cells by complementary DNA transfection rescued integrin-mediated adhesion. In wild-type cells, engagement of surface integrins induced a transient elevation in cytosolic calcium concentration owing to influx of extracellular calcium. This calcium transient was absent in calreticulin-deficient cells. In contrast, the amount of calcium in endomembrane stores, which is sensitive to both inositol 1,4,5-trisphosphate and thapsigargin, was indistinguishable in the two cell types. Our results indicate that calreticulin is an essential modulator both of integrin adhesive functions and integrin-initiated signalling, but that it may not play a significant role in the storage of luminal calcium.	UNIV TORONTO,SUNNYBROOK HLTH SCI CTR,DIV CANC RES,TORONTO,ON M4N 3M5,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO,ON M4N 3M5,CANADA; HOSP SICK CHILDREN,DIV CELL BIOL,TORONTO,ON M5G 1X8,CANADA; SHRINERS HOSP CRIPPLED CHILDREN,GENET UNIT,MONTREAL,PQ H3G 1A6,CANADA	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); McGill University				Dedhar, Shoukat/0000-0003-4355-1657; Demaurex, Nicolas/0000-0002-9933-6772				BASTIANUTTO C, 1995, J CELL BIOL, V130, P847, DOI 10.1083/jcb.130.4.847; BURNS K, 1994, NATURE, V367, P476, DOI 10.1038/367476a0; CAMACHO P, 1995, CELL, V82, P765, DOI 10.1016/0092-8674(95)90473-5; CAPECCHI MR, 1989, TRENDS GENET, V5, P70, DOI 10.1016/0168-9525(89)90029-2; COPPOLINO M, 1995, J BIOL CHEM, V270, P23132, DOI 10.1074/jbc.270.39.23132; DEDHAR S, 1994, NATURE, V367, P480, DOI 10.1038/367480a0; DEDHAR S, 1994, TRENDS BIOCHEM SCI, V19, P269, DOI 10.1016/0968-0004(94)90001-9; Dedhar S, 1996, CURR OPIN CELL BIOL, V8, P657, DOI 10.1016/S0955-0674(96)80107-4; Hogan B., 2014, MANIPULATING MOUSE E; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JALINK K, 1995, BIOCHEM J, V307, P609, DOI 10.1042/bj3070609; LEUNGHAGESTEIJN CY, 1994, J CELL SCI, V107, P589; LIU NG, 1994, J BIOL CHEM, V269, P28635; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCCAULIFFE DP, 1990, J CLIN INVEST, V86, P332, DOI 10.1172/JCI114704; Mery L, 1996, J BIOL CHEM, V271, P9332, DOI 10.1074/jbc.271.16.9332; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; MIYAKE K, 1991, J EXP MED, V173, P599, DOI 10.1084/jem.173.3.599; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; Opas M, 1996, J CELL BIOL, V135, P1913, DOI 10.1083/jcb.135.6.1913; ROJIANI MV, 1991, BIOCHEMISTRY-US, V30, P9859, DOI 10.1021/bi00105a008; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cb.11.110195.003001; SCHWARTZ MA, 1993, J CELL BIOL, V120, P1003, DOI 10.1083/jcb.120.4.1003; SJAASTAD MD, 1996, MOL BIOL CELL, V1, P1025; SONTHEIMER RD, 1995, J INVEST MED, V43, P362; STARNAUD R, 1995, J CELL BIOL, V131, P1351, DOI 10.1083/jcb.131.5.1351; VONTSCHARNER V, 1986, J BIOL CHEM, V261, P163; Williams Michael J., 1994, Trends in Cell Biology, V4, P109, DOI 10.1016/0962-8924(94)90059-0	29	332	352	0	25	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 24	1997	386	6627					843	847		10.1038/386843a0	http://dx.doi.org/10.1038/386843a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WV706	9126744				2022-12-01	WOS:A1997WV70600057
J	Tarlinton, D				Tarlinton, D			Immunology - Antigen presentation by memory B cells: The sting is in the tail	SCIENCE			English	Editorial Material							RECEPTOR				Tarlinton, D (corresponding author), WALTER & ELIZA HALL INST MED RES,PO ROYAL MELBOURNE HOSP,MELBOURNE,VIC 3050,AUSTRALIA.			Tarlinton, David/0000-0001-9928-686X				Achatz G, 1997, SCIENCE, V276, P409, DOI 10.1126/science.276.5311.409; AMIGORENA S, 1992, NATURE, V358, P337, DOI 10.1038/358337a0; BONNEROT C, 1995, IMMUNITY, V3, P335, DOI 10.1016/1074-7613(95)90118-3; Kaisho T, 1997, SCIENCE, V276, P412, DOI 10.1126/science.276.5311.412; KNIGHT AM, IN PRESS EMBO J; RETH M, 1992, ANNU REV IMMUNOL, V10, P97, DOI 10.1146/annurev.immunol.10.1.97; RETH M, 1991, IMMUNOL TODAY, V12, P196, DOI 10.1016/0167-5699(91)90053-V; VENKITARAMAN AR, 1991, NATURE, V352, P777, DOI 10.1038/352777a0; Weiser P, 1997, SCIENCE, V276, P407, DOI 10.1126/science.276.5311.407	9	26	26	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 18	1997	276	5311					374	375		10.1126/science.276.5311.374	http://dx.doi.org/10.1126/science.276.5311.374			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WU477	9139358				2022-12-01	WOS:A1997WU47700028
J	SosaPineda, B; Chowdhury, K; Torres, M; Oliver, G; Gruss, P				SosaPineda, B; Chowdhury, K; Torres, M; Oliver, G; Gruss, P			The Pax4 gene is essential for differentiation of insulin-producing beta cells In the mammalian pancreas	NATURE			English	Article							TRANSCRIPTION FACTOR; ENDOCRINE-CELLS; HOMEOBOX GENE; EXPRESSION; NEURONS; XENOPUS	The mammalian pancreas contains two distinct cell populations: endocrine cells which secrete hormones into the bloodstream, and exocrine cells, which secrete enzymes into the digestive tract(1). The four endocrine cell types found in the adult pancreas-alpha, beta, delta and PP-synthesize glucagon, insulin, somatostatin and pancreatic polypeptide, respectively(2). All of these endocrine cells arise from common multipotent precursors, which coexpress several hormones when they start to differentiate(3). Expression of some homeobox genes in the early developing pancreas has been reported(4-7). The Pax4 gene is expressed in the early pancreas, but is later restricted to beta cells, Inactivation of Pax4 by homologous recombination results in the absence of mature insulin- and somatostatin-producing cells (beta and delta, respectively) in the pancreas of Pax4 homozygous mutant mice, but glucagon-producing cr cells are present in considerably higher numbers. We propose that the early expression of Pax4 in a subset of endocrine progenitors is essential for the differentiation of the beta and delta cell lineages. A default pathway would explain the elevated number of alpha cells in the absence of Pax4.	MAX PLANCK INST BIOPHYS CHEM, D-37077 GOTTINGEN, GERMANY	Max Planck Society			Torres, Miguel/A-7388-2013; Torres, Miguel/CAG-0003-2022	Torres, Miguel/0000-0003-0906-4767; Torres, Miguel/0000-0003-0906-4767				ALPERT S, 1988, CELL, V53, P295, DOI 10.1016/0092-8674(88)90391-1; DENT JA, 1989, DEVELOPMENT, V105, P61; Githens Sherwood, 1993, P21; GITTES GK, 1992, P NATL ACAD SCI USA, V89, P1128, DOI 10.1073/pnas.89.3.1128; GUZ Y, 1995, DEVELOPMENT, V121, P11; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; MILLER CP, 1994, EMBO J, V13, P1145, DOI 10.1002/j.1460-2075.1994.tb06363.x; Offield MF, 1996, DEVELOPMENT, V122, P983; OHLSSON H, 1994, EMBO J, V13, P1145; OLIVER G, 1988, EMBO J, V7, P3199, DOI 10.1002/j.1460-2075.1988.tb03187.x; OLIVER G, 1993, MECH DEVELOP, V44, P3, DOI 10.1016/0925-4773(93)90012-M; PICTET RL, 1972, DEV BIOL, V29, P436, DOI 10.1016/0012-1606(72)90083-8; RAJU K, 1993, MECH DEVELOP, V44, P51, DOI 10.1016/0925-4773(93)90016-Q; Serup P, 1996, P NATL ACAD SCI USA, V93, P9015, DOI 10.1073/pnas.93.17.9015; SLACK JMW, 1995, DEVELOPMENT, V121, P1569; TEITELMAN G, 1993, DEVELOPMENT, V118, P1031; TURQUE N, 1994, MOL ENDOCRINOL, V8, P929, DOI 10.1210/me.8.7.929; WALTHER C, 1991, GENOMICS, V11, P424, DOI 10.1016/0888-7543(91)90151-4; WRIGHT CVE, 1989, DEVELOPMENT, V105, P787	19	615	642	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 27	1997	386	6623					399	402		10.1038/386399a0	http://dx.doi.org/10.1038/386399a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WQ170	9121556				2022-12-01	WOS:A1997WQ17000065
J	Ktistaki, E; Talianidis, I				Ktistaki, E; Talianidis, I			Modulation of hepatic gene expression by hepatocyte nuclear factor 1	SCIENCE			English	Article							ENRICHED TRANSCRIPTION FACTOR; HORMONE RECEPTOR SUPERFAMILY; DNA-BINDING; FACTOR-IV; LIVER; HNF-4; APOCIII; DOMAIN; LF-B1	Hepatocyte nuclear factors 1 and 4 (HNF-1 and HNF-4) are river-enriched transcription factors that function in the regulation of several liver-specific genes. HNF-1 activates genes containing promoters with HNF-1 binding sites. However, this factor negatively regulates its own expression and that of other HNF-4-dependent genes that lack HNF-1 binding sites in their promoter region. This repression is exerted by a direct interaction of HNF-1 with AF2, the main activation domain of HNF-4. The dual functions of gene activation and repression suggest that HNF-1 is a global regulator of the transcriptional network involved in the maintenance of hepatocyte-specific phenotype.	FDN RES & TECHNOL HELLAS,INST MOL BIOL & BIOTECHNOL,IRAKLION 71110,GREECE	Foundation for Research & Technology - Hellas (FORTH)			Talianidis, Iannis/F-7556-2016	Talianidis, Iannis/0000-0002-1209-3609				BAUMHUETER S, 1990, GENE DEV, V4, P372, DOI 10.1101/gad.4.3.372; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; DESIMONE V, 1991, EMBO J, V10, P1435, DOI 10.1002/j.1460-2075.1991.tb07664.x; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; KRITIS AA, 1993, NUCLEIC ACIDS RES, V21, P5882, DOI 10.1093/nar/21.25.5882; Kritis AA, 1996, GENE, V173, P275, DOI 10.1016/0378-1119(96)00183-7; KTISTAKI E, 1994, NUCLEIC ACIDS RES, V22, P4689, DOI 10.1093/nar/22.22.4689; Ktistaki E, 1997, MOL CELL BIOL, V17, P2790, DOI 10.1128/MCB.17.5.2790; KTISTAKI E, 1995, P NATL ACAD SCI USA, V92, P9876, DOI 10.1073/pnas.92.21.9876; KTISTAKI E, UNPUB; KUO CJ, 1992, NATURE, V355, P457, DOI 10.1038/355457a0; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LAI E, 1990, GENE DEV, V4, P1427, DOI 10.1101/gad.4.8.1427; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; MENDEL DB, 1991, SCIENCE, V254, P1762, DOI 10.1126/science.1763325; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; PIAGGIO G, 1994, NUCLEIC ACIDS RES, V22, P4284, DOI 10.1093/nar/22.20.4284; Pontoglio M, 1996, CELL, V84, P575, DOI 10.1016/S0092-8674(00)81033-8; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; SLADEK FM, 1994, LIVER GENE EXPRESSIO, pCH11; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TALIANIDIS I, 1995, BIOCHEMISTRY-US, V34, P10298, DOI 10.1021/bi00032a025; TIAN JM, 1991, GENE DEV, V5, P2225, DOI 10.1101/gad.5.12a.2225; TRONCHE F, 1994, LIVER GENE EXPRESSIO, pCH9; ZHONG WM, 1994, MOL CELL BIOL, V14, P7276, DOI 10.1128/MCB.14.11.7276	25	114	115	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 4	1997	277	5322					109	112		10.1126/science.277.5322.109	http://dx.doi.org/10.1126/science.277.5322.109			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XJ418	9204893				2022-12-01	WOS:A1997XJ41800051
J	Ichas, F; Jouaville, LS; Mazat, JP				Ichas, F; Jouaville, LS; Mazat, JP			Mitochondria are excitable organelles capable of generating and conveying electrical and calcium signals	CELL			English	Article							RAT-LIVER MITOCHONDRIA; ASCITES TUMOR-CELLS; PERMEABILITY TRANSITION; INOSITOL TRISPHOSPHATE; INTRACELLULAR CALCIUM; EXTRACELLULAR ATP; CA2+ TRANSIENTS; INNER MEMBRANE; TRANSPORT; RELEASE	We report Ca2+-induced release of Ca2+ from mitochondria (mCICR) dependent on transitory opening of the permeability transition pore (PTP) operating in a low conductance mode. The Ca2+ fluxes taking place during mCICR are a direct consequence of the mitochondrial depolarization spike (mDPS) caused by PTP opening. Both mDPS and mCICR can propagate from one mitochondrion to another in vitro, generating traveling depolarization and Ca2+ waves. Mitochondria thus appear to be excitable organelles capable of generating and conveying electrical and Ca2+ signals. In living cells, mDPS/mCICR is triggered during IP3-induced Ca2+ mobilization and results in the amplification of the Ca2+ signals primarily emitted from the endoplasmic reticulum.			Ichas, F (corresponding author), UNIV BORDEAUX 2,DEPT MED BIOCHEM & MOL BIOL,INTEGRATED BIOL SYST STUDY GRP,F-33076 BORDEAUX,FRANCE.		Ichas, François/ABD-8277-2020	Ichas, François/0000-0001-8184-5248				ALTSCHULD RA, 1992, AM J PHYSIOL, V262, pH1699, DOI 10.1152/ajpheart.1992.262.6.H1699; ARTALEJO AR, 1988, BIOCHIM BIOPHYS ACTA, V941, P48, DOI 10.1016/0005-2736(88)90212-X; BABCOCK DF, 1979, J BIOL CHEM, V254, P8117; Babcock DF, 1997, J CELL BIOL, V136, P833, DOI 10.1083/jcb.136.4.833; BEAVIS AD, 1985, J BIOL CHEM, V260, P3424; BERNARDI P, 1984, BIOCHEMISTRY-US, V23, P1645, DOI 10.1021/bi00303a010; BERNARDI P, 1996, J BIOENERG BIOMEMBR, V28, P129; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BIDEN TJ, 1984, J BIOL CHEM, V261, P7223; BRARN RJ, 1994, NATURE, V371, P355; Brustovetsky N, 1996, BIOCHEMISTRY-US, V35, P8483, DOI 10.1021/bi960833v; Budd SL, 1996, J NEUROCHEM, V66, P403, DOI 10.1046/j.1471-4159.1996.66010403.x; CASWELL AH, 1972, J MEMBRANE BIOL, V7, P345, DOI 10.1007/BF01867925; CASWELL AH, 1971, BIOCHEM BIOPH RES CO, V43, P625, DOI 10.1016/0006-291X(71)90660-7; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; COLL KE, 1982, J BIOL CHEM, V257, P8696; Connern CP, 1996, BIOCHEMISTRY-US, V35, P8172, DOI 10.1021/bi9525177; CROMPTON M, 1990, BIOCHEM J, V266, P33, DOI 10.1042/bj2660033; DENTON RM, 1990, ANNU REV PHYSIOL, V52, P451, DOI 10.1146/annurev.ph.52.030190.002315; DIVIRGILIO F, 1990, CELL CALCIUM, V11, P57, DOI 10.1016/0143-4160(90)90059-4; DUBUY HG, 1961, SCIENCE, V133, P196, DOI 10.1126/science.133.3447.196; DUBYAK GR, 1986, ARCH BIOCHEM BIOPHYS, V245, P84, DOI 10.1016/0003-9861(86)90192-X; DUCHEN MR, 1992, BIOCHEM J, V283, P41, DOI 10.1042/bj2830041; EVTODIENKO YV, 1994, CELL CALCIUM, V15, P143, DOI 10.1016/0143-4160(94)90053-1; Evtodienko YV, 1996, FEBS LETT, V393, P86, DOI 10.1016/0014-5793(96)00875-7; FABIATO A, 1979, NATURE, V281, P146, DOI 10.1038/281146a0; FRIEL DD, 1994, J NEUROSCI, V14, P4007; GRIFFITHS EJ, 1995, BIOCHEM J, V307, P93, DOI 10.1042/bj3070093; GROBLEWSKI GE, 1994, J BIOL CHEM, V269, P15111; GUNTER KK, 1994, J BIOENERG BIOMEMBR, V26, P471, DOI 10.1007/BF00762732; HAJNOCZKY G, 1994, J BIOL CHEM, V269, P10280; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; Herrington J, 1996, NEURON, V16, P219, DOI 10.1016/S0896-6273(00)80038-0; HOEK JB, 1995, BBA-MOL BASIS DIS, V1271, P93, DOI 10.1016/0925-4439(95)00015-V; HOLMUHAMEDOV EL, 1986, EUR J BIOCHEM, V158, P543, DOI 10.1111/j.1432-1033.1986.tb09788.x; HOLMUHAMEDOV EL, 1995, BIOCHEM MOL BIOL INT, V36, P39; ICHAS F, 1994, FEBS LETT, V348, P211, DOI 10.1016/0014-5793(94)00615-6; IGBAVBOA U, 1988, J BIOL CHEM, V263, P1405; IGBAVBOA U, 1991, BIOCHIM BIOPHYS ACTA, V1059, P339, DOI 10.1016/S0005-2728(05)80219-1; IKEDA K, 1993, HEARING RES, V66, P169, DOI 10.1016/0378-5955(93)90138-Q; JOUAVILLE LS, 1995, NATURE, V377, P348; KIM JV, 1984, CELL CALCIUM, V5, P29, DOI 10.1016/0143-4160(84)90152-0; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; LOEW LM, 1994, P NATL ACAD SCI USA, V91, P12579, DOI 10.1073/pnas.91.26.12579; LUTHRA R, 1976, BIOCHIM BIOPHYS ACTA, V440, P744, DOI 10.1016/0005-2728(76)90056-6; LUVISETTO S, 1991, EUR J BIOCHEM, V202, P121, DOI 10.1111/j.1432-1033.1991.tb16352.x; MASSARI S, 1972, J MEMBRANE BIOL, V9, P57, DOI 10.1007/BF01868043; Massari S, 1996, J BIOL CHEM, V271, P31942; MIYAZAKI S, 1995, CURR OPIN CELL BIOL, V7, P190, DOI 10.1016/0955-0674(95)80027-1; MOLLER IM, 1986, BIOCHEM J, V237, P765, DOI 10.1042/bj2370765; NICHOLLS D, 1982, BIOCHIM BIOPHYS ACTA, V683, P57, DOI 10.1016/0304-4173(82)90013-1; Nicholls D.G., 1982, BIOENERGETICS INTRO; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; NIEMINEN AL, 1995, BIOCHEM J, V307, P99, DOI 10.1042/bj3070099; PRALONG WF, 1994, J BIOL CHEM, V269, P27310; PUSKIN JS, 1973, BIOCHEM BIOPH RES CO, V51, P797, DOI 10.1016/0006-291X(73)91385-5; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; RUSTENBECK I, 1993, BIOCHEM BIOPH RES CO, V194, P1261, DOI 10.1006/bbrc.1993.1959; SCHONFELD P, 1992, FEBS LETT, V304, P273, DOI 10.1016/0014-5793(92)80636-U; SCHUSTER SM, 1974, J BIOL CHEM, V249, P7151; Simpson PB, 1996, J BIOL CHEM, V271, P33493, DOI 10.1074/jbc.271.52.33493; SPARAGNA GC, 1995, J BIOL CHEM, V270, P27510, DOI 10.1074/jbc.270.46.27510; TEDESCHI H, 1955, ARCH BIOCHEM BIOPHYS, V58, P52, DOI 10.1016/0003-9861(55)90092-8; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296; WINGROVE DE, 1984, J BIOL CHEM, V259, P9390; WISE D, 1984, CHROMOSOMA, V90, P156, DOI 10.1007/BF00292453; ZAMZAMI N, 1996, J EXP MED, V183, P1633; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	68	621	642	4	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 27	1997	89	7					1145	1153		10.1016/S0092-8674(00)80301-3	http://dx.doi.org/10.1016/S0092-8674(00)80301-3			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XG830	9215636	Bronze			2022-12-01	WOS:A1997XG83000018
J	Bone, RC				Bone, RC			Critical care medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NOSOCOMIAL SINUSITIS; PNEUMONIA; MORTALITY; UNIT				Bone, RC (corresponding author), RUSH PRESBYTERIAN ST LUKES MED CTR,1653 W CONGRESS PKWY,CHICAGO,IL 60612, USA.							AMATO MBP, 1995, AM J RESP CRIT CARE, V152, P1835, DOI 10.1164/ajrccm.152.6.8520744; Becker DM, 1996, ARCH INTERN MED, V156, P939, DOI 10.1001/archinte.156.9.939; BERT F, 1995, J INFECTION, V31, P5, DOI 10.1016/S0163-4453(95)91147-2; BERT F, 1995, AM J RESP CRIT CARE, V152, P1424, DOI 10.1164/ajrccm.152.4.7551404; Bone RC, 1996, JAMA-J AM MED ASSOC, V276, P565, DOI 10.1001/jama.276.7.565; BUENOCAVANILLAS A, 1994, CRIT CARE MED, V22, P55, DOI 10.1097/00003246-199401000-00013; Chatila W, 1996, CHEST, V109, P1577, DOI 10.1378/chest.109.6.1577; Hund EF, 1996, CRIT CARE MED, V24, P1328, DOI 10.1097/00003246-199608000-00010; KIRTON OC, 1995, CHEST, V108, P1021, DOI 10.1378/chest.108.4.1021; KOLLEF MH, 1995, CHEST, V108, P1655, DOI 10.1378/chest.108.6.1655; Latronico N, 1996, LANCET, V347, P1579, DOI 10.1016/S0140-6736(96)91074-0; Linden PK, 1996, CLIN INFECT DIS, V22, P663, DOI 10.1093/clinids/22.4.663; Meduri GU, 1996, CHEST, V109, P179, DOI 10.1378/chest.109.1.179; SILVERMAN HJ, 1995, ARCH INTERN MED, V155, P502, DOI 10.1001/archinte.155.5.502; Stein PD, 1996, CHEST, V109, P78, DOI 10.1378/chest.109.1.78	15	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	1997	277	23					1847	1848						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD544	9185794				2022-12-01	WOS:A1997XD54400013
J	Joynt, RJ; Kurlan, RM				Joynt, RJ; Kurlan, RM			Neurology	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											Joynt, RJ (corresponding author), UNIV ROCHESTER, 601 ELMWOOD AVE, ROCHESTER, NY 14627 USA.							Antel JP, 1996, NAT MED, V2, P1074, DOI 10.1038/nm1096-1074; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; Hsich G, 1996, NEW ENGL J MED, V335, P924, DOI 10.1056/NEJM199609263351303; Kittner SJ, 1996, NEW ENGL J MED, V335, P768, DOI 10.1056/NEJM199609123351102; Kretzschmar HA, 1996, ARCH NEUROL-CHICAGO, V53, P913, DOI 10.1001/archneur.1996.00550090125018; Lacomblez L, 1996, LANCET, V347, P1425, DOI 10.1016/S0140-6736(96)91680-3; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; *MULT AC STROK TRI, 1996, NEW ENGL J MED, V53, P1306; Petitti DB, 1996, NEW ENGL J MED, V335, P8, DOI 10.1056/NEJM199607043350102; Polymeropoulos MH, 1996, SCIENCE, V274, P1197, DOI 10.1126/science.274.5290.1197; Riggs JE, 1996, ARCH NEUROL-CHICAGO, V53, P1306, DOI 10.1001/archneur.1996.00550120118026; SANDON DA, 1996, ARCH NEUROL-CHICAGO, V53, P125; Snowdon DA, 1996, JAMA-J AM MED ASSOC, V275, P528, DOI 10.1001/jama.275.7.528; Vandenbark AA, 1996, NAT MED, V2, P1109, DOI 10.1038/nm1096-1109; WiedauPazos M, 1996, SCIENCE, V271, P515, DOI 10.1126/science.271.5248.515; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9	16	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	1997	277	23					1873	1874						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD544	9185810				2022-12-01	WOS:A1997XD54400029
J	Poland, GA; Borrud, A; Jacobson, RM; McDermott, K; Wollan, PC; Brakke, D; Charboneau, JW				Poland, GA; Borrud, A; Jacobson, RM; McDermott, K; Wollan, PC; Brakke, D; Charboneau, JW			Determination of deltoid fat pad thickness - Implications for needle length in adult immunization	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	29th Annual Meeting of the Infectious-Disease-Society-of-America	MAY   16, 1995	LOS ANGELES, CA	Infect Dis Soc Amer			HEPATITIS-B VACCINE; HEALTH-CARE PERSONNEL; INJECTION-SITE; INTRAMUSCULAR INJECTION; ANTIBODY-RESPONSE; EFFICACY; ULTRASOUND; DIPHTHERIA; IMMUNITY; TETANUS	Objective.-To measure deltoid fat pad thickness and determine the optimal needle length for deltoid intramuscular immunization in healthy adults. Design, Setting, and Participants.-Prospective study of 220 healthy health care workers (126 women, 94 men) at the Mayo Medical Center, Rochester, Minn. Main Outcome Measures.-Deltoid fat pad thickness determined by high-resolution ultrasound scanning, weight, height, and mid-deltoid arm circumference. Results.-We found a highly significant difference between women and men in deltoid fat pad thickness, with women having a thicker deltoid fat pad (11.7 vs 8.3 mm; P<.001), Women had a greater deltoid skin-fold thickness than men (34.7 vs 17.2 mm, P<.001) and an equal body mass index, According to the ultrasound findings, a standard 16-mm (5/8-in) needle would not have reached 5 mm into muscle in 17% (16/94) of men and 48.4% (61/126) of women in this study. Conclusions.-Among healthy adults of the age range we studied, the following needle lengths appear to be appropriate for true deltoid intramuscular immunization: For men across the weight ranges we studied (59-118 kg), use of a 25-mm (1-in) needle would result in at least 5 mm of muscle penetration in all subjects. For women who weighed less than 60 kg, a 16-mm (5/8-in) needle would be sufficient to achieve muscle penetration of 5 mm. For women between 60 and 90 kg, a 25-mm (1-in) needle would be sufficient, and women greater than 90 kg would require a 38-mm (1.5-in) needle to ensure intramuscular administration.	MAYO CLIN & MAYO FDN,SECT BIOSTT HLTH SCI EVALUAT,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT DIAGNOST RADIOL,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic	Poland, GA (corresponding author), MAYO CLIN & MAYO FDN,MAYO VACCINE RES GRP,CLIN PHARMACOL UNIT,200 1ST ST SW,601B GUGGENHEIM BLDG,ROCHESTER,MN 55905, USA.			Jacobson, Robert/0000-0002-6355-8752				*ACP TASK FORC AD, 1994, GUID AD IMM, P1; *AM AC PED, 1994, REP COMM INF DIS; BORKAN GA, 1982, AM J PHYS ANTHROPOL, V58, P307, DOI 10.1002/ajpa.1330580309; COCKSHOTT WP, 1982, NEW ENGL J MED, V307, P356, DOI 10.1056/NEJM198208053070607; DIENSTAG JL, 1984, ANN INTERN MED, V101, P34, DOI 10.7326/0003-4819-101-1-34; FRANCIS DP, 1982, ANN INTERN MED, V97, P362, DOI 10.7326/0003-4819-97-3-362; FRIED AM, 1986, INVEST RADIOL, V21, P71, DOI 10.1097/00004424-198601000-00012; FRISANCHO AR, 1974, AM J CLIN NUTR, V27, P1052, DOI 10.1093/ajcn/27.8.1052; GREENBLATT DJ, 1976, NEW ENGL J MED, V295, P542; GREENBLATT DJ, 1978, JAMA-J AM MED ASSOC, V240, P542, DOI 10.1001/jama.240.6.542; Haramati N, 1994, Arch Fam Med, V3, P146, DOI 10.1001/archfami.3.2.146; HATTORI K, 1991, HUM BIOL, V63, P53; HAYES PA, 1988, MED SCI SPORT EXER, V20, P303, DOI 10.1249/00005768-198806000-00015; HECKMATT JZ, 1988, J CLIN ULTRASOUND, V16, P171, DOI 10.1002/jcu.1870160305; HICK JF, 1989, PEDIATRICS, V84, P136; HOROWITZ MM, 1988, ANN INTERN MED, V108, P185, DOI 10.7326/0003-4819-108-2-185; IPP MM, 1989, PEDIATRICS, V83, P679; KOHRT WM, 1992, MED SCI SPORT EXER, V24, P832; LEMON SM, 1986, J GEN INTERN MED, V11, P199; LINDSAY KL, 1985, HEPATOLOGY, V5, P1088, DOI 10.1002/hep.1840050605; LO Y-S, 1992, Kaohsiung Journal of Medical Sciences, V8, P75; MCLEAN AA, 1985, MMWR-MORBID MORTAL W, V34, P105; MICHAELS L, 1970, CAN MED ASSOC J, V102, P626; *NAT ADV COMM IMM, 1989, CAN IMM GUID; PASKO MT, 1990, AM J PUBLIC HEALTH, V80, P590, DOI 10.2105/AJPH.80.5.590; PEAD PJ, 1985, LANCET, V1, P1152; RAMIREZ ME, 1993, INT J OBESITY, V17, P63; SENDEN TF, 1990, VACCINE, V8, P612, DOI 10.1016/0264-410X(90)90037-M; SHAW FE, 1989, VACCINE, V7, P425, DOI 10.1016/0264-410X(89)90157-6; SJOSTROM L, 1988, FAT DISTRIBUTION GRO, P43; SZMUNESS W, 1981, HEPATOLOGY, V1, P377, DOI 10.1002/hep.1840010502; UKENA T, 1985, NEW ENGL J MED, V313, P579; WAHL M, 1987, SCAND J INFECT DIS, V19, P617, DOI 10.3109/00365548709117195; WEBER DJ, 1985, JAMA-J AM MED ASSOC, V254, P3187, DOI 10.1001/jama.254.22.3187; WEISS LW, 1987, EUR J APPL PHYSIOL O, V56, P217, DOI 10.1007/BF00640647; WEITS T, 1986, INT J OBESITY, V10, P161; 1994, MMWR-MORBID MORTAL W, V43, P1	37	118	135	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 4	1997	277	21					1709	1711		10.1001/jama.277.21.1709	http://dx.doi.org/10.1001/jama.277.21.1709			3	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XB088	9169899				2022-12-01	WOS:A1997XB08800033
J	Bousser, MG				Bousser, MG			Aspirin or heparin immediately after a stroke?	LANCET			English	Editorial Material							ACUTE ISCHEMIC STROKE				Bousser, MG (corresponding author), HOP ST ANTOINE,DEPT NEUROL,F-75571 PARIS 12,FRANCE.							ADAMS HP, 1994, CIRCULATION, V90, P1588, DOI 10.1161/01.CIR.90.3.1588; CAPLAN LR, 1991, JAMA-J AM MED ASSOC, V266, P2413, DOI 10.1001/jama.266.17.2413; *EAFT STUD GROUP, 1993, LANCET, V342, P1255; Fisher M, 1997, STROKE, V28, P866, DOI 10.1161/01.STR.28.4.866; KAY R, 1995, NEW ENGL J MED, V333, P1588, DOI 10.1056/NEJM199512143332402; MARCHAL G, 1993, LANCET, V341, P2; *NAT I NEUR DIS ST, 1995, NEW ENGL J MED, V333, P1581; 1997, BRIT MED J, V31, P1151	8	41	41	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 31	1997	349	9065					1564	1565		10.1016/S0140-6736(97)22022-2	http://dx.doi.org/10.1016/S0140-6736(97)22022-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XB673	9174553				2022-12-01	WOS:A1997XB67300002
J	Lin, Q; Schwarz, J; Bucana, C; Olson, EN				Lin, Q; Schwarz, J; Bucana, C; Olson, EN			Control of mouse cardiac morphogenesis and myogenesis by transcription factor MEF2C	SCIENCE			English	Article							ENHANCER-BINDING FACTOR; LIGHT-CHAIN GENE; MUSCLE; EXPRESSION; DROSOPHILA; EMBRYOGENESIS; ACTIVATION; MUTATIONS; LINEAGES; PROTEINS	Members of the myocyte enhancer factor-2 (MEF2) family of MADS (MCM1, agamous, deficiens, serum response factor)-box transcription factors bind an A-T-rich DNA sequence associated with muscle-specific genes. The murine MEF2C gene is expressed in heart precursor cells before formation of the linear heart tube, In mice homozygous for a null mutation of MEF2C, the heart tube did not undergo looping morphogenesis, the future right ventricle did not form, and a subset of cardiac muscle genes was not expressed. The absence of the right ventricular region of the mutant heart correlated with down-regulation of the dHAND gene, which encodes a basic helix-loop-helix transcription factor required for cardiac morphogenesis. Thus, MEF2C is an essential regulator of cardiac myogenesis and right ventricular development.	UNIV TEXAS,SW MED CTR,DEPT MOL BIOL & ONCOL,DALLAS,TX 75235; UNIV TEXAS,SCH MED,DEPT INTERNAL MED,DIV CARDIOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT CELL BIOL,HOUSTON,TX 77030	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas System; UTMD Anderson Cancer Center					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053351] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL053351] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARTON PJR, 1988, J BIOL CHEM, V263, P12669; BIBEN C, COMMUNICATION; BOUR BA, 1995, GENE DEV, V9, P730, DOI 10.1101/gad.9.6.730; BREITBART RE, 1993, DEVELOPMENT, V118, P1095; CHAMBERS AE, 1994, GENE DEV, V8, P1324, DOI 10.1101/gad.8.11.1324; CSERJESI P, 1995, DEV BIOL, V170, P664, DOI 10.1006/dbio.1995.1245; DEHAAN RL, 1964, ORGANOGENESIS, P377; EDMONDSON DG, 1994, DEVELOPMENT, V120, P1251; Firulli AB, 1996, CIRC RES, V78, P196, DOI 10.1161/01.RES.78.2.196; FISCHMAN MC, 1994, CIRC RES, V74, P757; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; KAUSHAL S, 1994, SCIENCE, V266, P1236, DOI 10.1126/science.7973707; LEIFER D, 1993, P NATL ACAD SCI USA, V90, P1546, DOI 10.1073/pnas.90.4.1546; LILLY B, 1995, SCIENCE, V267, P688, DOI 10.1126/science.7839146; LIN QY, UNPUB; LINTS TJ, 1993, DEVELOPMENT, V119, P419; LYONS GE, 1995, J NEUROSCI, V15, P5727, DOI 10.1523/jneurosci.15-08-05727.1995; LYONS I, 1995, GENE DEV, V9, P1654, DOI 10.1101/gad.9.13.1654; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MARTIN JF, 1994, MOL CELL BIOL, V14, P1647, DOI 10.1128/MCB.14.3.1647; MARTIN JF, 1993, P NATL ACAD SCI USA, V90, P5282, DOI 10.1073/pnas.90.11.5282; MARTIN JF, 1995, GENE DEV, V9, P1237, DOI 10.1101/gad.9.10.1237; MCDERMOTT JC, 1993, MOL CELL BIOL, V13, P2564, DOI 10.1128/MCB.13.4.2564; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MOLKENTIN JD, 1993, J BIOL CHEM, V268, P19512; Molkentin JD, 1996, MOL CELL BIOL, V16, P3814; Molkentin JD, 1996, MOL CELL BIOL, V16, P2627; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; MOLKENTIN JD, UNPUB; NADALGINARD B, 1996, MECH DEVELOP, V57, P103; NAVANASATTUSAS S, MOL CELL BIOL, V12, P1469; OBRIEN TX, 1993, P NATL ACAD SCI USA, V90, P5157, DOI 10.1073/pnas.90.11.5157; Olson EN, 1996, SCIENCE, V272, P671, DOI 10.1126/science.272.5262.671; OLSON EN, 1995, DEV BIOL, V172, P280; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; RANGANAYAKULU G, 1995, DEV BIOL, V171, P169, DOI 10.1006/dbio.1995.1269; Rossant J, 1996, CIRC RES, V78, P349, DOI 10.1161/01.RES.78.3.349; SRIVASTAVA D, 1995, SCIENCE, V270, P1995, DOI 10.1126/science.270.5244.1995; SRIVASTAVA D, IN PRESS NATURE GENE; WONG MW, 1994, DEV BIOL, V166, P683, DOI 10.1006/dbio.1994.1347; Yu YT, 1996, J BIOL CHEM, V271, P24675; YU YT, 1995, GENE DEV, V9, P1388; ZELLER R, 1987, GENE DEV, V1, P693, DOI 10.1101/gad.1.7.693	43	730	769	0	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 30	1997	276	5317					1404	1407		10.1126/science.276.5317.1404	http://dx.doi.org/10.1126/science.276.5317.1404			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XB533	9162005	Green Accepted			2022-12-01	WOS:A1997XB53300046
J	Macknight, R; Bancroft, I; Page, T; Lister, C; Schmidt, R; Love, K; Westphal, L; Murphy, G; Sherson, S; Cobbett, C; Dean, C				Macknight, R; Bancroft, I; Page, T; Lister, C; Schmidt, R; Love, K; Westphal, L; Murphy, G; Sherson, S; Cobbett, C; Dean, C			FCA, a gene controlling flowering time in Arabidopsis, encodes a protein containing RNA-binding domains	CELL			English	Article							POLYMORPHISM LINKAGE MAP; WW DOMAIN; THALIANA; EXPRESSION; TRANSFORMATION; VERNALIZATION; DYSTROPHIN; DROSOPHILA; SELECTION; MUTANTS	A strong promoter of the transition to flowering in Arabidopsis is encoded by FCA. FCA has been cloned and shown to encode a protein containing two RNA-binding domains and a WW protein interaction domain. This suggests that FCA functions in the posttranscriptional regulation of transcripts involved in the flowering process. The FCA transcript is alternatively spliced with only one form encoding the entire FCA protein. Plants carrying the FCA gene fused to the strong constitutive 35S promoter flowered earlier, and the ratio and abundance of the different FCA transcripts were altered. Thus, FCA appears to be a component of a posttranscriptional cascade involved in the control of flowering time.	JOHN INNES CTR PLANT SCI RES,DEPT MOL GENET,NORWICH NR4 7UH,NORFOLK,ENGLAND; UNIV MELBOURNE,DEPT GENET,MELBOURNE,VIC 3052,AUSTRALIA	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; University of Melbourne			Bancroft, Ian/AAH-3831-2020	Macknight, Richard/0000-0003-1146-9042; Schmidt, Renate/0000-0002-8037-3581; Bancroft, Ian/0000-0001-7707-1171; Macknight, Richard/0000-0002-3300-7124				Amasino RM, 1996, CURR OPIN GENET DEV, V6, P480, DOI 10.1016/S0959-437X(96)80071-2; ANDRE B, 1994, BIOCHEM BIOPH RES CO, V205, P1201, DOI 10.1006/bbrc.1994.2793; Aukerman MJ, 1996, SEMIN CELL DEV BIOL, V7, P427, DOI 10.1006/scdb.1996.0053; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; BORK P, 1994, TRENDS BIOCHEM SCI, V19, P531, DOI 10.1016/0968-0004(94)90053-1; Brown JWS, 1996, PLANT J, V10, P771, DOI 10.1046/j.1365-313X.1996.10050771.x; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; BURN JE, 1993, GENETICA, V90, P145; Chan DC, 1996, EMBO J, V15, P1045, DOI 10.1002/j.1460-2075.1996.tb00442.x; CHANG C, 1988, P NATL ACAD SCI USA, V85, P6856, DOI 10.1073/pnas.85.18.6856; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; CLARKE JH, 1994, MOL GEN GENET, V242, P81, DOI 10.1007/BF00277351; DEAN C, 1992, PLANT J, V2, P69, DOI 10.1111/j.1365-313X.1992.00069.x; DEAN C, 1985, EMBO J, V4, P3055, DOI 10.1002/j.1460-2075.1985.tb04045.x; DOLEZAL O, 1991, PLANT PHYSIOL, V96, P1255, DOI 10.1104/pp.96.4.1255; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; Furner IJ, 1996, DEVELOPMENT, V122, P1041; Gao FB, 1996, J CELL SCI, V109, P579; GOOD PJ, 1995, P NATL ACAD SCI USA, V92, P4557, DOI 10.1073/pnas.92.10.4557; Hicks KA, 1996, SEMIN CELL DEV BIOL, V7, P409, DOI 10.1006/scdb.1996.0051; Jones Jonathan D. G., 1992, Transgenic Research, V1, P285, DOI 10.1007/BF02525170; KNECHT AK, 1995, DEVELOPMENT, V121, P1927; KOORNNEEF M, 1991, MOL GEN GENET, V229, P57, DOI 10.1007/BF00264213; Koushika SP, 1996, CURR BIOL, V6, P1634, DOI 10.1016/S0960-9822(02)70787-2; LEE I, 1993, MOL GEN GENET, V237, P171, DOI 10.1007/BF00282798; LEE I, 1994, PLANT CELL, V6, P75, DOI 10.1105/tpc.6.1.75; LUEHRSEN KR, 1994, GENE DEV, V8, P1117, DOI 10.1101/gad.8.9.1117; MARTINEZZAPATER JM, 1990, PLANT PHYSIOL, V92, P770, DOI 10.1104/pp.92.3.770; MARTINEZZAPATER JM, 1995, PLANT J, V7, P543, DOI 10.1046/j.1365-313X.1995.7040543.x; Mattox W, 1996, GENETICS, V143, P303; NAM HG, 1989, PLANT CELL, V1, P699, DOI 10.1105/tpc.1.7.699; NEWMAN T, 1994, PLANT PHYSIOL, V106, P1241, DOI 10.1104/pp.106.4.1241; NIWA M, 1992, NATURE, V360, P277, DOI 10.1038/360277a0; OLSZEWSKI NE, 1988, NUCLEIC ACIDS RES, V16, P10765, DOI 10.1093/nar/16.22.10765; PUTTERILL J, 1995, CELL, V80, P847, DOI 10.1016/0092-8674(95)90288-0; RICHTER K, 1988, P NATL ACAD SCI USA, V85, P8086, DOI 10.1073/pnas.85.21.8086; ROBINOW S, 1988, SCIENCE, V242, P1570, DOI 10.1126/science.3144044; Schmidt R, 1996, PLANT J, V9, P755, DOI 10.1046/j.1365-313X.1996.9050755.x; Schmidt R, 1995, METHOD MOL CELL BIOL, V5, P309; Simpson GG, 1996, PLANT MOL BIOL, V32, P1, DOI 10.1007/BF00039375; SUDOL M, 1995, J BIOL CHEM, V270, P14733, DOI 10.1074/jbc.270.24.14733; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536	45	393	430	3	50	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 30	1997	89	5					737	745		10.1016/S0092-8674(00)80256-1	http://dx.doi.org/10.1016/S0092-8674(00)80256-1			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XB925	9182761	Bronze			2022-12-01	WOS:A1997XB92500010
J	Bailar, JC; Gornik, HL				Bailar, JC; Gornik, HL			Cancer undefeated	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	Annual Ramazzini Days of the Collegium-Ramazzini	OCT 26, 1996	CARPI, ITALY	Collegium Ramazzini				Background Despite decades of basic and clinical research and trials of promising new therapies, cancer remains a major cause of morbidity and mortality. We assessed overall progress against cancer in the United States from 1970 through 1994 by analyzing changes in age-adjusted mortality rates. Methods We obtained from the National Center for Health Statistics data on all deaths from cancer and from cancer at specific sites, as well as on deaths due to cancer according to age, race, and sex, for the years 1970 through 1994. We computed age-specific mortality rates and adjusted them to the age distribution of the U.S. population in 1990. Results Age-adjusted mortality due to cancer in 1994 (200.9 per 100,000 population) was 6.0 percent higher than the rate in 1970 (189.6 per 100,000). After decades of steady increases, the age-adjusted mortality due to all malignant neoplasms plateaued, then decreased by 1.0 percent from 1991 to 1994. The decline in mortality due to cancer was greatest among black males and among persons under 55 years of age. Mortality among white males 55 or older has also declined recently. These trends reflect a combination of changes in death rates from specific types of cancer, with important declines due to reduced cigarette smoking and improved screening and a mixture of increases and decreases in the incidence of types of cancer not closely related to tobacco use. Conclusions The war against cancer is far from over. Observed changes in mortality due to cancer primarily reflect changing incidence or early detection. The effect of new treatments for cancer on mortality has been largely disappointing. The most promising approach to the control of cancer is a national commitment to prevention, with a concomitant rebalancing of the focus and funding of research. (C) 1997, Massachusetts Medical Society.			Bailar, JC (corresponding author), UNIV CHICAGO, DEPT HLTH STUDIES, 5841 S MARYLAND AVE, MC 2007, CHICAGO, IL 60637 USA.							BAILAR JC, 1990, ANN NY ACAD SCI, V609, P49, DOI 10.1111/j.1749-6632.1990.tb32056.x; BAILAR JC, 1986, NEW ENGL J MED, V314, P1226, DOI 10.1056/NEJM198605083141905; BAILAR JC, 1987, ISSUES SCI TECHNOL, V4, P16; BAILAR JC, 1992, CHRONIC DIS CAN S, V13, pS2; BRESLOW NE, 1987, IARC SCI PUBLICATION, V82; *BUR CENS, 1993, CURR POP REP P25, V1095; *BUR CENS, 1982, CURRENT POP REP P25, V917; Cole P, 1996, CANCER, V78, P2045, DOI 10.1002/(SICI)1097-0142(19961115)78:10<2045::AID-CNCR3>3.0.CO;2-N; DOLL R, 1981, JNCI-J NATL CANCER I, V66, P1191, DOI 10.1093/jnci/66.6.1192; *FIN MAN BRANCH, 1993, NCI FACT BOOK; *NAT CANC I, 1986, NCI MONOGRAPHS, V2; *NAT CTR HLTH STAT, 1994, VIT STAT US 1970 1 A, V2; *NAT CTR HLTH STAT, 1993, VIT STAT US 1970 1 A, V2; RIES LAG, IN PRESS SEER CANC S; SHALALA DE, 1996, NEW CANC MORTALITY R; SONDIK EJ, 1990, J NATL CANCER I, V82, P825; 1988, ISSUES SCI TECHNOL, V4, P14; 1987, NEW ENGL J MED, V316, P752; 1986, NEW ENGL J MED, V315, P963	19	344	357	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 29	1997	336	22					1569	1574		10.1056/NEJM199705293362206	http://dx.doi.org/10.1056/NEJM199705293362206			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	XB087	9164814				2022-12-01	WOS:A1997XB08700006
J	Lee, MM; Donahoe, PK; Silverman, BL; Hasegawa, T; Hasegawa, Y; Gustafson, ML; Chang, YC; MacLaughlin, DT				Lee, MM; Donahoe, PK; Silverman, BL; Hasegawa, T; Hasegawa, Y; Gustafson, ML; Chang, YC; MacLaughlin, DT			Measurements of serum Mullerian inhibiting substance in the evaluation of children with nonpalpable gonads	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	1996 Annual Meeting of the Pediatric-Academic-Societies	MAY 05-10, 1996	WASHINGTON, D.C.	Pediat Acad Soc			HCG STIMULATION; HORMONE; CRYPTORCHIDISM; TESTOSTERONE; IMMUNOASSAY; BOYS; DIAGNOSIS; ANORCHISM; INTERSEX; INFANTS	Background Mullerian inhibiting substance, produced constitutively by the prepubertal testes, promotes involution of the mullerian ducts during normal male sexual differentiation. In children with virilization and nonpalpable gonads, only those with testicular tissue should have detectable serum concentrations of mullerian inhibiting substance. Methods We measured serum mullerian inhibiting substance in 65 children with virilization at birth and nonpalpable gonads (age at diagnosis, 2 days to 11 years) and serum testosterone in 54 of them either after the administration of human chorionic gonadotropin or during the physiologic rise in testosterone that occurs in normal infants. Results The mean (+/-SD) serum mullerian inhibiting substance concentration in the 17 children with no testicular tissue was 0.7+/-0.5 ng per milliliter, as compared with 37.5+/-39.6 ng per milliliter in the 48 children with testes (P < 0.001). In the latter group, the mean values in the 14 children with abnormal testes and the 34 with normal testes were 11.5+/-11.8 and 48.2+/-42.1 ng per milliliter, respectively (P < 0.001). The sensitivity and specificity of the serum mullerian inhibiting substance assay for detecting the absence of testicular tissue were 92 percent and 98 percent, respectively, as compared with 69 percent and 83 percent for the measurement of serum testosterone. Furthermore, measurement of serum mullerian inhibiting substance was more sensitive than serum testosterone measurement for the identification of children with abnormal testes (67 percent vs. 25 percent), whereas the specificity of the two tests was similar. Conclusions Measurements of serum mullerian inhibiting substance can be used to determine testicular status in prepubertal children with nonpalpable gonads, thus differentiating anorchia from undescended testes in boys with bilateral cryptorchidism and serving as a measure of testicular integrity in children with intersexual anomalies. (C) 1997, Massachusetts Medical Society.	MASSACHUSETTS GEN HOSP, MED PRACTICES EVALUAT CTR, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, PEDIAT SURG RES LAB, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA; CHILDRENS MEM HOSP, DEPT PEDIAT ENDOCRINOL & DIABET, CHICAGO, IL 60614 USA; NW MED SCH, CHICAGO, IL USA; TOKYO METROPOLITAN KIYOSE CHILDRENS HOSP, DIV ENDOCRINOL & METAB, TOKYO, JAPAN	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Ann & Robert H. Lurie Children's Hospital of Chicago	Lee, MM (corresponding author), MASSACHUSETTS GEN HOSP, PEDIAT ENDOCRINE UNIT, ACC 709, BOSTON, MA 02114 USA.		Hasegawa, Tomonobu/L-3331-2013		NCI NIH HHS [CA 17393] Funding Source: Medline; NICHD NIH HHS [2F32HD07435] Funding Source: Medline; NIDDK NIH HHS [DK-02129] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [F32HD007435] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA017393] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002129] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAKER ML, 1993, J CLIN ENDOCR METAB, V76, P245, DOI 10.1210/jc.76.1.245; BAKER ML, 1990, J CLIN ENDOCR METAB, V70, P11, DOI 10.1210/jcem-70-1-11; DAVENPORT M, 1995, BRIT J UROL, V76, P790, DOI 10.1111/j.1464-410X.1995.tb00776.x; FOREST MG, 1979, J CLIN ENDOCR METAB, V49, P132, DOI 10.1210/jcem-49-1-132; FOREST MG, 1974, J CLIN INVEST, V53, P819, DOI 10.1172/JCI107621; FOREST MG, 1980, PEDIATR RES, V14, P819, DOI 10.1203/00006450-198006000-00009; FRIEDLAND GW, 1988, AM J ROENTGENOL, V151, P1107, DOI 10.2214/ajr.151.6.1107; GUSTAFSON ML, 1992, NEW ENGL J MED, V326, P466, DOI 10.1056/NEJM199202133260707; GUSTAFSON ML, 1993, J PEDIATR SURG, V28, P439, DOI 10.1016/0022-3468(93)90245-G; HREBINKO RL, 1993, J UROLOGY, V150, P458, DOI 10.1016/S0022-5347(17)35510-6; HUDSON PL, 1990, J CLIN ENDOCR METAB, V70, P16, DOI 10.1210/jcem-70-1-16; IMBEAUD S, 1994, HUM MOL GENET, V3, P125, DOI 10.1093/hmg/3.1.125; JAROW JP, 1986, J UROLOGY, V136, P277, DOI 10.1016/S0022-5347(17)44840-3; JOSSO N, 1995, HORM RES, V43, P243, DOI 10.1159/000184300; JOSSO N, 1993, RECENT PROG HORM RES, V48, P1; JOSSO N, 1993, EARLY HUM DEV, V33, P91, DOI 10.1016/0378-3782(93)90204-8; JOSSO N, 1991, TRENDS ENDOCRIN MET, V2, P227, DOI 10.1016/1043-2760(91)90029-M; JOSSO N, 1990, J CLIN ENDOCR METAB, V70, P23, DOI 10.1210/jcem-70-1-23; Jost A, 1947, ARCH ANAT MICR MORPH, P271; Lee MM, 1996, J CLIN ENDOCR METAB, V81, P571, DOI 10.1210/jc.81.2.571; LEE MM, 1993, ENDOCR REV, V14, P152, DOI 10.1210/er.14.2.152; LUSTIG RH, 1987, J UROLOGY, V138, P587, DOI 10.1016/S0022-5347(17)43266-6; MIETTINEN OS, 1970, BIOMETRICS, V26, P75, DOI 10.2307/2529046; ORTH JM, 1988, ENDOCRINOLOGY, V122, P787, DOI 10.1210/endo-122-3-787; REY R, 1993, J CLIN ENDOCR METAB, V77, P1220, DOI 10.1210/jc.77.5.1220; REY R, 1994, J CLIN ENDOCR METAB, V79, P960, DOI 10.1210/jc.79.4.960; Rey RA, 1996, AM J OBSTET GYNECOL, V174, P958, DOI 10.1016/S0002-9378(96)70333-2; SCHOLLER R, 1975, J STEROID BIOCHEM, V6, P95, DOI 10.1016/0022-4731(75)90189-2; URBAN MD, 1987, CLIN PEDIATR, V26, P512, DOI 10.1177/000992288702601003; VOLLSET SE, 1993, STAT MED, V12, P809, DOI 10.1002/sim.4780120902; Vollset SE, 1995, STAT MED, V14, P875; WINTER JSD, 1976, J CLIN ENDOCR METAB, V42, P679, DOI 10.1210/jcem-42-4-679; WINTER JSD, 1972, J CLIN ENDOCR METAB, V34, P348, DOI 10.1210/jcem-34-2-348	33	113	122	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 22	1997	336	21					1480	1486		10.1056/NEJM199705223362102	http://dx.doi.org/10.1056/NEJM199705223362102			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	WZ767	9154766	Green Published			2022-12-01	WOS:A1997WZ76700002
J	Campbell, MJ; Cogman, GR; Holgate, ST; Johnston, SL				Campbell, MJ; Cogman, GR; Holgate, ST; Johnston, SL			Age specific trends in asthma mortality in England and Wales, 1983-95: Results of an observational study	BRITISH MEDICAL JOURNAL			English	Article							DEATHS	Objective: To determine trends in asthma mortality by age group in England and Wales during 1983-95. Design: Observational study. Setting: England and Wales. Subjects: All deaths classified as having an underlying cause of asthma registered from 1 January 1983 to 31 December 1995. Main outcome measure: Time trends for age specific asthma deaths. Results: Deaths in the age group 5-14 pears showed an irregular downward trend during 1983-95; deaths in the age groups 15-44, 45-64, and 65-74 years peaked before 1989 and then showed a downward trend; and deaths in the age group 75-84 years peaked between 1988 and 1993 aad subsequently dropped. Trends were: age group 5-14 years, 6% (95% confidence interval 3% to 9%); 15-44 years, 6% (5% to 7%); 45-64 years, 5% (4% to 6%); 65-74 years, 2% (1% to 3%). Deaths in the 75-84 and 85 and over categories plateaued. Conclusions: There are downward tr ends in asthma mortality in Britain, which may be due to increased use of prophylactic treatment.	UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,DEPT MED,SOUTHAMPTON SP16 6YD,HANTS,ENGLAND	University of Southampton	Campbell, MJ (corresponding author), UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,DEPT MED STAT & COMP,SOUTHAMPTON SP16 6YD,HANTS,ENGLAND.		Johnston, Sebastian Lennox/I-2423-2012	Johnston, Sebastian Lennox/0000-0003-3009-9200				BALDWIN DR, 1990, THORAX, V45, P130, DOI 10.1136/thx.45.2.130; *BTA RES COMM, 1984, THORAX, V39, P505; BURNEY PGJ, 1986, LANCET, V2, P323; CADET B, 1994, REV EPIDEMIOL SANTE, V42, P103; GARRETT J, 1995, THORAX, V50, P303, DOI 10.1136/thx.50.3.303; HYNDMAN SJ, 1994, BRIT MED J, V308, P1596, DOI 10.1136/bmj.308.6944.1596; KHOT A, 1984, BRIT MED J, V289, P557, DOI 10.1136/bmj.289.6444.557; KHOT A, 1984, BRIT MED J, V289, P233, DOI 10.1136/bmj.289.6439.233; MACKAY TW, 1992, SCOT MED J, V37, P5, DOI 10.1177/003693309203700102; PHELAN PD, 1994, BRIT MED J, V308, P1584, DOI 10.1136/bmj.308.6944.1584; *STATC, 1997, STAT STAT SOFTW REL	11	133	134	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 17	1997	314	7092					1439	1441		10.1136/bmj.314.7092.1439	http://dx.doi.org/10.1136/bmj.314.7092.1439			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XA202	9167558	Green Published			2022-12-01	WOS:A1997XA20200019
J	Garceau, NY; Liu, Y; Loros, JJ; Dunlap, JC				Garceau, NY; Liu, Y; Loros, JJ; Dunlap, JC			Alternative initiation of translation and time-specific phosphorylation yield multiple forms of the essential clock protein FREQUENCY	CELL			English	Article							CIRCADIAN CLOCK; NEUROSPORA-CRASSA; PERIOD; GENE; RHYTHMS; MUTANTS; LIGHT; AUTOREGULATION; LOCALIZATION; OSCILLATOR	The frequency (frq) gene encodes central components of the transcription/translation-based negative-feedback loop comprising the core of the Neurospora circadian oscillator; posttranscriptional regulation associated with FRQ is surprisingly complex. Alternative use of translation initiation sites gives rise to two forms of FRQ whose levels peak 4-6 hr following the peak of frq transcript. Each form of FRQ is progressively phosphorylated over the course of the day, thus providing a number of temporally distinct FRQ products. The kinetics of these regulatory processes suggest a view of the clock where relatively rapid events involving translational regulation in the synthesis of FRQ and negative feedback of FRQ on fro transcript levels are followed by slower posttranslational regulation, ultimately driving the turnover of FRQ and reactivation of the frq gene.	DARTMOUTH COLL, SCH MED, DEPT BIOCHEM, HANOVER, NH 03755 USA	Dartmouth College			Dunlap, Jay/L-6232-2013; Loros, Jennifer/B-6293-2014	Dunlap, Jay/0000-0003-1577-0457; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034985, R37GM034985] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH044651, K05MH001186] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 34985] Funding Source: Medline; NIMH NIH HHS [MH01186, MH44651] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ARONSON BD, 1994, P NATL ACAD SCI USA, V91, P7683, DOI 10.1073/pnas.91.16.7683; ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; BellPedersen D, 1996, P NATL ACAD SCI USA, V93, P13096, DOI 10.1073/pnas.93.23.13096; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; CHANG F, 1992, MOL BIOL CELL, V3, P445, DOI 10.1091/mbc.3.4.445; CITRI Y, 1987, NATURE, V326, P42, DOI 10.1038/326042a0; COMOLLI J, 1994, J BIOL RHYTHM, V9, P13, DOI 10.1177/074873049400900102; CROSTHWAITE SK, 1995, CELL, V81, P1003, DOI 10.1016/S0092-8674(05)80005-4; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DUNLAP JC, 1993, ANNU REV PHYSIOL, V55, P683, DOI 10.1146/annurev.physiol.55.1.683; Dunlap JC, 1996, ANNU REV GENET, V30, P579, DOI 10.1146/annurev.genet.30.1.579; EBBOLE D, 1990, FUNGAL GENET NEWSL, V37, P15; EDELMANN SE, 1994, EXP MYCOL, V18, P70, DOI 10.1006/emyc.1994.1007; EDERY I, 1994, P NATL ACAD SCI USA, V91, P2260, DOI 10.1073/pnas.91.6.2260; FELDMAN JF, 1973, GENETICS, V75, P606; GEKAKIS N, 1995, SCIENCE, V270, P811, DOI 10.1126/science.270.5237.811; GRUBER A, 1995, BIOTECHNIQUES, V19, P28; HALL JC, 1995, TRENDS NEUROSCI, V18, P230, DOI 10.1016/0166-2236(95)93908-G; Hall JC, 1996, NEURON, V17, P799, DOI 10.1016/S0896-6273(00)80211-1; HARDIN P, 1995, SEMIN NEUROSCI, V7, P15, DOI 10.1016/1044-5765(95)90013-6; HASTINGS M, 1995, NATURE, V376, P296, DOI 10.1038/376296a0; HOTZVITATERNA M, 1994, SCIENCE, V264, P719; HunterEnsor M, 1996, CELL, V84, P677, DOI 10.1016/S0092-8674(00)81046-6; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KONDO T, 1994, SCIENCE, V266, P1233, DOI 10.1126/science.7973706; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; Lee CG, 1996, SCIENCE, V271, P1740, DOI 10.1126/science.271.5256.1740; Lewis MT, 1997, MOL GEN GENET, V253, P401, DOI 10.1007/s004380050338; LOROS J, 1995, SEMIN NEUROSCI, V7, P3, DOI 10.1016/1044-5765(95)90012-8; Luckow VA, 1992, BACULOVIRUS EXPRESSI; Merrow MW, 1997, P NATL ACAD SCI USA, V94, P3877, DOI 10.1073/pnas.94.8.3877; MICHEL S, 1993, SCIENCE, V259, P239, DOI 10.1126/science.8421785; MILLAR AJ, 1995, SCIENCE, V267, P1161, DOI 10.1126/science.7855595; Mittag M, 1996, PHYSIOL PLANTARUM, V96, P727; Myers MP, 1996, SCIENCE, V271, P1736, DOI 10.1126/science.271.5256.1736; NAKASHIMA H, 1981, PLANT CELL PHYSIOL, V22, P231; Nasmyth K, 1996, SCIENCE, V274, P1643, DOI 10.1126/science.274.5293.1643; PINES J, 1994, EMBO J, V13, P3772, DOI 10.1002/j.1460-2075.1994.tb06688.x; REPPERT SM, 1995, NEURON, V15, P983, DOI 10.1016/0896-6273(95)90086-1; Rosato E, 1997, NUCLEIC ACIDS RES, V25, P455, DOI 10.1093/nar/25.3.455; Sauman I, 1996, NEURON, V17, P901, DOI 10.1016/S0896-6273(00)80221-4; Sauman I, 1996, NEURON, V17, P889, DOI 10.1016/S0896-6273(00)80220-2; SEHGAL A, 1995, SEMIN NEUROSCI, V7, P27, DOI 10.1016/1044-5765(95)90014-4; SEHGAL A, 1995, SCIENCE, V270, P808, DOI 10.1126/science.270.5237.808; SIWICKI KK, 1988, NEURON, V1, P141, DOI 10.1016/0896-6273(88)90198-5; TAKAHASHI JS, 1989, RECENT PROG HORM RES, V45, P279; TAKAHASHI JS, 1995, ANNU REV NEUROSCI, V18, P531, DOI 10.1146/annurev.neuro.18.1.531; WELSH DK, 1995, NEURON, V14, P697, DOI 10.1016/0896-6273(95)90214-7; Zeng HK, 1996, NATURE, V380, P129, DOI 10.1038/380129a0	49	289	295	1	17	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 2	1997	89	3					469	476		10.1016/S0092-8674(00)80227-5	http://dx.doi.org/10.1016/S0092-8674(00)80227-5			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WX899	9150146	hybrid			2022-12-01	WOS:A1997WX89900017
J	Sharan, SK; Morimatsu, M; Albrecht, U; Lim, DS; Regel, E; Dinh, C; Sands, A; Eichele, G; Hasty, P; Bradley, A				Sharan, SK; Morimatsu, M; Albrecht, U; Lim, DS; Regel, E; Dinh, C; Sands, A; Eichele, G; Hasty, P; Bradley, A			Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2	NATURE			English	Article							MEIOTIC CHROMOSOME SYNAPSIS; CANCER SUSCEPTIBILITY GENE; FAMILIAL BREAST; OVARIAN-CANCER; RECA HOMOLOGS; PROTEIN; REPAIR; MOUSE; YEAST; RECOMBINATION	Inherited mutations in the human BRCA2 gene cause about half of the cases of early-onset breast cancer. The embryonic expression pattern of the mouse Brca2 gene is now defined and an interaction identified of the Brca2 protein with the DNA-repair protein Rad51. Developmental arrest in Brca2-deficient embryos, their radiation sensitivity, and the association of Brca2 with Rad51 indicate that Brca2 may be an essential cofactor in the Rad51-dependent DNA repair of double-strand breaks, thereby explaining the tumour-suppressor function of Brca2.	BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MOL & HUMAN GENET,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT BIOCHEM,HOUSTON,TX 77030; LEXICON GENET INC,THE WOODLANDS,TX 77381; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOL GENET,HOUSTON,TX 77030; HOKKAIDO UNIV,GRAD SCH VET MED,DEPT BIOMED SCI,SAPPORO,HOKKAIDO 060,JAPAN	Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; Baylor College of Medicine; Lexicon Pharmaceuticals; University of Texas System; UTMD Anderson Cancer Center; Hokkaido University			Albrecht, Urs/A-9831-2011; Morimatsu, Masami/A-6698-2012; Lim, Dae-Sik/C-1599-2011	Albrecht, Urs/0000-0002-0663-8676; Morimatsu, Masami/0000-0003-0740-0157; Lim, Dae-Sik/0000-0003-2356-7555; Hasty, Paul/0000-0003-3046-0131; Bradley, Allan/0000-0002-2349-8839				ALBECHT U, 1997, MOL CELLULAR METHODS, P23; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; BISHOP DK, 1994, CELL, V79, P1081, DOI 10.1016/0092-8674(94)90038-8; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; CARR AM, 1995, TRENDS CELL BIOL, V5, P32, DOI 10.1016/S0962-8924(00)88934-5; Couch FJ, 1996, NAT GENET, V13, P123, DOI 10.1038/ng0596-123; DEVILEE P, 1991, ONCOGENE, V6, P1705; DEVRIES A, 1995, NATURE, V377, P169, DOI 10.1038/377169a0; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONOVAN JW, 1994, GENE DEV, V8, P2552, DOI 10.1101/gad.8.21.2552; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EASTON DF, 1993, AM J HUM GENET, V52, P678; FEILOTTER HE, 1994, NUCLEIC ACIDS RES, V22, P1502, DOI 10.1093/nar/22.8.1502; Gayther SA, 1997, NAT GENET, V15, P103, DOI 10.1038/ng0197-103; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; HERRMANN BG, 1991, DEVELOPMENT, V113, P913; HU NP, 1994, ONCOGENE, V9, P1021; KAUFMAN MH, 1992, ATLAS MOUSE DEV, P2; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; Lim DS, 1996, MOL CELL BIOL, V16, P7133; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Malkova A, 1996, P NATL ACAD SCI USA, V93, P7131, DOI 10.1073/pnas.93.14.7131; MATZUK MM, 1992, NATURE, V360, P313, DOI 10.1038/360313a0; Miller, 1972, EXPT MOL GENETICS; Neuhausen S, 1996, NAT GENET, V13, P126, DOI 10.1038/ng0596-126; Phelan CM, 1996, NAT GENET, V13, P120, DOI 10.1038/ng0596-120; POWER MA, 1993, ANAT EMBRYOL, V187, P493; RADDING CM, 1991, J BIOL CHEM, V266, P5355; RAJAN IV, 1996, P NATL ACAD SCI USA, V93, P13078; RAMIREZSOLIS R, 1993, METHOD ENZYMOL, V225, P855; ROCKMILL B, 1995, GENE DEV, V9, P2684, DOI 10.1101/gad.9.21.2684; SANDS AT, 1995, NATURE, V377, P162, DOI 10.1038/377162a0; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Sharan SK, 1997, GENOMICS, V40, P234, DOI 10.1006/geno.1996.4573; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SMITH SA, 1992, NAT GENET, V2, P128, DOI 10.1038/ng1092-128; SNOW MHL, 1977, J EMBRYOL EXP MORPH, V42, P293; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; Thorlacius S, 1996, NAT GENET, V13, P117, DOI 10.1038/ng0596-117; Wick W, 1996, ONCOGENE, V12, P973; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0	46	867	893	1	41	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 24	1997	386	6627					804	810		10.1038/386804a0	http://dx.doi.org/10.1038/386804a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WV706	9126738	Green Submitted			2022-12-01	WOS:A1997WV70600046
J	Courtney, SM; Ungerleider, BG; Keil, K; Haxby, JV				Courtney, SM; Ungerleider, BG; Keil, K; Haxby, JV			Transient and sustained activity in a distributed neural system for human working memory	NATURE			English	Article							SHORT-TERM-MEMORY; PREFRONTAL CORTEX; TEMPORAL CORTEX; FRONTAL-CORTEX; NEURONS; TASK; DISSOCIATION; ACTIVATION	Working memory involves the short-term maintenance of an active representation of information so that it is available for further processing. Visual working memory tasks, in which subjects retain the memory of a stimulus over brief delays, require both the perceptual encoding of the stimulus and the subsequent maintenance of its representation after the stimulus is removed from view. Such tasks activate multiple areas in visual and prefrontal cortices(1-9). To delineate the roles these areas play in perception and working memory maintenance, we used functional magnetic resonance imaging (fMRI) to obtain dynamic measures of neural activity related to different components of a face working memory task-non-selective transient responses to visual stimuli, selective transient responses to faces, and sustained responses over memory delays. Three occipitotemporal areas in the ventral object vision pathway had mostly transient responses to stimuli, indicating their predominant role in perceptual processing, whereas three prefrontal areas demonstrated sustained activity over memory delays, indicating their predominant role in working memory. This distinction, however, was not absolute. Additionally, the visual areas demonstrated different degrees of selectivity, and the prefrontal areas demonstrated different strengths of sustained activity, revealing a continuum of functional specialization, from occipital through multiple prefrontal areas, regarding each area's relative contribution to perceptual and mnemonic processing.	NATL INST HLTH,SECT NEUROCIRCUITRY,LAB BRAIN & COGNIT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA	Courtney, SM (corresponding author), NATL INST HLTH,SECT FUNCT BRAIN IMAGING,10 CTR DR,MSC 1366,BETHESDA,MD 20892, USA.							Buckner RL, 1996, PSYCHON B REV, V3, P149, DOI 10.3758/BF03212413; Chao LL, 1996, COGNITIVE BRAIN RES, V4, P27, DOI 10.1016/0926-6410(95)00043-7; Cohen J D, 1994, Hum Brain Mapp, V1, P293, DOI 10.1002/hbm.460010407; Cohen JD, 1997, NATURE, V386, P604, DOI 10.1038/386604a0; Courtney S. M., 1996, Society for Neuroscience Abstracts, V22, P968; Courtney SM, 1996, CEREB CORTEX, V6, P39, DOI 10.1093/cercor/6.1.39; DEMB JB, 1995, J NEUROSCI, V15, P5870; DESIMONE R, 1984, J NEUROSCI, V4, P2051; Desimone R., 1989, HDB NEUROPSYCHOLOGY, P267; DESPOSITO M, 1995, NATURE, V378, P279, DOI 10.1038/378279a0; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; Fiez JA, 1996, J NEUROSCI, V16, P808; Friston K J, 1994, Hum Brain Mapp, V1, P210, DOI 10.1002/hbm.460010306; FRISTON KJ, 1995, NEUROIMAGE, V2, P45, DOI 10.1006/nimg.1995.1007; Fuster J.M., 1995, MEMORY CEREBRAL CORT; Gevins A, 1996, ELECTROEN CLIN NEURO, V98, P327, DOI 10.1016/0013-4694(96)00288-X; Haxby JV, 1996, P NATL ACAD SCI USA, V93, P922, DOI 10.1073/pnas.93.2.922; Haxby JV, 1995, HUM BRAIN MAPP, V3, P68, DOI 10.1002/hbm.460030204; MCCARTHY G, 1993, P NATL ACAD SCI USA, V90, P4952, DOI 10.1073/pnas.90.11.4952; MCCARTHY G, 1994, P NATL ACAD SCI USA, V91, P8690, DOI 10.1073/pnas.91.18.8690; MILLER EK, 1993, J NEUROSCI, V13, P1460; Miller EK, 1996, J NEUROSCI, V16, P5154; MIYASHITA Y, 1988, NATURE, V331, P68, DOI 10.1038/331068a0; Owen AM, 1996, CEREB CORTEX, V6, P31, DOI 10.1093/cercor/6.1.31; Paus T, 1996, NEUROPSYCHOLOGIA, V34, P475, DOI 10.1016/0028-3932(95)00134-4; PERRETT DI, 1982, EXP BRAIN RES, V47, P329; PETRIDES M, 1993, P NATL ACAD SCI USA, V90, P873, DOI 10.1073/pnas.90.3.873; Smith EE, 1996, CEREB CORTEX, V6, P11, DOI 10.1093/cercor/6.1.11; Talairach J., 1988, COPLANAR STEREOTAXIS; WILSON FAW, 1993, SCIENCE, V260, P1955, DOI 10.1126/science.8316836	30	730	755	1	54	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 10	1997	386	6625					608	611		10.1038/386608a0	http://dx.doi.org/10.1038/386608a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WT273	9121584				2022-12-01	WOS:A1997WT27300059
J	Carstea, ED; Morris, JA; Coleman, KG; Loftus, SK; Zhang, D; Cummings, C; Gu, J; Rosenfeld, MA; Pavan, WJ; Krizman, DB; Nagle, J; Polymeropoulos, MH; Sturley, SL; Ioannou, YA; Higgins, ME; Comly, M; Cooney, A; Brown, A; Kaneski, CR; BlanchetteMackie, EJ; Dwyer, NK; Neufeld, EB; Chang, TY; Liscum, L; Strauss, JF; Ohno, K; Zeigler, M; Carmi, R; Sokol, J; Markie, D; ONeill, RR; vanDiggelen, OP; Elleder, M; Patterson, MC; Brady, RO; Vanier, MT; Pentchev, PG; Tagle, DA				Carstea, ED; Morris, JA; Coleman, KG; Loftus, SK; Zhang, D; Cummings, C; Gu, J; Rosenfeld, MA; Pavan, WJ; Krizman, DB; Nagle, J; Polymeropoulos, MH; Sturley, SL; Ioannou, YA; Higgins, ME; Comly, M; Cooney, A; Brown, A; Kaneski, CR; BlanchetteMackie, EJ; Dwyer, NK; Neufeld, EB; Chang, TY; Liscum, L; Strauss, JF; Ohno, K; Zeigler, M; Carmi, R; Sokol, J; Markie, D; ONeill, RR; vanDiggelen, OP; Elleder, M; Patterson, MC; Brady, RO; Vanier, MT; Pentchev, PG; Tagle, DA			Niemann-Pick C1 disease gene: Homology to mediators of cholesterol homeostasis	SCIENCE			English	Article							LOW-DENSITY LIPOPROTEIN; NIEMANN-PICK DISEASE; DI-LEUCINE MOTIF; CULTURED FIBROBLASTS; STORAGE; ENDOCYTOSIS; LYSOSOMES; SITES	Niemann-Pick type C (NP-C) disease, a fatal neurovisceral disorder, is characterized by lysosomal accumulation of low density lipoprotein (LDL)-derived cholesterol. BY positional cloning methods, a gene (NPC1) with insertion, deletion, and missense mutations has been identified in NP-C patients. Transfection of NP-C fibroblasts with wild-type NPC1 cDNA resulted in correction of their excessive lysosomal storage of LDL cholesterol, thereby defining the critical role of NPC1 in regulation of intracellular cholesterol trafficking. The 1278-amino acid NPC1 protein has sequence similarity to the morphogen receptor PATCHED and the putative sterol-sensing regions of SREBP cleavage-activating protein (SCAP) and 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase.	NINCDS,NIH,BETHESDA,MD 20892; NIH,NATL HUMAN GENOME RES INST,BETHESDA,MD 20892; COLUMBIA UNIV COLL PHYS & SURG,NEW YORK,NY 10032; CUNY MT SINAI SCH MED,NEW YORK,NY 10029; NIDDKD,NIH,BETHESDA,MD 20892; DARTMOUTH COLL,SCH MED,HANOVER,NH 03755; TUFTS UNIV,SCH MED,BOSTON,MA 02111; UNIV PENN,PHILADELPHIA,PA 19104; HADASSAH UNIV HOSP,IL-91120 JERUSALEM,ISRAEL; BEN GURION UNIV NEGEV,IL-84105 BEER SHEVA,ISRAEL; HILLEL YAFFE MED CTR,HADERA,ISRAEL; DUNEDIN SCH MED,DUNEDIN,NEW ZEALAND; ERASMUS UNIV ROTTERDAM,ROTTERDAM,NETHERLANDS; FAC MED,PRAGUE,CZECH REPUBLIC; UNIV HOSP,PRAGUE,CZECH REPUBLIC; MAYO CLIN & MAYO FDN,ROCHESTER,MN 55905; INSERM,U189,OULLINS,FRANCE; TOTTORI UNIV,FAC MED,YONAGO,TOTTORI 683,JAPAN	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Columbia University; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Dartmouth College; Tufts University; University of Pennsylvania; Hebrew University of Jerusalem; Ben Gurion University; University of Otago; Erasmus University Rotterdam; General University Hospital Prague; Mayo Clinic; Institut National de la Sante et de la Recherche Medicale (Inserm); Tottori University			Patterson, Marc/AAI-5056-2020; Markie, David/I-7893-2019; Patterson, Marc C./H-5331-2019; Neufeld, Edward/R-3819-2019	Pavan, William/0000-0001-8281-5120; Patterson, Marc/0000-0002-1116-126X; Markie, David/0000-0001-5452-9194; Chang, Ta-Yuan/0000-0002-3249-0468; Kaneski, Christine/0000-0003-1453-2502; Loftus, Stacie/0000-0002-1958-4689				BLANCHETTEMACKIE EJ, 1988, P NATL ACAD SCI USA, V85, P8022, DOI 10.1073/pnas.85.21.8022; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CARSTEA ED, 1993, P NATL ACAD SCI USA, V90, P2002, DOI 10.1073/pnas.90.5.2002; CARSTEA ED, UNPUB; CHIN DJ, 1984, NATURE, V308, P613, DOI 10.1038/308613a0; COOPER JA, 1984, J BIOL CHEM, V259, P7835; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GOLDSTEIN JL, 1975, J BIOL CHEM, V250, P8487; GU JZ, IN PRESS P NATL ACAD; Hofmann K., 1993, BIOL CHEM, V374, P166; Hua XX, 1996, J BIOL CHEM, V271, P10379, DOI 10.1074/jbc.271.17.10379; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; KLEIN P, 1985, BIOCHIM BIOPHYS ACTA, V815, P468, DOI 10.1016/0005-2736(85)90375-X; Krizman D B, 1997, Methods Mol Biol, V68, P167; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LISCUM L, 1987, J BIOL CHEM, V262, P17002; Loftus SK, 1997, SCIENCE, V277, P232, DOI 10.1126/science.277.5323.232; MCGEOCH DJ, 1985, VIRUS RES, V3, P271, DOI 10.1016/0168-1702(85)90051-6; NAKAI K, 1991, PROTEINS, V11, P95, DOI 10.1002/prot.340110203; ORTGATA S, 1994, J BIOL CHEM, V269, P5210; Pentchev P. G., 1995, METABOLIC MOL BASES, P2625; PENTCHEV PG, 1987, FASEB J, V1, P40, DOI 10.1096/fasebj.1.1.3609608; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; SANDOVAL IV, 1994, J BIOL CHEM, V269, P6622; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; Vanier MT, 1996, AM J HUM GENET, V58, P118; WANG X, 1994, CELL, V77, P52	30	1130	1173	2	67	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 11	1997	277	5323					228	231		10.1126/science.277.5323.228	http://dx.doi.org/10.1126/science.277.5323.228			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK418	9211849	Green Submitted			2022-12-01	WOS:A1997XK41800042
J	Bangsberg, D; Tulsky, JP; Hecht, FM; Moss, AR				Bangsberg, D; Tulsky, JP; Hecht, FM; Moss, AR			Protease inhibitors in the homeless	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; NEW-YORK-CITY; TUBERCULOSIS; COMMUNITY; RISK; RESISTANT; ADULTS; HIV; PREVALENCE; MANAGEMENT		UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,MED SERV,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,AIDS PROGRAM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CTR AIDS PREVENT STUDIES,AIDS RES INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA; UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94143	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco				Hecht, Frederick/0000-0002-5782-1171	NHLBI NIH HHS [HL55729] Funding Source: Medline; NIMH NIH HHS [MH54907, R01 MH054907] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055729] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH054907] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ASHE J, 1996, SAN FRANCISCO DEATH; *BHIVA GUID COORD, 1997, LANCET, V349, P1086; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; BUSH CT, 1990, HOSP COMMUNITY PSYCH, V41, P647; *CDCP, 1996, MMWR-MORBID MORTAL W, V45, P151; CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0; CONLON CP, 1994, J INFECT DIS, V169, P411, DOI 10.1093/infdis/169.2.411; Deeks SG, 1997, JAMA-J AM MED ASSOC, V277, P145, DOI 10.1001/jama.277.2.145; DIEHR P, 1989, MED CARE, V27, P942, DOI 10.1097/00005650-198910000-00005; ElSadr W, 1996, AM J PUBLIC HEALTH, V86, P1146, DOI 10.2105/AJPH.86.8_Pt_1.1146; Fournier AM, 1996, AM J MED, V100, P582, DOI 10.1016/S0002-9343(95)00019-4; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; FRIEDEN TR, 1995, NEW ENGL J MED, V333, P329; Gerberding JL, 1996, ANN INTERN MED, V125, P497, DOI 10.7326/0003-4819-125-6-199609150-00011; HANZLICK R, 1993, PUBLIC HEALTH REP, V108, P488; Havlir DV, 1996, ANN INTERN MED, V124, P984, DOI 10.7326/0003-4819-124-11-199606010-00006; HIBBS JR, 1994, NEW ENGL J MED, V331, P304, DOI 10.1056/NEJM199408043310506; JOHNSON PA, 1993, ANN INTERN MED, V118, P593, DOI 10.7326/0003-4819-118-8-199304150-00004; Katz MH, 1997, NEW ENGL J MED, V336, P1097, DOI 10.1056/NEJM199704103361512; LELAND J, 1996, NEWSWEEK        1202, P65; MAYNARD C, 1986, AM J PUBLIC HEALTH, V76, P1446, DOI 10.2105/AJPH.76.12.1446; Molla A, 1996, NAT MED, V2, P760, DOI 10.1038/nm0796-760; MOORE RD, 1994, NEW ENGL J MED, V330, P763, DOI 10.1056/NEJM199403173301107; MOORE RD, 1989, JAMA-J AM MED ASSOC, V261, P403, DOI 10.1001/jama.261.3.403; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; POWE NR, 1992, JAMA-J AM MED ASSOC, V268, P1434, DOI 10.1001/jama.268.11.1434; SARAVOLATZ LD, 1982, ANN INTERN MED, V96, P11, DOI 10.7326/0003-4819-96-1-11; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; Sontag Deborah, 1997, N Y Times Web, pB6; Stansell JD, 1997, AM J RESP CRIT CARE, V155, P60, DOI 10.1164/ajrccm.155.1.9001290; STEIN LI, 1980, ARCH GEN PSYCHIAT, V37, P392; Susser E, 1997, AM J PUBLIC HEALTH, V87, P256, DOI 10.2105/AJPH.87.2.256; THOMAS SB, 1991, AM J PUBLIC HEALTH, V81, P1498, DOI 10.2105/AJPH.81.11.1498; TODD KH, 1993, JAMA-J AM MED ASSOC, V269, P1537, DOI 10.1001/jama.269.12.1537; WALDMAN A, 1997, WASHINGTON POST 0427, pCO1; Wilfert CM, 1996, CLIN INFECT DIS, V23, P438, DOI 10.1093/clinids/23.3.438; ZOLOPA AR, 1994, JAMA-J AM MED ASSOC, V272, P455, DOI 10.1001/jama.272.6.455	37	117	122	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 2	1997	278	1					63	65		10.1001/jama.278.1.63	http://dx.doi.org/10.1001/jama.278.1.63			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XG387	9207341				2022-12-01	WOS:A1997XG38700039
J	Xu, XZS; Li, HS; Guggino, WB; Montell, C				Xu, XZS; Li, HS; Guggino, WB; Montell, C			Coassembly of TRP and TRPL produces a distinct store-operated conductance	CELL			English	Article							CAPACITATIVE CALCIUM-ENTRY; LIGHT-SENSITIVE CHANNELS; DROSOPHILA TRP; PLASMA-MEMBRANE; HUMAN HOMOLOG; K+ CHANNEL; T-CELLS; GENE; PHOTOTRANSDUCTION; PHOTORECEPTORS	The Drosophila retinal-specific protein, TRP (transient receptor potential), is the founding member of a family of store-operated channels (SOCs) conserved from C. elegans to humans. In vitro studies indicate that TRP is a SOC, but that the related retinal protein, TRPL, is constitutively active. In the current work, we report that coexpression of TRP and TRPL leads to a store-operated, outwardly rectifying current distinct from that owing to either TRP or TRPL alone. TRP and TRPL interact directly, indicating that the TRP-TRPL-dependent current is mediated by heteromultimeric association between the two subunits. We propose that the light-activated current in photoreceptor cells is produced by a combination of TRP homo- and TRP-TRPL heteromultimers.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University	Xu, XZS (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205, USA.		Montell, Craig/AAH-3357-2021	Montell, Craig/0000-0001-5637-1482	NEI NIH HHS [EY10852] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY010852] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Arnon A, 1997, SCIENCE, V275, P1119, DOI 10.1126/science.275.5303.1119; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Chevesich J, 1997, NEURON, V18, P95, DOI 10.1016/S0896-6273(01)80049-0; COSENS DJ, 1969, NATURE, V224, P285, DOI 10.1038/224285a0; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Gillo B, 1996, P NATL ACAD SCI USA, V93, P14146, DOI 10.1073/pnas.93.24.14146; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hardie RC, 1995, J NEUROPHYSIOL, V74, P2590, DOI 10.1152/jn.1995.74.6.2590; HARDIE RC, 1994, J GEN PHYSIOL, V103, P409, DOI 10.1085/jgp.103.3.409; HARDIE RC, 1991, P ROY SOC B-BIOL SCI, V245, P203, DOI 10.1098/rspb.1991.0110; HARDIE RC, 1992, NEURON, V8, P643, DOI 10.1016/0896-6273(92)90086-S; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; HU YF, 1994, BIOCHEM BIOPH RES CO, V201, P1050, DOI 10.1006/bbrc.1994.1808; Huber A, 1996, J BIOL CHEM, V271, P11710, DOI 10.1074/jbc.271.20.11710; Huber A, 1996, EMBO J, V15, P7036, DOI 10.1002/j.1460-2075.1996.tb01095.x; JACKSON TR, 1988, BIOCHEM J, V253, P81, DOI 10.1042/bj2530081; JAN LY, 1992, CELL, V69, P715, DOI 10.1016/0092-8674(92)90280-P; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; Krause E, 1996, J BIOL CHEM, V271, P32523, DOI 10.1074/jbc.271.51.32523; LEWIS RS, 1989, CELL REGUL, V1, P99, DOI 10.1091/mbc.1.1.99; LUCKHOFF A, 1994, BIOPHYS J, V67, P177, DOI 10.1016/S0006-3495(94)80467-9; MCDONALD TV, 1993, J BIOL CHEM, V268, P3889; Minke B, 1996, MOL NEUROBIOL, V12, P163, DOI 10.1007/BF02740652; MONTELL C, 1985, SCIENCE, V230, P1040, DOI 10.1126/science.3933112; MONTELL C, 1989, NEURON, V2, P1313, DOI 10.1016/0896-6273(89)90069-X; NAKATANI K, 1988, J PHYSIOL-LONDON, V395, P695, DOI 10.1113/jphysiol.1988.sp016942; NEHER E, 1992, ION CHANNELS, P123; Niemeyer BA, 1996, CELL, V85, P651, DOI 10.1016/S0092-8674(00)81232-5; PETERSEN CCH, 1995, BIOCHEM J, V311, P41, DOI 10.1042/bj3110041; Philipp S, 1996, EMBO J, V15, P6166, DOI 10.1002/j.1460-2075.1996.tb01004.x; PHILLIPS AM, 1992, NEURON, V8, P631, DOI 10.1016/0896-6273(92)90085-R; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; PUTNEY JW, 1993, CELL, V75, P199, DOI 10.1016/0092-8674(93)80061-I; SALKOFF L, 1992, TRENDS NEUROSCI, V15, P161, DOI 10.1016/0166-2236(92)90165-5; SCHWARZ TL, 1988, NATURE, V331, P137, DOI 10.1038/331137a0; Shieh BH, 1996, NEURON, V16, P991, DOI 10.1016/S0896-6273(00)80122-1; Sinkins W. G., 1997, Biophysical Journal, V72, pA271; SUSSTOBY E, 1991, J GEN PHYSIOL, V98, P848; Tinker A, 1996, CELL, V87, P857, DOI 10.1016/S0092-8674(00)81993-5; VACA L, 1994, AM J PHYSIOL-CELL PH, V267, pC1501, DOI 10.1152/ajpcell.1994.267.5.C1501; WES PD, 1995, P NATL ACAD SCI USA, V92, P9652, DOI 10.1073/pnas.92.21.9652; WONG F, 1989, NEURON, V3, P81, DOI 10.1016/0896-6273(89)90117-7; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0; ZHU X, 1995, FEBS LETT, V373, P193, DOI 10.1016/0014-5793(95)01038-G; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; Zitt C, 1996, NEURON, V16, P1189, DOI 10.1016/S0896-6273(00)80145-2; ZWEIFACH A, 1995, J GEN PHYSIOL, V105, P209, DOI 10.1085/jgp.105.2.209	50	263	280	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 27	1997	89	7					1155	1164		10.1016/S0092-8674(00)80302-5	http://dx.doi.org/10.1016/S0092-8674(00)80302-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XG830	9215637	hybrid			2022-12-01	WOS:A1997XG83000019
J	DeCherney, AH; Koos, B				DeCherney, AH; Koos, B			Obstetrics and gynecology	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CALCIUM SUPPLEMENTATION; TRANSMISSION; PREECLAMPSIA; ZIDOVUDINE				DeCherney, AH (corresponding author), UNIV CALIF LOS ANGELES,LOS ANGELES,CA 90024, USA.		DeCherney, Alan H/AAS-2944-2020					BOYER PJ, 1994, JAMA-J AM MED ASSOC, V271, P1925, DOI 10.1001/jama.271.24.1925; Bucher HC, 1996, JAMA-J AM MED ASSOC, V275, P1113, DOI 10.1001/jama.275.14.1113; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; Dickover RE, 1996, JAMA-J AM MED ASSOC, V275, P599, DOI 10.1001/jama.275.8.599; Flake AW, 1996, NEW ENGL J MED, V335, P1806, DOI 10.1056/NEJM199612123352404; Kurtzberg J, 1996, NEW ENGL J MED, V335, P157, DOI 10.1056/NEJM199607183350303; RICHARDSON BE, 1995, AM J EPIDEMIOL, V141, P667, DOI 10.1093/oxfordjournals.aje.a117483; SANCHEZRAMOS L, 1995, OBSTET GYNECOL, V85, P915, DOI 10.1016/0029-7844(95)00052-S; SANCHEZRAMOS L, 1994, OBSTET GYNECOL, V84, P349; Sperling RS, 1996, NEW ENGL J MED, V335, P1621, DOI 10.1056/NEJM199611283352201; Touraine J L, 1996, J Hematother, V5, P195, DOI 10.1089/scd.1.1996.5.195	11	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	1997	277	23					1878	1879						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD544	9185813				2022-12-01	WOS:A1997XD54400032
J	Farr, GW; Scharl, EC; Schumacher, RJ; Sondek, S; Horwich, AL				Farr, GW; Scharl, EC; Schumacher, RJ; Sondek, S; Horwich, AL			Chaperonin-mediated folding in the eukaryotic cytosol proceeds through rounds of release of native and nonnative forms	CELL			English	Article							CYTOPLASMIC CHAPERONIN; BETA-ACTIN; G-PROTEIN; IN-VIVO; BINDING; ALPHA; TUBULIN; COMPLEX; TCP-1; EXTRACTS	The eukaryotic cytosolic chaperonin, CCT, plays an essential role in mediating ATP-dependent folding of actin and tubulin. There is debate about whether it mediates folding through a single round of association followed by release of native forms, or through cycles of binding and full release in which only a fraction of released molecules reaches native form in any cycle. We examine the fate of newly synthesized substrate proteins bound to CCT in reticulocyte lysate or intact Xenopus oocytes. When a chaperonin ''trap,'' able to bind but not release substrate protein, is introduced, production of the native state is strongly inhibited, associated with transfer to trap. While predominantly nonnative forms of actin, tubulin, and a newly identified substrate, G(alpha)-transducin, are released from CCT, a small fraction reaches native form with each round of release, inaccessible to trap. This overall mechanism resembles that of the bacterial chaperonin, GroEL.	YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MOL BIOPHYS & BIOCHEM,NEW HAVEN,CT 06510	Yale University; Howard Hughes Medical Institute; Yale University								Buchberger A, 1996, J MOL BIOL, V261, P328, DOI 10.1006/jmbi.1996.0465; Ellis RJ, 1996, FASEB J, V10, P20, DOI 10.1096/fasebj.10.1.8566542; FAUROBERT E, 1993, EMBO J, V12, P4191, DOI 10.1002/j.1460-2075.1993.tb06103.x; Fenton WA, 1997, PROTEIN SCI, V6, P743; Frydman J, 1996, SCIENCE, V272, P1497, DOI 10.1126/science.272.5267.1497; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GAO Y, 1994, J CELL BIOL, V125, P980; GAO YI, 1993, MOL CELL BIOL, V13, P2478, DOI 10.1128/MCB.13.4.2478; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; GRAGEROV A, 1992, P NATL ACAD SCI USA, V89, P10341, DOI 10.1073/pnas.89.21.10341; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; KUBOTA H, 1995, EUR J BIOCHEM, V230, P3, DOI 10.1111/j.1432-1033.1995.0003i.x; LAZARIDES E, 1974, P NATL ACAD SCI USA, V71, P4742, DOI 10.1073/pnas.71.12.4742; LEVILLIERS N, 1984, BIOCHIMIE, V66, P531, DOI 10.1016/0300-9084(84)90147-0; Lewis SA, 1996, J CELL BIOL, V132, P1, DOI 10.1083/jcb.132.1.1; MARCO S, 1994, BIOPHYS J, V67, P364, DOI 10.1016/S0006-3495(94)80489-8; Martin J, 1997, P NATL ACAD SCI USA, V94, P1107, DOI 10.1073/pnas.94.4.1107; MAZZONI MR, 1991, J BIOL CHEM, V266, P14072; MAZZONI MR, 1989, BIOCHEMISTRY-US, V28, P9873, DOI 10.1021/bi00451a047; MEDYNSKI DC, 1985, P NATL ACAD SCI USA, V82, P4311, DOI 10.1073/pnas.82.13.4311; MELKI R, 1994, MOL CELL BIOL, V14, P2895, DOI 10.1128/MCB.14.5.2895; Melki R, 1996, BIOCHEMISTRY-US, V35, P10422, DOI 10.1021/bi960788r; RANSON NA, 1995, J MOL BIOL, V250, P581, DOI 10.1006/jmbi.1995.0399; ROSENBLATT J, 1995, MOL BIOL CELL, V6, P227, DOI 10.1091/mbc.6.2.227; SHOEMAKER MT, 1993, BIOCHEMISTRY-US, V32, P1883, DOI 10.1021/bi00058a023; Skiba NP, 1996, J BIOL CHEM, V271, P413, DOI 10.1074/jbc.271.1.413; STERNLICHT H, 1979, J BIOL CHEM, V254, P540; STERNLICHT H, 1993, P NATL ACAD SCI USA, V90, P9422, DOI 10.1073/pnas.90.20.9422; TIAN GL, 1995, J BIOL CHEM, V270, P23910, DOI 10.1074/jbc.270.41.23910; Tian GL, 1996, CELL, V86, P287, DOI 10.1016/S0092-8674(00)80100-2; TIAN GL, 1995, NATURE, V375, P250, DOI 10.1038/375250a0; Todd MJ, 1996, P NATL ACAD SCI USA, V93, P4030, DOI 10.1073/pnas.93.9.4030; URSIC D, 1991, MOL CELL BIOL, V11, P2629, DOI 10.1128/MCB.11.5.2629; VINH DBN, 1994, P NATL ACAD SCI USA, V91, P9116, DOI 10.1073/pnas.91.19.9116; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; YAFFE MB, 1988, J BIOL CHEM, V263, P16023; YAFFE MB, 1992, NATURE, V358, P245, DOI 10.1038/358245a0	38	147	148	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 13	1997	89	6					927	937		10.1016/S0092-8674(00)80278-0	http://dx.doi.org/10.1016/S0092-8674(00)80278-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XE357	9200611	hybrid			2022-12-01	WOS:A1997XE35700013
J	Tanaka, K; Watase, K; Manabe, T; Yamada, K; Watanabe, M; Takahashi, K; Iwama, H; Nishikawa, T; Ichihara, N; Hori, S; Takimoto, M; Wada, K				Tanaka, K; Watase, K; Manabe, T; Yamada, K; Watanabe, M; Takahashi, K; Iwama, H; Nishikawa, T; Ichihara, N; Hori, S; Takimoto, M; Wada, K			Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1	SCIENCE			English	Article							AMINO-ACID TRANSPORTER; RAT-BRAIN; MOUSE-BRAIN; EXPRESSION; CLONING; RECEPTORS; KINETICS; DISEASE; DEATH	Extracellular levels of the excitatory neurotransmitter glutamate in the nervous system are maintained by transporters that actively remove glutamate from the extracellular space. Homozygous mice deficient in GLT-1, a widely distributed astrocytic glutamate transporter, show lethal spontaneous seizures and increased susceptibility to acute cortical injury. These effects can be attributed to elevated levels of residual glutamate in the brains of these mice.	UNIV TOKYO,FAC MED,DEPT NEUROPHYSIOL,TOKYO 113,JAPAN; HOKKAIDO UNIV,SCH MED,DEPT ANAT,SAPPORO,HOKKAIDO 060,JAPAN; NATL INST NEUROSCI,DEPT ANIM MODELS HUMAN DIS,KODAIRA,TOKYO 187,JAPAN; TAISHO PHARMACEUT CO LTD,MED RES LABS,LAB 1,OMIYA,SAITAMA 330,JAPAN; CIBA GEIGY JAPAN,INT RES LABS,TAKARAZUKA,HYOGO 665,JAPAN	University of Tokyo; Hokkaido University; National Center for Neurology & Psychiatry - Japan; Taisho Pharmaceutical Holdings Co Ltd	Tanaka, K (corresponding author), NATL INST NEUROSCI,DEPT DEGENERAT NEUROL DIS,KODAIRA,TOKYO 187,JAPAN.		WATANABE, Masahiko/A-4055-2012; Watanabe, Masahiko/S-3614-2019	WATANABE, Masahiko/0000-0001-5037-7138; Watanabe, Masahiko/0000-0001-5037-7138				CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CLEMENTS JD, 1992, SCIENCE, V258, P1498, DOI 10.1126/science.1359647; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; ISAACSON JS, 1993, J NEUROPHYSIOL, V70, P2187, DOI 10.1152/jn.1993.70.5.2187; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KIRSCHNER MA, 1994, GENOMICS, V24, P218, DOI 10.1006/geno.1994.1609; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MUKAINAKA Y, 1995, BBA-GEN SUBJECTS, V1244, P233, DOI 10.1016/0304-4165(95)00062-G; OURY TD, 1993, J BIOL CHEM, V268, P15394; PALMER AM, 1986, NEUROSCI LETT, V66, P199, DOI 10.1016/0304-3940(86)90190-4; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; PORTERACAILLIAU C, 1995, J NEUROSCI, V15, P3775, DOI 10.1523/jneurosci.15-05-03775.1995; RISE ML, 1991, SCIENCE, V253, P669, DOI 10.1126/science.1871601; ROBINSON MB, 1991, BRAIN RES, V544, P196, DOI 10.1016/0006-8993(91)90054-Y; ROGAWSKI MA, 1989, J PHARMACOL EXP THER, V249, P708; ROTHSTEIN JD, 1994, NEURON, V13, P713, DOI 10.1016/0896-6273(94)90038-8; ROTHSTEIN JD, 1995, ANN NEUROL, V38, P73, DOI 10.1002/ana.410380114; Shibata T, 1996, NEUROREPORT, V7, P705, DOI 10.1097/00001756-199602290-00006; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; SZATKOWSKI M, 1994, TRENDS NEUROSCI, V17, P359, DOI 10.1016/0166-2236(94)90040-X; Tanaka K., 1995, Society for Neuroscience Abstracts, V21, P1862; TANAKA K, 1993, NEUROSCI RES, V16, P149, DOI 10.1016/0168-0102(93)90082-2; WADICHE JI, 1995, NEURON, V14, P1019, DOI 10.1016/0896-6273(95)90340-2; Yamada K, 1996, NEUROREPORT, V7, P2013, DOI 10.1097/00001756-199608120-00032	27	1377	1410	1	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 13	1997	276	5319					1699	1702		10.1126/science.276.5319.1699	http://dx.doi.org/10.1126/science.276.5319.1699			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XD947	9180080				2022-12-01	WOS:A1997XD94700043
J	Morgan, G				Morgan, G			What, if any, is the effect of malnutrition on immunological competence?	LANCET			English	Editorial Material											Morgan, G (corresponding author), KUWAIT UNIV,FAC MED,POB 24923,KUWAIT 13110,KUWAIT.								0	47	47	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 7	1997	349	9066					1693	1695		10.1016/S0140-6736(96)12038-9	http://dx.doi.org/10.1016/S0140-6736(96)12038-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD100	9186397				2022-12-01	WOS:A1997XD10000045
J	Nielsen, BB; Liljestrand, J; Hedegaard, M; Thilsted, SH; Joseph, A				Nielsen, BB; Liljestrand, J; Hedegaard, M; Thilsted, SH; Joseph, A			Reproductive pattern, perinatal mortality, and sex preference in rural Tamil Nadu, South India: Community based, cross sectional study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CHILDHOOD MORTALITY; CHINA; MARRIAGE; BIRTH; BANGLADESH; FERTILITY; FEMALE; AGE; BEHAVIOR; CHILDREN	Objectives: To study reproductive pattern and perinatal mortality in rural Tamil Nadu, South India. Design: Community based, cross sectional questionnaire study of 30 randomly selected areas served by health subcentres. Setting: Rural parts of Salem District, Tamil Nadu, South India, Subjects: 1321 women and their offspring delivered in the 6 months before the interview. Main outcome measures: Number of pregnancies, pregnancy outcome, spacing of pregnancies, sex of offspring, perinatal and neonatal mortality rates. Results: 41% of the women (535) were primiparous; 7 women (0.5%) were grand multiparous (> 6 births). The women had a mean age of 22 years and a mean of 2.3 pregnancies and 1.8 live children. The sex ratio at birth of the index children was 107 boys per 100 girls. The stillbirth rate was 13.5/1000 births, the neonatal mortality rate was 35.3/1000, and the perinatal mortality rate was 42.0/1000. Girls had an excess neonatal mortality (rate ratio 3.42; 95% confidence interval 1.68 to 6.98; this was most pronounced among girls born to multiparous women with no living sons (rate ratio 15.48 (2.04 to 117.73) v 1.87 (0.63 to 5.58) in multiparous women with at least one son alive). Conclusions:In this rural part of Tamil Nadu, women had a controlled reproductive pattern. The excess neonatal mortality among girls constitutes about one third of the perinatal mortality rate. It seems to be linked to a preference for sons and should therefore be addressed through a holistic societal approach rather than through specific healthcare measures.	BALTIC INT SCH HLTH, S-37185 KARLSKRONA, SWEDEN; ROYAL VET & AGR UNIV, RES DEPT HUMAN NUTR, DK-1958 FREDERIKSBERG C, DENMARK; CHRISTIAN MED COLL & HOSP, DEPT COMMUNITY HLTH, VELLORE 632002, TAMIL NADU, INDIA	University of Copenhagen; Christian Medical College & Hospital (CMCH) Vellore	Nielsen, BB (corresponding author), AARHUS UNIV HOSP, PERINATAL EPIDEMIOL RES UNIT, DEPT OBSTET & GYNAECOL, DK-8200 AARHUS N, DENMARK.			Thilsted, Shakuntala/0000-0002-4041-1651				BLOOM DE, 1986, DEMOGRAPHY, V23, P509, DOI 10.2307/2061348; CALDWELL JC, 1983, POP STUD-J DEMOG, V37, P343, DOI 10.2307/2174503; CHEN LC, 1981, POPUL DEV REV, V7, P55, DOI 10.2307/1972764; CHOE MK, 1995, SOC BIOL, V42, P50; COALE AJ, 1994, DEMOGRAPHY, V31, P459, DOI 10.2307/2061752; DAS N, 1987, DEMOGRAPHY, V24, P517, DOI 10.2307/2061389; DASGUPTA M, 1987, POPUL DEV REV, V13, P77; DESILVA WI, 1990, J BIOSOC SCI, V22, P395, DOI 10.1017/S0021932000018812; DYSON T, 1983, POPUL DEV REV, V9, P35, DOI 10.2307/1972894; ELBADRY MA, 1969, J AM STAT ASSOC, V64, P1234, DOI 10.2307/2286064; GEORGE S, 1992, ECON POLIT WEEKLY, V27, P1153; Harper A, 1996, WHO, V12, P1; JOHANSSON S, 1991, POPUL DEV REV, V17, P35, DOI 10.2307/1972351; Kishor Sunita., 1994, UNDERSTANDING REPROD, P65; KOENIG MA, 1986, SOC SCI MED, V22, P15, DOI 10.1016/0277-9536(86)90303-5; Krishnaswamy S., 1988, Women in Indian society. A reader., P186; MUHURI PK, 1991, POPUL DEV REV, V17, P415, DOI 10.2307/1971948; NATH DC, 1994, J BIOSOC SCI, V26, P377, DOI 10.1017/S0021932000021453; PRESTON SH, 1984, POPUL DEV REV, V10, P481, DOI 10.2307/1973516; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P171; SIMMONS GB, 1982, DEMOGRAPHY, V19, P371, DOI 10.2307/2060977; SIVARAM M, 1995, J BIOSOC SCI, V27, P325, DOI 10.1017/S0021932000022847; *UNICEF, 1996, STAT WORLDS CHILDR, P10; Waldron I, 1987, World Health Stat Q, V40, P194; WALDRON I, 1982, FUNDAMENTAL CONNECTI, P69; WEN XY, 1993, J BIOSOC SCI, V25, P509, DOI 10.1017/S002193200002188X; XU BH, 1994, SCAND J SOC MED, V22, P242, DOI 10.1177/140349489402200402; YANG QH, 1990, J BIOSOC SCI, V22, P143, DOI 10.1017/S0021932000018496	28	40	41	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 24	1997	314	7093					1521	1524		10.1136/bmj.314.7093.1521	http://dx.doi.org/10.1136/bmj.314.7093.1521			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XB484	9169399	Green Published			2022-12-01	WOS:A1997XB48400025
J	Leone, G; DeGregori, J; Sears, R; Jakoi, L; Nevins, JR				Leone, G; DeGregori, J; Sears, R; Jakoi, L; Nevins, JR			Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F	NATURE			English	Article							SIGNAL-TRANSDUCTION; ACTIVATION; PROTEIN; TRANSFORMATION; INHIBITION; KINASES; GROWTH	Considerable evidence points to a role for G1 cyclin-dependent kinase (CDK) in allowing the accumulation of E2F transcription factor activity and induction of the S phase of the cell cycle(1,2). Numerous experiments have also demonstrated a critical role for both Myc and Ras activities in allowing cell-cycle progression(3). Here we show that inhibition of pas activity blocks the normal growth-dependent activation of G1 CDK, prevents activation of the target genes of E2F, and results in cell-cycle arrest in G1. We also show that Ras is essential for entry into the S phase in Rb+/+ fibroblasts but not in Rb-/- fibroblasts, establishing a link between Ras and the G1 CDK/Rb/E2F pathway, However, although expression of pas alone will not induce G1 CDK activity or S phase, coexpression of Ras with Myc allows the generation of cyclin E-dependent kinase activity and the induction of S phase, coincident with the loss of the p27 cyclin-dependent kinase inhibitor (CKI). These results suggest that pas, along with the activation of additional pathways, is required for the generation of G1 CDK activity, and that activation of cyclin E-dependent kinase in particular depends on the cooperative action of Ras and Myc.	DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DEPT GENET,DURHAM,NC 27710	Duke University; Howard Hughes Medical Institute				DeGregori, James/0000-0002-1287-1976				Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; Duronio RJ, 1996, GENE DEV, V10, P2505, DOI 10.1101/gad.10.19.2505; DURONIO RJ, 1995, GENE DEV, V9, P1445, DOI 10.1101/gad.9.12.1445; EISENMAN RN, 1995, NATURE, V378, P438, DOI 10.1038/378438a0; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; HATEKAYAMA M, 1994, GENE DEV, V8, P1759; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KOHL NE, 1987, ONCOGENE, V2, P41; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEONE G, UNPUB P NATL ACAD SC; LOWRY DR, 1993, ANNU REV BIOCHEM, V62, P851; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NEVINS JR, IN PRESS METHODS ENZ; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2	27	400	418	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 22	1997	387	6631					422	426		10.1038/387422a0	http://dx.doi.org/10.1038/387422a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XA496	9163430				2022-12-01	WOS:A1997XA49600065
J	Tagliavini, F; McArthur, RA; Canciani, B; Giaccone, G; Porro, M; Bugiani, M; Lievens, PMJ; Bugiani, O; Peri, E; DallAra, P; Rocchi, M; Poli, G; Forloni, G; Bandiera, T; Varasi, M; Suarato, A; Cassutti, P; Cervini, MA; Lansen, J; Salmona, M; Post, C				Tagliavini, F; McArthur, RA; Canciani, B; Giaccone, G; Porro, M; Bugiani, M; Lievens, PMJ; Bugiani, O; Peri, E; DallAra, P; Rocchi, M; Poli, G; Forloni, G; Bandiera, T; Varasi, M; Suarato, A; Cassutti, P; Cervini, MA; Lansen, J; Salmona, M; Post, C			Effectiveness of anthracycline against experimental prion disease in Syrian hamsters	SCIENCE			English	Article							INCUBATION PERIOD; PROTEIN-FRAGMENT; PRP ACCUMULATION; AMYLOID FIBRILS; DEXTRAN SULFATE; MOUSE SCRAPIE; CONGO RED; 4'-IODO-4'-DEOXYDOXORUBICIN; REPLICATION; INHIBITION	Prion diseases are transmissible neurodegenerative conditions characterized by the accumulation of protease-resistant forms of the prion protein (PrP), termed PrPres, in the brain. Insoluble PrPres tends to aggregate into amyloid fibrils. The anthracycline 4'-iodo-4'-deoxy-doxorubicin (IDX) binds to amyloid fibrils and induces amyloid resorption in patients with systemic amyloidosis. To test IDX in an experimental model of prion disease, Syrian hamsters were inoculated intracerebrally either with scrapie-infected brain homogenate or with infected homogenate coincubated with IDX. In IDX-treated hamsters, clinical signs of disease were delayed and survival time was prolonged. Neuropathological examination showed a parallel delay in the appearance of brain changes and in the accumulation of PrPres and PrP amyloid.	PHARMACIA & UPJOHN SPA, CNS RES, I-20014 NERVIANO, MI, ITALY; UNIV MILAN, IST MICROBIOL & IMMUNOL VET, I-20133 MILAN, ITALY; IST RIC FARMACOL MARIO NEGRI, I-20157 MILAN, ITALY; PHARMACIA & UPJOHN SPA, ONCOL RES, I-20014 NERVIANO, MI, ITALY	Pfizer; University of Milan; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Pfizer	Tagliavini, F (corresponding author), IST NAZL NEUROL CARLO BESTA, VIA CELORIA 11, I-20133 MILAN, ITALY.		Forloni, Gianluigi/AAB-2115-2020; salmona, mario/ABI-4066-2020; giaccone, giorgio/AAB-9978-2019; Tagliavini, Fabrizio/AAO-7891-2021; Giaccone, Giorgio/J-6212-2012; Canciani, Barbara/AAJ-6943-2020; salmona, mario/AAA-7116-2020; Dall'Ara, Paola/L-8658-2017	Forloni, Gianluigi/0000-0001-5374-3914; giaccone, giorgio/0000-0002-4803-0802; Tagliavini, Fabrizio/0000-0003-1039-7315; Canciani, Barbara/0000-0003-1942-1174; salmona, mario/0000-0002-9098-9873; Dall'Ara, Paola/0000-0002-8542-9476; Varasi, Mario/0000-0003-0367-8290				ADJOU KT, 1995, ANTIMICROB AGENTS CH, V39, P2810, DOI 10.1128/AAC.39.12.2810; BARBIERI B, 1987, CANCER RES, V47, P4001; Brown DR, 1996, NATURE, V380, P345, DOI 10.1038/380345a0; Brown P, 1990, ANTIVIR CHEM CHEMOTH, V1, P75, DOI 10.1177/095632029000100201; BROWN P, 1988, ANTIVIRAL AGENTS DEV, V2, P13; BRUCE ME, 1989, NEUROSCI LETT, V102, P1, DOI 10.1016/0304-3940(89)90298-X; CAUGHEY B, 1992, J NEUROCHEM, V59, P768, DOI 10.1111/j.1471-4159.1992.tb09437.x; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; DEARMOND SJ, 1985, CELL, V41, P221, DOI 10.1016/0092-8674(85)90076-5; DEARMOND SJ, 1993, P NATL ACAD SCI USA, V90, P6449, DOI 10.1073/pnas.90.14.6449; DEARMOND SJ, 1992, E H S NEURO, P483; EHLERS B, 1984, J GEN VIROL, V65, P1325, DOI 10.1099/0022-1317-65-8-1325; FARQUHAR CF, 1986, J GEN VIROL, V67, P463, DOI 10.1099/0022-1317-67-3-463; FOMELLI F, 1987, CANCER RES, V47, P5401; FORLONI G, 1994, EUR J NEUROSCI, V6, P1415, DOI 10.1111/j.1460-9568.1994.tb01003.x; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; GIANNI L, 1995, BLOOD, V86, P855; INGROSSO L, 1995, J VIROL, V69, P506, DOI 10.1128/JVI.69.1.506-508.1995; KIMBERLIN RH, 1986, ANTIMICROB AGENTS CH, V30, P409, DOI 10.1128/AAC.30.3.409; KIMBERLIN RH, 1993, ARCH VIROL, V78, P9; MERLINI G, 1995, P NATL ACAD SCI USA, V92, P2959, DOI 10.1073/pnas.92.7.2959; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; POCCHIARI M, 1987, J GEN VIROL, V68, P219, DOI 10.1099/0022-1317-68-1-219; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1994, ANNU REV MICROBIOL, V48, P655, DOI 10.1146/annurev.mi.48.100194.003255; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; SAFAR J, 1993, J BIOL CHEM, V268, P20276; Sambrook J., 1989, MOL CLONING LAB MANU; TAGLIAVINI F, 1994, CELL, V79, P695, DOI 10.1016/0092-8674(94)90554-1; XI YG, 1992, NATURE, V356, P598, DOI 10.1038/356598a0	30	155	170	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 16	1997	276	5315					1119	1122		10.1126/science.276.5315.1119	http://dx.doi.org/10.1126/science.276.5315.1119			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WZ225	9148807				2022-12-01	WOS:A1997WZ22500046
J	Kelley, RL; Wang, JW; Bell, L; Kuroda, MI				Kelley, RL; Wang, JW; Bell, L; Kuroda, MI			Sex lethal controls dosage compensation in Drosophila by a non-splicing mechanism	NATURE			English	Article							X-CHROMOSOME; TRANSLATIONAL REGULATION; MESSENGER-RNAS; GENE; BINDING; INITIATION; PROTEIN; MELANOGASTER; EXPRESSION; ENCODES	Dosage compensation in Drosophila requires the male-specific lethal (msl) proteins (MSL) to make gene expression from the single male X chromosome equivalent to that from both female X chromosomes(1,2). Expression of msl2 is repressed post-transcriptionally by Sex lethal (SXL), a female-specific RNA-binding protein that regulates alternative splicing in the sex-determination hierarchy, Although msl2 RNA is alternatively spliced in males and females, this does not alter its coding potential and splicing is not required for male-specific expression of MSL2 protein. Instead, our results suggest that the association of SXL protein with multiple sites in the 5' and 3' untranslated regions of the mxl2 transcript represses its translation in females. Thus, this well characterized alternative splicing factor regulates at least one target transcript by a distinct mechanism.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030; UNIV SO CALIF,PROGRAM MOL BIOL,LOS ANGELES,CA 90089	Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute; University of Southern California								BAKER BS, 1994, ANNU REV GENET, V28, P491, DOI 10.1146/annurev.ge.28.120194.002423; BASHAW GJ, 1995, DEVELOPMENT, V121, P3245; BELL LR, 1991, CELL, V65, P229, DOI 10.1016/0092-8674(91)90157-T; BELOTE JM, 1980, NATURE, V285, P573, DOI 10.1038/285573a0; BONE JR, 1994, GENE DEV, V8, P96, DOI 10.1101/gad.8.1.96; CAUGHMAN SW, 1988, J BIOL CHEM, V263, P19048; CLINE TW, 1984, GENETICS, V107, P231; CURTIS D, 1995, CELL, V81, P171, DOI 10.1016/0092-8674(95)90325-9; GEBALLE AP, 1994, TRENDS BIOCHEM SCI, V19, P159, DOI 10.1016/0968-0004(94)90277-1; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Hilfiker A, 1997, EMBO J, V16, P2054, DOI 10.1093/emboj/16.8.2054; KELLEY RL, 1995, CELL, V81, P867, DOI 10.1016/0092-8674(95)90007-1; KELLEY RL, 1995, SCIENCE, V270, P1607, DOI 10.1126/science.270.5242.1607; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LUCCHESI JC, 1981, CHROMOSOMA, V82, P217, DOI 10.1007/BF00286106; OH SK, 1992, GENE DEV, V6, P1643, DOI 10.1101/gad.6.9.1643; PALMER MJ, 1993, GENETICS, V134, P545; PALMER MJ, 1994, GENE DEV, V8, P698, DOI 10.1101/gad.8.6.698; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SAMUELS ME, 1994, MOL CELL BIOL, V14, P4975, DOI 10.1128/MCB.14.7.4975; SOSNOWSKI BA, 1989, CELL, V58, P449, DOI 10.1016/0092-8674(89)90426-1; Tarun SZ, 1996, EMBO J, V15, P7168, DOI 10.1002/j.1460-2075.1996.tb01108.x; WANG JW, 1994, GENE DEV, V8, P2072, DOI 10.1101/gad.8.17.2072; ZHOU SB, 1995, EMBO J, V14, P2884, DOI 10.1002/j.1460-2075.1995.tb07288.x	25	209	216	1	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 8	1997	387	6629					195	199		10.1038/387195a0	http://dx.doi.org/10.1038/387195a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WX945	9144292				2022-12-01	WOS:A1997WX94500058
J	Drevets, WC; Price, JL; Simpson, JR; Todd, RD; Reich, T; Vannier, M; Raichle, ME				Drevets, WC; Price, JL; Simpson, JR; Todd, RD; Reich, T; Vannier, M; Raichle, ME			Subgenual prefrontal cortex abnormalities in mood disorders	NATURE			English	Article							POSITRON EMISSION TOMOGRAPHY; UNIPOLAR DEPRESSION; GLUCOSE-METABOLISM; (H2O)-O-15; VALIDATION; VALIDITY; COMMON; RATES	Pathological disturbances of mood may follow a 'bipolar' course, in which normal moods alternate with both depression and mania, or a 'unipolar' course, in which only depression occurs(1-3). Both bipolar and unipolar disorders can be heritable illnesses associated with neurochemical, neuroendocrine and autonomic abnormalities. The neurobiological basis for these abnormalities has not been established(2,3). Using positron emission tomographic (PET) images of cerebral blood flow and rate of glucose metabolism to measure brain activity, we have now localized an area of abnormally decreased activity in the pre-frontal cortex ventral to the germ of the corpus callosum in both familial bipolar depressives and familial unipolar depressives. This decrement in activity was at least partly explained by a corresponding reduction in cortical volume(4) as magnetic resonance imaging (MRI) demonstrated reductions in the mean grey matter volume in the same area of 39 and 48% in the bipolar and unipolar samples, respectively. This region has previously been implicated in the mediation of emotional and autonomic responses to socially significant or provocative stimuli, and in the modulation of the neurotransmitter systems targeted by antidepressant drugs(3,5-10).	WASHINGTON UNIV, SCH MED, MALLINCKRODT INST RADIOL, DIV RADIOL SCI, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT ANAT & NEUROBIOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT GENET, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT NEUROL & NEUROL SURG NEUROL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, MCDONNELL CTR STUDIES HIGHER BRAIN FUNCT, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Drevets, WC (corresponding author), WASHINGTON UNIV, SCH MED, DEPT PSYCHIAT, ST LOUIS, MO 63110 USA.		anand, amit/A-7222-2009; Vannier, Michael W/AAI-6951-2021	Vannier, Michael/0000-0001-9898-384X				American Psychiatric Association, 1987, DIAGNOSTIC STAT MANU, V3rd; [Anonymous], 1993, NEUROBIOLOGY CINGULA; BAXTER LR, 1985, ARCH GEN PSYCHIAT, V42, P441; BAXTER LR, 1989, ARCH GEN PSYCHIAT, V46, P243; Bechara A, 1996, CEREB CORTEX, V6, P215, DOI 10.1093/cercor/6.2.215; BUCHSBAUM MS, 1986, J AFFECT DISORDERS, V10, P137, DOI 10.1016/0165-0327(86)90036-4; CARMICHAEL ST, 1994, J COMP NEUROL, V346, P366, DOI 10.1002/cne.903460305; Carmichael ST, 1995, J COMP NEUROL, V363, P615, DOI 10.1002/cne.903630408; COHEN RM, 1989, NEUROPSYCHOPHARMACOL, V2, P241, DOI 10.1016/0893-133X(89)90028-6; Damasio A, 1995, DESCARTES ERROR EMOT; DAMASIO AR, 1990, BEHAV BRAIN RES, V41, P81, DOI 10.1016/0166-4328(90)90144-4; DIROCCO RJ, 1989, COMPUT MED IMAG GRAP, V13, P81, DOI 10.1016/0895-6111(89)90080-3; DOLAN RJ, 1993, J NEUROL NEUROSUR PS, V56, P1290, DOI 10.1136/jnnp.56.12.1290; DREVETS WC, 1992, J NEUROSCI, V12, P3628; DREVETS WC, 1996, ADULT PSYCHIAT, P53; DREVETS WC, 1997, ADULT PSYCHIAT, P99; DREVETS WC, IN PRESS COGNIT EMOT; DREVETS WC, 1992, ABSTR SOC NEUROSCI, V18, P1596; FOX PT, 1985, J COMPUT ASSIST TOMO, V9, P141, DOI 10.1097/00004728-198501000-00025; FOX PT, 1989, J NUCL MED, V30, P141; Goodwin F.K., 2007, MANIC DEPRESSIVE ILL; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; MAZZIOTTA JC, 1981, J COMPUT ASSIST TOMO, V5, P734, DOI 10.1097/00004728-198110000-00029; Pearlson GD, 1997, BIOL PSYCHIAT, V41, P1, DOI 10.1016/S0006-3223(96)00373-3; PHELPS ME, 1979, ANN NEUROL, V6, P371, DOI 10.1002/ana.410060502; RAICHLE ME, 1983, J NUCL MED, V24, P790; SESACK SR, 1989, J COMP NEUROL, V290, P213, DOI 10.1002/cne.902900205; Talairach J., 1988, COPLANAR STEREOTAXIC, P1; WINOKUR G, 1982, PHARMACOPSYCHIATRIA, V15, P142, DOI 10.1055/s-2007-1019527; YOUNG RC, 1978, BRIT J PSYCHIAT, V133, P429, DOI 10.1192/bjp.133.5.429	30	1984	2040	3	146	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 24	1997	386	6627					824	827		10.1038/386824a0	http://dx.doi.org/10.1038/386824a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WV706	9126739				2022-12-01	WOS:A1997WV70600052
J	Lloyd, DA; Carty, H; Patterson, M; Butcher, CK; Roe, D				Lloyd, DA; Carty, H; Patterson, M; Butcher, CK; Roe, D			Predictive value of skull radiography for intracranial injury in children with blunt head injury	LANCET			English	Article							TRAUMA; HEMATOMA; ADULTS; RISKS	Background The value of routine skull radiography as a method of predicting intracranial injury is controversial. We aimed to assess the effectiveness of skull radiography by prospectively studying head-injured children admitted to a children's hospital that serves an urban population. Methods Over a 2-year period, 9269 children attended our accident and emergency department with head injury, and 6011 were referred for skull radiography. All children who were admitted to hospital or had a skull fracture (n=883) were included in the study. Computed tomography (CT) was done in children with skull fractures on radiography and in those without fractures if there were neurological indications. Findings Radiographs showed 162 fractures (2.7% of all radiographs and 18% of study group radiographs). Staff in the accident and emergency department missed 37 (23%) fractures. CT scan was done on 156 children, of whom 107 had a skull fracture. 23 children were found to have intracranial injuries on CT. The presence of neurological abnormalities had a sensitivity for identification of intracranial injury of 91% (21 of 23) and a negative predictive value of 97%. The corresponding values for skull fracture on radiography were 65% (15 of 23) and 83%. Four children died, of whom only one had a skull fracture. Interpretation In children, severe intracranial injury can occur in the absence of skull fracture. Skull radiography is not a reliable predictor of intracranial injury and is indicated only to confirm or exclude a suspected depressed fracture or penetrating injury, and when non-accidental injury is suspected, including in all infants younger than 2 years. Clinical neurological abnormalities are a reliable predictor of intracranial injury. If imaging is required, it should be with CT and not skull radiography.	ALDER HEY CHILDRENS HOSP,INST CHILD HLTH,DEPT RADIOL,LIVERPOOL L12 2AP,MERSEYSIDE,ENGLAND; UNIV LIVERPOOL,DEPT CHILD HLTH,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND	Alder Hey Children's NHS Foundation Trust; Alder Hey Children's Hospital; University of Liverpool; University of Liverpool	Lloyd, DA (corresponding author), ALDER HEY CHILDRENS HOSP,INST CHILD HLTH,DEPT PAEDIAT SURG,EATON RD,LIVERPOOL L12 2AP,MERSEYSIDE,ENGLAND.		Patterson Molloy, Marie (Mal)/A-2030-2014	Patterson Molloy, Marie (Mal)/0000-0002-5334-8567				BELL RS, 1971, NEW ENGL J MED, V284, P236, DOI 10.1056/NEJM197102042840504; Bell William O., 1995, P101; BONADIO WA, 1989, AM J DIS CHILD, V143, P194, DOI 10.1001/archpedi.1989.02150140084025; BOULIS ZF, 1978, BRIT J RADIOL, V51, P851, DOI 10.1259/0007-1285-51-611-851; CHAN KH, 1990, CHILD NERV SYST, V6, P27, DOI 10.1007/BF00262262; GORDANO U, 1992, CHILD NERV SYST, V8, P136; HARWOODNASH DC, 1971, RADIOLOGY, V101, P151, DOI 10.1148/101.1.151; LEONIDAS JC, 1982, PEDIATRICS, V69, P139; MACKWAYJONES K, 1993, ADV PAEDIAT LIFE SUP; MENDELOW AD, 1983, BRIT MED J, V287, P1173, DOI 10.1136/bmj.287.6400.1173; READ HS, 1995, INJURY, V20, P333; ROBERTS F, 1972, J ROENTGENOL, V114, P230; ROSENTHAL BW, 1989, J PEDIATR-US, V115, P346, DOI 10.1016/S0022-3476(89)80830-3; TEASDALE G, 1974, LANCET, V2, P81; TEASDALE GM, 1990, BRIT MED J, V300, P363, DOI 10.1136/bmj.300.6721.363	15	112	113	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 22	1997	349	9055					821	824		10.1016/S0140-6736(96)09356-7	http://dx.doi.org/10.1016/S0140-6736(96)09356-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WP403	9121256				2022-12-01	WOS:A1997WP40300009
J	Engel, S; Zhang, XM; Wandell, B				Engel, S; Zhang, XM; Wandell, B			Colour tuning in human visual cortex measured with functional magnetic resonance imaging	NATURE			English	Article							STRIATE CORTEX; CHROMATIC MECHANISMS; EVOKED-POTENTIALS; RED GREEN; MACAQUE; PHOTORECEPTORS; LUMINANCE; SPACE; CONE	The primate retina contains three classes of cones, the L, M and S cones, which respond preferentially to long-, middle- and short-wavelength visible light, respectively. Colour appearance results from neural processing of these cone signals within the retina and the brain. Perceptual experiments have identified three types of neural pathways that represent colour: a red-green pathway that signals differences between L- and M-cone responses; a blue-yellow pathway that signals differences between S-cone responses and a sum of L- and M-cone responses; and a luminance pathway that signals a sum of L- and M-cone responses(1-3). It might be expected that there are neurons in the primary visual cortex with response properties that resemble these three perceptual pathways, but attempts to find them have led to inconsistent results(4-7). We have therefore used functional magnetic resonance imaging (fMRI) to examine responses in the human brain to a large number of colours. In visual cortical areas V1 and V2, the strongest response is to red-green stimuli, and much of this activity is from neurons receiving opposing inputs from L and M cones. A strong response is also seen with blue-yellow stimuli, and this response declines rapidly as the temporal frequency of the stimulus is increased. These responses resemble psychophysical measurements, suggesting that colour signals relevant for perception are encoded in a large population of neurons in areas V1 and V2.	STANFORD UNIV, DEPT PSYCHOL, STANFORD, CA 94305 USA	Stanford University								BOYNTON RM, 1964, VISION RES, V4, P87, DOI 10.1016/0042-6989(64)90035-5; Calkins DJ, 1996, NATURE, V381, P613, DOI 10.1038/381613a0; COLE GR, 1993, J OPT SOC AM A, V10, P38, DOI 10.1364/JOSAA.10.000038; Cottaris N. P., 1996, Society for Neuroscience Abstracts, V22, P951; CURCIO CA, 1991, J COMP NEUROL, V312, P610, DOI 10.1002/cne.903120411; DACEY DM, 1994, NATURE, V367, P731, DOI 10.1038/367731a0; DERRINGTON AM, 1984, J PHYSIOL-LONDON, V357, P241, DOI 10.1113/jphysiol.1984.sp015499; DEVALOIS RL, 1965, COLD SPRING HARB SYM, V30, P567, DOI 10.1101/SQB.1965.030.01.055; DeYoe EA, 1996, P NATL ACAD SCI USA, V93, P2382, DOI 10.1073/pnas.93.6.2382; ENGEL SA, 1994, NATURE, V369, P525, DOI 10.1038/369525a0; Engel SA, 1997, CEREB CORTEX, V7, P181, DOI 10.1093/cercor/7.2.181; Gur M, 1997, VISION RES, V37, P377, DOI 10.1016/S0042-6989(96)00183-6; HURVICH LM, 1957, PSYCHOL REV, V64, P384, DOI 10.1037/h0041403; KELLY DH, 1971, J OPT SOC AM, V61, P537, DOI 10.1364/JOSA.61.000537; Kleinschmidt A, 1996, EXP BRAIN RES, V110, P279; LENNIE P, 1990, J NEUROSCI, V10, P649; LIVINGSTONE MS, 1984, J NEUROSCI, V4, P2830; MULLEN KT, 1985, J PHYSIOL-LONDON, V359, P381, DOI 10.1113/jphysiol.1985.sp015591; POIRSON AB, 1993, J OPT SOC AM A, V10, P2458, DOI 10.1364/JOSAA.10.002458; RABIN J, 1994, VISION RES, V34, P2657, DOI 10.1016/0042-6989(94)90222-4; REGAN D, 1973, VISION RES, V13, P2381, DOI 10.1016/0042-6989(73)90237-X; RODIECK RW, 1991, NATO ADV SCI I A-LIF, V203, P83; SERENO MI, 1995, SCIENCE, V268, P889, DOI 10.1126/science.7754376; STOCKMAN A, 1991, VISION RES, V31, P189, DOI 10.1016/0042-6989(91)90111-H; THORELL LG, 1984, VISION RES, V24, P751, DOI 10.1016/0042-6989(84)90216-5; THORNTON JE, 1983, SCIENCE, V219, P191, DOI 10.1126/science.6849131; TSO DY, 1988, J NEUROSCI, V8, P1712; VAUTIN RG, 1985, J NEUROPHYSIOL, V54, P273, DOI 10.1152/jn.1985.54.2.273; WANDELL BA, 1985, J OPT SOC AM A, V2, P62, DOI 10.1364/JOSAA.2.000062; WIESEL TN, 1966, J NEUROPHYSIOL, V29, P1115, DOI 10.1152/jn.1966.29.6.1115	30	249	268	0	48	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 3	1997	388	6637					68	71		10.1038/40398	http://dx.doi.org/10.1038/40398			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XJ143	9214503	Bronze			2022-12-01	WOS:A1997XJ14300051
J	Akashi, K; Kondo, M; vonFreedenJeffry, U; Murray, R; Weissman, IL				Akashi, K; Kondo, M; vonFreedenJeffry, U; Murray, R; Weissman, IL			Bcl-2 rescues T lymphopoiesis in interleukin-7 receptor-deficient mice	CELL			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; GAMMA-CHAIN; IL-2 RECEPTOR; POSITIVE SELECTION; NEGATIVE SELECTION; CELL-DEATH; B-CELLS; BCL-2-DEFICIENT MICE; FUNCTIONAL COMPONENT; LYMPHOID DEVELOPMENT	Mice lacking functional IL-7 or lL-7R alpha genes are severely deficient in developing thymocytes, T cells, and B cells. IL-7 and IL-7 receptor functions are believed to result in lymphoid cell proliferation and cell maturation, implying signal transduction pathways directly involved in mitogenesis and elaboration of developmentally specific new gene programs. Here, we show that enforced expression of the bcl-2 gene in T-lymphoid cells (by crossing in the E mu-bcl-2 transgene) in IL-7R alpha-deficient mice results in a significant restoration of thymic positive selection and T cell numbers and function. We propose cell survival signals to be the principal function of IL-7R engagement in thymic and T cell development.	STANFORD UNIV,SCH MED,DEPT DEV BIOL,STANFORD,CA 94305; DNAX RES INST MOL & CELLULAR BIOL INC,DEPT IMMUNOL,PALO ALTO,CA 94304	Stanford University; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	Akashi, K (corresponding author), STANFORD UNIV,SCH MED,DEPT PATHOL,STANFORD,CA 94305, USA.				NCI NIH HHS [CA42551] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042551] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADKINS B, 1987, ANNU REV IMMUNOL, V5, P325, DOI 10.1146/annurev.iy.05.040187.001545; Akashi K, 1996, IMMUNITY, V5, P147, DOI 10.1016/S1074-7613(00)80491-4; APPASAMY PM, 1993, J EXP MED, V178, P2201, DOI 10.1084/jem.178.6.2201; BHATIA SK, 1995, J EXP MED, V181, P1399, DOI 10.1084/jem.181.4.1399; BRANDLE D, 1994, EUR J IMMUNOL, V24, P145, DOI 10.1002/eji.1830240122; CAO XQ, 1995, IMMUNITY, V2, P223, DOI 10.1016/1074-7613(95)90047-0; Chen DF, 1997, NATURE, V385, P434, DOI 10.1038/385434a0; Corcoran AE, 1996, EMBO J, V15, P1924, DOI 10.1002/j.1460-2075.1996.tb00543.x; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; DISANTO JP, 1995, P NATL ACAD SCI USA, V92, P377, DOI 10.1073/pnas.92.2.377; FAIRBAIRN LJ, 1993, CELL, V74, P823, DOI 10.1016/0092-8674(93)90462-Y; FRIEND SL, 1994, EXP HEMATOL, V22, P321; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GRATIOTDEANS J, 1994, P NATL ACAD SCI USA, V91, P10685, DOI 10.1073/pnas.91.22.10685; GRATIOTDEANS J, 1993, J IMMUNOL, V151, P83; GUIDOS CJ, 1990, J EXP MED, V172, P835, DOI 10.1084/jem.172.3.835; Guidos CJ, 1996, CURR OPIN IMMUNOL, V8, P225, DOI 10.1016/S0952-7915(96)80061-6; GUTMAN GA, 1972, IMMUNOLOGY, V23, P465; He YW, 1996, J EXP MED, V184, P289, DOI 10.1084/jem.184.1.289; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; IKUTA K, 1992, P NATL ACAD SCI USA, V89, P1502, DOI 10.1073/pnas.89.4.1502; JAMESON SC, 1995, ANNU REV IMMUNOL, V13, P93, DOI 10.1146/annurev.immunol.13.1.93; KIMURA Y, 1995, INT IMMUNOL, V7, P115, DOI 10.1093/intimm/7.1.115; KONDO M, 1994, EUR J IMMUNOL, V24, P2026, DOI 10.1002/eji.1830240914; KONDO M, 1994, SCIENCE, V263, P1453, DOI 10.1126/science.8128231; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; KONDO M, 1997, IN PRESS IMMUNITY; KRAFT DL, 1993, J EXP MED, V178, P265, DOI 10.1084/jem.178.1.265; LINETTE GP, 1994, IMMUNITY, V1, P197, DOI 10.1016/1074-7613(94)90098-1; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; Lucas B, 1996, IMMUNITY, V5, P461, DOI 10.1016/S1074-7613(00)80502-6; Maki K, 1996, J EXP MED, V184, P2423, DOI 10.1084/jem.184.6.2423; Maraskovsky E, 1996, J IMMUNOL, V157, P5315; Mazel S, 1996, J EXP MED, V183, P2219, DOI 10.1084/jem.183.5.2219; NAKAYAMA K, 1994, P NATL ACAD SCI USA, V91, P3700, DOI 10.1073/pnas.91.9.3700; NAKAYAMA KI, 1995, J EXP MED, V182, P1101, DOI 10.1084/jem.182.4.1101; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; Ohbo K, 1996, BLOOD, V87, P956, DOI 10.1182/blood.V87.3.956.bloodjournal873956; PESCHON JJ, 1994, J EXP MED, V180, P1955, DOI 10.1084/jem.180.5.1955; PUCK JM, 1993, HUM MOL GENET, V2, P1099, DOI 10.1093/hmg/2.8.1099; RAY JR, 1996, EUR J IMMUNOL, V26, P10; RODEWALD HR, 1995, IMMUNITY, V3, P313, DOI 10.1016/1074-7613(95)90116-7; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SADLACK B, 1994, EUR J IMMUNOL, V24, P281, DOI 10.1002/eji.1830240144; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SHORTMAN K, 1991, J EXP MED, V173, P323, DOI 10.1084/jem.173.2.323; STEPHAN YL, 1997, J CLIN INVEST, V99, P169; STRASSER A, 1994, NATURE, V368, P457, DOI 10.1038/368457a0; SUDA T, 1991, J IMMUNOL, V146, P3068; SUDO T, 1993, P NATL ACAD SCI USA, V90, P9125, DOI 10.1073/pnas.90.19.9125; SWAT W, 1993, EUR J IMMUNOL, V23, P739, DOI 10.1002/eji.1830230326; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TAO W, 1994, J EXP MED, V179, P145, DOI 10.1084/jem.179.1.145; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; VEIS DJ, 1993, J IMMUNOL, V151, P2546; VONBOEHMER H, 1994, CELL, V76, P219, DOI 10.1016/0092-8674(94)90330-1; vonBoehmer H, 1996, J EXP MED, V183, P713, DOI 10.1084/jem.183.3.713; VONFREEDENJEFFRY U, 1995, J EXP MED, V181, P1519, DOI 10.1084/jem.181.4.1519; WEISSMAN IL, 1994, CELL, V76, P207, DOI 10.1016/0092-8674(94)90329-8; YAMASHITA I, 1993, INT IMMUNOL, V5, P1139, DOI 10.1093/intimm/5.9.1139; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; YOUNG E, 1997, IMMUNITY, V6, P23	66	517	525	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 27	1997	89	7					1033	1041		10.1016/S0092-8674(00)80291-3	http://dx.doi.org/10.1016/S0092-8674(00)80291-3			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XG830	9215626	Bronze			2022-12-01	WOS:A1997XG83000008
J	Naka, T; Narazaki, M; Hirata, M; Matsumoto, T; Minamoto, S; Aono, A; Nishimoto, N; Kajita, T; Taga, T; Yoshizaki, K; Akira, S; Kishimoto, T				Naka, T; Narazaki, M; Hirata, M; Matsumoto, T; Minamoto, S; Aono, A; Nishimoto, N; Kajita, T; Taga, T; Yoshizaki, K; Akira, S; Kishimoto, T			Structure and function of a new STAT-induced STAT inhibitor	NATURE			English	Article							TYROSINE PHOSPHORYLATION; TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; CYTOKINE RECEPTORS; ACTIVATION; INTERLEUKIN-6; PATHWAYS; GP130; FAMILY; IL-3	The signalling pathway that comprises JAK kinases and STAT proteins (for signal transducer and activator of transcription) is important for relaying signals from various cytokines outside the cell to the inside(1-3). The feedback mechanism responsible for switching off the cytokine signal has not been elucidated. We now report the cloning and characterization of an inhibitor of STAT activation which we name SSI-1 (for STAT-induced STAT inhibitor-1). We found that SSI-1 messenger RNA was induced by the cytokines interleukins 4 and 6 (IL-4, IL-6), leukaemia-inhibitory factor (LIF), and granulocyte colony-stimulating factor (G-CSF). Stimulation by IL-6 or LIF of murine myeloid leukaemia cells (M1 cells) induced SSI-1 mRNA expression which was blocked by transfection of a dominant-negative mutant of Stat3, indicating that the SSI-1 gene is a target of Stat3 (refs 4-7). Forced overexpression of SSI-1 complementary DNA interfered with IL-6- and LIF-mediated apoptosis and macrophage differentiation of M1 cells, as well as IL-6 induced tyrosine-phosphorylation of a receptor glycoprotein component, gp130, and of Stat3. When SSI-1 is overexpressed in COS7 cells, it can associate with the kinases Jak2 and Tyk2, These findings indicate that SSI-1 is responsible for negative-feedback regulation of the JAK-STAT pathway induced by cytokine stimulation.	OSAKA UNIV,SCH MED,DEPT MED 3,SUITA,OSAKA 565,JAPAN; INT REAGENTS CORP,CTR RES & DEV,NISHI KU,KOBE 65122,JAPAN; TOKYO MED & DENT UNIV,MED RES INST,DEPT MOL CELL BIOL,CHIYODA KU,TOKYO 101,JAPAN; HYOGO MED UNIV,DEPT BIOCHEM,NISHINOMIYA,HYOGO 663,JAPAN; OSAKA UNIV,SCH HLTH & SPORTS SCI,SUITA,OSAKA 565,JAPAN	Osaka University; Tokyo Medical & Dental University (TMDU); Hyogo College of Medicine; University of Hyogo; Osaka University			Kishimoto, Tadamitsu/C-8470-2009; Akira, Shizuo/C-3134-2009	Naka, Tetsuji/0000-0002-1269-3997; narazaki, masashi/0000-0002-5613-4409				Adachi M, 1996, CELL, V85, P15; AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; HULI J, 1989, J IMMUNOL, V142, P800; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KONDO M, 1994, SCIENCE, V263, P1453, DOI 10.1126/science.8128231; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; TAGA T, 1992, FASEB J, V6, P3387, DOI 10.1096/fasebj.6.15.1334470; TIAN SS, 1994, BLOOD, V84, P1760; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	27	1097	1148	0	64	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 26	1997	387	6636					924	929		10.1038/43219	http://dx.doi.org/10.1038/43219			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XG416	9202127	Bronze			2022-12-01	WOS:A1997XG41600057
J	Hensel, WA				Hensel, WA			Bea's legacy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 25	1997	277	24					1913	1914						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XF087	9200617				2022-12-01	WOS:A1997XF08700001
J	Heery, DM; Kalkhoven, E; Hoare, S; Parker, MG				Heery, DM; Kalkhoven, E; Hoare, S; Parker, MG			A signature motif in transcriptional co-activators mediates binding to nuclear receptor	NATURE			English	Article							STEROID-HORMONE RECEPTORS; ESTROGEN-RECEPTOR; PROTEIN; SUPERFAMILY; COACTIVATOR; SEQUENCE; PROMOTER	The binding of lipophilic hormones, retinoids and vitamins to members of the nuclear-receptor superfamily modifies the DNA-binding and transcriptional properties of these receptors, resulting in the activation or repression of target genes(1,2). Ligand binding induces conformational changes in nuclear receptors and promotes their association with a diverse group of nuclear proteins, including SRC1/p160 (refs 3-5), TIF-2/GRIP-1 (refs 6, 7) and CBP/p300 (refs 4, 5, 8, 9) which function as co-activators of transcription, and RIP-140 (ref. 10), TIF-1 (ref. II) and TRIP-1/SUG-1 (refs 12, 13) whose functions are unclear. Here we report that a short sequence motif LXXLL (where Lis leucine and X is any amino acid) present in RIP-140, SRC-1 and CBP is necessary and sufficient to mediate the binding of these proteins to liganded nuclear receptors. We show that the ability of SRC-1 to bind the oestrogen receptor and enhance its transcriptional activity is dependent upon the integrity of the LXXLL motifs and on key hydrophobic residues in a conserved helix (helix 12) of the oestrogen receptor that are required for its ligand-induced activation function(14). We propose that the LXXLL motif is a signature sequence that facilitates the interaction of different proteins with nuclear receptors, and is thus a defining feature of a new family of nuclear proteins.	IMPERIAL CANC RES FUND, MOL ENDOCRINOL LAB, LONDON WC2A 3PX, ENGLAND	Cancer Research UK; University of London; Queen Mary University London				Heery, David/0000-0002-5035-2392				ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Baur EV, 1996, EMBO J, V15, P110, DOI 10.1002/j.1460-2075.1996.tb00339.x; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; HEY S, 1996, P NATL ACAD SCI USA, V93, P5517; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEDOUARIN B, 1995, NUCLEIC ACIDS RES, V23, P876, DOI 10.1093/nar/23.5.876; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; LHorset F, 1996, MOL CELL BIOL, V16, P6029; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; METZGER D, 1992, NUCLEIC ACIDS RES, V20, P2813, DOI 10.1093/nar/20.11.2813; Montano MM, 1996, MOL ENDOCRINOL, V10, P230, DOI 10.1210/me.10.3.230; ONATE SA, 1995, SCIENCE, V270, P1354; ROST B, 1993, P NATL ACAD SCI USA, V90, P7558, DOI 10.1073/pnas.90.16.7558; STEIN B, 1995, MOL CELL BIOL, V15, P4971; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703	27	1691	1756	2	69	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 12	1997	387	6634					733	736		10.1038/42750	http://dx.doi.org/10.1038/42750			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XD869	9192902				2022-12-01	WOS:A1997XD86900061
J	Rudel, T; Bokoch, GM				Rudel, T; Bokoch, GM			Membrane and morphological changes in apoptotic cells regulated by caspase-mediated activation of PAK2	SCIENCE			English	Article							FLOW CYTOMETRIC DETECTION; PHOSPHATIDYLSERINE EXPRESSION; POLY(ADP-RIBOSE) POLYMERASE; ANNEXIN-V; PROTEASE; DEATH; INTERLEUKIN-1-BETA	Apoptosis of Jurkat T cells induced the caspase-mediated proteolytic cleavage of p21-activated kinase 2 (PAK2). Cleavage occurred between the amino-terminal regulatory domain and the carboxyl-terminal catalytic domain, which generated a constitutively active PAK2 fragment. Stable Jurkat cell lines that expressed a dominant-negative PAK mutant were resistant to the Fas-induced formation of apoptotic bodies, but had an enhanced externalization of phosphatidlyserine at the cell surface. Thus, proteolytic activation of PAK2 represents a guanosine triphosphatase-independent mechanism of PAK regulation that allows PAK2 to regulate morphological changes that are seen in apoptotic cells.	Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA	Scripps Research Institute					NHLBI NIH HHS [HL48008] Funding Source: Medline; NIGMS NIH HHS [GM39434] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039434] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALHEMRI ES, 1996, CELL, V87, P171; Brzeska H, 1997, P NATL ACAD SCI USA, V94, P1092, DOI 10.1073/pnas.94.4.1092; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; DHARMAWARDHANE S, UNPUB; Ding JB, 1996, J BIOL CHEM, V271, P24869, DOI 10.1074/jbc.271.40.24869; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOWARD AD, 1991, J IMMUNOL, V147, P2964; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; MAJNO G, 1995, AM J PATHOL, V246, P3; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MARTIN SJ, 1994, TRENDS BIOCHEM SCI, V19, P26, DOI 10.1016/0968-0004(94)90170-8; Martin SJ, 1996, J BIOL CHEM, V271, P28753, DOI 10.1074/jbc.271.46.28753; MARTIN SJ, 1995, J EXP MED, V182, P1; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; RUDEL T, UNPUB; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; SLEATH PR, 1990, J BIOL CHEM, V265, P14526; SQUIER MKT, 1995, J LEUKOCYTE BIOL, V57, P2, DOI 10.1002/jlb.57.1.2; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Vanags DM, 1996, J BIOL CHEM, V271, P31075, DOI 10.1074/jbc.271.49.31075; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Whyte M, 1996, TRENDS CELL BIOL, V6, P245, DOI 10.1016/0962-8924(96)20025-X; Wu CL, 1996, J BIOL CHEM, V271, P31787, DOI 10.1074/jbc.271.50.31787; YUAN BJ, 1995, CURR OPIN CELL BIOL, V7, P211	32	589	603	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 6	1997	276	5318					1571	1574		10.1126/science.276.5318.1571	http://dx.doi.org/10.1126/science.276.5318.1571			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XC701	9171063				2022-12-01	WOS:A1997XC70100046
J	Rigel, DS				Rigel, DS			Epiluminescence microscopy in clinical diagnosis of pigmented skin lesions?	LANCET			English	Editorial Material											Rigel, DS (corresponding author), NYU, MED CTR, RONALD O PERELMAN DEPT DERMATOL, NEW YORK, NY 10016 USA.							BINDER M, 1995, ARCH DERMATOL, V131, P286, DOI 10.1001/archderm.131.3.286; FRIEDMAN RJ, 1985, CA-CANCER J CLIN, V35, P130, DOI 10.3322/canjclin.35.3.130; KENET RO, 1994, JOURNAL OF DERMATOLOGY, VOL 21, NO 11, NOVEMBER 1994, P881, DOI 10.1111/j.1346-8138.1994.tb03306.x; NACHBAR F, 1994, J AM ACAD DERMATOL, V30, P551, DOI 10.1016/S0190-9622(94)70061-3; SOBER AJ, 1993, SEMIN SURG ONCOL, V9, P198; STEINER A, 1987, ANTICANCER RES, V7, P433	6	16	16	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 31	1997	349	9065					1566	1567		10.1016/S0140-6736(05)61625-X	http://dx.doi.org/10.1016/S0140-6736(05)61625-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XB673	9174555	hybrid			2022-12-01	WOS:A1997XB67300004
J	Berglund, JA; Chua, K; Abovich, N; Reed, R; Rosbash, M				Berglund, JA; Chua, K; Abovich, N; Reed, R; Rosbash, M			The splicing factor BBP interacts specifically with the pre-mRNA branchpoint sequence UACUAAC	CELL			English	Article							U2 SNRNP; PROTEIN; YEAST; COMPLEX; INTRON; MUTATIONS; SELECTION; BINDING; INVITRO; U1	The yeast splicing factor BBP (branchpoint bridging protein) interacts directly with pre-mRNA at or very near the highly conserved branchpoint sequence UACUAAC within the commitment complex. We also show that the recombinant protein recognizes the UACUAAC sequence. Therefore, BBP is also an acronym for branchpoint binding protein. The mammalian splicing factor SF1 is a BBP ortholog (mBBP) and an E complex component, and also has branchpoint sequence specificity. The relative conservation of this region in yeast and mammals correlates well with the RNA-binding differences between BBP and mBBP, suggesting that BBP contributes to branchpoint sequence definition in both systems.	BRANDEIS UNIV, HOWARD HUGHES MED INST, DEPT BIOL & BIOCHEM, WALTHAM, MA 02254 USA; HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA	Brandeis University; Howard Hughes Medical Institute; Harvard University; Harvard Medical School			Berglund, Andrew/AAS-1065-2021		NIGMS NIH HHS [GM-23549] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023549] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOVICH N, 1994, GENE DEV, V8, P843, DOI 10.1101/gad.8.7.843; Abovich N, 1997, CELL, V89, P403, DOI 10.1016/S0092-8674(00)80221-4; Arning S, 1996, RNA, V2, P794; CHAMPIONARNAUD P, 1995, MOL CELL BIOL, V15, P5750; Chiara MD, 1996, MOL CELL BIOL, V16, P3317; DALY TJ, 1989, NATURE, V342, P816, DOI 10.1038/342816a0; DARLIX JL, 1995, J MOL BIOL, V254, P523, DOI 10.1006/jmbi.1995.0635; England T E, 1980, Methods Enzymol, V65, P65; FOUSER LA, 1986, CELL, V45, P81, DOI 10.1016/0092-8674(86)90540-4; HALL KB, 1992, NUCLEIC ACIDS RES, V20, P4283, DOI 10.1093/nar/20.16.4283; JACQUIER A, 1986, P NATL ACAD SCI USA, V83, P5835, DOI 10.1073/pnas.83.16.5835; KRAINER AR, 1985, CELL, V42, P725, DOI 10.1016/0092-8674(85)90269-7; KRAMER A, 1992, MOL CELL BIOL, V12, P4545; LU JR, 1995, J MOL BIOL, V247, P739, DOI 10.1016/S0022-2836(05)80152-4; MACMILLAN AM, 1994, GENE DEV, V8, P3008, DOI 10.1101/gad.8.24.3008; Moore M., 1993, RNA WORLD, P303; Musco G, 1996, CELL, V85, P237, DOI 10.1016/S0092-8674(00)81100-9; PARKER R, 1987, CELL, V49, P229, DOI 10.1016/0092-8674(87)90564-2; PIKIELNY CW, 1986, NATURE, V324, P341, DOI 10.1038/324341a0; Query CC, 1996, EMBO J, V15, P1392, DOI 10.1002/j.1460-2075.1996.tb00481.x; SERAPHIN B, 1991, EMBO J, V10, P1209, DOI 10.1002/j.1460-2075.1991.tb08062.x; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193; TEEM JL, 1983, P NATL ACAD SCI-BIOL, V80, P4403, DOI 10.1073/pnas.80.14.4403; UMEN JG, 1995, GENE DEV, V9, P855, DOI 10.1101/gad.9.7.855; WU J, 1989, GENE DEV, V3, P1553, DOI 10.1101/gad.3.10.1553; ZAMORE PD, 1991, EMBO J, V10, P207, DOI 10.1002/j.1460-2075.1991.tb07937.x; ZHUANG Y, 1989, Proceedings of the National Academy of Sciences of the United States of America, V86, P2752, DOI 10.1073/pnas.86.8.2752; ZHUANG Y, 1989, GENE DEV, V3, P1545, DOI 10.1101/gad.3.10.1545	28	270	272	1	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 30	1997	89	5					781	787		10.1016/S0092-8674(00)80261-5	http://dx.doi.org/10.1016/S0092-8674(00)80261-5			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XB925	9182766	Bronze			2022-12-01	WOS:A1997XB92500015
J	Bussey, H; Storms, RK; Ahmed, A; Albermann, K; Allen, E; Ansorge, W; Araujo, R; Aparicio, A; Barrell, B; Badcock, K; Benes, V; Botstein, D; Bowman, S; Bruckner, M; Carpenter, J; Cherry, JM; Chung, E; Churcher, C; Coster, F; Davis, K; Davis, RW; Dietrich, FS; Delius, H; DiPaolo, T; Dubois, E; Dusterhoft, A; Duncan, M; Floeth, M; Fortin, N; Friesen, JD; Fritz, C; Goffeau, A; Hall, J; Hebling, U; Heumann, K; Hilbert, H; Hillier, L; HunickeSmith, S; Hyman, R; Johnston, M; Kalman, S; Kleine, K; Komp, C; Kurdi, O; Lashkari, D; Lew, H; Lin, A; Lin, D; Louis, EJ; Marathe, R; Messenguy, F; Mewes, HW; Mirtipati, S; Moestl, D; MullerAuer, S; Namath, A; Nentwich, U; Oefner, P; Pearson, D; Petel, FX; Pohl, TM; Purnelle, B; Rajandream, MA; Rechmann, S; Rieger, M; Riles, L; Roberts, D; Schafer, M; Scharfe, M; Scherens, B; Schramm, S; Schroder, M; Sdicu, AM; Tettelin, H; Urrestarazu, LA; Ushinsky, S; Vierendeels, F; Vissers, S; Voss, H; Walsh, SV; Wambutt, R; Wang, Y; Wedler, E; Wedler, H; Winnett, E; Zhong, WW; Zollner, A; Vo, DH; Hani, J				Bussey, H; Storms, RK; Ahmed, A; Albermann, K; Allen, E; Ansorge, W; Araujo, R; Aparicio, A; Barrell, B; Badcock, K; Benes, V; Botstein, D; Bowman, S; Bruckner, M; Carpenter, J; Cherry, JM; Chung, E; Churcher, C; Coster, F; Davis, K; Davis, RW; Dietrich, FS; Delius, H; DiPaolo, T; Dubois, E; Dusterhoft, A; Duncan, M; Floeth, M; Fortin, N; Friesen, JD; Fritz, C; Goffeau, A; Hall, J; Hebling, U; Heumann, K; Hilbert, H; Hillier, L; HunickeSmith, S; Hyman, R; Johnston, M; Kalman, S; Kleine, K; Komp, C; Kurdi, O; Lashkari, D; Lew, H; Lin, A; Lin, D; Louis, EJ; Marathe, R; Messenguy, F; Mewes, HW; Mirtipati, S; Moestl, D; MullerAuer, S; Namath, A; Nentwich, U; Oefner, P; Pearson, D; Petel, FX; Pohl, TM; Purnelle, B; Rajandream, MA; Rechmann, S; Rieger, M; Riles, L; Roberts, D; Schafer, M; Scharfe, M; Scherens, B; Schramm, S; Schroder, M; Sdicu, AM; Tettelin, H; Urrestarazu, LA; Ushinsky, S; Vierendeels, F; Vissers, S; Voss, H; Walsh, SV; Wambutt, R; Wang, Y; Wedler, E; Wedler, H; Winnett, E; Zhong, WW; Zollner, A; Vo, DH; Hani, J			The nucleotide sequence of Saccharomyces cerevisiae chromosome XVI	NATURE			English	Article							COMPLETE DNA-SEQUENCE; PHYSICAL MAPS; PROTEINS; SYNTHASE; HISTONE; CLONING; GENES	The nucleotide sequence of the 948,061 base pairs of chromosome XVI has been determined, completing the sequence of the yeast genome. Chromosome XVI was the last yeast chromosome identified(1), and some of the genes mapped early to it, such as GAL4, PEP4 and RAD1 (ref. 2) have played important roles in the development of yeast biology. The architecture of this final chromosome seems to be typical of the large yeast chromosomes, and shows large duplications with other yeast chromosomes. Chromosome XVI contains 487 potential protein-encoding genes, 17 tRNA genes and two small nuclear RNA genes; 27% of the genes have significant similarities to human gene products, and 48% are new and of unknown biological function. Systematic efforts to explore gene function have begun.	CONCORDIA UNIV,DEPT BIOL,MONTREAL,PQ H3G 1M8,CANADA; HOSP SICK CHILDREN,RES INST,TORONTO,ON M5G 1X8,CANADA; MAX PLANCK INST BIOCHEM,MARTINSRIEDER INST PROT SEQUENZEN,D-82152 MARTINSRIED,GERMANY; STANFORD UNIV,DEPT BIOCHEM,STANFORD,CA 94305; EUROPEAN MOL BIOL LAB,PROT DESIGN GRP,D-69117 HEIDELBERG,GERMANY; SANGER CTR,CAMBRIDGE CB10 1SA,ENGLAND; GENOTYPE GMBH,D-69259 WILHELMSFELD,GERMANY; UNIV CATHOLIQUE LOUVAIN,UNITE BIOCHIM PHYSIOL,B-1348 LOUVAIN,BELGIUM; DEUTSCH KREBSFORSCHUNGSZENTRUM,D-69120 HEIDELBERG,GERMANY; CERIA COOVI,RES INST,B-1070 BRUSSELS,BELGIUM; FREE UNIV BRUSSELS,MICROBIOL LAB,B-1050 BRUSSELS,BELGIUM; QIAGEN GMBH,D-40724 HILDEN,GERMANY; WASHINGTON UNIV,SCH MED,GENOME SEQUENCING CTR,ST LOUIS,MO 63110; JOHN RADCLIFFE HOSP,INST MOL MED,OXFORD OX3 9DU,ENGLAND; GESELL ANAL TECH & CONSULTING MBH,D-78467 CONSTANCE,GERMANY; GESELL MOL BIOL TECHNOL MBH,AGON,D-12489 BERLIN,GERMANY; VLAAMS INSTERUNIV INST BIOTHECHNOL,DEPT MICROBIOL,B-1070 BRUSSELS,BELGIUM; FREE UNIV BRUSSELS,LAB ERFELIJKHEIDSLEER & MICROBIOL,BRUSSELS,BELGIUM; FREE UNIV BRUSSELS,LAB PHYSIOL CELLULAIRE & GENET LEVURES,B-1050 BRUSSELS,BELGIUM	Concordia University - Canada; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Max Planck Society; Stanford University; European Molecular Biology Laboratory (EMBL); Wellcome Trust Sanger Institute; Universite Catholique Louvain; Helmholtz Association; German Cancer Research Center (DKFZ); Universite Libre de Bruxelles; Vrije Universiteit Brussel; QIAGEN GmbH; Washington University (WUSTL); University of Oxford; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Bussey, H (corresponding author), MCGILL UNIV,DEPT BIOL,1205 DR PENFIELD AVE,MONTREAL,PQ H3A 1B1,CANADA.		Storms, Reginald/B-2405-2013; Louis, Edward/B-7920-2008; Wilson, Richard K./AAF-4139-2019; Johnston, Mark/K-3543-2019; Ansorge, Wilhelm/AAN-8780-2020; Johnston, Mark/R-6156-2019; Mewes, Hans-Werner/A-8204-2019	Louis, Edward/0000-0003-1157-3608; Wilson, Richard K./0000-0002-1992-1358; Johnston, Mark/0000-0002-4932-7229; Benes, Vladimir/0000-0002-0352-2547; Cherry, J. Michael/0000-0001-9163-5180; Mewes, Hans-Werner/0000-0002-9713-6398	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Bassett DE, 1996, NATURE, V379, P589, DOI 10.1038/379589a0; BROACH JR, 1981, MOL BIOL YEAST SACCH, P653; BUSSEY H, 1995, P NATL ACAD SCI USA, V92, P3809, DOI 10.1073/pnas.92.9.3809; Dujon B, 1996, TRENDS GENET, V12, P263, DOI 10.1016/0168-9525(96)10027-5; DUJON B, 1994, NATURE, V369, P371, DOI 10.1038/369371a0; FELDMANN H, 1994, EMBO J, V13, P5795, DOI 10.1002/j.1460-2075.1994.tb06923.x; FORSTERMANN U, 1994, HYPERTENSION, V23, P1121, DOI 10.1161/01.HYP.23.6.1121; Galibert F, 1996, EMBO J, V15, P2031, DOI 10.1002/j.1460-2075.1996.tb00557.x; GOEBL MG, 1986, CELL, V46, P983, DOI 10.1016/0092-8674(86)90697-5; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; GOFFEAU A, 1993, FEBS LETT, V325, P112, DOI 10.1016/0014-5793(93)81425-Y; GOFFEAU A, 1996, SCIENCE, V274, P563, DOI DOI 10.1126/SCIENCE.274.5287.546; GUELIN E, 1993, J BIOL CHEM, V268, P161; HAWTHORNE DC, 1968, GENETICS, V60, P735; HEUMANN K, UNPUB NATURE GENET; HEUMANN K, 1996, P 4 INT C INT SYST M; JOHNSTON M, 1994, SCIENCE, V265, P2077, DOI 10.1126/science.8091229; KLEIN P, 1985, BIOCHIM BIOPHYS ACTA, V815, P468, DOI 10.1016/0005-2736(85)90375-X; Lander HM, 1996, NATURE, V381, P380, DOI 10.1038/381380a0; LOUIS EJ, 1995, GENETICS, V139, P125; LOUIS EJ, 1995, BIOCHEMICA, V3, P25; Lussier M, 1997, YEAST, V13, P267, DOI 10.1002/(SICI)1097-0061(19970315)13:3<267::AID-YEA72>3.0.CO;2-K; MORTIMER RK, 1992, YEAST, V8, P817, DOI 10.1002/yea.320081002; RILES L, 1993, GENETICS, V134, P81; ROEMER T, 1994, YEAST, V10, P1527, DOI 10.1002/yea.320101117; SIROTKIN AM, 1995, P NATL ACAD SCI USA, V92, P6434, DOI 10.1073/pnas.92.14.6434; TANAKA S, 1992, NUCLEIC ACIDS RES, V21, P1149; Ushinsky SC, 1997, YEAST, V13, P151, DOI 10.1002/(SICI)1097-0061(199702)13:2<151::AID-YEA94>3.0.CO;2-5; VANVUUREN AJ, 1993, EMBO J, V12, P3693, DOI 10.1002/j.1460-2075.1993.tb06044.x; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; ZLATANOVA J, 1994, FASEB J, V8, P1260, DOI 10.1096/fasebj.8.15.8001738	31	57	581	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 29	1997	387	6632		S			103	105		10.1038/387s103	http://dx.doi.org/10.1038/387s103			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XB546	9169875				2022-12-01	WOS:A1997XB54600015
J	VanGijn, J				VanGijn, J			Slip-ups in diagnosis of subarachnoid haemorrhage	LANCET			English	Editorial Material							HEMORRHAGE				VanGijn, J (corresponding author), UNIV UTRECHT,DEPT NEUROL,NL-3504 GA UTRECHT,NETHERLANDS.		van Gijn, Jan/A-9444-2008					Hop JW, 1997, STROKE, V28, P660, DOI 10.1161/01.STR.28.3.660; Linn FHH, 1996, STROKE, V27, P625, DOI 10.1161/01.STR.27.4.625; LINN FHH, 1994, LANCET, V344, P590, DOI 10.1016/S0140-6736(94)91970-4; Mayer PL, 1996, STROKE, V27, P1558, DOI 10.1161/01.STR.27.9.1558; NeilDwyer G, 1997, J ROY COLL PHYS LOND, V31, P49; Pascual J, 1996, NEUROLOGY, V46, P1520, DOI 10.1212/WNL.46.6.1520; VANDERWEE N, 1995, J NEUROL NEUROSUR PS, V58, P357, DOI 10.1136/jnnp.58.3.357; VERMEULEN M, 1989, J NEUROL NEUROSUR PS, V52, P826, DOI 10.1136/jnnp.52.7.826	8	18	18	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 24	1997	349	9064					1492	1492		10.1016/S0140-6736(05)62095-8	http://dx.doi.org/10.1016/S0140-6736(05)62095-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XA901	9167456				2022-12-01	WOS:A1997XA90100006
J	Rothman, JE; Sollner, TH				Rothman, JE; Sollner, TH			Membrane trafficking - Throttles and dampers: Controlling the engine of membrane fusion	SCIENCE			English	Editorial Material							BINDING YPT1 PROTEIN; TRANSPORT VESICLES; ENDOPLASMIC-RETICULUM; GOLGI TRANSPORT; YEAST; SECRETION; SYNTAXIN; GTPASES; COMPLEX; SEC4				Rothman, JE (corresponding author), MEM SLOAN KETTERING CANC CTR,CELLULAR BIOCHEM & BIOPHYS PROGRAM,1275 YORK AVE,NEW YORK,NY 10021, USA.							AALTO MK, 1992, CELL, V68, P181, DOI 10.1016/0092-8674(92)90462-L; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; BRENNWALD P, 1994, CELL, V79, P245, DOI 10.1016/0092-8674(94)90194-5; BRENNWALD P, 1993, NATURE, V362, P560, DOI 10.1038/362560a0; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; DUNN B, 1993, NATURE, V362, P563, DOI 10.1038/362563a0; GARCIA EP, 1994, P NATL ACAD SCI USA, V91, P2003, DOI 10.1073/pnas.91.6.2003; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; LIAN JP, 1993, CELL, V73, P735, DOI 10.1016/0092-8674(93)90253-M; Lupashin VV, 1997, SCIENCE, V276, P1255, DOI 10.1126/science.276.5316.1255; OSSIG R, 1991, MOL CELL BIOL, V11, P2980, DOI 10.1128/MCB.11.6.2980; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Rybin V, 1996, NATURE, V383, P266, DOI 10.1038/383266a0; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SCHMITT HD, 1988, CELL, V53, P635, DOI 10.1016/0092-8674(88)90579-X; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SEGEV N, 1991, SCIENCE, V252, P1553, DOI 10.1126/science.1904626; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0	24	91	94	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 23	1997	276	5316					1212	1213		10.1126/science.276.5316.1212	http://dx.doi.org/10.1126/science.276.5316.1212			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XA497	9182331				2022-12-01	WOS:A1997XA49700029
J	Antoch, MP; Song, EJ; Chang, AM; Vitaterna, MH; Zhao, YL; Wilsbacher, LD; Sangoram, AM; King, DP; Pinto, LH; Takahashi, JS				Antoch, MP; Song, EJ; Chang, AM; Vitaterna, MH; Zhao, YL; Wilsbacher, LD; Sangoram, AM; King, DP; Pinto, LH; Takahashi, JS			Functional identification of the mouse circadian Clock gene by transgenic BAC rescue	CELL			English	Article							MESSENGER-RNA LEVELS; DROSOPHILA-MELANOGASTER; PERIOD LOCUS; BIOLOGICAL CLOCKS; DNA; RHYTHMICITY; EXPRESSION; AUTOREGULATION; TRANSFORMATION; MUTAGENESIS	As a complementary approach to positional cloning, we used in vivo complementation with bacterial artificial chromosome (BAC) clones expressed in transgenic mice to identify the circadian Clock gene. A 140 kb BAC transgene completely rescued both the long period and the loss-of-rhythm phenotypes in Clock mutant mice. Analysis with overlapping BAC transgenes demonstrates that a large transcription unit spanning similar to 100,000 base pairs is the Clock gene and encodes a novel basic-helix-loop-helix-PAS domain protein. Overexpression of the Clock transgene can shorten period length beyond the wild-type range, which provides additional evidence that Clock is an integral component of the circadian pacemaking system. Taken together, these results provide a proof of principle that ''cloning by rescue'' is an efficient and definitive method in mice.	NORTHWESTERN UNIV, DEPT NEUROBIOL & PHYSIOL, NATL SCI FDN CTR BIOL TIMING, EVANSTON, IL 60208 USA	National Science Foundation (NSF); NSF - Center for Biological Timing; Northwestern University			Takahashi, Joseph S./Y-2781-2019; Takahashi, Joseph S/E-8482-2012	Takahashi, Joseph S./0000-0003-0384-8878; Takahashi, Joseph S/0000-0003-0384-8878; Chang, Anne-Marie/0000-0002-3943-416X; Antoch, mantoch/0000-0003-3001-8511	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD028048] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008152] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH039592] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NICHD NIH HHS [P30 HD28048] Funding Source: Medline; NIGMS NIH HHS [T32 GM008152, T32 GM08152] Funding Source: Medline; NIMH NIH HHS [R37 MH39592] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AKAGI J, 1988, BIOCHEM BIOPH RES CO, V157, P548, DOI 10.1016/S0006-291X(88)80284-5; ALUBAIDI MR, 1990, J BIOL CHEM, V265, P20563; ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; BARGIELLO TA, 1984, NATURE, V312, P752, DOI 10.1038/312752a0; BAYLIES MK, 1987, NATURE, V326, P390, DOI 10.1038/326390a0; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; BLOCK GD, 1993, INT REV CYTOL, V146, P83, DOI 10.1016/S0074-7696(08)60381-2; Bracewell R. N., 1986, HARTLEY TRANSFORM; BRUNKOW ME, 1995, GENOMICS, V25, P421, DOI 10.1016/0888-7543(95)80042-K; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COTE GG, 1986, J THEOR BIOL, V121, P487, DOI 10.1016/S0022-5193(86)80104-7; DIETRICH W, 1992, GENETICS, V131, P423; DOVE WF, 1987, GENETICS, V116, P5; DUNLAP JC, 1993, ANNU REV PHYSIOL, V55, P683, DOI 10.1146/annurev.physiol.55.1.683; Dunlap JC, 1996, ANNU REV GENET, V30, P579, DOI 10.1146/annurev.genet.30.1.579; FAVELLO A, 1995, GENOMIC DNA SEQUENCI, P551; FRISCH B, 1994, NEURON, V12, P555, DOI 10.1016/0896-6273(94)90212-7; GIBSON S, 1993, TRENDS BIOCHEM SCI, V21, P93; HALL JC, 1995, TRENDS NEUROSCI, V18, P230, DOI 10.1016/0166-2236(95)93908-G; HAMBLEN M, 1986, J NEUROGENET, V3, P249, DOI 10.3109/01677068609106855; HAMILTON BA, 1997, IN PRESS NEURON; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; HARDIN PE, 1992, P NATL ACAD SCI USA, V89, P11711, DOI 10.1073/pnas.89.24.11711; Hogan B., 2014, MANIPULATING MOUSE E; Kim UJ, 1996, GENOMICS, V34, P213, DOI 10.1006/geno.1996.0268; Klein D.C., 1991, SUPRACHIASMATIC NUCL; LEVINE AJ, 1990, BIOESSAYS, V12, P60, DOI 10.1002/bies.950120203; MCCLUNG CR, 1989, NATURE, V339, P558, DOI 10.1038/339558a0; MEIJER JH, 1989, PHYSIOL REV, V69, P671, DOI 10.1152/physrev.1989.69.3.671; Mello C, 1995, METHOD CELL BIOL, P452; MOORE RY, 1995, CIBA F SYMP, V183, P88; Moore RY, 1996, PROG BRAIN RES, V111, P103, DOI 10.1016/S0079-6123(08)60403-3; MURALIDHAR MG, 1993, NEURON, V11, P253, DOI 10.1016/0896-6273(93)90182-Q; Peterson KR, 1997, TRENDS GENET, V13, P61, DOI 10.1016/S0168-9525(97)01003-2; PITTENDRIGH CS, 1993, ANNU REV PHYSIOL, V55, P16; RALPH MR, 1990, SCIENCE, V247, P975, DOI 10.1126/science.2305266; RUTILA JE, 1992, J NEUROGENET, V8, P101, DOI 10.3109/01677069209084155; Sambrook J., 1989, MOL CLONING LAB MANU, V3; SCHEDL A, 1993, NATURE, V362, P258, DOI 10.1038/362258a0; SEHGAL A, 1995, SCIENCE, V270, P808, DOI 10.1126/science.270.5237.808; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; SMITH DJ, 1995, GENOMICS, V27, P425, DOI 10.1006/geno.1995.1073; SMITH RF, 1981, MOL GEN GENET, V183, P243, DOI 10.1007/BF00270625; SOKOLOVE PG, 1978, FDN P, V38, P2589; TAKAHASHI JS, 1993, ANNU REV PHYSIOL, V55, P729, DOI 10.1146/annurev.physiol.55.1.729; TAKAHASHI JS, 1989, RECENT PROG HORM RES, V45, P279; TAKAHASHI JS, 1995, ANNU REV NEUROSCI, V18, P531, DOI 10.1146/annurev.neuro.18.1.531; Tosini G, 1996, SCIENCE, V272, P419, DOI 10.1126/science.272.5260.419; TUREK FW, 1994, RECENT PROG HORM RES, V49, P43; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Yamaguchi T, 1996, J BIOCHEM-TOKYO, V120, P494; ZEHRING WA, 1984, CELL, V39, P369, DOI 10.1016/0092-8674(84)90015-1; ZENG HK, 1994, EMBO J, V13, P3590, DOI 10.1002/j.1460-2075.1994.tb06666.x; [No title captured]; [No title captured]; [No title captured]	57	508	525	0	25	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 16	1997	89	4					655	667		10.1016/S0092-8674(00)80246-9	http://dx.doi.org/10.1016/S0092-8674(00)80246-9			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WZ323	9160756	Green Accepted, Bronze			2022-12-01	WOS:A1997WZ32300018
J	Mothes, W; Heinrich, SU; Graf, R; Nilsson, IM; vonHeijne, G; Brunner, J; Rapoport, TA				Mothes, W; Heinrich, SU; Graf, R; Nilsson, IM; vonHeijne, G; Brunner, J; Rapoport, TA			Molecular mechanism of membrane protein integration into the endoplasmic reticulum	CELL			English	Article							SIGNAL-SEQUENCE; SECRETORY PROTEINS; ER MEMBRANE; NASCENT POLYPEPTIDES; CONDUCTING CHANNEL; ESCHERICHIA-COLI; TRANSLOCATION; INSERTION; ENVIRONMENT; GLYCOPROTEIN	As proteins are integrated into the membrane of the endoplasmic reticulum, some hydrophilic polypeptide segments are transported through the translocation channel, others remain in the cytosol, and hydrophobic transmembrane sequences are released into the lipid phase. We have addressed the molecular mechanism by which these events occur. We demonstrate that both the lumenal and the cytosolic domains of a membrane protein are synthesized while the ribosome is membrane bound, so that even cytosolic domains come in contact with the translocation channel. We also find that, before translation of the protein is terminated, transmembrane sequences can laterally exit the translocation channel and enter the lipid environment. These results have significant implications for the folding and assembly of membrane proteins.	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; ETH ZURICH,BIOCHEM LAB,CH-8092 ZURICH,SWITZERLAND; UNIV STOCKHOLM,ARRHENIUS LAB,DEPT BIOCHEM,S-10691 STOCKHOLM,SWEDEN	Harvard University; Harvard Medical School; Swiss Federal Institutes of Technology Domain; ETH Zurich; Stockholm University			Nilsson, IngMarie/H-2887-2012; von Heijne, Gunnar/AAH-9389-2019; von Heijne, Gunnar/F-5576-2011	von Heijne, Gunnar/0000-0002-4490-8569				BIBI E, 1991, P NATL ACAD SCI USA, V88, P7271, DOI 10.1073/pnas.88.16.7271; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; Borel AC, 1996, CELL, V85, P379, DOI 10.1016/S0092-8674(00)81116-2; BRUNNER J, 1980, J BIOL CHEM, V255, P3313; BRUNNER J, 1980, J BIOL CHEM, V255, P3319; CONNOLLY T, 1989, J CELL BIOL, V108, P299, DOI 10.1083/jcb.108.2.299; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; Do H, 1996, CELL, V85, P369, DOI 10.1016/S0092-8674(00)81115-0; EHRMANN M, 1991, J BIOL CHEM, V266, P16530; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GAFVELIN G, 1994, CELL, V77, P401, DOI 10.1016/0092-8674(94)90155-4; Gafvelin G, 1997, J BIOL CHEM, V272, P6119, DOI 10.1074/jbc.272.10.6119; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; HANEIN D, 1996, CELL, V87, P731; HEDGE RS, 1996, CELL, V85, P217; HIGH S, 1993, J CELL BIOL, V121, P743, DOI 10.1083/jcb.121.4.743; JUNGNICKEL B, 1995, CELL, V82, P261, DOI 10.1016/0092-8674(95)90313-5; KALIES KU, 1994, J CELL BIOL, V126, P925, DOI 10.1083/jcb.126.4.925; KRIEG UC, 1986, P NATL ACAD SCI USA, V83, P8604, DOI 10.1073/pnas.83.22.8604; LINGAPPA VR, 1978, J BIOL CHEM, V253, P8667; LOCKER JK, 1992, J BIOL CHEM, V267, P21911; MARTOGLIO B, 1995, CELL, V81, P207, DOI 10.1016/0092-8674(95)90330-5; MATLACK KES, 1995, J BIOL CHEM, V270, P6170, DOI 10.1074/jbc.270.11.6170; MCCUNE JM, 1980, J EXP MED, V152, P463, DOI 10.1084/jem.152.2.463; MCGOVERN K, 1991, EMBO J, V10, P2773, DOI 10.1002/j.1460-2075.1991.tb07826.x; MOTHES W, 1994, EMBO J, V13, P3973, DOI 10.1002/j.1460-2075.1994.tb06713.x; NILSSON I, 1994, J CELL BIOL, V126, P1127, DOI 10.1083/jcb.126.5.1127; OOI CE, 1992, CELL, V71, P87, DOI 10.1016/0092-8674(92)90268-H; RAPOPORT TA, 1985, FEBS LETT, V187, P1, DOI 10.1016/0014-5793(85)81202-3; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; SABATINI DD, 1982, J CELL BIOL, V92, P1, DOI 10.1083/jcb.92.1.1; SHAW AS, 1988, P NATL ACAD SCI USA, V85, P7592, DOI 10.1073/pnas.85.20.7592; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SINGER SJ, 1987, P NATL ACAD SCI USA, V84, P1960, DOI 10.1073/pnas.84.7.1960; SKACH WR, 1993, J BIOL CHEM, V268, P23552; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; THRIFT RN, 1991, J CELL BIOL, V112, P809, DOI 10.1083/jcb.112.5.809; Ulbrandt ND, 1997, CELL, V88, P187, DOI 10.1016/S0092-8674(00)81839-5; VONHEIJNE G, 1989, NATURE, V341, P456, DOI 10.1038/341456a0; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cellbio.10.1.87; WESSELS HP, 1988, CELL, V55, P61, DOI 10.1016/0092-8674(88)90009-8; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0	44	172	175	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 16	1997	89	4					523	533		10.1016/S0092-8674(00)80234-2	http://dx.doi.org/10.1016/S0092-8674(00)80234-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WZ323	9160744	Bronze			2022-12-01	WOS:A1997WZ32300006
J	Tskhovrebova, L; Trinick, J; Sleep, JA; Simmons, RM				Tskhovrebova, L; Trinick, J; Sleep, JA; Simmons, RM			Elasticity and unfolding of single molecules of the giant muscle protein titin	NATURE			English	Article							STRIATED-MUSCLE; FIBRONECTIN; CONNECTIN; FILAMENTS; DOMAINS	The giant muscle protein titin, also called connectin, is responsible for the elasticity of relaxed striated muscle, as well as acting as the molecular scaffold for thick-filament formation(1,2). The titin molecule consists largely of tandem domains of the immunoglobulin and fibronectin-III types, together with specialized binding regions and a putative elastic region, the PEVK domain(3). We have done mechanical experiments on single molecules of titin to determine their visco-elastic properties, using an optical-tweezers technique. On a fast (0.1s) timescale tit in is elastic and force-extension data can be fitted with standard random-coil polymer models, showing that there are two main sources of elasticity: one deriving from the entropy of straightening the molecule; the other consistent with extension of the polypeptide chain in the PEVK region. On a slower timescale and above a certain force threshold, the molecule displays stress-relaxation, which occurs in rapid steps of a few piconewtons, corresponding to yielding of internal structures by about 20 nm. This stress-relaxation probably derives from unfolding of immunoglobulin and fibronectin domains.	UNIV LONDON KINGS COLL,MRC,MUSCLE & CELL MOTIL UNIT,RANDALL INST,LONDON WC2B 5RL,ENGLAND; UNIV BRISTOL,DEPT VET CLIN SCI,MUSCLE RES GRP,BRISTOL BS18 7DY,AVON,ENGLAND	University of London; King's College London; University of Bristol								ERICKSON HP, 1994, P NATL ACAD SCI USA, V91, P10114, DOI 10.1073/pnas.91.21.10114; FIXMAN M, 1973, J CHEM PHYS, V58, P1564, DOI 10.1063/1.1679396; FLORY PJ, 1989, STAT MECH CHAIN MOL, P316; Fong S, 1996, J MOL BIOL, V264, P624, DOI 10.1006/jmbi.1996.0665; FURST DO, 1988, J CELL BIOL, V106, P1563, DOI 10.1083/jcb.106.5.1563; Gautel M, 1996, FEBS LETT, V385, P11, DOI 10.1016/0014-5793(96)00338-9; HIGUCHI H, 1993, BIOPHYS J, V65, P1906, DOI 10.1016/S0006-3495(93)81261-X; KELLERMAYER MS, IN PRESS SCIENCE; Kellermayer MSZ, 1996, BIOCHEM BIOPH RES CO, V221, P491, DOI 10.1006/bbrc.1996.0624; LABEIT S, 1995, SCIENCE, V270, P293, DOI 10.1126/science.270.5234.293; Linke WA, 1996, J MUSCLE RES CELL M, V17, P425, DOI 10.1007/BF00123359; Linke WA, 1996, J MOL BIOL, V261, P62, DOI 10.1006/jmbi.1996.0441; LITVINOVICH SV, 1992, BIOCHIM BIOPHYS ACTA, V1119, P57, DOI 10.1016/0167-4838(92)90234-5; MARUYAMA K, 1994, BIOPHYS CHEM, V50, P73, DOI 10.1016/0301-4622(94)85021-6; Plaxco KW, 1996, P NATL ACAD SCI USA, V93, P10703, DOI 10.1073/pnas.93.20.10703; POLITOU AS, 1994, BIOCHEMISTRY-US, V33, P4730, DOI 10.1021/bi00181a604; Politou AS, 1995, BIOPHYS J, V69, P2601, DOI 10.1016/S0006-3495(95)80131-1; RIEF M, IN PRESS SCIENCE; Simmons RM, 1996, BIOPHYS J, V70, P1813, DOI 10.1016/S0006-3495(96)79746-1; SOTERIOU A, 1993, P ROY SOC B-BIOL SCI, V254, P83, DOI 10.1098/rspb.1993.0130; SOTERIOU A, 1993, J CELL SCI, V104, P119; Trinick J, 1996, CURR BIOL, V6, P258, DOI 10.1016/S0960-9822(02)00472-4; Tskhovrebova L, 1997, J MOL BIOL, V265, P100, DOI 10.1006/jmbi.1996.0717; WANG K, 1993, BIOPHYS J, V64, P1161, DOI 10.1016/S0006-3495(93)81482-6; WHITING A, 1989, J MOL BIOL, V205, P263, DOI 10.1016/0022-2836(89)90381-1	25	639	646	1	79	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 15	1997	387	6630					308	312		10.1038/387308a0	http://dx.doi.org/10.1038/387308a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WZ167	9153398				2022-12-01	WOS:A1997WZ16700059
J	Manski, TJ; Heffner, DK; Glenn, GM; Patronas, NJ; Pikus, AT; Katz, D; Lebovics, R; Sledjeski, K; Choyke, PL; Zbar, B; Linehan, WM; Oldfield, EH				Manski, TJ; Heffner, DK; Glenn, GM; Patronas, NJ; Pikus, AT; Katz, D; Lebovics, R; Sledjeski, K; Choyke, PL; Zbar, B; Linehan, WM; Oldfield, EH			Endolymphatic sac tumors - A source of morbid hearing loss in von Hippel-Lindau disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MIDDLE-EAR; SUPPRESSOR GENE; TEMPORAL BONE; PAPILLARY CYSTADENOMA; ADENOCARCINOMA; ADENOMA; IDENTIFICATION; MUTATIONS; ORIGIN	Objectives.-Isolated reports suggest a possible association of endolymphatic sac tumors (ELSTs), which are extremely rare in the general population, with von Hippel-Lindau disease (VHL). To determine if hearing loss and ELSTs are a component of VHL, we examined prevalence, clinical presentation, and natural history of hearing loss and ELSTs in VHL. Design.-Brain magnetic resonance images (MRIs) from 374 patients screened for VHL were reviewed for evidence of ELSTs. The VHL patients with MRI evidence suggestive of ELSTs or a history of hearing loss, tinnitus, or vertigo underwent additional radiologic and audiologic evaluations. To further assess prevalence of hearing loss and ELST in VHL, the next 66 patients screened in the VHL clinic (49 with proven VHL, 17 at risk for VHL) received MRI and audiologic assessment, Setting.-Referral center. Participants.-Study subjects comprised 374 persons screened for VHL, 66 consecutive patients with VHL or at risk for VHL, 4 patients with 6 ELSTs, and 13 previously reported patients with VHL and invasive tumors of the temporal bone. Intervention.-Magnetic resonance image and computed tomographic (CT) scan of the posterior fossa and audiologic assessment. Main Outcome Measures.-Any ELST visible on MRI or CT and hearing loss compatible with ELST. Results.-Magnetic resonance imaging revealed evidence of 15 ELSTs in 13 (11%) of 121 patients with VHL, but in none of the 253 patients without evidence of VHL (P<.001), Clinical findings in these 13 patients included hearing toss (13), tinnitus (12), vertigo (8), and facial paresis (1). Mean age al onset of hearing loss was 22 years (range, 12-50 years). Hearing for pure tones was abnormal in all affected ears and in 6 of the 11 additional, allegedly unaffected ears. In 8 patients (62%), hearing loss was the first manifestation of VHL. Presence or absence of hearing loss was associated with duration of symptoms (P<.002) and with tumor size (P<.01). Further, 43 (65%) of the 66 patients from the VHL clinic had pure tone threshold abnormalities, abnormalities that occurred bilaterally in 23 (54%) of the 43 affected subjects; however, evidence is lacking for a definitive association with ELST (3 [6%] of 49 patients with proven VHL had ELST evident on MRI). Conclusions.-Hearing loss and ELSTs are frequently associated with VHL syndrome and should be considered when screening individuals at risk for VHL and when monitoring patients with an established diagnosis of VHL. Many patients with VHL have hearing loss without radiographic evidence of an ELST. Whether it is caused by an ELST that is too small to be detected by MRI or is produced by some other etiology is still unknown. Audiologic evaluation and MRI should allow early detection and enhance management of hearing loss in these patients.	NINCDS, SURG NEUROL BRANCH, NIH, BETHESDA, MD 20892 USA; NATL NAVAL MED CTR, DEPT NEUROSURG, BETHESDA, MD 20889 USA; ARMED FORCES INST PATHOL, DEPT OTOLARYNG PATHOL, BETHESDA, MD USA; NCI, GENET EPIDEMIOL BRANCH, DIV CANC EPIDEMIOL & GENET, BETHESDA, MD 20892 USA; NIH, DEPT RADIOL, HENRY M JACKSON FDN, WARREN GRANT MAGNUSON CLIN CTR, BETHESDA, MD 20892 USA; NATL INST DEAFNESS & OTHER COMMUN DISORDERS, NEUROOTOL BRANCH, BETHESDA, MD USA; NINCDS, OFF CLIN DIRECTOR, BETHESDA, MD 20892 USA; NCI, PATHOL LAB, BETHESDA, MD 20892 USA; NCI, IMMUNOBIOL LAB, DIV CANC BIOL DIAG & CTR, FREDERICK CANC RES FACIL, BETHESDA, MD 20892 USA; NCI, UROL ONCOL BRANCH,CLIN ONCOL PROGRAM, DIV CANC THERAPY,NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Walter Reed National Military Medical Center; United States Department of Defense; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc; National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ANSON BJ, 1970, ANN OTO RHINOL LARYN, V79, P710, DOI 10.1177/000348947007900404; ANSON BJ, 1969, ARCH OTOLARYNGOL, V89, P70; ANSON BJ, 1968, ANN OTO RHINOL LARYN, V77, P588; BENECKE JE, 1990, AM J OTOL, V11, P20; BLAMIRES TL, 1992, EYE, V6, P90, DOI 10.1038/eye.1992.18; BLAMIRES TL, 1992, J LARYNGOL OTOL, V106, P429, DOI 10.1017/S0022215100119747; CHEN F, 1995, HUM MUTAT, V5, P66, DOI 10.1002/humu.1380050109; CHRISTOFERSON L, 1961, JAMA-J AM MED ASSOC, V178, P280, DOI 10.1001/jama.1961.03040420020005; CILLUFFO JM, 1981, J NEUROSURG, V55, P952, DOI 10.3171/jns.1981.55.6.0952; Donaldson J, 1992, SURG ANATOMY TEMPORA; Donaldson JA, 1991, OTOLARYNGOLOGY, P23; EBY TL, 1988, ANN OTO RHINOL LARYN, V97, P605, DOI 10.1177/000348948809700606; Freedman Steven F., 1992, Ear Nose and Throat Journal, V71, P655; GLENN GM, 1990, PROBL UROL, V4, P312; GUSSEN R, 1971, LARYNGOSCOPE, V81, P1695; HASSARD AD, 1984, J OTOLARYNGOL, V13, P213; HEFFNER DK, 1989, CANCER, V64, P2292, DOI 10.1002/1097-0142(19891201)64:11<2292::AID-CNCR2820641119>3.0.CO;2-#; Jefferson G, 1931, BRIT J SURG, V19, P55, DOI 10.1002/bjs.1800197307; JUHN SK, 1991, OTOLARYNGOLOGY, P523; KANNO H, 1994, CANCER RES, V54, P4845; KERR D, 1992, J NEUROPATH EXP NEUR, V51, P367; KRANES A, 1966, NEW ENGL J MED, V275, P950, DOI 10.1056/NEJM196610272751710; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LAURITSEN JG, 1973, ACTA CHIR SCAND, V139, P482; LAWRENCE M, 1969, ARCH OTOLARYNGOL, V89, P85; Lawrence M., 1991, OTOLARYNGOLOGY, P199; LI JC, 1993, LARYNGOSCOPE, V103, P1342; LINEHAN WM, 1995, JAMA-J AM MED ASSOC, V273, P564; LO WWM, 1993, RADIOLOGY, V189, P199, DOI 10.1148/radiology.189.1.8372194; LO WWM, 1993, AM J NEURORADIOL, V14, P1322; MELMON KL, 1964, AM J MED, V36, P595, DOI 10.1016/0002-9343(64)90107-X; MEYER JR, 1993, AM J NEURORADIOL, V14, P1319; MEYER JS, 1964, CANCER, V17, P1241, DOI 10.1002/1097-0142(196410)17:10<1241::AID-CNCR2820171004>3.0.CO;2-Y; Michaels, 1987, EAR NOSE THROAT HIST; NADOL JB, 1993, NEW ENGL J MED, V329, P1092, DOI 10.1056/NEJM199310073291507; PALLANCH JF, 1982, LARYNGOSCOPE, V92, P47; PALMER JM, 1989, OTOLARYNG HEAD NECK, V100, P64, DOI 10.1177/019459988910000110; POE DS, 1993, OTOLARYNG HEAD NECK, V108, P80, DOI 10.1177/019459989310800112; PRICE EB, 1971, ARCH PATHOL, V91, P456; PYESMITH PH, 1884, T PATHOL SOC LOND, V36, P17; RENGACHARY SS, 1985, NEUROSURGERY, P50; Schuknecht HF., 1993, PATHOLOGY EAR; THOMAS CB, 1993, SURG PATHOL, V5, P63; VIGNAUD J, 1986, EAR DIAGNOSTIC IMAGI, P8	44	186	192	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 14	1997	277	18					1461	1466		10.1001/jama.277.18.1461	http://dx.doi.org/10.1001/jama.277.18.1461			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WX852	9145719				2022-12-01	WOS:A1997WX85200031
J	Skjaerven, R; Wilcox, AJ; Oyen, N; Magnus, P				Skjaerven, R; Wilcox, AJ; Oyen, N; Magnus, P			Mothers' birth weight and survival of their offspring: Population based study	BRITISH MEDICAL JOURNAL			English	Article							GESTATIONAL-AGE; PERINATAL-MORTALITY; GENERATIONS; GROWTH	Objective: To test the hypothesis that a baby's survival is related to the mother's birth weight. Design: Population based dataset for two generations. Setting: Population registry in Norway. Subjects: All birth records for women born in Norway since 1967 were linked to births during 1981-94, thereby forming 105 104 mother-offspring units. Main outcome measures: Perinatal mortality specific for weight for offspring in groups of maternal birth weight (with 500 g categories in both). Results: A mother's birth weight was strongly associated with the weight of her baby. Maternal birth weight was associated with perinatal survival of her baby only for mothers with birth weights under 2000 g. These mothers were more likely to lose a baby in the perinatal period (odds ratio 2.3, 95% confidence interval 1.4 to 3.7). Among mothers with a birth weight over 2000 g there was no overall association between mother's weight and infant survival. There was, however, a strong interaction between mother's birth weight, infant birth weight, and infant survival. Mortality among small babies was much higher for those whose mothers had been large at birth. For example, babies weighing 2500-2999 g had a threefold higher mortality if their mother's birth weight had been high (greater than or equal to 4000 g) than if the mother had been small (2500-2999 g). Conclusion: Mothers who weighed less than 2000 g at birth have a higher risk of losing their own babies. For mothers who weighed greater than or equal to 2000 g their birth weight provides a benchmark for judging the growth of their offspring. Babies who are small relative to their mother's birth weight are at increased risk of mortality.	NIEHS,EPIDEMIOL BRANCH,RES TRIANGLE PK,NC 27709; UNIV BERGEN,DEPT PUBL HLTH & PRIMARY HLTH CARE,N-5021 BERGEN,NORWAY; NATL INST PUBL HLTH,DEPT EPIDEMIOL,N-0403 OSLO,NORWAY	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Bergen	Skjaerven, R (corresponding author), UNIV BERGEN,MED INFORMAT & STAT SECT,ARMAUER HANSENS BLDG,N-5021 BERGEN,NORWAY.		Wilcox, Allen J/C-7723-2019	Wilcox, Allen J/0000-0002-3376-1311				Alberman E, 1992, Paediatr Perinat Epidemiol, V6, P134, DOI 10.1111/j.1365-3016.1992.tb00755.x; BAKKETEIG LS, 1983, ACTA OBSTET GYN SCAN, V62, P385, DOI 10.3109/00016348309154207; BAKKETEIG LS, 1986, EARLY HUM DEV, V14, P187, DOI 10.1016/0378-3782(86)90180-5; Barker DJP, 1992, FETAL INFANT ORIGINS; BILLEWICZ WZ, 1973, J OBSTET GYN BR COMM, V80, P491; BRENNER WE, 1976, AM J OBSTET GYNECOL, V126, P555, DOI 10.1016/0002-9378(76)90748-1; CAWLEY RH, 1954, AM J HUM GENET, V6, P448; DIXON WJ, 1992, BMDP STATISTICAL SOF, V2; EMANUEL I, 1992, BRIT J OBSTET GYNAEC, V99, P67, DOI 10.1111/j.1471-0528.1992.tb14396.x; HACKMAN E, 1983, JAMA-J AM MED ASSOC, V250, P2016, DOI 10.1001/jama.250.15.2016; KLEBANOFF MA, 1984, JAMA-J AM MED ASSOC, V252, P2423, DOI 10.1001/jama.252.17.2423; Little R E, 1987, Paediatr Perinat Epidemiol, V1, P19, DOI 10.1111/j.1365-3016.1987.tb00084.x; MAGNUS P, 1984, CLIN GENET, V25, P15; MAGNUS P, 1993, ANN HUM BIOL, V20, P231, DOI 10.1080/03014469300002662; MAGNUS P, 1984, CLIN GENET, V26, P397; PANETH N, 1995, BRIT MED J, V310, P411, DOI 10.1136/bmj.310.6977.411; PARKER DJP, 1994, MOTHERS BABIES DIS L; SANDERSON M, 1995, PAEDIATR PERINAT EP, V9, P391, DOI 10.1111/j.1365-3016.1995.tb00162.x; SKJAERVEN R, 1988, INT J EPIDEMIOL, V17, P830, DOI 10.1093/ije/17.4.830; Skjaerven R, 1989, Paediatr Perinat Epidemiol, V3, P432, DOI 10.1111/j.1365-3016.1989.tb00531.x; SMITH DM, 1996, 96192 U LANC DEP MAT; *STAT SCI, 1995, S PLUS GUID STAT MAT; Wang XB, 1995, NEW ENGL J MED, V333, P1744, DOI 10.1056/NEJM199512283332606; WILCOX AJ, 1986, INT J EPIDEMIOL, V15, P188, DOI 10.1093/ije/15.2.188; WILCOX AJ, 1983, EARLY HUM DEV, V8, P189, DOI 10.1016/0378-3782(83)90001-4	25	55	55	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 10	1997	314	7091					1376	1380						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WZ169	9161309	Green Published			2022-12-01	WOS:A1997WZ16900023
J	Zhang, PM; Liegeois, NJ; Wong, C; Finegold, M; Hou, H; Thompson, JC; Silverman, A; Harper, JW; DePinho, RA; Elledge, SJ				Zhang, PM; Liegeois, NJ; Wong, C; Finegold, M; Hou, H; Thompson, JC; Silverman, A; Harper, JW; DePinho, RA; Elledge, SJ			Altered cell differentiation and proliferation in mice lacking p57(KIP2) indicates a role in Beckwith-Wiedemann syndrome	NATURE			English	Article							DEPENDENT KINASE INHIBITOR; DISRUPTION; PROTEIN; PALATE; TUMOR; MOUSE; GENE	Mice lacking the imprinted Cdk inhibitor p57(KIP2) have altered cell proliferation and differentiation, leading to abdominal muscle defects; cleft palate; endochondral bone ossification defects with incomplete differentiation of hypertrophic chondrocytes; renal medullary dysplasia; adrenal cortical hyperplasia and cytomegaly; and lens cell hyperproliferation and apoptosis. Many of these phenotypes are also seen in patients with Beckwith-Wiedemann syndrome, a pleiotropic hereditary disorder characterized by overgrowth and predisposition to cancer, suggesting that loss of p57(KIP2) expression may play a role in the condition.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MICROBIOL & IMMUNOL,BRONX,NY 10461; BAYLOR COLL MED,VERNA & MARRS MCLEAN DEPT BIOCHEM,HOUSTON,TX 77030; BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT PATHOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MOL & HUMAN GENET,HOUSTON,TX 77030	Yeshiva University; Albert Einstein College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; Baylor College of Medicine			Thompson, Jessica/GXW-0323-2022	DePinho, Ronald/0000-0002-5625-577X; Harper, Jeffrey/0000-0002-6944-7236; Liegeois, Nanette/0000-0001-5002-1799				BECKWITH J B, 1969, Birth Defects Original Article Series, V5, P188; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DYNLACHT BD, IN PRESS METHODS ENZ; ELLIOTT M, 1994, CLIN GENET, V46, P168; FERGUSON MWJ, 1988, DEVELOPMENT, V103, P41; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; HASTIE ND, 1994, ANNU REV GENET, V28, P523; Hatada I, 1996, NAT GENET, V14, P171, DOI 10.1038/ng1096-171; HATADA I, 1995, NAT GENET, V11, P204, DOI 10.1038/ng1095-204; HEPINSTALL RH, 1992, PATHOLOGY KIDNEY, V1, P114; Hoovers JMN, 1995, P NATL ACAD SCI USA, V92, P12456, DOI 10.1073/pnas.92.26.12456; JACENKO O, 1993, NATURE, V365, P56, DOI 10.1038/365056a0; Junien C, 1992, CURR OPIN GENET DEV, V2, P431, DOI 10.1016/S0959-437X(05)80154-6; Kaufman M.H., 1992, ATLAS MOUSE DEV; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; Matsuoka S, 1996, P NATL ACAD SCI USA, V93, P3026, DOI 10.1073/pnas.93.7.3026; MCAVOY JW, 1996, DIFFERENTIATION, V17, P137; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; RAMIREZSOLIS R, 1993, CELL, V73, P279, DOI 10.1016/0092-8674(93)90229-J; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SOTELOAVILA C, 1980, J PEDIATR-US, V96, P47, DOI 10.1016/S0022-3476(80)80322-2; TAKATO T, 1989, ANN PLAS SURG, V22, P347, DOI 10.1097/00000637-198904000-00011; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEKSBERG R, 1993, NAT GENET, V5, P143, DOI 10.1038/ng1093-143; WIEDEMANN HR, 1983, EUR J PEDIATR, V141, P129, DOI 10.1007/BF00496807	33	618	641	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 8	1997	387	6629					151	158		10.1038/387151a0	http://dx.doi.org/10.1038/387151a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WX945	9144284				2022-12-01	WOS:A1997WX94500046
J	McVean, GT; Hurst, LD				McVean, GT; Hurst, LD			Evidence for a selectively favourable reduction in the mutation rate of the X chromosome	NATURE			English	Article							DRIVEN MOLECULAR EVOLUTION; DELETERIOUS MUTATIONS; SEX; NUCLEOTIDE; SUBSTITUTION; RODENTS; GENES; USAGE	The equilibrium per-genome mutation rate in sexual species is thought to result from a trade-off between the benefits of reducing the deleterious mutation rate and the costs of increasing fidelity(1,2). We propose that selection will often favour a lower mutation rate on the X chromosome than on autosomes, owing to the exposure of deleterious recessive mutations on hemizygous chromosomes. We tested this hypothesis by examining 33 X-linked genes that have been sequenced in both mouse and rat, and compared their rate of evolution against 238 autosomal genes. The X-linked genes were found to have a significantly lower rate of synonymous substitution than the autosomal genes. Neither the supposed higher mutation rate in males nor stronger purifying selection against slightly deleterious mutations on the X chromosome can account for the low value. The most parsimonious explanation is that rodents have a lower mutation rate on the X chromosome than on autosomes. It is therefore likely that previous indirect estimates of the excess male mutation rate are inaccurate. Indeed, after correction we find no evidence for a male-biased mutation rate in rodents. Furthermore, the rate of synonymous substitution in Y-linked genes is not significantly different from that in autosomal ones. The extent to which enhanced male mutation rates are problematic(3) for the mutational deterministic model(4) of the evolution of sex must, in turn, be questioned.	UNIV BATH,SCH BIOL & BIOCHEM,BATH BA2 7AY,AVON,ENGLAND	University of Bath	McVean, GT (corresponding author), UNIV CAMBRIDGE,DEPT GENET,DOWNING ST,CAMBRIDGE CB2 3EH,ENGLAND.		Hurst, Laurence/F-9215-2010	Hurst, Laurence/0000-0002-1002-1054				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bulmer MG., 1979, PRINCIPLES STAT; CHANG BHJ, 1994, P NATL ACAD SCI USA, V91, P827, DOI 10.1073/pnas.91.2.827; CHANG BHJ, 1995, J MOL EVOL, V40, P70, DOI 10.1007/BF00166597; CHARLESWORTH B, 1987, AM NAT, V130, P113, DOI 10.1086/284701; CHARLESWORTH B, 1994, GENET RES, V63, P213, DOI 10.1017/S0016672300032365; Crow JF, 1983, GENET BIOL DROSOPHIL, P1; DRISCOLL DJ, 1990, SOMAT CELL MOLEC GEN, V16, P267, DOI 10.1007/BF01233363; EYREWALKER AC, 1991, J MOL EVOL, V33, P442, DOI 10.1007/BF02103136; *GCG, 1994, WISC PACK VERS 8 MAN; GILLESPIE JH, 1995, J MOL EVOL, V40, P64, DOI 10.1007/BF00166596; Hurst LD, 1996, TRENDS ECOL EVOL, V11, pA46; *JACKS LAB, 1996, MOUS GEN DAT 3 1 MOU; JEFFREYS AJ, 1994, NAT GENET, V6, P136, DOI 10.1038/ng0294-136; KETTERLING RP, 1993, AM J HUM GENET, V52, P152; KIMURA M, 1967, GENET RES, V9, P23, DOI 10.1017/S0016672300010284; KONDRASHOV AS, 1988, NATURE, V336, P435, DOI 10.1038/336435a0; KONDRASHOV AS, 1995, GENET RES, V66, P53, DOI 10.1017/S001667230003439X; LEIGH EG, 1970, AM NAT, V104, P301, DOI 10.1086/282663; LI WH, 1985, MOL BIOL EVOL, V2, P150; LI WH, 1987, J MOL EVOL, V24, P337, DOI 10.1007/BF02134132; LI WH, 1993, J MOL EVOL, V36, P96, DOI 10.1007/BF02407308; Li WH, 1996, MOL PHYLOGENET EVOL, V5, P182, DOI 10.1006/mpev.1996.0012; MIYATA T, 1987, COLD SPRING HARB SYM, V52, P863, DOI 10.1101/SQB.1987.052.01.094; OHTA T, 1993, P NATL ACAD SCI USA, V90, P10676, DOI 10.1073/pnas.90.22.10676; REDFIELD RJ, 1994, NATURE, V369, P145, DOI 10.1038/369145a0; SHARP PM, 1989, EVOLUTION ANIMAL BRE, P24; SHIMMIN LC, 1993, J MOL EVOL, V37, P160, DOI 10.1007/BF02407351; WOLFE KH, 1989, NATURE, V337, P283, DOI 10.1038/337283a0; WOLFE KH, 1993, J MOL EVOL, V37, P441, DOI 10.1007/BF00178874	30	117	117	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 27	1997	386	6623					388	392		10.1038/386388a0	http://dx.doi.org/10.1038/386388a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WQ170	9121553				2022-12-01	WOS:A1997WQ17000062
J	RodriguezEsteban, C; Schwabe, JWR; DeLaPena, J; Foys, B; Eshelman, B; Belmonte, JCI				RodriguezEsteban, C; Schwabe, JWR; DeLaPena, J; Foys, B; Eshelman, B; Belmonte, JCI			Radical fringe positions the apical ectodermal ridge at the dorsoventral boundary of the vertebrate limb	NATURE			English	Article							CHICK LIMB; DEVELOPMENTAL BIOLOGY; WING DEVELOPMENT; ADDITIONAL LIMB; SONIC-HEDGEHOG; GROWTH-FACTORS; FEEDBACK LOOP; BUD; GENE; DORSAL	Vertebrate limb outgrowth requires a structure called the apical ectodermal ridge, formation of which follows the previous establishment of the dorsoventral limb axis. Radical fringe is expressed in the dorsal ectoderm before the ridge appears, and is repressed by Engrailed-I, which is expressed in the ventral ectoderm. Misexpression of these genes indicates that a ridge is formed wherever there is a boundary between cells expressing and not expressing Radical fringe, Thus, as in Drosophila, Radical fringe positions the ridge at the dorsoventral limb boundary.	SALK INST BIOL STUDIES,GENE EXPRESS LAB,LA JOLLA,CA 92037	Salk Institute			Schwabe, John WR/A-9132-2008	Schwabe, John WR/0000-0003-2865-4383				COHN MJ, 1995, CELL, V80, P739, DOI 10.1016/0092-8674(95)90352-6; COPE LD, 1991, MOL MICROBIOL, V5, P1113, DOI 10.1111/j.1365-2958.1991.tb01884.x; Couso JP, 1995, CURR BIOL, V5, P1437, DOI 10.1016/S0960-9822(95)00281-8; Crossley PH, 1996, CELL, V84, P127, DOI 10.1016/S0092-8674(00)80999-X; deCelis JF, 1996, DEVELOPMENT, V122, P359; DiazBenjumea FJ, 1995, DEVELOPMENT, V121, P4215; DUBOULE D, 1994, SCIENCE, V266, P575, DOI 10.1126/science.7939709; FALLON JF, 1994, SCIENCE, V264, P104, DOI 10.1126/science.7908145; FRANCIS PH, 1994, DEVELOPMENT, V120, P209; GARCIABELLIDO A, 1994, EUR REV, V2, P15; GILBERT SF, 1995, DEV BIOL; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; IRVINE KD, 1994, CELL, V79, P595, DOI 10.1016/0092-8674(94)90545-2; IZPISUABELMONTE JC, 1993, CELL, V74, P645, DOI 10.1016/0092-8674(93)90512-O; IZPISUABELMONTE JC, 1991, EMBO J, V10, P2279, DOI 10.1002/j.1460-2075.1991.tb07764.x; IZPISUABELMONTE JC, 1991, NATURE, V350, P585, DOI 10.1038/350585a0; Kim J, 1996, NATURE, V382, P133, DOI 10.1038/382133a0; KIM J, 1995, CELL, V82, P795, DOI 10.1016/0092-8674(95)90476-X; Laufer E, 1997, NATURE, V386, P366, DOI 10.1038/386366a0; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; Loomis CA, 1996, NATURE, V382, P360, DOI 10.1038/382360a0; MACCABE JA, 1974, DEV BIOL, V39, P69, DOI 10.1016/S0012-1606(74)80009-6; MADEN M, 1994, NATURE, V371, P560, DOI 10.1038/371560a0; MAHMOOD R, 1995, CURR BIOL, V5, P797, DOI 10.1016/S0960-9822(95)00157-6; Marigo V, 1996, DEVELOPMENT, V122, P1225; MARTIN GR, 1995, NATURE, V374, P410, DOI 10.1038/374410a0; MORGAN BA, 1992, NATURE, V358, P236, DOI 10.1038/358236a0; Myat A, 1996, DEV BIOL, V174, P233, DOI 10.1006/dbio.1996.0069; Neumann CJ, 1996, DEVELOPMENT, V122, P3477; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; OHUCHI H, 1995, BIOCHEM BIOPH RES CO, V209, P809, DOI 10.1006/bbrc.1995.1572; PARR BA, 1995, NATURE, V374, P350, DOI 10.1038/374350a0; PAUTOU MP, 1973, CR ACAD SCI D NAT, V277, P1225; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; RIDDLE RD, 1995, CELL, V83, P631, DOI 10.1016/0092-8674(95)90103-5; Ros MA, 1996, DEVELOPMENT, V122, P2319; Saunders J. W., 1968, EPITHELIAL MESENCHYM, P78; SAUNDERS JW, 1948, J EXP ZOOL, V108, P363, DOI 10.1002/jez.1401080304; Shawber C, 1996, DEV BIOL, V180, P370, DOI 10.1006/dbio.1996.0310; TABIN C, 1995, CELL, V80, P671, DOI 10.1016/0092-8674(95)90343-7; TICKLE C, 1975, NATURE, V254, P199, DOI 10.1038/254199a0; TODT WL, 1984, J EMBRYOL EXP MORPH, V80, P21; Vogel A, 1996, DEVELOPMENT, V122, P1737; VOGEL A, 1995, NATURE, V378, P716, DOI 10.1038/378716a0; Wu JY, 1996, SCIENCE, V273, P355, DOI 10.1126/science.273.5273.355; YANG YZ, 1995, CELL, V80, P939, DOI 10.1016/0092-8674(95)90297-X; Yuan YP, 1997, CELL, V88, P9, DOI 10.1016/S0092-8674(00)81852-8; ZECCA M, 1995, DEVELOPMENT, V121, P2265	51	161	164	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 27	1997	386	6623					360	366		10.1038/386360a0	http://dx.doi.org/10.1038/386360a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WQ170	9121551				2022-12-01	WOS:A1997WQ17000055
J	Shi, YG; Hata, A; Lo, RS; Massague, J; Pavletich, NP				Shi, YG; Hata, A; Lo, RS; Massague, J; Pavletich, NP			A structural basis for mutational inactivation of the tumour suppressor Smad4	NATURE			English	Article							PROTEIN	The Smad4/DPC4 tumour suppressor(1) is inactivated in nearly half of pancreatic carcinomas(2) and to a lesser extent in a variety of other cancers(2-4). Smad4/DPC4, and the related tumour suppressor Smad2, belong to the SMAD family of proteins that mediate signalling by the TGF-beta/activin/BMP-2/4 cytokine superfamily from receptor Ser/Thr protein kinases at the cell surface to the nucleus(5-7). SMAD proteins, which are phosphorylated by the activated receptor, propagate the signal, in part, through homo- and hetero-oligomeric interactions(8-13). Smad4/DPC4 plays a central role as it is the shared hetero-oligomerization partner of the other SMADs. The conserved carboxy-terminal domains of SMADs are sufficient for inducing most of the ligand-specific effects, and are the primary targets of tumorigenic inactivation. We now describe the crystal structure of the C-terminal domain (CTD) of the Smad4/DPC4 tumour suppressor, determined at 2.5 Angstrom resolution. The structure reveals that the Smad4/DPC4 CTD forms a crystallographic trimer through a conserved protein-protein interface, to which the majority of the tumour-derived missense mutations map. These mutations disrupt homooligomerization in vitro and in vivo indicating that the trimeric assembly of the Smad4/DPC4 CTD is critical for signalling and is disrupted by tumorigenic mutations.	MEM SLOAN KETTERING CANC CTR, CELLULAR BIOCHEM & BIOPHYS PROGRAM, NEW YORK, NY 10021 USA; MEM SLOAN KETTERING CANC CTR, CELL BIOL PROGRAM, NEW YORK, NY 10021 USA; MEM SLOAN KETTERING CANC CTR, HOWARD HUGHES MED INST, NEW YORK, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center				Massague, Joan/0000-0001-9324-8408; Shi, Yigong/0000-0003-2030-168X				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; BRUNGER AT, 1991, X PLOR SYSTEM CRYSTA; Derynck R, 1996, CELL, V87, P173, DOI 10.1016/S0092-8674(00)81335-5; Derynck R, 1996, CURR BIOL, V6, P1226, DOI 10.1016/S0960-9822(96)00702-6; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; IECHLEIDER RJ, 1996, J BIOL CHEM, V271, P17617; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim SK, 1996, CANCER RES, V56, P2519; KLAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Nagatake M, 1996, CANCER RES, V56, P2718; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Savage C, 1996, P NATL ACAD SCI USA, V93, P790, DOI 10.1073/pnas.93.2.790; Schutte M, 1996, CANCER RES, V56, P2527; SEKELSKY JJ, 1995, GENETICS, V139, P1347; SHELDRICK G, 1991, PATTERSON INTERPRETA; STURA EA, 1992, CRYSTALLIZATION NUCL, P99; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; Uchida K, 1996, CANCER RES, V56, P5583; Yingling JM, 1996, P NATL ACAD SCI USA, V93, P8940, DOI 10.1073/pnas.93.17.8940; ZHANG KYJ, 1993, ACTA CRYSTALLOGR D, V49, P213, DOI 10.1107/S0907444992007911; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	30	368	392	1	45	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 3	1997	388	6637					87	93		10.1038/40431	http://dx.doi.org/10.1038/40431			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XJ143	9214508	Bronze			2022-12-01	WOS:A1997XJ14300056
J	Shorr, RI; Ray, WA; Daugherty, JR; Griffin, MR				Shorr, RI; Ray, WA; Daugherty, JR; Griffin, MR			Antihypertensives and the risk of serious hypoglycemia in older persons using insulin or sulfonylureas	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ANGIOTENSIN-CONVERTING ENZYME; ACUTE MYOCARDIAL-INFARCTION; DIABETIC-PATIENTS; AUTONOMIC NEUROPATHY; BETA-BLOCKERS; PROPRANOLOL; UNAWARENESS; INHIBITORS; METOPROLOL; ATENOLOL	Context.-beta-Blockers and angiotensin-converting enzyme (ACE) inhibitors are effective antihypertensive agents for patients with diabetes mellitus, However, beta-blockers attenuate some components of the autonomic response to hypoglycemia and could increase the risk of hypoglycemia. ACE inhibitors may increase insulin sensitivity and predispose users to hypoglycemia. Objective.-To determine whether use of cardioselective beta-blockers, nonselective beta-blockers, ACE inhibitors, thiazide diuretics, calcium channel blockers, or other antihypertensive drugs alters the risk of developing serious hypoglycemia among older persons prescribed insulin or sulfonylureas, Design.-Retrospective cohort study, Setting.-Tennessee Medicaid Program, Patients.-A total of 13 559 elderly (mean age, 78+/-7 years) Medicaid enrollees, who were prescribed insulin (n=5171, 38%) or sulfonylureas (n=8368, 62%) from 1985 through 1989, These enrollees contributed a total of 33 107 person-years of insulin or sulfonylurea use for follow-up. Measurements.-Hospitalization, emergency department admission, or death associated with hypoglycemic symptoms and a concomitant blood glucose determination of less than 2.8 mmol/L (50 mg/dL), Results.-We identified 598 persons with an episode of serious hypoglycemia during the study period, The rate of serious hypoglycemia was 2.01 per 100 person-years among those who were not prescribed antihypertensives. Crude rates of serious hypoglycemia were highest among users of ACE inhibitors (2.47 per 100 person-years) and lowest among users of cardioselective beta-blockers (1.23 per 100 person-years), However, when we controlled for demographic characteristics and markers of comorbidity, there was no statistically significant increase or decrease in risk of serious hypoglycemia among users of any class of antihypertensive agents compared with nonusers of antihyperiensive drugs. Using nonselective beta-blockers as the reference group, each of these agents was associated with a lower, but not statistically significant, risk of hypoglycemia. Conclusions.-In this population, specific antihypertensive drug therapy had little impact an the risk of hypoglycemia in older diabetic patients. Therapy should be chosen based on other considerations of safety and effectiveness.	UNIV TENNESSEE,MEMPHIS COLL MED,DEPT PREVENT MED,MEMPHIS,TN; VANDERBILT UNIV,SCH MED,DEPT PREVENT MED,DIV PHARMACOEPIDEMIOL,NASHVILLE,TN 37212	University of Tennessee System; University of Tennessee Health Science Center; Vanderbilt University	Shorr, RI (corresponding author), METHODIST HOSP MEMPHIS,DEPT MED EDUC,1265 UNION AVE,MEMPHIS,TN 38104, USA.				NATIONAL INSTITUTE ON AGING [K08AG000559] Funding Source: NIH RePORTER; NIA NIH HHS [K08-AG00559] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		*1ST INT STUD INF, 1986, LANCET, V2, P57; ARAUZPACHECO C, 1990, AM J MED, V89, P811, DOI 10.1016/0002-9343(90)90227-5; *AUSTR SWED PIND S, 1983, EUR HEART J, V4, P367; BARNETT AH, 1980, BRIT MED J, V280, P976, DOI 10.1136/bmj.280.6219.976; *BET BLOCK HEART A, 1982, JAMA-J AM MED ASSOC, V247, P1707; DEACON SP, 1977, BRIT MED J, V2, P1255, DOI 10.1136/bmj.2.6097.1255; Fatourechi V, 1996, MAYO CLIN PROC, V71, P53, DOI 10.4065/71.1.53; Harris M I, 1990, Clin Geriatr Med, V6, P703; HEPBURN DA, 1990, DIABETIC MED, V7, P711, DOI 10.1111/j.1464-5491.1990.tb01475.x; HERINGS RMC, 1995, LANCET, V345, P1195, DOI 10.1016/S0140-6736(95)91988-0; HJALMARSON A, 1981, LANCET, V2, P823; *JOINT NAT COMM DE, 1993, ARCH INTERN MED, V153, P154; KASISKE BL, 1993, ANN INTERN MED, V118, P129, DOI 10.7326/0003-4819-118-2-199301150-00009; KERR D, 1990, BRIT J CLIN PHARMACO, V29, P685, DOI 10.1111/j.1365-2125.1990.tb03689.x; KJEKSHUS J, 1990, EUR HEART J, V11, P43, DOI 10.1093/oxfordjournals.eurheartj.a059591; *MIAMI TRIAL RES G, 1985, EUR HEART J, V6, P199; *NORW MULT STUD GR, 1981, NEW ENGL J MED, V304, P801; PAYNE CD, 1987, GEN LINEAR INTERACTI; RETT K, 1988, NEW ENGL J MED, V319, P1609; RYDER REJ, 1990, BMJ-BRIT MED J, V301, P783, DOI 10.1136/bmj.301.6755.783; TSE WY, 1994, DIABETIC MED, V11, P137, DOI 10.1111/j.1464-5491.1994.tb02009.x; US Dept of Health and Human Services . International Classification of Diseases, 1988, INT CLASS DIS; WALLIN JD, 1987, ARCH INTERN MED, V147, P654, DOI 10.1001/archinte.147.4.654; *WORK GROUP HYP DI, 1987, ARCH INTERN MED, V147, P830; 1993, DIABETES CARE, V16, P1394	25	79	82	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 2	1997	278	1					40	43		10.1001/jama.278.1.40	http://dx.doi.org/10.1001/jama.278.1.40			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG387	9207336				2022-12-01	WOS:A1997XG38700034
J	Coleman, JL; Gebbia, JA; Piesman, J; Degen, JL; Bugge, TH; Benach, JL				Coleman, JL; Gebbia, JA; Piesman, J; Degen, JL; Bugge, TH; Benach, JL			Plasminogen is required for efficient dissemination of B-burgdorferi in ticks and for enhancement of spirochetemia in mice	CELL			English	Article							LYME-DISEASE SPIROCHETE; OUTER SURFACE-PROTEIN; BORRELIA-BURGDORFERI; IXODES-DAMMINI; HUMAN-PLASMA; ACTIVATOR; UROKINASE; BLOOD; TRANSMISSION; SYSTEM	The role of the host plasminogen activation system in transmission of and invasion by Borrelia burgdorferi, the tick-borne spirochetal agent of Lyme disease, was investigated using plasminogen (Plg)-knockout mice. PLG was not detected in spirochetes from unfed ticks, but binding occurred as ticks fed on the host's blood. Plasminogen activators were derived from the host blood meal. PLG was required for efficient dissemination of B. burgdorferi within the tick and for enhancement of spirochetemia in mice but was not critical for transmission and infection. These results provide evidence for a bacterium using a vertebrate protease to disseminate in an invertebrate vector and underscores the interplay among vector, pathogen, and host in promoting the life cycle and disease.	SUNY STONY BROOK,HLTH SCI CTR,DEPT PATHOL,STONY BROOK,NY 11794; CHILDRENS HOSP RES FDN,CINCINNATI,OH 45229; CTR DIS CONTROL & PREVENT,FT COLLINS,CO 80522	State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; Centers for Disease Control & Prevention - USA	Coleman, JL (corresponding author), SUNY STONY BROOK,HLTH SCI CTR,NEW YORK STATE DEPT HLTH,STONY BROOK,NY 11794, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047826] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI027044, R01AI027044] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040445] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 47826] Funding Source: Medline; NIAID NIH HHS [AI 27044] Funding Source: Medline; NIAMS NIH HHS [AR 40445] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BARTHOLD SW, 1990, J INFECT DIS, V162, P133, DOI 10.1093/infdis/162.1.133; BENACH JL, 1988, J IMMUNOL, V140, P265; BENACH JL, 1983, NEW ENGL J MED, V308, P740, DOI 10.1056/NEJM198303313081302; BENACH JL, 1987, J INFECT DIS, V155, P1300, DOI 10.1093/infdis/155.6.1300; Boyle MDP, 1997, THROMB HAEMOSTASIS, V77, P1; BUGGE TH, 1995, GENE DEV, V9, P794, DOI 10.1101/gad.9.7.794; Bugge TH, 1996, CELL, V87, P709, DOI 10.1016/S0092-8674(00)81390-2; BURGDORFER W, 1982, SCIENCE, V216, P1317, DOI 10.1126/science.7043737; BURKOT TR, 1994, J INFECT DIS, V170, P883, DOI 10.1093/infdis/170.4.883; CASTELLINO FJ, 1973, BIOCHEM BIOPH RES CO, V53, P845, DOI 10.1016/0006-291X(73)90170-8; COLEMAN JL, 1995, INFECT IMMUN, V63, P2478, DOI 10.1128/IAI.63.7.2478-2484.1995; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DEGEN SJF, 1990, GENOMICS, V8, P49, DOI 10.1016/0888-7543(90)90225-J; DESILVA AM, 1995, AM J TROP MED HYG, V53, P397, DOI 10.4269/ajtmh.1995.53.397; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; FINGERLE V, 1995, J CLIN MICROBIOL, V33, P1867, DOI 10.1128/JCM.33.7.1867-1869.1995; FUCHS H, 1994, P NATL ACAD SCI USA, V91, P12594, DOI 10.1073/pnas.91.26.12594; Fuchs H, 1996, INFECT IMMUN, V64, P4307, DOI 10.1128/IAI.64.10.4307-4312.1996; GARCIAMONCO JC, 1990, J INFECT DIS, V161, P1187, DOI 10.1093/infdis/161.6.1187; GARCIAMONCO JC, 1995, ANN NEUROL, V37, P691, DOI 10.1002/ana.410370602; Gebbia JA, 1995, EXP APPL ACAROL, V19, P593, DOI 10.1007/BF00048814; Gebbia JA, 1997, GENE, V188, P221, DOI 10.1016/S0378-1119(96)00811-6; GOODMAN JL, 1995, AM J MED, V99, P6, DOI 10.1016/S0002-9343(99)80097-7; HU LT, 1995, INFECT IMMUN, V63, P3491, DOI 10.1128/IAI.63.9.3491-3496.1995; JUHANVAGUE I, 1984, THROMB RES, V33, P523, DOI 10.1016/0049-3848(84)90018-5; KIELBERG V, 1985, FEBS LETT, V182, P441, DOI 10.1016/0014-5793(85)80350-1; KLEMPNER MS, 1995, J INFECT DIS, V171, P1258, DOI 10.1093/infdis/171.5.1258; KRUITHOF EKO, 1984, BLOOD, V64, P907; LARSSON LI, 1984, J CELL BIOL, V98, P894, DOI 10.1083/jcb.98.3.894; LOTTENBERG R, 1985, AM J HEMATOL, V19, P181, DOI 10.1002/ajh.2830190211; MCDONOUGH KA, 1993, J MED ENTOMOL, V30, P772, DOI 10.1093/jmedent/30.4.772; Montgomery RR, 1996, J EXP MED, V183, P261, DOI 10.1084/jem.183.1.261; MUNDERLOH UG, 1995, ANNU REV ENTOMOL, V40, P221, DOI 10.1146/annurev.en.40.010195.001253; NADELMAN RB, 1990, AM J MED, V88, P21, DOI 10.1016/0002-9343(90)90122-T; Perides G, 1996, BIOCHEM BIOPH RES CO, V219, P690, DOI 10.1006/bbrc.1996.0296; PIESMAN J, 1987, J CLIN MICROBIOL, V25, P557, DOI 10.1128/JCM.25.3.557-558.1987; PIESMAN J, 1995, J MED ENTOMOL, V32, P519, DOI 10.1093/jmedent/32.4.519; PIESMAN J, 1993, J INFECT DIS, V167, P1082, DOI 10.1093/infdis/167.5.1082; PIESMAN J, 1993, J MED ENTOMOL, V30, P199, DOI 10.1093/jmedent/30.1.199; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SAPPINO AP, 1991, J CLIN INVEST, V87, P962, DOI 10.1172/JCI115104; SCHWAN TG, 1995, P NATL ACAD SCI USA, V92, P2909, DOI 10.1073/pnas.92.7.2909; SHIH CM, 1992, J INFECT DIS, V166, P827, DOI 10.1093/infdis/166.4.827; SINSKY RJ, 1989, J CLIN MICROBIOL, V27, P1723, DOI 10.1128/JCM.27.8.1723-1727.1989; Sonenshine D.E., 1993, BIOL TICKS; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; STEERE AC, 1983, NEW ENGL J MED, V308, P733, DOI 10.1056/NEJM198303313081301; VASSALLI JD, 1991, J CLIN INVEST, V88, P1067, DOI 10.1172/JCI115405; WERB Z, 1977, NEW ENGL J MED, V296, P1017, DOI 10.1056/NEJM197705052961801; WHEELER CM, 1989, J INFECT DIS, V59, P265; YANG LM, 1994, INFECT IMMUN, V62, P492, DOI 10.1128/IAI.62.2.492-500.1994; ZUNG JL, 1989, CAN J ZOOL, V67, P1737, DOI 10.1139/z89-249	52	272	281	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 27	1997	89	7					1111	1119		10.1016/S0092-8674(00)80298-6	http://dx.doi.org/10.1016/S0092-8674(00)80298-6			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XG830	9215633	Bronze			2022-12-01	WOS:A1997XG83000015
J	Lagasse, E; Weissman, IL				Lagasse, E; Weissman, IL			Enforced expression of Bcl-2 in monocytes rescues macrophages and partially reverses osteopetrosis in op/op mice	CELL			English	Article							COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM-CELLS; MONONUCLEAR PHAGOCYTE SYSTEM; OP OP MOUSE; GROWTH-FACTOR; FACTOR CSF-1; APOPTOSIS; LINEAGE; MURINE; DEATH	Osteopetrotic (op/op) mice lack functional M-CSF and have depressed levels of macrophages and osteoclasts. We prepared transgenic mice (hMRP8bcl-2) that express human Bcl-2 in monocytes. in vitro hMRP8bcl-2 monocytes do not undergo apoptosis in the absence of serum and M-CSF, while op/op and wild-type monocytes die. These Bcl-2-expressing monocytes spontaneously undergo macrophage differentiation. In vivo, the op/op hMRP8bcl-2 mice show significant replenishment of tissue macrophages. Their long bone osteopetrosis is largely reversed, and extensive medullary hematopoiesis appears in the bone marrow. We propose that M-CSF augments monocyte survival, permitting them to respond to internal and external cues for their differentiation.			Lagasse, E (corresponding author), STANFORD UNIV, SCH MED, DEPT PATHOL & DEV BIOL, STANFORD, CA 94305 USA.							BALNER H, 1963, TRANSPLANTATION, V1, P217, DOI 10.1097/00007890-196301020-00009; BUTCHER EC, 1980, J IMMUNOL METHODS, V37, P109, DOI 10.1016/0022-1759(80)90196-9; BYRNE PV, 1981, J CELL BIOL, V91, P848, DOI 10.1083/jcb.91.3.848; CARAYON P, 1992, J IMMUNOL METHODS, V147, P225, DOI 10.1016/S0022-1759(12)80012-3; CECCHINI MG, 1994, DEVELOPMENT, V120, P1357; CHAMBERS TJ, 1993, P NATL ACAD SCI USA, V90, P5578, DOI 10.1073/pnas.90.12.5578; COLIGAN JE, 1991, CURRENT PROTOCOLS IM, P3; CURRY JL, 1967, SCIENCE, V236, P1229; CYSTER JG, 1994, NATURE, V371, P389, DOI 10.1038/371389a0; FAIRBAIRN LJ, 1993, CELL, V74, P823, DOI 10.1016/0092-8674(93)90462-Y; FELIX R, 1990, ENDOCRINOLOGY, V127, P2592, DOI 10.1210/endo-127-5-2592; FERNANDEZSARABIA MJ, 1993, NATURE, V366, P274, DOI 10.1038/366274a0; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; GUILBERT LJ, 1980, J CELL BIOL, V85, P153, DOI 10.1083/jcb.85.1.153; GUTMAN GA, 1973, TRANSPLANTATION, V16, P621, DOI 10.1097/00007890-197312000-00014; HAGENAARS CE, 1989, BONE MINER, V6, P179, DOI 10.1016/0169-6009(89)90049-4; HATTERSLEY G, 1989, J CELL PHYSIOL, V140, P478, DOI 10.1002/jcp.1041400311; HUME DA, 1988, J IMMUNOL, V141, P3405; HUME DA, 1983, J EXP MED, V158, P1522, DOI 10.1084/jem.158.5.1522; IWAI K, 1994, BLOOD, V84, P1201; KODAMA H, 1991, J EXP MED, V173, P269, DOI 10.1084/jem.173.1.269; KOIKE K, 1986, BLOOD, V67, P859; KORN A P, 1973, Experimental Hematology (Charlottesville), V1, P362; Lagasse E, 1996, J IMMUNOL METHODS, V197, P139, DOI 10.1016/0022-1759(96)00138-X; LAGASSE E, 1992, BLOOD, V79, P1907; LAGASSE E, 1994, J EXP MED, V179, P1047, DOI 10.1084/jem.179.3.1047; LEE MY, 1992, BLOOD, V80, P1710; LIESCHKE GJ, 1994, BLOOD, V84, P27; MANGAN DF, 1991, J IMMUNOL, V147, P3408; MARKS SC, 1976, J HERED, V67, P11, DOI 10.1093/oxfordjournals.jhered.a108657; MARKS SC, 1984, CLIN ORTHOP RELAT R, P239; MCARTHUR GA, 1994, BLOOD, V83, P972; METCALF D, 1985, SCIENCE, V229, P16, DOI 10.1126/science.2990035; METCALF D, 1991, SCIENCE, V254, P529, DOI 10.1126/science.1948028; METCALF D, 1970, J CELL PHYSIOL, V76, P89, DOI 10.1002/jcp.1040760113; MUNN DH, 1995, J EXP MED, V181, P127, DOI 10.1084/jem.181.1.127; NAKAHATA T, 1982, J CELL PHYSIOL, V113, P455, DOI 10.1002/jcp.1041130314; Olweus J, 1996, BLOOD, V88, P3741, DOI 10.1182/blood.V88.10.3741.bloodjournal88103741; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.neuro.14.1.453; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Silva M, 1996, BLOOD, V88, P1576, DOI 10.1182/blood.V88.5.1576.1576; SIMINOVITCH L, 1963, J CELL COMPAR PHYSL, V62, P327, DOI 10.1002/jcp.1030620313; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; STANLEY ER, 1983, J CELL BIOCHEM, V21, P151, DOI 10.1002/jcb.240210206; STANLEY ER, 1976, J EXP MED, V143, P631, DOI 10.1084/jem.143.3.631; STANLEY ER, 1977, J BIOL CHEM, V252, P4305; STANLEY ER, 1981, LYMPHOKINES, P102; TILL JE, 1964, P NATL ACAD SCI USA, V51, P29, DOI 10.1073/pnas.51.1.29; TILL JE, 1961, RADIAT RES, V14, P213, DOI 10.2307/3570892; TUSHINSKI RJ, 1982, CELL, V28, P71, DOI 10.1016/0092-8674(82)90376-2; VANFURTH R, 1968, J EXP MED, V128, P415, DOI 10.1084/jem.128.3.415; VANFURTH R, 1988, J IMMUNOL METHODS, V108, P45, DOI 10.1016/0022-1759(88)90401-2; VANFURTH R, 1985, MONONUCLEAR PHAGOCYT, P201; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VEIS DJ, 1993, J IMMUNOL, V151, P2546; VOLKMAN A, 1965, BRIT J EXP PATHOL, V46, P62; WANG HG, 1994, ONCOGENE, V9, P2751; WIKTORJEDRZEJCZAK W, 1991, EXP HEMATOL, V19, P1049; WIKTORJEDRZEJCZAK W, 1990, P NATL ACAD SCI USA, V87, P4828, DOI 10.1073/pnas.87.12.4828; WIKTORJEDRZEJCZAK W, 1982, J EXP MED, V156, P1516, DOI 10.1084/jem.156.5.1516; WIKTORJEDRZEJCZAK W, 1994, ENDOCRINOLOGY, V134, P1932, DOI 10.1210/en.134.4.1932; WU AM, 1967, J CELL PHYSIOL, V69, P177, DOI 10.1002/jcp.1040690208; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0	64	250	256	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 27	1997	89	7					1021	1031		10.1016/S0092-8674(00)80290-1	http://dx.doi.org/10.1016/S0092-8674(00)80290-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XG830	9215625	Bronze			2022-12-01	WOS:A1997XG83000007
J	Sikorski, R; Peters, R				Sikorski, R; Peters, R			A cell growth switch	SCIENCE			English	Article																		Blau CA, 1997, P NATL ACAD SCI USA, V94, P3076, DOI 10.1073/pnas.94.7.3076	1	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 20	1997	276	5320					1891	1891		10.1126/science.276.5320.1891	http://dx.doi.org/10.1126/science.276.5320.1891			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XF103	9206844				2022-12-01	WOS:A1997XF10300058
J	Gosser, YQ; Nomanbhoy, TK; Aghazadeh, B; Manor, D; Combs, C; Cerione, RA; Rosen, MK				Gosser, YQ; Nomanbhoy, TK; Aghazadeh, B; Manor, D; Combs, C; Cerione, RA; Rosen, MK			C-terminal binding domain of rho GDP-dissociation inhibitor directs N-terminal inhibitory peptide to GTPases	NATURE			English	Article							NUCLEAR-MAGNETIC-RESONANCE; REGULATORY PROTEIN; GTP; SPECTROSCOPY; ASSIGNMENTS; AFFINITIES; MEMBRANES; P20	The Rho GDP-dissociation inhibitors (GDIs) negatively regulate Rho-family GTPases(1,2). The inhibitory activity of GDI derives both from an ability to bind the carboxy-terminal isoprene of Rho family members and extract them from membranes(3,4), and from inhibition of GTPase cycling between the GTP- and GDP-bound states(4,5). Here we demonstrate that these binding and inhibitory functions of rhoGDI can be attributed to two structurally distinct regions of the protein, A carboxy-terminal folded domain of relative molecular mass 16,000 (M-r 16K) binds strongly to the Rho-family member Cdc42, yet has little effect on the rate of nucleotide dissociation from the GTPase. The solution structure of this domain shows a beta-sandwich motif with a narrow hydrophobic cleft that binds isoprenes, and an exposed surface that interacts with the protein portion of Cdc42. The amino-terminal region of rhoGDI is unstructured in the absence of target and contributes little to binding, but is necessary to inhibit nucleotide dissociation from Cdc42. These results lead to a model of rhoGDI function in which the carboxy-terminal binding domain targets the amino-terminal inhibitory region to GTPases, resulting in membrane extraction and inhibition of nucleotide cycling.	MEM SLOAN KETTERING CANC CTR,CELLULAR BIOCHEM & BIOPHYS PROGRAM,NEW YORK,NY 10021; CORNELL UNIV,DEPT BIOCHEM MOL & CELL BIOL,ITHACA,NY 14853; CORNELL UNIV,DEPT PHARMACOL,ITHACA,NY 14853; CORNELL UNIV,GRAD SCH MED SCI,GRAD PROGRAM PHYSIOL & BIOPHYS,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Cornell University; Cornell University; Cornell University								ALCMAN G, 1996, J BIOL CHEM, V271, P30366; BOKOCH GM, 1993, FASEB J, V7, P750, DOI 10.1096/fasebj.7.9.8330683; BRUNGER AT, 1993, XPLOR MANUAL; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CLORE GM, 1994, METHOD ENZYMOL, V239, P349; Danley DE, 1996, J IMMUNOL, V157, P500; EDISON AS, 1994, METHOD ENZYMOL, V239, P3; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; GHOMASHCHI F, 1995, BIOCHEMISTRY-US, V34, P11910, DOI 10.1021/bi00037a032; HANCOCK JF, 1993, EMBO J, V12, P1915, DOI 10.1002/j.1460-2075.1993.tb05840.x; HOFFMANN RW, 1989, CHEM REV, V89, P1841, DOI 10.1021/cr00098a009; ISOMURA M, 1991, ONCOGENE, V6, P119; KAY LE, 1995, CURR OPIN STRUC BIOL, V5, P674, DOI 10.1016/0959-440X(95)80061-1; KUBONIWA H, 1994, J BIOMOL NMR, V4, P871, DOI 10.1007/BF00398416; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LEONARD DA, 1994, BIOCHEMISTRY-US, V33, P12323, DOI 10.1021/bi00206a040; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; NERI D, 1989, BIOCHEMISTRY-US, V28, P7510, DOI 10.1021/bi00445a003; NICHOLS A, 1990, PROTEIN-STRUCT FUNCT, V11, P281; NILGES M, 1990, BIOPOLYMERS, V29, P813, DOI 10.1002/bip.360290415; Nomanbhoy TK, 1996, J BIOL CHEM, V271, P10004, DOI 10.1074/jbc.271.17.10004; PHILIPS MR, 1993, SCIENCE, V259, P977, DOI 10.1126/science.8438158; PLATKO JV, 1995, P NATL ACAD SCI USA, V92, P2974, DOI 10.1073/pnas.92.7.2974; Schalk I, 1996, NATURE, V381, P42, DOI 10.1038/381042a0; SILVIUS JR, 1994, BIOCHEMISTRY-US, V33, P3014, DOI 10.1021/bi00176a034; SPERA S, 1991, J AM CHEM SOC, V117, P5491; STORCH J, 1993, MOL CELL BIOCHEM, V123, P45, DOI 10.1007/BF01076474; UEDA T, 1990, J BIOL CHEM, V265, P9373; WIBERG KB, 1988, J AM CHEM SOC, V110, P8029, DOI 10.1021/ja00232a012; WU JE, IN PRESS J BIOL CHEM	30	146	152	1	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 19	1997	387	6635					814	819		10.1038/42961	http://dx.doi.org/10.1038/42961			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XF144	9194563	Bronze			2022-12-01	WOS:A1997XF14400053
J	BujBello, A; Adu, J; Pinon, LGP; Horton, A; Thompson, J; Rosenthal, A; Chinchetru, M; Buchman, VL; Davies, AM				BujBello, A; Adu, J; Pinon, LGP; Horton, A; Thompson, J; Rosenthal, A; Chinchetru, M; Buchman, VL; Davies, AM			Neurturin responsiveness requires a GPI-linked receptor and the Ret receptor tyrosine kinase	NATURE			English	Article							NEUROTROPHIC FACTOR; SURVIVAL FACTOR; NEURONS; GDNF; PROTEIN; TRKB; CD14	Neurturin (NTN)(1) is a recently identified homologue of glial-cellline-derived neurotrophic factor (GDNF)(2). Both factors promote the survival of a variety of neurons(1-5), and GDNF is required for the development of the enteric nervous system and kidney(6-8). GDNF signals through a receptor complex consisting of the receptor tyrosine kinase Ret and a glycosyl-phosphatidylinositol (GPI)-linked receptor termed GDNFR-alpha(9-13). Here we report the cloning of a new GPI-linked receptor termed NTNR-alpha that is homologous with GDNFR-alpha and is widely expressed in the nervous system and other tissues. By using microinjection to introduce expression plasmids into neurons, we show that coexpression of NTNR-alpha with Ret confers a survival response to neurturin but not GDNF, and that coexpression of GDNFR-alpha with Ret confers a survival response to GDNF but not neurturin. Our findings indicate that GDNF and neurturin promote neuronal survival by signalling through similar multicomponent receptors that consist of a common receptor tyrosine kinase and a member of a GPI-linked family of receptors that determines ligand specificity.	UNIV ST ANDREWS,SCH BIOL & MED SCI,ST ANDREWS KY16 9AT,FIFE,SCOTLAND; GENENTECH INC,DEPT NEUROSCI,S SAN FRANCISCO,CA 94080	University of St Andrews; Roche Holding; Genentech			Buchman, Vladimir L/A-4814-2010; Davies, Alun M/A-4334-2010; Adu, Jimi/R-8434-2019; BUJ-BELLO, Anna/J-7556-2013	Buchman, Vladimir L/0000-0002-7631-8352; Davies, Alun M/0000-0001-5841-8176; Adu, Jimi/0000-0002-7838-9699; Chinchetru, Miguel Angel/0000-0002-0559-7403	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLSOPP TE, 1993, CELL, V73, P295, DOI 10.1016/0092-8674(93)90230-N; Baka ID, 1996, MOL CELL NEUROSCI, V7, P289, DOI 10.1006/mcne.1996.0022; BUJBELLO A, 1994, DEVELOPMENT, V120, P1573; BUJBELLO A, 1995, NEURON, V15, P821, DOI 10.1016/0896-6273(95)90173-6; DAVIES AM, 1995, EMBO J, V14, P4482, DOI 10.1002/j.1460-2075.1995.tb00127.x; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; GERBER LD, 1992, J BIOL CHEM, V267, P12168; HENDERSON CE, 1994, SCIENCE, V266, P1062, DOI 10.1126/science.7973664; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; Klein RD, 1997, NATURE, V387, P717, DOI 10.1038/42722; Koke J A, 1991, Protein Expr Purif, V2, P51, DOI 10.1016/1046-5928(91)90009-8; Kotzbauer PT, 1996, NATURE, V384, P467, DOI 10.1038/384467a0; LEE JD, 1993, P NATL ACAD SCI USA, V90, P9930, DOI 10.1073/pnas.90.21.9930; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; Ninkina N, 1996, EMBO J, V15, P6385, DOI 10.1002/j.1460-2075.1996.tb01029.x; Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0; PUGIN J, 1993, P NATL ACAD SCI USA, V90, P2744, DOI 10.1073/pnas.90.7.2744; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; TRUPP M, 1995, J CELL BIOL, V130, P137, DOI 10.1083/jcb.130.1.137; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; Vega QC, 1996, P NATL ACAD SCI USA, V93, P10657, DOI 10.1073/pnas.93.20.10657	25	249	262	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 12	1997	387	6634					721	724		10.1038/42729	http://dx.doi.org/10.1038/42729			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XD869	9192899	Bronze			2022-12-01	WOS:A1997XD86900058
J	Breslin, PAS; Beauchamp, GK				Breslin, PAS; Beauchamp, GK			Salt enhances flavour by suppressing bitterness	NATURE			English	Letter							SODIUM-CHLORIDE; MIXTURES				Breslin, PAS (corresponding author), MONELL CHEM SENSES CTR, 3500 MARKET ST, PHILADELPHIA, PA 19104 USA.			Breslin, Paul/0000-0001-5988-8401				BRAND JG, 1992, IFT BAS SYM, V7, P517; Breslin PAS, 1996, TRENDS FOOD SCI TECH, V7, P390, DOI 10.1016/S0924-2244(96)10039-X; Breslin PAS, 1995, CHEM SENSES, V20, P609, DOI 10.1093/chemse/20.6.609; DEGRAAF C, 1989, CHEM SENSES, V14, P81; Denton D.A., 1982, HUNGER SALT; FORSYTHE RH, 1980, BIOL BEHAVIORAL ASPE, P221; GILLETTE M, 1985, FOOD TECHNOL-CHICAGO, V39, P47; KEMP SE, 1994, J FOOD SCI, V59, P682, DOI 10.1111/j.1365-2621.1994.tb05592.x; LAWLESS HT, 1979, J COMP PHYSIOL PSYCH, V93, P538, DOI 10.1037/h0077582; Michell A R, 1989, Nutr Res Rev, V2, P149, DOI 10.1079/NRR19890012; WOSKOW MH, 1969, FOOD TECHNOL-CHICAGO, V23, P1364	11	158	163	3	55	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 5	1997	387	6633					563	563		10.1038/42388	http://dx.doi.org/10.1038/42388			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XC522	9177340				2022-12-01	WOS:A1997XC52200035
J	Cheng, AC; vanHoek, AN; Yeager, M; Verkman, AS; Mitra, AK				Cheng, AC; vanHoek, AN; Yeager, M; Verkman, AS; Mitra, AK			Three-dimensional organization of a human water channel	NATURE			English	Article							ELECTRON CRYSTALLOGRAPHY; AQUAPORIN CHIP; PROTEIN; RESOLUTION; MEMBRANE; PROJECTION; MODEL; RECONSTITUTION; CRYOMICROSCOPY; PURIFICATION	Aquaporins (AQP) are members of the major intrinsic protein (MIP) superfamily of integral membrane proteins and facilitate water transport in various eukaryotes and prokaryotes(1,2). The archetypal aquaporin AQP1 is a partly glycosylated water-selective channel(3,4) that is widely expressed in the plasma membranes of several water-permeable epithelial and endothelial cells(2,5). Here we report the three-dimensional structure of deglycosylated, human erythrocyte AQP1,determined at 7 Angstrom resolution in the membrane plane by electron crystallography of frozen-hydrated two-dimensional crystals(6,7). The structure has an inplane, intramolecular 2-fold axis of symmetry located in the hydrophobic core of the bilayer. The AQP1 monomer is composed of six membrane-spanning, tilted alpha-helices. These helices form a barrel that encloses a vestibular region leading to the water-selective channel, which is outlined by densities attributed to the functionally important NPA boxes(8) and their bridges to the surrounding helices. The intramolecular symmetry within the AQP1 molecule represents a new moth for the topology and design of membrane protein channels, and is a simple and elegant solution to the problem of bidirectional transport across the bilayer.	Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA USA; UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, SAN FRANCISCO, CA USA; SCRIPPS CLIN, DIV CARDIOVASC DIS, LA JOLLA, CA 92037 USA	Scripps Research Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Scripps Research Institute			Mitra, Alok/P-7800-2016	Mitra, Alok/0000-0003-0891-5697; Van Hoek, Alfred/0000-0003-2724-6855				AGARD DA, 1983, J MOL BIOL, V167, P849, DOI 10.1016/S0022-2836(83)80114-4; AGRE P, 1995, CURR OPIN CELL BIOL, V7, P472, DOI 10.1016/0955-0674(95)80003-4; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; CHOTHIA C, 1981, J MOL BIOL, V145, P215, DOI 10.1016/0022-2836(81)90341-7; DENKER BM, 1988, J BIOL CHEM, V263, P15634; GORIN MB, 1984, CELL, V39, P49, DOI 10.1016/0092-8674(84)90190-9; Grigorieff N, 1996, J MOL BIOL, V259, P393, DOI 10.1006/jmbi.1996.0328; HENDERSON R, 1990, J MOL BIOL, V213, P899, DOI 10.1016/S0022-2836(05)80271-2; HENDERSON R, 1975, NATURE, V257, P28, DOI 10.1038/257028a0; JAP BK, 1995, J MOL BIOL, V251, P413, DOI 10.1006/jmbi.1995.0444; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JUNG JS, 1994, J BIOL CHEM, V269, P14648; KUHLBRANDT W, 1991, NATURE, V350, P130, DOI 10.1038/350130a0; MITRA AK, 1995, NAT STRUCT BIOL, V2, P726, DOI 10.1038/nsb0995-726; MITRA AK, 1994, BIOCHEMISTRY-US, V33, P12735, DOI 10.1021/bi00209a001; Park JH, 1996, J MEMBRANE BIOL, V153, P171, DOI 10.1007/s002329900120; PRESTON GM, 1994, J BIOL CHEM, V269, P1668; Sather William A., 1994, Current Opinion in Neurobiology, V4, P313, DOI 10.1016/0959-4388(94)90091-4; SMITH BL, 1991, J BIOL CHEM, V266, P6407; UNGER VM, 1995, BIOPHYS J, V68, P1776, DOI 10.1016/S0006-3495(95)80354-1; UPSON C, 1989, IEEE COMPUT GRAPH, V9, P30, DOI 10.1109/38.31462; VANHOEK AN, 1995, BIOCHEMISTRY-US, V34, P2212, DOI 10.1021/bi00007a015; VANHOEK AN, 1992, J BIOL CHEM, V267, P18267; Verkman AS, 1996, AM J PHYSIOL-CELL PH, V270, pC12, DOI 10.1152/ajpcell.1996.270.1.C12; Verkman AS, 1993, WATER CHANNELS; WALZ T, 1995, NAT STRUCT BIOL, V2, P730, DOI 10.1038/nsb0995-730; Walz T, 1996, J MOL BIOL, V264, P907, DOI 10.1006/jmbi.1996.0686; WISTOW GJ, 1991, TRENDS BIOCHEM SCI, V16, P170, DOI 10.1016/0968-0004(91)90065-4; ZEIDEL ML, 1992, BIOCHEMISTRY-US, V31, P7436, DOI 10.1021/bi00148a002	29	236	249	1	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 5	1997	387	6633					627	630		10.1038/42517	http://dx.doi.org/10.1038/42517			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XC522	9177354				2022-12-01	WOS:A1997XC52200062
J	Sechi, LA; Kronenberg, F; DeCarli, S; Falleti, E; Zingaro, L; Catena, C; Utermann, G; Bartoli, E				Sechi, LA; Kronenberg, F; DeCarli, S; Falleti, E; Zingaro, L; Catena, C; Utermann, G; Bartoli, E			Association of serum lipoprotein(a) levels and apolipoprotein(a) size polymorphism with target-organ damage in arterial hypertension	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	11th Meeting of the American-Society-of-Hypertension	MAY 15-18, 1996	NEW YORK, NY	Amer Soc Hypertens			CORONARY HEART-DISEASE; BLOOD-PRESSURE; DENSITY LIPOPROTEIN; PLASMA-LIPIDS; RISK FACTOR; ATHEROSCLEROSIS; QUANTITATION; PHENOTYPES; LP(A); RECOMMENDATIONS	Objective.-To investigate the association between lipoprotein(a) [Lp(a)] and other plasma lipids and apolipoproteins and target-organ damage (TOD) in patients with arteria[ hypertension. Design.-Cross-sectional study of a case series. Setting.-University medical center. Participants.-Lipoprotein(a) and apolipoproteins were analyzed in 277 untreated patients with mild to moderate essential hypertension and in 102 healthy controls. Apolipoprotein(a) [apo(a)] phenotypes were additionally analyzed in an independent sample set of 106 hypertensive and 105 control subjects. Main Outcome Measures.-Staging of TOD obtained according to World Health Organization guidelines by clinical evaluation, and laboratory tests including measurments of creatinine clearance, proteinuria, ophthalmoscopy, electrocardiography, echocardiography, and ultrasound examination of major arteries; levels of lipids, apolipoproteins, Lp(a), fibrinogen, and apo(a) phenotypes. Results.-Blood pressure, duration of hypertension, and levels of total cholesterol, low-density lipoprotein cholesterol, apolipoprotein B, Lp(a), and fibrinogen were significantly related to the presence and severity of TOD in univariate analysis. Stepwise multivariate analysis showed Lp(a) levels (P<.001) to be the best discriminator of the presence of TOD, followed by systolic blood pressure (P<.001), duration of hypertension (P=.01), and low-density lipoprotein cholesterol (P=.04). The Lp(a) levels were related to TOD independent of the level of blood pressure. We confirmed this association between Lp(a) concentrations and severity of TOD in a second independent sample set and observed a significantly higher frequency of low-molecular-weight apo(a) isoforms with increasing severity of TOD (P=.02). Conclusions.-Lipoprotein(a) and apo(a) phenotype are sensitive indicators of the severity of TOD in patients with essential hypertension, and their evaluation might permit identification of hypertensive subjects liable to the development of organ damage. The higher frequency of low-molecular-weight apo(a) isoforms in patients with TOD demonstrates a genetically determined risk for the development of TOD in hypertensive patients.	UNIV UDINE, HYPERTENS UNIT, DEPT INTERNAL MED, I-33100 UDINE, ITALY; UNIV UDINE, DEPT LAB MED, I-33100 UDINE, ITALY; UNIV INNSBRUCK, INST MED BIOL & HUMAN GENET, A-6020 INNSBRUCK, AUSTRIA	University of Udine; University of Udine; University of Innsbruck			Kronenberg, Florian/B-1736-2008; Sechi, Leonardo Antonio/Y-3109-2018	Kronenberg, Florian/0000-0003-2229-1120; Catena, Cristiana/0000-0001-5039-435X				BERG K, 1963, ACTA PATHOL MIC SC, V59, P369; BOERWINKLE E, 1992, J CLIN INVEST, V90, P52, DOI 10.1172/JCI115855; Bostom AG, 1996, JAMA-J AM MED ASSOC, V276, P544, DOI 10.1001/jama.276.7.544; BRUNNER C, 1993, P NATL ACAD SCI USA, V90, P11643, DOI 10.1073/pnas.90.24.11643; CASALE PN, 1986, ANN INTERN MED, V105, P173, DOI 10.7326/0003-4819-105-2-173; CUSHING GL, 1989, ARTERIOSCLEROSIS, V9, P593, DOI 10.1161/01.ATV.9.5.593; DAHLEN GH, 1986, CIRCULATION, V74, P758, DOI 10.1161/01.CIR.74.4.758; DEVEREUX RB, 1986, AM J CARDIOL, V57, P450, DOI 10.1016/0002-9149(86)90771-X; DIEKSTALL F, 1987, OPHTHALMOLOGIE, V84, P369; FLESCH M, 1994, CLIN INVESTIGATOR, V72, P944, DOI 10.1007/BF00577733; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GALLE J, 1995, CIRCULATION, V92, P1582, DOI 10.1161/01.CIR.92.6.1582; GRAINGER DJ, 1994, NATURE, V370, P460, DOI 10.1038/370460a0; GRAINGER DJ, 1993, SCIENCE, V260, P1655, DOI 10.1126/science.8503012; HAJJAR KA, 1989, NATURE, V339, P303, DOI 10.1038/339303a0; JAUHIAINEN M, 1991, ATHEROSCLEROSIS, V89, P59, DOI 10.1016/0021-9150(91)90007-P; KANNEL WB, 1990, HYPERTENSION PATHOPH, P101; KOSCHINSKY ML, 1993, J BIOL CHEM, V268, P19819; KRAFT HG, 1989, J CLIN INVEST, V83, P137, DOI 10.1172/JCI113849; KRAFT HG, 1992, HUM GENET, V90, P220; Kraft HG, 1996, ATHEROSCLEROSIS, V125, P53, DOI 10.1016/0021-9150(96)05844-3; KREMPLER F, 1980, J CLIN INVEST, V65, P1483, DOI 10.1172/JCI109813; Kronenberg F, 1996, CRIT REV CL LAB SCI, V33, P495, DOI 10.3109/10408369609080056; Kronenberg F, 1996, AM J KIDNEY DIS, V27, P1, DOI 10.1016/S0272-6386(96)90026-8; KRONENBERG F, 1995, J AM SOC NEPHROL, V6, P110; LEHMANN EL, 1975, NONPARAMETRICS; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MAIOLI M, 1993, DIABETOLOGIA, V36, P88, DOI 10.1007/BF00399100; MILES LA, 1989, NATURE, V339, P301, DOI 10.1038/339301a0; MOLGAARD J, 1992, ARTERIOSCLER THROMB, V12, P895, DOI 10.1161/01.ATV.12.8.895; PETRIE JC, 1986, BRIT MED J, V293, P611, DOI 10.1136/bmj.293.6547.611; RADER DJ, 1994, J CLIN INVEST, V93, P2758, DOI 10.1172/JCI117292; RADER DJ, 1994, ANN INTERN MED, V120, P1012, DOI 10.7326/0003-4819-120-12-199406150-00008; RATH M, 1989, ARTERIOSCLEROSIS, V9, P579, DOI 10.1161/01.ATV.9.5.579; RIDKER PM, 1993, JAMA-J AM MED ASSOC, V270, P2195, DOI 10.1001/jama.270.18.2195; ROSSI E, 1988, THROMB RES, V52, P453, DOI 10.1016/0049-3848(88)90029-1; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; SALONEN R, 1988, ARTERIOSCLEROSIS, V8, P788, DOI 10.1161/01.ATV.8.6.788; SANDHOLZER C, 1992, ARTERIOSCLER THROMB, V12, P1214, DOI 10.1161/01.ATV.12.10.1214; SCANU AM, 1990, J CLIN INVEST, V85, P1709, DOI 10.1172/JCI114625; SCHEIE HG, 1953, AMA ARCH OPHTHALMOL, V49, P117; SCHREINER PJ, 1993, ARTERIOSCLER THROMB, V13, P826, DOI 10.1161/01.ATV.13.6.826; SECHI LA, 1992, METABOLISM, V41, P1261, DOI 10.1016/0026-0495(92)90019-7; SHINTANI S, 1993, STROKE, V24, P965, DOI 10.1161/01.STR.24.7.965; STEINMETZ A, 1993, CLIN INVESTIGATOR, V71, P145; TSURUMI Y, 1995, J AM COLL CARDIOL, V26, P1242, DOI 10.1016/0735-1097(95)00321-5; UTERMANN G, 1989, SCIENCE, V246, P904, DOI 10.1126/science.2530631; UTERMANN G, 1987, J CLIN INVEST, V80, P458, DOI 10.1172/JCI113093; ZANCHETTI A, 1993, HYPERTENSION, V22, P392; ZENKER G, 1986, STROKE, V17, P942, DOI 10.1161/01.STR.17.5.942	50	58	59	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 4	1997	277	21					1689	1695		10.1001/jama.277.21.1689	http://dx.doi.org/10.1001/jama.277.21.1689			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	XB088	9169895				2022-12-01	WOS:A1997XB08800029
J	Chang, H; Riese, DJ; Gilbert, W; Stern, DF; McMahan, UJ				Chang, H; Riese, DJ; Gilbert, W; Stern, DF; McMahan, UJ			Ligands for ErbB-family receptors encoded by a neuregulin-like gene	NATURE			English	Article							EPIDERMAL GROWTH-FACTOR; CARDIAC DEVELOPMENT; HEREGULIN; ACTIVATION; MEMBER; ARIA; HER4/P180(ERBB4); REQUIREMENT; EXPRESSION; SUBSET	Neuregulins (also called ARIA(1), GGF(2), heregulin(3) or NDF4) are a group of polypeptide factors that arise from alternative RNA splicing of a single gene. Through their interaction with the ErbB family of receptors (ErbB2, ErbB3 and ErbB4), neuregulins help to regulate cell growth and differentiation in many tissue(5-7). Here we report the cloning of a second neuregulin-like gene, neuregulin-2. The encoded product of the neuregulin-2 gene has a motif structure similar to that of neuregulins and an alternative splicing site in the epidermal growth factor(EGF)-like domain gives rise to two isoforms (alpha and beta). Northern blot and in situ hybridization analysis of adult rat tissues indicate that expression of neuregulin-2 is highest in the cerebellum, and the expression pattern is different from that of neuregulins. Recombinant neuregulin-2 beta induces the tyrosine-phosphorylation of ErbB2, ErbB3 and ErbB4 in cell Lines expressing all of these ErbB-family receptors. However, in cell lines with defined combinations of ErbBs, neuregulin-2 beta only activates those with ErbB3 and/or ErbB4, suggesting that signalling by neuregulin-2 is mediated by ErbB3 and/or ErbB4 receptors.	YALE UNIV,DEPT BIOL,NEW HAVEN,CT 06340; YALE UNIV,DEPT PATHOL,NEW HAVEN,CT 06340; HARVARD UNIV,DEPT MOL & CELLULAR BIOL,CAMBRIDGE,MA 02138	Yale University; Yale University; Harvard University	Chang, H (corresponding author), STANFORD UNIV,SCH MED,DEPT NEUROBIOL,STANFORD,CA 94305, USA.		Riese, David/AAF-3581-2020	Riese, David/0000-0002-8823-5802				BARBACCI EG, 1995, J BIOL CHEM, V270, P9585, DOI 10.1074/jbc.270.16.9585; BEERLI RR, 1995, MOL CELL BIOL, V15, P6496; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CARRAWAY KL, 1995, CURR OPIN NEUROBIOL, V5, P606, DOI 10.1016/0959-4388(95)80065-4; Chang H., 1994, Society for Neuroscience Abstracts, V20, P1694; CORFAS G, 1995, NEURON, V14, P103, DOI 10.1016/0896-6273(95)90244-9; DIGIOVANNA MP, 1995, CANCER RES, V55, P1946; DOBASHI Y, 1991, ONCOGENE, V6, P1151; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; LEMKE G, 1993, NATURE, V362, P291, DOI 10.1038/362291a0; MARCHIONNI MA, 1995, NATURE, V378, P334, DOI 10.1038/378334a0; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Riese DJ, 1996, ONCOGENE, V12, P345; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121	29	255	298	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 29	1997	387	6632					509	512		10.1038/387509a0	http://dx.doi.org/10.1038/387509a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XB479	9168114				2022-12-01	WOS:A1997XB47900050
J	Lang, BF; Burger, G; OKelly, CJ; Cedergren, R; Golding, GB; Lemieux, C; Sankoff, D; Turmel, M; Gray, MW				Lang, BF; Burger, G; OKelly, CJ; Cedergren, R; Golding, GB; Lemieux, C; Sankoff, D; Turmel, M; Gray, MW			An ancestral mitochondrial DNA resembling a eubacterial genome in miniature	NATURE			English	Article							COMPLETE SEQUENCE; ENDOSYMBIONT HYPOTHESIS; GENE CONTENT; ORGANIZATION; RECLINOMONAS; EUKARYOTES; EVOLUTION	Mitochondria, organelles specialized in energy conservation reactions in eukaryotic cells, have evolved from eubacteria-like endosymbionts(1-3) whose closest known relatives are the rickettsial group of alpha-proteobacteria(4,5). Because characterized mitochondrial genomes vary markedly in structure(3), it has been impossible to infer from them the initial form of the proto-mitochondrial genome. This would require the identification of minimally derived mitochondrial DNAs that better reflect the ancestral state, Here we describe such a primitive mitochondrial genome, in the freshwater protozoon Reclinomonas americana(6). This protist displays ultrastructural characteristics that ally it with the retortamonads(7,8), a protozoan group that lacks mitochondria(8,9). R. americana mtDNA (69,034 base pairs) contains the largest collection of genes (97) so far identified in any mtDNA, including genes for 5S ribosomal RNA, the RNA component of RNase P, and at least 18 proteins not previously known to be encoded in mitochondria, Most surprising are four genes specifying a multisubunit, eubacterial-type RNA polymerase. Features of gene content together with eubacterial characteristics of genome organization and expression not found before in mitochondrial genomes indicate that R. americana mtDNA more closely resembles the ancestral proto-mitochondrial genome than any other mtDNA investigated to date.	DALHOUSIE UNIV,DEPT BIOCHEM,HALIFAX,NS B3H 4H7,CANADA; UNIV MONTREAL,DEPT BIOCHIM,MONTREAL,PQ H3C 3J7,CANADA; UNIV MONTREAL,CTR RECH MATH,MONTREAL,PQ H3C 3J7,CANADA; BIGELOW LAB OCEAN SCI,BOOTHBAY HARBOR,ME 04575; MCMASTER UNIV,DEPT BIOL,HAMILTON,ON L8S 4K1,CANADA; UNIV LAVAL,DEPT BIOCHIM,QUEBEC CITY,PQ G1K 7P4,CANADA; DALHOUSIE UNIV,DEPT BIOCHEM,HALIFAX,NS B3H 4H7,CANADA	Dalhousie University; Universite de Montreal; Universite de Montreal; Bigelow Laboratory for Ocean Sciences; McMaster University; Laval University; Dalhousie University			Lemieux, Claude/L-8831-2015; Turmel, Monique/AAC-9752-2020	Lemieux, Claude/0000-0001-9580-8042; Turmel, Monique/0000-0001-7060-035X; Gray, Michael/0000-0001-7125-2625				BOGORAD L, 1991, MOL BIOL PLASTIDS, P93; Brugerolle G., 1990, P259; Burger G, 1996, P NATL ACAD SCI USA, V93, P2328, DOI 10.1073/pnas.93.6.2328; BURGER G, 1995, J MOL BIOL, V245, P522, DOI 10.1006/jmbi.1994.0043; CAVALIERSMITH T, 1987, NATURE, V326, P332, DOI 10.1038/326332a0; Cermakian N, 1996, NUCLEIC ACIDS RES, V24, P648, DOI 10.1093/nar/24.4.648; Chen B, 1996, J BIOL CHEM, V271, P6537, DOI 10.1074/jbc.271.11.6537; DARR SC, 1992, TRENDS BIOCHEM SCI, V17, P178, DOI 10.1016/0968-0004(92)90262-8; FLAVIN M, 1993, J EUKARYOT MICROBIOL, V40, P172, DOI 10.1111/j.1550-7408.1993.tb04900.x; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; Glick BS, 1996, PROTEIN SCI, V5, P2651, DOI 10.1002/pro.5560051229; GRAY MW, 1982, MICROBIOL REV, V46, P1; GRAY MW, 1993, CURR OPIN GENET DEV, V3, P884, DOI 10.1016/0959-437X(93)90009-E; GRAY MW, 1992, INT REV CYTOL, V141, P233, DOI 10.1016/S0074-7696(08)62068-9; GRAY MW, 1996, EVOLUTION MICROBIAL, P00109; GRAY MW, 1995, MOL BIOL PLANT MITOC, P635; ITO K, 1995, ADV CELL MOL BIOL M, V4, P35; Lang BF, 1996, J MOL BIOL, V261, P607, DOI 10.1006/jmbi.1996.0486; Lee YC, 1996, EUR J BIOCHEM, V235, P297, DOI 10.1111/j.1432-1033.1996.00297.x; Margulis L, 1970, ORIGIN EUKARYOTIC CE; MASTERS BS, 1987, CELL, V51, P89, DOI 10.1016/0092-8674(87)90013-4; ODA K, 1992, J MOL BIOL, V223, P1, DOI 10.1016/0022-2836(92)90708-R; OKELLY CJ, 1993, J EUKARYOT MICROBIOL, V40, P627, DOI 10.1111/j.1550-7408.1993.tb06120.x; REITH M, 1995, ANNU REV PLANT PHYS, V46, P549, DOI 10.1146/annurev.arplant.46.1.549; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; Siegel RW, 1996, RNA, V2, P452; WISE CA, 1991, J BIOL CHEM, V266, P19154; WOLFF G, 1994, J MOL BIOL, V237, P75, DOI 10.1006/jmbi.1994.1210; YANG D, 1985, P NATL ACAD SCI USA, V82, P4443, DOI 10.1073/pnas.82.13.4443	30	470	506	1	44	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 29	1997	387	6632					493	497		10.1038/387493a0	http://dx.doi.org/10.1038/387493a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XB479	9168110				2022-12-01	WOS:A1997XB47900046
J	Freedman, DM; Zahm, SH; Dosemeci, M				Freedman, DM; Zahm, SH; Dosemeci, M			Residential and occupational exposure to sunlight and mortality from non-Hodgkin's lymphoma: Composite (threefold) case-control study	BRITISH MEDICAL JOURNAL			English	Article							WESTERN-CANADA-MELANOMA; MALIGNANT-MELANOMA; SUN EXPOSURE; SKIN-CANCER; SOCIOECONOMIC-STATUS; CUTANEOUS MELANOMA; UNITED-STATES; RISK-FACTORS	Objective: To determine whether non-Hodgkin's lymphoma mortality is associated with sunlight exposure. Design: Three case-control studies based on death certificates of non-Hodgkin's lymphoma, melanoma, and skin cancer mortality examining associations with potential sunlight exposure from residence and occupation. Setting: 24 states in the United States. Subjects: All cases were deaths from non-Hodgkin's lymphoma, melanoma, and non-melanotic skin cancer between 1984 and 1991. Two age, sex, and race frequency matched controls per case were selected from non-cancer deaths. Main outcome measures: Odds ratios for non-Hodgkin's lymphoma, melanoma, and skin cancer from residential and occupational sunlight exposure adjusted for age, sex, race, socioeconomic status, and farming occupation. Results: Non-Hodgkin's lymphoma mortality was not positively associated with sunlight exposure based on residence. Both melanoma and skin cancer were positively associated with residential sunlight exposure. Adjusted odds ratios for residing in states with the highest sunlight exposure were 0.83 (95% confidence interval 0.81 to 0.86) for non-Hodgkin's lymphoma, 1.12 (1.06 to 1.19) for melanoma, and 1.30 (1.18 to 1.43) for skin cancer. In addition, non-Hodgkin's lymphoma mortality was not positively associated with occupational sunlight exposure (odds ratio 0.88; 0.81 to 0.96). Skin cancer was slightly positively associated with occupational sunlight exposure (1.14; 0.96 to 1.36). Conclusions: Unlike skin cancer and to some extent melanoma, non-Hodgkin's lymphoma mortality was not positively associated with exposure to sunlight The findings do not therefore support the hypothesis that sunlight exposure contributes to the rising rates of non-Hodgkin's lymphoma.	NCI,DIV CANC EPIDEMIOL & GENET,ROCKVILLE,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Freedman, DM (corresponding author), NCI,DIV CANC PREVENT & CONTROL,EPN-240J,ROCKVILLE,MD 20892, USA.		Zahm, Shelia H/B-5025-2015					ADAMI J, 1995, BRIT MED J, V310, P1491, DOI 10.1136/bmj.310.6993.1491; ADAMI J, 1995, BMJ-BRIT MED J, V311, P750, DOI 10.1136/bmj.311.7007.750b; Bentham G, 1996, BRIT MED J, V312, P1128; CARTWRIGHT R, 1994, LEUKEMIA LYMPHOMA, V14, P387, DOI 10.3109/10428199409049694; *CDC, 1994, MMWR-MORBID MORTAL W, V43, P4; DEVESA SS, 1992, CANCER RES, V52, pS5432; DUBIN N, 1990, INT J EPIDEMIOL, V19, P811, DOI 10.1093/ije/19.4.811; ELWOOD JM, 1990, INT J EPIDEMIOL, V19, P801, DOI 10.1093/ije/19.4.801; ELWOOD JM, 1984, BRIT MED J, V288, P99, DOI 10.1136/bmj.288.6411.99; ELWOOD JM, 1985, INT J CANCER, V35, P427, DOI 10.1002/ijc.2910350403; FIGGS LW, 1995, AM J IND MED, V27, P817, DOI 10.1002/ajim.4700270606; GARLAND CF, 1980, INT J EPIDEMIOL, V9, P227, DOI 10.1093/ije/9.3.227; GLASS AG, 1989, JAMA-J AM MED ASSOC, V262, P2097, DOI 10.1001/jama.262.15.2097; GOODMAN KJ, 1995, CANCER CAUSE CONTROL, V6, P451, DOI 10.1007/BF00052186; GREEN LW, 1970, PUBLIC HEALTH REP, V85, P815, DOI 10.2307/4593972; HALL P, 1995, INT J CANCER, V62, P519, DOI 10.1002/ijc.2910620505; Hartge P, 1996, J NATL CANCER I, V88, P298, DOI 10.1093/jnci/88.5.298; HARTGE P, 1992, CANCER RES, V52, pS5566; HARTGE P, 1994, CANCER SURV, V19, P423; KIRKPATRICK CS, 1990, INT J CANCER, V46, P1; KRICKER A, 1994, CANCER CAUSE CONTROL, V5, P367, DOI 10.1007/BF01804988; LEE JAH, 1980, BRIT J CANCER, V41, P757, DOI 10.1038/bjc.1980.138; McMichael AJ, 1996, BRIT J CANCER, V73, P945, DOI 10.1038/bjc.1996.169; MIETTINEN OS, 1981, AM J EPIDEMIOL, V114, P144, DOI 10.1093/oxfordjournals.aje.a113161; Mueller N, 1994, Oncology (Williston Park), V8, P83; OSTERLIND A, 1988, INT J CANCER, V42, P319, DOI 10.1002/ijc.2910420303; SCHERR PA, 1992, CANCER RES, V52, pS5503; ZAHM SH, 1992, CANCER RES, V52, pS5485	28	78	79	1	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 17	1997	314	7092					1451	1455		10.1136/bmj.314.7092.1451	http://dx.doi.org/10.1136/bmj.314.7092.1451			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XA202	9167561	Green Published			2022-12-01	WOS:A1997XA20200022
J	Perelson, AS; Essunger, P; Cao, YZ; Vesanen, M; Hurley, A; Saksela, K; Markowitz, M; Ho, DD				Perelson, AS; Essunger, P; Cao, YZ; Vesanen, M; Hurley, A; Saksela, K; Markowitz, M; Ho, DD			Decay characteristics of HIV-1-infected compartments during combination therapy	NATURE			English	Article							DENDRITIC CELLS; VIRUS; INFECTION; LYMPHOCYTES; HIV-1; QUANTITATION; MACROPHAGES; AIDS	Analysis of changes in viral load after initiation of treatment with potent antiretroviral agents has provided substantial insight into the dynamics of human immunodeficiency virus type 1 (HIV-1)(1-3). The concentration of HIV-1 in plasma drops by similar to 99% in the first two weeks of treatment owing to the rapid elimination of free virus with a half-life (t(1/2)) of less than or equal to 6 hours and loss of productively infected cells with a t(1/2) of 1.6 days(3). Here we show that with combination therapy this initial decrease is followed by a slower second-phase decay of plasma viraemia. Detailed mathematical analysis shows that the loss of long-lived infected cells (t(1/2) of 1-4 weeks) is a major contributor to the second phase, whereas the activation of latently infected lymphocytes (t(1/2) of 0.5-2 weeks) is only a minor source. Based on these decay characteristics, we estimate that 2.3-3.1 years of a completely inhibitory treatment would be required to eliminate HIV-1 from these compartments. To eradicate HIV-1 completely, even longer treatment may be needed because of the possible existence of undetected viral compartments or sanctuary sites.	ROCKEFELLER UNIV, AARON DIAMOND AIDS RES CTR, NEW YORK, NY 10016 USA; LOS ALAMOS NATL LAB, DIV THEORET, LOS ALAMOS, NM 87545 USA; TAMPERE UNIV, INST MED TECHNOL, FIN-33101 TAMPERE, FINLAND	Rockefeller University; United States Department of Energy (DOE); Los Alamos National Laboratory; Tampere University			Perelson, Alan S/Z-1959-2019	Perelson, Alan S/0000-0002-2455-0002				CAO YZ, 1992, AIDS, V6, P65, DOI 10.1097/00002030-199201000-00008; CHUN TW, 1995, NAT MED, V1, P1284, DOI 10.1038/nm1295-1284; Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; CONNOR RI, 1993, J VIROL, V67, P1772, DOI 10.1128/JVI.67.4.1772-1777.1993; DESTGROTH SF, 1982, J IMMUNOL METHODS, V49, pR11, DOI 10.1016/0022-1759(82)90269-1; Efron B., 1986, STAT SCI, V1, P54, DOI DOI 10.1214/SS/1177013815; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; Haase AT, 1996, SCIENCE, V274, P985, DOI 10.1126/science.274.5289.985; HEATH SL, 1995, NATURE, V377, P740, DOI 10.1038/377740a0; Herz AVM, 1996, P NATL ACAD SCI USA, V93, P7247, DOI 10.1073/pnas.93.14.7247; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; HO DD, 1986, J CLIN INVEST, V77, P1712, DOI 10.1172/JCI112491; KOENIG S, 1986, SCIENCE, V233, P1089, DOI 10.1126/science.3016903; MITCHIE CA, 1992, NATURE, V360, P264; Moreno P, 1996, AIDS, V10, P682, DOI 10.1097/00002030-199606000-00019; Nowak MA, 1997, J THEOR BIOL, V184, P205, DOI 10.1006/jtbi.1996.0307; Patick AK, 1996, ANTIMICROB AGENTS CH, V40, P292, DOI 10.1128/AAC.40.2.292; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; POPE M, 1994, CELL, V78, P389, DOI 10.1016/0092-8674(94)90418-9; SHAW GM, 1995, 10 C CENT GARD, P9; TREPEL F, 1974, KLIN WOCHENSCHR, V52, P511, DOI 10.1007/BF01468720; VANFURTH R, 1992, INFLAMMATION BASIC P, P325; Vesanen M, 1996, J VIROL, V70, P9035, DOI 10.1128/JVI.70.12.9035-9040.1996; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0	25	1482	1531	3	68	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 8	1997	387	6629					188	191		10.1038/387188a0	http://dx.doi.org/10.1038/387188a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WX945	9144290				2022-12-01	WOS:A1997WX94500056
J	Todorov, LD; MihaylovaTodorova, S; Westfall, TD; Sneddon, P; Kennedy, C; Bjur, RA; Westfall, DP				Todorov, LD; MihaylovaTodorova, S; Westfall, TD; Sneddon, P; Kennedy, C; Bjur, RA; Westfall, DP			Neuronal release of soluble nucleotidases and their role in neurotransmitter inactivation	NATURE			English	Article							PIG VAS-DEFERENS; EXTRACELLULAR ATP; TOXOPLASMA-GONDII; URINARY-BLADDER; ECTONUCLEOTIDASES; 5'-NUCLEOTIDASE; ANALOGS	Efficient control of synaptic transmission requires a rapid mechanism for terminating the actions of neurotransmitters. For amino acids and monoamines, this is achieved by their uptake into the cell by specific high-affinity transporters(1); acetylcholine is first broken down in the extracellular space and then choline is taken up by the cell(2). Because ATP is hydrolysed to adenosine by membrane-bound enzymes (ectonucleotidases) that are present in most tissues(3,4), it has been assumed that these enzymes terminate the neurotransmitter actions of ATP in the brain(5) and in the periphery(6,7). We show here, however that stimulation of sympathetic nerves innervating the guinea-pig vas deferens releases not only neuronal ATP, but also soluble nucleotidases that. break down this ATP to adenosine, indicating that inactivation of ATP is increased by nerve activity. This release of specific nucleotidases together with ATP represents a new mechanism for terminating the actions of a neurotransmitter.	UNIV NEVADA,SCH MED,DEPT PHARMACOL,RENO,NV 89557; UNIV STRATHCLYDE,ROYAL COLL,DEPT PHYSIOL & PHARMACOL,GLASGOW G1 1XW,LANARK,SCOTLAND	Nevada System of Higher Education (NSHE); University of Nevada Reno; University of Strathclyde					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; ASAI T, 1995, J BIOL CHEM, V270, P11391, DOI 10.1074/jbc.270.19.11391; BAILEY SJ, 1994, BRIT J PHARMACOL, V112, P219, DOI 10.1111/j.1476-5381.1994.tb13055.x; BERMUDES D, 1994, J BIOL CHEM, V269, P29252; BOWMAN WC, 1980, TXB PHARM; BURNSTOCK G, 1990, ANN NY ACAD SCI, V603, P1; CRACK BE, 1995, BRIT J PHARMACOL, V114, P475, DOI 10.1111/j.1476-5381.1995.tb13251.x; EDWARDS FA, 1992, NATURE, V359, P144, DOI 10.1038/359144a0; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; HOURANI SMO, 1989, GEN PHARMACOL, V20, P413, DOI 10.1016/0306-3623(89)90188-2; KENNEDY C, 1995, TRENDS PHARMACOL SCI, V16, P168, DOI 10.1016/S0165-6147(00)89010-0; KHAKH BS, 1995, BRIT J PHARMACOL, V115, pP2; LEVITT B, 1984, ANAL BIOCHEM, V137, P93, DOI 10.1016/0003-2697(84)90352-X; MALISZEWSKI CR, 1994, J IMMUNOL, V153, P3574; MISUMI Y, 1990, EUR J BIOCHEM, V191, P563, DOI 10.1111/j.1432-1033.1990.tb19158.x; MISUMI Y, 1990, J BIOL CHEM, V265, P2178; PEARSON JD, 1985, BIOCHEM J, V230, P503, DOI 10.1042/bj2300503; PLESNER L, 1995, INT REV CYTOL, V158, P141; SCHULDINER S, 1995, PHYSIOL REV, V75, P369, DOI 10.1152/physrev.1995.75.2.369; Sneddon P, 1996, SEMIN NEUROSCI, V8, P201, DOI 10.1006/smns.1996.0026; Stout JG, 1995, BIOCHEM MOL BIOL INT, V36, P927; Todorov LD, 1996, J PHYSIOL-LONDON, V496, P731, DOI 10.1113/jphysiol.1996.sp021723; Wang TF, 1996, J BIOL CHEM, V271, P9898, DOI 10.1074/jbc.271.17.9898; WELFORD LA, 1987, EUR J PHARMACOL, V141, P123, DOI 10.1016/0014-2999(87)90418-3; WELFORD LA, 1986, EUR J PHARMACOL, V129, P217, DOI 10.1016/0014-2999(86)90431-0; Westfall TD, 1996, BRIT J PHARMACOL, V117, P867, DOI 10.1111/j.1476-5381.1996.tb15273.x; ZIGANSHIN AU, 1994, DRUG DEVELOP RES, V32, P134, DOI 10.1002/ddr.430320303	27	206	209	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 1	1997	387	6628					76	79		10.1038/387076a0	http://dx.doi.org/10.1038/387076a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WW758	9139824				2022-12-01	WOS:A1997WW75800050
J	Walker, SA; Kennedy, MT; Zasadzinski, JA				Walker, SA; Kennedy, MT; Zasadzinski, JA			Encapsulation of bilayer vesicles by self-assembly	NATURE			English	Article							MEMBRANE-FUSION; LIPID VESICLES; LIPOSOMES; PHARMACOKINETICS	Vesicles of lipid bilayers have been investigated as drug-delivery vehicles for almost 20 years(1-8). The vesicles' interior space is separated from the surrounding solution because small molecules have only limited permeability through the bilayer. Single-walled (unilamellar) vesicles are made by a variety of non-equilibrium techniques, including mechanical disruption of lamellar phases by sonication or extrusion through filters, or chemical disruption by detergent dialysis or solvent removal(5). These techniques do not, however, allow the encapsulation of a specific volume, nor can they be used to encapsulate other vesicles. Here we show that molecular-recognition processes mediated by lipophilic receptors and substrates (here the biotin-streptavidin complex)(9) can be used to produce a multicompartmental aggregate of tethered vesicles encapsulated within a large bilayer vesicle. We call these encapsulated aggregates vesosomes. Encapsulation is achieved by unrolling bilayers from cochleate clyinders(5,10-12) which are tethered to the aggregate by biotin-streptavidin coupling. These compartmentalized vesosomes could provide vehicles for multicomponent or multifunctional drug delivery(2-4,6); in particular the encapsulating membrane could significantly modify permeation properties, or could be used to enhance the biocompatibility of the system.	UNIV CALIF SANTA BARBARA,DEPT CHEM ENGN,SANTA BARBARA,CA 93106; UNIV CALIF SANTA BARBARA,MAT RES LAB,SANTA BARBARA,CA 93106	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara								ALLEN TM, 1995, ADV DRUG DELIVER REV, V16, P267, DOI 10.1016/0169-409X(95)00029-7; ALLEN TM, 1987, FEBS LETT, V223, P42, DOI 10.1016/0014-5793(87)80506-9; BANGHAM AD, 1965, J MOL BIOL, V13, P238, DOI 10.1016/S0022-2836(65)80093-6; CHIRUVOLU S, 1994, SCIENCE, V264, P1753, DOI 10.1126/science.8209255; CHIRUVOLU S, 1994, STRUCTURE FLOW SURFA, pCH5; COOSSEN JR, 1995, BIOPHYS J, V68, P1009; Fendler J., 1983, MEMBRANE MIMETIC CHE; Gregoriadis G., 1988, LIPOSOMES DRUG CARRI; KENNEDY MT, 1998, THESIS U CALIFORNIA; LASIC DD, 1993, LIPOSOMES PHYSICS AP; New RRC., 1990, LIPOSOMES PRACTICAL; PAPAHADJOPOULOS D, 1991, P NATL ACAD SCI USA, V88, P11460, DOI 10.1073/pnas.88.24.11460; PAPAHADJOPOULOS D, 1975, BIOCHIM BIOPHYS ACTA, V394, P483, DOI 10.1016/0005-2736(75)90299-0; PAPAHADJOPOULOS D, 1977, BIOCHIM BIOPHYS ACTA, V465, P579, DOI 10.1016/0005-2736(77)90275-9; PAPAHADJOPOULOS D, 1976, BIOCHIM BIOPHYS ACTA, V448, P265, DOI 10.1016/0005-2736(76)90241-8; Spector MS, 1996, LANGMUIR, V12, P4704, DOI 10.1021/la960218s; SZOKA F, 1980, ANNU REV BIOPHYS BIO, V9, P467, DOI 10.1146/annurev.bb.09.060180.002343; Tardi PG, 1996, J DRUG TARGET, V4, P129, DOI 10.3109/10611869609015970; Uster PS, 1996, FEBS LETT, V386, P243, DOI 10.1016/0014-5793(96)00452-8; WALKER SA, 1996, THESIS U CALIFORNIA; Wong JY, 1997, SCIENCE, V275, P820, DOI 10.1126/science.275.5301.820; Zalipsky S, 1996, J CONTROL RELEASE, V39, P153, DOI 10.1016/0168-3659(95)00149-2	22	176	180	0	79	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 1	1997	387	6628					61	64		10.1038/387061a0	http://dx.doi.org/10.1038/387061a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WW758	9139822				2022-12-01	WOS:A1997WW75800045
J	Tibbs, GR; Goulding, EH; Siegelbaum, SA				Tibbs, GR; Goulding, EH; Siegelbaum, SA			Allosteric activation and tuning of ligand efficacy in cyclic-nucleotide-gated channels	NATURE			English	Article							ACETYLCHOLINE-RECEPTOR CHANNEL; MOLECULAR MECHANISM; POTASSIUM CHANNELS; INACTIVATION; BINDING; PROTEIN; DOMAIN; SUBUNIT	Despite recent advances in the identification of ligand-binding(1,2) and voltage-sensing(3) regions of ion channels, the domains that couple such regions to channel opening have not been identified, Moreover, it is uncertain whether ligand binding or depolarization are obligatory steps that must precede channel opening (according to linear reaction schemes(4,5)) or whether they act to stabilize the channel in an open state that can exist independently of ligand binding or depolarization (according to cyclic allosteric models(6-8)), By comparing ligand-independent and ligand-dependent channel openings, we now show that retinal and olfactory cyclic-nucleotide-gated channels(2) are activated by a cyclic allosteric mechanism, We further show that an amino-terminal domain, distinct from the pore and ligand-binding motifs, participates in the allosteric gating transition, accounting for differences in the free energy of gating of the two channels, The allosteric transition provides an important mechanism for tuning the physiological response of ligand-binding proteins, such as cyclic-nucleotidegated channels, to different biological signals.	COLUMBIA UNIV,HOWARD HUGHES MED INST,DEPT PHARMACOL,NEW YORK,NY 10032	Columbia University; Howard Hughes Medical Institute	Tibbs, GR (corresponding author), COLUMBIA UNIV,HOWARD HUGHES MED INST,CTR NEUROBIOL & BEHAV,722 W 168 ST,NEW YORK,NY 10032, USA.							Auerbach A, 1996, J PHYSIOL-LONDON, V494, P155, DOI 10.1113/jphysiol.1996.sp021482; BABILA T, 1994, NEURON, V12, P615, DOI 10.1016/0896-6273(94)90217-8; BUBIS J, 1988, J BIOL CHEM, V263, P9668; DELCASTILLO J, 1957, PROC R SOC SER B-BIO, V146, P369; GORDON SE, 1992, NEURON, V9, P739, DOI 10.1016/0896-6273(92)90036-D; GORDON SE, 1995, NEURON, V14, P857, DOI 10.1016/0896-6273(95)90229-5; GOULDING EH, 1993, NATURE, V364, P61, DOI 10.1038/364061a0; GOULDING EH, 1992, NEURON, V8, P45, DOI 10.1016/0896-6273(92)90107-O; GOULDING EH, 1994, NATURE, V372, P369, DOI 10.1038/372369a0; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; JACKSON MB, 1984, P NATL ACAD SCI-BIOL, V81, P3901, DOI 10.1073/pnas.81.12.3901; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; KRAMER RH, 1994, NEURON, V12, P655, DOI 10.1016/0896-6273(94)90220-8; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; LIU MY, 1994, SCIENCE, V266, P1348, DOI 10.1126/science.266.5189.1348; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; MURRELLLAGNADO RD, 1993, J GEN PHYSIOL, V102, P977, DOI 10.1085/jgp.102.6.977; PERUTZ M, 1990, MECH COOPERATIVITY A, P10; PICONES A, 1995, J PHYSIOL-LONDON, V485, P699, DOI 10.1113/jphysiol.1995.sp020763; SHABB JB, 1992, J BIOL CHEM, V267, P5723; SHEN NV, 1993, NEURON, V11, P67; STERNBACH Y, 1994, NEURON, V13, P1345, DOI 10.1016/0896-6273(94)90420-0; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; Tu LW, 1996, J BIOL CHEM, V271, P18904, DOI 10.1074/jbc.271.31.18904; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; VARNUM MD, 1995, NEURON, V15, P619, DOI 10.1016/0896-6273(95)90150-7; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520; Zagotta WN, 1996, ANNU REV NEUROSCI, V19, P235, DOI 10.1146/annurev.ne.19.030196.001315	30	92	94	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 10	1997	386	6625					612	615		10.1038/386612a0	http://dx.doi.org/10.1038/386612a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WT273	9121585				2022-12-01	WOS:A1997WT27300060
J	Maltepe, E; Schmidt, JV; Baunoch, D; Bradfield, CA; Simon, MC				Maltepe, E; Schmidt, JV; Baunoch, D; Bradfield, CA; Simon, MC			Abnormal angiogenesis and responses to glucose and oxygen deprivation in mice lacking the protein ARNT	NATURE			English	Article							HYPOXIA-INDUCIBLE FACTOR-1; AH-RECEPTOR; TRANSCRIPTIONAL REGULATION; FACTOR EXPRESSION; FACTOR-I; GENES; ELEMENTS; ISCHEMIA; CLONING; CELLS	The arylhydrocarbon-receptor nuclear translocator (ARNT) is a member of the basic-helix-loop-helix-PAS family of heterodimeric transcription factors which includes the arylhydrocarbon receptor (AHR), hypoxia-inducible factor-1 alpha (HIF-1 alpha) and the Drosophila single-minded protein (Sim)(1-4), ARNT forms heterodimeric complexes with the arylhydrocarbon receptor, HIF-1 alpha, Sim and the PAS protein Per(2,4-6). In response to environmental pollutants, AHR-ARNT heterodimers regulate genes involved in the metabolism of xenobiotics(7-9), whereas ARNT-HIF-1 alpha heterodimers probably regulate those involved in the response to oxygen deprivation(10-13). By generating a targeted disruption of the Arnt locus in the mouse, we show here that Arnt(-/-) embryonic stem cells fail to activate genes that normally respond to low oxygen tension, Arnt(-/-) ES cells also failed to respond to a decrease in glucose concentration, indicating that ARNT is crucial in the response to hypoxia and to hypoglycaemia. Arnt(-/-) embryos were not viable past embryonic day 10.5 and showed defective angiogenesis of the yolk sac and branchial arches, stunted development and embryo wasting, The defect in blood vessel formation in Arnt(-/-) yolk sacs is similar to the angiogenic abnormalities reported for mice deficient in vascular endothelial growth factor(14,15) or tissue factor(16). On the basis of these findings, we propose a model in which increasing tissue mass during organogenesis leads to the formation of hyoxic/nutrient-deprived cells, the subsequent activation of ARNT, and a concomitant increase in the expression of genes (including that encoding vascular endothelial growth factor) that promote vascularization of the developing yolk sac and solid tissues.	UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637; UNIV CHICAGO,MOL GENET & CELL BIOL,CHICAGO,IL 60637; UNIV CHICAGO,HOWARD HUGHES MED INST,CHICAGO,IL 60637; NORTHWESTERN UNIV,SCH MED,DEPT MOL PHARMACOL & BIOL CHEM,CHICAGO,IL 60611; UNIV WISCONSIN,MCARDLE LAB CANC RES,MADISON,WI 53706	University of Chicago; University of Chicago; Howard Hughes Medical Institute; University of Chicago; Northwestern University; University of Wisconsin System; University of Wisconsin Madison	Maltepe, E (corresponding author), UNIV CHICAGO,DEPT PATHOL,5841 S MARYLAND AVE,MC 1028,CHICAGO,IL 60637, USA.		Simon, Celeste/AAG-3941-2021					Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; Carmeliet P, 1996, NATURE, V383, P73, DOI 10.1038/383073a0; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; CLAUSS M, 1990, J EXP MED, V172, P1535, DOI 10.1084/jem.172.6.1535; COMPEAU CG, 1994, AM J RESP CELL MOL, V11, P446, DOI 10.1165/ajrcmb.11.4.7917312; Ema M, 1996, BIOCHEM BIOPH RES CO, V218, P588, DOI 10.1006/bbrc.1996.0104; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pa.35.040195.001515; Hirose K, 1996, MOL CELL BIOL, V16, P1706; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; Isaac DD, 1996, GENE DEV, V10, P103, DOI 10.1101/gad.10.1.103; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; NEBERT DW, 1987, ANNU REV BIOCHEM, V56, P945, DOI 10.1146/annurev.biochem.56.1.945; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SHWEIKI D, 1995, P NATL ACAD SCI USA, V92, P768, DOI 10.1073/pnas.92.3.768; SOGAWA K, 1995, P NATL ACAD SCI USA, V92, P1936, DOI 10.1073/pnas.92.6.1936; STEIN I, 1995, MOL CELL BIOL, V15, P5363; SWANSON HI, 1995, J BIOL CHEM, V270, P26292, DOI 10.1074/jbc.270.44.26292; TELAKOWSKIHOPKINS CA, 1988, P NATL ACAD SCI USA, V85, P1000, DOI 10.1073/pnas.85.4.1000; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; WANG GL, 1993, J BIOL CHEM, V268, P21513; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wilk R, 1996, GENE DEV, V10, P93, DOI 10.1101/gad.10.1.93; Wood SM, 1996, J BIOL CHEM, V271, P15117, DOI 10.1074/jbc.271.25.15117; ZHANG YM, 1994, J CLIN INVEST, V94, P1320, DOI 10.1172/JCI117451	30	602	614	0	27	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 27	1997	386	6623					403	407		10.1038/386403a0	http://dx.doi.org/10.1038/386403a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WQ170	9121557				2022-12-01	WOS:A1997WQ17000066
J	Loftus, SK; Morris, JA; Carstea, ED; Gu, JZ; Cummings, C; Brown, A; Ellison, J; Ohno, K; Rosenfeld, MA; Tagle, DA; Pentchev, PG; Pavan, WJ				Loftus, SK; Morris, JA; Carstea, ED; Gu, JZ; Cummings, C; Brown, A; Ellison, J; Ohno, K; Rosenfeld, MA; Tagle, DA; Pentchev, PG; Pavan, WJ			Murine model of Niemann-Pick C disease: Mutation in a cholesterol homeostasis gene	SCIENCE			English	Article							MOUSE; ACCUMULATION; LOCALIZATION; DEGRADATION; REDUCTASE; DOMAIN; MOTIF	An integrated human-mouse positional candidate approach was used to identify the gene responsible for the phenotypes observed in a mouse model of Niemann-Pick type C (NP-C) disease. The predicted murine NPC1 protein has sequence homology to the putative transmembrane domains of the Hedgehog signaling molecule Patched, to the cholesterol-sensing regions of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase and SREBP cleavage-activating protein (SCAP), and to the NPC1 orthologs identified in human, the nematode Caenorhabditis elegans, and the yeast Saccharomyces cerevisiae. The mouse model may provide an important resource for studying the role of NPC1 in cholesterol homeostasis and neurodegeneration and for assessing the efficacy of new drugs for NP-C disease.	NIH, NATL HUMAN GENOME RES INST, LAB GENET DIS RES, BETHESDA, MD 20892 USA; NINCDS, NATL HUMAN GENOME RES INST, NIH, BETHESDA, MD 20892 USA; NINCDS, DEV & METAB NEUROL BRANCH, NIH, BETHESDA, MD 20892 USA; TOTTORI UNIV, FAC MED, SCH LIFE SCI, YONAGO, TOTTORI 683, JAPAN	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Tottori University				Pavan, William/0000-0001-8281-5120; Loftus, Stacie/0000-0002-1958-4689				Akaboshi S, 1997, HUM GENET, V99, P350, DOI 10.1007/s004390050370; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BLANCHETTEMACKIE EJ, 1988, P NATL ACAD SCI USA, V85, P8022, DOI 10.1073/pnas.85.21.8022; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; CORDONNIER A, 1995, J VIROL, V69, P5890, DOI 10.1128/JVI.69.9.5890-5897.1995; COXEY RA, 1993, J LIPID RES, V34, P1165; DUDOV KP, 1984, CELL, V37, P457, DOI 10.1016/0092-8674(84)90376-3; Erickson RP, 1997, MAMM GENOME, V8, P355, DOI 10.1007/s003359900440; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; Gu JZ, 1997, P NATL ACAD SCI USA, V94, P7378, DOI 10.1073/pnas.94.14.7378; HEILEIN UAO, 1986, NUCLEIC ACIDS RES, V14, P6403; Herz J, 1997, NAT GENET, V15, P123, DOI 10.1038/ng0297-123; HIGASHI Y, 1991, INT CONGR SER, V962, P85; HOFFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166; HOMANICS GE, 1993, P NATL ACAD SCI USA, V90, P2389, DOI 10.1073/pnas.90.6.2389; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; Hunziker W, 1996, BIOESSAYS, V18, P379, DOI 10.1002/bies.950180508; KELLY RG, 1994, GENOMICS, V24, P509, DOI 10.1006/geno.1994.1660; KLEIN P, 1985, BIOCHIM BIOPHYS ACTA, V815, P468, DOI 10.1016/0005-2736(85)90375-X; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; MCGEOCH DJ, 1985, VIRUS RES, V3, P271, DOI 10.1016/0168-1702(85)90051-6; MIYAWAKI S, 1982, J HERED, V73, P257, DOI 10.1093/oxfordjournals.jhered.a109635; MORRIS C, 1982, AM J PATHOL, V140, P140; NAKAI K, 1991, PROTEINS, V11, P95, DOI 10.1002/prot.340110203; Neufeld EB, 1996, J BIOL CHEM, V271, P21604, DOI 10.1074/jbc.271.35.21604; OGATA S, 1994, J BIOL CHEM, V269, P5210; Pentchev P. G., 1995, METABOLIC MOL BASES, P2625; Pentchev Peter G., 1994, Trends in Cell Biology, V4, P365, DOI 10.1016/0962-8924(94)90086-8; PENTCHEV PG, 1977, BIOCHIM BIOPHYS ACTA, V488, P312, DOI 10.1016/0005-2760(77)90189-8; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; Porter JA, 1996, CELL, V86, P21, DOI 10.1016/S0092-8674(00)80074-4; SAKAI Y, 1991, BIOCHEM GENET, V29, P103, DOI 10.1007/BF00578243; Salen G, 1996, J LIPID RES, V37, P1169; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SKALNIK DG, 1988, J BIOL CHEM, V263, P6836; SMIT AFA, 1993, NUCLEIC ACIDS RES, V21, P1863, DOI 10.1093/nar/21.8.1863; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; Willnow TE, 1996, P NATL ACAD SCI USA, V93, P8460, DOI 10.1073/pnas.93.16.8460; Yamamoto Toshiharu, 1994, No To Hattatsu, V26, P318	41	672	706	0	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 11	1997	277	5323					232	235		10.1126/science.277.5323.232	http://dx.doi.org/10.1126/science.277.5323.232			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK418	9211850				2022-12-01	WOS:A1997XK41800043
J	Bachmann, MF; Kalinke, U; Althage, A; Freer, G; Burkhart, C; Roost, HP; Aguet, M; Hengartner, H; Zinkernagel, RM				Bachmann, MF; Kalinke, U; Althage, A; Freer, G; Burkhart, C; Roost, HP; Aguet, M; Hengartner, H; Zinkernagel, RM			The role of antibody concentration and avidity in antiviral protection	SCIENCE			English	Article							VESICULAR STOMATITIS-VIRUS; MONOCLONAL-ANTIBODIES; MEDIATED CLEARANCE; RABIES VIRUS; T-CELL; INFECTION; AFFINITY; MECHANISMS; RESPONSES; MICE	Neutralizing antibodies are necessary and sufficient for protection against infection with vesicular stomatitis virus(VSV). The in vitro neutralization capacities and in vivo protective capacities of a panel of immunoglobulin G monoclonal antibodies to the glycoprotein of VSV were evaluated. In vitro, neutralizing activity correlated with avidity and with neutralization rate constant, a measure of on-rate. However, in vivo, protection was independent of immunoglobulin subclass, avidity, neutralization rate constant, and in vitro neutralizing activity; above a minimal avidity threshold, protection depended simply on a minimum serum concentration. These two biologically defined thresholds of antibody specificity offer hope for the development of adoptive therapy with neutralizing antibodies.	UNIV ZURICH HOSP,INST EXPT IMMUNOL,DEPT PATHOL,CH-8091 ZURICH,SWITZERLAND; SWISS INST EXPT CANC RES,CH-1066 EPALINGES,SWITZERLAND	University of Zurich; University Zurich Hospital; Swiss Institute Experimental Cancer Research			freer, giulia/H-4609-2012	Kalinke, Ulrich/0000-0003-0503-9564				BACHMANN M, UNPUB; BACHMANN MF, 1994, J IMMUNOL, V152, P4235; BACHMANN MF, 1993, J VIROL, V67, P3917, DOI 10.1128/JVI.67.7.3917-3922.1993; BACHMANN MF, 1993, SCIENCE, V262, P1448, DOI 10.1126/science.8248784; Bachmann MF, 1995, EUR J IMMUNOL, V25, P3445, DOI 10.1002/eji.1830251236; BRILES DE, 1984, EUR J IMMUNOL, V14, P1027, DOI 10.1002/eji.1830141112; COHN M, 1990, IMMUNOL REV, V115, P7, DOI 10.1111/j.1600-065X.1990.tb00783.x; CYBINSKI DH, 1990, J GEN VIROL, V71, P2065, DOI 10.1099/0022-1317-71-9-2065; DESTGROTH SF, 1981, IMMUNE SYSTEM, P155; DIETZSCHOLD B, 1992, P NATL ACAD SCI USA, V89, P7252, DOI 10.1073/pnas.89.15.7252; EISEN HN, 1964, BIOCHEMISTRY-US, V3, P996, DOI 10.1021/bi00895a027; FLAMAND A, 1993, VIROLOGY, V194, P302, DOI 10.1006/viro.1993.1261; FOOTE J, 1991, NATURE, V352, P530, DOI 10.1038/352530a0; FOOTE J, 1995, P NATL ACAD SCI USA, V92, P1254, DOI 10.1073/pnas.92.5.1254; FORGER JM, 1991, J VIROL, V65, P4950, DOI 10.1128/JVI.65.9.4950-4958.1991; GOBET R, 1988, EXP CELL BIOL, V56, P175; Kalinke U, 1996, EUR J IMMUNOL, V26, P2801, DOI 10.1002/eji.1830261202; LEFRANCOIS L, 1984, J VIROL, V51, P208, DOI 10.1128/JVI.51.1.208-214.1984; LEFRANCOIS L, 1982, VIROLOGY, V121, P157, DOI 10.1016/0042-6822(82)90125-8; LEVINE B, 1991, SCIENCE, V254, P856, DOI 10.1126/science.1658936; MILSTEIN C, 1991, IMMUNOL TODAY, V12, P93, DOI 10.1016/0167-5699(91)90164-O; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; RAJEWSKY K, 1989, PROGR IMMUNOLOGY, V7, P397; ROOST HP, 1995, P NATL ACAD SCI USA, V92, P1257, DOI 10.1073/pnas.92.5.1257; ROOST HP, 1996, J IMMUNOL METHODS, V189, P283; STEINHOFF U, 1995, J VIROL, V69, P2153, DOI 10.1128/JVI.69.4.2153-2158.1995; STEWARD MW, 1991, IMMUNOLOGY, V72, P99; TYLER KL, 1993, J VIROL, V67, P3446, DOI 10.1128/JVI.67.6.3446-3453.1993; WAGNER RR, 1987, RHABDOVIRUSES; WRIGHT KE, 1991, J VIROL, V65, P3001, DOI 10.1128/JVI.65.6.3001-3006.1991	30	210	223	2	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 27	1997	276	5321					2024	2027		10.1126/science.276.5321.2024	http://dx.doi.org/10.1126/science.276.5321.2024			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XG748	9197261				2022-12-01	WOS:A1997XG74800059
J	Rydall, AC; Rodin, GM; Olmsted, MP; Devenyi, RG; Daneman, D				Rydall, AC; Rodin, GM; Olmsted, MP; Devenyi, RG; Daneman, D			Disordered eating behavior and microvascular complications in young women with insulin-dependent diabetes mellitus	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	55th Annual Meeting and Scientific Sessions of the American-Diabetes-Association	JUN 10-13, 1995	ATLANTA, GA	Amer Diabet Assoc			GLYCEMIC CONTROL; ADOLESCENTS; BULIMIA; IDDM; NERVOSA; ADULTS	Background insulin-dependent diabetes mellitus (IDDM) and eating disorders are relatively common among young women in North America. Their coexistence could lead to poor metabolic control and an increased risk of the microvascular complications of IDDM. Methods We studied 91 young women with IDDM at base line and four to five years later to determine the prevalence and persistence of disordered eating behavior (on the basis of self-reported eating and weight-loss practices, including the intentional omission or underdosing of insulin to control weight) and the association of such eating disorders with metabolic control, diabetic retinopathy, and urinary albumin excretion. At base line, the mean age of the young women was 15+/-2 years and the duration of diabetes was 7+/-4 years. Results At base line, 26 of 97 young women (29 percent) had highly or moderately disordered eating behavior, which persisted in 76 (18 percent) and improved in 10 (11 percent). Of the 65 women with normal eating behavior at base line (71 percent), 14 (15 percent) had disordered eating at follow-up. Omission or underdosing of insulin to lose weight was reported by 12 of 88 young women (14 percent) at base line and 30 (34 percent) at follow-up (P=0.003). At base line, the mean (+/-SD) hemoglobin A,, value was higher in the group with highly disordered eating behavior (11.1+/-1.2 percent) than in the groups whose eating behavior was moderately disordered (8.9 +/- 1.7 percent) or nondisordered (8.7+/-1.6 percent, P<0.001). Disordered eating at base line was associated with retinopathy four years later (P=0.004), when 86 percent of the young women with highly disordered eating behavior, 43 percent of those with moderately disordered eating behavior, and 24 percent of those with nondisordered eating behavior had retinopathy. Conclusions Disordered eating behavior is common and persistent in young women with IDDM and is associated with impaired metabolic control and a higher risk of diabetic retinopathy. (C) 1997, Massachusetts Medical Society.	TORONTO HOSP, DEPT PSYCHIAT, TORONTO, ON M5G 2C4, CANADA; HOSP SICK CHILDREN, TORONTO, ON M5G 1X8, CANADA; UNIV TORONTO, TORONTO, ON, CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto				Rydall, Anne/0000-0002-4692-9101; Rodin, Gary/0000-0002-6626-6974				[Anonymous], 1981, INVEST OPHTH VIS SCI, V21, P210; [Anonymous], 1991, Ophthalmology, V98, P786; BIGGS MM, 1994, DIABETES CARE, V17, P1186, DOI 10.2337/diacare.17.10.1186; Birk R, 1989, Diabetes Educ, V15, P336, DOI 10.1177/014572178901500415; COLAS C, 1991, DIABETOLOGIA, V34, P288, DOI 10.1007/BF00405092; COLE TJ, 1995, ARCH DIS CHILD, V73, P25, DOI 10.1136/adc.73.1.25; DIXON WJ, 1988, BMDP STATISTICAL SOF, V1; DRASH AL, 1987, CLIN INVEST MED, V10, P432; ELLIS G, 1984, CLIN CHEM, V30, P1746; FAIRBURN CG, 1991, BRIT MED J, V303, P17, DOI 10.1136/bmj.303.6793.17; Fairburn CG, 1996, AM J PSYCHIAT, V153, P386; FRIEDMAN S, 1995, ANN MED-PSYCHOL, V153, P282; HUDSON JI, 1983, JAMA-J AM MED ASSOC, V249, P2501, DOI 10.1001/jama.249.18.2501; JOHNSON C, 1985, HDB PSYCHOTHERAPY AN, P19; KROLEWSKI AS, 1986, DIABETES CARE, V9, P443, DOI 10.2337/diacare.9.5.443; KROLEWSKI AS, 1985, AM J MED, V78, P785, DOI 10.1016/0002-9343(85)90284-0; LAWSON ML, 1994, EATING DISORDERS, V2, P261; LITTLEFIELD CH, 1992, DIABETES CARE, V15, P90, DOI 10.2337/diacare.15.1.90; MCKENNA MJ, 1991, ARCH INTERN MED, V151, P1745, DOI 10.1001/archinte.151.9.1745; NORUSIS MJ, 1992, SPSS PC PLUS BASE SY; PEVELER RC, 1992, INT J EAT DISORDER, V11, P45, DOI 10.1002/1098-108X(199201)11:1&lt;45::AID-EAT2260110107&gt;3.0.CO;2-R; POLONSKY WH, 1994, DIABETES CARE, V17, P1178, DOI 10.2337/diacare.17.10.1178; RODIN G, 1991, PSYCHOSOMATICS, V32, P171, DOI 10.1016/S0033-3182(91)72088-4; RODIN GM, 1992, DIABETES CARE, V15, P1402, DOI 10.2337/diacare.15.10.1402; RODIN GM, 1986, INT J PSYCHIAT MED, V16, P49, DOI 10.2190/HULH-CTPR-4V17-383C; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SOCHETT E, 1988, J PEDIATR-US, V112, P744, DOI 10.1016/S0022-3476(88)80694-2; STANCIN T, 1989, DIABETES CARE, V12, P601, DOI 10.2337/diacare.12.9.601; STEEL JM, 1987, BRIT MED J, V294, P859, DOI 10.1136/bmj.294.6576.859; STEEL JM, 1989, BRIT J PSYCHIAT, V155, P515, DOI 10.1192/bjp.155.4.515; SZMUKLER GI, 1983, BRIT J PSYCHIAT, V142, P305, DOI 10.1192/bjp.142.3.305; VILA G, 1993, CAN J PSYCHIAT, V38, P606, DOI 10.1177/070674379303800908; WARD A, 1995, POSTGRAD MED J, V71, P546, DOI 10.1136/pgmj.71.839.546; WING RR, 1986, DIABETES CARE, V9, P162, DOI 10.2337/diacare.9.2.162	34	307	312	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 26	1997	336	26					1849	1854		10.1056/NEJM199706263362601	http://dx.doi.org/10.1056/NEJM199706263362601			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	XF756	9197212	Bronze			2022-12-01	WOS:A1997XF75600001
J	Richards, SA; Carey, KL; Macara, IG				Richards, SA; Carey, KL; Macara, IG			Requirement of guanosine triphosphate-bound Ran for signal-mediated nuclear protein export	SCIENCE			English	Article							CHROMOSOME CONDENSATION; BINDING PROTEIN; RCC1; ACTIVATION; MUTANT	A leucine-rich nuclear export signal (NES) allows rapid export of proteins from cell nuclei. Microinjection studies revealed a role for the guanosine triphosphatase (GTPase) Ran in NES-mediated export. Nuclear injection of a Ran mutant (Thr(24)-->Asn) blocked protein export but not import, whereas depletion of the Ran nucleotide exchange factor RCC1 blocked protein import but not export. However, injection of Ran GTPase-activating protein (RanGAP) into RCC1-depleted cell nuclei inhibited export. Coinjection with Ran mutants insensitive to RanGAP prevented this inhibition. Therefore, NES-mediated protein export appears to require a Ran-GTP complex but does not require Ran-dependent GTP hydrolysis.	UNIV VIRGINIA,HLTH SCI CTR,CTR CELL SIGNALING,CHARLOTTESVILLE,VA 22908; UNIV VERMONT,DEPT PATHOL,BURLINGTON,VT 05405	University of Virginia; University of Vermont				Carey, Kimberly/0000-0002-0836-8710	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007122] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050526] Funding Source: NIH RePORTER; NIEHS NIH HHS [EST3207122] Funding Source: Medline; NIGMS NIH HHS [GM 50526] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; Carey KL, 1996, J CELL BIOL, V133, P985, DOI 10.1083/jcb.133.5.985; DASSO M, 1994, EMBO J, V13, P5732, DOI 10.1002/j.1460-2075.1994.tb06911.x; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; FUKUDA M, 1996, J BIOL CHEM, V271, P21124; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; Kim FJ, 1996, MOL CELL BIOL, V16, P5147; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P12543, DOI 10.1021/bi00039a008; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P639, DOI 10.1021/bi00002a031; Lounsbury KM, 1996, J BIOL CHEM, V271, P32834, DOI 10.1074/jbc.271.51.32834; Murphy R, 1996, NATURE, V383, P357, DOI 10.1038/383357a0; NISHIMOTO T, 1978, CELL, V15, P475, DOI 10.1016/0092-8674(78)90017-X; NISHITANI H, 1991, EMBO J, V10, P1555, DOI 10.1002/j.1460-2075.1991.tb07675.x; Noguchi E, 1996, EMBO J, V15, P5595, DOI 10.1002/j.1460-2075.1996.tb00944.x; RICHARDS S, UNPUB; RICHARDS SA, 1995, J BIOL CHEM, V270, P14405, DOI 10.1074/jbc.270.24.14405; Richards SA, 1996, J CELL BIOL, V134, P1157, DOI 10.1083/jcb.134.5.1157; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2	19	166	166	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 20	1997	276	5320					1842	1844		10.1126/science.276.5320.1842	http://dx.doi.org/10.1126/science.276.5320.1842			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XF103	9188526				2022-12-01	WOS:A1997XF10300043
J	Gu, W; Shi, XL; Roeder, RG				Gu, W; Shi, XL; Roeder, RG			Synergistic activation of transcription by CBP and p53	NATURE			English	Article							NUCLEAR-PROTEIN CBP; FACTOR CREB; COACTIVATOR; BINDING; SUPPRESSION; DOMAIN; MDM-2; CAMP	The tumour suppressor p53 is a transcriptional regulator whose ability to inhibit cell growth is dependent upon its transactivation function(1-3). Here we demonstrate that the transcription factor CBP, which is also implicated in cell proliferation and differentiation(4-14), acts as a p53 coactivator and potentiates its transcriptional activity. The amino-terminal activation domain of p53 interacts with the carboxy-terminal portion of the CBP protein both in vitro and in vivo. In transfected SaoS-2 cells, CBP potentiates activation of the mdm-2 gene by p53 and, reciprocally, p53 potentiates activation of a Gal4-responsive target gene by a Gal4(1-147)-CBP(1678-2441) fusion protein. A double point mutation that destroys the transactivation function of p53 also abolishes its binding to CBP and its synergistic function with CBP The ability of p53 to interact physically and functionally with a coactivator (CBP) that has histone acetyltransferase activity(15,16) and with components (TAFs)(17,18) of the general transcription machinery indicates that it may have different functions in a multistep activation pathway.	ROCKEFELLER UNIV,BIOCHEM & MOL BIOL LAB,NEW YORK,NY 10021	Rockefeller University								ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BANISTER AJ, 1996, NATURE, V384, P641; BANISTER AJ, 1995, EMBO J, V14, P4758; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FERRERI K, 1994, P NATL ACAD SCI USA, V91, P1210, DOI 10.1073/pnas.91.4.1210; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; Godley LA, 1996, GENE DEV, V10, P836, DOI 10.1101/gad.10.7.836; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Lee JS, 1996, MOL CELL BIOL, V16, P4312; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONATE SA, 1995, SCIENCE, V270, P1354; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; Steegenga WT, 1996, MOL CELL BIOL, V16, P2101; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WONG HK, 1994, J VIROL, V68, P4910, DOI 10.1128/JVI.68.8.4910-4920.1994; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0	30	516	527	0	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 19	1997	387	6635					819	823		10.1038/42972	http://dx.doi.org/10.1038/42972			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XF144	9194564	Bronze			2022-12-01	WOS:A1997XF14400054
J	Takagi, T; Moore, CR; Diehn, F; Buratowski, S				Takagi, T; Moore, CR; Diehn, F; Buratowski, S			An RNA 5'-triphosphatase related to the protein tyrosine phosphatases	CELL			English	Article							CAPPING ENZYME; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; GUANYLYLTRANSFERASE; DNA; PURIFICATION; ASSOCIATION; SUBUNITS; LIGASES; GENES	mRNA capping requires the sequential action of three enzymatic activities: RNA triphosphatase, guanylyltransferase, and methyltransferase. Here we characterize a gene (GEL-I) believed to encode the C., elegans capping enzyme. CEL-1 has a C-terminal domain containing motifs found in yeast and vaccinia virus capping enzyme guanylyltransferases. The N-terminal domain of CEL-1 has RNA tri phosphatase activity. Surprisingly, this domain does not resemble the vaccinia virus capping enzyme but does have significant sequence similarity to the protein tyrosine phosphatase (PTP) enzyme family. However, CEL-1 has no detectable PTP activity. The mechanism of the RNA triphosphatase is similar to that of PTPs: the active site contains a conserved nucleophilic cysteine required for activity. These results broaden the superfamily of PTP-like phosphatases to include enzymes with RNA substrates.			Takagi, T (corresponding author), HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOL PHARMACOL,BOSTON,MA 02115, USA.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Denu JM, 1996, CELL, V87, P361, DOI 10.1016/S0092-8674(00)81356-2; Fauman EB, 1996, TRENDS BIOCHEM SCI, V21, P413, DOI 10.1016/S0968-0004(96)10059-1; FRESCO LD, 1994, P NATL ACAD SCI USA, V91, P6624, DOI 10.1073/pnas.91.14.6624; GUO PX, 1990, P NATL ACAD SCI USA, V87, P4023, DOI 10.1073/pnas.87.11.4023; ITOH N, 1987, J BIOL CHEM, V262, P1989; ITOH N, 1984, J BIOL CHEM, V259, P3930; ITOH N, 1984, J BIOL CHEM, V259, P3923; JOVE R, 1984, J BIOL CHEM, V259, P8513; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MAO XD, 1995, MOL CELL BIOL, V15, P4167; MIZUMOTO K, 1987, PROG NUCLEIC ACID RE, V34, P1, DOI 10.1016/S0079-6603(08)60491-2; Myette JR, 1996, J BIOL CHEM, V271, P11945, DOI 10.1074/jbc.271.20.11945; NILES EG, 1986, VIROLOGY, V153, P96, DOI 10.1016/0042-6822(86)90011-5; RASMUSSEN EB, 1993, P NATL ACAD SCI USA, V90, P7923, DOI 10.1073/pnas.90.17.7923; SHENG ZQ, 1993, J BIOL CHEM, V268, P4728; SHIBAGAKI Y, 1992, J BIOL CHEM, V267, P9521; SHUMAN S, 1990, J BIOL CHEM, V265, P11960; SHUMAN S, 1994, P NATL ACAD SCI USA, V91, P12046, DOI 10.1073/pnas.91.25.12046; SHUMAN S, 1995, MOL MICROBIOL, V17, P405, DOI 10.1111/j.1365-2958.1995.mmi_17030405.x; SHUMAN S, 1980, J BIOL CHEM, V255, P1588; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; YAGI Y, 1983, EMBO J, V2, P611, DOI 10.1002/j.1460-2075.1983.tb01471.x; YamadaOkabe T, 1996, MICROBIOL-UK, V142, P2515, DOI 10.1099/00221287-142-9-2515; Yu L, 1996, J VIROL, V70, P6162, DOI 10.1128/JVI.70.9.6162-6168.1996	26	105	111	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 13	1997	89	6					867	873		10.1016/S0092-8674(00)80272-X	http://dx.doi.org/10.1016/S0092-8674(00)80272-X			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XE357	9200605	Bronze			2022-12-01	WOS:A1997XE35700007
J	Wolfe, KH; Shields, DC				Wolfe, KH; Shields, DC			Molecular evidence for an ancient duplication of the entire yeast genome	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; GENE; EVOLUTION; SEQUENCES	Gene duplication is an important source of evolutionary novelty(1,2). Most duplications are of just a single gene, but Ohno(1) proposed that whole-genome duplication (polyploidy) is an important evolutionary mechanism. Many duplicate genes have been found in Saccharomyces cerevisiae, and these often seem to be phenotypically redundant(3-7) Here we show that the arrangement of duplicated genes in the S. cerevisiae genome is consistent with Ohno's hypothesis. We propose a model in which this species is a degenerate tetraploid resulting from a whole-genome duplication that occurred after the divergence of Saccharomyces from Kluyveromyces. Only a small fraction of the genes were subsequently retained in duplicate (most were deleted), and gene order was rearranged by many reciprocal translocations between chromosomes. Protein pairs derived from this duplication event make up 13% of all yeast proteins, and include pairs of transcription factors, protein kinases, myosins, cyclins and pheromones. Tetraploidy may have facilitated the evolution of anaerobic fermentation in Saccharomyces.			Wolfe, KH (corresponding author), UNIV DUBLIN TRINITY COLL,DEPT GENET,DUBLIN 2,IRELAND.		Wolfe, Kenneth H/B-4653-2009	Wolfe, Kenneth/0000-0003-4992-4979; Shields, Denis/0000-0003-4015-2474	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AHN S, 1993, P NATL ACAD SCI USA, V90, P7980, DOI 10.1073/pnas.90.17.7980; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BERGKAMPSTEFFENS GK, 1992, YEAST, V8, P903, DOI 10.1002/yea.320081102; DOHRMANN PR, 1992, GENE DEV, V6, P93, DOI 10.1101/gad.6.1.93; FITCH WM, 1967, SCIENCE, V155, P279, DOI 10.1126/science.155.3760.279; Friis E. M., 1987, ORIGINS ANGIOSPERMS; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; HENDRIKS L, 1992, SYST APPL MICROBIOL, V15, P98, DOI 10.1016/S0723-2020(11)80145-1; HEUS JJ, 1993, MOL GEN GENET, V236, P355; HUGHES AL, 1994, P ROY SOC B-BIOL SCI, V256, P119, DOI 10.1098/rspb.1994.0058; HURWITZ N, 1995, P NATL ACAD SCI USA, V92, P11009, DOI 10.1073/pnas.92.24.11009; Jansen RP, 1996, CELL, V84, P687, DOI 10.1016/S0092-8674(00)81047-8; KABACK DB, 1995, YEASTS, V6, P179; Kielland- Brandt M. C., 1995, YEASTS, P223; LALO D, 1993, CR ACAD SCI III-VIE, V316, P367; LARSON GP, 1994, GENE, V150, P35, DOI 10.1016/0378-1119(94)90854-0; MELNICK L, 1993, J MOL BIOL, V233, P372, DOI 10.1006/jmbi.1993.1518; Ohno S., 1970, EVOLUTION GENE DUPLI, DOI [DOI 10.1007/978-3-642-86659-3, 10.1007/978-3-642-86659-3_11]; OLSON MV, 1991, MOL CELLULAR BIOL YE, V1, P1; ROMAN H, 1953, P NATL ACAD SCI USA, V39, P171, DOI 10.1073/pnas.39.3.171; Ryu SL, 1996, YEAST, V12, P757, DOI 10.1002/(SICI)1097-0061(19960630)12:8<757::AID-YEA970>3.0.CO;2-H; Schmidt A, 1996, P NATL ACAD SCI USA, V93, P13780, DOI 10.1073/pnas.93.24.13780; SMITH MM, 1987, J MOL EVOL, V24, P252, DOI 10.1007/BF02111238; Spring J, 1997, FEBS LETT, V400, P2, DOI 10.1016/S0014-5793(96)01351-8; STARK MJR, 1989, YEAST, V5, P35, DOI 10.1002/yea.320050106	25	1327	1363	0	115	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 12	1997	387	6634					708	713		10.1038/42711	http://dx.doi.org/10.1038/42711			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XD869	9192896	Bronze			2022-12-01	WOS:A1997XD86900055
J	Collins, MJ				Collins, MJ			A child's pain	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 4	1997	277	21					1668	1668		10.1001/jama.277.21.1668	http://dx.doi.org/10.1001/jama.277.21.1668			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XB088	9169883				2022-12-01	WOS:A1997XB08800010
J	Couch, FJ; DeShano, ML; Blackwood, MA; Calzone, K; Stopfer, J; Campeau, L; Ganguly, A; Rebbeck, T; Weber, BL; Jablon, L; Cobleigh, MA; Hoskins, K; Garber, JE				Couch, FJ; DeShano, ML; Blackwood, MA; Calzone, K; Stopfer, J; Campeau, L; Ganguly, A; Rebbeck, T; Weber, BL; Jablon, L; Cobleigh, MA; Hoskins, K; Garber, JE			BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OVARIAN-CANCER; SUSCEPTIBILITY GENE; FAMILY HISTORY; CARRIERS; KINDREDS	Background To define the incidence of BRCA1 mutations among patients seen in clinics that evaluate the risk of breast cancer, we analyzed DNA samples from women seen in this setting and constructed probability tables to provide estimates of the likelihood of finding a BRCA1 mutation in individual families. Methods Clinical information, family histories, and blood for DNA analysis were obtained from 263 women with breast cancer. Conformation-sensitive gel electrophoresis and DNA sequencing were used to identify BRCA1 mutations. Results BRCA1 mutations were identified in 16 percent of women with a family history of breast cancer. Only 7 percent of women from families with a history of breast cancer but not ovarian cancer had BRCA1 mutations. The rates were higher among women from families with a history of both breast and ovarian cancer. Among family members, an average age of less than 55 years at the diagnosis of breast cancer, the presence of ovarian cancer, the presence of breast and ovarian cancer in the same woman, and Ashkenazi Jewish ancestry were all associated with an increased risk of detecting a BRCA1 mutation. No association was found between the presence of bilateral breast cancer or the number of breast cancers in a family and the detection of a BRCA1 mutation, or between the position of the mutation in the BRCA1 gene and the presence of ovarian an cancer in a family. Conclusions Among women with breast cancer and a family history of the disease, the percentage with BRCA1 coding-region mutations is less than the 45 percent predicted by genetic-linkage analysis. These results suggest that even in a referral clinic specializing in screening women from high-risk families, the majority of tests for BRCA1 mutations will be negative and therefore uninformative. (C) 1997, Massachusetts Medical Society.	UNIV PENN,DEPT MED,STELLAR CHANCE LABS 1009,PHILADELPHIA,PA 19104; UNIV PENN,DEPT GENET,PHILADELPHIA,PA 19104; UNIV PENN,DEPT BIOSTAT & EPIDEMIOL,PHILADELPHIA,PA 19104; ALBERT EINSTEIN MED CTR,PHILADELPHIA,PA 19141; RUSH PRESBYTERIAN ST LUKES MED CTR,CHICAGO,IL 60612; ROCKFORD MEM HOSP,ROCKFORD,IL; DANA FARBER CANC INST,BOSTON,MA 02115	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Yeshiva University; Rush University; Harvard University; Dana-Farber Cancer Institute			Rebbeck, Timothy/GLU-8348-2022	Rebbeck, Timothy/0000-0002-4799-1900; Calzone, Kathleen/0000-0002-2354-6810				Bapat B, 1996, AM J HUM GENET, V59, P736; Berry DA, 1997, J NATL CANCER I, V89, P227, DOI 10.1093/jnci/89.3.227; BROWNSTEIN MH, 1978, CANCER, V41, P2393, DOI 10.1002/1097-0142(197806)41:6<2393::AID-CNCR2820410644>3.0.CO;2-K; CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; COLDITZ GA, 1993, JAMA-J AM MED ASSOC, V270, P1548; COLDITZ GA, 1993, JAMA-J AM MED ASSOC, V270, P338, DOI 10.1001/jama.270.3.338; Couch FJ, 1996, HUM MUTAT, V8, P8, DOI 10.1002/humu.1380080102; EASTON DF, 1995, AM J HUM GENET, V56, P265; EASTON DF, 1993, AM J HUM GENET, V52, P678; FitzGerald MG, 1996, NEW ENGL J MED, V334, P143, DOI 10.1056/NEJM199601183340302; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; GAIL MH, 1989, J NATL CANCER I, V81, P1879, DOI 10.1093/jnci/81.24.1879; GANGULY A, 1993, P NATL ACAD SCI USA, V90, P10325, DOI 10.1073/pnas.90.21.10325; GAYTHER SA, 1995, NAT GENET, V11, P428, DOI 10.1038/ng1295-428; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; KOLODNER RD, 1994, GENOMICS, V24, P516, DOI 10.1006/geno.1994.1661; Langston AA, 1996, NEW ENGL J MED, V334, P137, DOI 10.1056/NEJM199601183340301; LI FP, 1988, CANCER RES, V48, P5358; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MUIR EG, 1967, BRIT J SURG, V54, P191, DOI 10.1002/bjs.1800540309; Roa BB, 1996, NAT GENET, V14, P185, DOI 10.1038/ng1096-185; SLATTERY ML, 1993, JAMA-J AM MED ASSOC, V270, P1563, DOI 10.1001/jama.270.13.1563; STATTUCKEIDENS D, 1995, JAMA-J AM MED ASSOC, V273, P535; STREUWING JP, 1995, NAT GENET, V11, P198; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; Tonin P, 1996, NAT MED, V2, P1179, DOI 10.1038/nm1196-1179; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0	28	535	547	0	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 15	1997	336	20					1409	1415		10.1056/NEJM199705153362002	http://dx.doi.org/10.1056/NEJM199705153362002			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WY577	9145677				2022-12-01	WOS:A1997WY57700002
J	Lee, JK; Houk, KN				Lee, JK; Houk, KN			A proficient enzyme revisited: The predicted mechanism for orotidine monophosphate decarboxylase	SCIENCE			English	Article							OROTIDYLATE DECARBOXYLASE; ACID; CATALYSIS; OROTATE; 5'-MONOPHOSPHATE; 5'-PHOSPHATE	A mechanism is proposed to explain the activity of orotidine 5'-monophosphate decarboxylase (ODCase). This enzyme is the one of the most proficient known, with a catalytic proficiency (k(cat)/K-m)/k(non) = 10(23) M-1. Quantum mechanical calculations predict a mechanism involving a stabilized carbene intermediate, which represents a previously unrecognized mode of enzymatic activity for ODCase. The proposed mechanism involves proton transfer from a weak acid (pK(a) = 7, where K-a is the acid constant) concerted with decarboxylation, in a nonpolar enzyme environment. Such a mechanism makes possible different approaches to the design of ODCase inhibitors. Furthermore, the prediction that general acid catalysis may only be effective in low dielectric media is of general significance for understanding the activity of many enzymes.			Lee, JK (corresponding author), UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,405 HILGARD AVE,LOS ANGELES,CA 90095, USA.							ACHESON SA, 1990, BIOCHEMISTRY-US, V29, P3198, DOI 10.1021/bi00465a007; ARDUENGO AJ, 1994, J AM CHEM SOC, V116, P6812, DOI 10.1021/ja00094a040; BEAK P, 1976, J AM CHEM SOC, V98, P3601, DOI 10.1021/ja00428a035; BELL JB, 1991, PROTEINS, V9, P143, DOI 10.1002/prot.340090208; BENDER ML, 1971, MECH HOMOGENEOUS CAT, P165; BRUICE TC, 1966, BIOORGANIC MECH, V2, P188; CARTER CM, COMMUNICATION; Castellano J.A., 1992, HDB DISPLAY TECHNOLO; Frisch M.J., 2009, GAUSSIAN16; GILSON MK, 1986, BIOPOLYMERS, V25, P2097, DOI 10.1002/bip.360251106; Hehre J., 1986, AB INITIO MOL ORBITA; JENCKS WP, 1972, J AM CHEM SOC, V94, P4731, DOI 10.1021/ja00768a052; Kern D, 1997, SCIENCE, V275, P67, DOI 10.1126/science.275.5296.67; KING G, 1991, J CHEM PHYS, V95, P4366, DOI 10.1063/1.461760; KLUGER R, 1987, CHEM REV, V87, P863, DOI 10.1021/cr00081a001; Kohn W, 1996, J PHYS CHEM-US, V100, P12974, DOI 10.1021/jp960669l; Lavorato D, 1996, J AM CHEM SOC, V118, P11898, DOI 10.1021/ja961954l; LEVINE HL, 1980, BIOCHEMISTRY-US, V19, P4993, DOI 10.1021/bi00563a010; LIAS SG, 1988, J PHYS CHEM REF D S1, V17; MCCLARD RW, 1980, BIOCHEMISTRY-US, V19, P4699, DOI 10.1021/bi00561a024; RADZICKA A, 1995, SCIENCE, V267, P90, DOI 10.1126/science.7809611; SHOSTAK K, 1992, BIOCHEMISTRY-US, V31, P12155, DOI 10.1021/bi00163a026; SILVERMAN RB, 1982, J AM CHEM SOC, V104, P6434, DOI 10.1021/ja00387a047; Simonson T, 1996, J AM CHEM SOC, V118, P8452, DOI 10.1021/ja960884f; SMILEY JA, 1991, BIOCHEMISTRY-US, V30, P6216, DOI 10.1021/bi00239a020; SMILEY JA, 1994, P NATL ACAD SCI USA, V91, P8319, DOI 10.1073/pnas.91.18.8319; SMILEY JA, 1992, BIOCHEMISTRY-US, V31, P12162, DOI 10.1021/bi00163a027; SMILEY JA, 1995, J AM CHEM SOC, V117, P3877, DOI 10.1021/ja00118a028; WAGNER R, 1970, HELV CHIM ACTA, V53, P299, DOI 10.1002/hlca.19700530210; WARSHEL A, 1991, ANNU REV BIOPHYS BIO, V20, P267, DOI 10.1146/annurev.bb.20.060191.001411	30	162	162	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 9	1997	276	5314					942	945		10.1126/science.276.5314.942	http://dx.doi.org/10.1126/science.276.5314.942			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WY792	9139656				2022-12-01	WOS:A1997WY79200046
J	Luboldt, W; Bauerfeind, P; Steiner, P; Fried, M; Krestin, GP; Debatin, JF				Luboldt, W; Bauerfeind, P; Steiner, P; Fried, M; Krestin, GP; Debatin, JF			Preliminary assessment of three-dimensional magnetic resonance imaging for various colonic disorders	LANCET			English	Article							GD-DTPA	Background Improvements in magnetic resonance imaging (MRI) technology have enabled the acquisition of three-dimensional MRI datasets in a single breath hold. We adopted this technique to make a three-dimensional intraluminal and extraluminal assessment of the colon in three patients with various colonic disorders. Methods One patient was studied after having a double-contrast barium enema. Two patients had MRI scans after colonoscopy, which showed three colonic tumours in one and multiple polyps in the ascending colon of the other. The process of rectal filling with 1.5-2.0 L water mixed with 15-20 mt 0.5 mol/L gadolinium-diethylenetriaminepentaacetic acid (Gd-DTPA) was monitored with MR fluoroscopic sequence. Three-dimensional datasets of the contrast-filled colon were taken with patients in prone (before and after intravenous administration of 0.1 mmol/kg bodyweight Gd-DTPA) and supine positions. 64 sections with a voxel-resolution of 2.0X2.0x1.25 mm(3)-were taken during a 28 s breath hold. Three-dimensional maximum intensity projection, multiplanar reconstruction, and virtual colonoscopic images of the colon were created from these. Findings Analysis of the coronal source images in conjunction with multiplanar reconstructions revealed all relevant abnormalities, including diverticula, carcinomas, and polyps. Three dimensional maximum-intensity projections gave a morphological overview of the whole colon. Targeted projections, made up of a limited number of coronal source images, showed diverticula and smaller polyps more clearly. After patients were given intravenous contrast all colonic mass lesions were enhanced. Datasets obtained in prone patients gave the best intraluminal views of the colon. Virtual magnetic resonance colonoscopy showed colonic haustra as well as the ileocaecal valve, but did not show clearly the diverticula. All intraluminal mass lesions, on the other hand, were easy to see. Interpretation The potential of three-dimensional colonic MRI to provide accurate, minimally invasive, cost-effective polyp screening, as well as comprehensive colonic tumour staging, warrants further investigation.	UNIV ZURICH HOSP, INST DIAGNOST RADIOL, CH-8091 ZURICH, SWITZERLAND; UNIV ZURICH HOSP, INST GASTROENTEROL, CH-8091 ZURICH, SWITZERLAND	University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital			Bauerfeind, Peter/AAV-2069-2020					COHAN RH, 1991, INVEST RADIOL, V26, P224, DOI 10.1097/00004424-199103000-00005; Davis CP, 1996, RADIOLOGY, V199, P37, DOI 10.1148/radiology.199.1.8633169; Hara AK, 1996, RADIOLOGY, V200, P49, DOI 10.1148/radiology.200.1.8657944; Hara AK, 1996, GASTROENTEROLOGY, V110, P284, DOI 10.1053/gast.1996.v110.pm8536869; LEUNG DA, 1996, RADIOLOGY, V201, P569; PRINCE MR, 1995, RADIOLOGY, V197, P785, DOI 10.1148/radiology.197.3.7480757; Rubin GD, 1996, RADIOLOGY, V199, P321, DOI 10.1148/radiology.199.2.8668772; SCHUHMANNGIAMPIERI G, 1991, INVEST RADIOL, V26, P975, DOI 10.1097/00004424-199111000-00009; WEISS KL, 1990, MAGN RESON IMAGING, V8, P817, DOI 10.1016/0730-725X(90)90019-X	9	100	101	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 3	1997	349	9061					1288	1291		10.1016/S0140-6736(96)11332-5	http://dx.doi.org/10.1016/S0140-6736(96)11332-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW899	9142064				2022-12-01	WOS:A1997WW89900011
J	Nagy, L; Kao, HY; Chakravarti, D; Lin, RJ; Hassig, CA; Ayer, DE; Schreiber, SL; Evans, RM				Nagy, L; Kao, HY; Chakravarti, D; Lin, RJ; Hassig, CA; Ayer, DE; Schreiber, SL; Evans, RM			Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase	CELL			English	Article							THYROID-HORMONE RECEPTOR; AVIAN ERYTHROBLASTOSIS VIRUS; RETINOIC ACID; ERBB ONCOGENES; CO-REPRESSOR; V-ERBA; EXPRESSION; DIFFERENTIATION; ACTIVATION; INTERACTS	The transcriptional corepressors SMRT and N-CoR function as silencing mediators for retinoid and thyroid hormone receptors. Here we show that SMRT and N-CoR directly interact with mSin3A, a corepressor for the Mad-Max heterodimer and a homolog of the yeast global-transcriptional repressor Sin3p. In addition, we demonstrate that the recently characterized histone deacetylase 1 (HDAC1) interacts with Sin3A and SMRT to form a multisubunit repressor complex. Consistent with this model, we find that HDAC inhibitors synergize with retinoic acid to stimulate hormone-responsive genes and differentiation of myeloid leukemia (HL-60) cells. This work establishes a convergence of repression pathways for bHLH-Zip proteins and nuclear receptors and suggests this type of regulation may be more widely conserved than previously suspected.	UNIV CALIF SAN DIEGO,SCH MED,GRAD PROGRAM MOL PATHOL,LA JOLLA,CA 92093; HARVARD UNIV,HOWARD HUGHES MED INST,DEPT CHEM & BIOL CHEM,CAMBRIDGE,MA 02138; UNIV UTAH,HUNTSMAN CANC INST,DEPT ONCOL SCI,SALT LAKE CITY,UT 84112	University of California System; University of California San Diego; Harvard University; Howard Hughes Medical Institute; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah	Nagy, L (corresponding author), SALK INST BIOL STUDIES,HOWARD HUGHES MED INST,LA JOLLA,CA 92037, USA.		Evans, Ronald/AAF-4001-2019; Nagy, Laszlo/A-3814-2008	Evans, Ronald/0000-0002-9986-5965; Nagy, Laszlo/0000-0001-6653-2155; Lin, Richard/0000-0002-0834-7880; Chakravarti, Debabrata/0000-0001-8446-8599; Ayer, Donald/0000-0002-5595-3269	NICHD NIH HHS [HD27183] Funding Source: Medline; NIGMS NIH HHS [GM26444] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027183] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM026444, R01GM026444] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; BANIAHMAD A, 1995, MOL CELL BIOL, V15, P76, DOI 10.1128/MCB.15.1.76; Bartsch J, 1996, P NATL ACAD SCI USA, V93, P10741, DOI 10.1073/pnas.93.20.10741; BRACKMAN D, 1995, LEUKEMIA RES, V19, P57, DOI 10.1016/0145-2126(94)00061-E; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; CASANOVA J, 1994, MOL CELL BIOL, V14, P5756, DOI 10.1128/MCB.14.9.5756; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chen JD, 1996, P NATL ACAD SCI USA, V93, P7567, DOI 10.1073/pnas.93.15.7567; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; COLLINS SJ, 1987, BLOOD, V70, P1233; DAMM K, 1987, EMBO J, V6, P375, DOI 10.1002/j.1460-2075.1987.tb04765.x; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Felsenfeld G, 1996, CELL, V86, P13, DOI 10.1016/S0092-8674(00)80073-2; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; FRAGOSO G, 1995, GENE DEV, V9, P1933, DOI 10.1101/gad.9.15.1933; GRAF T, 1983, CELL, V34, P7, DOI 10.1016/0092-8674(83)90130-7; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; HICKS RM, 1983, P NUTR SOC, V43, P83; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; LEBLANC BP, 1995, GENE DEV, V9, P1811, DOI 10.1101/gad.9.15.1811; Li C, 1997, P NATL ACAD SCI USA, V94, P2278, DOI 10.1073/pnas.94.6.2278; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; Sande S, 1996, MOL ENDOCRINOL, V10, P813, DOI 10.1210/me.10.7.813; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; Seol W, 1996, MOL ENDOCRINOL, V10, P1646, DOI 10.1210/me.10.12.1646; STERNBERG PW, 1987, CELL, V48, P567, DOI 10.1016/0092-8674(87)90235-2; STILLMAN DJ, 1994, GENETICS, V136, P781; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Wolffe AP, 1996, CURR BIOL, V6, P234, DOI 10.1016/S0960-9822(02)00465-7; Wolffe AP, 1996, SCIENCE, V272, P371, DOI 10.1126/science.272.5260.371; Yang Men-Ming, 1996, Proceedings of the National Academy of Sciences of the United States of America, V93, P12845; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626	39	1077	1107	2	38	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 2	1997	89	3					373	380		10.1016/S0092-8674(00)80218-4	http://dx.doi.org/10.1016/S0092-8674(00)80218-4			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WX899	9150137	Bronze			2022-12-01	WOS:A1997WX89900008
J	Featherstone, C				Featherstone, C			Escherichia coli O157: Superbug or mere sensation?	LANCET			English	News Item																			0	7	7	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 29	1997	349	9056					930	930		10.1016/S0140-6736(05)62711-0	http://dx.doi.org/10.1016/S0140-6736(05)62711-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WR254	9132514				2022-12-01	WOS:A1997WR25400031
J	Hetzer, M; Wurzer, G; Schweyen, RJ; Mueller, MW				Hetzer, M; Wurzer, G; Schweyen, RJ; Mueller, MW			Trans-activation of group II intron splicing by nuclear U5 snRNA	NATURE			English	Article							RNA; SPLICEOSOME; INVITRO; SITES; LARIAT	Similarities between RNA splicing during autocatalytic excision of group II introns and pre-mRNA processing led to the hypothesis that group II introns might be the evolutionary predecessors of spliceosomal small nuclear RNAs(1-4). The ID3 subdomain stem-loop structure of group II introns, the proposed analogue of the spliceosomal U5 snRNA(5), is thought to be essential for 5' splice site recognition and anchoring of the free 5' exon(6). Using the group II intron bI1 we have analysed the role of ID3 in splicing. In the absence of ID3 the 5' splice site was recognized accurately and efficiently, but exon anchoring was greatly reduced. This step was restored in the presence of RNA fragments consisting of either the terminal stem-loop structure of ID3 or spliceosomal U5 snRNA. This suggests that the predominant role of both RNAs is to anchor the 5' exon during exon ligation. Furthermore, as U5 complements for the loss of ID3, a similar network of structural RNAs may form the catalytic core of both group II introns and spliceosomes.	UNIV VIENNA,INST MICROBIOL & GENET,A-1030 VIENNA,AUSTRIA	University of Vienna			Wurzer, Georg/AAE-3159-2022	Wurzer, Georg/0000-0002-2532-0073				BACHL J, 1990, J MOL BIOL, V212, P113, DOI 10.1016/0022-2836(90)90308-9; FRANK DN, 1994, MOL CELL BIOL, V14, P2180, DOI 10.1128/MCB.14.3.2180; HARRISKERR CL, 1993, P NATL ACAD SCI USA, V90, P10658, DOI 10.1073/pnas.90.22.10658; JACQUIER A, 1987, CELL, V50, P17, DOI 10.1016/0092-8674(87)90658-1; JACQUIER A, 1990, TRENDS BIOCHEM SCI, V15, P351, DOI 10.1016/0968-0004(90)90075-M; MADHANI HD, 1994, ANNU REV GENET, V28, P1; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; MICHEL F, 1995, ANNU REV BIOCHEM, V64, P435, DOI 10.1146/annurev.bi.64.070195.002251; MICHELS WJ, 1995, BIOCHEMISTRY-US, V34, P2965, DOI 10.1021/bi00009a028; Moore M., 1993, RNA WORLD, P303; MOORE MJ, 1993, NATURE, V365, P364, DOI 10.1038/365364a0; MUELLER M W, 1991, Journal of Molecular Biology, V222, P145; MUELLER MW, 1993, SCIENCE, V261, P1035, DOI 10.1126/science.8351516; NEWMAN AJ, 1992, CELL, V68, P743, DOI 10.1016/0092-8674(92)90149-7; OKeefe RT, 1996, CELL, V86, P679, DOI 10.1016/S0092-8674(00)80140-3; PADGETT RA, 1994, SCIENCE, V266, P1685, DOI 10.1126/science.7527587; PEEBLES CL, 1986, CELL, V44, P213, DOI 10.1016/0092-8674(86)90755-5; SCHMELZER C, 1986, CELL, V46, P557, DOI 10.1016/0092-8674(86)90881-0; SHARP PA, 1991, SCIENCE, V254, P663, DOI 10.1126/science.1948046; SONTHEIMER EJ, 1993, SCIENCE, V262, P1989, DOI 10.1126/science.8266094; SUCHY M, 1991, J MOL BIOL, V222, P179, DOI 10.1016/0022-2836(91)90204-J; VANDERVEEN R, 1986, CELL, V44, P225, DOI 10.1016/0092-8674(86)90756-7; WEINER AM, 1993, CELL, V72, P161, DOI 10.1016/0092-8674(93)90654-9; WISE JA, 1993, SCIENCE, V262, P1978, DOI 10.1126/science.8266091	24	62	67	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 27	1997	386	6623					417	420		10.1038/386417a0	http://dx.doi.org/10.1038/386417a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WQ170	9121561				2022-12-01	WOS:A1997WQ17000070
J	KaneiIshii, C; Tanikawa, J; Nakai, A; Morimoto, RI; Ishii, S				KaneiIshii, C; Tanikawa, J; Nakai, A; Morimoto, RI; Ishii, S			Activation of heat shock transcription factor 3 by c-Myb in the absence of cellular stress	SCIENCE			English	Article							HSP70 GENE-TRANSCRIPTION; DNA-BINDING ABILITY; COILED-COIL; MOLECULAR-CLONING; LEUCINE-ZIPPER; OLIGOMERIZATION; EXPRESSION; HSF1; TRANSACTIVATION; TRIMERIZATION	In vertebrates, the presence of multiple heat shock transcription factors (HSFs) indicates that these factors may be regulated by distinct stress signals. HSF3 was specifically activated in unstressed proliferating cells by direct binding to the c-myb proto-oncogene product (c-Myb). These factors formed a complex through their DNA binding domains that stimulated the nuclear entry and formation of the transcriptionally active trimer of HSF3. Because c-Myb participates in cellular proliferation, this regulatory pathway may provide a link between cellular proliferation and the stress response.	RIKEN, TSUKUBA LIFE SCI CTR, MOL GENET LAB, TSUKUBA, IBARAKI 305, JAPAN; KYOTO UNIV, DEPT CELL BIOL, CHEST DIS RES INST, KYOTO 606, JAPAN; NORTHWESTERN UNIV, DEPT BIOCHEM MOL BIOL & CELL BIOL, RICE INST BIOMED RES, EVANSTON, IL 60208 USA; OSAKA UNIV, MICROBIAL DIS RES INST, SUITA, OSAKA 565, JAPAN	RIKEN; Kyoto University; Northwestern University; Osaka University			Ishii, Shunsuke/A-5271-2016	Ishii, Shunsuke/0000-0002-6530-2478				BALER R, 1993, MOL CELL BIOL, V13, P2486, DOI 10.1128/MCB.13.4.2486; CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; Dix DJ, 1996, P NATL ACAD SCI USA, V93, P3264, DOI 10.1073/pnas.93.8.3264; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; KANEIISHII C, 1994, J BIOL CHEM, V269, P15768; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; KARISEDER J, 1996, BICOH BIOPHYS RES CO, V220, P153; KIMURA Y, IN PRESS GENES DEV; LIS J, 1993, CELL, V74, P1, DOI 10.1016/0092-8674(93)90286-Y; MILARSKI KL, 1986, P NATL ACAD SCI USA, V83, P9517, DOI 10.1073/pnas.83.24.9517; MORIMOTO RI, 1993, SCIENCE, V259, P1409, DOI 10.1126/science.8451637; MOROMOTO RI, 1994, BIOL HEAT SHOCK PROT, P417; MOSSER DD, 1988, MOL CELL BIOL, V8, P4736, DOI 10.1128/MCB.8.11.4736; NAIR SC, IN PRESS CELL STRESS; NAKAI A, 1993, MOL CELL BIOL, V13, P1983, DOI 10.1128/MCB.13.4.1983; NAKAI A, 1995, MOL CELL BIOL, V15, P5268; OESTERREICH S, 1993, CANCER RES, V53, P4443; Ogata K, 1996, NAT STRUCT BIOL, V3, P178, DOI 10.1038/nsb0296-178; PETERANDERL R, 1992, BIOCHEMISTRY-US, V31, P12272, DOI 10.1021/bi00163a042; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; RAMSAY RG, 1989, ONCOGENE RES, V4, P259; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SARGE KD, 1991, GENE DEV, V5, P1902, DOI 10.1101/gad.5.10.1902; SCHUETZ TJ, 1991, P NATL ACAD SCI USA, V88, P6911, DOI 10.1073/pnas.88.16.6911; SISTONEN L, 1994, MOL CELL BIOL, V14, P2087, DOI 10.1128/MCB.14.3.2087; SORGER PK, 1991, CELL, V65, P363, DOI 10.1016/0092-8674(91)90452-5; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; WESTWOOD JT, 1993, MOL CELL BIOL, V13, P3481, DOI 10.1128/MCB.13.6.3481; WESTWOOD JT, 1991, NATURE, V353, P822, DOI 10.1038/353822a0; Wu C., 1994, BIOL HEAT SHOCK PROT, P395; ZUO JR, 1994, MOL CELL BIOL, V14, P7557, DOI 10.1128/MCB.14.11.7557	34	58	58	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 11	1997	277	5323					246	248		10.1126/science.277.5323.246	http://dx.doi.org/10.1126/science.277.5323.246			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK418	9211854				2022-12-01	WOS:A1997XK41800047
J	Lindahl, P; Johansson, BR; Leveen, P; Betsholtz, C				Lindahl, P; Johansson, BR; Leveen, P; Betsholtz, C			Pericyte loss and microaneurysm formation in PDGF-B-deficient mice	SCIENCE			English	Article							RECEPTOR TYROSINE KINASE; SMOOTH-MUSCLE CELLS; GROWTH-FACTOR; ENDOTHELIAL-CELLS; BETA-RECEPTOR; EXPRESSION; INHIBITION; EMBRYO; TEK	Platelet-derived growth factor (pDGF)-B-deficient mouse embryos were found to lack microvascular pericytes, which normally form part of the capillary wall, and they developed numerous capillary microaneurysms that ruptured at late gestation. Endothelial cells of the sprouting capillaries in the mutant mice appeared to be unable to attract pDGF-R beta-positive pericyte progenitor cells. Pericytes may contribute to the mechanical stability of the capillary wall, Comparisons made between PDGF null mouse phenotypes suggest a general role for PDGFs in the development of myofibroblasts.	GOTHENBURG UNIV,DEPT MED BIOCHEM,S-41390 GOTHENBURG,SWEDEN; GOTHENBURG UNIV,DEPT ANAT & CELL BIOL,S-41390 GOTHENBURG,SWEDEN	University of Gothenburg; University of Gothenburg								BERNSTEIN LR, 1982, J CELL SCI, V56, P71; Bostrom H, 1996, CELL, V85, P863, DOI 10.1016/S0092-8674(00)81270-2; BUZNEY SM, 1977, INVEST OPHTH VIS SCI, V16, P392; Carmeliet P, 1996, NATURE, V383, P73, DOI 10.1038/383073a0; COGAN DG, 1961, ARCH OPHTHALMOL-CHIC, V66, P366, DOI 10.1001/archopht.1961.00960010368014; CROCKER DJ, 1970, EXP MOL PATHOL, V13, P51, DOI 10.1016/0014-4800(70)90084-5; DAMORE PA, 1993, GROWTH FACTORS, V8, P61, DOI 10.3109/08977199309029135; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; DUMONT DJ, 1992, ONCOGENE, V7, P1471; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; Fujimoto K, 1995, ANAT RECORD, V242, P562, DOI 10.1002/ar.1092420412; HELDIN CH, 1992, EMBO J, V11, P4251, DOI 10.1002/j.1460-2075.1992.tb05523.x; HENRIQUE D, 1995, NATURE, V375, P787, DOI 10.1038/375787a0; Hogan B., 2014, MANIPULATING MOUSE E; HOLMGREN L, 1991, DEVELOPMENT, V113, P749; KORHONEN J, 1995, BLOOD, V86, P1828, DOI 10.1182/blood.V86.5.1828.bloodjournal8651828; KUWABARA T, 1963, ARCH OPHTHALMOL-CHIC, V69, P492, DOI 10.1001/archopht.1963.00960040498013; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; LINDAHL P, UNPUB; ORLIDGE A, 1987, J CELL BIOL, V105, P1455, DOI 10.1083/jcb.105.3.1455; OSTERBY R, 1974, ACTA MED SCAND, V574, P1; PURI MC, 1995, EMBO J, V14, P5884, DOI 10.1002/j.1460-2075.1995.tb00276.x; Raines E.W., 1990, PEPTIDE GROWTH FACTO, DOI [10.1007/978-3-642-49295-2_5, DOI 10.1007/978-3-642-49295-2_5]; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; SATO Y, 1989, J CELL BIOL, V109, P309, DOI 10.1083/jcb.109.1.309; SCHLONDORFF D, 1987, FASEB J, V1, P272, DOI 10.1096/fasebj.1.4.3308611; SHINBROT E, 1994, DEV DYNAM, V199, P169, DOI 10.1002/aja.1001990302; SIMS DE, 1986, TISSUE CELL, V18, P153, DOI 10.1016/0040-8166(86)90026-1; SORIANO P, 1994, GENE DEV, V8, P1888, DOI 10.1101/gad.8.16.1888; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Vikkula M, 1996, CELL, V87, P1181, DOI 10.1016/S0092-8674(00)81814-0; WESTERMARK B, 1993, BIOL PLATELET DERIVE	33	1582	1638	4	70	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 11	1997	277	5323					242	245		10.1126/science.277.5323.242	http://dx.doi.org/10.1126/science.277.5323.242			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK418	9211853				2022-12-01	WOS:A1997XK41800046
J	Zwilling, S; Dieckmann, A; Pfisterer, P; Angel, P; Wirth, T				Zwilling, S; Dieckmann, A; Pfisterer, P; Angel, P; Wirth, T			Inducible expression and phosphorylation of coactivator BOB.1/OBF.1 in T cells	SCIENCE			English	Article							BINDING TRANSCRIPTION FACTORS; FUNCTIONAL-CHARACTERIZATION; IMMUNOGLOBULIN PROMOTERS; OCT2 TRANSACTIVATION; ACTIVATION; SITES	BOB.1/OBF.1 is a transcriptional coactivator that is constitutively expressed in B cells and interacts with the Oct1 and Oct2 transcription factors. Upon activation of Jurkat T cells and primary murine thymocytes with phorbol esters and ionomycin, BOB.1/OBF.1 expression and transactivation function were induced. BOB.1/OBF.1 was phosphorylated at Ser(184) both in vivo and in vitro, and this modification was required for inducible activation. Mutation of Ser(184) also diminished transactivation function in B cells, suggesting that the activating phosphorylation that is inducible in T cells is constitutively present in B cells. Thus, BOB.1/OBF.1 is a transcriptional coactivator that is critically regulated by posttranslational modifications to mediate cell type-specific gene expression.	UNIV WURZBURG, INST MED STRAHLENKUNDE & ZELLFORSCH, D-97078 WURZBURG, GERMANY; DEUTSCH KREBSFORSCHUNGSZENTRUM, ABT SIGNALTRANSDUKT & WACHSTUMSKONTROLLE, D-69120 HEIDELBERG, GERMANY	University of Wurzburg; Helmholtz Association; German Cancer Research Center (DKFZ)			Wirth, Thomas/X-7172-2019					ANNWEILER A, 1994, NUCLEIC ACIDS RES, V22, P4250, DOI 10.1093/nar/22.20.4250; ANNWEILER A, 1992, MOL CELL BIOL, V12, P3107, DOI 10.1128/MCB.12.7.3107; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Cepek KL, 1996, GENE DEV, V10, P2079, DOI 10.1101/gad.10.16.2079; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRUARTGOUILLEUX V, 1995, EUR J IMMUNOL, V25, P1431, DOI 10.1002/eji.1830250544; Gstaiger M, 1996, EMBO J, V15, P2781, DOI 10.1002/j.1460-2075.1996.tb00638.x; GSTAIGER M, 1995, NATURE, V373, P360, DOI 10.1038/373360a0; KAMPS MP, 1990, MOL CELL BIOL, V10, P5464, DOI 10.1128/MCB.10.10.5464; Kim U, 1996, NATURE, V383, P542, DOI 10.1038/383542a0; KONIG H, 1995, GENE DEV, V9, P1598, DOI 10.1101/gad.9.13.1598; LUO Y, 1992, CELL, V71, P231, DOI 10.1016/0092-8674(92)90352-D; LUO Y, 1995, MOL CELL BIOL, V15, P4115; Nielsen PJ, 1996, EUR J IMMUNOL, V26, P3214, DOI 10.1002/eji.1830261255; PFEUFFER I, 1994, J IMMUNOL, V153, P5572; PFISTERER P, 1994, EMBO J, V13, P1654, DOI 10.1002/j.1460-2075.1994.tb06429.x; PFISTERER P, 1995, J BIOL CHEM, V270, P29870, DOI 10.1074/jbc.270.50.29870; PIERANI A, 1990, MOL CELL BIOL, V10, P6204, DOI 10.1128/MCB.10.12.6204; Schubart DB, 1996, NATURE, V383, P538, DOI 10.1038/383538a0; STAUDT LM, 1991, ANNU REV IMMUNOL, V9, P373; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; ULLMAN KS, 1993, GENE DEV, V7, P188, DOI 10.1101/gad.7.2.188; WIRTH T, 1995, IMMUNOBIOLOGY, V193, P161, DOI 10.1016/S0171-2985(11)80540-1	23	76	77	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 11	1997	277	5323					221	225		10.1126/science.277.5323.221	http://dx.doi.org/10.1126/science.277.5323.221			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK418	9211847				2022-12-01	WOS:A1997XK41800040
J	Ulmasov, T; Hagen, G; Guilfoyle, TJ				Ulmasov, T; Hagen, G; Guilfoyle, TJ			ARF1, a transcription factor that binds to auxin response elements	SCIENCE			English	Article							GENE; ENCODES	The plant hormone auxin regulates plant physiology by modulating the interaction of transcription factors with auxin response elements (AuxREs) of the affected genes. A transcription factor, Auxin Response Factor 1 (ARF1), that binds to the sequence TGTCTC in AuxREs was cloned from Arabidopsis by using a yeast one-hybrid system. ARF1 has an amino-terminal DNA-binding domain related to the carboxyl terminus of the maize transactivator Viviparous-1. Sequence requirements for ARF1 binding in vitro are identical to those that confer auxin responsiveness in vivo. The carboxyl terminus of ARF1 contains two motifs found in the Aux/IAA class of proteins and appears to mediate protein-protein interactions.	UNIV MISSOURI,DEPT BIOCHEM,COLUMBIA,MO 65211	University of Missouri System; University of Missouri Columbia								Abel S, 1996, PLANT PHYSIOL, V111, P9, DOI 10.1104/pp.111.1.9; ABEL S, 1994, P NATL ACAD SCI USA, V91, P326, DOI 10.1073/pnas.91.1.326; Ausubel F.M., 1995, CURRENT PROTOCOLS MO; BALLAS N, 1995, P NATL ACAD SCI USA, V92, P3483, DOI 10.1073/pnas.92.8.3483; Bennett MJ, 1996, SCIENCE, V273, P948, DOI 10.1126/science.273.5277.948; GIRAUDAT J, 1992, PLANT CELL, V4, P1251, DOI 10.1105/tpc.4.10.1251; GUILFOYLE TJ, 1993, AUST J PLANT PHYSIOL, V20, P489, DOI 10.1071/PP9930489; Lehman A, 1996, CELL, V85, P183, DOI 10.1016/S0092-8674(00)81095-8; LEYSER HMO, 1993, NATURE, V364, P161, DOI 10.1038/364161a0; LIU ZB, 1994, PLANT CELL, V6, P645, DOI 10.1105/tpc.6.5.645; MCCARTY DR, 1991, CELL, V66, P895, DOI 10.1016/0092-8674(91)90436-3; TRELZENBERG SJ, 1995, CURR BIOL, V5, P190; ULMASOV T, 1995, PLANT CELL, V7, P1611, DOI 10.1105/tpc.7.10.1611; ULMASOV T, UNPUB; YAMAMOTO KR, 1992, TRANSCRIPTIONAL REGU, P1169	15	675	744	6	116	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 20	1997	276	5320					1865	1868		10.1126/science.276.5320.1865	http://dx.doi.org/10.1126/science.276.5320.1865			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XF103	9188533				2022-12-01	WOS:A1997XF10300050
J	Groenewoud, JH; van der Maas, PJ; vanderWal, G; Hengeveld, MW; Tholen, AJ; Schudel, WJ; vanderHeide, A				Groenewoud, JH; van der Maas, PJ; vanderWal, G; Hengeveld, MW; Tholen, AJ; Schudel, WJ; vanderHeide, A			Physician-assisted death in psychiatric practice in the Netherlands	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EUTHANASIA; CONSULTATION; SUICIDE	Background In 1994 the Dutch Supreme Court ruled that in exceptional instances, physician-assist ed suicide might be justifiable for patients with unbearable mental suffering but no physical illness. We studied physician-assisted suicide and euthanasia in psychiatric practice in the Netherlands. Methods In 1996, we sent questionnaires to 673 Dutch psychiatrists - about half of all such special ists in the country - and received 552 responses from the 667 who met the study criteria (response rate, 83 percent). We estimated the annual frequencies of requests for physician-assisted suicide by psychiatrists and actual instances of assistance. Results Of the respondents, 205 (37 percent) had at least once received an explicit, persistent request for physician-assisted suicide and 12 had complied. We estimate there are 320 requests a year in psychiatric practice and 2 to 5 assisted suicides. Excluding those who had ever assisted, 345 of the respondents (64 percent) thought physician-assisted suicide because of a mental disorder could be acceptable, including 241 who said they could conceive of instances in which they themselves would be willing to assist. The most frequent reasons for refusing were the belief that the patient had a treatable mental disorder, opposition to assisted suicide in principle, and doubt that the suffering was unbearable or hopeless. Most, but not all, patients who had been assisted by their psychiatrists in suicide had both a mental disorder and a serious physical illness, often in a terminal phase. Thirty percent of the respondents had been consulted at least once by a physician in another specialty about a patient's request for assisted death. The annual number of such consultations was estimated at 310, about 3 percent of the estimated 9700 requests for euthanasia or physician-assisted suicide in medical practice. Conclusions Explicit requests for physician-assisted suicide are not uncommon in psychiatric practice in the Netherlands, but these requests are rarely granted. Psychiatric consultation for medical patients who request physician-assisted death is relatively rare. (C)1997, Massachusetts Medical Society.	ERASMUS UNIV ROTTERDAM, DEPT PSYCHIAT, NL-3000 DR ROTTERDAM, NETHERLANDS; VRIJE UNIV AMSTERDAM, INST RES EXTRAMURAL MED, AMSTERDAM, NETHERLANDS; LEIDEN UNIV, DEPT PSYCHIAT, LEIDEN, NETHERLANDS; UNIV GRONINGEN, UNIV HOSP GRONINGEN, DEPT PSYCHIAT, GRONINGEN, NETHERLANDS	Erasmus University Rotterdam; Vrije Universiteit Amsterdam; Leiden University; Leiden University - Excl LUMC; University of Groningen	Groenewoud, JH (corresponding author), ERASMUS UNIV ROTTERDAM, DEPT PUBL HLTH, POB 1738, NL-3000 DR ROTTERDAM, NETHERLANDS.							BAILE WF, 1993, CANCER, V72, P2786, DOI 10.1002/1097-0142(19931101)72:9<2786::AID-CNCR2820720942>3.0.CO;2-2; BLOCK SD, 1995, PSYCHOSOMATICS, V36, P445, DOI 10.1016/S0033-3182(95)71625-5; Bokhove J., 1996, BALANS REKENONDERWIJ; CHOCHINOV HM, 1995, AM J PSYCHIAT, V152, P1185; *COMM AANV LEV HAN, 1993, DISC NOT HULP BIJ ZE; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; GEVERS S, 1995, BIOETHICS, V9, P309, DOI 10.1111/j.1467-8519.1995.tb00366.x; Griffiths J., 1995, MOD LAW REV, V58, P232, DOI [10.1111/j.1468-2230.1995.tb02006.x, DOI 10.1111/J.1468-2230.1995.TB02006.X]; Humphrey D., 1991, FINAL EXIT PRACTICAL; HUYSE FJ, 1993, HOSP COMMUNITY PSYCH, V44, P733; van der Maas PJ, 1995, JAMA-J AM MED ASSOC, V273, P1411, DOI 10.1001/jama.273.18.1411; van der Maas PJ, 1996, NEW ENGL J MED, V335, P1699, DOI 10.1056/NEJM199611283352227; vanderWal G, 1996, NEW ENGL J MED, V335, P1706; 1994, NED JURISPRUDENTIE, V656, P3142	14	77	78	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 19	1997	336	25					1795	1801		10.1056/NEJM199706193362506	http://dx.doi.org/10.1056/NEJM199706193362506			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XE485	9187071	Green Published			2022-12-01	WOS:A1997XE48500006
J	Albertsen, PC				Albertsen, PC			Urology	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											Albertsen, PC (corresponding author), UNIV CONNECTICUT,CTR HLTH,FARMINGTON,CT 06032, USA.							Boyle P, 1996, UROLOGY, V48, P398, DOI 10.1016/S0090-4295(96)00353-6; DelaRosette JJMCH, 1996, J UROLOGY, V156, P97, DOI 10.1016/S0022-5347(01)65952-4; Dugan JA, 1996, JAMA-J AM MED ASSOC, V275, P288, DOI 10.1001/jama.275.4.288; Gerber GS, 1996, JAMA-J AM MED ASSOC, V276, P615; Grimm PD, 1996, HEMATOL ONCOL CLIN N, V10, P653, DOI 10.1016/S0889-8588(05)70359-2; GROVE A, 1996, FORTUNE, V133, P54; Helgesen F, 1996, JNCI-J NATL CANCER I, V88, P1216, DOI 10.1093/jnci/88.17.1216; Lepor H, 1996, NEW ENGL J MED, V335, P533, DOI 10.1056/NEJM199608223350801; Linet OI, 1996, NEW ENGL J MED, V334, P873, DOI 10.1056/NEJM199604043341401; Lowe FC, 1996, UROLOGY, V48, P12, DOI 10.1016/S0090-4295(96)00077-5; LuYao GL, 1996, J NATL CANCER I, V88, P166, DOI 10.1093/jnci/88.3-4.166; Morgan TO, 1996, NEW ENGL J MED, V335, P304, DOI 10.1056/NEJM199608013350502; Smith DS, 1996, JAMA-J AM MED ASSOC, V276, P1309, DOI 10.1001/jama.276.16.1309; Smith JR, 1996, SCIENCE, V274, P1371, DOI 10.1126/science.274.5291.1371; TROCKMAN BA, 1995, J UROLOGY, V154, P1841, DOI 10.1016/S0022-5347(01)66796-X	15	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	1997	277	23					1904	1905						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD544	9185828				2022-12-01	WOS:A1997XD54400047
J	Levin, LA				Levin, LA			Ophthalmology	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TRIAL				Levin, LA (corresponding author), UNIV WISCONSIN,SCH MED,MADISON,WI 53706, USA.							Andersen JS, 1997, ARCH OPHTHALMOL-CHIC, V115, P384, DOI 10.1001/archopht.1997.01100150386012; BAILEY RL, 1993, LANCET, V342, P453, DOI 10.1016/0140-6736(93)91591-9; BUTLER VP, 1995, ANN INTERN MED, V123, P676, DOI 10.7326/0003-4819-123-9-199511010-00006; Camras CB, 1996, OPHTHALMOLOGY, V103, P138, DOI 10.1016/S0161-6420(96)30749-5; Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147; Gallie BL, 1996, ARCH OPHTHALMOL-CHIC, V114, P1321, DOI 10.1001/archopht.1996.01100140521001; Kingston JE, 1996, ARCH OPHTHALMOL-CHIC, V114, P1339, DOI 10.1001/archopht.1996.01100140539004; MARTIN DF, 1994, ARCH OPHTHALMOL-CHIC, V112, P1531, DOI 10.1001/archopht.1994.01090240037023; Marx JL, 1996, ARCH OPHTHALMOL-CHIC, V114, P815, DOI 10.1001/archopht.1996.01100140029003; Murphree AL, 1996, ARCH OPHTHALMOL-CHIC, V114, P1348, DOI 10.1001/archopht.1996.01100140548005; Rahhal FM, 1996, ANN INTERN MED, V125, P98, DOI 10.7326/0003-4819-125-2-199607150-00003; SCHUMAN JS, IN PRESS ARCH OPHTHA; Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141; Semina EV, 1996, NAT GENET, V14, P392, DOI 10.1038/ng1296-392; Shields CL, 1996, ARCH OPHTHALMOL-CHIC, V114, P1330, DOI 10.1001/archopht.1996.01100140530002; Stone EM, 1997, SCIENCE, V275, P668, DOI 10.1126/science.275.5300.668; Tabbara KF, 1996, OPHTHALMOLOGY, V103, P842	17	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	1997	277	23					1881	1883						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD544	9185815				2022-12-01	WOS:A1997XD54400034
J	Adler, MW				Adler, MW			Sexual health - A Health of the Nation failure	BRITISH MEDICAL JOURNAL			English	Article											Adler, MW (corresponding author), UCL, SCH MED, DEPT SEXUALLY TRANSMITTED DIS, MORTIMER ST, LONDON WC1E 6AU, ENGLAND.							BABB P, 1993, POPULATION TRENDS, V74, P12; Catchpole MA, 1996, BRIT MED J, V312, P539, DOI 10.1136/bmj.312.7030.539; *COMM DIS SURV CTR, 1996, CDR, V6, P418; *COMM DIS SURV CTR, 1997, CDR, V4, P29; CONNOR N, IN PRESS CDR; COWAN FM, 1994, BRIT MED J, V309, P1325, DOI 10.1136/bmj.309.6965.1325; *DEP HLTH, 1996, UNL AN HIV PREV MON; Haines A, 1997, BRIT MED J, V314, P529, DOI 10.1136/bmj.314.7080.529; Johnson AM, 1996, GENITOURIN MED, V72, P197; Lacey CJN, 1997, BRIT MED J, V314, P1715, DOI 10.1136/bmj.314.7096.1715; Low N, 1997, BRIT MED J, V314, P1719, DOI 10.1136/bmj.314.7096.1719; MILLER E, 1995, BRIT MED J, V311, P545, DOI 10.1136/bmj.311.7004.545; *NHS CTR REV DIS U, 1997, EFFECTIVE HLTH CARE, V3; Secretary of State for Health, 1992, HLTH NAT STRAT HLTH; 1996, CDR, P6	15	40	40	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 14	1997	314	7096					1743	1747		10.1136/bmj.314.7096.1743	http://dx.doi.org/10.1136/bmj.314.7096.1743			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XE909	9202507	Green Published			2022-12-01	WOS:A1997XE90900030
J	Vaidya, JS; Mittra, I				Vaidya, JS; Mittra, I			Fraction of normal remaining life span: A new method for expressing survival in cancer	BMJ-BRITISH MEDICAL JOURNAL			English	Article									TATA MEM HOSP, DEPT SURG, BOMBAY 400012, MAHARASHTRA, INDIA	Tata Memorial Centre (TMC); Tata Memorial Hospital			Vaidya, Jayant S/F-7717-2010; Vaidya, Jayant S/A-7218-2008	Vaidya, Jayant S/0000-0003-1760-1278; Vaidya, Jayant S/0000-0003-1760-1278; Mittra, Indraneel/0000-0002-5768-3821				BERKSON J, 1950, P STAFF M MAYO CLIN, V25, P270; Berrino F, 1995, IARC SCI PUBL, V132, P1; BRINKLEY D, 1975, LANCET, V2, P95; EDERER FRED, 1961, NATL CANCER INST MONOGR, V6, P101; HAKAMA M, 1977, J CHRON DIS, V30, P585, DOI 10.1016/0021-9681(77)90057-1; HAKULINEN T, 1982, BIOMETRICS, V38, P933, DOI 10.2307/2529873; HAKULINEN T, 1977, J CHRON DIS, V30, P431, DOI 10.1016/0021-9681(77)90036-4; WALTER G, 1992, ACTUARIAL SURVIVAL C	8	9	9	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 7	1997	314	7095					1682	1684		10.1136/bmj.314.7095.1682	http://dx.doi.org/10.1136/bmj.314.7095.1682			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD874	9193295	Green Published			2022-12-01	WOS:A1997XD87400032
J	Cornell, BA; BraachMaksvytis, VLB; King, LG; Osman, PDJ; Raguse, B; Wieczorek, L; Pace, RJ				Cornell, BA; BraachMaksvytis, VLB; King, LG; Osman, PDJ; Raguse, B; Wieczorek, L; Pace, RJ			A biosensor that uses ion-channel switches	NATURE			English	Article							BIOMIMETIC MEMBRANES; LIPID BILAYERS; ATTACHMENT; GOLD	Biosensors are molecular sensors that combine a biological recognition mechanism with a physical transduction technique. They provide a new class of inexpensive, portable instrument that permit sophisticated analytical measurements to be undertaken rapidly at decentralized locations(1). However, the adoption of biosensors for practical applications other than the measurement of blood glucose is currently limited by the expense, insensitivity and inflexibility of the available transduction methods. Here we describe the development of a biosensing technique in which the conductance of a population of molecular ion channels is switched by the recognition event. The approach mimics biological sensory functions(2,3) and can be used with most types of receptor, including antibodies and nucleotides. The technique is very flexible and even in its simplest form it is sensitive to picomolar concentrations of proteins. The sensor is essentially an impedance element whose dimensions can readily be reduced to become an integral component of a microelectronic circuit. It may be used in a wide range of applications and in complex media, including blood. These uses might include cell typing, the detection of large proteins, viruses, antibodies, DNA, electrolytes, drugs, pesticides and other low-molecular-weight compounds.	AUSTRALIAN NATL UNIV,FAC SCI,DEPT CHEM,CANBERRA,ACT,AUSTRALIA	Australian National University	Cornell, BA (corresponding author), COOPERAT RES CTR MOL ENGN & TECHNOL,126 GREVILLE ST,CHATSWOOD,NSW 2067,AUSTRALIA.		Cornell, Bruce/B-8758-2013; Pace, Ronald J/T-5906-2017	cornell, bruce/0000-0003-4166-3241; osman, peter/0000-0003-1795-0582				AVRON E, 1995, BIOSYSTEMS, V36, P101, DOI 10.1016/0303-2647(95)01531-O; FLORIN EL, 1993, BIOPHYS J, V64, P375, DOI 10.1016/S0006-3495(93)81378-X; FOLKERS JP, 1994, J PHYS CHEM-US, V98, P563, DOI 10.1021/j100053a035; HEYSEL S, 1995, PROTEIN SCI, V4, P2532, DOI 10.1002/pro.5560041210; Hladky SB, 1995, BIOPHYS J, V69, P1758, DOI 10.1016/S0006-3495(95)80046-9; Koeppe RE, 1996, ANNU REV BIOPH BIOM, V25, P231; LANG H, 1994, LANGMUIR, V10, P197, DOI 10.1021/la00013a029; Lu XD, 1996, BIOELECTROCH BIOENER, V39, P285, DOI 10.1016/0302-4598(95)05039-6; MCCONNELL HM, 1986, BIOCHIM BIOPHYS ACTA, V864, P95, DOI 10.1016/0304-4157(86)90016-X; Nikolelis DP, 1996, ANAL CHEM, V68, P1735, DOI 10.1021/ac950403v; PLANT AL, 1994, BIOPHYS J, V67, P1126, DOI 10.1016/S0006-3495(94)80579-X; Reiken SR, 1996, BIOSENS BIOELECTRON, V11, P91, DOI 10.1016/0956-5663(96)83716-X; Rickert J, 1996, BIOSENS BIOELECTRON, V11, P591, DOI 10.1016/0956-5663(96)83294-5; Sackmann E, 1996, SCIENCE, V271, P43, DOI 10.1126/science.271.5245.43; SCHELLER FW, 1996, FRONTIERS BIOSENSORI, V1; Steinem C, 1996, BBA-BIOMEMBRANES, V1279, P169, DOI 10.1016/0005-2736(95)00274-X; STEIZLE M, 1993, J PHYS CHEM-US, V97, P2974; Stetter KO, 1996, FEMS MICROBIOL REV, V18, P149, DOI 10.1111/j.1574-6976.1996.tb00233.x	18	954	1012	6	383	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 5	1997	387	6633					580	583		10.1038/42432	http://dx.doi.org/10.1038/42432			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XC522	9177344				2022-12-01	WOS:A1997XC52200049
J	Dyker, AG; Weir, CJ; Lees, KR				Dyker, AG; Weir, CJ; Lees, KR			Influence of cholesterol on survival after stroke: Retrospective study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CEREBRAL INFARCTION; RISK-FACTORS; MEN; MORTALITY; ARTERIES; RABBITS; AKITA	Objective: To investigate the association between Serum cholesterol concentrat Design: Retrospective study. Setting: Acute stroke unit of inner city general hospital. Subjects: 977 patients with acute stroke. Main outcome measures: Serum total cholesterol concentration, type of stroke investigated by computed tomography or magnetic resonance imaging, three month outcome (good (alive at home) or bad (dead ol in care)), long term mortality Results: After adjustment for known prognostic factors, higher serum cholesterol concentrations were associated with reduced long term mortality after stroke (relative hazard 0.91 (95% confidence interval 0.84 to 0,98) per mmol/l increase in cholesterol) independently of stroke type, vascular territory and extent, age, and hyperglycaemia. Three month outcome was also influenced independently by serum cholesterol (P = 0.024). Conclusions: Our data suggest an association between poor stroke outcome and lower serum cholesterol concentration. Until a prospective controlled study has confirmed the benefits of lowering cholesterol concentration in elderly subjects, the application of cholesterol lowering guidelines cannot be justified as secondary prevention of acute stroke.			Dyker, AG (corresponding author), UNIV GLASGOW, WESTERN INFIRM, DEPT MED & THERAPEUT, ACUTE STROKE UNIT, GLASGOW G11 6NT, LANARK, SCOTLAND.			Weir, Christopher/0000-0002-6494-4903				[Anonymous], 1995, J Clin Epidemiol, V48, P1441; BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O; Butterworth RJ, 1997, CEREBROVASC DIS, V7, P10, DOI 10.1159/000108156; CHUI DH, 1991, BIOMED PHARMACOTHER, V45, P409, DOI 10.1016/0753-3322(91)90005-E; CHUI DH, 1991, BIOMED PHARMACOTHER, V45, P37, DOI 10.1016/0753-3322(91)90152-J; COX DR, 1972, J R STAT SOC B, V34, P187; ERYUREK FG, 1990, RES COMMUN CHEM PATH, V69, P245; ISLES CG, 1986, J HYPERTENS, V4, P141, DOI 10.1097/00004872-198604000-00003; ISO H, 1989, NEW ENGL J MED, V320, P904, DOI 10.1056/NEJM198904063201405; KAGAN A, 1980, STROKE, V11, P14, DOI 10.1161/01.STR.11.1.14; KENDRICK S, 1993, HLTH B EDINB, V51, P1; KONISHI M, 1993, STROKE, V24, P954, DOI 10.1161/01.STR.24.7.954; MORRIS AD, 1993, J NEUROL NEUROSUR PS, V56, P352, DOI 10.1136/jnnp.56.4.352; PEDERSEN TR, 1994, LANCET, V344, P1383; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; SIMONSEN U, 1991, CLIN SCI, V80, P119, DOI 10.1042/cs0800119; TANAKA H, 1982, STROKE, V13, P62, DOI 10.1161/01.STR.13.1.62; UESHIMA H, 1980, PREV MED, V9, P722, DOI 10.1016/0091-7435(80)90017-1	19	92	96	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 31	1997	314	7094					1584	1588		10.1136/bmj.314.7094.1584	http://dx.doi.org/10.1136/bmj.314.7094.1584			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XC500	9169402	Green Published			2022-12-01	WOS:A1997XC50000020
J	Tang, HL; Gaietta, GM; Fischer, WH; Ellisman, MH; WongStaal, F				Tang, HL; Gaietta, GM; Fischer, WH; Ellisman, MH; WongStaal, F			A cellular cofactor for the constitutive transport element of type D retrovirus	SCIENCE			English	Article							HELA-CELLS; RNA; INHIBITION; CYTOPLASM; NUCLEUS	A human nuclear protein that specifically interacts with the constitutive transport element (CTE) of simian retrovirus was identified as adenosine 5'-triphosphate-dependent RNA helicase A. This protein could bind to functional CTE but not to inactive CTE mutants. The interaction of helicase A with CTE was distinct from previously described helicase activity of this protein. Helicase A shuttled from the nucleus to the cytoplasm in the presence of a transcription inhibitor or in cells transiently overexpressing CTE-containing RNA. In vivo colocalization of helicase A and CTE was observed in experiments that combined in situ hybridization and immunostaining, These results suggest that helicase A plays a role in the nuclear export of CTE-containing RNA.	UNIV CALIF SAN DIEGO,DEPT MED & BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT NEUROSCI,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,SAN DIEGO MICROSCOPY IMAGING RESOURCE,LA JOLLA,CA 92093; SALK INST BIOL STUDIES,CLAYTON FDN LABS PEPTIDE BIOL,LA JOLLA,CA 92097	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Salk Institute			Tang, Hengli/F-2085-2014		NCRR NIH HHS [RR 04050] Funding Source: Medline; NINDS NIH HHS [NS 14718] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR004050] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS014718] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BRAY M, 1994, P NATL ACAD SCI USA, V91, P1256, DOI 10.1073/pnas.91.4.1256; Ernst RK, 1997, MOL CELL BIOL, V17, P135, DOI 10.1128/MCB.17.1.135; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; LEE CG, 1993, J BIOL CHEM, V268, P16822; LEE CG, 1992, J BIOL CHEM, V267, P4398; Liang S, 1996, MOL CELL BIOL, V16, P5139; LUZNIK L, 1993, AIDS RES HUM RETROV, V11, P795; MEYER BE, 1994, GENE DEV, V8, P1538, DOI 10.1101/gad.8.13.1538; Ohno M, 1996, GENE DEV, V10, P997, DOI 10.1101/gad.10.8.997; PERRY RP, 1970, J CELL PHYSIOL, V76, P127, DOI 10.1002/jcp.1040760202; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; SEHGAL PB, 1976, CELL, V9, P473, DOI 10.1016/0092-8674(76)90092-1; Tabernero C, 1996, J VIROL, V70, P5998, DOI 10.1128/JVI.70.9.5998-6011.1996; Tang HL, 1997, VIROLOGY, V228, P333, DOI 10.1006/viro.1996.8407; Xu Yuan, 1996, Journal of Biomedical Science, V3, P82, DOI 10.1007/BF02255535; Yeakley JM, 1996, P NATL ACAD SCI USA, V93, P7582, DOI 10.1073/pnas.93.15.7582; ZOLOTUKHIN AS, 1994, J VIROL, V68, P7944, DOI 10.1128/JVI.68.12.7944-7952.1994; [No title captured]	18	125	127	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 30	1997	276	5317					1412	1415		10.1126/science.276.5317.1412	http://dx.doi.org/10.1126/science.276.5317.1412			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XB533	9162007				2022-12-01	WOS:A1997XB53300048
J	Scott, ERD; Yamaguchi, A; Krot, AN				Scott, ERD; Yamaguchi, A; Krot, AN			Petrological evidence for shock melting of carbonates in the Martian meteorite ALH84001	NATURE			English	Article							ORDINARY CHONDRITES; RECOVERY EXPERIMENTS; METAMORPHISM; IMPACT	The meteorite ALH84001-a shacked igneous rock of probable martian origin-contains chemically and isotopically heterogeneous carbonate globules(1-8), associated with which are organic and inorganic structures that have been interpreted? as possible fossil remains of ancient martian biota, A critical assumption underlying this suggestion is that the carbonates formed from low-temperature fluids penetrating the cracks and voids of the host rock(3). Here we report petrological studies of ALH84001 which investigate the effects of shock on the various mineralogical components of the rock We find that carbonate, plagiodase and silica were melted and partly redistributed by the same shock event responsible for the intense local crushing(1,2) of pyroxene in the meteorite, Texture and compositional data show that, during the period of shock decompression, monomineralic melts were injected into pyroxene fractures that were subsequently cooled and resealed within seconds, Our results therefore suggest that the carbonates in ALH84001 could not have formed at low temperatures, but instead crystallized from shock-melted material; this conclusion weakens significantly the arguments that these carbonates could host the fossilized remnants of biogenic activity.			Scott, ERD (corresponding author), UNIV HAWAII MANOA,SCH OCEAN & EARTH SCI & TECHNOL,HAWAII INST GEOPHYS & PLANETOL,HONOLULU,HI 96822, USA.			Scott, Edward/0000-0002-5137-3830				BISCHOFF A, 1983, EARTH PLANET SC LETT, V66, P1, DOI 10.1016/0012-821X(83)90121-8; Chen M, 1996, SCIENCE, V271, P1570, DOI 10.1126/science.271.5255.1570; DENCE MR, 1974, CONTRIB MINERAL PETR, V46, P81, DOI 10.1007/BF00377497; Dobson DP, 1996, EARTH PLANET SC LETT, V143, P207, DOI 10.1016/0012-821X(96)00139-2; Harvey RP, 1996, NATURE, V382, P49, DOI 10.1038/382049a0; IONOV DA, 1993, EARTH PLANET SC LETT, V119, P283, DOI 10.1016/0012-821X(93)90139-Z; IRVING AJ, 1975, GEOCHIM COSMOCHIM AC, V39, P35, DOI 10.1016/0016-7037(75)90183-0; Joreau P, 1997, METEORIT PLANET SCI, V32, P309, DOI 10.1111/j.1945-5100.1997.tb01268.x; JULL AJT, 1995, METEORITICS, V30, P311, DOI 10.1111/j.1945-5100.1995.tb01129.x; Jull AJT, 1997, J GEOPHYS RES-PLANET, V102, P1663, DOI 10.1029/96JE03111; Kirschvink JL, 1997, SCIENCE, V275, P1629, DOI 10.1126/science.275.5306.1629; LANGE MA, 1986, EARTH PLANET SC LETT, V77, P409, DOI 10.1016/0012-821X(86)90150-0; Lee WJ, 1996, J PETROL, V37, P1125, DOI 10.1093/petrology/37.5.1125; MARTINEZ I, 1995, J GEOPHYS RES-SOL EA, V100, P15465, DOI 10.1029/95JB01151; McKay DS, 1996, SCIENCE, V273, P924, DOI 10.1126/science.273.5277.924; MITTLEFEHLDT DW, 1994, METEORITICS, V29, P214, DOI 10.1111/j.1945-5100.1994.tb00673.x; ROMANEK CS, 1994, NATURE, V372, P655, DOI 10.1038/372655a0; RUBIN AE, 1992, GEOCHIM COSMOCHIM AC, V56, P1705, DOI 10.1016/0016-7037(92)90236-C; SCHAAL RB, 1977, P LUNAR PLANET SCI C, V8, P1697; SCHMITT RT, 1994, METEORITICS, V29, P529; SEMENENKO VP, 1994, GEOCHIM COSMOCHIM AC, V58, P1525, DOI 10.1016/0016-7037(94)90554-1; STOFFLER D, 1984, J NON-CRYST SOLIDS, V67, P465, DOI 10.1016/0022-3093(84)90171-6; STOFFLER D, 1986, GEOCHIM COSMOCHIM AC, V50, P889, DOI 10.1016/0016-7037(86)90371-6; STOFFLER D, 1991, GEOCHIM COSMOCHIM AC, V55, P3845, DOI 10.1016/0016-7037(91)90078-J; Stoffler D., 1988, METEORITES EARLY SOL, P165; THOMAS KL, 1996, LUNAR PLANET SCI, V27, P1327; TREIMAN AH, 1995, METEORITICS, V30, P294, DOI 10.1111/j.1945-5100.1995.tb01127.x; Valley JW, 1997, SCIENCE, V275, P1633, DOI 10.1126/science.275.5306.1633; WRIGHT IP, 1989, NATURE, V340, P220, DOI 10.1038/340220a0; Wyllie P.J., 1989, CARBONATITES GENESIS, P500	30	87	91	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 22	1997	387	6631					377	379		10.1038/387377a0	http://dx.doi.org/10.1038/387377a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XA496	9163421				2022-12-01	WOS:A1997XA49600052
J	StOnge, L; SosaPineda, B; Chowdhury, K; Mansouri, A; Gruss, P				StOnge, L; SosaPineda, B; Chowdhury, K; Mansouri, A; Gruss, P			Pax6 Is required for differentiation of glucagon-producing alpha-cells in mouse pancreas	NATURE			English	Article							ENDOCRINE PANCREAS; ADHESION MOLECULE; GENE; EXPRESSION; AGGREGATION; POLYPEPTIDE; INSULIN; ISLETS; MICE	The functional unit of the endocrine pancreas is the islet of Langerhans. Islets are nested within the exocrine tissue of the pancreas and are composed of alpha-, beta-, delta- and gamma-cells(1). P-Cells produce insulin and form the core of the islet, whereas alpha-, delta- and gamma-cells are arranged at the periphery of the islet and secrete glucagon, somatostatin and a pancreatic polypeptide, respectively. Little is known about the molecular and genetic factors regulating the lineage of the different endocrine cells. Pancreas development is known to be abolished in Pdx1-mutant mice(2) and Pax4 mutants lack insulin-producing beta-cells(3). Here we show that the paired-box gene Pax6 is expressed during the early stages of pancreatic development and in mature endocrine cells. The pancreas of Pax6 homozygous mutant mice lack glucagon-producing cells, suggesting that Pax6 is essential for the differentiation of alpha-cells. As mice lacking Pax4 and Pax6 fail to develop any mature endocrine cells, we conclude that both Pax genes are required for endocrine fate in the pancreas.	MAX PLANCK INST BIOPHYS CHEM,D-37077 GOTTINGEN,GERMANY	Max Planck Society								CHALEPAKIS G, 1994, DNA CELL BIOL, V13, P891, DOI 10.1089/dna.1994.13.891; Dahl U, 1996, DEVELOPMENT, V122, P2895; DELTOUR L, 1991, DEVELOPMENT, V112, P1115; GITTES GK, 1992, P NATL ACAD SCI USA, V89, P1128, DOI 10.1073/pnas.89.3.1128; GRINDLEY JC, 1995, DEVELOPMENT, V121, P1433; HERRERA PL, 1991, DEVELOPMENT, V113, P1257; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; LEMOUELLIC H, 1990, P NATL ACAD SCI USA, V87, P4712, DOI 10.1073/pnas.87.12.4712; MOLLER CJ, 1992, MOL ENDOCRINOL, V6, P1332, DOI 10.1210/me.6.8.1332; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; NAGY A, 1993, GENE TARGETING PRACT, P145; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; ROUILLER DG, 1991, DEV BIOL, V148, P233, DOI 10.1016/0012-1606(91)90332-W; SLACK JMW, 1995, DEVELOPMENT, V121, P1569; SosaPineda B, 1997, NATURE, V386, P399, DOI 10.1038/386399a0; Stoykova A, 1996, DEVELOPMENT, V122, P3453; TEITELMAN G, 1993, DEVELOPMENT, V118, P1031; TURQUE N, 1994, MOL ENDOCRINOL, V8, P929, DOI 10.1210/me.8.7.929; WALTHER C, 1991, DEVELOPMENT, V113, P1435; Wurst W., 1993, Gene targeting: a practical approach., P33	20	634	650	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 22	1997	387	6631					406	409		10.1038/387406a0	http://dx.doi.org/10.1038/387406a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XA496	9163426				2022-12-01	WOS:A1997XA49600061
J	Catalona, WJ; Smith, DS; Ornstein, DK				Catalona, WJ; Smith, DS; Ornstein, DK			Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination - Enhancement of specificity with free PSA measurements	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ANTIGEN; ALPHA-1-ANTICHYMOTRYPSIN; COMPLEX; DIAGNOSIS; EXTENT	Objective.-To determine the detection rate of prostate cancer in a screening population of men with prostate-specific antigen (PSA) concentrations of 2.6 to 4.0 ng/mL and a benign prostate examination, to assess the clinicopathological features of the cancers detected, and to assess the usefulness of measuring the ratio of free to total PSA to reduce the number of prostatic biopsies. Design.-A community-based study of serial screening for prostate cancer with serum PSA measurements and prostate examinations. Setting.-University medical center. Subjects.-A total of 914 consecutive screening volunteers aged 50 years or older with serum PSA levels of 2.6 to 4.0 ng/mL who had a benign prostate examination and no prior screening tests suspicious for prostate cancer, 332 (36%) of whom underwent biopsy of the prostate. Main Outcome Measures.-Cancer detection rate, clinical and pathological features of cancers detected, and specificity for cancer detection using measurements of percentage of free PSA. Results.-Cancer was detected in 22% (73/332) of men who underwent biopsy. All cancers detected were clinically localized, and 81% (42/52) that were surgically staged were pathologically organ confined. Ten percent of the cancers were clinically low-volume and low-grade tumors, and 17% of those surgically staged were low-volume and low-grade or moderately low-grade tumors (possibly harm less). Using a percentage of free PSA cutoff of 27% or less as a criterion for performing prostatic biopsy would have detected 90% of cancers, avoided 18% of benign biopsies, and yielded a positive predictive value of 24% in men who underwent biopsy. Conclusions.-There is an appreciable rate of detectable prostate cancer in men with serum PSA levels of 2.6 to 4.0 ng/mL. The great majority of cancers detected have the features of medically important tumors. Free serum PSA measurements may reduce the number of additional biopsies required by the lower PSA cutoff.			Catalona, WJ (corresponding author), WASHINGTON UNIV,SCH MED,DEPT SURG,DIV UROL SURG,4960 CHILDRENS PL,ST LOUIS,MO 63110, USA.							BANGMA CH, 1995, UROLOGY, V46, P773, DOI 10.1016/S0090-4295(99)80342-2; BENSON MC, 1992, J UROLOGY, V147, P815, DOI 10.1016/S0022-5347(17)37393-7; CATALONA WJ, 1991, NEW ENGL J MED, V324, P1156, DOI 10.1056/NEJM199104253241702; CATALONA WJ, 1993, JAMA-J AM MED ASSOC, V270, P948, DOI 10.1001/jama.270.8.948; CATALONA WJ, 1995, JAMA-J AM MED ASSOC, V274, P1214; CATALONA WJ, 1994, J UROLOGY, V151, P1283, DOI 10.1016/S0022-5347(17)35233-3; CHRISTENSSON A, 1993, J UROLOGY, V150, P100, DOI 10.1016/S0022-5347(17)35408-3; COLBERG JW, 1993, J UROLOGY, V149, P507, DOI 10.1016/S0022-5347(17)36130-X; EPSTEIN JI, 1994, JAMA-J AM MED ASSOC, V271, P368, DOI 10.1001/jama.271.5.368; GANN PH, 1995, JAMA-J AM MED ASSOC, V273, P289, DOI 10.1001/jama.273.4.289; Iemeshow S, 1989, APPL LOGISTIC REGRES, P89; JACOBSEN SJ, 1995, JAMA-J AM MED ASSOC, V274, P1445, DOI 10.1001/jama.274.18.1445; LILJA H, 1991, CLIN CHEM, V37, P1618; LUDERER AA, 1995, UROLOGY, V46, P187, DOI 10.1016/S0090-4295(99)80192-7; Morgan TO, 1996, NEW ENGL J MED, V335, P304, DOI 10.1056/NEJM199608013350502; Smith DS, 1996, JAMA-J AM MED ASSOC, V276, P1309, DOI 10.1001/jama.276.16.1309; SMITH DS, 1994, J UROLOGY, V152, P1732, DOI 10.1016/S0022-5347(17)32372-8; Smith DS, 1996, J UROLOGY, V156, P1366, DOI 10.1016/S0022-5347(01)65588-5; STENMAN UH, 1991, CANCER RES, V51, P222; STENMAN UH, 1994, LANCET, V344, P1594, DOI 10.1016/S0140-6736(94)90405-7; TERRIS MK, 1991, J UROLOGY, V145, P984, DOI 10.1016/S0022-5347(17)38508-7; Wingo PA, 1996, CA-CANCER J CLIN, V46, P113, DOI 10.3322/canjclin.46.2.113	22	509	528	0	18	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 14	1997	277	18					1452	1455		10.1001/jama.277.18.1452	http://dx.doi.org/10.1001/jama.277.18.1452			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WX852	9145717				2022-12-01	WOS:A1997WX85200029
J	Eddleston, ALWF				Eddleston, ALWF			Hepatitis B and health-care workers	LANCET			English	Editorial Material											Eddleston, ALWF (corresponding author), UNIV LONDON KINGS COLL,SCH MED & DENT,INST LIVER STUDIES,LONDON SE5 9PJ,ENGLAND.							CARMAN WF, 1989, LANCET, V2, P588; Harpaz R, 1996, NEW ENGL J MED, V334, P549, DOI 10.1056/NEJM199602293340901; *INC INV TEAMS OTH, 1997, NEW ENGL J MED, V336, P178; NAUMOV NV, 1994, GUT, V35, P1013; *UK HLTH DEP, 1993, PROT HLTH CAR WORK P; WELCH J, 1989, LANCET, V1, P205	6	4	4	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 10	1997	349	9062					1339	1340		10.1016/S0140-6736(05)63199-6	http://dx.doi.org/10.1016/S0140-6736(05)63199-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WY342	9149693				2022-12-01	WOS:A1997WY34200005
J	Chun, TW; Carruth, L; Finzi, D; Shen, XF; DiGiuseppe, JA; Taylor, H; Hermankova, M; Chadwick, K; Margolick, J; Quinn, TC; Kuo, YH; Brookmeyer, R; Zeiger, MA; BarditchCrovo, P; Siliciano, RF				Chun, TW; Carruth, L; Finzi, D; Shen, XF; DiGiuseppe, JA; Taylor, H; Hermankova, M; Chadwick, K; Margolick, J; Quinn, TC; Kuo, YH; Brookmeyer, R; Zeiger, MA; BarditchCrovo, P; Siliciano, RF			Quantification of latent tissue reservoirs and total body viral load in HIV-1 Infection	NATURE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; PERIPHERAL-BLOOD; INSITU HYBRIDIZATION; IN-VIVO; T-CELL; LYMPHOCYTES; INDIVIDUALS; PLASMA; CD4; DNA	The capacity of HIV-1 to establish latent infection of CD4(+) T cells may allow viral persistence despite immune responses and antiretroviral therapy. Measurements of infectious virus(1,2) and viral RNA(3,4) in plasma and of infectious virus(1), viral DNA(5-10) and viral messenger RNA species(11-14) in infected cells all suggest that HIV-1 replication continues throughout the course of infection. Uncertainty remains over what fraction of CD4(+) T cells are infected and whether there are latent reservoirs for the virus. We show here that during the asymptomatic phase of infection there is an extremely low total body load of latently infected resting CD4(+) T cells with replication-competent integrated provirus (< 10(7) cells). The most prevalent form of HIV-1 DNA in resting and activated CD4(+) T cells is a full-length, linear, unintegrated form that is not replication competent. The infection progresses even though at any given time in the lymphoid tissues integrated HIV-1 DNA is present in only a minute fraction of the susceptible populations, including resting and activated CD4(+) T cells and macrophages.	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT SURG,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV HOSP,SCH HYG & PUBL HLTH,DEPT MOL MICROBIOL & IMMUNOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV HOSP,SCH HYG & PUBL HLTH,DEPT BIOSTAT,BALTIMORE,MD 21205; NIAID,NIH,BETHESDA,MD 20892	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Quinn, Thomas/A-2494-2010; Abrams, William R/A-5782-2008; Chun, Tae-Wook/W-9187-2019; DiGiuseppe, Joseph/AAD-1935-2019; Chun, Tae-Wook/AAC-3101-2020	Chun, Tae-Wook/0000-0001-5153-7340; 				ADAMS M, 1994, P NATL ACAD SCI USA, V91, P3862, DOI 10.1073/pnas.91.9.3862; BAGASRA O, 1992, NEW ENGL J MED, V326, P1385, DOI 10.1056/NEJM199205213262103; BROWN PO, 1989, P NATL ACAD SCI USA, V86, P2525, DOI 10.1073/pnas.86.8.2525; BUKRINSKY MI, 1991, SCIENCE, V254, P423, DOI 10.1126/science.1925601; BUKRINSKY MI, 1992, P NATL ACAD SCI USA, V89, P6580, DOI 10.1073/pnas.89.14.6580; CHUN TW, 1995, NAT MED, V1, P1284, DOI 10.1038/nm1295-1284; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; DICKOVER RE, 1992, J ACQ IMMUN DEF SYND, V5, P31; DIMITROV DS, 1993, J VIROL, V67, P2182, DOI 10.1128/JVI.67.4.2182-2190.1993; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; Haase AT, 1996, SCIENCE, V274, P985, DOI 10.1126/science.274.5289.985; HARPER ME, 1986, P NATL ACAD SCI USA, V83, P772, DOI 10.1073/pnas.83.3.772; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; MELLORS IW, 1986, SCIENCE, V272, P1167; MICHIE CA, 1992, NATURE, V360, P264, DOI 10.1038/360264a0; MYERS LE, 1994, J CLIN MICROBIOL, V32, P732, DOI 10.1128/JCM.32.3.732-739.1994; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PATEL SS, 1988, J IMMUNOL, V141, P3726; PATTERSON BK, 1993, SCIENCE, V260, P976, DOI 10.1126/science.8493534; PAUZA CD, 1990, VIROLOGY, V179, P886; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; SCHNITTMAN SM, 1989, SCIENCE, V245, P305, DOI 10.1126/science.2665081; SESHAMMA T, 1992, P NATL ACAD SCI USA, V89, P10663, DOI 10.1073/pnas.89.22.10663; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L	30	1614	1664	2	78	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 8	1997	387	6629					183	188		10.1038/387183a0	http://dx.doi.org/10.1038/387183a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WX945	9144289				2022-12-01	WOS:A1997WX94500055
J	Nightingale, SL				Nightingale, SL			Safety alert re risk of misdiagnosis of group B streptococcal infection	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,MAIL CODE HFI-40,ROCKVILLE,MD 20857, USA.								0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 7	1997	277	17					1343	1343		10.1001/jama.277.17.1343	http://dx.doi.org/10.1001/jama.277.17.1343			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW261	9134926				2022-12-01	WOS:A1997WW26100004
J	Kearns, BG; McGee, TP; Mayinger, P; Gedvilaite, A; Phillips, SE; Kagiwada, S; Bankaitis, VA				Kearns, BG; McGee, TP; Mayinger, P; Gedvilaite, A; Phillips, SE; Kagiwada, S; Bankaitis, VA			Essential role for diacylglycerol in protein transport from the yeast Golgi complex	NATURE			English	Article							PHOSPHOLIPID TRANSFER ACTIVITY; SACCHAROMYCES-CEREVISIAE; PHOSPHATIDYLINOSITOL TRANSFER; ENDOPLASMIC-RETICULUM; ESCHERICHIA-COLI; GENE; BIOSYNTHESIS; SPHINGOLIPIDS; SEC14; TRANSLOCATION	Yeast phosphatidylinositol transfer protein (Sec14p) is required for the production of secretory vesicles from the Golgi. This requirement can be relieved by inactivation of the cytosine 5'-diphosphate (CDP)-choline pathway for phosphatidylcholine biosynthesis, indicating that Sec14p is an essential component of a regulatory pathway linking phospholipid metabolism with vesicle trafficking (the Sec14p pathway(1-6)). Sac1p (refs 7 and 8) is an integral membrane protein related to inositol-5-phosphatases such as synaptojanin(9), a protein found in rat brain, Here we show that defects in Sac1p also relieve the requirement for Sec14p by altering phospholipid metabolism so as to expand the pool of diacylglycerol (DAG) in the Golgi. Moreover, although short-chain DAG improves secretory function in strains with a temperature-sensitive Sec14p, expression of diacylglycerol kinase from Escherichia call further impairs it. The essential function of Sec14p may therefore be to maintain a sufficient pool of DAG in the Golgi to support the production of secretory vesicles.	UNIV ALABAMA,DEPT CELL BIOL,BIRMINGHAM,AL 35294; ZENTRUM MOL BIOL,D-69120 HEIDELBERG,GERMANY	University of Alabama System; University of Alabama Birmingham; Ruprecht Karls University Heidelberg				McGee, Todd/0000-0002-3901-1001; PHILLIPS, SCOTT/0000-0002-5451-0984	NIGMS NIH HHS [R01 GM044530] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALB JG, 1995, P NATL ACAD SCI USA, V92, P8826, DOI 10.1073/pnas.92.19.8826; BANKAITIS VA, 1989, J CELL BIOL, V108, P1271, DOI 10.1083/jcb.108.4.1271; BANKAITIS VA, 1990, NATURE, V347, P561, DOI 10.1038/347561a0; BECKER GW, 1980, J BACTERIOL, V142, P747, DOI 10.1128/JB.142.3.747-754.1980; BUTTKE TM, 1982, J BACTERIOL, V152, P747; Cleves A, 1991, Trends Cell Biol, V1, P30, DOI 10.1016/0962-8924(91)90067-J; CLEVES AE, 1989, J CELL BIOL, V109, P2939, DOI 10.1083/jcb.109.6.2939; CLEVES AE, 1991, CELL, V64, P789, DOI 10.1016/0092-8674(91)90508-V; Fang M, 1996, EMBO J, V15, P6447, DOI 10.1002/j.1460-2075.1996.tb01036.x; GANONG BR, 1984, BIOCHEMISTRY-US, V23, P4977, DOI 10.1021/bi00316a023; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Kagiwada S, 1996, GENETICS, V143, P685; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; LESTER RL, 1993, ADV LIPID RES, V26, P253; LIGHTNER VA, 1983, J BIOL CHEM, V258, P856; LIPSKY NG, 1985, J CELL BIOL, V100, P27, DOI 10.1083/jcb.100.1.27; LOPES JM, NUCLEIC ACIDS RES, V14, P3987; Lopez M., 1994, J CELL BIOL, V124, P113; MAYINGER P, 1995, J CELL BIOL, V131, P1377, DOI 10.1083/jcb.131.6.1377; MCGEE TP, 1994, J CELL BIOL, V124, P273, DOI 10.1083/jcb.124.3.273; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; ORRWEAVER TL, 1983, METHOD ENZYMOL, V101, P202; PUOTI A, 1991, J CELL BIOL, V113, P515, DOI 10.1083/jcb.113.3.515; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SALAMA SR, 1990, J BACTERIOL, V172, P4510, DOI 10.1128/jb.172.8.4510-4521.1990; SKINNER HB, 1995, P NATL ACAD SCI USA, V92, P112, DOI 10.1073/pnas.92.1.112; SKINNER HB, 1993, EMBO J, V12, P4775, DOI 10.1002/j.1460-2075.1993.tb06166.x; STEINER MR, 1972, BIOCHIM BIOPHYS ACTA, V260, P222, DOI 10.1016/0005-2760(72)90035-5; WHITTERS EA, 1993, J CELL BIOL, V122, P79, DOI 10.1083/jcb.122.1.79	30	224	227	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 1	1997	387	6628					101	105		10.1038/387101a0	http://dx.doi.org/10.1038/387101a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WW758	9139830	Green Accepted			2022-12-01	WOS:A1997WW75800056
J	Borges, M; Linnoila, RI; vandeVelde, HJK; Chen, H; Nelkin, BD; Mabry, M; Baylin, SB; Ball, DW				Borges, M; Linnoila, RI; vandeVelde, HJK; Chen, H; Nelkin, BD; Mabry, M; Baylin, SB; Ball, DW			An achaete-scute homologue essential for neuroendocrine differentiation in the lung	NATURE			English	Article							SMALL-CELL CARCINOMA; CANCER; GROWTH; LINES; ESTABLISHMENT; IDENTIFICATION; EXPRESSION; ENDOCRINE; TUMORS	In Drosophila and in vertebrates, the achaete-scute family of basic helix-loop-helix transcription factors plays a critical developmental role in neuronal commitment and differentiation(1-6). Relatively little is known, however about the transcriptional control of neural features in cells outside a neuronal context. A minority of normal bronchial epithelial cells and many Lung cancers, especially small-cell lung cancer, exhibit a neuroendocrine phenotype that may reflect a common precursor cell population(7-11). We show here that human achaete-scute homologue-1 (hASW1) is selectively expressed in normal fetal pulmonary neuroendocrine cells, as well as in the diverse range of lung cancers with neuroendocfine features. Strikingly, newborn mice bearing a disruption of the ASR1 gene have no detectable pulmonary neuroendocrine cells. Depletion of this transcription factor from lung cancer cells by antisense oligonucleotides results in a significant decrease in the expression of neuroendrocrine markers. Thus, a homologue of Drosophila neural fate determination genes seems to be necessary for progression of lung epithelial cells through a neuroendocrine differentiation pathway that is a feature of small-cell lung cancer, the most. lethal form of human lung cancer.	JOHNS HOPKINS MED INST, CTR ONCOL, BALTIMORE, MD 21231 USA; JOHNS HOPKINS MED INST, DEPT MED, BALTIMORE, MD 21231 USA; JOHNS HOPKINS MED INST, DEPT SURG, BALTIMORE, MD 21231 USA; NCI, MED BRANCH, DIV CLIN SCI, NIH, ROCKVILLE, MD 20850 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								BALL DW, 1993, P NATL ACAD SCI USA, V90, P5648, DOI 10.1073/pnas.90.12.5648; BAYLIN SB, 1981, SMALL CELL LUNG CANC, P123; BERGH J, 1981, ANTICANCER RES, V1, P317; BROERS JLV, 1993, AM J RESP CELL MOL, V9, P33, DOI 10.1165/ajrcmb/9.1.33; BROWER M, 1986, CANCER RES, V46, P798; CAMPUZANO S, 1985, CELL, V40, P327, DOI 10.1016/0092-8674(85)90147-3; CARNEY DN, 1985, CANCER RES, V45, P2913; CHEN HC, IN PRESS P NATL ACAD; FALCO JP, 1990, J CLIN INVEST, V85, P1740, DOI 10.1172/JCI114630; GAZDAR AF, 1980, CANCER RES, V40, P3502; GAZDAR AF, 1985, CANCER RES, V45, P2924; GAZDAR AF, 1988, CANCER RES, V48, P4078; Gazdar AF, 1981, SMALL CELL LUNG CANC, P145; GomezSkarmeta JL, 1996, CELL, V85, P95, DOI 10.1016/S0092-8674(00)81085-5; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; Ishibashi M, 1995, GENE DEV, V9, P3136, DOI 10.1101/gad.9.24.3136; JAN YN, 1994, ANNU REV GENET, V28, P373, DOI 10.1146/annurev.ge.28.120194.002105; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; Lewis JG, 1996, P NATL ACAD SCI USA, V93, P3176, DOI 10.1073/pnas.93.8.3176; LINNOILA RI, 1988, AM J CLIN PATHOL, V90, P641, DOI 10.1093/ajcp/90.6.641; LINNOILA RI, 1994, CHEST, V106, pS367, DOI 10.1378/chest.106.6.367S; Linnoila RI, 1996, J CELL BIOCHEM, P92; LINNOILA RI, 1994, CL ALLER IM, V4, P197; LINNOILA RI, 1995, LUNG CANCER, P73; LO LC, 1991, GENE DEV, V5, P1524, DOI 10.1101/gad.5.9.1524; MABRY M, 1991, CANCER CELL-MON REV, V3, P53; NELKIN BD, 1990, BIOCHEM BIOPH RES CO, V170, P140, DOI 10.1016/0006-291X(90)91251-M; PETTENGILL OS, 1980, CANCER-AM CANCER SOC, V45, P906, DOI 10.1002/1097-0142(19800301)45:5<906::AID-CNCR2820450513>3.0.CO;2-H; Sommer L, 1995, NEURON, V15, P1245, DOI 10.1016/0896-6273(95)90005-5	30	303	317	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 24	1997	386	6627					852	855		10.1038/386852a0	http://dx.doi.org/10.1038/386852a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WV706	9126746				2022-12-01	WOS:A1997WV70600059
J	Kenyon, TA; Ridzon, R; LuskinHawk, R; Schultz, C; Paul, WS; Valway, SE; Onorato, IM; Castro, K				Kenyon, TA; Ridzon, R; LuskinHawk, R; Schultz, C; Paul, WS; Valway, SE; Onorato, IM; Castro, K			A nosocomial outbreak of multidrug-resistant tuberculosis	ANNALS OF INTERNAL MEDICINE			English	Article							HIV-INFECTED PATIENTS; LENGTH-POLYMORPHISM ANALYSIS; HEALTH-CARE WORKERS; MYCOBACTERIUM-TUBERCULOSIS; TRANSMISSION; UNIT	Background: An outbreak of seven cases (in six patients and one health care worker, all of whom had AIDS) of multidrug-resistant tuberculosis occurred in a hospital in Chicago. The hospital had a respirator-fit testing program but no acid-fast bacilli isolation rooms. Objective: To identify risk factors for transmission of Mycobacterium tuberculosis. Design: Retrospective cohort study. Setting: Private hospital. Participants: Patients and health care workers exposed to M. tuberculosis. Measurements: Analysis of M. tuberculosis isolates, tuberculin skin testing, assessment of exposure, and assessment of participant characteristics. Results: All seven M. tuberculosis isolates had matching DNA fingerprints. Of patients exposed to M. tuberculosis, those who developed tuberculosis had lower CD4(+) T-lymphocyte counts (P = 0.02) and were more likely to be ambulatory (P = 0.03) than those who did not. Of 74 exposed health care workers, the 11 (15%)who had conversion on tuberculin skin testing were no more likely than those who did not have conversion to report that they always wore a respirator with a high-efficiency particulate air filter. Conclusions: Transmission of M. tuberculosis occurred in a hospital that did not have recommended isolation rooms. A respirator-fit testing program did not protect health care workers in this setting.	CTR DIS CONTROL & PREVENT, DIV TB ELIMINAT, ATLANTA, GA 30333 USA; ST JOSEPH HOSP, CHICAGO, IL USA; CHICAGO DEPT PUBL HLTH, CHICAGO, IL USA	Centers for Disease Control & Prevention - USA; Chicago Department of Public Health			Castro, Kenneth G/P-1882-2018	Castro, Kenneth G/0000-0001-7964-6354				Centers for Disease Control and Prevention (CDC), 1994, MMWR Morb Mortal Wkly Rep, V43, P1; BECKSAGUE C, 1992, JAMA-J AM MED ASSOC, V268, P1280, DOI 10.1001/jama.268.10.1280; BLUMBERG HM, 1995, ANN INTERN MED, V122, P658, DOI 10.7326/0003-4819-122-9-199505010-00003; CAIAFFA WT, 1995, ARCH INTERN MED, V155, P2111, DOI 10.1001/archinte.155.19.2111; Chaves F, 1996, J CLIN MICROBIOL, V34, P1118, DOI 10.1128/JCM.34.5.1118-1123.1996; CORONADO VG, 1993, J INFECT DIS, V168, P1052, DOI 10.1093/infdis/168.4.1052; Dean A.G., 1994, EPI INFO VERSION 6 W; Dooley S W Jr, 1990, MMWR Recomm Rep, V39, P1; DOOLEY SW, 1992, JAMA-J AM MED ASSOC, V267, P2632, DOI 10.1001/jama.267.19.2632; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; FISCHL MA, 1992, ANN INTERN MED, V117, P177, DOI 10.7326/0003-4819-117-3-177; FRIDKIN SK, 1995, INFECT CONT HOSP EP, V16, P129; IKEDA RM, 1995, INFECT CONT HOSP EP, V16, P152; JEREB JA, 1993, J INFECT DIS, V168, P1219, DOI 10.1093/infdis/168.5.1219; PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191; STROUD LA, 1995, INFECT CONT HOSP EP, V16, P141; VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406, DOI 10.1128/JCM.31.2.406-409.1993; WENGER PN, 1995, LANCET, V345, P235, DOI 10.1016/S0140-6736(95)90228-7	18	63	65	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1997	127	1					32	36		10.7326/0003-4819-127-1-199707010-00006	http://dx.doi.org/10.7326/0003-4819-127-1-199707010-00006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG914	9214250				2022-12-01	WOS:A1997XG91400005
J	Endo, TA; Masuhara, M; Yokouchi, M; Suzuki, R; Sakamoto, H; Mitsui, K; Matsumoto, A; Tanimura, S; Ohtsubo, M; Misawa, H; Miyazaki, T; Leonor, N; Taniguchi, T; Fujita, T; Kanakura, Y; Komiya, S; Yoshimura, A				Endo, TA; Masuhara, M; Yokouchi, M; Suzuki, R; Sakamoto, H; Mitsui, K; Matsumoto, A; Tanimura, S; Ohtsubo, M; Misawa, H; Miyazaki, T; Leonor, N; Taniguchi, T; Fujita, T; Kanakura, Y; Komiya, S; Yoshimura, A			A new protein containing an SH2 domain that inhibits JAK kinases	NATURE			English	Article							RECEPTORS	The proliferation and differentiation of cells of many Lineages are regulated by secreted proteins known as cytokines. Cytokines exert their biological effect through binding to cell-surface receptors that are associated with one or more members of the JAK family of cytoplasmic tyrosine kinases. Cytokine-induced receptor dimerization leads to the activation of JAKs, rapid tyrosine-phosphorylation of the cytoplasmic domains, and subsequent recruitment of various signalling proteins, including members of the STAT family of transcription factors, to the receptor complex(1-5). Using the yeast two-hybrid system, we have now isolated a new SH2-domain-containing protein, TAB, which is a JAK-binding protein that interacts with the Jak2 tyrosine-kinase JH1 domain(6). JAB is structurally related to CIS, a cytokine-inducible SH2 protein(7,8). Interaction of JAB with Jak1, Jak2 or Jak3 markedly reduces their tyrosine-kinase activity and suppresses the tyrosine-phosphorylation and activation of STATs. TAB and CIS appear to function as negative regulators in the JAK signalling pathway.	KURUME UNIV,INST LIFE SCI,KURUME 839,JAPAN; KURUME UNIV,DEPT ORTHOPED SURG,KURUME 839,JAPAN; UNIV TOKYO,FAC MED,DEPT IMMUNOL,BUNKYO KU,TOKYO 113,JAPAN; TOKYO METROPOLITAN INST MED SCI,DEPT TUMOR CELL BIOL,BUNKYO KU,TOKYO 113,JAPAN; OSAKA UNIV,SCH MED,DEPT HEMATOL & ONCOL,SUITA,OSAKA 565,JAPAN	Kurume University; Kurume University; University of Tokyo; Tokyo Metropolitan Institute of Medical Science; Osaka University			Miyazaki, Tadaaki/D-9368-2012; Nogueira, Leonor/L-2034-2014; Endo, Takaho/B-5763-2017; Yoshimura, Akihiko/K-5515-2013; Mitsui, Kaoru/E-1464-2011	Endo, Takaho/0000-0002-2801-2463; Mitsui, Kaoru/0000-0003-0534-9845; ohtsubo, motoaki/0000-0002-2479-3178				Briscoe J, 1996, EMBO J, V15, P799, DOI 10.1002/j.1460-2075.1996.tb00415.x; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Feng J, 1997, MOL CELL BIOL, V17, P2497, DOI 10.1128/MCB.17.5.2497; HARPER JW, 1993, CELL, V75, P805; HARPUR AG, 1992, ONCOGENE, V7, P1347; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; KAWAHARA A, 1995, P NATL ACAD SCI  US, V92, P8721; KITAYAMA H, 1995, BLOOD, V85, P790, DOI 10.1182/blood.V85.3.790.bloodjournal853790; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.iy.10.040192.001455; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Schluter G, 1996, MOL REPROD DEV, V43, P1, DOI 10.1002/(SICI)1098-2795(199601)43:1&lt;1::AID-MRD1&gt;3.0.CO;2-W; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x	19	1186	1255	0	47	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 26	1997	387	6636					921	924		10.1038/43213	http://dx.doi.org/10.1038/43213			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XG416	9202126	Bronze			2022-12-01	WOS:A1997XG41600056
J	Atherton, JJ; Moore, TD; Lele, SS; Thomson, HL; Galbraith, AJ; Belenkie, I; Tyberg, JV; Frenneaux, MP				Atherton, JJ; Moore, TD; Lele, SS; Thomson, HL; Galbraith, AJ; Belenkie, I; Tyberg, JV; Frenneaux, MP			Diastolic ventricular interaction in chronic heart failure	LANCET			English	Article							ACUTE PULMONARY-EMBOLISM; PRESSURE; VOLUME; PERICARDIUM; ADAPTATION; DOGS	Background Diastolic ventricular interaction describes a situation in which the volume of one ventricle is directly influenced by the volume of the other ventricle, Such interaction is normally negligible, but it is accentuated in circumstances associated with pulmonary hypertension and volume overload. When this interaction occurs, acute volume unloading results in a reduction in right ventricular end-diastolic volume, as expected, but left ventricular end-diastolic volume paradoxically increases. Since chronic heart failure is a volume overloaded state associated with pulmonary hypertension, we hypothesised that this interaction may be clinically important in patients with heart failure. Methods A radionuclide technique incorporating cardiac scintigraphy was used to measure the effect of acute volume unloading, achieved by 30 mm Hg lower-body suction, an right and left ventricular end-diastolic volumes in 21 patients with chronic heart failure and 12 healthy individuals (controls). Findings In nine heart-failure patients, there was a paradoxical increase in left ventricular end-diastolicic volume in association with an expected decrease in right ventricular end-diastolic volume during lower-body suction, This response was not seen in the control group. The mean change in left Ventricular end-diastolic volume differed significantly between the heart-failure patients and controls (6 [SD 19] vs -19 [12] mL, p=0.0003). However, the change in right ventricular end-diastolic volume was similar in the two groups (-18 [11] vs -20 [8]%, p=0.70). Patients who increased left ventricular end-diastolic volume during lower-body suction had higher resting pulmonary arterial and pulmonary capillary wedge pressures than the remaining heart-failure patients. Interpretation The response of nine patients in our study suggests diastolic ventricular interaction, which we believe could be common in patients with chronic heart failure. This finding is relevant to their management, since ii emphasises the importance of venodilator therapy, The relation between stroke volume and left Ventricular end-diastolic volume, by the Frank-Starling law of the heart, may explain why some patients with chronic heart failure paradoxically increase stroke volume when pulmonary capillary wedge pressure is lowered with vasodilators.	UNIV WALES COLL MED, DEPT CARDIOL, CARDIFF CF4 4XN, S GLAM, WALES; UNIV QUEENSLAND, HEART FAILURE RES UNIT, BRISBANE, QLD, AUSTRALIA; UNIV CALGARY, DEPT MED, CALGARY, AB T2N 1N4, CANADA; UNIV CALGARY, DEPT MED PHYSIOL, CALGARY, AB T2N 1N4, CANADA	Cardiff University; University of Queensland; University of Calgary; University of Calgary			Atherton, John J/B-9994-2011	Atherton, John J/0000-0003-2271-578X				ABBOUD FM, 1981, DISTURBANCES NEUROGE; APPLEGATE RJ, 1992, AM J PHYSIOL, V262, pH1725, DOI 10.1152/ajpheart.1992.262.6.H1725; Atherton J., 1995, European Heart Journal, V16, P83; ATHERTON JJ, 1995, EUR J CARD PACING EL, V5, P188; BELENKIE I, 1989, CIRCULATION, V80, P178, DOI 10.1161/01.CIR.80.1.178; BELENKIE I, 1988, CIRCULATION, V78, P761, DOI 10.1161/01.CIR.78.3.761; BLANCHARD DG, 1992, CIRCULATION, V85, P1414, DOI 10.1161/01.CIR.85.4.1414; DAUTERMAN K, 1995, ANN INTERN MED, V122, P737, DOI 10.7326/0003-4819-122-10-199505150-00001; DIBONA GF, 1994, AM J PHYSIOL, V266, pR27, DOI 10.1152/ajpregu.1994.266.1.R27; DUPUIS J, 1990, AM HEART J, V120, P625, DOI 10.1016/0002-8703(90)90021-O; FRANK O, 1959, AM HEART J, V58, P282, DOI 10.1016/0002-8703(59)90345-X; FRANK O, 1959, AM HEART J, V58, P467, DOI 10.1016/0002-8703(59)90164-4; GREENBER.TT, 1973, CIRC RES, V33, P424, DOI 10.1161/01.RES.32.4.424; Howell W.H., 1884, PHILOS T ROY SOC LON, V175, P139; JARDIN F, 1984, AM REV RESPIR DIS, V129, P135; JARDIN F, 1987, J AM COLL CARDIOL, V10, P1201, DOI 10.1016/S0735-1097(87)80119-5; LEWINTER MM, 1982, CIRC RES, V50, P501, DOI 10.1161/01.RES.50.4.501; LINKS JM, 1982, CIRCULATION, V65, P82, DOI 10.1161/01.CIR.65.1.82; MARK AL, 1983, J AM COLL CARDIOL, V1, P90, DOI 10.1016/S0735-1097(83)80014-X; MOHANTY PK, 1989, AM HEART J, V118, P78, DOI 10.1016/0002-8703(89)90075-6; NISHIAN K, 1993, CLIN SCI, V84, P271, DOI 10.1042/cs0840271; Patterson SW, 1914, J PHYSIOL-LONDON, V48, P465; Patterson SW, 1914, J PHYSIOL-LONDON, V48, P357; STEVENSON LW, 1986, CIRCULATION, V74, P1303, DOI 10.1161/01.CIR.74.6.1303; TYBERG JV, 1986, CIRCULATION, V73, P428, DOI 10.1161/01.CIR.73.3.428; ZOLLER RP, 1972, J CLIN INVEST, V51, P2967, DOI 10.1172/JCI107121; ZUCKER IH, 1977, J CLIN INVEST, V60, P323, DOI 10.1172/JCI108780	27	158	171	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 14	1997	349	9067					1720	1724		10.1016/S0140-6736(96)05109-4	http://dx.doi.org/10.1016/S0140-6736(96)05109-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XE065	9193381				2022-12-01	WOS:A1997XE06500008
J	Low, N; DakerWhite, G; Barlow, D; Pozniak, AL				Low, N; DakerWhite, G; Barlow, D; Pozniak, AL			Gonorrhoea in inner London: Results of a cross sectional study	BRITISH MEDICAL JOURNAL			English	Article; Proceedings Paper	Spring Meeting of the Medical-Society-for-the-Study-of-Venereal-Diseases	MAY 09-11, 1996	EDINBURGH, SCOTLAND	Med Soc Study Venereal Dis			DEPRIVATION; RATES	Objectives: To estimate population based incidence rates of gonorrhoea in an inner London area and examine relations with age, ethnic group, and socioeconomic deprivation. Design: Cross sectional study. Setting: 11 departments of genitourinary medicine in south and central London. Subjects: 1978 first episodes of gonorrhoea diagnosed in 1994 and 1995 in residents of 73 electoral wards in the boroughs of Lambeth, Southwark, and Lewisham who attended any of the departments of genitourinary medicine. Main outcome measures: Yearly age,sex, and ethnic group specific rates of gonorrhoea per 100 000 population aged 15-59 years; rate ratios for the effects of age and ethnic group on gonorrhoea rates in women and men before and after adjustment for confounding factors. Results: Overall incidence rates of gonorrhoea in residents of Lambeth, Southwark, and Lewisham were 138.3 cases-yearly per 100 000 women and 291.9 cases yearly per 100 000 men aged 15-59 years. At all ages gonorrhoea rates were higher in non-white minority ethnic groups. Rate ratios for the effect of age adjusted for ethnic group and underprivilege were 15.2 (95% cofidence interval 11.6 to 19.7) for women and 2.0 (1.7 to 2.5) for men aged 15-19 years compared with those over 30. After deprivation score and age were taken into account, women from black minority groups were 10.5 (8.6 to 12.8) times as likely and men 11.0 (9.7 to 12.6) times as likely as white people to experience gonorrhoea Conclusions: Gonorrhoea rates in Lambeth, Southwark, and Lewisham in 1994-5 were six to seven times higher than for England and Wales one year earlier. The presentation of national trends thus hides the disproportionate contribution of ongoing endemic transmission in the study area. Teenage women and young adult men, particularly those from black minority ethnic groups, are the most heavily affected, even when socioeconomic underprivilege is taken into account. There is urgent need for resources for culturally appropriate research and effective intervention to prevent gonococcal infections and their long term sequelae in this population.	GUYS & ST THOMAS NHS TRUST,DEPT GENITOURINARY MED,LONDON SE1 7EH,ENGLAND	Guy's & St Thomas' NHS Foundation Trust	Low, N (corresponding author), UNIV LONDON KINGS COLL,SCH MED & DENT,ACAD UNIT,DEPT GENITOURINARY MED,CALDECOT CTR,LONDON SE5 9RS,ENGLAND.		Low, Nicola/H-4718-2019	Low, Nicola/0000-0003-4817-8986				[Anonymous], 1994, MMWR Recomm Rep, V43, P1; ARAL SO, 1988, AM J PUBLIC HEALTH, V78, P702, DOI 10.2105/AJPH.78.6.702; BEVERIDGE MM, 1962, BRIT J VENER DIS, V38, P154; Blair I, 1994, Commun Dis Rep CDR Rev, V4, pR25; Calman K, 1996, BRIT J HOSP MED, V56, P125; Cooper R S, 1993, Ann Epidemiol, V3, P137; CURTIS SE, 1990, J EPIDEMIOL COMMUN H, V44, P62, DOI 10.1136/jech.44.1.62; DakerWhite G, 1997, INT J STD AIDS, V8, P32, DOI 10.1258/0956462971918733; Dale A, 1993, 1991 CENSUS USERS GU; *DEP HLTH, 1992, HLTH NAT STRAT HLTH, P92; ELLEN JM, 1995, AM J PUBLIC HEALTH, V85, P1546, DOI 10.2105/AJPH.85.11.1546; *GOV STAT SERV, 1996, SEX TRANSM DIS ENGL, P1; HOLMES KK, 1990, SEXUALLY TRANSMITTED; JOHNSON AM, 1991, HLTH NATION BMJ VIEW, P83; LAIRD SM, 1962, BRIT J VENER DIS, V38, P181; Langlands A, 1996, BRIT J HOSP MED, V56, P171; MORRIS R, 1991, J PUBLIC HEALTH MED, V13, P318; *OFF POP CENS SURV, 1994, 1991 CENS US GUID 58; RICE RJ, 1991, AM J PUBLIC HEALTH, V81, P1252, DOI 10.2105/AJPH.81.10.1252; *ROYAL MAIL, 1995, ROYAL MAIL POST ADDR; SHERRARD J, 1993, LANCET, V341, P245, DOI 10.1016/0140-6736(93)90110-3; TOOMEY KE, 1993, INFECT DIS CLIN N AM, V7, P739; WATT I, 1958, BR J VENER DIS, V34, P9; 1995, COMMUN DIS REP CDR W, V5, P62; [No title captured]; 1996, COMMUN DIS REP CDR W, V6, P304	26	95	96	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 14	1997	314	7096					1719	1723		10.1136/bmj.314.7096.1719	http://dx.doi.org/10.1136/bmj.314.7096.1719			5	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XE909	9185497	Green Published			2022-12-01	WOS:A1997XE90900020
J	Duncan, MJ; Levison, HF				Duncan, MJ; Levison, HF			A disk of scattered icy objects and the origin of Jupiter-family comets	SCIENCE			English	Article							SHORT-PERIOD COMETS; SOLAR-SYSTEM; NEPTUNE; DELIVERY	Orbital integrations carried out for 4 billion years produced a disk of scattered objects beyond the orbit of Neptune, Objects in this disk can be distinguished from Kuiper belt objects by a greater range of eccentricities and inclinations. This disk was formed in the simulations by encounters with Neptune during the early evolution of the outer solar system. After particles first encountered Neptune, the simulations show that about 1 percent of the particles survive in this disk for the age of the solar system, A disk currently containing as few as similar to 6 x 10(8) objects could supply all of the observed Jupiter-family comets. Two recently discovered objects, 1996 RQ(20) and 1996 TL66, have orbital elements similar to those predicted for objects in this disk, suggesting that they are thus far the only members of this disk to be identified.	SW RES INST, DEPT SPACE SCI, BOULDER, CO 80302 USA		Duncan, MJ (corresponding author), QUEENS UNIV, DEPT PHYS, KINGSTON, ON K7L 3N6, CANADA.		Levison, Harold F/C-6061-2013	Levison, Harold F/0000-0001-5847-8099				AHearn MF, 1995, ICARUS, V118, P223, DOI 10.1006/icar.1995.1190; Davis DR, 1997, ICARUS, V125, P50, DOI 10.1006/icar.1996.5595; DUNCAN M, 1988, ASTROPHYS J, V328, pL69, DOI 10.1086/185162; Duncan MJ, 1995, ASTRON J, V110, P3073, DOI 10.1086/117748; Edgeworth K.E., 1943, J BR ASTRON ASS, V53, P181; EDGEWORTH KE, 1949, MON NOT R ASTRON SOC, V109, P600, DOI 10.1093/mnras/109.5.600; FERNANDEZ J, 1982, MON NOT R ASTRON SOC, V192, P481; FERNANDEZ JA, 1983, ICARUS, V54, P377, DOI 10.1016/0019-1035(83)90235-X; FERNANDEZ JA, 1984, ICARUS, V58, P109, DOI 10.1016/0019-1035(84)90101-5; HELIN E, 1997, MINOR PLANET ELECT B, V19; HOLMAN MJ, 1993, ASTRON J, V105, P1987, DOI 10.1086/116574; Jewitt D, 1996, ASTRON J, V112, P1225, DOI 10.1086/118093; KOZAI Y, 1962, ASTRON J, V67, P591, DOI 10.1086/108790; Kuiper G.P., 1951, ASTROPHYSICS TOPICAL, P357; LEVISON HF, 1993, ASTROPHYS J, V406, pL35, DOI 10.1086/186780; Levison HF, 1996, ASTR SOC P, V107, P173; LEVISON HF, IN PRESS ICARUS; Luu J, 1997, NATURE, V387, P573, DOI 10.1038/42413; MALHOTRA R, 1995, ASTRON J, V110, P420, DOI 10.1086/117532; QUINN T, 1990, ASTROPHYS J, V355, P667, DOI 10.1086/168800; STERN SA, 1995, ASTRON J, V110, P856, DOI 10.1086/117568; TORBETT MV, 1989, ASTRON J, V98, P1477, DOI 10.1086/115233; TRUJILLO C, 1997, MINOR PLANET ELECT B, V18; WEISSMAN PR, 1990, GEOL SOC AM SPEC PAP, V247, P263; WEISSMAN PR, IN PRESS PLUTO	25	330	332	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 13	1997	276	5319					1670	1672		10.1126/science.276.5319.1670	http://dx.doi.org/10.1126/science.276.5319.1670			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XD947	9180070				2022-12-01	WOS:A1997XD94700033
J	Huppertz, HI; Rutkowski, S; Aleksic, S; Karch, H				Huppertz, HI; Rutkowski, S; Aleksic, S; Karch, H			Acute and chronic diarrhoea and abdominal colic associated with enteroaggregative Escherichia coli in young children living in western Europe	LANCET			English	Article							PERSISTENT DIARRHEA; IDENTIFICATION; ADHERENCE; PATHOGEN; PROBE	Background Enteroaggregative Escherichia coli (EAggEC or EAEC) can spread and cause disease in developing countries, but it is not presently known whether it spreads disease in industrialised countries. Therefore, we did a prospective study to assess the incidence and the clinical manifestations of infections due to EAEC in children in Germany. Methods 798 children with diarrhoea, admitted to hospital within a defined geographical area during a 24-month period, were included in the trial, EAEC were cultured from stool specimens, screened by PCR,and identified by colony hybridisation from DNA sequences found on the virulence plasmid, The findings were confirmed by aggregative adherence to HEp-2 cells. Stool samples from 580 children admitted to hospital without diarrhoea were also studied as controls. Findings EAEC were found in the stools of 16 (2%) of 798 children with diarrhoea, but in none of 580 children without diarrhoea, Only four of the EAEC-infected children had travelled to developing countries. Most EAEC infections were acquired in the summer months. infection with EAEC was associated with acute, watery diarrhoea in 12 children, and with chronic diarrhoea of up to 5 months' duration in four, Five children had abdominal-colic that lasted for 2-4 weeks as their main symptom. The incidence of EAEC infection was 7.7 patients admitted to hospital per 100 000 children in the general population aged younger than 16 years. Interpretation EAEC infection is associated with acute, watery diarrhoea and may be acquired in industrialised countries. Chronic diarrhoea or abdominal colic of unknown aetiology in young children may also be caused by EAEC infection.	UNIV WURZBURG,INST HYG & MICROBIOL,WURZBURG,GERMANY; INST HYG,HAMBURG,GERMANY; NATL REFERENCE CTR ENTEROBACTERIACEAE,HAMBURG,GERMANY	University of Wurzburg	Huppertz, HI (corresponding author), UNIV WURZBURG,CHILDRENS HOSP,KINDERKLIN,D-97080 WURZBURG,GERMANY.							ALBERT MJ, 1993, J CLIN MICROBIOL, V31, P1397, DOI 10.1128/JCM.31.5.1397-1399.1993; BAUDRY B, 1990, J INFECT DIS, V161, P1249, DOI 10.1093/infdis/161.6.1249; BHAN MK, 1989, J INFECT DIS, V159, P1061, DOI 10.1093/infdis/159.6.1061; BHATNAGAR S, 1993, SCAND J INFECT DIS, V25, P579, DOI 10.3109/00365549309008546; BROOK MG, 1994, EPIDEMIOL INFECT, V112, P63, DOI 10.1017/S0950268800057423; Cobeljic M, 1996, EPIDEMIOL INFECT, V117, P11, DOI 10.1017/S0950268800001072; Giammanco A, 1996, J CLIN MICROBIOL, V34, P689, DOI 10.1128/JCM.34.3.689-694.1996; Huppertz HI, 1996, J PEDIATR-US, V128, P341, DOI 10.1016/S0022-3476(96)70278-0; Mews CF, 1993, PEDIAT GASTROINTESTI, P177; NATARO JP, 1987, PEDIATR INFECT DIS J, V6, P829, DOI 10.1097/00006454-198709000-00008; PHILLIPS AD, 1994, J PEDIAT GASTROENTER, V18, P87; SCHMIDT H, 1995, J CLIN MICROBIOL, V33, P701, DOI 10.1128/JCM.33.3.701-705.1995; SCOTLAND SM, 1991, J MED MICROBIOL, V35, P278, DOI 10.1099/00222615-35-5-278; SMITH HR, 1994, J INFECT DIS, V170, P1610, DOI 10.1093/infdis/170.6.1610; WILDE J, 1991, LANCET, V337, P323, DOI 10.1016/0140-6736(91)90945-L	15	72	75	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 7	1997	349	9066					1660	1662		10.1016/S0140-6736(96)12485-5	http://dx.doi.org/10.1016/S0140-6736(96)12485-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD100	9186384				2022-12-01	WOS:A1997XD10000010
J	Rosenbaum, JT				Rosenbaum, JT			Lessons from litigation over silicone breast implants: A call for activism by scientists	SCIENCE			English	Editorial Material							CONNECTIVE-TISSUE DISEASES; RHEUMATOID-ARTHRITIS; COSMETIC SURGERY; AUGMENTATION; CANCER; RISK; SYMPTOMS; WOMEN; SCLERODERMA				Rosenbaum, JT (corresponding author), OREGON HLTH SCI UNIV,CASEY EYE INST,3375 SW TERWILLIGER BLVD,PORTLAND,OR 97201, USA.							*AM MED ASS COUNC, 1993, JAMA-J AM MED ASSOC, V270, P2602; ANGELL M, 1996, SCIENCE TRIAL; BIRDSELL DC, 1993, PLAST RECONSTR SURG, V92, P795, DOI 10.1097/00006534-199392050-00003; BRIDGES AJ, 1993, ANN INTERN MED, V118, P929, DOI 10.7326/0003-4819-118-12-199306150-00003; Brinton LA, 1996, PLAST RECONSTR SURG, V97, P269, DOI 10.1097/00006534-199602000-00001; BRYANT H, 1995, NEW ENGL J MED, V332, P1535, DOI 10.1056/NEJM199506083322302; BURNS CG, 1994, THESIS U MICHIGAN; DEAPEN DM, 1995, J CLIN EPIDEMIOL, V48, P551, DOI 10.1016/0895-4356(94)00212-9; DUGOWSON CE, 1992, ARTHRITIS RHEUM, V35, pS66; ENGLERT HJ, 1994, AUST NZ J MED, V24, P74, DOI 10.1111/j.1445-5994.1994.tb04439.x; GABRIEL SE, 1994, NEW ENGL J MED, V330, P1697, DOI 10.1056/NEJM199406163302401; GILTAY EJ, 1994, ANN RHEUM DIS, V53, P194, DOI 10.1136/ard.53.3.194; GOLDMAN JA, 1995, J CLIN EPIDEMIOL, V48, P571, DOI 10.1016/0895-4356(94)00215-C; GOTT D, 1994, SILICONE IMPLANTS CO; Hennekens CH, 1996, JAMA-J AM MED ASSOC, V275, P616, DOI 10.1001/jama.275.8.616; HOCHBERG MC, 1993, ANN INTERN MED, V118, P981, DOI 10.7326/0003-4819-118-12-199306150-00013; Hochberg MC, 1996, ARTHRITIS RHEUM, V39, P1125, DOI 10.1002/art.1780390708; HUBER PW, 1991, GALILEOS REVENGE JUN, P111; Kaiser J, 1997, SCIENCE, V275, P21; KESSLER DA, 1992, NEW ENGL J MED, V326, P1713, DOI 10.1056/NEJM199206183262525; KUMAGAI Y, 1984, ARTHRITIS RHEUM-US, V27, P1, DOI 10.1002/art.1780270101; Martin L., 1995, Arthritis and Rheumatism, V38, pS264; MCLAUGHLIN JK, 1994, J NATL CANCER I, V86, P1424, DOI 10.1093/jnci/86.18.1424; Rosenbaum J, 1996, ARTHRITIS RHEUM, V39, P1765, DOI 10.1002/art.1780391024; SANCHEZGUERRERO J, 1994, ARTHRITIS RHEUM-US, V37, P158; SANCHEZGUERRERO J, 1995, NEW ENGL J MED, V332, P1666, DOI 10.1056/NEJM199506223322502; SCHELL RW, 1996, MEALEYS BREAST IMPLA, P471; SCHUSTERMAN MA, 1993, ANN PLAS SURG, V31, P1; Silverman Stuart, 1996, Arthritis and Rheumatism, V39, pS51; SPIERA H, 1988, JAMA-J AM MED ASSOC, V260, P236, DOI 10.1001/jama.260.2.236; STROM BL, 1994, J CLIN EPIDEMIOL, V47, P1211, DOI 10.1016/0895-4356(94)90109-0; WEISMAN MH, 1988, PLAST RECONSTR SURG, V82, P626, DOI 10.1097/00006534-198810000-00011; WELLS KE, 1994, PLAST RECONSTR SURG, V93, P907, DOI 10.1097/00006534-199404001-00002; *WGBH ED FDN, 1996, FRONTLI; Williams HJ, 1997, ARTHRITIS RHEUM, V40, P437, DOI 10.1002/art.1780400308; Wolfe F., 1995, Arthritis and Rheumatism, V38, pS265	36	19	19	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 6	1997	276	5318					1524	1525		10.1126/science.276.5318.1524	http://dx.doi.org/10.1126/science.276.5318.1524			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XC701	9190690				2022-12-01	WOS:A1997XC70100030
J	Sudo, S; Fujikawa, T; Nagakura, T; Ohkubo, T; Sakaguchi, K; Tanaka, M; Nakashima, K; Takahashi, T				Sudo, S; Fujikawa, T; Nagakura, T; Ohkubo, T; Sakaguchi, K; Tanaka, M; Nakashima, K; Takahashi, T			Structures of mollusc shell framework proteins	NATURE			English	Letter									MIE UNIV,FAC BIORESOURCES,DEPT AGR CHEM,TSU,MIE 514,JAPAN	Mie University	Sudo, S (corresponding author), MIE UNIV,FAC MED,DEPT BIOCHEM,TSU,MIE 514,JAPAN.							Belcher AM, 1996, NATURE, V381, P56, DOI 10.1038/381056a0; Falini G, 1996, SCIENCE, V271, P67, DOI 10.1126/science.271.5245.67; Guerette PA, 1996, SCIENCE, V272, P112, DOI 10.1126/science.272.5258.112; MANN S, 1988, NATURE, V332, P119, DOI 10.1038/332119a0; Miyamoto H, 1996, P NATL ACAD SCI USA, V93, P9657, DOI 10.1073/pnas.93.18.9657; NAKAHARA H, 1982, Venus the Japanese Journal of Malacology, V41, P33; SAMATA T, 1988, Venus the Japanese Journal of Malacology, V47, P127; Simmons AH, 1996, SCIENCE, V271, P84, DOI 10.1126/science.271.5245.84; WEINER S, 1980, FEBS LETT, V111, P311, DOI 10.1016/0014-5793(80)80817-9; WILBUR KM, 1963, ANN NY ACAD SCI, V109, P82, DOI 10.1111/j.1749-6632.1963.tb13463.x	10	357	396	3	72	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 5	1997	387	6633					563	564		10.1038/42391	http://dx.doi.org/10.1038/42391			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XC522	9177341				2022-12-01	WOS:A1997XC52200036
J	Otto, F; Thornell, AP; Crompton, T; Denzel, A; Gilmour, KC; Rosewell, IR; Stamp, GWH; Beddington, RSP; Mundlos, S; Olsen, BR; Selby, PB; Owen, MJ				Otto, F; Thornell, AP; Crompton, T; Denzel, A; Gilmour, KC; Rosewell, IR; Stamp, GWH; Beddington, RSP; Mundlos, S; Olsen, BR; Selby, PB; Owen, MJ			Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development	CELL			English	Article							EXPRESSION; FAMILY	We have generated Cbfa1-deficient mice. Homozygous mutants die of respiratory failure shortly after birth. Analysis of their skeletons revealed an absence of osteoblasts and bane. Heterozygous mice showed specific skeletal abnormalities that are characteristic of the human heritable skeletal disorder, cleidocranial dysplasia (CCD). These defects are also observed in a mouse Ccd mutant for this disease. The Cbfa1 gene was shown to be deleted in the Ccd mutation. Analysis of embryonic Cbfa1 expression using a lacZ reporter gene revealed strong expression at sites of bone formation prior to the earliest stages of ossification. Thus, the Cbfa1 gene is essential for osteoblast differentiation and bone formation, and the Cbfa1 heterozygous mouse is a paradigm for a human skeletal disorder.	IMPERIAL CANC RES FUND,LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT HISTOPATHOL,LONDON W12 0HS,ENGLAND; NATL INST MED RES,LONDON NW7 1AA,ENGLAND; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; OAK RIDGE NATL LAB,DIV LIFE SCI,OAK RIDGE,TN 37830	Cancer Research UK; Imperial College London; MRC National Institute for Medical Research; Harvard University; Harvard Medical School; United States Department of Energy (DOE); Oak Ridge National Laboratory			SHINNO, Yasuo/B-2290-2011; Mundlos, Stefan/ABH-9585-2020	Crompton, Tessa/0000-0002-8973-4021	NIAMS NIH HHS [AR36819] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR036819, R01AR036819] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Banerjee C, 1996, P NATL ACAD SCI USA, V93, P4968, DOI 10.1073/pnas.93.10.4968; BEDDINGTON RSP, 1989, DEVELOPMENT, V106, P37; DUCY P, 1995, MOL CELL BIOL, V15, P1858; ERLEBACHER A, 1995, CELL, V80, P371, DOI 10.1016/0092-8674(95)90487-5; Geoffroy V, 1995, J BIOL CHEM, V270, P30973, DOI 10.1074/jbc.270.52.30973; Hamvas R, 1996, MAMM GENOME, V6, pS281; Ito Y, 1996, J CANCER RES CLIN, V122, P266, DOI 10.1007/BF01261402; KAUFMAN MH, 1992, ATLAS MOUSE DEV, P495; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; MALIK NJ, 1982, J CLIN PATHOL, V35, P1092, DOI 10.1136/jcp.35.10.1092; MUNDLOS S, 1995, HUM MOL GENET, V4, P71, DOI 10.1093/hmg/4.1.71; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Ramesar RS, 1996, J MED GENET, V33, P511, DOI 10.1136/jmg.33.6.511; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; SELBY PB, 1978, MUTAT RES, V51, P199, DOI 10.1016/S0027-5107(78)80019-0; SILIENCE DO, 1987, AM J MED GENET, V27, P75; Speck NA, 1995, CRIT REV EUKAR GENE, V5, P337, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.60; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444	19	2288	2373	7	90	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 30	1997	89	5					765	771		10.1016/S0092-8674(00)80259-7	http://dx.doi.org/10.1016/S0092-8674(00)80259-7			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XB925	9182764	Bronze			2022-12-01	WOS:A1997XB92500013
J	Dujon, B; Albermann, K; Aldea, M; Alexandraki, D; Ansorge, W; Arino, J; Benes, V; Bohn, C; BolotinFukuhara, M; Bordonne, R; Boyer, J; Camasses, A; Casamayor, A; Casas, C; Cheret, G; Cziepluch, C; DaignanFornier, B; Dang, DV; deHaan, M; Delius, H; Durand, P; Fairhead, C; Feldmann, H; Gaillon, L; Galisson, F; Gamo, FJ; Gancedo, C; Goffeau, A; Goulding, SE; Grivell, LA; Habbig, B; Hand, NJ; Hani, J; Hattenhorst, U; Hebling, U; Hernando, Y; Herrero, E; Heumann, K; Hiesel, R; Hilger, F; Hofmann, B; Hollenberg, CP; Hughes, B; Jauniaux, JC; Kalogeropoulos, A; Katsoulou, C; Kordes, E; Lafuente, MJ; Landt, O; Louis, EJ; Maarse, AC; Madania, A; Mannhaupt, G; Marck, C; Martin, RP; Mewes, HW; Michaux, G; Paces, V; ParleMcDermott, AG; Pearson, BM; Perrin, A; Pettersson, B; Poch, O; Pohl, TM; Poirey, R; Portetelle, D; Pujol, A; Purnelle, B; Rad, MR; Rechmann, S; Schwager, C; Schweizer, M; Sor, F; Sterky, F; Tarassov, IA; Teodoru, C; Tettelin, H; Thierry, A; Tobiasch, E; Tzermia, M; Uhlen, M; Unseld, M; Valens, M; Vandenbol, M; Vetter, I; Vicek, C; Voet, M; Volckaert, G; Voss, H; Wambutt, R; Wedler, H; Wiemann, S; Winsor, B; Wolfe, KH; Zollner, A; Zumstein, E; Kleine, K				Dujon, B; Albermann, K; Aldea, M; Alexandraki, D; Ansorge, W; Arino, J; Benes, V; Bohn, C; BolotinFukuhara, M; Bordonne, R; Boyer, J; Camasses, A; Casamayor, A; Casas, C; Cheret, G; Cziepluch, C; DaignanFornier, B; Dang, DV; deHaan, M; Delius, H; Durand, P; Fairhead, C; Feldmann, H; Gaillon, L; Galisson, F; Gamo, FJ; Gancedo, C; Goffeau, A; Goulding, SE; Grivell, LA; Habbig, B; Hand, NJ; Hani, J; Hattenhorst, U; Hebling, U; Hernando, Y; Herrero, E; Heumann, K; Hiesel, R; Hilger, F; Hofmann, B; Hollenberg, CP; Hughes, B; Jauniaux, JC; Kalogeropoulos, A; Katsoulou, C; Kordes, E; Lafuente, MJ; Landt, O; Louis, EJ; Maarse, AC; Madania, A; Mannhaupt, G; Marck, C; Martin, RP; Mewes, HW; Michaux, G; Paces, V; ParleMcDermott, AG; Pearson, BM; Perrin, A; Pettersson, B; Poch, O; Pohl, TM; Poirey, R; Portetelle, D; Pujol, A; Purnelle, B; Rad, MR; Rechmann, S; Schwager, C; Schweizer, M; Sor, F; Sterky, F; Tarassov, IA; Teodoru, C; Tettelin, H; Thierry, A; Tobiasch, E; Tzermia, M; Uhlen, M; Unseld, M; Valens, M; Vandenbol, M; Vetter, I; Vicek, C; Voet, M; Volckaert, G; Voss, H; Wambutt, R; Wedler, H; Wiemann, S; Winsor, B; Wolfe, KH; Zollner, A; Zumstein, E; Kleine, K			The nucleotide sequence of Saccharomyces cerevisiae chromosome XV	NATURE			English	Article							OPEN READING FRAMES; COMPLETE DNA-SEQUENCE; LEFT ARM; FRAGMENT; GENE; CONTAINS; SEGMENT	Chromosome XV was one of the last two chromosomes of Saccharomyces cerevisiae to be discovered(1). It is the third-largest yeast chromosome after chromosomes XII and IV, and is very similar in size to chromosome VII. It alone represents 9% of the yeast genome (8% if ribosomal DNA is included). When systematic sequencing of chromosome XV was started, 93 genes or markers were identified, and most of them were mapped(2). However, very little else was known about chromosome XV which, in contrast to shorter chromosomes, had not been the object of comprehensive genetic or molecular analysis. It was therefore decided to start sequencing chromosome XV only in the third phase of the European Yeast Genome Sequencing Programme, after experience was gained on chromosomes III, XI and II (refs 3-5). The sequence of chromosome XV has been determined from a set of partly overlapping cosmid clones derived from a unique yeast strain, and physically mapped at 3.3-kilobase resolution before sequencing. As well as numerous new open reading frames (ORFs) and genes encoding tRNA or small RNA molecules, the sequence of 1,091,283 base pairs confirms the high proportion of orphan genes and reveals a number of ancestral and successive duplications with other yeast chromosomes.	UNIV PARIS 06, INST PASTEUR, UFR 927, F-75724 PARIS 15, FRANCE; MAX PLANCK INST BIOCHEM, MARTINSRIEDER INST PROT SEQUENZEN, D-82152 MARTINSRIED, GERMANY; UNIV LLEIDA, FAC MED, DEPT BASIC MED SCI, E-25006 LLEIDA, SPAIN; FDN RES & TECHNOL HELLAS, IMBB, IRAKLION 71110, CRETE, GREECE; UNIV CRETE, DEPT BIOL, IRAKLION 71110, CRETE, GREECE; EUROPEAN MOL BIOL LAB, BIOCHEM INSTRUMENTAT PROGRAM, D-69117 HEIDELBERG, GERMANY; UNIV AUTONOMA BARCELONA, DEPT BIOQUIM & BIOL MOL, E-08193 BELLATERRA, SPAIN; UNIV PARIS 11, INST GENET & MICROBIOL, F-91405 ORSAY, FRANCE; CNRS, UPR 9005 MMDCD, F-67084 STRASBOURG, FRANCE; INST CURIE, F-91405 ORSAY, FRANCE; DEUTSCH KREBSFORSCHUNGSZENTRUM, TUMORVIROL ABT 0610, D-69009 HEIDELBERG, GERMANY; DEUTSCH KREBSFORSCHUNGSZENTRUM, INSERM, U375, D-69009 HEIDELBERG, GERMANY; UNIV AMSTERDAM, DEPT MOL CELL BIOL, MOL BIOL SECT, NL-1098 SM AMSTERDAM, NETHERLANDS; DEUTSCH KREBSFORSCHUNGSZENTRUM, ABT ANGEW TUMORVIROL, D-69120 HEIDELBERG, GERMANY; FAC UNIV SCI AGRON, UNITE MICROBIOL, B-5030 GEMBLOUX, BELGIUM; UNIV MUNICH, INST PHYSIOL CHEM PHYS BIOCHEM & ZELLBIOL, D-80336 MUNICH, GERMANY; CSIC, INST INVEST BIOMED, E-28029 MADRID, SPAIN; UNIV CATHOLIQUE LOUVAIN, UNITE BIOCHIM PHYSIOL, B-1348 LOUVAIN, BELGIUM; UNIV DUBLIN TRINITY COLL, DEPT GENET, DUBLIN 2, IRELAND; UNIV DUSSELDORF, INST MIKROBIOL, D-40225 DUSSELDORF, GERMANY; INST FOOD RES, DEPT GENET & MICROBIOL, NORWICH NR4 7UA, NORFOLK, ENGLAND; INST GENBIOL FORSCH, D-14195 BERLIN, GERMANY; GATC GESELL ANAL TECH & CONSULTING MBH, D-78467 CONSTANCE, GERMANY; TIB MOLBIOL, D-10829 BERLIN, GERMANY; JOHN RADCLIFFE HOSP, INST MOL MED, OXFORD OX3 9DU, ENGLAND; CEA SACLAY, DSV, DEPT BIOL CELLULAIRE & MOL, SERV BIOCHIM & GENET MOL, F-91191 GIF SUR YVETTE, FRANCE; ROYAL INST TECHNOL, DEPT BIOCHEM & BIOTECHNOL, S-10044 STOCKHOLM, SWEDEN; KATHOLIEKE UNIV LEUVEN, LAB GENE TECHNOL, B-3001 LOUVAIN, BELGIUM; AGON GMBH, D-12489 BERLIN, GERMANY	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Sorbonne Universite; Max Planck Society; Universitat de Lleida; Foundation for Research & Technology - Hellas (FORTH); University of Crete; European Molecular Biology Laboratory (EMBL); Autonomous University of Barcelona; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Institut National de la Sante et de la Recherche Medicale (Inserm); University of Amsterdam; Helmholtz Association; German Cancer Research Center (DKFZ); University of Liege; University of Munich; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Universite Catholique Louvain; Trinity College Dublin; Heinrich Heine University Dusseldorf; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Quadram Institute; University of East Anglia; University of Oxford; CEA; UDICE-French Research Universities; Universite Paris Saclay; Royal Institute of Technology; KU Leuven	Dujon, B (corresponding author), INST PASTEUR, UNITE GENET MOL LEVURES, CNRS, URA 1149, 25 RUE DR ROUX, F-75724 PARIS 15, FRANCE.		Dujon, Bernard A/F-4971-2010; Wiemann, Stefan/E-4424-2013; Paces, Vaclav/G-3831-2014; Arino, Joaquin/D-3756-2011; Hernando, Yolanda/D-2520-2014; Hand, Nicholas J/O-2508-2016; Pujol, Aurora/N-4990-2014; Fairhead, Cecile/D-9011-2014; Michaux, Gregoire/X-6586-2019; Casamayor, Antonio/C-2509-2017; Uhlen, Mathias/B-3262-2016; Wolfe, Kenneth H/B-4653-2009; Casas, Celia/B-4963-2010; Louis, Edward/B-7920-2008; Poirey, Rémy/A-4324-2017; Casamayor, Antonio/A-3190-2012; Hand, Nicholas/Q-4235-2019; Ansorge, Wilhelm/AAN-8780-2020; Aldea, Marti/K-3962-2014; Uhlen, Mathias/AAV-8746-2021; Herrero, Enrique/B-5592-2009; Gancedo, Carlos/E-9831-2016; Mewes, Hans-Werner/A-8204-2019	Wiemann, Stefan/0000-0003-4683-3174; Arino, Joaquin/0000-0002-6774-2987; Hernando, Yolanda/0000-0001-7378-9434; Hand, Nicholas J/0000-0002-8172-1816; Pujol, Aurora/0000-0002-9606-0600; Michaux, Gregoire/0000-0003-1222-5461; Uhlen, Mathias/0000-0002-4858-8056; Casas, Celia/0000-0003-4140-5533; Louis, Edward/0000-0003-1157-3608; Casamayor, Antonio/0000-0003-2788-7329; Hand, Nicholas/0000-0002-8172-1816; Aldea, Marti/0000-0002-8710-5336; Herrero, Enrique/0000-0002-6763-111X; Gancedo, Carlos/0000-0002-6278-3667; Arino Carmona, Joaquin/0000-0002-0390-4270; Poirey, Remy/0000-0001-8171-3317; Benes, Vladimir/0000-0002-0352-2547; Mewes, Hans-Werner/0000-0002-9713-6398; Bohn, Chantal/0000-0003-1569-9072; /0000-0003-3281-8088; Bolotin-Fukuhara, Monique/0000-0002-5285-5006; Fairhead, Cecile/0000-0002-0456-0377				Aldea M, 1996, YEAST, V12, P1053; Bordonne R, 1997, YEAST, V13, P73; Boyer J, 1996, YEAST, V12, P1575, DOI 10.1002/(SICI)1097-0061(199612)12:15<1575::AID-YEA45>3.3.CO;2-5; CASAMAYOR A, 1995, YEAST, V11, P1281, DOI 10.1002/yea.320111308; Casamayor A, 1996, YEAST, V12, P1013, DOI 10.1002/(SICI)1097-0061(199609)12:10B<1013::AID-YEA980>3.3.CO;2-X; CASAS C, 1995, YEAST, V11, P1061, DOI 10.1002/yea.320111107; Cheret G, 1996, YEAST, V12, P1059, DOI 10.1002/(SICI)1097-0061(199609)12:10B<1059::AID-YEA994>3.0.CO;2-7; DUJON B, 1996, TRENDS GENET, V12, P2263; DUJON B, 1994, NATURE, V396, P371; FELDMANN H, 1994, EMBO J, V13, P5795, DOI 10.1002/j.1460-2075.1994.tb06923.x; Galisson F, 1996, YEAST, V12, P877, DOI 10.1002/(SICI)1097-0061(199607)12:9<877::AID-YEA969>3.0.CO;2-S; Gamo FJ, 1996, YEAST, V12, P709, DOI 10.1002/(SICI)1097-0061(19960615)12:7<709::AID-YEA957>3.0.CO;2-1; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; GOFFEAU A, 1993, FEBS LETT, V325, P112, DOI 10.1016/0014-5793(93)81425-Y; HAWTHORNE DC, 1968, GENETICS, V60, P735; Lafuente MJ, 1996, YEAST, V12, P1041; Madania A, 1996, YEAST, V12, P1563; Mannhaupt G, 1996, YEAST, V12, P67, DOI 10.1002/(SICI)1097-0061(199601)12:1<67::AID-YEA884>3.0.CO;2-F; MORTIMER RK, 1992, YEAST, V8, P817, DOI 10.1002/yea.320081002; OLIVER SG, 1992, NATURE, V357, P38, DOI 10.1038/357038a0; Parle-Mcdermott Anne G., 1996, Yeast, V12, P999, DOI 10.1002/(SICI)1097-0061(199609)12:10B<999::AID-YEA976>3.0.CO;2-E; Pearson BM, 1996, YEAST, V12, P1021; Purnelle B, 1996, YEAST, V12, P1475, DOI 10.1002/(SICI)1097-0061(199611)12:14<1475::AID-YEA32>3.0.CO;2-V; Richard GF, 1996, GENE, V174, P165, DOI 10.1016/0378-1119(96)00514-8; Sterky F, 1996, YEAST, V12, P1091; THIERRY A, 1992, NUCLEIC ACIDS RES, V20, P5625, DOI 10.1093/nar/20.21.5625; VANDENBOL M, 1995, YEAST, V11, P1069, DOI 10.1002/yea.320111108; Wiemann S, 1996, YEAST, V12, P281; ZUMSTEIN E, 1994, YEAST, V10, P1383, DOI 10.1002/yea.320101015; ZUMSTEIN E, 1995, YEAST, V11, P975, DOI 10.1002/yea.320111009	30	43	653	0	82	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 29	1997	387	6632		S			98	102		10.1038/387s098	http://dx.doi.org/10.1038/387s098			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XB546	9169874				2022-12-01	WOS:A1997XB54600014
J	Schindelin, N; Kisker, C; Sehlessman, JL; Howard, JB; Rees, DC				Schindelin, N; Kisker, C; Sehlessman, JL; Howard, JB; Rees, DC			Structure of ADP center dot AIF(4)(-)-stabilized nitrogenase complex and its implications for signal transduction	NATURE			English	Article							MOLYBDENUM-IRON PROTEIN; AZOTOBACTER-VINELANDII; CRYSTAL-STRUCTURE; GTP HYDROLYSIS; CRYSTALLOGRAPHIC STRUCTURE; CONFORMATIONAL-CHANGES; FE-PROTEIN; MECHANISM; MGATP; PROGRAM	The coupling of ATP hydrolysis to electron transfer by the enzyme nitrogenase during biological nitrogen fixation is an important example of a nucleotide-dependent transduction mechanism. The crystal structure has been determined for the complex between the Fe-protein and MoFe-protein components of nitrogenase stabilized by ADP AlF4-, previously used as a nucleoside triphosphate analogue in nucleotide-switch proteins. The structure reveals that the dimeric re-protein has undergone substantial conformational changes. The beta-phosphate and AlF4- groups are stabilized through intersubunit contacts that are critical for catalysis and the redox centre is repositioned to facilitate electron transfer. Interactions in the nitrogenase complex have broad implications for signal and energy transduction mechanisms In multiprotein complexes.	UNIV MINNESOTA, DEPT BIOCHEM, MINNEAPOLIS, MN 55455 USA; CALTECH, DIV CHEM & CHEM ENGN, PASADENA, CA 91125 USA	University of Minnesota System; University of Minnesota Twin Cities; California Institute of Technology			Kisker, Caroline/T-1724-2019; Schindelin, Hermann/Q-2697-2019	Kisker, Caroline/0000-0002-0216-6026				BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BOLIN JT, 1993, ACS SYM SER, V535, P186; BROWNBRIDGE GG, 1993, J BIOL CHEM, V268, P10914; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Burgess BK, 1996, CHEM REV, V96, P2983, DOI 10.1021/cr950055x; CHEN L, 1994, J BIOL CHEM, V269, P3290; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; Duyvis MG, 1996, FEBS LETT, V380, P233, DOI 10.1016/0014-5793(96)00019-1; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; FRECH M, 1994, BIOCHEMISTRY-US, V33, P3237, DOI 10.1021/bi00177a014; GEORGIADIS MM, 1992, SCIENCE, V257, P1653, DOI 10.1126/science.1529353; HOWARD JB, 1993, ACS SYM SER, V535, P271; Howard JB, 1996, CHEM REV, V96, P2965, DOI 10.1021/cr9500545; HOWARD JB, 1994, ANNU REV BIOCHEM, V63, P235, DOI 10.1146/annurev.bi.63.070194.001315; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; KIM JS, 1992, SCIENCE, V257, P1677, DOI 10.1126/science.1529354; KIM JS, 1992, NATURE, V360, P553, DOI 10.1038/360553a0; Kleywegt G. J., 1994, P CCP4 STUD WEEK 1 M, P59; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANZILOTTA WN, 1995, BIOCHEMISTRY-US, V34, P10713, DOI 10.1021/bi00034a003; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LUDDEN PW, 1989, CURR TOP CELL REGUL, V30, P23; Maegley KA, 1996, P NATL ACAD SCI USA, V93, P8160, DOI 10.1073/pnas.93.16.8160; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mittal R, 1996, SCIENCE, V273, P115, DOI 10.1126/science.273.5271.115; MORTENSON LE, 1993, ADV ENZYMOL RAMB, V67, P299; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; Peters JW, 1997, BIOCHEMISTRY-US, V36, P1181, DOI 10.1021/bi9626665; PETERS JW, 1995, ANNU REV MICROBIOL, V49, P335, DOI 10.1146/annurev.mi.49.100195.002003; Renner KA, 1996, BIOCHEMISTRY-US, V35, P5353, DOI 10.1021/bi960441o; RYLE MJ, 1995, J BIOL CHEM, V270, P13112, DOI 10.1074/jbc.270.22.13112; Ryle MJ, 1996, BIOCHEMISTRY-US, V35, P4766, DOI 10.1021/bi960026w; SEEFELDT LC, 1992, J BIOL CHEM, V267, P6680; SEEFELDT LC, 1993, PROTEIN SCI, V2, P93; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; Stiefel E. I., 1993, MOLYBDENUM ENZYMES C; WILLING A, 1990, J BIOL CHEM, V265, P6596; WOLLE D, 1992, J BIOL CHEM, V267, P3667; WOLLE D, 1992, SCIENCE, V258, P992, DOI 10.1126/science.1359643	44	408	415	2	39	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 22	1997	387	6631					370	376		10.1038/387370a0	http://dx.doi.org/10.1038/387370a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XA496	9163420				2022-12-01	WOS:A1997XA49600051
J	vanHaeften, TW; deVries, J; Sixma, JJ				vanHaeften, TW; deVries, J; Sixma, JJ			Concordance of phenprocoumon dosage in married couples	BMJ-BRITISH MEDICAL JOURNAL			English	Article							WARFARIN		UNIV UTRECHT HOSP, DEPT HAEMATOL, NL-3508 GA UTRECHT, NETHERLANDS	Utrecht University; Utrecht University Medical Center	vanHaeften, TW (corresponding author), UNIV UTRECHT HOSP, DEPT INTERNAL MED G02228, THROMBOSIS SERV, POB 85500, NL-3508 GA UTRECHT, NETHERLANDS.							BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; CERMEER C, 1991, THROMB HAEMOSTASIS, V66, P153; COLVIN BT, 1990, J CLIN PATHOL, V43, P177; PEDERSEN FM, 1991, J INTERN MED, V229, P517, DOI 10.1111/j.1365-2796.1991.tb00388.x; ROUTLEDGE PA, 1979, BRIT J CLIN PHARMACO, V8, P243, DOI 10.1111/j.1365-2125.1979.tb01009.x	5	6	6	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 10	1997	314	7091					1386	1386						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WZ169	9161311				2022-12-01	WOS:A1997WZ16900027
J	Jordan, BD; Relkin, NR; Ravdin, LD; Jacobs, AR; Bennett, A; Gandy, S				Jordan, BD; Relkin, NR; Ravdin, LD; Jacobs, AR; Bennett, A; Gandy, S			Apolipoprotein E epsilon 4 associated with chronic traumatic brain injury in boxing	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AMYLOID PROTEIN DEPOSITION; SEVERE HEAD-INJURY; ALZHEIMERS-DISEASE; DEMENTIA-PUGILISTICA; PRECURSOR PROTEIN; TYPE-4 ALLELE; BETA-PROTEIN; BOXERS; AFTERMATH; DAMAGE	Context.-Given the similarities between Alzheimer disease and dementia pugilistica, we evaluated the relationship between apolipoprotein E (APOE) genotype and chronic traumatic brain injury (CTBI) in boxers to determine whether there is a genetic susceptibility to the effects of head trauma. Objective.-To assess the relationship between CTBI and APOE genotype in boxers. Design and Setting.-Clinical characterization of 24 volunteer and 6 referred boxers in an outpatient setting. Participants.-Thirty professional boxers aged 23 to 76 years underwent neurologic and behavioral assessment in conjunction with APOE genotyping. Main Outcome Measures.-Apolipoprotein E genotype was examined in relationship to measures of CTBI. A 10-point clinical rating scale (0-9), the Chronic Brain Injury (CBI) scale, was devised to assess the severity of traumatic encephalopathy associated with boxing, Boxers with abnormal CTBI scores were further classified on the basis of whether their impairments were possibly or probably related to boxing. Scores were analyzed in relation to boxing exposure (number of bouts) and APOE genotype. Results.-Among the 30 boxers, 11 were found to be normal (CBI score=0), 12 showed mild deficits (CBI score=1-2), 4 were moderately impaired (CBI score=3-4), and 3 showed signs of severe impairment (CBI score >4). High-exposure boxers tie, those with greater than or equal to 12 professional bouts) had significantly higher CBI scores (mean [SD], 2.6 [1.9]) than low-exposure boxers (mean [SD], 0.3 [0.7]) (P<.001), indicating that neurologic impairment as measured by the CBI scale seems related to boxing exposure. The APOE genotype frequencies of the study population were approximately the same as those found in the general population. Boxers with low exposure had mean CBI scores of 0.33, irrespective of APOE genotype. However, high-exposure boxers with an APOE epsilon 4 allele had significantly greater CBI scores (mean [SD], 3.9 [2.3]) than high-exposure boxers without APOE epsilon 4 (mean [SD], 1.8 [1.2]) (P=.04), All boxers with severe impairment possessed at least 1 APOE epsilon 4 allele. The tendency for greater CTBI among those with both high exposure and an epsilon 4 allele was statistically significant at the P<.001 level. ConcIusions.-These preliminary findings suggest that possession or an APOE epsilon 4 allele may be associated with increased severity of chronic neurologic deficits in high-exposure boxers.	CORNELL UNIV MED COLL,NEW YORK HOSP,DEPT NEUROL & NEUROSCI,NEW YORK,NY; CORNELL UNIV MED COLL,HOSP SPECIAL SURG,SPORTS NEUROL PROGRAM,NEW YORK,NY	Cornell University; NewYork-Presbyterian Hospital; Cornell University								BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BUTLER RJ, 1994, BRIT J SPORT MED, V28, P187, DOI 10.1136/bjsm.28.3.187; CHARTIERHARLIN MC, 1994, HUM MOL GENET, V3, P569, DOI 10.1093/hmg/3.4.569; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; CRITCHLEY M, 1957, BMJ-BRIT MED J, V1, P357, DOI 10.1136/bmj.1.5015.357; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; DALE GE, 1991, J NEUROL NEUROSUR PS, V54, P116, DOI 10.1136/jnnp.54.2.116; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GRAHAM DI, 1995, NEUROPATH APPL NEURO, V21, P27, DOI 10.1111/j.1365-2990.1995.tb01025.x; HAGLUND Y, 1993, AM J SPORT MED, V21, P97, DOI 10.1177/036354659302100117; HOF PR, 1992, ACTA NEUROPATHOL, V85, P23, DOI 10.1007/BF00304630; JOHNSON J, 1969, BRIT J PSYCHIAT, V115, P45, DOI 10.1192/bjp.115.518.45; JORDAN BD, 1992, RADIOLOGY, V185, P509, DOI 10.1148/radiology.185.2.1410364; JORDAN BD, 1995, ANN NEUROL, V38, P698, DOI 10.1002/ana.410380429; JORDAN BD, 1993, MED ASPECTS BOXING, P147; JORDAN BD, 1993, MED ASPECTS BOXING, P177; Katzman R, 1996, NEUROLOGY, V46, P889; LEHMANN EL, 1975, NONPARAMETRICS; MAESTRE G, 1995, ANN NEUROL, V37, P254, DOI 10.1002/ana.410370217; MANN HB, 1947, ANN MATH STAT, V18, P50, DOI 10.1214/aoms/1177730491; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; MENDEZ MF, 1995, INT J PSYCHIAT MED, V25, P249, DOI 10.2190/CUMK-THT1-X98M-WB4C; *NAT I AG ALZH ASS, 1996, LANCET, V347, P1091; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Roberts, 1969, BRAIN DAMAGE BOXERS, P1; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; TOKUDA T, 1991, ACTA NEUROPATHOL, V82, P280, DOI 10.1007/BF00308813; UHL GR, 1982, ANN NEUROL, V12, P99; vanDuijn CM, 1996, J NEUROL NEUROSUR PS, V60, P478, DOI 10.1136/jnnp.60.5.478; WENHAM PR, 1991, LANCET, V337, P1158, DOI 10.1016/0140-6736(91)92823-K	37	493	505	0	29	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 9	1997	278	2					136	140		10.1001/jama.278.2.136	http://dx.doi.org/10.1001/jama.278.2.136			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XH667	9214529				2022-12-01	WOS:A1997XH66700034
J	Maisonpierre, PC; Suri, C; Jones, PF; Bartunkova, S; Wiegand, S; Radziejewski, C; Compton, D; McClain, J; Aldrich, TH; Papadopoulos, N; Daly, TJ; Davis, S; Sato, TN; Yancopoulos, GD				Maisonpierre, PC; Suri, C; Jones, PF; Bartunkova, S; Wiegand, S; Radziejewski, C; Compton, D; McClain, J; Aldrich, TH; Papadopoulos, N; Daly, TJ; Davis, S; Sato, TN; Yancopoulos, GD			Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis	SCIENCE			English	Article							RECEPTOR TYROSINE KINASE; ENDOTHELIAL GROWTH-FACTOR; MOLECULAR-CLONING; EXPRESSION; PROTEIN; GENES; TEK; VASCULOGENESIS; INHIBITION; PATTERNS	Angiogenesis is thought to depend on a precise balance of positive and negative regulation. Angiopoietin-1 (Ang1) is an angiogenic factor that signals through the endothelial cell-specific Tie2 receptor tyrosine kinase. Like Vascular endothelial growth factor, Ang1 is essential for normal vascular development in the mouse. An Ang1 relative, termed angiopoietin-2 (Ang2), was identified by homology screening and shown to be a naturally occurring antagonist for Ang1 and Tie2. Transgenic overexpression of Ang2 disrupts blood vessel formation in the mouse embryo. in adult mice and humans, Ang2 is expressed only at sites of vascular remodeling. Natural antagonists for vertebrate receptor tyrosine kinases are atypical; thus, the discovery of a negative regulator acting on Tie2 emphasizes the need for exquisite regulation of this angiogenic receptor system.	REGENERON PHARMACEUT INC,TARRYTOWN,NY 10591; BETH ISRAEL DEACONESS MED CTR,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA 02215	Regeneron; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School								AREND WP, 1990, J CLIN INVEST, V85, P1694, DOI 10.1172/JCI114622; BACHARACH E, 1992, P NATL ACAD SCI USA, V89, P10686, DOI 10.1073/pnas.89.22.10686; Cioce V, 1996, J BIOL CHEM, V271, P13110, DOI 10.1074/jbc.271.22.13110; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Davis S.M, UNPUB; DUMONT DJ, 1992, ONCOGENE, V7, P1471; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FINDLAY JK, 1986, J ENDOCRINOL, V111, P357, DOI 10.1677/joe.0.1110357; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hirschi KK, 1996, CARDIOVASC RES, V32, P687, DOI 10.1016/S0008-6363(96)00063-6; IWAMA A, 1993, BIOCHEM BIOPH RES CO, V195, P301, DOI 10.1006/bbrc.1993.2045; JACKSON D, 1994, SCIENCE, V266, P1581, DOI 10.1126/science.7527157; MAISONPIERRE P, UNPUB; MAISONPIERRE PC, 1993, ONCOGENE, V8, P1631; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; PARTANEN J, 1992, MOL CELL BIOL, V12, P1698, DOI 10.1128/MCB.12.4.1698; PHILLIPS HS, 1990, ENDOCRINOLOGY, V127, P965, DOI 10.1210/endo-127-2-965; RISAU W, 1995, FASEB J, V9, P926, DOI 10.1096/fasebj.9.10.7615161; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; SATO TN, 1993, P NATL ACAD SCI USA, V90, P9355, DOI 10.1073/pnas.90.20.9355; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; Schlaeger TM, 1997, P NATL ACAD SCI USA, V94, P3058, DOI 10.1073/pnas.94.7.3058; SCHNURCH H, 1993, DEVELOPMENT, V119, P957; SCHWEITZER R, 1995, NATURE, V376, P699, DOI 10.1038/376699a0; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHALABY F, 1996, NATURE, V380, P435; SHWEIKI D, 1993, J CLIN INVEST, V91, P2235, DOI 10.1172/JCI116450; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Vikkula M, 1996, CELL, V87, P1181, DOI 10.1016/S0092-8674(00)81814-0; ZIEGLER SF, 1993, ONCOGENE, V8, P663	37	2720	2980	2	81	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 4	1997	277	5322					55	60		10.1126/science.277.5322.55	http://dx.doi.org/10.1126/science.277.5322.55			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XJ418	9204896				2022-12-01	WOS:A1997XJ41800036
J	Noll, KS; Roush, TL; Cruikshank, DP; Johnson, RE; Pendleton, YJ				Noll, KS; Roush, TL; Cruikshank, DP; Johnson, RE; Pendleton, YJ			Detection of ozone on Saturn's satellites Rhea and Dione	NATURE			English	Article							CHARGED-PARTICLE IRRADIATION; EUROPA; GANYMEDE; OXYGEN; CALLISTO; SPECTRA; ALBEDO; SEARCH; ICES; LIFE	The satellites Rhea and Dione orbit within the magnetosphere of Saturn, where they are exposed to particle irradiation from trapped ions. A similar situation applies to the galilean moons Europa, Ganymede and Callisto, which reside within Jupiter's radiation belts. All of these satellites have surfaces rich in water ice(1,2). Laboratory studies of the interaction of charged-particle radiation with water ice predicted(3) the tenuous oxygen atmospheres recently found on Europa(4) and Ganymede(5). However, theoretical investigations did not anticipate the trapping of significantly larger quantities of O-2 within the surface ice(6). The accumulation of detectable abundances of O-3, produced by the action of ultraviolet or charged-particle radiation on O-2, was also not predicted before being observed on Ganymede(7). Here we report the identification of O-3 in spectra of the saturnian satellites Rhea and Dione. The presence of trapped O-3 is thus no longer unique to Ganymede, suggesting that special circumstances may not be required for its production.	NASA, AMES RES CTR, MOFFETT FIELD, CA 94035 USA; SAN FRANCISCO STATE UNIV, DEPT GEOSCI, SAN FRANCISCO, CA 94132 USA; UNIV VIRGINIA, CHARLOTTESVILLE, VA 22901 USA	National Aeronautics & Space Administration (NASA); NASA Ames Research Center; California State University System; San Francisco State University; University of Virginia	Noll, KS (corresponding author), SPACE TELESCOPE SCI INST, 3700 SAN MARTIN DR, BALTIMORE, MD 21218 USA.		Noll, Keith/C-8447-2012					BARTH CA, IN PRESS GEOPHYS RES; BURATTI B, 1984, ICARUS, V58, P254, DOI 10.1016/0019-1035(84)90042-3; BURATTI BJ, 1990, ICARUS, V87, P339, DOI 10.1016/0019-1035(90)90138-Y; BURATTI BJ, 1991, ICARUS, V92, P312, DOI 10.1016/0019-1035(91)90054-W; BURKE BF, 1986, NATURE, V322, P340, DOI 10.1038/322340a0; CLARK RN, 1980, ICARUS, V44, P388, DOI 10.1016/0019-1035(80)90033-0; CLARK RN, 1984, ICARUS, V58, P265, DOI 10.1016/0019-1035(84)90043-5; ELSILA J, IN PRESS ASTROPHYS J; HALL DT, 1995, NATURE, V373, P677, DOI 10.1038/373677a0; Johnson RE, 1997, ASTROPHYS J, V480, pL79, DOI 10.1086/310614; Johnson RE., 1990, ENERGETIC CHARGED PA, DOI 10.1007/978-3-642-48375-2; KHARE BN, 1993, ICARUS, V103, P290, DOI 10.1006/icar.1993.1071; LANE AL, 1981, NATURE, V292, P38, DOI 10.1038/292038a0; LEGER A, 1994, ADV SPACE RES, V14, P117, DOI 10.1016/0273-1177(94)90016-7; MATICH AJ, 1993, J PHYS CHEM-US, V97, P10539, DOI 10.1021/j100143a007; MORRISON D, 1975, ICARUS, V24, P157, DOI 10.1016/0019-1035(75)90093-7; Noll KS, 1997, GEOPHYS RES LETT, V24, P1139, DOI 10.1029/97GL00876; Noll KS, 1996, SCIENCE, V273, P341, DOI 10.1126/science.273.5273.341; NOLL KS, 1995, J GEOPHYS RES-PLANET, V100, P19057, DOI 10.1029/94JE03294; OWEN T, 1992, NATURE, V358, P43, DOI 10.1038/358043a0; POSPIESZALSKA MK, 1989, ICARUS, V78, P1, DOI 10.1016/0019-1035(89)90065-1; ROUSH TL, 1995, VOLATILES EARTH SOLA, V341, P143; SPENCER JR, 1995, J GEOPHYS RES-PLANET, V100, P19049, DOI 10.1029/95JE01503; TAUBE H, 1957, T FARADAY SOC, V53, P656, DOI 10.1039/tf9575300656; THOMPSON WR, 1987, J GEOPHYS RES, V92, P14933, DOI 10.1029/JA092iA13p14933; TIELENS AGGM, 1982, ASTRON ASTROPHYS, V114, P245; VAIDA V, 1989, J PHYS CHEM-US, V93, P506, DOI 10.1021/j100339a003; Vilas F, 1996, ICARUS, V124, P262, DOI 10.1006/icar.1996.0202; WOODS TN, 1993, J GEOPHYS RES-ATMOS, V98, P10679, DOI 10.1029/93JD00463	29	128	128	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 3	1997	388	6637					45	47		10.1038/40348	http://dx.doi.org/10.1038/40348			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XJ143	9214500				2022-12-01	WOS:A1997XJ14300043
J	Eisenberg, DM				Eisenberg, DM			Advising patients who seek alternative medical therapies	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							EOSINOPHILIA-MYALGIA-SYNDROME; HERBAL MEDICINES; CHIROPRACTIC MANIPULATION; SPINAL MANIPULATION; ADVERSE REACTIONS; CLINICAL-TRIALS; UNITED-STATES; CHINESE HERBS; CHRONIC PAIN; HEPATITIS-B	Alternative medical therapies, such as chiropractic, acupuncture, homeopathy, and herbal remedies, are in great public demand. Some managed care organizations now offer these therapies as an ''expanded benefit.'' Because the safety and efficacy of these practices remain largely unknown, advising patients who use or seek alternative treatments presents a professional challenge. A step-by-step strategy is proposed whereby conventionally trained medical providers and their patients can preactively discuss the use or avoidance of alternative therapies. This strategy involves a formal discussion of patients' preferences and expectations, the maintenance of symptom diaries, and follow-up visits to monitor for potentially harmful situations. In the absence of professional medical and legal guidelines, the proposed management plan emphasizes patient safety, the need for documentation in the patient record, and the importance of shared decision making.			Eisenberg, DM (corresponding author), BETH ISRAEL DEACONESS MED CTR, CTR ALTERNAT MED RES, 330 BROOKLINE AVE, BOSTON, MA 02215 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [U24AR043441] Funding Source: NIH RePORTER; NIAMS NIH HHS [U24 AR43441] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Anderson IB, 1996, ANN INTERN MED, V124, P726, DOI 10.7326/0003-4819-124-8-199604150-00004; ANGELL M, 1985, NEW ENGL J MED, V312, P1570, DOI 10.1056/NEJM198506133122411; [Anonymous], 1988, HERBAL MED; ASSENDELFT WJJ, 1992, J MANIP PHYSIOL THER, V15, P487; BAILEY DG, 1994, CLIN PHARMACOKINET, V26, P91, DOI 10.2165/00003088-199426020-00002; BARRETT S, 1990, HLTH SCHEMES SCAMS F; BELLAVITE P, 1995, HOMEOPATHY FRONTIER; Bigos S, 1994, CLIN PRACTICE GUIDEL; BLUMENTHAL M, 1996, COMMISSION E MONOGRA; *BURT GOLDB GROUP, 1993, ALT MED DEF GUID; BUTLER K, 1992, CONSUMERS GUIDE ALTE; CARRON H, 1974, JAMA-J AM MED ASSOC, V228, P1552; Carton Barbara, 1995, WALL ST J       0116, pB1; CHAN TYK, 1993, LANCET, V342, P1532, DOI 10.1016/S0140-6736(05)80091-1; CHENG TO, 1989, AM J MED, V87, P489, DOI 10.1016/S0002-9343(89)80853-8; COLLINGE W, 1996, COMPLETE GUIDE ALTER; CONN JW, 1968, J AMER MED ASSOC, V205, P492, DOI 10.1001/jama.205.7.492; Coulter ID, 1995, APPROPRIATENESS SPIN; COWLEY G, 1996, NEWSWEEK        0603, P60; DANDEKAR UP, 1992, J ETHNOPHARMACOL, V35, P285, DOI 10.1016/0378-8741(92)90026-N; DARCY PF, 1991, ADVERSE DRUG REACT T, V10, P189; DARCY PF, 1993, ADVERSE DRUG REACT T, V12, P147; De Smet P. A. G. M., 1992, P1209; De Smet P. A. G. M., 1993, ADVERSE EFFECTS HERB; De Smet PAGM, 1992, TOXICOLOGICAL OUTLOO, P1; DESMET PAGM, 1995, DRUG SAFETY, V13, P81, DOI 10.2165/00002018-199513020-00003; DESMET PAGM, 1991, J ETHNOPHARMACOL, V32, P43, DOI 10.1016/0378-8741(91)90102-J; DUNKIN A, 1995, BUSINESS WEEK   1127, P134; Egan Timothy, 1996, NY TIMES, pA6; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; EISENBERG DM, 1996, HARVARD MED ALUMNI B, V70, P20; EPSTEIN WL, 1987, ANN EMERG MED, V16, P950, DOI 10.1016/S0196-0644(87)80739-4; FAST A, 1987, SPINE, V12, P840, DOI 10.1097/00007632-198711000-00003; FRIEDMAN RA, 1996, NY TIMES        0419, pA29; Fugh-Berman A., 1996, ALTERNATIVE MED WHAT; FUSHIMI R, 1989, LANCET, V1, P339, DOI 10.1016/S0140-6736(89)91361-5; Gevitz N., 1988, OTHER HEALERS UNORTH, P124; GLOCK M, 1995, NIH PUBLICATION; GOLDMAN JA, 1991, ARTHRITIS RHEUM, V34, P1207, DOI 10.1002/art.1780340922; GOLEMAN D, 1993, MIND BODY MED HOW US; GORDON DW, 1995, JAMA-J AM MED ASSOC, V273, P489, DOI 10.1001/jama.273.6.489; HALDEMAN S, 1992, SPINE, V17, P1469, DOI 10.1097/00007632-199212000-00005; HENDEE WR, 1987, JAMA-J AM MED ASSOC, V257, P1929; HERTZMAN PA, 1990, NEW ENGL J MED, V322, P869, DOI 10.1056/NEJM199003293221301; HEWALL CA, 1996, HERBAL MED GUIDE HLT; HILTS PJ, 1995, NY TIMES        1227, pB10; HOGAN RP, 1983, JAMA-J AM MED ASSOC, V249, P2679, DOI 10.1001/jama.249.19.2679; Hurwitz EL, 1996, SPINE, V21, P1746, DOI 10.1097/00007632-199608010-00007; HUXTABLE RJ, 1990, DRUG SAFETY, V5, P126, DOI 10.2165/00002018-199000051-00020; JACKSON C, 1996, TAMPA TRIBUNE   0108, P8; James, 1995, ACUPUNCT MED, V13, P26, DOI [10.1136/aim.13.1.26, DOI 10.1136/AIM.13.1.26]; KAMB ML, 1992, JAMA-J AM MED ASSOC, V267, P77, DOI 10.1001/jama.267.1.77; KANE JA, 1995, GUT, V36, P146, DOI 10.1136/gut.36.1.146; Kaptchuk T.J., 1983, WEB HAS NO WEAVER; KASSIRER JP, 1983, NEW ENGL J MED, V308, P898, DOI 10.1056/NEJM198304143081511; KEMPIN SJ, 1983, NEW ENGL J MED, V308, P1229; KENT GP, 1988, AM J EPIDEMIOL, V127, P591, DOI 10.1093/oxfordjournals.aje.a114834; KLEIJNEN J, 1991, THORAX, V46, P799, DOI 10.1136/thx.46.11.799; KLEIJNEN J, 1991, BRIT MED J, V302, P316, DOI 10.1136/bmj.302.6772.316; KRAUSS C, 1996, NY TIMES        0524, pB1; LAGNADO L, 1996, WALL STREET J   1007, pB9; LARREY D, 1992, ANN INTERN MED, V117, P129, DOI 10.7326/0003-4819-117-2-129; LEE KP, 1995, NEUROLOGY, V45, P1213, DOI 10.1212/WNL.45.6.1213; LERNER M, 1994, CHOICES HEALING INTE; Marti J, 1995, ALTERNATIVE HLTH MED; MICOZZI MS, 1996, FUNDAMENTALS COMPLEN; MOORE JS, 1993, CHIROPRACTIC AM HIST; NEFF R, 1995, BUSINESS WEEK   0130, P60; *NIH OFF ALT MED, 1994, ALT MED EXP MED HOR; OConnor BB, 1995, STUDIES HLTH ILLNESS, Vxxiv; OLIVER LD, 1984, TEX MED, V80, P40; PATEL M, 1989, INT J EPIDEMIOL, V18, P900, DOI 10.1093/ije/18.4.900; PHALON R, 1993, FORBES          1220, P254; PIZZORNO JE, 1993, TXB NATURAL MED; POWELL FC, 1993, NEUROSURGERY, V33, P73; RASO J, 1993, MYSTICAL DIETS PARAN; REILLY D, 1994, LANCET, V344, P1601, DOI 10.1016/S0140-6736(94)90407-3; RIDKER PM, 1989, LANCET, V1, P657, DOI 10.1016/S0140-6736(89)92154-5; ROBERTS IF, 1979, BRIT MED J, V1, P296, DOI 10.1136/bmj.1.6159.296; RUSSELL FE, 1975, JAMA-J AM MED ASSOC, V233, P341, DOI 10.1001/jama.233.4.341; RUSSELL S, 1996, SAN FRANCISCO C 0925, pA1; SALE JD, 1994, OVERVIEW LEGISLATIVE; SCHECK A, 1995, INVESTORS BUSIN 0620; SEGELMAN AB, 1976, JAMA-J AM MED ASSOC, V236, P477, DOI 10.1001/jama.236.5.477; SHEKELLE PG, 1992, ANN INTERN MED, V117, P590, DOI 10.7326/0003-4819-117-7-590; SHERLOCK P, 1967, J AMER MED ASSOC, V199, P794, DOI 10.1001/jama.199.11.794; SLATER PE, 1988, EUR J EPIDEMIOL, V4, P322, DOI 10.1007/BF00148918; SMITH GW, 1993, BRIT J RHEUMATOL, V32, P87; STALKER D, 1989, EXAMINING HOLISTIC M; STRYKER WS, 1986, J FAM PRACTICE, V22, P155; TAI YT, 1992, LANCET, V340, P1254, DOI 10.1016/0140-6736(92)92951-B; TAYLOR GD, 1985, CAN MED ASSOC J, V133, P767; TERRIET G, 1990, J CLIN EPIDEMIOL, V43, P1191, DOI 10.1016/0895-4356(90)90020-P; TERRIET G, 1990, BRIT J GEN PRACT, V40, P379; TRESOLINI CP, 1994, HLTH ED RELATIONSHIP; Tyler, 1994, HERBS CHOICE THERAPE; Tyler VE, 1993, HONEST HERBAL SENSIB, V3rd; *US C, 1990, OTAH405; VANHERWEGHEM JL, 1993, LANCET, V341, P387, DOI 10.1016/0140-6736(93)92984-2; Vickers AJ, 1996, J ROY SOC MED, V89, P303, DOI 10.1177/014107689608900602; Vithoulkas G., 1980, SCI HOMEOPATHY; VITTECOQ D, 1989, NEW ENGL J MED, V320, P250; WARDWELL W, 1992, CHIROPRACTIC HIST EV; WEINER M, 1982, COMPLETE BOOK HOMEOP; Werbach MR, 1994, BOT INFLUENCES ILLNE; *WHO, 1992, HERB MED CONT GERM W; WILKINSON JA, 1995, BRIT J PHYTOTHERAPY, V4, P34; WOOLF GM, 1994, ANN INTERN MED, V121, P729, DOI 10.7326/0003-4819-121-10-199411150-00001; Zwicky JF, 1993, READERS GUIDE ALTERN; 1996, NY TIMES        1009, pA11; 1997, J MIND BODY HLTH, V13, P79; 1990, CAN MED ASSOC J, V143, P1009; 1995, MMWR-MORBID MORTAL W, V44, P41; 1997, INNOVIOSN COMMUNICAT, V3, P125; 1997, UPC C TRAIN SEM ALT, V3, P72; 1993, MMWR-MORBID MORTAL W, V42, P521	116	299	303	0	29	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1997	127	1					61	69		10.7326/0003-4819-127-1-199707010-00010	http://dx.doi.org/10.7326/0003-4819-127-1-199707010-00010			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG914	9214254				2022-12-01	WOS:A1997XG91400009
J	Chao, QM; Rothenberg, M; Solano, R; Roman, G; Terzaghi, W; Ecker, JR				Chao, QM; Rothenberg, M; Solano, R; Roman, G; Terzaghi, W; Ecker, JR			Activation of the ethylene gas response pathway in Arabidopsis by the nuclear protein ETHYLENE-INSENSITIVE3 and related proteins	CELL			English	Article							SIGNAL-TRANSDUCTION PATHWAY; DNA-BINDING PROTEINS; MAP KINASE CASCADE; 2-COMPONENT REGULATORS; MUTANT ARABIDOPSIS; WILD-TYPE; YEAST; THALIANA; GENE; PLANTS	Mutations in the Arabidopsis ETHYLENE-INSENSITIVE3 (EIN3) gene severely limit a plant's response to the gaseous hormone ethylene. ein3 mutants show a loss of ethylene-mediated effects including gene expression, the triple response, cell growth inhibition, and accelerated senescence. EIN3 acts downstream of the histidine kinase ethylene receptor, ETR1, and the Raf-like kinase, CTR1. The EIN3 gene encodes a novel nuclear-localized protein that shares sequence similarity, structural features, and genetic function with three EIN3-LIKE (EIL) proteins. In addition to EIN3, EIL1 or EIL2 were able to complement ein3, suggesting their participation in the ethylene signaling pathway. Overexpression of EIN3 or EIL2 in wild-type or ethylene-insensitive2 plants conferred constitutive ethylene phenotypes, indicating their sufficiency for activation of the pathway in the absence of ethylene.	UNIV PENN,INST PLANT SCI,DEPT BIOL,PHILADELPHIA,PA 19104	University of Pennsylvania			Roman, Gregg/W-1586-2019; Solano, Roberto/O-5908-2017; Ecker, Joseph R/B-9144-2008	Roman, Gregg/0000-0003-1519-4699; Solano, Roberto/0000-0001-5459-2417; Ecker, Joseph R/0000-0001-5799-5895; Terzaghi, William/0000-0002-7536-6432	NIGMS NIH HHS [1F32GM18003-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM018003] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEL S, 1994, PLANT J, V5, P421, DOI 10.1111/j.1365-313X.1994.00421.x; Abeles F.B., 2012, ETHYLENE PLANT BIOL; BAULCOMBE DC, 1986, NATURE, V321, P446, DOI 10.1038/321446a0; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BLEECKER AB, 1988, SCIENCE, V241, P1086, DOI 10.1126/science.241.4869.1086; Bleecker AB, 1996, PLANT PHYSIOL, V111, P653, DOI 10.1104/pp.111.3.653; Chang C, 1996, TRENDS BIOCHEM SCI, V21, P129, DOI 10.1016/0968-0004(96)10019-0; CHANG C, 1993, SCIENCE, V262, P539, DOI 10.1126/science.8211181; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; CHEN QHG, 1995, PLANT PHYSIOL, V108, P597, DOI 10.1104/pp.108.2.597; Darwin CR., 1881, POWER MOVEMENT PLANT; DOLAN JW, 1990, GENE DEV, V4, P492, DOI 10.1101/gad.4.4.492; ECKER J R, 1990, Methods (Orlando), V1, P186, DOI 10.1016/S1046-2023(05)80134-3; ECKER JR, 1995, SCIENCE, V268, P667, DOI 10.1126/science.7732375; FELDMANN KA, 1991, PLANT J, V1, P71, DOI 10.1111/j.1365-313X.1991.00071.x; Ferrell JE, 1996, CURR TOP DEV BIOL, V33, P1, DOI 10.1016/S0070-2153(08)60336-1; GOESCHL JD, 1966, PLANT PHYSIOL, V41, P877, DOI 10.1104/pp.41.5.877; GUZMAN P, 1990, PLANT CELL, V2, P513, DOI 10.1105/tpc.2.6.513; HARPHAM NVJ, 1991, ANN BOT-LONDON, V68, P55, DOI 10.1093/oxfordjournals.aob.a088218; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HUA J, 1995, SCIENCE, V269, P1712, DOI 10.1126/science.7569898; Kakimoto T, 1996, SCIENCE, V274, P982, DOI 10.1126/science.274.5289.982; KENDE H, 1993, ANNU REV PLANT PHYS, V44, P283, DOI 10.1146/annurev.pp.44.060193.001435; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; KIEBER JJ, 1993, TRENDS GENET, V9, P356, DOI 10.1016/0168-9525(93)90041-F; KNIGHT LI, 1910, SCIENCE, V31, P635; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; LAWTON KA, 1994, PLANT CELL, V6, P581, DOI 10.1105/tpc.6.5.581; LISTER C, 1993, PLANT J, V4, P745, DOI 10.1046/j.1365-313X.1993.04040745.x; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/S0968-0004(96)10052-9; Madhani HD, 1997, SCIENCE, V275, P1314, DOI 10.1126/science.275.5304.1314; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; Matallana E., 1992, Methods in Arabidopsis research., P144; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORAN R, 1982, PLANT PHYSIOL, V69, P1376, DOI 10.1104/pp.69.6.1376; ODonnell PJ, 1996, SCIENCE, V274, P1914, DOI 10.1126/science.274.5294.1914; OHMETAKAGI M, 1995, PLANT CELL, V7, P173, DOI 10.1105/tpc.7.2.173; Orzaez D, 1997, PLANT J, V11, P137, DOI 10.1046/j.1365-313X.1997.11010137.x; OTA IM, 1993, SCIENCE, V262, P566, DOI 10.1126/science.8211183; Penmetsa RV, 1997, SCIENCE, V275, P527, DOI 10.1126/science.275.5299.527; Penninckx IAMA, 1996, PLANT CELL, V8, P2309, DOI 10.1105/tpc.8.12.2309; Posas F, 1996, CELL, V86, P865, DOI 10.1016/S0092-8674(00)80162-2; RESTREPO MA, 1990, PLANT CELL, V2, P987, DOI 10.1105/tpc.2.10.987; ROBERTS RL, 1994, GENE DEV, V8, P2974, DOI 10.1101/gad.8.24.2974; ROMAN G, 1995, GENETICS, V139, P1393; Rothenberg M, 1993, SEMIN DEV BIOL, V4, P3, DOI [10.1006/sedb.1993.1002, DOI 10.1006/SEDB.1993.1002]; RUIS H, 1995, BIOESSAYS, V17, P959, DOI 10.1002/bies.950171109; SCHALLER GE, 1995, SCIENCE, V270, P1809, DOI 10.1126/science.270.5243.1809; SCHARDL CL, 1987, GENE, V61, P1, DOI 10.1016/0378-1119(87)90359-3; Tanimoto M, 1995, PLANT J, V8, P943, DOI 10.1046/j.1365-313X.1995.8060943.x; Terzaghi WB, 1997, PLANT J, V11, P967, DOI 10.1046/j.1365-313X.1997.11050967.x; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; VAN DER STRAETEN D, 1993, PLANT PHYSIOL, V102, P401, DOI 10.1104/pp.102.2.401; WEIGEL D, 1995, PLANT CELL, V7, P338; ZHOU JM, 1993, PLANT MOL BIOL, V22, P517, DOI 10.1007/BF00015980	55	713	803	7	129	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 27	1997	89	7					1133	1144		10.1016/S0092-8674(00)80300-1	http://dx.doi.org/10.1016/S0092-8674(00)80300-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XG830	9215635	hybrid			2022-12-01	WOS:A1997XG83000017
J	Starr, R; Willson, TA; Viney, EM; Murray, LJL; Rayner, JR; Jenkins, BJ; Gonda, TJ; Alexander, WS; Metcalf, D; Nicola, NA; Hilton, DJ				Starr, R; Willson, TA; Viney, EM; Murray, LJL; Rayner, JR; Jenkins, BJ; Gonda, TJ; Alexander, WS; Metcalf, D; Nicola, NA; Hilton, DJ			A family of cytokine-inducible inhibitors of signalling	NATURE			English	Article							TYROSINE PHOSPHORYLATION; ACTIVATION; RECEPTORS; CLONING; CHAIN	Cytokines are secreted proteins that regulate important cellular responses such as proliferation and differentiation(1). Key events in cytokine signal transduction are well defined: cytokines induce receptor aggregation, leading to activation of members of the JAK family of cytoplasmic tyrosine kinases. In turn, members af the STAT family of transcription factors are phosphorylated, dimerize and increase the transcription of genes with STAT recognition sites in their promoters(1-4). Less is known of how cytokine signal transduction is switched off. We have cloned a complementary DNA encoding a protein SOCS-1, containing an SH2-domain, by its ability to inhibit the macrophage differentiation of M1 cells in response to interleukin-6. Expression of SOCS-1 inhibited both interleukin-6-induced receptor phosphorylation and STAT activation. We have also cloned two-relatives of SOCS-1, named SOCS-2 and SOCS-3, which together with the previously described CIS (ref. 5) form a new family of proteins. Transcription of all four SOCS genes is increased rapidly in response to interleukin-6, in vitro and in vivo, suggesting they may act in a classic negative feedback loop to regulate cytokine signal transduction.	ROYAL MELBOURNE HOSP, WALTER & ELIZA HALL INST MED RES, PARKVILLE, VIC 3052, AUSTRALIA; COOPERAT RES CTR CELLULAR GROWTH FACTORS, PARKVILLE, VIC 3052, AUSTRALIA; INST MED & VET SCI, HANSON CTR CANC RES, ADELAIDE, SA 5000, AUSTRALIA	Royal Melbourne Hospital; Walter & Eliza Hall Institute; Institute Medical & Veterinary Science Australia			Gonda, Thomas J/A-3620-2012; jenkins, brendan/J-7854-2012; Nicola, Nicos/D-2989-2011; Hilton, Douglas J/C-7250-2013; jenkins, brendan/A-2401-2009	Nicola, Nicos/0000-0003-1054-7889; Hilton, Douglas J/0000-0002-7698-2392; Jenkins, Brendan/0000-0002-7552-4656				ALEXANDER WS, 1995, EMBO J, V14, P5569, DOI 10.1002/j.1460-2075.1995.tb00244.x; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; FENG J, IN PRESS MOL CELL BI; Hilton DJ, 1996, J BIOL CHEM, V271, P4699; HILTON DJ, 1994, EMBO J, V13, P4765, DOI 10.1002/j.1460-2075.1994.tb06802.x; Howard M, 1994, GUIDEBOOK CYTOKINES; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; IHLE JN, 1994, BLOOD CELLS, V20, P65; LOTEM J, 1989, LEUKEMIA, V3, P804; METCALF D, 1988, LEUKEMIA, V2, P216; METCALF D, 1995, LEUKEMIA, V9, P1556; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Nicola NA, 1996, GROWTH FACTORS, V13, P141, DOI 10.3109/08977199609034574; NOVAK U, 1995, BLOOD, V86, P2948, DOI 10.1182/blood.V86.8.2948.bloodjournal8682948; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; QUELLE EW, 1996, MOL CELL BIOL, V16, P1622; Rasko JEJ, 1995, LEUKEMIA, V9, P2058; RAYNER JR, 1994, MOL CELL BIOL, V14, P880, DOI 10.1128/MCB.14.2.880; Schluter G, 1996, MOL REPROD DEV, V43, P1, DOI 10.1002/(SICI)1098-2795(199601)43:1&lt;1::AID-MRD1&gt;3.0.CO;2-W; Smith A, 1997, EMBO J, V16, P451, DOI 10.1093/emboj/16.3.451; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x	27	1732	1845	0	85	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 26	1997	387	6636					917	921		10.1038/43206	http://dx.doi.org/10.1038/43206			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XG416	9202125	Bronze			2022-12-01	WOS:A1997XG41600055
J	OBrien, CP; McLellan, AT				OBrien, CP; McLellan, AT			Addiction medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ALCOHOL DEPENDENCE; LIVER-TRANSPLANTATION; NALTREXONE; DISEASE				OBrien, CP (corresponding author), UNIV PENN, PHILADELPHIA, PA 19104 USA.							Allen JP, 1997, J STUD ALCOHOL, V58, P7; BENJAMIN D, 1993, BRAIN RES, V621, P137, DOI 10.1016/0006-8993(93)90309-B; Fleming MF, 1997, JAMA-J AM MED ASSOC, V277, P1039, DOI 10.1001/jama.277.13.1039; Gianoulakis C, 1996, ARCH GEN PSYCHIAT, V53, P250; GISH RG, 1993, AM J GASTROENTEROL, V88, P1337; King AC, 1997, PSYCHOPHARMACOLOGY, V129, P15, DOI 10.1007/s002130050156; LITTLETON J, 1995, ADDICTION, V90, P1179, DOI 10.1046/j.1360-0443.1995.90911793.x; MASON BJ, 1994, ALCOHOL CLIN EXP RES, V18, P1162, DOI 10.1111/j.1530-0277.1994.tb00098.x; OMALLEY SS, 1992, ARCH GEN PSYCHIAT, V49, P881; Sass H, 1996, ARCH GEN PSYCHIAT, V53, P673; Shelton W, 1997, ALCOHOL CLIN EXP RES, V21, P93, DOI 10.1111/j.1530-0277.1997.tb03734.x; VANTHIEL DH, 1995, ALCOHOL CLIN EXP RES, V19, P1151; VOLPICELLI JR, 1990, ALCOHOL, V7, P133, DOI 10.1016/0741-8329(90)90074-M; VOLPICELLI JR, 1992, ARCH GEN PSYCHIAT, V49, P876; VOLPICELLI JR, 1990, OPIOIDS, BULIMIA, AND ALCOHOL ABUSE & ALCOHOLISM, P195	15	6	6	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	1997	277	23					1840	1841						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XD544	9185790				2022-12-01	WOS:A1997XD54400009
J	MaymoGatell, X; Chien, YT; Gossett, JM; Zinder, SH				MaymoGatell, X; Chien, YT; Gossett, JM; Zinder, SH			Isolation of a bacterium that reductively dechlorinates tetrachloroethene to ethene	SCIENCE			English	Article							ENRICHMENT CULTURE; TRICHLOROETHYLENE; METHANOGENESIS; ABSENCE	Tetrachloroethene is a prominent groundwater pollutant that can be reductively dechlorinated by mixed anaerobic microbial populations to the nontoxic product ethene. Strain 195, a coccoid bacterium that dechlorinates tetrachloroethene to ethene, was isolated and characterized. Growth of strain 195 with H-2 and tetrachloroethene as the electron donor and acceptor pair required extracts from mixed microbial cultures. Growth of strain I 195 was resistant to ampicillin and vancomycin; its cell wall did not react with a peptidoglycan-specific lectin and its ultrastructure resembled S-layers of Archaea. Analysis of the 16S ribosomal DNA sequence of strain 195 indicated that it is a eubacterium without close affiliation to any known groups.	CORNELL UNIV, MICROBIOL SECT, ITHACA, NY 14853 USA; CORNELL UNIV, SCH CIVIL & ENVIRONM ENGN, ITHACA, NY 14853 USA	Cornell University; Cornell University								ABELSON PH, 1990, SCIENCE, V250, P73; Bozzola JJ., 1992, ELECT MICROSCOPY PRI, P16; COLLINS MD, 1994, INT J SYST BACTERIOL, V44, P812, DOI 10.1099/00207713-44-4-812; DEBRUIN WP, 1992, APPL ENVIRON MICROB, V58, P1996, DOI 10.1128/AEM.58.6.1996-2000.1992; DISTEFANO TD, 1992, APPL ENVIRON MICROB, V58, P3622, DOI 10.1128/AEM.58.11.3622-3629.1992; DISTEFANO TD, 1991, APPL ENVIRON MICROB, V57, P2287, DOI 10.1128/AEM.57.8.2287-2292.1991; ENSLEY BD, 1991, ANNU REV MICROBIOL, V45, P283; Felsenstein J., 1993, PHYLOGENETIC INFEREN; Fennell DE, 1995, BIOREMED SER, V3, P9; FREEDMAN DL, 1989, APPL ENVIRON MICROB, V55, P2144, DOI 10.1128/AEM.55.9.2144-2151.1989; GANTZER CJ, 1991, ENVIRON SCI TECHNOL, V25, P715, DOI 10.1021/es00016a017; Gerritse J, 1996, ARCH MICROBIOL, V165, P132, DOI 10.1007/s002030050308; GOODWIN DC, 1993, BIOTECHNIQUES, V15, P438; HINCHEE RE, 1995, BIOREMEDIATION CHLOR; HOLLIGER C, 1993, APPL ENVIRON MICROB, V59, P2991, DOI 10.1128/AEM.59.9.2991-2997.1993; Johnson John L., 1994, P683; KANDLER O, 1994, SYST APPL MICROBIOL, V16, P501; Krumholz LR, 1996, APPL ENVIRON MICROB, V62, P4108, DOI 10.1128/AEM.62.11.4108-4113.1996; MAIDAK BL, 1994, NUCLEIC ACIDS RES, V22, P3485, DOI 10.1093/nar/22.17.3485; MAYMOGATELL X, 1995, APPL ENVIRON MICROB, V61, P3928; MAYMOGATELL X, UNPUB; MOHN WW, 1992, MICROBIOL REV, V56, P482, DOI 10.1128/MMBR.56.3.482-507.1992; SCHOLZMURAMATSU H, 1995, ARCH MICROBIOL, V163, P48, DOI 10.1007/BF00262203; Sharma PK, 1996, APPL ENVIRON MICROB, V62, P761, DOI 10.1128/AEM.62.3.761-765.1996; SIZEMORE RK, 1990, APPL ENVIRON MICROB, V56, P2245, DOI 10.1128/AEM.56.7.2245-2247.1990; Sprott G. Dennis, 1994, P72; TANDOI V, 1994, ENVIRON SCI TECHNOL, V28, P973, DOI 10.1021/es00054a033; WESTRICK JJ, 1984, J AM WATER WORKS ASS, V76, P52	28	811	853	6	256	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 6	1997	276	5318					1568	1571		10.1126/science.276.5318.1568	http://dx.doi.org/10.1126/science.276.5318.1568			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XC701	9171062				2022-12-01	WOS:A1997XC70100045
J	Walz, T; Hirai, T; Murata, K; Heymann, JB; Mitsuoka, K; Fujiyoshi, Y; Smith, BL; Agre, P; Engel, A				Walz, T; Hirai, T; Murata, K; Heymann, JB; Mitsuoka, K; Fujiyoshi, Y; Smith, BL; Agre, P; Engel, A			The three-dimensional structure of aquaporin-1	NATURE			English	Article							ELECTRON CRYSTALLOGRAPHY; WATER CHANNELS; CHIP; RESOLUTION; PROJECTION; PROTEIN; MODEL	The entry and exit of water from cells is a fundamental process of life. Recognition of the high water permeability of red blood cells led to the proposal that specialized water pores exist in the plasma membrane(1). Expression in Xenopus oocytes and functional studies of an erythrocyte integral membrane protein of relative molecular mass 28,000, identified it as the mercury-sensitive water channel, aquaporin-1 (AQP1)(2). Many related proteins, all belonging to the major intrinsic protein (MIP) family, are found throughout nature(3). AQP1 is a homotetramer containing four independent aqueous channels(4-6). When reconstituted into lipid bilayers, the protein forms two-dimensional lattices with a unit cell containing two tetramers in opposite orientation(7-10). Here we present the three-dimensional structure of AQP1 determined at 6 Angstrom resolution by cryo-electron microscopy. Each AQP1 monomer has six tilted, bilayer-spanning alpha-helices which form a right-handed bundle surrounding a central density. These results, together with functional studies, provide a model that identifies the aqueous pore in the AQP1 molecule and indicates the organization of the tetrameric complex in the membrane.	UNIV BASEL, BIOZENTRUM, ME MULLER INST MICROSCOP STRUCT BIOL, CH-4056 BASEL, SWITZERLAND; MATSUSHITA ELECT IND CO LTD, INT INST ADV RES, SEIKA 61902, JAPAN; KYOTO UNIV, FAC SCI, DEPT BIOPHYS, KYOTO 60601, JAPAN; JOHNS HOPKINS UNIV, SCH MED, DEPT BIOL CHEM, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT MED, BALTIMORE, MD 21205 USA	University of Basel; Panasonic; Kyoto University; Johns Hopkins University; Johns Hopkins University			Fujiyoshi, Yoshinori/E-5989-2012; Hirai, Teruhisa/G-2105-2015; Heymann, Bernard/H-8265-2019; Heymann, Bernard/F-6825-2011	Fujiyoshi, Yoshinori/0000-0002-8070-1493; Hirai, Teruhisa/0000-0002-2114-8149; Heymann, Bernard/0000-0002-8872-5326; Walz, Thomas/0000-0003-2606-2835				CABIAUX V, IN PRESS BIOPHYSICAL; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; FUJIYOSHI Y, 1991, ULTRAMICROSCOPY, V38, P241, DOI 10.1016/0304-3991(91)90159-4; HENDERSON R, 1990, J MOL BIOL, V213, P899, DOI 10.1016/S0022-2836(05)80271-2; Henn C, 1996, J STRUCT BIOL, V116, P86, DOI 10.1006/jsbi.1996.0015; JAP BK, 1995, J MOL BIOL, V251, P413, DOI 10.1006/jmbi.1995.0444; JUNG JS, 1994, J BIOL CHEM, V269, P14648; MITRA AK, 1995, NAT STRUCT BIOL, V2, P726, DOI 10.1038/nsb0995-726; MITSUOKA K, IN PRESS ULTRAMICROS; Park JH, 1996, J MEMBRANE BIOL, V153, P171, DOI 10.1007/s002329900120; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1994, J BIOL CHEM, V269, P1668; SIDEL VW, 1957, J GEN PHYSIOL, V41, P243, DOI 10.1085/jgp.41.2.243; SMITH BL, 1991, J BIOL CHEM, V266, P6407; VERBAVATZ JM, 1993, J CELL BIOL, V123, P605, DOI 10.1083/jcb.123.3.605; Walther D, 1996, J MOL BIOL, V255, P536, DOI 10.1006/jmbi.1996.0044; WALZ T, 1994, J BIOL CHEM, V269, P1583; WALZ T, 1994, EMBO J, V13, P2985, DOI 10.1002/j.1460-2075.1994.tb06597.x; WALZ T, 1995, NAT STRUCT BIOL, V2, P730, DOI 10.1038/nsb0995-730; Walz T, 1996, J MOL BIOL, V264, P907, DOI 10.1006/jmbi.1996.0686	20	327	351	4	60	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 5	1997	387	6633					624	627		10.1038/42512	http://dx.doi.org/10.1038/42512			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XC522	9177353				2022-12-01	WOS:A1997XC52200061
J	Hendin, H; Rutenfrans, C; Zylicz, Z				Hendin, H; Rutenfrans, C; Zylicz, Z			Physician-assisted suicide and euthanasia in the Netherlands - Lessons from the Dutch	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							DEATH		NEW YORK MED COLL,DEPT PSYCHIAT,NEW YORK,NY; DEPT JUSTICE,THE HAGUE,NETHERLANDS; HOSP ROSENHUYVEL,ROZENDAAL,NETHERLANDS	New York Medical College	Hendin, H (corresponding author), AMER FDN SUICIDE PREVENT,120 WALL ST,NEW YORK,NY 10005, USA.							ANGELL M, 1996, NEW ENGL J MED, V335, P1675; Bokhove J., 1996, BALANS REKENONDERWIJ; *BRIT MED ASS WORK, 1988, EUTHANASIA, P49; Callahan Daniel, 1996, Univ Richmond Law Rev, V30, P1; DORREPAAL KL, 1989, CANCER, V63, P593, DOI 10.1002/1097-0142(19890201)63:3<593::AID-CNCR2820630332>3.0.CO;2-5; *GEN BOARD ROYAL D, 1994, EUTHANASIA NETHERLAN; GOMEZ G, 1991, REGULATING DEATH EUT; GUNNING KF, 1991, LANCET, V338, P1010, DOI 10.1016/0140-6736(91)91867-T; Hendin H, 1997, NEW ENGL J MED, V336, P1385; HENDIN H, 1995, HASTINGS CENT REP, V25, P19, DOI 10.2307/3562109; Hendin H, 1996, Duquesne Law Rev, V35, P427; HENDIN H, 1996, SEDUCED DEATH DOCTOR; Keown J., 1995, EUTHANASIA EXAMINED; TENHAVE H, 1985, GENEESKUNDE TUSSEN D; Twycross R., 1995, EUTHANASIA EXAMINED; van der Maas P. J., 1992, EUTHANASIA OTHER MED; Van der Mass PJ, 1996, NEW ENGL J MED, V335, P1609; vanderWal G, 1996, NEW ENGL J MED, V335, P1706; WALTON J, 1994, J ROY COLL PHYS LOND, V28, P235; Zylic Zbigniew, 1993, AM J HOSPICE PAL JUL, V30; ZYLICZ Z, 1991, LANCET, V338, P1150, DOI 10.1016/0140-6736(91)92010-Y	21	51	51	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 4	1997	277	21					1720	1722		10.1001/jama.277.21.1720	http://dx.doi.org/10.1001/jama.277.21.1720			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XB088	9169901				2022-12-01	WOS:A1997XB08800035
J	Martinot, M; Marcellin, P; Boyer, N; Detmer, J; Pouteau, M; Castelnau, C; Degott, C; Auperin, A; Collins, M; Kolberg, J; Wilber, J; Benhamou, JP; Erlinger, S				Martinot, M; Marcellin, P; Boyer, N; Detmer, J; Pouteau, M; Castelnau, C; Degott, C; Auperin, A; Collins, M; Kolberg, J; Wilber, J; Benhamou, JP; Erlinger, S			Influence of hepatitis G virus infection on the severity of liver disease and response to interferon-alpha in patients with chronic hepatitis C	ANNALS OF INTERNAL MEDICINE			English	Article						hepatitis C; hepatitis agents, GB; hepatitis, viral, human; hepatitis C-like viruses; interferon-alpha	ASSAY; RNA	Background: Dual infection with hepatitis G virus (HGV) and hepatitis C virus (HCV) is common. The effect of HGV infection on chronic hepatitis C is not well known. Objective: To assess the prevalence of HGV infection; the effect of HCV infection on the clinical, virologic, and histologic features of patients with chronic hepatitis C treated with interferon-alpha; and the influence of HGV infection on response to interferon-alpha therapy. Design: Retrospective study. Setting: A university hospital in France. Patients: 228 patients with chronic hepatitis C treated with interferon-alpha (3 million U or 5 million U subcutaneously 3 times a week for 3, 6, or 12 months). Measurements: Before initiation of treatment, serum HCV RNA and serum HCV RNA were detected with branched-DNA assays and HCV genotype was determined with a line probe assay. Serum HGV RNA and serum HCV RNA were detected by polymerase chain reaction at the end of treatment and 6 months after treatment. Results: Infection with HGV was detected in 21% of patients and 32% of intravenous drug users. The median serum HGV RNA level was 33 x 10(6) genome equivalents/mL. Infection with HGV was more frequently found in men with a history of intravenous drug use and was associated with HCV genotype 3a (P = 0.02) independent of the source of infection. Serum HCV RNA levels, liver histologic findings, and response to interferon-a therapy did not differ between patients with and those without HGV infection. The loss of serum HCV RNA was not correlated with the biochemical response contrarily to the loss of serum HCV RNA. Conclusions: Infection with HGV occurred frequently in this sample of patients with chronic hepatitis C, especially in patients infected with HCV genotype 3a. The level of HGV viremia was high relative to the level of HCV viremia. Infection with HGV did not influence the severity of liver disease or response to interferon-alpha therapy.	HOP BEAUJON, INSERM, U24, F-92118 CLICHY, FRANCE; HOP BEAUJON, SERV HEPATOL, F-92118 CLICHY, FRANCE; HOP BEAUJON, SERV ANAT & CYTOL PATHOL, F-92118 CLICHY, FRANCE; CHIRON CORP, EMERYVILLE, CA 94608 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; Novartis								Aikawa T, 1996, NEW ENGL J MED, V334, P195, DOI 10.1056/NEJM199601183340316; ALLIE R, 1996, LANCET, V347, P1552; Alter HJ, 1996, NEW ENGL J MED, V334, P1536, DOI 10.1056/NEJM199606063342310; BELLEZZO JM, 1995, HEPATOLOGY, V22, P1036; BENHAMOU JP, 1995, HEPATOLOGY, V22, P37; COLLINS ML, 1995, ANAL BIOCHEM, V226, P120, DOI 10.1006/abio.1995.1199; deLamballerie X, 1996, NEW ENGL J MED, V334, P1549, DOI 10.1056/NEJM199606063342319; Detmer J, 1996, J CLIN MICROBIOL, V34, P901, DOI 10.1128/JCM.34.4.901-907.1996; Feucht HH, 1996, LANCET, V347, P615, DOI 10.1016/S0140-6736(96)91309-4; HORN T, 1995, TETRAHEDRON LETT, V36, P2033, DOI 10.1016/0040-4039(95)00230-A; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; Kuroki T, 1996, LANCET, V347, P908, DOI 10.1016/S0140-6736(96)91395-1; Linnen J, 1996, SCIENCE, V271, P505, DOI 10.1126/science.271.5248.505; MARCELLIN P, 1994, HEPATOLOGY, V20, pA154; MARTINOTPEIGNOUX M, 1995, HEPATOLOGY, V22, P1050, DOI 10.1016/0270-9139(95)90608-8; Masuko K, 1996, NEW ENGL J MED, V334, P1485, DOI 10.1056/NEJM199606063342301; Nubling CM, 1996, LANCET, V347, P68, DOI 10.1016/S0140-6736(96)91605-0; OHTO H, 1994, NEW ENGL J MED, V330, P744, DOI 10.1056/NEJM199403173301103; Schmidt B, 1996, LANCET, V347, P909, DOI 10.1016/S0140-6736(96)91396-3; SIMONS JN, 1995, P NATL ACAD SCI USA, V92, P3401, DOI 10.1073/pnas.92.8.3401; SIMONS JN, 1995, NAT MED, V1, P564, DOI 10.1038/nm0695-564; STUYVER L, 1993, J GEN VIROL, V74, P1093, DOI 10.1099/0022-1317-74-6-1093; Tanaka E, 1996, ANN INTERN MED, V125, P740, DOI 10.7326/0003-4819-125-9-199611010-00007; TONG MJ, 1995, NEW ENGL J MED, V332, P1463, DOI 10.1056/NEJM199506013322202; YOSHIBA M, 1995, LANCET, V346, P1131, DOI 10.1016/S0140-6736(95)91802-7; YOUNG KKY, 1993, J CLIN MICROBIOL, V31, P882, DOI 10.1128/JCM.31.4.882-886.1993	26	62	63	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1997	126	11					874	+		10.7326/0003-4819-126-11-199706010-00004	http://dx.doi.org/10.7326/0003-4819-126-11-199706010-00004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XA911	9163288				2022-12-01	WOS:A1997XA91100004
J	Taylor, CJ; Threlfall, D				Taylor, CJ; Threlfall, D			Postural drainage techniques and gastrooesophageal reflux in cystic fibrosis	LANCET			English	Editorial Material							GASTROESOPHAGEAL REFLUX; INFANTS		UNIV SHEFFIELD, SHEFIELD CHILDRENS HOSP, DEPT PHYSIOTHERAPY, SHEFFIELD S10 2TH, S YORKSHIRE, ENGLAND	Sheffield Children's NHS Foundation Trust; Sheffield Children's Hospital; University of Sheffield	Taylor, CJ (corresponding author), UNIV SHEFFIELD, SHEFIELD CHILDRENS HOSP, DEPT PAEDIAT, SHEFFIELD S10 2TH, S YORKSHIRE, ENGLAND.							Button BM, 1997, ARCH DIS CHILD, V76, P148, DOI 10.1136/adc.76.2.148; CUCCHIARA S, 1991, ARCH DIS CHILD, V66, P617, DOI 10.1136/adc.66.5.617; KHAN TZ, 1995, AM J RESP CRIT CARE, V151, P1075; MALFROOT A, 1991, ARCH DIS CHILD, V66, P1339, DOI 10.1136/adc.66.11.1339; MCVEAGH P, 1987, AM J DIS CHILD, V141, P917, DOI 10.1001/archpedi.1987.04460080103039; VANDENPLAS Y, 1991, PEDIATRICS, V88, P834; VANVANDENPLAS Y, 1987, J PEDIATR GASTR NUTR, V6, P220, DOI 10.1097/00005176-198703000-00010	7	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 31	1997	349	9065					1567	1568		10.1016/S0140-6736(05)61626-1	http://dx.doi.org/10.1016/S0140-6736(05)61626-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XB673	9174556				2022-12-01	WOS:A1997XB67300005
J	Glover, JR; Kowal, AS; Schirmer, EC; Patino, MM; Liu, JJ; Lindquist, S				Glover, JR; Kowal, AS; Schirmer, EC; Patino, MM; Liu, JJ; Lindquist, S			Self-seeded fibers formed by Sup35, the protein determinant of [PSI+], a heritable prion-like factor of S-cerevisiae	CELL			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; ALZHEIMERS-DISEASE; AMYLOID FORMATION; GENE; SCRAPIE; TERMINATION; PROPAGATION; TRANSLATION; EXPRESSION; VECTORS	The [PSI+] factor of S. cerevisiae represents a new form of inheritance: cytosolic transmission of an altered phenotype is apparently based upon inheritance of an altered protein structure rather than an altered nucleic acid. The molecular basis of its propagation is unknown. We report that purified Sup35 and subdomains that induce [PSI+] elements in vivo form highly ordered fibers in vitro. Fibers bind Congo red and are rich in beta sheet, characteristics of amyloids found in certain human diseases, including the prion diseases. Some fibers have distinct structures and these, once initiated, are self-perpetuating. Preformed fibers greatly accelerate fiber formation by unpolymerized protein. These data support a ''protein-only'' seeded polymerization model for the inheritance of [PSI+].	UNIV CHICAGO, HOWARD HUGHES MED INST, DEPT MOL GENET & CELL BIOL, CHICAGO, IL 60637 USA	Howard Hughes Medical Institute; University of Chicago				Schirmer, Eric/0000-0003-2635-1338	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025874, R37GM025874] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 25874] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKASURA S, 1970, ADV BIOPHYS, V1, P99; BESSEN RA, 1994, J VIROL, V68, P7859, DOI 10.1128/JVI.68.12.7859-7868.1994; BESSEN RA, 1995, NATURE, V375, P698, DOI 10.1038/375698a0; Caughey B, 1995, CHEM BIOL, V2, P807, DOI 10.1016/1074-5521(95)90087-X; Caughey B, 1997, TRENDS CELL BIOL, V7, P56, DOI 10.1016/S0962-8924(96)10054-4; CHERNOFF YO, 1995, SCIENCE, V268, P880, DOI 10.1126/science.7754373; CHERNOFF YO, 1993, CURR GENET, V24, P268, DOI 10.1007/BF00351802; CLOS J, 1994, PROTEIN EXPRES PURIF, V5, P133, DOI 10.1006/prep.1994.1020; COME JH, 1993, P NATL ACAD SCI USA, V90, P5959, DOI 10.1073/pnas.90.13.5959; COX BS, 1988, YEAST, V4, P159, DOI 10.1002/yea.320040302; COX BS, 1965, HEREDITY, V20, P505, DOI 10.1038/hdy.1965.65; Derkatch IL, 1996, GENETICS, V144, P1375; DIDICHENKO SA, 1991, EUR J BIOCHEM, V198, P705, DOI 10.1111/j.1432-1033.1991.tb16070.x; DOEL SM, 1994, GENETICS, V137, P659; Harper JD, 1997, CHEM BIOL, V4, P119, DOI 10.1016/S1074-5521(97)90255-6; Horwich AL, 1997, CELL, V89, P499, DOI 10.1016/S0092-8674(00)80232-9; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; Kelly JW, 1996, CURR OPIN STRUC BIOL, V6, P11, DOI 10.1016/S0959-440X(96)80089-3; KLUNK WE, 1989, J HISTOCHEM CYTOCHEM, V37, P1293, DOI 10.1177/37.8.2666512; KUSHNIROV VV, 1990, YEAST, V6, P461, DOI 10.1002/yea.320060603; LANSBURY PT, 1995, CHEM BIOL, V2, P1, DOI 10.1016/1074-5521(95)90074-8; Lindquist S, 1997, CELL, V89, P495, DOI 10.1016/S0092-8674(00)80231-7; NESIONEY CL, 1996, BIOORGAN MED CHEM, V4, P739; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; Patino MM, 1996, SCIENCE, V273, P622, DOI 10.1126/science.273.5275.622; Paushkin SV, 1997, MOL CELL BIOL, V17, P2798, DOI 10.1128/MCB.17.5.2798; Paushkin SV, 1996, EMBO J, V15, P3127, DOI 10.1002/j.1460-2075.1996.tb00675.x; PRUSINER SB, 1994, ANNU REV MICROBIOL, V48, P655, DOI 10.1146/annurev.mi.48.100194.003255; Sambrook J., 1989, MOL CLONING LAB MANU, V3; SCOTT M, 1989, CELL, V59, P847, DOI 10.1016/0092-8674(89)90608-9; SHERMAN F, 1986, MANUAL METHODS YEAST; SIKORSKI RS, 1989, GENETICS, V122, P19; SIPE JD, 1994, CRIT REV CL LAB SCI, V31, P325, DOI 10.3109/10408369409084679; SPIESS E, 1987, ELECT MICROSCOPY MOL, P147; STANSFIELD I, 1995, EMBO J, V14, P4365, DOI 10.1002/j.1460-2075.1995.tb00111.x; STANSFIELD I, 1994, CURR GENET, V25, P385, DOI 10.1007/BF00351776; TERAVANESYAN MD, 1994, GENETICS, V137, P671; TERAVANESYAN MD, 1993, MOL MICROBIOL, V7, P683, DOI 10.1111/j.1365-2958.1993.tb01159.x; THIELE DJ, 1988, MOL CELL BIOL, V8, P2745, DOI 10.1128/MCB.8.7.2745; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; ZHOURAVLEVA G, 1995, EMBO J, V14, P4065, DOI 10.1002/j.1460-2075.1995.tb00078.x	42	536	545	0	32	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 30	1997	89	5					811	819		10.1016/S0092-8674(00)80264-0	http://dx.doi.org/10.1016/S0092-8674(00)80264-0			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XB925	9182769	Bronze			2022-12-01	WOS:A1997XB92500018
J	Carraway, KL; Weber, JL; Unger, MJ; Ledesma, J; Yu, N; Gassmann, M; Lai, C				Carraway, KL; Weber, JL; Unger, MJ; Ledesma, J; Yu, N; Gassmann, M; Lai, C			Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases	NATURE			English	Article							NEU DIFFERENTIATION FACTOR; CARDIAC DEVELOPMENT; NERVOUS-SYSTEM; RECEPTOR; HEREGULIN; EXPRESSION; FAMILY; ERBB2; ARIA; HER4/P180(ERBB4)	The neuregulins (NRGs) are a family of multipotent epidermal-growth-factor-like (EGF-like) factors that arise from splice variants of a single gene. They influence the growth, differentiation, survival and fate of several cell types. We have now discovered a set of new neuregulin-like growth factors, which we call neuregulin-2 (NRG-2): these are encoded by their own gene and exhibit a distinct expression pattern in adult brain and developing heart. Like NRG-1, the EGF-like domain of the new ligands binds to both the ErbB3- and ErbB4-receptor tyrosine kinases. However, NRG-2 stimulates different ErbB-receptor tyrosine-phosphorylation profiles from NRG-1. Our results indicate that NRG-1 and NRG-2 mediate distinct biological processes by acting at different sites in tissues and eliciting different biochemical responses in cells.	Scripps Res Inst, DEPT NEUROPHARMACOL, LA JOLLA, CA 92037 USA; HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02215 USA; BETH ISRAEL HOSP, DIV SIGNAL TRANSDUCT, BOSTON, MA 02215 USA; SALK INST BIOL STUDIES, MOL NEUROBIOL LAB, LA JOLLA, CA 92037 USA	Scripps Research Institute; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Salk Institute				Gassmann, Martin/0000-0001-6201-3032				ALIMANDI M, 1995, ONCOGENE, V10, P1813; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CARRAWAY KL, 1995, CURR OPIN NEUROBIOL, V5, P606, DOI 10.1016/0959-4388(95)80065-4; Carraway KL, 1996, BIOESSAYS, V18, P263, DOI 10.1002/bies.950180403; CHEN MS, 1994, J COMP NEUROL, V349, P389, DOI 10.1002/cne.903490306; CORFAS G, 1995, NEURON, V14, P103, DOI 10.1016/0896-6273(95)90244-9; CULOUSCOU JM, 1993, J BIOL CHEM, V268, P18407; DONG Z, 1995, NEURON, V15, P585, DOI 10.1016/0896-6273(95)90147-7; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; GOODEARL ADJ, 1995, J CELL BIOL, V130, P1423, DOI 10.1083/jcb.130.6.1423; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; JO SA, 1995, NATURE, V373, P158, DOI 10.1038/373158a0; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; Lemke G, 1996, MOL CELL NEUROSCI, V7, P247, DOI 10.1006/mcne.1996.0019; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; MORRISSEY TK, 1995, P NATL ACAD SCI USA, V92, P1431, DOI 10.1073/pnas.92.5.1431; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; STERN DF, 1994, BIOCHIM BIOPHYS ACTA, V1198, P165; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	30	336	377	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 29	1997	387	6632					512	516		10.1038/387512a0	http://dx.doi.org/10.1038/387512a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XB479	9168115				2022-12-01	WOS:A1997XB47900051
J	Gullette, ECD; Blumenthal, JA; Babyak, M; Jiang, W; Waugh, RA; Frid, DJ; OConnor, CM; Morris, JJ; Krantz, DS				Gullette, ECD; Blumenthal, JA; Babyak, M; Jiang, W; Waugh, RA; Frid, DJ; OConnor, CM; Morris, JJ; Krantz, DS			Effects of mental stress on myocardial ischemia during daily life	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-ARTERY DISEASE; ST-SEGMENT DEPRESSION; AMBULATORY PATIENTS; CASE-CROSSOVER; HEART-DISEASE; INFARCTION; MORTALITY; RISK; ASSOCIATION; PROGNOSIS	Objective.-To determine the relative risk of myocardial ischemia triggered by specific emotions during daily life. Design and Setting.-Relative risk was calculated by the recently developed case-crossover method, in which the frequency of a presumed trigger during nonischemic, or control, hours is compared with the trigger's frequency during ischemic, or case, hours. Outpatients at Duke University Medical Center, Durham, NC, underwent 48 hours of ambulatory electrocardiographic (EGG) monitoring with concurrent self-report measures of activities and emotions. Occurrences of negative emotions in the hour before the onset of myocardial ischemia were compared with their usual frequency based on all hours in which ischemia did not occur. Subjects.-From a sample of 132 patients with coronary artery disease and recent evidence of exercise-induced ischemia who underwent 48 hours of ambulatory ECG. monitoring, 58 patients exhibited ambulatory ischemia and were included in the analysis. Outcome Measures.-Myocardial ischemia during 48-hour ECG monitoring was defined as horizontal or downsloping ST-segment depression of 1 mm (0.1 mV) or more for 1 minute or longer compared with resting baseline. The ECG data were cross-tabulated with subjects' concurrent diary ratings of 3 negative emotions-tension, sadness, and frustration-and 2 positive emotions-happiness and feeling in control-on a 5-point scale of intensity. Results.-The unadjusted relative risk of occurrence of myocardial ischemia in the hour following high levels of negative emotions was 3.0 (95% confidence interval [CI], 1.5-5.9; P<.01) for tension, 2.9 (95% CI, 1.0-8.0; P<.05) for sadness, and 2.6 (95% CI, 1.3-5.1; P<.01) for frustration. The corresponding risk ratios adjusted for physical activity and time of day were 2.2 (95% CI, 1.1-4.5; P<.05) for tension, 2.2 (95% CI, 0.7-6.4; P=.16) for sadness, and 2.2 (95% CI, 1.1-4.3; P<.05) for frustration. Conclusions.-Mental stress during daily life, including reported feelings of tension, frustration, and sadness, can more than double the risk of myocardial ischemia in the subsequent hour. The clinical significance of mental stress-induced ischemia during daily life needs to be further evaluated.	DUKE UNIV, SCH MED, DEPT MED, DURHAM, NC 27710 USA; OHIO STATE UNIV, DEPT MED, COLUMBUS, OH 43210 USA; UNIFORMED SERV UNIV HLTH SCI, DEPT MED & CLIN PSYCHOL, BETHESDA, MD 20814 USA	Duke University; University System of Ohio; Ohio State University; Uniformed Services University of the Health Sciences - USA	Gullette, ECD (corresponding author), DUKE UNIV, SCH MED, DEPT PSYCHIAT & BEHAV SCI, BEHAV CARDIOL LAB, BOX 3119, DURHAM, NC 27710 USA.		Krantz, David S./L-5364-2015	Krantz, David/0000-0002-1671-1355	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047337, R01HL049572, R01HL043028] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 47337, HL 49572, HL 43028] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAIREY CN, 1991, J AM COLL CARDIOL, V17, P1388, DOI 10.1016/S0735-1097(10)80152-4; BAREFOOT JC, 1983, PSYCHOSOM MED, V45, P59, DOI 10.1097/00006842-198303000-00008; BARRY J, 1988, AM J CARDIOL, V61, P989, DOI 10.1016/0002-9149(88)90112-9; BLUMENTHAL JA, 1995, CIRCULATION, V92, P2102, DOI 10.1161/01.CIR.92.8.2102; Burg MM, 1993, J AM COLL CARDIOL, V22, P440, DOI 10.1016/0735-1097(93)90048-6; Cohn K, 1976, Adv Cardiol, V17, P85; DEANFIELD JE, 1984, LANCET, V2, P1001; ELLESTAD MH, 1979, PROG CARDIOVASC DIS, V21, P431, DOI 10.1016/0033-0620(79)90025-2; FRASURESMITH N, 1995, HEALTH PSYCHOL, V14, P388, DOI 10.1037/0278-6133.14.5.388; FREEMAN LJ, 1987, AM HEART J, V114, P477, DOI 10.1016/0002-8703(87)90741-1; Gabbay FH, 1996, J AM COLL CARDIOL, V27, P585, DOI 10.1016/0735-1097(95)00510-2; GOTTDIENER JS, 1994, J AM COLL CARDIOL, V24, P1645, DOI 10.1016/0735-1097(94)90169-4; GOTTLIEB SO, 1988, JAMA-J AM MED ASSOC, V259, P1030, DOI 10.1001/jama.259.7.1030; HEDGES SM, 1990, J PSYCHOPATHOL BEHAV, V12, P203, DOI 10.1007/BF00960618; JIANG W, 1997, J AM COLL CARDIOL  S, V29, P236; KARK JD, 1995, JAMA-J AM MED ASSOC, V273, P1208, DOI 10.1001/jama.273.15.1208; Kawachi I, 1996, CIRCULATION, V94, P2090, DOI 10.1161/01.CIR.94.9.2090; KAWACHI I, 1994, CIRCULATION, V90, P2225, DOI 10.1161/01.CIR.90.5.2225; KRANTZ DS, 1994, AM HEART J, V128, P703, DOI 10.1016/0002-8703(94)90268-2; Kubzansky LD, 1997, CIRCULATION, V95, P818; Leor J, 1996, NEW ENGL J MED, V334, P413, DOI 10.1056/NEJM199602153340701; MACLURE M, 1991, AM J EPIDEMIOL, V133, P144, DOI 10.1093/oxfordjournals.aje.a115853; MITTLEMAN MA, 1993, NEW ENGL J MED, V329, P1677, DOI 10.1056/NEJM199312023292301; MITTLEMAN MA, 1995, AM J EPIDEMIOL, V142, P91, DOI 10.1093/oxfordjournals.aje.a117550; MITTLEMAN MA, 1995, CIRCULATION, V92, P1720, DOI 10.1161/01.CIR.92.7.1720; MODENA MG, 1989, CLIN CARDIOL, V12, P21, DOI 10.1002/clc.4960120104; Muller JE, 1996, JAMA-J AM MED ASSOC, V275, P1405, DOI 10.1001/jama.275.18.1405; NABEL EG, 1988, CIRCULATION, V78, P60, DOI 10.1161/01.CIR.78.1.60; PARMLEY WW, 1989, CIRCULATION, V80, P68; PATTERSON SM, 1993, PSYCHOPHYSIOLOGY, V30, P296, DOI 10.1111/j.1469-8986.1993.tb03356.x; ROZANSKI A, 1987, AM HEART J, V114, P627, DOI 10.1016/0002-8703(87)90761-7; ROZANSKI A, 1988, NEW ENGL J MED, V318, P1005, DOI 10.1056/NEJM198804213181601; SCHANG SJ, 1977, AM J CARDIOL, V39, P396, DOI 10.1016/S0002-9149(77)80095-7; TAVAZZI L, 1990, ADV CARDIOL, V37, P53	34	229	233	0	22	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 21	1997	277	19					1521	1526		10.1001/jama.277.19.1521	http://dx.doi.org/10.1001/jama.277.19.1521			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WY969	9153365				2022-12-01	WOS:A1997WY96900029
J	Wong, PC; Zheng, H; Chen, H; Becher, MW; Sirinathsinghji, DJS; Trumbauer, ME; Chen, HY; Price, DL; VanderPloeg, LHT; Sisodia, SS				Wong, PC; Zheng, H; Chen, H; Becher, MW; Sirinathsinghji, DJS; Trumbauer, ME; Chen, HY; Price, DL; VanderPloeg, LHT; Sisodia, SS			Presenilin 1 is required for Notch1 DII1 expression in the paraxial mesoderm	NATURE			English	Article							FAMILIAL ALZHEIMERS-DISEASE; MISSENSE MUTATIONS; VERTEBRAL COLUMN; GENE; SOMITES; EMBRYO; PAX-1; CELLS	Approximately 10% of cases of Alzheimer's disease are familial and associated with autosomal dominant inheritance of mutations in genes encoding the amyloid precursor protein(1), presenilin 1 (PS1)(2) and presenilin 2 (pS2)(3,4). Mutations in PSI are Linked to about 25% of cases of early-onset familial Alzheimer's disease(5). PS1, which is endoproteolytically processed in vivo(6), is a multipass transmembrane protein and is a functional homologue of SEL-12 (ref. 7), a Caenorhabditis elegans protein that facilitates signalling mediated by the Notch/LIN-12 family of receptors(8,9). To examine 1 potential roles for PS1 in facilitating Notch-mediated signalling during mammalian embryogenesis, we generated mice with targeted disruptions of PSI alleles (PS1(-/-) mice). PS1(-/-) embryos exhibited abnormal patterning of the axial skeleton and spinal ganglia, phenotypes traced to defects in somite segmentation and differentiation. Moreover, expression of mRNA encoding Notch1 and Dill (delta-like gene 1)(10), a vertebrate Notch ligand, is markedly reduced in the presomitic mesoderm of PS1(-/-) embryos compared to controls. Hence, PS1 is required for the spatiotemporal expression of Notch1 and Dll1, which are essential for somite segmentation and maintenance of somite borders(11-13).	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,NEUROPATHOL LAB,BALTIMORE,MD 21205; MERCK RES LABS,DEPT GENET & MOL BIOL,RAHWAY,NJ 07065; MERCK SHARP & DOHME RES LABS,NEUROSCI RES CTR,HARLOW CM20 2QR,ESSEX,ENGLAND	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Merck & Company; Merck & Company	Wong, PC (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21205, USA.							ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; BETTENHAUSEN B, 1995, DEVELOPMENT, V121, P2407; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; BURGESS R, 1995, DEV BIOL, V168, P296, DOI 10.1006/dbio.1995.1081; Busfield Frances, 1995, P59, DOI 10.1016/B978-012286965-5/50006-6; CHRIST B, 1992, ANN ANAT, V174, P23, DOI 10.1016/S0940-9602(11)80337-7; CONLON RA, 1995, DEVELOPMENT, V121, P1533; Cruts M, 1996, HUM MOL GENET, V5, P1449, DOI 10.1093/hmg/5.Supplement_1.1449; deAngelis MH, 1997, NATURE, V386, P717, DOI 10.1038/386717a0; DEUTSCH U, 1988, CELL, V53, P617, DOI 10.1016/0092-8674(88)90577-6; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Hogan B., 2014, MANIPULATING MOUSE E; Joutel A, 1996, NATURE, V383, P707, DOI 10.1038/383707a0; KALCHEIM C, 1989, DEVELOPMENT, V106, P85; KOSEKI H, 1993, DEVELOPMENT, V119, P649; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; Lee MK, 1996, J NEUROSCI, V16, P7513, DOI 10.1523/jneurosci.16-23-07513.1996; Levitan D, 1996, P NATL ACAD SCI USA, V93, P14940, DOI 10.1073/pnas.93.25.14940; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MONTARRAS D, 1991, NEW BIOL, V3, P592; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; STERN CD, 1987, DEVELOPMENT, V99, P261; SWIATEK PJ, 1994, GENE DEV, V8, P707, DOI 10.1101/gad.8.6.707; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; VERBOUT AJ, 1985, ADV ANAT EMBRYOL CEL, V90, P1; ZHENG H, 1995, CELL, V81, P571	30	623	647	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 15	1997	387	6630					288	292		10.1038/387288a0	http://dx.doi.org/10.1038/387288a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WZ167	9153393				2022-12-01	WOS:A1997WZ16700054
J	Levitt, JB; Lund, JS				Levitt, JB; Lund, JS			Contrast dependence of contextual effects in primate visual cortex	NATURE			English	Article							NEOCORTICAL PYRAMIDAL NEURONS; CLASSICAL RECEPTIVE-FIELD; CAT STRIATE CORTEX; INTRINSIC CONNECTIONS; MACAQUE MONKEY; ORIENTATION SELECTIVITY; FUNCTIONAL ARCHITECTURE; RESPONSES; MECHANISMS; CIRCUITS	The responses of neurons in the visual cortex to stimuli presented within their receptive fields can be markedly modulated by stimuli presented in surrounding regions that do not themselves evoke responses(1-7). This modulation depends on the relative orientation and direction of motion of the centre and surround stimuli, and it has been suggested that local cortical circuits linking cells with similar stimulus selectivities underlie these phenomena(8-16). However, the functional relevance and nature of these integrative processes remain unclear. Here we investigate how such integration depends on the relative activity levels of neurons at different points across the cortex by varying the relative contrast of stimuli over the receptive field and surrounding regions. We show that simply altering the balance of the excitation driving centre and surround regions can dramatically change the sign and stimulus selectivity of these contextual effects. Thus, the way that single neurons integrate information across the visual field depends not only on the precise form of stimuli at different locations, but also crucially on their relative contrasts. We suggest that these effects reflect a complex gain-control mechanism that regulates cortical neuron responsiveness, which permits dynamic modification of response properties of cortical neurons.			Levitt, JB (corresponding author), UCL, INST OPHTHALMOL, DEPT VISUAL SCI, BATH ST, LONDON EC1V 9EL, ENGLAND.							ALLMAN J, 1985, ANNU REV NEUROSCI, V8, P407, DOI 10.1146/annurev.ne.08.030185.002203; AMIR Y, 1993, J COMP NEUROL, V334, P19, DOI 10.1002/cne.903340103; DEANGELIS GC, 1994, J NEUROPHYSIOL, V71, P347, DOI 10.1152/jn.1994.71.1.347; DEUCHARS J, 1994, J PHYSIOL-LONDON, V478, P423, DOI 10.1113/jphysiol.1994.sp020262; DOUGLAS RJ, 1995, SCIENCE, V269, P981, DOI 10.1126/science.7638624; GILBERT CD, 1989, J NEUROSCI, V9, P2432; GILBERT CD, 1990, VISION RES, V30, P1689, DOI 10.1016/0042-6989(90)90153-C; GILBERT CD, 1983, J NEUROSCI, V3, P1116; HEEGER DJ, 1992, VISUAL NEUROSCI, V9, P181, DOI 10.1017/S0952523800009640; KNIERIM JJ, 1992, J NEUROPHYSIOL, V67, P961, DOI 10.1152/jn.1992.67.4.961; LAMME VAF, 1995, J NEUROSCI, V15, P1605; LI CY, 1994, VISION RES, V34, P2337, DOI 10.1016/0042-6989(94)90280-1; LUND JS, 1993, CEREB CORTEX, V3, P148, DOI 10.1093/cercor/3.2.148; MALACH R, 1993, P NATL ACAD SCI USA, V90, P10469, DOI 10.1073/pnas.90.22.10469; MARKRAM H, 1995, J PHYSIOL-LONDON, V485, P1; NELSON JI, 1978, BRAIN RES, V139, P359, DOI 10.1016/0006-8993(78)90937-X; ROCKLAND KS, 1983, J COMP NEUROL, V216, P303, DOI 10.1002/cne.902160307; ROCKLAND KS, 1982, J COMP NEUROL, V209, P41, DOI 10.1002/cne.902090105; SILLITO AM, 1995, NATURE, V378, P492, DOI 10.1038/378492a0; SOMERS DC, 1995, J NEUROSCI, V15, P5448; STUART G, 1995, NEURON, V15, P1065, DOI 10.1016/0896-6273(95)90095-0; THOMSON AM, 1994, TRENDS NEUROSCI, V17, P119, DOI 10.1016/0166-2236(94)90121-X; Toth LJ, 1996, P NATL ACAD SCI USA, V93, P9869, DOI 10.1073/pnas.93.18.9869; TSO DY, 1986, J NEUROSCI, V6, P1160; Yoshioka T, 1996, CEREB CORTEX, V6, P297, DOI 10.1093/cercor/6.2.297; Zipser K, 1996, J NEUROSCI, V16, P7376	26	414	421	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 1	1997	387	6628					73	76		10.1038/387073a0	http://dx.doi.org/10.1038/387073a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WW758	9139823				2022-12-01	WOS:A1997WW75800049
J	Leonardo, ED; Hinck, L; Masu, M; KeinoMasu, K; Ackerman, SL; TessierLavigne, M				Leonardo, ED; Hinck, L; Masu, M; KeinoMasu, K; Ackerman, SL; TessierLavigne, M			Vertebrate homologues of C-elegans UNC-5 are candidate netrin receptors	NATURE			English	Article							PIONEER AXON MIGRATIONS; SPINAL-CORD; FLOOR PLATE; GUIDES CELL; MOTOR AXONS; PROTEIN; CHEMOREPELLENT; ELONGATION; GUIDANCE; GROWTH	In the developing nervous system, migrating cells and axons are guided to their targets by cues in the extracellular environment. The netrins are a family of phylogenetically conserved guidance cues that can function as diffusible attractants and repellents for different classes of cells and axons(1-10). In vertebrates, insects and nematodes, members of the DCC subfamily of the immunoglobulin superfamily have been implicated as receptors that are involved in migration towards netrin sources(6,11-13,15). The mechanisms that direct migration away from netrin sources (presumed repulsions) are less well understood. In Caenorhabditis elegans, the transmembrane protein UNC-5 (ref. 14) has been implicated in these responses, as loss of unc-5 function causes migration defects(16,17) and ectopic expression of unc-5 in some neurons can redirect their axons away from a netrin source(18). Whether UNC-5 is a netrin receptor or simply an accessory to such a receptor has not, however, been defined. We now report the identification of two vertebrate homologues of UNC-5 which, with UNC-5 and the product of the mouse rostral cerebellar malformation gene (rcm)(19), define a new subfamily of the immunoglobulin superfamily, and whose messenger RNAs show prominent expression in various classes of differentiating neurons. We provide evidence that these two UNC-5 homologues, as well as the rcm gene product, are netrin-binding proteins, supporting the hypothesis that UNC-5 and its relatives are netrin receptors.	UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT ANAT,PROGRAM CELL & DEV BIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT ANAT,NEUROSCI PROGRAM,SAN FRANCISCO,CA 94143; NATL DEF MED COLL,DEPT PHYSIOL,TOKOROZAWA,SAITAMA 359,JAPAN; JACKSON LAB,BAR HARBOR,ME 04609	Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; National Defense Medical College - Japan; Jackson Laboratory			Leonardo, Eduardo/AAH-1525-2020	Leonardo, Eduardo/0000-0001-7426-0217; Hinck, Lindsay/0000-0002-4009-3913				Ackerman SL, 1997, NATURE, V386, P838, DOI 10.1038/386838a0; ALTMAN J, 1984, ADV ANAT EMBRYOL CEL, V85, P1; Cajal S. R., 1911, HISTOLOGIE SYSTEME N, V2; Chan SSY, 1996, CELL, V87, P187, DOI 10.1016/S0092-8674(00)81337-9; COLAMARINO SA, 1995, CELL, V81, P621, DOI 10.1016/0092-8674(95)90083-7; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Fazeli A, 1997, NATURE, V386, P796, DOI 10.1038/386796a0; GUTHRIE S, 1995, NEURON, V14, P1117, DOI 10.1016/0896-6273(95)90260-0; HAMELIN M, 1993, NATURE, V364, P327, DOI 10.1038/364327a0; Harris R, 1996, NEURON, V17, P217, DOI 10.1016/S0896-6273(00)80154-3; HEDGECOCK EM, 1990, NEURON, V2, P61; ISHII N, 1992, NEURON, V9, P873, DOI 10.1016/0896-6273(92)90240-E; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; KLAR A, 1992, CELL, V69, P95, DOI 10.1016/0092-8674(92)90121-R; Kolodziej PA, 1996, CELL, V87, P197, DOI 10.1016/S0092-8674(00)81338-0; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; LIVESEY FJ, IN PRESS MOL CELL NE; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; MCINTIRE SL, 1992, NEURON, V8, P307, DOI 10.1016/0896-6273(92)90297-Q; MESSERSMITH EK, 1995, NEURON, V14, P949, DOI 10.1016/0896-6273(95)90333-X; Mitchell KJ, 1996, NEURON, V17, P203, DOI 10.1016/S0896-6273(00)80153-1; RAKIC P, 1971, J COMP NEUROL, V141, P283, DOI 10.1002/cne.901410303; Serafini T, 1996, CELL, V87, P1001, DOI 10.1016/S0092-8674(00)81795-X; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; SHIRASAKI R, 1995, NEURON, V14, P961, DOI 10.1016/0896-6273(95)90334-8; Shirasaki R, 1996, NEURON, V17, P1079, DOI 10.1016/S0896-6273(00)80241-X; VarelaEchavarria A, 1997, NEURON, V18, P193, DOI 10.1016/S0896-6273(00)80261-5; Wadsworth WG, 1996, NEURON, V16, P35, DOI 10.1016/S0896-6273(00)80021-5; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834	32	413	433	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 24	1997	386	6627					833	838		10.1038/386833a0	http://dx.doi.org/10.1038/386833a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WV706	9126742				2022-12-01	WOS:A1997WV70600055
J	McElduff, P; Dobson, AJ				McElduff, P; Dobson, AJ			How much alcohol and how often? Population based case-control study of alcohol consumption and risk of a major coronary event	BRITISH MEDICAL JOURNAL			English	Article							HEART-DISEASE; MYOCARDIAL-INFARCTION; HEALTH; MEN; MORTALITY	Objective: To quantify the effects of quantity and frequency of alcohol consumption on risk of acute myocardial infarction and coronary death. Design: Case-control study. Setting: Lower Hunter region of New South Wales, Australia, 1983-94. Subjects: Men and women aged 35-69 years. Main outcome measure: Acute myocardial infarction or coronary death. Results: Alcohol consumption patterns were compared between 11 511 cases of acute myocardial infarction or coronary death and 6077 controls randomly selected from the same study population. After adjusting for the effects of age, smoking, and medical history, men and women who consumed one or two drinks of alcohol on five or six days a week had a reduction in risk of a major coronary event compared with men and women who were non-drinkers (odds ratios: men 0.31 (95% confidence interval 0.22 to 0.45); women 0.33 (0.18 to 0.59)). A similar reduction in risk was found after excluding non-drinkers who were formerly moderate to heavy drinkers. An acute protective effect of alcohol consumption was also found for regular drinkers who consumed one or two drinks in the 24 hours preceding the onset of symptoms (odds ratios: men 0.74 (0.51 to 1.09); women 0.43 (0.20 to 0.95)). Conclusions: Frequency and quantity of alcohol consumption are important in assessing the risk of a major coronary event Risk is lowest among men who report one to four drinks daily on five or six days a week and among women who report one or two drinks daily on five or six days a week.	UNIV NEWCASTLE,CTR CLIN EPIDEMIOL & BIOSTAT,NEWCASTLE,NSW 2308,AUSTRALIA	University of Newcastle	McElduff, P (corresponding author), UNIV NEWCASTLE,DEPT STAT,NEWCASTLE,NSW 2308,AUSTRALIA.		Dobson, Annette J/B-5273-2008					CULLEN KJ, 1993, AM J EPIDEMIOL, V137, P242, DOI 10.1093/oxfordjournals.aje.a116665; HENDRIKS HFJ, 1994, BRIT MED J, V308, P1003, DOI 10.1136/bmj.308.6935.1003; JACKSON R, 1991, BRIT MED J, V303, P211, DOI 10.1136/bmj.303.6796.211; JACKSON R, 1992, AM J EPIDEMIOL, V136, P819, DOI 10.1093/aje/136.7.819; KAUFMAN DW, 1985, AM J EPIDEMIOL, V121, P548, DOI 10.1093/oxfordjournals.aje.a114032; MIDANIK L, 1982, BRIT J ADDICT, V77, P357; MILLER GJ, 1990, INT J EPIDEMIOL, V19, P923, DOI 10.1093/ije/19.4.923; RIMM EB, 1991, LANCET, V338, P464, DOI 10.1016/0140-6736(91)90542-W; ROMELSJO A, 1995, INT J EPIDEMIOL, V24, P929, DOI 10.1093/ije/24.5.929; RUSSELL M, 1991, AM J PUBLIC HEALTH, V81, P452, DOI 10.2105/AJPH.81.4.452; *SAS I INC, 1993, P243 SAS I INC; SHAPER AG, 1994, INT J EPIDEMIOL, V23, P482, DOI 10.1093/ije/23.3.482; SUH I, 1992, ANN INTERN MED, V116, P881, DOI 10.7326/0003-4819-116-11-881; TUNSTALLPEDOE H, 1994, CIRCULATION, V90, P583, DOI 10.1161/01.CIR.90.1.583; WOODWARD M, 1995, J EPIDEMIOL COMMUN H, V49, P354, DOI 10.1136/jech.49.4.354	15	195	197	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 19	1997	314	7088					1159	1164		10.1136/bmj.314.7088.1159	http://dx.doi.org/10.1136/bmj.314.7088.1159			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WV705	9146388	Green Published			2022-12-01	WOS:A1997WV70500022
J	Ralph, J; MacKay, JJ; Hatfield, RD; OMalley, DM; Whetten, RW; Sederoff, RR				Ralph, J; MacKay, JJ; Hatfield, RD; OMalley, DM; Whetten, RW; Sederoff, RR			Abnormal lignin in a loblolly pine mutant	SCIENCE			English	Article							CINNAMYL-ALCOHOL-DEHYDROGENASE; BROWN-MIDRIB MUTANT; COMPRESSION WOOD; BM3 MUTATION; CROSS-LINKS; MAIZE; CONIFERYL; GRASSES; GENE; NMR	Novel lignin is formed in a mutant loblolly pine (Pinus taeda L.) severely depleted in cinnamyl alcohol dehydrogenase (E.C. 1.1.1.195), which converts coniferaldehyde to coniferyl alcohol, the primary lignin precursor in pines. Dihydrocbniferyl alcohol, a monomer not normally associated with the lignin biosynthetic pathway, is the major component of the mutant's lignin, accounting for similar to 30 percent (versus similar to 3 percent in normal pine) of the units. The level of aldehydes, including new 2-methoxybenzaldehydes, is also increased. The mutant pines grew normally indicating that, even within a species, extensive variations in lignin composition need not disrupt the essential functions of lignin.	UNIV WISCONSIN, DEPT FORESTRY, MADISON, WI 53706 USA; N CAROLINA STATE UNIV, DEPT GENET, RALEIGH, NC 27695 USA; N CAROLINA STATE UNIV, DEPT FORESTRY, RALEIGH, NC 27695 USA	University of Wisconsin System; University of Wisconsin Madison; University of North Carolina; North Carolina State University; University of North Carolina; North Carolina State University	Ralph, J (corresponding author), USDA ARS, US DAIRY FORAGE RES CTR, 1925 LINDEN DR W, MADISON, WI 53706 USA.		Whetten, Ross W/A-9734-2013; MacKay, John/M-6978-2014; Ralph, John/C-3161-2009	MacKay, John/0000-0002-4883-195X; Ralph, John/0000-0002-6093-4521	NIGMS NIH HHS [GM45344-07] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER E, 1948, ACTA CHEM SCAND, V2, P839, DOI 10.3891/acta.chem.scand.02-0839; ADLER E, 1948, ACTA CHEM SCAND, V2, P93, DOI 10.3891/acta.chem.scand.02-0093; Baucher M, 1996, PLANT PHYSIOL, V112, P1479, DOI 10.1104/pp.112.4.1479; BJORKMAN A, 1954, NATURE, V174, P1057, DOI 10.1038/1741057a0; BUCHOLTZ DL, 1980, J AGR FOOD CHEM, V28, P1239, DOI 10.1021/jf60232a045; Campbell MM, 1996, PLANT PHYSIOL, V110, P3, DOI 10.1104/pp.110.1.3; CHABBERT B, 1994, J SCI FOOD AGR, V64, P349, DOI 10.1002/jsfa.2740640317; CHAPPLE CCS, 1992, PLANT CELL, V4, P1413, DOI 10.1105/tpc.4.11.1413; CHERNEY JH, 1991, ADV AGRON, V46, P157; Davin LB, 1997, SCIENCE, V275, P362, DOI 10.1126/science.275.5298.362; FREUDENBERG K, 1959, NATURE, V183, P1152, DOI 10.1038/1831152a0; FUKUSHIMA K, 1991, WOOD SCI TECHNOL, V25, P371, DOI 10.1007/BF00226177; GRAND C, 1985, PHYSIOL VEG, V23, P905; HALPIN C, 1994, PLANT J, V6, P339, DOI 10.1046/j.1365-313X.1994.06030339.x; Harkin J.M., 1967, OXIDATIVE COUPLING P, P243; HARKIN JM, 1973, CHEMISTRY BIOCHEMIST, V1, P323; HATFIELD RD, 1994, J SCI FOOD AGR, V65, P51, DOI 10.1002/jsfa.2740650109; HIBINO T, 1995, BIOSCI BIOTECH BIOCH, V59, P929, DOI 10.1271/bbb.59.929; HIGUCHI T, 1994, J BIOTECHNOL, V37, P151, DOI 10.1016/0168-1656(94)90006-X; KAMISAKA S, 1983, PLANT CELL PHYSIOL, V24, P369; KARHUNEN P, 1995, TETRAHEDRON LETT, V36, P169, DOI 10.1016/0040-4039(94)02203-N; KUC J, 1964, ARCH BIOCHEM BIOPHYS, V105, P103, DOI 10.1016/0003-9861(64)90240-1; LAPIERRE C, 1988, CR ACAD SCI III-VIE, V307, P723; LAPIERRE C, 1993, FORAGE CELL WALL STRUCTURE AND DIGESTIBILITY, P133; LAPIERRE C, 1988, HOLZFORSCHUNG, V42, P409, DOI 10.1515/hfsg.1988.42.6.409; LERNER L, 1986, J MAGN RESON, V69, P375, DOI 10.1016/0022-2364(86)90091-0; LU F, IN PRESS J AGR FOOD; Ludley FH, 1996, J AGR FOOD CHEM, V44, P2942, DOI 10.1021/jf9604908; MACKAY JJ, 1997, THESIS N CAROLINA ST; MACKAY JJ, IN PRESS P NATL ACAD; Meyer K, 1996, P NATL ACAD SCI USA, V93, P6869, DOI 10.1073/pnas.93.14.6869; MONTIES B, 1995, ANN P PHYTOCHEM SOC, V5, P161; NAKAMURA M, 1978, MOL CELL ENDOCRINOL, V12, P209; NAKAMURA Y, 1976, HOLZFORSCHUNG, V30, P187, DOI 10.1515/hfsg.1976.30.6.187; Nakamura Y, 1978, CELL CHEM TECHNOL, V12, P199; NIMZ HH, 1981, HOLZFORSCHUNG, V35, P16, DOI 10.1515/hfsg.1981.35.1.16; OMALLEY DM, 1992, PLANT PHYSIOL, V98, P1364, DOI 10.1104/pp.98.4.1364; PILLONEL C, 1991, PLANTA, V185, P538, DOI 10.1007/BF00202964; QUIDEAU S, 1992, J AGR FOOD CHEM, V40, P1108, DOI 10.1021/jf00019a003; RALPH J, 1992, J CHEM SOC PERK T 1, P2961, DOI 10.1039/p19920002961; Ralph J, 1996, J NAT PROD, V59, P341, DOI 10.1021/np960143s; RALPH J, 1994, J AM CHEM SOC, V116, P9448, DOI 10.1021/ja00100a006; RALPH J, 1995, CARBOHYD RES, V275, P167, DOI 10.1016/0008-6215(95)00237-N; RALPH J, IN PRESS LIGNIN LIGN; Rolando C., 1992, METHODS LIGNIN CHEM, P334, DOI DOI 10.1007/978-3-642-74065-7_23; SARKANEN KV, 1967, TAPPI, V50, P587; SARKANEN KV, 1971, LIGNINS; SAVIDGE RA, 1987, PHYTOCHEMISTRY, V26, P93, DOI 10.1016/S0031-9422(00)81488-0; Timell TE, 1986, COMPRESSION WOOD GYM; VIGNOLS F, 1995, PLANT CELL, V7, P407, DOI 10.1105/tpc.7.4.407	50	246	267	3	49	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 11	1997	277	5323					235	239		10.1126/science.277.5323.235	http://dx.doi.org/10.1126/science.277.5323.235			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK418	9211851				2022-12-01	WOS:A1997XK41800044
J	Soderstrom, CA; Smith, GS; Dischinger, PC; McDuff, DR; Hebel, JR; Gorelick, DA; Kerns, TJ; Ho, SM; Read, KM				Soderstrom, CA; Smith, GS; Dischinger, PC; McDuff, DR; Hebel, JR; Gorelick, DA; Kerns, TJ; Ho, SM; Read, KM			Psychoactive substance use disorders among seriously injured trauma center patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	40th Annual Meeting of the Association-for-the-Advancement-of-Automotive-Medicine	OCT 07-09, 1996	VANCOUVER, CANADA	Assoc Adv Automot Med			HARMFUL ALCOHOL-CONSUMPTION; UNITED-STATES; COLLABORATIVE PROJECT; CAGE QUESTIONNAIRE; SCREENING-TEST; FOLLOW-UP; ABUSE; DEPENDENCE; PREVALENCE; DISEASE	Objective.-To assess the prevalence of psychoactive substance use disorders (PSUDs) among a large, unselected group of seriously injured trauma center patients, using a standardized diagnostic interview and criteria. Design.-Prevalence study. Setting.-A level I regional trauma center. Patients. Trauma center patients fulfilling the following criteria were eligible subjects: aged 18 years or older, admission from injury scene, length of stay of 2 days or longer, and intact cognition. Outcome Measures. The PSUDs were diagnosed using the Structured Clinical Interview (SCID) for the Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition (DSM-III-R) and were categorized as abuse or dependence and past or current (within past 6 months). The SCID results were analyzed with respect to demographic factors, injury type, and blood alcohol concentration and urine toxicology results, using chi(2) and logistic regression techniques. Results.-Of the 1220 patients approached for study, 1118 (91.6%) consented. More than half (54.2%) had a diagnosis of a PSUD in their lifetime. Approximately 90% of alcohol and other drug use diagnoses were for dependence and more than 62% were current. Overall, 24.1% of patients were currently alcohol dependent (men, 27.7%; women, 14.7%; P<.001), and 17.7% were currently dependent on other drugs (men, 20.2%; women, 11.2%; P<.001). Current alcohol dependence rates were not associated with race; rates of dependence on other drugs were higher among nonwhites and victims classified with intentional injuries. While 54.3% of blood alcohol-positive patients were currently alcohol dependent and 38.7% of patients with positive urine screening test results for drugs other than alcohol and nicotine were currently drug dependent, 11.7% of blood alcohol-negative and 3.9% of drug-negative patients, respectively, had current diagnoses of dependence on psychoactive substances. Conclusions. A high percentage of seriously injured trauma center patients are at risk of having current PSUDs. Patients with positive toxicology screening test results and/or positive screening questionnaire responses should be referred for formal evaluation and treatment.	JOHNS HOPKINS UNIV, CTR INJURY RES & POLICY, BALTIMORE, MD USA; UNIV MARYLAND, SCH MED, NATL STUDY CTR TRAUMA & EMERGENCY MED SYST, BALTIMORE, MD 21201 USA; UNIV MARYLAND, SCH MED, DEPT PSYCHIAT, BALTIMORE, MD 21201 USA; UNIV MARYLAND, SCH MED, DEPT EPIDEMIOL, BALTIMORE, MD 21201 USA; NIDA, DIV INTRAMURAL RES, BALTIMORE, MD USA	Johns Hopkins University; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA)	Soderstrom, CA (corresponding author), UNIV MARYLAND, MED SYST, CTR SHOCK TRAUMA, 22 S GREENE ST, BALTIMORE, MD 21201 USA.		Gorelick, David/ABF-4941-2021	Smith, Gordon/0000-0002-2911-3071	NIAAA NIH HHS [R01 AA09050] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA009050] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		American Psychiatric Association, 1987, DIAGNOSTIC STAT MANU, V3rd; American Psychiatric Association (Washington), 2000, DSM 4 T DIAGN STAT M; ANDA RF, 1988, JAMA-J AM MED ASSOC, V260, P2529, DOI 10.1001/jama.260.17.2529; *ASS ADV AUT MED, 1990, ABBR INJ SCAL; BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; CHAMPION HR, 1990, J TRAUMA, V30, P1356, DOI 10.1097/00005373-199011000-00008; CHERPITEL CJ, 1995, ANN EMERG MED, V26, P158, DOI 10.1016/S0196-0644(95)70146-X; CLARK DE, 1985, ANN EMERG MED, V14, P274, DOI 10.1016/S0196-0644(85)80456-X; Collins JJ, 1993, ALCOHOL HEALTH RES W, V17, P93; COTTROL C, 1993, HOSP COMMUNITY PSYCH, V44, P715; Dunham C M, 1989, Md Med J, V38, P227; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; FLOERCHINGER SL, 1992, AM COLL SURG COMM TR; FULLER MG, 1995, J STUD ALCOHOL, V56, P267, DOI 10.15288/jsa.1995.56.267; GENTILELLO LM, 1995, JAMA-J AM MED ASSOC, V274, P1043, DOI 10.1001/jama.274.13.1043; GRANT BF, 1994, ALCOHOL HEALTH RES W, V18, P243; JURKOVICH GJ, 1993, JAMA-J AM MED ASSOC, V270, P51, DOI 10.1001/jama.270.1.51; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; KITCHENS JM, 1994, JAMA-J AM MED ASSOC, V272, P1782, DOI 10.1001/jama.272.22.1782; LINDENBAUM GA, 1989, J TRAUMA, V29, P1654, DOI 10.1097/00005373-198912000-00012; LOWENFELS AB, 1984, ANN EMERG MED, V13, P1056, DOI 10.1016/S0196-0644(84)80070-0; LUNDBERG GD, 1984, JAMA-J AM MED ASSOC, V252, P1911, DOI 10.1001/jama.252.14.1911; MACKENZIE EJ, 1989, J TRAUMA, V29, P757, DOI 10.1097/00005373-198906000-00011; Maio RF, 1997, ACAD EMERG MED, V4, P256, DOI 10.1111/j.1553-2712.1997.tb03545.x; MCGINNIS JM, 1993, JAMA-J AM MED ASSOC, V270, P2207, DOI 10.1001/jama.270.18.2207; MCGONIGAL MD, 1993, J TRAUMA, V35, P532, DOI 10.1097/00005373-199310000-00006; *NAT I ALC AB ALC, 1991, ALCOHOL ALERT, V285, P1; *NAT I ALC AB ALC, 1991, ALCOHOL ALERT, V294, P1; NILSSEN O, 1994, J TRAUMA, V36, P784, DOI 10.1097/00005373-199406000-00006; PARRAN TV, 1995, J TRAUMA, V38, P278, DOI 10.1097/00005373-199502000-00026; POKORNY AD, 1972, AM J PSYCHIAT, V129, P342, DOI 10.1176/ajp.129.3.342; POOLE GV, 1993, SURGERY, V113, P608; RIVARA FP, 1993, ARCH SURG-CHICAGO, V128, P907; RIVARA FP, 1993, JAMA-J AM MED ASSOC, V270, P1962, DOI 10.1001/jama.270.16.1962; RIVARA FP, 1989, J TRAUMA, V29, P462, DOI 10.1097/00005373-198904000-00008; RUTLEDGE R, 1992, J TRAUMA, V33, P737, DOI 10.1097/00005373-199211000-00024; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; SAUNDERS JB, 1993, ADDICTION, V88, P349, DOI 10.1111/j.1360-0443.1993.tb00822.x; *SECR HLTH HUM SER, 1994, NIH PUBL; SELZER ML, 1975, J STUD ALCOHOL, V36, P117, DOI 10.15288/jsa.1975.36.117; SLOAN EP, 1989, J TRAUMA, V29, P1647, DOI 10.1097/00005373-198912000-00011; SODERSTROM CA, 1994, J TRAUMA, V36, P68, DOI 10.1097/00005373-199401000-00010; Soderstrom CA, 1997, J TRAUMA, V42, P67, DOI 10.1097/00005373-199701000-00012; SODERSTROM CA, 1992, JAMA-J AM MED ASSOC, V267, P2756, DOI 10.1001/jama.267.20.2756; Spitzer R. L., STRUCTURED CLIN INTE; *US DEP HHS, 1992, MOD TRAUM SYST CAR P; WALLER PF, 1986, JAMA-J AM MED ASSOC, V256, P1461, DOI 10.1001/jama.256.11.1461; WALLER PF, 1995, P ASS ADV AUTOMOTIVE, V39, P89; WEISBESKI D, 1989, J TRAUMA, V29, P940, DOI 10.1097/00005373-198907000-00006; Zuska J J, 1981, Bull Am Coll Surg, V66, P5	50	180	182	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 11	1997	277	22					1769	1774		10.1001/jama.277.22.1769	http://dx.doi.org/10.1001/jama.277.22.1769			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	XC499	9178789				2022-12-01	WOS:A1997XC49900029
J	Rout, MP; Blobel, G; Aitchison, JD				Rout, MP; Blobel, G; Aitchison, JD			A distinct nuclear import pathway used by ribosomal proteins	CELL			English	Article							PORE COMPLEX PROTEINS; SACCHAROMYCES-CEREVISIAE; LOCALIZATION SIGNALS; YEAST SACCHAROMYCES; TRANSPORT SUBSTRATE; CYTOSOLIC FACTORS; MEDIATED BINDING; CELL-CYCLE; IDENTIFICATION; ENVELOPE	Protein transport into the nucleus is governed by the interaction of soluble transport factors with their import substrates and nuclear pore complexes. Here, we identify a major distinct nuclear import pathway, mediated by a previously uncharacterized yeast beta karyopherin Kap123p. The predominant substrates for this pathway are ribosomal proteins, which must be imported into the nucleus prior to assembly into pre-ribosomes. Kap123p binds directly to its transport substrates, repeat motif-containing nucleoporins, and Ran-GTP. We show that the related protein Pse1p is also a karyopherin and can functionally substitute for Kap123p; both are capable of specifically directing a ribosomal nuclear localization signal reporter to the nucleus in vivo.			Rout, MP (corresponding author), ROCKEFELLER UNIV, HOWARD HUGHES MED INST, CELL BIOL LAB, NEW YORK, NY 10021 USA.		Rout, Michael/Y-7090-2018	Rout, Michael/0000-0003-2010-706X				ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; Aitchison JD, 1995, J CELL BIOL, V131, P1659, DOI 10.1083/jcb.131.6.1659; AITCHISON JD, 1995, J CELL BIOL, V131, P1133, DOI 10.1083/jcb.131.5.1133; Aitchison JD, 1996, SCIENCE, V274, P624, DOI 10.1126/science.274.5287.624; ANDRADE MA, 1995, NAT GENET, V11, P115, DOI 10.1038/ng1095-115; BOEHLKE KW, 1975, J BACTERIOL, V121, P429, DOI 10.1128/JB.121.2.429-433.1975; BONIFACI N, 1997, IN PRESS P NATL ACAD; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; CHOW TYK, 1992, J CELL SCI, V101, P709; COUTAVAS E, 1993, NATURE, V366, P585, DOI 10.1038/366585a0; DAVIS LI, 1990, CELL, V61, P965, DOI 10.1016/0092-8674(90)90062-J; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Enenkel C, 1996, P NATL ACAD SCI USA, V93, P12986, DOI 10.1073/pnas.93.23.12986; ENENKEL C, 1995, J BIOL CHEM, V270, P16499, DOI 10.1074/jbc.270.28.16499; FERNANDEZ J, 1994, ANAL BIOCHEM, V218, P112, DOI 10.1006/abio.1994.1148; FISCHER U, 1991, J CELL BIOL, V113, P705, DOI 10.1083/jcb.113.4.705; Fornerod M, 1997, EMBO J, V16, P807, DOI 10.1093/emboj/16.4.807; GARCIABUSTOS JF, 1991, J BIOL CHEM, V266, P22303; Gharahdaghi F, 1996, ANAL BIOCHEM, V233, P94, DOI 10.1006/abio.1996.0012; GHARAHDAGHI F, 1992, TECHNIQUES PROTEIN C, P249; Goldfarb D, 1991, Trends Cell Biol, V1, P20, DOI 10.1016/0962-8924(91)90065-H; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Gorlich D, 1996, EMBO J, V15, P1810, DOI 10.1002/j.1460-2075.1996.tb00530.x; HALL MN, 1990, P NATL ACAD SCI USA, V87, P6954, DOI 10.1073/pnas.87.18.6954; IMAMOTO N, 1995, J BIOL CHEM, V270, P8559, DOI 10.1074/jbc.270.15.8559; IMAMOTO N, 1995, EMBO J, V14, P3617, DOI 10.1002/j.1460-2075.1995.tb00031.x; Iovine MK, 1995, J CELL BIOL, V131, P1699, DOI 10.1083/jcb.131.6.1699; KILMARTIN JV, 1984, J CELL BIOL, V98, P922, DOI 10.1083/jcb.98.3.922; KRAEMER DM, 1995, J BIOL CHEM, V270, P19017, DOI 10.1074/jbc.270.32.19017; Makkerh JPS, 1996, CURR BIOL, V6, P1025, DOI 10.1016/S0960-9822(02)00648-6; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MICHAUD N, 1991, J CELL BIOL, V112, P215, DOI 10.1083/jcb.112.2.215; MICHAUD N, 1992, J CELL BIOL, V116, P851, DOI 10.1083/jcb.116.4.851; MOORE MS, 1992, CELL, V69, P939, DOI 10.1016/0092-8674(92)90613-H; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; MORELAND RB, 1985, P NATL ACAD SCI USA, V82, P6561, DOI 10.1073/pnas.82.19.6561; Moroianu J, 1996, P NATL ACAD SCI USA, V93, P7059, DOI 10.1073/pnas.93.14.7059; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; MUTVEI A, 1992, EUR J CELL BIOL, V59, P280; NEHRBASS U, 1993, EUR J CELL BIOL, V62, P1; NELSON M, 1989, MOL CELL BIOL, V9, P384, DOI 10.1128/MCB.9.2.384; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Rout Michael P., 1994, Trends in Cell Biology, V4, P357, DOI 10.1016/0962-8924(94)90085-X; ROUT MP, 1993, J CELL BIOL, V123, P771, DOI 10.1083/jcb.123.4.771; ROUT MP, 1990, J CELL BIOL, V111, P1913, DOI 10.1083/jcb.111.5.1913; ROUT MP, 1994, CELL BIOL LAB HDB, P605; SCHAAP PJ, 1991, J MOL BIOL, V221, P225; SCHMIDT C, 1995, MOL BIOL CELL, V6, P1875, DOI 10.1091/mbc.6.12.1875; Smith V, 1996, SCIENCE, V274, P2069, DOI 10.1126/science.274.5295.2069; STRAMBIODECASTILLIA C, 1995, J CELL BIOL, V131, P19, DOI 10.1083/jcb.131.1.19; UNDERWOOD MR, 1990, EMBO J, V9, P91, DOI 10.1002/j.1460-2075.1990.tb08084.x; WARNER JR, 1985, MOL CELL BIOL, V5, P1512, DOI 10.1128/MCB.5.6.1512; WARNER JR, 1989, MICROBIOL REV, V53, P256, DOI 10.1128/MMBR.53.2.256-271.1989; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; Weis K, 1996, EMBO J, V15, P1818, DOI 10.1002/j.1460-2075.1996.tb00531.x; WENTE SR, 1992, J CELL BIOL, V119, P705, DOI 10.1083/jcb.119.4.705; WOZNIAK RW, 1994, J CELL BIOL, V125, P31, DOI 10.1083/jcb.125.1.31; YANO R, 1992, MOL CELL BIOL, V12, P5640, DOI 10.1128/MCB.12.12.5640; ZINKER S, 1976, J BIOL CHEM, V251, P1799	66	300	305	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 30	1997	89	5					715	725		10.1016/S0092-8674(00)80254-8	http://dx.doi.org/10.1016/S0092-8674(00)80254-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XB925	9182759	Bronze			2022-12-01	WOS:A1997XB92500008
J	Cole, CW				Cole, CW			Prospects for screening for abdominal aortic aneurysms	LANCET			English	Editorial Material											Cole, CW (corresponding author), OTTAWA GEN HOSP,DEPT SURG,OTTAWA,ON K1H 8L6,CANADA.							Cole C W, 1996, Chronic Dis Can, V17, P51; FRAME PS, 1993, ANN INTERN MED, V119, P411, DOI 10.7326/0003-4819-119-5-199309010-00010; LEDERLE FA, 1994, J VASC SURG, V20, P296, DOI 10.1016/0741-5214(94)90019-1; Lindholt JS, 1997, BRIT J SURG, V84, P40; POWELL JT, 1993, LANCET, V342, P1473, DOI 10.1016/0140-6736(93)92939-Q; SCOTT RAP, 1995, BRIT J SURG, V82, P1066, DOI 10.1002/bjs.1800820821	6	4	4	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 24	1997	349	9064					1490	1491		10.1016/S0140-6736(05)62093-4	http://dx.doi.org/10.1016/S0140-6736(05)62093-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XA901	9167454				2022-12-01	WOS:A1997XA90100004
J	Marder, SR; Torruellas, WE; BlanchardDesce, M; Ricci, V; Stegeman, GI; Gilmour, S; Bredas, JL; Li, J; Bublitz, GU; Boxer, SG				Marder, SR; Torruellas, WE; BlanchardDesce, M; Ricci, V; Stegeman, GI; Gilmour, S; Bredas, JL; Li, J; Bublitz, GU; Boxer, SG			Large molecular third-order optical nonlinearities in polarized carotenoids	SCIENCE			English	Article							POLARIZABILITIES; SUSCEPTIBILITY; GENERATION; POLYENES; LENGTH; BETA	Garito and cc-workers have suggested a mechanism to dramatically increase the second hyperpolarizability, gamma, in linear pi-electron-conjugated molecules. Polarization is introduced that leads to a difference between the dipole moments of the molecule's ground state and excited state. Here a series of carotenoids was examined that had increasing intramolecular charge transfer (ICT) from the polyenic chain to the acceptor moiety in the ground state, and gamma was measured for these compounds as a function of wavelength by third-harmonic generation. The compound with the greatest ICT exhibited a 35-fold enhancement of gamma(max) (the gamma measured at the peak of the three-photon resonance) relative to the symmetric molecule beta-carotene, which itself has one of the largest third-order nonlinearities known. Stark spectroscopic measurements revealed the existence of a large difference dipole moment, Delta mu, between the ground and excited state. Quantum-chemical calculations underline the importance of interactions involving states with large Delta mu.	CALTECH,JET PROP LAB,PASADENA,CA 91109; UNIV CENT FLORIDA,CTR RES EDUC OPT & LASERS,ORLANDO,FL 32816; ECOLE NORMALE SUPER,DEPT CHIM,URA 1679,CNRS,F-75231 PARIS 05,FRANCE; UNIV MONS,CTR RES MOL ELECT & PHOTON,B-7000 MONS,BELGIUM; STANFORD UNIV,DEPT CHEM,STANFORD,CA 94305	California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); State University System of Florida; University of Central Florida; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); Universite Paris Cite; University of Mons; Stanford University	Marder, SR (corresponding author), CALTECH,BECKMAN INST,PASADENA,CA 91125, USA.		Bredas, Jean-Luc E/A-3431-2008	Bredas, Jean-Luc E/0000-0001-7278-4471; Boxer, Steven/0000-0001-9167-4286				ALMOGY G, 1994, OPT LETT, V19, P1828, DOI 10.1364/OL.19.001828; ARAMAKI S, 1991, OPT COMMUN, V85, P527, DOI 10.1016/0030-4018(91)90590-A; BELJONNE D, IN PRESS PHYS REV B; Blanchard-Desce M., 1995, Nonlinear Optics, Principles, Materials, Phenomena and Devices, V10, P23; BLANCHARDDESCE M, IN PRESS J PHOTOCH A; BLANCHARDFDESCE M, IN PRESS CHEM EUR J; CAPASSO F, 1994, IEEE J QUANTUM ELECT, V30, P1313, DOI 10.1109/3.303697; DEHU C, 1993, J AM CHEM SOC, V115, P6198, DOI 10.1021/ja00067a039; DIRK CW, 1992, INT J QUANTUM CHEM, V43, P27, DOI 10.1002/qua.560430106; FEJER MM, 1989, PHYS REV LETT, V62, P1041, DOI 10.1103/PhysRevLett.62.1041; Garito A. F., 1988, Proceedings of the SPIE - The International Society for Optical Engineering, V971, P2, DOI 10.1117/12.948209; GARITO AF, 1989, ORGANIC MAT NONLINEA, P16; GILMOUR S, 1993, J CHEM SOC CHEM COMM, P432, DOI 10.1039/c39930000432; HALVORSON C, 1994, SCIENCE, V265, P1215, DOI 10.1126/science.265.5176.1215; HERMANN JP, 1974, J APPL PHYS, V45, P5100, DOI 10.1063/1.1663197; LAO KQ, 1995, J PHYS CHEM-US, V99, P496, DOI 10.1021/j100002a007; Liptay W., 1974, Excited states. Vol.1, P129; MARDER SR, 1994, SCIENCE, V265, P632, DOI 10.1126/science.265.5172.632; Messier J., 1992, Nonlinear Optics, Principles, Materials, Phenomena and Devices, V2, P53; MEYERS F, 1994, J AM CHEM SOC, V116, P10703, DOI 10.1021/ja00102a040; PIERCE BM, 1991, SPIE P, V1560, P148; PUCCETTI G, 1993, J PHYS CHEM-US, V97, P9385, DOI 10.1021/j100139a022	22	337	345	0	54	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 23	1997	276	5316					1233	1236		10.1126/science.276.5316.1233	http://dx.doi.org/10.1126/science.276.5316.1233			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XA497	9157876				2022-12-01	WOS:A1997XA49700035
J	Muttukrishna, S; Knight, PG; Groome, NP; Redman, CWG; Ledger, WL				Muttukrishna, S; Knight, PG; Groome, NP; Redman, CWG; Ledger, WL			Activin A and inhibin A as possible endocrine markers for pre-eclampsia	LANCET			English	Article							HUMAN MENSTRUAL-CYCLE; SERUM CONCENTRATIONS; DIMERIC INHIBIN; PREGNANCY; PREECLAMPSIA; HYPERTENSION; PLACENTA	Background Inhibin A and activin A are produced by the placenta during human pregnancy. This study aimed to measure circulating concentrations of inhibin A, pro alpha C-containing inhibins, and activin A in the serum of women with pre-eclampsia and of healthy matched control pregnant women, and to establish the molecular-weight forms of circulating inhibin A and activin A in pre-eclampsia. Methods In a retrospective cross-sectional study, blood samples were taken from 20 women in hospital with established pre-eclampsia, and from 20 control pregnant women attending antenatal clinics, who were matched for duration of gestation (preeclampsia mean 29.15 [SD 3.75] weeks; controls 29.30 [3.93] weeks), parity, and maternal age. Serum samples were analysed for inhibin A, inhibin B, pro alpha C, and activin A. Pooled samples of control (n=3) and pre-eclampsia serum (n=3) subsequently underwent fast protein liquid chromatographic analysis to assess the molecular-weight forms of inhibin A and activin A. Results are expressed as mean and SD for all variables measured. Findings Serum concentrations of inhibin A, activin A, and pro alpha C were significantly higher in pre-eclampsia than in control normal pregnancy (inhibin A 3.05 [1.8] vs 0.36 [0.14] ng/mL, p<0.001; activin A 38.08 [25.88] vs 3.95 [2.32] ng/mL, p<0.001; pro alpha C-containing inhibins 2.2 [0.81] vs 0.71 [0.33] ng/mL, p<0.001). Inhibin B concentrations in maternal serum were not increased. Molecular-weight forms of inhibin A (32 kDa) and activin A (>100 kDa) were similar in pre-eclampsia and normal pregnancy. The mean concentrations of hCG were 59.05 [43.98] and 16.3 [8.72] ng/mL, respectively. Interpretation Higher maternal serum concentrations of inhibin A, pro alpha C, and total activin A in preeclampsia than in control pregnancies could be helpful in the diagnosis of preeclampsia. These changes are interpreted as further evidence for trophoblast dysfunction in pre-eclampsia.	UNIV READING,SCH ANIM & MICROBIAL SCI,READING RG6 2AJ,BERKS,ENGLAND; OXFORD BROOKES UNIV,SCH BIOL & MOL SCI,OXFORD OX3 0BP,ENGLAND	University of Reading; Oxford Brookes University	Muttukrishna, S (corresponding author), UNIV OXFORD,JOHN RADCLIFFE HOSP,NUFFIELD DEPT OBSTET & GYNAECOL,OXFORD OX3 9DU,ENGLAND.		Ledger, William/L-9089-2017	Ledger, William/0000-0001-6465-4343; knight, philip/0000-0003-0300-1554				ARNHOLDT H, 1991, VIRCHOWS ARCH B, V60, P365, DOI 10.1007/BF02899568; Baird D T, 1993, Oxf Rev Reprod Biol, V15, P191; GROOME N, 1993, J IMMUNOL METHODS, V165, P167, DOI 10.1016/0022-1759(93)90342-5; GROOME NP, 1994, CLIN ENDOCRINOL, V40, P717, DOI 10.1111/j.1365-2265.1994.tb02504.x; GROOME NP, 1995, J CLIN ENDOCR METAB, V80, P2926, DOI 10.1210/jc.80.10.2926; Groome NP, 1996, J CLIN ENDOCR METAB, V81, P1401, DOI 10.1210/jc.81.4.1401; Illingworth PJ, 1996, J CLIN ENDOCR METAB, V81, P1471, DOI 10.1210/jc.81.4.1471; Knight PG, 1996, J ENDOCRINOL, V148, P267, DOI 10.1677/joe.0.1480267; Muller F, 1996, AM J OBSTET GYNECOL, V175, P37, DOI 10.1016/S0002-9378(96)70247-8; Muttukrishna S, 1996, J CLIN ENDOCR METAB, V81, P3328, DOI 10.1210/jc.81.9.3328; MUTTUKRISHNA S, 1994, HUM REPROD, V9, P1634, DOI 10.1093/oxfordjournals.humrep.a138765; MUTTUKRISHNA S, 1995, CLIN ENDOCRINOL, V42, P391, DOI 10.1111/j.1365-2265.1995.tb02648.x; MUTTUKRISHNA S, 1996, HUM REPROD, V11, P155; NAKAMURA T, 1990, SCIENCE, V247, P836, DOI 10.1126/science.2106159; PETRAGLIA F, 1995, PLACENTA, V16, P447, DOI 10.1016/0143-4004(95)90102-7; REDMAN CWG, 1991, PLACENTA, V12, P301, DOI 10.1016/0143-4004(91)90339-H; ROBERTS JM, 1993, LANCET, V341, P1447, DOI 10.1016/0140-6736(93)90889-O; Vale Wylie, 1994, P1861; WOLFE CDA, 1988, BRIT J OBSTET GYNAEC, V95, P1003, DOI 10.1111/j.1471-0528.1988.tb06504.x; WONG WLT, 1993, J IMMUNOL METHODS, V165, P1, DOI 10.1016/0022-1759(93)90100-L	20	232	241	1	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 3	1997	349	9061					1285	1288		10.1016/S0140-6736(96)09264-1	http://dx.doi.org/10.1016/S0140-6736(96)09264-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW899	9142063				2022-12-01	WOS:A1997WW89900010
J	vanderHorst, GTJ; vanSteeg, H; Berg, RJW; vanGool, AJ; deWit, J; Weeda, G; Morreau, H; Beems, RB; vanKreijl, CF; deGruijl, FR; Bootsma, D; Hoeijmakers, JHJ				vanderHorst, GTJ; vanSteeg, H; Berg, RJW; vanGool, AJ; deWit, J; Weeda, G; Morreau, H; Beems, RB; vanKreijl, CF; deGruijl, FR; Bootsma, D; Hoeijmakers, JHJ			Defective transcription-coupled repair in Cockayne syndrome B mice is associated with skin cancer predisposition	CELL			English	Article							GROUP-A GENE; DNA-REPAIR; XERODERMA-PIGMENTOSUM; ULTRAVIOLET-B; ACTIVE GENES; DHFR GENE; PROTEIN; LACKING; CELLS; SUSCEPTIBILITY	A mouse model for the nucleotide excision repair disorder Cockayne syndrome (CS) was generated by mimicking a truncation in the CSB(ERCC6) gene of a CS-B patient. CSB-deficient mice exhibit all of the CS repair characteristics: ultraviolet (UV) sensitivity, inactivation of transcription-coupled repair, unaffected global genome repair, and inability to resume RNA synthesis after UV exposure. Other CS features thought to involve the functioning of basal transcription/repair factor TFIIH, such as growth failure and neurologic dysfunction, are present in mild form. In contrast to the human syndrome, CSB-deficient mice show increased susceptibility to skin cancer. Our results demonstrate that transcription-coupled repair of UV-induced cyclobutane pyrimidine dimers contributes to the prevention of carcinogenesis in mice. Further, they suggest that the lack of cancer predisposition in CS patients is attributable to a global genome repair process that in humans is more effective than in rodents.	NATL INST PUBL HLTH & ENVIRONM PROTECT,DEPT CARCINOGENESIS MUTAGENESIS & GENET,NL-3720 BA BILTHOVEN,NETHERLANDS; UNIV UTRECHT,DEPT DERMATOL,NL-3584 CX UTRECHT,NETHERLANDS; UNIV LEIDEN HOSP,DEPT PATHOL,NL-2300 RL LEIDEN,NETHERLANDS	Netherlands National Institute for Public Health & the Environment; Utrecht University; Leiden University; Leiden University Medical Center (LUMC)	vanderHorst, GTJ (corresponding author), ERASMUS UNIV ROTTERDAM,DEPT CELL BIOL & GENET,CTR MED GENET,POB 1738,NL-3000 DR ROTTERDAM,NETHERLANDS.		Hoeijmakers, Jan/AAX-6972-2021; van der Horst, Gijsbertus TJ/E-3661-2015; van Gool, Alain J/G-3806-2010; van Gool, Alain J./L-4328-2015	van der Horst, Gijsbertus TJ/0000-0002-7773-6396; van Gool, Alain/0000-0003-0010-5286				ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; BOOTSMA D, 1993, NATURE, V363, P114, DOI 10.1038/363114a0; BOOTSMA D, 1996, IN PRESS METABOLIC B; BRADLEY A, 1987, TERATOCARCINOMAS EMB, P113; DEVRIES A, 1995, NATURE, V377, P169, DOI 10.1038/377169a0; FRIEDBERG EC, 1995, DNA REPAIR; HANAWALT PC, 1994, CURR BIOL, V4, P518, DOI 10.1016/S0960-9822(00)00112-3; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; HENNING KA, 1995, CELL, V82, P555, DOI 10.1016/0092-8674(95)90028-4; HOEIJMAKERS JHJ, 1994, EUR J CANCER, V30A, P1912, DOI 10.1016/0959-8049(94)00381-E; Hoeijmakers JHJ, 1996, CURR OPIN GENET DEV, V6, P26, DOI 10.1016/S0959-437X(96)90006-4; ITIN PH, 1990, J AM ACAD DERMATOL, V22, P705, DOI 10.1016/0190-9622(90)70096-Z; Ljungman M, 1996, ONCOGENE, V13, P823; MAYNE LV, 1982, CANCER RES, V42, P1473; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; NAKANE H, 1995, NATURE, V377, P165, DOI 10.1038/377165a0; NANCE MA, 1992, AM J MED GENET, V42, P68, DOI 10.1002/ajmg.1320420115; Peterson CL, 1996, CURR OPIN GENET DEV, V6, P171, DOI 10.1016/S0959-437X(96)80047-5; RUVEN HJT, 1994, MUTAT RES-DNA REPAIR, V315, P189, DOI 10.1016/0921-8777(94)90018-3; SANDS AT, 1995, NATURE, V377, P162, DOI 10.1038/377162a0; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHAEFFER L, 1994, EMBO J, V13, P2388, DOI 10.1002/j.1460-2075.1994.tb06522.x; Sijbers AM, 1996, CELL, V86, P811, DOI 10.1016/S0092-8674(00)80155-5; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; VANGOOL AJ, 1994, EMBO J, V13, P5361, DOI 10.1002/j.1460-2075.1994.tb06871.x; VANHOFFEN A, 1993, NUCLEIC ACIDS RES, V21, P5890, DOI 10.1093/nar/21.25.5890; vanOosterwijk MF, 1996, MOL CELL BIOL, V16, P4436; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4707, DOI 10.1073/pnas.87.12.4707; Verhage RA, 1996, MOL CELL BIOL, V16, P496; VERMEULEN W, 1994, AM J HUM GENET, V54, P191; VERMEULEN W, 1994, COLD SPRING HARB SYM, V59, P317, DOI 10.1101/SQB.1994.059.01.036; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031	33	263	264	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 2	1997	89	3					425	435		10.1016/S0092-8674(00)80223-8	http://dx.doi.org/10.1016/S0092-8674(00)80223-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WX899	9150142	Bronze, Green Published			2022-12-01	WOS:A1997WX89900013
J	Thomas, SA; Palmiter, RD				Thomas, SA; Palmiter, RD			Thermoregulatory and metabolic phenotypes of mice lacking noradrenaline and adrenaline	NATURE			English	Article							BROWN ADIPOSE-TISSUE; DIET-INDUCED THERMOGENESIS; NOREPINEPHRINE; PROTEIN; OBESITY; STIMULATION; RATS; GENE	Adrenaline and noradrenaline, the main effecters of the sympathetic nervous system and adrenal medulla, respectively, are thought to control adiposity and energy balance through several mechanisms, They promote catabolism of triglycerides and glycogen(1), stimulate food intake when injected into the central nervous system(2), activate thermogenesis in brown adipose tissue(3,4), and regulate heat loss through modulation of peripheral vasoconstriction and piloerection(1), Thermogenesis in brown adipose tissue occurs in response to cold and overeating (diet induced)(5-7), and there is an inverse relationship between diet-induced thermogenesis and obesity bath in humans(8) and in animal models(9-12). As a potential model for obesity, we generated mice that cannot synthesize noradrenaline or adrenaline by inactivating the gene that encodes dopamine beta-hydroxylase. These mice are cold intolerant because they have impaired peripheral vasoconstriction and are unable to induce thermogenesis in brown adipose tissue through uncoupling protein (UCP1), The mutants have increased food intake but do not become obese because their basal metabolic rate is also elevated, The unexpected increase in basal metabolic rate is not due to hyperthyroidism, compensation by the widely expressed uncoupling protein UCP2, or shivering.	UNIV WASHINGTON, HOWARD HUGHES MED INST, DEPT BIOCHEM, SEATTLE, WA 98195 USA	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle								AHREN B, IN PRESS AM J PHYSL; BRAY GA, 1989, VITAM HORM, V45, P1; BROOKS SL, 1980, NATURE, V286, P274, DOI 10.1038/286274a0; Enerback S, 1997, NATURE, V387, P90, DOI 10.1038/387090a0; Erickson JC, 1996, NATURE, V381, P415, DOI 10.1038/381415a0; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; GELOEN A, 1988, AM J PHYSIOL, V254, pC175, DOI 10.1152/ajpcell.1988.254.1.C175; GLICK Z, 1981, SCIENCE, V213, P1125, DOI 10.1126/science.7268419; GOLDMAN CK, 1985, EUR J PHARMACOL, V115, P11, DOI 10.1016/0014-2999(85)90578-3; Hamann A, 1996, ENDOCRINOLOGY, V137, P21, DOI 10.1210/en.137.1.21; HIMMSHAGEN J, 1995, P SOC EXP BIOL MED, V208, P159, DOI 10.3181/00379727-208-43847A; JUNG RT, 1979, NATURE, V279, P322, DOI 10.1038/279322a0; KLAUS S, 1991, INT J BIOCHEM, V23, P791, DOI 10.1016/0020-711X(91)90062-R; Landsberg L., 1992, WILLIAMS TXB ENDOCRI, P621; Larsen PR, 1992, WILLIAMS TXB ENDOCRI, P357; LEIBOWITZ SF, 1991, BRAIN RES BULL, V27, P333, DOI 10.1016/0361-9230(91)90121-Y; LOWELL BB, 1993, NATURE, V366, P740, DOI 10.1038/366740a0; MCGREGOR IS, 1991, BRAIN RES BULL, V26, P683, DOI 10.1016/0361-9230(91)90161-C; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; ROTHWELL NJ, 1979, NATURE, V281, P31, DOI 10.1038/281031a0; SILVA JE, 1988, MOL ENDOCRINOL, V2, P706, DOI 10.1210/mend-2-8-706; SIVIY SM, 1989, BRAIN RES, V487, P79, DOI 10.1016/0006-8993(89)90942-6; SUSULIC VS, 1995, J BIOL CHEM, V270, P29483, DOI 10.1074/jbc.270.49.29483; THOMAS SA, 1995, NATURE, V374, P643, DOI 10.1038/374643a0; ZOLOVICK AJ, 1982, EUR J PHARMACOL, V77, P265, DOI 10.1016/0014-2999(82)90128-5	25	214	220	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 1	1997	387	6628					94	97		10.1038/387094a0	http://dx.doi.org/10.1038/387094a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WW758	9139828				2022-12-01	WOS:A1997WW75800054
J	Lengauer, C; Kinzler, KW; Vogelstein, B				Lengauer, C; Kinzler, KW; Vogelstein, B			Genetic instability in colorectal cancers	NATURE			English	Article							WILD-TYPE P53; INSITU HYBRIDIZATION; GENOMIC INSTABILITY; CELL-LINES; MUTATIONS; TUMORIGENICITY; AMPLIFICATION; FLUORESCENCE; DEFECTS; TUMORS	It has long been considered that genetic instability is an integral component of human neoplasia(1-3), In a small fraction of tumours, mismatch repair deficiency leads to a microsatellite instability at the nucleotide sequence level(4,5), In other tumours, an abnormal chromosome number (aneuploidy) has suggested an instability, but the nature and magnitude of the postulated instability is a matter of conjecture. We show here that colorectal tumours without microsatellite instability exhibit a striking defect in chromosome segregation, resulting in gains or losses in excess of 10(-2) per chromosome per generation. This form of chromosomal instability reflected a continuing cellular defect that persisted throughout the lifetime of the tumour cell and was not simply related to chromosome number. While microsatellite instability is a recessive trait(6,7), chromosomal instability appeared to be dominant, These data indicate that persistent genetic instability may be critical for the development of all colorectal cancers, and that such instability can arise through two distinct pathways.	HOWARD HUGHES MED INST,BALTIMORE,MD 21231; JOHNS HOPKINS ONCOL CTR,BALTIMORE,MD 21231	Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins Medicine								AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BHATTACHARYYA NP, 1990, P NATL ACAD SCI USA, V87, P7555; BOCKER M, 1996, J PATHOL, V179, P15; Casares S, 1995, ONCOGENE, V11, P2303; Cottu PH, 1996, ONCOGENE, V13, P2727; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; HARTWELL L, 1994, COLD SPRING HARB SYM, V59, P259, DOI 10.1101/SQB.1994.059.01.030; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HEIM S, 1987, CANC CYTOGENETICS; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Huang J, 1996, P NATL ACAD SCI USA, V93, P9049, DOI 10.1073/pnas.93.17.9049; KOI M, 1994, CANCER RES, V54, P4302; LENGAUER C, 1994, GENET ANAL-BIOMOL E, V11, P140, DOI 10.1016/1050-3862(94)90034-5; LICHTER P, 1991, GENET ANAL-BIOMOL E, V8, P24, DOI 10.1016/1050-3862(91)90005-C; LICHTER P, 1992, HUMAN CYTOGENETICS P, P157; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOEB LA, 1991, CANCER RES, V51, P3075; MARRA G, 1995, J NATL CANCER I, V87, P1114, DOI 10.1093/jnci/87.15.1114; MAYER VW, 1990, MUTAT RES, V231, P177, DOI 10.1016/0027-5107(90)90024-X; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; RIED T, 1992, P NATL ACAD SCI USA, V89, P1388, DOI 10.1073/pnas.89.4.1388; RIED T, 1992, GENE CHROMOSOME CANC, V4, P69, DOI 10.1002/gcc.2870040109; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; SHACKNEY SE, 1989, CANCER RES, V49, P3344; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; TANAKA K, 1991, NATURE, V349, P340, DOI 10.1038/349340a0; UMAR A, 1994, J BIOL CHEM, V269, P14367; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	29	1551	1601	2	76	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 10	1997	386	6625					623	627		10.1038/386623a0	http://dx.doi.org/10.1038/386623a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WT273	9121588				2022-12-01	WOS:A1997WT27300063
J	Tong, S; Caddy, D; Short, RV				Tong, S; Caddy, D; Short, RV			Use of dizygotic to monozygotic twinning ratio as a measure of fertility	LANCET			English	Article							QUALITY; SEMEN; RATES	Background Monozygotic (Mt, identical) twinning occurs at a rate of around three per 1000 maternities in all populations, whereas dizygotic (Dz, fraternal) twinning is highly heritable, and varies with age and race, The Dz/Mz twinning ratio reflects the frequency of twin ovulations, and can provide a useful measure of human fertility. Methods 1625 pairs of twins of known sex were born in Tsan Yuk Obstetric Hospital in Hong Kong during the period 1960-95. The yearly Dz/Mz ratio was calculated, and trends were analysed by chi(2) test with the Bonferroni correction. Ages of mothers of all opposite-sexed twins were recorded and trends analysed by ANOVA and linear regression. Findings The Dz/Mz ratio declined significantly from 1.12 in 1960 to 0.05 in 1978 (p<0.001), and then rose significantly to an average of 0.86 in 1994-95 (p<0.003). There was a significant declining trend in age of mothers of opposite-sexed twins from 1960 to 1978 (p<0.001), but there were no significant changes in maternal age after 1978(p=0.38). Interpretation If we are correct in assuming that the frequency of Mt twinning remained constant during the study period, the declining Dz/Mz ratio from 1960 to 1978, which also occurred in many developed countries, could reflect some adverse environmental effect on human fertility. The increasing proportion of Dz twins in the past two decades is probably due to increasing use of ovulation-inducing drugs such as clomiphene citrate, which could mask a serious and continuing decline in human fertility. It is therefore important to continue to monitor the Dz/Mz ratio in the future in this and other subpopulations, after exclusion of any women who have taken drugs that stimulate fertility.	ROYAL HOSP WOMEN,DEPT PERINATAL MED,MELBOURNE,VIC,AUSTRALIA		Tong, S (corresponding author), MONASH UNIV,DEPT PHYSIOL,MELBOURNE,VIC 3168,AUSTRALIA.			Tong, Stephen/0000-0002-2319-0586				AUGER J, 1995, NEW ENGL J MED, V332, P281, DOI 10.1056/NEJM199502023320501; BLAND M, 1992, INTRO MED STAT; Bulmer MG, 1970, BIOL TWINNING MAN; CARLSEN E, 1992, BRIT MED J, V305, P609, DOI 10.1136/bmj.305.6854.609; CHANG KSF, 1960, J ANAT, V94, P543; CHEN CJ, 1987, ACTA GENET MED GEMEL, V36, P335, DOI 10.1017/S0001566000006085; COBORN T, 1996, OUR STOLEN FUTURE; DEROM C, 1993, FERTIL STERIL, V60, P493; IMAIZUMI Y, 1992, ACTA GENET MED GEMEL, V41, P165, DOI 10.1017/S0001566000002373; Irvine S, 1996, BMJ-BRIT MED J, V312, P467, DOI 10.1136/bmj.312.7029.467; James WH, 1995, HUM REPROD, V10, P3042, DOI 10.1093/oxfordjournals.humrep.a135843; JAMES WH, 1982, J BIOSOC SCI, V14, P481, DOI 10.1017/S0021932000014346; Lichtenstein P, 1996, BRIT MED J, V312, P879; ORELEBEKE JF, 1991, ACTA GENET MED GEMEL, V40, P319; Pajarinen J, 1997, BRIT MED J, V314, P13, DOI 10.1136/bmj.314.7073.13; PARAZZINI F, 1994, HUM REPROD, V9, P1784, DOI 10.1093/oxfordjournals.humrep.a138797; SHORT RV, 1984, 1 MED; WOOD JW, 1989, OXFORD REV REPROD B, V11, P61; *WORLD BANK, 1993, WORLD BANK WORLD DEV	19	45	45	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 22	1997	349	9055					843	845		10.1016/S0140-6736(96)10003-9	http://dx.doi.org/10.1016/S0140-6736(96)10003-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WP403	9121260				2022-12-01	WOS:A1997WP40300013
J	Helbing, D; Keltsch, J; Molnar, P				Helbing, D; Keltsch, J; Molnar, P			Modelling the evolution of human trail systems	NATURE			English	Article							ACTIVE WALKER MODELS; GROWTH-PATTERNS	Many human social phenomena, such as cooperation(1-3), the growth of settlements(4), traffic dynamics(5-7) and pedestrian movement(7-10), appear to be accessible to mathematical descriptions that invoke self-organization(11,12). Here we develop a model of pedestrian motion to explore the evolution of trails in urban green spaces such as parks. Our aim is to address such questions as what the topological structures of these trail systems are(13), and whether optimal path systems can be predicted for urban planning. We use an 'active walker' model(14-19) that takes into account pedestrian motion and orientation and the concomitant feedbacks with the surrounding environment. Such models have previously been applied to the study of complex structure formation in physical(14-16), chemical(17) and biological(18,19) systems. We find that our model is able to reproduce many of the observed large-scale spatial features of trail systems.	SCI COMP,D-72070 TUBINGEN,GERMANY; CLARK ATLANTA UNIV,CTR THEORET STUDIES PHYS SYST,ATLANTA,GA 30314	Clark Atlanta University	Helbing, D (corresponding author), UNIV STUTTGART,INST THEORET PHYS,PFAFFENWALDRING 57-3,D-70550 STUTTGART,GERMANY.		Helbing, Dirk/C-6114-2008					AXELROD R, 1988, SCIENCE, V242, P1385, DOI 10.1126/science.242.4884.1385; BENJACOB E, 1994, NATURE, V368, P46, DOI 10.1038/368046a0; CLEARWATER SH, 1991, SCIENCE, V254, P1181, DOI 10.1126/science.254.5035.1181; Eigen M, 1979, HYPERCYCLE; Feistel R, 1989, EVOLUTION COMPLEX SY; HAKEN H, 1987, ADV SYNERGETICS; HELBING D, 1995, PHYS REV E, V51, P4282, DOI 10.1103/PhysRevE.51.4282; Helbing D., 1995, QUANTITATIVE SOCIODY; Helbing D., 1997, VERKEHRSDYNAMIK NEUE; HENDERSON LF, 1971, NATURE, V229, P381, DOI 10.1038/229381a0; HENDERSON LF, 1972, NATURE, V240, P353, DOI 10.1038/240353a0; HERMAN R, 1979, SCIENCE, V204, P148, DOI 10.1126/science.204.4389.148; HERMAN R, 1973, SCIENCE, V179, P918, DOI 10.1126/science.179.4076.918; Hillier B., 1996, SPACE MACHINE CONFIG; KAYSER DR, 1992, PHYSICA A, V191, P17, DOI 10.1016/0378-4371(92)90499-G; LAM L, 1995, CHAOS SOLITON FRACT, V6, P267, DOI 10.1016/0960-0779(95)80033-D; MAKSE HA, 1995, NATURE, V377, P608, DOI 10.1038/377608a0; Nicolis G., 1977, SELF ORG NONEQUILIBR; SCHENK M, 1995, THESIS U STUTTGART; SCHIMANSKYGEIER L, 1995, PHYS LETT A, V207, P140, DOI 10.1016/0375-9601(95)00700-D; SCHWEITZER F, 1994, PHYSICA A, V206, P359, DOI 10.1016/0378-4371(94)90312-3; Stevens A, 1997, MATH BIOSCI INTERAC, P183; TIMMERMANS H, 1992, TRANSPORT RES B-METH, V26, P45, DOI 10.1016/0191-2615(92)90019-S	23	236	251	5	84	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 3	1997	388	6637					47	50		10.1038/40353	http://dx.doi.org/10.1038/40353			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XJ143	9214501	Green Submitted, Bronze			2022-12-01	WOS:A1997XJ14300044
J	Vitek, CR; Redd, SC; Redd, SB; Hadler, SC				Vitek, CR; Redd, SC; Redd, SB; Hadler, SC			Trends in importation of measles to the United States, 1986-1994	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							REPORTING EFFICIENCY	Objectives.-To describe patterns among imported measles cases to the United States. Design.-Descriptive analysis of national case-based surveillance data on measles cases. Setting.-United States in the period 1986 through 1994. Patients.-All reported confirmed cases of measles. Main Outcome Measures.-Demographic variables, immunization history, country of exposure, and reporting state. Results.-The number of reported imported cases of measles to the United States has dropped from an average of 99 cases annually in 1986 through 1988 and 190 cases in 1989 through 1991 to 61 cases in 1992 through 1994. Since 1990, the number of imported cases originating in Latin America declined by 98%, despite continued increase in the number of travelers to this region; cases from other regions remained relatively constant. This decrease paralleled the rapid decrease in measles incidence in the Western Hemisphere associated with national measles elimination programs. Most imported cases occurred among children, although 22% of cases occurred among young adults. Rates of measles cases per 1 million travelers are higher among non-US citizens than among US citizens. Conclusions.-The sharp decline in importations into the United States from Latin America since 1991 provides evidence of the success of measles control efforts undertaken there. The decrease in imported cases has been associated with a decline in total measles cases in the United States. Sustained elimination of measles in the United States will require improved measles control in other countries in addition to a high level of population immunity.			Vitek, CR (corresponding author), CTR DIS CONTROL & PREVENT,NATL IMMUNIZAT PROGRAM,EPIDEMIOL & SURVEILLANCE DIV,MAILSTOP E-61,ATLANTA,GA 30333, USA.							[Anonymous], 1990, MMWR Recomm Rep, V39, P1; *CDCP, 1994, MMWR-MORBID MORTAL W, V43, P57; *CDCP, 1993, MMWR-MORBID MORTAL W, V42, P925; *CDCP, 1978, MMWR-MORBID MORTAL W, V27, P391; Centers for Disease Control and Prevention (CDC), 1995, MMWR Morb Mortal Wkly Rep, V44, P486; CONRAD JL, 1971, AM J PUBLIC HEALTH N, V61, P2304, DOI 10.2105/AJPH.61.11.2304; DAVIS SF, 1993, AM J PUBLIC HEALTH, V83, P1011, DOI 10.2105/AJPH.83.7.1011; deQuadros CA, 1996, JAMA-J AM MED ASSOC, V275, P224, DOI 10.1001/jama.275.3.224; EWERT DP, 1994, AM J PUBLIC HEALTH, V84, P868, DOI 10.2105/AJPH.84.5.868-a; HERSH BS, 1992, JAMA-J AM MED ASSOC, V267, P1936, DOI 10.1001/jama.267.14.1936; *OFF RES US TRAV T, 1994, ABSTR INT TRAV US 19; Rota JS, 1996, J INFECT DIS, V173, P32, DOI 10.1093/infdis/173.1.32; *US IMM NAT SERV, 1996, STAT YB IMM NAT SERV; World Health Organization, 1995, WHO PUBL; 1989, MMWR MORB MORTAL S9, V38, P1; 1996, WKLY EPIDEMIOL REC, V71, P305	16	23	23	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 25	1997	277	24					1952	1956						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XF087	9200636				2022-12-01	WOS:A1997XF08700040
J	Orenstein, JM; Fox, C; Wahl, SM				Orenstein, JM; Fox, C; Wahl, SM			Macrophages as a source of HIV during opportunistic infections	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TUBERCULOSIS; COINFECTION; TYPE-1; AIDS	The source of increasing viremia that characterizes the latter stages of human immunodeficiency virus (HIV) disease has remained a paradox because it occurs at a time when lymphoid tissue is quantitatively and qualitatively impaired, and the patients' CD4 T lymphocytes are steadily declining. Here, macrophages, both infected and uninfected with common opportunistic pathogens of HIV disease such as Mycobacterium avium complex and Pneumocystis carinii, were identified as highly productive sources of HIV in coinfected lymph nodes. These observations indicate that tissue macrophages are not only infected with HIV, but that common pathogens of HIV disease can dramatically increase their production of virus. Thus, prevention or successful treatment of opportunistic coinfections, or both, potentially benefits the patient twofold by limiting the pathology caused by opportunistic infection and by controlling induction of HIV replication.	MOL HISTOL INC,GAITHERSBURG,MD 20879; NIDR,ORAL INFECT & IMMUN BRANCH,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Orenstein, JM (corresponding author), GEORGE WASHINGTON UNIV,DEPT PATHOL,WASHINGTON,DC 20037, USA.				NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012585] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE12585] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; CHIN DP, 1994, J INFECT DIS, V170, P578, DOI 10.1093/infdis/170.3.578; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; CLAYDON EJ, 1991, AIDS, V5, P113, DOI 10.1097/00002030-199101000-00022; COOPER ER, 1997, 4 C RETR OPP INF WAS, P185; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; DENIS M, 1994, CLIN EXP IMMUNOL, V97, P76; Donovan RM, 1996, J INFECT DIS, V174, P401, DOI 10.1093/infdis/174.2.401; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; FAUCI AS, 1993, SCIENCE, V262, P1011, DOI 10.1126/science.8235617; Feinberg MB, 1996, LANCET, V348, P239, DOI 10.1016/S0140-6736(96)06231-9; FOX CH, 1991, J INFECT DIS, V164, P1051, DOI 10.1093/infdis/164.6.1051; GHASSEMI M, 1995, J INFECT DIS, V171, P68, DOI 10.1093/infdis/171.1.68; Goletti D, 1996, J IMMUNOL, V157, P1271; HENG MCY, 1994, LANCET, V343, P255, DOI 10.1016/S0140-6736(94)91110-X; LAZZAROTTO T, 1994, J INFECTION, V28, P287, DOI 10.1016/S0163-4453(94)91843-0; Magro CM, 1996, HUM PATHOL, V27, P1066, DOI 10.1016/S0046-8177(96)90285-3; PANTALEO G, 1994, IMMUNOL REV, V140, P104; PAPE JW, 1993, LANCET, V342, P268, DOI 10.1016/0140-6736(93)91817-6; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; POLI G, 1990, P NATL ACAD SCI USA, V87, P782, DOI 10.1073/pnas.87.2.782; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; TOOSSI Z, 1993, J EXP MED, V177, P1511, DOI 10.1084/jem.177.5.1511; WAHL SM, IN PRESS J LEUKOCYTE; WAHL SM, 1996, IMMUNOLOGY HIV INFEC, P303; WHALEN C, 1995, AM J RESP CRIT CARE, V151, P129, DOI 10.1164/ajrccm.151.1.7812542; Whalen C, 1997, AIDS, V11, P455, DOI 10.1097/00002030-199704000-00008; ZHANG YH, 1995, J CLIN INVEST, V95, P2324, DOI 10.1172/JCI117924	30	445	449	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 20	1997	276	5320					1857	1861		10.1126/science.276.5320.1857	http://dx.doi.org/10.1126/science.276.5320.1857			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XF103	9188531				2022-12-01	WOS:A1997XF10300048
J	Andreasen, NC; OLeary, DS; Flaum, M; Nopoulos, P; Watkins, GL; Ponto, LLB; Hichwa, RD				Andreasen, NC; OLeary, DS; Flaum, M; Nopoulos, P; Watkins, GL; Ponto, LLB; Hichwa, RD			Hypofrontality in schizophrenia: Distributed dysfunctional circuits in neuroleptic-naive patients	LANCET			English	Article							DORSOLATERAL PREFRONTAL CORTEX; POSITRON EMISSION TOMOGRAPHY; CEREBRAL BLOOD-FLOW; GLUCOSE-METABOLISM; PHYSIOLOGIC DYSFUNCTION; ABNORMALITIES; DISORDERS; MEMORY	Background There have been reports that patients with schizophrenia have decreased metabolic activity in prefrontal cortex. However, findings have been confounded by medication effects, chronic illness, and difficulties of measurement. We aimed to address these problems by examination of cerebral blood flow with positron emission tomography (PET). Methods We studied 17 neuroleptic-native patients at the early stages of illness by means of image analysis and statistical methods that can detect abnormalities at the gyral level. Findings An initial omnibus test with a randomisation analysis indicated that patients differed from normal controls at the 0.06 level. In the follow-up analysis, three separate prefrontal regions had decreased perfusion (lateral, orbital, medial), as well as regions in inferior temporal and parietal cortex that are known to be anatomically connected. Regions with increased perfusion were also identified (eg, thalamus, cerebellum, retrosplenial cingulate), which suggests an imbalance in distributed cortical and subcortical circuits. Interpretation These distributed dysfunctional circuits may form the neural basis of schizophrenia through cognitive impairment of the brain, which prevents it from processing input efficiently and producing output effectively, thereby leading to symptoms such as hallucinations, delusions, and loss of volition.	UNIV IOWA,COLL MED,PET IMAGING CTR,IOWA CITY,IA 52242; UNIV IOWA HOSP & CLIN,IOWA CITY,IA 52242	University of Iowa; University of Iowa	Andreasen, NC (corresponding author), UNIV IOWA,COLL MED,MENTAL HLTH CLIN RES CTR,IOWA CITY,IA 52242, USA.			Ponto, Laura/0000-0003-1197-6714; Nopoulos, Peggy/0000-0001-8810-1903; O'Leary, Daniel/0000-0003-1959-6521				ANDREASEN N, 1986, ARCH GEN PSYCHIAT, V43, P136; ANDREASEN NC, 1995, AM J PSYCHIAT, V152, P1576; Andreasen NC, 1996, P NATL ACAD SCI USA, V93, P9985, DOI 10.1073/pnas.93.18.9985; ANDREASEN NC, 1992, ARCH GEN PSYCHIAT, V49, P943; Andreasen NC, 1996, J COMPUT ASSIST TOMO, V20, P98, DOI 10.1097/00004728-199601000-00018; ANDREASEN NC, 1994, JAMA-J AM MED ASSOC, V272, P1763, DOI 10.1001/jama.272.22.1763; ANDREASEN NC, 1995, P NATL ACAD SCI USA, V92, P5111, DOI 10.1073/pnas.92.11.5111; Arndt S, 1996, J CEREBR BLOOD F MET, V16, P1271, DOI 10.1097/00004647-199611000-00023; BENES FM, 1995, NEUROSCIENTIST, V1, P104; BERMAN KF, 1986, ARCH GEN PSYCHIAT, V43, P126; BERMAN KF, 1988, ARCH GEN PSYCHIAT, V45, P616; BILDER RM, 1992, PSYCHOPHARMACOL BULL, V28, P353; BUCHSBAUM MS, 1990, BRIT J PSYCHIAT, V156, P216, DOI 10.1192/bjp.156.2.216; BUCHSBAUM MS, 1982, ARCH GEN PSYCHIAT, V39, P251; CLEGHORN JM, 1989, PSYCHIAT RES, V28, P119, DOI 10.1016/0165-1781(89)90040-1; EARLY TS, 1987, P NATL ACAD SCI USA, V84, P561, DOI 10.1073/pnas.84.2.561; Frith C., 1992, COGNITIVE NEUROPSYCH; Goldman-Rakic P. S., 1987, HDB PHYSL, V5, P373, DOI DOI 10.1002/CPHY.CP010509; GOLDMANRAKIC PS, 1984, NEUROSCIENCE, V12, P719, DOI 10.1016/0306-4522(84)90166-0; GUR RC, 1995, LANCET, V345, P1383, DOI 10.1016/S0140-6736(95)92591-0; GUR RE, 1995, ARCH GEN PSYCHIAT, V52, P657; GUR RE, 1985, ARCH GEN PSYCHIAT, V42, P329; INGVAR DH, 1974, ACTA PSYCHIAT SCAND, V50, P425, DOI 10.1111/j.1600-0447.1974.tb09707.x; LIDDLE PF, 1992, BRIT J PSYCHIAT, V160, P179, DOI 10.1192/bjp.160.2.179; MEGA MS, 1994, J NEUROPSYCH CLIN N, V6, P358; SILBERSWEIG DA, 1995, NATURE, V378, P176, DOI 10.1038/378176a0; SZECHTMAN H, 1988, ARCH GEN PSYCHIAT, V45, P523; VOLKOW ND, 1987, AM J PSYCHIAT, V144, P151; WEINBERGER DR, 1986, ARCH GEN PSYCHIAT, V43, P114; WIESEL FA, 1987, ACTA PSYCHIAT SCAND, V76, P642, DOI 10.1111/j.1600-0447.1987.tb02934.x	30	489	500	1	18	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 14	1997	349	9067					1730	1734		10.1016/S0140-6736(96)08258-X	http://dx.doi.org/10.1016/S0140-6736(96)08258-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XE065	9193383				2022-12-01	WOS:A1997XE06500010
J	Reich, Z; Boniface, JJ; Lyons, DS; Borochov, N; Wachtel, EJ; Davis, MM				Reich, Z; Boniface, JJ; Lyons, DS; Borochov, N; Wachtel, EJ; Davis, MM			Ligand-specific oligomerization of T-cell receptor molecules	NATURE			English	Article							LIPID-LINKED FORM; ANTIGEN RECEPTOR; MHC; EXPRESSION; COMPLEXES	T cells initiate many immune responses through the interaction of their T-cell antigen receptors (TCR) with antigenic peptides bound to major histocompatibility complex (MHC) molecules, This interaction sends a biochemical signal into the T cell by a mechanism that is not clearly understood. We have used quasielastic light scattering (QELS) to show that, in the presence of MHC molecules bound to a full agonist peptide, TCR/peptide-MHC complexes oligomerize in solution to form supramolecular structures at concentrations near the dissociation constant of the binding reaction. The size of the oligomers is concentration dependent and is calculated to contain two to six ternary complexes for the concentrations tested here. This effect is specific as neither molecule forms oligomers by itself, nor were oligomers observed unless the correct peptide was bound to the MHC. These results provide direct evidence for models of T-cell signalling based on the specific assembly of multiple TCR/peptide-MHC complexes(1-4) in which the degree of assembly determines the extent and qualitative nature of the transduced signal(5). They may also explain how T cells maintain sensitivity to antigens present in only low abundance on the antigen-presenting cell.	STANFORD UNIV,DEPT MICROBIOL & IMMUNOL,STANFORD,CA 94305; CTR TECHNOL EDUC HOLON,HOLON,ISRAEL; WEIZMANN INST SCI,CHEM SERV UNIT,IL-76100 REHOVOT,ISRAEL	Stanford University; Weizmann Institute of Science	Reich, Z (corresponding author), STANFORD UNIV,SCH MED,HOWARD HUGHES MED INST,STANFORD,CA 94305, USA.			Davis, Mark/0000-0001-6868-657X				Alam SM, 1996, NATURE, V381, P616, DOI 10.1038/381616a0; BLOOMFIE.V, 1967, BIOPOLYMERS, V5, P135, DOI 10.1002/bip.1967.360050202; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; DAVIS MM, 1995, NATURE, V375, P104, DOI 10.1038/375104a0; FIELDS BA, 1995, SCIENCE, V270, P1821, DOI 10.1126/science.270.5243.1821; Fremont DH, 1996, SCIENCE, V272, P1001, DOI 10.1126/science.272.5264.1001; Garboczi DN, 1996, NATURE, V384, P134, DOI 10.1038/384134a0; Garcia KC, 1996, NATURE, V384, P577, DOI 10.1038/384577a0; Garcia KC, 1996, SCIENCE, V274, P209, DOI 10.1126/science.274.5285.209; GERMAIN RN, 1993, CURR BIOL, V3, P586, DOI 10.1016/0960-9822(93)90004-8; GHOSH P, 1995, NATURE, V378, P457, DOI 10.1038/378457a0; HELDIN CH, 1995, CELL, V80, P200; KIRKWOOD JG, 1954, J POLYM SCI, V12, P1, DOI 10.1002/pol.1954.120120102; KUPFER A, 1989, ANNU REV IMMUNOL, V7, P309, DOI 10.1146/annurev.immunol.7.1.309; LIN AY, 1990, SCIENCE, V249, P677, DOI 10.1126/science.1696397; Lyons DS, 1996, IMMUNITY, V5, P53, DOI 10.1016/S1074-7613(00)80309-X; MATSUI K, 1994, P NATL ACAD SCI USA, V91, P12862, DOI 10.1073/pnas.91.26.12862; MCKEITHAN TW, 1995, P NATL ACAD SCI USA, V92, P5042, DOI 10.1073/pnas.92.11.5042; PROVENCHER SW, 1982, COMPUT PHYS COMMUN, V27, P229, DOI 10.1016/0010-4655(82)90174-6; Rabinowitz JD, 1996, P NATL ACAD SCI USA, V93, P1401, DOI 10.1073/pnas.93.4.1401; SETTE A, 1994, ANNU REV IMMUNOL, V12, P413, DOI 10.1146/annurev.immunol.12.1.413; SYMER DE, 1992, J EXP MED, V176, P1421, DOI 10.1084/jem.176.5.1421; TAKAHAMA Y, 1994, NATURE, V371, P67, DOI 10.1038/371067a0; WETTSTEIN DA, 1991, J EXP MED, V174, P219, DOI 10.1084/jem.174.1.219	24	204	209	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 5	1997	387	6633					617	620		10.1038/42500	http://dx.doi.org/10.1038/42500			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XC522	9177351				2022-12-01	WOS:A1997XC52200059
J	Rapiejko, PJ; Gilmore, R				Rapiejko, PJ; Gilmore, R			Empty site forms of the SRP54 and SR alpha GTPases mediate targeting of ribosome nascent chain complexes to the endoplasmic reticulum	CELL			English	Article							SIGNAL-RECOGNITION PARTICLE; METHIONINE-RICH DOMAIN; GTP-BINDING; PROTEIN TRANSLOCATION; SEQUENCE RECOGNITION; RECEPTOR; MEMBRANE; SUBUNIT; HYDROLYSIS; POLYPEPTIDE	The SRP54 and SR alpha subunits of the signal recognition particle (SRP) and the SRP receptor (SR) undergo a tightly coupled GTPase cycle that mediates the signal sequence-dependent attachment of ribosomes to the Sec61 complex. Here, we show that SRP54 and SR alpha are in the empty site conformation prior to contact between the SRP-ribosome complex and the membrane-bound SR. Cooperative binding of GTP to SRP54 and SR alpha stabilizes the SRP-SR complex and initiates signal sequence transfer from SRP54 to Sec61 alpha. The GTP-bound conformations of SR alpha and SRP54 perform distinct roles, with SR alpha performing a predominant role in complex stabilization. Hydrolysis by both SRP54 and SR alpha is a prerequisite for dissociation of the SRP-SR complex.	UNIV MASSACHUSETTS, SCH MED, DEPT BIOCHEM & MOL BIOL, WORCESTER, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester				Rapiejko, Piotr/0000-0003-3868-0294	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035687] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 35687] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTHOFF SM, 1994, MOL CELL BIOL, V14, P7839, DOI 10.1128/MCB.14.12.7839; ANDREWS DW, 1989, J CELL BIOL, V108, P797, DOI 10.1083/jcb.108.3.797; Bacher G, 1996, NATURE, V381, P248, DOI 10.1038/381248a0; BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CONNOLLY T, 1991, SCIENCE, V252, P1171, DOI 10.1126/science.252.5009.1171; CONNOLLY T, 1993, J CELL BIOL, V123, P799, DOI 10.1083/jcb.123.4.799; CONNOLLY T, 1989, CELL, V57, P599, DOI 10.1016/0092-8674(89)90129-3; CONNOLLY T, 1986, J CELL BIOL, V103, P2253, DOI 10.1083/jcb.103.6.2253; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; Freymann DM, 1997, NATURE, V385, P361, DOI 10.1038/385361a0; GILMORE R, 1983, CELL, V35, P677, DOI 10.1016/0092-8674(83)90100-9; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; Hanein D, 1996, CELL, V87, P721, DOI 10.1016/S0092-8674(00)81391-4; HIGH S, 1991, J CELL BIOL, V113, P25, DOI 10.1083/jcb.113.1.25; HWANG YW, 1987, J BIOL CHEM, V262, P13081; KALIES KU, 1994, J CELL BIOL, V126, P925, DOI 10.1083/jcb.126.4.925; KELLARIS KV, 1991, J CELL BIOL, V114, P21, DOI 10.1083/jcb.114.1.21; KRIEG UC, 1986, P NATL ACAD SCI USA, V83, P8604, DOI 10.1073/pnas.83.22.8604; KURZCHALIA TV, 1986, NATURE, V320, P634, DOI 10.1038/320634a0; LUTCKE H, 1992, EMBO J, V11, P1543, DOI 10.1002/j.1460-2075.1992.tb05199.x; MARKBY DW, 1993, SCIENCE, V262, P1895, DOI 10.1126/science.8266082; MILLER JD, 1995, J CELL BIOL, V128, P273, DOI 10.1083/jcb.128.3.273; MILLER JD, 1994, NATURE, V367, P657, DOI 10.1038/367657a0; MILLER JD, 1993, NATURE, V366, P351, DOI 10.1038/366351a0; Montoya G, 1997, NATURE, V385, P365, DOI 10.1038/385365a0; POWERS T, 1995, SCIENCE, V269, P1422, DOI 10.1126/science.7660124; RAPIEJKO PJ, 1994, MOL BIOL CELL, V5, P887, DOI 10.1091/mbc.5.8.887; RAPIEJKO PJ, 1992, J CELL BIOL, V117, P493, DOI 10.1083/jcb.117.3.493; ROMISCH K, 1989, NATURE, V340, P478, DOI 10.1038/340478a0; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; Ulbrandt ND, 1997, CELL, V88, P187, DOI 10.1016/S0092-8674(00)81839-5; WALTER P, 1981, J CELL BIOL, V91, P545, DOI 10.1083/jcb.91.2.545; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cellbio.10.1.87; Yanachkov I, 1997, MOL PHARMACOL, V51, P47, DOI 10.1124/mol.51.1.47; YOUNG JC, 1995, J BIOL CHEM, V270, P15650, DOI 10.1074/jbc.270.26.15650; ZOPF D, 1990, EMBO J, V9, P4511, DOI 10.1002/j.1460-2075.1990.tb07902.x	39	108	109	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 30	1997	89	5					703	713		10.1016/S0092-8674(00)80253-6	http://dx.doi.org/10.1016/S0092-8674(00)80253-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XB925	9182758	Bronze			2022-12-01	WOS:A1997XB92500007
J	Hale, SP; Auld, DS; Schmidt, E; Schimmel, P				Hale, SP; Auld, DS; Schmidt, E; Schimmel, P			Discrete determinants in transfer RNA for editing and aminoacylation	SCIENCE			English	Article							PHENYLALANINE TRANSFER-RNA; PROTEIN-SYNTHESIS; ESCHERICHIA-COLI; RECOGNITION; SYNTHETASE; ISOLEUCINE; RESOLUTION; SIEVE	During translation errors of aminoacylation are corrected in editing reactions which ensure that an amino acid is stably attached to its corresponding transfer RNA (tRNA). Previous studies have not shown whether the tRNA nucleotides needed for effecting translational editing are the same as or distinct from those required for aminoacylation, but several considerations have suggested that they are the same. Here, designed tRNAs that are highly active for aminoacylation but are not active in translational editing are presented. The editing reaction can be controlled by manipulation of nucleotides at the corner of the L-shaped tRNA. In contrast, these manipulations do not affect aminoacylation. These results demonstrate the segregation of nucleotide determinants for the editing and aminoacylation functions of tRNA.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT)					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM015539, R01GM015539] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM15539] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALDWIN AN, 1966, J BIOL CHEM, V241, P839; ELDRED EW, 1972, J BIOL CHEM, V247, P2961; Fersht A. R., 1985, ENZYME STRUCTURE MEC, P347; FERSHT AR, 1979, BIOCHEMISTRY-US, V18, P2627, DOI 10.1021/bi00579a030; GIEGE R, 1993, PROG NUCLEIC ACID RE, V45, P129, DOI 10.1016/S0079-6603(08)60869-7; Hale SP, 1996, P NATL ACAD SCI USA, V93, P2755, DOI 10.1073/pnas.93.7.2755; HIPPS D, 1995, EMBO J, V14, P4050, DOI 10.1002/j.1460-2075.1995.tb00076.x; JAKUBOWSKI H, 1992, MICROBIOL REV, V56, P412, DOI 10.1128/MMBR.56.3.412-429.1992; KIM SH, 1974, SCIENCE, V185, P435, DOI 10.1126/science.185.4149.435; LADNER JE, 1975, P NATL ACAD SCI USA, V72, P4414, DOI 10.1073/pnas.72.11.4414; Lin L, 1996, NATURE, V384, P33, DOI 10.1038/384033b0; LOFTFIELD RB, 1963, BIOCHEM J, V89, P82, DOI 10.1042/bj0890082; MURAMATSU T, 1988, NATURE, V336, P179, DOI 10.1038/336179a0; NUREKI O, 1994, J MOL BIOL, V236, P710, DOI 10.1006/jmbi.1994.1184; ROBERTUS JD, 1974, NATURE, V250, P546, DOI 10.1038/250546a0; SAKS ME, 1994, ADHESION SCI, V283, P191; SCHMIDT E, 1995, BIOCHEMISTRY-US, V34, P11204, DOI 10.1021/bi00035a028; SCHMIDT E, 1994, SCIENCE, V264, P265, DOI 10.1126/science.8146659; SCHMIDT E, 1996, THESIS MIT CAMBRIDGE, P120; SCHULMAN LH, 1991, PROG NUCLEIC ACID RE, V41, P23; SHEPARD A, 1992, P NATL ACAD SCI USA, V89, P9964, DOI 10.1073/pnas.89.20.9964; Stoll A., 1958, FESTSCHRIFT A STOLL, P597; VARSHNEY U, 1991, J BIOL CHEM, V266, P24712	23	77	79	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 23	1997	276	5316					1250	1252		10.1126/science.276.5316.1250	http://dx.doi.org/10.1126/science.276.5316.1250			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XA497	9157882				2022-12-01	WOS:A1997XA49700041
J	Eggleston, AK; Mitchell, AH; West, SC				Eggleston, AK; Mitchell, AH; West, SC			In vitro reconstitution of the late steps of genetic recombination in E-coli	CELL			English	Article							DNA STRAND EXCHANGE; HOLLIDAY JUNCTION RESOLVASE; COMPLEX IN-VITRO; ESCHERICHIA-COLI; RUVB PROTEINS; RECA PROTEIN; BRANCH MIGRATION; DUPLEX DNA; HOMOLOGOUS RECOMBINATION; REPAIR PROTEINS	Purified proteins have been used to reconstitute an in vitro system for the medial-to-late stages of recombination in E. coli. In this system, RecA protein formed recombination intermediates that were processed by the actions of the RuvA, RuvB, and RuvC proteins. RuvAB was found to promote branch migration, to dissociate the RecA filament, and to modulate the orientation of cleavage of Holliday junction resolution by RuvC. Monoclonal antibodies directed against RuvA, RuvB, or RuvC inhibited resolution in the reconstituted system. Specific protein-protein interactions between the branch migration motor (RuvB) and the resolvase (RuvC) were also observed. These results provide evidence for coordinated action during the late stages of recombination, possibly involving the assembly of a RuvABC branch migration/resolution complex.	IMPERIAL CANC RES FUND, CLARE HALL LABS, S MIMMS EN6 3LD, HERTS, ENGLAND					West, Stephen/0000-0001-8848-9418; Eggleston, Angela/0000-0001-8682-397X; Mitchell, Alison/0000-0003-2001-1738				Adams DE, 1996, J MOL BIOL, V263, P582, DOI 10.1006/jmbi.1996.0600; ADAMS DE, 1995, J MOL BIOL, V247, P404, DOI 10.1006/jmbi.1995.0149; ADAMS DE, 1994, P NATL ACAD SCI USA, V91, P9901, DOI 10.1073/pnas.91.21.9901; ARIYOSHI M, 1994, CELL, V78, P1063, DOI 10.1016/0092-8674(94)90280-1; Bennett RJ, 1996, P NATL ACAD SCI USA, V93, P12217, DOI 10.1073/pnas.93.22.12217; BENNETT RJ, 1993, CELL, V74, P1021, DOI 10.1016/0092-8674(93)90724-5; BENNETT RJ, 1995, J MOL BIOL, V252, P213, DOI 10.1006/jmbi.1995.0489; BENSON FE, 1988, NUCLEIC ACIDS RES, V16, P1541, DOI 10.1093/nar/16.4.1541; CHIU SK, 1990, J BIOL CHEM, V265, P21262; DIXON DA, 1991, CELL, V66, P361, DOI 10.1016/0092-8674(91)90625-9; DUNDERDALE HJ, 1991, NATURE, V354, P506, DOI 10.1038/354506a0; DUNDERDALE HJ, 1994, J BIOL CHEM, V269, P5187; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GRIFFITH J, 1985, BIOCHEMISTRY-US, V24, P158, DOI 10.1021/bi00322a022; HAHN TR, 1988, J BIOL CHEM, V263, P7431; HIOM K, 1995, CELL, V80, P787, DOI 10.1016/0092-8674(95)90357-7; IWASAKI H, 1989, J BACTERIOL, V171, P5276, DOI 10.1128/jb.171.10.5276-5280.1989; IWASAKI H, 1991, EMBO J, V10, P4381, DOI 10.1002/j.1460-2075.1991.tb05016.x; IWASAKI H, 1992, GENE DEV, V6, P2214, DOI 10.1101/gad.6.11.2214; IYPE LE, 1994, J BIOL CHEM, V269, P24967; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.biophys.20.1.539; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; LINDSLEY JE, 1990, J BIOL CHEM, V265, P9043; LLOYD RG, 1996, ESCHERICHIA COLI SAL, P2236; Mahdi AA, 1996, J MOL BIOL, V257, P561, DOI 10.1006/jmbi.1996.0185; MANDAL TN, 1993, J BACTERIOL, V175, P4325, DOI 10.1128/JB.175.14.4325-4334.1993; MITCHELL AH, 1994, J MOL BIOL, V243, P208, DOI 10.1006/jmbi.1994.1648; Mitchell AH, 1996, J BIOL CHEM, V271, P19497, DOI 10.1074/jbc.271.32.19497; MOREL P, 1994, J BIOL CHEM, V269, P19830; MULLER B, 1993, J BIOL CHEM, V268, P17185; MULLER B, 1993, J BIOL CHEM, V268, P17179; PARSONS CA, 1995, EMBO J, V14, P5736, DOI 10.1002/j.1460-2075.1995.tb00260.x; PARSONS CA, 1995, NATURE, V374, P375, DOI 10.1038/374375a0; PARSONS CA, 1993, J MOL BIOL, V232, P397, DOI 10.1006/jmbi.1993.1399; PARSONS CA, 1992, P NATL ACAD SCI USA, V89, P5452, DOI 10.1073/pnas.89.12.5452; PUGH BF, 1987, J BIOL CHEM, V262, P1326; PUGH BF, 1987, J BIOL CHEM, V262, P1337; Rafferty JB, 1996, SCIENCE, V274, P415, DOI 10.1126/science.274.5286.415; ROMAN LJ, 1991, P NATL ACAD SCI USA, V88, P3367, DOI 10.1073/pnas.88.8.3367; SAITO A, 1995, P NATL ACAD SCI USA, V92, P7470, DOI 10.1073/pnas.92.16.7470; Sambrook E., 1989, MOL CLONING LAB MANU; Shah R, 1997, EMBO J, V16, P1464, DOI 10.1093/emboj/16.6.1464; SHAH R, 1994, CELL, V79, P853, DOI 10.1016/0092-8674(94)90074-4; Shan Q, 1996, J MOL BIOL, V257, P756, DOI 10.1006/jmbi.1996.0200; SHARPLES GJ, 1990, MOL GEN GENET, V221, P219, DOI 10.1007/BF00261724; SHARPLES GJ, 1994, EMBO J, V13, P6133, DOI 10.1002/j.1460-2075.1994.tb06960.x; SHIBA T, 1993, MOL GEN GENET, V237, P395, DOI 10.1007/BF00279443; SHIBA T, 1994, NUCL ACIDS S SERIES, V31, P221; Shida T, 1996, J BIOL CHEM, V271, P26105, DOI 10.1074/jbc.271.42.26105; SHINAGAWA H, 1988, J BACTERIOL, V170, P4322, DOI 10.1128/jb.170.9.4322-4329.1988; TSANEVA IR, 1992, MOL GEN GENET, V235, P1, DOI 10.1007/BF00286175; TSANEVA IR, 1992, CELL, V69, P1171, DOI 10.1016/0092-8674(92)90638-S; TSANEVA IR, 1993, P NATL ACAD SCI USA, V90, P1315, DOI 10.1073/pnas.90.4.1315; WANG TCV, 1989, MOL GEN GENET, V216, P315, DOI 10.1007/BF00334370; West SC, 1996, CELL, V86, P177, DOI 10.1016/S0092-8674(00)80088-4; Whitby MC, 1996, J MOL BIOL, V264, P878, DOI 10.1006/jmbi.1996.0684; Yu X, 1997, J MOL BIOL, V266, P217, DOI 10.1006/jmbi.1996.0799	57	105	106	1	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 16	1997	89	4					607	617		10.1016/S0092-8674(00)80242-1	http://dx.doi.org/10.1016/S0092-8674(00)80242-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WZ323	9160752	Bronze			2022-12-01	WOS:A1997WZ32300014
J	Elwood, ET; Larsen, CP; Maurer, MH; Routenberg, KL; Neylan, NF; Whelchel, JD; OBrien, DP; Pearson, TC				Elwood, ET; Larsen, CP; Maurer, MH; Routenberg, KL; Neylan, NF; Whelchel, JD; OBrien, DP; Pearson, TC			Microchimerism and rejection in clinical transplantation	LANCET			English	Article							ALLOGRAFT RECIPIENTS; GRAFT ACCEPTANCE; CELL-MIGRATION; CHIMERISM; KIDNEY; LIVER; TOLERANCE; HEART; PCR	Background Haemopoietic microchimerism has been identified in recipients of solid-organ transplants and is thought by some to be critical for the development and maintenance of immunological tolerance. The aim of this study was to correlate prospectively the persistence of donor cells with clinical outcome in recipients of kidney, kidney and pancreas, and liver transplants. Methods Persistence of donor cells in recipient peripheral blood was assessed at. 3 days, and at 1, 3, 6, and 12 months after transplantation by a two-stage nested PCR technique to detect donor MHC HLA DR gene specifically, A pretransplant blood sample was collected from each patient to serve as an individual negative control, Seven liver, six kidney and pancreas, and 17 kidney patients were enrolled, 12 of the 17 kidney patients and all of the kidney and pancreas, and liver recipients were suitable for analysis. Exact matches for donors and recipients at the HLA DR loci (n=1) or inability to obain primer pair specificity among similar HLA DR types (n=4), meant that we were unable to analyse five patients. Findings Donor DNA was detected in 20 (80%) of 25,ten (40%) of 25, seven (30%) of 23, five (22%) of 23, and six (32%) of 19 recipients at 3 days, and 1, 3, 6 and 12 months post-transplant, respectively. Within individuals, the detection of donor DNA varied over time; only two patients had detectable donor DNA at all times. Analysis of the whole group of transplant patients showed a similar frequency and severity of rejection episodes in patients with and without microchimerism as defined by detectable donor DR genes. Interpretation These data suggest that a significant percentage of the recipients had persistent donor class II DNA in the peripheral circulation for at least 1 year after transplantation, We showed that a pretransplant blood sample is critical to avoid a false-positive result, and suggest that detectable chimerism may vary over time in individual patients, Therefore, analysis of microchimerism with a single, post-transplant analysis may not help in malting clinical decisions for individual patients.	EMORY UNIV,SCH MED,DEPT SURG,ATLANTA,GA 30322; EMORY UNIV,SCH MED,DEPT MED,ATLANTA,GA 30322; EMORY UNIV,SCH MED,DEPT PATHOL,ATLANTA,GA 30322	Emory University; Emory University; Emory University			Larsen, Christian P./B-6906-2012	Larsen, Christian P./0000-0001-6573-2649				ALARD P, 1995, TRANSPLANTATION, V60, P1125, DOI 10.1097/00007890-199511270-00012; BEIN G, 1992, TISSUE ANTIGENS, V39, P68, DOI 10.1111/j.1399-0039.1992.tb01909.x; FONTES P, 1994, LANCET, V344, P151, DOI 10.1016/S0140-6736(94)92756-1; Hisanaga M, 1996, TRANSPLANTATION, V61, P40, DOI 10.1097/00007890-199601150-00010; ILDSTAD ST, 1984, NATURE, V307, P168, DOI 10.1038/307168a0; Ishida H, 1996, TRANSPLANTATION, V62, P126, DOI 10.1097/00007890-199607150-00024; KWOK S, 1994, PCR METH APPL, V3, pS39; LARSEN CP, 1990, J EXP MED, V171, P307, DOI 10.1084/jem.171.1.307; OLERUP P, 1992, TISSUE ANTIGENS, V38, P255; ROLLES K, 1994, LANCET, V343, P263, DOI 10.1016/S0140-6736(94)91113-4; RUDERT WA, 1994, TRANSPLANTATION, V58, P964, DOI 10.1097/00007890-199410270-00022; SCHLITT HJ, 1994, LANCET, V343, P1469, DOI 10.1016/S0140-6736(94)92584-4; SCHLITT HJ, 1993, TRANSPLANTATION, V56, P1001, DOI 10.1097/00007890-199310000-00042; SHARABI Y, 1989, J EXP MED, V169, P493, DOI 10.1084/jem.169.2.493; SOLEZ K, 1993, KIDNEY INT, V44, P411, DOI 10.1038/ki.1993.259; STARZL TE, 1993, HEPATOLOGY, V17, P1127; STARZL TE, 1992, LANCET, V339, P1579, DOI 10.1016/0140-6736(92)91840-5; Starzl TE, 1996, TRANSPLANTATION, V62, P703, DOI 10.1097/00007890-199609150-00035; SUBERBIELLE C, 1994, LANCET, V343, P1468, DOI 10.1016/S0140-6736(94)92583-6	19	121	132	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 10	1997	349	9062					1358	1360		10.1016/S0140-6736(96)09105-2	http://dx.doi.org/10.1016/S0140-6736(96)09105-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WY342	9149698				2022-12-01	WOS:A1997WY34200010
J	Ruff, CB; Trinkaus, E; Holliday, TW				Ruff, CB; Trinkaus, E; Holliday, TW			Body mass and encephalization in Pleistocene Homo	NATURE			English	Article							POSTCRANIAL ROBUSTICITY; BRAIN SIZE; EVOLUTION; ERECTUS; FEMUR	Many dramatic changes in morphology within the genus Homo have occurred over the past 2 million years or more, including large increases in absolute brain size and decreases in postcanine dental size and skeletal robusticity. Body mass, as the 'size' variable against which other morphological features are usually judged, has been important for assessing these changes(1-5). Yet past body mass estimates for Pleistocene Homo have varied greatly, sometimes by as much as 50% for the same individuals(2,3,6-12). Here we show that two independent methods of body-mass estimation yield concordant results when applied to Pleistocene Homo specimens. On the basis of an analysis of 163 individuals, body mass in Pleistocene Homo averaged significantly (about 10%) larger than a representative sample of living humans. Relative to body mass, brain mass in late archaic H. sapiens (Neanderthals) was slightly smaller than in early 'anatomically modern' humans, but the major increase in encephalization within Homo occurred earlier during the Middle Pleistocene (600-150 thousand years before present (kyr BP)), preceded by a long period of stasis extending through the Early Pleistocene (1,800 kyr BP).	UNIV NEW MEXICO,DEPT ANTHROPOL,ALBUQUERQUE,NM 87131; UNIV BORDEAUX 1,CNRS,F-33405 TALENCE,FRANCE; COLL WILLIAM & MARY,DEPT ANTHROPOL,WILLIAMSBURG,VA 23187	University of New Mexico; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; William & Mary	Ruff, CB (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT CELL BIOL & ANAT,725 N WOLFE ST,BALTIMORE,MD 21205, USA.		Klein, Richard G/B-5910-2009					AIELLO LC, 1994, AM J PHYS ANTHROPOL, V95, P409, DOI 10.1002/ajpa.1330950405; BEALS KL, 1984, CURR ANTHROPOL, V25, P301, DOI 10.1086/203138; BROWN F, 1985, NATURE, V316, P788, DOI 10.1038/316788a0; Frayer DW, 1984, ORIGINS MODERN HUMAN, P211; GAULD SC, 1993, AM J PHYS ANTHR S, V16, P93; GRINE FE, 1995, AM J PHYS ANTHROPOL, V97, P151, DOI 10.1002/ajpa.1330970207; Hartwig-Scherer Sigrid, 1994, Courier Forschungsinstitut Senckenberg, V171, P267; HENNEBERG M, 1988, HUM BIOL, V60, P395; HOLLIDAY TW, 1995, THESIS U NEW MEXICO; Hooton EA, 1930, PAPERS PHILLIPS ACAD; Kappelman J, 1996, J HUM EVOL, V30, P243, DOI 10.1006/jhev.1996.0021; LEIGH SR, 1992, AM J PHYS ANTHROPOL, V87, P1, DOI 10.1002/ajpa.1330870102; Martin R.D., 1990, PRIMATE ORIGINS EVOL; MARTIN RD, 1981, NATURE, V293, P57, DOI 10.1038/293057a0; McHenry H.M., 1988, P133; MCHENRY HM, 1992, AM J PHYS ANTHROPOL, V87, P407, DOI 10.1002/ajpa.1330870404; MCHENRY HM, 1994, J HUM EVOL, V27, P77, DOI 10.1006/jhev.1994.1036; MCHENRY HM, 1976, AM J PHYS ANTHROPOL, V45, P77, DOI 10.1002/ajpa.1330450110; PILBEAM D, 1974, SCIENCE, V186, P892, DOI 10.1126/science.186.4167.892; Rightmire G.P., 1986, ANTHROPOS BRNO, V23, P139; RIGHTMIRE GP, 1981, PALEOBIOLOGY, V7, P241, DOI 10.1017/S0094837300004012; RUFF CB, 1993, AM J PHYS ANTHROPOL, V91, P21, DOI 10.1002/ajpa.1330910103; RUFF CB, 1991, AM J PHYS ANTHROPOL, V86, P397, DOI 10.1002/ajpa.1330860306; Ruff Christopher B., 1993, P234; Ruff Christopher B., 1994, Yearbook of Physical Anthropology, V37, P65; STEPHAN H, 1970, PRIMATE BRAIN, P289; TOBIAS PV, 1985, J HUM EVOL, V14, P347, DOI 10.1016/S0047-2484(85)80041-5; TRINKAUS E, 1994, AM J PHYS ANTHROPOL, V93, P1, DOI 10.1002/ajpa.1330930102; Walker Alan, 1993, P411; WOOD B, 1992, NATURE, V355, P783, DOI 10.1038/355783a0	30	545	568	3	108	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 8	1997	387	6629					173	176		10.1038/387173a0	http://dx.doi.org/10.1038/387173a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	WX945	9144286				2022-12-01	WOS:A1997WX94500052
J	Cohen, JD; Perlstein, WM; Braver, TS; Nystrom, LE; Noll, DC; Jonides, J; Smith, EE				Cohen, JD; Perlstein, WM; Braver, TS; Nystrom, LE; Noll, DC; Jonides, J; Smith, EE			Temporal dynamics of brain activation during a working memory task	NATURE			English	Article							SENSORY STIMULATION; CORTEX; SYSTEM	Working memory is responsible for the short-term storage and online manipulation of information necessary for higher cognitive functions, such as language, planning and problem-solving(1,2). Traditionally, working memory has been divided into two types of processes: executive control (governing the encoding manipulation and retrieval of information in working memory) and active maintenance (keeping information available 'online'). It has also been proposed that these two types of processes may be subserved by distinct cortical structures, with the prefrontal cortex housing the executive control processes, and more posterior regions housing the content-specific buffers (for example verbal versus visuospatial) responsible for active maintenance(3,4). However, studies in non-human primates suggest that dorsolateral regions of the prefrontal cortex may alsb be involved in active maintenance(5-8). We have used functional magnetic resonance imaging to examine brain activation in human subjects during performance of a working memory task. We used the temporal resolution of this technique to examine the dynamics of regional activation, and to show that prefrontal cortex along with parietal cortex appears to play a role in active maintenance.	UNIV PITTSBURGH,DEPT PSYCHIAT,PITTSBURGH,PA 15213; UNIV PITTSBURGH,MED CTR,DEPT RADIOL,PITTSBURGH,PA 15213; UNIV MICHIGAN,DEPT PSYCHOL,ANN ARBOR,MI 48109	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Michigan System; University of Michigan	Cohen, JD (corresponding author), CARNEGIE MELLON UNIV,DEPT PSYCHOL,PITTSBURGH,PA 15213, USA.		Noll, Douglas C/D-8124-2014	Noll, Douglas C/0000-0002-0983-3805; Braver, Todd/0000-0002-2631-3393				Awh E, 1996, PSYCHOL SCI, V7, P25, DOI 10.1111/j.1467-9280.1996.tb00662.x; Baddeley A.D., 1986, WORKING MEMORY; BARCH DM, IN PRESS NEUROPSYCHO; BARONE P, 1989, EXP BRAIN RES, V78, P447; Braver TS, 1997, NEUROIMAGE, V5, P49, DOI 10.1006/nimg.1996.0247; COHEN J, 1993, BEHAV RES METH INSTR, V25, P257, DOI 10.3758/BF03204507; Cohen J D, 1994, Hum Brain Mapp, V1, P293, DOI 10.1002/hbm.460010407; Cohen JD, 1996, PHILOS T R SOC B, V351, P1515, DOI 10.1098/rstb.1996.0138; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; DESPOSITO M, 1995, NATURE, V378, P279, DOI 10.1038/378279a0; Fiez JA, 1996, J NEUROSCI, V16, P808; FORMAN SD, 1995, MAGNET RESON MED, V33, P636, DOI 10.1002/mrm.1910330508; FUSTER JM, 1971, SCIENCE, V173, P652, DOI 10.1126/science.173.3997.652; Gathercole S., 1994, NEUROPSYCHOLOGY, V8, P494, DOI DOI 10.1037/0894-4105.8.4.494; Goldman-Rakic P. S., 1987, HDB PHYSL, V5, P373, DOI DOI 10.1002/CPHY.CP010509; JONIDES J, IN PRESS J COGN NEUR; KWONG KK, 1992, P NATL ACAD SCI USA, V89, P5675, DOI 10.1073/pnas.89.12.5675; Miller EK, 1996, J NEUROSCI, V16, P5154; NOLL DC, 1995, JMRI-J MAGN RESON IM, V5, P49, DOI 10.1002/jmri.1880050112; OGAWA S, 1992, P NATL ACAD SCI USA, V89, P5951, DOI 10.1073/pnas.89.13.5951; PAULESU E, 1993, NATURE, V362, P342, DOI 10.1038/362342a0; PETRIDES M, 1991, P ROY SOC B-BIOL SCI, V246, P293, DOI 10.1098/rspb.1991.0157; SAVOY RL, 1995, SOC MAGN RES 3 M INT, P450; Shallice T, 1988, NEUROPSYCHOLOGY MENT, DOI DOI 10.1017/IPM.2020.45; Smith EE, 1996, CEREB CORTEX, V6, P11, DOI 10.1093/cercor/6.1.11; TULVING E, 1994, P NATL ACAD SCI USA, V91, P2012, DOI 10.1073/pnas.91.6.2012; VAZQUEZ AL, 1996, P INT SOC MAGN RES M, P1765; WATERS GS, 1992, J MEM LANG, V31, P54, DOI 10.1016/0749-596X(92)90005-I; WOODS RP, 1992, J COMPUT ASSIST TOMO, V16, P620, DOI 10.1097/00004728-199207000-00024	29	1411	1439	6	147	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 10	1997	386	6625					604	608		10.1038/386604a0	http://dx.doi.org/10.1038/386604a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	WT273	9121583	Green Submitted			2022-12-01	WOS:A1997WT27300058
J	Dove, SL; Joung, JK; Hochschild, A				Dove, SL; Joung, JK; Hochschild, A			Activation of prokaryotic transcription through arbitrary protein-protein contacts	NATURE			English	Article							RNA-POLYMERASE-II; CAMP RECEPTOR PROTEIN; ESCHERICHIA-COLI; LAMBDA-REPRESSOR; SYNERGISTIC ACTIVATION; GENE ACTIVATION; ALPHA-SUBUNIT; PROMOTER; RECOGNITION; INITIATION	Many transcriptional activators in prokaryotes are known to bind near a promoter and contact RNA polymerase(1-5), but it is not dear whether a protein-protein contact between an activator and RNA polymerase is enough to activate gene transcription, Here we show that contact between a DNA-bound protein and a heterologous protein domain fused to RNA polymerase can elicit transcriptional activation; moreover, the strength of this engineered protein-protein interaction determines the amount of gene activation, Our results indicate that an arbitrary interaction between a DNA-bound protein and RNA polymerase can activate transcription. We also find that when the DNA-bound 'activator' makes contact with two different components of the polymerase, the effect of these two interactions on transcription is synergistic.	HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOL GENET,BOSTON,MA 02115	Harvard University; Harvard Medical School					NIH HHS [DP1 OD006862] Funding Source: Medline; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP1OD006862] Funding Source: NIH RePORTER	NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		BACKMAN K, 1978, CELL, V13, P65, DOI 10.1016/0092-8674(78)90138-1; BARBERIS A, 1995, CELL, V81, P359, DOI 10.1016/0092-8674(95)90389-5; BUSBY S, 1994, CELL, V79, P743, DOI 10.1016/0092-8674(94)90063-9; BUSHMAN FD, 1989, CELL, V58, P1163, DOI 10.1016/0092-8674(89)90514-X; CHATTERJEE S, 1995, NATURE, V374, P820, DOI 10.1038/374820a0; DOVE SL, 1994, MOL MICROBIOL, V14, P975, DOI 10.1111/j.1365-2958.1994.tb01332.x; EBRIGHT RH, 1995, CURR OPIN GENET DEV, V5, P197, DOI 10.1016/0959-437X(95)80008-5; Farrell S, 1996, GENE DEV, V10, P2359, DOI 10.1101/gad.10.18.2359; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; HAWLEY DK, 1982, J MOL BIOL, V157, P493, DOI 10.1016/0022-2836(82)90473-9; HOCHSCHILD A, 1988, NATURE, V336, P353, DOI 10.1038/336353a0; ISHIHAMA A, 1993, J BACTERIOL, V175, P2483, DOI 10.1128/JB.175.9.2483-2489.1993; ISHIHAMA A, 1992, MOL MICROBIOL, V6, P3283, DOI 10.1111/j.1365-2958.1992.tb02196.x; JOUNG JK, 1993, P NATL ACAD SCI USA, V90, P3083, DOI 10.1073/pnas.90.7.3083; JOUNG JK, 1994, SCIENCE, V265, P1863, DOI 10.1126/science.8091212; JOUNG JK, 1996, THESIS HARVARD U; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KLAGES N, 1995, NATURE, V374, P822, DOI 10.1038/374822a0; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KULDELL N, 1994, J BACTERIOL, V176, P2991, DOI 10.1128/JB.176.10.2991-2998.1994; LI M, 1994, SCIENCE, V263, P75, DOI 10.1126/science.8272867; Monsalve M, 1996, P NATL ACAD SCI USA, V93, P8913, DOI 10.1073/pnas.93.17.8913; Niu W, 1996, CELL, V87, P1123, DOI 10.1016/S0092-8674(00)81806-1; PTASHNE M, 1992, GENETIC SWITCH GENE; ROSS W, 1993, SCIENCE, V262, P1407, DOI 10.1126/science.8248780; SAUER R, 1979, THESIS HARVARD U; Sauer R T, 1990, Adv Protein Chem, V40, P1, DOI 10.1016/S0065-3233(08)60286-7; TANG H, 1994, GENE DEV, V8, P3058, DOI 10.1101/gad.8.24.3058; WHIPPLE FW, 1994, GENE DEV, V8, P1212, DOI 10.1101/gad.8.10.1212; XIAO H, 1995, MOL CELL BIOL, V15, P5757	30	214	234	0	26	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 10	1997	386	6625					627	630		10.1038/386627a0	http://dx.doi.org/10.1038/386627a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WT273	9121589				2022-12-01	WOS:A1997WT27300064
J	Mukherjee, R; Davies, PJA; Crombie, DL; Bischoff, ED; Cesario, RM; Jow, L; Hamann, LG; Boehm, MF; Mondon, CE; Nadzan, AM; Paterniti, JR; Heyman, RA				Mukherjee, R; Davies, PJA; Crombie, DL; Bischoff, ED; Cesario, RM; Jow, L; Hamann, LG; Boehm, MF; Mondon, CE; Nadzan, AM; Paterniti, JR; Heyman, RA			Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists	NATURE			English	Article							THYROID-HORMONE; NUCLEAR RECEPTOR; RESPONSE PATHWAY; AGENT CS-045; ACID; LIGAND; BINDING; CLONING; ANALOGS; GAMMA	Retinoic acid receptors (RAR), thyroid hormone receptors (TR), peroxisome proliferator activated receptors (PPARs) and the orphan receptor, LXR, bind preferentially to DNA as heterodimers with a common partner, retinoid X receptor (RXR), to regulate transcription(1-6). We investigated whether RXR-selective agonists replicate the activity of ligands for several of these receptors! We demonstrate here that RXR-selective ligands (referred to as rexinoids) function as RXR heterodimer-selective agonists, activating RXR: PPAR gamma and RXR:LXR dimers but not RXR:RAR or RXR:TR heterodimers. Because PPAR gamma is a target for antidiabetic agents, we investigated whether RXR ligands could alter insulin and glucose signalling. In mouse models of noninsulin-dependent diabetes mellitus (NIDDM) and obesity, RXR agonists function as insulin sensitizers and can decrease hyperglycaemia, hypertriglyceridaemia and hyperinsulinaemia, This antidiabetic activity can be further enhanced by combination treatment with PPAR gamma agonists, such as thiazolidinediones. These data suggest that the RXR:PPAR gamma heterodimer is a single-function complex serving as a molecular target for treatment of insulin resistance, Activation of the RXR:PPAR gamma dimer with rexinoids may provide a new and effective treatment for NIDDM.	LIGAND PHARMACEUT,DEPT RETINOID RES,SAN DIEGO,CA 92121; LIGAND PHARMACEUT,DEPT CARDIOVASC RES,SAN DIEGO,CA 92121; LIGAND PHARMACEUT,DEPT RETINOID CHEM,SAN DIEGO,CA 92121; LIGAND PHARMACEUT,DEPT ENDOCRINE CHEM,SAN DIEGO,CA 92121; UNIV TEXAS,HLTH SCI CTR,SCH MED,DEPT PHARMACOL & MED,HOUSTON,TX 77225; METABOLEX INC,HAYWARD,CA 94545	Ligand Pharmaceuticals; Ligand Pharmaceuticals; Ligand Pharmaceuticals; Ligand Pharmaceuticals; University of Texas System; University of Texas Health Science Center Houston								BERGER TS, 1992, J STEROID BIOCHEM, V41, P733, DOI 10.1016/0960-0760(92)90414-E; BOEHM MF, 1995, J MED CHEM, V38, P3146, DOI 10.1021/jm00016a018; BOEHM MF, 1994, J MED CHEM, V37, P2930, DOI 10.1021/jm00044a014; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FUJIWARA T, 1988, DIABETES, V37, P1549, DOI 10.2337/diabetes.37.11.1549; INGALLS AM, 1950, J HERED, V41, P317, DOI 10.1093/oxfordjournals.jhered.a106073; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; Lala DS, 1996, NATURE, V383, P450, DOI 10.1038/383450a0; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MONDON CE, 1981, AM J PHYSIOL, V240, pE482, DOI 10.1152/ajpendo.1981.240.5.E482; Mukherjee R, 1997, J BIOL CHEM, V272, P8071, DOI 10.1074/jbc.272.12.8071; SPORN MB, 1976, FED PROC, V35, P1332; SUTER SL, 1992, DIABETES CARE, V15, P193, DOI 10.2337/diacare.15.2.193; Trinder P, 1969, ANNALS CLINICAL BIOC, V6, P24, DOI DOI 10.1177/000456326900600108; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; Willson TM, 1996, J MED CHEM, V39, P665, DOI 10.1021/jm950395a; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	29	540	583	3	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 27	1997	386	6623					407	410		10.1038/386407a0	http://dx.doi.org/10.1038/386407a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WQ170	9121558				2022-12-01	WOS:A1997WQ17000067
J	Hata, A; Lo, RS; Wotton, D; Lagna, G; Massague, J				Hata, A; Lo, RS; Wotton, D; Lagna, G; Massague, J			Mutations increasing autoinhibition inactivate tumour suppressors Smad2 and Smad4	NATURE			English	Article							BETA	Smad2 and Smad4 are related tumour-suppressor proteins(1,2), which, when stimulated by the growth factor TGF-beta, form a complex to inhibit growth(3). The effector function of Smad2 and Smad4 is located in the conserved carboxy-terminal domain (C domain) of these proteins and is inhibited by the presence of their amino-terminal domains (N domain)(4,5). This inhibitory function of the N domain is shown here to involve an interaction with the C domain that prevents the association of Smad2 with Smad4. This inhibitory function is increased in tumour-derived forms of Smad2 and 4 that carry a missense mutation in a conserved N domain arginine residue. The mutant N domains have an increased affinity for their respective C domains, inhibit the Smad2-Smad4 interaction, and prevent TGF beta-induced Smad2-Smad4 association and signalling. Whereas mutations in the C domain disrupt the effector function of the Smad proteins, N-domain arginine mutations inhibit SMAD signalling through a g-ain of autoinhibitory function. Gain of autoinhibitory function isa new mechanism for inactivating tumour suppressors.	ROCKEFELLER UNIV,CELL BIOL LAB,NEW YORK,NY 10021; ROCKEFELLER UNIV,HOWARD HUGHES MED INST,MEM SLOAN KETTERING CANC CTR,NEW YORK,NY 10021; ROCKEFELLER UNIV,MOL EMBRYOL LAB,NEW YORK,NY 10021	Rockefeller University; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Rockefeller University; Rockefeller University				Massague, Joan/0000-0001-9324-8408; Wotton, David/0000-0002-4652-5350				Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; Barrett MT, 1996, CANCER RES, V56, P4351; Bartel PL, 1993, CELLULAR INTERACTION, P153; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HEMMATIBRIVANLOU A, 1994, CELL, V77, P273, DOI 10.1016/0092-8674(94)90319-0; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Kim SK, 1996, CANCER RES, V56, P2519; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; Nagatake M, 1996, CANCER RES, V56, P2718; Riggins GJ, 1996, NAT GENET, V13, P347, DOI 10.1038/ng0796-347; Schutte M, 1996, CANCER RES, V56, P2527; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; Uchida K, 1996, CANCER RES, V56, P5583; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	24	295	308	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 3	1997	388	6637					82	87		10.1038/40424	http://dx.doi.org/10.1038/40424			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XJ143	9214507	Bronze			2022-12-01	WOS:A1997XJ14300055
J	Lappalainen, P; Drubin, DG				Lappalainen, P; Drubin, DG			Cofilin promotes rapid actin filament turnover in vivo	NATURE			English	Article							DEPOLYMERIZING FACTOR; SACCHAROMYCES-CEREVISIAE; INTERNALIZATION STEP; GENE ENCODES; YEAST; CYTOSKELETON; ENDOCYTOSIS; POLYMERIZATION; ORGANIZATION; INHIBITION	The ability of actin filaments to function in cell morphogenesis and motility is coupled to their capacity for rapid assembly and disassembly. Because disassembly in vitro is much slower than in vivo, cellular factors that stimulate disassembly have long been assumed to exist. Although numerous proteins can affect actin dynamics in vitro, demonstration of in vivo relevance of these effects has not been achieved. We have used genetics and an actin-inhibitor in yeast to demonstrate that rapid cycles of actin assembly and disassembly depend on the small actin-binding protein cofilin, and that cofilin stimulates filament disassembly. These results may explain why cofilin is ubiquitous in eukaryotes and is essential for viability in every organism in which its function has been tested genetically. Magnitudes of disassembly defects in cofilin mutants in vivo were found to be correlated closely with the magnitudes of disassembly defects observed in vitro, supporting our conclusions. Furthermore, these cofilin mutants provided an opportunity to distinguish in living cells those actin functions that depend specifically on filament turnover (endocytosis) from those that do not (cortical actin patch motility).	UNIV CALIF BERKELEY, DEPT MOL & CELL BIOL, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley				Lappalainen, Pekka/0000-0001-6227-0354				Abe H, 1996, J CELL BIOL, V132, P871, DOI 10.1083/jcb.132.5.871; ADAMS AEM, 1991, NATURE, V354, P404, DOI 10.1038/354404a0; AGNEW BJ, 1995, J BIOL CHEM, V270, P17582, DOI 10.1074/jbc.270.29.17582; Ausubel FA, 1990, CURRENT PROTOCOLS MO; Ayscough KR, 1997, J CELL BIOL, V137, P399, DOI 10.1083/jcb.137.2.399; BAMBURG JR, 1980, FEBS LETT, V121, P178, DOI 10.1016/0014-5793(80)81292-0; BENEDETTI H, 1994, MOL BIOL CELL, V5, P1023, DOI 10.1091/mbc.5.9.1023; Buzan JM, 1996, P NATL ACAD SCI USA, V93, P91, DOI 10.1073/pnas.93.1.91; Carlier MF, 1997, J CELL BIOL, V136, P1307, DOI 10.1083/jcb.136.6.1307; COUE M, 1987, FEBS LETT, V213, P316, DOI 10.1016/0014-5793(87)81513-2; Doyle T, 1996, P NATL ACAD SCI USA, V93, P3886, DOI 10.1073/pnas.93.9.3886; DULIC V, 1991, METHOD ENZYMOL, V194, P697; FREEMAN NL, 1995, J BIOL CHEM, V270, P5680, DOI 10.1074/jbc.270.10.5680; Geli MI, 1996, SCIENCE, V272, P533, DOI 10.1126/science.272.5261.533; Goodson HV, 1996, J CELL BIOL, V133, P1277, DOI 10.1083/jcb.133.6.1277; GUNSALUS KC, 1995, J CELL BIOL, V131, P1243, DOI 10.1083/jcb.131.5.1243; HAWKINS M, 1993, BIOCHEMISTRY-US, V32, P9985, DOI 10.1021/bi00089a014; HAYDEN SM, 1993, BIOCHEMISTRY-US, V32, P9994, DOI 10.1021/bi00089a015; HOLTZMAN DA, 1993, J CELL BIOL, V122, P635, DOI 10.1083/jcb.122.3.635; KUBLER E, 1993, EMBO J, V12, P2855, DOI 10.1002/j.1460-2075.1993.tb05947.x; Lila T, 1997, MOL BIOL CELL, V8, P367, DOI 10.1091/mbc.8.2.367; MCKIM KS, 1994, MOL GEN GENET, V242, P346, DOI 10.1007/BF00280425; MOON A, 1995, MOL BIOL CELL, V6, P1423, DOI 10.1091/mbc.6.11.1423; MOON AL, 1993, J CELL BIOL, V120, P421, DOI 10.1083/jcb.120.2.421; MULHOLLAND J, 1994, J CELL BIOL, V125, P381, DOI 10.1083/jcb.125.2.381; Rosenblatt J, 1997, J CELL BIOL, V136, P1323, DOI 10.1083/jcb.136.6.1323; Waddle JA, 1996, J CELL BIOL, V132, P861, DOI 10.1083/jcb.132.5.861; WELCH MD, 1997, OPIN CELL BIOL, V9, P54; YONEZAWA N, 1985, J BIOL CHEM, V260, P4410; YONEZAWA N, 1990, J BIOL CHEM, V265, P8382	30	366	369	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 3	1997	388	6637					78	82		10.1038/40418	http://dx.doi.org/10.1038/40418			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XJ143	9214506	Bronze			2022-12-01	WOS:A1997XJ14300054
J	Babcock, M; deSilva, D; Oaks, R; DavisKaplan, S; Jiralerspong, S; Montermini, L; Pandolfo, M; Kaplan, J				Babcock, M; deSilva, D; Oaks, R; DavisKaplan, S; Jiralerspong, S; Montermini, L; Pandolfo, M; Kaplan, J			Regulation of mitochondrial iron accumulation by Yfh1p, a putative homolog of frataxin	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; FRIEDREICHS ATAXIA	The gene responsible for Friedreich's ataxia, a disease characterized by neurodegeneration and cardiomyopathy, has recently been cloned and its product designated frataxin. A gene in Saccharomyces cerevisiae was characterized whose predicted protein product has high sequence similarity to the human frataxin protein. The yeast gene (yeast frataxin homolog, YFH1) encodes a mitochondrial protein involved in iron homeostasis and respiratory function. Human frataxin also was shown to be a mitochondrial protein. Characterizing the mechanism by which YFH1 regulates iron homeostasis in yeast may help to define the pathologic process leading to cell damage in Friedreich's ataxia.	UNIV UTAH, SCH MED, DEPT PATHOL, DIV CELL BIOL & IMMUNOL, SALT LAKE CITY, UT 84132 USA; CTR RECH LOUIS CHARLES SIMARD, MONTREAL, PQ H2L 4M1, CANADA; UNIV MONTREAL, DEPT MED, MONTREAL, PQ H2L 4M1, CANADA; MCGILL UNIV, DEPT NEUROL & NEUROSURG, MONTREAL, PQ H3A 2B4, CANADA	Utah System of Higher Education; University of Utah; Universite de Montreal; Universite de Montreal; McGill University			Pandolfo, Massimo/B-2853-2010		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030534, R37DK030534, P50DK049219] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034192] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK30534, DK49219] Funding Source: Medline; NINDS NIH HHS [NS34192] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Askwith C, 1997, J BIOL CHEM, V272, P401; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; BARBEAU A, 1980, CAN J NEUROL SCI, V7, P455, DOI 10.1017/S0317167100023064; BENHAMIDA M, 1993, NEUROLOGY, V43, P2179, DOI 10.1212/WNL.43.11.2179; BLASS JP, 1976, NEW ENGL J MED, V295, P62, DOI 10.1056/NEJM197607082950202; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; Carvajal JJ, 1996, NAT GENET, V14, P157, DOI 10.1038/ng1096-157; CHAMBERLAIN S, 1982, J NEUROL NEUROSUR PS, V45, P1136, DOI 10.1136/jnnp.45.12.1136; Cossee M, 1997, NAT GENET, V15, P337, DOI 10.1038/ng0497-337; DIJKSTRA UJ, 1983, ANN NEUROL, V13, P325, DOI 10.1002/ana.410130317; Durr A, 1996, NEW ENGL J MED, V335, P1169, DOI 10.1056/NEJM199610173351601; Filla A, 1996, AM J HUM GENET, V59, P554; FINOCCHIARO G, 1988, NEUROLOGY, V38, P1292, DOI 10.1212/WNL.38.8.1292; GEOFFROY G, 1976, Canadian Journal of Neurological Sciences, V3, P279; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; HARDING AE, 1981, BRAIN, V104, P589, DOI 10.1093/brain/104.3.589; HARDING AE, 1993, ADV NEUROL, V61, P1; HARDING AE, 1983, Q J MED, V52, P489; JIRALERSPONG S, IN PRESS NEUROBIOL D; Lamarche J., 1993, HDB CEREBELLAR DIS, P453; Montermini L, 1997, ANN NEUROL, V41, P675, DOI 10.1002/ana.410410518; MORGAN RO, 1979, CAN J NEUROL SCI, V6, P227, DOI 10.1017/S0317167100119699; NAKAI K, 1991, B I CHEM RES KYOTO U, V69, P269; Niedenthal RK, 1996, YEAST, V12, P773, DOI 10.1002/(SICI)1097-0061(19960630)12:8<773::AID-YEA972>3.3.CO;2-C; Schols L, 1996, EUR J NEUROL, V3, P55, DOI 10.1111/j.1468-1331.1996.tb00190.x; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; STUMPF DA, 1982, NEUROLOGY, V32, P221, DOI 10.1212/WNL.32.3.221; THOMAS SM, 1989, BIOCHIM BIOPHYS ACTA, V1002, P189, DOI 10.1016/0005-2760(89)90286-5; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x	30	756	775	1	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 13	1997	276	5319					1709	1712		10.1126/science.276.5319.1709	http://dx.doi.org/10.1126/science.276.5319.1709			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XD947	9180083				2022-12-01	WOS:A1997XD94700046
J	Cwirla, SE; Balasubramanian, P; Duffin, DJ; Wagstrom, CR; Gates, CM; Singer, SC; Davis, AM; Tansik, RL; Mattheakis, LC; Boytos, CM; Schatz, PJ; Baccanari, DP; Wrighton, NC; Barrett, RW; Dower, WJ				Cwirla, SE; Balasubramanian, P; Duffin, DJ; Wagstrom, CR; Gates, CM; Singer, SC; Davis, AM; Tansik, RL; Mattheakis, LC; Boytos, CM; Schatz, PJ; Baccanari, DP; Wrighton, NC; Barrett, RW; Dower, WJ			Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine	SCIENCE			English	Article							FILAMENTOUS PHAGE; LIGANDS; MPL; SUPERFAMILY; INTERFACE; LIBRARIES; INSERTION; HORMONE; DOMAIN	Two families of small peptides that bind to the human thrombopoietin receptor and compete with the binding of the natural ligand thrombopoietin (TPO) were identified from recombinant peptide libraries, The sequences of these peptides were not found in the primary sequence of TPO, Screening libraries of variants of one of these families under affinity-selective conditions yielded a 14-amino acid peptide (Ile-Glu-Gly-Pro-Thr-Leu-Arg-Gln-Trp-Leu-Ala-Ala-Arg-Ala) with high affinity (dissociation constant approximate to 2 nanomolar) that stimulates the proliferation of a TPO-responsive Ba/F3 cell line with a median effective concentration (EC50) of 400 nanomolar, Dimerization of this peptide by a carboxyl-terminal linkage to a lysine branch produced a compound with an EC50 of 100 picomolar, which was equipotent to the 332-amino acid natural cytokine in cell-based assays, The peptide dimer also stimulated the in vitro proliferation and maturation of megakaryocytes from human bone marrow cells and promoted an increase in platelet count when administered to normal mice.	AFFYMAX RES INST,PALO ALTO,CA 94304; GLAXO WELLCOME INC,RES INST,RES TRIANGLE PK,NC 27709	GlaxoSmithKline								ALEXANDER WS, 1995, EMBO J, V14, P5569, DOI 10.1002/j.1460-2075.1995.tb00244.x; BARRETT RW, 1992, ANAL BIOCHEM, V204, P357, DOI 10.1016/0003-2697(92)90252-3; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CULL MG, 1992, P NATL ACAD SCI USA, V89, P1865, DOI 10.1073/pnas.89.5.1865; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DOMSIFE R, 1991, ANTIMICROB AGENTS CH, V35, P322; DUFFIN DJ, UNPUB; Gates CM, 1996, J MOL BIOL, V255, P373, DOI 10.1006/jmbi.1996.0031; KAUSHANSKY K, 1994, NATURE, V369, P568, DOI 10.1038/369568a0; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; MARTENS CL, 1995, J BIOL CHEM, V270, P21129, DOI 10.1074/jbc.270.36.21129; Mattheakis LC, 1996, METHOD ENZYMOL, V267, P195; MATTHEAKIS LC, 1994, P NATL ACAD SCI USA, V91, P9022, DOI 10.1073/pnas.91.19.9022; MCCONNELL HM, 1992, SCIENCE, V257, P1906, DOI 10.1126/science.1329199; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PETERS EA, 1994, J BACTERIOL, V176, P4296, DOI 10.1128/jb.176.14.4296-4305.1994; Schatz PJ, 1996, METHOD ENZYMOL, V267, P171; VIGON I, 1992, P NATL ACAD SCI USA, V89, P5640, DOI 10.1073/pnas.89.12.5640; WHITEHORN EA, 1995, BIO-TECHNOL, V13, P1215, DOI 10.1038/nbt1195-1215; Wrighton N. C., 1996, Blood, V88, p543A; Wrighton NC, 1996, SCIENCE, V273, P458, DOI 10.1126/science.273.5274.458; Yanofsky SD, 1996, P NATL ACAD SCI USA, V93, P7381, DOI 10.1073/pnas.93.14.7381; YMER S, 1985, NATURE, V317, P255, DOI 10.1038/317255a0	24	348	457	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 13	1997	276	5319					1696	1699		10.1126/science.276.5319.1696	http://dx.doi.org/10.1126/science.276.5319.1696			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XD947	9180079				2022-12-01	WOS:A1997XD94700042
J	Wagner, S; Castel, M; Gainer, H; Yarom, Y				Wagner, S; Castel, M; Gainer, H; Yarom, Y			GABA in the mammalian suprachiasmatic nucleus and its role in diurnal rhythmicity	NATURE			English	Article							NEURONS; CLOCK; ACID; NEUROTRANSMISSION; HYPOTHALAMUS; MECHANISMS; RESPONSES; RECEPTORS; HAMSTER	Mammals manifest circadian behaviour timed by an endogenous clock in the hypothalamic suprachiasmatic nucleus (SCN)(1). Considerable progress has been made in identifying the molecular basis of the circadian clock(2,3), but the mechanisms by which it is translated into cyclic firing activity, high during the day and low at night, are still poorly understood. GABA (gamma-aminobutyric acid), a common inhibitory neurotransmitter in the central nervous system, is particularly densely distributed within the SCN, where it is located in the majority of neuronal somata(4,5) and synaptic terminals(6,7). Using an in vitro brain-slice technique, we have now studied the effect of bath-applied GABA on adult SCN neurons at various times of the day. We find that GABA acts as an inhibitory neurotransmitter at night, decreasing the firing frequency; but during the day GABA acts as an excitatory neurotransmitter, increasing the firing frequency. We show that this dual effect, which is mediated by GABA(A) receptors, may be attributed to an oscillation in intracellular chloride concentration. A likely explanation is that the amplitude of the oscillation in firing rate, displayed by individual neurons, is amplified by the dual effect of GABA in the SCN's GABAergic network.	HEBREW UNIV JERUSALEM,INST LIFE SCI,DEPT CELL & ANIM BIOL,IL-91904 JERUSALEM,ISRAEL; NINCDS,NEUROCHEM LAB,NIH,BETHESDA,MD 20892	Hebrew University of Jerusalem; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Wagner, S (corresponding author), HEBREW UNIV JERUSALEM,INST LIFE SCI,DEPT NEUROBIOL,IL-91904 JERUSALEM,ISRAEL.			Wagner, Shlomo/0000-0002-7618-0752				ANDERSEN P, 1980, J PHYSIOL-LONDON, V305, P279, DOI 10.1113/jphysiol.1980.sp013363; Belenky M, 1996, NEUROSCIENCE, V70, P127, DOI 10.1016/0306-4522(95)00327-F; BOS NPA, 1993, BRAIN RES BULL, V31, P67, DOI 10.1016/0361-9230(93)90012-Z; BUIJS RM, 1994, J COMP NEUROL, V340, P381, DOI 10.1002/cne.903400308; BUIJS RM, 1995, J COMP NEUROL, V358, P343, DOI 10.1002/cne.903580304; CASTEL M, 1993, EUR J NEUROSCI, V5, P368, DOI 10.1111/j.1460-9568.1993.tb00504.x; CASTEL M, 1990, EUR J NEUROSCI, V3, P111; CHERUBINI E, 1991, TRENDS NEUROSCI, V14, P515, DOI 10.1016/0166-2236(91)90003-D; COLLINGE J, 1994, NATURE, V370, P295, DOI 10.1038/370295a0; DECAVEL C, 1990, J COMP NEUROL, V302, P1019, DOI 10.1002/cne.903020423; Estibeiro JP, 1996, TRENDS NEUROSCI, V19, P257, DOI 10.1016/S0166-2236(96)30010-6; Gillette MU, 1991, SUPRACHIASMATIC NUCL, P125; Klein D.C., 1991, SUPRACHIASMATIC NUCL; LIOU SY, 1990, BRAIN RES BULL, V25, P93, DOI 10.1016/0361-9230(90)90257-Z; MASON R, 1991, BRAIN RES, V552, P53, DOI 10.1016/0006-8993(91)90659-J; MOORE RY, 1993, NEUROSCI LETT, V150, P112, DOI 10.1016/0304-3940(93)90120-A; MYERS MP, 1995, SCIENCE, V270, P805, DOI 10.1126/science.270.5237.805; OBRIETAN K, 1995, J NEUROSCI, V15, P5065; OKAMURA H, 1989, NEUROSCI LETT, V102, P131, DOI 10.1016/0304-3940(89)90067-0; PAGE TL, 1994, SCIENCE, V263, P1570, DOI 10.1126/science.8128243; PROSSER RA, 1989, J NEUROSCI, V9, P1073; RALPH MR, 1989, J NEUROSCI, V9, P2858; SMITH RD, 1990, BRAIN RES, V530, P275, DOI 10.1016/0006-8993(90)91295-R; STALEY KJ, 1995, SCIENCE, V269, P977, DOI 10.1126/science.7638623; Strecker G. J., 1994, Society for Neuroscience Abstracts, V20, P1439; STRECKER GJ, 1995, SEMIN NEUROSCI, V7, P43, DOI 10.1016/1044-5765(95)90016-0; Tobler I, 1996, NATURE, V380, P639, DOI 10.1038/380639a0; WELSH DK, 1995, NEURON, V14, P697, DOI 10.1016/0896-6273(95)90214-7	28	272	273	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 5	1997	387	6633					598	603		10.1038/42468	http://dx.doi.org/10.1038/42468			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XC522	9177347				2022-12-01	WOS:A1997XC52200055
J	Lip, GYH				Lip, GYH			Does paroxysmal atrial fibrillation confer a paroxysmal thromboembolic risk?	LANCET			English	Editorial Material							SPONTANEOUS ECHO CONTRAST; EMBOLIC COMPLICATIONS				Lip, GYH (corresponding author), UNIV BIRMINGHAM,CITY HOSP,DEPT MED,HAEMOSTASIS THROMBOSIS & VASC BIOL UNIT,BIRMINGHAM B18 7QH,W MIDLANDS,ENGLAND.							*ATR FIBR INV, 1994, ARCH INTERN MED, V154, P1449; BLACK IW, 1993, J AM COLL CARDIOL, V21, P451, DOI 10.1016/0735-1097(93)90688-W; FATKIN D, 1994, AM J CARDIOL, V73, P672, DOI 10.1016/0002-9149(94)90932-6; KANNEL WB, 1983, AM HEART J, V106, P389, DOI 10.1016/0002-8703(83)90208-9; LIP GYH, 1995, INT J CARDIOL, V51, P245, DOI 10.1016/0167-5273(95)02434-X; LIP GYH, 1995, LANCET, V346, P1313, DOI 10.1016/S0140-6736(95)92339-X; Lip GYH, 1996, AM HEART J, V131, P724, DOI 10.1016/S0002-8703(96)90278-1; Lip GYH, 1996, BRIT MED J, V312, P45, DOI 10.1136/bmj.312.7022.45; OBARSKI TP, 1990, AM HEART J, V120, P988, DOI 10.1016/0002-8703(90)90224-L; PETERSEN P, 1986, STROKE, V17, P622, DOI 10.1161/01.STR.17.4.622; PETERSEN P, 1989, ACTA NEUROL SCAND, V79, P482, DOI 10.1111/j.1600-0404.1989.tb03818.x; ROY D, 1986, AM HEART J, V112, P1039, DOI 10.1016/0002-8703(86)90318-2; Sohara H, 1997, J AM COLL CARDIOL, V29, P106, DOI 10.1016/S0735-1097(96)00427-5	13	25	26	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 31	1997	349	9065					1565	1566		10.1016/S0140-6736(05)61624-8	http://dx.doi.org/10.1016/S0140-6736(05)61624-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XB673	9174554				2022-12-01	WOS:A1997XB67300003
J	Rossjohn, J; Feil, SC; McKinstry, WJ; Tweten, RK; Parker, MW				Rossjohn, J; Feil, SC; McKinstry, WJ; Tweten, RK; Parker, MW			Structure of a cholesterol-binding, thiol-activated cytolysin and a model of its membrane form	CELL			English	Article							PERFRINGENS THETA-TOXIN; STREPTOLYSIN-O; PERFRINGOLYSIN-O; CLOSTRIDIUM-PERFRINGENS; ERYTHROCYTE-MEMBRANES; CRYSTAL-STRUCTURE; ELECTRON-MICROSCOPY; 2.5-A RESOLUTION; CELL-MEMBRANES; PROTEIN MODELS	The mechanisms by which proteins gain entry into membranes is a fundamental problem in biology. Here, we present the first crystal structure of a thiol-activated cytolysin, perfringolysin O, a member of a large family of toxins that kill eukaryotic cells by punching holes in their membranes. The molecule adopts an unusually elongated shape rich in beta sheet. We have used electron microscopy data to construct a detailed model of the membrane channel form of the toxin. The structures reveal a novel mechanism for membrane insertion. Surprisingly, the toxin receptor, cholesterol, appears to play multiple roles: targeting, promotion of oligomerization, triggering a membrane insertion competent form, and stabilizing the membrane pore.	ST VINCENTS INST MED RES,IAN POTTER FDN,PROT CRYSTALLOG LAB,FITZROY,VIC 3065,AUSTRALIA; UNIV OKLAHOMA,HLTH SCI CTR,DEPT MICROBIOL & IMMUNOL,OKLAHOMA CITY,OK 73190	St. Vincent's Institute of Medical Research; University of Oklahoma System; University of Oklahoma Health Sciences Center			McKinstry, William J/D-2612-2013; Parker, Michael W/F-9069-2013; Rossjohn, Jamie/F-9032-2013	McKinstry, William J/0000-0001-9668-9364; Parker, Michael W/0000-0002-3101-1138; Rossjohn, Jamie/0000-0002-2020-7522				Alouf JE, 1991, SOURCEBOOK BACTERIAL, P147; BERENDES R, 1993, SCIENCE, V262, P427, DOI 10.1126/science.7692599; BHAKDI S, 1988, PROG ALLERGY, V40, P1; BHAKDI S, 1993, MED MICROBIOL IMMUN, V182, P167; BOULNOIS GJ, 1990, BACTERIAL PROTEIN TO, P43; BREITER DR, 1991, BIOCHEMISTRY-US, V30, P603, DOI 10.1021/bi00217a002; Brunger A. T., 1993, XPLOR SYSTEM XRAY CR; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; COWELL JL, 1978, BIOCHIM BIOPHYS ACTA, V507, P230, DOI 10.1016/0005-2736(78)90419-4; Darji A, 1996, INFECT IMMUN, V64, P2356, DOI 10.1128/IAI.64.6.2356-2358.1996; DEJONGH HHJ, 1994, BIOCHEMISTRY-US, V33, P14529, DOI 10.1021/bi00252a020; DelaCruz X, 1996, PROTEIN SCI, V5, P857; delosToyos JR, 1996, INFECT IMMUN, V64, P480, DOI 10.1128/IAI.64.2.480-484.1996; DUNCAN JL, 1975, J CELL BIOL, V67, P160, DOI 10.1083/jcb.67.1.160; Feil SC, 1996, FEBS LETT, V397, P290, DOI 10.1016/S0014-5793(96)01200-8; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; HAMILTON JA, 1993, J BIOL CHEM, V268, P2416; HARRIS RW, 1991, J BIOL CHEM, V266, P6936; HILL J, 1994, INFECT IMMUN, V62, P757, DOI 10.1128/IAI.62.2.757-758.1994; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HOLM L, 1994, PROTEINS, V19, P256, DOI 10.1002/prot.340190309; IWAMOTO M, 1990, EUR J BIOCHEM, V194, P25, DOI 10.1111/j.1432-1033.1990.tb19422.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KATCHALSKIKATZIR E, 1992, P NATL ACAD SCI USA, V89, P2195, DOI 10.1073/pnas.89.6.2195; Laskowski R. A., 1993, J APPL CRYSTALLOGR, V26, P282; LI JD, 1991, NATURE, V353, P815, DOI 10.1038/353815a0; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; MICHEL E, 1990, MOL MICROBIOL, V4, P2167, DOI 10.1111/j.1365-2958.1990.tb00578.x; MITSUI K, 1979, BIOCHIM BIOPHYS ACTA, V558, P307, DOI 10.1016/0005-2736(79)90265-7; MITSUI K, 1979, BIOCHIM BIOPHYS ACTA, V554, P68, DOI 10.1016/0005-2736(79)90007-5; MORGAN PJ, 1994, J BIOL CHEM, V269, P25315; MORGAN PJ, 1995, FEBS LETT, V371, P77, DOI 10.1016/0014-5793(95)00887-F; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; NAKAMURA M, 1995, BIOCHEMISTRY-US, V34, P6513, DOI 10.1021/bi00019a032; NAMBUDRIPAD R, 1991, SCIENCE, V252, P1305, DOI 10.1126/science.1925543; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NIEDERMEYER W, 1985, TOXICON, V23, P425, DOI 10.1016/0041-0101(85)90026-1; OHNOIWASHITA Y, 1992, BIOCHIM BIOPHYS ACTA, V1109, P81, DOI 10.1016/0005-2736(92)90190-W; OLOFSSON A, 1993, FEBS LETT, V319, P125, DOI 10.1016/0014-5793(93)80050-5; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; OWEN RHG, 1994, FEMS MICROBIOL LETT, V121, P217, DOI 10.1016/0378-1097(94)90129-5; PALMER M, 1995, EUR J BIOCHEM, V231, P388, DOI 10.1111/j.1432-1033.1995.tb20711.x; PARKER MW, 1989, NATURE, V337, P93, DOI 10.1038/337093a0; PARKER MW, 1994, NATURE, V367, P292, DOI 10.1038/367292a0; PARKER MW, 1996, PROTEIN TOXIN STRUCT; Petosa C, 1997, NATURE, V385, P833, DOI 10.1038/385833a0; PINKNEY M, 1989, INFECT IMMUN, V57, P2553, DOI 10.1128/IAI.57.8.2553-2558.1989; ROTTEM S, 1982, J BACTERIOL, V152, P888; SAUNDERS FK, 1989, INFECT IMMUN, V57, P2547, DOI 10.1128/IAI.57.8.2547-2552.1989; SEKIYA K, 1993, J BACTERIOL, V175, P5953, DOI 10.1128/JB.175.18.5953-5961.1993; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; Strynadka NCJ, 1996, NAT STRUCT BIOL, V3, P233, DOI 10.1038/nsb0396-233; TWETEN RK, 1991, J BIOL CHEM, V266, P12449; TWETEN RK, 1995, VIRULENCE MECHANISMS OF BACTERIAL PATHOGENS, 2ND EDITION, P207; TWETEN RK, 1988, INFECT IMMUN, V56, P3235, DOI 10.1128/IAI.56.12.3235-3240.1988; WALEV I, 1995, INFECT IMMUN, V63, P1188, DOI 10.1128/IAI.63.4.1188-1194.1995; 1994, ACTA CRYSTALLOGR D, V50, P750	58	376	394	2	37	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 30	1997	89	5					685	692		10.1016/S0092-8674(00)80251-2	http://dx.doi.org/10.1016/S0092-8674(00)80251-2			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XB925	9182756	Bronze			2022-12-01	WOS:A1997XB92500005
J	Kivelson, MG; Khurana, KK; Joy, S; Russell, CT; Southwood, DJ; Walker, RJ; Polanskey, C				Kivelson, MG; Khurana, KK; Joy, S; Russell, CT; Southwood, DJ; Walker, RJ; Polanskey, C			Europa's magnetic signature: Report from Galileo's pass on 19 December 1996	SCIENCE			English	Article							FIELD	On 19 December 1996 as Galileo passed close to Jupiter's moon, Europa, the magnetometer measured substantial departures from the slowly Varying background field of Jupiter's magnetosphere. Currents coupling Europa to Jupiter's magnetospheric plasma could produce perturbations of the observed size. However, the trend of the field perturbations is here modeled as the signature of a Europa-centered dipole moment whose maximum surface magnitude is similar to 240 nanotesla, giving a rough upper limit to the internal field. The dipole orientation is oblique to Europa's spin axis. This orientation may not be probable for a field generated by a core dynamo, but higher order multipoles may be important as they are at Uranus and Neptune. Although the data can be modeled as contributions of an internal field of Europa, they do not confirm its existence. The dipole orientation is also oblique to the imposed field of Jupiter and thus not directly produced as a response to that field. Close to Europa, plasma currents appear to produce perturbations with scale sizes that are smalt compared with a Europa radius.	UNIV CALIF LOS ANGELES,DEPT EARTH & SPACE SCI,LOS ANGELES,CA 90095; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,DEPT PHYS,LONDON SW7 2BZ,ENGLAND; JET PROPULS LAB,PASADENA,CA 91109	University of California System; University of California Los Angeles; Imperial College London; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL)	Kivelson, MG (corresponding author), UNIV CALIF LOS ANGELES,INST GEOPHYS & PLANETARY PHYS,LOS ANGELES,CA 90095, USA.		Kivelson, Margaret G/I-9019-2012; Russell, Christopher T/E-7745-2012	Kivelson, Margaret G/0000-0003-3859-8581; Russell, Christopher T/0000-0003-1639-8298; Khurana, Krishan/0000-0002-2856-1171				Anderson JD, 1996, SCIENCE, V272, P709, DOI 10.1126/science.272.5262.709; ANDERSON JD, 1997, SCIENCE, V276, P1237; CONNERNEY JEP, 1991, J GEOPHYS RES-PLANET, V96, P19023, DOI 10.1029/91JA01165; CONNERNEY JEP, 1987, J GEOPHYS RES, V92, P15329, DOI 10.1029/JA092iA13p15329; Dessler A.J., 1983, PHYS JOVIAN MAGNETOS, P498; Khurana KK, 1997, NATURE, V387, P262, DOI 10.1038/387262a0; KHURANA KK, IN PRESS J GEOPHYS R; KIVELSON MG, 1992, SPACE SCI REV, V60, P357, DOI 10.1007/BF00216862; Kivelson MG, 1996, SCIENCE, V273, P337, DOI 10.1126/science.273.5273.337; Kivelson MG, 1996, SCIENCE, V274, P396, DOI 10.1126/science.274.5286.396; Kivelson MG, 1996, NATURE, V384, P537, DOI 10.1038/384537a0; RUSSELL CB, UNPUB; Schubert G, 1996, NATURE, V384, P544, DOI 10.1038/384544a0; *UCLA I GEOPHY PLA, UCLA I GEOPH PLAN PH, V4864	14	72	73	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 23	1997	276	5316					1239	1241		10.1126/science.276.5316.1239	http://dx.doi.org/10.1126/science.276.5316.1239			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XA497	9157878				2022-12-01	WOS:A1997XA49700037
J	Yirrell, DI; Robertson, P; Goldberg, DJ; McMenamin, J; Cameron, S; Brown, AJL				Yirrell, DI; Robertson, P; Goldberg, DJ; McMenamin, J; Cameron, S; Brown, AJL			Molecular investigation into outbreak of HIV in a Scottish prison	BRITISH MEDICAL JOURNAL			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; RISK BEHAVIORS; INFECTION; TRANSMISSION; PREVALENCE; EPIDEMIOLOGY; SEQUENCES; EDINBURGH; ENTRANTS	Objectives: To support already established epidemiological links between inmates of Glenochil prison positive for HIV infection by using molecular techniques and thus provide evidence of the extent of acquisition during a recent outbreak of the disease resulting from needle sharing. To identify possible sources of the outbreak, and to demonstrate the ability of the methodology to make further links beyond the original outbreak. Design: Viral sequences obtained from the blood of HIV positive prisoners previously identified by standard epidemiological methods were compared with each other and with sequences from other Scottish patients. Setting: Glenochil prison for men, central Scotland. Subjects: Adults inmates and their possible contacts. Results: Phylogenetic analysis of viral sequences in two different genomic regions showed that 13 of the 14 HIV positive prisoners had been infected from a common source. Previous research had shown that six of these had acquired their infection in Glenochil; molecular evidence suggests that more than double this number were infected while incarcerated. Virus from two long term HIV positive patients who were in the prison at the time of the outbreak but who were not identified in the original or subsequent surveys was sufficiently different to make it unlikely that they were the source, A viral sequence from heterosexual transmission from one inmate showed the ability of these techniques to follow the infection through different routes of infection. Conclusion: The number of prisoners infected with HIV during the 1993 outbreak within Glenochil prison was more than twice that previously shown. This shows the potential for the spread of bloodborne diseases within prisons bg injecting drugs.	RUCHILL HOSP, SCOTTISH CTR INFECT & ENVIRONM HLTH, GLASGOW G20 9BN, LANARK, SCOTLAND; RUCHILL HOSP, REG VIRUS LAB, GLASGOW G20 9NB, LANARK, SCOTLAND		Yirrell, DI (corresponding author), UNIV EDINBURGH, INST CELL ANIM & POPULAT BIOL, CTR HIV RES, W MAINS RD, EDINBURGH EH9 3JN, MIDLOTHIAN, SCOTLAND.		Brown, Andrew Leigh/ABF-8269-2020; Leigh Brown, Andrew/F-3802-2010	Brown, Andrew Leigh/0000-0002-5700-3128; Leigh Brown, Andrew/0000-0002-5700-3128				ALBERT J, 1993, NATURE, V361, P595, DOI 10.1038/361595b0; ALBERT J, 1994, J VIROL, V68, P5918, DOI 10.1128/JVI.68.9.5918-5924.1994; BIRD AG, 1993, BRIT MED J, V307, P228, DOI 10.1136/bmj.307.6898.228; BIRD AG, 1992, AIDS, V6, P725, DOI 10.1097/00002030-199207000-00017; BROWN AJL, 1995, HIV PRACTICAL APPROA, V1, P161; CARVELL ALM, 1990, BRIT MED J, V300, P1383, DOI 10.1136/bmj.300.6736.1383; Clewley JP, 1996, LANCET, V347, P1487, DOI 10.1016/S0140-6736(96)91724-9; Connick E, 1996, AIDS RES HUM RETROV, V12, P1129, DOI 10.1089/aid.1996.12.1129; CROFTS N, 1995, BRIT MED J, V310, P285, DOI 10.1136/bmj.310.6975.285; GAUGHWIN MD, 1991, AIDS, V5, P845, DOI 10.1097/00002030-199107000-00008; GOJOBORI T, 1990, P NATL ACAD SCI USA, V87, P10015, DOI 10.1073/pnas.87.24.10015; GORE SM, 1993, BRIT MED J, V307, P147, DOI 10.1136/bmj.307.6897.147; GORE SM, 1995, BRIT MED J, V310, P293, DOI 10.1136/bmj.310.6975.293; HILLIS DM, 1994, NATURE, V369, P24, DOI 10.1038/369024a0; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HOLMES EC, 1993, J INFECT DIS, V167, P1411, DOI 10.1093/infdis/167.6.1411; HOLMES EC, 1995, J INFECT DIS, V171, P45, DOI 10.1093/infdis/171.1.45; JAFFE HW, 1994, ANN INTERN MED, V121, P855, DOI 10.7326/0003-4819-121-11-199412010-00005; KISHINO H, 1989, J MOL EVOL, V4, P406; Leitner T, 1996, P NATL ACAD SCI USA, V93, P10864, DOI 10.1073/pnas.93.20.10864; MARTIN V, 1990, AIDS, V4, P1023, DOI 10.1097/00002030-199010000-00013; OU CY, 1992, SCIENCE, V256, P1165, DOI 10.1126/science.256.5060.1165; POWER KG, 1991, BMJ-BRIT MED J, V303, P783, DOI 10.1136/bmj.303.6805.783-b; SIMMONDS P, 1991, J VIROL, V65, P6266, DOI 10.1128/JVI.65.11.6266-6276.1991; SotoRamirez LE, 1996, SCIENCE, V271, P1291, DOI 10.1126/science.271.5253.1291; TAYLOR A, 1995, BRIT MED J, V310, P289, DOI 10.1136/bmj.310.6975.289; VLAHOV D, 1991, JAMA-J AM MED ASSOC, V265, P1129, DOI 10.1001/jama.265.9.1129; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; ZHANG LQ, 1993, J VIROL, V67, P3345, DOI 10.1128/JVI.67.6.3345-3356.1993; ZHANG LQ, 1991, AIDS, V5, P575	30	59	59	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 17	1997	314	7092					1446	1450		10.1136/bmj.314.7092.1446	http://dx.doi.org/10.1136/bmj.314.7092.1446			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XA202	9167560	Green Published, Green Submitted			2022-12-01	WOS:A1997XA20200021
J	Deshler, JO; Highett, MI; Schnapp, BJ				Deshler, JO; Highett, MI; Schnapp, BJ			Localization of Xenopus Vg1 mRNA by vera protein and the endoplasmic reticulum	SCIENCE			English	Article							MATERNAL MESSENGER-RNA; IN-VITRO; OOCYTES; EXTRACTS; TRANSLOCATION; MICROTUBULES; EXPRESSION; ATTACHMENT; OOGENESIS; MEMBRANES	In many organisms, pattern formation in the embryo develops from the polarized distributions of messenger RNAs (mRNAs) in the egg, in Xenopus, the mRNA encoding Vg1, a growth factor involved in mesoderm induction, is localized to the vegetal cortex of oocytes. A protein named Vera was shown to be involved in Vg1 mRNA localization. Vera cofractionates with endoplasmic reticulum (ER) membranes, and endogenous Vg1 mRNA is associated with a subcompartment of the ER. Vera may promote mRNA localization in Xenopus oocytes by mediating an interaction between the Vg1 3' untranslated region and the ER subcompartment.	HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM016114] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026846] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM16114-03] Funding Source: Medline; NINDS NIH HHS [NS-26846] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AINGER K, 1993, J CELL BIOL, V123, P431, DOI 10.1083/jcb.123.2.431; ALLAN V, 1995, J CELL BIOL, V128, P879, DOI 10.1083/jcb.128.5.879; ALLAN V, 1994, J CELL SCI, V107, P1885; BANERJEE U, 1987, CELL, V49, P281, DOI 10.1016/0092-8674(87)90569-1; DABORA SL, 1988, CELL, V54, P27, DOI 10.1016/0092-8674(88)90176-6; DALE L, 1989, EMBO J, V8, P1057, DOI 10.1002/j.1460-2075.1989.tb03473.x; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; FERRANDON D, 1994, CELL, V79, P1221, DOI 10.1016/0092-8674(94)90013-2; FORRISTALL C, 1995, DEVELOPMENT, V121, P201; GAVIS ER, 1992, CELL, V71, P301, DOI 10.1016/0092-8674(92)90358-J; HARTMANN E, 1993, EUR J BIOCHEM, V214, P375, DOI 10.1111/j.1432-1033.1993.tb17933.x; KLOC M, 1995, DEVELOPMENT, V121, P287; LEE C, 1988, CELL, V54, P37, DOI 10.1016/0092-8674(88)90177-8; MELTON DA, 1987, NATURE, V328, P80, DOI 10.1038/328080a0; MOURY KL, 1997, P NATL ACAD SCI USA, V93, P14608; MOWRY KL, 1992, SCIENCE, V255, P991, DOI 10.1126/science.1546297; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; SCHWARTZ SP, 1992, P NATL ACAD SCI USA, V89, P11895, DOI 10.1073/pnas.89.24.11895; TANNAHILL D, 1989, DEVELOPMENT, V106, P775; TANNER NK, 1988, BIOCHEMISTRY-US, V27, P8852, DOI 10.1021/bi00424a025; TEPASS U, 1990, CELL, V61, P787, DOI 10.1016/0092-8674(90)90189-L; THOMSEN GH, 1993, CELL, V74, P433, DOI 10.1016/0092-8674(93)80045-G; TREMBLEAU A, 1994, J NEUROSCI, V14, P39; WANG SX, 1994, NATURE, V369, P400, DOI 10.1038/369400a0; WATERMANSTORER CM, 1995, J CELL BIOL, V130, P1161, DOI 10.1083/jcb.130.5.1161; WEEKS DL, 1987, CELL, V51, P861, DOI 10.1016/0092-8674(87)90109-7; YISRAELI JK, 1988, NATURE, V336, P592, DOI 10.1038/336592a0; YISRAELI JK, 1989, METHOD ENZYMOL, V180, P42; YISRAELI JK, 1990, DEVELOPMENT, V108, P289	30	233	235	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 16	1997	276	5315					1128	1131		10.1126/science.276.5315.1128	http://dx.doi.org/10.1126/science.276.5315.1128			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WZ225	9148809				2022-12-01	WOS:A1997WZ22500049
J	Ostareck, DH; OstareckLederer, A; Wilm, M; Thiele, BJ; Mann, M; Hentze, MW				Ostareck, DH; OstareckLederer, A; Wilm, M; Thiele, BJ; Mann, M; Hentze, MW			mRNA silencing in erythroid differentiation: hnRNP K and hnRNP E1 regulate 15-lipoxygenase translation from the 3' end	CELL			English	Article							MESSENGER-RNA; BINDING-PROTEIN; UNTRANSLATED REGION; INITIATION; SEQUENCE; LIPOXYGENASE; COMPLEX; DOMAIN; ASSAY; GENE	Although LOX mRNA accumulates early during differentiation, a differentiation control element in its 3' untranslated region confers translational silencing until late stage erythropoiesis. We have purified two proteins from rabbit reticulocytes that specifically mediate LOX silencing and identified them as hnRNPs K and E1. Transfection of hnRNP K and hnRNP E1 into HeLa cells specifically silenced the translation of reporter mRNAs bearing a differentiation control element in their 3' untranslated region. Silenced LOX mRNA in rabbit reticulocytes specifically coimmunoprecipitated with hnRNP K. In a reconstituted cell-free translation system, addition of recombinant hnRNP K and hnRNP E1 recapitulates this regulation via a specific inhibition of 80S ribosome assembly on LOX mRNA. Both proteins can control cap-dependent and internal ribosome entry site-mediated translation by binding to differentiation control elements. Our data suggest a specific cytoplasmic function for hnRNPs as translational regulatory proteins.	EUROPEAN MOL BIOL LAB,GENE EXPRESS PROGRAMME,D-69117 HEIDELBERG,GERMANY; EUROPEAN MOL BIOL LAB,PROT & PEPTIDE GRP,D-69117 HEIDELBERG,GERMANY; HUMBOLDT UNIV BERLIN,INST BIOCHEM,D-10115 BERLIN,GERMANY	European Molecular Biology Laboratory (EMBL); European Molecular Biology Laboratory (EMBL); Humboldt University of Berlin			Mann, Matthias/A-3454-2013; Hentze, Matthias W/V-3980-2017	Mann, Matthias/0000-0003-1292-4799; Hentze, Matthias W/0000-0002-4023-7876; Ostareck-Lederer, Antje/0000-0003-0733-7071; Wilm, Matthias/0000-0002-5461-6834; Ostareck, Dirk/0000-0001-9406-7190				AASHEIM HC, 1994, NUCLEIC ACIDS RES, V22, P959, DOI 10.1093/nar/22.6.959; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BUSTELO XR, 1995, MOL CELL BIOL, V15, P1324; CURTIS D, 1995, CELL, V81, P171, DOI 10.1016/0092-8674(95)90325-9; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; Dubnau J, 1996, NATURE, V379, P694, DOI 10.1038/379694a0; EVANS TC, 1994, CELL, V77, P183, DOI 10.1016/0092-8674(94)90311-5; FLEMING J, 1989, GENE, V79, P181, DOI 10.1016/0378-1119(89)90103-0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAY NK, 1994, EMBO J, V13, P3882, DOI 10.1002/j.1460-2075.1994.tb06699.x; GRAY NK, 1993, EUR J BIOCHEM, V218, P657, DOI 10.1111/j.1432-1033.1993.tb18420.x; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HAHM K, 1993, NUCLEIC ACIDS RES, V21, P3894, DOI 10.1093/nar/21.16.3894; HAKE LE, 1994, CELL, V79, P617, DOI 10.1016/0092-8674(94)90547-9; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; HINNEBUSCH AG, 1994, TRENDS BIOCHEM SCI, V19, P409, DOI 10.1016/0968-0004(94)90089-2; HOBERT O, 1994, J BIOL CHEM, V269, P20225; HOHNE M, 1988, BIOMED BIOCHIM ACTA, V47, P75; HUARTE J, 1992, CELL, V69, P1021, DOI 10.1016/0092-8674(92)90620-R; HUNT T, 1989, TRENDS BIOCHEM SCI, V14, P393, DOI 10.1016/0968-0004(89)90280-6; IZAURRAIDE E, 1997, IN PRESS J CELL BIOL; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P50; JACKSON RJ, 1993, CELL, V74, P9, DOI 10.1016/0092-8674(93)90290-7; KAMINSKI A, 1990, EMBO J, V9, P3753, DOI 10.1002/j.1460-2075.1990.tb07588.x; KILEDJIAN M, 1995, EMBO J, V14, P4357, DOI 10.1002/j.1460-2075.1995.tb00110.x; Kollmus H, 1996, RNA, V2, P316; LEFFERS H, 1995, EUR J BIOCHEM, V230, P447, DOI 10.1111/j.1432-1033.1995.tb20581.x; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; MATUNIS EL, 1994, P NATL ACAD SCI USA, V91, P2781, DOI 10.1073/pnas.91.7.2781; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; Michelotti EF, 1996, MOL CELL BIOL, V16, P2350, DOI 10.1128/mcb.16.5.2350; MIN HS, 1995, GENE DEV, V9, P2659, DOI 10.1101/gad.9.21.2659; OSTARECKLEDERER A, 1994, EMBO J, V13, P1476, DOI 10.1002/j.1460-2075.1994.tb06402.x; PANTOPOULOS K, 1995, P NATL ACAD SCI USA, V92, P1267, DOI 10.1073/pnas.92.5.1267; Pinol-Roma Serafin, 1993, Trends in Cell Biology, V3, P151, DOI 10.1016/0962-8924(93)90135-N; RAPOPORT SM, 1986, BIOCHIM BIOPHYS ACTA, V864, P471, DOI 10.1016/0304-4157(86)90006-7; RiveraPomar R, 1996, NATURE, V379, P746, DOI 10.1038/379746a0; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; SCHEWE T, 1986, ADV ENZYMOL RAMB, V58, P191; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; STRIPECKE R, 1994, MOL CELL BIOL, V14, P5898, DOI 10.1128/MCB.14.9.5898; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; TAKIMOTO M, 1993, J BIOL CHEM, V268, P18249; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; THIELE BJ, 1982, EUR J BIOCHEM, V129, P133, DOI 10.1111/j.1432-1033.1982.tb07031.x; THIELE BJ, 1981, ACTA BIOL MED GER, V40, P597; VANSEUNINGEN I, 1995, J BIOL CHEM, V270, P26976, DOI 10.1074/jbc.270.45.26976; WANG XM, 1995, MOL CELL BIOL, V15, P1769; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; WICKENS M, 1993, NATURE, V363, P305, DOI 10.1038/363305a0; Wickens M., 1996, TRANSLATIONAL CONTRO, P411; Wilm M, 1996, ANAL CHEM, V68, P527, DOI 10.1021/ac950875+; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519; WILM MS, 1994, INT J MASS SPECTROM, V136, P167, DOI 10.1016/0168-1176(94)04024-9	56	428	436	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 16	1997	89	4					597	606		10.1016/S0092-8674(00)80241-X	http://dx.doi.org/10.1016/S0092-8674(00)80241-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WZ323	9160751	hybrid			2022-12-01	WOS:A1997WZ32300013
J	Degner, LF; Kristjanson, LJ; Bowman, D; Sloan, JA; Carriere, KC; ONeil, J; Bilodeau, B; Watson, P; Mueller, B				Degner, LF; Kristjanson, LJ; Bowman, D; Sloan, JA; Carriere, KC; ONeil, J; Bilodeau, B; Watson, P; Mueller, B			Information needs and decisional preferences in women with breast cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COMMUNICATION; RADIATION; ILLNESS; SURGERY	Objective.-To determine the degree of involvement women with breast cancer wanted in medical decision making, extent to which they believed they had achieved their preferred level of involvement, and types of information they judged to be most important. Design and Setting.-Cross-sectional survey at 2 tertiary oncology referral clinics and 2 community hospital oncology clinics in Winnipeg, Manitoba. Patients.-Consecutive sample of 1012 women with a confirmed diagnosis of breast cancer who were scheduled for a visit at 1 of 4 hospital oncology clinics. Main Outcome Measures.-The following measures were used: (1) Preferences about various levels of participation in treatment decision making; (2) the extent to which subjects believed they had achieved their preferred levels of involvement in decision making; and (3) priority needs for information and how these needs differed by selected sociodemographic, disease, and treatment variables. Results.-A total of 22% of women wanted to select their own cancer treatment, 44% wanted to select their treatment collaboratively with their physicians, and 34% wanted to delegate this responsibility to their physicians. Only 42% of women believed they had achieved their preferred level of control in decision making. The 2 most highly ranked types of information were related to knowing about chances of cure and spread of disease. Women younger than 50 years rated information about physical and sexual attractiveness as more important than did older women (P<.001); women older than 70 years rated information about self-care as more important than did younger women (P=.002); and women who had a positive family history of breast cancer rated information about family risk as more important than did other women (P=.03). Conclusions.-The substantial discrepancy between women's preferred and attained levels of involvement in treatment decision making suggests that systematic approaches to assess and respond to women's desired level of participation in treatment decision making need to be evaluated. Priorities for information identified in this study provide an empirical basis to guide communication with women seeking care for breast cancer.	UNIV MANITOBA,FAC NURSING,WINNIPEG,MB,CANADA; UNIV MANITOBA,FAC MED,DEPT INTERNAL MED,WINNIPEG,MB R3E 0W3,CANADA; UNIV MANITOBA,FAC MED,DEPT COMMUNITY HLTH SCI,WINNIPEG,MB,CANADA; UNIV MANITOBA,FAC MED,DEPT PATHOL,WINNIPEG,MB,CANADA; MANITOBA CANC TREATMENT & RES FDN,WINNIPEG,MB R3E 0V9,CANADA; UNIV ALBERTA,DEPT MATH SCI,EDMONTON,AB,CANADA	University of Manitoba; University of Manitoba; University of Manitoba; University of Manitoba; University of Alberta								Beaver K, 1996, CANCER NURS, V19, P8, DOI 10.1097/00002820-199602000-00002; Bilodeau B A, 1996, Oncol Nurs Forum, V23, P691; BLANCHARD CG, 1988, SOC SCI MED, V27, P1139, DOI 10.1016/0277-9536(88)90343-7; CASSELITH BR, 1990, ANN INTERN MED, V92, P832; CAWLEY M, 1990, CANCER NURS, V13, P90; Cooley M E, 1995, Oncol Nurs Forum, V22, P1345; Davison B J, 1995, Oncol Nurs Forum, V22, P1401; DEGNER LF, 1988, RES NURS HEALTH, V11, P367, DOI 10.1002/nur.4770110604; DEGNER LF, 1992, J CLIN EPIDEMIOL, V45, P941, DOI 10.1016/0895-4356(92)90110-9; DEGNER LF, 1987, LIFE DEATH DECISIONS; DERDIARIAN AK, 1986, NURS RES, V35, P276; DODD MJ, 1987, CANCER NURS, V10, P244; FALLOWFIELD LJ, 1990, BRIT MED J, V301, P575, DOI 10.1136/bmj.301.6752.575; Galloway S., 1994, CAN ONCOL NURS J, V4, P29; HACK TF, 1994, SOC SCI MED, V39, P279, DOI 10.1016/0277-9536(94)90336-0; HAILEY BJ, 1988, WOMEN HEALTH, V14, P75, DOI 10.1300/J013v14n01_06; Hopkins M B, 1986, Cancer Nurs, V9, P256; LAUER P, 1982, NURS RES, V31, P11; LUKER KA, 1995, J ADV NURS, V22, P134, DOI 10.1046/j.1365-2648.1995.22010134.x; Maranell GM, 1974, SCALING SOURCEBOOK B, P81; MESSERLI ML, 1980, AM J ORTHOPSYCHIAT, V50, P728, DOI 10.1111/j.1939-0025.1980.tb03339.x; MYEROWITZ BE, 1983, CANCER, V52, P1541; NAYFIELD SG, 1994, J NATL CANCER I, V86, P1202, DOI 10.1093/jnci/86.16.1202; Neufeld K R, 1993, Oncol Nurs Forum, V20, P631; NORTHOUSE LL, 1989, CANCER NURS, V12, P276; PIERCE PF, 1993, NURS RES, V42, P22; RAINEY LC, 1985, CANCER, V56, P1056, DOI 10.1002/1097-0142(19850901)56:5<1056::AID-CNCR2820560516>3.0.CO;2-Z; REYNOLDS PM, 1981, BRIT MED J, V282, P1449, DOI 10.1136/bmj.282.6274.1449; Ross R. T, 1974, SCALING SOURCEBOOK B, P106; SIMINOFF LA, 1989, J CLIN ONCOL, V7, P1192, DOI 10.1200/JCO.1989.7.9.1192; STREET RL, 1991, SOC SCI MED, V32, P541, DOI 10.1016/0277-9536(91)90288-N; *SUBC STAT WOM, 1992, REP STAND COMM HLTH, P33; SUTHERLAND HJ, 1989, J ROY SOC MED, V82, P260, DOI 10.1177/014107688908200506; WALLER M, 1995, CAN MED ASSOC J, V152, P165; WARD S, 1989, CANCER NURS, V12, P344; [No title captured]	36	850	860	2	67	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 14	1997	277	18					1485	1492		10.1001/jama.277.18.1485	http://dx.doi.org/10.1001/jama.277.18.1485			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WX852	9145723				2022-12-01	WOS:A1997WX85200038
J	Elliott, G				Elliott, G			Upper-extremity deep vein thrombosis	LANCET			English	Editorial Material									UNIV UTAH,SALT LAKE CITY,UT 84143	Utah System of Higher Education; University of Utah	Elliott, G (corresponding author), LATTER DAY ST HOSP,DIV PULM & CRIT CARE,SALT LAKE CITY,UT 84143, USA.							BECKER DM, 1991, ARCH INTERN MED, V151, P1934, DOI 10.1001/archinte.151.10.1934; HYERS TM, 1995, CHEST, V108, pS335, DOI 10.1378/chest.108.4_Supplement.335S; LINBLAD B, 1988, EUR J VASCULAR SURG, V2, P161; Prandoni P, 1997, ARCH INTERN MED, V157, P57, DOI 10.1001/archinte.157.1.57; WELLS PS, 1995, LANCET, V345, P1326, DOI 10.1016/S0140-6736(95)92535-X	5	28	29	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 26	1997	349	9060					1188	1189		10.1016/S0140-6736(05)62408-7	http://dx.doi.org/10.1016/S0140-6736(05)62408-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW717	9130936				2022-12-01	WOS:A1997WW71700004
J	Fazeli, A; Dickinson, SL; Hermiston, ML; Tighe, RV; Steen, RG; Small, CG; Stoeckli, ET; KeinoMasu, K; Masu, M; Rayburn, H; Simons, J; Bronson, RT; Gordon, JI; TessierLavigne, M; Weinberg, RA				Fazeli, A; Dickinson, SL; Hermiston, ML; Tighe, RV; Steen, RG; Small, CG; Stoeckli, ET; KeinoMasu, K; Masu, M; Rayburn, H; Simons, J; Bronson, RT; Gordon, JI; TessierLavigne, M; Weinberg, RA			Phenotype of mice lacking functional Deleted in colorectal cancer (Dcc) gene	NATURE			English	Article							MULTIPLE INTESTINAL NEOPLASIA; EPITHELIAL-CELL LINEAGES; TRANSGENIC MICE; DIFFERENTIATION PROGRAMS; COMMISSURAL AXONS; C-ELEGANS; MOUSE; EXPRESSION; CHROMOSOME-18; PROGRESSION	The DCC (Deleted in colorectal cancer) gene was first identified as a candidate for a tumour-suppressor gene on human chromosome 18q. More recently, in vitro studies In rodents have provided evidence that DCC might function as a receptor for the axonal chemoattractant netrin-1. Inactivation of the murine Dcc gene caused defects in axonal projections that are similar to those observed in netrin-1-deficient mice but did not affect growth, differentiation, morphogenesis or tumorigenesis in mouse intestine. These observations fail to support a tumour-suppressor function for Dcc, but are consistent with the hypothesis that DCC Is a component of a receptor for netrin-1.	MIT,WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142; MIT,DEPT BIOL,CAMBRIDGE,MA 02142; WASHINGTON UNIV,SCH MED,DEPT MOL BIOL & PHARMACOL,ST LOUIS,MO 63110; MIT,WHITEHEAD INST GENOME CTR,CAMBRIDGE,MA 02142; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT ANAT,CELL BIOL PROGRAM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT ANAT,PROGRAM DEV BIOL & NEUROSCI,SAN FRANCISCO,CA 94143; NATL DEF MED COLL,DEPT PHYSIOL,TOKOROZAWA,SAITAMA 359,JAPAN; MIT,CTR CANC RES,CAMBRIDGE,MA 02139; JOHNS HOPKINS UNIV,JAMES BUCHANAN BRADY UROL INST,BALTIMORE,MD 21207; TUFTS UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02111; TUFTS UNIV,SCH VET MED,DEPT PATHOL,BOSTON,MA 02111	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Washington University (WUSTL); Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; National Defense Medical College - Japan; Massachusetts Institute of Technology (MIT); Johns Hopkins University; Tufts University; Tufts University				Stoeckli, Esther/0000-0002-8485-0648				BOLAND CR, 1995, NAT MED, V1, P902, DOI 10.1038/nm0995-902; BRY L, 1994, P NATL ACAD SCI USA, V91, P10335, DOI 10.1073/pnas.91.22.10335; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; Chan SSY, 1996, CELL, V87, P187, DOI 10.1016/S0092-8674(00)81337-9; CHANDRASEKARAN C, 1993, P NATL ACAD SCI USA, V90, P8871, DOI 10.1073/pnas.90.19.8871; CHO KR, 1994, GENOMICS, V19, P525, DOI 10.1006/geno.1994.1102; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; Ekstrand BC, 1995, ONCOGENE, V11, P2393; FALK P, 1994, AM J PHYSIOL, V266, pG987, DOI 10.1152/ajpgi.1994.266.6.G987; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fearon ER, 1995, MOL BASIS CANC, P340; GOODMAN CS, 1994, CELL, V78, P353, DOI 10.1016/0092-8674(94)90413-8; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Harris R, 1996, NEURON, V17, P217, DOI 10.1016/S0896-6273(00)80154-3; HEDRICK L, 1994, GENE DEV, V8, P1174, DOI 10.1101/gad.8.10.1174; HERMISTON ML, 1993, P NATL ACAD SCI USA, V90, P8866, DOI 10.1073/pnas.90.19.8866; HERMISTON ML, 1995, J CELL BIOL, V129, P489, DOI 10.1083/jcb.129.2.489; HOHNE MW, 1992, CANCER RES, V52, P2616; ISHII N, 1992, NEURON, V9, P873, DOI 10.1016/0896-6273(92)90240-E; JUSTICE MJ, 1992, GENOMICS, V13, P1281, DOI 10.1016/0888-7543(92)90047-V; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; KIKUCHIYANOSHITA R, 1992, CANCER RES, V52, P3801; KLINGELHUTZ AJ, 1995, ONCOGENE, V10, P1581; Kolodziej PA, 1996, CELL, V87, P197, DOI 10.1016/S0092-8674(00)81338-0; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; LEVY DB, 1994, CANCER RES, V54, P5953; LOUVARD D, 1992, ANNU REV CELL BIOL, V8, P157, DOI 10.1146/annurev.cellbio.8.1.157; LUONGO C, 1993, GENOMICS, V15, P3, DOI 10.1006/geno.1993.1002; LUONGO C, 1994, CANCER RES, V54, P5947; Mitchell KJ, 1996, NEURON, V17, P203, DOI 10.1016/S0896-6273(00)80153-1; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; MOSER AR, 1992, J CELL BIOL, V116, P1517, DOI 10.1083/jcb.116.6.1517; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; NARAYANAN R, 1992, ONCOGENE, V7, P553; PLACZEK M, 1990, DEVELOPMENT, V110, P19; ROTH KA, 1990, P NATL ACAD SCI USA, V87, P6408, DOI 10.1073/pnas.87.16.6408; SCHMIDT GH, 1988, DEVELOPMENT, V103, P785; Serafini T, 1996, CELL, V87, P1001, DOI 10.1016/S0092-8674(00)81795-X; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; STOECKLI ET, 1995, NEURON, V14, P1165, DOI 10.1016/0896-6273(95)90264-3; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; TANAKA K, 1991, NATURE, V349, P340, DOI 10.1038/349340a0; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Wadsworth WG, 1996, NEURON, V16, P35, DOI 10.1016/S0896-6273(00)80021-5	50	634	645	0	27	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 24	1997	386	6627					796	804		10.1038/386796a0	http://dx.doi.org/10.1038/386796a0			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WV706	9126737				2022-12-01	WOS:A1997WV70600045
J	Bhagwanjee, S; Muckart, DJJ; Jeena, PM; Moodley, P				Bhagwanjee, S; Muckart, DJJ; Jeena, PM; Moodley, P			Does HIV status influence the outcome of patients admitted to a surgical intensive care unit? A prospective double blind study	BRITISH MEDICAL JOURNAL			English	Article							MULTIPLE-ORGAN FAILURE; SEPSIS; PRINCIPLES; DISEASE; SYSTEM; AIDS	Objectives: (a) To assess the impact of HIV status (HIV negative, HIV positive, AIDS) on the outcome of patients admitted to intensive care units for diseases unrelated to HIV; (b) to decide whether a positive test result for HIV should be a criterion for excluding patients from intensive care for diseases unrelated to HIV. Design: A prospective double blind study of all admissions over six months. HIV status was determined in all patients by enzyme linked immunosorbent assay (ELISA), immunofluorescence assay, western blotting, and now cytometry. The ethics committee considered the clinical implications of the study important enough to waive patients' right to informed consent Staff and patients were blinded to HIV results. On discharge patients could be advised of their HIV status if they wished. Setting: A 16 bed surgical intensive care unit. Subjects: All 267 men and 135 women admitted to the unit during the study period. Interventions: None. Main outcome measures: APACHE II score (acute physiological, age, and chronic health evaluation), organ failure, septic shock, durations of intensive care unit and hospital stay, and intensive care unit and hospital mortality. Results: No patient had AIDS. 52 patients were tested positive for HIV and 350 patients were tested negative. The two groups were similar in sex distribution but differed significantly in age, incidence of organ failure (37 (71%) v 171 (49%) patients), and incidence of septic shock (20 (38%) v 54 (15%)). After adjustment for age there were no differences in intensive care unit or hospital mortality or in the durations of stay in die intensive care unit or hospital. Conclusions: Morbidity was higher in HIV positive patients but there was no difference in mortality. In this patient population a positive HIV test result should not be a criterion for excluding a patient from intensive care.			Bhagwanjee, S (corresponding author), UNIV NATAL,FAC MED,PRIVATE BAG 7,ZA-4013 CONGELLA,SOUTH AFRICA.							BAUE AE, 1992, ARCH SURG-CHICAGO, V127, P1451; BROWN J, 1993, CRIT CARE CLIN, V9, P115, DOI 10.1016/S0749-0704(18)30211-2; CHENG EY, 1993, CURR OPIN ANAESTH, V6, P309; DHAINAUT JFA, 1994, CRIT CARE MED, V22, P1720, DOI 10.1097/00003246-199422110-00005; Ellison GTH, 1996, S AFR MED J, V86, P1257; GILKS CF, 1993, LANCET, V342, P1037, DOI 10.1016/0140-6736(93)92885-W; GORIS RJA, 1985, ARCH SURG-CHICAGO, V120, P1109; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KNAUS WA, 1993, JAMA-J AM MED ASSOC, V270, P1233, DOI 10.1001/jama.270.10.1233; KNAUS WA, 1985, ANN SURG, V202, P685, DOI 10.1097/00000658-198512000-00004; LIN RY, 1994, CRIT CARE MED, V22, P1595; LUCE JM, 1992, CRIT CARE MED, V20, P313, DOI 10.1097/00003246-199203000-00001; *MEMB AM COLL CHES, 1992, CRIT CARE MED, V20, P864; MUNOZ C, 1991, J CLIN INVEST, V88, P1747, DOI 10.1172/JCI115493; PANTALEO G, 1993, NEW ENGL J MED, V328, P327, DOI 10.1056/NEJM199302043280508; ROSEN MJ, 1993, CRIT CARE CLIN, V9, P107, DOI 10.1016/S0749-0704(18)30210-0; RUARK JE, 1988, NEW ENGL J MED, V318, P25, DOI 10.1056/NEJM198801073180106; STEIN DS, 1992, J INFECT DIS, V165, P352, DOI 10.1093/infdis/165.2.352; 1992, MMWR-MORBID MORTAL W, V41, P1	19	64	65	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 12	1997	314	7087					1077	1081		10.1136/bmj.314.7087.1077a	http://dx.doi.org/10.1136/bmj.314.7087.1077a			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU236	9133887	Green Published			2022-12-01	WOS:A1997WU23600021
J	Lusser, A; Brosch, G; Loidl, A; Haas, H; Loidl, P				Lusser, A; Brosch, G; Loidl, A; Haas, H; Loidl, P			Identification of maize histone deacetylase HD2 as an acidic nucleolar phosphoprotein	SCIENCE			English	Article							ACETYLATION	The steady state of histone acetylation is established and maintained by multiple histone acetyltransferases and deacetylases, and this steady state affects chromatin structure and function. The identification of a maize complementary DNA encoding the chromatin-bound deacetylase HD2 is reported. This protein was not homologous to the yeast RPD3 transcriptional regulator. It was expressed throughout embryo germination in correlation with the proliferative activity of cells. Antibodies against recombinant HD2-p39 immunoprecipitated the native enzyme complex, which was composed of phosphorylated p39 subunits. Immunofluorescence microscopy and sequence homologies suggested nucleolar localization. HD2 is an acidic nucleolar phosphoprotein that might regulate ribosomal chromatin structure and function.	UNIV INNSBRUCK, SCH MED, DEPT MICROBIOL, A-6020 INNSBRUCK, AUSTRIA	University of Innsbruck				Lusser, Alexandra/0000-0002-2226-9081				Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BROSCH G, 1992, J BIOL CHEM, V267, P20561; BROSCH G, 1995, PLANT CELL, V7, P1941, DOI 10.1105/tpc.7.11.1941; Brosch G, 1996, BIOCHEMISTRY-US, V35, P15907, DOI 10.1021/bi961294x; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; DarkinRattray SJ, 1996, P NATL ACAD SCI USA, V93, P13143, DOI 10.1073/pnas.93.23.13143; DeRubertis F, 1996, NATURE, V384, P589; GEORGIEVA EI, 1994, PLANTA, V192, P118, DOI 10.1007/BF00198701; GRABHER A, 1994, BIOCHEMISTRY-US, V33, P14887, DOI 10.1021/bi00253a028; KLEFF S, 1995, J BIOL CHEM, V270, P24674, DOI 10.1074/jbc.270.42.24674; Lechner T, 1996, BBA-PROTEIN STRUCT M, V1296, P181, DOI 10.1016/0167-4838(96)00069-6; LECHNER T, UNPUB; LOIDL P, 1994, CHROMOSOMA, V103, P441; LUSSER A, UNPUB; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Trendelenburg MF, 1996, HISTOCHEM CELL BIOL, V106, P167; TURNER BM, 1991, J CELL SCI, V99, P13; Tyler JK, 1996, MOL CELL BIOL, V16, P6149; VOIT R, 1992, EMBO J, V11, P2211, DOI 10.1002/j.1460-2075.1992.tb05280.x; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845	23	193	216	1	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 4	1997	277	5322					88	91		10.1126/science.277.5322.88	http://dx.doi.org/10.1126/science.277.5322.88			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XJ418	9204905				2022-12-01	WOS:A1997XJ41800045
J	Rettig, MB; Ma, HJ; Vescio, RA; Pold, M; Schiller, G; Belson, D; Savage, A; Nishikubo, C; Wu, C; Fraser, J; Said, JW; Berenson, JR				Rettig, MB; Ma, HJ; Vescio, RA; Pold, M; Schiller, G; Belson, D; Savage, A; Nishikubo, C; Wu, C; Fraser, J; Said, JW; Berenson, JR			Kaposi's sarcoma-associated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients	SCIENCE			English	Article							MONOCLONAL GAMMOPATHY; DNA-SEQUENCES; UNDETERMINED SIGNIFICANCE; INTERLEUKIN-6; CYTOKINES; RECEPTOR	Kaposi's sarcoma-associated herpesvirus (KSHV) was found in the bone marrow dendritic cells of multiple myeloma patients but not in malignant plasma cells or bone marrow dendritic cells from normal individuals or patients with other malignancies. In addition the virus was detected in the bone marrow dendritic cells from two out of eight patients with monoclonal gammopathy of undetermined significance (MGUS), a precursor to myeloma. Viral interleukin-6, the human homolog of which is a growth factor for myeloma, was found to be transcribed in the myeloma bone marrow dendritic cells. KSHV may be required for transformation from MGUS to myeloma and perpetuate the growth of malignant plasma cells.	UNIV CALIF LOS ANGELES,SCH MED,DIV HEMATOL & ONCOL,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH MED,JONSSON COMPREHENS CANC CTR,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH MED,DEPT PATHOL,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Rettig, MB (corresponding author), W LOS ANGELES VET AFFAIRS MED CTR,DIV HEMATOL ONCOL,11301 WILSHIRE BLVD,111-H,LOS ANGELES,CA 90073, USA.		Fraser, John K/I-7309-2013					ANDERSON KC, 1989, BLOOD, V73, P1915; BERAL V, 1991, CANCER SURV, V10, P5; BLADE J, 1992, BRIT J HAEMATOL, V81, P391, DOI 10.1111/j.1365-2141.1992.tb08245.x; BOSHOFF C, 1995, NAT MED, V1, P1274, DOI 10.1038/nm1295-1274; BOSHOFF C, 1995, LANCET, V345, P1043; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Corbellino M, 1996, CLIN INFECT DIS, V22, P1120, DOI 10.1093/clinids/22.6.1120; Dubois B, 1997, J EXP MED, V185, P941, DOI 10.1084/jem.185.5.941; Gao SJ, 1996, NAT MED, V2, P925, DOI 10.1038/nm0896-925; Gao SJ, 1996, NEW ENGL J MED, V335, P233, DOI 10.1056/NEJM199607253350403; GARTNER S, 1980, P NATL ACAD SCI-BIOL, V77, P4756, DOI 10.1073/pnas.77.8.4756; Gessain A, 1996, BLOOD, V87, P414; HIRANO T, 1991, INT J CELL CLONING, V9, P166, DOI 10.1002/stem.5530090303; HO J, 1994, APPL IMMUNOHISTOCHEM, V2, P282; Kedes DH, 1996, NAT MED, V2, P918, DOI 10.1038/nm0896-918; KING AG, 1988, J IMMUNOL, V141, P2016; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; KITTLER ELW, 1992, BLOOD, V79, P3168; KYLE RA, 1978, AM J MED, V64, P814, DOI 10.1016/0002-9343(78)90522-3; KYLE RA, 1993, MAYO CLIN PROC, V68, P26, DOI 10.1016/S0025-6196(12)60015-9; LICHTENSTEIN A, 1989, BLOOD, V74, P1266; LICHTENSTEIN A, 1995, CELL IMMUNOL, V162, P248, DOI 10.1006/cimm.1995.1076; LINDSTROM FD, 1978, CLIN IMMUNOL IMMUNOP, V10, P168, DOI 10.1016/0090-1229(78)90024-7; Miller G, 1996, NEW ENGL J MED, V334, P1292, DOI 10.1056/NEJM199605163342003; Moore PS, 1996, J VIROL, V70, P549, DOI 10.1128/JVI.70.1.549-558.1996; Moore PS, 1996, SCIENCE, V274, P1739, DOI 10.1126/science.274.5293.1739; MOSEIGLOS G, 1996, AM J PATHOL, V148, P593; Paladini G, 1989, Recenti Prog Med, V80, P123; PASTORE C, 1995, BRIT J HAEMATOL, V91, P918, DOI 10.1111/j.1365-2141.1995.tb05410.x; PETERMAN TA, 1993, AIDS, V7, P605, DOI 10.1097/00002030-199305000-00001; Pinkus GS, 1997, AM J PATHOL, V150, P543; Said JW, 1996, BLOOD, V87, P4937, DOI 10.1182/blood.V87.12.4937.bloodjournal87124937; SCHALLING M, 1995, NAT MED, V1, P707, DOI 10.1038/nm0795-707; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; UCHIYAMA H, 1993, BLOOD, V82, P3712; VESCIO RA, 1995, CANC TREATMENT, P1094; Weiss RA, 1996, NAT MED, V2, P277, DOI 10.1038/nm0396-277; Zhong WD, 1996, P NATL ACAD SCI USA, V93, P6641, DOI 10.1073/pnas.93.13.6641; ZHOU LJ, 1995, J IMMUNOL, V154, P3821	40	402	424	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 20	1997	276	5320					1851	1854		10.1126/science.276.5320.1851	http://dx.doi.org/10.1126/science.276.5320.1851			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XF103	9188529				2022-12-01	WOS:A1997XF10300046
J	Schwartz, SH; Tan, BC; Gage, DA; Zeevaart, JAD; McCarty, DR				Schwartz, SH; Tan, BC; Gage, DA; Zeevaart, JAD; McCarty, DR			Specific oxidative cleavage of carotenoids by VP14 of maize	SCIENCE			English	Article							ABSCISIC-ACID; RETINOIC ACID; BEAN-LEAVES; BIOSYNTHESIS; METABOLISM; EXPRESSION; CLONING	The plant growth regulator abscisic acid (ABA) is formed by the oxidative cleavage of an epoxy-carotenoid. The synthesis of other apocarotenoids, such as vitamin A in animals, may occur by a similar mechanism. In ABA biosynthesis, oxidative cleavage is the first committed reaction and is believed to be the key regulatory step. A new ABA-deficient mutant of maize has been identified and the corresponding gene, Vp14, has been cloned. The recombinant VP14 protein catalyzes the cleavage of 9-cis-epoxy-carotenoids to form C-25 apo-aldehydes and xanthoxin, a precursor of ABA in higher plants.	MICHIGAN STATE UNIV, DEPT ENERGY, PLANT RES LAB, E LANSING, MI 48824 USA; UNIV FLORIDA, GRAD PROGRAM PLANT MOL & CELLULAR BIOL, GAINESVILLE, FL 32611 USA; MICHIGAN STATE UNIV, DEPT BIOCHEM, E LANSING, MI 48824 USA	Michigan State University; State University System of Florida; University of Florida; Michigan State University				Schwartz, Steve/0000-0002-5982-8553				BIBIKOV SI, 1993, P NATL ACAD SCI USA, V90, P9446, DOI 10.1073/pnas.90.20.9446; BULOCK JD, 1983, BIOSYNTHESIS ISOPREN, P437; CREELMAN RA, 1984, PLANT PHYSIOL, V75, P166, DOI 10.1104/pp.75.1.166; Douce R., 1979, Advances in Botanical Research, V7, P1, DOI 10.1016/S0065-2296(08)60087-7; FOSTER KW, 1984, NATURE, V311, P756, DOI 10.1038/311756a0; GASKIN P, 1992, GC MS GIBBERELLINS R, pS885; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GOODMAN DS, 1966, J BIOL CHEM, V241, P1929; HAMEL CP, 1993, J BIOL CHEM, V268, P15751; JUTTNER F, 1985, ARCH MICROBIOL, V141, P337, DOI 10.1007/BF00428846; KAMODA S, 1993, BIOSCI BIOTECH BIOCH, V57, P926, DOI 10.1271/bbb.57.926; Kaneko T, 1996, DNA Res, V3, P109; LI Y, 1990, PLANT PHYSIOL, V92, P551, DOI 10.1104/pp.92.3.551; OLSON JA, 1993, AM J CLIN NUTR, V57, P833, DOI 10.1093/ajcn/57.6.833; PARRY AD, 1991, PHYTOCHEMISTRY, V30, P815, DOI 10.1016/0031-9422(91)85258-2; PARRY AD, 1993, METHODS PLANT BIOCH, V9, P381; ROCK CD, 1991, P NATL ACAD SCI USA, V88, P7496, DOI 10.1073/pnas.88.17.7496; SINDHU RK, 1987, PLANT PHYSIOL, V85, P916, DOI 10.1104/pp.85.4.916; Tan B. S. W., UNPUB; TAYLOR HF, 1967, NATURE, V215, P1513, DOI 10.1038/2151513a0; Taylor IB., 1991, ABSCISIC ACID PHYSL, P23; WALD G, 1968, SCIENCE, V162, P230, DOI 10.1126/science.162.3850.230; WANG XD, 1992, ARCH BIOCHEM BIOPHYS, V293, P298, DOI 10.1016/0003-9861(92)90399-H; ZECHMEISTER L, 1962, CIS T ISOMERIC CAROT, P85; ZEEVAART JAD, 1988, ANNU REV PLANT PHYS, V39, P439, DOI 10.1146/annurev.pp.39.060188.002255	25	670	734	6	112	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 20	1997	276	5320					1872	1874		10.1126/science.276.5320.1872	http://dx.doi.org/10.1126/science.276.5320.1872			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XF103	9188535				2022-12-01	WOS:A1997XF10300052
J	Panush, RS; Arend, WP				Panush, RS; Arend, WP			Rheumatology	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ARTHRITIS		UNIV COLORADO,HLTH SCI CTR,DENVER,CO	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Panush, RS (corresponding author), ST BARNABAS HOSP,LIVINGSTON,NJ 07039, USA.							Albani S, 1996, IMMUNOL TODAY, V17, P466, DOI 10.1016/0167-5699(96)20029-G; AREND WP, 1995, ARTHRITIS RHEUM, V38, P151, DOI 10.1002/art.1780380202; Bresnihan B., 1996, Arthritis and Rheumatism, V39, pS73; Epstein WV, 1996, ARTHRITIS RHEUM, V39, P1773, DOI 10.1002/art.1780391102; FOX DA, IN PRESS PERSPECT BI; Kavanaugh A. F., 1996, Arthritis and Rheumatism, V39, pS123; Kotzin BL, 1996, CELL, V85, P303, DOI 10.1016/S0092-8674(00)81108-3; Moreland LW, 1997, ARTHRITIS RHEUM, V40, P397, DOI 10.1002/art.1780400302; Mottonen T, 1996, ARTHRITIS RHEUM, V39, P996, DOI 10.1002/art.1780390617; Muller-Ladner U, 1996, Curr Opin Rheumatol, V8, P210; PANUSH RS, 1995, J RHEUMATOL, V22, P2197; STRAND V, 1996, P EARLY DECISIONS DM, V4, P1; Vyse TJ, 1996, CELL, V85, P311, DOI 10.1016/S0092-8674(00)81110-1; WEYAND CM, 1995, J CLIN INVEST, V95, P2120, DOI 10.1172/JCI117900; Wilske KR, 1996, J RHEUMATOL, V23, P1	15	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	1997	277	23					1899	1900						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD544	9185825				2022-12-01	WOS:A1997XD54400044
J	Snow, RW; Omumbo, JA; Lowe, B; Molyneux, CS; Obiero, JO; Palmer, A; Weber, MW; Pinder, M; Nahlen, B; Obonyo, C; Newbold, C; Gupta, S; Marsh, K				Snow, RW; Omumbo, JA; Lowe, B; Molyneux, CS; Obiero, JO; Palmer, A; Weber, MW; Pinder, M; Nahlen, B; Obonyo, C; Newbold, C; Gupta, S; Marsh, K			Relation between severe malaria morbidity in children and level of Plasmodium falciparum transmission in Africa	LANCET			English	Article							INDICATORS; MORTALITY	Background Malaria remains a major cause of mortality and morbidity in Africa; Many approaches to malaria control involve reducing the chances of infection but little is known of the relations between parasite exposure and the development of effective clinical immunity so the longterm effect of suck approaches to control on the pattern and frequency of malaria cannot be predicted. Methods We have prospectively recorded paediatric admissions with severe malaria over three to five years from five discrete communities in The Gambia and Kenya, Demographic analysis of the communities exposed to disease risk allowed the estimation of age-specific rates for severe malaria. Within each community the exposure to Plasmodium falciparum infection was determined through repeated parasitological and serological surveys among children and infants,We used acute respiratory-tract infections (ARI) as a comparison. Findings 3556 malaria admissions were recorded for the five sites. Marked differences were observed in age, clinical spectrum and rates of severe malaria between the five sites, Paradoxically, the risks of severe disease in childhood were lowest among populations with the highest transmission intensities, and the highest disease risks were observed among populations exposed to low-to-moderate intensities of transmission. For severe malaria, for example, admission rates (per 1000 per year) for children up to their 10th birthday were estimated as 3.9, 25.8, 25.9, 16.7 and 18.0 in the five communities; the forces of infection estimated for those communities (new infections per infant per month) were 0.001, 0.034, 0.050, 0.093, and 0.176, respectively. Similar trends were noted for cerebral malaria and for severe malaria anaemia but not for ARI. Mean age of disease decreased with increasing transmission intensity. Interpretation We propose that a critical determinant of life-time disease risk is the ability to develop clinical immunity early in life during a period when other protective mechanisms may operate. In highly endemic areas measures which reduce parasite transmission,and thus immunity, may lead to a change in both the clinical spectrum of severe disease and the overall burden of severe malaria morbidity.	UNIV OXFORD,JOHN RADCLIFFE HOSP,NUFFIELD DEPT CLIN MED,MOL PARASITOL GRP,INST MOL MED,OXFORD OX3 9DU,ENGLAND; KENYA GOVT MED RES CTR,CLIN RES CTR,COASTAL UNIT,KILIFI,KENYA; ROYAL VICTORIA HOSP,DEPT PAEDIAT,BANJUL,GAMBIA; MRC,FAJARA,GAMBIA; CTR DIS CONTROL,KENYA MED RES INST,COLLABORAT PROGRAMME,VECTOR BIOL & CONTROL RES CTR,KISUMU,KENYA; CTR DIS CONTROL & PREVENT,DIV PARASIT DIS,ATLANTA,GA; UNIV OXFORD,WELLCOME CTR EPIDEMIOL INFECT DIS,DEPT ZOOL,OXFORD OX1 2JD,ENGLAND	University of Oxford; Kenya Medical Research Institute; University of London; London School of Hygiene & Tropical Medicine; Kenya Medical Research Institute; Centers for Disease Control & Prevention - USA; University of Oxford	Snow, RW (corresponding author), KENYA GOVT MED RES CTR,WELLCOME TRUST COLLABORAT PROGRAMME,POB 43640,NAIROBI,KENYA.		Snow, Robert William/AFR-1436-2022; Obonyo, Charles/AAX-5992-2020; Nahlen, Bernard/AAH-2051-2021	Snow, Robert William/0000-0003-3725-6088; Obonyo, Charles/0000-0003-0741-8533; Omumbo, Judy/0000-0002-9475-9346; Molyneux, Catherine/0000-0001-9522-416X; Newbold, Chris/0000-0002-9274-3789	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALONSO PL, 1991, LANCET, V337, P1499, DOI 10.1016/0140-6736(91)93194-E; Arriaga E.E., 1994, POPULATION ANAL MICR; Brabin B., 1990, Tropical Diseases Bulletin, V87, pR1; BREWSTER DR, 1990, LANCET, V336, P1039, DOI 10.1016/0140-6736(90)92498-7; English M, 1996, AM J TROP MED HYG, V55, P521, DOI 10.4269/ajtmh.1996.55.521; EWBANK DC, 1981, AGE MISREPORTING AGE, P1; GARNHAM PCC, 1949, ANN TROP MED PARASIT, V43, P47, DOI 10.1080/00034983.1949.11685394; GREENWOOD B, 1991, PARASITOL TODAY, V7, P277, DOI 10.1016/0169-4758(91)90096-7; LACRITZ EM, 1992, LANCET, V340, P524; LINDSAY SW, 1990, ANN TROP MED PARASIT, V84, P553, DOI 10.1080/00034983.1990.11812510; Macdonald G., 1950, Tropical Diseases Bulletin, V47, P915; MARSH K, 1992, PARASITOLOGY, V104, pS53, DOI 10.1017/S0031182000075247; MARSH K, 1995, NEW ENGL J MED, V332, P1399, DOI 10.1056/NEJM199505253322102; MCGREGOR IA, 1970, CLIN EXP IMMUNOL, V7, P51; MESELAAR D, 1959, TROP GEOG MED, V11, P157; MOLYNEUX ME, 1989, Q J MED, V71, P441; MULLHOLLAND EK, 1997, LANCET, V349, P1191; Nevill CG, 1996, TROP MED INT HEALTH, V1, P139; Snow RW, 1996, AM J TROP MED HYG, V55, P144, DOI 10.4269/ajtmh.1996.55.2.TM0550020144; SNOW RW, 1994, INT J EPIDEMIOL, V23, P1013, DOI 10.1093/ije/23.5.1013; SNOW RW, 1995, PARASITOL TODAY, V11, P188, DOI 10.1016/0169-4758(95)80156-1; SNOW RW, 1992, LANCET, V340, P351, DOI 10.1016/0140-6736(92)91414-4; SNOW RW, 1994, EVALUATION IMPACT HL, P297; TODD JE, 1994, ANN TROP PAEDIATR, V14, P31, DOI 10.1080/02724936.1994.11747689; Trape JF, 1996, PARASITOL TODAY, V12, P236, DOI 10.1016/0169-4758(96)10015-6; vanHensbroek MB, 1996, NEW ENGL J MED, V335, P69, DOI 10.1056/NEJM199607113350201; WARRELL DA, 1990, T R SOC TROP MED S2, V84; *WHO, 1950, TECH REP SER WHO, V38, P1; Wilson D. B., 1950, Tropical Diseases Bulletin, V47, P677	29	493	497	0	58	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 7	1997	349	9066					1650	1654		10.1016/S0140-6736(97)02038-2	http://dx.doi.org/10.1016/S0140-6736(97)02038-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD100	9186382				2022-12-01	WOS:A1997XD10000008
J	Ducy, P; Zhang, R; Geoffroy, V; Ridall, AL; Karsenty, G				Ducy, P; Zhang, R; Geoffroy, V; Ridall, AL; Karsenty, G			Osf2/Cbfa1: A transcriptional activator of osteoblast differentiation	CELL			English	Article							OSTEOCALCIN GENE; C-FOS; RUNT; EXPRESSION; FAMILY; DROSOPHILA; DYSPLASIA; PROMOTER; CELLS; BONE	The osteoblast is the bone-forming cell. The molecular basis of osteoblast-specific gene expression and differentiation is unknown. We previously identified an osteoblast-specific cis-acting element, termed OSE2, in the Osteocalcin promoter. We have now cloned the cDNA encoding Osf2/Cbfa1, the protein that binds to OSE2. Osf2/Cbfa1 expression is initiated in the mesenchymal condensations of the developing skeleton, is strictly restricted to cells of the osteoblast lineage thereafter, and is regulated by BMP7 and vitamin D-3. Osf2/Cbfa1 binds to and regulates the expression of multiple genes expressed in osteoblasts. Finally, forced expression of Osf2/Cbfa1 in nonosteoblastic cells induces the expression of the principal osteoblast-specific genes. this study identifies Osf2/Cbfa1 as an osteoblast-specific transcription factor and as a regulator of osteoblast differentiation.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT MOL GENET,HOUSTON,TX 77030; UNIV TEXAS,DENT BRANCH,DEPT BASIC SCI,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System			Geoffroy, Valerie/P-1521-2014	Geoffroy, Valerie/0000-0003-3920-7482	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE011290] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE-11290] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Aubin Jane E., 1996, P51; BAE SC, 1993, ONCOGENE, V8, P809; BOGDANOVIC Z, 1994, J BONE MINER RES, V9, P285; Cohn MJ, 1996, TRENDS GENET, V12, P253, DOI 10.1016/0168-9525(96)10030-5; DUCY P, 1995, MOL CELL BIOL, V15, P1858; FURUKAWA K, 1990, CELL GROWTH DIFFER, V1, P135; Geoffroy V, 1995, J BIOL CHEM, V270, P30973, DOI 10.1074/jbc.270.52.30973; GERGEN JP, 1985, DEV BIOL, V109, P321, DOI 10.1016/0012-1606(85)90459-2; GOODMAN WG, 1994, KIDNEY INT, V46, P1160, DOI 10.1038/ki.1994.380; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Horton William A., 1993, P73; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; KAUFMAN MH, 1992, ATLAS MOUSE DEV, P389; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KUO CJ, 1992, NATURE, V355, P457, DOI 10.1038/355457a0; Luo GB, 1997, NATURE, V386, P78, DOI 10.1038/386078a0; MERRIMAN HL, 1995, BIOCHEMISTRY-US, V34, P13125, DOI 10.1021/bi00040a025; Molkentin JD, 1996, P NATL ACAD SCI USA, V93, P9366, DOI 10.1073/pnas.93.18.9366; MUNDLOS S, 1995, HUM MOL GENET, V4, P71, DOI 10.1093/hmg/4.1.71; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; Rossert JA, 1996, P NATL ACAD SCI USA, V93, P1027, DOI 10.1073/pnas.93.3.1027; Sambrook J., 1989, MOL CLONING LAB MANU; SATAKE M, 1995, MOL CELL BIOL, V15, P1662; SILLENCE DO, 1987, AM J MED GENET, V27, P75, DOI 10.1002/ajmg.1320270109; SIMEONE A, 1995, DEV DYNAM, V203, P61, DOI 10.1002/aja.1002030107; Speck NA, 1995, CRIT REV EUKAR GENE, V5, P337, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.60; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; SUNDIN OH, 1990, DEVELOPMENT, V108, P47; TOWLER DA, 1994, MOL ENDOCRINOL, V8, P614, DOI 10.1210/me.8.5.614; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WIJMENGA C, 1995, GENOMICS, V26, P611, DOI 10.1016/0888-7543(95)80185-O; Zhang R, 1997, J BIOL CHEM, V272, P110, DOI 10.1074/jbc.272.1.110	36	3383	3611	18	192	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 30	1997	89	5					747	754		10.1016/S0092-8674(00)80257-3	http://dx.doi.org/10.1016/S0092-8674(00)80257-3			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XB925	9182762	Bronze			2022-12-01	WOS:A1997XB92500011
J	Jacq, C; AltMorbe, J; Andre, B; Arnold, W; Bahr, A; Ballesta, JPG; Bargues, M; Baron, L; Becker, A; Biteau, N; Blocker, H; Blugeon, C; Boskovic, J; Brandt, P; Bruckner, M; Buitrago, MJ; Coster, F; Delaveau, T; delRey, F; Dujon, B; Eide, LG; GarciaCantalejo, JM; Goffeau, A; GomezPeris, A; Granotier, C; Hanemann, V; Hankeln, T; Hoheisel, JD; Jager, W; Jimenez, A; Jonniaux, JL; Kramer, C; Kuster, H; Laamanen, P; Legros, Y; Louis, E; MollerRieker, S; Monnet, A; Moro, M; MullerAuer, S; Nussbaumer, B; Paricio, N; Paulin, L; Perea, J; PerezAlonso, M; PerezOrtin, JE; Pohl, TM; Prydz, H; Purnelle, B; Rasmussen, SW; Remacha, M; Revuelta, JL; Rieger, M; Salom, D; Saluz, HP; Saiz, JE; Saren, AM; Schafer, M; Scharfe, M; Schmidt, ER; Schneider, C; Scholler, P; Schwarz, S; SolerMira, A; Urrestarazu, LA; Verhasselt, P; Vissers, S; Voet, M; Volckaert, G; Wagner, G; Wambutt, R; Wedler, E; Wedler, H; Wolfl, S; Harris, DE; Bowman, S; Brown, D; Churcher, CM; Connor, R; Dedman, K; Gentles, S; Hamlin, N; Hunt, S; Jones, L; McDonald, S; Murphy, L; Niblett, D; Odell, C; Oliver, K; Rajandream, MA; Richards, C; Shore, L; Walsh, SV; Barrell, BG; Dietrich, FS; Mulligan, J; Allen, E; Araujo, R; Aviles, E; Berno, O; Carpenter, J; Chen, E; Cherry, JM; Chung, E; Duncan, M; HunickeSmith, S; Hyman, R; Komp, C; Lashkari, D; Lew, H; Lin, D; Mosedale, D; Nakahara, K; Namath, A; Oefner, P; Oh, C; Petel, FX; Roberts, D; Schramm, S; Schroeder, M; Shogren, T; Shroff, N; Winant, A; Yelton, M; Botstein, D; Davis, RW; Johnston, M; Hillier, L; Riles, L; Albermann, K; Hani, J; Heumann, K; Kleine, K; Mewes, HW; Zollner, A; Zaccaria, P				Jacq, C; AltMorbe, J; Andre, B; Arnold, W; Bahr, A; Ballesta, JPG; Bargues, M; Baron, L; Becker, A; Biteau, N; Blocker, H; Blugeon, C; Boskovic, J; Brandt, P; Bruckner, M; Buitrago, MJ; Coster, F; Delaveau, T; delRey, F; Dujon, B; Eide, LG; GarciaCantalejo, JM; Goffeau, A; GomezPeris, A; Granotier, C; Hanemann, V; Hankeln, T; Hoheisel, JD; Jager, W; Jimenez, A; Jonniaux, JL; Kramer, C; Kuster, H; Laamanen, P; Legros, Y; Louis, E; MollerRieker, S; Monnet, A; Moro, M; MullerAuer, S; Nussbaumer, B; Paricio, N; Paulin, L; Perea, J; PerezAlonso, M; PerezOrtin, JE; Pohl, TM; Prydz, H; Purnelle, B; Rasmussen, SW; Remacha, M; Revuelta, JL; Rieger, M; Salom, D; Saluz, HP; Saiz, JE; Saren, AM; Schafer, M; Scharfe, M; Schmidt, ER; Schneider, C; Scholler, P; Schwarz, S; SolerMira, A; Urrestarazu, LA; Verhasselt, P; Vissers, S; Voet, M; Volckaert, G; Wagner, G; Wambutt, R; Wedler, E; Wedler, H; Wolfl, S; Harris, DE; Bowman, S; Brown, D; Churcher, CM; Connor, R; Dedman, K; Gentles, S; Hamlin, N; Hunt, S; Jones, L; McDonald, S; Murphy, L; Niblett, D; Odell, C; Oliver, K; Rajandream, MA; Richards, C; Shore, L; Walsh, SV; Barrell, BG; Dietrich, FS; Mulligan, J; Allen, E; Araujo, R; Aviles, E; Berno, O; Carpenter, J; Chen, E; Cherry, JM; Chung, E; Duncan, M; HunickeSmith, S; Hyman, R; Komp, C; Lashkari, D; Lew, H; Lin, D; Mosedale, D; Nakahara, K; Namath, A; Oefner, P; Oh, C; Petel, FX; Roberts, D; Schramm, S; Schroeder, M; Shogren, T; Shroff, N; Winant, A; Yelton, M; Botstein, D; Davis, RW; Johnston, M; Hillier, L; Riles, L; Albermann, K; Hani, J; Heumann, K; Kleine, K; Mewes, HW; Zollner, A; Zaccaria, P			The nucleotide sequence of Saccharomyces cerevisiae chromosome IV	NATURE			English	Article							COMPLETE DNA-SEQUENCE; YEAST; RESOLUTION; ELEMENTS; XI	The complete DNA sequence of the yeast Saccharomyces cerevisiae chromosome IV has been determined. Apart from chromosome XII, which contains the 1-2 Mb rDNA cluster, chromosome IV is the longest S. cerevisiae chromosome. It was split into three parts, which were sequenced by a consortium from the European Community, the Sanger Centre, and groups from St Louis and Stanford in the United States. The sequence of 1,531,974 base pairs contains 796 predicted or known genes, 318 (39.9%) of which have been previously identified. Of the 478 new genes, 225 (28.3%) are homologous to previously identified genes and 253 (32%) have unknown functions or correspond to spurious open reading frames (ORFs). On average there is one gene approximately every two kilobases. Superimposed on alternating regional variations in G+C composition, there is a large central domain with a lower G+C content that contains all the yeast transposon (Ty) elements and most of the tRNA genes. Chromosome IV shares with chromosomes II, V, XII, XIII and XV some long clustered duplications which partly explain its origin.	LAB DNA ANALYT, D-79100 FREIBURG, GERMANY; LAB PHYSIOL CELLULAIRE & GENET LEVURES, B-1050 BRUSSELS, BELGIUM; UNIV BIELEFELD, FAK BIOL, LEHRSTUHL GENET, D-33501 BIELEFELD, GERMANY; UNIV MAINZ, INST GENET MOL, D-55099 MAINZ, GERMANY; CSIC, CTR BIOL MOL, E-28049 MADRID, SPAIN; UNIV AUTONOMA MADRID, E-28049 MADRID 28049, SPAIN; UNIV VALENCIA, DEPT GENET, E-46100 BURJASSOT, SPAIN; PHARM BIOTECH, F-91898 ORSAY, FRANCE; GB GENOME ANAL, D-38124 BRAUNSCHWEIG, GERMANY; GENOTYPE GMBH, D-69259 WILHELMSFELD, GERMANY; UNIV SALAMANCA, DEPT MICROBIOL & GENET, E-37007 SALAMANCA, SPAIN; UNIV CATHOLIQUE LOUVAIN, UNITE BIOCHIM PHYSIOL, B-1348 LOUVAIN, BELGIUM; INST PASTEUR, DEPT BIOTECHNOL, UNITE GENET MOL LEVURES, F-75724 PARIS 15, FRANCE; CTR BIOTECHNOL, N-0371 OSLO, NORWAY; UNIV VALENCIA, FAC BIOL, DEPT BIOQUIM & BIOL MOL, E-46100 BURJASSOT, SPAIN; HANS KNOLL INST, D-07745 JENA, GERMANY; DEUTSCH KREBSFORSCHUNGSZENTRUM, D-69210 HEIDELBERG, GERMANY; UNIV HELSINKI, INST BIOTECHNOL, DNA SYNTH & SEQUENCING LAB, FIN-00014 HELSINKI, FINLAND; JOHN RADCLIFFE HOSP, INST MOL MED, DEPT YEAST GENET, OXFORD OX3 9DU, ENGLAND; LNCIB, AREA SCI PK, I-34012 TRIESTE, ITALY; GATC GMBH, D-78467 CONSTANCE, GERMANY; CARLSBERG LAB, DK-2500 COPENHAGEN, DENMARK; AGON GMBH, D-12489 BERLIN, GERMANY; KATHOLIEKE UNIV LEUVEN, LAB GENE TECHNOL, B-3001 LOUVAIN, BELGIUM; SANGER CTR, CAMBRIDGE CB10 1SA, ENGLAND; STANFORD UNIV, BECKMAN CTR, DEPT BIOCHEM, STANFORD, CA 94305 USA; WASHINGTON UNIV, SCH MED, DEPT GENET, GENOME SEQUENCING CTR, ST LOUIS, MO 63110 USA; MAX PLANCK INST BIOCHEM, MARTINSRIEDER INST PROT SEQUENZEN, D-82152 MARTINSRIED, GERMANY	University of Bielefeld; Johannes Gutenberg University of Mainz; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Autonomous University of Madrid; University of Valencia; University of Salamanca; Universite Catholique Louvain; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Valencia; Hans Knoll Institute (HKI); Helmholtz Association; German Cancer Research Center (DKFZ); University of Helsinki; University of Oxford; KU Leuven; Wellcome Trust Sanger Institute; Stanford University; Washington University (WUSTL); Max Planck Society	Jacq, C (corresponding author), ECOLE NORMALE SUPER, CNRS, URA 1302, GENET MOL LAB, 46 RUE ULM, F-75230 PARIS 05, FRANCE.		boskovic, jasminka/L-5117-2018; Pérez-Ortín, José E./K-8582-2014; Remacha, Miguel/G-1250-2016; Gómez, Ana/K-6998-2014; Küster, Helge/A-4487-2013; Revuelta, Jose Luis/ABG-1502-2020; Revuelta, Jose L/C-2324-2012; Pérez-Alonso, Manuel/M-3333-2014; Wilson, Richard K./AAF-4139-2019; André, Bruno/D-1725-2010; Oh, Chulmin/ABB-6024-2021; Dujon, Bernard A/F-4971-2010; del Rey, Francisco/L-7132-2014; Louis, Edward/B-7920-2008; Paricio, Nuria/K-2184-2014	boskovic, jasminka/0000-0001-6135-0686; Pérez-Ortín, José E./0000-0002-1992-513X; Gómez, Ana/0000-0003-4714-8064; Küster, Helge/0000-0002-9197-9802; Revuelta, Jose Luis/0000-0001-7838-5308; Revuelta, Jose L/0000-0001-7838-5308; Pérez-Alonso, Manuel/0000-0002-3266-0340; Wilson, Richard K./0000-0002-1992-1358; del Rey, Francisco/0000-0002-6517-7400; Louis, Edward/0000-0003-1157-3608; Paricio, Nuria/0000-0001-7193-2532; Buitrago, Maria Jose/0000-0003-1878-6067; Biteau, Nicolas/0000-0003-1301-0665; Salom, David/0000-0002-3208-1509; Cherry, J. Michael/0000-0001-9163-5180; Hunt, Sarah/0000-0002-8350-1235; Garcia-Cantalejo, Jesus/0000-0001-6465-1273; Murphy, Lee/0000-0001-6467-7449				BUSSEY H, 1995, P NATL ACAD SCI USA, V92, P3809, DOI 10.1073/pnas.92.9.3809; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; Casari G, 1996, TRENDS GENET, V12, P244, DOI 10.1016/0168-9525(96)30057-7; Dujon B, 1996, TRENDS GENET, V12, P263, DOI 10.1016/0168-9525(96)10027-5; DUJON B, 1994, NATURE, V369, P371, DOI 10.1038/369371a0; FELDMANN H, 1994, EMBO J, V13, P5795, DOI 10.1002/j.1460-2075.1994.tb06923.x; Galibert F, 1996, EMBO J, V15, P2031, DOI 10.1002/j.1460-2075.1996.tb00557.x; HEUMANN K, UNPUB NATURE GENET; II H, 1993, CELL, V73, P1007; JINKSROBERTSON S, 1985, P NATL ACAD SCI USA, V82, P3350, DOI 10.1073/pnas.82.10.3350; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; JOHNSTON M, 1994, SCIENCE, V265, P2077, DOI 10.1126/science.8091229; KALOGEROPOULOS A, 1995, YEAST, V11, P555, DOI 10.1002/yea.320110605; KUPIEC M, 1988, MOL CELL BIOL, V8, P2942, DOI 10.1128/MCB.8.7.2942; LALO D, 1993, CR ACAD SCI III-VIE, V316, P367; LOCHMULLER H, 1989, CURR GENET, V16, P247, DOI 10.1007/BF00422110; LOUIS EJ, 1995, GENETICS, V139, P125; MELNICK L, 1993, J MOL BIOL, V233, P372, DOI 10.1006/jmbi.1993.1518; MURAKAMI Y, 1995, NAT GENET, V10, P261, DOI 10.1038/ng0795-261; NAVARRE C, 1994, J BIOL CHEM, V269, P21262; OLIVER SG, 1992, NATURE, V357, P38, DOI 10.1038/357038a0; Oliver SG, 1996, NATURE, V379, P597, DOI 10.1038/379597a0; Olson M., 1991, MOL CELLULAR BIOL YE, P1; PRYDE FE, 1995, YEAST, V11, P371, DOI 10.1002/yea.320110410; RILES L, 1993, GENETICS, V134, P81; SANGER F, 1975, J MOL BIOL, V94, P441, DOI 10.1016/0022-2836(75)90213-2; Termier M, 1996, YEAST, V12, P369, DOI 10.1002/(SICI)1097-0061(19960330)12:4<369::AID-YEA922>3.0.CO;2-#; THIERRY A, 1995, YEAST, V11, P121, DOI 10.1002/yea.320110204; VOYTAS DF, 1993, TRENDS GENET, V9, P421, DOI 10.1016/0168-9525(93)90105-Q	29	80	938	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 29	1997	387	6632		S			75	78		10.1038/387s075	http://dx.doi.org/10.1038/387s075			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XB546	9169867				2022-12-01	WOS:A1997XB54600007
J	Tettelin, H; Carbone, MLA; Albermann, K; Albers, M; Arroyo, J; Backes, U; Barreiros, T; Bertani, I; Bjourson, AJ; Bruckner, M; Bruschi, CV; Carignani, G; Castagnoli, L; Cerdan, E; Clemente, ML; Coblenz, A; Coglievina, M; Coissac, E; Defoor, E; DelBino, S; Delius, H; Delneri, D; deWergifosse, P; Dujon, B; Durand, P; Entian, KD; Eraso, P; Escribano, V; Fabiani, L; Fartmann, B; Feroli, F; Feuermann, M; Frontali, L; GarciaGonzalez, M; GarciaSaez, MI; Goffeau, A; Guerreiro, P; Hani, J; Hansen, M; Hebling, U; Hernandez, K; Heumann, K; Hilger, F; Hofmann, B; Indge, KJ; James, CM; Klima, R; Kotter, P; Kramer, B; Kramer, W; Lauquin, G; Leuther, H; Louis, EJ; Maillier, E; Marconi, A; Martegani, E; Mazon, MJ; Mazzoni, C; McReynolds, ADK; Melchioretto, P; Mewes, HW; Minenkova, O; MullerAuer, S; Nawrocki, A; Netter, P; Neu, R; Nombela, C; Oliver, SG; Panzeri, L; Paoluzi, S; Plevani, P; Portetelle, D; Portillo, F; Potier, S; Purnelle, B; Rieger, M; Riles, L; Rinaldi, T; Robben, J; RodriguesPousada, C; RodriguezBelmonte, E; RodriguezTorres, AM; Rose, M; Ruzzi, M; Saliola, M; SanchezPerez, M; Schafer, B; Schafer, M; Scharfe, M; Schmidhelni, T; Schreer, A; Skala, J; Souciet, JL; Steensma, HY; Talla, E; Thierry, A; Vandenbol, M; vanderAart, QJM; VanDyck, L; Vanoni, M; Verhasselt, P; Voet, M; Volckaert, G; Wambutt, R; Watson, MD; Weber, N; Wedler, E; Wedler, H; Wipfli, P; Wolf, K; Wright, LF; Zaccaria, P; Zimmermann, M; Zollner, A; Kleine, K				Tettelin, H; Carbone, MLA; Albermann, K; Albers, M; Arroyo, J; Backes, U; Barreiros, T; Bertani, I; Bjourson, AJ; Bruckner, M; Bruschi, CV; Carignani, G; Castagnoli, L; Cerdan, E; Clemente, ML; Coblenz, A; Coglievina, M; Coissac, E; Defoor, E; DelBino, S; Delius, H; Delneri, D; deWergifosse, P; Dujon, B; Durand, P; Entian, KD; Eraso, P; Escribano, V; Fabiani, L; Fartmann, B; Feroli, F; Feuermann, M; Frontali, L; GarciaGonzalez, M; GarciaSaez, MI; Goffeau, A; Guerreiro, P; Hani, J; Hansen, M; Hebling, U; Hernandez, K; Heumann, K; Hilger, F; Hofmann, B; Indge, KJ; James, CM; Klima, R; Kotter, P; Kramer, B; Kramer, W; Lauquin, G; Leuther, H; Louis, EJ; Maillier, E; Marconi, A; Martegani, E; Mazon, MJ; Mazzoni, C; McReynolds, ADK; Melchioretto, P; Mewes, HW; Minenkova, O; MullerAuer, S; Nawrocki, A; Netter, P; Neu, R; Nombela, C; Oliver, SG; Panzeri, L; Paoluzi, S; Plevani, P; Portetelle, D; Portillo, F; Potier, S; Purnelle, B; Rieger, M; Riles, L; Rinaldi, T; Robben, J; RodriguesPousada, C; RodriguezBelmonte, E; RodriguezTorres, AM; Rose, M; Ruzzi, M; Saliola, M; SanchezPerez, M; Schafer, B; Schafer, M; Scharfe, M; Schmidhelni, T; Schreer, A; Skala, J; Souciet, JL; Steensma, HY; Talla, E; Thierry, A; Vandenbol, M; vanderAart, QJM; VanDyck, L; Vanoni, M; Verhasselt, P; Voet, M; Volckaert, G; Wambutt, R; Watson, MD; Weber, N; Wedler, E; Wedler, H; Wipfli, P; Wolf, K; Wright, LF; Zaccaria, P; Zimmermann, M; Zollner, A; Kleine, K			The nucleotide sequence of Saccharomyces cerevisiae chromosome VII	NATURE			English	Article							OPEN READING FRAMES; MEMBRANE-SPANNING PROTEINS; COMPLETE DNA-SEQUENCE; RIGHT ARM; KB SEGMENT; ATE1 LOCI; FRAGMENT; REVEALS; GENES; XI	The complete nucleotide sequence of Saccharomyces cerevisiae chromosome VII has 572 predicted open reading frames (ORFs), of which 341 are new. No correlation was found between G+C content and gene density along the chromosome, and their variations are random. Of the ORFs, 17% show high similarity to human proteins. Almost half of the ORFs could be classified in functional categories, and there is a slight increase in the number of transcription (7.0 %) and translation (5.2 %) factors when compared with the complete S. cerevisiae genome. Accurate verification procedures demonstrate that there are less than two errors per 10,000 base pairs in the published sequence.	UNIV CATHOLIQUE LOUVAIN, UNITE BIOCHIM PHYSIOL, B-1348 LOUVAIN, BELGIUM; UNIV MILAN, DIPARTIMENTO GENET & BIOL MICROORGANISMI, I-20133 MILAN, ITALY; MAX PLANCK INST BIOCHEM, MARTINSRIEDER INST PROT SEQUENZEN, D-82152 MARTINSRIED, GERMANY; RHEIN WESTFAL TH AACHEN, INST BIOL 4, D-52056 AACHEN, GERMANY; UNIV COMPLUTENSE MADRID, FAC FARM, DEPT MICROBIOL 2, E-28040 MADRID, SPAIN; UNIV COMPLUTENSE MADRID, FAC FARM, UCM, CTR SECUENCIAC DNA, E-28040 MADRID, SPAIN; GULBENKIAN INST SCI, GENET MOL LAB, P-2781 OEIRAS, PORTUGAL; INT CTR GENET ENGN & BIOTECHNOL, MICROBIOL GRP, I-34012 TRIESTE, ITALY; QUEENS UNIV BELFAST, BIOTECHNOL CTR ANIM & PLANT HLTH, BELFAST BT9 5PX, ANTRIM, NORTH IRELAND; GENOTYPE GMBH, D-69259 WILHELMSFELD, GERMANY; UNIV PADUA, DIPARTIMENTO CHIM BIOL, I-35121 PADUA, ITALY; UNIV ROMA TOR VERGATA, DIPARTIMENTO BIOL, I-00133 ROME, ITALY; UNIV LA CORUNA, FAC CIENCIAS, DEPT BIOL CELULAR & MOL, LA CORUNA, SPAIN; UNIV PARIS 06, CTR GENET MOL, CNRS, LAB ASSOCIE, F-91198 GIF SUR YVETTE, FRANCE; KATHOLIEKE UNIV LEUVEN, LAB GENE TECHNOL, B-3001 LOUVAIN, BELGIUM; DEUTSCH KREBSFORSCHUNGSZENTRUM, DEPT APPL VIROL, D-69120 HEIDELBERG, GERMANY; FAC UNIV SCI AGRON GEMBLOUX, UNITE MICROBIOL, B-5030 GEMBLOUX, BELGIUM; UNIV FRANKFURT, INST MIKROBIOL, D-60439 FRANKFURT, GERMANY; UNIV AUTONOMA MADRID, FAC MED, CSIC, INST INVEST BIOMED, E-28029 MADRID, SPAIN; UNIV AUTONOMA MADRID, FAC MED, DEPT BIOQUIM, E-28029 MADRID, SPAIN; UNIV ROMA LA SAPIENZA, DIPARTIMENTO BIOL CELLULARE & SVILUPPO, I-00185 ROME, ITALY; UNIV GOTTINGEN, INST MOL GENET, D-37077 GOTTINGEN, GERMANY; UNIV STRASBOURG 1, CNRS, INST BOT, LAB MICROBIOL & GENET, URA 1481, F-67083 STRASBOURG, FRANCE; MICROSYNTH GMBH, CH-9436 BALGACH, SWITZERLAND; UNIV MANCHESTER, INST SCI & TECHNOL, DEPT BIOCHEM & APPL MOL BIOL, MANCHESTER M60 1QD, LANCS, ENGLAND; CNRS, INST BIOCHIM CELLULAIRE, F-33077 BORDEAUX, FRANCE; JOHN RADCLIFFE HOSP, INST MOL MED, OXFORD OX3 9DU, ENGLAND; UNIV MILAN, DIPARTIMENTO FISIOL & BIOCHIM GEN, I-20133 MILAN, ITALY; UNIV WROCLAW, INST MICROBIOL, PL-51148 WROCLAW, POLAND; WASHINGTON UNIV, SCH MED, DEPT GENET, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, GENOME SEQUENCING CTR, ST LOUIS, MO 63110 USA; UNIV TUSCIA, DIPARTIMENTO AGROBIOL & AGROCHIM, I-01100 VITERBO, ITALY; AGON GMBH, D-12489 BERLIN, GERMANY; LEIDEN UNIV, INST MOL PLANT SCI, NL-2333 AL LEIDEN, NETHERLANDS; DELFT UNIV TECHNOL, DEPT MICROBIOL & ENZYMOL, NL-2628 BC DELFT, NETHERLANDS; UNIV DURHAM, DEPT BIOL SCI, DURHAM DH1 3LE, ENGLAND; INST PASTEUR, DEPT BIOTECHNOL,CNRS,URA 1149, UNITE GENET MOL LEVURES, F-75724 PARIS 15, FRANCE; UNIV PARIS 06, INST PASTEUR, DEPT BIOTECHNOL, UPR 927, F-75724 PARIS 15, FRANCE	Universite Catholique Louvain; University of Milan; Max Planck Society; RWTH Aachen University; Complutense University of Madrid; Complutense University of Madrid; International Center for Genetic Engineering & Biotechnology (ICGEB); Queens University Belfast; University of Padua; University of Rome Tor Vergata; Universidade da Coruna; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay; KU Leuven; Helmholtz Association; German Cancer Research Center (DKFZ); University of Liege; Goethe University Frankfurt; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Autonomous University of Madrid; Sapienza University Rome; University of Gottingen; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Manchester; Centre National de la Recherche Scientifique (CNRS); University of Oxford; University of Milan; University of Wroclaw; Washington University (WUSTL); Washington University (WUSTL); Tuscia University; Leiden University; Leiden University - Excl LUMC; Delft University of Technology; Durham University; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Sorbonne Universite			Arroyo, Javier/E-9308-2016; Ruzzi, Maurizio/N-1312-2015; Dujon, Bernard A/F-4971-2010; Rodríguez-Belmonte, Esther/AAL-5653-2020; Calpena, María Jesús Mazón/E-9168-2016; Nombela Cano, César/H-2565-2015; Rodríguez-Belmonte, Esther/E-1675-2012; Louis, Edward/B-7920-2008; Entian, Karl-Dieter/D-3080-2011; RUZZI, Maurizio/AAC-2603-2020; Coissac, Éric/AAE-8735-2019; Mazmela, Pilar Eraso/E-9248-2016; Dujon, Bernard/AAL-8410-2021; Mazzoni, Cristina/U-2658-2018; Rinaldi, Teresa/AAC-9710-2020; CERDAN, MARIA ESPERANZA/D-5644-2013; Mewes, Hans-Werner/A-8204-2019	Arroyo, Javier/0000-0002-1971-1721; Ruzzi, Maurizio/0000-0003-4616-1507; Calpena, María Jesús Mazón/0000-0003-4151-4051; Nombela Cano, César/0000-0003-0757-4034; Rodríguez-Belmonte, Esther/0000-0001-8243-1303; Louis, Edward/0000-0003-1157-3608; Coissac, Éric/0000-0001-7507-6729; Mazmela, Pilar Eraso/0000-0002-6928-3219; Dujon, Bernard/0000-0003-4661-3534; Mazzoni, Cristina/0000-0002-1504-6189; Rinaldi, Teresa/0000-0001-6291-245X; CERDAN, MARIA ESPERANZA/0000-0001-8540-1417; PLEVANI, PAOLO/0000-0003-1869-2626; Rodrigues-Pousada, Claudina/0000-0002-5075-3639; Delneri, Daniela/0000-0001-8070-411X; Mewes, Hans-Werner/0000-0002-9713-6398; John, Anthony/0000-0002-1105-7147; Feuermann, Marc/0000-0002-4187-2863; Castagnoli, Luisa/0000-0001-5283-8671; Guerreiro, Paulo/0000-0002-0070-7757; TALLA, Emmanuel/0000-0002-7775-8296; Del Bino, Sandra/0000-0002-8488-1890; Martegani, Enzo/0000-0001-9196-4224; Portillo Perez, Francisco/0000-0003-4922-346X				ARROYO J, 1995, YEAST, V11, P587, DOI 10.1002/yea.320110609; BERTANI I, 1995, YEAST, V11, P1187, DOI 10.1002/yea.320111209; CAPIEAUX E, 1991, YEAST, V7, P275, DOI 10.1002/yea.320070309; CHEN WN, 1991, YEAST, V7, P287, DOI 10.1002/yea.320070311; COGLIEVINA M, 1995, YEAST, V11, P767, DOI 10.1002/yea.320110808; Coissac E, 1996, YEAST, V12, P1555; Dujon B, 1996, TRENDS GENET, V12, P263, DOI 10.1016/0168-9525(96)10027-5; DUJON B, 1994, NATURE, V369, P371, DOI 10.1038/369371a0; Escribano V, 1996, YEAST, V12, P887; GOFFEAU A, 1993, YEAST, V9, P691, DOI 10.1002/yea.320090703; Guerreiro P, 1996, YEAST, V12, P273, DOI 10.1002/(SICI)1097-0061(19960315)12:3<273::AID-YEA898>3.0.CO;2-1; GUERREIRO P, 1995, YEAST, V11, P1087, DOI 10.1002/yea.320111110; Hansen M, 1996, YEAST, V12, P1273, DOI 10.1002/(SICI)1097-0061(19960930)12:12<1273::AID-YEA21>3.0.CO;2-J; JAMES CM, 1995, YEAST, V11, P1413, DOI 10.1002/yea.320111409; KLEIN P, 1985, BIOCHIM BIOPHYS ACTA, V815, P468, DOI 10.1016/0005-2736(85)90375-X; Klima R, 1996, YEAST, V12, P1033; LOUIS EJ, 1995, GENETICS, V139, P125; MILOSAVLJEVIC A, 1993, CABIOS, V9, P409; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; OLIVER SG, 1992, NATURE, V357, P38, DOI 10.1038/357038a0; OLSON MV, 1991, MOL CELLULAR BIOL YE, V1, P1; RodriguezBelmonte E, 1996, YEAST, V12, P145, DOI 10.1002/(SICI)1097-0061(199602)12:2<145::AID-YEA888>3.0.CO;2-E; RYMOND BC, 1993, P NATL ACAD SCI USA, V90, P848, DOI 10.1073/pnas.90.3.848; SKALA J, 1995, YEAST, V11, P1421, DOI 10.1002/yea.320111410; TETTELIN H, 1995, METHODS MOL GENETICS; THIERRY A, 1995, YEAST, V11, P121, DOI 10.1002/yea.320110204; Tizon B, 1996, YEAST, V12, P1047, DOI 10.1002/(SICI)1097-0061(199609)12:10B<1047::AID-YEA991>3.3.CO;2-E; Vandenbol M, 1995, YEAST, V11, P1519, DOI 10.1002/yea.320111507; vanderAart QJM, 1996, YEAST, V12, P385; WOOLFORD JL, 1991, MOL CELLULAR BIOL YE, V1, P597	30	45	655	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 29	1997	387	6632		S			81	84		10.1038/387s081	http://dx.doi.org/10.1038/387s081			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XB546	9169869				2022-12-01	WOS:A1997XB54600009
J	Weissenhorn, W; Dessen, A; Harrison, SC; Skehel, JJ; Wiley, DC				Weissenhorn, W; Dessen, A; Harrison, SC; Skehel, JJ; Wiley, DC			Atomic structure of the ectodomain from HIV-1 gp41	NATURE			English	Article							INFLUENZA-VIRUS HEMAGGLUTININ; MEMBRANE-FUSION; TRANSMEMBRANE GLYCOPROTEIN; ENVELOPE GLYCOPROTEIN; SOLUBLE CD4; TYPE-1; PH; CONFORMATION; PROTEINS; RELEASE	Fusion of viral and cellular membranes by the envelope glycoprotein gp120/gp41 effects entry of HIV-1 into the cell. The precursor, gp160, is cleaved post-translationally into gp120 and gp41 (refs 1, 2), which remain non-covalently associated. Binding to both CD4 and a co-receptor leads to the conformational changes in gp120/gp41 needed for membrane fusion(3). We used X-ray crystallography to determine the structure of the protease-resistant part(4,5) of a gp41 ectodomain solubilized with a trimeric GCN4 coiled coil in place of the amino-terminal fusion peptide(6). The core of the molecule is found to be an extended, triple-stranded alpha-helical coiled coil with the amino terminus at its tip. A carboxy-terminal alpha-helix packs in the reverse direction against the outside of the coiled coil, placing the amino and carboxy termini near each other at one end of the long rod. These features, and the existence of a similar reversal of chain direction in the fusion pH-induced conformation of influenza virus HA2 (ref. 7) and in the transmembrane subunit of Moloney murine leukaemia virus(8) (Fig. 1a-d), suggest a common mechanism for initiating fusion.	CHILDRENS HOSP, MOL MED LAB, BOSTON, MA 02215 USA; CHILDRENS HOSP, HOWARD HUGHES MED INST, BOSTON, MA 02215 USA; HARVARD UNIV, HOWARD HUGHES MED INST, DEPT MOL & CELLULAR BIOL, CAMBRIDGE, MA 02138 USA; NATL INST MED RES, LONDON NW7 1AA, ENGLAND	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Howard Hughes Medical Institute; MRC National Institute for Medical Research				Dessen, Andrea/0000-0001-6487-4020				ALLAN JS, 1985, SCIENCE, V228, P1091, DOI 10.1126/science.2986290; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BLACKLOW SC, 1995, BIOCHEMISTRY-US, V34, P14955, DOI 10.1021/bi00046a001; Brunger AT, 1992, XPLOR VERSION 3 1 MA; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; CHAMBERS P, 1990, J GEN VIROL, V71, P3075, DOI 10.1099/0022-1317-71-12-3075; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; CHEN CH, 1995, J VIROL, V69, P3771, DOI 10.1128/JVI.69.6.3771-3777.1995; Chen J, 1995, P NATL ACAD SCI USA, V92, P12205, DOI 10.1073/pnas.92.26.12205; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; Danieli T, 1996, J CELL BIOL, V133, P559, DOI 10.1083/jcb.133.3.559; DSouza MP, 1996, NAT MED, V2, P1293, DOI 10.1038/nm1296-1293; DUBAY JW, 1992, J VIROL, V66, P4748, DOI 10.1128/JVI.66.8.4748-4756.1992; Fass D, 1996, NAT STRUCT BIOL, V3, P465, DOI 10.1038/nsb0596-465; GALLAHER WR, 1989, AIDS RES HUM RETROV, V5, P431, DOI 10.1089/aid.1989.5.431; HARBURY PB, 1994, NATURE, V371, P80, DOI 10.1038/371080a0; HART TK, 1991, P NATL ACAD SCI USA, V88, P2189, DOI 10.1073/pnas.88.6.2189; KANASEKI T, IN PRESS J CELL BIOL; KIRSH R, 1990, AIDS RES HUM RETROV, V6, P1209, DOI 10.1089/aid.1990.6.1209; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEIKIN S, 1993, ANNU REV PHYS CHEM, V44, P369, DOI 10.1146/annurev.physchem.44.1.369; LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075; MOORE JP, 1990, SCIENCE, V250, P1139, DOI 10.1126/science.2251501; MYERS G, 1995, THEORETICAL BIOL BIO; REY FA, 1995, NATURE, V375, P291, DOI 10.1038/375291a0; RUIGROK RWH, 1988, J GEN VIROL, V69, P2785, DOI 10.1099/0022-1317-69-11-2785; SKEHEL JJ, 1982, P NATL ACAD SCI-BIOL, V79, P968, DOI 10.1073/pnas.79.4.968; Skehel JJ, 1995, COLD SPRING HARB SYM, V60, P573, DOI 10.1101/SQB.1995.060.01.061; VERONESE FD, 1985, SCIENCE, V229, P1402, DOI 10.1126/science.2994223; Weissenhorn W, 1996, EMBO J, V15, P1507, DOI 10.1002/j.1460-2075.1996.tb00494.x; WEISSENHORN W, IN PRESS P NATL ACAD; WHARTON SA, 1995, EMBO J, V14, P240, DOI 10.1002/j.1460-2075.1995.tb06997.x; WILD C, 1992, P NATL ACAD SCI USA, V89, P10537, DOI 10.1073/pnas.89.21.10537; WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770	35	1422	1483	1	101	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 22	1997	387	6631					426	430		10.1038/387426a0	http://dx.doi.org/10.1038/387426a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XA496	9163431				2022-12-01	WOS:A1997XA49600066
J	Rexrode, KM; Hennekens, CH; Willett, WC; Colditz, GA; Stampfer, MJ; RichEdwards, JW; Speizer, FE; Manson, JE				Rexrode, KM; Hennekens, CH; Willett, WC; Colditz, GA; Stampfer, MJ; RichEdwards, JW; Speizer, FE; Manson, JE			A prospective study of body mass index, weight change, and risk of stroke in women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; CARDIOVASCULAR-DISEASE; FAT DISTRIBUTION; FOLLOW-UP; PROSPECTIVE COHORT; CIGARETTE-SMOKING; DIABETES-MELLITUS; SERUM-CHOLESTEROL; HYPERTENSIVE MEN; RELATIVE WEIGHT	Objective.-To examine the associations of body mass index (BMI) and weight change with risk of stroke in women. Setting and Design.-Prospective cohort study among US female registered nurses participating in the Nurses' Health Study. Participants.-A total of 116 759 women aged 30 to 55 years in 1976 who were free from diagnosed coronary heart disease, stroke, and cancer. Main Outcome Measure.-Incidence of ischemic stroke, hemorrhagic stroke (subarachnoid or intraparenchymal hemorrhage), and total stroke. Results.-During 16 years of follow-up, 866 total strokes (including 403 ischemic strokes and 269 hemorrhagic strokes) were documented. In multivariate analyses adjusted for age, smoking, postmenopausal hormone use, and menopausal status, women with increased BMI (greater than or equal to 27 kg/m(2)) had significantly increased risk of ischemic stroke, with relative risks (RRs) of 1.75 (95% confidence interval [CI], 1.17-2.59) for BMI of 27 to 28.9 kg/m(2); 1.90 (95% CI, 1.28-2.82) for BMI of 29 to 31.9 kg/m(2); and 2.37 (95% CI, 1.60-3.50) for BMI of 32 kg/m(2) or more (P for trend<.001), as compared with those with a BMI of less than 21 kg/m(2). For hemorrhagic stroke there was a nonsignificant inverse relation between obesity and hemorrhagic stroke, with the highest risk among women in the leanest BMI category (P for trend=.20). For total stroke the RRs were somewhat attenuated compared with those for ischemic stroke but remained elevated for women with higher BMI (P for trend<.001). In multivariate analyses that also adjusted for BMI at age 18 years, weight gain from age 18 years until 1976 was associated with an RR for ischemic stroke of 1.69 (95% CI, 1.26-2.29) for a gain of 11 to 19.9 kg and 2.52 (95% CI, 1.80-3.52) for a gain of 20 kg or more (P for trend<.001), as compared with women who maintained stable weight (loss or gain <5 kg). Although weight change was not related to risk of hemorrhagic stroke (P for trend=.20), a direct relationship was observed between weight gain and total stroke risk (P for trend<.001). Conclusions.-These prospective data indicate that both obesity and weight gain in women are important risk factors for ischemic and total stroke but not hemorrhagic stroke. The relationship between obesity and total stroke depends on the distribution of stroke subtypes in the population.	BRIGHAM & WOMENS HOSP,DEPT MED,CHANNING LAB,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT AMBULATORY CARE & PREVENT,BOSTON,MA; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT ENVIRONM HLTH,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Rexrode, KM (corresponding author), BRIGHAM & WOMENS HOSP,DIV PREVENT MED,900 COMMONWEALTH AVE E,BOSTON,MA 02115, USA.		Colditz, Graham/A-3963-2009; Rexrode, Kathryn M/I-1177-2018	Colditz, Graham/0000-0002-7307-0291; Rexrode, Kathryn/0000-0003-3387-8429	NATIONAL CANCER INSTITUTE [R01CA040356, R37CA040356] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034595] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABBOTT RD, 1994, STROKE, V25, P2370, DOI 10.1161/01.STR.25.12.2370; BLOOM E, 1986, JAMA-J AM MED ASSOC, V256, P2972, DOI 10.1001/jama.256.21.2972; CARMAN WJ, 1994, CIRCULATION, V89, P703, DOI 10.1161/01.CIR.89.2.703; COLDITZ GA, 1987, AM J EPIDEMIOL, V126, P319, DOI 10.1093/aje/126.2.319; COLDITZ GA, 1986, AM J EPIDEMIOL, V123, P894, DOI 10.1093/oxfordjournals.aje.a114319; COLDITZ GA, 1988, NEW ENGL J MED, V318, P937, DOI 10.1056/NEJM198804143181501; COLDITZ GA, 1990, AM J EPIDEMIOL, V132, P501, DOI 10.1093/oxfordjournals.aje.a115686; DIPIETRO L, 1994, AM J PUBLIC HEALTH, V84, P14, DOI 10.2105/AJPH.84.1.14; FIEBACH NH, 1989, AM J EPIDEMIOL, V130, P646; FOLSOM AR, 1990, STROKE, V21, P701, DOI 10.1161/01.STR.21.5.701; GOLDBOURT U, 1987, HYPERTENSION, V10, P22, DOI 10.1161/01.HYP.10.1.22; HEYDEN S, 1971, ARCH INTERN MED, V128, P956, DOI 10.1001/archinte.128.6.956; HUBERT HB, 1983, CIRCULATION, V67, P968, DOI 10.1161/01.CIR.67.5.968; ISO H, 1989, NEW ENGL J MED, V320, P904, DOI 10.1056/NEJM198904063201405; KNEKT P, 1991, J CLIN EPIDEMIOL, V44, P933, DOI 10.1016/0895-4356(91)90056-F; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; LAPIDUS L, 1984, BMJ-BRIT MED J, V289, P1257, DOI 10.1136/bmj.289.6454.1257; LARSSON B, 1984, BRIT MED J, V288, P1401, DOI 10.1136/bmj.288.6428.1401; LINDENSTROM E, 1993, STROKE, V24, P1468, DOI 10.1161/01.STR.24.10.1468; LINDSTED K, 1991, INT J OBESITY, V15, P397; MANSON JAE, 1990, NEW ENGL J MED, V322, P882, DOI 10.1056/NEJM199003293221303; MANSON JE, 1991, ARCH INTERN MED, V151, P1141, DOI 10.1001/archinte.151.6.1141; MANSON JE, 1991, LANCET, V338, P774, DOI 10.1016/0140-6736(91)90664-B; PAFFENBARGER RS, 1971, AM J EPIDEMIOL, V94, P524, DOI 10.1093/oxfordjournals.aje.a121351; PHILLIPS A, 1989, LANCET, V1, P1005; RHOADS GG, 1983, LANCET, V1, P492; RIMM EB, 1995, AM J EPIDEMIOL, V141, P1117, DOI 10.1093/oxfordjournals.aje.a117385; SELMER R, 1995, J EPIDEMIOL COMMUN H, V49, P265, DOI 10.1136/jech.49.3.265; SHAPER AG, 1991, BRIT MED J, V302, P1111, DOI 10.1136/bmj.302.6785.1111; SHINTON R, 1991, J EPIDEMIOL COMMUN H, V45, P138, DOI 10.1136/jech.45.2.138; SPIEGELMAN D, 1992, AM J CLIN NUTR, V55, P1033, DOI 10.1093/ajcn/55.6.1033; Stamler J, 1991, Ann Epidemiol, V1, P347, DOI 10.1016/1047-2797(91)90045-E; STAMLER R, 1991, HYPERTENSION, V17, P553, DOI 10.1161/01.HYP.17.4.553; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; TANAKA H, 1982, STROKE, V13, P62, DOI 10.1161/01.STR.13.1.62; TERRY RB, 1992, INT J OBESITY, V16, P417; Thom T J, 1993, Ann Epidemiol, V3, P509; TROY LM, 1995, INT J OBESITY, V19, P570; Walker AE, 1981, STROKE S1, V12, pI13; WALKER S, 1995, AM J EPIDEMIOL, V141, pS41; WELIN L, 1987, NEW ENGL J MED, V317, P521, DOI 10.1056/NEJM198708273170901; WILLETT W, 1983, AM J EPIDEMIOL, V117, P651, DOI 10.1093/oxfordjournals.aje.a113598; WILLETT WC, 1995, JAMA-J AM MED ASSOC, V273, P461, DOI 10.1001/jama.273.6.461; YANO K, 1989, STROKE, V20, P1460, DOI 10.1161/01.STR.20.11.1460	44	410	417	0	15	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 21	1997	277	19					1539	1545		10.1001/jama.277.19.1539	http://dx.doi.org/10.1001/jama.277.19.1539			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WY969	9153368				2022-12-01	WOS:A1997WY96900032
J	Mahal, LK; Yarema, KJ; Bertozzi, CR				Mahal, LK; Yarema, KJ; Bertozzi, CR			Engineering chemical reactivity on cell surfaces through oligosaccharide biosynthesis	SCIENCE			English	Article							N-ACETYLNEURAMINIC ACID; SIALIC-ACID; MONOCLONAL-ANTIBODIES; RICIN; MODULATION; PROTEINS; ALDOLASE; ANALOGS; VIRUS	Cell surface oligosaccharides can be engineered to display unusual functional groups for the selective chemical remodeling of cell surfaces. An unnatural derivative of N-acetylmannosamine, which has a ketone group, was converted to the corresponding sialic acid and incorporated into cell surface oligosaccharides metabolically, resulting in the cell surface display of ketone groups. The ketone group on the cell surface can then be covalently ligated under physiological conditions with molecules carrying a complementary reactive functional group such as the hydrazide. Cell surface reactions of this kind should prove useful in the introduction of new recognition epitopes, such as peptides, oligosaccharides, or small organic molecules, onto cell surfaces and in the subsequent modulation of cell-cell or cell-small molecule binding events. The versatility of this technology was demonstrated by an example of selective drug delivery. Cells were decorated with biotin through selective conjugation to ketone groups, and selectively killed in the presence of a ricin A chain-avidin conjugate.	UNIV CALIF BERKELEY,LAWRENCE BERKELEY LAB,CTR ADV MAT,DIV SCI MAT,BERKELEY,CA 94720	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Mahal, LK (corresponding author), UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720, USA.		Mahal, Lara/GRY-7287-2022; Yarema, Kevin/A-3329-2010	Mahal, Lara/0000-0003-4791-8524				AUSUBEL FM, 1994, CURRENT PROTOCOLS MO, V2; BARBIERI L, 1993, BIOCHIM BIOPHYS ACTA, V1154, P237, DOI 10.1016/0304-4157(93)90002-6; CANNE LE, 1995, J AM CHEM SOC, V117, P2998, DOI 10.1021/ja00116a005; DRZENIEK R, 1973, HISTOCHEM J, V5, P271, DOI 10.1007/BF01004994; FITZ W, 1994, J ORG CHEM, V59, P8279, DOI 10.1021/jo00105a057; KAYSER H, 1992, J BIOL CHEM, V267, P16934; KEPPLER OT, 1995, J BIOL CHEM, V270, P1308, DOI 10.1074/jbc.270.3.1308; KOSA RE, 1993, BIOCHEM BIOPH RES CO, V190, P914, DOI 10.1006/bbrc.1993.1136; LIN CH, 1992, J AM CHEM SOC, V114, P10138, DOI 10.1021/ja00052a008; LORD JM, 1994, FASEB J, V8, P201, DOI 10.1096/fasebj.8.2.8119491; NICOLSON GL, 1974, BIOCHEMISTRY-US, V13, P196, DOI 10.1021/bi00698a029; PILLER V, 1990, J BIOL CHEM, V265, P9264; Potvin B, 1995, J BIOL CHEM, V270, P30415, DOI 10.1074/jbc.270.51.30415; RAMAKRISHNAN S, 1984, CANCER RES, V44, P201; RIDEOUT D, 1994, CANCER INVEST, V12, P189, DOI 10.3109/07357909409024874; RIDEOUT D, 1990, BIOPOLYMERS, V29, P247, DOI 10.1002/bip.360290129; ROSE K, 1994, J AM CHEM SOC, V116, P30, DOI 10.1021/ja00080a004; SELL S, 1990, HUM PATHOL, V21, P1003, DOI 10.1016/0046-8177(90)90250-9; SHAMES S L, 1991, Glycobiology, V1, P187, DOI 10.1093/glycob/1.2.187; SHAO J, 1995, J AM CHEM SOC, V117, P3893, DOI 10.1021/ja00119a001; SPARKS MA, 1993, TETRAHEDRON, V49, P1, DOI 10.1016/S0040-4020(01)80502-0; VARKI A, 1991, FASEB J, V5, P226, DOI 10.1096/fasebj.5.2.2004668; WAERREN L, 1994, BOUND CARBOHYDRATES; WRIGHT HT, 1987, ARCH BIOCHEM BIOPHYS, V256, P280, DOI 10.1016/0003-9861(87)90447-4	25	575	670	11	180	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 16	1997	276	5315					1125	1128		10.1126/science.276.5315.1125	http://dx.doi.org/10.1126/science.276.5315.1125			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WZ225	9173543	Green Submitted			2022-12-01	WOS:A1997WZ22500048
J	Kavanagh, AM; Broom, DH				Kavanagh, AM; Broom, DH			Women's understanding of abnormal cervical smear test results: A qualitative interview study	BRITISH MEDICAL JOURNAL			English	Article								Objective: To describe how women interpret their experiences of diagnosis and treatment of a cervical abnormality and how healthcare services for such women can be improved, Design: Qualitative study using detailed individual interviews. Setting: Australian gynaecology clinics. Subjects: 29 Women who had a cervical cytological abnormality and who attended a gynaecologist Main outcome measures: Women's views on their diagnosis and their information needs. Results: Most women wanted to participate in decisions about their care but found it difficult to get the information they required from doctors because they were confused by what their doctors told them and felt unable to ask questions in the consultation. Medical terms such as wart virus and precancer were difficult to understand. Not being able to see their cervix also made it hard for women to understand what their abnormality meant and what treatment entailed. Most women tried to make sense of their abnormality in the context of their everyday lives. For some women their gynaecological care was not consistent with the way they understood their abnormality Conclusions: The inherent power structure of medical practice combined with time pressures often make it difficult for doctors to give the detailed information and reassurance patients need when a diagnosis is distressing or when investigation and treatment are strange and upsetting.	AUSTRALIAN NATL UNIV,NATL CTR EPIDEMIOL & POPULAT HLTH,CANBERRA,ACT 0200,AUSTRALIA	Australian National University	Kavanagh, AM (corresponding author), ANTICANC COUNCIL VICTORIA,CANC EPIDEMIOL CTR,1 RATHDOWNE ST,CARLTON,VIC 3053,AUSTRALIA.		Sandall, Jane/D-4146-2009; Kavanagh, Anne/U-4826-2019	Sandall, Jane/0000-0003-2000-743X; Kavanagh, Anne/0000-0002-1573-3464				BRITTEN N, 1995, BRIT MED J, V311, P251, DOI 10.1136/bmj.311.6999.251; CAMPION MJ, 1988, BRIT J OBSTET GYNAEC, V95, P175, DOI 10.1111/j.1471-0528.1988.tb06848.x; Kavanagh A M, 1996, J Med Screen, V3, P29; LATHER P, 1991, GETTING SMART FEMISI; LERMAN C, 1991, AM J OBSTET GYNECOL, V165, P658, DOI 10.1016/0002-9378(91)90304-A; MAYS N, 1995, BRIT MED J, V311, P109, DOI 10.1136/bmj.311.6997.109; MCDONALD TW, 1989, GYNECOL ONCOL, V34, P345, DOI 10.1016/0090-8258(89)90170-4; Posner T, 1988, PREVENTION CERVICAL; QUILLAM S, 1989, POSITIVE SMEAR; RICHARDS T, 1992, NUDIST 2 3; SCHMERLING A, 1993, MED J AUSTRALIA, V158, P619; Silverman D., 1987, COMMUNICATION MED PR	12	104	104	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 10	1997	314	7091					1388	1391						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WZ169	9161314				2022-12-01	WOS:A1997WZ16900030
J	Brown, RH; Cruikshank, DP; Pendleton, Y; Veeder, GJ				Brown, RH; Cruikshank, DP; Pendleton, Y; Veeder, GJ			Surface composition of Kuiper belt object 1993SC	SCIENCE			English	Article							TRITON; PLUTO; ICES	The 1.42- to 2.40-micrometer spectrum of Kuiper belt object 1993SC was measured at the Keck Observatory in October 1996. It shows a strongly red continuum reflectance and several prominent infrared absorption features. The strongest absorptions in 1993SC's spectrum occur near 1.62, 1.79, 1.95, 2.20, and 2.32 micrometers in wavelength, Features near the same wavelengths in the spectra of Pluto and Neptune's satellite Triton are due to CH4 on their surfaces, suggesting the presence of a simple hydrocarbon ice such as CH4, C2H6, C2H4, or C2H2 on 1993SC. In addition, the red continuum reflectance of 1993SC suggests the presence of more complex hydrocarbons.	UNIV ARIZONA,STEWARD OBSERV,TUCSON,AZ 85721; NASA,AMES RES CTR,MOFFETT FIELD,CA 94035; CALTECH,JET PROP LAB,PASADENA,CA 91109	University of Arizona; National Aeronautics & Space Administration (NASA); NASA Ames Research Center; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL)	Brown, RH (corresponding author), UNIV ARIZONA,LUNAR & PLANETARY LAB,TUCSON,AZ 85721, USA.							BOHN RB, 1994, ICARUS, V111, P151, DOI 10.1006/icar.1994.1138; BROWN GN, 1979, ADV CRYOGEN ENG, V25, P662; *CEL, PROGR EPH MARK CEL; COCHRAN AJ, 1995, ASTRON J, V110, P342; CRUIKSHANK DP, 1993, SCIENCE, V261, P742, DOI 10.1126/science.261.5122.742; CRUIKSHANK DP, UNPUB; DUNCAN M, 1988, ASTROPHYS J, V328, pL69, DOI 10.1086/185162; EDGEWORTH KE, 1949, MON NOT R ASTRON SOC, V109, P600, DOI 10.1093/mnras/109.5.600; Herzberg G., 1945, INFRARED RAMAN SPECT, V2; Jewitt D, 1996, ASTRON J, V112, P1225, DOI 10.1086/118093; Kuiper G.P., 1951, ASTROPHYSICS TOPICAL, P357; Luu JX, 1996, ASTRON J, V111, P499, DOI 10.1086/117801; MARSDEN B, 1996, ORBITAL ELEMENTS OBT; Oort J., 1950, BAIN, V11, P91; OWEN TB, UNPUB; OWEN TC, 1993, SCIENCE, V261, P745, DOI 10.1126/science.261.5122.745; QUIRICO E, 1996, THESIS U J FOURNIER; SAGAN C, 1979, NATURE, V277, P102, DOI 10.1038/277102a0; SCHMITT B, 1995, 27 M DIV PLAN SCI AM; WILLIAMS IP, 1995, ICARUS, V116, P180, DOI 10.1006/icar.1995.1119	20	51	51	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 9	1997	276	5314					937	939		10.1126/science.276.5314.937	http://dx.doi.org/10.1126/science.276.5314.937			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WY792	9163038				2022-12-01	WOS:A1997WY79200044
J	Gottesfeld, JM; Neely, L; Trauger, JW; Baird, EE; Dervan, PB				Gottesfeld, JM; Neely, L; Trauger, JW; Baird, EE; Dervan, PB			Regulation of gene expression by small molecules	NATURE			English	Article							SEQUENCE-SPECIFIC RECOGNITION; POSITIVE TRANSCRIPTION FACTOR; DOUBLE-HELICAL DNA; RNA GENES; MINOR GROOVE; ZINC FINGERS; 5S-RNA GENE; FACTOR-IIIA; COMPLEXES; BINDING	Small molecules that target specific DNA sequences have the potential to control gene expression. Ligands designed for therapeutic application must bind any predetermined DNA sequence with high affinity and permeate living cells. Synthetic polyamides containing-N-methylimidazole and N-methylpyrrole amino acids have an affinity and specificity for DNA comparable to naturally occurring DNA-binding proteins(1). We report here that an eight-ring polyamide targeted to a specific region of the transcription factor TFIIIA binding site interferes with 5S RNA gene expression in Xenopus kidney cells. Our results indicate that pyrrole-imidazole polyamides are cell-permeable and can inhibit the transcription of specific genes.	CALTECH, DIV CHEM & CHEM ENGN, PASADENA, CA 91125 USA; CALTECH, BECKMAN INST, PASADENA, CA 91125 USA	California Institute of Technology; California Institute of Technology	Gottesfeld, JM (corresponding author), SCRIPPS RES INST, DEPT MOL BIOL, LA JOLLA, CA 92037 USA.			Gottesfeld, Joel/0000-0002-4643-5777				Baird EE, 1996, J AM CHEM SOC, V118, P6141, DOI 10.1021/ja960720z; CLEMENS KR, 1992, P NATL ACAD SCI USA, V89, P10822, DOI 10.1073/pnas.89.22.10822; CLEMENS KR, 1994, J MOL BIOL, V244, P23, DOI 10.1006/jmbi.1994.1701; DUVALVALENTIN G, 1992, P NATL ACAD SCI USA, V89, P504, DOI 10.1073/pnas.89.2.504; ENGELKE DR, 1980, CELL, V19, P717, DOI 10.1016/S0092-8674(80)80048-1; FAIRALL L, 1986, J MOL BIOL, V192, P577, DOI 10.1016/0022-2836(86)90278-0; GEIERSTANGER BH, 1994, SCIENCE, V266, P646, DOI 10.1126/science.7939719; HARTL P, 1993, J CELL BIOL, V120, P613, DOI 10.1083/jcb.120.3.613; HAYES JJ, 1992, J MOL BIOL, V227, P407, DOI 10.1016/0022-2836(92)90897-S; HO SN, 1994, P NATL ACAD SCI USA, V91, P9203, DOI 10.1073/pnas.91.20.9203; KEILY JJ, 1996, P NATL ACAD SCI USA, V93, P6981; Liu C, 1996, P NATL ACAD SCI USA, V93, P940, DOI 10.1073/pnas.93.2.940; MAHER LJ, 1992, BIOCHEMISTRY-US, V31, P70, DOI 10.1021/bi00116a012; MOSER HE, 1987, SCIENCE, V238, P645, DOI 10.1126/science.3118463; MRKSICH M, 1992, P NATL ACAD SCI USA, V89, P7586, DOI 10.1073/pnas.89.16.7586; Parks ME, 1996, J AM CHEM SOC, V118, P6147, DOI 10.1021/ja960721r; PELTON JG, 1989, P NATL ACAD SCI USA, V86, P5723, DOI 10.1073/pnas.86.15.5723; PETERSON RC, 1980, CELL, V20, P131, DOI 10.1016/0092-8674(80)90241-X; ROEDER RG, 1983, J BIOL CHEM, V258, P1932; SAKONJU S, 1982, CELL, V31, P395, DOI 10.1016/0092-8674(82)90133-7; SCHLISSEL MS, 1984, CELL, V37, P903, DOI 10.1016/0092-8674(84)90425-2; SMITH DR, 1984, CELL, V37, P645, DOI 10.1016/0092-8674(84)90396-9; STUTZ F, 1989, GENE DEV, V3, P1190, DOI 10.1101/gad.3.8.1190; THUONG NT, 1993, ANGEW CHEM INT EDIT, V32, P666, DOI 10.1002/anie.199306661; Trauger JW, 1996, NATURE, V382, P559, DOI 10.1038/382559a0; Trauger JW, 1996, J AM CHEM SOC, V118, P6160, DOI 10.1021/ja960726o; WADE WS, 1992, J AM CHEM SOC, V114, P8784; White S, 1996, BIOCHEMISTRY-US, V35, P12532, DOI 10.1021/bi960744i; WOLFFE AP, 1988, SCIENCE, V241, P1626, DOI 10.1126/science.3420414	29	458	485	0	26	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 8	1997	387	6629					202	205		10.1038/387202a0	http://dx.doi.org/10.1038/387202a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WX945	9144294				2022-12-01	WOS:A1997WX94500060
J	Martinelli, I; Cattaneo, M; Panzeri, D; Taioli, E; Mannucci, PM				Martinelli, I; Cattaneo, M; Panzeri, D; Taioli, E; Mannucci, PM			Risk factors for deep venous thrombosis of the upper extremities	ANNALS OF INTERNAL MEDICINE			English	Article							ACTIVATED PROTEIN-C; AXILLOSUBCLAVIAN VEIN-THROMBOSIS; RESISTANCE; HYPERHOMOCYST(E)INEMIA; THROMBOPHILIA; PATHOGENESIS; PREVALENCE	Background: Hypercoagulable states and triggering factors (surgery, trauma, immobilization, pregnancy, and use of oral contraceptives) are associated with an increased risk for deep venous thrombosis of the lower extremities. In contrast, risk factors for deep venous thrombosis of the upper extremities have not been identified. Objective: To evaluate the prevalence of hypercoagulable states and triggering factors in patients with primary deep venous thrombosis of the upper extremities. Design: Frequency-matched case-control study. Setting: Hemophilia and thrombosis center at a university hospital. Patients: 36 patients who had primary deep venous thrombosis of the upper extremities, 121 patients who had primary deep venous thrombosis of the lower extremities, end 108 healthy controls. Patients who had deep venous thrombosis of the lower extremities and study controls were frequency-matched by age, sex, geographic origin, and social status with patients who had deep venous thrombosis of the upper extremities. Measurements: Resistance to activated protein C was evaluated by a clotting method based on the activated partial thromboplastin time. If test results were abnormal or borderline, DNA analysis for substitution in coagulation factor V gene was done. Antithrombin, protein C, protein S, antiphospholipid antibodies, and total plasma homocysteine levels were also measured. Results: Prevalences of abnormalities of the natural anticoagulant system (9 %) and hyperhomocysteinemia (6 %) in patients who had deep venous thrombosis of the upper extremities were similar to prevalences of both factors in controls (6% and 7%, respectively) but lower than in patients who had deep venous thrombosis of the lower extremities (31% and 14%, respectively). Antiphospholipid antibodies were found only in patients who had venous thrombosis of the lower extremities (7%). The overall prevalence of hypercoagulable states in patients who had thrombosis of the upper extremities (15%) was similar to that in controls (12%) but was significantly lower than that in patients who had thrombosis of the lower extremities (56%). A recent history of strenuous exercise of muscles in the affected extremity was the most frequent triggering factor for patients who had deep venous thrombosis in the upper extremities (33%). Conclusions: This preliminary study indicates that the prevalence of hypercoagulable states is low in patients who have primary deep venous thrombosis of the upper extremities.	UNIV MILAN, MAGGIORE HOSP, IST RICOVERO & CURA CARATTERE SCI, EPIDEMIOL UNIT, I-20122 MILAN, ITALY	IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan	Martinelli, I (corresponding author), UNIV MILAN, MAGGIORE HOSP, IST RICOVERO & CURA CARATTERE SCI, I-20122 MILAN, ITALY.		Cattaneo, Marco/AAT-4080-2020; Martinelli, ida/J-2287-2015	Martinelli, ida/0000-0001-9218-3622; Cattaneo, Marco/0000-0002-7343-4534				ABURAHMA AF, 1991, AM J SURG, V161, P459, DOI 10.1016/0002-9610(91)91112-V; AZIZ S, 1986, AM J SURG, V152, P57, DOI 10.1016/0002-9610(86)90141-8; BERNARDI E, 1995, DEEP VEIN THROMBOSIS, P191; DAHLBACK B, 1995, BLOOD, V85, P607, DOI 10.1182/blood.V85.3.607.bloodjournal853607; DEMETER SL, 1982, ANGIOLOGY, V33, P743, DOI 10.1177/000331978203301107; DENHEIJER M, 1995, LANCET, V345, P882, DOI 10.1016/S0140-6736(95)90008-X; DERONDE H, 1994, THROMB HAEMOSTASIS, V72, P880; DeStefano V, 1996, BLOOD, V87, P3531, DOI 10.1182/blood.V87.9.3531.bloodjournal8793531; DONAYRE CE, 1986, AM J SURG, V152, P179, DOI 10.1016/0002-9610(86)90238-2; FAIONI EM, 1993, THROMB HAEMOSTASIS, V70, P1067; FALCON CR, 1994, ARTERIOSCLER THROMB, V14, P1080, DOI 10.1161/01.ATV.14.7.1080; Frezzato M, 1996, AM J EPIDEMIOL, V143, P1257; HORATTAS MC, 1988, SURGERY, V104, P561; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; MALINOW MR, 1989, CIRCULATION, V79, P1180, DOI 10.1161/01.CIR.79.6.1180; MALINOW MR, 1994, J INTERN MED, V236, P603, DOI 10.1111/j.1365-2796.1994.tb00854.x; Martinelli I, 1996, THROMB HAEMOSTASIS, V75, P393; PRESCOTT SM, 1979, CIRCULATION, V59, P350, DOI 10.1161/01.CIR.59.2.350; ROCHESTER JR, 1995, BRIT J SURG, V82, P433, DOI 10.1002/bjs.1800820402; Thomas D, 1994, HAEMOSTASIS THROMBOS, P1335	20	80	82	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1997	126	9					707	711		10.7326/0003-4819-126-9-199705010-00006	http://dx.doi.org/10.7326/0003-4819-126-9-199705010-00006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW147	9139557				2022-12-01	WOS:A1997WW14700006
J	Summerfield, JA; Sumiya, M; Levin, M; Turner, MW				Summerfield, JA; Sumiya, M; Levin, M; Turner, MW			Association of mutations in mannose binding protein gene with childhood infection in consecutive hospital series	BRITISH MEDICAL JOURNAL			English	Article							IMMUNODEFICIENCY; DEFECT	Objective: To determine the extent to which mutations in the mannose binding protein gene predispose to childhood infection. Design: Clinical details and genotype of mannose binding protein determined in consecutive children attending a paediatric department. Setting: Inner city hospital paediatric service in London. Subjects: 617 children attending hospital between October 1993 and August 1995. Main outcome measure: Infection as the cause for attendance or admission in relation to mutations in the mannose binding protein gene. Results: The prevalence of mutations in the mannose binding protein gene in children with infection (146/345) was about twice that in children without infection (64/272) (P < 0.0001). Increased susceptibility to infection was found in both heterozygotic and homozygotic children. 13 out of 17 children homozygotic for variant alleles presented with strikingly severe infections, including 6 with septicaemia. Conclusions: The findings suggest that mutations in the mannose binding protein gene are an important risk factor for infections in children. Screening for such mutations should be included in the investigation of severe or frequent infections.	INST CHILD HLTH,IMMUNOBIOL UNIT,LONDON WC1N 1EH,ENGLAND	University of London; University College London	Summerfield, JA (corresponding author), ST MARYS HOSP,IMPERIAL COLL SCH MED,PRAED ST,LONDON W2 1NY,ENGLAND.			Levin, Michael/0000-0003-2767-6919				GARRED P, 1995, LANCET, V346, P941, DOI 10.1016/S0140-6736(95)91559-1; Lipscombe R. J., 1992, Human Molecular Genetics, V1, P709, DOI 10.1093/hmg/1.9.709; Lipscombe RJ, 1996, EUR J HUM GENET, V4, P13; LIPSCOMBE RJ, 1995, IMMUNOLOGY, V85, P660; MADSEN HO, 1994, IMMUNOGENETICS, V40, P37, DOI 10.1007/BF00163962; RICHARDSON VF, 1983, ARCH DIS CHILD, V58, P799, DOI 10.1136/adc.58.10.799; SUMIYA M, 1991, LANCET, V337, P1569, DOI 10.1016/0140-6736(91)93263-9; Sumiya M, 1996, QJM-MON J ASSOC PHYS, V89, P723, DOI 10.1093/qjmed/89.10.723; SUMMERFIELD JA, 1995, LANCET, V345, P886, DOI 10.1016/S0140-6736(95)90009-8; SUPER M, 1989, LANCET, V2, P1236; Turner M W, 1991, Clin Exp Allergy, V21 Suppl 1, P182, DOI 10.1111/j.1365-2222.1991.tb01725.x	11	316	326	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 26	1997	314	7089					1229	1232		10.1136/bmj.314.7089.1229	http://dx.doi.org/10.1136/bmj.314.7089.1229			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW718	9154025	Green Published			2022-12-01	WOS:A1997WW71800016
J	Emerich, DF; Winn, SR; Hantraye, PM; Peschanski, M; Chen, EY; Chu, YP; McDermott, P; Baetge, EE; Kordower, JH				Emerich, DF; Winn, SR; Hantraye, PM; Peschanski, M; Chen, EY; Chu, YP; McDermott, P; Baetge, EE; Kordower, JH			Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington's disease	NATURE			English	Article							PROGRESSIVE MOTOR NEURONOPATHY; FACTOR PREVENTS DEGENERATION; EXCITATORY AMINO-ACIDS; QUINOLINIC ACID; NEURONAL DEATH; NERVOUS-SYSTEM; IMPLANTATION; STRIATUM; MOUSE; NGF	Huntington's disease is a genetic disorder that results from degeneration of striatal neurons, particularly those containing GABA (gamma-aminobutyric acid)(1). There is no effective treatment for preventing or slowing this neuronal degeneration. Ciliary neurotrophic factor (CNTF) is a trophic factor for striatal neurons(2,3) and therefore a potential therapeutic agent for Huntington's disease. Here we evaluate CNTF as a neuroprotective agent in a nonhuman primate model of Huntington's disease. We gave cynomolgus monkeys intrastriatal implants of polymer-encapsulated baby hamster kidney fibroblasts that had been genetically modified to secrete human CNTF. One week later, monkeys received unilateral injections of quinolinic acid into the previously implanted striatum to reproduce the neuropathology seen in Huntington's disease(4,5). Human CNTF was found to exert a neuroprotective effect on several populations of striatal cells, including GABAergic, cholinergic and diaphorase-positive neurons which were all destined to die following: administration of quinolinic acid. Human CNTF also prevented the retrograde atrophy of layer V neurons in motor cortex and exerted a significant protective effect on the GABAergic innervation of the two important target fields of the striatal output neurons (the globus pallidus and pars reticulata of the substantia nigra). Our results show that human CNTF has a trophic influence on degenerating: striatal neurons as well as on critical non-striatal regions such as the cerebral cortex, supporting the idea that human CNTF may help to prevent the degeneration of vulnerable striatal populations and cortical-striatal basal ganglia circuits in Huntington's disease.	CYTOTHERAPEUT INC,PROVIDENCE,RI 02906; OREGON HLTH SCI UNIV,DEPT SURG,PORTLAND,OR 97201; SVC HOSP FREDER JOLIET,CNRS,URA 1285,F-91406 ORSAY,FRANCE; INSERM,U421,FAC MED,F-94010 CRETEIL,FRANCE; RUSH PRESBYTERIAN ST LUKES MED CTR,RES CTR BRAIN REPAIR,CHICAGO,IL 60612; RUSH PRESBYTERIAN ST LUKES MED CTR,DEPT NEUROL SCI,CHICAGO,IL 60612	Oregon Health & Science University; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Franche-Comte; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Rush University; Rush University			Peschanski, Marc/N-5769-2017					ALBIN RL, 1992, NEUROLOGY, V42, P733, DOI 10.1212/WNL.42.4.733; Anderson KD, 1996, P NATL ACAD SCI USA, V93, P7346, DOI 10.1073/pnas.93.14.7346; APFEL SC, 1993, BRAIN RES, V604, P1, DOI 10.1016/0006-8993(93)90345-N; BAETGE EE, 1986, P NATL ACAD SCI USA, V83, P5454, DOI 10.1073/pnas.83.15.5454; BEAL MF, 1992, ANN NEUROL, V31, P119, DOI 10.1002/ana.410310202; BEAL MF, 1986, NATURE, V321, P168, DOI 10.1038/321168a0; BEAL MF, 1989, SYNAPSE, V3, P38, DOI 10.1002/syn.890030106; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CLATTERBUCK RE, 1993, P NATL ACAD SCI USA, V90, P2222, DOI 10.1073/pnas.90.6.2222; EMERICH DF, 1994, EXP NEUROL, V130, P141, DOI 10.1006/exnr.1994.1193; EMERICH DF, 1994, J COMP NEUROL, V349, P148, DOI 10.1002/cne.903490110; Emerich DF, 1996, J NEUROSCI, V16, P5168; EMERICH DF, 1992, NEUROMETHODS, V17, P65; FERRANTE RJ, 1987, BRAIN RES, V415, P178; FRIM DM, 1993, J NEUROSCI RES, V35, P452, DOI 10.1002/jnr.490350413; FRIM DM, 1993, NEUROREPORT, V4, P67; HAGG T, 1992, NEURON, V8, P145, DOI 10.1016/0896-6273(92)90116-U; HAGG T, 1993, P NATL ACAD SCI USA, V90, P6315, DOI 10.1073/pnas.90.13.6315; Kordower JH, 1996, NEUROSCIENCE, V72, P63, DOI 10.1016/0306-4522(95)00543-9; OLNEY JW, 1989, BIOL PSYCHIAT, V26, P505, DOI 10.1016/0006-3223(89)90072-3; PARKER WD, 1990, NEUROLOGY, V40, P1231, DOI 10.1212/WNL.40.8.1231; REINER A, 1988, P NATL ACAD SCI USA, V85, P5733, DOI 10.1073/pnas.85.15.5733; ROBERTS RC, 1989, SYNAPSE, V3, P363, DOI 10.1002/syn.890030410; SAGOT Y, 1995, EUR J NEUROSCI, V7, P1313, DOI 10.1111/j.1460-9568.1995.tb01122.x; SCHUMACHER JM, 1991, NEUROSCIENCE, V45, P561, DOI 10.1016/0306-4522(91)90271-O; SENDTNER M, 1992, NATURE, V358, P502, DOI 10.1038/358502a0; TULIPAN N, 1988, EXP NEUROL, V102, P325, DOI 10.1016/0014-4886(88)90227-0; WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953; WINN SR, 1994, P NATL ACAD SCI USA, V91, P23	29	238	248	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 27	1997	386	6623					395	399		10.1038/386395a0	http://dx.doi.org/10.1038/386395a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WQ170	9121555				2022-12-01	WOS:A1997WQ17000064
J	Salvarani, C; Cantini, F; Olivieri, I; Barozzi, L; Macchioni, L; Niccoli, L; Padula, A; DeMatteis, M; Pavlica, P				Salvarani, C; Cantini, F; Olivieri, I; Barozzi, L; Macchioni, L; Niccoli, L; Padula, A; DeMatteis, M; Pavlica, P			Proximal bursitis in active polymyalgia rheumatica	ANNALS OF INTERNAL MEDICINE			English	Article							GIANT-CELL ARTERITIS; FOLLOW-UP; SYNOVITIS; JOINT; ARTHRITIS; SHOULDER; CRITERIA	Background: The cause of musculoskeletal symptoms in the proximal extremities of patients who have polymyalgia rheumatica is not completely understood. The diffuse and severe discomfort can only be partially explained by the mild joint synovitis that is observed in these patients. Objective: To determine the involvement of the synovial structures of the shoulder girdle of patients who have active symptoms of polymyalgia rheumatica. Design: Case-control study. Setting: 2 secondary referral centers of rheumatology. Patients: 13 case-patients who had active symptoms of polymyalgia rheumatica seen during a 6-month period, 9 control-patients who had early symptoms of elderly-onset rheumatoid arthritis, and 10 age-matched healthy controls. Measurements: Magnetic resonance imaging of the shoulder was done on the 13 case-patients, 9 control-patients, and 10 healthy controls. Results: The frequency of subacromial and subdeltoid bursitis was significantly higher in the case-patients (who had polymyalgia rheumatica) than in the control-patients (who had elderly-onset rheumatoid arthritis). The frequencies of synovitis of the joints and tenosynovitis of the biceps did not significantly differ between the 13 case-patients and the 9 control-patients. None of the healthy controls showed evidence of fluid accumulation in the joints, bursae, or sheaths of the long head of the biceps. Conclusions: Inflammation of subacromial and subdeltoid bursae in association with synovitis of the glenohumeral joints and tenosynovitis of the biceps may contribute to the diffuse discomfort in the shoulder girdle observed in patients with polymyalgia rheumatica.	AZIENDA OSPED ARCISPEDALE S MARIA NUOVA, DIV MED INTERNA 2, UNITA REUMATOL, I-42100 REGGIO EMILIA, ITALY; OSPED PRATO, DIV MED INTERNA 2, UNITA REUMATOL, PRATO, ITALY; AZIENDA OSPED S ORSOLA MALPIGHI, SERV REUMATOL, BOLOGNA, ITALY; AZIENDA OSPED S ORSOLA MALPIGHI, SERV RADIOL, BOLOGNA, ITALY	IRCCS Arcispedale S. Maria Nuova; Prato Hospital; IRCCS Azienda Ospedaliero-Universitaria di Bologna; IRCCS Azienda Ospedaliero-Universitaria di Bologna	Salvarani, C (corresponding author), AZIENDA OSPED ARCISPEDALE S MARIA NUOVA, DIV MED INTERNA, UNITA REUMATOL 2, V UMBERTO 1 N50, I-42100 REGGIO EMILIA, ITALY.		Salvarani, Carlo/K-2431-2018	Salvarani, Carlo/0000-0001-5426-5133				ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; Boiardi L, 1996, BRIT J RHEUMATOL, V35, P642; CHOU CT, 1984, ARTHRITIS RHEUM-US, V27, P1107, DOI 10.1002/art.1780271005; CHUANG TY, 1982, ANN INTERN MED, V97, P672, DOI 10.7326/0003-4819-97-5-672; DOUGLAS WAC, 1983, ANN RHEUM DIS, V42, P311, DOI 10.1136/ard.42.3.311; HEALEY LA, 1984, SEMIN ARTHRITIS RHEU, V13, P322, DOI 10.1016/0049-0172(84)90012-X; KIEFT GJ, 1990, ANN RHEUM DIS, V49, P7, DOI 10.1136/ard.49.1.7; KOSKI JM, 1992, BRIT J RHEUMATOL, V31, P201; MCCARTY DJ, 1985, JAMA-J AM MED ASSOC, V254, P2763, DOI 10.1001/jama.254.19.2763; Meliconi R, 1996, ARTHRITIS RHEUM-US, V39, P1199, DOI 10.1002/art.1780390719; ODUFFY JD, 1976, MAYO CLIN PROC, V51, P519; OLIVIERI I, IN PRESS J CLIN EXP; ROCHE NE, 1993, ARTHRITIS RHEUM, V36, P1286, DOI 10.1002/art.1780360913; SALVARANI C, 1992, J RHEUMATOL, V19, P1100; SALVARANI C, 1995, ARTHRITIS RHEUM, V38, P369, DOI 10.1002/art.1780380311; Salvarani C, 1996, ARTHRITIS RHEUM, V39, P73, DOI 10.1002/art.1780390110; SALVARANI C, 1991, ARTHRITIS RHEUM, V34, P351, DOI 10.1002/art.1780340313; SALVARANI C, 1987, J RHEUMATOL, V14, P1209; SCHWEITZER ME, 1995, RADIOLOGY, V194, P821, DOI 10.1148/radiology.194.3.7862986	19	118	121	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1997	127	1					27	31		10.7326/0003-4819-127-1-199707010-00005	http://dx.doi.org/10.7326/0003-4819-127-1-199707010-00005			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG914	9214249				2022-12-01	WOS:A1997XG91400004
J	Stamler, JS; Jia, L; Eu, JP; McMahon, TJ; Demchenko, IT; Bonaventura, J; Gernert, K; Piantadosi, CA				Stamler, JS; Jia, L; Eu, JP; McMahon, TJ; Demchenko, IT; Bonaventura, J; Gernert, K; Piantadosi, CA			Blood flow regulation by S-nitrosohemoglobin in the physiological oxygen gradient	SCIENCE			English	Article							NITRIC-OXIDE; ARTERIOLES; INHIBITION; CLEARANCE	The binding of oxygen to heme irons in hemoglobin promotes the binding of nitric oxide (NO) to cysteine beta 93, forming S-nitrosohemoglobin. Deoxygenation is accompanied by an allosteric transition in S-nitrosohemoglobin [from the R (oxygenated) to the T (deoxygenated) structure] that releases the NO group, S-nitrosohemoglobin contracts blood vessels and decreases cerebral perfusion in the R structure and relaxes vessels to improve blood flow in the T structure. By thus sensing the physiological oxygen gradient in tissues, hemoglobin exploits conformation-associated changes in the position of cysteine beta 93 SNO to bring local blood flow into line with oxygen requirements.	DUKE UNIV,MED CTR,DEPT MED,DIV CARDIOVASC MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,NICHOLAS SCH ENVIRONM,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University; Duke University; Duke University; Duke University	Stamler, JS (corresponding author), DUKE UNIV,MED CTR,DEPT MED,DIV RESP MED,ROOM 321 MSRB,BOX 2612,DURHAM,NC 27710, USA.		McMahon, Tim/K-3986-2012; Demchenko, Ivan/AAN-8346-2020; Alekseeva, Olga/B-4180-2012	McMahon, Tim/0000-0002-3404-3223; JIA, LEE/0000-0001-6839-5545; Stamler, Jonathan/0000-0002-6866-1572; Demchenko, Ivan/0000-0003-1246-135X; Alekseeva, Olga/0000-0001-5688-347X	NHLBI NIH HHS [HL 52529, HR59130] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052529] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Antonini E., 1971, FRONT BIOL, DOI DOI 10.1126/SCIENCE.178.4058.296; BRAUNWALD E, 1988, HEART DISEASE TXB CA; BUERK DG, 1993, MICROVASC RES, V45, P134, DOI 10.1006/mvre.1993.1013; Casadevall M, 1996, GASTROENTEROLOGY, V110, P1156, DOI 10.1053/gast.1996.v110.pm8613005; DEWHIRST MW, 1994, CANCER RES, V54, P3333; DULING BR, 1970, CIRC RES, V27, P669, DOI 10.1161/01.RES.27.5.669; FILHO IPT, 1996, MICROVASC RES, V51, P202; GUYTON AC, 1981, TXB MED PHYSL, P208; GUYTON AC, 1981, TXB MED PHYSL, P504; HAMPL V, 1993, J APPL PHYSIOL, V75, P1748, DOI 10.1152/jappl.1993.75.4.1748; HEISS WD, 1981, STROKE, V12, P161, DOI 10.1161/01.STR.12.2.161; Intaglietta M, 1996, CARDIOVASC RES, V32, P632; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; Kasper SM, 1996, ANESTH ANALG, V83, P921; KERGER H, 1995, AM J PHYSIOL-HEART C, V268, pH802, DOI 10.1152/ajpheart.1995.268.2.H802; KING CE, 1994, J APPL PHYSIOL, V76, P1166, DOI 10.1152/jappl.1994.76.3.1166; Mitchell D, 1996, AM J PHYSIOL-HEART C, V270, pH1696, DOI 10.1152/ajpheart.1996.270.5.H1696; OAE S, 1983, ORG PREP PROCED INT, V15, P165, DOI 10.1080/00304948309355444; PARK KH, 1992, CIRC RES, V71, P992, DOI 10.1161/01.RES.71.4.992; PERSSON MG, 1990, BRIT J PHARMACOL, V100, P463, DOI 10.1111/j.1476-5381.1990.tb15829.x; PERUTZ MF, 1987, MOL BASIS BLOOD DISE, P127; Piantadosi CA, 1997, FREE RADICAL BIO MED, V22, P725, DOI 10.1016/S0891-5849(96)00423-6; POPEL AS, 1989, AM J PHYSIOL, V256, pH921, DOI 10.1152/ajpheart.1989.256.3.H921; POPEL AS, 1989, AM J PHYSIOL, V256, pH247; POPEL AS, 1991, AM J PHYSIOL, V261, P669; STAMLER J, UNPUB; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; Stamler JS, 1996, NATURE, V380, P108; STRYER L, 1981, BIOCHEMISTRY-US, P43; Tibbles PM, 1996, NEW ENGL J MED, V334, P1642, DOI 10.1056/NEJM199606203342506; YOUNG W, 1980, STROKE, V11, P552, DOI 10.1161/01.STR.11.5.552	31	881	906	1	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 27	1997	276	5321					2034	2037		10.1126/science.276.5321.2034	http://dx.doi.org/10.1126/science.276.5321.2034			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XG748	9197264				2022-12-01	WOS:A1997XG74800062
J	Emanuel, EJ				Emanuel, EJ			Care for dying patients	LANCET			English	Editorial Material									HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	Emanuel, EJ (corresponding author), DANA FARBER CANC INST,CTR OUTCOMES & POLICY RES,BOSTON,MA 02115, USA.							COOK DJ, 1995, JAMA-J AM MED ASSOC, V273, P703, DOI 10.1001/jama.273.9.703; EMANUEL L, 1995, JAMA-J AM MED ASSOC, V274, P501, DOI 10.1001/jama.274.6.501; LEE DKP, 1994, JAMA-J AM MED ASSOC, V271, P1358, DOI 10.1001/jama.271.17.1358; Prendergast TJ, 1997, AM J RESP CRIT CARE, V155, P15, DOI 10.1164/ajrccm.155.1.9001282; *SUPPORT PRINC INV, 1995, JAMA-J AM MED ASSOC, V274, P1591; Tulsky JA, 1996, ARCH INTERN MED, V156, P1285, DOI 10.1001/archinte.156.12.1285	6	15	16	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 14	1997	349	9067					1714	1714		10.1016/S0140-6736(05)62952-2	http://dx.doi.org/10.1016/S0140-6736(05)62952-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XE065	9193379				2022-12-01	WOS:A1997XE06500006
J	Krauzlis, RJ; Basso, MA; Wurtz, RH				Krauzlis, RJ; Basso, MA; Wurtz, RH			Shared motor error for multiple eye movements	SCIENCE			English	Article							SUPERIOR COLLICULUS; FIXATION; LESIONS; SYSTEM; MONKEY; AREA	Most natural actions are accomplished with a seamless combination of individual movements, Such coordination poses a problem: How does the motor system orchestrate multiple movements to produce a single goal-directed action? The results from current experiments suggest one possible solution. Oculomotor neurons in the superior colliculus of a primate responded to mismatches between eye and target positions, even when the animal made two different types of eye movements. This neuronal activity therefore does not appear to convey a command for a specific type of eye movement but instead encodes an error signal that could be used by multiple movements, The use of shared inputs is one possible strategy for ensuring that different movements share a common goal.	NEI,SENSORIMOTOR RES LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)				Richard, Krauzlis/0000-0002-1826-0447				Freedman Edward G., 1994, Society for Neuroscience Abstracts, V20, P142; Krauzlis RJ, 1996, VISION RES, V36, P1973, DOI 10.1016/0042-6989(95)00307-X; Krauzlis RJ, 1996, J NEUROPHYSIOL, V76, P2822, DOI 10.1152/jn.1996.76.5.2822; Leigh RJ, 1991, NEUROLOGY EYE MOVEME, V2; MUNOZ DP, 1992, J NEUROPHYSIOL, V67, P1000, DOI 10.1152/jn.1992.67.4.1000; MUNOZ DP, 1993, J NEUROPHYSIOL, V70, P559, DOI 10.1152/jn.1993.70.2.559; MUNOZ DP, 1991, J NEUROPHYSIOL, V66, P1624, DOI 10.1152/jn.1991.66.5.1624; NEWSOME WT, 1985, J NEUROSCI, V5, P825; SCHILLER PH, 1994, VISUAL NEUROSCI, V11, P229, DOI 10.1017/S0952523800001590; SINGER W, 1995, ANNU REV NEUROSCI, V18, P555, DOI 10.1146/annurev.neuro.18.1.555; SPARKS DL, 1990, ANNU REV NEUROSCI, V13, P309, DOI 10.1146/annurev.ne.13.030190.001521; VANESSEN DC, 1994, NEURON, V13, P1, DOI 10.1016/0896-6273(94)90455-3; WERNER W, 1993, EUR J NEUROSCI, V5, P335, DOI 10.1111/j.1460-9568.1993.tb00501.x; Zeki S., 1993, VISION BRAIN	14	142	143	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 13	1997	276	5319					1693	1695		10.1126/science.276.5319.1693	http://dx.doi.org/10.1126/science.276.5319.1693			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XD947	9180078				2022-12-01	WOS:A1997XD94700041
J	Marcotrigiano, J; Gingras, AC; Sonenberg, N; Burley, SK				Marcotrigiano, J; Gingras, AC; Sonenberg, N; Burley, SK			Cocrystal structure of the messenger RNA 5' cap-binding protein (eIF4E) bound to 7-methyl-GDP	CELL			English	Article							TRANSLATION INITIATION-FACTOR; IMPORTANT AROMATIC-COMPOUNDS; SITE-DIRECTED MUTAGENESIS; FACTOR EIF-4E; INDOLE-DERIVATIVES; EUKARYOTIC TRANSLATION; STACKING INTERACTION; CRYSTAL-STRUCTURE; SEQUENCE; RECOGNITION	The X-ray structure of the eukaryotic translation initiation factor 4E (elF4E), bound to 7-methyl-GDP, has been determined at 2.2 Angstrom resolution. elF4E recognizes 5' 7-methyl-G(5')ppp(5')N mRNA caps during the rate-limiting initiation step of translation. The protein resembles a cupped hand and consists of a curved, 8-stranded antiparallel beta sheet, backed by three long alpha helices. 7-methyl-GDP binds in a narrow cap-binding slot on the molecule's concave surface, where 7-methyl-guanine recognition is mediated by base sandwiching between two conserved tryptophans, plus formation of three hydrogen bonds and a van der Waals contact between its N7-methyl group and a third conserved tryptophan. The convex dorsal surface of the molecule displays a phylogenetically conserved hydrophobic/acidic portion, which may interact with other translation initiation factors and regulatory proteins.	ROCKEFELLER UNIV,MOL BIOPHYS LAB,NEW YORK,NY 10021; ROCKEFELLER UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10021; MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,MCGILL CANC CTR,MONTREAL,PQ H3G 1Y6,CANADA	Rockefeller University; Howard Hughes Medical Institute; Rockefeller University; McGill University; McGill University			Gingras, Anne-Claude/ABA-8341-2020; Marcotrigiano, Joseph/K-6697-2016; Gingras, Anne-Claude/E-9982-2010	Gingras, Anne-Claude/0000-0002-6090-4437; Marcotrigiano, Joseph/0000-0003-0346-3353; Gingras, Anne-Claude/0000-0002-6090-4437; Burley, Stephen/0000-0002-2487-9713	NIGMS NIH HHS [GM07982] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS BL, 1978, J BIOL CHEM, V253, P2589; ALTMANN M, 1989, NUCLEIC ACIDS RES, V17, P5923, DOI 10.1093/nar/17.15.5923; Altmann M, 1997, EMBO J, V16, P1114, DOI 10.1093/emboj/16.5.1114; ALTMANN M, 1988, J BIOL CHEM, V263, P17229; ALTMANN M, 1989, J BIOL CHEM, V264, P12145; ALTMANN M, 1987, MOL CELL BIOL, V7, P998, DOI 10.1128/MCB.7.3.998; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1993, X PLOR V 3 1 MANUAL; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHRISTIANSON DW, 1989, ACCOUNTS CHEM RES, V22, P62, DOI 10.1021/ar00158a003; Cohen SL, 1996, STRUCTURE, V4, P1013, DOI 10.1016/S0969-2126(96)00108-6; DARZYNKIEWICZ E, 1988, NUCLEIC ACIDS RES, V16, P8953, DOI 10.1093/nar/16.18.8953; DARZYNKIEWICZ E, 1985, BIOCHEMISTRY-US, V24, P1701, DOI 10.1021/bi00328a020; DARZYNKIEWICZ E, 1989, BIOCHEMISTRY-US, V28, P4771, DOI 10.1021/bi00437a038; EDERY I, 1988, GENE, V74, P517, DOI 10.1016/0378-1119(88)90184-9; FRIEDLAND DE, 1996, PROTEIN SCI, V6, P125; FURUICHI Y, 1979, J BIOL CHEM, V254, P6732; GILSON MK, 1988, J COMPUT CHEM, V9, P327, DOI 10.1002/jcc.540090407; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HERNANDEZ G, 1995, BBA-GENE STRUCT EXPR, V1261, P427, DOI 10.1016/0167-4781(95)00039-J; Hodel AE, 1996, CELL, V85, P247, DOI 10.1016/S0092-8674(00)81101-0; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; ISHIDA T, 1991, J CHEM SOC PERK T 1, P1847, DOI 10.1039/p19910001847; ISHIDA T, 1983, BIOCHEMISTRY-US, V22, P3571, DOI 10.1021/bi00284a006; ISHIDA T, 1988, J AM CHEM SOC, V110, P2286, DOI 10.1021/ja00215a046; IZAURRALDE E, 1994, CELL, V78, P657, DOI 10.1016/0092-8674(94)90530-4; Jones RM, 1996, MOL CELL BIOL, V16, P4754; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JOSHI B, 1995, J BIOL CHEM, V270, P14597, DOI 10.1074/jbc.270.24.14597; Kjeldgaard M, 1996, FASEB J, V10, P1347, DOI 10.1096/fasebj.10.12.8903506; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; MADER S, 1995, MOL CELL BIOL, V15, P4990; MANTEUFFEL SR, 1996, P NATL ACAD SCI USA, V93, P4076; Mathews M. B., 1996, TRANSLATIONAL CONTRO, P1; Merrick WC., 1996, TRANSLATION CONTROL, P31; METZ AM, 1992, NUCLEIC ACIDS RES, V20, P4096, DOI 10.1093/nar/20.15.4096; MINICH WB, 1994, P NATL ACAD SCI USA, V91, P7668, DOI 10.1073/pnas.91.16.7668; Miyagi Y, 1995, LAB INVEST, V73, P890; Morino S, 1996, EUR J BIOCHEM, V239, P597, DOI 10.1111/j.1432-1033.1996.0597u.x; Nagai K, 1996, CURR OPIN STRUC BIOL, V6, P53, DOI 10.1016/S0959-440X(96)80095-9; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; PATIKOGLOU G, 1997, ANNU REV BIOPH BIOM, V26, P287; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Ptushkina M, 1996, J BIOL CHEM, V271, P32818, DOI 10.1074/jbc.271.51.32818; RHOADS RE, 1983, BIOCHEMISTRY-US, V22, P6084, DOI 10.1021/bi00295a007; RYCHLIK W, 1987, P NATL ACAD SCI USA, V84, P945, DOI 10.1073/pnas.84.4.945; RYCHLIK W, 1992, NUCLEIC ACIDS RES, V20, P6415, DOI 10.1093/nar/20.23.6415; SACHS A, 1993, J BIOL CHEM, V268, P22955; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; SHATKIN AJ, 1976, CELL, V9, P645, DOI 10.1016/0092-8674(76)90128-8; SONENBERG N, 1978, P NATL ACAD SCI USA, V75, P4843, DOI 10.1073/pnas.75.10.4843; SONENBERG N, 1979, P NATL ACAD SCI USA, V76, P4345, DOI 10.1073/pnas.76.9.4345; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; Svitkin YV, 1996, EMBO J, V15, P7147, DOI 10.1002/j.1460-2075.1996.tb01106.x; UEDA H, 1991, FEBS LETT, V280, P207, DOI 10.1016/0014-5793(91)80294-D; UEDA H, 1991, J BIOCHEM-TOKYO, V109, P882, DOI 10.1093/oxfordjournals.jbchem.a123475; VALEGARD K, 1994, NATURE, V371, P623, DOI 10.1038/371623a0; Vasilescu S, 1996, J BIOL CHEM, V271, P7030, DOI 10.1074/jbc.271.12.7030; WAKIYAMA M, 1995, FEBS LETT, V360, P191, DOI 10.1016/0014-5793(95)00081-J; Whalen SG, 1996, J BIOL CHEM, V271, P11831, DOI 10.1074/jbc.271.20.11831	64	553	561	1	49	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 13	1997	89	6					951	961		10.1016/S0092-8674(00)80280-9	http://dx.doi.org/10.1016/S0092-8674(00)80280-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XE357	9200613	Bronze			2022-12-01	WOS:A1997XE35700015
J	Flatau, G; Lemichez, E; Gauthier, M; Chardin, P; Paris, S; Fiorentini, C; Boquet, P				Flatau, G; Lemichez, E; Gauthier, M; Chardin, P; Paris, S; Fiorentini, C; Boquet, P			Toxin-induced activation of the G protein p21 Rho by deamidation of glutamine	NATURE			English	Article							CYTOTOXIC NECROTIZING FACTOR; ACTIN STRESS FIBERS; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; FOCAL ADHESIONS; FACTOR-I; GTP; CELLS; RAC; PURIFICATION	Pathogenic Escherichia coli are responsible for a variety of diseases, including diarrhoea, haemolytic uraemic syndrome, kidney infection, septicaemia, pneumonia and meningitis. Toxins called cytotoxic necrotizing factors (CNFs) are among the virulence factors produced by uropathogenic (CNF1)(1) or enteropathogenic (CNF2)(2) E. coli strains that cause diseases in humans and animals, respectively. CNFs induce an increase in the content of actin stress fibres and focal contacts in cultured cells(3,4). Effects of CNFs on the actin cytoskeleton correlated with a decrease in the electrophoretic mobility of the GTP-binding protein Rho(4,5) and indirect evidence indicates that CNF1 might constitutively activate Rho(6). Here we show that CNF1 catalyses the deamidation of a glutamine residue at position 63 of Rho, turning it into glutamic acid, which inhibits both intrinsic GTP hydrolysis and that stimulated by its GTPase-activating protein (GAP). Thus, this deamidation of glutamine 63 by CNF1 leads to the constitutive activation of Rho, and induces the reorganization of actin stress fibres. To our knowledge, CNF1 is the first example of a bacterial toxin acting by deamidation of a specific target protein.	FAC MED,INSERM,U452,F-06107 NICE 2,FRANCE; CNRS,INST PHARMACOL MOL & CELLULAIRE,ROUTE LUCIOLES,SOPHIA ANTIPOLIS,F-06560 VALBONNE,FRANCE; IST SUPER SANITA,DEPT ULTRASTRUCT,I-00161 ROME,ITALY	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Universite de Franche-Comte; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Istituto Superiore di Sanita (ISS)			Fiorentini, Carla/Q-2088-2015; FIORENTINI, CARLA/AAG-8005-2019; Lemichez, Emmanuel/G-3559-2013	Fiorentini, Carla/0000-0003-1707-6282; FIORENTINI, CARLA/0000-0003-1707-6282; Lemichez, Emmanuel/0000-0001-9080-7761				Adam T, 1996, EMBO J, V15, P3315, DOI 10.1002/j.1460-2075.1996.tb00696.x; CAPRIOLI A, 1983, INFECT IMMUN, V39, P1300, DOI 10.1128/IAI.39.3.1300-1306.1983; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; DERYCKE J, 1990, J CLIN MICROBIOL, V28, P694, DOI 10.1128/JCM.28.4.694-699.1990; FALBO V, 1993, INFECT IMMUN, V61, P4909, DOI 10.1128/IAI.61.11.4909-4914.1993; FALZANO L, 1993, MOL MICROBIOL, V9, P1247, DOI 10.1111/j.1365-2958.1993.tb01254.x; FIORENTINI C, 1988, TOXICON, V26, P1047, DOI 10.1016/0041-0101(88)90203-6; FIORENTINI C, 1995, INFECT IMMUN, V63, P3936, DOI 10.1128/IAI.63.10.3936-3944.1995; FIORENTINI C, 1994, ZBL BAKT S, V24, P404; Franco M, 1996, J BIOL CHEM, V271, P1573, DOI 10.1074/jbc.271.3.1573; GARRETT MD, 1991, BIOCHEM J, V276, P833, DOI 10.1042/bj2760833; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P757; HORIGUCHI Y, 1995, J CELL SCI, V108, P3243; Machesky LM, 1996, TRENDS CELL BIOL, V6, P304, DOI 10.1016/0962-8924(96)10026-X; NISHIYAMA T, 1994, MOL CELL BIOL, V14, P2447, DOI 10.1128/MCB.14.4.2447; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OSWALD E, 1994, P NATL ACAD SCI USA, V91, P3814, DOI 10.1073/pnas.91.9.3814; RIDLEY AJ, 1995, METHOD ENZYMOL, V256, P313; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SELF AJ, 1995, METHOD ENZYMOL, V256, P67; SELF AJ, 1995, METHOD ENZYMOL, V256, P3; SRIVASTAVA SK, 1985, P NATL ACAD SCI USA, V82, P38, DOI 10.1073/pnas.82.1.38; WALKER KE, 1994, INFECT IMMUN, V62, P3817, DOI 10.1128/IAI.62.9.3817-3828.1994; Watarai M, 1997, J EXP MED, V185, P281, DOI 10.1084/jem.185.2.281; YERAMIAN P, 1987, NUCLEIC ACIDS RES, V15, P1869, DOI 10.1093/nar/15.4.1869	27	406	411	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 12	1997	387	6634					729	733		10.1038/42743	http://dx.doi.org/10.1038/42743			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XD869	9192901	Bronze			2022-12-01	WOS:A1997XD86900060
J	MarslenWilson, WD; Tyler, LK				MarslenWilson, WD; Tyler, LK			Dissociating types of mental computation	NATURE			English	Article							MORPHOLOGY; LANGUAGE; APHASICS; DYSLEXIA; WORDS	A fundamental issue in the study of cognition and the brain is the nature of mental computation. How far does this depend on internally represented systems of rules, expressed as strings of symbols with a syntax, as opposed to more distributed neural systems, operating subsymbolically and without syntax? The mental representation of the regular and irregular past tense of the English verb has become a crucial test case for this debate. Single-mechanism approaches argue that current multilayer connectionist networks can account for the learning and representation both of regular and of irregular forms(1,2). Dual-mechanism approaches, although accepting connectionist accounts for the irregular forms, argue that a symbolic, rule-based system is required to explain the properties of the regular past tense and, by extension, the properties of language and cognition in general(3-5). We show here that the regular and irregular past tense are supported by different neural systems, which can become dissociated by damage to the brain(6,7). This is evidence for functional and neurological distinctions in the types of mental computation that support these different aspects of linguistic and cognitive performance.			MarslenWilson, WD (corresponding author), UNIV LONDON BIRKBECK COLL,CTR SPEECH & LANGUAGE,MALET ST,LONDON WC1E 7HY,ENGLAND.			Tyler, Lorraine/0000-0002-9943-118X; Marslen-Wilson, William/0000-0003-0690-6308	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Black M., 1991, J NEUROLINGUIST, V6, P79; FUNNELL E, 1987, Q J EXP PSYCHOL-A, V39, P497, DOI 10.1080/14640748708401801; GOODGLASS H, 1982, ASSESSMENT APHASIA R; Kay J.M., 1992, PALPA PSYCHOLINGUIST; LINEBARGER MC, 1983, COGNITION, V13, P361, DOI 10.1016/0010-0277(83)90015-X; OSTRIN RK, 1995, COGNITIVE NEUROPSYCH, V12, P345, DOI 10.1080/02643299508252002; PATTERSON KE, 1977, Q J EXP PSYCHOL, V29, P307, DOI 10.1080/14640747708400606; PINKER S, 1988, COGNITION, V28, P73, DOI 10.1016/0010-0277(88)90032-7; PINKER S, 1991, SCIENCE, V253, P530, DOI 10.1126/science.1857983; PLUNKETT K, 1993, COGNITION, V48, P21, DOI 10.1016/0010-0277(93)90057-3; PRASADA S, 1993, LANG COGNITIVE PROC, V8, P1, DOI 10.1080/01690969308406948; Rumelhart D.E., 1986, PARALLEL DISTRIBUTED, P216; SHALLICE T, 1988, NEUROPYSHCOLOGY MENT; TEUBER HL, 1955, ANNU REV PSYCHOL, V9, P267; TYLER LK, 1995, BRAIN LANG, V48, P131, DOI 10.1006/brln.1995.1007; TYLER LK, 1994, NEUROPSYCHOLOGIA, V32, P1001, DOI 10.1016/0028-3932(94)90049-3; TYLER LK, 1992, SPOKEN LANGUAGE COMP	17	168	172	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 5	1997	387	6633					592	594		10.1038/42456	http://dx.doi.org/10.1038/42456			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	XC522	9177345				2022-12-01	WOS:A1997XC52200053
J	Baskaran, R; Wood, LD; Whitaker, LL; Canman, CE; Morgan, SE; Xu, Y; Barlow, C; Baltimore, D; WynshawBoris, A; Kastan, MB; Wang, JYJ				Baskaran, R; Wood, LD; Whitaker, LL; Canman, CE; Morgan, SE; Xu, Y; Barlow, C; Baltimore, D; WynshawBoris, A; Kastan, MB; Wang, JYJ			Ataxia telangiectasia mutant protein activates c-Abl tyrosine kinase in response to ionizing radiation	NATURE			English	Article							CYCLE CHECKPOINT PATHWAY; DNA-DAMAGING AGENTS; CELL-CYCLE; P53; INDUCTION; DOMAIN; GENE; UV	Ataxia telangiectasia (AT) is a rare human autosomal recessive disorder with pleiotropic phenotypes, including neuronal degeneration, immune dysfunction, premature ageing and increased cancer risk. The gene mutated in AT, ATM, encodes a putative lipid or protein kinase(1,2). Most of the human AT patient phenotypes are recapitulated in Atm-deficient mice(3,4). Cells derived from Atm(-/-) mice, like those from AT patients, exhibit abnormal response to ionizing radiation(3,5,6). One of the known responses to ionizing radiation is the activation of a nuclear tyrosine kinase encoded by the c-abl proto-oncogene(7,8). Ionizing radiation does not activate c-Abl in cells from AT patients or in thymocytes or fibroblasts from the Arm-deficient mice. Ectopic expression of a functional ATM kinase domain corrects this defect, as it phosphorylates the c-Abl tyrosine kinase in vitro at Ser 465, leading to the activation of c-Abl. A mutant c-Abl with Ser 465 changed to Ala 465 is not activated by ionizing radiation or ATM kinase in vivo. These findings identify the c-Abl tyrosine kinase as a downstream target of phosphorylation and activation by the ATM kinase in the cellular response to ionizing radiation.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR MOL GENET,LA JOLLA,CA 92093; JOHNS HOPKINS ONCOL CTR,BALTIMORE,MD 21205; MIT,DEPT BIOL,CAMBRIDGE 02139,ENGLAND; NIH,NCHGR,LAB GENET DIS RES,BETHESDA,MD 20892	University of California System; University of California San Diego; University of California System; University of California San Diego; Johns Hopkins University; Johns Hopkins Medicine; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)			Wood, Laura/ABF-1531-2020	Xu, Yang/0000-0001-5574-921X; , Christine/0000-0001-8892-7430	NATIONAL CANCER INSTITUTE [R37CA043054, R01CA043054] Funding Source: NIH RePORTER; NCI NIH HHS [R37 CA043054, R01 CA043054] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BANNISTER AJ, 1993, NUCLEIC ACIDS RES, V21, P1289, DOI 10.1093/nar/21.5.1289; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Baskaran R, 1996, MOL CELL BIOL, V16, P3361; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; Byrd PJ, 1996, HUM MOL GENET, V5, P145, DOI 10.1093/hmg/5.1.145; CANMAN CE, 1994, CANCER RES, V54, P5054; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FRIEDBERG EC, 1995, DNA REPAIR; Gilad S, 1996, HUM MOL GENET, V5, P433, DOI 10.1093/hmg/5.4.433; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KHANNA KK, 1993, ONCOGENE, V8, P3307; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; LEONARDO AD, 1994, GENE DEV, V8, P2540; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Morgan SE, 1997, MOL CELL BIOL, V17, P2020, DOI 10.1128/MCB.17.4.2020; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; Sanchez Y, 1996, SCIENCE, V271, P357, DOI 10.1126/science.271.5247.357; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; Siede W, 1996, J BACTERIOL, V178, P5841, DOI 10.1128/jb.178.19.5841-5843.1996; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0	25	456	467	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 29	1997	387	6632					516	519		10.1038/387516a0	http://dx.doi.org/10.1038/387516a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XB479	9168116				2022-12-01	WOS:A1997XB47900052
J	Appella, DH; Christianson, LA; Klein, DA; Powell, DR; Huang, XL; Barchi, JJ; Gellman, SH				Appella, DH; Christianson, LA; Klein, DA; Powell, DR; Huang, XL; Barchi, JJ; Gellman, SH			Residue-based control of helix shape in beta-peptide oligomers	NATURE			English	Article							SECONDARY STRUCTURE; PROGRAM; POLY(ALPHA-ISOBUTYL-L-ASPARTATE); DERIVATIVES; POLYAMIDE; ACID	Proteins and RNA are unique among known polymers in their ability to adopt compact and well-defined folding patterns. These two biopolymers can perform complex chemical operations such as catalysis and highly selective recognition, and these functions are linked to folding in that the creation of an active site requires proper juxtaposition of reactive groups. So the development of new types of polymeric backbones with well-defined and predictable folding propensities ('foldamers') might lead to molecules with useful functions(1,2). The first step in foldamer development is to identify synthetic oligomers with specific secondary structural preferences(3-13). Whereas alpha-amino acids can adopt the well-known alpha-helical motif of proteins, it was shown recently(11-13) that beta-peptides(3) constructed from carefully chosen beta-amino acids can adopt a different, stable helical conformation defined by interwoven 14-membered-ring hydrogen bonds (a 14-helix; Fig. 1a). Here we report that beta-amino acids can also be used to design beta-peptides with a very different secondary structure, a 12-helix (Fig. 1a). This demonstrates that by altering the nature of beta-peptide residues, one can exert rational control over the secondary structure.	NCI,MED CHEM LAB,DIV BASIC SCI,BETHESDA,MD 20892; UNIV WISCONSIN,DEPT CHEM,MADISON,WI 53706	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Wisconsin System; University of Wisconsin Madison			Barchi, Joseph J/N-3784-2014	Barchi, Joseph/0000-0001-9906-0799				Appella DH, 1996, J AM CHEM SOC, V118, P13071, DOI 10.1021/ja963290l; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; Ball P., 1994, DESIGNING MOL WORLD; BARLOW DJ, 1988, J MOL BIOL, V201, P601, DOI 10.1016/0022-2836(88)90641-9; BELLA J, 1992, MACROMOLECULES, V25, P5225, DOI 10.1021/ma00046a018; BOTHNERBY AA, 1984, J AM CHEM SOC, V106, P811, DOI 10.1021/ja00315a069; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Creighton TE, 1993, PROTEINS STRUCTURES; DADO GP, 1994, J AM CHEM SOC, V116, P1054, DOI 10.1021/ja00082a029; ESCHENMOSER A, 1994, ORIGINS LIFE EVOL B, V24, P389, DOI 10.1007/BF01582017; FERNANDEZSANTIN JM, 1984, NATURE, V311, P53, DOI 10.1038/311053a0; FERNANDEZSANTIN JM, 1987, MACROMOLECULES, V20, P62, DOI 10.1021/ma00167a013; GENNARI C, 1994, ANGEW CHEM INT EDIT, V33, P2067, DOI 10.1002/anie.199420671; HAGIHARA M, 1992, J AM CHEM SOC, V114, P6568, DOI 10.1021/ja00042a052; Hamuro Y, 1996, J AM CHEM SOC, V118, P7529, DOI 10.1021/ja9539857; HERRADON B, 1989, HELV CHIM ACTA, V72, P690, DOI 10.1002/hlca.19890720410; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LOKEY RS, 1995, NATURE, V375, P303; LOPEZCARRASQUERO F, 1995, BIOPOLYMERS, V36, P263, DOI 10.1002/bip.360360302; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Nowick JS, 1996, J AM CHEM SOC, V118, P1066, DOI 10.1021/ja9536072; Sanders JK, 1995, SUPRAMOLECULAR CHEM, V107, P2617; Schenck HL, 1996, J AM CHEM SOC, V118, P12487, DOI 10.1021/ja962026p; Seebach D, 1996, HELV CHIM ACTA, V79, P913, DOI 10.1002/hlca.19960790402; Seebach D, 1996, HELV CHIM ACTA, V79, P2043, DOI 10.1002/hlca.19960790802; SMITH AB, 1994, J AM CHEM SOC, V116, P9947, DOI 10.1021/ja00101a017; TILLEY JW, 1992, J MED CHEM, V35, P3774, DOI 10.1021/jm00099a005; XIONG HY, 1995, P NATL ACAD SCI USA, V92, P6349, DOI 10.1073/pnas.92.14.6349; YUKI H, 1978, J POLYM SCI POL CHEM, V16, P2237, DOI 10.1002/pol.1978.170160913	30	563	565	2	125	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 22	1997	387	6631					381	384		10.1038/387381a0	http://dx.doi.org/10.1038/387381a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XA496	9163422				2022-12-01	WOS:A1997XA49600054
J	Iavarone, A; Massague, J				Iavarone, A; Massague, J			Repression of the CDK activator Cdc25A and cell-cycle arrest by cytokine TGF-beta in cells lacking the CDK inhibitor p15	NATURE			English	Article							DEPENDENT KINASES; GENE; PHOSPHORYLATION; PHOSPHATASES; P27(KIP1); GROWTH; ROLES; LINE	The activity of the cyclin-dependent kinases (CDKs) that control cell growth and division can be negatively regulated by tyrosine phosphorylation or by the binding of various CDK inhibitors(1). Whereas regulation by tyrosine phosphorylation is well documented in CDKs that function during mitosis, little is known about its role in the regulation of CDKs that act in the G1 phase of the cell cycle(2). In contrast, much evidence has accumulated on the regulation of G1 CDKs by CDK inhibitors(1). The cytokine TGF-beta inhibits growth by causing cell-cycle arrest as a result of increasing the concentration of the Cdk4/6 Inhibitor p15(INK4B/MTS2) (refs 3, 4). Here we report that TGF-beta can also cause the inhibition of Cdk4 and Cdk6 by increasing their level of tyrosine phosphorylation. Tyrosine phosphorylation and inactivation of Cdk4/6 in a human mammary epithelial cell line are shown to result from the ability of TGF-beta to repress expression of the CDK tyrosine phosphatase Cdc25A. Repression of Cdc25A and induction of p15 are independent effects mediating the inhibition of Cdk4/6 by TFG-beta.	MEM SLOAN KETTERING CANC CTR,CELL BIOL & GENET PROGRAM,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center				Massague, Joan/0000-0001-9324-8408				BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; GIARETTI W, 1994, METHOD CELL BIOL, V41, P389; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SOULE HD, 1990, CANCER RES, V50, P6075; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103	30	310	315	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 22	1997	387	6631					417	422						6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XA496	9163429				2022-12-01	WOS:A1997XA49600064
J	Haupt, Y; Maya, R; Kazaz, A; Oren, M				Haupt, Y; Maya, R; Kazaz, A; Oren, M			Mdm2 promotes the rapid degradation of p53	NATURE			English	Article							EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; MUTANT P53; CELL-LINES; PROTEIN; ONCOPROTEIN; EXPRESSION; ACTIVATION; PATHWAY; CANCER	The p53 tumour-suppressor protein exerts antiproliferative effects, including growth arrest and apoptosis, in response to various types of stress'. The activity of p53 is abrogated by mutations that occur frequently in tumours, as well as by several viral and cellular proteins(1,2). The Mdm2 oncoprotein is a potent inhibitor of p53 (ref. 3). Mdm2 binds the transcriptional activation domain of p53 and blocks its ability to regulate target genes(3,4) and to exert antiproliferative effects(4-7). On the other hand, p53 activates the expression of the mdm2 gene(1) in an autoregulatory feedback loop(3). The interval between p53 activation and consequent Mdm2 accumulation defines a time window during which p53 exerts its effects(8). We now report that Mdm2 also promotes the rapid degradation of p53 under conditions in which p53 is otherwise stabilized. This effect of Mdm2 requires binding of p53; moreover, a small domain of p53, encompassing the Mdm2-binding site, confers Mdm2-dependent detstabilization upon heterologous proteins. Raised amounts of Mdm2 strongly repress mutant p53 accumulation in tumour-derived cells. During recovery from DNA damage, maximal Mdm2 induction coincides with rapid p53 loss. We propose that the Mdm2-promoted degradation of p53 provides a new mechanism to ensure effective termination of the p53 signal.	WEIZMANN INST SCI,DEPT MOL CELL BIOL,IL-76100 REHOVOT,ISRAEL; HEBREW UNIV JERUSALEM,HADASSAH MED SCH,LAUTENBERG CTR GEN & TUMOR IMMUNOL,IL-91120 JERUSALEM,ISRAEL	Weizmann Institute of Science; Hebrew University of Jerusalem								BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BARTEK J, 1990, ONCOGENE, V5, P893; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; Chen JD, 1996, MOL CELL BIOL, V16, P2445; CHEN JD, 1995, MOL MED, V1, P141; FISCELLA M, 1993, ONCOGENE, V8, P1519; Gottlieb E, 1996, CELL GROWTH DIFFER, V7, P301; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; KASTAN MB, 1991, CANCER RES, V51, P6304; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; LANE DP, 1994, INT J CANCER, V57, P623, DOI 10.1002/ijc.2910570502; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LUNA RMD, 1995, NATURE, V378, P203; Maki CG, 1996, CANCER RES, V56, P2649; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Momand J, 1996, ONCOGENE, V12, P2279; OREN M, 1982, MOL CELL BIOL, V2, P443, DOI 10.1128/MCB.2.4.443; OTTO A, 1993, ONCOGENE, V8, P2591; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; PICKSLEY SM, 1993, BIOESSAYS, V15, P689, DOI 10.1002/bies.950151008; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SHEN YQ, 1995, CURR OPIN GENET DEV, V5, P105, DOI 10.1016/S0959-437X(95)90061-6; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Yonish-Rouach E, 1994, Cell Death Differ, V1, P39	29	3566	3693	9	325	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 15	1997	387	6630					296	299		10.1038/387296a0	http://dx.doi.org/10.1038/387296a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WZ167	9153395				2022-12-01	WOS:A1997WZ16700056
J	Strutt, DI; Weber, U; Mlodzik, M				Strutt, DI; Weber, U; Mlodzik, M			The role of RhoA in tissue polarity and Frizzled signalling	NATURE			English	Article							DROSOPHILA-MELANOGASTER; GENETIC MOSAICS; LOCUS ENCODES; CELL FATES; PROTEIN; PHENOTYPES; PATHWAYS; GTPASES; RAC1; EYE	The tissue polarity genes of Drosophila are required for correct establishment of planar polarity in epidermal structures(1,2), which in the eye is shown in the mirror-image symmetric arrangement of ommatidia relative to the dorsoventral midline. Mutations in the genes frizzled (fz), dishevelled (dsh) and prickle-spiny-legs (pk-sple) result in the loss of this mirror-image symmetry(3-5). fz encodes a serpentine receptor-like transmembrane protein required for reception and transmission of a polarity signal(5,6), Little else is known of the signalling pathway(s) involved other than that Dsh acts downstream of Fz(7). We have identified mutations in the Drosophila homologue of RhoA p21 GTPase, and by analysis of their phenotype show that RhoA is required for the generation of tissue polarity, Genetic interactions indicate a role for RhoA in signalling mediated by Fz and Dsh, and furthermore suggest that JNK/SAPK-like kinases are involved, These data are consistent with a Fz/RhoA signalling cascade analogous to the yeast pheromone signalling pathway(8) and that proposed for activation of the serum response factor (SRF) in vertebrate cells(9).	EUROPEAN MOL BIOL LAB,DEV BIOL PROGRAMME,D-69117 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			Strutt, David/E-6196-2010	Strutt, David/0000-0001-8185-4515				ADLER PN, 1992, BIOESSAYS, V14, P735, DOI 10.1002/bies.950141103; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; BIGGS WH, 1994, EMBO J, V13, P1628, DOI 10.1002/j.1460-2075.1994.tb06426.x; BRAND AH, 1993, DEVELOPMENT, V118, P401; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; CHOI KW, 1994, CELL, V78, P125, DOI 10.1016/0092-8674(94)90579-7; EATON S, 1995, J CELL BIOL, V131, P151, DOI 10.1083/jcb.131.1.151; GUBB D, 1982, J EMBRYOL EXP MORPH, V68, P37; GUBB D, 1993, DEVELOPMENT, P269; HARDEN N, 1995, DEVELOPMENT, V121, P903; HARIHARAN IK, 1995, EMBO J, V14, P292, DOI 10.1002/j.1460-2075.1995.tb07003.x; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; KLINGENSMITH J, 1994, GENE DEV, V8, P118, DOI 10.1101/gad.8.1.118; KRASNOW RE, 1994, DEVELOPMENT, V120, P1883; Krasnow RE, 1995, DEVELOPMENT, V121, P4095; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; Machesky LM, 1996, TRENDS CELL BIOL, V6, P304, DOI 10.1016/0962-8924(96)10026-X; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; RiesgoEscovar JR, 1996, GENE DEV, V10, P2759, DOI 10.1101/gad.10.21.2759; Sluss HK, 1996, GENE DEV, V10, P2745, DOI 10.1101/gad.10.21.2745; THEISEN H, 1994, DEVELOPMENT, V120, P347; TOROK T, 1993, GENETICS, V135, P71; VINCENT JP, 1994, DEV BIOL, V164, P328, DOI 10.1006/dbio.1994.1203; VINSON CR, 1989, NATURE, V338, P263, DOI 10.1038/338263a0; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; XU T, 1993, DEVELOPMENT, V117, P1223; YANAGAWA SI, 1995, GENE DEV, V9, P1087, DOI 10.1101/gad.9.9.1087; ZHENG L, 1995, DEVELOPMENT, V121, P3045	29	472	475	1	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 15	1997	387	6630					292	295		10.1038/387292a0	http://dx.doi.org/10.1038/387292a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WZ167	9153394				2022-12-01	WOS:A1997WZ16700055
J	Vasan, RS; Larson, MG; Benjamin, EJ; Evans, JC; Levy, D				Vasan, RS; Larson, MG; Benjamin, EJ; Evans, JC; Levy, D			Left ventricular dilatation and the risk of congestive heart failure in people without myocardial infarction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							M-MODE ECHOCARDIOGRAPHY; PROGNOSTIC IMPLICATIONS; FRAMINGHAM; MEN; DYSFUNCTION; SURVIVAL; DISEASE; VOLUME; PREDICTORS; INHIBITION	Background Left ventricular dilatation is a well-recognized precursor of ventricular dysfunction and congestive heart failure after myocardial infarction. The effect of left ventricular dilatation on the risk of heart failure in people initially free of myocardial infarction is not known. Methods We examined the relation of the left ventricular end-diastolic and end-systolic internal dimensions, as measured by M-mode echocardiography, to the risk of congestive heart failure in 4744 subjects (2661 women and 2083 men) who had not sustained a myocardial infarction and who were free of congestive heart failure. We used sex-stratified proportional-hazards regression to assess the association between base-line left ventricular internal dimensions and the subsequent risk of congestive heart failure, after adjusting for age, blood pressure, hypertension treatment, body-mass index, diabetes, valve disease, and interim myocardial infarction. Results Over an 11-year follow-up period, congestive heart failure developed in 74 subjects (38 men and 36 women). The risk-factor-adjusted hazard ratio for congestive heart failure was 1.47 (95 percent confidence interval, 1.25 to 1.73) for an increment of 1 SD in the left ventricular end-diastolic dimension, indexed for height. We obtained similar results using the left ventricular end-systolic dimension (hazard ratio, 1.43; 95 percent confidence interval, 1.24 to 1.65). Conclusions An increase in left ventricular internal dimension is a risk factor for congestive heart failure in men and women who have not had a myocardial infarction. Knowledge of the left ventricular dimension improves predictions of the risk of congestive heart failure made on the basis of traditional risk factors, perhaps by aiding in the identification of subjects with subclinical left ventricular dysfunction. (C)1997, Massachusetts Medical Society.	FRAMINGHAM HEART DIS EPIDEMIOL STUDY, FRAMINGHAM, MA 01701 USA; BETH ISRAEL HOSP, DIV CARDIOL, BOSTON, MA 02215 USA; BETH ISRAEL HOSP, DIV CLIN EPIDEMIOL, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA; BOSTON UNIV, SCH MED, CARDIOL SECT, BOSTON, MA 02118 USA; BOSTON UNIV, SCH MED, DEPT PREVENT MED & EPIDEMIOL, BOSTON, MA 02118 USA; NHLBI, BETHESDA, MD 20892 USA	Framingham Heart Study; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Boston University; Boston University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)			Ramachandran, Vasan/Y-2527-2019; Levy, Daniel/ABB-2752-2021; Levy, Daniel/ABF-6873-2021; Benjamin, Emelia/E-7103-2011	Ramachandran, Vasan/0000-0001-7357-5970; Levy, Daniel/0000-0003-1843-8724; Larson, Martin/0000-0002-9631-1254; Benjamin, Emelia/0000-0003-4076-2336	NHLBI NIH HHS [N0I-HC-38038] Funding Source: Medline; NINDS NIH HHS [2-ROI-NS17950-11] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC038038] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017950] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERNING J, 1990, AM J CARDIOL, V65, P567, DOI 10.1016/0002-9149(90)91032-2; CAIDAHL K, 1988, BRIT HEART J, V59, P329; COHN JN, 1995, CIRCULATION, V91, P2504, DOI 10.1161/01.CIR.91.10.2504; Cox DR., 1984, ANAL SURVIVAL DATA; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; DEVEREUX RB, 1977, CIRCULATION, V55, P613, DOI 10.1161/01.CIR.55.4.613; ERIKSSON SV, 1995, BRIT HEART J, V74, P124; FRISHMAN WH, 1992, AM HEART J, V124, P1026, DOI 10.1016/0002-8703(92)90987-7; GALDERISI M, 1992, AM J CARDIOL, V70, P971, DOI 10.1016/0002-9149(92)90345-Y; GAUDRON P, 1992, AM HEART J, V123, P377, DOI 10.1016/0002-8703(92)90649-G; GAUDRON P, 1993, CIRCULATION, V87, P755, DOI 10.1161/01.CIR.87.3.755; GREENBERG B, 1995, CIRCULATION, V91, P2573, DOI 10.1161/01.CIR.91.10.2573; HAMMERMEISTER KE, 1979, CIRCULATION, V59, P89, DOI 10.1161/01.CIR.59.1.89; JACOB R, 1988, BASIC RES CARDIOL, V83, P461, DOI 10.1007/BF01906676; KANNEL WB, 1979, AM J EPIDEMIOL, V110, P281, DOI 10.1093/oxfordjournals.aje.a112813; KANNEL WB, 1987, NIH PUBLICATION; KEREN A, 1986, CARDIOLOGY, V73, P139, DOI 10.1159/000173997; KLEBER FX, 1991, AM J CARDIOL, V68, pD121; LAUER MS, 1995, J AM COLL CARDIOL, V26, P1039, DOI 10.1016/0735-1097(95)00275-0; LAUER MS, 1992, AM J CARDIOL, V70, P1180, DOI 10.1016/0002-9149(92)90052-Z; LEE TH, 1993, AM J CARDIOL, V72, P672, DOI 10.1016/0002-9149(93)90883-E; LINZBACH AJ, 1960, AM J CARDIOL, V5, P370, DOI 10.1016/0002-9149(60)90084-9; MCKEE PA, 1971, NEW ENGL J MED, V285, P1441, DOI 10.1056/NEJM197112232852601; PFEFFER MA, 1990, CIRCULATION, V81, P1161, DOI 10.1161/01.CIR.81.4.1161; ROSS J, 1976, PROG CARDIOVASC DIS, V18, P255, DOI 10.1016/0033-0620(76)90021-9; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; SANDVIK L, 1993, EUR HEART J, V14, P592, DOI 10.1093/eurheartj/14.5.592; *SAS I INC, 1989, SAS STAT US GUID VER, V2, P1351; *SAS I INC, 1996, SAS STAT SOFTW CHANG, P381; SAVAGE DD, 1987, HYPERTENSION, V9, P40; SUTTON MS, 1994, CIRCULATION, V89, P68, DOI 10.1161/01.CIR.89.1.68; UNVERFERTH DV, 1984, AM J CARDIOL, V54, P147, DOI 10.1016/0002-9149(84)90320-5; WHITE HD, 1987, CIRCULATION, V76, P44, DOI 10.1161/01.CIR.76.1.44; WONG M, 1993, CIRCULATION, V87, P65; 1993, ARCH INTERN MED, V153, P154	35	273	282	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 8	1997	336	19					1350	1355		10.1056/NEJM199705083361903	http://dx.doi.org/10.1056/NEJM199705083361903			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WX851	9134875	Bronze			2022-12-01	WOS:A1997WX85100003
J	Nightingale, SL				Nightingale, SL			Action to prevent accidental iron poisonings in children	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,MAIL CODE HFI-40,ROCKVILLE,MD 20857, USA.								0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 7	1997	277	17					1343	1343		10.1001/jama.277.17.1343	http://dx.doi.org/10.1001/jama.277.17.1343			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW261	9134926				2022-12-01	WOS:A1997WW26100006
J	Lethem, R; Orrell, M				Lethem, R; Orrell, M			Antioxidants and dementia	LANCET			English	Editorial Material							ALZHEIMERS-DISEASE; OXIDATION; STROKE		UCL, SCH MED, DEPT PSYCHIAT & BEHAV SCI, LONDON W1N 8AA, ENGLAND; WHITTINGTON HOSP, DEPT PSYCHIAT, LONDON N19 5NF, ENGLAND	University of London; University College London; UCL Medical School; University of London; University College London				Orrell, Martin/0000-0002-1169-3530				DESMOND DW, 1993, ARCH NEUROL-CHICAGO, V50, P162, DOI 10.1001/archneur.1993.00540020040015; Frey WH, 1996, BRAIN RES, V714, P87, DOI 10.1016/0006-8993(95)01497-7; Gale CR, 1996, BRIT MED J, V312, P608; GILLMAN MW, 1995, JAMA-J AM MED ASSOC, V273, P1113, DOI 10.1001/jama.273.14.1113; JACKSON CVE, 1988, J MENT DEFIC RES, V32, P479; RICHARDSON JS, 1993, ANN NY ACAD SCI, V695, P73, DOI 10.1111/j.1749-6632.1993.tb23031.x; RUBINSZTEIN DC, 1995, PSYCHOL MED, V25, P223, DOI 10.1017/S0033291700036138; SACK MN, 1994, LANCET, V343, P269, DOI 10.1016/S0140-6736(94)91117-7; SPARKS DL, 1994, EXP NEUROL, V126, P88, DOI 10.1006/exnr.1994.1044; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; Thomas T, 1996, NATURE, V380, P168, DOI 10.1038/380168a0; WITZTUM JL, 1994, LANCET, V344, P793, DOI 10.1016/S0140-6736(94)92346-9	12	48	50	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 26	1997	349	9060					1189	1190		10.1016/S0140-6736(05)62409-9	http://dx.doi.org/10.1016/S0140-6736(05)62409-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW717	9130937				2022-12-01	WOS:A1997WW71700005
J	Senn, S				Senn, S			Are placebo run ins justified?	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PHYSICIANS HEALTH; CLINICAL-TRIALS; EFFICIENCY; COST				Senn, S (corresponding author), UCL, DEPT STAT SCI, MORTIMER ST, LONDON WC1E 6BT, ENGLAND.		Senn, Stephen J/A-8101-2008; Senn, Stephen/B-2903-2013	Senn, Stephen/0000-0002-7558-8473				[Anonymous], 1988, NEW ENGL J MED, V318, P262; ASPINALL RL, 1995, BRIT MED J, V311, P844, DOI 10.1136/bmj.311.7009.844; BRITTAIN E, 1990, CONTROL CLIN TRIALS, V11, P327, DOI 10.1016/0197-2456(90)90174-Z; BURING JE, 1990, STAT MED, V9, P29, DOI 10.1002/sim.4780090109; Fisher R. A., 1990, STAT METHODS EXPT DE; Freedman Benjamin, 1990, IRB, V12, P1, DOI 10.2307/3564541; Hulley S., 2007, DESIGNING CLIN RES E; LANG JM, 1990, STAT MED, V9, P87, DOI 10.1002/sim.4780090115; LANG JM, 1991, STAT MED, V10, P1585, DOI 10.1002/sim.4780101010; MITCHELL J, 1995, BRIT MED J, V310, P43, DOI 10.1136/bmj.310.6971.43; Pocock SJ., 1983, CLIN TRIALS PRACTICA; ROTHMAN KJ, 1994, NEW ENGL J MED, V331, P394, DOI 10.1056/NEJM199408113310611; SCHECHTMAN KB, 1993, STAT MED, V12, P111, DOI 10.1002/sim.4780120204; SENN S, 1994, STAT MED, V13, P217, DOI 10.1002/sim.4780130305; Senn S, 1995, STAT MED, V14, P2661, DOI 10.1002/sim.4780142406; SENN SJ, 1991, STAT MED, V10, P1361, DOI 10.1002/sim.4780100905; Spilker B., 1991, GUIDE CLIN TRIALS; Temple R, 1982, DRUG INF J, V10-17, DOI DOI 10.1177/009286158201600102	18	32	32	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 19	1997	314	7088					1191	1193		10.1136/bmj.314.7088.1191	http://dx.doi.org/10.1136/bmj.314.7088.1191			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WV705	9146400	Green Published			2022-12-01	WOS:A1997WV70500035
J	Brunn, GJ; Hudson, CC; Sekulic, A; Williams, JM; Hosoi, H; Houghton, PJ; Lawrence, JC; Abraham, RT				Brunn, GJ; Hudson, CC; Sekulic, A; Williams, JM; Hosoi, H; Houghton, PJ; Lawrence, JC; Abraham, RT			Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin	SCIENCE			English	Article							ACTIVATED PROTEIN-KINASE; MALIGNANT TRANSFORMATION; MAP KINASE; INITIATION; INSULIN; IDENTIFICATION; ADIPOCYTES; REGULATOR; COMPLEX; BINDS	The immunosuppressant rapamycin interferes with G(1)-phase progression in lymphoid and other cell types by inhibiting the function; of the mammalian target of rapamycin (mTOR), mTOR was determined to be a terminal kinase in a signaling pathway that couples mitogenic stimulation to the phosphorylation of the eukaryotic initiation factor (eIF)-4E-binding protein, PHAS-I. The rapamycin-sensitive protein kinase activity of mTOR was required for phosphorylation of PHAS-I in insulin-stimulated human embryonic kidney cells. mTOR phosphorylated PHAS-I on serine and threonine residues in vitro, and these modifications inhibited the binding of PHAS-I to eIF-4E. These studies define a role for mTOR in translational control and offer further insights into the mechanism whereby rapamycin inhibits G(1)-phase progression in mammalian cells.	MAYO CLIN, DIV ONCOL RES, ROCHESTER, MN 55905 USA; UNIV VIRGINIA, SCH MED, DEPT PHARMACOL, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, SCH MED, DEPT MED, CHARLOTTESVILLE, VA 22908 USA; ST JUDE CHILDRENS RES HOSP, DEPT MOL PHARMACOL, MEMPHIS, TN 38105 USA	Mayo Clinic; University of Virginia; University of Virginia; St Jude Children's Research Hospital					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028312] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR41189] Funding Source: Medline; NIDDK NIH HHS [DK50628, DK28312] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abraham RT, 1996, CURR OPIN IMMUNOL, V8, P412, DOI 10.1016/S0952-7915(96)80132-4; Abraham RT, 1996, ANNU REV IMMUNOL, V14, P483, DOI 10.1146/annurev.immunol.14.1.483; Barbet NC, 1996, MOL BIOL CELL, V7, P25, DOI 10.1091/mbc.7.1.25; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Brown EJ, 1996, CELL, V86, P517, DOI 10.1016/S0092-8674(00)80125-7; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; BRUNN GJ, UNPUB; CHEN J, 1995, P NATL ACAD SCI USA, V92, P4947, DOI 10.1073/pnas.92.11.4947; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DiComo CJ, 1996, GENE DEV, V10, P1904, DOI 10.1101/gad.10.15.1904; DOWNWARD J, 1994, NATURE, V371, P378, DOI 10.1038/371378a0; Fadden P, 1997, J BIOL CHEM, V272, P10240; GRAVES LM, 1995, P NATL ACAD SCI USA, V92, P7222, DOI 10.1073/pnas.92.16.7222; Hall MN, 1996, BIOCHEM SOC T, V24, P234, DOI 10.1042/bst0240234; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; HU CB, 1994, P NATL ACAD SCI USA, V91, P3730, DOI 10.1073/pnas.91.9.3730; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; KAMITZ LM, 1995, MOL CELL BIOL, V15, P3049; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; LAWRENCE J, IN PRESS ADV ENZYME; LAZARISKARATZAS A, 1992, GENE DEV, V6, P1631, DOI 10.1101/gad.6.9.1631; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Lin TA, 1996, J BIOL CHEM, V271, P30199, DOI 10.1074/jbc.271.47.30199; LIN TA, 1995, J BIOL CHEM, V270, P18531, DOI 10.1074/jbc.270.31.18531; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Rousseau D, 1996, ONCOGENE, V13, P2415; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; SMITH M R, 1990, New Biologist, V2, P648; Sonenberg Nahum, 1993, Gene Expression, V3, P317; vonManteuffel SR, 1996, P NATL ACAD SCI USA, V93, P4076, DOI 10.1073/pnas.93.9.4076	35	773	793	1	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 4	1997	277	5322					99	101		10.1126/science.277.5322.99	http://dx.doi.org/10.1126/science.277.5322.99			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XJ418	9204908				2022-12-01	WOS:A1997XJ41800048
J	Eghbali, M; Curmi, JP; Birnir, B; Gage, PW				Eghbali, M; Curmi, JP; Birnir, B; Gage, PW			Hippocampal GABA(A) channel conductance increased ky diazepam	NATURE			English	Article							OPEN-STATE SUBSTRUCTURE; PIG HEART-CELLS; CHLORIDE CHANNELS; POTASSIUM CHANNELS; RECEPTOR CHANNELS; AMINO-ACIDS; NEURONS; CULTURE; BENZODIAZEPINE; CLAMP	Benzodiazepines, which are widely used clinically for relief of anxiety and for sedation(1), are thought to enhance synaptic inhibition in the central nervous system by increasing the open probability of chloride channels activated by the inhibitory neurotransmitter gamma-aminobutyric acid (GABA)(2,3). Here we show that the benzodiazepine diazepam tan also increase the conductance of GABA(A) channels activated by low concentrations of GABA (0.5 or 5 mu M) in rat cultured hippocampal neurons. Before exposure to diazepam, chloride channels activated by GABA had conductances of 8 to 53 pS. Diazepam caused a concentration-dependent and reversible increase in the conductance of these channels towards a maximum conductance of 70-80 pS and the effect was as great as 7-fold in channels of lowest initial conductance. Increasing the conductance of GABA(A) channels tonically activated by low ambient concentrations of GABA in the extracellular environment(4) maybe an important way in which these drugs depress excitation in the central nervous system. That any drug has such a large effect on single channel conductance has not been reported previously and has implications for models of channel structure and conductance.	AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,CANBERRA,ACT 2601,AUSTRALIA	Australian National University; John Curtin School of Medical Research				Birnir, Bryndis/0000-0002-1763-0266				BIRNIR B, 1994, J MEMBRANE BIOL, V142, P93; CURMI JP, 1993, J MEMBRANE BIOL, V136, P2673; FATIMASHAD K, 1992, P ROY SOC B-BIOL SCI, V250, P99, DOI 10.1098/rspb.1992.0136; GAGE PW, 1994, P ROY SOC B-BIOL SCI, V255, P167, DOI 10.1098/rspb.1994.0024; GRAY R, 1985, J NEUROPHYSIOL, V54, P134, DOI 10.1152/jn.1985.54.1.134; LERMA J, 1986, BRAIN RES, V384, P145, DOI 10.1016/0006-8993(86)91230-8; LUDEWIG W, 1996, NATURE, V383, P340; MATHERS DA, 1991, CAN J PHYSIOL PHARM, V69, P1057, DOI 10.1139/y91-157; MATSUDA H, 1989, J PHYSIOL-LONDON, V413, P139, DOI 10.1113/jphysiol.1989.sp017646; MATSUDA H, 1988, J PHYSIOL-LONDON, V397, P237, DOI 10.1113/jphysiol.1988.sp016998; Middleton RE, 1996, NATURE, V383, P337, DOI 10.1038/383337a0; MILLER C, 1982, PHILOS T ROY SOC B, V299, P401, DOI 10.1098/rstb.1982.0140; MODY I, 1994, TRENDS NEUROSCI, V17, P517, DOI 10.1016/0166-2236(94)90155-4; Otis TS, 1992, P NATL ACAD SCI USA, V78, P7180; PREMKUMAR LS, 1990, P ROY SOC B-BIOL SCI, V241, P153, DOI 10.1098/rspb.1990.0079; ROGERS CJ, 1994, J PHYSIOL-LONDON, V475, P69, DOI 10.1113/jphysiol.1994.sp020050; SEGAL M, 1984, J NEUROPHYSIOL, V52, P469, DOI 10.1152/jn.1984.52.3.469; SMITH GB, 1995, TRENDS PHARMACOL SCI, V16, P162, DOI 10.1016/S0165-6147(00)89009-4; STUDY RE, 1981, P NATL ACAD SCI-BIOL, V78, P7180, DOI 10.1073/pnas.78.11.7180; TANELIAN DL, 1993, ANESTHESIOLOGY, V78, P757, DOI 10.1097/00000542-199304000-00020; TOSSMAN U, 1986, ACTA PHYSIOL SCAND, V127, P533, DOI 10.1111/j.1748-1716.1986.tb07938.x; TWYMAN RE, 1989, ANN NEUROL, V25, P213, DOI 10.1002/ana.410250302; VICINI S, 1987, J PHARMACOL EXP THER, V243, P1195	23	132	135	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 3	1997	388	6637					71	75		10.1038/40404	http://dx.doi.org/10.1038/40404			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XJ143	9214504	Bronze			2022-12-01	WOS:A1997XJ14300052
J	Kallipolitis, BH; NorregaardMadsen, M; ValentinHansen, P				Kallipolitis, BH; NorregaardMadsen, M; ValentinHansen, P			Protein-protein communication: Structural model of the repression complex formed by CytR and the global regulator CRP	CELL			English	Article							CAMP RECEPTOR PROTEIN; ESCHERICHIA-COLI; CLONING VECTORS; ACTIVATOR COMPLEX; CRYSTAL-STRUCTURE; DEOP2 PROMOTER; DNA; BINDING; PROGRAM; GENE	The cAMP receptor protein (CRP) and the Lad-related CytR antiactivator bind cooperatively to adjacent DNA sites at or near promoters, an interaction that involves direct protein contacts. Here, we identify a collection of amino acid substitutions in CytR that reestablish protein-protein communication to mutant CRP proteins specifically defective in cooperative binding with wild-type CytR. To assess the location and spatial arrangement of these substitutions, we built a three-dimensional model of CytR based on the recent X-ray structure of the highly homologous PurR repressor bound to DNA. This approach enables us to specify the patch on CytR's surface that contacts CRP. Furthermore, our results permit the construction of a three-dimensional structure of the higher order nucleoprotein complex formed by CytR and CRP.			Kallipolitis, BH (corresponding author), ODENSE UNIV, DEPT MOL BIOL, CAMPUSVEJ 55, DK-5230 ODENSE M, DENMARK.			Kallipolitis, Birgitte H./0000-0003-1233-9776				BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; CHURCHWARD G, 1984, GENE, V31, P165, DOI 10.1016/0378-1119(84)90207-5; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CLARK DJ, 1967, J MOL BIOL, V23, P99, DOI 10.1016/S0022-2836(67)80070-6; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; Davies DR, 1996, P NATL ACAD SCI USA, V93, P7, DOI 10.1073/pnas.93.1.7; GERLACH P, 1991, J BACTERIOL, V173, P5419, DOI 10.1128/jb.173.17.5419-5430.1991; GHOSAINI LR, 1988, BIOCHEMISTRY-US, V27, P5257, DOI 10.1021/bi00414a046; GREER J, 1991, METHOD ENZYMOL, V202, P239; HOLST B, 1992, EMBO J, V11, P3635, DOI 10.1002/j.1460-2075.1992.tb05448.x; JIN L, 1992, J MOL BIOL, V226, P851, DOI 10.1016/0022-2836(92)90636-X; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; KELLEY RF, 1993, BIOCHEMISTRY-US, V32, P6828, DOI 10.1021/bi00078a005; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LARSEN JEL, 1984, GENE, V28, P45, DOI 10.1016/0378-1119(84)90086-6; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leung DW, 1989, TECHNIQUE, V1, P11; Lewis M, 1996, SCIENCE, V271, P1247, DOI 10.1126/science.271.5253.1247; Maniatis T, 1989, MOL CLONING; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MOLLEGAARD NE, 1993, J BIOL CHEM, V268, P17471; NAGADOI A, 1995, STRUCTURE, V3, P1217, DOI 10.1016/S0969-2126(01)00257-X; PEDERSEN H, 1992, J MOL BIOL, V227, P396, DOI 10.1016/0022-2836(92)90896-R; PEDERSEN H, 1991, J BIOL CHEM, V266, P17804; PEDERSEN H, 1995, MOL MICROBIOL, V17, P843, DOI 10.1111/j.1365-2958.1995.mmi_17050843.x; Pedersen H, 1997, EMBO J, V16, P2108, DOI 10.1093/emboj/16.8.2108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; SCHREIBER G, 1995, J MOL BIOL, V248, P478, DOI 10.1016/S0022-2836(95)80064-6; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SCHUMACHER MA, 1994, SCIENCE, V266, P763, DOI 10.1126/science.7973627; SOGAARDANDERSEN L, 1993, CELL, V75, P557, DOI 10.1016/0092-8674(93)90389-8; SOGAARDANDERSEN L, 1991, P NATL ACAD SCI USA, V88, P4921, DOI 10.1073/pnas.88.11.4921; Spronk CAEM, 1996, NAT STRUCT BIOL, V3, P916, DOI 10.1038/nsb1196-916; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; ValentinHansen P, 1996, MOL MICROBIOL, V20, P461, DOI 10.1046/j.1365-2958.1996.5341056.x; VALENTINHANSEN P, 1986, NUCLEIC ACIDS RES, V14, P2215, DOI 10.1093/nar/14.5.2215; VANGUNSTEREN WF, 1977, MOL PHYS, V34, P1311, DOI 10.1080/00268977700102571; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; WEICKERT MJ, 1992, J BIOL CHEM, V267, P15869; Wells JA, 1996, P NATL ACAD SCI USA, V93, P1, DOI 10.1073/pnas.93.1.1; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	43	35	35	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 27	1997	89	7					1101	1109		10.1016/S0092-8674(00)80297-4	http://dx.doi.org/10.1016/S0092-8674(00)80297-4			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XG830	9215632	Bronze			2022-12-01	WOS:A1997XG83000014
J	Johns, ME; Niparko, JK				Johns, ME; Niparko, JK			Otolaryngology head and neck surgery	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											Johns, ME (corresponding author), JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD 21218, USA.							Califano J, 1996, CANCER RES, V56, P2488; CLARY R, 1996, HEAD NECK SURG, V122, P1189; COHEN H, 1995, ARCH OTOLARYNGOL, V121, P29; Gates GA, 1996, ARCH OTOLARYNGOL, V122, P161; Gleich LL, 1996, LARYNGOSCOPE, V106, P1378, DOI 10.1097/00005537-199611000-00013; HARALDSSON PO, 1995, ARCH OTOLARYNGOL, V121, P90; Johns ME, 1996, ARCH OTOLARYNGOL, V122, P1039; Johns MM, 1996, CANCER RES, V56, P1151; Koch WM, 1996, JNCI-J NATL CANCER I, V88, P1580, DOI 10.1093/jnci/88.21.1580; Omori K, 1996, LARYNGOSCOPE, V106, P689, DOI 10.1097/00005537-199606000-00006; Orten SS, 1996, ARCH OTOLARYNGOL, V122, P1174; PICCIRILLO J, 1996, ARCH OTOLARYNGOL, V2122, P1045; Piccirillo J F, 1995, Oncology (Williston Park), V9, P831; Pradhan PS, 1996, LARYNGOSCOPE, V106, P1393, DOI 10.1097/00005537-199611000-00016; Shy C, 1996, OTOLARYNG HEAD NECK, V115, P442; Wyatt JR, 1996, LARYNGOSCOPE, V106, P816, DOI 10.1097/00005537-199607000-00006	16	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	1997	277	23					1886	1887						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD544	9185817				2022-12-01	WOS:A1997XD54400036
J	Gueiros, FJ; Beverley, SM				Gueiros, FJ; Beverley, SM			Trans-kingdom transposition of the Drosophila element mariner within the protozoan Leishmania	SCIENCE			English	Article							TRANSPOSABLE ELEMENT; HORIZONTAL TRANSMISSION; STABLE TRANSFECTION; GENE REPLACEMENT; DNA; EXPRESSION; MELANOGASTER; REPLICATION; INSECTS; MUTANTS	Transposable elements of the mariner/Tc1 family are postulated to have spread by horizontal transfer and be relatively independent of host-specific factors. This was tested by introducing the Drosophila mauritiana element mariner into the human parasite Leishmania major, a trypanosomatid protozoan belonging to one of the most ancient eukaryotic lineages, Transposition in Leishmania was efficient, occurring in more than 20 percent of random transfectants, and proceeded by the same mechanism as in Drosophila. Insertional inactivation of a specific gene was obtained, and a modified mariner element was used to select for gene fusions, establishing mariner as a powerful genetic tool for Leishmania and other organisms, These experiments demonstrate the evolutionary range of mariner transposition in vivo and underscore the ability of this ubiquitous DNA to parasitize the eukaryotic genome.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOL PHARMACOL,BOSTON,MA 02115	Harvard University; Harvard Medical School			Gueiros-Filho, Frederico J./D-2160-2013	Gueiros-Filho, Frederico J./0000-0001-5425-2439; Beverley, Stephen/0000-0001-5319-0811	NIAID NIH HHS [AI2964] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; CAPY P, 1994, TRENDS GENET, V10, P7, DOI 10.1016/0168-9525(94)90012-4; CAPY P, 1994, GENETICA, V93, P161, DOI 10.1007/BF01435248; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COATES CJ, 1995, MOL GEN GENET, V249, P246, DOI 10.1007/BF00290372; CRUZ A, 1991, P NATL ACAD SCI USA, V88, P7170, DOI 10.1073/pnas.88.16.7170; CRUZ A, 1990, NATURE, V348, P171, DOI 10.1038/348171a0; DELAFAILLE MAC, 1992, J BIOL CHEM, V267, P23839; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FREEDMAN DJ, 1993, MOL BIOCHEM PARASIT, V62, P37, DOI 10.1016/0166-6851(93)90175-W; GARCIAFERNANDEZ J, 1995, MOL BIOL EVOL, V12, P421; GueirosFilho FJ, 1996, MOL CELL BIOL, V16, P5655; KAPLER GM, 1990, MOL CELL BIOL, V10, P1084, DOI 10.1128/MCB.10.3.1084; KAPLER GM, 1987, NUCLEIC ACIDS RES, V15, P3369, DOI 10.1093/nar/15.8.3369; Kawasaki ES, 1990, PCR PROTOCOLS GUIDE; KIDWELL MG, 1993, NATURE, V362, P202, DOI 10.1038/362202a0; LACALLE RA, 1989, GENE, V79, P375, DOI 10.1016/0378-1119(89)90220-5; Lampe DJ, 1996, EMBO J, V15, P5470, DOI 10.1002/j.1460-2075.1996.tb00930.x; LEBOWITZ JH, 1991, GENE, V103, P119, DOI 10.1016/0378-1119(91)90402-W; LEBOWITZ JH, 1990, P NATL ACAD SCI USA, V87, P9736, DOI 10.1073/pnas.87.24.9736; LIDHOLM DA, 1993, GENETICS, V134, P859; LOHE AR, 1995, MOL BIOL EVOL, V12, P62, DOI 10.1093/oxfordjournals.molbev.a040191; LOUKERIS TG, 1995, P NATL ACAD SCI USA, V92, P9485, DOI 10.1073/pnas.92.21.9485; LOUKERIS TG, 1995, SCIENCE, V270, P2002, DOI 10.1126/science.270.5244.2002; Lozovskaya ER, 1996, GENETICS, V142, P173; MARTINPARRAS L, 1992, J BIOL CHEM, V267, P22496; MARUYAMA K, 1991, J MOL EVOL, V33, P514, DOI 10.1007/BF02102804; MEDHORA M, 1991, GENETICS, V128, P311; MEDINAACOSTA E, 1993, MOL BIOCHEM PARASIT, V59, P327, DOI 10.1016/0166-6851(93)90231-L; OBrochta DA, 1996, GENETICS, V142, P907; Plasterk RHA, 1996, CURR TOP MICROBIOL, V204, P125; Reiter LT, 1996, NAT GENET, V12, P288, DOI 10.1038/ng0396-288; ROBERTSON HM, 1995, J INSECT PHYSIOL, V41, P99, DOI 10.1016/0022-1910(94)00082-R; ROBERTSON HM, 1993, NATURE, V362, P241, DOI 10.1038/362241a0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 1989, MOL CLONING LAB MANU; SCHWARTZ F, 1991, P NATL ACAD SCI USA, V88, P10416, DOI 10.1073/pnas.88.23.10416; SOGIN ML, 1986, P NATL ACAD SCI USA, V83, P1383, DOI 10.1073/pnas.83.5.1383; Vos JC, 1996, GENE DEV, V10, P755, DOI 10.1101/gad.10.6.755; WARREN AM, 1994, PARASITOL TODAY, V10, P56	40	125	137	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 13	1997	276	5319					1716	1719		10.1126/science.276.5319.1716	http://dx.doi.org/10.1126/science.276.5319.1716			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XD947	9180085				2022-12-01	WOS:A1997XD94700048
J	Subramanian, K; Meyer, T				Subramanian, K; Meyer, T			Calcium-induced restructuring of nuclear envelope and endoplasmic reticulum calcium stores	CELL			English	Article							GREEN-FLUORESCENT PROTEIN; MEIOTIC MATURATION; CA2+ STORES; SEA-URCHIN; RELEASE; REORGANIZATION; FERTILIZATION; CELLS; EGG; GRADIENTS	The spatial organization of endoplasmic reticulum (ER) and nuclear envelope (NE) calcium stores is important for the regulation of localized calcium signals and sustained calcium gradients. Here, we have used a lumenal GFP fusion protein and shown that, in resting cells, large molecules can rapidly diffuse across the cell within the lumenal storage space defined by the ER and NE membranes. Increases in cytosolic calcium concentration reversibly fragmented ER tubules and prevented lumenal diffusion. However, the integrity of the NE was maintained, and a significant fraction of NE lumenal protein accumulated in an NE-associated vesicle. These dynamic properties of ER-NE calcium stores provide insights into the spatiotemporal control of calcium signaling.	DUKE UNIV, MED CTR, DEPT CELL BIOL, DURHAM, NC 27710 USA	Duke University				Meyer, Tobias/0000-0003-4339-3804	NIGMS NIH HHS [GM-51457, GM-48113] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM048113, R01GM048113] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLBRITTON NL, 1994, P NATL ACAD SCI USA, V91, P12458, DOI 10.1073/pnas.91.26.12458; ALMOHANNA FA, 1994, NATURE, V367, P745, DOI 10.1038/367745a0; BAITINGER C, 1990, J CELL BIOL, V111, P1763, DOI 10.1083/jcb.111.5.1763; BOOTMAN MD, 1995, CELL, V83, P675, DOI 10.1016/0092-8674(95)90179-5; BRUNDAGE RA, 1991, SCIENCE, V254, P703, DOI 10.1126/science.1948048; Button D, 1996, MOL BIOL CELL, V7, P419, DOI 10.1091/mbc.7.3.419; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHANG DC, 1995, J CELL BIOL, V131, P1539, DOI 10.1083/jcb.131.6.1539; CHENG H, 1993, SCIENCE, V262, P740, DOI 10.1126/science.8235594; Cole NB, 1996, SCIENCE, V273, P797, DOI 10.1126/science.273.5276.797; Crameri A, 1996, NAT BIOTECHNOL, V14, P315, DOI 10.1038/nbt0396-315; DOWD DR, 1995, ADV SEC MESS PHOSPH, V30, P255; ELLIOTT AC, 1992, PFLUG ARCH EUR J PHY, V422, P245, DOI 10.1007/BF00376209; GERASIMENKO OV, 1995, CELL, V80, P439, DOI 10.1016/0092-8674(95)90494-8; Golovina VA, 1997, SCIENCE, V275, P1643, DOI 10.1126/science.275.5306.1643; GREBER UF, 1995, J CELL BIOL, V128, P5, DOI 10.1083/jcb.128.1.5; GULLBERG U, 1995, J BIOL CHEM, V270, P12912, DOI 10.1074/jbc.270.21.12912; HASHIMOTO S, 1988, J CELL BIOL, V107, P2523, DOI 10.1083/jcb.107.6.2523; Hein R, 1996, CURR BIOL, V6, P178, DOI 10.1016/S0960-9822(02)00450-5; HENSON JH, 1989, J CELL BIOL, V109, P149, DOI 10.1083/jcb.109.1.149; HEPLER PK, 1994, CELL CALCIUM, V16, P322, DOI 10.1016/0143-4160(94)90096-5; HIROSE K, 1994, NATURE, V372, P791; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; JAFFE LA, 1994, DEV BIOL, V164, P579, DOI 10.1006/dbio.1994.1225; KOCH GLE, 1988, J CELL SCI, V91, P511; MEHLMANN LM, 1995, DEV BIOL, V170, P607, DOI 10.1006/dbio.1995.1240; MELDOLESI J, 1992, J PHYSIOLOGY-PARIS, V86, P23, DOI 10.1016/S0928-4257(05)80004-X; MEYER T, 1990, P NATL ACAD SCI USA, V87, P3841, DOI 10.1073/pnas.87.10.3841; MEYER T, 1995, CIBA F SYMP, V188, P252; Mogami H, 1997, CELL, V88, P49, DOI 10.1016/S0092-8674(00)81857-7; MOHR FC, 1990, AM J PHYSIOL, V258, pC217, DOI 10.1152/ajpcell.1990.258.2.C217; MUALLEM S, 1989, J BIOL CHEM, V264, P205; NICOTERA P, 1994, CELL CALCIUM, V16, P279, DOI 10.1016/0143-4160(94)90091-4; Parys JB, 1996, PFLUG ARCH EUR J PHY, V432, P359, DOI 10.1007/s004240050145; PETERSEN OH, 1995, CIBA F SYMP, V188, P85; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SPEKSNIJDER JE, 1993, J CELL BIOL, V120, P1337, DOI 10.1083/jcb.120.6.1337; STEHNOBITTEL L, 1995, SCIENCE, V270, P1835, DOI 10.1126/science.270.5243.1835; Terasaki M, 1996, DEV BIOL, V179, P320, DOI 10.1006/dbio.1996.0263; TERASAKI M, 1991, J CELL BIOL, V114, P929, DOI 10.1083/jcb.114.5.929; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; TRUMP BF, 1981, CELL DEATH BIOL PATH, P209; Vertel B M, 1992, Semin Cell Biol, V3, P325, DOI 10.1016/1043-4682(92)90019-R; WAYBILL MM, 1991, AM J PHYSIOL, V261, pE49, DOI 10.1152/ajpendo.1991.261.1.E49; Yokoe E, 1996, NAT BIOTECHNOL, V14, P1252, DOI 10.1038/nbt1096-1252	46	190	194	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 13	1997	89	6					963	971		10.1016/S0092-8674(00)80281-0	http://dx.doi.org/10.1016/S0092-8674(00)80281-0			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XE357	9200614	Bronze			2022-12-01	WOS:A1997XE35700016
J	Klein, RD; Sherman, D; Ho, WH; Stone, D; Bennett, GL; Moffat, B; Vandlen, R; Simmons, L; Gu, QM; Hongo, JA; Devaux, B; Poulsen, K; Armanini, M; Nozaki, C; Asai, N; Goddard, A; Phillips, H; Henderson, CE; Takahashi, M; Rosenthal, A				Klein, RD; Sherman, D; Ho, WH; Stone, D; Bennett, GL; Moffat, B; Vandlen, R; Simmons, L; Gu, QM; Hongo, JA; Devaux, B; Poulsen, K; Armanini, M; Nozaki, C; Asai, N; Goddard, A; Phillips, H; Henderson, CE; Takahashi, M; Rosenthal, A			A GPI-linked protein that interacts with Ret to form a candidate neurturin receptor	NATURE			English	Article							NEUROTROPHIC FACTOR; TRANSFORMING GENE; SURVIVAL FACTOR; GDNF; ACTIVATION; NEURONS; CELLS; PROTOONCOGENE; NEUROBLASTOMA; EXPRESSION	Glial-cell-line-derived neurotrophic factor (GDNF) and neurturin (NTN) are two structurally related, potent survival factors for sympathetic, sensory and central nervous system neurons(1-6). GDNF mediates its actions through a multicomponent receptor system composed of a ligand-binding glycosyl-phosphatidylinositol (GPI)-linked protein (designated GDNFR-alpha) and the trans-membrane protein tyrosine kinase Ret(7-12). In contrast, the mechanism by which the NTN signal is transmitted is not well understood. Here we describe the identification and tissue distribution of a GPI-linked protein (designated NTNR-alpha) that is structurally related to GDNFR-alpha. We further demonstrate that NTNR-alpha binds NTN (K-d-10 pM) but not GDNF with high affinity; that GDNFR-alpha binds to GDNF but not NTN with high affinity; and that cellular responses to NTN require the presence of NTNR-alpha. Finally, we show that NTN, in the presence of NTNR-alpha, induces tyrosine-phosphorylation of Ret, and that NTN, NTNR-alpha and Ret form a physical complex on the cell surface. These findings identify Ret and NTNR-alpha as signalling and ligand-binding components, respectively, of a receptor for NTN and define a novel family of receptors for neurotrophic and differentiation factors composed of a shared transmembrane protein tyrosine kinase and a ligand-specific GPI-linked protein.	GENENTECH INC,DEPT NEUROSCI,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT BIOANALYT TECHNOL,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT PROT BIOCHEM,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT MOL BIOL,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT ANTIBODY TECHNOL,S SAN FRANCISCO,CA 94080; NAGOYA UNIV,SCH MED,DEPT PATHOL,SHOWA KU,NAGOYA,AICHI 466,JAPAN; DEV BIOL INST MARSEILLE,INSERM,U382,F-13288 MARSEILLE 09,FRANCE	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Nagoya University; Institut National de la Sante et de la Recherche Medicale (Inserm)			ASAI, Naoya/I-7377-2014; Takahashi, Masahide/AAN-4770-2020; TAKAHASHI, Masahide/I-7244-2014	Takahashi, Masahide/0000-0002-2803-2683; Henderson, Christopher/0000-0002-9936-3279				Arenas E, 1995, NEURON, V15, P1465, DOI 10.1016/0896-6273(95)90024-1; BUJBELLO A, 1995, NEURON, V15, P821, DOI 10.1016/0896-6273(95)90173-6; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; Durbec PL, 1996, DEVELOPMENT, V122, P349; Henderson C.E., 1995, NERVE CELL CULTURE P, P69; HENDERSON CE, 1994, SCIENCE, V266, P1062, DOI 10.1126/science.7973664; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; IKEDA I, 1990, ONCOGENE, V5, P1291; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Koke J A, 1991, Protein Expr Purif, V2, P51, DOI 10.1016/1046-5928(91)90009-8; Kotzbauer PT, 1996, NATURE, V384, P467, DOI 10.1038/384467a0; LEE JD, 1993, P NATL ACAD SCI USA, V90, P9930, DOI 10.1073/pnas.90.21.9930; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; Lindsay RM, 1996, NEURON, V17, P571, DOI 10.1016/S0896-6273(00)80189-0; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0; PUGIN J, 1993, P NATL ACAD SCI USA, V90, P2744, DOI 10.1073/pnas.90.7.2744; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; TAKAHASHI M, 1991, ONCOGENE, V6, P297; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; TRUPP M, 1995, J CELL BIOL, V130, P137, DOI 10.1083/jcb.130.1.137; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0	28	340	357	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 12	1997	387	6634					717	721		10.1038/42722	http://dx.doi.org/10.1038/42722			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XD869	9192898	Bronze			2022-12-01	WOS:A1997XD86900057
J	Alpers, A; Lo, B				Alpers, A; Lo, B			Does it make clinical sense to equate terminally ill patients who require life-sustaining interventions with those who do not?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHYSICIAN-ASSISTED SUICIDE; DEATH	Two US courts of appeals have ruled that competent, terminally ill patients have a constitutional right to physician-assisted suicide. The cases are now before the US Supreme Court, which is expected to issue a ruling later this year. This article analyzes the keystone of the courts' ruling: their assertion that competent, terminally ill patients who are being kept alive on life support are equivalent to competent, terminally ill patients who do not require such support. Because the former are permitted to end their lives by refusing treatment, the courts found that the latter also have a right to determine the time and manner of their death, through prescriptions for lethal doses of medication. This article analyzes whether the courts' thinking is premised on a clinically plausible view of the care of terminally ill patients, Based on a discussion of common situations involving terminal illness, we argue that the courts' reasoning is deeply flawed. The article also analyzes how the implications of the courts' reasoning might undermine the care of terminally ill patients.	UNIV CALIF SAN FRANCISCO,PROGRAM MED ETH,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CTR AIDS PREVENT STUDIES,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DIV GEN INTERNAL MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NIMH NIH HHS [MH42459] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH042459] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALPERS A, 1995, JAMA-J AM MED ASSOC, V274, P483, DOI 10.1001/jama.274.6.483; ALPERS A, 1995, JAMA-J AM MED ASSOC, V273, P156, DOI 10.1001/jama.273.2.156; Angell M, 1997, NEW ENGL J MED, V336, P50, DOI 10.1056/NEJM199701023360108; Annas GJ, 1996, NEW ENGL J MED, V335, P683, DOI 10.1056/NEJM199608293350924; Beauchamp TL, 2009, PRINCIPLES BIOMEDICA, V7; BRODY H, 1992, NEW ENGL J MED, V327, P1384, DOI 10.1056/NEJM199211053271912; BRODY H, 1996, BIOLAW, V2, P154; Cantor NL., 1993, CIVILIZATION MIDDLE; CURTIS JR, 1995, JAMA-J AM MED ASSOC, V273, P124, DOI 10.1001/jama.273.2.124; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; Foley KM, 1997, NEW ENGL J MED, V336, P54, DOI 10.1056/NEJM199701023360109; JECKER N, 1995, J AM GERONTOL, V46, P696; KADISH SH, 1992, CALIF LAW REV, V80, P857, DOI 10.2307/3480699; Kamisar Y, 1996, Duquesne Law Rev, V35, P481; Lee MA, 1996, ANN INTERN MED, V124, P267, DOI 10.7326/0003-4819-124-2-199601150-00014; LO B, 1995, RESOLVING ETHICAL DI, P24; MEISEL A, 1995, LIMITATIONS DECISION, P470; MILLER FG, 1994, NEW ENGL J MED, V331, P119, DOI 10.1056/NEJM199407143310211; Orentlicher D, 1996, NEW ENGL J MED, V335, P663, DOI 10.1056/NEJM199608293350912; QUILL TE, 1992, NEW ENGL J MED, V327, P1380, DOI 10.1056/NEJM199211053271911; SINGER PA, 1990, NEW ENGL J MED, V322, P1881, DOI 10.1056/NEJM199006283222610; 1996, DUQUESNE LAW REV, V35, P1; 1996, JAMA-J AM MED ASSOC, V275, P1232; 1996, BIOLAW           JUL, V2, P119; 1995, JAMA-J AM MED ASSOC, V274, P1591	25	17	17	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 4	1997	277	21					1705	1708		10.1001/jama.277.21.1705	http://dx.doi.org/10.1001/jama.277.21.1705			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XB088	9169898				2022-12-01	WOS:A1997XB08800032
J	Jeltsch, M; Kaipainen, A; Joukov, V; Meng, XJ; Lakso, M; Rauvala, H; Swartz, M; Fukumura, D; Jain, RK; Alitalo, K				Jeltsch, M; Kaipainen, A; Joukov, V; Meng, XJ; Lakso, M; Rauvala, H; Swartz, M; Fukumura, D; Jain, RK; Alitalo, K			Hyperplasia of lymphatic vessels in VEGF-C transgenic mice	SCIENCE			English	Article							RECEPTOR TYROSINE KINASE; GROWTH-FACTOR; ENDOTHELIAL-CELLS; EXPRESSION; GENE; FLT4; ANGIOGENESIS; FLK-1; TIE	No growth factors specific for the lymphatic vascular system have yet been described. Vascular endothelial growth factor (VEGF) regulates vascular permeability and angiogenesis, but does not promote lymphangiogenesis. Overexpression of VEGF-C, a ligand of the VEGF receptors VEGFR-3 and VEGFR-2, in the skin of transgenic mice resulted in lymphatic, but not vascular, endothelial proliferation and vessel enlargement. Thus, VEGF-C induces selective hyperplasia of the lymphatic vasculature, which is involved in the draining of interstitial fluid and in immune function, inflammation, and tumor metastasis. VEGF-C may play a role in disorders involving the lymphatic system and may be of potential use in therapeutic lymphangiogenesis.	UNIV HELSINKI, HAARTMAN INST, MOL CANC BIOL LAB, SF-00014 HELSINKI, FINLAND; UNIV HELSINKI, INST BIOTECHNOL, HELSINKI 00014, FINLAND; MASSACHUSETTS GEN HOSP, DEPT RADIAT ONCOL, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02114 USA	University of Helsinki; University of Helsinki; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School			Swartz, Melody A./F-9563-2011; Jeltsch, Michael/I-5340-2012; Alitalo, Kari K/J-5013-2014; Joukov, Vladimir/K-3525-2019; Jain, Rakesh K/I-1384-2017	Jeltsch, Michael/0000-0003-2890-7790; Alitalo, Kari K/0000-0002-7331-0902; Jain, Rakesh K/0000-0001-7571-3548; Rauvala, Heikki/0000-0001-7809-9811				DUMONT DJ, 1995, DEV DYNAM, V203, P80, DOI 10.1002/aja.1002030109; FERRARA N, IN PRESS ENDOCR REV; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; Folkman J, 1996, NEW ENGL J MED, V334, P921; FOSSUM TW, 1992, J VET INTERN MED, V6, P283, DOI 10.1111/j.1939-1676.1992.tb00353.x; FUKUMURA D, 1995, CANCER RES, V55, P4824; GALLAND F, 1993, ONCOGENE, V8, P1233; Grimmond S, 1996, GENOME RES, V6, P124, DOI 10.1101/gr.6.2.124; Joukov V, 1996, EMBO J, V15, P290; JOUKOV V, UNPUB; KAIPAINEN A, 1993, J EXP MED, V178, P2077, DOI 10.1084/jem.178.6.2077; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; Klagsbrun Michael, 1996, Cytokine and Growth Factor Reviews, V7, P259, DOI 10.1016/S1359-6101(96)00027-5; KORHONEN J, 1994, ONCOGENE, V9, P395; Kukk E, 1996, DEVELOPMENT, V122, P3829; LEAK L V, 1970, Microvascular Research, V2, P361, DOI 10.1016/0026-2862(70)90031-2; Lee J, 1996, P NATL ACAD SCI USA, V93, P1988, DOI 10.1073/pnas.93.5.1988; LEU AJ, 1994, AM J PHYSIOL-HEART C, V267, pH1507, DOI 10.1152/ajpheart.1994.267.4.H1507; LEU HJ, 1995, VASCULAR PATHOLOGY, P509; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; MILLAUER B, 1993, CELL, V72, P83; MURAGAKI Y, 1995, P NATL ACAD SCI USA, V92, P8763, DOI 10.1073/pnas.92.19.8763; Olofsson B, 1996, P NATL ACAD SCI USA, V93, P2576, DOI 10.1073/pnas.93.6.2576; PAJUSOLA K, 1992, CANCER RES, V52, P5738; REHN M, 1994, P NATL ACAD SCI USA, V91, P4234, DOI 10.1073/pnas.91.10.4234; SCHMELZ M, 1994, DIFFERENTIATION, V57, P97, DOI 10.1046/j.1432-0436.1994.5720097.x; Swartz MA, 1996, AM J PHYSIOL-HEART C, V270, pH324, DOI 10.1152/ajpheart.1996.270.1.H324; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; VASSAR R, 1989, P NATL ACAD SCI USA, V86, P1563, DOI 10.1073/pnas.86.5.1563; YAMAGUCHI TP, 1993, DEVELOPMENT, V118, P489	30	1010	1115	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 30	1997	276	5317					1423	1425		10.1126/science.276.5317.1423	http://dx.doi.org/10.1126/science.276.5317.1423			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XB533	9162011				2022-12-01	WOS:A1997XB53300052
J	Sudlow, M; Rodgers, H; Kenny, RA; Thomson, R				Sudlow, M; Rodgers, H; Kenny, RA; Thomson, R			Population based study of use of anticoagulants among patients with atrial fibrillation in the community	BRITISH MEDICAL JOURNAL			English	Article									UNIV NEWCASTLE UPON TYNE,SCH MED,DIV EPIDEMIOL & PUBL HLTH,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND	Newcastle University - UK	Sudlow, M (corresponding author), UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT MED,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND.			Kenny, Rose Anne/0000-0002-9336-8124				*ATR FIBR INV, 1994, ARCH INTERN MED, V154, P1449; LIP GYH, 1994, BRIT HEART J, V71, P92; OConnell JE, 1996, AGE AGEING, V25, P307, DOI 10.1093/ageing/25.4.307; *STROK PREV ATR FI, 1991, CIRCULATION, V84, P597; SWEENEY KG, 1995, BRIT J GEN PRACT, V45, P153	5	76	76	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 24	1997	314	7093					1529	1530		10.1136/bmj.314.7093.1529	http://dx.doi.org/10.1136/bmj.314.7093.1529			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XB484	9183202	Green Published			2022-12-01	WOS:A1997XB48400028
J	Anderson, JD; Lau, EL; Sjogren, WL; Schubert, G; Moore, WB				Anderson, JD; Lau, EL; Sjogren, WL; Schubert, G; Moore, WB			Europa's differentiated internal structure: Inferences from two Galileo encounters	SCIENCE			English	Article							GRAVITY-FIELD; TRACKING DATA; SATELLITES; JUPITER	Doppler data generated with the Galileo spacecraft's radio carrier wave during two Europa encounters on 19 December 1996 (E4) and 20 February 1997 (E6) were used to measure Europa's external gravitational field. The measurements indicate that Europa has a predominantly water ice-liquid outer shell about 100 to 200 kilometers thick and a deep interior with a density in excess of about 4000 kilograms per cubic meter. The deep interior could be a mixture of metal and rock or it could consist of a metal core with a radius about 40 percent of Europa's radius surrounded by a rock mantle with a density of 3000 to 3500 kilograms per cubic meter. The metallic core is favored if Europa has a magnetic field.	UNIV CALIF LOS ANGELES,INST GEOPHYS & PLANETARY PHYS,DEPT EARTH & SPACE SCI,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles	Anderson, JD (corresponding author), CALTECH,JET PROP LAB,4800 OAK GROVE DR,PASADENA,CA 91109, USA.							Anderson JD, 1996, NATURE, V384, P541, DOI 10.1038/384541a0; Anderson JD, 1996, SCIENCE, V272, P709, DOI 10.1126/science.272.5262.709; ANDERSON JD, 1974, EXPT GRAVITATION, P163; ANDERSON JD, IN PRESS NATURE; CAMPBELL JK, 1985, ASTRON J, V90, P364, DOI 10.1086/113741; DERMOTT SF, 1979, ICARUS, V37, P310, DOI 10.1016/0019-1035(79)90137-4; HUBBARD WB, 1978, ICARUS, V33, P336, DOI 10.1016/0019-1035(78)90153-7; JEFFREYS H, 1962, EARTH; Kaula W. M., 1966, THEORY SATELLITE GEO; Kaula W.M., 1968, INTRO PLANETARY PHYS; Kivelson MG, 1997, SCIENCE, V276, P1239, DOI 10.1126/science.276.5316.1239; MOYER TD, 1973, TR321527 JET PROP LA, P396; NULL GW, 1976, ASTRON J, V81, P1153, DOI 10.1086/111999; NULL GW, 1975, SCIENCE, V188, P476, DOI 10.1126/science.188.4187.476; SCHUBERT G, 1986, SATELLITES, P629; TAPLEY BD, 1973, RECENT ADV DYNAMICAL, P396; ZHARKOV VN, 1985, ICARUS, V61, P92, DOI 10.1016/0019-1035(85)90157-5	17	111	117	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 23	1997	276	5316					1236	1239		10.1126/science.276.5316.1236	http://dx.doi.org/10.1126/science.276.5316.1236			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XA497	9157877				2022-12-01	WOS:A1997XA49700036
J	Freiberg, C; Fellay, R; Bairoch, A; Broughton, WJ; Rosenthal, A; Perret, X				Freiberg, C; Fellay, R; Bairoch, A; Broughton, WJ; Rosenthal, A; Perret, X			Molecular basis of symbiosis between Rhizobium and legumes	NATURE			English	Article							SP NGR234; NITROGEN-FIXATION; VIGNA-UNGUICULATA; PLASMID TRANSFER; STRAIN NGR234; GENES; PSOPHOCARPUS; GENOME	Access to mineral nitrogen often limits plant growth, and so symbiotic relationships have evolved between plants and a variety of nitrogen-fixing organisms, These associations are responsible for reducing 120 million tonnes of atmospheric nitrogen to ammonia each year, In agriculture, independence from nitrogenous fertilizers expands crop production and minimizes pollution of water tables, lakes and rivers. Here we present the complete nucleotide sequence and gene complement of the plasmid from Rhizobium sp. NGR234 that endows the bacterium with the ability to associate symbiotically with leguminous plants, In conjunction with transcriptional analyses, these data demonstrate the presence of new symbiotic loci and signalling mechanisms. The sequence and organization of genes involved in replication and conjugal transfer are similar to those of Agrobacterium, suggesting a recent lateral transfer of genetic information.	INST MOL BIOTECHNOL,ABT GENOMANAL,D-07745 JENA,GERMANY; UNIV GENEVA,CTR MED UNIV,CH-1292 CHAMBESY 4,GENEVE,SWITZERLAND	University of Geneva			Bairoch, Amos/X-7411-2019	Bairoch, Amos/0000-0003-2826-6444				BADENOCHJONES J, 1989, GENE, V77, P141, DOI 10.1016/0378-1119(89)90368-5; Bairoch A, 1996, NUCLEIC ACIDS RES, V24, P189, DOI 10.1093/nar/24.1.189; BORODOVSKY M, 1994, NUCLEIC ACIDS RES, V22, P4756, DOI 10.1093/nar/22.22.4756; BROUGHTON WJ, 1987, FEMS MICROBIOL LETT, V40, P251; BROUGHTON WJ, 1986, J CELL BIOL, V102, P1173, DOI 10.1083/jcb.102.4.1173; BROUGHTON WJ, 1984, P NATL ACAD SCI-BIOL, V81, P3093, DOI 10.1073/pnas.81.10.3093; BROUGHTON WJ, 1972, ANAL BIOCHEM, V46, P164, DOI 10.1016/0003-2697(72)90408-3; Denarie J, 1996, ANNU REV BIOCHEM, V65, P503, DOI 10.1146/annurev.bi.65.070196.002443; FELLAY R, 1995, MOL MICROBIOL, V16, P657, DOI 10.1111/j.1365-2958.1995.tb02428.x; FELLAY R, 1995, PATHOGENESIS HOST PA, V1, P199; FISCHER HM, 1994, MICROBIOL REV, V58, P352, DOI 10.1128/MMBR.58.3.352-386.1994; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; Freiberg C, 1996, GENOME RES, V6, P590, DOI 10.1101/gr.6.7.590; Galas D, 1989, MOBILE DNA, P109; HANIN M, IN PRESS MOL MICROBI; JABBOURI S, 1995, J BIOL CHEM, V270, P22968, DOI 10.1074/jbc.270.39.22968; Jabbouri S, 1996, BIOLOGY OF PLANT-MICROBE INTERACTIONS, P319; KRISHNAN HB, 1995, MICROBIOL-SGM, V141, P2245, DOI 10.1099/13500872-141-9-2245; LEIGH JA, 1994, TRENDS GENET, V10, P63, DOI 10.1016/0168-9525(94)90151-1; LEWIN A, 1987, PLANT MOL BIOL, V8, P447, DOI 10.1007/BF00017990; MartinezRomero E, 1996, CRIT REV PLANT SCI, V15, P113, DOI 10.1080/713608131; MORRISON NA, 1984, J BACTERIOL, V160, P483, DOI 10.1128/JB.160.1.483-487.1984; PERRET X, 1991, P NATL ACAD SCI USA, V88, P1923, DOI 10.1073/pnas.88.5.1923; PIPER KR, 1993, NATURE, V362, P448, DOI 10.1038/362448a0; PRICE NPJ, 1992, MOL MICROBIOL, V6, P3575, DOI 10.1111/j.1365-2958.1992.tb01793.x; Spaink HP, 1996, CRIT REV PLANT SCI, V15, P559; SULLIVAN JT, 1995, P NATL ACAD SCI USA, V92, P8985, DOI 10.1073/pnas.92.19.8985; Tepfer D., 1989, Plant-microbe interactions., P294; VANSLOOTEN JC, 1990, J BACTERIOL, V172, P5563, DOI 10.1128/jb.172.10.5563-5574.1990; VANSLOOTEN JC, 1992, MOL PLANT MICROBE IN, V5, P179, DOI 10.1094/MPMI-5-179; ZHANG LH, 1993, NATURE, V362, P446, DOI 10.1038/362446a0	32	560	970	6	268	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 22	1997	387	6631					394	401		10.1038/387394a0	http://dx.doi.org/10.1038/387394a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XA496	9163424				2022-12-01	WOS:A1997XA49600059
J	Mackenzie, PA; Smith, EA; Wallace, PGM				Mackenzie, PA; Smith, EA; Wallace, PGM			Transfer of adults between intensive care units in the United Kingdom: Postal survey	BRITISH MEDICAL JOURNAL			English	Article							ILL PATIENTS; AUDIT		UNIV GLASGOW,GLASGOW ROYAL INFIRM,GLASGOW G4 0SF,LANARK,SCOTLAND	University of Glasgow	Mackenzie, PA (corresponding author), UNIV GLASGOW,WESTERN INFIRM,DIRECTORATE ANAESTHESIA,GLASGOW G11 6NT,LANARK,SCOTLAND.							*ASS AN GB IR, 1994, REC STAND MON AN REC; BION JF, 1988, BRIT MED J, V296, P170, DOI 10.1136/bmj.296.6616.170; GENTLEMAN D, 1990, LANCET, V335, P330, DOI 10.1016/0140-6736(90)90615-C; OAKLEY PA, 1994, ANAESTHESIA, V49, P565; WRIGHT IH, 1988, BRIT MED J, V296, P543, DOI 10.1136/bmj.296.6621.543	5	39	40	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 17	1997	314	7092					1455	1456		10.1136/bmj.314.7092.1455	http://dx.doi.org/10.1136/bmj.314.7092.1455			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XA202	9167562	Green Published			2022-12-01	WOS:A1997XA20200023
J	Astumian, RD				Astumian, RD			Thermodynamics and kinetics of a Brownian motor	SCIENCE			English	Article							STOCHASTIC RESONANCE; JOSEPHSON-JUNCTION; INDUCED TRANSPORT; THERMAL RATCHETS; MOLECULAR MOTORS; DRIVEN RATCHETS; ELECTRIC-FIELD; FREE-ENERGY; NOISE; PARTICLES	Nonequilibrium fluctuations, whether generated externally or by a chemical reaction far from equilibrium, can bias the Brownian motion of a particle in an anisotropic medium without thermal gradients, a net force such as gravity, or a macroscopic electric field. Fluctuation-driven transport is one mechanism by which chemical energy can directly drive the motion of particles and macromolecules and may find application in a wide variety of fields, including particle separation and the design of molecular motors and pumps.	UNIV CHICAGO,DEPT BIOCHEM & MOL BIOL,CHICAGO,IL 60637	University of Chicago	Astumian, RD (corresponding author), UNIV CHICAGO,DEPT SURG,MC6035,CHICAGO,IL 60637, USA.		Astumian, Raymond Dean/H-7440-2013	Astumian, Raymond Dean/0000-0001-7472-187X	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R29ES006620] Funding Source: NIH RePORTER; NIEHS NIH HHS [R29ES06620] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AJDARI A, 1992, CR ACAD SCI II, V315, P1635; ANISHCHENKO VS, 1994, INT J BIFURCAT CHAOS, V4, P441, DOI 10.1142/S0218127494000290; ASTUMIAN RD, 1994, PHYS REV LETT, V72, P1766, DOI 10.1103/PhysRevLett.72.1766; ASTUMIAN RD, 1987, P NATL ACAD SCI USA, V84, P434, DOI 10.1073/pnas.84.2.434; Astumian RD, 1996, J PHYS CHEM-US, V100, P19075, DOI 10.1021/jp961614m; ASTUMIAN RD, 1993, J AM CHEM SOC, V115, P11063, DOI 10.1021/ja00077a001; ASTUMIAN RD, 1995, P NATL ACAD SCI USA, V92, P3740, DOI 10.1073/pnas.92.9.3740; ASTUMIAN RD, 1989, PHYS REV A, V39, P6416, DOI 10.1103/PhysRevA.39.6416; ASTUMIAN RD, 1989, J CHEM PHYS, V91, P4891, DOI 10.1063/1.456728; ASTUMIAN RD, 1996, BIOPHYS J, V70, P689; BARTUSSEK R, 1994, EUROPHYS LETT, V28, P459, DOI 10.1209/0295-5075/28/7/001; Bartussek R, 1996, PHYS REV LETT, V76, P1166, DOI 10.1103/PhysRevLett.76.1166; BENNETT CH, 1982, INT J THEOR PHYS, V21, P905, DOI 10.1007/BF02084158; Berg H. C., 1983, RANDOM WALKS BIOL; Bier M, 1996, PHYS LETT A, V211, P12, DOI 10.1016/0375-9601(95)00920-5; Bier M, 1996, PHYS REV LETT, V76, P4277, DOI 10.1103/PhysRevLett.76.4277; Bier M, 1996, BIOELECTROCH BIOENER, V39, P67, DOI 10.1016/0302-4598(95)01833-6; Bulsara AR, 1996, PHYS TODAY, V49, P39, DOI 10.1063/1.881491; BUTTIKER M, 1983, PHYS REV B, V28, P1268, DOI 10.1103/PhysRevB.28.1268; Buttiker M., 1982, NONLINEAR PHENOMENA, P111; CHAWIN JF, 1995, EUROPHYS LETT, V32, P373; DERENYI I, 1995, PHYS REV LETT, V75, P374, DOI 10.1103/PhysRevLett.75.374; Derenyi I, 1996, PHYS REV E, V54, pR5, DOI 10.1103/PhysRevE.54.R5; DOERING CR, 1995, NUOVO CIMENTO D, V17, P685, DOI 10.1007/BF02451826; DOERING CR, 1994, PHYS REV LETT, V72, P2984, DOI 10.1103/PhysRevLett.72.2984; Einstein A, 1906, ANN PHYS-BERLIN, V19, P371; FAUCHEUX LP, 1995, PHYS REV LETT, V74, P1504, DOI 10.1103/PhysRevLett.74.1504; FEYNMAN RP, 1966, FEYNMAN LECT PHYS, V1, pCH46; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; FULINSKI A, 1994, PHYS LETT A, V193, P267, DOI 10.1016/0375-9601(94)90595-9; HANGGI P, 1990, REV MOD PHYS, V62, P251, DOI 10.1103/RevModPhys.62.251; HIBBS AD, 1995, J APPL PHYS, V77, P2582, DOI 10.1063/1.358720; JULICHER F, 1995, PHYS REV LETT, V75, P2618, DOI 10.1103/PhysRevLett.75.2618; LANDAUER R, 1985, PHYS SCRIPTA, VT9, P155, DOI 10.1088/0031-8949/1985/T9/027; Langevin P, 1908, CR HEBD ACAD SCI, V146, P530; LAUGER P, 1991, ELECTROGENIC ION PUM, P56; LEIBLER S, 1994, NATURE, V370, P412, DOI 10.1038/370412a0; LIU DS, 1990, J BIOL CHEM, V265, P7260; MAGNASCO MO, 1993, PHYS REV LETT, V71, P1477, DOI 10.1103/PhysRevLett.71.1477; Mielke A, 1995, ANN PHYS-LEIPZIG, V4, P721, DOI 10.1002/andp.19955070802; MIELKE A, 1995, ANN PHYS-LEIPZIG, V4, P476, DOI 10.1002/andp.19955070507; MILLONAS MM, 1994, PHYS LETT A, V185, P65, DOI 10.1016/0375-9601(94)90989-X; PESKIN CS, 1994, CELL MECH CELLULAR E; PROST J, 1994, PHYS REV LETT, V72, P2652, DOI 10.1103/PhysRevLett.72.2652; Risken H., 1989, FOKKER PLANCK EQUATI; ROUSE R, 1995, APPL PHYS LETT, V66, P108, DOI 10.1063/1.114161; ROUSSELET J, 1994, NATURE, V370, P446, DOI 10.1038/370446a0; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; TARLIE M, UNPUB; TSONG TY, 1986, BIOELECTROCH BIOENER, V15, P457, DOI 10.1016/0302-4598(86)85034-6; von Smoluchowski M, 1912, PHYS Z, V13, P1069; WIESENFELD K, 1995, NATURE, V373, P33, DOI 10.1038/373033a0; XIE TD, 1994, BIOPHYS J, V67, P1247, DOI 10.1016/S0006-3495(94)80594-6; XIE TD, IN PRESS BIOPHYS J; Zhou HX, 1996, PHYS REV LETT, V77, P194, DOI 10.1103/PhysRevLett.77.194	55	1193	1210	3	276	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 9	1997	276	5314					917	922		10.1126/science.276.5314.917	http://dx.doi.org/10.1126/science.276.5314.917			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WY792	9139648	Green Submitted			2022-12-01	WOS:A1997WY79200038
J	Haberli, RM; Gombosi, TI; DeZeeuw, DL; Combi, MR; Powell, KG				Haberli, RM; Gombosi, TI; DeZeeuw, DL; Combi, MR; Powell, KG			Modeling of cometary X-rays caused by solar wind minor ions	SCIENCE			English	Article							ELECTRON-CAPTURE; ABUNDANCES; OXYGEN; COLLISIONS; JUPITER; CARBON; H-2	X-ray emission was discovered in comet Hyakutake (C/1996 B2) by the Rontgen satellite in 1996, and these emissions were attributed to the excitation of high charge state solar wind ions due to electron capture from cometary molecules or atoms. Using the plasma flow in the coma of Hyakutake calculated by a three-dimensional adaptive magneto-hydrodynamic model, the density distribution of solar wind ions in the coma and the resulting x-ray emission were computed. The calculated High Resolution imager count rate of 4.4 per second and the spatial distribution of the x-ray emission agree with the observations. A detailed energy spectrum of cometary x-rays is predicted in the 80 to 2000 electronvolt energy range. Cometary x-rays present a sensitive tool to monitor cometary activity and solar wind ion composition.	UNIV MICHIGAN,SPACE PHYS RES LAB,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT AEROSP ENGN,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			Gombosi, Tamas I/G-4238-2011; Combi, Michael R/J-1697-2012; De Zeeuw, Darren L/F-3667-2011	Gombosi, Tamas I/0000-0001-9360-4951; Combi, Michael R/0000-0002-9805-0078; De Zeeuw, Darren L/0000-0002-4313-5998; Powell, Kenneth/0000-0002-3708-8814				BAME SJ, 1975, SOL PHYS, V43, P463, DOI 10.1007/BF00152368; Bingham R, 1997, SCIENCE, V275, P49, DOI 10.1126/science.275.5296.49; BOCHSLER P, 1986, SOL PHYS, V103, P177, DOI 10.1007/BF00154867; Combi M. R., 1996, B AM ASTRON SOC, V28, P1094; Combi MR, 1996, ICARUS, V123, P207, DOI 10.1006/icar.1996.0150; CRAVENS TE, 1995, J GEOPHYS RES-SPACE, V100, P17153, DOI 10.1029/95JA00970; Cravens TE, 1997, GEOPHYS RES LETT, V24, P105, DOI 10.1029/96GL03780; DEZEEUW D, 1993, J COMPUT PHYS, V104, P56, DOI 10.1006/jcph.1993.1007; DIJKKAMP D, 1985, J PHYS B-AT MOL OPT, V18, P737, DOI 10.1088/0022-3700/18/4/018; GEISS J, 1994, EOS, V75, P278; Gombosi TI, 1996, J GEOPHYS RES-SPACE, V101, P15233, DOI 10.1029/96JA01075; HABERLI RM, 1996, B AM ASTRON SOC, V28, P1085; Haser L., 1957, B SOC R SCI 51 GE, V43, P740; ISLER RC, 1994, PLASMA PHYS CONTR F, V36, P171, DOI 10.1088/0741-3335/36/2/001; KRANKOWSKY D, 1986, NATURE, V321, P326, DOI 10.1038/321326a0; KRASNOPOLSKY VA, 1996, B AM ASTRON SOC, V28, P1095; Lisse CM, 1996, SCIENCE, V274, P205, DOI 10.1126/science.274.5285.205; MANN R, 1981, J PHYS B; Mumma MJ, 1996, SCIENCE, V272, P1310, DOI 10.1126/science.272.5266.1310; NORTHROP TG, IN PRESS ICARUS; OLSON RE, 1989, PHYS SCRIPTA, VT28, P71, DOI 10.1088/0031-8949/1989/T28/013; OLSON RE, 1980, J PHYS B-AT MOL OPT, V13, P483, DOI 10.1088/0022-3700/13/3/012; Palumbo L.J., 1973, ATOMIC IONIC EMISSIO; PHANEUF RA, 1982, PHYS REV A, V26, P1892, DOI 10.1103/PhysRevA.26.1892; Tawara H., 1978, Atomic Data and Nuclear Data Tables, V22, P491, DOI 10.1016/0092-640X(78)90021-9; VONSTEIGER R, 1992, ASTROPHYS J, V389, P791, DOI 10.1086/171252; WAITE JH, 1994, J GEOPHYS RES-SPACE, V99, P14799, DOI 10.1029/94JA01005	27	129	130	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 9	1997	276	5314					939	942		10.1126/science.276.5314.939	http://dx.doi.org/10.1126/science.276.5314.939			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WY792	9139655				2022-12-01	WOS:A1997WY79200045
J	Kadosh, D; Struhl, K				Kadosh, D; Struhl, K			Repression by Ume6 involves recruitment of a complex containing Sin3 corepressor and Rpd3 histone deacetylase to target promoters	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; TRANSCRIPTIONAL REPRESSION; YEAST; GENE; EXPRESSION; REGULATOR; ENCODES; DOMAIN; SITE	Sin3 and Rpd3 negatively regulate a diverse set of yeast genes. A mouse Sin3-related protein is a transcriptional corepressor, and a human Rpd3 homolog is a histone deacetylase. Here, we show that Sin3 and Rpd3 are specifically required for transcriptional repression by Ume6, a DNA-binding protein that regulates genes involved in meiosis. A short region of Ume6 is sufficient to repress transcription, and this repression domain mediates a two-hybrid and physical interaction with Sin3. Coimmunoprecipitation and two-hybrid experiments indicate that Sin3 and Rpd3 are associated in a complex distinct from TFIID and Pol II holoenzyme. Rpd3 is specifically required for repression by Sin3, and artificial recruitment of Rpd3 results in repression. These results suggest that repression by Ume6 involves recruitment of a Sin3-Rpd3 complex and targeted histone deacetylation.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOL PHARMACOL,BOSTON,MA 02115	Harvard University; Harvard Medical School					NIGMS NIH HHS [GM 53720] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BOWDISH KS, 1995, MOL CELL BIOL, V15, P2955; BOWDISH KS, 1993, MOL CELL BIOL, V13, P2172, DOI 10.1128/MCB.13.4.2172; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; DeRubertis F, 1996, NATURE, V384, P589; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; Jackson JC, 1996, NUCLEIC ACIDS RES, V24, P1322, DOI 10.1093/nar/24.7.1322; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; MCKENZIE EA, 1993, MOL GEN GENET, V240, P374, DOI 10.1007/BF00280389; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; NEHLIN JO, 1992, NUCLEIC ACIDS RES, V20, P5271, DOI 10.1093/nar/20.20.5271; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PARK HD, 1992, NUCLEIC ACIDS RES, V20, P1909, DOI 10.1093/nar/20.8.1909; Peterson CL, 1996, CURR OPIN GENET DEV, V6, P171, DOI 10.1016/S0959-437X(96)80047-5; Roth SY, 1996, CELL, V87, P5, DOI 10.1016/S0092-8674(00)81316-1; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SLEKAR KH, 1995, NUCLEIC ACIDS RES, V23, P1964, DOI 10.1093/nar/23.11.1964; STILLMAN DJ, 1994, GENETICS, V136, P781; STRICH R, 1994, GENE DEV, V8, P796, DOI 10.1101/gad.8.7.796; Struhl K, 1996, CELL, V84, P179, DOI 10.1016/S0092-8674(00)80970-8; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; TZAMARIAS D, 1994, NATURE, V369, P758, DOI 10.1038/369758a0; VIDAL M, 1991, MOL CELL BIOL, V11, P6317, DOI 10.1128/MCB.11.12.6317; VINCENT AC, 1992, MOL CELL BIOL, V12, P5394, DOI 10.1128/MCB.12.12.5394; WANG HM, 1993, MOL CELL BIOL, V13, P1805, DOI 10.1128/MCB.13.3.1805; Wilson CJ, 1996, CELL, V84, P235, DOI 10.1016/S0092-8674(00)80978-2; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0	33	463	475	1	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 2	1997	89	3					365	371		10.1016/S0092-8674(00)80217-2	http://dx.doi.org/10.1016/S0092-8674(00)80217-2			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WX899	9150136	Bronze			2022-12-01	WOS:A1997WX89900007
J	Zhang, Y; Iratni, R; ErdjumentBromage, H; Tempst, P; Reinberg, D				Zhang, Y; Iratni, R; ErdjumentBromage, H; Tempst, P; Reinberg, D			Histone deacetylases and SAP18, a novel polypeptide, are components of a human Sin3 complex	CELL			English	Article							NEGATIVE REGULATOR; SACCHAROMYCES-CEREVISIAE; REPRESSOR SIN3; YEAST; TRANSCRIPTION; ACETYLATION; GENE; ACTIVATION; HO; MECHANISM	An important event in gene expression is the covalent modification of histone proteins. We have found that the mammalian transcriptional repressor Sin3 (mSin3) exists in a complex with histone deacetylases HDAC1 and HDAC2. Consistent with the observation that mSin3-mediated repression of transcription involves the modification of histone polypeptides, we found that the mSin3-containing complex includes polypeptides that tether the mSin3 complex to core histone proteins. In addition, two novel mSin3-associated polypeptides, SAP18 and SAP30, were identified. We isolated a cDNA encoding human SAP18 and found that SAP18 is a component of an mSin3-containing complex in vivo. Moreover, we demonstrate a direct interaction between SAP18 and mSin3. SAP18 represses transcription in vivo when tethered to the promoter, consistent with the ability of SAP18 to interact with mSin3.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,HOWARD HUGHES MED INST,PISCATAWAY,NJ 08854; MEM SLOAN KETTERING CANC CTR,PROGRAM MOL BIOL,NEW YORK,NY 10021	Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University Medical Center; Memorial Sloan Kettering Cancer Center			Iratni, Rabah/M-5224-2016	Zhang, Yi/0000-0002-2789-0811; Reinberg, Danny/0000-0003-4288-2016; Erdjument-Bromage, Hediye/0000-0003-0224-3594	NCI NIH HHS [5P309CA08748] Funding Source: Medline; NIGMS NIH HHS [GM-48518, GM-37120] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM037120, R01GM037120] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; Ayer DE, 1996, MOL CELL BIOL, V16, P5772; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; Bunker CA, 1996, P NATL ACAD SCI USA, V93, P10820, DOI 10.1073/pnas.93.20.10820; DeRubertis F, 1996, NATURE, V384, P589; GARCIARAMIREZ M, 1995, J BIOL CHEM, V270, P17923, DOI 10.1074/jbc.270.30.17923; Harlow E LD, 1988, ANTIBODIES LAB MANUA, V1st; Harper SE, 1996, P NATL ACAD SCI USA, V93, P8536, DOI 10.1073/pnas.93.16.8536; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; Lui M, 1996, ANAL BIOCHEM, V241, P156, DOI 10.1006/abio.1996.0393; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; NASMYTH K, 1987, CELL, V48, P579, DOI 10.1016/0092-8674(87)90236-4; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Parthun MR, 1996, CELL, V87, P85, DOI 10.1016/S0092-8674(00)81325-2; QIAN YW, 1993, NATURE, V364, P648, DOI 10.1038/364648a0; QIAN YW, 1995, J BIOL CHEM, V270, P25507, DOI 10.1074/jbc.270.43.25507; Roussel MF, 1996, MOL CELL BIOL, V16, P2796; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; STERNBERG PW, 1987, CELL, V48, P567, DOI 10.1016/0092-8674(87)90235-2; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Tempst Paul, 1994, Methods (Orlando), V6, P248, DOI 10.1006/meth.1994.1027; Tyler JK, 1996, MOL CELL BIOL, V16, P6149; Verreault A, 1996, CELL, V87, P95, DOI 10.1016/S0092-8674(00)81326-4; VIDAL M, 1991, MOL CELL BIOL, V11, P6317, DOI 10.1128/MCB.11.12.6317; VIDAL M, 1991, MOL CELL BIOL, V11, P6306, DOI 10.1128/MCB.11.12.6306; WADE PA, 1997, CURR BIOL, V7, P82; WANG HM, 1993, MOL CELL BIOL, V13, P1805, DOI 10.1128/MCB.13.3.1805; WANG HM, 1990, MOL CELL BIOL, V10, P5927, DOI 10.1128/MCB.10.11.5927; WANG HM, 1990, P NATL ACAD SCI USA, V87, P9761, DOI 10.1073/pnas.87.24.9761; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; Wolffe AP, 1996, SCIENCE, V272, P371, DOI 10.1126/science.272.5260.371; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; YEUNG KC, 1994, GENE DEV, V8, P2097, DOI 10.1101/gad.8.17.2097	44	388	400	2	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 2	1997	89	3					357	364		10.1016/S0092-8674(00)80216-0	http://dx.doi.org/10.1016/S0092-8674(00)80216-0			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WX899	9150135	Bronze			2022-12-01	WOS:A1997WX89900006
J	Zhong, HH; SuYang, H; ErdjumentBromage, H; Tempst, P; Ghosh, S				Zhong, HH; SuYang, H; ErdjumentBromage, H; Tempst, P; Ghosh, S			The transcriptional activity of NF-kappa B is regulated by the I kappa B-associated PKAc subunit through a cyclic AMP-independent mechanism	CELL			English	Article							DEPENDENT PROTEIN-KINASE; SODIUM DODECYL-SULFATE; CATALYTIC SUBUNIT; DORSAL; ACTIVATION; DISSOCIATION; TOLL	Stimulation of cells with inducers of NF-kappa B such as LPS and IL-1 leads to the degradation of I kappa B-alpha and I kappa B-beta proteins and translocation of NF-kappa B to the nucleus. We now demonstrate that, besides the physical partitioning of inactive NF-kappa B to the cytosol, the transcriptional activity of NF-kappa B is regulated through phosphorylation of NF-kappa B p65 by protein kinase A (PKA). The catalytic subunit of PKA (PKAc) is maintained in an inactive state through association with I kappa B-alpha or I kappa B-beta in an NF-kappa B-I kappa B-PKAc complex. Signals that cause the degradation of I kappa B result in activation of PKAc in a cAMP-independent manner and the subsequent phosphorylation of p65. Therefore, this pathway represents a novel mechanism for the cAMP-independent activation of PKA and the regulation of NF-kappa B activity.	YALE UNIV,SCH MED,HOWARD HUGHES MED INST,IMMUNOBIOL SECT,NEW HAVEN,CT 06520; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MOL BIOPHYS & BIOCHEM,NEW HAVEN,CT 06520; MEM SLOAN KETTERING CANC CTR,PROGRAM MOL BIOL,NEW YORK,NY 10021	Howard Hughes Medical Institute; Yale University; Howard Hughes Medical Institute; Yale University; Memorial Sloan Kettering Cancer Center				Erdjument-Bromage, Hediye/0000-0003-0224-3594	NIAID NIH HHS [R01 AI33443] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033443] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; CHEN D, 1994, J EXP MED, V179, P931, DOI 10.1084/jem.179.3.931; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; GILLESPIE SKH, 1994, MOL CELL BIOL, V14, P3559, DOI 10.1128/MCB.14.6.3559; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KOPP EB, 1995, ADV IMMUNOL, V58, P1, DOI 10.1016/S0065-2776(08)60618-5; LANE ME, 1993, GENE DEV, V7, P1229, DOI 10.1101/gad.7.7a.1229; MOSIALOS G, 1992, ONCOGENE, V8, P721; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; NEUMANN M, 1995, EMBO J, V14, P1991, DOI 10.1002/j.1460-2075.1995.tb07191.x; NORRIS JL, 1992, GENE DEV, V6, P1654, DOI 10.1101/gad.6.9.1654; SassoneCorsi P, 1995, ANNU REV CELL DEV BI, V11, P355, DOI 10.1146/annurev.cb.11.110195.002035; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCOTT JD, 1991, PHARMACOL THERAPEUT, V50, P123, DOI 10.1016/0163-7258(91)90075-W; Suyang H, 1996, MOL CELL BIOL, V16, P5444; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WALSH DA, 1994, FASEB J, V8, P1227, DOI 10.1096/fasebj.8.15.8001734; WHALEN AM, 1993, J CELL BIOL, V123, P523, DOI 10.1083/jcb.123.3.523	25	716	730	2	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 2	1997	89	3					413	424		10.1016/S0092-8674(00)80222-6	http://dx.doi.org/10.1016/S0092-8674(00)80222-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WX899	9150141	hybrid			2022-12-01	WOS:A1997WX89900012
J	Dolmetsch, RE; Lewis, RS; Goodnow, CC; Healy, JI				Dolmetsch, RE; Lewis, RS; Goodnow, CC; Healy, JI			Differential activation of transcription factors induced by Ca2+ response amplitude and duration	NATURE			English	Article							NF-KAPPA-B; T-LYMPHOCYTES; SIGNAL-TRANSDUCTION; RECEPTOR; PHOSPHORYLATION; DISSOCIATION; ASSOCIATION; EXPRESSION; CHANNELS	An increase in the intracellular calcium ion concentration ([Ca2+](i)) controls a diverse range of cell functions, including adhesion, motility, gene expression and proliferation(1,2). Calcium signalling patterns can occur as single transients, repetitive oscillations or sustained plateaux(2,3), but it is not known whether these patterns are responsible for encoding the specificity of cellular responses. We report here that the amplitude and duration of calcium signals in B lymphocytes controls differential activation of the pro-inflammatory transcriptional regulators NF-kappa B, c-Jun N-terminal kinase (JNK) and NFAT. NF-kappa B and JNK are selectively activated by a large transient [Ca2+](i) rise, whereas NFAT is activated by a low sustained Ca2+ plateau. Differential activation results from differences in the Ca2+ sensitivities and kinetic behaviour of the three pathways. Our results show how downstream effecters can decode information contained in the amplitude and duration of Ca2+ signals, revealing a mechanism by which a multifunctional second messenger such as Ca2+ can achieve specificity in signalling to the nucleus.	STANFORD UNIV,SCH MED,DEPT CELLULAR & MOL PHYSIOL,STANFORD,CA 94305; STANFORD UNIV,SCH MED,NEUROSCI PROGRAM,STANFORD,CA 94305; STANFORD UNIV,SCH MED,PROGRAM IMMUNOL,STANFORD,CA 94305; STANFORD UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,STANFORD,CA 94305; STANFORD UNIV,SCH MED,HOWARD HUGHES MED INST,STANFORD,CA 94305	Stanford University; Stanford University; Stanford University; Stanford University; Howard Hughes Medical Institute; Stanford University			Goodnow, Christopher C/V-8108-2018	Goodnow, Christopher C/0000-0001-5296-6155; Lewis, Richard/0000-0002-6010-7403	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045374] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM045374] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CAMBIER JC, 1994, ANNU REV IMMUNOL, V12, P457, DOI 10.1146/annurev.iy.12.040194.002325; CHOQUET D, 1993, J CELL BIOL, V121, P355, DOI 10.1083/jcb.121.2.355; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.biochem.63.1.1045; Cyster JG, 1996, NATURE, V381, P325, DOI 10.1038/381325a0; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; DOLMETSCH RE, 1994, J GEN PHYSIOL, V103, P365, DOI 10.1085/jgp.103.3.365; ERNST P, 1995, IMMUNITY, V2, P311, DOI 10.1016/1074-7613(95)90139-6; FANGER CM, 1995, J CELL BIOL, V131, P655, DOI 10.1083/jcb.131.3.655; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FRANTZ B, 1994, EMBO J, V13, P861, DOI 10.1002/j.1460-2075.1994.tb06329.x; GAJEWSKI TF, 1990, J IMMUNOL, V144, P4110; GAJEWSKI TF, 1994, J EXP MED, V179, P481, DOI 10.1084/jem.179.2.481; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; GOLD MR, 1994, ADV IMMUNOL, V55, P221; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; GU XN, 1995, NATURE, V375, P784, DOI 10.1038/375784a0; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HEALY JI, IN PRESS IMMUNITY; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; NEGULESCU PA, 1994, P NATL ACAD SCI USA, V91, P2873, DOI 10.1073/pnas.91.7.2873; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; SloanLancaster J, 1996, J EXP MED, V184, P1525, DOI 10.1084/jem.184.4.1525; SU B, 1994, CELL, V77, P7727; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WILSON HA, 1987, J IMMUNOL, V138, P1712	30	1475	1521	1	82	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 24	1997	386	6627					855	858		10.1038/386855a0	http://dx.doi.org/10.1038/386855a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WV706	9126747				2022-12-01	WOS:A1997WV70600060
J	Hemmelgarn, B; Suissa, S; Huang, A; Boivin, JF; Pinard, G				Hemmelgarn, B; Suissa, S; Huang, A; Boivin, JF; Pinard, G			Benzodiazepine use and the risk of motor vehicle crash in the elderly	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DRIVING PERFORMANCE; HIP FRACTURE; OLDER ADULTS; PSYCHOMOTOR; DIAZEPAM; COHORT; DRUGS; ACCIDENTS; INJURIES; DRIVERS	Context.-Benzodiazepines, used by a sizable number of the elderly population, may affect the ability to drive and thus increase the risk of a motor vehicle crash. Epidemiologic studies of this question have produced inconsistent results that may be due to the different effects of long- and short-half-life benzodiazepines and variations in their duration of use. Objective.-To determine whether the use of benzodiazepines of either long- or short-elimination half-life is associated with the risk of injurious motor vehicle crash in the elderly. Design and Setting.-Nested case-control design within a cohort of 224 734 drivers from the Canadian province of Quebec, aged 67 to 84 years, followed up from 1990 to 1993. Computerized data for the study were obtained from provincial driver's license files, police reports of injurious crashes, and health insurance records. Patients.-We identified all 5579 drivers involved in an injurious crash (cases) and a random sample of 10 controls per case selected from a subcohort of 13 256 subjects. Main Outcome.-Involvement of a cohort member as a driver in a motor vehicle crash in which at least 1 person (not necessarily the driver) sustained bodily injury. Results.-The adjusted rate ratio of crash involvement within the first week of long-half-life benzodiazepine use was 1.45 (95% confidence interval [CI], 1.04-2.03). The rate ratio for continuous use of longer duration up to 1 year was slightly lower but remained significant (rate ratio, 1.26; 95% CI, 1.09-1.45). In contrast, there was no increased risk after the initiation of treatment with short-half-life benzodiazepines (rate ratio, 1.04; 95% CI, 0.81-1.34) or with their continued use (rate ratio, 0.91; 95% CI, 0.82-1.01). Conclusions.-Brief or extended periods of exposure to long-half-life benzodiazepines are associated with an increased risk of motor vehicle crash involvement in the elderly population. There is no such elevated risk for short-half-life benzodiazepines.	ROYAL VICTORIA HOSP, DIV CLIN EPIDEMIOL, MONTREAL, PQ H3A 1A1, CANADA; MCGILL UNIV, DEPT EPIDEMIOL & BIOSTAT, MCGILL PHARMACOEPIDEMIOL RES UNIT, MONTREAL, PQ, CANADA; MCGILL UNIV, DEPT MED, MONTREAL, PQ, CANADA; MCGILL UNIV, DEPT PSYCHIAT, MONTREAL, PQ, CANADA	McGill University; Royal Victoria Hospital; McGill University; McGill University; McGill University			Hemmelgarn, Brenda R./I-6894-2012					ADAMS WL, 1990, J AM GERIATR SOC, V38, P211, DOI 10.1111/j.1532-5415.1990.tb03493.x; ARANKO K, 1983, BRIT J CLIN PHARMACO, V15, P545, DOI 10.1111/j.1365-2125.1983.tb02088.x; BARR RA, 1991, HUM FACTORS, V33, P597, DOI 10.1177/001872089103300510; BROOKHUIS KA, 1990, EUR J CLIN PHARMACOL, V39, P83, DOI 10.1007/BF02657065; *CAN PHARM ASS, 1992, COMP PHARM SPEC, P27; CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202; EMOND A, 1988, SANTE CA VA RAPPORT; GILLEY DW, 1991, ARCH INTERN MED, V151, P941, DOI 10.1001/archinte.151.5.941; GREENBLATT DJ, 1991, NEW ENGL J MED, V324, P1691, DOI 10.1056/NEJM199106133242403; GREENBLATT DJ, 1989, J CLIN PHARMACOL, V29, P866, DOI 10.1002/j.1552-4604.1989.tb03246.x; HONKANEN R, 1980, BRIT MED J, V281, P1309, DOI 10.1136/bmj.281.6251.1309; Hosmer DW, 2000, APPL LOGISTIC REGRES, V2nd; JICK H, 1981, AM J PUBLIC HEALTH, V71, P1399, DOI 10.2105/AJPH.71.12.1399; JOHNSON RE, 1994, J CLIN EPIDEMIOL, V47, P1191, DOI 10.1016/0895-4356(94)90106-6; Kleinbaum D.G, 1982, EPIDEMIOLOGIC RES PR, P220; LABERGENADEAU C, 1984, U MONTREAL PUBLICATI, V340; LAGIER G, 1993, DRUG ALCOHOL DEPEN, V33, P19; LEVEILLE SG, 1994, EPIDEMIOLOGY, V5, P591, DOI 10.1097/00001648-199411000-00006; LIDDELL FDK, 1977, J R STAT SOC A STAT, V140, P469, DOI 10.2307/2345280; LINNOILA M, 1983, J CLIN PSYCHOPHARM, V3, P88; LUBIN JH, 1984, BIOMETRICS, V40, P63, DOI 10.2307/2530744; LUCKI I, 1986, PSYCHOPHARMACOLOGY, V88, P426; Neutel C. Ineke, 1995, Annals of Epidemiology, V5, P239; PRENTICE RL, 1986, BIOMETRIKA, V73, P1; RAY WA, 1992, J CLIN PSYCHOPHARM, V12, P386; RAY WA, 1992, AM J EPIDEMIOL, V136, P873, DOI 10.1093/aje/136.7.873; RAY WA, 1989, JAMA-J AM MED ASSOC, V262, P3303, DOI 10.1001/jama.262.23.3303; REGESTEIN QR, 1992, CLIN GERIATRIC PSYCH, P235; SALZMAN C, 1992, CLIN GERIATRIC PSYCH, P189; SKEGG DCG, 1979, BRIT MED J, V1, P917, DOI 10.1136/bmj.1.6168.917; SUISSA S, 1994, PHARMACOEPIDEM DR S, P629; TAMBLYN R, 1995, J CLIN EPIDEMIOL, V48, P999, DOI 10.1016/0895-4356(94)00234-H; TAMBLYN RM, 1994, CAN MED ASSOC J, V150, P1801; VANLAAR MW, 1992, J CLIN PSYCHOPHARM, V12, P86; Volkerts ER, 1986, DRUGS DRIVING, P123; VONKORFF M, 1992, J CLIN EPIDEMIOL, V45, P197, DOI 10.1016/0895-4356(92)90016-G; WILLIAMS AF, 1989, AM J PUBLIC HEALTH, V79, P326, DOI 10.2105/AJPH.79.3.326; WOLF ME, 1992, ANNU REV PUBL HEALTH, V13, P509, DOI 10.1146/annurev.pu.13.050192.002453; WOODS JH, 1992, PHARMACOL REV, V44, P151	39	265	274	1	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 2	1997	278	1					27	31		10.1001/jama.278.1.27	http://dx.doi.org/10.1001/jama.278.1.27			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG387	9207334				2022-12-01	WOS:A1997XG38700032
J	Chang, MH; Chen, CJ; Lai, MS; Hsu, HM; Wu, TC; Kong, MS; Liang, DC; Shau, WY; Chen, DS				Chang, MH; Chen, CJ; Lai, MS; Hsu, HM; Wu, TC; Kong, MS; Liang, DC; Shau, WY; Chen, DS			Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANTIGEN CARRIER MOTHERS; SURFACE-ANTIGEN; MATERNAL TRANSMISSION; VIRUS-INFECTION; CHILDHOOD; PROGRAM; INFANTS; LIVER	Background A nationwide hepatitis B vaccination program was implemented in Taiwan in July 1984. To assess the effect of the program on the development of hepatocellular carcinoma, we studied the incidence of this cancer in children in Taiwan from 1981 to 1994. Methods We collected data on liver cancer in children from Taiwan's National Cancer Registry, which receives reports from each of the country's 142 hospitals with more than 50 beds. Data on childhood liver cancer were also obtained from Taiwan's 17 major medical centers. To prevent the inclusion of cases of hepatoblastoma, the primary analysis was confined to liver cancers in children six years of age or older. Data were also obtained on mortality from liver cancer among children. Results The average annual incidence of hepatocellular carcinoma in children 6 to 14 years of age declined from 0.70 per 100,000 children between 1981 and 1986 to 0.57 between 1986 and 1990, and to 0.36 between 1990 and 1994 (P<0.01). The corresponding rates of mortality from hepatocellular carcinoma also decreased. The incidence of hepatocellular carcinoma in children 6 to 9 years of age declined from 0.52 for those born between 1974 and 1984 to 0.13 for those born between 1984 and 1986 (P<0.001). Conclusions Since the institution of Taiwan's program of universal hepatitis B vaccination, the incidence of hepatocellular carcinoma in children has declined. (C) 1997, Massachusetts Medical Society.	NATL TAIWAN UNIV, COLL MED, HEPATITIS RES CTR, TAIPEI, TAIWAN; NATL TAIWAN UNIV, GRAD INST EPIDEMIOL, COLL PUBL HLTH, TAIPEI, TAIWAN; EXECUT YUAN, DEPT HLTH, TAIPEI, TAIWAN; VET GEN HOSP, DEPT PEDIAT, TAIPEI, TAIWAN; CHANG GUNG CHILDRENS HOSP, DEPT PEDIAT, LINKOU, TAOYUAN, TAIWAN; MACKAY MEM HOSP, DEPT PEDIAT, TAIPEI, TAIWAN	National Taiwan University; National Taiwan University; Chang Gung Memorial Hospital; Mackay Memorial Hospital	Chang, MH (corresponding author), NATL TAIWAN UNIV HOSP, DEPT PEDIAT, 7 CHANG SHAN S RD, TAIPEI, TAIWAN.		Chen, Chien-Jen/C-6976-2008; Chen, Chien-Jen/N-4723-2019	Chang, Mei Hwei/0000-0002-3648-9261; Lai, Mei-shu/0000-0001-6130-3468; CHEN, DING-SHINN/0000-0001-7791-6154				BEASLEY RP, 1981, LANCET, V2, P1129; BRECHOT C, 1981, LANCET, V2, P765; CHANG MH, 1991, HEPATOLOGY, V13, P316, DOI 10.1016/0270-9139(91)92446-F; CHANG MH, 1989, CANCER-AM CANCER SOC, V64, P2377, DOI 10.1002/1097-0142(19891201)64:11<2377::AID-CNCR2820641130>3.0.CO;2-8; CHEN D-S, 1987, Journal of the American Medical Association, V257, P2597, DOI 10.1001/jama.257.19.2597; Chen D-S, 1987, NEOPLASMS LIVER, P71; CHEN DS, 1990, J INFECT DIS, V162, P817, DOI 10.1093/infdis/162.4.817; Chen HL, 1996, JAMA-J AM MED ASSOC, V276, P906, DOI 10.1001/jama.276.11.906; HSU HM, 1988, JAMA-J AM MED ASSOC, V260, P2231, DOI 10.1001/jama.260.15.2231; KUO C-Y, 1991, Acta Paediatrica Sinica, V32, P79; LAROUZE B, 1976, LANCET, V2, P534; NI YH, 1991, CANCER, V68, P1737, DOI 10.1002/1097-0142(19911015)68:8<1737::AID-CNCR2820680815>3.0.CO;2-G; POPPER H, 1982, HEPATOLOGY, V2, pS1; POPPER H, 1987, P NATL ACAD SCI USA, V84, P866, DOI 10.1073/pnas.84.3.866; SELVIN S, 1995, PRACTICAL BIOSTATIST, P342; Selvin S, 1995, PRACTICAL BIOSTATIST, P455; STEVENS CE, 1975, NEW ENGL J MED, V292, P771, DOI 10.1056/NEJM197504102921503; SUNG JL, 1980, SCAND J GASTROENTERO, V15, P321, DOI 10.3109/00365528009181477; WHO, 1977, MAN INT STAT CLASS D, V1; WU TC, 1987, HEPATOLOGY, V7, P46, DOI 10.1002/hep.1840070111	20	1329	1370	3	61	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 26	1997	336	26					1855	1859		10.1056/NEJM199706263362602	http://dx.doi.org/10.1056/NEJM199706263362602			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XF756	9197213				2022-12-01	WOS:A1997XF75600002
J	Zhang, YF; Suga, N; Yan, J				Zhang, YF; Suga, N; Yan, J			Corticofugal modulation of frequency processing in bat auditory system	NATURE			English	Article							RECEPTIVE-FIELD PLASTICITY; MEDIAL GENICULATE-BODY; INFERIOR COLLICULUS; MUSTACHED BAT; CORTEX; NEURONS; CAT; REPRESENTATION; PROJECTIONS; STIMULATION	Auditory signals are transmitted from the inner ear through the brainstem to the higher auditory regions of the brain. Neurons throughout the auditory system are tuned to stimulus frequency, and in many auditory regions are arranged in topographical maps with respect to their preferred frequency, These properties are assumed to arise from the interactions of convergent and divergent projections ascending from lower to higher auditory areas(1); such a view, however, ignores the possible role of descending projections from cortical to subcortical regions(2-10). In the bat auditory system, such corticofugal connections modulate neuronal activity to improve the processing of echo-delay information(11,12), a specialized feature. Here we show that corticofugal projections are also involved in the most common type of auditory processing, frequency tuning. When cortical neurons tuned to a specific frequency are inactivated, the auditory responses of subcortical neurons tuned to the same frequency are reduced. Moreover, the responses of other subcortical neurons tuned to different frequencies are increased, and their preferred frequencies are shifted towards that of the inactivated cortical neurons. Thus the corticofugal system mediates a positive feedback which, in combination with widespread lateral inhibition, sharpens and adjusts the tuning of neurons at earlier stages in the auditory processing pathway.	WASHINGTON UNIV, DEPT BIOL, ST LOUIS, MO 63130 USA	Washington University (WUSTL)								ANDERSEN P, 1973, BRAIN BEHAV EVOLUT, V6, P170, DOI 10.1159/000123705; ANDERSEN RA, 1980, J COMP NEUROL, V191, P479, DOI 10.1002/cne.901910310; EDELINE JM, 1991, BEHAV NEUROSCI, V105, P154, DOI 10.1037/0735-7044.105.1.154; EDELINE JM, 1992, BEHAV NEUROSCI, V106, P81, DOI 10.1037/0735-7044.106.1.81; EDELINE JM, 1993, BEHAV NEUROSCI, V107, P539, DOI 10.1037/0735-7044.107.4.539; GOLDMAN LJ, 1977, BEHAV ECOL SOCIOBIOL, V2, P411, DOI 10.1007/BF00299509; HERBERT H, 1991, J COMP NEUROL, V304, P103, DOI 10.1002/cne.903040108; HUFFMAN RF, 1990, BRAIN RES REV, V15, P295, DOI 10.1016/0165-0173(90)90005-9; JOHNSON RA, 1974, J ACOUST SOC AM, V55, pS53, DOI 10.1121/1.1919792; MASSOPUST LC, 1962, EXP NEUROL, V6, P465, DOI 10.1016/0014-4886(62)90072-9; MITANI A, 1983, NEUROSCI LETT, V42, P185, DOI 10.1016/0304-3940(83)90404-4; OLSEN JF, 1986, THESIS WASHINGTON U; RYUGO DK, 1976, EXP NEUROL, V51, P377, DOI 10.1016/0014-4886(76)90262-4; SUGA N, 1987, J NEUROPHYSIOL, V58, P643, DOI 10.1152/jn.1987.58.4.643; Suga N, 1997, J NEUROPHYSIOL, V77, P2098, DOI 10.1152/jn.1997.77.4.2098; SUGA N, 1990, NEURAL NETWORKS, V3, P3, DOI 10.1016/0893-6080(90)90043-K; SUGA N, 1982, J NEUROPHYSIOL, V47, P225, DOI 10.1152/jn.1982.47.2.225; SUGA N, 1985, J NEUROPHYSIOL, V53, P1109, DOI 10.1152/jn.1985.53.4.1109; SUGA N, 1983, J NEUROPHYSIOL, V49, P1573, DOI 10.1152/jn.1983.49.6.1573; SUGA N, 1976, SCIENCE, V194, P542, DOI 10.1126/science.973140; SUGA N, 1995, NEUROSCI RES, V21, P287, DOI 10.1016/0168-0102(94)00868-G; SUGA N, 1975, J EXP BIOL, V63, P161; SUGA N, 1995, ACTIVE HEARING, P13; SUN X, 1989, BRAIN RES, V495, P1, DOI 10.1016/0006-8993(89)91212-2; VILLA AEP, 1991, EXP BRAIN RES, V86, P506, DOI 10.1007/BF00230524; Winer J.A., 1992, Springer Handbook of Auditory Research, V1, P222; Yan J, 1996, SCIENCE, V273, P1100, DOI 10.1126/science.273.5278.1100; YANG LC, 1992, J NEUROPHYSIOL, V68, P1760, DOI 10.1152/jn.1992.68.5.1760	28	181	184	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 26	1997	387	6636					900	903		10.1038/43180	http://dx.doi.org/10.1038/43180			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XG416	9202121	Bronze			2022-12-01	WOS:A1997XG41600051
J	Masai, H; Arai, K				Masai, H; Arai, K			Frpo: A novel single-stranded DNA promoter for transcription and for primer RNA synthesis of DNA replication	CELL			English	Article							F-SEX FACTOR; COLE1 DNA; NUCLEOTIDE-SEQUENCE; SELECTIVE CLONING; BINDING-PROTEIN; LEADING REGION; ABC-PRIMOSOME; PLASMID DNA; ORIGIN; INITIATION	We describe a novel promoter for E. coli RNA polymerase that functions efficiently only in the form of single-stranded DNA. Derived from the leading region of F plasmid, single-stranded Frpo sequence directs RNA polymerase to initiate transcription at a specific site within Frpo, and this specific transcription is highly stimulated by SSB. Prior denaturation activates transcription from otherwise inactive duplex DNA containing Frpo. Since RNAs synthesized on SSB-coated single-stranded Frpo are efficiently elongated into DNA chains by DNA polymerase III holoenzyme, transcription at Frpo serves also for priming DNA replication. A mode of recognition by RNA polymerase of a unique secondary structure within Frpo is proposed, and possible roles of this novel single-stranded promoter in expression and replication during conjugal transfer of F plasmid are discussed.			Masai, H (corresponding author), UNIV TOKYO, INST MED SCI, DEPT MOL & DEV BIOL, MINATO KU, 4-6-1 SHIROKANEDAI, TOKYO 108, JAPAN.							BAGDASARIAN M, 1992, MOL MICROBIOL, V6, P885, DOI 10.1111/j.1365-2958.1992.tb01539.x; BOUCHE JP, 1978, J BIOL CHEM, V253, P765; CHASE JW, 1983, P NATL ACAD SCI-BIOL, V80, P5480, DOI 10.1073/pnas.80.18.5480; CRAM D, 1984, PLASMID, V11, P221, DOI 10.1016/0147-619X(84)90028-3; DUTTA A, 1993, CURR BIOL, V3, P709, DOI 10.1016/0960-9822(93)90076-Z; FROST LS, 1994, MICROBIOL REV, V58, P162, DOI 10.1128/MMBR.58.2.162-210.1994; FULLER RS, 1981, P NATL ACAD SCI-BIOL, V78, P7370, DOI 10.1073/pnas.78.12.7370; GEIDER K, 1978, P NATL ACAD SCI USA, V75, P645, DOI 10.1073/pnas.75.2.645; GEIDER K, 1974, J BIOL CHEM, V249, P3999; GLUCKSMANN MA, 1992, CELL, V70, P491, DOI 10.1016/0092-8674(92)90173-A; HIGASHITANI N, 1993, J VIROL, V67, P2175, DOI 10.1128/JVI.67.4.2175-2181.1993; Higashitani N, 1996, GENES CELLS, V1, P829, DOI 10.1046/j.1365-2443.1996.d01-279.x; HONDA Y, 1989, GENE, V80, P155; HORIUCHI K, 1976, P NATL ACAD SCI USA, V73, P2341, DOI 10.1073/pnas.73.7.2341; ITOH T, 1980, P NATL ACAD SCI-BIOL, V77, P2450, DOI 10.1073/pnas.77.5.2450; ITOH T, 1979, COLD SPRING HARB SYM, V43, P409, DOI 10.1101/SQB.1979.043.01.047; JONES AL, 1992, MOL MICROBIOL, V6, P605, DOI 10.1111/j.1365-2958.1992.tb01507.x; KAGUNI JM, 1982, J BIOL CHEM, V257, P5437; LOH S, 1989, MOL GEN GENET, V219, P177, DOI 10.1007/BF00261174; LOHMAN TM, 1994, ANNU REV BIOCHEM, V63, P527, DOI 10.1146/annurev.bi.63.070194.002523; MARKIEWICZ P, 1992, GENE DEV, V6, P2010, DOI 10.1101/gad.6.10.2010; MASAI H, 1995, EUR J BIOCHEM, V230, P384; MASAI H, 1989, J BIOL CHEM, V264, P8082; MASAI H, 1990, J BIOL CHEM, V265, P15124; MASAI H, 1990, J BIOL CHEM, V265, P15134; MASAI H, 1994, EMBO J, V13, P5338, DOI 10.1002/j.1460-2075.1994.tb06868.x; MASAI H, 1996, FRONT BIOSCI, V1, P49; MELENDY T, 1993, J BIOL CHEM, V268, P3389; NOMURA N, 1982, GENE, V18, P239, DOI 10.1016/0378-1119(82)90161-5; NOMURA N, 1982, P NATL ACAD SCI-BIOL, V79, P3153, DOI 10.1073/pnas.79.10.3153; NOMURA N, 1991, GENE, V108, P15; ONEILL MC, 1989, J BIOL CHEM, V264, P5522; RAY DS, 1982, GENE, V18, P231, DOI 10.1016/0378-1119(82)90160-3; Roberts CW, 1996, CELL, V86, P495; Sambrook J., 1989, MOL CLONING LAB MANU, V3; TANAKA K, 1991, PLASMID, V25, P125, DOI 10.1016/0147-619X(91)90024-Q; THOMPSON R, 1984, EMBO J, V3, P1175, DOI 10.1002/j.1460-2075.1984.tb01947.x; VANWEZENBEEK PMGF, 1980, GENE, V11, P129, DOI 10.1016/0378-1119(80)90093-1; WILLETTS N, 1984, MICROBIOL REV, V48, P24, DOI 10.1128/MMBR.48.1.24-41.1984	39	52	52	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 13	1997	89	6					897	907		10.1016/S0092-8674(00)80275-5	http://dx.doi.org/10.1016/S0092-8674(00)80275-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XE357	9200608	Bronze			2022-12-01	WOS:A1997XE35700010
J	Adema, GJ; Hartgers, F; Verstraten, R; deVries, E; Marland, G; Menon, S; Foster, J; Xu, YM; Nooyen, P; McClanahan, T; Bacon, KB; Figdor, CG				Adema, GJ; Hartgers, F; Verstraten, R; deVries, E; Marland, G; Menon, S; Foster, J; Xu, YM; Nooyen, P; McClanahan, T; Bacon, KB; Figdor, CG			A dendritic-cell-derived C-C chemokine that preferentially attracts naive T cells	NATURE			English	Article							MIP-1-ALPHA; MIP-1-BETA; ALPHA	Dendritic cells form a system of highly efficient antigen-presenting cells. After capturing antigen in the periphery, they migate to lymphoid organs where they present the antigen to T cells(1,2). Their seemingly unique ability to interact with and sensitize naive T cells gives dendritic cells a central role in the initiation of immune responses and allows them to be used in therapeutic strategies against cancer, viral infection and other diseases. How they interact preferentially with naive rather than activated T lymphocytes is still poorly understood. Chemokines direct the transport of white blood cells in immune surveillance(3,4). Here we report the identification and characterization of a C-C chemokine (DC-CK1) that is specifically expressed by human dendritic cells at high levels. Tissue distribution analysis demonstrates that dendritic cells present in germinal centres and T-cell areas of secondary lymphoid organs express this chemokine. We show that DC-CK1, in contrast to RANTES, MIP-1 alpha, and interleukin-8, preferentially attracts naive T cells (CD45RA(+)). The specific expression of DC-CK1 by dendritic cells at the site of initiation of an immune response, combined with its chemotactic activity for naive T cells, suggests that DC-CK1 has an important rule in the induction of immune responses.	UNIV NIJMEGEN ST RADBOUD HOSP,DEPT PATHOL,NL-6525 EX NIJMEGEN,NETHERLANDS; DNAX RES INST MOL & CELLULAR BIOL INC,DEPT IMMUNOL,PALO ALTO,CA 94304; DNAX RES INST MOL & CELLULAR BIOL INC,DEPT BIOL MOL,PALO ALTO,CA 94304	Radboud University Nijmegen; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	Adema, GJ (corresponding author), UNIV NIJMEGEN ST RADBOUD HOSP,DEPT TUMOR IMMUNOL,PHILIPS VAN LEYDENLAAN 25,NL-6525 EX NIJMEGEN,NETHERLANDS.		Figdor, Carl G/A-4232-2010; Adema, G.J./H-8007-2014	Figdor, Carl G/0000-0002-2366-9212; 				BACON KB, 1988, BRIT J PHARMACOL, V95, P966, DOI 10.1111/j.1476-5381.1988.tb11727.x; BAKKER ABH, 1995, CANCER RES, V55, P5330; BAUMHUETER S, 1993, SCIENCE, V262, P436, DOI 10.1126/science.7692600; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; FIGDOR CG, 1982, BLOOD, V60, P46; Grouard G, 1996, NATURE, V384, P364, DOI 10.1038/384364a0; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; MARLAND G, 1997, STEM CELLS, V14, P501; MATTIJSSEN V, 1991, J IMMUNOTHER, V10, P63, DOI 10.1097/00002371-199102000-00009; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; Peters JH, 1996, IMMUNOL TODAY, V17, P273, DOI 10.1016/0167-5699(96)80544-5; Premack BA, 1996, NAT MED, V2, P1174, DOI 10.1038/nm1196-1174; ROMANI N, 1994, J EXP MED, V180, P83, DOI 10.1084/jem.180.1.83; ROSS JS, 1991, J IMMUNOL METHODS, V140, P219, DOI 10.1016/0022-1759(91)90374-O; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; SCHALL TJ, 1993, J EXP MED, V177, P1821, DOI 10.1084/jem.177.6.1821; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; Steinmann RM, 1999, ANNU REV IMMUNOL, V9, P271; Thomson, 1994, CYTOKINE HDB, P418; VANGRONINGEN JJ, 1995, CANCER RES, V15, P6237	20	431	462	1	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 12	1997	387	6634					713	717		10.1038/42716	http://dx.doi.org/10.1038/42716			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XD869	9192897	Green Submitted			2022-12-01	WOS:A1997XD86900056
J	Bateman, DN				Bateman, DN			Proton-pump inhibitors: Three of a kind?	LANCET			English	Editorial Material							OMEPRAZOLE				Bateman, DN (corresponding author), UNIV NEWCASTLE UPON TYNE,WOLFSON UNIT CLIN PHARMACOL,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND.			Bateman, David Nicholas/0000-0002-8971-862X				Buckley C, 1996, BRIT J DERMATOL, V135, P660, DOI 10.1111/j.1365-2133.1996.tb03863.x; KRAUS A, 1995, LANCET, V345, P461, DOI 10.1016/S0140-6736(95)90449-2; Kuipers EJ, 1996, NEW ENGL J MED, V334, P1018, DOI 10.1056/NEJM199604183341603; LINDQUIST M, 1992, BRIT MED J, V305, P451, DOI 10.1136/bmj.305.6851.451; Neal KR, 1996, BRIT MED J, V312, P414; PINSON DM, 1995, GASTROENTEROLOGY, V108, P1068, DOI 10.1016/0016-5085(95)90204-X; RICCI RM, 1986, CUTIS, V57, P434; Schapira M, 1996, ACTA GASTRO-ENT BELG, V59, P168; SCHONHOFER PS, 1994, LANCET, V343, P665, DOI 10.1016/S0140-6736(94)92654-9; Shiba S, 1996, DIGEST DIS SCI, V41, P1615, DOI 10.1007/BF02087909; SHIN JM, 1994, ALIMENT PHARM THER, V8, P11; TUCKER GT, 1994, ALIMENT PHARM THERAP, V8, P33; 1995, DRUG THER B, V33, P36; 1991, CURR PROBL       JUN	14	14	14	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 7	1997	349	9066					1637	1638		10.1016/S0140-6736(05)62629-3	http://dx.doi.org/10.1016/S0140-6736(05)62629-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD100	9186377				2022-12-01	WOS:A1997XD10000003
J	Cullen, SA; Drysdale, HC; Mayes, RW				Cullen, SA; Drysdale, HC; Mayes, RW			Role of medical factors in 1000 fatal aviation accidents: Case note study	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-AVIATION; INCAPACITATION		RAF,INST HLTH & MED TRAINING,DEPT AVIAT TOXICOL,HALTON HP22 5PG,BUCKS,ENGLAND		Cullen, SA (corresponding author), RAF,INST HLTH & MED TRAINING,DEPT AVIAT PATHOL,HALTON HP22 5PG,BUCKS,ENGLAND.							BOOZE CF, 1989, AVIAT SPACE ENVIR MD, V60, P332; FROOM P, 1988, AVIAT SPACE ENVIR MD, V59, P278; KUHLMAN JJ, 1991, J FORENSIC SCI, V36, P1121; MCCORMICK TJ, 1991, AVIAT SPACE ENVIR MD, V62, P884; MORGAN D, 1989, BMA GUIDE ALCOHOL AC	5	13	14	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 31	1997	314	7094					1592	1592		10.1136/bmj.314.7094.1592	http://dx.doi.org/10.1136/bmj.314.7094.1592			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XC500	9186169	Green Published			2022-12-01	WOS:A1997XC50000023
J	Rothwell, PM; McDowell, Z; Wong, CK; Dorman, PJ				Rothwell, PM; McDowell, Z; Wong, CK; Dorman, PJ			Doctors and patients don't agree: Cross sectional study of patient's and doctors' perceptions and assessments of disability in multiple sclerosis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							QUALITY-OF-LIFE; HEALTH SURVEY QUESTIONNAIRE; OUTCOME MEASURE; SCALE; CARE	Objectives: To compare the judgments of clinicians on which domains of health in the short form questionnaire (SF-36) would be most important to patients with multiple sclerosis with the opinions of patients themselves; to compare assessment of physical disability in multiple sclerosis by a clinician using Kurtzke's expanded disability status scale and a non-clinically qualified assistant using the Office of Population Census and Surveys' (OPCS) disability scale with self assessment of disability and other domains of health related quality of life by patients using the SF-36 and the EuroQol questionnaire; and to compare the scores of patients for each domain of the SF-36 with control data matched for age and sex. Design: Cross sectional study. Setting: Clinical department of neurology, Edinburgh. Subjects: 42 consecutive patients with multiple sclerosis attending a neurology outpatient clinic for review or a neurology ward for rehabilitation. Main outcome measures: Scores on the SF-36; EuroQol; Kurtzke's expanded disability status scale; the OPCS disability scale. Results: Patients and clinicians disagreed on which domains of health status were most important (chi(2) = 21, df = 7, P = 0.003). Patients' assessment of their physical disability using the physical functioning domain of the SF-36 was highly correlated with the clinicians' assessment (r = -0.87, P < 0.001) and the non-clinical assessment (r = -0.90, P < 0.001). However, none of the measures of physical disability correlated with overall health related quality of life measured with EuroQol. Quality of life correlated with vitality, general health, and mental health in the SF-36, each of which patients rated as more important than clinicians and for each of which patients scored lower than the controls. Conclusions: Patients with multiple sclerosis, and possibly those with other chronic diseases, are less concerned than their clinicians about physical disability in their illness. Clinical trials in multiple sclerosis should assess the effect of treatment on the other elements of health status that patients consider important, which are also affected by the disease process, are more closely related to overall health related quality of life, and may well be adversely affected by side effects of treatment.	WESTERN GEN HOSP, DEPT CLIN NEUROSCI, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND	University of Edinburgh	Rothwell, PM (corresponding author), RADCLIFFE INFIRM, DEPT CLIN NEUROL, OXFORD OX2 6HE, ENGLAND.		Rothwell, Peter/ABE-5913-2020	Rothwell, Peter/0000-0001-9739-9211	Medical Research Council [G0500987] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		AMATO MP, 1988, ARCH NEUROL-CHICAGO, V45, P746, DOI 10.1001/archneur.1988.00520310052017; BRAZIER JE, 1992, BMJ-BRIT MED J, V305, P160, DOI 10.1136/bmj.305.6846.160; CHALMERS I, 1995, BRIT MED J, V310, P1315, DOI 10.1136/bmj.310.6990.1315; COHEN G, 1995, BRIT MED J, V311, P722, DOI 10.1136/bmj.311.7007.722; DUQUETTE P, 1995, NEUROLOGY, V45, P1277; DUQUETTE P, 1993, NEUROLOGY, V43, P655, DOI 10.1212/wnl.43.4.655; GARRATT AM, 1993, BMJ-BRIT MED J, V306, P1440, DOI 10.1136/bmj.306.6890.1440; GERHART KA, 1994, ANN EMERG MED, V23, P807, DOI 10.1016/S0196-0644(94)70318-3; GOODARE H, 1995, BMJ-BRIT MED J, V310, P1277, DOI 10.1136/bmj.310.6990.1277; HUTCHINSON J, 1995, J NEUROL, V242, P650, DOI 10.1007/BF00866915; Jacobs LD, 1996, ANN NEUROL, V39, P285, DOI 10.1002/ana.410390304; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; Martin J., 1988, OPCS SURVEYS DISABIL, V1; Neilley LK, 1996, NEUROLOGY, V46, P552, DOI 10.1212/WNL.46.2.552; NOSEWORTHY JH, 1994, NEUROLOGY, V44, P16, DOI 10.1212/WNL.44.1.16; OBOYLE CA, 1992, LANCET, V339, P1088, DOI 10.1016/0140-6736(92)90673-Q; PATY DW, 1993, NEUROLOGY, V43, P662, DOI 10.1212/WNL.43.4.662; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; SCHWARTZ CE, 1995, ARCH NEUROL-CHICAGO, V52, P754, DOI 10.1001/archneur.1995.00540320026010; SLEVIN ML, 1988, BRIT J CANCER, V57, P109, DOI 10.1038/bjc.1988.20; VICKREY BG, 1995, QUAL LIFE RES, V4, P187, DOI 10.1007/BF02260859; WILLIAMS A, 1990, HEALTH POLICY, V16, P199	22	423	425	0	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 31	1997	314	7094					1580	1583		10.1136/bmj.314.7094.1580	http://dx.doi.org/10.1136/bmj.314.7094.1580			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XC500	9169401	Green Published			2022-12-01	WOS:A1997XC50000019
J	Ruoslahti, E				Ruoslahti, E			Cell biology - Stretching is good for a cell	SCIENCE			English	Editorial Material							INTEGRINS; APOPTOSIS				Ruoslahti, E (corresponding author), BURNHAM INST,10901 M TORREY PINES RD,LA JOLLA,CA 92037, USA.							Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Lin TH, 1997, J BIOL CHEM, V272, P8849; Maniotis AJ, 1997, P NATL ACAD SCI USA, V94, P849, DOI 10.1073/pnas.94.3.849; Meredith JE, 1997, TRENDS CELL BIOL, V7, P146, DOI 10.1016/S0962-8924(97)01002-7; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; RE F, 1994, J CELL BIOL, V127, P537, DOI 10.1083/jcb.127.2.537; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cb.11.110195.003001; VERDE F, 1995, J CELL BIOL, V131, P1529, DOI 10.1083/jcb.131.6.1529; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6	14	182	189	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 30	1997	276	5317					1345	1346		10.1126/science.276.5317.1345	http://dx.doi.org/10.1126/science.276.5317.1345			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XB533	9190676				2022-12-01	WOS:A1997XB53300030
J	Casasnovas, JM; Springer, TA; Liu, JH; Harrison, SC; Wang, JH				Casasnovas, JM; Springer, TA; Liu, JH; Harrison, SC; Wang, JH			Crystals structure of ICAM-2 reveals a distinctive integrin recognition surface	NATURE			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; CELL-ADHESION; PLASMODIUM-FALCIPARUM; BINDING-SITE; IMMUNOGLOBULIN SUPERFAMILY; HUMAN RHINOVIRUS; LFA-1; RECEPTOR; FRAGMENT; DOMAIN-1	Recognition by integrin proteins on the cell surface regulates the adhesive interactions between cells and their surroundings(1,2). The structure of the 'I' domain that is found in some but not all integrins, has been determined(3,4). However, the only integrin ligands for which structures are known, namely fibronectin and VCAM-1 (refs 5-7), are recognized by integrins that lack I domains. The intercellular adhesion molecules ICAM-1, 2 and 3 are, like VCAM-1, members of the immunoglobulin superfamily (IgSF), but they are recognized by an I domain-containing integrin, lymphocyte-function-associated antigen 1 (LFA-1, or CD11a/CD18). Here we present the crystal structure of the extracellular region of ICAM-2. The glutamic acid residue at position 37 is critical for LFA-1 binding and is proposed to coordinate the Mg2+ ion in the I domain; this Glu 37 is surrounded by a relatively flat recognition surface and lies in a beta-strand, whereas the critical aspartic acid residue in VCAM-1 and fibronectin lie in protruding loops. This finding suggests that there are differences in the architecture of recognition sites between integrins that contain or lack I domains. A bend between domains 1 and 2 of ICAM-2 and a tripod-like arrangement of N-linked glycans in the membrane-proximal region of domain 2 may be important for presenting the recognition surface to LFA-1. A model of ICAM-1 based on the ICAM-2 structure provides a framework for understanding its recognition by pathogens.	HARVARD UNIV,SCH MED,CTR BLOOD RES,BOSTON,MA 02115; HARVARD UNIV,DEPT CELLULAR & MOL BIOL,CAMBRIDGE,MA 02138; HARVARD UNIV,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02138	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard University; Howard Hughes Medical Institute			Casasnovas, Jose M/L-6299-2014	Casasnovas, Jose M/0000-0002-2873-6410				BERENDT AR, 1989, NATURE, V341, P57, DOI 10.1038/341057a0; BERENDT AR, 1992, CELL, V68, P71, DOI 10.1016/0092-8674(92)90207-S; BODIAN DL, 1994, STRUCTURE, V2, P755, DOI 10.1016/S0969-2126(94)00076-X; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CASASNOVAS JM, 1995, J BIOL CHEM, V270, P13216, DOI 10.1074/jbc.270.22.13216; GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0; HARPAZ Y, 1994, J MOL BIOL, V238, P528, DOI 10.1006/jmbi.1994.1312; HOLNESS CL, 1995, J BIOL CHEM, V270, P877, DOI 10.1074/jbc.270.2.877; HUANG CC, 1995, J BIOL CHEM, V270, P19008, DOI 10.1074/jbc.270.32.19008; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JONES EY, 1995, NATURE, V373, P539, DOI 10.1038/373539a0; Klickstein LB, 1996, J BIOL CHEM, V271, P23920, DOI 10.1074/jbc.271.39.23920; Leahy DJ, 1996, CELL, V84, P155, DOI 10.1016/S0092-8674(00)81002-8; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; MCCLELLAND A, 1991, P NATL ACAD SCI USA, V88, P7993, DOI 10.1073/pnas.88.18.7993; MUSAFIA B, 1995, J MOL BIOL, V254, P761, DOI 10.1006/jmbi.1995.0653; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OCKENHOUSE CF, 1992, CELL, V68, P63, DOI 10.1016/0092-8674(92)90206-R; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; REGISTER RB, 1991, J VIROL, V65, P6589, DOI 10.1128/JVI.65.12.6589-6596.1991; SADHU C, 1994, CELL ADHES COMMUN, V2, P429, DOI 10.3109/15419069409004453; SALI A, 1991, THESIS U LONDON; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Springer TA, 1997, P NATL ACAD SCI USA, V94, P65, DOI 10.1073/pnas.94.1.65; STANLEY P, 1989, MOL CELL BIOL, V9, P377, DOI 10.1128/MCB.9.2.377; STAUNTON DE, 1989, CELL, V56, P849, DOI 10.1016/0092-8674(89)90689-2; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; STAUNTON DE, 1989, NATURE, V339, P61, DOI 10.1038/339061a0; WANG JH, 1995, P NATL ACAD SCI USA, V92, P5714, DOI 10.1073/pnas.92.12.5714; Wang JH, 1996, ACTA CRYSTALLOGR D, V52, P369, DOI 10.1107/S0907444995012352; WILLIAMS AF, 1987, IMMUNOL TODAY, V8, P298, DOI 10.1016/0167-5699(87)90016-8	31	92	93	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 15	1997	387	6630					312	315		10.1038/387312a0	http://dx.doi.org/10.1038/387312a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WZ167	9153399				2022-12-01	WOS:A1997WZ16700060
J	Prechtl, HFR; Einspieler, C; Cioni, G; Bos, AF; Ferrari, F; Sontheimer, D				Prechtl, HFR; Einspieler, C; Cioni, G; Bos, AF; Ferrari, F; Sontheimer, D			An early marker for neurological deficits after perinatal brain lesions	LANCET			English	Article							GENERAL MOVEMENTS; QUALITATIVE CHANGES; PRETERM INFANTS; MOTOR BEHAVIOR; TERM INFANTS; MOTILITY; FETUS	Background In normal awake infants, fidgety movements are seen from the age of 6 weeks to 20 weeks. The aim of the study was to test the predictive value of absent or abnormal spontaneous movements in young infants for the later development of neurological deficits. Methods In a collaborative study involving five hospitals we collected data on the normal and abnormal quality of fidgety movements of 130 infants and compared it with assessments of neurological development done longitudinally until the age of 2 years. On the basis of ultrasound scans infants were classified as at low-risk or at high-risk of neurological deficits. Infants were videoed for Ih every week from birth to discharge and then for 15 min every 3 to 4 weeks; quality of general movements was assessed, Repeated neurological assessments were also done until 24 months of corrected age. Findings 67 (96%) of 70 infants with normal fidgety movements had a normal neurological outcome. Abnormal quality or total absence of fidgety movements was followed by neurological abnormalities in 57 (95%) of the 60 infants (49 had cerebral palsy and eight had developmental retardation or minor neurological signs). Specificity and sensitivity of fidgety movement assessment were higher (96% and 95%, respectively) than of ultrasound imaging of the infants' brain (83% and 80%, respectively). Interpretation Our technique of assessing spontaneous motor activity can identify and distinguish between those infants who require early intervention for neurological abnormalities and those who do not. Our technique is simple, non-intrusive, reliable, quick, and can be done on very young infants.	UNIV PISA, INST DEV NEUROL PSYCHIAT & EDUC PSYCHOL, PISA, ITALY; STELLA MARIS FDN, PISA, ITALY; UNIV GRONINGEN, UNIV HOSP GRONINGEN, BEATRIX CHILDRENS HOSP, DIV NEONATOL, DEPT PAEDIAT, GRONINGEN, NETHERLANDS; UNIV HOSP, DIV NEONATOL, DEPT PAEDIAT, MODENA, ITALY; UNIV HOSP, DIV NEONATOL, DEPT PAEDIAT, HEIDELBERG, GERMANY	University of Pisa; IRCCS Fondazione Stella Maris; University of Groningen; Universita di Modena e Reggio Emilia; Universita di Modena e Reggio Emilia Hospital; Ruprecht Karls University Heidelberg	Prechtl, HFR (corresponding author), KARL FRANZENS UNIV GRAZ, DEPT PHYSIOL, HARRACHGASSE 21-5, A-8010 GRAZ, AUSTRIA.		Ferrari, Fabrizio/F-5980-2012; Cioni, Giovanni/A-4178-2015	Ferrari, Fabrizio/0000-0001-6504-4715; Cioni, Giovanni/0000-0002-6526-5566				ALBERS S, 1994, BIOL NEONATE, V66, P182; Amiel-Tison C., 1983, NEUROLOGIC EVALUATIO; Bayley N, 1969, BAYLEY SCALES INFANT; BEKEDAM DJ, 1985, EARLY HUM DEV, V12, P155, DOI 10.1016/0378-3782(85)90178-1; CIONI G, 1990, EARLY HUM DEV, V23, P159, DOI 10.1016/0378-3782(90)90012-8; CIONI G, 1989, EARLY HUM DEV, V18, P247, DOI 10.1016/0378-3782(89)90020-0; CIONI G, 1997, IN PRESS J PEDIAT; DEVRIES JIP, 1982, EARLY HUM DEV, V7, P301, DOI 10.1016/0378-3782(82)90033-0; DEVRIES LS, 1992, BEHAV BRAIN RES, V49, P1, DOI 10.1016/S0166-4328(05)80189-5; EINSPIELER C, 1994, EARLY HUM DEV, V36, P31, DOI 10.1016/0378-3782(94)90031-0; FERRARI F, 1990, EARLY HUM DEV, V23, P193, DOI 10.1016/0378-3782(90)90013-9; GEERDINK JJ, 1993, EUR J PEDIATR, V152, P362, DOI 10.1007/BF01956755; GRIFFITHS R, 1954, ABILITIES BABIES; HADDERSALGRA M, 1992, EARLY HUM DEV, V28, P201, DOI 10.1016/0378-3782(92)90167-F; HOPKINS B, CONTINUITY NEURAL FU; LEVINE MI, 1982, ARCH DIS CHILD, V57, P410; PRECHTL HFR, 1990, EARLY HUM DEV, V23, P151, DOI 10.1016/0378-3782(90)90011-7; PRECHTL HFR, 1986, EARLY HUM DEV, V14, P233, DOI 10.1016/0378-3782(86)90184-2; PRECHTL HFR, 1979, DEV MED CHILD NEUROL, V21, P3; PRECHTL HFR, 1993, EARLY HUM DEV, V35, P91, DOI 10.1016/0378-3782(93)90096-D; PRECHTL HFR, 1989, FETAL NEUROLOGY, P1; TOUWEN BCL, 1976, CDM, V58	22	417	435	0	19	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 10	1997	349	9062					1361	1363		10.1016/S0140-6736(96)10182-3	http://dx.doi.org/10.1016/S0140-6736(96)10182-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WY342	9149699				2022-12-01	WOS:A1997WY34200011
J	Shaper, AG; Wannamethee, SG; Walker, M				Shaper, AG; Wannamethee, SG; Walker, M			Body weight: Implications for the prevention of coronary heart disease, stroke, and diabetes mellitus in a cohort study of middle aged men	BRITISH MEDICAL JOURNAL			English	Article							BRITISH MEN; RISK-FACTORS; BLOOD-LIPIDS; MORTALITY; SMOKING; WOMEN; DEATH	Objective: To determine the body mass index associated with the lowest morbidity and mortality. Design: Prospective study of a male cohort. Setting: One general practice in each of 24 British towns. Subjects:7735 men aged 40-59 years at screening. Main outcome measures: All cause death rate, heart attacks, and stroke (fatal and non-fatal) and development of diabetes, or any of these outcomes (combined end point) over an average follow up of 14.8 years. Results: There were 1271 deaths from all causes, 974 heart attacks, 290 strokes, and 245 new cases of diabetes mellitus. All cause mortality was increased only in men with a body mass index (kg/m(2)) <20 and in men with an index greater than or equal to 30. However, risk of cardiovascular death, heart attack, and diabetes increased progressively from an index of <20 even after age, smoking, social dass, alcohol consumption, and physical activity were adjusted for. For the combined end point the lowest risks were seen for an index of 20.0-23.9. In never smokers and former smokers, deaths from any cause rose progressively from an index of 20.0-21.9 and for the combined end point, from 20.0-23.9. Age adjusted levels of a wide range of cardiovascular risk factors rose or felt progressively from an index <20. Conclusion: A healthy body mass index in these middle aged British men seems to be about 22.			Shaper, AG (corresponding author), ROYAL FREE HOSP,SCH MED,DEPT PRIMARY CARE & POPULAT SCI,LONDON NW3 2PF,ENGLAND.		Lennon, Lucy/ABB-9433-2020	Lennon, Lucy/0000-0002-1738-1351; Wannamethee, Sasiwarang/0000-0001-9484-9977				*AM HLTH FDN, 1996, AM J CLIN NUTR S, V63, P409; *AM I NUTR, 1994, J NUTR, V124, P2240; [Anonymous], 1988, OBESITY RELATED DIS; Bennett N, 1995, HLTH SURVEY ENGLAND; BYERS T, 1995, NEW ENGL J MED, V333, P723, DOI 10.1056/NEJM199509143331109; COX DR, 1972, J R STAT SOC B, V34, P187; *DEP HLTH, 1995, OB REV INCR PROBL OB; *DEP HTLH, 1992, HLTH NAT STRAT HLTH; GARRISON RJ, 1993, INT J OBESITY, V17, P417; Jousilahti P, 1996, CIRCULATION, V93, P1372, DOI 10.1161/01.CIR.93.7.1372; KUSHNER RF, 1993, NUTR REV, V51, P127, DOI 10.1111/j.1753-4887.1993.tb03089.x; LARSSON B, 1992, AM J EPIDEMIOL, V135, P266, DOI 10.1093/oxfordjournals.aje.a116280; MANSON JE, 1995, NEW ENGL J MED, V333, P677, DOI 10.1056/NEJM199509143331101; Metropolitan Life Foundation New weight standards for men and women, 1959, STAT B, V40, P1; PAMUK ER, 1993, ANN INTERN MED, V119, P744, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00023; PERRY IJ, 1995, BRIT MED J, V310, P560, DOI 10.1136/bmj.310.6979.560; PERRY IJ, IN PRESS AM J EPIDEM; SHAPER AG, 1993, BRIT HEART J, V70, P49; SHAPER AG, 1985, J EPIDEMIOL COMMUN H, V39, P197, DOI 10.1136/jech.39.3.197; SHAPER AG, 1991, BRIT HEART J, V66, P384; SHAPER AG, 1981, BRIT MED J, V283, P179, DOI 10.1136/bmj.283.6285.179; THELLE DS, 1983, BRIT HEART J, V49, P205, DOI 10.1136/hrt.49.3.205; TOKUNAGA K, 1991, INT J OBESITY, V15, P1; WALKER M, 1984, J ROY COLL GEN PRACT, V34, P365; WALKER M, 1995, INT J EPIDEMIOL, V24, P694, DOI 10.1093/ije/24.4.694; WANNAMETHEE G, 1989, BRIT MED J, V299, P1497, DOI 10.1136/bmj.299.6714.1497; WANNAMETHEE G, 1992, J EPIDEMIOL COMMUN H, V46, P197, DOI 10.1136/jech.46.3.197; WANNAMETHEE G, 1994, J EPIDEMIOL COMMUN H, V48, P112, DOI 10.1136/jech.48.2.112; WILLIAMSON DF, 1995, AM J EPIDEMIOL, V141, P1128, DOI 10.1093/oxfordjournals.aje.a117386	29	164	174	1	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 3	1997	314	7090					1311	1317		10.1136/bmj.314.7090.1311	http://dx.doi.org/10.1136/bmj.314.7090.1311			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WX975	9158466	Green Published			2022-12-01	WOS:A1997WX97500022
J	Abovich, N; Rosbash, M				Abovich, N; Rosbash, M			Cross-intron bridging interactions in the yeast commitment complex are conserved in mammals	CELL			English	Article							PRE-MESSENGER-RNA; 5' SPLICE SITE; SMALL NUCLEAR RIBONUCLEOPROTEIN; U2 SNRNP ADDITION; U1 SNRNA; PREMESSENGER RNA; BIOCHEMICAL-CHARACTERIZATION; POLYPYRIMIDINE TRACT; AUXILIARY FACTOR; WW DOMAIN	The commitment complex is the first defined step in the yeast (S. cerevisiae) splicing pathway. It contains U1 snRNP as well as Mud2p, which resembles human U2AF65. In a genetic screen, we identified the yeast gene MSL-5, which is a novel commitment complex component. Genetic and biochemical criteria indicate a direct interaction between MsI5p and both Mud2p and the U1 snRNP protein Prp40p. This defines a bridge between the two ends of the intron. MsI5p (renamed BBP for branchpoint bridging protein) has a mammalian ortholog, the splicing factor SF1. Our results show that SF1 interacts strongly with human U2AF65, and that SF1 is a bona fide E complex component. This implies that aspects of these novel cross-intron protein-protein interactions are conserved between yeast and mammals.	BRANDEIS UNIV, HOWARD HUGHES MED INST, DEPT BIOL, WALTHAM, MA 02254 USA	Brandeis University; Howard Hughes Medical Institute					NIGMS NIH HHS [GM-23549] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023549] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOVICH N, 1994, GENE DEV, V8, P843, DOI 10.1101/gad.8.7.843; Arning S, 1996, RNA, V2, P794; Ast G, 1996, SCIENCE, V272, P881, DOI 10.1126/science.272.5263.881; BEDFORD MT, 1997, IN PRESS EMBO J; BELANGER KD, 1994, J CELL BIOL, V126, P619, DOI 10.1083/jcb.126.3.619; BENNETT M, 1992, GENE DEV, V6, P1986, DOI 10.1101/gad.6.10.1986; BORK P, 1994, TRENDS BIOCHEM SCI, V19, P531, DOI 10.1016/0968-0004(94)90053-1; Chan DC, 1996, EMBO J, V15, P1045, DOI 10.1002/j.1460-2075.1996.tb00442.x; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; DARLIX JL, 1995, J MOL BIOL, V254, P523, DOI 10.1006/jmbi.1995.0635; FABRIZIO P, 1994, SCIENCE, V264, P261, DOI 10.1126/science.8146658; FRANK D, 1992, MOL CELL BIOL, V12, P5197, DOI 10.1128/MCB.12.11.5197; FRANK D, 1992, GENE DEV, V6, P2112, DOI 10.1101/gad.6.11.2112; GUARENTE L, 1982, P NATL ACAD SCI-BIOL, V79, P7410, DOI 10.1073/pnas.79.23.7410; JACKSON SP, 1988, MOL CELL BIOL, V8, P1067, DOI 10.1128/MCB.8.3.1067; JAMISON SF, 1992, P NATL ACAD SCI USA, V89, P5482, DOI 10.1073/pnas.89.12.5482; Kao HY, 1996, MOL CELL BIOL, V16, P960; KRAMER A, 1992, MOL CELL BIOL, V12, P4545; KRANZ JE, 1990, P NATL ACAD SCI USA, V87, P6629, DOI 10.1073/pnas.87.17.6629; LEGRAIN P, 1988, MOL CELL BIOL, V8, P3755, DOI 10.1128/MCB.8.9.3755; LIAO XC, 1992, THESIS BRANDEIS U WA; LIAO XLC, 1992, NUCLEIC ACIDS RES, V20, P4237, DOI 10.1093/nar/20.16.4237; LIAO XLC, 1993, GENE DEV, V7, P419, DOI 10.1101/gad.7.3.419; Macias MJ, 1996, NATURE, V382, P646, DOI 10.1038/382646a0; MICHAUD S, 1993, GENE DEV, V7, P1008, DOI 10.1101/gad.7.6.1008; MICHAUD S, 1991, GENE DEV, V5, P2534, DOI 10.1101/gad.5.12b.2534; Moore M., 1993, RNA WORLD, P303; Musco G, 1996, CELL, V85, P237, DOI 10.1016/S0092-8674(00)81100-9; NANDABALAN K, 1993, CELL, V73, P407, DOI 10.1016/0092-8674(93)90239-M; NEWMAN AJ, 1992, CELL, V68, P743, DOI 10.1016/0092-8674(92)90149-7; Reed R, 1996, CURR OPIN GENET DEV, V6, P215, DOI 10.1016/S0959-437X(96)80053-0; ROSBASH M, 1991, TRENDS BIOCHEM SCI, V16, P187, DOI 10.1016/0968-0004(91)90073-5; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; RUBY SW, 1988, SCIENCE, V242, P1028, DOI 10.1126/science.2973660; Rutila JE, 1996, NEURON, V17, P921, DOI 10.1016/S0896-6273(00)80223-8; RYMOND BC, 1985, NATURE, V317, P735, DOI 10.1038/317735a0; SERAPHIN B, 1989, CELL, V59, P349, DOI 10.1016/0092-8674(89)90296-1; SERAPHIN B, 1988, EMBO J, V7, P2533, DOI 10.1002/j.1460-2075.1988.tb03101.x; SIEBEL CW, 1995, GENE DEV, V9, P269, DOI 10.1101/gad.9.3.269; SILICIANO PG, 1988, GENE DEV, V2, P1258, DOI 10.1101/gad.2.10.1258; SINGH R, 1995, SCIENCE, V268, P1173, DOI 10.1126/science.7761834; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH V, 1991, EMBO J, V10, P2627, DOI 10.1002/j.1460-2075.1991.tb07805.x; TODA T, 1994, HUM MOL GENET, V3, P465, DOI 10.1093/hmg/3.3.465; UMEN JG, 1995, GENE DEV, V9, P855, DOI 10.1101/gad.9.7.855; VALCARCEL J, 1993, NATURE, V362, P171, DOI 10.1038/362171a0; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; WYATT JR, 1992, GENE DEV, V6, P2542, DOI 10.1101/gad.6.12b.2542; ZAMORE PD, 1991, EMBO J, V10, P207, DOI 10.1002/j.1460-2075.1991.tb07937.x; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZAMORE PD, 1989, P NATL ACAD SCI USA, V86, P9243, DOI 10.1073/pnas.86.23.9243; ZHANG Y, 1995, EMBO J, V14, P5358, DOI 10.1002/j.1460-2075.1995.tb00220.x; ZHUANG Y, 1986, CELL, V46, P827, DOI 10.1016/0092-8674(86)90064-4; Zuo P, 1996, GENE DEV, V10, P1356, DOI 10.1101/gad.10.11.1356	55	278	284	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 2	1997	89	3					403	412		10.1016/S0092-8674(00)80221-4	http://dx.doi.org/10.1016/S0092-8674(00)80221-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WX899	9150140	Bronze			2022-12-01	WOS:A1997WX89900011
J	Laherty, CD; Yang, WM; Sun, JM; Davie, JR; Seto, E; Eisenman, RN				Laherty, CD; Yang, WM; Sun, JM; Davie, JR; Seto, E; Eisenman, RN			Histone deacetylases associated with the mSin3 corepressor mediate Mad transcriptional repression	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; RAS COTRANSFORMATION; DNA-BINDING; MYC-MAX; EXPRESSION; PROTEIN; SIN3; MXI1; DIFFERENTIATION; TRANSFORMATION	Transcriptional repression by Mad-Max heterodimers requires interaction of Mad with the corepressors mSin3A/B. Sin3p, the S. cerevisiae homolog of mSin3, functions in the same pathway as Rpd3p, a protein related to two recently identified mammalian histone deacetylases, HDAC1 and HDAC2 Here, we demonstrate that mSin3A and HDAC1/2 are associated in vivo. HDAC2 binding requires a conserved region of mSin3A capable of mediating transcriptional repression. In addition, Mad1 forms a complex with mSin3 and HDAC2 that contains histone deacetylase activity. Trichostatin A, an inhibitor of histone deacetylases, abolishes Mad repression. We propose that Mad-Max functions by recruiting the mSin3-HDAC corepressor complex that deacetylates nucleosomal histones, producing alterations in chromatin structure that block transcription.	UNIV S FLORIDA,H LEE MOFFITT CANC CTR & RES INST,DEPT MED MICROBIOL & IMMUNOL,TAMPA,FL 33612; UNIV MANITOBA,DEPT BIOCHEM & MOL BIOL,WINNIPEG,MB R3E 0W3,CANADA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; University of Manitoba	Laherty, CD (corresponding author), FRED HUTCHINSON CANC RES CTR,DIV BASIC SCI,1124 COLUMBIA ST,SEATTLE,WA 98104, USA.			Davie, James/0000-0002-0420-6888; Yang, Wen-Ming/0000-0002-5871-5979				AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; Ayer DE, 1996, MOL CELL BIOL, V16, P5772; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; BRASIER AR, 1995, CURRENT PROTOCOLS MO, V3; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Carmen AA, 1996, J BIOL CHEM, V271, P15837, DOI 10.1074/jbc.271.26.15837; CHEN J, 1995, NAT MED, V1, P638, DOI 10.1038/nm0795-638; DAVIE JR, 1994, J CELL BIOCHEM, V55, P98, DOI 10.1002/jcb.240550112; Harper SE, 1996, P NATL ACAD SCI USA, V93, P8536, DOI 10.1073/pnas.93.16.8536; HEINZEL T, 1997, IN PRESS NATURE, V387; HENDZEL MJ, 1991, J BIOL CHEM, V266, P21936; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Hurlin PJ, 1995, ONCOGENE, V11, P2487; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; KOSKINEN PJ, 1995, CELL GROWTH DIFFER, V6, P623; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAHOZ EG, 1994, P NATL ACAD SCI USA, V91, P5503, DOI 10.1073/pnas.91.12.5503; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; Rao G, 1996, ONCOGENE, V12, P1165; Reifsnyder C, 1996, NAT GENET, V14, P42, DOI 10.1038/ng0996-42; Roth SY, 1996, NAT GENET, V14, P3, DOI 10.1038/ng0996-3; Roussel MF, 1996, MOL CELL BIOL, V16, P2796; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; STILLMAN DJ, 1994, GENETICS, V136, P781; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; VanLint C, 1996, GENE EXPRESSION, V5, P245; VIDAL M, 1991, MOL CELL BIOL, V11, P6317, DOI 10.1128/MCB.11.12.6317; WANG HM, 1993, MOL CELL BIOL, V13, P1805, DOI 10.1128/MCB.13.3.1805; WANG HM, 1990, MOL CELL BIOL, V10, P5927, DOI 10.1128/MCB.10.11.5927; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; Wolffe AP, 1996, SCIENCE, V272, P371, DOI 10.1126/science.272.5260.371; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	48	836	875	0	33	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 2	1997	89	3					349	356		10.1016/S0092-8674(00)80215-9	http://dx.doi.org/10.1016/S0092-8674(00)80215-9			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WX899	9150134	Bronze			2022-12-01	WOS:A1997WX89900005
J	Liu, Y; Garceau, NY; Loros, JJ; Dunlap, JC				Liu, Y; Garceau, NY; Loros, JJ; Dunlap, JC			Thermally regulated translational control of FRQ mediates aspects of temperature responses in the Neurospora circadian clock	CELL			English	Article							MESSENGER-RNA; DROSOPHILA; PROTEIN; FREQUENCY; MUTANTS; PERIOD; PHASE; CYANOBACTERIA; COMPENSATION; TIMELESS	Two forms of FRQ, a central component of the Neurospora circadian clock, arise through alternative inframe initiation of translation. Either form alone suffices for a functional clock at some temperatures, but both are always necessary for robust rhythmicity. Temperature regulates the ratio of FRQ forms by favoring different initiation codons at different temperatures; when either initiation codon is eliminated, the temperature range permissive for rhythmicity is demonstrably reduced. This temperature-influenced choice of translation - initiation site represents a novel adaptive mechanism that extends the physiological temperature range over which clocks function. Additionally, a temperature-dependent threshold level of FRQ is required to establish the feedback loop comprising the oscillator. These data may explain how temperature limits permissive for rhythmicity are established, thus providing a molecular understanding for a basic characteristic of circadian clocks.	DARTMOUTH COLL,SCH MED,DEPT BIOCHEM,HANOVER,NH 03755	Dartmouth College			Dunlap, Jay/L-6232-2013; Loros, Jennifer/B-6293-2014	Dunlap, Jay/0000-0003-1577-0457; 	NIGMS NIH HHS [GM34985] Funding Source: Medline; NIMH NIH HHS [MH44651, MH01186] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034985, R01GM034985] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH044651, K05MH001186] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ARONSON BD, 1994, P NATL ACAD SCI USA, V91, P7683, DOI 10.1073/pnas.91.16.7683; ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; BellPedersen D, 1996, P NATL ACAD SCI USA, V93, P13096, DOI 10.1073/pnas.93.23.13096; BellPedersen D, 1996, MOL CELL BIOL, V16, P513; Bunning E, 1973, PHYSL CLOCK; CROSTHWAITE SK, 1995, CELL, V81, P1003, DOI 10.1016/S0092-8674(05)80005-4; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DUNCAN RF, 1996, TRANSLATIONAL CONTRO, P271; DUNLAP JC, 1993, ANNU REV PHYSIOL, V55, P683, DOI 10.1146/annurev.physiol.55.1.683; Dunlap JC, 1996, ANNU REV GENET, V30, P579, DOI 10.1146/annurev.genet.30.1.579; EDERY I, 1994, SCIENCE, V263, P237, DOI 10.1126/science.8284676; FELDMAN J F, 1973, Genetics, V75, P605; FRANCIS CD, 1979, PLANT PHYSIOL, V64, P1000, DOI 10.1104/pp.64.6.1000; GEBALLE AP, 1996, TRANSLATIONAL CONTRO, P173; GOOCH VD, 1994, J BIOL RHYTHM, V9, P83, DOI 10.1177/074873049400900108; HALL JC, 1995, TRENDS NEUROSCI, V18, P230, DOI 10.1016/0166-2236(95)93908-G; HASTINGS JW, 1957, P NATL ACAD SCI USA, V43, P804, DOI 10.1073/pnas.43.9.804; Hinnebusch A.G., 1996, TRANSLATIONAL CONTRO, P199; HUANG ZJ, 1995, SCIENCE, V267, P1169, DOI 10.1126/science.7855598; JACKSON RJ, 1996, TRANSLATIONAL CONTRO, P71; KALMUS HANS, 1934, ZEITSCHR WISS BIOL ABT C ZEITSCHR VERGLEICH PHYSIOL, V20, P405; KONDO T, 1994, SCIENCE, V266, P1233, DOI 10.1126/science.7973706; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; LAKINTHOMAS PI, 1991, J BIOL RHYTHM, V6, P281, DOI 10.1177/074873049100600401; LIU Y, 1995, GENE DEV, V9, P1469, DOI 10.1101/gad.9.12.1469; LOROS JJ, 1989, SCIENCE, V243, P385, DOI 10.1126/science.2563175; Luo ZL, 1996, J BACTERIOL, V178, P2172, DOI 10.1128/jb.178.8.2172-2177.1996; MARTINOCATT S, 1992, P NATL ACAD SCI USA, V89, P3731, DOI 10.1073/pnas.89.9.3731; Merrow MW, 1997, P NATL ACAD SCI USA, V94, P3877, DOI 10.1073/pnas.94.8.3877; MILLAR AJ, 1995, SCIENCE, V267, P1161, DOI 10.1126/science.7855595; Nakashima H, 1996, SEMIN CELL DEV BIOL, V7, P765, DOI 10.1006/scdb.1996.0094; NJUS D, 1977, J COMP PHYSIOL, V117, P335, DOI 10.1007/BF00691559; NJUS D, 1974, NATURE, V248, P116, DOI 10.1038/248116a0; Pittendrigh C, 1993, ANNU REV PHYSIOL, V55, P17; SARGENT ML, 1972, PLANT PHYSIOL, V50, P171, DOI 10.1104/pp.50.1.171; SEHGAL A, 1995, SEMIN NEUROSCI, V7, P27, DOI 10.1016/1044-5765(95)90014-4; SEHGAL A, 1994, SCIENCE, V263, P1603, DOI 10.1126/science.8128246; SWEENEY BM, 1960, COLD SPRING HARB SYM, V25, P87, DOI 10.1101/SQB.1960.025.01.009; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; Worden, 1974, NEUROSCIENCES 3RD ST, P437; ZIMMERMAN WF, 1968, J INSECT PHYSIOL, V14, P669, DOI 10.1016/0022-1910(68)90226-6	43	191	198	1	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 2	1997	89	3					477	486		10.1016/S0092-8674(00)80228-7	http://dx.doi.org/10.1016/S0092-8674(00)80228-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WX899	9150147	hybrid			2022-12-01	WOS:A1997WX89900018
J	Campos, EC				Campos, EC			Future directions in the treatment of amblyopia	LANCET			English	Editorial Material											Campos, EC (corresponding author), UNIV BOLOGNA,EYE SERV 1,I-40138 BOLOGNA,ITALY.							CAMPOS E, 1995, SURV OPHTHALMOL, V40, P23, DOI 10.1016/S0039-6257(95)80044-1; CAMPOS EC, 1995, GRAEF ARCH CLIN EXP, V233, P307, DOI 10.1007/BF00177654; Campos EC, 1991, G IT ORTOTTE TEC STR, V8, P185; FoleyNolan A, 1997, BRIT J OPHTHALMOL, V81, P54, DOI 10.1136/bjo.81.1.54; GOTTLOB I, 1992, INVEST OPHTH VIS SCI, V33, P2722; JAMPOLSKY AJ, 1978, S STRAB T NEW ORL AC, P358; REPKA MX, 1993, OPHTHALMOLOGY, V100, P769; VONNOORDEN GK, 1979, AM J OPHTHALMOL, V55, P511	8	11	11	1	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 26	1997	349	9060					1190	1190		10.1016/S0140-6736(05)62410-5	http://dx.doi.org/10.1016/S0140-6736(05)62410-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW717	9130938				2022-12-01	WOS:A1997WW71700006
J	Cai, RH; Pouget, A; SchlagRey, M; Schlag, J				Cai, RH; Pouget, A; SchlagRey, M; Schlag, J			Perceived geometrical relationships affected by eye-movement signals	NATURE			English	Article							VERNIER ACUITY; VISUAL HYPERACUITY; NEURONS; CORTEX; TASKS; REPRESENTATION; POSITION; SACCADES; VISION; CELLS	To determine the location of visual objects relative to the observer, the visual system must take account not only of the location of the stimulus on the retina, but also of the direction of gaze(1). In contrast, the perceived spatial relationship between visual stimuli is normally assumed to depend on retinal information alone, and not to require information about eye position. We now show, however, that the perceived alignment of three dots-tested by a veinier alignment task(2,3)-is systematically altered in the period immediately preceding a saccade. Thus, information about eye position can modify not only the perceived relationship of the entire retinal image to the observer, but also the relations between elements within the image. The processing of relative position and of egocentric (observer-centred) position may therefore be less distinct than previously believed(4-6).	GEORGETOWN UNIV,INST COGNIT & COMPUTAT SCI,WASHINGTON,DC 20007	Georgetown University	Cai, RH (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,BRAIN RES INST,LOS ANGELES,CA 90095, USA.			Pouget, Alexandre/0000-0003-3054-6365				ANDERSEN RA, 1985, SCIENCE, V230, P456, DOI 10.1126/science.4048942; DEVALOIS RL, 1991, VISION RES, V31, P1619, DOI 10.1016/0042-6989(91)90138-U; DUHAMEL JR, 1992, SCIENCE, V255, P90, DOI 10.1126/science.1553535; FAHLE M, 1981, PROC R SOC SER B-BIO, V213, P451, DOI 10.1098/rspb.1981.0075; GALLETTI C, 1989, J NEUROSCI, V9, P1112; GROLL SL, 1987, J OPT SOC AM A, V4, P1535, DOI 10.1364/JOSAA.4.001535; Grusser O J, 1982, Hum Neurobiol, V1, P73; HONDA H, 1991, VISION RES, V31, P1915, DOI 10.1016/0042-6989(91)90186-9; Honda H., 1990, ATTENTION PERFORM, V13, P567; LEVI DM, 1994, VISION RES, V34, P2215, DOI 10.1016/0042-6989(94)90104-X; Levi DM, 1996, VISION RES, V36, P2111, DOI 10.1016/0042-6989(95)00264-2; LINDBLOM B, 1989, J OPT SOC AM A, V6, P585, DOI 10.1364/JOSAA.6.000585; MACKAY DM, 1973, HDB SENSORY PHYSIOLO, V7, P307; MATIN L, 1972, HDB SENSORY PHYSIOL, V7, P307; PARKER A, 1985, J OPT SOC AM A, V2, P1101, DOI 10.1364/JOSAA.2.001101; POSNER MI, 1980, Q J EXP PSYCHOL, V32, P3, DOI 10.1080/00335558008248231; Pouget A, 1997, J COGNITIVE NEUROSCI, V9, P222, DOI 10.1162/jocn.1997.9.2.222; POUGET A, 1993, J COGNITIVE NEUROSCI, V5, P150, DOI 10.1162/jocn.1993.5.2.150; Ross J, 1997, NATURE, V386, P598, DOI 10.1038/386598a0; SCHLAG J, 1995, VISION RES, V35, P2347, DOI 10.1016/0042-6989(95)00021-Q; SHAPLEY R, 1986, SCIENCE, V231, P999, DOI 10.1126/science.3945816; SWINDALE NV, 1986, NATURE, V319, P591, DOI 10.1038/319591a0; TROTTER Y, 1992, SCIENCE, V257, P1279, DOI 10.1126/science.1519066; VOLKMANN FC, 1969, J OPT SOC AM, V58, P562; WEHRHAHN C, 1993, VISUAL NEUROSCI, V10, P13, DOI 10.1017/S0952523800003187; WESTHEIMER G, 1977, VISION RES, V17, P941, DOI 10.1016/0042-6989(77)90069-4; WESTHEIMER G, 1975, INVEST OPHTH VISUAL, V14, P570; WEYAND TG, 1993, J NEUROPHYSIOL, V69, P2258, DOI 10.1152/jn.1993.69.6.2258; WHITAKER D, 1992, VISION RES, V32, P1481, DOI 10.1016/0042-6989(92)90204-V	29	95	95	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 10	1997	386	6625					601	604		10.1038/386601a0	http://dx.doi.org/10.1038/386601a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WT273	9121582				2022-12-01	WOS:A1997WT27300057
J	Ross, J; Morrone, MC; Burr, DC				Ross, J; Morrone, MC; Burr, DC			Compression of visual space before saccades	NATURE			English	Article							EYE-MOVEMENTS; DISPLACEMENT; REPRESENTATION; LOCALIZATION; IMAGE	Saccadic eye movements, in which the eye moves rapidly between two resting positions, shift the position of our retinal images, If our perception of the world is to remain stable, the visual directions associated with retinal sites, and others they report to, must be updated to compensate for changes in the point of gaze, It has long been suspected that this compensation is achieved by a uniform shift of coordinates driven by an extraretinal position signal(1-3), although some consider this to be unnecessary(4-6). Considerable effort has been devoted to a search for such a signal and to measuring its time course and accuracy, Here, by using multiple as well as single targets under normal viewing conditions, we show that changes in apparent visual direction anticipate saccades and are not of the same size, or even in the same direction, for all parts of the visual field, We also show that there is a compression of visual space sufficient to reduce the spacing and even the apparent number of pattern elements,The results are in part consistent with electrophysiological findings of anticipatory shifts in the receptive fields of neurons in parietal cortex(7) and superior colliculi(8).	CNR,IST NEUROFISIOL,I-56127 PISA,ITALY; UNIV ROMA LA SAPIENZA,DEPT PSYCHOL,I-00185 ROME,ITALY; UNIV WESTERN AUSTRALIA,DEPT PSYCHOL,VIS LAB,NEDLANDS,WA 6907,AUSTRALIA	Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome; University of Western Australia			; Morrone, Maria Concetta/C-6756-2014	Burr, David/0000-0003-1541-8832; Morrone, Maria Concetta/0000-0002-1025-0316				BENHAMED S, 1996, SOC NEUR ABSTR, P1619; BISCHOF N, 1968, PSYCHOL FORSCH, V32, P185, DOI 10.1007/BF00418660; BOWEN RW, 1981, VISION RES, V21, P1457, DOI 10.1016/0042-6989(81)90216-9; BRIDGEMAN B, 1991, VISION RES, V31, P1903, DOI 10.1016/0042-6989(91)90185-8; BRIDGEMAN B, 1994, BEHAV BRAIN SCI, V17, P247, DOI 10.1017/S0140525X00034361; BURR DC, 1994, NATURE, V371, P511, DOI 10.1038/371511a0; DANIEL PM, 1961, J PHYSIOL-LONDON, V159, P203, DOI 10.1113/jphysiol.1961.sp006803; DASSONVILLE P, 1992, VISUAL NEUROSCI, V9, P261, DOI 10.1017/S0952523800010671; Deubel H, 1996, VISION RES, V36, P985, DOI 10.1016/0042-6989(95)00203-0; DUHAMEL JR, 1992, SCIENCE, V255, P90, DOI 10.1126/science.1553535; HONDA H, 1995, VISION RES, V35, P3021, DOI 10.1016/0042-6989(95)00108-C; HONDA H, 1993, VISION RES, V33, P709, DOI 10.1016/0042-6989(93)90190-8; MACKAY DM, 1970, NATURE, V225, P90, DOI 10.1038/225872a0; MATIN L, 1965, SCIENCE, V148, P1485, DOI 10.1126/science.148.3676.1485; MATIN L, 1972, HDB SENSORY PHYSIOLO, V7, P331; MISHKIN M, 1983, TRENDS NEUROSCI, V6, P414, DOI 10.1016/0166-2236(83)90190-X; OREGAN JK, 1984, PERCEPT PSYCHOPHYS, V36, P1, DOI 10.3758/BF03206348; Sperling G., 1990, EYE MOVEMENTS THEIR, P307; SPERRY RW, 1950, J COMP PHYSIOL PSYCH, V43, P482, DOI 10.1037/h0055479; VONHELMHOLTZ H, 1866, HDB PHYSIOL OPTIK; VONHOLST E, 1954, NATURWISSENSCHAFTEN, V37, P464; WALKER MF, 1995, J NEUROPHYSIOL, V73, P1988, DOI 10.1152/jn.1995.73.5.1988	22	345	346	1	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 10	1997	386	6625					598	601		10.1038/386598a0	http://dx.doi.org/10.1038/386598a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WT273	9121581				2022-12-01	WOS:A1997WT27300056
J	Mathiowitz, E; Jacob, JS; Jong, YS; Carino, GP; Chickering, DE; Chaturvedi, P; Santos, CA; Vijayaraghavan, K; Montgomery, S; Bassett, M; Morrell, C				Mathiowitz, E; Jacob, JS; Jong, YS; Carino, GP; Chickering, DE; Chaturvedi, P; Santos, CA; Vijayaraghavan, K; Montgomery, S; Bassett, M; Morrell, C			Biologically erodable microsphere as potential oral drug delivery system	NATURE			English	Article							DIRECT GENE-TRANSFER; PEYERS PATCHES; BIOADHESIVE MICROSPHERES; BIOERODIBLE POLYMERS; MUSCLE INVIVO; LATEX; POLYANHYDRIDES; MICROSCOPY; EPITHELIUM; PARTICLES	Biologically adhesive delivery systems offer important advantages(1-5) over conventional drug delivery systems(6). Here we show that engineered polymer microspheres made of biologically erodable polymers, which display strong adhesive interactions with gastrointestinal mucus and cellular linings, can traverse both the mucosal absorptive epithelium and the follicle-associated epithelium covering the lymphoid tissue of Peyer's patches. The polymers maintain contact with intestinal epithelium for extended periods of time and actually penetrate it, through and between cells. Thus, once loaded with compounds of pharmacological interest, the microspheres could be developed as delivery systems to transfer biologically active molecules to the circulation, We show that these microspheres increase the absorption of three model substances of widely different molecular size: dicumarol, insulin and plasmid DNA.			Mathiowitz, E (corresponding author), BROWN UNIV,DEPT MOL PHARMACOL PHYSIOL & BIOTECHNOL,DIV BIOL & MED,PROVIDENCE,RI 02912, USA.							AKERS MJ, 1973, J PHARM SCI, V62, P391, DOI 10.1002/jps.2600620308; [Anonymous], 1990, BIODEGRADABLE POLYM; BOCKMAN DE, 1973, AM J ANAT, V136, P455, DOI 10.1002/aja.1001360406; Carino G., 1995, P 22 INT S CONTR REL, P314; Chickering D, 1996, BIOTECHNOL BIOENG, V52, P96, DOI 10.1002/(SICI)1097-0290(19961005)52:1<96::AID-BIT9>3.0.CO;2-U; CHICKERING DE, 1995, REACT POLYM, V25, P189, DOI 10.1016/0923-1137(94)00098-P; CHICKERING DE, 1995, J CONTROL RELEASE, V34, P251, DOI 10.1016/0168-3659(95)00011-V; DAVIS SS, 1988, BIOMATERIALS, V9, P111, DOI 10.1016/0142-9612(88)90081-6; DOMB AJ, 1991, J POLYM SCI POL CHEM, V29, P571, DOI 10.1002/pola.1991.080290413; ERMAK TH, 1995, CELL TISSUE RES, V279, P433, DOI 10.1007/BF00318501; FLORENCE AT, 1994, DRUG SAFETY, V10, P233, DOI 10.2165/00002018-199410030-00005; FLORENCE AT, 1995, J CONTROL RELEASE, V36, P39, DOI 10.1016/0168-3659(95)00059-H; FRISBIE CD, 1994, SCIENCE, V265, P2071, DOI 10.1126/science.265.5181.2071; Goodman L., 1975, PHARM BASIS THERAPEU; HILLERY AM, 1994, J DRUG TARGET, V2, P151, DOI 10.3109/10611869409015904; JACOB J, 1995, P 22 INT S CONTR REL, P312; JANI P, 1990, J PHARM PHARMACOL, V42, P821, DOI 10.1111/j.2042-7158.1990.tb07033.x; JANI P, 1989, J PHARM PHARMACOL, V41, P809, DOI 10.1111/j.2042-7158.1989.tb06377.x; LAU C, 1995, HUM GENE THER, V6, P1145, DOI 10.1089/hum.1995.6.9-1145; LEE SW, 1993, CIRC RES, V73, P797, DOI 10.1161/01.RES.73.5.797; LEFEVRE ME, 1978, P SOC EXP BIOL MED, V159, P298; LEFEVRE ME, 1985, P SOC EXP BIOL MED, V179, P522; Lenaerts V., 1990, BIOADHESIVE DRUG DEL, P93; MATHIOWITZ E, 1993, MACROMOLECULES, V26, P6756, DOI 10.1021/ma00077a010; Peppas N A, 1987, HYDROGELS MED PHARM; PONCHEL G, 1991, HIGH PERFORMANCE BIO, P231; SANDERS E, 1961, EXP CELL RES, V22, P137, DOI 10.1016/0014-4827(61)90092-1; TUTWILER GF, 1978, DIABETES, V27, P856, DOI 10.2337/diabetes.27.8.856; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; WOLFF JA, 1991, BIOTECHNIQUES, V11, P474	30	703	798	3	199	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 27	1997	386	6623					410	414		10.1038/386410a0	http://dx.doi.org/10.1038/386410a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WQ170	9121559				2022-12-01	WOS:A1997WQ17000068
J	Wah, DA; Hirsch, JA; Dorner, LF; Schildkraut, I; Aggarwal, AK				Wah, DA; Hirsch, JA; Dorner, LF; Schildkraut, I; Aggarwal, AK			Structure of the multimodular endonuclease FokI bound to DNA	NATURE			English	Article							CRYSTAL-STRUCTURE; RESTRICTION-ENDONUCLEASE; ZINC FINGERS; RNA GENE; BINDING; RECOGNITION; COMPLEX; MUTANTS; DOMAINS; SITES	FokI is a member of an unusual class of bipartite restriction enzymes that recognize a specific DNA sequence and cleave DNA nonspecifically a short distance away from that sequence(1-3) Because of its unusual bipartite nature, FokI has been used to create artificial enzymes with new specificities(4-7). We have determined the crystal structure at 2.8 Angstrom resolution of the complete FokI enzyme bound to DNA. As anticipated, the enzyme contains amino- and carboxy-terminal domains corresponding to the DNA-recognition and cleavage functions, respectively. The recognition domain is made of three smaller subdomains (D1, D2 and D3) which are evolutionarily related to the helix-turn-helix-containing DNA-binding domain of the catabolite gene activator protein CAP(8). The CAP core has been extensively embellished in the first two subdomains, whereas in the third subdomain it has been co-opted for protein-protein interactions. Surprisingly, the cleavage domain contains only a single catalytic centre, raising the question of how monomeric FokI manages to cleave both DNA strands. Unexpectedly, the cleavage domain is sequestered in a 'piggyback' fashion by the recognition domain. The structure suggests a new mechanism for nuclease activation and provides a framework for the design of chimaeric enzymes with altered specificities.	COLUMBIA UNIV,DEPT BIOCHEM & MOL BIOPHYS,NEW YORK,NY 10032; NEW ENGLAND BIOLABS INC,BEVERLY,MA 01915	Columbia University			Wilson, Matthew H/K-3193-2013; Hirsch, Joel/AAC-8000-2021	Hirsch, Joel/0000-0001-7544-8668				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; CHURCHILL MEA, 1990, P NATL ACAD SCI USA, V87, P5528, DOI 10.1073/pnas.87.14.5528; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; CLEMENS KR, 1992, P NATL ACAD SCI USA, V89, P10822, DOI 10.1073/pnas.89.22.10822; FUREY W, 1993, PHASES PROGRAM PACKA; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.biochem.59.1.933; HEITMAN J, 1990, EMBO J, V9, P3369, DOI 10.1002/j.1460-2075.1990.tb07538.x; Hirsch JA, 1997, FEBS LETT, V403, P136, DOI 10.1016/S0014-5793(97)00039-2; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Huang BH, 1996, J PROTEIN CHEM, V15, P481, DOI 10.1007/BF01886856; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim YG, 1996, P NATL ACAD SCI USA, V93, P1156, DOI 10.1073/pnas.93.3.1156; KIM YG, 1994, P NATL ACAD SCI USA, V91, P883, DOI 10.1073/pnas.91.3.883; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; LI L, 1993, GENE, V133, P79, DOI 10.1016/0378-1119(93)90227-T; LI L, 1992, P NATL ACAD SCI USA, V89, P4275, DOI 10.1073/pnas.89.10.4275; NEWMAN M, 1994, NATURE, V368, P660, DOI 10.1038/368660a0; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PODHAJSKA AJ, 1985, GENE, V40, P175, DOI 10.1016/0378-1119(85)90040-X; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SKOWRON P, 1993, GENE, V125, P1, DOI 10.1016/0378-1119(93)90738-O; SUGISAKI H, 1981, GENE, V16, P73; WAUGH DS, 1993, P NATL ACAD SCI USA, V90, P9596, DOI 10.1073/pnas.90.20.9596; WAUGH DS, 1994, J BIOL CHEM, V269, P12298; WILSON KP, 1992, P NATL ACAD SCI USA, V89, P9257, DOI 10.1073/pnas.89.19.9257; YONEZAWA A, 1994, BBA-GENE STRUCT EXPR, V1219, P369, DOI 10.1016/0167-4781(94)90061-2	29	212	276	2	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 3	1997	388	6637					97	100		10.1038/40446	http://dx.doi.org/10.1038/40446			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XJ143	9214510				2022-12-01	WOS:A1997XJ14300058
J	Hayashi, H; Abdollah, S; Qiu, YB; Cai, JX; Xu, YY; Grinnell, BW; Richardson, MA; Topper, JN; Gimbrone, MA; Wrana, JL; Falb, D				Hayashi, H; Abdollah, S; Qiu, YB; Cai, JX; Xu, YY; Grinnell, BW; Richardson, MA; Topper, JN; Gimbrone, MA; Wrana, JL; Falb, D			The MAD-related protein Smad7 associates with the TGF beta receptor and functions as an antagonist of TGF beta signaling	CELL			English	Article							COMPLEX	TGF beta signaling is initiated when the type I receptor phosphorylates the MAD-related protein, Smad2, on C-terminal serine residues. This leads to Smad2 association with Smad4, translocation to the nucleus, and regulation of transcriptional responses. Here we demonstrate that Smad7 is an inhibitor of TGF beta signaling. Smad7 prevents TGF beta-dependent formation of Smad2/Smad4 complexes and inhibits the nuclear accumulation of Smad2. Smad7 interacts stably with the activated TGF beta type I receptor, thereby blocking the association, phosphorylation, and activation of Smad2. Furthermore, mutations in Smad7 that interfere with receptor binding disrupt its inhibitory activity. These studies thus define a novel function for MAD-related proteins as intracellular antagonists of the type I kinase domain of TGF beta family receptors.	HOSP SICK CHILDREN,DIV GASTROENTEROL,TORONTO,ON M5G 1X8,CANADA; MILLENNIUM PHARMACEUT INC,CAMBRIDGE,MA 02139; LILLY RES LABS,DIV RES TECHNOL & PROT,INDIANAPOLIS,IN 46285; BRIGHAM & WOMENS HOSP,DEPT MED,DIV VASC RES,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT PATHOL,DIV CARDIOVASC,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals; Eli Lilly; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Hayashi, H (corresponding author), HOSP SICK CHILDREN,PROGRAM DEV BIOL,555 UNIV AVE,TORONTO,ON M5G 1X8,CANADA.		Wrana, Jeffrey/F-8857-2013					Attisano L, 1996, MOL CELL BIOL, V16, P1066; Attisano Liliana, 1996, Cytokine and Growth Factor Reviews, V7, P327, DOI 10.1016/S1359-6101(96)00042-1; Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Derynck R, 1996, CURR BIOL, V6, P1226, DOI 10.1016/S0960-9822(96)00702-6; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HOODLESS P, 1997, IN PRESS CURRENT TOP; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Lechleider RJ, 1996, J BIOL CHEM, V271, P17617, DOI 10.1074/jbc.271.30.17617; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Markowitz Sanford D., 1996, Cytokine and Growth Factor Reviews, V7, P93, DOI 10.1016/1359-6101(96)00001-9; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; Sambrook J., 1989, MOL CLONING LAB MANU; Savage C, 1996, P NATL ACAD SCI USA, V93, P790, DOI 10.1073/pnas.93.2.790; SEKELSKY JJ, 1995, GENETICS, V139, P1347; Thomsen GH, 1996, DEVELOPMENT, V122, P2359; Topper JN, 1996, P NATL ACAD SCI USA, V93, P10417, DOI 10.1073/pnas.93.19.10417; TOPPER JN, 1997, IN PRESS P NATL ACAD; WeisGarcia F, 1996, EMBO J, V15, P276, DOI 10.1002/j.1460-2075.1996.tb00358.x; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Wrana JL, 1996, TRENDS GENET, V12, P493, DOI 10.1016/S0168-9525(96)30109-1; Yingling JM, 1996, P NATL ACAD SCI USA, V93, P8940, DOI 10.1073/pnas.93.17.8940; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	31	1117	1184	1	21	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 27	1997	89	7					1165	1173		10.1016/S0092-8674(00)80303-7	http://dx.doi.org/10.1016/S0092-8674(00)80303-7			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XG830	9215638	Bronze			2022-12-01	WOS:A1997XG83000020
J	Moghaddam, A; Rosenzweig, M; LeeParritz, D; Annis, B; Johnson, RP; Wang, F				Moghaddam, A; Rosenzweig, M; LeeParritz, D; Annis, B; Johnson, RP; Wang, F			An animal model for acute and persistent Epstein-Barr virus infection	SCIENCE			English	Article							HERPESVIRUS PAPIO; MALIGNANT-LYMPHOMA; REPLICATION; ACTIVATION; EXPRESSION; SEQUENCE; ORIGIN; CELLS; DNA	Epstein-Barr virus (EBV) is a human lymphocryptovirus that causes infectious mononucleosis, persists asymptomatically for life in nearly all adults, and is associated with the development of B cell lymphomas and nasopharyngeal carcinomas. A highly similar rhesus lymphocryptovirus naturally endemic in rhesus monkeys was used to orally inject naive animals from a pathogen-free colony. This animal model reproduced key aspects of human EBV injection, including oral transmission, atypical lymphocytosis, lymphadenopathy, activation of CD23(+) peripheral blood B cells, sustained serologic responses to lytic and latent EBV antigens, latent infection in the peripheral blood, and virus persistence in oropharyngeal secretions. This system may be useful for studying the pathogenesis, prevention, and treatment of EBV infection and associated oncogenesis.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,NEW ENGLAND REG PRIMATE RES CTR,SCH MED,DIV IMMUNOL,SOUTHBOROUGH,MA 01172; HARVARD UNIV,NEW ENGLAND REG PRIMATE RES CTR,SCH MED,DIV PRIMATE RESOURCES,SOUTHBOROUGH,MA 01172; HARVARD UNIV,SCH MED,MASSACHUSETTS GEN HOSP,AIDS RES CTR,CHARLESTOWN,MA 02129; HARVARD UNIV,SCH MED,MASSACHUSETTS GEN HOSP,INFECT DIS UNIT,CHARLESTOWN,MA 02129	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard University; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital					NATIONAL CANCER INSTITUTE [R01CA065319, R01CA068051] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000168] Funding Source: NIH RePORTER; NCI NIH HHS [CA68051, CA65319] Funding Source: Medline; NCRR NIH HHS [P51RR00168] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ABLASHI DV, 1979, COMP IMMUNOL MICROB, V2, P229, DOI 10.1016/0147-9571(79)90011-0; Alfieri C, 1996, BLOOD, V87, P812, DOI 10.1182/blood.V87.2.812.bloodjournal872812; DANIEL MD, 1988, INT J CANCER, V41, P601, DOI 10.1002/ijc.2910410421; DUNKEL VC, 1972, J NATL CANCER I, V49, P435; FEICHTINGER H, 1992, J EXP MED, V176, P281, DOI 10.1084/jem.176.1.281; Frank A, 1976, Adv Cancer Res, V23, P171, DOI 10.1016/S0065-230X(08)60546-1; Franken M, 1996, J VIROL, V70, P7819, DOI 10.1128/JVI.70.11.7819-7826.1996; FRANKEN M, 1995, J VIROL, V69, P8011, DOI 10.1128/JVI.69.12.8011-8019.1995; FURUKAWA S, 1992, J INFECT DIS, V166, P691, DOI 10.1093/infdis/166.3.691; GERBER P, 1977, INT J CANCER, V20, P448, DOI 10.1002/ijc.2910200318; GERBER P, 1969, P SOC EXP BIOL MED, V130, P14, DOI 10.3181/00379727-130-33478; GRATAMA JW, 1989, TRANSPLANT P, V21, P307; HELLER M, 1981, J VIROL, V37, P698, DOI 10.1128/JVI.37.2.698-709.1981; HENLE G, 1968, P NATL ACAD SCI USA, V59, P94, DOI 10.1073/pnas.59.1.94; HESTON L, 1982, NATURE, V295, P160, DOI 10.1038/295160a0; KALTER SS, 1972, NATURE, V238, P353, DOI 10.1038/238353a0; Kieff E, 1996, VIROLOGY, P2343; KINTNER C, 1981, NATURE, V294, P458, DOI 10.1038/294458a0; LEVINE MD, 1980, PEDIATRICS, V66, P341; LEVY JA, 1971, NATURE, V233, P559, DOI 10.1038/233559a0; LING PD, 1995, J VIROL, V69, P1944, DOI 10.1128/JVI.69.3.1944-1950.1995; LOEB DD, 1990, J VIROL, V64, P2876, DOI 10.1128/JVI.64.6.2876-2883.1990; MOGHADDAM A, UNPUB; MOSIER DE, 1990, CURR TOP MICROBIOL, V166, P317; RANGAN SRS, 1986, INT J CANCER, V38, P425, DOI 10.1002/ijc.2910380319; Rickinson AB, 1996, VIROLOGY, P2397; RYON JJ, 1993, J VIROL, V67, P4006, DOI 10.1128/JVI.67.7.4006-4016.1993; SHOPE T, 1973, P NATL ACAD SCI USA, V70, P2487, DOI 10.1073/pnas.70.9.2487; THORLEYLAWSON DA, 1985, J IMMUNOL, V134, P3007; YAO QY, 1985, INT J CANCER, V35, P35, DOI 10.1002/ijc.2910350107; YOUNG L, 1989, NEW ENGL J MED, V321, P1080, DOI 10.1056/NEJM198910193211604	31	139	144	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 27	1997	276	5321					2030	2033		10.1126/science.276.5321.2030	http://dx.doi.org/10.1126/science.276.5321.2030			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XG748	9197263				2022-12-01	WOS:A1997XG74800061
J	Yoshida, T; Terada, M				Yoshida, T; Terada, M			Oncology	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											Yoshida, T (corresponding author), NATL CANC CTR,RES INST,TOKYO 104,JAPAN.							Barnes LD, 1996, BIOCHEMISTRY-US, V35, P11529, DOI 10.1021/bi961415t; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CHEN QX, 1996, NAT MED, V2, P1033; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Dietrich WF, 1996, NATURE, V380, P149, DOI 10.1038/380149a0; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HAHNE M, 1996, SCIENCE, V274, P1368; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Naik P, 1996, GENE DEV, V10, P2105, DOI 10.1101/gad.10.17.2105; Nawroz H, 1996, NAT MED, V2, P1035, DOI 10.1038/nm0996-1035; Negrini M, 1996, CANCER RES, V56, P3173; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Roth JA, 1996, NAT MED, V2, P985, DOI 10.1038/nm0996-985; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Schutte M, 1996, CANCER RES, V56, P2527; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8	18	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	1997	277	23					1880	1881						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD544	9185814				2022-12-01	WOS:A1997XD54400033
J	Smith, LEH; Kopchick, JJ; Chen, W; Knapp, J; Kinose, F; Daley, D; Foley, E; Smith, RG; Schaeffer, JM				Smith, LEH; Kopchick, JJ; Chen, W; Knapp, J; Kinose, F; Daley, D; Foley, E; Smith, RG; Schaeffer, JM			Essential role of growth hormone in ischemia-induced retinal neovascularization	SCIENCE			English	Article							TRANSGENIC MICE; DIABETIC-RETINOPATHY; IGF-I; SOMATOSTATIN ANALOG; MOUSE; BINDING; PHOTOCOAGULATION; OCTREOTIDE; EXPRESSION; INHIBITION	Retinal neovascularization is the major cause of untreatable blindness, The role of growth hormone (GH) in ischemia-associated retinal neovascularization was studied in transgenic mice expressing a GH antagonist gene and in normal mice given an inhibitor of GH secretion (MK678), Retinal neovascularization was inhibited in these mice in inverse proportion to serum levels of GH and a downstream effector, insulin-like growth factor-I (IGF-I), Inhibition was reversed with exogenous IGF-I administration, GH inhibition did not diminish hypoxia-stimulated retinal vascular endothelial growth factor (VEGF) or VEGF receptor expression, These data suggest that systemic inhibition of GH or IGF-I, or both, may have therapeutic potential in preventing some forms of retinopathy.	CHILDRENS HOSP, BOSTON, MA 02115 USA; OHIO UNIV, EDISON BIOTECHNOL INST, ATHENS, OH 45701 USA; MERCK RES LABS, RAHWAY, NJ 07065 USA	Harvard University; Boston Children's Hospital; University System of Ohio; Ohio University; Merck & Company	Smith, LEH (corresponding author), HARVARD UNIV, SCH MED, DEPT OPHTHALMOL, BOSTON, MA 02115 USA.		CLIHON, Residencia Medica/K-4896-2013	CLIHON, Residencia Medica/0000-0001-6734-2513	NEI NIH HHS [EY08670] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY008670] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457; AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; AMIEL SA, 1984, DIABETES, V33, P1175, DOI 10.2337/diabetes.33.12.1175; [Anonymous], 1979, Arch Ophthalmol, V97, P654; [Anonymous], 1981, OPHTHALMOLOGY, V88, P583; Burren CP, 1996, INVEST OPHTH VIS SCI, V37, P1459; BURRIN JM, 1989, METABOLISM, V38, P5896; CHEN WY, 1991, J BIOL CHEM, V266, P2252; CHEN WY, 1991, MOL ENDOCRINOL, V5, P1845, DOI 10.1210/mend-5-12-1845; CHEN WY, 1990, P NATL ACAD SCI USA, V87, P5061, DOI 10.1073/pnas.87.13.5061; CHEN WY, 1991, ENDOCRINOLOGY, V129, P1402, DOI 10.1210/endo-129-3-1402; DAMATO R, 1993, MICROVASC RES, V46, P135, DOI 10.1006/mvre.1993.1042; DILLS DG, 1990, DIABETES, V39, P191, DOI 10.2337/diabetes.39.2.191; DILLS DG, 1991, DIABETES, V40, P1725, DOI 10.2337/diabetes.40.12.1725; Early Treatment Diabetic Retinopathy Study Res Grp, 1991, OPHTHALMOLOGY, V98, P766; Ferrara N, 1996, EUR J CANCER, V32A, P2413, DOI 10.1016/S0959-8049(96)00387-5; FLIER JS, 1989, ENDOCRINOLOGY, V2, P1389; GRANT M, 1986, DIABETES, V35, P416, DOI 10.2337/diabetes.35.4.416; GRANT MB, 1993, REGUL PEPTIDES, V48, P267, DOI 10.1016/0167-0115(93)90356-D; Hammes HP, 1996, NAT MED, V2, P529, DOI 10.1038/nm0596-529; JILIAL I, 1985, ENDOCRINOLOGY, V117, P1222; KIRKEGAARD C, 1990, ACTA ENDOCRINOL-COP, V122, P766, DOI 10.1530/acta.0.1220766; KLEIN HA, 1970, NIH DHEW PUBLICATION; KNAPP JR, 1994, J ANIM SCI, V72, P2812, DOI 10.2527/1994.72112812x; LARON Z, 1980, EUR J PEDIATR, V134, P79, DOI 10.1007/BF00442408; MALLET B, 1992, DIABETES METAB, V18, P438; MCCOMBE M, 1991, Eye (London), V5, P569; MCNAMARA JA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1714, DOI 10.1001/archopht.1992.01080240054029; MERIMEE TJ, 1970, J CLIN INVEST, V49, P1096, DOI 10.1172/JCI106325; MERIMEE TJ, 1983, NEW ENGL J MED, V309, P527, DOI 10.1056/NEJM198309013090904; MEYERSCHWICKERATH R, 1993, J CLIN INVEST, V92, P2620, DOI 10.1172/JCI116877; MORIARTY P, 1994, BRIT J OPHTHALMOL, V78, P638, DOI 10.1136/bjo.78.8.638; PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905; POULSEN JE, 1953, DIABETES, V2, P7, DOI 10.2337/diab.2.1.7; RAYNOR K, 1993, MOL PHARMACOL, V43, P838; Robinson GS, 1996, P NATL ACAD SCI USA, V93, P4851, DOI 10.1073/pnas.93.10.4851; SHUMACK SL, 1990, CLIN INVEST MED, V5, P287; SMITH LA, UNPUB; SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101; WRIGHT AD, 1969, BRIT MED J, V2, P343; ZIMMERGALLER IE, 1995, INT OPHTHALMOL CLIN, V35, P37, DOI 10.1097/00004397-199503540-00005; 1990, ARCH OPHTHALMOL-CHIC, V108, P1408	42	320	335	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 13	1997	276	5319					1706	1709		10.1126/science.276.5319.1706	http://dx.doi.org/10.1126/science.276.5319.1706			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XD947	9180082				2022-12-01	WOS:A1997XD94700045
J	Gao, GF; Tormo, J; Gerth, UC; Wyer, JR; McMichael, AJ; Stuart, DI; Bell, JI; Jones, EY; Jakobsen, BK				Gao, GF; Tormo, J; Gerth, UC; Wyer, JR; McMichael, AJ; Stuart, DI; Bell, JI; Jones, EY; Jakobsen, BK			Crystal structure of the complex between human CD8 alpha alpha and HLA-A2	NATURE			English	Article							PEPTIDE-MHC COMPLEXES; CLASS-I MOLECULES; ALPHA-3 DOMAIN; CD8; BINDING; ANTIGEN; CHAIN; RESOLUTION; PROGRAM	The dimeric cell-surface glycoprotein CD8 is crucial to the positive selection of cytotoxic T cells in the thymus(1). The homodimer CD8 alpha alpha or the heterodimer alpha beta stabilizes the interaction of the T-cell antigen receptor(TCR) with major histocompatibility complex (MHC) class I/peptide by binding to the class I molecule(2). Here we report the crystal structure at 2.7 Angstrom resolution of a complex between CD8 alpha alpha and the human MHC molecule HLA-A2, which is associated with peptide. CD8 alpha alpha binds one HLA-A2/ peptide molecule, interfacing with the alpha 2 and alpha 3 domains of HLA-A2 and also contacting beta(2)-microglobulin. A flexible loop of the alpha 3 domain (residues 223-229) is damped between the complementarity-determining region (CDR)-like loops of the two CD8 subunits in the classic manner of an antibody-antigen interaction, precluding the binding of a second MHC molecule. The position of the alpha 3 domain is different from that in uncomplexed HLA-A2 (refs 3, 4), being most similar to that in the TCR/Tax/HLA-A2 complex(5), but no conformational change extends to the MHC/peptide surface presented for TCR recognition. Although these shifts in alpha 3 may provide a synergistic modulation of affinity, the binding of CD8 to MHC is clearly consistent with an avidity-based contribution from CD8 to TCR-peptide-MHC interactions.	JOHN RADCLIFFE HOSP,INST MOL MED,NUFFIELD DEPT CLIN MED,MOL IMMUNOL GRP,OXFORD OX3 9DU,ENGLAND; LAB MOL BIOPHYS,OXFORD OX1 3QU,ENGLAND; OXFORD CTR MOL SCI,OXFORD OX1 3QT,ENGLAND	University of Oxford; University of Oxford; University of Oxford			Jones, Yvonne/J-2293-2016; Gao, George Fu/ABD-5229-2021; Jones, Yvonne/N-8111-2019	Jones, Yvonne/0000-0002-3834-1893; Jones, Yvonne/0000-0002-3834-1893; Stuart, David/0000-0002-3426-4210				BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Garboczi DN, 1996, NATURE, V384, P134, DOI 10.1038/384134a0; Garcia KC, 1996, NATURE, V384, P577, DOI 10.1038/384577a0; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; GIBLIN PA, 1994, P NATL ACAD SCI USA, V91, P1716, DOI 10.1073/pnas.91.5.1716; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KIRSZBAUM L, 1989, J IMMUNOL, V142, P3931; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEAHY DJ, 1992, CELL, V68, P1145, DOI 10.1016/0092-8674(92)90085-Q; LUESCHER IF, 1995, NATURE, V373, P353, DOI 10.1038/373353a0; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; MADDEN DR, 1995, ANNU REV IMMUNOL, V13, P587, DOI 10.1146/annurev.immunol.13.1.587; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NORMENT AM, 1988, NATURE, V336, P79, DOI 10.1038/336079a0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; REIC SW, 1996, FEBS LETT, V383, P119; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SALTER RD, 1989, NATURE, V338, P345, DOI 10.1038/338345a0; Smith KJ, 1996, IMMUNITY, V4, P215, DOI 10.1016/S1074-7613(00)80430-6; STUART DI, 1979, J MOL BIOL, V134, P109, DOI 10.1016/0022-2836(79)90416-9; SUN JR, 1995, J EXP MED, V182, P1275, DOI 10.1084/jem.182.5.1275; WHEELER CJ, 1992, NATURE, V357, P247, DOI 10.1038/357247a0; WILSON IA, 1994, CURR OPIN STRUC BIOL, V4, P857, DOI 10.1016/0959-440X(94)90267-4; ZAMOYSKA R, 1994, IMMUNITY, V1, P243, DOI 10.1016/1074-7613(94)90075-2	28	378	412	0	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 5	1997	387	6633					630	634		10.1038/42523	http://dx.doi.org/10.1038/42523			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XC522	9177355				2022-12-01	WOS:A1997XC52200063
J	Peters, A; Doring, A; Wichmann, HE; Koenig, W				Peters, A; Doring, A; Wichmann, HE; Koenig, W			Increased plasma viscosity during an air pollution episode: A link to mortality?	LANCET			English	Article							CARDIOVASCULAR RISK FACTOR; FIBRINOGEN; DISEASE; ADMISSIONS; PEOPLE; CITIES; EVENT; DEATH	Background Air pollution episodes have been consistently associated with increased mortality, and most strikingly with mortality due to cardiovascular disease. One hypothesis to explain this association is that inflammation of the peripheral airways caused by pollution might increase blood coagulability. We have tested this hypothesis in a cross-sectional study by comparing measurements of plasma viscosity during a severe episode of air pollution during 1985 with those made on less polluted days. Methods Plasma viscosity was measured as part of the MONICA Augsburg survey during the winter of 1984-85 in 3256 randomly selected men and women aged 25-64 years. Daily mean concentrations of air pollutants and meteorological variables were measured in Augsburg as part of the automated Bavarian air-quality network. We compared measurements of plasma viscosity made in 324 people who attended for screening during the pollution episode and in 2932 people screened during the remainder of the survey period. Findings In January, 1985, high concentrations of sulphur dioxide (mean 200 mu g/m(3)) and total suspended particles (mean 98 mu g/m(3)) were recorded during a 13-day period in Augsburg. In men, the odds ratio for plasma viscosity above the 95th percentile of the distribution (1.38 mPa s) was 3.6 (95% CI 1.6-8.1) comparing measurements during the air pollution episode with non-episode measurements after adjustment for cardiovascular risk factors and meteorological variables. The corresponding odds ratio for women (95th percentile of plasma viscosity 1.37 mPa s) was 2.3 (1.0-5.3). High concentrations of carbon monoxide were also associated with increased plasma viscosity in women. Interpretation During the 1985 air pollution episode, an increased risk of extreme values of plasma viscosity was observed in both men and women. Altered blood rheology due to inflammatory processes in the lung that induce an acute-phase reaction might therefore be part of the pathological mechanisms linking air pollution to mortality.	UNIV ULM, MED CTR, DEPT INTERNAL MED CARDIOL 2, ULM, GERMANY	Ulm University	Peters, A (corresponding author), GSF, NATL RES CTR ENVIRONM & HLTH, INST EPIDEMIOL, POSTFACH 1129, D-85758 OBERSCHLEISSHEIM, GERMANY.		Wichmann, Heinz Erich/AAA-5695-2022; Peters, Annette/A-6117-2011	Peters, Annette/0000-0001-6645-0985				AYRES J, 1989, ENVIRON HEALTH PERSP, V79, P83, DOI 10.2307/3430533; Bascom R, 1996, AM J RESP CRIT CARE, V153, P3, DOI 10.1164/ajrccm.153.1.8542133; BATES DV, 1992, ENVIRON RES, V59, P336, DOI 10.1016/S0013-9351(05)80040-4; Benderly M, 1996, ARTERIOSCL THROM VAS, V16, P351, DOI 10.1161/01.ATV.16.3.351; BURNETT RT, 1995, AM J EPIDEMIOL, V142, P15, DOI 10.1093/oxfordjournals.aje.a117540; DASSEN W, 1986, JAPCA J AIR WASTE MA, V36, P1223, DOI 10.1080/00022470.1986.10466168; DELEEUW FAAM, 1989, ENVIRON HEALTH PERSP, V79, P53, DOI 10.2307/3430529; DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; DOCKERY DW, 1994, ANNU REV PUBL HEALTH, V15, P107, DOI 10.1146/annurev.pu.15.050194.000543; ERNST E, 1993, ANN INTERN MED, V118, P956, DOI 10.7326/0003-4819-118-12-199306150-00008; Godleski JJ, 1996, AM J RESP CRIT CARE, V153, pA15; Haverkate F, 1997, LANCET, V349, P462, DOI 10.1016/S0140-6736(96)07591-5; Jousilahti P, 1996, LANCET, V348, P567, DOI 10.1016/S0140-6736(96)02374-4; KEIL U, 1988, ACTA MED SCAND, P119; KOENIG W, 1992, CIRCULATION, V86, P1045, DOI 10.1161/01.CIR.86.3.1045; KOENIG W, 1994, LANCET, V344, P711, DOI 10.1016/S0140-6736(94)92207-1; LEWIS SM, 1982, CLIN LAB HAEMATOL, V4, P83; LIP GYH, 1995, QJM-INT J MED, V88, P155; MORRIS RD, 1995, AM J PUBLIC HEALTH, V85, P1361, DOI 10.2105/AJPH.85.10.1361; POPE CA, 1995, AM J RESP CRIT CARE, V151, P669, DOI 10.1164/ajrccm/151.3_Pt_1.669; SCHWARTZ J, 1995, AM J EPIDEMIOL, V142, P23, DOI 10.1093/oxfordjournals.aje.a117541; SCHWARTZ J, 1994, ENVIRON RES, V64, P36, DOI 10.1006/enrs.1994.1005; SCHWARTZ J, 1994, ENVIRON RES, V64, P26, DOI 10.1006/enrs.1994.1004; SEATON A, 1995, LANCET, V345, P176, DOI 10.1016/S0140-6736(95)90173-6; THOMPSON SG, 1995, NEW ENGL J MED, V332, P635, DOI 10.1056/NEJM199503093321003; WICHMANN HE, 1989, ENVIRON HEALTH PERSP, V79, P89, DOI 10.2307/3430534; WOODHOUSE PR, 1994, LANCET, V343, P435, DOI 10.1016/S0140-6736(94)92689-1; World Health Organization, 1990, MONICA MAN; YARNELL JWG, 1991, CIRCULATION, V83, P836, DOI 10.1161/01.CIR.83.3.836	29	528	555	1	26	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 31	1997	349	9065					1582	1587		10.1016/S0140-6736(97)01211-7	http://dx.doi.org/10.1016/S0140-6736(97)01211-7			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XB673	9174559				2022-12-01	WOS:A1997XB67300008
J	Bowman, S; Churcher, C; Badcock, K; Brown, D; Chillingworth, T; Connor, R; Dedman, K; Devlin, K; Gentles, S; Hamlin, N; Hunt, S; Jagels, K; Lye, G; Moule, S; Odell, C; Pearson, D; Rajandream, M; Rice, P; Skelton, J; Walsh, S; Whitehead, S; Barrell, B				Bowman, S; Churcher, C; Badcock, K; Brown, D; Chillingworth, T; Connor, R; Dedman, K; Devlin, K; Gentles, S; Hamlin, N; Hunt, S; Jagels, K; Lye, G; Moule, S; Odell, C; Pearson, D; Rajandream, M; Rice, P; Skelton, J; Walsh, S; Whitehead, S; Barrell, B			The nucleotide sequence of Saccharomyces cerevisiae chromosome XIII	NATURE			English	Article							COMPLETE DNA-SEQUENCE; YEAST; GENE; HOMOLOG; INTERACTS; RECQ; SGS1	Systematic sequencing of the genome of Saccharomyces cerevisiae has revealed thousands of new predicted genes and allowed analysis of long-range features of chromosomal organization. Generally, genes and predicted genes seem to be distributed evenly throughout the genome, having no overall preference for DNA strand. Apart from the smaller chromosomes, which can have substantially lower gene density in their telomeric: regions(1-3), there is a consistent average of one open reading frame (ORF) approximately every two kilobases. However, one of the most surprising findings for a eukaryote with approximately 6,000 genes was the amount of apparent redundancy in its genome. This redundancy occurs both between individual ORFs and over more extensive chromosome regions, which have been duplicated preserving gene order and orientation(4-6). Here we report the entire nucleotide sequence of chromosome XIII, the sixth-largest S. cerevisiae chromosome, and demonstrate that its features and organization are consistent with those observed for other S. cerevisiae chromosomes. Analysis revealed 459 ORFs, 284 have not been identified previously. Both intra- and interchromosomal duplications of regions of this chromosome have occurred.	SANGER CTR,CAMBRIDGE CB10 1SA,ENGLAND	Wellcome Trust Sanger Institute				Hunt, Sarah/0000-0002-8350-1235	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2247, DOI 10.1093/nar/19.suppl.2247; Bairoch A, 1996, NUCLEIC ACIDS RES, V24, P21, DOI 10.1093/nar/24.1.21; BUSSEY H, 1995, P NATL ACAD SCI USA, V92, P3809, DOI 10.1073/pnas.92.9.3809; CALDER KM, 1990, NUCLEIC ACIDS RES, V18, P1632, DOI 10.1093/nar/18.6.1632; DEAR S, 1991, NUCLEIC ACIDS RES, V19, P3907, DOI 10.1093/nar/19.14.3907; DUJON B, 1994, NATURE, V369, P371, DOI 10.1038/369371a0; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; FELDMANN H, 1994, EMBO J, V13, P5795, DOI 10.1002/j.1460-2075.1994.tb06923.x; FITZGERALDHAYES M, 1987, YEAST, V3, P187, DOI 10.1002/yea.320030306; Galibert F, 1996, EMBO J, V15, P2031, DOI 10.1002/j.1460-2075.1996.tb00557.x; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; JOHNSTON M, 1994, SCIENCE, V265, P2077, DOI 10.1126/science.8091229; KEARSEY SE, 1993, DNA SEQUENCE, V4, P69, DOI 10.3109/10425179309015625; LOUIS EJ, 1994, GENETICS, V136, P789; LOUIS EJ, 1995, BIOCHEMICA, V3, P25; MURAKAMI Y, 1995, NAT GENET, V10, P261, DOI 10.1038/ng0795-261; OLIVER SG, 1992, NATURE, V357, P38, DOI 10.1038/357038a0; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PROLLA TA, 1994, MOL CELL BIOL, V14, P407, DOI 10.1128/MCB.14.1.407; SMITH V, 1993, METHOD ENZYMOL, V218, P173; STRAND M, 1995, P NATL ACAD SCI USA, V92, P10418, DOI 10.1073/pnas.92.22.10418; Termier M, 1996, YEAST, V12, P369, DOI 10.1002/(SICI)1097-0061(19960330)12:4<369::AID-YEA922>3.0.CO;2-#; WATT PM, 1995, CELL, V81, P253, DOI 10.1016/0092-8674(95)90335-6; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; [No title captured]	27	38	560	1	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 29	1997	387	6632		S			90	93		10.1038/387s090	http://dx.doi.org/10.1038/387s090			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XB546	9169872				2022-12-01	WOS:A1997XB54600012
J	Herwaldt, BL; Ackers, ML; Farrar, J; Richardson, S; Nelson, R; Fletcher, M; Levy, M; Katz, D; Kumar, S; Malecki, J; Lowdermilk, M; Mackey, L; Bell, J; Portesi, D; Lacey, C; Letendre, L; Hamlin, D; Knowlton, R; Barry, A; Chew, D; Finelli, L; Genese, C; Miller, J; Layton, M; Guzewich, J; Salehi, E; Weltman, A; Caceres, V; Ball, R; Barnett, B; Hendricks, K; Taylor, J; Bell, R; Schoenfeld, S; Bryan, F; Neamatullah, S; Werker, D; Manuel, D; LeBer, C; Arrieta, M; Morrison, D; Klein, R; Wahlquist, S; Alfano, E; Eberhard, M; Arrowood, M; HannakDonaldson, K; Beach, M; Kramer, M; Hightower, A; Swerdlow, D; Winickoff, J; Shapiro, R; Messonnier, M				Herwaldt, BL; Ackers, ML; Farrar, J; Richardson, S; Nelson, R; Fletcher, M; Levy, M; Katz, D; Kumar, S; Malecki, J; Lowdermilk, M; Mackey, L; Bell, J; Portesi, D; Lacey, C; Letendre, L; Hamlin, D; Knowlton, R; Barry, A; Chew, D; Finelli, L; Genese, C; Miller, J; Layton, M; Guzewich, J; Salehi, E; Weltman, A; Caceres, V; Ball, R; Barnett, B; Hendricks, K; Taylor, J; Bell, R; Schoenfeld, S; Bryan, F; Neamatullah, S; Werker, D; Manuel, D; LeBer, C; Arrieta, M; Morrison, D; Klein, R; Wahlquist, S; Alfano, E; Eberhard, M; Arrowood, M; HannakDonaldson, K; Beach, M; Kramer, M; Hightower, A; Swerdlow, D; Winickoff, J; Shapiro, R; Messonnier, M			An outbreak in 1996 of cyclosporiasis associated with imported raspberries	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FOREIGN RESIDENTS; UNITED-STATES; DIARRHEA; EPIDEMIOLOGY; TRAVELERS; ORGANISM; NEPAL	Background Cyclospora cayetanensis is a parasite that causes gastroenteritis. Until last year most of the documented cases of cyclosporiasis in North America were in overseas travelers. In 1996, a large outbreak of cyclosporiasis occurred in North America. We investigated this outbreak. Methods Health departments solicited information from clinicians and laboratories on cases of cyclosporiasis, which were then reported to the Centers for Disease Control and Prevention and to Health Canada. We conducted retrospective cohort studies for the cases associated with events (e.g., luncheons) and attempted to identify the sources of the implicated food. Results A total of 1465 cases of cyclosporiasis were reported by 20 states, the District of Columbia, and 2 provinces. Of these cases, 978 (66.8 percent) were laboratory confirmed and 725 (49.5 percent) were associated with 55 events that were held from May 3 through June 14. Raspberries were definitely served at 50 events and may have been served at 4 events, For 27 of the 41 events for which adequate data were available (65.8 percent), the associations between the consumption of berries (raspberries with or without other berries) and cyclosporiasis were statistically significant (P<0.05). For all 29 events for which there were good data, the raspberries definitely came from Guatemala (21 events, 72.4 percent) or may have come from Guatemala (8 events, 27.6 percent). As few as five Guatemalan farms could have accounted for the 25 events for which the raspberries could be traced to a single exporter per event. The mode of contamination of the raspberries remains unclear. Conclusions This large outbreak of cyclosporiasis in North America in 1996 was associated with the consumption of Guatemalan raspberries. The outbreak illustrates the need to consider that a local cluster of foodborne illness may be part of a widespread outbreak and to pursue investigations of the source of the implicated vehicle. (C) 1997, Massachusetts Medical Society.	CTR DIS CONTROL & PREVENT, NATL CTR INFECT DIS, ATLANTA, GA 30341 USA; CTR DIS CONTROL & PREVENT, EPIDEM INTELLIGENCE SERV, EPIDEMIOL PROGRAM OFF, ATLANTA, GA 30341 USA; CONNECTICUT DEPT PUBL HLTH & ADDICT SERV, HARTFORD, CT 06106 USA; FLORIDA DEPT HLTH & REHABIL SERV, TALLAHASSEE, FL 32399 USA; PALM BEACH CTY HLTH DEPT, W PALM BEACH, FL USA; LAKE CTY HLTH DEPT, WAUKEGAN, IL USA; MARYLAND DEPT HLTH & MENTAL HYG, BALTIMORE, MD 21201 USA; MONTGOMERY CTY DEPT HLTH & HUMAN SERV, ROCKVILLE, MD USA; MASSACHUSETTS DEPT PUBL HLTH, BOSTON, MA 02111 USA; BOSTON DEPT HLTH & HOSP, BOSTON, MA USA; NEW JERSEY DEPT HLTH & SENIOR SERV, TRENTON, NJ USA; NEW YORK CITY DEPT HLTH, ALBANY, NY 12237 USA; NEW YORK STATE DEPT HLTH, ALBANY, NY 12237 USA; OHIO DEPT HLTH, COLUMBUS, OH 43266 USA; PENN DEPT HLTH, HARRISBURG, PA 17108 USA; S CAROLINA DEPT HLTH & ENVIRONM CONTROL, COLUMBIA, SC 29201 USA; TEXAS DEPT HLTH, AUSTIN, TX 78756 USA; HOUSTON DEPT HLTH & HUMAN SERV, HOUSTON, TX USA; VERMONT DEPT HLTH, BURLINGTON, VT 05402 USA; HLTH CANADA, OTTAWA, ON, CANADA; DEPT PUBL HLTH, ALBANY, NY 12237 USA; ONTARIO MINIST HLTH, TORONTO, ON, CANADA; MONTREAL CHILDRENS HOSP, MONTREAL, PQ H3H 1P3, CANADA; MED ENTOMOL RES & TRAINING UNIT, GUATEMALA CITY, GUATEMALA; CDC, NATL CTR INFECT DIS, DIV PARASIT DIS, ATLANTA, GA 30333 USA; CDC, NATL CTR INFECT DIS, DIV BACTERIAL & MYCOT DIS, ATLANTA, GA 30333 USA; CDC, NATL CTR INFECT DIS, EPIDEMIOL PROGRAM OFF, ATLANTA, GA 30333 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Florida Department of Health; Maryland Department of Health & Mental Hygiene; Massachusetts Department of Public Health; New Jersey Department of Health & Senior Services; New York City Department of Health & Mental Hygiene; State University of New York (SUNY) System; Texas Department of State Health Services; Health Canada; McGill University; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Herwaldt, BL (corresponding author), CTR DIS CONTROL & PREVENT, EPIDEMIOL BRANCH, DIV PARASIT DIS, 4770 BUFORD HWY NE, MAILSTOP F22, ATLANTA, GA 30341 USA.		Finelli, Lyn/AAK-2360-2020					ASHFORD RW, 1979, ANN TROP MED PARASIT, V73, P497, DOI 10.1080/00034983.1979.11687291; BENDALL RP, 1993, LANCET, V341, P590, DOI 10.1016/0140-6736(93)90352-H; Blaser MJ, 1996, NEW ENGL J MED, V334, P1324, DOI 10.1056/NEJM199605163342009; Carter R., 1996, 30 INT C ANT AG CHEM, P259; CHALKER RB, 1988, REV INFECT DIS, V10, P111; CHEW D, 1996, 36 INT C ANT AG CHEM; Colley DG, 1996, EMERG INFECT DIS, V2, P354, DOI 10.3201/eid0204.960413; *COMM COMM DIS AFF, 1991, PROC IMPL HAZ AN CRI, P1; CONNOR BA, 1995, LANCET, V346, P1634, DOI 10.1016/S0140-6736(95)91972-4; *DEP AGR, IN PRESS FRESH FRUIT; FLEMING C, 1996, 36 INT C ANT AG CHEM, P11; GARCIA LS, 1997, DIAGNOSTIC MED PARAS, P66; GarciaLopez HL, 1996, EMERG INFECT DIS, V2, P356, DOI 10.3201/eid0204.960414; HART AS, 1990, LANCET, V335, P169, DOI 10.1016/0140-6736(90)90042-4; HEDBERG CW, 1994, CLIN INFECT DIS, V18, P671, DOI 10.1093/clinids/18.5.671; HOGE CW, 1995, LANCET, V345, P691, DOI 10.1016/S0140-6736(95)90868-4; HOGE CW, 1993, LANCET, V341, P1175, DOI 10.1016/0140-6736(93)91002-4; Hoge CW, 1995, LANCET, V345, P1060; HUANG P, 1995, ANN INTERN MED, V123, P409, DOI 10.7326/0003-4819-123-6-199509150-00002; KATZ D, 1996, 124 ANN M EXP AM PUB; KOUMANS EH, 1996, 45 ANN EP INT SERV E, P60; *NAT ADV COMM MICR, 1992, INT J FOOD MICROBIOL, V16, P1; NEAMATULLAH S, 1996, 64 CONJ M INF DIS HA, pM6; ORTEGA YR, 1993, NEW ENGL J MED, V328, P1308, DOI 10.1056/NEJM199305063281804; Pieniazek NJ, 1996, EMERG INFECT DIS, V2, P357, DOI 10.3201/eid0204.960415; RABOLD JG, 1994, LANCET, V344, P1360, DOI 10.1016/S0140-6736(94)90716-1; Relman DA, 1996, J INFECT DIS, V173, P440, DOI 10.1093/infdis/173.2.440; ROBBINS JA, 1988, J AM SOC HORTIC SCI, V113, P474; ROXAS C, 1996, 96 GEN M AM SOC MICR, P19; Smith HV, 1996, VET REC, V138, P528; Soave R, 1996, CLIN INFECT DIS, V23, P429, DOI 10.1093/clinids/23.3.429; Sun T, 1996, AM J CLIN PATHOL, V105, P216; Tauxe RV, 1996, BMJ-BRIT MED J, V313, P1093, DOI 10.1136/bmj.313.7065.1093; Visvesvara GS, 1997, J CLIN MICROBIOL, V35, P730, DOI 10.1128/JCM.35.3.730-733.1997; ZERPA R, 1995, J TROP MED HYG, V98, P325; 1991, MMWR-MORBID MORTAL W, V40, P325; 1996, MMWR-MORBID MORTAL W, V45, P611; 1996, MMWR MORTAL WKLY REP, V45, P549	38	271	286	0	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 29	1997	336	22					1548	1556		10.1056/NEJM199705293362202	http://dx.doi.org/10.1056/NEJM199705293362202			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XB087	9164810				2022-12-01	WOS:A1997XB08700002
J	Ni, JW; Tien, AL; Fournier, MJ				Ni, JW; Tien, AL; Fournier, MJ			Small nucleolar RNAs direct site-specific synthesis of pseudouridine in ribosomal RNA	CELL			English	Article							SMALL NUCLEAR RNAS; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; PEPTIDYLTRANSFERASE CENTER; SYNTHASE; PURIFICATION; RESIDUES; CLONING; SNRNAS; U8	Ten ACA yeast small nucleolar RNAs (snoRNAs) were shown to be required for site-specific synthesis of pseudouridine (psi) in ribosomal RNA. A common secondary folding motif for the snoRNAs and rRNA target segments predicts that site selection involves: (1) base pairing of the snoRNA with complementary rRNA elements flanking the site of modification, and (2) identification of a uridine located at a near-constant distance from the snoRNA ACA box. The model is supported by mutations showing that: (1) reducing the complementarity between the snoRNA and rRNA disrupts psi formation, and (2) altering the distance between the ACA box and target uridine causes an adjacent uridine to be modified. This discovery implies that most snoRNAs function in targeting nucleotide modification in rRNA: ribose methylation for the box C/D snoRNAs and psi formation for the ACA snoRNAs.	UNIV MASSACHUSETTS,PROGRAM MOL & CELLULAR BIOL,DEPT BIOCHEM & MOL BIOL,AMHERST,MA 01003	University of Massachusetts System; University of Massachusetts Amherst					NIGMS NIH HHS [GM 19351] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019351] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACHELLERIE JP, 1995, TRENDS BIOCHEM SCI, V20, P261, DOI 10.1016/S0968-0004(00)89039-8; BAKIN A, 1995, NUCLEIC ACIDS RES, V23, P3290, DOI 10.1093/nar/23.16.3290; BAKIN A, 1994, BIOCHEMISTRY-US, V33, P13475, DOI 10.1021/bi00249a036; BAKIN A, 1993, BIOCHEMISTRY-US, V32, P9754, DOI 10.1021/bi00088a030; Balakin AG, 1996, CELL, V86, P823, DOI 10.1016/S0092-8674(00)80156-7; BALAKIN AG, 1993, NUCLEIC ACIDS RES, V21, P5391, DOI 10.1093/nar/21.23.5391; Cavaille J, 1996, NATURE, V383, P732, DOI 10.1038/383732a0; CHEN BW, 1994, BIOTECHNIQUES, V17, P657; CLARKE MW, 1990, J CELL BIOL, V11, P1741; Enright CA, 1996, RNA, V2, P1094; Enright CA, 1996, RNA, V2, P1318; Goldwasser E, 1966, Prog Nucleic Acid Res Mol Biol, V5, P399, DOI 10.1016/S0079-6603(08)60241-X; HUANG GM, 1992, MOL CELL BIOL, V12, P4456, DOI 10.1128/MCB.12.10.4456; KAMMEN HO, 1988, J BIOL CHEM, V263, P2255; Kiss T, 1996, MOL CELL BIOL, V16, P1391; KissLaszlo Z, 1996, CELL, V85, P1077, DOI 10.1016/S0092-8674(00)81308-2; Koonin EV, 1996, NUCLEIC ACIDS RES, V24, P2411, DOI 10.1093/nar/24.12.2411; LANE BG, 1992, FEBS LETT, V302, P1, DOI 10.1016/0014-5793(92)80269-M; LANE BG, 1995, BIOCHIMIE, V77, P7, DOI 10.1016/0300-9084(96)88098-9; Lygerou Z, 1996, SCIENCE, V272, P268, DOI 10.1126/science.272.5259.268; Maden B E, 1990, Prog Nucleic Acid Res Mol Biol, V39, P241, DOI 10.1016/S0079-6603(08)60629-7; Maden T, 1996, NATURE, V383, P675, DOI 10.1038/383675a0; MAXWELL ES, 1995, ANNU REV BIOCHEM, V35, P897; MORRISSEY JP, 1993, MOL CELL BIOL, V13, P2469, DOI 10.1128/MCB.13.4.2469; Nicoloso M, 1996, J MOL BIOL, V260, P178, DOI 10.1006/jmbi.1996.0391; NURSE K, 1995, RNA, V1, P102; Ofengand J, 1995, BIOCHEM CELL BIOL, V73, P915, DOI 10.1139/o95-099; PARKER R, 1988, MOL CELL BIOL, V8, P3150, DOI 10.1128/MCB.8.8.3150; PATTON JR, 1994, BIOCHIMIE, V76, P1129, DOI 10.1016/0300-9084(94)90041-8; Peculis BA, 1996, CURR BIOL, V6, P1413, DOI 10.1016/S0960-9822(96)00745-2; PECULIS BA, 1994, GENE DEV, V8, P2241, DOI 10.1101/gad.8.18.2241; Reddy R, 1988, STRUCTURE FUNCTION M, P1, DOI [10.1007/978-3-642-73020-7_1, 10.1007/978-3-642-73020-7_1.]; SAMARSKY DA, 1995, NUCLEIC ACIDS RES, V23, P2548, DOI 10.1093/nar/23.13.2548; SIKORSKI RS, 1989, GENETICS, V122, P19; Simos G, 1996, EMBO J, V15, P2270, DOI 10.1002/j.1460-2075.1996.tb00580.x; TERNS MP, 1995, EMBO J, V14, P4860, DOI 10.1002/j.1460-2075.1995.tb00167.x; Tollervey D, 1996, SCIENCE, V273, P1056, DOI 10.1126/science.273.5278.1056; TOLLERVEY D, 1987, EMBO J, V6, P4169, DOI 10.1002/j.1460-2075.1987.tb02763.x; TYC K, 1989, EMBO J, V8, P3113, DOI 10.1002/j.1460-2075.1989.tb08463.x; Tycowski KT, 1996, P NATL ACAD SCI USA, V93, P14480, DOI 10.1073/pnas.93.25.14480; Tycowski KT, 1996, NATURE, V379, P464, DOI 10.1038/379464a0; Venema J, 1995, YEAST, V11, P1629, DOI 10.1002/yea.320111607; WISE JA, 1983, CELL, V35, P743, DOI 10.1016/0092-8674(83)90107-1; WRZESINSKI J, 1995, BIOCHEMISTRY-US, V34, P8904, DOI 10.1021/bi00027a043; WRZESINSKI J, 1995, RNA, V1, P437	45	409	440	3	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 16	1997	89	4					565	573		10.1016/S0092-8674(00)80238-X	http://dx.doi.org/10.1016/S0092-8674(00)80238-X			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WZ323	9160748	Bronze			2022-12-01	WOS:A1997WZ32300010
J	Kubbutat, MHG; Jones, SN; Vousden, KH				Kubbutat, MHG; Jones, SN; Vousden, KH			Regulation of p53 stability by Mdm2	NATURE			English	Article							EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; ONCOPROTEIN MDM2; PROTEIN; DOMAIN; TRANSACTIVATION; DEGRADATION; EXPRESSION; ACTIVATION; BINDING	The tumour-suppressor p53 is a short-lived protein that is maintained at low, often undetectable, levels in normal cells. Stabilization of the protein in response to an activating signal, such as DNA damage, results in a rapid rise in p53 levels and subsequent inhibition of cell growth(1). Tight regulation of p53 function is critical for normal cell growth and development, and one mechanism by which p53 function is controlled is through interaction with the Mdm2 protein(2-4). Mdm2 inhibits p53 cell-cycle arrest and apoptic functions(5,6) and we show here that interaction with Mdm2 can also result in a large reduction in p53 protein levels through enhanced proteasome-dependent degradation. Endogenous levels of Mdm2 are sufficient to regulate p53 stability, and overexpression of Mdm2 can reduce the amount of endogenous p53. Because mdm2 is transcriptionally activated by p53 (refs 7, 8), this degradative pathway may contribute to the maintenance of low p53 concentrations in normal cells. Furthermore, mechanisms regulating the Mdm2-induced degradation of p53 may play a role in controlling the extent and duration of the p53 response.	NCI,ABL BASIC RES PROGRAM,FCRDC,FREDERICK,MD 21701; BAYLOR COLL MED,DEPT MOL & HUMAN GENET,HOUSTON,TX 77030	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Baylor College of Medicine								BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; BATES S, 1996, CURRENT OPIN GENET D, V6, P1; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; Chen JD, 1996, MOL CELL BIOL, V16, P2445; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; HUBBERT NL, 1992, J VIROL, V66, P6237, DOI 10.1128/JVI.66.10.6237-6241.1992; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Jones SN, 1996, P NATL ACAD SCI USA, V93, P14106, DOI 10.1073/pnas.93.24.14106; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LUNA RMD, 1995, NATURE, V378, P203; Maki CG, 1996, CANCER RES, V56, P2649; MARSTON NJ, 1994, ONCOGENE, V9, P2707; MARSTON NJ, 1996, THESIS U LONDON; MARSTON NJ, 1995, ONCOGENE, V10, P1707; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; WREDE D, 1991, MOL CARCINOGEN, V4, P171, DOI 10.1002/mc.2940040302; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0	30	2735	2809	3	186	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 15	1997	387	6630					299	303		10.1038/387299a0	http://dx.doi.org/10.1038/387299a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WZ167	9153396				2022-12-01	WOS:A1997WZ16700057
J	Weir, CJ; Murray, GD; Dyker, AG; Lees, KR				Weir, CJ; Murray, GD; Dyker, AG; Lees, KR			Is hyperglycaemia an independent predictor of poor outcome after acute stroke? Results of a long term follow up study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ISCHEMIC BRAIN INFARCTION; BLOOD-GLUCOSE; MORBIDITY; MORTALITY; PRESSURE; STRESS; DAMAGE	Objective: To determine whether raised plasma glucose concentration independently influences outcome after acute stroke or is a stress response reflecting increased stroke severity. Design: Long term follow up study of patients admitted to an acute stroke unit. Setting Western Infirmary, Glasgow. Subjects: 811 patients with acute stroke confirmed by computed tomography. Analysis was restricted to the 750 non-diabetic patients. Main outcome measures: Survival time and placement three months after stroke. Results: 645 patients (86%) had ischaemic stroke and 105 patients (14%) haemorrhagic stroke. Cox's proportional hazards modelling with stratification according to Oxfordshire Community Stroke Project categories identified increased age (relative hazard 1.36 per decade; 95% confidence interval 1.21 to 1.53), haemorrhagic stroke (relative hazard 1.67; 1.22 to 2.28), time to resolution of symptoms > 72 hours (relative hazard 2.15; 1.15 to 4.05), and hyperglycaemia (relative hazard 1.87; 1.43 to 2.45) as predictors of mortality. The effect of glucose concentration on survival nas greatest in the first month. Conclusions: Plasma glucose concentration above 8 mmol/l after acute stroke predicts a poor prognosis after correcting for age, stroke severity, and stroke subtype. Raised plasma glucose concentration is therefore unlikely to be solely a stress response and should arguably be treated actively. A randomised trial is warranted.	UNIV GLASGOW, ROBERTSON CTR BIOSTAT, GLASGOW G12 8QQ, LANARK, SCOTLAND	University of Glasgow	Weir, CJ (corresponding author), UNIV GLASGOW, WESTERN INFIRM, DEPT MED & THERAPEUT, ACUTE STROKE UNIT, GLASGOW G11 6NT, LANARK, SCOTLAND.			Weir, Christopher/0000-0002-6494-4903; Murray, Gordon/0000-0001-9866-4734				[Anonymous], 1995, J Clin Epidemiol, V48, P1441; BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O; CANDELISE L, 1985, ARCH NEUROL-CHICAGO, V42, P661, DOI 10.1001/archneur.1985.04060070051014; CARLBERG B, 1991, STROKE, V22, P527, DOI 10.1161/01.STR.22.4.527; CARLBERG B, 1991, CEREBROVASC DIS, V1, P281, DOI 10.1159/000108855; CHEW W, 1991, AM J NEURORADIOL, V12, P603; COX DR, 1972, J R STAT SOC B, V34, P187; DECHIARA S, 1993, CEREBROVASC DIS, V3, P111, DOI 10.1159/000108682; ENGELMAN L, 1990, BMDP STATISTICAL SOF, V2, P1013; HELGASON CM, 1988, STROKE, V19, P1049, DOI 10.1161/01.STR.19.8.1049; ISLES CG, 1986, J HYPERTENS, V4, P141, DOI 10.1097/00004872-198604000-00003; JORGENSEN HS, 1994, STROKE, V25, P1977, DOI 10.1161/01.STR.25.10.1977; KENDRICK S, 1993, HLTH B EDINB, V51, P1; KIERS L, 1992, J NEUROL NEUROSUR PS, V55, P263, DOI 10.1136/jnnp.55.4.263; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; MELAMED E, 1976, J NEUROL SCI, V29, P267, DOI 10.1016/0022-510X(76)90176-3; MOHR JP, 1994, CEREBROVASC DIS, V4, P197, DOI 10.1159/000108482; MURROS K, 1993, J NEUROL SCI, V116, P12, DOI 10.1016/0022-510X(93)90083-B; MURROS K, 1992, J NEUROL SCI, V111, P59, DOI 10.1016/0022-510X(92)90112-X; ONEILL PA, 1991, STROKE, V22, P842, DOI 10.1161/01.STR.22.7.842; PULSINELLI WA, 1982, NEUROLOGY, V32, P1239, DOI 10.1212/WNL.32.11.1239; REHNCRONA S, 1981, J CEREBR BLOOD F MET, V1, P297, DOI 10.1038/jcbfm.1981.34; TONI D, 1992, J NEUROL, V239, P382; VANKOOTEN F, 1993, STROKE, V24, P1129, DOI 10.1161/01.STR.24.8.1129; WOO E, 1988, STROKE, V19, P185, DOI 10.1161/01.STR.19.2.185; WOO J, 1990, ARCH NEUROL-CHICAGO, V47, P1174, DOI 10.1001/archneur.1990.00530110028011	26	384	389	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 3	1997	314	7090					1303	1306		10.1136/bmj.314.7090.1303	http://dx.doi.org/10.1136/bmj.314.7090.1303			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WX975	9158464	Green Published			2022-12-01	WOS:A1997WX97500020
J	Alland, L; Muhle, R; Hou, H; Potes, J; Chin, L; SchreiberAgus, N; DePinho, RA				Alland, L; Muhle, R; Hou, H; Potes, J; Chin, L; SchreiberAgus, N; DePinho, RA			Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression	NATURE			English	Article							THYROID-HORMONE RECEPTOR; MYC TRANSGENIC MICE; SACCHAROMYCES-CEREVISIAE; CHROMATIN STRUCTURE; YEAST; PROTEIN; ACTIVATION; COMPLEX; DOMAIN; GENES	Normal mammalian growth and development ave highly dependent on the regulation of the expression and activity of the Myo family of transcription factors. Mxi1-mediated inhibition of Myc activities requires interaction with mammalian Sin3A or Sin3B proteins, which have been purported to act as scaffolds for additional co-repressor factors. The identification of two such Sin3-associated factors, the nuclear receptor co-repressor (N-CoR) and histone deacetylase (HD1), provides a basis for Mxi1/Sin3-induced transcriptional repression and tumour suppression.	ALBERT EINSTEIN COLL MED, DEPT MICROBIOL & IMMUNOL, NEW YORK, NY 10461 USA; ALBERT EINSTEIN COLL MED, DEPT PEDIAT, NEW YORK, NY 10461 USA; ALBERT EINSTEIN COLL MED, DIV DERMATOL, NEW YORK, NY 10461 USA	Yeshiva University; Yeshiva University; Yeshiva University				DePinho, Ronald/0000-0002-5625-577X				Ayer DE, 1996, MOL CELL BIOL, V16, P5772; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; CHIBA H, 1994, NUCLEIC ACIDS RES, V22, P1815, DOI 10.1093/nar/22.10.1815; COOPER JP, 1994, GENE DEV, V8, P1400, DOI 10.1101/gad.8.12.1400; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; DeRubertis F, 1996, NATURE, V384, P589; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Harper SE, 1996, P NATL ACAD SCI USA, V93, P8536, DOI 10.1073/pnas.93.16.8536; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HERSCHBACH BM, 1994, NATURE, V370, P309, DOI 10.1038/370309a0; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; KOSKINEN PJ, 1995, CELL GROWTH DIFFER, V6, P623; Lee LA, 1996, J CLIN INVEST, V97, P1687, DOI 10.1172/JCI118595; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; MATALLANA E, 1992, MOL GEN GENET, V231, P395, DOI 10.1007/BF00292708; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; NASMYTH K, 1987, CELL, V48, P579, DOI 10.1016/0092-8674(87)90236-4; Rao G, 1996, ONCOGENE, V12, P1165; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; STILLMAN DJ, 1994, GENETICS, V136, P781; Strober BE, 1996, MOL CELL BIOL, V16, P1576; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; TZAMARIAS D, 1994, NATURE, V369, P758, DOI 10.1038/369758a0; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VANLOHUIZEN M, 1991, NATURE, V353, P353, DOI 10.1038/353353a0; VIDAL M, 1991, MOL CELL BIOL, V11, P6317, DOI 10.1128/MCB.11.12.6317; VIDAL M, 1991, MOL CELL BIOL, V11, P6306, DOI 10.1128/MCB.11.12.6306; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WADE PA, IN PRESS TRENDS BIOC; WANG HM, 1993, MOL CELL BIOL, V13, P1805, DOI 10.1128/MCB.13.3.1805; WANG HM, 1990, MOL CELL BIOL, V10, P5927, DOI 10.1128/MCB.10.11.5927; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90300-S; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; Wolffe AP, 1996, SCIENCE, V272, P371, DOI 10.1126/science.272.5260.371; WONG JM, 1995, GENE DEV, V9, P2696, DOI 10.1101/gad.9.21.2696; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; Zamir I, 1996, MOL CELL BIOL, V16, P5458	50	730	740	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 1	1997	387	6628					49	55		10.1038/387049a0	http://dx.doi.org/10.1038/387049a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WW758	9139821				2022-12-01	WOS:A1997WW75800042
J	Sinicco, A; Fora, R; Raiteri, R; Sciandra, M; Bechis, G; Calvo, MM; Gioannini, P				Sinicco, A; Fora, R; Raiteri, R; Sciandra, M; Bechis, G; Calvo, MM; Gioannini, P			Is the clinical course of HIV-1 changing? Cohort study	BRITISH MEDICAL JOURNAL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SYNCYTIUM-INDUCING PHENOTYPE; CD4 LYMPHOCYTE COUNTS; DISEASE PROGRESSION; INFECTION; TYPE-1; AIDS; SEROCONVERSION; RESISTANCE; CORRELATE	Objective: To assess whether the clinical course of HIV infection has changed from 1985 to 1995. Design: Cohort study. Setting: Infectious diseases clinic. Subjects: 285 patients recruited from September 1985 to January 1995 with less than or equal to 12 months between the dates of their last seronegative and first seropositive test result and with first follow up visit in the six months after seroconversion and at least 12 months' follow up. Patients were grouped according to the date of seroconversion. Main outcome measures: Time to CD4 cell count of < 500, 400, and 200 x 10(6) cells/l and clinical outcome defining AIDS; variation in cell count per day between consecutive visits, and ratio between this variation and time from estimated date of seroconversion at each visit. Results: The groups were similar in age, number with acute primary HIV infection, CD4 cell count at intake, and cell count at the beginning of antiretroviral treatment; they differed in sex ratio, risk factors for HIV,probability of CD4 cell decline to < 500, 400, and 200 x 10(6) cells/l, and risk of developing AIDS. Acute infection, seroconversion after December 1989, and serum beta 2 microglobulin > 296 nmol/l were independent predictors of poor clinical course. The speed of CD4 cell decline, expressed as cell variation divided by the number of days between consecutive visits, increased with more recent seroconversion (P = 0.02). Ratio between the speed of CD4 cell decline and time from estimated date of seroconversion at each visit was also higher in the patients who seroconverted after December 1989. Conclusions: The faster disease progression and the higher speed of CD4 cell decline at early stages in the patients with recently acquired HIV infection suggest changes in the clinical course of HIV infection.			Sinicco, A (corresponding author), UNIV TURIN,AMEDEO SAVOIA HOSP,DEPT MED & SURG SCI,INFECT DIS SECT,I-10149 TURIN,ITALY.							ADLEMAN LM, 1993, J ACQ IMMUN DEF SYND, V6, P144; Ball J. C., 1991, EFFECTIVENESS METHAD; CHENGMAYER C, 1988, SCIENCE, V240, P80, DOI 10.1126/science.2832945; CLOYD MW, 1990, VIROLOGY, V174, P103, DOI 10.1016/0042-6822(90)90059-Z; CONNOR RI, 1993, J VIROL, V67, P1772, DOI 10.1128/JVI.67.4.1772-1777.1993; Cox DR., 1984, ANAL SURVIVAL DATA; ERICE A, 1993, NEW ENGL J MED, V328, P1163, DOI 10.1056/NEJM199304223281605; FENYO EM, 1992, J VIROL, V66, P4414; Galai N, 1996, AM J EPIDEMIOL, V143, P278; GIORGI JV, 1990, CLIN IMMUNOL IMMUNOP, V55, P173, DOI 10.1016/0090-1229(90)90096-9; GORHAM ED, 1993, ARCH INTERN MED, V153, P869, DOI 10.1001/archinte.153.7.869; HEAGY W, 1991, J CLIN INVEST, V87, P1916, DOI 10.1172/JCI115217; HOMBERG SD, 1995, J ACQ IMMUN DEF SYND, V9, P291; Hu DJ, 1996, JAMA-J AM MED ASSOC, V275, P210, DOI 10.1001/jama.275.3.210; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; LEE TH, 1994, J ACQ IMMUN DEF SYND, V7, P381; LOVEDAY C, 1995, LANCET, V345, P820, DOI 10.1016/S0140-6736(95)92963-0; Lowinson J. H., 1992, COMPREHENSIVE TXB SU; MALONE JL, 1990, J ACQ IMMUN DEF SYND, V3, P144; OBRIEN TR, 1995, AM J EPIDEMIOL, V142, P636, DOI 10.1093/oxfordjournals.aje.a117687; REZZA G, 1994, HIV EPIDEMIOLOGY, P279; RICHMAN DD, 1994, J INFECT DIS, V169, P968, DOI 10.1093/infdis/169.5.968; SAAG MS, 1988, NATURE, V334, P440, DOI 10.1038/334440a0; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; SCHWARCZ SK, 1995, AM J EPIDEMIOL, V142, P314, DOI 10.1093/oxfordjournals.aje.a117637; SIEGRIST CA, 1994, LANCET, V344, P1771, DOI 10.1016/S0140-6736(94)92911-4; SINICCO A, 1993, J ACQ IMMUN DEF SYND, V6, P575; *SPSS, 1993, STAT PACK SOC SCI VE; *STATS, 1995, STAT 5 0; STCLAIR MH, 1993, J ACQ IMMUN DEF SYND, V6, P891; TAYLOR JMG, 1991, J ACQ IMMUN DEF SYND, V4, P69; WEISS PJ, 1992, J INFECT DIS, V166, P1149, DOI 10.1093/infdis/166.5.1149; [No title captured]	33	31	31	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 26	1997	314	7089					1232	1237		10.1136/bmj.314.7089.1232	http://dx.doi.org/10.1136/bmj.314.7089.1232			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW718	9154026	Green Published			2022-12-01	WOS:A1997WW71800017
J	Ackerman, SL; Kozak, LP; Przyborski, SA; Rund, LA; Boyer, BB; Knowles, BB				Ackerman, SL; Kozak, LP; Przyborski, SA; Rund, LA; Boyer, BB; Knowles, BB			The mouse rostral cerebellar malformation gene encodes an UNC-5-like protein	NATURE			English	Article							C-ELEGANS; MIGRATIONS; EXPRESSION; MUTATION; UNC-6; AXONS	Migration of neurons from proliferative zones to their functional sites is fundamental to the normal development of the central nervous system(1,2). Mice homozyous for the spontaneous rostral cerebellar malformation mutation (rcm(s)) or a newly identified transgenic insertion allele (rcm(tg)) exhibit cerebellar and midbrain defects, apparently as a result of abnormal neuronal migration. Laminar structure abnormalities in lateral regions of the rostral cerebellar cortex have been described in homozygous rcm(5)-mice(3). We now demonstrate that the cerebellum of both rcm(5) and rcm(tg) homozygotes is smaller and has fewer folia than in the wild-type, ectopic cerebellar cells are present in midbrain regions by three days after birth, and there are abnormalities in postnatal cerebellar neuronal migration. We have cloned the rcm complementary DNA, which encodes a transmembrane receptor of the immunoglobulin superfamily. The sequence of the rcm protein (Rcm) is highly similar to that of UNC-5, a Caenorhabditis elegans protein that is essential for dorsal guidance of pioneer axons and for the movement of cells away from the netrin ligand, which is encoded by the unc-6 gene(4-7). As Rcm is a member of a newly described family of vertebrate homologues of UNC-5 which are netrin-binding proteins, our results indicate that UNC-5-like proteins may have a conserved function in mediating netrin-guided migrations(8).			Ackerman, SL (corresponding author), JACKSON LAB,600 MAIN ST,BAR HARBOR,ME 04609, USA.			Knowles, Barbara B./0000-0002-2597-5619; rund, laurie/0000-0003-0761-7196				AKAZAWA C, 1995, J BIOL CHEM, V270, P8730, DOI 10.1074/jbc.270.15.8730; BenArie N, 1996, HUM MOL GENET, V5, P1207, DOI 10.1093/hmg/5.9.1207; BOYER BB, 1991, MOL CELL BIOL, V11, P4147, DOI 10.1128/MCB.11.8.4147; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COWAN WM, 1981, DEV NERVOUS SYSTEM; HAMELIN M, 1993, NATURE, V364, P327, DOI 10.1038/364327a0; HATTEN ME, 1995, ANNU REV NEUROSCI, V18, P385, DOI 10.1146/annurev.ne.18.030195.002125; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; HUI CC, 1993, NAT GENET, V3, P241, DOI 10.1038/ng0393-241; JOHNSON KR, 1992, GENOMICS, V12, P503, DOI 10.1016/0888-7543(92)90441-T; KLEIN P, 1985, BIOCHIM BIOPHYS ACTA, V815, P468, DOI 10.1016/0005-2736(85)90375-X; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANE PW, 1992, J HERED, V83, P315, DOI 10.1093/oxfordjournals.jhered.a111221; Leonardo ED, 1997, NATURE, V386, P833, DOI 10.1038/386833a0; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; LIVESEY FJ, IN PRESS MOL CELL NE; Sambrook J., 1989, MOL CLONING LAB MANU; Serafini T, 1996, CELL, V87, P1001, DOI 10.1016/S0092-8674(00)81795-X; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cellbio.6.1.247; STERNBERG N, 1994, GENET ANAL-BIOMOL E, V11, P171, DOI 10.1016/1050-3862(94)90038-8; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WADSWORTHH WG, 1996, NEURON, V16, P36; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834	24	295	307	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 24	1997	386	6627					838	842		10.1038/386838a0	http://dx.doi.org/10.1038/386838a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WV706	9126743				2022-12-01	WOS:A1997WV70600056
J	Ghahramani, Z; Wolpert, DM				Ghahramani, Z; Wolpert, DM			Modular decomposition in visuomotor learning	NATURE			English	Article							MOTOR CONTROL; REPRESENTATIONS; ADAPTATION; DIRECTION; MOVEMENT	The principle of 'divide-and-conquer' the decomposition of a complex task into simpler subtasks each learned by a separate module, has been proposed as a computational strategy during learning(1-3). We explore the possibility that the human motor system uses such a modular decomposition strategy to learn the visuomotor map, the relationship between visual inputs and motor outputs, Using a virtual reality system, subjects were exposed to opposite prism-like visuomotor remappings-discrepancies between actual and visually perceived hand locations-for movements starting from two distinct locations, Despite this conflicting pairing between visual and motor space, subjects learned the two starting-point-dependent visuomotor mappings and the generalization of this learning to intermediate starting locations demonstrated an interpolation of the two learned maps. This interpolation was a weighted average of the two learned visuomotor mappings, with the weighting sigmoidally dependent on starting location, a prediction made by a computational model of modular learning known as the ''mixture of experts'''. These results provide evidence that the brain may employ a modular decomposition strategy during learning.	MIT,DEPT BRAIN & COGNIT SCI,CAMBRIDGE,MA 02139; INST NEUROL,SOBELL DEPT NEUROPHYSIOL,LONDON WC1N 3BG,ENGLAND	Massachusetts Institute of Technology (MIT); University of London; University College London				Wolpert, Daniel/0000-0003-2011-2790	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDERSEN RA, 1985, SCIENCE, V230, P456, DOI 10.1126/science.4048942; BAKER JF, 1987, EXP BRAIN RES, V69, P220; BEDFORD FL, 1989, J EXP PSYCHOL HUMAN, V15, P232, DOI 10.1037/0096-1523.15.2.232; BIZZI E, 1991, SCIENCE, V253, P287, DOI 10.1126/science.1857964; Bridle J. S., 1990, Neurocomputing, Algorithms, Architectures and Applications. Proceedings of the NATO Advanced Research Workshop, P227; CACCIATORE TW, 1994, ADV NEURAL INFORMATI, V6, P719; Clower DM, 1996, NATURE, V383, P618, DOI 10.1038/383618a0; Efron B., 1982, JACKKNIFE BOOTSTRAP; Gandolfo F, 1996, P NATL ACAD SCI USA, V93, P3843, DOI 10.1073/pnas.93.9.3843; GEORGOPOULOS AP, 1995, TRENDS NEUROSCI, V18, P506, DOI 10.1016/0166-2236(95)92775-L; GEORGOPOULOS AP, 1986, SCIENCE, V233, P1416, DOI 10.1126/science.3749885; Ghahramani Z, 1996, J NEUROSCI, V16, P7085; GRAYBIEL AM, 1994, SCIENCE, V265, P1826, DOI 10.1126/science.8091209; HAY JC, 1966, J EXP PSYCHOL, V72, P640, DOI 10.1037/h0023737; IMAMIZU H, 1995, J EXP PSYCHOL HUMAN, V21, P1174, DOI 10.1037/0096-1523.21.5.1174; JACOBS RA, 1991, COGNITIVE SCI, V15, P219, DOI 10.1207/s15516709cog1502_2; Jacobs RA, 1991, NEURAL COMPUT, V3, P79, DOI 10.1162/neco.1991.3.1.79; JORDAN MI, 1994, NEURAL COMPUT, V6, P181, DOI 10.1162/neco.1994.6.2.181; KALASKA JF, 1992, SCIENCE, V255, P1517, DOI 10.1126/science.1549781; Kohler I., 1951, OSTERREICHISCHE AKAD, V227, P1; KRAVITZ JH, 1972, PERCEPT PSYCHOPHYS, V11, P38, DOI 10.3758/BF03212680; KRAVITZ JH, 1972, PERCEPT PSYCHOPHYS, V12, P305, DOI 10.3758/BF03207210; Martin TA, 1996, BRAIN, V119, P1199, DOI 10.1093/brain/119.4.1199; MCGONIGLE BO, 1978, NATURE, V272, P364, DOI 10.1038/272364a0; SHELHAMER M, 1991, ANN NY ACAD SCI, V656, P889; SOECHTING JF, 1989, J NEUROPHYSIOL, V62, P582, DOI 10.1152/jn.1989.62.2.582; WELCH RB, 1993, PERCEPT PSYCHOPHYS, V54, P195, DOI 10.3758/BF03211756; WELCH RB, 1971, PERCEPT PSYCHOPHYS, V10, P90, DOI 10.3758/BF03214321; WOLPERT DM, 1995, SCIENCE, V269, P1880, DOI 10.1126/science.7569931; WOLPERT DM, 1995, EXP BRAIN RES, V103, P460	30	171	175	0	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 27	1997	386	6623					392	395		10.1038/386392a0	http://dx.doi.org/10.1038/386392a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WQ170	9121554				2022-12-01	WOS:A1997WQ17000063
J	Woo, K; Fraser, SE				Woo, K; Fraser, SE			Specification of the zebrafish nervous system by nonaxial signals	SCIENCE			English	Article							FIBROBLAST GROWTH-FACTOR; RETINOIC ACID CAUSES; ANTEROPOSTERIOR AXIS; XENOPUS EMBRYOS; MUTANT EMBRYOS; MOUSE EMBRYO; EXPRESSION; GENE; HINDBRAIN; INDUCTION	The organizer of the amphibian gastrula provides the neurectoderm with both neuralizing and posteriorizing (transforming) signals. In zebrafish, transplantations show that a spatially distinct transformer signal emanates from tissues other than the organizer. Cells of the germring (nonaxial mesendoderm) posteriorized forebrain progenitors when grafted nearby, resulting in an ectopic hindbrain-like structure; in contrast, cells of the organizer (axial mesendoderm) caused no posterior transformation, Local application of basic fibroblast growth factor, a candidate transformer in Xenopus, caused malformation but not hindbrain transformation in the forebrain, Thus, the zebrafish gastrula may integrate spatially distinct signals from the organizer and the germring to pattern the neural axis.	CALTECH, BECKMAN INST, DIV BIOL, PASADENA, CA 91125 USA; CALTECH, BECKMAN INST, BIOL IMAGING CTR, PASADENA, CA 91125 USA	California Institute of Technology; California Institute of Technology			Fraser, Scott/Y-3406-2019	Fraser, Scott/0000-0002-5377-0223				ALTABA AR, 1993, J NEUROBIOL, V24, P1276, DOI 10.1002/neu.480241004; ANG SL, 1994, CELL, V78, P561, DOI 10.1016/0092-8674(94)90522-3; Blader P, 1996, DEV GENES EVOL, V206, P3, DOI 10.1007/s004270050025; Blumberg B, 1997, DEVELOPMENT, V124, P373; Cox WG, 1995, DEVELOPMENT, V121, P4349; DAI ZS, 1995, J NEUROSCI, V15, P5466; DOMINGUEZ I, 1995, P NATL ACAD SCI USA, V92, P8498, DOI 10.1073/pnas.92.18.8498; DONIACH T, 1993, J NEUROBIOL, V24, P1256, DOI 10.1002/neu.480241003; Doniach T, 1995, CELL, V83, P1067, DOI 10.1016/0092-8674(95)90133-7; DURSTON AJ, 1989, NATURE, V340, P140, DOI 10.1038/340140a0; EYAL-GILADI H., 1954, ARCH BIOL [PARIS], V65, P179; GRIFFIN K, 1995, DEVELOPMENT, V121, P2983; HAMMERSCHMIDT M, 1993, DEVELOPMENT, V119, P1107; He X, 1997, SCIENCE, V275, P1652, DOI 10.1126/science.275.5306.1652; HOLDER N, 1991, DEVELOPMENT, V113, P1159; Hyatt GA, 1996, DEVELOPMENT, V122, P195; JOLY JS, 1993, DEVELOPMENT, V119, P1261; KELLY GM, 1995, DEVELOPMENT, V121, P1787; KELLY GM, 1995, DEV GENET, V17, P129, DOI 10.1002/dvg.1020170205; KELLY GM, 1993, DEV BIOL, V158, P113, DOI 10.1006/dbio.1993.1172; KELLY OG, 1995, TRENDS GENET, V11, P273, DOI 10.1016/S0168-9525(00)89074-5; KENGAKU M, 1995, DEVELOPMENT, V121, P3121; KESSLER DS, 1994, SCIENCE, V266, P596, DOI 10.1126/science.7939714; KRAUSS S, 1992, DEVELOPMENT, V116, P249; Kroll KL, 1996, DEVELOPMENT, V122, P3173; LAMB TM, 1995, DEVELOPMENT, V121, P3627; LI Y, 1994, WEINBERG MECH DEV, V48, P229; Mason I, 1996, CURR BIOL, V6, P672, DOI 10.1016/S0960-9822(09)00446-1; MCGREW LL, 1995, DEV BIOL, V172, P337, DOI 10.1006/dbio.1995.0027; Moon RT, 1997, TRENDS GENET, V13, P157, DOI 10.1016/S0168-9525(97)01093-7; NIEUWKOOP PD, 1952, J EXP ZOOL, V120, P1, DOI 10.1002/jez.1401200102; OXTOBY E, 1993, NUCLEIC ACIDS RES, V21, P1087, DOI 10.1093/nar/21.5.1087; PAPALOPULU N, 1991, DEVELOPMENT, V113, P1145; Psychoyos D, 1996, DEVELOPMENT, V122, P3263; Sagerstrom CG, 1996, DEVELOPMENT, V122, P1873; Sala M., 1955, Proceedings Akademie van Wetenschappen Amsterdam, V58C, P635; Sasai Y, 1997, DEV BIOL, V182, P5, DOI 10.1006/dbio.1996.8445; SAXEN L, 1992, PRIMARY EMBRYONIC IN; SCHULTEMERKER S, 1992, DEVELOPMENT, V116, P1021; SHARPE CR, 1991, NEURON, V7, P239, DOI 10.1016/0896-6273(91)90262-X; SHIH J, 1995, DEVELOPMENT, V121, P2755; Shih J, 1996, DEVELOPMENT, V122, P1313; Sive H, 1996, DEV DYNAM, V205, P265, DOI 10.1002/(SICI)1097-0177(199603)205:3<265::AID-AJA7>3.0.CO;2-G; SLACK JMW, 1992, DEVELOPMENT, V114, P285; Spemann H., 1938, EMBRYONIC DEV INDUCT; TAKADA S, 1994, GENE DEV, V8, P174, DOI 10.1101/gad.8.2.174; THISSE C, 1993, DEVELOPMENT, V119, P1203; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1; WOO K, 1995, DEVELOPMENT, V121, P2595; WOO K, 1995, DEV BIOL, V170, P764; WOO K, UNPUB; Yoshikawa Y, 1997, DEV BIOL, V183, P234, DOI 10.1006/dbio.1997.8502	52	118	119	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 11	1997	277	5323					254	257		10.1126/science.277.5323.254	http://dx.doi.org/10.1126/science.277.5323.254			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK418	9211857				2022-12-01	WOS:A1997XK41800050
J	Mellors, JW; Munoz, A; Giorgi, JV; Margolick, JB; Tassoni, CJ; Gupta, P; Kingsley, LA; Todd, JA; Saah, AJ; Detels, R; Phair, JP; Rinaldo, CR				Mellors, JW; Munoz, A; Giorgi, JV; Margolick, JB; Tassoni, CJ; Gupta, P; Kingsley, LA; Todd, JA; Saah, AJ; Detels, R; Phair, JP; Rinaldo, CR			Plasma viral load and CD4(+) lymphocytes as prognostic markers of HIV-1 infection	ANNALS OF INTERNAL MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; MULTICENTER AIDS COHORT; NATURAL-HISTORY; RNA; QUANTITATION	Background: The rate of disease progression among persons infected with human immunodeficiency virus type 1 (HIV-1) varies widely, and the relative prognostic value of markers of disease activity has not been defined. Objective: To compare clinical, serologic, cellular, and virologic markers for their ability to predict progression to the acquired immunodeficiency syndrome (AIDS) and death during a 10-year period. Design: Prospective, multicenter cohort study. Setting: Four university-based clinical centers participating in the Multicenter AIDS Cohort Study. Patients: 1604 men infected with HIV-1. Measurements: The markers compared were oral candidiasis (thrush) or fever; serum neopterin levels; serum beta(2)-microglobulin levels; number and percentage of CD3(+), CD4(+), and CD8(+) lymphocytes; and plasma viral load, which was measured as the concentration of HIV-1 RNA found using a sensitive branched-DNA signal-amplification assay. Results: Plasma viral load was the single best predictor of progression to AIDS and death, followed (in order of predictive strength) by CD4(+) lymphocyte count and serum neopterin levels, serum beta(2)-microglobulin levels, and thrush or fever. Plasma viral load discriminated risk at all levels of CD4(+) lymphocyte counts and predicted their subsequent rate of decline. Five risk categories were defined by plasma HIV-l RNA concentrations: 500 copies/mL or less, 501 to 3000 copies/mL, 3001 to 10 000 copies/mL, 10 001 to 30 000 copies/mL, and more than 30 000 copies/mL. Highly significant (P < 0.001) differences in the percentages of participants who progressed to AIDS within 6 years were seen in the five risk categories: 5.4%, 16.6%, 31.7%, 55.2%, and 80.0%, respectively. Highly significant (P < 0.001) differences in the percentages of participants who died of AIDS within 6 years were also seen in the five risk categories: 0.9%, 6.3%, 18.1%, 34.9%, and 69.5%, respectively. A regression tree incorporating both HIV-1 RNA measurements and CD4(+) lymphocyte counts provided better discrimination of outcome than did either marker alone; use of both variables defined categories of risk for AIDS within 6 yea rs that ranged from less than 2% to 98%. Conclusions: Plasma viral load strongly predicts the rate of decrease in CD4(+) lymphocyte count and progression to AIDS and death, but the prognosis of HIV-infected persons is more accurately defined by combined measurement of plasma HIV-1 RNA and CD4(+) lymphocytes.	JOHNS HOPKINS SCH PUBL HLTH, DEPT EPIDEMIOL, BALTIMORE, MD 21205 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, SCH PUBL HLTH, DEPT EPIDEMIOL, CTR HLTH SCI, LOS ANGELES, CA 90095 USA; CHIRON CORP, EMERYVILLE, CA 94608 USA; NORTHWESTERN UNIV, SCH MED, COMPREHENS AIDS CTR, CHICAGO, IL 60611 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; Novartis; Northwestern University	Mellors, JW (corresponding author), UNIV PITTSBURGH, GRAD SCH PUBL HLTH, 603 PARRAN HALL, 130 DESOTO ST, PITTSBURGH, PA 15261 USA.			Kingsley, Lawrence/0000-0002-7000-8556	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000722] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI035043, U01AI035042] Funding Source: NIH RePORTER; NCRR NIH HHS [5-MO1-RR-00722] Funding Source: Medline; NIAID NIH HHS [U01-AI-35042, UO1-AI-35043] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CIAMPI A, 1988, J CLIN EPIDEMIOL, V41, P737, DOI 10.1016/0895-4356(88)90160-6; DIGGLE PJ, 1994, ANAL LONGITUDINAL DA, P79; Efron B, 1993, INTRO BOOTSTRAP, V13, P170; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; GIORGI JV, 1990, CLIN IMMUNOL IMMUNOP, V55, P173, DOI 10.1016/0090-1229(90)90096-9; HENRARD DR, 1995, JAMA-J AM MED ASSOC, V274, P554, DOI 10.1001/jama.274.7.554; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HOLODNIY M, 1995, J CLIN MICROBIOL, V33, P1562, DOI 10.1128/JCM.33.6.1562-1566.1995; JURRIAANS S, 1994, VIROLOGY, V204, P223, DOI 10.1006/viro.1994.1526; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI, P10; KASLOW RA, 1987, AM J EPIDEMIOL, V126, P310, DOI 10.1093/aje/126.2.310; KIEVITS T, 1991, J VIROL METHODS, V35, P273, DOI 10.1016/0166-0934(91)90069-C; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; MULDER J, 1994, J CLIN MICROBIOL, V32, P292, DOI 10.1128/JCM.32.2.292-300.1994; Munoz A, 1996, STAT MED, V15, P2459, DOI 10.1002/(SICI)1097-0258(19961130)15:22<2459::AID-SIM464>3.0.CO;2-Q; OBrien TR, 1996, JAMA-J AM MED ASSOC, V276, P105, DOI 10.1001/jama.276.2.105; PACHL C, 1995, J ACQ IMMUN DEF SYND, V8, P446, DOI 10.1097/00042560-199504120-00003; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Pezzotti P, 1996, BRIT MED J, V313, P583; PHAIR J, 1992, J ACQ IMMUN DEF SYND, V5, P490; SHEPPARD HW, 1993, AIDS, V7, P1159, DOI 10.1097/00002030-199309000-00002; TODD J, 1995, J ACQ IMMUN DEF SYND, V10, pS35; TSOUKAS CM, 1994, CLIN MICROBIOL REV, V7, P14, DOI 10.1128/CMR.7.1.14-28.1994; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; [No title captured]	26	1548	1608	1	64	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1997	126	12					946	954		10.7326/0003-4819-126-12-199706150-00003	http://dx.doi.org/10.7326/0003-4819-126-12-199706150-00003			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XE549	9182471				2022-12-01	WOS:A1997XE54900006
J	Stoltzfus, RJ				Stoltzfus, RJ			Rethinking anaemia surveillance	LANCET			English	Editorial Material							IRON-DEFICIENCY; INFANT				Stoltzfus, RJ (corresponding author), JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, CTR HUMAN NUTR, 615 N WOLFE ST, BALTIMORE, MD 21205 USA.							Christian P, 1996, FASEB J, V10, P1417; COOK JD, 1986, BLOOD, V68, P803; Dreyfuss ML, 1996, FASEB J, V10, P4219; DREYFUSS ML, IN PRESS J NEPAL MED; FAO, 1992, WORLD FOOD SUPPL PRE, P1; *FAO WHO, 1992, 6 FAO WHO; FerroLuzzi A, 1995, WHO TECH REP SER, V854, P1; FISHER KD, 1985, AM J CLIN NUTR, V42, P1318; GILLESPIE S, 1991, CONTROLLING IRON DEF, P1; HAAS JD, 1989, AM J CLIN NUTR, V50, P703, DOI 10.1093/ajcn/50.3.703; MASON JB, 1984, NUTR SURVEILLANCE, P1; SCHOLL TO, 1992, AM J CLIN NUTR, V55, P985, DOI 10.1093/ajcn/55.5.985; SHAPIRO S, 1980, AM J OBSTET GYNECOL, V136, P363, DOI 10.1016/0002-9378(80)90863-7; STOLTZFUS RJ, 1993, J NUTR, V123, P666, DOI 10.1093/jn/123.4.666; Stoltzfus RJ, 1997, AM J CLIN NUTR, V65, P153, DOI 10.1093/ajcn/65.1.153; Tyler RD, 1996, COMP HAEMATOL INT, V6, P1, DOI 10.1007/BF00368096; *UNICEF, 1995, STAT WORLDS CHILDR, P1; United Nations Administrative Committee on Coordination-Sub-Committee on Nutrition, 1992, 2 REP WORLD NUTR SIT, V1; VONSCHENCK H, 1986, CLIN CHEM, V32, P526; World Bank, 2013, WOR DEV REP, P1, DOI 10.1596/978-0-8213-9575-2; Yip Ray, 1996, P31; Zhou LM, 1997, FASEB J, V11, P3770	22	59	60	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 14	1997	349	9067					1764	1766		10.1016/S0140-6736(96)12355-2	http://dx.doi.org/10.1016/S0140-6736(96)12355-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XE065	9193395	hybrid			2022-12-01	WOS:A1997XE06500044
J	Anderson, K; Moore, MJ				Anderson, K; Moore, MJ			Bimolecular exon ligation by the human spliceosome	SCIENCE			English	Article							PRE-MESSENGER-RNA; MAMMALIAN INTRONS; SPLICING INVITRO; SITE SELECTION; SEQUENCE; PRECURSORS; TRANS; ENHANCER; PROTEINS; LENGTH	Intron excision is an essential step in eukaryotic gene expression, but the molecular mechanisms by which the spliceosome accurately identifies splice sites in nuclear precursors to messenger RNAs (pre-mRNAs) are not well understood. A bimolecular assay for the second step of splicing has now revealed that exon ligation by the human spliceosome does not require covalent attachment of a 3' splice site to the branch site. Furthermore, accurate definition of the 3' splice site in this system is independent of either a covalently attached polypyrimidine tract or specific 3' exon sequences. Rather, in this system 3' splice site selection apparently occurs with a 5' --> 3' directionality.	BRANDEIS UNIV, DEPT BIOCHEM, WM KECK INST CELLULAR VISUALIZAT, WALTHAM, MA 02254 USA	Brandeis University					NIGMS NIH HHS [GM53007] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053007] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON K, UNPUB; BRUZIK JP, 1992, NATURE, V360, P692, DOI 10.1038/360692a0; BRUZIK JP, 1995, P NATL ACAD SCI USA, V92, P7056, DOI 10.1073/pnas.92.15.7056; CHIARA MD, 1995, NATURE, V375, P510, DOI 10.1038/375510a0; FRENDEWEY D, 1985, CELL, V42, P355, DOI 10.1016/S0092-8674(85)80131-8; FU XD, 1995, RNA, V1, P663; FURDON PJ, 1988, MOL CELL BIOL, V8, P860, DOI 10.1128/MCB.8.2.860; GHETTI A, 1995, P NATL ACAD SCI USA, V92, P11461, DOI 10.1073/pnas.92.25.11461; GOZANI O, 1994, EMBO J, V13, P3356, DOI 10.1002/j.1460-2075.1994.tb06638.x; KONARSKA MM, 1985, CELL, V42, P165, DOI 10.1016/S0092-8674(85)80112-4; KONFORTI BB, 1995, RNA, V1, P815; KRAINER AR, 1984, CELL, V36, P993, DOI 10.1016/0092-8674(84)90049-7; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; Kramer A., 1995, PREMRNA PROCESSING, P35; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; MASCHHOFF KL, 1993, NUCLEIC ACIDS RES, V21, P5456, DOI 10.1093/nar/21.23.5456; MCKEOWN M, 1992, ANNU REV CELL BIOL, V8, P133, DOI 10.1146/annurev.cb.08.110192.001025; Moore M., 1993, RNA WORLD, P303; MOORE MJ, 1993, NATURE, V365, P364, DOI 10.1038/365364a0; MOORE MJ, 1992, SCIENCE, V256, P992, DOI 10.1126/science.1589782; NILSEN TW, 1992, INFECT AGENT DIS, V1, P212; NILSEN TW, 1995, MOL BIOCHEM PARASIT, V73, P1, DOI 10.1016/0166-6851(94)00107-X; NILSEN TW, 1994, CELL, V78, P1, DOI 10.1016/0092-8674(94)90563-0; NOBLE JCS, 1989, MOL CELL BIOL, V9, P2007, DOI 10.1128/MCB.9.5.2007; PADGETT RA, 1984, SCIENCE, V225, P898, DOI 10.1126/science.6206566; PARENT A, 1987, J BIOL CHEM, V262, P11284; Pasman Z, 1996, NUCLEIC ACIDS RES, V24, P1638, DOI 10.1093/nar/24.9.1638; PATTERSON B, 1991, CELL, V64, P181, DOI 10.1016/0092-8674(91)90219-O; RAMCHATESINGH J, 1995, MOL CELL BIOL, V15, P4898; REED R, 1989, GENE DEV, V3, P2113, DOI 10.1101/gad.3.12b.2113; Reed R, 1996, CURR OPIN GENET DEV, V6, P215, DOI 10.1016/S0959-437X(96)80053-0; ROSCIGNO RF, 1993, J BIOL CHEM, V268, P11222; RUSKIN B, 1984, CELL, V38, P317, DOI 10.1016/0092-8674(84)90553-1; RUSKIN B, 1985, NATURE, V317, P732, DOI 10.1038/317732a0; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; SMITH CWJ, 1989, NATURE, V342, P243, DOI 10.1038/342243a0; SMITH CWJ, 1993, MOL CELL BIOL, V13, P4939, DOI 10.1128/MCB.13.8.4939; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; SOLNICK D, 1985, CELL, V42, P157, DOI 10.1016/S0092-8674(85)80111-2; TURNBULLROSS AD, 1988, NUCLEIC ACIDS RES, V16, P395, DOI 10.1093/nar/16.2.395; UMEN JG, 1995, GENE DEV, V9, P855, DOI 10.1101/gad.9.7.855; Umen JG, 1995, RNA, V1, P869; Valcarcel J, 1996, TRENDS BIOCHEM SCI, V21, P296, DOI 10.1016/S0968-0004(96)10039-6	43	68	69	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 13	1997	276	5319					1712	1716		10.1126/science.276.5319.1712	http://dx.doi.org/10.1126/science.276.5319.1712			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XD947	9180084				2022-12-01	WOS:A1997XD94700047
J	Horne, JH; Meyer, T				Horne, JH; Meyer, T			Elementary calcium-release units induced by inositol trisphosphate	SCIENCE			English	Article							1,4,5-TRISPHOSPHATE; MUSCLE	The extent to which inositol 1,4,5-trisphosphate (InsP(3))-induced calcium signals are localized is a critical parameter for understanding the mechanism of effector activation, The spatial characteristics of InsP(3)-mediated calcium signals were determined by targeting a dextran-based calcium indicator to intracellular membranes through the in situ addition of a geranylgeranyl lipid group. Elementary calcium-release events observed with this indicator typically lasted less than 33 milliseconds, had diameters less than 2 micrometers, and were uncoupled from each other by the calcium buffer EGTA. Cellwide calcium transients are likely to result from synchronized triggering of such local release events, suggesting that calcium-dependent effector proteins could be selectively activated by localization near sites of local calcium release.	DUKE UNIV, MED CTR, DEPT CELL BIOL, DURHAM, NC 27710 USA	Duke University				Meyer, Tobias/0000-0003-4339-3804	NHLBI NIH HHS [P01-HL-47053] Funding Source: Medline; NIGMS NIH HHS [GM-51457, R01-GM-48113] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL047053] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048113] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BOOTMAN MD, 1995, CELL, V83, P675, DOI 10.1016/0092-8674(95)90179-5; CANNELL MB, 1995, SCIENCE, V268, P1045, DOI 10.1126/science.7754384; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; HIROSE K, 1994, NATURE, V372, P791; HORNE JH, 1995, BIOCHEMISTRY-US, V34, P12738, DOI 10.1021/bi00039a033; HORNE JH, UNPUB; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; Klein MG, 1996, NATURE, V379, P455, DOI 10.1038/379455a0; MEYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153, DOI 10.1146/annurev.bb.20.060191.001101; NELSON MT, 1995, SCIENCE, V270, P633, DOI 10.1126/science.270.5236.633; Oancea E, 1996, J BIOL CHEM, V271, P17253, DOI 10.1074/jbc.271.29.17253; STERN MD, 1992, CELL CALCIUM, V13, P183, DOI 10.1016/0143-4160(92)90046-U; TERUEL M, UNPUB; THOM P, 1993, CELL, V74, P661; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2396, DOI 10.1021/bi00552a018; WALKER JW, 1989, BIOCHEMISTRY-US, V28, P3272, DOI 10.1021/bi00434a023; YAO Y, 1995, J PHYSIOL-LONDON, V482, P533, DOI 10.1113/jphysiol.1995.sp020538; Yokoe E, 1996, NAT BIOTECHNOL, V14, P1252, DOI 10.1038/nbt1096-1252; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	21	85	86	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 13	1997	276	5319					1690	1693		10.1126/science.276.5319.1690	http://dx.doi.org/10.1126/science.276.5319.1690			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XD947	9180077				2022-12-01	WOS:A1997XD94700040
J	Shalaby, F; Ho, J; Stanford, WL; Fischer, KD; Schuh, AC; Schwartz, L; Bernstein, A; Rossant, J				Shalaby, F; Ho, J; Stanford, WL; Fischer, KD; Schuh, AC; Schwartz, L; Bernstein, A; Rossant, J			A requirement for Flk1 in primitive and definitive hematopoiesis and vasculogenesis	CELL			English	Article							RECEPTOR TYROSINE KINASE; ENDOTHELIAL GROWTH-FACTOR; YOLK-SAC; MOUSE EMBRYO; STEM-CELLS; PARAAORTIC SPLANCHNOPLEURA; VASCULAR ENDOTHELIUM; INVITRO DEVELOPMENT; ES CELLS; C-KIT	Mouse embryos lacking the receptor tyrosine kinase, Flk1, die without mature endothelial and hematopoietic cells. To investigate the role of Flk1 during vasculogenesis and hematopoiesis, we examined the developmental potential of Flk1(-/-) embryonic stem cells in chimeras. We show that Flk1 is required cell autonomously for endothelial development. Furthermore, Flk1(-/-) cells do not contribute to primitive hematopoiesis in chimeric yolk sacs or definitive hematopoiesis in adult chimeras and chimeric fetal livers. We also demonstrate that cells lacking Flk1 are unable to reach the correct location to form blood islands, suggesting that Flk1 is involved in the movement of cells from the posterior primitive streak to the yolk sac and, possibly, to the intraembryonic sites of early hematopoiesis.	MT SINAI HOSP, SAMUEL LUNENFELD RES INST, TORONTO, ON M5G 1X5, CANADA; UNIV TORONTO, DEPT MOL & MED GENET, TORONTO, ON, CANADA; UNIV TORONTO, DEPT MED, DEPT MED BIOPHYS, TORONTO, ON, CANADA; UNIV TORONTO, DEPT OBSTET & GYNECOL, TORONTO, ON, CANADA; TORONTO HOSP, DIV HEMATOL ONCOL, TORONTO, ON M5G 2C4, CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto			Ho, Jackie/AAP-1531-2021	Ho, Jackie/0000-0001-7115-1381; Stanford, William/0000-0002-5813-8016				Batard P, 1996, BLOOD, V87, P2212, DOI 10.1182/blood.V87.6.2212.bloodjournal8762212; Bautch VL, 1996, DEV DYNAM, V205, P1; BERGER CN, 1995, DEV BIOL, V170, P651, DOI 10.1006/dbio.1995.1244; BRUNKOW ME, 1995, GENOMICS, V25, P421, DOI 10.1016/0888-7543(95)80042-K; CUMANO A, 1993, P NATL ACAD SCI USA, V90, P6429, DOI 10.1073/pnas.90.14.6429; Cumano A, 1996, CELL, V86, P907, DOI 10.1016/S0092-8674(00)80166-X; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DIETERLENLIEVRE F, 1981, DEV BIOL, V88, P180, DOI 10.1016/0012-1606(81)90228-1; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; DUMONT DJ, 1992, ONCOGENE, V7, P1471; DUMONT DJ, 1995, DEV DYNAM, V203, P80, DOI 10.1002/aja.1002030109; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; DZIERZAK E, 1995, TRENDS GENET, V11, P359, DOI 10.1016/S0168-9525(00)89107-6; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; GARCIAPORRERO JA, 1995, ANAT EMBRYOL, V192, P427; GODIN I, 1995, P NATL ACAD SCI USA, V92, P773, DOI 10.1073/pnas.92.3.773; GODIN IE, 1993, NATURE, V364, P67, DOI 10.1038/364067a0; Hashiyama M, 1996, BLOOD, V87, P93; HUANG H, 1993, P NATL ACAD SCI USA, V90, P10110, DOI 10.1073/pnas.90.21.10110; IWAMA A, 1993, BIOCHEM BIOPH RES CO, V195, P301, DOI 10.1006/bbrc.1993.2045; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; Kennedy M, 1997, NATURE, V386, P488, DOI 10.1038/386488a0; LIU CP, 1991, DEVELOPMENT, V113, P1315; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; Medvinsky A, 1996, CELL, V86, P897, DOI 10.1016/S0092-8674(00)80165-8; MEDVINSKY AL, 1993, NATURE, V364, P64, DOI 10.1038/364064a0; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MOORE MAS, 1970, BRIT J HAEMATOL, V18, P279, DOI 10.1111/j.1365-2141.1970.tb01443.x; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; MULLER AM, 1994, IMMUNITY, V1, P291, DOI 10.1016/1074-7613(94)90081-7; Murray PDF, 1932, P R SOC LOND B-CONTA, V111, P497, DOI 10.1098/rspb.1932.0070; Nagy A., 1993, Gene targeting: a practical approach., P147; OGAWA M, 1993, DEVELOPMENT, V117, P1089; PARTANEN J, 1992, MOL CELL BIOL, V12, P1698, DOI 10.1128/MCB.12.4.1698; Partanen J, 1996, DEVELOPMENT, V122, P3013; PERAH G, 1977, J CELL PHYSIOL, V91, P193, DOI 10.1002/jcp.1040910205; Porcher C, 1996, CELL, V86, P47, DOI 10.1016/S0092-8674(00)80076-8; PURI MC, 1995, EMBO J, V14, P5884, DOI 10.1002/j.1460-2075.1995.tb00276.x; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; REITH AD, 1991, GENOME ANAL, V3, P105; RISAU W, 1991, PHARMACOL THERAPEUT, V51, P371, DOI 10.1016/0163-7258(91)90066-U; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; Sabin FR, 1920, CONTRIB EMBRYOL, V9, P215; Sanchez MJ, 1996, IMMUNITY, V5, P513, DOI 10.1016/S1074-7613(00)80267-8; SATO TN, 1993, P NATL ACAD SCI USA, V90, P9355, DOI 10.1073/pnas.90.20.9355; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; SCHMITT RM, 1991, GENE DEV, V5, P728, DOI 10.1101/gad.5.5.728; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHIBUYA M, 1990, ONCOGENE, V5, P519; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; SONODA T, 1983, DEV BIOL, V97, P89, DOI 10.1016/0012-1606(83)90066-0; SPRITZ RA, 1994, GENOMICS, V22, P431, DOI 10.1006/geno.1994.1405; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; SYMANN M, 1978, EXP HEMATOL, V6, P749; WAGNER RC, 1980, ADV MICROCIRCULAT, V9, P45; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; WILES MV, 1991, DEVELOPMENT, V111, P259; WONG PMC, 1986, P NATL ACAD SCI USA, V83, P3851, DOI 10.1073/pnas.83.11.3851; Wurst W., 1993, Gene targeting: a practical approach., P33; YAMAGUCHI TP, 1993, DEVELOPMENT, V118, P489	61	695	730	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 13	1997	89	6					981	990		10.1016/S0092-8674(00)80283-4	http://dx.doi.org/10.1016/S0092-8674(00)80283-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XE357	9200616	Bronze			2022-12-01	WOS:A1997XE35700018
J	Mathers, PH; Grinberg, A; Mahon, KA; Jamrich, M				Mathers, PH; Grinberg, A; Mahon, KA; Jamrich, M			The Rx homeobox gene is essential for vertebrate eye development	NATURE			English	Article							XENOPUS-LAEVIS; NERVOUS-SYSTEM; EYELESS GENE; EXPRESSION; DROSOPHILA; ANIRIDIA; RETINA; MOUSE; HEAD	Development of the vertebrate eye requires a series of steps including specification of the anterior neural plate, evagination of the optic vesicles from the ventral forebrain, and the cellular differentiation of the lens and retina. Homeobox-containing genes, especially the transcription regulator Pax6, play a critical role in vertebrate and invertebrate eye formation. Mutations in Pax6 function result in eye malformations known as Aniridia in humans and Small eye syndrome in mice(1-3). The Drosophila homologue of Pax6, eyeless, is also necessary for correct invertebrate eye development, and its misexpression leads to formation of ectopic eyes in Drosophila(4,5). Here we show that a conserved vertebrate homeobox gene, Rx, is essential for normal eye development, and that its misexpression has profound effects on eye morphology. Xenopus embryos injected with synthetic Rx RNA develop ectopic retinal tissue and display hyperproliferation in the neuroretina. Mouse embryos carrying a null allele of this gene do not form optic cups and so do not develop eyes. The Rx gene family plays an important role in the establishment and/or proliferation of retinal progenitor cells.	US FDA,DEV BIOL LAB,ROCKVILLE,MD 20852; NICHHD,LAB MAMMALIAN GENES & DEV,BETHESDA,MD 20892; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Baylor College of Medicine								BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; Campos-Ortega JA., 1997, EMBRYONIC DEV DROSOP; CONLON RA, 1992, DEVELOPMENT, V116, P357; GLASER T, 1994, NAT GENET, V7, P463, DOI 10.1038/ng0894-463; GRINDLEY JC, 1995, DEVELOPMENT, V121, P1433; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HEMMATIBRIVANLOU A, 1991, DEVELOPMENT, V111, P715; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; HOGAN BLM, 1986, J EMBRYOL EXP MORPH, V97, P95; HOLT CE, 1988, NEURON, V1, P15, DOI 10.1016/0896-6273(88)90205-X; HUANG S, 1993, J NEUROSCI, V13, P3193; JAMRICH M, 1989, DEVELOPMENT, V105, P779; MATHERS PH, 1995, DEV BIOL, V171, P641, DOI 10.1006/dbio.1995.1311; Nieuwkoop P.D., 1994, NORMAL TABLES XENOPU; NOLL M, 1993, CURR OPIN GENET DEV, V3, P595, DOI 10.1016/0959-437X(93)90095-7; QUIRING R, 1994, SCIENCE, V265, P785, DOI 10.1126/science.7914031; RICHTER K, 1988, P NATL ACAD SCI USA, V85, P8086, DOI 10.1073/pnas.85.21.8086; SAKAGUCHI DA, 1990, NEUR ABSTR, V16; SIVE HL, 1989, CELL, V58, P171, DOI 10.1016/0092-8674(89)90413-3; STIEMKE MM, 1995, DIFFERENTIATION, V58, P189, DOI 10.1046/j.1432-0436.1995.5830189.x; TON CCT, 1991, CELL, V67, P1059, DOI 10.1016/0092-8674(91)90284-6; WETTS R, 1988, SCIENCE, V239, P1142, DOI 10.1126/science.2449732; WETTS R, 1989, DEV BIOL, V136, P154; YOUNOSSIHARTENSTEIN A, 1993, ROUX ARCH DEV BIOL, V203, P60, DOI 10.1007/BF00539891	25	552	566	0	40	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 5	1997	387	6633					603	607		10.1038/42475	http://dx.doi.org/10.1038/42475			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XC522	9177348				2022-12-01	WOS:A1997XC52200056
J	Aguinaldo, AMA; Turbeville, JM; Linford, LS; Rivera, MC; Garey, JR; Raff, RA; Lake, JA				Aguinaldo, AMA; Turbeville, JM; Linford, LS; Rivera, MC; Garey, JR; Raff, RA; Lake, JA			Evidence for a clade of nematodes, arthropods and other moulting animals	NATURE			English	Article							EVOLUTIONARY TREES; PHYLOGENETIC ANALYSIS; DNA; SEQUENCES; METAZOA; ORIGIN	The arthropods constitute the most diverse animal group, but, despite their rich fossil record and a century of study, their phylogenetic relationships remain unclear(1). Taxa previously proposed to be sister groups to the arthropods include Annelida, Onychophora, Tardigrada and others, but hypotheses of phylogenetic relationships have been conflicting(2,3). For example, onychophorans, like arthropods, moult periodically, have an arthropod arrangement of haemocoel(1,4), and have been related to arthropods in morphological and mitochondrial DNA sequence analyses(4,5). Like annelids, they possess segmental nephridia and muscles that are a combination of smooth and obliquely striated fibres(6). Our phylogenetic analysis of 18S ribosomal DNA sequences indicates a close relationship between arthropods, nematodes and all other moulting phyla. The results suggest that ecdysis (moulting) arose once and support the idea of a new clade, Ecdysozoa, containing moulting animals: arthropods, tardigrades, onychophorans, nematodes, nematomorphs, kinorhynchs and priapulids. No support is found for a clade of segmented animals, the Articulata, uniting annelids with arthropods. The hypothesis that nematodes are related to arthropods has important implications for developmental genetic studies using as model systems the nematode Caenorhabditis elegans and the arthropod Drosophila melanogaster, which are generally held to be phylogenetically distant from each other.	UNIV CALIF LOS ANGELES, INST MOL BIOL, LOS ANGELES, CA 90095 USA; UNIV ARKANSAS, DEPT BIOL SCI, FAYETTEVILLE, AR 72701 USA; UNIV S FLORIDA, DEPT BIOL, TAMPA, FL 33620 USA; DUQUESNE UNIV, DEPT SCI BIOL, PITTSBURGH, PA 15282 USA; INDIANA UNIV, DEPT BIOL, BLOOMINGTON, IN 47405 USA; INDIANA UNIV, INDIANA MOL BIOL INST, BLOOMINGTON, IN 47405 USA	University of California System; University of California Los Angeles; University of Arkansas System; University of Arkansas Fayetteville; State University System of Florida; University of South Florida; Duquesne University; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington			Rivera, Maria/GYU-2150-2022; Garey, James/J-1062-2017	Garey, James/0000-0001-8205-5563				Balavoine G, 1997, CR ACAD SCI III-VIE, V320, P83, DOI 10.1016/S0764-4469(99)80090-0; BALLARD JWO, 1992, SCIENCE, V258, P1345, DOI 10.1126/science.1455227; BOORE JL, 1995, NATURE, V376, P163, DOI 10.1038/376163a0; Boudreaux H. B., 1979, ARTHROPOD PHYLOGENY; Brusca R.C., 1990, INVERTEBRATES; DEQUEIROZ K, 1990, SYST ZOOL, V39, P307, DOI 10.2307/2992353; EERNISSE DJ, 1992, SYST BIOL, V41, P305, DOI 10.1093/sysbio/41.3.305; Felsenstein J, 1996, MOL BIOL EVOL, V13, P93, DOI 10.1093/oxfordjournals.molbev.a025575; FIELD KG, 1988, SCIENCE, V239, P748, DOI 10.1126/science.3277277; Garey JR, 1996, INVERTEBR BIOL, V115, P79, DOI 10.2307/3226943; Gee H., 1996, BACKBONE VIEWS ORIGI; GOLDMAN N, 1993, J MOL EVOL, V37, P650; HALANYCH KM, 1995, SCIENCE, V267, P1641, DOI 10.1126/science.7886451; HILLIS DM, 1993, SYST BIOL, V42, P182, DOI 10.2307/2992540; LAKE JA, 1991, MOL BIOL EVOL, V8, P378; LAKE JA, 1995, P NATL ACAD SCI USA, V92, P9662, DOI 10.1073/pnas.92.21.9662; LAKE JA, 1994, P NATL ACAD SCI USA, V91, P1455, DOI 10.1073/pnas.91.4.1455; LAKE JA, 1990, P NATL ACAD SCI USA, V87, P763, DOI 10.1073/pnas.87.2.763; LOCKHART PJ, 1994, MOL BIOL EVOL, V11, P605; MORRIS SC, 1993, NATURE, V361, P219, DOI 10.1038/361219a0; Nielsen C., 1995, ANIMAL EVOLUTION INT; PATTERSON C, 1989, INT CONGR SER, V824, P471; RAFF RA, 1994, ANNU REV ECOL SYST, V25, P351, DOI 10.1146/annurev.es.25.110194.002031; Ruppert EE, 1991, MICROSCOPIC ANATOMY, V4, P1; STEWART CB, 1993, NATURE, V361, P603, DOI 10.1038/361603a0; VALENTINE JW, 1989, P NATL ACAD SCI USA, V86, P2272, DOI 10.1073/pnas.86.7.2272; Wallace RL, 1996, INVERTEBR BIOL, V115, P104, DOI 10.2307/3227041; WEYGOLDT P, 1986, Z ZOOL SYST EVOL, V24, P19; WINNEPENNINCKX B, 1995, MOL BIOL EVOL, V12, P1132; WRIGHT KA, 1991, MICROSCOPIC ANATOMY, V4, P111	30	1248	1285	2	173	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 29	1997	387	6632					489	493		10.1038/387489a0	http://dx.doi.org/10.1038/387489a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XB479	9168109				2022-12-01	WOS:A1997XB47900045
J	Cherry, JM; Ball, C; Weng, S; Juvik, G; Schmidt, R; Adler, C; Dunn, B; Dwight, S; Riles, L; Mortimer, RK; Botstein, D				Cherry, JM; Ball, C; Weng, S; Juvik, G; Schmidt, R; Adler, C; Dunn, B; Dwight, S; Riles, L; Mortimer, RK; Botstein, D			Genetic and physical maps of Saccharomyces cerevisiae	NATURE			English	Article								Genetic and physical maps for the 16 chromosomes of Saccharomyces cerevisiae are presented. The genetic map is the result of 40 years of genetic analysis. The physical map was produced from the results of an international systematic sequencing effort. The data for the maps are accessible electronically from the Saccharomyces Genome Database (SGD: http://genome-www.stanford. edu/Saccharomyces/).	UNIV CALIF BERKELEY,DEPT MOL & CELL BIOL,BERKELEY,CA 94720; WASHINGTON UNIV,SCH MED,DEPT GENET,ST LOUIS,MO 63110	University of California System; University of California Berkeley; Washington University (WUSTL)	Cherry, JM (corresponding author), STANFORD UNIV,SCH MED,DEPT GENET,STANFORD,CA 94305, USA.			Cherry, J. Michael/0000-0001-9163-5180; Dunn, Barbara/0000-0002-7041-0035	NHGRI NIH HHS [P41 HG001315, P41 HG001315-06] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P41HG001315] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		HAWTHORNE DC, 1960, GENETICS, V45, P1085; HAWTHORNE DC, 1968, GENETICS, V60, P735; KING JS, 1991, GENETICS, V129, P597; Mortimer R K, 1975, Methods Cell Biol, V11, P221, DOI 10.1016/S0091-679X(08)60325-8; MORTIMER RK, 1973, GENETICS, V74, P33; MORTIMER RK, 1985, MICROBIOL REV, V49, P181, DOI 10.1128/MMBR.49.3.181-213.1985; MORTIMER RK, 1992, YEAST, V8, P817, DOI 10.1002/yea.320081002; MORTIMER RK, 1980, MICROBIOL REV, V44, P519, DOI 10.1128/MMBR.44.4.519-571.1980; MORTIMER RK, 1966, GENETICS, V53, P165; MORTIMER RK, 1989, YEAST, V5, P321, DOI 10.1002/yea.320050503; MORTIMER RK, 1984, MICROBIOL SCI, V1, P145; Mortimer RK, 1982, MOL BIOL YEAST SACCH, P639; RILES L, 1993, GENETICS, V134, P81	13	323	332	4	30	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 29	1997	387	6632		S			67	73		10.1038/387s067	http://dx.doi.org/10.1038/387s067			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XB546	9169866				2022-12-01	WOS:A1997XB54600006
J	Laurila, A; Bloigu, A; Nayha, S; Hassi, J; Leinonen, M; Saikku, P				Laurila, A; Bloigu, A; Nayha, S; Hassi, J; Leinonen, M; Saikku, P			Chlamydia pneumoniae antibodies and serum lipids in Finnish men: Cross sectional study	BRITISH MEDICAL JOURNAL			English	Article									REG INST OCCUPAT HLTH,FIN-90220 OULU,FINLAND		Laurila, A (corresponding author), NATL PUBL HLTH INST,POB 310,FIN-90101 OULU,FINLAND.							GALLIN JI, 1969, NEW ENGL J MED, V281, P1081, DOI 10.1056/NEJM196911132812001; NAYHA S, 1993, SOCIAL INS I PUBLICA; PATEL P, 1995, BRIT MED J, V311, P711, DOI 10.1136/bmj.311.7007.711; Ward ME, 1995, APMIS, V103, P769, DOI 10.1111/j.1699-0463.1995.tb01436.x	4	41	42	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 17	1997	314	7092					1456	1457		10.1136/bmj.314.7092.1456	http://dx.doi.org/10.1136/bmj.314.7092.1456			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XA202	9167563	Green Published			2022-12-01	WOS:A1997XA20200024
J	Shen, J; Bronson, RT; Chen, DF; Xia, WM; Selkoe, DJ; Tonegawa, S				Shen, J; Bronson, RT; Chen, DF; Xia, WM; Selkoe, DJ; Tonegawa, S			Skeletal and CNS defects in Presenilin-1-deficient mice	CELL			English	Article							FAMILIAL ALZHEIMERS-DISEASE; MISSENSE MUTATIONS; GENE; SOMITES; NOTCH1	Presenilin-1 (PS1) is the major gene responsible for early-onset familiar Alzheimer's disease (FAD). To understand the normal function of PS1, we have generated a targeted null mutation in the murine homolog of PS1. We report that PS1(-/-) mice die shortly after natural birth or Caesarean section. The skeleton of homozygous mutants is grossly deformed. Hemorrhages occur in the CNS of PS1 null mutants with varying location, severity, and time of onset. The ventricular zone of PS1(-/-) brains is markedly thinner by embryonic day 14.5, indicating an impairment in neurogenesis. Bilateral cerebral cavitation caused by massive neuronal loss in specific subregions of the mutant brain is prominent after embryonic day 16.5. These results show that PS1 is required for proper formation of the axial skeleton, normal neurogenesis, and neuronal survival.	MIT,CTR CANC RES,CTR LEARNING & MEMORY,HOWARD HUGHES MED INST,DEPT BIOL,CAMBRIDGE,MA 02139; TUFTS UNIV,SCH MED,DEPT PATHOL,SCH VET MED,BOSTON,MA 02111; HARVARD UNIV,SCH MED,BRIGHAM & WOMENS HOSP,DEPT NEUROL,CTR NEUROL DIS,BOSTON,MA 02115	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Tufts University; Harvard University; Brigham & Women's Hospital; Harvard Medical School			xia, weiming/E-5465-2016	xia, weiming/0000-0002-7463-3295	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032925] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG006173, R37AG006173] Funding Source: NIH RePORTER; NIA NIH HHS [AG06173] Funding Source: Medline; NINDS NIH HHS [NS32925] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; BAUMEISTER R, 1997, IN PRESS GENES FUNCT; Berezovska O, 1997, J NEUROPATH EXP NEUR, V56, P40, DOI 10.1097/00005072-199701000-00004; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Burgess R, 1996, NATURE, V384, P570, DOI 10.1038/384570a0; BURGESS R, 1995, DEV BIOL, V168, P296, DOI 10.1006/dbio.1995.1081; CAMPION D, 1995, HUM MOL GENET, V4, P2373, DOI 10.1093/hmg/4.12.2373; CHAPMAN J, 1995, LANCET, V346, P1040, DOI 10.1016/S0140-6736(95)91723-3; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; CONLON RA, 1995, DEVELOPMENT, V121, P1533; CRUTS M, 1995, HUM MOL GENET, V4, P2363, DOI 10.1093/hmg/4.12.2363; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; *GROUP ALZH DIS CO, 1995, NAT GENET, V11, P219; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; Lee MK, 1996, J NEUROSCI, V16, P7513, DOI 10.1523/jneurosci.16-23-07513.1996; Lemere CA, 1996, NAT MED, V2, P1146, DOI 10.1038/nm1096-1146; Levitan D, 1996, P NATL ACAD SCI USA, V93, P14940, DOI 10.1073/pnas.93.25.14940; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; PerezTur J, 1995, NEUROREPORT, V7, P297; Podlisny MB, 1997, NEUROBIOL DIS, V3, P325, DOI 10.1006/nbdi.1997.0129; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Sambrook J., 1989, MOL CLONING LAB MANU; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SLUNT HH, 1995, AMYLOID, V2, P188, DOI 10.3109/13506129509036925; SUSUKI T, 1996, BIOCHEM BIOPH RES CO, V219, P708; SWIATEK PJ, 1994, GENE DEV, V8, P707, DOI 10.1101/gad.8.6.707; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Vito P, 1996, SCIENCE, V271, P521, DOI 10.1126/science.271.5248.521; Walter J, 1996, MOL MED, V2, P673, DOI 10.1007/BF03401652; WASCO W, 1995, NAT MED, V1, P848, DOI 10.1038/nm0995-848a; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; Xia WM, 1997, J BIOL CHEM, V272, P7977, DOI 10.1074/jbc.272.12.7977	36	815	846	2	28	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 16	1997	89	4					629	639		10.1016/S0092-8674(00)80244-5	http://dx.doi.org/10.1016/S0092-8674(00)80244-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WZ323	9160754	Bronze			2022-12-01	WOS:A1997WZ32300016
J	Nicolaou, KC; Winssinger, N; Pastor, J; Ninkovic, S; Sarabia, F; He, Y; Vourloumis, D; Yang, Z; Li, T; Giannakakou, P; Hamel, E				Nicolaou, KC; Winssinger, N; Pastor, J; Ninkovic, S; Sarabia, F; He, Y; Vourloumis, D; Yang, Z; Li, T; Giannakakou, P; Hamel, E			Synthesis of epothilones A and B in solid and solution phase	NATURE			English	Article							TAXOL	Epothilones A and B, two compounds that have been recently isolated(1) from myxobacterium Sorangium cellulosum strain 90, have generated intense interest(2-16) among chemists, biologists and clinicians erring to the structural complexity, unusual mechanism of interaction with microtubules and anticancer potential of these molecules. Like taxol* (refs 17, 18), they exhibit cytotoxicity against tumour cells by inducing microtubule assembly and stabilization(3,4), even in taxol-resistant cell lines. Following the structural elucidation of these molecules by X-ray crystallography in 1996(1), several syntheses of epothilones A (refs 12-16) and B (ref. 19) have been reported, indicative of the potential importance of these molecules in the cancer field. Here we report the first solid-phase synthesis of epothilone A, the total synthesis of epothilone B, and the generation of a small epothilone library. The solid-phase synthesis applied here to epothilone A could open up new possibilities in natural-product synthesis and, together with solution-phase synthesis of other epothilones, paves the way for the generation of large combinatorial libraries of these important molecules for biological screening.	Scripps Res Inst, SKAGGS INST CHEM BIOL, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, DEPT CHEM & BIOCHEM, LA JOLLA, CA 92093 USA; NCI, MED BRANCH, DCS, NIH, BETHESDA, MD 20892 USA; NCI, LAB DRUG DISCOVERY RES & DEV,DEV THERAPEUT PROGRAM, DCTDC,FREDERICK CANC RES & DEV CTR, FREDERICK, MD 21702 USA	Scripps Research Institute; University of California System; University of California San Diego; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Nicolaou, KC (corresponding author), Scripps Res Inst, DEPT CHEM, 10550 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		Sarabia, Francisco/M-1845-2014; Fernandez, Joaquin Pastor/I-4567-2015; Yang, Zhen/J-6306-2015; Li, Tianhu/G-3531-2010; Yang, Zhen/GWQ-4960-2022; Winssinger, Nicolas/B-6710-2017	Sarabia, Francisco/0000-0002-5149-3576; Fernandez, Joaquin Pastor/0000-0003-0553-8021; Yang, Zhen/0000-0001-8036-934X; Winssinger, Nicolas/0000-0003-1636-7766				Balog A, 1996, ANGEW CHEM INT EDIT, V35, P2801, DOI 10.1002/anie.199628011; BERNARD M, 1983, J ORG CHEM, V48, P326, DOI 10.1021/jo00151a010; Bertinato P, 1996, J ORG CHEM, V61, P8000, DOI 10.1021/jo961674o; BOLLAG DM, 1995, CANCER RES, V55, P2325; Claus E, 1997, TETRAHEDRON LETT, V38, P1359, DOI 10.1016/S0040-4039(96)02493-8; Gabriel T, 1997, TETRAHEDRON LETT, V38, P1363, DOI 10.1016/S0040-4039(96)02494-X; GIANNAKAKOU P, IN PRESS J BIOL CHEM; GREVER MR, 1992, SEMIN ONCOL, V19, P622; GRUBBS RH, 1995, ACCOUNTS CHEM RES, V28, P446, DOI 10.1021/ar00059a002; Hofle GH, 1996, ANGEW CHEM INT EDIT, V35, P1567, DOI 10.1002/anie.199615671; Kowalski RJ, 1997, J BIOL CHEM, V272, P2534; Lin CM, 1996, CANCER CHEMOTH PHARM, V38, P136, DOI 10.1007/s002800050461; Meng DF, 1996, J ORG CHEM, V61, P7998, DOI 10.1021/jo961673w; Meng DF, 1997, J AM CHEM SOC, V119, P2733, DOI 10.1021/ja964275j; MILLER JF, 1997, 213 AM CHEM SOC NATL; Miller SJ, 1996, J AM CHEM SOC, V118, P9606, DOI 10.1021/ja961626l; MILLER SJ, 1997, J AM CHEM SOC; Mulzer J, 1996, TETRAHEDRON LETT, V37, P9179, DOI 10.1016/S0040-4039(96)02156-9; Nicolaou KC, 1996, ANGEW CHEM INT EDIT, V35, P2399, DOI 10.1002/anie.199623991; Nicolaou KC, 1997, ANGEW CHEM INT EDIT, V36, P525, DOI 10.1002/anie.199705251; NICOLAOU KC, 1994, ANGEW CHEM INT EDIT, V33, P15, DOI 10.1002/anie.199400151; ROGAN AM, 1984, SCIENCE, V224, P994, DOI 10.1126/science.6372095; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; Schinzer D, 1996, CHEM-EUR J, V2, P1477, DOI 10.1002/chem.19960021121; Schinzer D, 1997, ANGEW CHEM INT EDIT, V36, P523, DOI 10.1002/anie.199705231; Schuster M, 1996, ANGEW CHEM INT EDIT, V35, P1979, DOI 10.1002/anie.199619791; Su DS, 1997, ANGEW CHEM INT EDIT, V36, P757, DOI 10.1002/anie.199707571; vanMaarseveen JH, 1996, TETRAHEDRON LETT, V37, P8249, DOI 10.1016/0040-4039(96)01881-3; Xu ZM, 1996, J AM CHEM SOC, V118, P10926, DOI 10.1021/ja9626603; YANG D, 1995, J ORG CHEM, V60, P3887, DOI 10.1021/jo00117a046; Yang Z, 1997, ANGEW CHEM INT EDIT, V36, P166, DOI 10.1002/anie.199701661	31	365	438	3	69	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 15	1997	387	6630					268	272		10.1038/387268a0	http://dx.doi.org/10.1038/387268a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC); Current Chemical Reactions (CCR-EXPANDED)	Science & Technology - Other Topics	WZ167	9153390				2022-12-01	WOS:A1997WZ16700048
J	Sawicki, G; Salas, E; Murat, J; MisztaLane, H; Radomski, MW				Sawicki, G; Salas, E; Murat, J; MisztaLane, H; Radomski, MW			Release of gelatinase A during platelet activation mediates aggregation	NATURE			English	Article							EXTRACELLULAR-MATRIX; ENDOTHELIAL-CELLS; TISSUE INHIBITOR; METALLOPROTEINASES; COLLAGENASE; EXPRESSION; FAMILY; TIMP-2	Blood platelets limit blood loss at sites of vascular injury by forming a mechanical plug. They are also involved in thrombosis, atherosclerosis, inflammation and metastasis. Platelet activation is essential for these physiological and pathological reactions and depends upon their adhesion to the vessel wall and attachment to each other in the aggregation process. The two known pathways of aggregation are mediated by the release of endoperoxides/thromboxane A(2) and ADP(1-3) which amplify platelet aggregation. Here we report the identification of a new pathway of aggregation which is mediated by the release of a metalloproteinase enzyme, gelatinase A.	UNIV ALBERTA, DEPT PHARMACOL, EDMONTON, AB T6G 2H7, CANADA; UNIV ALBERTA, DEPT OBSTET & GYNAECOL, EDMONTON, AB T6G 2H7, CANADA	University of Alberta; University of Alberta			Radomski, Marek W/C-5195-2014; Salas, Eduardo/AAL-4836-2020	Salas, Eduardo/0000-0002-6837-2471				BIRKEDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728, DOI 10.1016/0955-0674(95)80116-2; CHESNEY CM, 1974, J CLIN INVEST, V53, P1647, DOI 10.1172/JCI107715; COLMAN RW, 1990, FASEB J, V4, P1425, DOI 10.1096/fasebj.4.5.2407587; CRUWYS SC, 1990, BRIT J PHARMACOL, V100, P631, DOI 10.1111/j.1476-5381.1990.tb15858.x; FEINMAN RD, 1985, PLATELETS PHYSL PHAR, P429; Goetzl EJ, 1996, J IMMUNOL, V156, P1; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; HENNEY AM, 1991, P NATL ACAD SCI USA, V88, P8154, DOI 10.1073/pnas.88.18.8154; HERRON GS, 1986, J BIOL CHEM, V261, P2810; HEUSSEN C, 1980, ANAL BIOCHEM, V102, P196, DOI 10.1016/0003-2697(80)90338-3; JOSEPH R, 1989, THROMB RES, V53, P485, DOI 10.1016/0049-3848(89)90203-X; Komoszynski M, 1996, BBA-MOL CELL RES, V1310, P233, DOI 10.1016/0167-4889(95)00135-2; LEVEN RM, 1990, EXP HEMATOL, V18, P743; LIBBY P, 1995, CIRCULATION, V91, P2844, DOI 10.1161/01.CIR.91.11.2844; MCEVER RP, 1991, THROMB HAEMOSTASIS, V66, P80; PETREQUIN PR, 1987, BLOOD, V69, P605; RADOMSKI M, 1983, THROMB RES, V30, P383, DOI 10.1016/0049-3848(83)90230-X; RADOMSKI MW, 1995, NITRIC OXIDE MODULAT, P43; RAY JM, 1994, EUR RESPIR J, V7, P2062; Salvesen G, 1989, PROTEOLYTIC ENZYMES, P83; SARGEANT P, 1994, PHARMACOL THERAPEUT, V64, P395, DOI 10.1016/0163-7258(94)90019-1; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SELTZER JL, 1994, EXP CELL RES, V213, P365, DOI 10.1006/excr.1994.1211; SIESS W, 1989, PHYSIOL REV, V69, P58, DOI 10.1152/physrev.1989.69.1.58; SOUTHGATE KM, 1992, BIOCHEM J, V288, P93, DOI 10.1042/bj2880093; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; WOESSNER JF, 1994, ANN NY ACAD SCI, V732, P11; ZEMBOWICZ A, 1995, J CLIN INVEST, V96, P1688, DOI 10.1172/JCI118211	29	285	295	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 10	1997	386	6625					616	619		10.1038/386616a0	http://dx.doi.org/10.1038/386616a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WT273	9121586				2022-12-01	WOS:A1997WT27300061
J	Cumming, RG; Mitchell, P; Leeder, SR				Cumming, RG; Mitchell, P; Leeder, SR			Use of inhaled corticosteroids and the risk of cataracts	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BEAVER DAM EYE; STEROID-THERAPY; LENS OPACITIES; ASTHMA; BECLOMETHASONE; ASSOCIATION; PREVALENCE; CHILDREN; AEROSOL	Background The use of systemic corticosteroids is a risk factor for the development of posterior subcapsular cataracts, but the association between inhaled corticosteroids and cataracts is uncertain. Methods We conducted a population-based, cross-sectional study of vision and common eye diseases in an urban area of the Blue Mountains, near Sydney, Australia. We recruited 3654 people 49 to 97 years of age; the participation rare was 82 percent. We collected information by questionnaire on potential risk factors for cataracts, including the current or prior use of inhaled corticosteroids (beclomethasone or budesonide). Photographs of the subjects' lenses were graded, without information on the subjects, to determine the presence and severity of cortical, nuclear, and posterior subcapsular cataracts. Results Three hundred seventy subjects reported using inhaled corticosteroids, 164 currently and 206 previously. Among these subjects, after adjustment for age and sex, there was a higher prevalence of nuclear cataracts (relative prevalence, 1.5; 95 percent confidence interval, 1.2 to 1.9) and posterior subcapsular cataracts (relative prevalence, 1.9; 95 percent confidence interval, 1.3 to 2.8) than among the subjects with no inhaled-corticosteroid use, but the prevalence of cortical cataracts was nor significantly higher (relative prevalence, 1.1; 95 percent confidence interval, 0.9 to 1.3). Higher cumulative lifetime doses of beclomethasone were associated with higher risks of posterior subcapsular cataracts (P for trend <0.001); the highest prevalence (27 percent) was found in subjects whose lifetime dose was over 2000 mg (relative prevalence, 5.5). Adjusting for the use of systemic corticosteroids and other potential confounders had little effect on the magnitude of the associations. The associations with posterior subcapsular cataracts, but not those with nuclear cataracts, were less marked when the analyses were restricted to subjects who had never used systemic corticosteroids. Conclusions The use of inhaled corticosteroids is associated with the development of posterior subcapsular and nuclear cataracts. (C) 1997, Massachusetts Medical Society.	UNIV SYDNEY, DEPT OPHTHALMOL, SYDNEY, NSW 2006, AUSTRALIA; WESTMEAD HOSP, SYDNEY, NSW, AUSTRALIA	University of Sydney; University of Sydney	Cumming, RG (corresponding author), UNIV SYDNEY, DEPT PUBL HLTH & COMMUNITY MED, BLDG A27, SYDNEY, NSW 2006, AUSTRALIA.		Cumming, Robert G/R-1548-2016	Cumming, Robert G/0000-0002-0261-6103				ABUEKTEISH F, 1995, THORAX, V50, P674, DOI 10.1136/thx.50.6.674; ADAMSONS I, 1991, ARCH OPHTHALMOL-CHIC, V109, P993, DOI 10.1001/archopht.1991.01080070105046; ALLEN MB, 1989, BRIT MED J, V299, P432, DOI 10.1136/bmj.299.6696.432; ARMSTRONG BG, 1989, AM J EPIDEMIOL, V129, P191, DOI 10.1093/oxfordjournals.aje.a115109; Attebo K, 1996, OPHTHALMOLOGY, V103, P357; BLACK RL, 1960, JAMA-J AM MED ASSOC, V174, P166, DOI 10.1001/jama.1960.63030020005014; Hodge WG, 1995, EPIDEMIOL REV, V17, P336, DOI 10.1093/oxfordjournals.epirev.a036197; IP M, 1994, CHEST, V105, P1722, DOI 10.1378/chest.105.6.1722; KARIM AKA, 1989, EXP EYE RES, V48, P215, DOI 10.1016/S0014-4835(89)80071-5; KEWLEY GD, 1980, AUST PAEDIATR J, V16, P117; KLEIN BEK, 1990, OPHTHALMOLOGY, V97, P1428; KLEIN BEK, 1992, OPHTHALMOLOGY, V99, P546; Mitchell P, 1997, OPHTHALMOLOGY, V104, P581, DOI 10.1016/S0161-6420(97)30266-8; NASSIF E, 1987, J ALLERGY CLIN IMMUN, V80, P518, DOI 10.1016/0091-6749(87)90002-9; PANCHAPAKESAN J, IN PRESS OPHTHALMIC; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P17; SIMONS FER, 1993, LANCET, V342, P776, DOI 10.1016/0140-6736(93)91541-S; TINKELMAN DG, 1993, PEDIATRICS, V92, P64; TOOGOOD JH, 1993, J ALLERGY CLIN IMMUN, V91, P571, DOI 10.1016/0091-6749(93)90263-F; TOOGOOD JH, 1993, BRONCHIAL ASTHMA MEC, P818; URBAN RC, 1986, SURV OPHTHALMOL, V31, P102, DOI 10.1016/0039-6257(86)90077-9	21	373	381	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 3	1997	337	1					8	14		10.1056/NEJM199707033370102	http://dx.doi.org/10.1056/NEJM199707033370102			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XH186	9203425				2022-12-01	WOS:A1997XH18600002
J	Tearney, GJ; Brezinski, ME; Bouma, BE; Boppart, SA; Pitris, C; Southern, JF; Fujimoto, JG				Tearney, GJ; Brezinski, ME; Bouma, BE; Boppart, SA; Pitris, C; Southern, JF; Fujimoto, JG			In vivo endoscopic optical biopsy with optical coherence tomography	SCIENCE			English	Article								Current medical imaging technologies allow visualization of tissue anatomy in the human body at resolutions ranging from 100 micrometers to 1 millimeter. These technologies are generally not sensitive enough to detect early-stage tissue abnormalities associated with diseases such as cancer and atherosclerosis, which require micrometer-scale resolution. Here, optical coherence tomography was adapted to allow high-speed visualization of tissue in a living animal with a catheter-endoscope 1 millimeter in diameter. This method, referred to as ''optical biopsy,'' was used to obtain cross-sectional images of the rabbit gastrointestinal and respiratory tracts at 10-micrometer resolution.	MIT,DEPT ELECT ENGN & COMP SCI,CAMBRIDGE,MA 02139; MIT,ELECT RES LAB,CAMBRIDGE,MA 02139; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,CARDIAC UNIT,KNIGHT CATHETERIZAT LAB,BOSTON,MA 02114; SINAI SAMARITAN HOSP,DEPT PATHOL,MILWAUKEE,WI 53233	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School; Massachusetts General Hospital			Boppart, Stephen A/C-7338-2009	Pitris, Costas/0000-0002-5559-1050; Boppart, Stephen/0000-0002-9386-5630	NATIONAL EYE INSTITUTE [R01EY011289] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL055686] Funding Source: NIH RePORTER; NEI NIH HHS [NIH-9-RO1-EY11289] Funding Source: Medline; NHLBI NIH HHS [NIH-1-R29-HL55686-01A1] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bouma BE, 1996, OPT LETT, V21, P1839, DOI 10.1364/OL.21.001839; Brezinski ME, 1996, CIRCULATION, V93, P1206, DOI 10.1161/01.CIR.93.6.1206; BREZINSKI ME, IN PRESS J SURG RES; FERCHER AF, 1993, AM J OPHTHALMOL, V116, P113, DOI 10.1016/S0002-9394(14)71762-3; FUJIMOTO JG, 1995, NAT MED, V1, P970, DOI 10.1038/nm0995-970; FULIAFITO CA, 1995, OPHTHALMOLOGY, V102, P217; Gelikonov V. M., 1995, JETP LETT, V61, P149; HEE MR, 1995, ARCH OPHTHALMOL-CHIC, V113, P325, DOI 10.1001/archopht.1995.01100030081025; HERITAGE JP, 1985, OPT LETT, V10, P609, DOI 10.1364/OL.10.000609; HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169; KWONG KF, 1993, OPT LETT, V18, P558, DOI 10.1364/OL.18.000558; PHILLIPS RW, 1991, GASTROENTEROL CLIN N, V20, P791; SCHMITT JM, 1994, PHYS MED BIOL, V39, P1705, DOI 10.1088/0031-9155/39/10/013; SCHMITT JM, 1995, DERMATOLOGY, V191, P93, DOI 10.1159/000246523; SEAS A, 1992, OPT LETT, V17, P937, DOI 10.1364/OL.17.000937; SWANSON EA, 1993, OPT LETT, V18, P1864, DOI 10.1364/OL.18.001864; Tearney GJ, 1996, OPT LETT, V21, P1408, DOI 10.1364/OL.21.001408; Tearney GJ, 1996, OPT LETT, V21, P543, DOI 10.1364/OL.21.000543; TEARNEY GJ, 1997, J UROLOGY, V157, P1913; TEARNEY GJ, IN PRESS AM J GASTRO	20	1102	1324	6	168	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 27	1997	276	5321					2037	2039		10.1126/science.276.5321.2037	http://dx.doi.org/10.1126/science.276.5321.2037			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XG748	9197265				2022-12-01	WOS:A1997XG74800063
J	Daley, J; Delbanco, TL; Hartman, EE				Daley, J; Delbanco, TL; Hartman, EE			A 17-year-old mother seeking contraception, 1 year later	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article																		Grimes DA, 1996, JAMA-J AM MED ASSOC, V276, P1163, DOI 10.1001/jama.276.14.1163	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 25	1997	277	24					1976	1976						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XF087	9200640				2022-12-01	WOS:A1997XF08700044
J	Pleskoff, O; Treboute, C; Brelot, A; Heveker, N; Seman, M; Alizon, M				Pleskoff, O; Treboute, C; Brelot, A; Heveker, N; Seman, M; Alizon, M			Identification of a chemokine receptor encoded by human cytomegalovirus as a cofactor for HIV-1 entry	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; BRAIN-DERIVED CELLS; CMV INFECTION; ENVELOPE GLYCOPROTEIN; T-CELLS; TYPE-1; AIDS; REPLICATION; HEMOPHILIACS; LYMPHOCYTES	The human cytomegalovirus encodes a beta-chemokine receptor (US28) that is distantly related to the human chemokine receptors CCR5 and CXCR4, which also serve as cofactors for the entry into cells of human immunodeficiency virus-type 1 (HIV-1). Like CCR5, US28 allowed infection of CD4-positive human cell lines by primary isolates of HIV-1 and HIV-2, as well as fusion of these cell lines with cells expressing the viral envelope proteins. In addition, US28 mediated infection by cell line-adapted HIV-1 for which CXCR4 was an entry cofactor.	INST COCHIN GENET MOL,INSERM,U332,F-75014 PARIS,FRANCE; UNIV PARIS 07,LAB IMMUNODIFFERENCIAT,F-75005 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite			Brelot, Anne/P-4129-2017; Heveker, Nikolaus/G-5306-2012	Brelot, Anne/0000-0002-8095-4909				AHUJA SK, 1993, J BIOL CHEM, V268, P20691; Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Bates P, 1996, CELL, V86, P1, DOI 10.1016/S0092-8674(00)80070-7; BECHERER PR, 1990, AM J HEMATOL, V34, P204, DOI 10.1002/ajh.2830340310; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; BRAUN RW, 1986, J VIROL, V60, P29, DOI 10.1128/JVI.60.1.29-36.1986; Broder CC, 1996, PATHOBIOLOGY, V64, P171, DOI 10.1159/000164032; BRUNVEZINET F, 1987, LANCET, V1, P128; CANN AJ, 1992, J VIROL, V66, P305, DOI 10.1128/JVI.66.1.305-309.1992; CHEE MS, 1990, NATURE, V344, P774, DOI 10.1038/344774a0; Chen ZW, 1997, J VIROL, V71, P2705, DOI 10.1128/JVI.71.4.2705-2714.1997; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; CLAVEL F, 1994, J VIROL, V68, P1179, DOI 10.1128/JVI.68.2.1179-1185.1994; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; DSouza MP, 1996, NAT MED, V2, P1293, DOI 10.1038/nm1296-1293; Endres MJ, 1996, CELL, V87, P745, DOI 10.1016/S0092-8674(00)81393-8; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FINKLE C, 1991, J ACQ IMMUN DEF SYND, V4, P735; GAO JL, 1994, J BIOL CHEM, V269, P28539; HARRINGTON RD, 1993, J VIROL, V67, P5939, DOI 10.1128/JVI.67.10.5939-5947.1993; He JL, 1997, NATURE, V385, P645, DOI 10.1038/385645a0; HIRKA G, 1991, J VIROL, V65, P2732, DOI 10.1128/JVI.65.5.2732-2735.1991; HO WZ, 1991, J ACQ IMMUN DEF SYND, V4, P1098; HO WZ, 1990, J GEN VIROL, V71, P97, DOI 10.1099/0022-1317-71-1-97; IBANEZ CE, 1991, J VIROL, V65, P6581, DOI 10.1128/JVI.65.12.6581-6588.1991; JACKSON JB, 1988, TRANSFUSION, V28, P187, DOI 10.1046/j.1537-2995.1988.28288179029.x; JAULT FM, 1994, J VIROL, V68, P959, DOI 10.1128/JVI.68.2.959-973.1994; KOVAL V, 1991, J VIROL, V65, P6969, DOI 10.1128/JVI.65.12.6969-6978.1991; LATHEY JL, 1994, VIROLOGY, V199, P98, DOI 10.1006/viro.1994.1101; LEACH CT, 1993, J ACQ IMMUN DEF SYND, V6, P407; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; MOORE JP, 1993, VIRAL FUSION MECHANI, P233; NELSON JA, 1988, VIROLOGY, V165, P286, DOI 10.1016/0042-6822(88)90685-X; NELSON JA, 1990, AIDS, V4, P1, DOI 10.1097/00002030-199001000-00001; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; Nicholas J, 1996, J VIROL, V70, P5975, DOI 10.1128/JVI.70.9.5975-5989.1996; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; PEDEN K, 1991, VIROLOGY, V185, P661, DOI 10.1016/0042-6822(91)90537-L; Pleskoff O, 1997, J VIROL, V71, P3259, DOI 10.1128/JVI.71.4.3259-3262.1997; PLESKOFF O, UNPUB; RABKIN CS, 1993, J INFECT DIS, V168, P1260, DOI 10.1093/infdis/168.5.1260; RANDO RF, 1990, VIROLOGY, V176, P87, DOI 10.1016/0042-6822(90)90233-H; Rawlinson WD, 1996, J VIROL, V70, P8833, DOI 10.1128/JVI.70.12.8833-8849.1996; RICE GPA, 1984, P NATL ACAD SCI-BIOL, V81, P6134, DOI 10.1073/pnas.81.19.6134; SABIN CA, 1995, EPIDEMIOL INFECT, V114, P361, DOI 10.1017/S095026880005799X; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; SCHRIER RD, 1985, SCIENCE, V230, P1048, DOI 10.1126/science.2997930; SCHWARTZ O, 1994, VIROLOGY, V198, P360, DOI 10.1006/viro.1994.1042; Simmons G, 1996, J VIROL, V70, P8355, DOI 10.1128/JVI.70.12.8355-8360.1996; SKOLNIK PR, 1989, AM J OPHTHALMOL, V107, P361, DOI 10.1016/0002-9394(89)90659-4; SKOLNIK PR, 1988, J INFECT DIS, V157, P508, DOI 10.1093/infdis/157.3.508; SPIRE B, 1989, GENE, V81, P275, DOI 10.1016/0378-1119(89)90188-1; TOTH FD, 1995, J VIROL, V69, P2223; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; WEBSTER A, 1989, LANCET, V2, P63; WEBSTER A, 1992, CLIN EXP IMMUNOL, V88, P6; WELCH AR, 1991, J VIROL, V65, P3915, DOI 10.1128/JVI.65.7.3915-3918.1991; WESTERVELT P, 1991, P NATL ACAD SCI USA, V88, P3097, DOI 10.1073/pnas.88.8.3097; WILEY CA, 1988, AM J PATHOL, V133, P73; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; Zhang LQ, 1996, NATURE, V383, P768, DOI 10.1038/383768a0	68	271	274	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 20	1997	276	5320					1874	1878		10.1126/science.276.5320.1874	http://dx.doi.org/10.1126/science.276.5320.1874			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XF103	9188536				2022-12-01	WOS:A1997XF10300053
J	DeCock, KM; Low, N				DeCock, KM; Low, N			HIV and AIDS, other sexually transmitted diseases, and tuberculosis in ethnic minorities in United Kingdom: Is surveillance serving its purpose?	BRITISH MEDICAL JOURNAL			English	Article							STATES; INFECTION	Experience of disease differs across ethnic groups, and ethnicity is a relevant personal characteristic for descriptive epidemiology, Information about ethnicity and country of birth is omitted from the routine notification of many diseases, HIV infection and AIDS, other sexually transmitted diseases, and tuberculosis have different incidence rates in different ethnic groups in the United Kingdom. Omission of ethnic data from surveillance activities allows such differences in incidence to go undetected and unaddressed. Surveillance data that included ethnic details could guide interventions to reduce inequalities in health between different subpopulations.	UNIV LONDON KINGS COLL,SCH MED & DENT,DEPT GENITOURINARY MED,LONDON,ENGLAND	University of London; King's College London	DeCock, KM (corresponding author), LONDON SCH HYG & TROP MED,LONDON WC1E 7HT,ENGLAND.		Low, Nicola/H-4718-2019	Low, Nicola/0000-0003-4817-8986				ADES AE, 1993, BRIT MED J, V306, P1296, DOI 10.1136/bmj.306.6888.1296; BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; Catchpole M A, 1992, Commun Dis Rep CDR Rev, V2, pR1; *CDC, 1989, MMWR-MORBID MORTAL W, V38, P236; *CDCP, 1996, MMWR-MORBID MORTAL W, V45, P121; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; DelAmo J, 1996, AIDS, V10, P1563, DOI 10.1097/00002030-199611000-00016; *DEP HLTH, 1996, UNL AN HIV PREV MON; *DEP HLTH, 1992, HLTH NAT; DOHERTY MJ, 1995, TUBERCLE LUNG DIS, V76, P196, DOI 10.1016/S0962-8479(05)80004-8; FRIEDEN TR, 1995, NEW ENGL J MED, V333, P229, DOI 10.1056/NEJM199507273330406; HAHN RA, 1992, JAMA-J AM MED ASSOC, V267, P268, DOI 10.1001/jama.267.2.268; Herrera J. L., 1993, Morbidity and Mortality Weekly Report, V42, P1; HOLMES KK, 1990, SEXUALLY TRANSMITTED; Johnson AM, 1994, SEXUAL ATTITUDES LIF; LACEY CJN, 1995, 11 M INT SOC STD RES; LAGA M, 1994, AIDS S1, V8, pS119; LANGMUIR AD, 1963, NEW ENGL J MED, V268, P182, DOI 10.1056/NEJM196301242680405; LOW N, 1996, GENITORURIN MED, V72, P305; MacDonagh SE, 1996, BRIT MED J, V313, P532; MCKENNA MT, 1995, NEW ENGL J MED, V332, P1071, DOI 10.1056/NEJM199504203321606; Mortimer J Y, 1995, Commun Dis Rep CDR Rev, V5, pR183; NAVARRO V, 1990, LANCET, V336, P1238, DOI 10.1016/0140-6736(90)92846-A; Noone A, 1991, CDR (Lond Engl Rev), V1, pR39; *OFF POP CENS SURV, 1993, 1991 CENS; *OFF POP CENS SURV, 1993, 1991 CENS US GUID 58; Ormerod P, 1996, BRIT J HOSP MED, V56, P209; *PHLS AIDS CTR, 1991, CDR REV, V1, pR51; *PUBL HLTH AB SERV, 1995, CDR WKLY, V5, P62; *PUBL HLTH LAB SER, 1996, COMMUN DIS REP CDR R, V6, P251; Rieder HL, 1996, EUR RESPIR J, V9, P1097, DOI 10.1183/09031936.96.09051097; SENIOR PA, 1994, BRIT MED J, V309, P327, DOI 10.1136/bmj.309.6950.327; THACKER SB, 1994, AM J EPIDEMIOL, V140, P383, DOI 10.1093/oxfordjournals.aje.a117261; WATSON JM, 1993, BRIT MED J, V306, P221, DOI 10.1136/bmj.306.6872.221	34	32	32	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 14	1997	314	7096					1747	1751		10.1136/bmj.314.7096.1747	http://dx.doi.org/10.1136/bmj.314.7096.1747			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XE909	9202508	Green Published			2022-12-01	WOS:A1997XE90900031
J	Kawata, T; Shevchenko, A; Fukuzawa, M; Jermyn, KA; Totty, NF; Zhukovskaya, NV; Sterling, AE; Mann, M; Williams, JG				Kawata, T; Shevchenko, A; Fukuzawa, M; Jermyn, KA; Totty, NF; Zhukovskaya, NV; Sterling, AE; Mann, M; Williams, JG			SH2 signaling in a lower eukaryote: A STAT protein that regulates stalk cell differentiation in Dictyostelium	CELL			English	Article							GENE-EXPRESSION; PRESTALK CELLS; DISCOIDEUM; KINASE; PRESPORE; CAMP; SPORE; MATURATION; MORPHOGEN; DNA	The TTGA-binding factor is a transcriptional regulator activated by DIF, the chlorinated hexaphenone that induces prestalk cell differentiation in Dictyostelium. The same activity also functions as a repressor, controlling stalk cell differentiation. We show that the TTGA-binding factor is a STAT protein. Like the metazoan STATs, it functions via the reciprocal interaction of a phosphotyrosine residue on one molecule with an SH2 domain on a dimerizing partner. Furthermore, it will bind specifically to a mammalian interferon-stimulated response element. In Saccharomyces cerevisiae, where the entire genomic sequence is known, SH2 domains have not been identified. It would seem, therefore, that SH2 signaling pathways arose very early in the evolution of multicellular organisms, perhaps to facilitate intercellular communication.	UCL, DEPT BIOL, LONDON WC1E 6BT, ENGLAND; EUROPEAN MOL BIOL LAB, PROT & PEPTIDE GRP, D-69117 HEIDELBERG, GERMANY; LUDWIG INST CANC RES, LONDON W1P 8BT, ENGLAND	University of London; University College London; European Molecular Biology Laboratory (EMBL); Ludwig Institute for Cancer Research	Kawata, T (corresponding author), UCL, MRC, MOL CELL BIOL LAB, GOWER ST, LONDON WC1E 6BT, ENGLAND.		Fukuzawa, Masashi/G-1726-2014; Mann, Matthias/A-3454-2013	Mann, Matthias/0000-0003-1292-4799; Kawata, Takefumi/0000-0002-3685-4492	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Adler K, 1996, FEBS LETT, V395, P286, DOI 10.1016/0014-5793(96)01053-8; Briscoe J, 1996, PHILOS T ROY SOC B, V351, P167, DOI 10.1098/rstb.1996.0013; CECCARELLI A, 1991, CELL, V65, P983, DOI 10.1016/0092-8674(91)90550-I; Clarke M, 1995, EXPERIENTIA, V51, P1124, DOI 10.1007/BF01944730; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; EARLY A, 1995, CELL, V83, P91, DOI 10.1016/0092-8674(95)90237-6; FUKUZAWA M, 1997, IN PRESS DEVELOPMENT, V124; Gamper M, 1996, MOL CELL BIOL, V16, P2431; HARWOOD AJ, 1993, DEVELOPMENT, V118, P1041; HARWOOD AJ, 1992, CELL, V69, P615, DOI 10.1016/0092-8674(92)90225-2; HOPPER NA, 1993, EMBO J, V12, P2459, DOI 10.1002/j.1460-2075.1993.tb05900.x; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Hou XS, 1996, CELL, V84, P411, DOI 10.1016/S0092-8674(00)81286-6; HOWARD PK, 1994, MOL CELL BIOL, V14, P5154, DOI 10.1128/MCB.14.8.5154; HOWARD PK, 1992, CELL, V71, P637, DOI 10.1016/0092-8674(92)90597-6; Hunter T, 1997, TRENDS BIOCHEM SCI, V22, P18, DOI 10.1016/S0968-0004(96)10068-2; IMPROTA T, 1994, P NATL ACAD SCI USA, V91, P4776, DOI 10.1073/pnas.91.11.4776; INOUYE K, 1993, DEVELOPMENT, V118, P523; INSALL R, 1990, EMBO J, V9, P3323, DOI 10.1002/j.1460-2075.1990.tb07532.x; Jensen ON, 1996, RAPID COMMUN MASS SP, V10, P1371, DOI 10.1002/(SICI)1097-0231(199608)10:11<1371::AID-RCM682>3.0.CO;2-5; JERMYN KA, 1987, DEVELOPMENT, V100, P745; Kawata T, 1996, EMBO J, V15, P3085, DOI 10.1002/j.1460-2075.1996.tb00671.x; KAY RR, 1983, NATURE, V303, P242, DOI 10.1038/303242a0; KAY RR, 1989, DEVELOPMENT, V105, P753; KIMMEL AR, 1985, MOL CELL BIOL, V5, P2123, DOI 10.1128/MCB.5.8.2123; KUBOHARA Y, 1993, EXP CELL RES, V207, P107, DOI 10.1006/excr.1993.1168; MAEDA M, 1988, DEV GROWTH DIFFER, V30, P573; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; MANN SKO, 1993, DEVELOPMENT, V119, P135; MANN SKO, 1994, P NATL ACAD SCI USA, V91, P10561, DOI 10.1073/pnas.91.22.10561; MORRIS HR, 1987, NATURE, V328, P811, DOI 10.1038/328811a0; Nuckolls GH, 1996, DEVELOPMENT, V122, P3295; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; QURESHI SA, 1995, P NATL ACAD SCI USA, V92, P3829, DOI 10.1073/pnas.92.9.3829; RICHARDSON DL, 1994, DEVELOPMENT, V120, P2891; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SIMON MN, 1992, NATURE, V356, P171, DOI 10.1038/356171a0; TAN JL, 1990, MOL CELL BIOL, V10, P3578, DOI 10.1128/MCB.10.7.3578; TOWN CD, 1976, NATURE, V262, P717, DOI 10.1038/262717a0; WATTS DJ, 1970, BIOCHEM J, V119, P171, DOI 10.1042/bj1190171; WILLIAMS JG, 1989, CELL, V59, P1157, DOI 10.1016/0092-8674(89)90771-X; WILLIAMS JG, 1987, CELL, V49, P185, DOI 10.1016/0092-8674(87)90559-9; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519; Yan RQ, 1996, CELL, V84, P421, DOI 10.1016/S0092-8674(00)81287-8	47	187	189	0	7	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JUN 13	1997	89	6					909	916		10.1016/S0092-8674(00)80276-7	http://dx.doi.org/10.1016/S0092-8674(00)80276-7			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XE357	9200609	Bronze			2022-12-01	WOS:A1997XE35700011
J	Skuse, DH; James, RS; Bishop, DVM; Coppin, B; Dalton, P; AamodtLeeper, G; BacareseHamilton, M; Creswell, C; McGurk, R; Jacobs, PA				Skuse, DH; James, RS; Bishop, DVM; Coppin, B; Dalton, P; AamodtLeeper, G; BacareseHamilton, M; Creswell, C; McGurk, R; Jacobs, PA			Evidence from Turner's syndrome of an imprinted X-linked locus affecting cognitive function	NATURE			English	Article							BEHAVIOR PROBLEMS; INACTIVATION; DIAGNOSIS; MOUSE	Turner's syndrome is a sporadic disorder of human females in which all or part of one X chromosome is deleted(1). Intelligence is usually normal(2) but social adjustment problems are common(3). Here we report a study of 80 females with Turner's syndrome and a single X chromosome, in 55 of which the X was maternally derived (45,X-m) and in 25 it was of paternal origin (45,X-p). Members of the 45,XP group were significantly better adjusted, with superior verbal and higher-order executive function skills, which mediate social interactions(4). Our observations suggest that there is a genetic locus for social cognition, which is imprinted(5) and is not expressed from the maternally derived X chromosome. Neuropsychological and molecular investigations of eight females with partial deletions of the short arm of the X chromosome(6) indicate that the putative imprinted locus escapes inactivation(7), and probably lies on Xq or close to the centromere on Xp. If expressed only from the X chromosome of paternal origin, the existence of this locus could explain why 46,XY males (whose single X chromosome is maternal) are more vulnerable to developmental disorders of language and social cognition, such as autism, than are 46,XX females(8).	SALISBURY DIST HOSP,WESSEX REG GENET LAB,SALISBURY SP2 8BJ,WILTS,ENGLAND; MRC,APPL PSYCHOL UNIT,CAMBRIDGE CB2 2EF,ENGLAND; PRINCESS ANNE HOSP,WESSEX REG GENET SERV,SOUTHAMPTON SO16 5YA,HANTS,ENGLAND	Salisbury District Hospital; University of Cambridge	Skuse, DH (corresponding author), INST CHILD HLTH,BEHAV SCI UNIT,30 GUILFORD ST,LONDON WC1N 1EH,ENGLAND.		Creswell, Cathy/L-9306-2013	Creswell, Cathy/0000-0003-1889-0956; Bishop, Dorothy/0000-0002-2448-4033	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Achenbach, 1991, MANUAL TEACHERS REPO; Achenbach T. M., 1987, MANUAL YOUTH SELF RE; ACHENBACH TM, 1991, MANUAL CHILD BEHAVIO; Bailey A, 1996, J CHILD PSYCHOL PSYC, V37, P89, DOI 10.1111/j.1469-7610.1996.tb01381.x; Ballabio Andrea, 1992, Human Molecular Genetics, V1, P221, DOI 10.1093/hmg/1.4.221; BARLOW DP, 1995, SCIENCE, V270, P1610, DOI 10.1126/science.270.5242.1610; Bjorklund DF, 1996, PSYCHOL BULL, V120, P163, DOI 10.1037/0033-2909.120.2.163; BORYS SV, 1982, J EXP CHILD PSYCHOL, V33, P87, DOI 10.1016/0022-0965(82)90008-X; DAMASIO AR, 1995, P NY ACAD SCI, V769, P241; DISTECHE CM, 1995, TRENDS GENET, V11, P17, DOI 10.1016/S0168-9525(00)88981-7; EAGLY AH, 1995, AM PSYCHOL, V50, P145, DOI 10.1037/0003-066X.50.3.145; HASSOLD T, 1992, HUM GENET, V89, P647; JACOBS PA, 1990, ANN HUM GENET, V54, P209, DOI 10.1111/j.1469-1809.1990.tb00379.x; LEDBETTER DH, 1995, HUM MOL GENET, V4, P1757, DOI 10.1093/hmg/4.suppl_1.1757; LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0; MANLY T, TEST EVERYDAY ATTENT; MCCAULEY E, 1987, CHILD DEV, V58, P464, DOI 10.2307/1130523; MCCAULEY E, 1986, J AM ACAD CHILD PSY, V25, P105, DOI 10.1016/S0002-7138(09)60606-3; PENNINGTON BF, 1985, CORTEX, V21, P391, DOI 10.1016/S0010-9452(85)80004-6; Pennington BF, 1996, J CHILD PSYCHOL PSYC, V37, P51, DOI 10.1111/j.1469-7610.1996.tb01380.x; RABBITT PMA, IN PRESS METHODOLOGI; SAENGER P, 1993, J CLIN ENDOCR METAB, V77, P297, DOI 10.1210/jcem.77.2.8345029; SKUSE D, 1994, GROWTH STATURE ADAPT, P151; TEMPLE CM, 1995, CORTEX, V31, P109, DOI 10.1016/S0010-9452(13)80109-8; Wechsler D., 1986, WECHSLER ADULT INTEL; Wechsler D., 1992, WECHSLER INTELLIGENC; Wolff DJ, 1996, AM J HUM GENET, V58, P154; World Health Organization, 1992, ICD 10 CLASS MENT BE; ZUCCOTTI M, 1995, NAT GENET, V9, P316, DOI 10.1038/ng0395-316	29	500	507	0	57	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 12	1997	387	6634					705	708		10.1038/42706	http://dx.doi.org/10.1038/42706			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	XD869	9192895	Green Submitted, Bronze			2022-12-01	WOS:A1997XD86900054
J	Ikeda, S; Nasrallah, JB; Dixit, R; Preiss, S; Nasrallah, ME				Ikeda, S; Nasrallah, JB; Dixit, R; Preiss, S; Nasrallah, ME			An aquaporin-like gene required for the Brassica self-incompatibility response	SCIENCE			English	Article							RECEPTOR KINASE GENE; ARABIDOPSIS-THALIANA; WATER CHANNELS; PLASMA-MEMBRANE; POLLEN; PROTEIN; LOCUS; EXPRESSION; CLONING; CELLS	Self-incompatibility in Brassica refers to the rejection of self-related pollen and is mediated by a receptor protein kinase localized to the plasma membrane of the stigma epidermis in the flower. The recessive mutation mod eliminates self-incompatibility in the stigma. In mod mutants, self-compatibility was shown to be associated with the absence of transcripts encoded by an aquaporin-related gene. This observation suggests that a water channel is required for the self-incompatibility response of Brassica, which is consistent with the concept that regulation of water transfer from the stigma to pollen is a checkpoint in the early events of pollination in the crucifer family.	CORNELL UNIV, DIV BIOL SCI, ITHACA, NY 14853 USA	Cornell University								AGRE P, 1995, CURR OPIN CELL BIOL, V7, P472, DOI 10.1016/0955-0674(95)80003-4; Bower MS, 1996, PLANT CELL, V8, P1641, DOI 10.1105/tpc.8.9.1641; CHRISPEELS MJ, 1994, PLANT PHYSIOL, V105, P9, DOI 10.1104/pp.105.1.9; DANIELS MJ, 1994, PLANT PHYSIOL, V106, P1325, DOI 10.1104/pp.106.4.1325; de Nettancourt D., 1977, INCOMPATIBILITY ANGI, DOI DOI 10.1007/BF00276804; DICKINSON H, 1995, SEX PLANT REPROD, V8, P1, DOI 10.1007/BF00228756; GORING DR, 1993, PLANT CELL, V5, P531, DOI 10.1105/tpc.5.5.531; HESLOPHARRISON J, 1979, AM J BOT, V66, P737, DOI 10.2307/2442418; HESLOPHARRISON J, 1975, ANNU REV PLANT PHYS, V26, P403, DOI 10.1146/annurev.pp.26.060175.002155; HOFTE H, 1992, PLANT PHYSIOL, V99, P561, DOI 10.1104/pp.99.2.561; HULSKAMP M, 1995, PLANT J, V8, P703, DOI 10.1046/j.1365-313X.1995.08050703.x; JOHNSON KD, 1990, PLANT CELL, V2, P525, DOI 10.1105/tpc.2.6.525; KAMMERLOHER W, 1994, PLANT J, V6, P187, DOI 10.1046/j.1365-313X.1994.6020187.x; KANDASAMY MK, 1989, DEV BIOL, V134, P462, DOI 10.1016/0012-1606(89)90119-X; KATSURA T, 1995, P NATL ACAD SCI USA, V92, P7212, DOI 10.1073/pnas.92.16.7212; KHO YO, 1968, EUPHYTICA, V17, P298; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; MAUREL C, 1995, EMBO J, V14, P3028, DOI 10.1002/j.1460-2075.1995.tb07305.x; NASRALLAH JB, 1994, PLANT J, V5, P373, DOI 10.1111/j.1365-313X.1994.00373.x; NASRALLAH JB, 1994, SCIENCE, V266, P1505, DOI 10.1126/science.266.5190.1505; NASRALLAH ME, 1992, PLANT J, V2, P497, DOI 10.1111/j.1365-313X.1992.00497.x; NASRALLAH ME, UNPUB; NASRALLAH ME, 1989, PLANT REPRODUCTION F, V1, P146; Park JH, 1996, J MEMBRANE BIOL, V153, P171, DOI 10.1007/s002329900120; PREUSS D, 1993, GENE DEV, V7, P974, DOI 10.1101/gad.7.6.974; REIZER J, 1993, CRIT REV BIOCHEM MOL, V28, P235, DOI 10.3109/10409239309086796; Robinson DC, 1996, PLANT PHYSIOL, V111, P645, DOI 10.1104/pp.111.2.645; Stein JC, 1996, PLANT CELL, V8, P429, DOI 10.1105/tpc.8.3.429; STEIN JC, 1991, P NATL ACAD SCI USA, V88, P8816, DOI 10.1073/pnas.88.19.8816; YAMAGUCHISHINOZAKI K, 1992, PLANT CELL PHYSIOL, V33, P217, DOI 10.1093/oxfordjournals.pcp.a078243; [No title captured]	31	95	110	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 6	1997	276	5318					1564	1566		10.1126/science.276.5318.1564	http://dx.doi.org/10.1126/science.276.5318.1564			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XC701	9171060				2022-12-01	WOS:A1997XC70100043
J	Mundlos, S; Otto, F; Mundlos, C; Mulliken, JB; Aylsworth, AS; Albright, S; Lindhout, D; Cole, WG; Henn, W; Knoll, JHM; Owen, MJ; Mertelsmann, R; Zabel, BU; Olsen, BR				Mundlos, S; Otto, F; Mundlos, C; Mulliken, JB; Aylsworth, AS; Albright, S; Lindhout, D; Cole, WG; Henn, W; Knoll, JHM; Owen, MJ; Mertelsmann, R; Zabel, BU; Olsen, BR			Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia	CELL			English	Article							FLUORESCENCE INSITU HYBRIDIZATION; ACUTE MYELOID-LEUKEMIA; AML1 GENE; DROSOPHILA; FAMILY; PROTEIN; CHROMOSOME-6; MICE; PCR	Cleidocranial dysplasia (CCD) is an autosomal-dominant condition characterized by hypoplasia/aplasia of clavicles, patent fontanelles, supernumerary teeth, short stature, and other changes in skeletal patterning and growth. In some families, the phenotype segregates with deletions resulting in heterozygous loss of CBFA1, a member of the runt family of transcription factors. In other families, insertion, deletion, and missense mutations lead to translational stop codons in the DNA binding domain or in the C-terminal transactivating region. In-frame expansion of a polyalanine stretch segregates in an affected family with brachydactyly and minor clinical findings of CCD. We conclude that CBFA1 mutations cause CCD and that heterozygous loss of function is sufficient to produce the disorder.	HARVARD UNIV,SCH MED,CHILDRENS HOSP,DEPT CELL BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,CHILDRENS HOSP,DIV GENET,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BETH ISRAEL DEACONESS MED CTR,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,CHILDRENS HOSP,DIV PLAST SURG,BOSTON,MA 02115; HARVARD UNIV,SCH DENT MED,HARVARD FORSYTH DEPT ORAL BIOL,BOSTON,MA 02115; KLINIKUM ALBERT LUDWIGS UNIV,HAMATOL ONKOL ABT,D-79108 FREIBURG,GERMANY; UNIV N CAROLINA,DEPT GENET,DIV GENET & METAB,CHAPEL HILL,NC 27599; ERASMUS UNIV ROTTERDAM,DEPT CLIN GENET,MGC,NL-3000 DR ROTTERDAM,NETHERLANDS; HOSP SICK CHILDREN,DIV ORTHOPAED,TORONTO,ON M5G 1X8,CANADA; UNIV SAARLAND,INST HUMANGENET,HOMBURG,GERMANY; IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard School of Dental Medicine; University of Freiburg; University of North Carolina; University of North Carolina Chapel Hill; Erasmus University Rotterdam; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Saarland University; Cancer Research UK	Mundlos, S (corresponding author), KLINIKUM JOHANNES GUTENBERG UNIV,KINDERKLIN,D-55101 MAINZ,GERMANY.		Mundlos, Stefan/ABH-9585-2020; Lindhout, Dick/AAH-5765-2019; Henn, Wolfram/AAU-1608-2020	Knoll, Joan/0000-0001-6691-1710; Lindhout, Dick/0000-0001-9580-624X	NIAMS NIH HHS [AR 36819, AR35820] Funding Source: Medline; NICHD NIH HHS [HD 18658] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD018658] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR036819, R01AR036819] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BAE SC, 1994, MOL CELL BIOL, V14, P3242, DOI 10.1128/MCB.14.5.3242; BALDINI A, 1992, GENOMICS, V14, P181, DOI 10.1016/S0888-7543(05)80303-9; BIRREN B, 1993, PULSED FIELD GEL ELE, P49; ERLEBACHER A, 1995, CELL, V80, P371, DOI 10.1016/0092-8674(95)90487-5; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; Jones K. L., 1997, SMITHS RECOGNIZABLE; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; KNOLL JHM, 1994, CURRENT PROTOCOLS HU; KWIATKOWSKI TJ, 1991, GENOMICS, V10, P921, DOI 10.1016/0888-7543(91)90180-M; LEDLEY FD, 1988, AM J HUM GENET, V42, P839; LEHRACH H., 1990, GENOME ANAL, P39; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; MERRIMAN HL, 1995, BIOCHEMISTRY-US, V34, P13125, DOI 10.1021/bi00040a025; MIYOSHI H, 1995, NUCLEIC ACIDS RES, V23, P2762, DOI 10.1093/nar/23.14.2762; Mortlock DP, 1996, NAT GENET, V13, P284, DOI 10.1038/ng0796-284; Mundlos S, 1997, FASEB J, V11, P227, DOI 10.1096/fasebj.11.4.9068611; Mundlos S, 1997, FASEB J, V11, P125, DOI 10.1096/fasebj.11.2.9039954; MUNDLOS S, 1995, HUM MOL GENET, V4, P71, DOI 10.1093/hmg/4.1.71; Muragaki Y, 1996, SCIENCE, V272, P548, DOI 10.1126/science.272.5261.548; NIENHAUS H, 1993, AM J MED GENET, V46, P630, DOI 10.1002/ajmg.1320460605; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; SELBY PB, 1978, MUTAT RES, V51, P199, DOI 10.1016/S0027-5107(78)80019-0; SILLENCE DO, 1987, AM J MED GENET, V27, P75, DOI 10.1002/ajmg.1320270109; Tagle Danilo A., 1992, Human Molecular Genetics, V1, P121, DOI 10.1093/hmg/1.2.121; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444	30	1200	1266	0	37	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 30	1997	89	5					773	779		10.1016/S0092-8674(00)80260-3	http://dx.doi.org/10.1016/S0092-8674(00)80260-3			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XB925	9182765	Bronze, Green Published			2022-12-01	WOS:A1997XB92500014
J	Zhang, ZJ; Kundu, GC; Yuan, CJ; Ward, JM; Lee, EJ; DeMayo, F; Westphal, H; Mukherjee, AB				Zhang, ZJ; Kundu, GC; Yuan, CJ; Ward, JM; Lee, EJ; DeMayo, F; Westphal, H; Mukherjee, AB			Severe fibronectin-deposit renal glomerular disease in mice lacking uteroglobin	SCIENCE			English	Article							GENE-EXPRESSION; PROTEIN; RABBIT; BINDING; GLOMERULONEPHRITIS; TRANSGLUTAMINASE; ANTIGENICITY; PROLACTIN; REGION; FAMILY	Despite myriads of biological activities ascribed to uteroglobin (UG), a steroid-inducible secreted protein, its physiological functions are unknown. Mice in which the uteroglobin gene was disrupted had severe renal disease that was associated with massive glomerular deposition of predominantly multimeric fibronectin (Fn), The molecular mechanism that normally prevents Fn deposition appears to involve high-affinity binding of UG with Fn to form Fn-UG heteromers that counteract Fn self-aggregation,which is required for abnormal tissue deposition, Thus, UG is essential for maintaining normal renal function in mice, which raises the possibility that an analogous pathogenic mechanism may underlie genetic Fn-deposit human glomerular disease.	NICHHD,SECT DEV GENET,HERITABLE DISORDERS BRANCH,NIH,BETHESDA,MD 20892; NCI,VET & TUMOR PATHOL SECT,OFF LAB ANIM SCI,FREDERICK,MD 21702; NICHHD,LAB MAMMALIAN GENET & DEV,NIH,BETHESDA,MD 20892; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Baylor College of Medicine			Kundu, Gopal C./ABA-9897-2020		NHLBI NIH HHS [HL47620] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047620] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aoki A, 1996, MOL HUM REPROD, V2, P489, DOI 10.1093/molehr/2.7.489; ASSMANN KJM, 1995, AM J KIDNEY DIS, V25, P781, DOI 10.1016/0272-6386(95)90555-3; BEATO M, 1976, J STEROID BIOCHEM, V7, P327, DOI 10.1016/0022-4731(76)90091-1; BEIER HM, 1968, BIOCHIM BIOPHYS ACTA, V160, P289, DOI 10.1016/0005-2795(68)90108-6; BORDER WA, 1992, J CLIN INVEST, V90, P1, DOI 10.1172/JCI115821; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CHERNOUSOV MA, 1991, J BIOL CHEM, V266, P10851; CHILTON BS, 1988, MOL ENDOCRINOL, V2, P1169, DOI 10.1210/mend-2-12-1169; Gemperle O, 1996, AM J KIDNEY DIS, V28, P668, DOI 10.1016/S0272-6386(96)90247-4; GILLNER M, 1988, J STEROID BIOCHEM, V31, P27, DOI 10.1016/0022-4731(88)90201-4; GONZALEZ KD, 1995, FEBS LETT, V361, P255, DOI 10.1016/0014-5793(95)00167-8; HYNES RO, 1991, FIBRONECTINS; JACKSON PJ, 1988, J CHROMATOGR, V452, P359, DOI 10.1016/S0021-9673(01)81460-6; KIKUKAWA T, 1989, MOL CELL ENDOCRINOL, V62, P177, DOI 10.1016/0303-7207(89)90004-X; KOLLER BH, 1992, ANNU REV IMMUNOL, V10, P705, DOI 10.1146/annurev.iy.10.040192.003421; KRISHNAN RS, 1967, SCIENCE, V158, P490, DOI 10.1126/science.158.3800.490; Kundu GC, 1996, P NATL ACAD SCI USA, V93, P2915, DOI 10.1073/pnas.93.7.2915; LEVIN SW, 1986, LIFE SCI, V38, P1813, DOI 10.1016/0024-3205(86)90135-9; MAGDALENO SM, IN PRESS AM J PHYSL; MAZZUCCO G, 1992, HUM PATHOL, V23, P63, DOI 10.1016/0046-8177(92)90013-S; MIELE L, 1987, ENDOCR REV, V8, P474, DOI 10.1210/edrv-8-4-474; MIELE L, 1994, J ENDOCRINOL INVEST, V17, P679, DOI 10.1007/BF03349687; MIELE L, 1988, NATURE, V335, P726, DOI 10.1038/335726a0; Mosher Deane F., 1992, Current Opinion in Cell Biology, V4, P810, DOI 10.1016/0955-0674(92)90104-K; MUKHERJEE AB, 1982, AM J REPROD IMMUNOL, V2, P135, DOI 10.1111/j.1600-0897.1982.tb00154.x; MUKHERJEE DC, 1983, SCIENCE, V219, P989, DOI 10.1126/science.6130601; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; OH E, 1981, P NATL ACAD SCI-BIOL, V78, P3218, DOI 10.1073/pnas.78.5.3218; PERI A, 1995, J CLIN INVEST, V96, P343, DOI 10.1172/JCI118040; PERI A, 1993, J CLIN INVEST, V92, P2099, DOI 10.1172/JCI116810; RANDALL GW, 1991, J REPROD FERTIL, V91, P249, DOI 10.1530/jrf.0.0910249; RAY MK, 1993, BIOCHEM BIOPH RES CO, V197, P163, DOI 10.1006/bbrc.1993.2455; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; SINGH G, 1988, BIOCHIM BIOPHYS ACTA, V950, P329, DOI 10.1016/0167-4781(88)90129-7; STROM EH, 1995, KIDNEY INT, V48, P163, DOI 10.1038/ki.1995.280; VASANTHAKUMAR G, 1988, BIOCHEM PHARMACOL, V37, P389, DOI 10.1016/0006-2952(88)90204-3; Watson MA, 1996, CANCER RES, V56, P860; WU CY, 1995, CELL, V83, P715, DOI 10.1016/0092-8674(95)90184-1; Zhang QH, 1996, J BIOL CHEM, V271, P33284, DOI 10.1074/jbc.271.52.33284; ZHANG QH, 1994, J CELL BIOL, V127, P1447, DOI 10.1083/jcb.127.5.1447; Zhang Z., UNPUB; Zhang ZJ, 1997, DNA CELL BIOL, V16, P73, DOI 10.1089/dna.1997.16.73	42	114	128	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 30	1997	276	5317					1408	1412		10.1126/science.276.5317.1408	http://dx.doi.org/10.1126/science.276.5317.1408			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XB533	9162006				2022-12-01	WOS:A1997XB53300047
J	Cook, SP; Vulchanova, L; Hargreaves, KM; Elde, R; McCleskey, EW				Cook, SP; Vulchanova, L; Hargreaves, KM; Elde, R; McCleskey, EW			Distinct ATP receptors on pain-sensing and stretch-sensing neurons	NATURE			English	Article							SENSORY NEURONS; EXTRACELLULAR ATP; NERVE ACTIVITY; CHANNELS; RAT; CAT	The initial pain from tissue damage may result from the release of cytoplasmic components that act upon nociceptors, the sensors for pain. ATP was proposed to fill this role(1,2) because it elicits pain when applied intradermally(3) and may be the active compound in cytoplasmic fractions that cause pain(4). Moreover, ATP opens ligand-gated ion channels (P2X receptors) in sensory neurons(5,6,7) and only sensory neurons express messenger RNA for the P2X3 receptor(8,9). To test whether ATP contributes to nociception, we developed a tissue culture system that allows comparison of nociceptive (tooth-pulp afferent) and non-nociceptive (muscle-stretch receptor) rat sensory neurons. Low concentrations of ATP evoked action potentials and large inward currents in both types of neuron. Nociceptors had currents that were similar to those of heterologously expressed channels containing P2X3 subunits, and had P2X3 immunoreactivity in their sensory endings and cell bodies. Stretch receptors had currents that differed from those of P2X3 channels, and had no P2X3 immunoreactivity. These results support the theory that P2X3 receptors mediate a form of nociception, but also suggest non-nociceptive roles for ATP in sensory neurons.	UNIV MINNESOTA,DEPT CELL BIOL & NEUROANAT,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities	Cook, SP (corresponding author), OREGON HLTH SCI UNIV,VOLLUM INST L474,3181 SW SAM JACKSON PK RD,PORTLAND,OR 97201, USA.		Hargreaves, Kenneth M/F-5308-2010	Vulchanova, Lucy/0000-0002-6577-4467				ABERCROMBIE M, 1946, ANAT REC, V94, P239, DOI 10.1002/ar.1090940210; AHLQUIST ML, 1985, ADV PAIN RES THER, V9, P351; AHLQUIST ML, 1984, PAIN, V19, P353, DOI 10.1016/0304-3959(84)90081-2; ANDERSON DJ, 1967, ARCH ORAL BIOL, V12, P417, DOI 10.1016/0003-9969(67)90227-0; ARVIDSSON U, 1995, J NEUROSCI, V15, P3328; BEAN BP, 1990, J NEUROSCI, V10, P1; BLEEHEN T, 1976, J PHYSIOL-LONDON, V262, P131, DOI 10.1113/jphysiol.1976.sp011589; BLEEHEN T, 1977, PAIN, V3, P367, DOI 10.1016/0304-3959(77)90066-5; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; Burnstock G, 1996, LANCET, V347, P1604, DOI 10.1016/S0140-6736(96)91082-X; CHEN CC, 1995, NATURE, V377, P428, DOI 10.1038/377428a0; CODY FWJ, 1972, J PHYSIOL-LONDON, V226, P249, DOI 10.1113/jphysiol.1972.sp009983; Collo G, 1996, J NEUROSCI, V16, P2495; CORBIN KB, 1940, J NEUROPHYSIOL, V3, P425; EDWALL L, 1977, PAIN, V3, P121, DOI 10.1016/0304-3959(77)90075-6; HOLTON P, 1959, J PHYSIOL-LONDON, V145, P494, DOI 10.1113/jphysiol.1959.sp006157; JAHR CE, 1983, NATURE, V304, P730, DOI 10.1038/304730a0; JYVASJARVI E, 1987, J PHYSIOL-LONDON, V391, P193, DOI 10.1113/jphysiol.1987.sp016733; KENNEDY C, 1995, NATURE, V377, P285; KHAHK BS, 1997, J PHYSL, V498, P709; KRISHTAL OA, 1988, NEUROSCIENCE, V27, P995, DOI 10.1016/0306-4522(88)90203-5; Lawson SN., 1992, SENSORY NEURONS DIVE, P27; LESTER RAJ, 1993, J NEUROSCI, V13, P1088; LEWIS C, 1995, NATURE, V377, P432, DOI 10.1038/377432a0; Nakamura F, 1996, P NATL ACAD SCI USA, V93, P10465, DOI 10.1073/pnas.93.19.10465; NARHI M, 1994, ARCH ORAL BIOL, V39, pA23; PHILLIS JW, 1978, GEN PHARMACOL, V9, P239, DOI 10.1016/0306-3623(78)90043-5; TADDESE A, 1995, SCIENCE, V270, P1366, DOI 10.1126/science.270.5240.1366; VALERA S, 1994, NATURE, V371, P516, DOI 10.1038/371516a0; Vulchanova L, 1996, P NATL ACAD SCI USA, V93, P8063, DOI 10.1073/pnas.93.15.8063; WILLIS WD, 1978, SENSORY MECHANISMS S, P1	31	392	400	0	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 29	1997	387	6632					505	508		10.1038/387505a0	http://dx.doi.org/10.1038/387505a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XB479	9168113				2022-12-01	WOS:A1997XB47900049
J	Mewes, HW; Albermann, K; Bahr, M; Frishman, D; Gleissner, A; Hani, J; Heumann, K; Kleine, K; Maierl, A; Oliver, SG; Pfeiffer, F; Zollner, A				Mewes, HW; Albermann, K; Bahr, M; Frishman, D; Gleissner, A; Hani, J; Heumann, K; Kleine, K; Maierl, A; Oliver, SG; Pfeiffer, F; Zollner, A			Overview of the yeast genome	NATURE			English	Editorial Material							CHROMOSOME-III	The collaboration of more than 600 scientists from over 100 laboratories to sequence the Saccharomyces cerevisiae genome was the largest decentralised experiment in modern molecular biology and resulted in a unique data resource representing the first complete set of genes from a eukaryotic organism, 12 million bases were sequenced in a truly international effort involving European, US, Canadian and Japanese laboratories. While the yeast genome represents only a small fraction of the information in today's pubic sequence databases, the complete, ordered and non-redundant sequence provides an invaluable resource for the detailed analysis of cellular gene function and genome architecture. In terms of throughput, completeness and information content, yeast has always been the lead eukaryotic organism in genomics; it is still the largest genome to be completely sequenced.	UNIV MANCHESTER,INST SCI & TECHNOL,MANCHESTER M60 1QD,LANCS,ENGLAND	University of Manchester	Mewes, HW (corresponding author), MAX PLANCK INST BIOCHEM,KLOPFERSPITZ 18A,D-82152 MARTINSRIED,GERMANY.		Frishman, Dmitrij/AAT-7815-2020; Mewes, Hans-Werner/A-8204-2019	Mewes, Hans-Werner/0000-0002-9713-6398; Pfeiffer, Friedhelm/0000-0003-4691-3246				Bairoch A, 1996, NUCLEIC ACIDS RES, V24, P189, DOI 10.1093/nar/24.1.189; BORK P, 1992, PROTEIN SCI, V1, P1677, DOI 10.1002/pro.5560011216; CASARI G, 1995, NATURE, V376, P647, DOI 10.1038/376647a0; DAYHOFF MO, 1976, FED PROC, V35, P2132; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; HEUMANN K, 1996, P 4 INT C INT SYST M, P98; KOONIN EV, 1994, EMBO J, V13, P493, DOI 10.1002/j.1460-2075.1994.tb06287.x; Oliver S, 1996, TRENDS GENET, V12, P241, DOI 10.1016/0168-9525(96)30053-X; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RILEY M, 1993, MICROBIOL REV, V57, P862, DOI 10.1128/MMBR.57.4.862-952.1993	10	436	454	1	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 29	1997	387	6632		S			7	8		10.1038/387s007	http://dx.doi.org/10.1038/387s007			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XB546	9169865	Bronze			2022-12-01	WOS:A1997XB54600002
J	Brooke, H; Gibson, A; Tappin, D; Brown, H				Brooke, H; Gibson, A; Tappin, D; Brown, H			Case-control study of sudden infant death syndrome in Scotland, 1992-5	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SMOKING; SIDS	Objective: To investigate the relation between routine infant care practices and the sudden infant death syndrome in Scotland. Methods: National study of 201 infants dying of the sudden infant death syndrome (cases) and 276 controls by means of home interviews comparing methods of infant care and socioeconomic factors. Results: Sleeping prone (odds ratio 6.96 (95% confidence interval 1.51 to 31.97)) and drug treatment in the previous week (odds ratio 2.33 (1.10 to 4.94)) were more common in the cases than controls on multivariate analysis. Smoking was confirmed as a significant risk factor (odds ratio for mother and father both smoking 5.19 (2.26 to 11.91)). The risk increased with the number of parents smoking (P < 0.0001), with the number of cigarettes smoked by mother or father (P = 0.0001), and with bed sharing (P < 0.005). A new finding was an increased risk of dying of the syndrome for infants who slept at night on a mattress previously used by another infant or adult (odds ratio 2.51 (1.39 to 4.52)). However, this increased risk was not established for mattresses totally covered by polyvinyl chloride. Conclusions: Sleeping prone and parental smoking are confirmed as modifiable risk factors for the sudden infant death syndrome. Sleeping on an old mattress may be important but needs confirmation before recommendations can be made.	UNIV EDINBURGH, SCH MED, MED STAT UNIT, EDINBURGH EH8 9AG, MIDLOTHIAN, SCOTLAND; UNIV GLASGOW, GLASGOW G12 8QQ, LANARK, SCOTLAND	University of Edinburgh; University of Glasgow	Brooke, H (corresponding author), ROYAL HOSP SICK CHILDREN, SCOTTISH COT DEATH TRUST, GLASGOW G3 8SJ, LANARK, SCOTLAND.							ARNEIL GC, 1985, LANCET, V1, P740; Carstairs V., 1991, DEPRIVATION HLTH SCO; CLULOW E, 1978, TEXTILES, V1, P2; COWAN SF, 1996, 4 SIDS INT C WASH DC; COWNA S, 1996, HLTH ED, V1, P20; ENGELBERTS AC, 1991, J PAEDIATR CHILD H, V27, P329, DOI 10.1111/j.1440-1754.1991.tb00413.x; FAROOQI S, 1993, PAEDIATR PERINAT EP, V57, P245; FLEMING PJ, 1990, BRIT MED J, V301, P85, DOI 10.1136/bmj.301.6743.85; GANTLEY M, 1993, BRIT MED J, V306, P16, DOI 10.1136/bmj.306.6869.16; GIBSON AAM, 1992, J CLIN PATHOL, V45, P7; GIBSON AAM, 1994, 3 SIDS INT C STAV NO; KLONOFFCOHEN H, 1995, BMJ-BRIT MED J, V311, P1269, DOI 10.1136/bmj.311.7015.1269; MALLOY MH, 1992, AM J PUBLIC HEALTH, V82, P1380, DOI 10.2105/AJPH.82.10.1380; MITCHELL EA, 1993, PEDIATRICS, V91, P893; MITCHELL EA, 1992, J PAEDIATR CHILD H, V28, pS3, DOI 10.1111/j.1440-1754.1992.tb02729.x; MITCHELL EA, 1988, AUST NZ J MED, V18, P861, DOI 10.1111/j.1445-5994.1988.tb01646.x; RICHARDSON BA, 1990, LANCET, V335, P670, DOI 10.1016/0140-6736(90)90463-F; SCHECHTMAN VL, 1992, PEDIATRICS, V89, P865; SCRAGG R, 1993, BMJ-BRIT MED J, V307, P1312, DOI 10.1136/bmj.307.6915.1312; Scragg RKR, 1996, LANCET, V347, P7, DOI 10.1016/S0140-6736(96)91554-8; [No title captured]	21	148	152	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 24	1997	314	7093					1516	1520		10.1136/bmj.314.7093.1516	http://dx.doi.org/10.1136/bmj.314.7093.1516			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XB484	9169398	Green Published			2022-12-01	WOS:A1997XB48400023
J	Kozarsky, KF; Donahee, MH; Rigotti, A; Iqbal, SN; Edelman, ER; Krieger, M				Kozarsky, KF; Donahee, MH; Rigotti, A; Iqbal, SN; Edelman, ER; Krieger, M			Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels	NATURE			English	Article							HIGH-DENSITY-LIPOPROTEIN; SELECTIVE UPTAKE; GENE-TRANSFER; A-I; RAT; HYPERCHOLESTEROLEMIA; HEPATOCYTES; MICE; ADENOVIRUSES; METABOLISM	The risk of atherosclerosis, a leading cause of cardiovascular disease and death, is inversely related to plasma levels of high-density lipoprotein (HDL) cholesterol, although the mechanism of this protective effect is unclear(1). The class B scavenger receptor, SR-BI, is the first HDL receptor to be well defined at a molecular level and is a mediator of selective cholesterol uptake in vitro(2). It is expressed most abundantly in steroidogenic tissues, where it is coordinately regulated with steroidogenesis by adrenocorticotropic hormone (ACTH), human chorionic gonadotropin (hCG) and oestrogen, and in the liver, where its expression in rats is suppressed by oestrogen(3,4). Here we show that adenovirus-mediated, hepatic overexpression of SR-BI in mice on both sinusoidal and canalicular surfaces of hepatocytes results in the virtual disappearance of plasma HDL and a substantial increase in biliary cholesterol, SR-BI may directly mediate these effects by increasing hepatic HDL cholesterol uptake or by increasing cholesterol secretion into bile, or both, These results indicate that SR-BI may be important in hepatic HDL metabolism, in determining plasma HDL concentrations, and in controlling cholesterol concentrations in bile, and thus may influence the development and progression of atherosclerosis and gallstone disease.	UNIV PENN,MED CTR,DEPT MOL & CELLULAR ENGN,PHILADELPHIA,PA 19104; MIT,DEPT BIOL,CAMBRIDGE,MA 02139; BRIGHAM & WOMENS HOSP,DEPT MED,DIV CARDIOVASC,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115; HARVARD UNIV,MIT,DIV HLTH SCI & TECHNOL,CAMBRIDGE,MA 02139	University of Pennsylvania; Massachusetts Institute of Technology (MIT); Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts Institute of Technology (MIT)	Kozarsky, KF (corresponding author), UNIV PENN,MED CTR,INST HUMAN GENE THERAPY,PHILADELPHIA,PA 19104, USA.		Eckhardt, Erik/G-1567-2010					Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; BOTHAM KM, 1995, PROG LIPID RES, V34, P71, DOI 10.1016/0163-7827(94)00007-9; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CAREY MC, 1996, BILE ACIDS CHOLESTAS, P147; DELPOZO R, 1983, BIOCHIM BIOPHYS ACTA, V753, P164, DOI 10.1016/0005-2760(83)90004-8; DOMINGO N, 1992, J LIPID RES, V33, P1419; ENGELHARDT JF, 1993, NAT GENET, V4, P27, DOI 10.1038/ng0593-27; GLASS C, 1983, P NATL ACAD SCI-BIOL, V80, P5435, DOI 10.1073/pnas.80.17.5435; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; GWYNNE JT, 1989, J BIOL CHEM, V264, P8141; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; KOZARSKY K, 1993, SOMAT CELL MOLEC GEN, V19, P449, DOI 10.1007/BF01233250; Kozarsky KF, 1996, NAT GENET, V13, P54, DOI 10.1038/ng0596-54; KOZARSKY KF, 1994, J BIOL CHEM, V269, P13695; Landschulz KT, 1996, J CLIN INVEST, V98, P984, DOI 10.1172/JCI118883; LEITERSDORF E, 1984, BIOCHIM BIOPHYS ACTA, V796, P72, DOI 10.1016/0005-2760(84)90240-6; PITTMAN RC, 1987, J BIOL CHEM, V262, P2443; REAVEN E, 1984, J CLIN INVEST, V74, P1384, DOI 10.1172/JCI111549; Rigotti A, 1996, J BIOL CHEM, V271, P33545, DOI 10.1074/jbc.271.52.33545; RIGOTTI A, 1989, J LIPID RES, V30, P1041; Rigotti Attilio, 1994, V40, P579; RINNINGER F, 1994, HEPATOLOGY, V19, P1100, DOI 10.1002/hep.1840190507; SEWELL RB, 1983, J LIPID RES, V24, P391; THORNTON JR, 1981, BRIT MED J, V283, P1352, DOI 10.1136/bmj.283.6303.1352; TURLEY SD, 1988, LIVER BIOL PATHOBIOL, P617; ULLOA N, 1987, HEPATOLOGY, V7, P234; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194; Ye XH, 1996, J BIOL CHEM, V271, P3639; YOKODE M, 1990, SCIENCE, V250, P1273, DOI 10.1126/science.2244210	30	603	620	0	26	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 22	1997	387	6631					414	417		10.1038/387414a0	http://dx.doi.org/10.1038/387414a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XA496	9163428				2022-12-01	WOS:A1997XA49600063
J	Beckerman, JL; Naider, F; Ebbole, DJ				Beckerman, JL; Naider, F; Ebbole, DJ			Inhibition of pathogenicity of the rice blast fungus by Saccharomyces cerevisiae alpha-factor	SCIENCE			English	Article							MAGNAPORTHE-GRISEA; MATING PHEROMONES; YEAST	Magnaporthe grisea is a fungal pathogen with two mating types, MAT1-1 and MAT1-2, that forms a specialized cell necessary for pathogenesis, the appressorium, Saccharomyces cerevisiae alpha-factor pheromone blocked appressorium formation in a mating type-specific manner and protected plants from infection by MAT1-2 strains. Experiments with alpha-factor analogs suggest that the observed activity is due to a specific interaction of alpha-factor with an M. grisea receptor. Culture filtrates of a MAT1-1 strain contained an activity that inhibited appressorium formation of mating type MAT1-2 strains. These findings provide evidence that a pheromone response pathway exists in M. grisea that can be exploited for plant protection.	TEXAS A&M UNIV,DEPT PLANT PATHOL & MICROBIOL,COLLEGE STN,TX 77843; CUNY COLL STATEN ISL,DEPT CHEM,STATEN ISL,NY 10314	Texas A&M University System; Texas A&M University College Station; City University of New York (CUNY) System; College of Staten Island (CUNY)					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022086, R29GM047977, R56GM022086] Funding Source: NIH RePORTER; NIGMS NIH HHS [R29GM47977, GM22086] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECKER J, R29GM47977 USPHS TEX; BECKER J, GM22086 USPHS FN TEX; Beckerman JL, 1996, MOL PLANT MICROBE IN, V9, P450, DOI 10.1094/MPMI-9-0450; GARIBALDI JA, 1955, J AM CHEM SOC, V77, P2429, DOI 10.1021/ja01614a021; HAMER JE, 1988, SCIENCE, V239, P288, DOI 10.1126/science.239.4837.288; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HISATOMI T, 1988, CURR GENET, V13, P25, DOI 10.1007/BF00365752; HOWARD RJ, 1991, P NATL ACAD SCI USA, V88, P11281, DOI 10.1073/pnas.88.24.11281; HOWARD RJ, 1994, RICE BLAST DISEASE, P3; KANG SC, 1994, GENETICS, V138, P289; LEE YH, 1993, PLANT CELL, V5, P693, DOI 10.1105/tpc.5.6.693; LOUMAYE E, 1982, SCIENCE, V218, P1323, DOI 10.1126/science.6293058; MARCUS S, 1991, MOL CELL BIOL, V11, P3603, DOI 10.1128/MCB.11.7.3603; MCCULLOUGH J, 1979, J BACTERIOL, V138, P146, DOI 10.1128/JB.138.1.146-154.1979; Nelson MA, 1996, TRENDS GENET, V12, P69, DOI 10.1016/0168-9525(96)81403-X; RATHS SK, 1988, J BIOL CHEM, V263, P17333; VALENT B, 1990, PHYTOPATHOLOGY, V80, P33, DOI 10.1094/Phyto-80-33; XUE CB, 1989, BIOCHEM BIOPH RES CO, V162, P253, DOI 10.1016/0006-291X(89)91989-X	18	30	34	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 16	1997	276	5315					1116	1119		10.1126/science.276.5315.1116	http://dx.doi.org/10.1126/science.276.5315.1116			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WZ225	9148806				2022-12-01	WOS:A1997WZ22500045
J	Kay, SA				Kay, SA			UPDATE: Circadian rhythms - As time PASses: The first mammalian clock gene	SCIENCE			English	Editorial Material											Kay, SA (corresponding author), SCRIPPS RES INST, NSF CTR BIOL TIMING, DEPT CELL BIOL, LA JOLLA, CA 92037 USA.		Kay, Steve A/F-6025-2011	Kay, Steve A/0000-0002-0402-2878				Antoch MP, 1997, CELL, V89, P655, DOI 10.1016/S0092-8674(00)80246-9; Crosthwaite SK, 1997, SCIENCE, V276, P763, DOI 10.1126/science.276.5313.763; Dunlap JC, 1996, ANNU REV GENET, V30, P579, DOI 10.1146/annurev.genet.30.1.579; Kay SA, 1997, SCIENCE, V276, P753, DOI 10.1126/science.276.5313.753; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; KING DP, IN PRESS GENETIC; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325	7	5	5	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 16	1997	276	5315					1093	1093		10.1126/science.276.5315.1093	http://dx.doi.org/10.1126/science.276.5315.1093			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WZ225	9173542				2022-12-01	WOS:A1997WZ22500037
J	McDonald, P; Friedman, EHI; Banks, A; Anderson, R; Carman, V				McDonald, P; Friedman, EHI; Banks, A; Anderson, R; Carman, V			Pneumococcal vaccine campaign based in general practice	BRITISH MEDICAL JOURNAL			English	Article							POLYSACCHARIDE VACCINE; HIGH-RISK; PNEUMONIA; EFFICACY; CARE; INFECTIONS; INFLUENZA; AGE	Objective: To show whether a general practice setting is a practical and effective medium for increasing uptake of pneumococcal vaccine. Design: Follow up study of responses of general practices (debriefing by questionnaire or small group session) and patients (questionnaire sent to 429 patients vaccinated in a two week period) to vaccination campaign. Setting and subjects: Patients registered with general practices of one family health services authority. Interventions: Pneumococcal vaccination campaign including clinical guidelines and support materials. Main outcome measures: Proportion of general practitioners offering pneumococcal vaccine; proportion of patients at risk who were vaccinated between 1 May and 31 December 1995; number of splenectomised patients identified and vaccinated in same period; views of patients who were vaccinated. Results: Proportion of general practitioners offering pneumococcal vaccine increased from 17% to 89% during the campaign. Estimated number of patients at risk who were vaccinated increased from 656 (4%) to 5982 (33%) during campaign. Of 61 splenectomised patients identified, 30 had been vaccinated previously and 27 were vaccinated during campaign. Practices in which a general practitioner took or shared the lead had higher vaccination rates and used vaccine up faster. Of the 384 patients whose questionnaires were used in analysis, only 35 had heard of pneumococcal vaccine before the campaign, 198 reported side effects (mostly minor and local, but systemic and severe local reactions were more common than expected), and 337 were pleased they had been vaccinated (only five expressed dissatisfaction). Conclusion: A practice based campaign is an effective method of increasing uptake of pneumococcal vaccine by high risk groups.	W PENNINE HLTH AUTHOR,OLDHAM OL1 2PL,ENGLAND									Aszkenasy O M, 1995, Commun Dis Rep CDR Rev, V5, pR45; AUSTRIAN R, 1964, ANN INTERN MED, V60, P759, DOI 10.7326/0003-4819-60-5-759; BLOOM HG, 1988, J AM GERIATR SOC, V36, P897, DOI 10.1111/j.1532-5415.1988.tb05782.x; BUTLER JC, 1993, JAMA-J AM MED ASSOC, V270, P1826, DOI 10.1001/jama.270.15.1826; CARTWRIGHT KAV, 1995, INT C S SERIES, V210, P63; CLANCY CM, 1992, J GEN INTERN MED, V7, P14, DOI 10.1007/BF02599095; *DEP HLTH WELSH OF, 1992, IMM INF DIS; FEDSON DS, 1994, ARCH INTERN MED, V154, P2531, DOI 10.1001/archinte.154.22.2531; FEDSON DS, 1982, JAMA-J AM MED ASSOC, V248, P1989; Fedson DS, 1994, VACCINES, P517; FEDSON DS, 1995, INT C S SERIES, V210, P49; GABLE CB, 1990, JAMA-J AM MED ASSOC, V264, P2910, DOI 10.1001/jama.264.22.2910; GEORGE R, 1995, INT C S SERIES, V210, P1; GILLILAND AEW, 1992, FAM PRACT, V9, P441, DOI 10.1093/fampra/9.4.441; GOWDA R, 1995, BRIT MED J, V311, P26, DOI 10.1136/bmj.311.6996.26; HEDLUND JU, 1992, LANCET, V340, P396, DOI 10.1016/0140-6736(92)91473-L; HILLEMAN MR, 1981, REV INFECT DIS, V3, pS31; HOOK EW, 1983, JAMA-J AM MED ASSOC, V249, P1055, DOI 10.1001/jama.249.8.1055; JACOBY LL, 1993, J EXPT PSYCHOL GENER, V2, P1; KLEIN RS, 1983, ARCH INTERN MED, V143, P1878, DOI 10.1001/archinte.143.10.1878; KOIVULA I, 1994, AM J MED, V96, P313, DOI 10.1016/0002-9343(94)90060-4; LINNEMANN CC, 1986, ARCH INTERN MED, V146, P1554, DOI 10.1001/archinte.146.8.1554; MACINNES J, 1995, CDR REV, V12, pR173; MAKELA PH, 1995, INT C S SERIES, V210, P41; MAYOWHITE D, 1994, CARE ELDERLY, P355; MCFARLIN RF, 1995, ABSTR PAP AM CHEM S, V210, P9; NOAH N, 1996, GUIDE PNEUMOCOCCAL V; POLIS M, 1988, ANN EMERG MED, V37, P1016; RODRIGUEZ R, 1993, ANN INTERN MED, V22, P93; ROSE DN, 1993, AM J MED, V94, P161; SHAPIRO ED, 1984, ANN INTERN MED, V101, P325, DOI 10.7326/0003-4819-101-3-325; SIMS RV, 1988, ANN INTERN MED, V108, P653, DOI 10.7326/0003-4819-108-5-653; SIMS RV, 1992, AGE AGEING, V21, P357, DOI 10.1093/ageing/21.5.357; SISK JE, 1986, ANN INTERN MED, V104, P79, DOI 10.7326/0003-4819-104-1-79; STEVEN A, 1994, HLTH CARE NEEDS ASSE, V1, P307; STEWART DA, 1995, MMWR-MORBID MORTAL W, V44, P741; TOBACMAN JK, 1992, INFECT CONT HOSP EP, V13, P144; Whitelaw FG, 1996, BRIT J GEN PRACT, V46, P181; WISCHNACK LL, 1995, PEDIATRICS, V95, P350; WRENN K, 1994, J GEN INTERN MED, V9, P425, DOI 10.1007/BF02599056; 1995, MMWR-MORBID MORTAL W, V44, P741; 1995, CARE ELDERLY, V7, P11	42	34	34	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 12	1997	314	7087					1094	1098		10.1136/bmj.314.7087.1094	http://dx.doi.org/10.1136/bmj.314.7087.1094			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU236	9133894	Green Published			2022-12-01	WOS:A1997WU23600029
J	Krongrad, A; Lai, H; Lai, SH				Krongrad, A; Lai, H; Lai, SH			Survival after radical prostatectomy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CANCER; MORTALITY; OUTCOMES	Context.-The generalizability of currently available estimates of survival after radical prostatectomy is theoretically limited. Objective.-To obtain generalizable estimates of survival after radical prostatectomy. Design.-A population-based retrospective cohort study. Setting.-Nine regions of the United States. Patients.-Patients who were diagnosed with prostate cancer between 1983 and 1987 and underwent radical prostatectomy and lymph node dissection. Main Outcome Measures-Proportional hazards models incorporating geographical region, age, race, pathological stage, lymph node involvement, and tumor grade to identify independent correlates of disease-specific and overall survival and life table analyses to estimate 10-year survival distributions. Results.-A total of 3626 patients with a mean age of 65 years were included in the study; 92.6% were white, 54.2% had moderate-grade cancer, 60.4% had no extension beyond the prostate, and 91.2% had no lymph node involvement. Using San Francisco-Oakland, Calif, as a reference region, no other region was significantly associated with a risk of disease-specific or overall mortality. Older age and black race were independently associated with worse overall but not disease-specific survival. Higher grade, extension beyond the prostate, and lymph node involvement were independently associated with worse disease-specific and overall survival. Estimates of 10-year disease-specific survival ranged from 75% to 97% for patients with well-differentiated and moderately differentiated cancers and from 60% to 86% for patients with poorly differentiated cancers. Conclusions.-Neither disease-specific nor overall survival varied by region, suggesting geographically uniform assessments of risk in patient selection for radical prostatectomy. Across regions, overall survival varied by patient and prostate cancer characteristic while disease-specific survival varied substantially by prostate cancer but not patient characteristics. The present analyses provide the most generalizable current estimates of survival after radical prostatectomy.	UNIV MIAMI,SCH MED,DEPT UROL,MIAMI,FL; UNIV MIAMI,SCH MED,DEPT MED,MIAMI,FL; UNIV MIAMI,SCH MED,DEPT EPIDEMIOL & PUBL HLTH,MIAMI,FL; UNIV MIAMI,SYLVESTER COMPREHENS CANC CTR,MIAMI,FL 33152	University of Miami; University of Miami; University of Miami; University of Miami	Krongrad, A (corresponding author), VET AFFAIRS MED CTR,CTR GERIATR RES EDUC & CLIN,1201 NW 16TH ST,MIAMI,FL 33125, USA.							BENNETT CL, 1991, CANCER, V67, P2633, DOI 10.1002/1097-0142(19910515)67:10<2633::AID-CNCR2820671039>3.0.CO;2-9; COX DR, 1972, J R STAT SOC B, V34, P187; Fryback DG, 1996, JAMA-J AM MED ASSOC, V276, P1723; Gerber GS, 1996, JAMA-J AM MED ASSOC, V276, P615; Gilliland FD, 1996, UROLOGY, V48, P67, DOI 10.1016/S0090-4295(96)00083-0; Helgesen F, 1996, JNCI-J NATL CANCER I, V88, P1216, DOI 10.1093/jnci/88.17.1216; HSING AW, 1994, CANCER EPIDEM BIOMAR, V3, P527; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; Krongrad A, 1996, J UROLOGY, V156, P1084, DOI 10.1016/S0022-5347(01)65710-0; Krongrad A, 1996, Urol Oncol, V2, P35, DOI 10.1016/1078-1439(96)00038-5; KRONGRAD A, IN PRESS J UROL; KRONGRAD A, IN PRESS MANAGE CLIN; LERNER SE, 1995, J UROLOGY, V154, P1447, DOI 10.1016/S0022-5347(01)66888-5; LUYAO GL, 1993, JAMA-J AM MED ASSOC, V269, P2633, DOI 10.1001/jama.269.20.2633; Riley G, 1985, Health Care Financ Rev, V7, P37; Schellhammer P, 1997, UROLOGY, V49, P27, DOI 10.1016/S0090-4295(99)80321-5; WALSH PC, 1982, J UROLOGY, V128, P492, DOI 10.1016/S0022-5347(17)53012-8; WENNBERG JE, 1987, JAMA-J AM MED ASSOC, V257, P933, DOI 10.1001/jama.257.7.933	18	38	38	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 2	1997	278	1					44	46						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG387	9207337				2022-12-01	WOS:A1997XG38700035
J	Kohler, RH; Cao, J; Zipfel, WR; Webb, WW; Hanson, MR				Kohler, RH; Cao, J; Zipfel, WR; Webb, WW; Hanson, MR			Exchange of protein molecules through connections between higher plant plastids	SCIENCE			English	Article							CHLOROPLASTS; MICROSCOPY	Individual plastids of vascular plants have generally been considered to be discrete autonomous entities that do not directly communicate with each other. However, in transgenic plants in which the plastid stroma was labeled with green fluorescent protein (GFP), thin tubular projections emanated from individual plastids and sometimes connected to other plastids. Flow of GFP between interconnected plastids could be observed when a single plastid or an interconnecting plastid tubule was photobleached and the loss of green fluorescence by both plastids was seen. These tubules allow the exchange of molecules within an interplastid communication system, which may facilitate the coordination of plastid activities.	CORNELL UNIV,GENET & DEV SECT,ITHACA,NY 14853; CORNELL UNIV,SCH APPL & ENGN PHYS,ITHACA,NY 14853	Cornell University; Cornell University			Webb, Watt W./B-5905-2011; Hanson, Maureen R/D-3879-2009; Zipfel, Warren/B-4059-2016	Hanson, Maureen R/0000-0001-8141-3058; Zipfel, Warren/0000-0003-2640-329X; kohler, rainer/0000-0001-6269-6590	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR004224] Funding Source: NIH RePORTER; NCRR NIH HHS [RR04224] Funding Source: Medline; PHS HHS [R07719] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		[Anonymous], [No title captured]; CERUTTI H, 1992, P NATL ACAD SCI USA, V89, P8068, DOI 10.1073/pnas.89.17.8068; CLINE R, 1996, ANN REV CELL DEV BIO, V12, P1; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; EHARA T, 1990, EXP CELL RES, V190, P104, DOI 10.1016/0014-4827(90)90150-9; GRAY MW, 1992, INT REV CYTOL, V141, P233, DOI 10.1016/S0074-7696(08)62068-9; HASELOFF J, 1995, TRENDS GENET, V11, P328, DOI 10.1016/0168-9525(95)90186-8; HONGLADAROM T, 1965, ORGANELLES LIVING PL; HOOD EE, 1986, J BACTERIOL, V168, P1291, DOI 10.1128/jb.168.3.1291-1301.1986; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; HUANG JT, 1990, PLANT CELL, V2, P1249, DOI 10.1105/tpc.2.12.1249; Kirk J.T.O., 1978, PLASTIDS THEIR CHEM; KOHLER R, UNPUB; Kohler RH, 1997, PLANT J, V11, P613, DOI 10.1046/j.1365-313X.1997.11030613.x; MENZEL D, 1994, PROTOPLASMA, V179, P166, DOI 10.1007/BF01403955; OSAFUNE T, 1993, J ELECT MICROSC, V42, P201; PAYAN LA, 1991, J CELL BIOL, V112, P603, DOI 10.1083/jcb.112.4.603; SPENCER D, 1962, AUST J BIOL SCI, V15, P599, DOI 10.1071/BI9620599; TOBIAS M, 1996, PLANT J, V10, P523; VESK MARET, 1965, AUSTRALIAN J BOT, V13, P161; WELER TE, 1962, AM J BOT, V49, P807; WILDMAN SG, 1962, SCIENCE, V138, P434, DOI 10.1126/science.138.3538.434; Wildman SG, 1967, BIOCHEM CHLOROP, V2, P295; WILLIAMS RM, 1994, FASEB J, V8, P804, DOI 10.1096/fasebj.8.11.8070629; ZHAO JM, 1995, J BIOL CHEM, V270, P6081, DOI 10.1074/jbc.270.11.6081	25	475	501	0	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 27	1997	276	5321					2039	2042		10.1126/science.276.5321.2039	http://dx.doi.org/10.1126/science.276.5321.2039			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XG748	9197266				2022-12-01	WOS:A1997XG74800064
J	Barkai, N; Leibler, S				Barkai, N; Leibler, S			Robustness in simple biochemical networks	NATURE			English	Article							BACTERIAL CHEMOTAXIS; SIGNAL-TRANSDUCTION; ESCHERICHIA-COLI; METHYLATION; ADAPTATION; MODEL; MECHANISM; PROTEINS	Cells use complex networks of interacting molecular components to transfer and process information, These ''computational devices of living cells''(1) are responsible for many important cellular processes, including cell-cycle regulation and signal transduction. Here we address the issue of the sensitivity of the networks to variations in their biochemical parameters, We propose a mechanism for robust adaptation in simple signal transduction networks. We show that this mechanism applies in particular to bacterial chemotaxis(2-7). This is demonstrated within a quantitative model which explains, in a unified way, many aspects of chemotaxis, including proper responses to chemical gradients(8-12). The adaptation property(10,13-16) is a consequence of the network's connectivity and does not require the 'fine-tuning' of parameters. We argue that the key properties of biochemical networks should be robust in order to ensure their proper functioning.	PRINCETON UNIV,DEPT PHYS,PRINCETON,NJ 08544; PRINCETON UNIV,DEPT MOL BIOL,PRINCETON,NJ 08544	Princeton University; Princeton University								ADLER J, 1966, SCIENCE, V153, P708, DOI 10.1126/science.153.3737.708; ADLER J, 1975, ANNU REV BIOCHEM, V44, P341, DOI 10.1146/annurev.bi.44.070175.002013; ASAKURA S, 1984, J MOL BIOL, V176, P349, DOI 10.1016/0022-2836(84)90494-7; BERG HC, 1975, P NATL ACAD SCI USA, V72, P3235, DOI 10.1073/pnas.72.8.3235; BERG HC, 1972, NATURE, V239, P500, DOI 10.1038/239500a0; BLOCK SM, 1982, CELL, V31, P215, DOI 10.1016/0092-8674(82)90421-4; BOURRET RB, 1991, ANNU REV BIOCHEM, V60, P401, DOI 10.1146/annurev.bi.60.070191.002153; BRAY D, 1995, NATURE, V376, P307, DOI 10.1038/376307a0; BRAY D, 1993, MOL BIOL CELL, V4, P469, DOI 10.1091/mbc.4.5.469; HAURI DC, 1995, BIOPHYS J, V68, P708, DOI 10.1016/S0006-3495(95)80232-8; HAZELBAUER GL, 1993, CELL, V73, P15, DOI 10.1016/0092-8674(93)90156-K; KHAN S, 1995, P NATL ACAD SCI USA, V92, P9757, DOI 10.1073/pnas.92.21.9757; KLEENE SJ, 1979, P NATL ACAD SCI USA, V76, P6309, DOI 10.1073/pnas.76.12.6309; KOSHLAND DE, 1977, SCIENCE, V196, P1055, DOI 10.1126/science.870969; KOSHLAND DE, 1982, SCIENCE, V217, P220, DOI 10.1126/science.7089556; MACNAB RM, 1972, P NATL ACAD SCI USA, V69, P2509, DOI 10.1073/pnas.69.9.2509; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; SEGEL LA, 1986, J THEOR BIOL, V120, P151, DOI 10.1016/S0022-5193(86)80171-0; SPRINGER MS, 1979, NATURE, V280, P279, DOI 10.1038/280279a0; SPUDICH JL, 1976, NATURE, V262, P467, DOI 10.1038/262467a0; Stock JB, 1996, ESCHERICHIA COLI SAL, P1103	21	1068	1093	2	120	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 26	1997	387	6636					913	917		10.1038/43199	http://dx.doi.org/10.1038/43199			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XG416	9202124				2022-12-01	WOS:A1997XG41600054
J	Her, LS; Lund, E; Dahlberg, JE				Her, LS; Lund, E; Dahlberg, JE			Inhibition of Ran guanosine triphosphatase-dependent nuclear transport by the matrix protein of vesicular stomatitis virus	SCIENCE			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; BINDING-PROTEIN; ACTIVATING PROTEIN; CAP TRIMETHYLATION; EXPORT PATHWAY; RNA TRANSPORT; U-SNRNA; IMPORT; RAN/TC4; TRANSCRIPTION	Transport of macromolecules into and out of nuclei, essential steps in gene expression, are potential points of control. The matrix protein (M protein) of vesicular stomatitis virus (VSV) was shown to block transport of RNAs and proteins between the nucleus and cytoplasm of Xenopus laevis oocytes. The pattern of inhibition indicated that M protein interfered with transport that is dependent on the ras-like nuclear guanosine triphosphatase (GTPase) Ran-TC4 and its associated factors. This inhibition of nuclear transport by M protein explains several observations about the effects of VSV infection on host cell gene expression and suggests that RNA export is closely coupled to protein import.	UNIV WISCONSIN, DEPT BIOMOL CHEM, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison					NIGMS NIH HHS [GM30220] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030220, R01GM030220] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; Aitchison JD, 1996, SCIENCE, V274, P624, DOI 10.1126/science.274.5287.624; AMBERG DC, 1993, EMBO J, V12, P233, DOI 10.1002/j.1460-2075.1993.tb05649.x; AZUMA Y, 1995, P NATL ACAD SCI USA, V92, P5159, DOI 10.1073/pnas.92.11.5159; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; BISCHOFF FR, 1995, P NATL ACAD SCI USA, V92, P1749, DOI 10.1073/pnas.92.5.1749; BLACK BL, 1994, J VIROL, V68, P555, DOI 10.1128/JVI.68.1.555-560.1994; BLACK BL, 1992, J VIROL, V66, P4058, DOI 10.1128/JVI.66.7.4058-4064.1992; BRAY M, 1994, P NATL ACAD SCI USA, V91, P1256, DOI 10.1073/pnas.91.4.1256; CHENG Y, 1995, SCIENCE, V267, P1807, DOI 10.1126/science.7534442; CORBETT AH, 1995, J CELL BIOL, V130, P1017, DOI 10.1083/jcb.130.5.1017; COUTAVAS E, 1993, NATURE, V366, P585, DOI 10.1038/366585a0; CRONE DE, 1989, J VIROL, V63, P4172, DOI 10.1128/JVI.63.10.4172-4180.1989; CULLEN BR, 1991, TRENDS BIOCHEM SCI, V16, P346, DOI 10.1016/0968-0004(91)90141-H; Dahlberg JE, 1997, SEMIN CELL DEV BIOL, V8, P65, DOI 10.1006/scdb.1996.0123; DAVIS LI, 1995, ANNU REV BIOCHEM, V64, P865, DOI 10.1146/annurev.bi.64.070195.004245; FABRE E, 1994, CURR OPIN CELL BIOL, V6, P335, DOI 10.1016/0955-0674(94)90023-X; FELDHERR C, 1995, MOL CELL BIOL, V15, P7043; FISCHER U, 1991, J CELL BIOL, V113, P705, DOI 10.1083/jcb.113.4.705; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; FORRESTER W, 1992, GENE DEV, V6, P1914, DOI 10.1101/gad.6.10.1914; FRESCO LD, 1987, MOL CELL BIOL, V7, P1148, DOI 10.1128/MCB.7.3.1148; Fridell RA, 1996, P NATL ACAD SCI USA, V93, P4421, DOI 10.1073/pnas.93.9.4421; Fritz CC, 1996, CURR BIOL, V6, P848, DOI 10.1016/S0960-9822(02)00608-5; GERACE L, 1995, CELL, V82, P341, DOI 10.1016/0092-8674(95)90420-4; GOLDFARB DS, 1994, CURR BIOL, V4, P57, DOI 10.1016/S0960-9822(00)00013-0; Gorlich D, 1996, CELL, V87, P21, DOI 10.1016/S0092-8674(00)81319-7; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; Grimm C, 1997, EMBO J, V16, P793, DOI 10.1093/emboj/16.4.793; GRIMM C, UNPUB; Hadjilov AA, 1985, NUCL RIBOSOME BIOGEN; HER LS, UNPUB; IZAURRALDE E, 1995, CELL, V81, P153, DOI 10.1016/0092-8674(95)90323-2; IZAURRALDE E, 1995, NATURE, V376, P709, DOI 10.1038/376709a0; Izaurralde E, 1997, J CELL BIOL, V137, P27, DOI 10.1083/jcb.137.1.27; KADOWAKI T, 1993, EMBO J, V12, P2929, DOI 10.1002/j.1460-2075.1993.tb05955.x; Koepp DM, 1996, J CELL BIOL, V133, P1163, DOI 10.1083/jcb.133.6.1163; Koepp DM, 1996, CELL, V87, P1, DOI 10.1016/S0092-8674(00)81315-X; LEFRANCOIS L, 1982, VIROLOGY, V121, P157, DOI 10.1016/0042-6822(82)90125-8; LOUNSBURY KM, 1994, J BIOL CHEM, V269, P11285; LUND E, 1989, EMBO J, V8, P287, DOI 10.1002/j.1460-2075.1989.tb03375.x; LUND E, UNPUB; Lyles DS, 1996, VIROLOGY, V225, P172, DOI 10.1006/viro.1996.0585; Marshallsay C, 1996, NUCLEIC ACIDS RES, V24, P1829, DOI 10.1093/nar/24.10.1829; MATTAJ IW, 1986, CELL, V46, P905, DOI 10.1016/0092-8674(86)90072-3; MELCHIOR F, 1995, CURR OPIN CELL BIOL, V7, P310, DOI 10.1016/0955-0674(95)80084-0; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MICHAEL WM, 1995, CELL, V83, P415; MICHAUD N, 1991, J CELL BIOL, V112, P215, DOI 10.1083/jcb.112.2.215; MOORE MS, 1994, TRENDS BIOCHEM SCI, V19, P211, DOI 10.1016/0968-0004(94)90024-8; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; Palacios I, 1996, J CELL BIOL, V133, P485, DOI 10.1083/jcb.133.3.485; Pante N, 1996, SCIENCE, V273, P1729, DOI 10.1126/science.273.5282.1729; Pante N, 1995, INT REV CYTOL, V162B, P225; Pante N, 1996, CURR OPIN CELL BIOL, V8, P397, DOI 10.1016/S0955-0674(96)80016-0; Paschal BM, 1996, P NATL ACAD SCI USA, V93, P7679, DOI 10.1073/pnas.93.15.7679; Pasquinelli AE, 1995, RNA, V1, P957; PINOLROMA S, 1993, TRENDS CELL BIOL, V315, P730; POLLARD VW, 1996, TRENDS CELL BIOL, V86, P985; Powers MA, 1997, J CELL BIOL, V136, P241, DOI 10.1083/jcb.136.2.241; POWERS MA, 1994, CELL, V79, P931, DOI 10.1016/0092-8674(94)90024-8; QUI Y, 1994, J VIROL, V68, P2425; Rush MG, 1996, BIOESSAYS, V18, P103, DOI 10.1002/bies.950180206; Saavedra C, 1996, GENE DEV, V10, P1608, DOI 10.1101/gad.10.13.1608; Sazer S, 1996, TRENDS CELL BIOL, V6, P81, DOI 10.1016/0962-8924(96)80992-5; SCHLENSTEDT G, 1995, P NATL ACAD SCI USA, V92, P225, DOI 10.1073/pnas.92.1.225; SCHLENSTEDT G, 1995, EMBO J, V14, P5367, DOI 10.1002/j.1460-2075.1995.tb00221.x; Stutz F, 1996, MOL CELL BIOL, V16, P7144; TACHIBANA T, 1994, J BIOL CHEM, V269, P24542; TERNS MP, 1994, SCIENCE, V264, P959, DOI 10.1126/science.8178154; THOMAS D, 1985, J VIROL, V54, P598, DOI 10.1128/JVI.54.2.598-607.1985; TOROK I, 1995, J CELL BIOL, V129, P1473, DOI 10.1083/jcb.129.6.1473; VARVEL V, UNPUB; Visa N, 1996, CELL, V84, P253, DOI 10.1016/S0092-8674(00)80980-0; Visa N, 1996, J CELL BIOL, V133, P5, DOI 10.1083/jcb.133.1.5; WAGNER RR, 1984, COMPR VIROL, V19, P223; WECK PK, 1979, J VIROL, V30, P410, DOI 10.1128/JVI.30.1.410-413.1979; WU FS, 1980, BIOCHEMISTRY-US, V19, P804, DOI 10.1021/bi00545a029; WU J, 1995, J BIOL CHEM, V270, P14209, DOI 10.1074/jbc.270.23.14209; YOKOYAMA N, 1995, NATURE, V376, P184, DOI 10.1038/376184a0	81	152	156	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 20	1997	276	5320					1845	1848		10.1126/science.276.5320.1845	http://dx.doi.org/10.1126/science.276.5320.1845			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XF103	9188527				2022-12-01	WOS:A1997XF10300044
J	Lacey, CJN; Merrick, DW; Bensley, DC; Fairley, I				Lacey, CJN; Merrick, DW; Bensley, DC; Fairley, I			Analysis of the sociodemographic of gonorrhoea in Leeds, 1989-93	BRITISH MEDICAL JOURNAL			English	Article							TRANSMISSION; INTERVENTION; PREVENTION	Objective: To investigate the epidemiology of gonorrhoea in an urban area in the United Kingdom. Design: Analysis of all cases of gonorrhoea with regard to age, sex, ethnic group, and socioeconomic group with 1991 census data: as a denominator. Setting: Leeds, a comparatively large urban area (population around 700 000) in the United Kingdom. Subjects: All residents of Leeds with culture proved cases of gonorrhoea during 1989-93. Main outcome measure: Relative risk of gonorrhoea Results: Sex, age, race, and socioeconomic group and area of residence were all independently predictive of risk of infection. Young black men aged 20-29 were at highest risk, with incidences of 3-4% per year. Black subjects were 10 times more likely than white subjects to acquire-infection, and subjects from the most deprived socioeconomic areas were more than four times more likely than those from the most affluent areas to acquire infection. Conclusions: Different ethnic and socioeconomic groups vary in their risk of infection with gonorrhoea within an urban area Targeted interventions and screening to reduce the incidence of sexually transmitted disease are now priorities.	GEN INFIRM,DEPT GENITOURINARY MED,LEEDS LS1 3EX,W YORKSHIRE,ENGLAND; NO & YORKSHIRE REG HLTH AUTHOR,REG PUBL HLTH ANAL UNIT,HARROGATE HG1 5AH,N YORKSHIRE,ENGLAND	Leeds General Infirmary								BENSLEY DC, 1994, CENSUS BASED VIEW PO; Blair I, 1994, Commun Dis Rep CDR Rev, V4, pR25; Breslow NE, 1980, IARC SCI PUBL, VI; BRESLOW NE, 1987, IARC SCI PUBL, V82; BROWN B, 1994, DESIGN CONSTRUCTION; Department of Health, 1992, HLTH NAT STRAT HLTH; FURSTENBERG FF, 1987, MILBANK Q, V65, P381, DOI 10.2307/3349996; JEMMOTT JB, 1992, AM J PUBLIC HEALTH, V82, P372, DOI 10.2105/AJPH.82.3.372; Johnson AM, 1994, SEXUAL ATTITUDES LIF; KELLY JA, 1994, AM J PUBLIC HEALTH, V84, P1918, DOI 10.2105/AJPH.84.12.1918; MAY RM, 1981, NATURE, V291, P376, DOI 10.1038/291376a0; MIETTINEN OS, 1970, BIOMETRICS, V26, P75, DOI 10.2307/2529046; POTTERAT JJ, 1985, SEX TRANSM DIS, V12, P25, DOI 10.1097/00007435-198501000-00006; RALEIGH VS, 1994, BRIT MED J, V309, P287, DOI 10.1136/bmj.309.6950.287; RICE RJ, 1991, AM J PUBLIC HEALTH, V81, P1252, DOI 10.2105/AJPH.81.10.1252; ROTHENBERG RB, 1983, AM J EPIDEMIOL, V117, P688, DOI 10.1093/oxfordjournals.aje.a113602; Wallace R, 1997, BRIT MED J, V314, P1341, DOI 10.1136/bmj.314.7090.1341; Webster Linda A., 1993, Morbidity and Mortality Weekly Report, V42, P1; YORKE JA, 1978, SEX TRANSM DIS, V5, P51, DOI 10.1097/00007435-197804000-00003; [No title captured]; 1995, COMMUN DIS REP CDR W, V5, P62; 1996, COMMUN DIS REP CDR W, V6, P110	22	85	85	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 14	1997	314	7096					1715	1718		10.1136/bmj.314.7096.1715	http://dx.doi.org/10.1136/bmj.314.7096.1715			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XE909	9185496	Green Published			2022-12-01	WOS:A1997XE90900018
J	Sniegowski, PD; Gerrish, PJ; Lenski, RE				Sniegowski, PD; Gerrish, PJ; Lenski, RE			Evolution of high mutation rates in experimental populations of E-coli	NATURE			English	Article							TERM EXPERIMENTAL EVOLUTION; ESCHERICHIA-COLI; GENE-PRODUCT; IDENTIFICATION; ADAPTATION; ENVIRONMENT; COMPETITION; SELECTION; CLONING; MUTS	Most mutations are likely to be deleterious, and so the spontaneous mutation rate is generally held at a very low value(1). Nonetheless, evolutionary theory predicts that high mutation rates can evolve under certain circumstances(2-4). Empirical observations have previously been limited to short-term studies of the fates of mutator strains deliberately introduced into laboratory populations of Escherichia coli(5-7), an to the effects of intense selective events on mutator frequencies in E. coli(8). Here we report the rise of spontaneously originated mutators in populations of E. coli undergoing long-term adaptation to a new environment; Our results corroborate computer simulations of mutator evolution in adapting clonal populations(4), and may help to explain observations that associate high mutation rates with emerging pathogens' and with certain cancers(10).	MICHIGAN STATE UNIV,CTR MICROBIAL ECOL,E LANSING,MI 48824	Michigan State University	Sniegowski, PD (corresponding author), UNIV PENN,DEPT BIOL,PHILADELPHIA,PA 19104, USA.		Gerrish, Philip/AAE-7346-2019	Lenski, Richard/0000-0002-1064-8375; Gerrish, Philip/0000-0001-6393-0553				BHATNAGAR SK, 1988, J BIOL CHEM, V263, P8953; Carlton BC, 1981, MANUAL METHODS GENER, P222; CHAO L, 1983, EVOLUTION, V37, P125, DOI 10.1111/j.1558-5646.1983.tb05521.x; COX EC, 1974, GENETICS, V77, P169; DRAKE JW, 1991, ANNU REV GENET, V25, P125, DOI 10.1146/annurev.ge.25.120191.001013; Elena SF, 1996, SCIENCE, V272, P1802, DOI 10.1126/science.272.5269.1802; HORIUCHI T, 1981, P NATL ACAD SCI-BIOL, V78, P3770, DOI 10.1073/pnas.78.6.3770; ISHII K, 1989, GENETICS, V121, P163; LeClerc JE, 1996, SCIENCE, V274, P1208, DOI 10.1126/science.274.5290.1208; LEDERBERG S, 1966, J BACTERIOL, V91, P1029, DOI 10.1128/JB.91.3.1029-1036.1966; LEIGH EG, 1970, AM NAT, V104, P301, DOI 10.1086/282663; LENSKI RE, 1991, AM NAT, V138, P1315, DOI 10.1086/285289; LENSKI RE, 1994, P NATL ACAD SCI USA, V91, P6808, DOI 10.1073/pnas.91.15.6808; Luria SE, 1943, GENETICS, V28, P491; MA WT, 1992, J APPL PROBAB, V29, P255, DOI 10.2307/3214564; Mao EF, 1997, J BACTERIOL, V179, P417, DOI 10.1128/jb.179.2.417-422.1997; Miller J.H., 1992, SHORT COURSE BACTERI, P150; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; MODRICH P, 1995, PHILOS T ROY SOC B, V347, P89, DOI 10.1098/rstb.1995.0014; MOXON ER, 1994, CURR BIOL, V4, P24, DOI 10.1016/S0960-9822(00)00005-1; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; PANG PP, 1985, J BACTERIOL, V163, P1007, DOI 10.1128/JB.163.3.1007-1015.1985; Sambrook E., 1989, MOL CLONING LAB MANU; SCHAAPER RM, 1992, J BACTERIOL, V174, P1974, DOI 10.1128/jb.174.6.1974-1982.1992; STEWART FM, 1994, GENETICS, V137, P1139; Taddei F, 1997, NATURE, V387, P700, DOI 10.1038/42696; TAUCHERSCHOLZ G, 1983, EUR J BIOCHEM, V137, P573, DOI 10.1111/j.1432-1033.1983.tb07864.x; Travisano M, 1996, GENETICS, V143, P15; TROBNER W, 1984, MOL GEN GENET, V198, P175, DOI 10.1007/BF00328719; VASI F, 1994, AM NAT, V144, P432, DOI 10.1086/285685	30	641	652	3	132	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 12	1997	387	6634					703	705		10.1038/42701	http://dx.doi.org/10.1038/42701			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XD869	9192894	Bronze			2022-12-01	WOS:A1997XD86900053
J	SuarezAlmazor, ME; Belseck, E; Russell, AS; Mackel, JV				SuarezAlmazor, ME; Belseck, E; Russell, AS; Mackel, JV			Use of lumbar radiographs for the early diagnosis of low back pain - Proposed guidelines would increase utilization	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							X-RAY; SPINE EXAMINATION; PRIMARY CARE	Objective.-The Agency for Health Care Policy and Research (AHCPR) has recently published guidelines for the management of patients with acute low back pain, which include recommendations for the use of lumbar radiographs, based on the identification of ''red flags'' for fractures, tumors, or infections. The purpose of this study was to evaluate the potential impact of these guidelines in patients with new episodes of low back pain seen in primary care settings. Design.-Retrospective cohort study. Setting.-Four family clinics (18 physicians) in Edmonton, Alberta. Patients.-The records of all patients seen in 1992 and 1993 with a new episode of low back pain were reviewed: 963 patients had a history of back pain of less than 3 months. Outcome Measures.-Lumbar radiograph utilization at the initial low back pain visit. Charts were also reviewed to determine subsequent occurrence of spinal tumors, infection, or fractures that could be related to low back pain. Results.-One hundred twenty-seven (13%) of the 963 patients with acute low back pain had lumbar radiographs during their first visit, 68 (54%) with oblique views. If the AHCPR guidelines had been applied to this population, 426 (44%) of the patients would have undergone radiography, increasing current utilization by 238%. Eight of the 963 patients had a diagnosis of fracture or bone tumor during follow-up. The sensitivity of the guidelines to potentially detect these diseases was higher than the physicians' utilization patterns, but their specificity and positive predictive values were low. Conclusions.-The implementation of the AHCPR guidelines for the initial use of radiographs in patients with low back pain may increase utilization and economic costs. A more restricted and cost-efficient set of guidelines should be proposed.	UNIV ALBERTA,DEPT MED,EDMONTON,AB,CANADA; UNIV ALBERTA,DEPT FAMILY MED,EDMONTON,AB,CANADA	University of Alberta; University of Alberta	SuarezAlmazor, ME (corresponding author), UNIV ALBERTA,HERITAGE MED RES CTR 214,HEALTHCARE QUAL & OUTCOMES RES CTR,DEPT PUBL HLTH SCI,EDMONTON,AB T6G 2S2,CANADA.							ABENHAIM L, 1987, J OCCUP ENVIRON MED, V29, P670; [Anonymous], 1994, AHCPR PUBL, V94-0592; Barton J E, 1976, J Fam Pract, V3, P363; BIERINGSORENSEN F, 1983, SCAND J REHABIL MED, V15, P89; BIERINGSORENSEN F, 1985, SPINE, V10, P445, DOI 10.1097/00007632-198506000-00008; BIGOS S, 1994, AAHCPR PUBL; BREKKAN A, 1983, CLIN RADIOL, V34, P321, DOI 10.1016/S0009-9260(83)80349-3; CYPRESS BK, 1983, AM J PUBLIC HEALTH, V73, P389, DOI 10.2105/AJPH.73.4.389; DEYO RA, 1986, J GEN INTERN MED, V1, P328, DOI 10.1007/BF02596214; DEYO RA, 1986, J GEN INTERN MED, V1, P20, DOI 10.1007/BF02596320; Edelstyn G A, 1967, Clin Radiol, V18, P158, DOI 10.1016/S0009-9260(67)80010-2; FRAZIER LM, 1986, ARCH INTERN MED, V149, P47; FRYMOYER JW, 1980, SPINE, V5, P419, DOI 10.1097/00007632-198009000-00005; HALL FM, 1976, RADIOLOGY, V120, P443, DOI 10.1148/120.2.443; HALPIN SFS, 1991, BRIT MED J, V303, P813, DOI 10.1136/bmj.303.6806.813; LIANG M, 1982, ARCH INTERN MED, V142, P1108, DOI 10.1001/archinte.142.6.1108; MAGORA A, 1980, SCAND J REHABIL MED, V12, P47; NACHEMSON A L, 1976, Spine, V1, P59, DOI 10.1097/00007632-197603000-00009; RHEA JT, 1980, RADIOLOGY, V134, P45, DOI 10.1148/radiology.134.1.7350633; SACKETT DS, 1985, CLIN EPIDEMIOLOGY BA, P148; SARASTE H, 1984, INT ORTHOP, V8, P163, DOI 10.1007/BF00269912; SCAVONE JG, 1981, AM J ROENTGENOL, V136, P715, DOI 10.2214/ajr.136.4.715; SCHROTH WS, 1992, J GEN INTERN MED, V7, P486, DOI 10.1007/BF02599449; SIMMONS ED, 1995, SPINE, V20, P1839, DOI 10.1097/00007632-199508150-00017; SKOVRON ML, 1992, BAILLIERE CLIN RHEUM, V6, P559, DOI 10.1016/S0950-3579(05)80127-X; Spitzer WO, 1987, SPINE, V12, P1, DOI DOI 10.1097/00007632-198701000-00001; *US DEP HHS, 1988, INT CLASS DIS 9 REV; WHALEN JP, 1982, DIS MON, V28, P73; *WHO, 1983, RAT APPR RAD INV, P31; *WHO, 1983, WHO TECHN REP SER, V689; WITT I, 1984, SPINE, V9, P298, DOI 10.1097/00007632-198404000-00014	31	75	75	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 11	1997	277	22					1782	1786		10.1001/jama.277.22.1782	http://dx.doi.org/10.1001/jama.277.22.1782			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XC499	9178791				2022-12-01	WOS:A1997XC49900031
J	Swerdlow, AJ; Higgins, CD; Pike, MC				Swerdlow, AJ; Higgins, CD; Pike, MC			Risk of testicular cancer in cohort of boys with cryptorchidism	BRITISH MEDICAL JOURNAL			English	Article							INGUINAL-HERNIA; TESTIS; BIOPSY; AGE	Objective: To determine the risk of testicular cancer in relation to undescended testis and its treatment based on recorded details of the maldescent, treatment, and biopsy from case notes. Design: Cohort study. Setting: Hospital for Sick Children, Great Ormond Street, London. Subjects: 1075 boys with cryptorchidism treated by orchidopexy or hormones at the hospital during 1951-64. Main outcome measures: Relative risk of testicular cancer in the cohort compared with men in the general population. Results: 12 testicular cancers occurred in 11 of the patients during follow up to mid-1990 (relative risk of cancer in males with cryptorchidism = 7.5 (95% confidence interval 3.9 to 12.8)). The relative risk fell significantly beyond 15 years after orchidopexy but did not decrease with younger age at orchidopexy. Risk was significantly raised in testes that had had biopsy samples removed during orchidopexy (relative risk = 66.7 (23.9 to 143.3) compared with a testis in a man in the general population) and was significantly greater in these testes than in undescended testes that had not had biopsy samples taken at orchidopexy (6.7 (2.7 to 13.5)). No reasons for biopsy or distinguishing clinical aspects of the testes that had had biopsy samples taken and later developed malignancies were evident in the case notes. No histological abnormalities were evident at initial biopsy except in one testis that had features of dysgenesis. Conclusions: Biopsy seems to be a stronger risk factor for testicular cancer than any factor previously identified. The trauma of open biopsy may contribute substantially to risk of malignancy or the testes may have been selected for biopsy on the basis of clinical factors predictive of malignancy but not mentioned in the case notes.	UNIV SO CALIF,SCH MED,DEPT PREVENT MED,NORRIS COTTON CANC CTR,LOS ANGELES,CA 90033	Norris Cotton Cancer Center; University of Southern California	Swerdlow, AJ (corresponding author), LONDON SCH HYG & TROP MED,EPIDEMIOL MONITORING UNIT,DEPT EPIDEMIOL & POPULAT SCI,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.			Swerdlow, Anthony/0000-0001-5550-4159	NCI NIH HHS [CA14089] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA014089] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENSON RC, 1991, MAYO CLIN PROC, V66, P372, DOI 10.1016/S0025-6196(12)60660-0; CHILVERS C, 1986, J PEDIATR SURG, V21, P691, DOI 10.1016/S0022-3468(86)80389-X; CHILVERS C, 1992, EUROPEAN UROLOGY UPD, V1, P74; Farrington GH, 1971, CONGENITAL DEFORMITI; FORMAN D, 1994, BRIT MED J, V308, P1393, DOI 10.1136/bmj.308.6941.1393; GASSNER FX, 1955, FERTIL STERIL, V6, P290; GIWERCMAN A, 1987, J UROLOGY, V138, P1214, DOI 10.1016/S0022-5347(17)43553-1; GORDON DL, 1965, FERTIL STERIL, V16, P522; HAWKINS MM, 1992, BRIT J CANCER, V66, P408, DOI 10.1038/bjc.1992.279; HENDERSON BE, 1983, UROLOGICAL CANCER, P237; HJORT T, 1974, CLIN EXP IMMUNOL, V18, P201; JOHNSON DE, 1968, SURGERY, V63, P919; MENGEL W, 1974, J PEDIATR SURG, V9, P445, DOI 10.1016/S0022-3468(74)80003-5; PARKINSON MC, 1994, BRIT J UROL, V73, P431, DOI 10.1111/j.1464-410X.1994.tb07610.x; PIKE MC, 1986, LANCET, V1, P1246; PINCZOWSKI D, 1991, J UROLOGY, V146, P1291, DOI 10.1016/S0022-5347(17)38071-0; PLOEN L, 1984, DEV RECENTS ENDOCRIN, V123, P97; POTTERN LM, 1985, J NATL CANCER I, V74, P377; Prener A, 1996, EPIDEMIOLOGY, V7, P14, DOI 10.1097/00001648-199601000-00004; PRESTON DL, 1993, EPICURE; PRESTONMARTIN S, 1990, CANCER RES, V50, P7415; ROWLEY MJ, 1969, J UROLOGY, V101, P347, DOI 10.1016/S0022-5347(17)62341-3; Schwedes U, 1974, Andrologia, V6, P71; SPITZ MR, 1986, CANCER, V58, P1785, DOI 10.1002/1097-0142(19861015)58:8<1785::AID-CNCR2820580836>3.0.CO;2-2; STAMPFLI M, 1991, EUR J PEDIATR SURG, V1, P36, DOI 10.1055/s-2008-1042456; STRADER CH, 1988, AM J EPIDEMIOL, V127, P1013, DOI 10.1093/oxfordjournals.aje.a114877; SWERDLOW AJ, 1988, BRIT J UROL, V61, P518, DOI 10.1111/j.1464-410X.1988.tb05094.x; SWERDLOW AJ, 1988, BRIT J IND MED, V45, P225; SWERDLOW AJ, 1987, BRIT J CANCER, V55, P97, DOI 10.1038/bjc.1987.20; VERP MS, 1987, CANCER GENET CYTOGEN, V25, P191, DOI 10.1016/0165-4608(87)90180-4	30	145	148	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 24	1997	314	7093					1507	1511		10.1136/bmj.314.7093.1507	http://dx.doi.org/10.1136/bmj.314.7093.1507			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XB484	9169396	Green Published			2022-12-01	WOS:A1997XB48400020
J	Romero, MF; Hediger, MA; Boulpaep, EL; Boron, WF				Romero, MF; Hediger, MA; Boulpaep, EL; Boron, WF			Expression cloning and characterization of a renal electrogenic Na+/HCO3- cotransporter	NATURE			English	Article							SODIUM-BICARBONATE COTRANSPORT; ACID-BASE TRANSPORT; SQUID GIANT-AXONS; NA-H EXCHANGE; INTRACELLULAR PH; BASOLATERAL MEMBRANE; PROXIMAL TUBULE; RAT HEPATOCYTES; GLIAL-CELLS; CDNA	Bicarbonate transporters are the principal regulators of pH in animal cells, and play a vital role in acid-base movement in the stomach, pancreas, intestine, kidney, reproductive system and central nervous system. The functional family of HCO3- transporters includes Cl--HCO3- exchangers, three Na+/HCO3- cotransporters(1-3), a K+/HCO3- cotransporter(4,5), and a Na+-driven Cl--HCO3- exchanger(6,7). Molecular information is sparse on HCO3- transporters, apart from Cl--HCO3- exchangers ('anion exchangers'), whose complementary DNAs were cloned several years ago(8-11). Attempts to done other HCO3- transporters, based on binding of inhibitors, protein purification or homology with anion exchangers, have so far been unsuccessful. Here we monitor the intracellular PH and membrane voltage in Xenopus oocytes to follow the expression of the most electrogenic transporter known: the renal 1:3 electrogenic Na+/HCO3- cotransporter from the salamander Ambystoma tigrinum. We now report the successful cloning and characterization of a cDNA encoding a cation-coupled HCO3- transporter. The encoded protein is 1,035 amino acids long with several potential membrane-spanning domains. We show that when it is expressed in Xenopus oocytes, this protein is electrogenic, Na+ and HCO3- dependent, and blocked by the anion-transport inhibitor DIDS, and conclude that it is the renal electrogenic sodium bicarbonate cotransporter (NBC).	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT BIOL CHEM & MOL PHARMACOL,RENAL DIV,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Romero, MF (corresponding author), YALE UNIV,SCH MED,DEPT CELLULAR & MOL PHYSIOL,NEW HAVEN,CT 06510, USA.		Boron, Walter/ABI-1564-2020	Romero, Michael F/0000-0002-1555-7835; Boron, Walter/0000-0003-4741-7287; Hediger, Matthias/0000-0003-1946-027X	NIDDK NIH HHS [F32 DK009342, F32 DK009342-03, F32 DK009342-02, F32 DK009342-01] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009342] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALPER SL, 1988, J BIOL CHEM, V263, P17092; ALPER SL, 1991, ANNU REV PHYSIOL, V53, P549, DOI 10.1146/annurev.physiol.53.1.549; BORON WF, 1983, J GEN PHYSIOL, V81, P53, DOI 10.1085/jgp.81.1.53; DART C, 1992, J PHYSIOL-LONDON, V451, P365, DOI 10.1113/jphysiol.1992.sp019169; DEITMER JW, 1987, J PHYSIOL-LONDON, V388, P261, DOI 10.1113/jphysiol.1987.sp016614; FITZ JG, 1989, AM J PHYSIOL, V256, pG491, DOI 10.1152/ajpgi.1989.256.3.G491; GLEESON D, 1989, J CLIN INVEST, V84, P312, DOI 10.1172/JCI114156; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; HEDIGER MA, 1994, PHYSIOL REV, V74, P993, DOI 10.1152/physrev.1994.74.4.993; HOGAN EM, 1995, J GEN PHYSIOL, V106, P821, DOI 10.1085/jgp.106.5.821; HOGAN EM, 1995, J GEN PHYSIOL, V106, P845, DOI 10.1085/jgp.106.5.845; Ishiguro H, 1996, J PHYSIOL-LONDON, V495, P169, DOI 10.1113/jphysiol.1996.sp021582; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KOPITO RR, 1985, NATURE, V316, P234, DOI 10.1038/316234a0; KOPITO RR, 1989, CELL, V59, P927, DOI 10.1016/0092-8674(89)90615-6; KUDRYCKI KE, 1990, J BIOL CHEM, V265, P462; NEWMAN EA, 1991, GLIA, V4, P424, DOI 10.1002/glia.440040411; Newman EA, 1996, J NEUROSCI, V16, P159; RAJENDRAN VM, 1991, J CLIN INVEST, V88, P1379, DOI 10.1172/JCI115444; REITHMEIER RAF, 1993, CURR OPIN STRUC BIOL, V3, P515, DOI 10.1016/0959-440X(93)90077-X; RUSSELL JM, 1976, NATURE, V264, P73, DOI 10.1038/264073a0; Sambrook J., 1989, MOL CLONING LAB MANU; SOLEIMANI M, 1987, J CLIN INVEST, V79, P1276, DOI 10.1172/JCI112948; SOLEIMANI M, 1992, J BIOL CHEM, V267, P18349; THOMAS RC, 1977, J PHYSIOL-LONDON, V273, P317, DOI 10.1113/jphysiol.1977.sp012096; WEINTRAUB WH, 1989, AM J PHYSIOL, V257, pG317, DOI 10.1152/ajpgi.1989.257.3.G317; YOSHITOMI K, 1985, PFLUG ARCH EUR J PHY, V405, P360, DOI 10.1007/BF00595689	27	356	367	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 22	1997	387	6631					409	413		10.1038/387409a0	http://dx.doi.org/10.1038/387409a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XA496	9163427				2022-12-01	WOS:A1997XA49600062
J	King, DP; Zhao, YL; Sangoram, AM; Wilsbacher, LD; Tanaka, M; Antoch, MP; Steeves, TDL; Vitaterna, MH; Kornhauser, JM; Lowrey, PL; Turek, FW; Takahashi, JS				King, DP; Zhao, YL; Sangoram, AM; Wilsbacher, LD; Tanaka, M; Antoch, MP; Steeves, TDL; Vitaterna, MH; Kornhauser, JM; Lowrey, PL; Turek, FW; Takahashi, JS			Positional cloning of the mouse circadian Clock gene	CELL			English	Article							ARTIFICIAL CHROMOSOME LIBRARY; MESSENGER-RNA LEVELS; DROSOPHILA PERIOD; AH-RECEPTOR; DNA-BINDING; TRANSCRIPTION FACTOR; PROTEIN-INTERACTION; DIOXIN RECEPTOR; TIMELESS; DOMAIN	We used positional cloning to identify the circadian Clock gene in mice. Clock is a large transcription unit with 24 exons spanning similar to 100,000 bp of DNA from which transcript classes of 7.5 and similar to 10 kb arise. Clock encodes a novel member of the bHLH-PAS family of transcription factors. In the Clock mutant allele, an A-->T nucleotide transversion in a splice donor site causes exon skipping and deletion of 51 amino acids in the CLOCK protein. Clock is a unique gene with known circadian function and with features predicting DNA binding, protein dimerization, and activation domains. CLOCK represents the second example of a PAS domain-containing clock protein (besides Drosophila PERIOD), which suggests that this motif may define an evolutionarily conserved feature of the circadian clock mechanism.	NORTHWESTERN UNIV, DEPT NEUROBIOL & PHYSIOL, NATL SCI FDN CTR BIOL TIMING, EVANSTON, IL 60208 USA	National Science Foundation (NSF); NSF - Center for Biological Timing; Northwestern University			Takahashi, Joseph S./Y-2781-2019; Takahashi, Joseph S/E-8482-2012	Takahashi, Joseph S./0000-0003-0384-8878; Takahashi, Joseph S/0000-0003-0384-8878; Antoch, mantoch/0000-0003-3001-8511	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD028048] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008152] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH039592] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AKAGI J, 1988, BIOCHEM BIOPH RES CO, V157, P548, DOI 10.1016/S0006-291X(88)80284-5; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; BRUNKOW ME, 1995, GENOMICS, V25, P421, DOI 10.1016/0888-7543(95)80042-K; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; CHARTIER FL, 1992, NAT GENET, V1, P132, DOI 10.1038/ng0592-132; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINSON IR, 1994, BIOCHEMISTRY-US, V33, P7971, DOI 10.1021/bi00191a026; DIETRICH W, 1992, GENETICS, V131, P423; DOVE WF, 1987, GENETICS, V116, P5; Dracopoli NC, 1994, CURRENT PROTOCOLS HU; Dunlap JC, 1996, ANNU REV GENET, V30, P579, DOI 10.1146/annurev.genet.30.1.579; EDERY I, 1994, P NATL ACAD SCI USA, V91, P2260, DOI 10.1073/pnas.91.6.2260; Fukada S, 1996, MOL REPROD DEV, V45, P285, DOI 10.1002/(SICI)1098-2795(199611)45:3&lt;285::AID-MRD4&gt;3.0.CO;2-O; Fukuda S., 1995, Development, Growth & Differentiation, V37, P379, DOI 10.1046/j.1440-169X.1995.t01-3-00004.x; GEKAKIS N, 1995, SCIENCE, V270, P811, DOI 10.1126/science.270.5237.811; Gradin K, 1996, MOL CELL BIOL, V16, P5221; HALL JC, 1995, TRENDS NEUROSCI, V18, P230, DOI 10.1016/0166-2236(95)93908-G; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; HARDIN PE, 1992, P NATL ACAD SCI USA, V89, P11711, DOI 10.1073/pnas.89.24.11711; HAWKINS TL, 1994, NUCLEIC ACIDS RES, V22, P4543, DOI 10.1093/nar/22.21.4543; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; Klein D.C., 1991, SUPRACHIASMATIC NUCL; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; KRAWCZAK M, 1992, HUM GENET, V90, P41; KUSUMI K, 1993, MAMM GENOME, V4, P391, DOI 10.1007/BF00360591; LARIN Z, 1991, P NATL ACAD SCI USA, V88, P4123, DOI 10.1073/pnas.88.10.4123; Lee CG, 1996, SCIENCE, V271, P1740, DOI 10.1126/science.271.5256.1740; LINDEBRO MC, 1995, EMBO J, V14, P3528, DOI 10.1002/j.1460-2075.1995.tb07359.x; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; LOVETT M, 1994, TRENDS GENET, V10, P352, DOI 10.1016/0168-9525(94)90131-7; Lynch G. Robert, 1992, V8, P251; MEIJER JH, 1989, PHYSIOL REV, V69, P671, DOI 10.1152/physrev.1989.69.3.671; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOORE RY, 1995, CIBA F SYMP, V183, P88; MURALIDHAR MG, 1993, NEURON, V11, P253, DOI 10.1016/0896-6273(93)90182-Q; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MYERS MP, 1995, SCIENCE, V270, P805, DOI 10.1126/science.270.5237.805; NAMBU JR, 1991, CELL, V67, P1157, DOI 10.1016/0092-8674(91)90292-7; Pittendrigh C, 1993, ANNU REV PHYSIOL, V55, P17; RALPH MR, 1988, SCIENCE, V241, P1225, DOI 10.1126/science.3413487; RALPH MR, 1990, SCIENCE, V247, P975, DOI 10.1126/science.2305266; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; Saez L, 1996, NEURON, V17, P911, DOI 10.1016/S0896-6273(00)80222-6; Sambrook J., 1989, MOL CLONING LAB MANU, V3; SCHWARTZ WJ, 1990, J NEUROSCI, V10, P3685; SEHGAL A, 1995, SCIENCE, V270, P808, DOI 10.1126/science.270.5237.808; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; SIWICKI KK, 1988, NEURON, V1, P141, DOI 10.1016/0896-6273(88)90198-5; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; SUHR ST, 1989, MOL ENDOCRINOL, V3, P1693, DOI 10.1210/mend-3-11-1693; SWANSON HI, 1993, PHARMACOGENETICS, V3, P213, DOI 10.1097/00008571-199310000-00001; SWANSON HI, 1995, J BIOL CHEM, V270, P26292, DOI 10.1074/jbc.270.44.26292; Takahashi J S, 1991, Curr Opin Neurobiol, V1, P556, DOI 10.1016/S0959-4388(05)80028-5; TAKAHASHI JS, 1994, SCIENCE, V264, P1724, DOI 10.1126/science.8209253; TAKAHASHI JS, 1995, ANNU REV NEUROSCI, V18, P531, DOI 10.1146/annurev.neuro.18.1.531; TAKAHASHI JS, 1992, SCIENCE, V258, P238, DOI 10.1126/science.1384127; Tosini G, 1996, SCIENCE, V272, P419, DOI 10.1126/science.272.5260.419; TUREK FW, 1996, HDB PHYSL 4, V2, P1329; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; Wilk R, 1996, GENE DEV, V10, P93, DOI 10.1101/gad.10.1.93; Yamaguchi T, 1996, J BIOCHEM-TOKYO, V120, P494; ZENG HK, 1994, EMBO J, V13, P3590, DOI 10.1002/j.1460-2075.1994.tb06666.x; Zhou YD, 1997, P NATL ACAD SCI USA, V94, P713, DOI 10.1073/pnas.94.2.713; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]	74	1061	1116	2	74	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 16	1997	89	4					641	653		10.1016/S0092-8674(00)80245-7	http://dx.doi.org/10.1016/S0092-8674(00)80245-7			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WZ323	9160755	Bronze, Green Accepted			2022-12-01	WOS:A1997WZ32300017
J	Rief, M; Gautel, M; Oesterhelt, F; Fernandez, JM; Gaub, HE				Rief, M; Gautel, M; Oesterhelt, F; Fernandez, JM; Gaub, HE			Reversible unfolding of individual titin immunoglobulin domains by AFM	SCIENCE			English	Article							ATOMIC-FORCE MICROSCOPE; ELASTICITY; MUSCLE; PROTEINS; ADHESION; ENERGY; DNA	Single-molecule atomic force microscopy (AFM) was used to investigate the mechanical properties of titin, the giant sarcomeric protein of striated muscle. Individual titin molecules were repeatedly stretched, and the applied force was recorded as a function of the elongation. At large extensions, the restoring force exhibited a sawtoothlike pattern, with a periodicity that varied between 25 and 28 nanometers. Measurements of recombinant titin immunoglobulin segments of two different lengths exhibited the same pattern and allowed attribution of the discontinuities to the unfolding of individual immunoglobutin domains. The forces required to unfold individual domains ranged from 150 to 300 piconewtons and depended on the pulling speed. Upon relaxation, refolding of immunoglobulin domains was observed.	LEHRSTUHL ANGEW PHYS,D-80799 MUNICH,GERMANY; EUROPEAN MOL BIOL LAB,BIOL STRUCT DIV,D-69012 HEIDELBERG,GERMANY; MAYO CLIN & MAYO FDN,DEPT PHYSIOL & BIOPHYS,ROCHESTER,MN 55905	University of Munich; European Molecular Biology Laboratory (EMBL); Mayo Clinic			Gautel, Mathias/AAB-9860-2019					BELL GI, 1978, SCIENCE, V200, P618, DOI 10.1126/science.347575; BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930; BINNIG G, 1987, REV MOD PHYS, V59, P615, DOI 10.1103/RevModPhys.59.615; BUSTAMANTE C, 1994, SCIENCE, V265, P1599, DOI 10.1126/science.8079175; Cluzel P, 1996, SCIENCE, V271, P792, DOI 10.1126/science.271.5250.792; Dammer U, 1996, BIOPHYS J, V70, P2437, DOI 10.1016/S0006-3495(96)79814-4; ERICKSON HP, 1994, P NATL ACAD SCI USA, V91, P10114, DOI 10.1073/pnas.91.21.10114; Evans E, 1997, BIOPHYS J, V72, P1541, DOI 10.1016/S0006-3495(97)78802-7; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; FLORIN EL, 1994, SCIENCE, V264, P415, DOI 10.1126/science.8153628; Fong S, 1996, J MOL BIOL, V264, P624, DOI 10.1006/jmbi.1996.0665; FRAUENFELDER H, 1991, SCIENCE, V254, P1598, DOI 10.1126/science.1749933; Gautel M, 1996, FEBS LETT, V385, P11, DOI 10.1016/0014-5793(96)00338-9; Grubmuller H, 1996, SCIENCE, V271, P997, DOI 10.1126/science.271.5251.997; Hinterdorfer P, 1996, P NATL ACAD SCI USA, V93, P3477, DOI 10.1073/pnas.93.8.3477; LABEIT S, 1995, SCIENCE, V270, P293, DOI 10.1126/science.270.5234.293; LEE GU, 1994, SCIENCE, V266, P771, DOI 10.1126/science.7973628; Linke WA, 1996, J MOL BIOL, V261, P62, DOI 10.1006/jmbi.1996.0441; Marko JF, 1995, MACROMOLECULES, V28, P8759, DOI 10.1021/ma00130a008; MARUYAMA K, 1977, J BIOCHEM, V82, P317; MULLER DJ, 1995, J MOL BIOL, V249, P239, DOI 10.1006/jmbi.1995.0292; PAN KM, 1994, BIOCHEMISTRY-US, V33, P8255, DOI 10.1021/bi00193a012; PERKINS TT, 1995, SCIENCE, V268, P83, DOI 10.1126/science.7701345; Politou AS, 1996, J MOL BIOL, V255, P604, DOI 10.1006/jmbi.1996.0050; Politou AS, 1995, BIOPHYS J, V69, P2601, DOI 10.1016/S0006-3495(95)80131-1; POLITOU AS, 1994, FEBS LETT, V352, P27, DOI 10.1016/0014-5793(94)00911-2; RADMACHER M, 1994, SCIENCE, V265, P1577, DOI 10.1126/science.8079171; Rief M, 1997, SCIENCE, V275, P1295, DOI 10.1126/science.275.5304.1295; Smith SB, 1996, SCIENCE, V271, P795, DOI 10.1126/science.271.5250.795; SOTERIOU A, 1993, P ROY SOC B-BIOL SCI, V254, P83, DOI 10.1098/rspb.1993.0130; WANG K, 1979, P NATL ACAD SCI USA, V76, P3698, DOI 10.1073/pnas.76.8.3698	31	2461	2511	13	680	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 16	1997	276	5315					1109	1112		10.1126/science.276.5315.1109	http://dx.doi.org/10.1126/science.276.5315.1109			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WZ225	9148804				2022-12-01	WOS:A1997WZ22500043
J	Anderson, JD; Lau, EL; Sjogren, WL; Schubert, G; Moore, WB				Anderson, JD; Lau, EL; Sjogren, WL; Schubert, G; Moore, WB			Gravitational evidence for an undifferentiated Callisto	NATURE			English	Article							GALILEAN SATELLITES; GRAVITY-FIELD; TRACKING DATA; JUPITER	Before the arrival of the Galileo spacecraft at Jupiter, models for the interior structure of the four galilean satellites-Io, Europa, Ganymede and Callisto-ranged from uniform mixtures of rock and ice (that is, undifferentiated objects) or rocky cores surrounded by a mantle of water ice(1). Now it appears that Io has a large metallic core(2) and that Ganymede is strongly differentiated, most probably into a three-layer structure consisting of a metallic core, a silicate mantle and a deep outer layer of ice(3). Direct information on the interior structure of Callisto determined from previous spacecraft fly-bys(4-6) was essentially limited to an estimate of the mean density being intermediate between pure ice and pure rock, Here we report measurements of Callisto's gravitational field which reveal that, in contrast to Io and Ganymede, this galilean satellite is most probably a homogeneous object consisting of a solar mixture of 40% compressed ice and 60% rock (including iron and iron sulphide), Callisto's undifferentiated state is consistent with the apparent lack of an intrinsic magnetic field(7), and indicates that the outermost galilean satellite has not experienced a heating phase sufficiently high to separate its rock and metal components from the lighter ices.	UNIV CALIF LOS ANGELES,INST GEOPHYS & PLANETARY PHYS,DEPT EARTH & SPACE SCI,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles	Anderson, JD (corresponding author), CALTECH,JET PROP LAB,4800 OAK GROVE DR,PASADENA,CA 91109, USA.							Anderson JD, 1996, NATURE, V384, P541, DOI 10.1038/384541a0; Anderson JD, 1996, SCIENCE, V272, P709, DOI 10.1126/science.272.5262.709; ANDERSON JD, 1974, EXPT GRAVITATION, P163; CAMPBELL JK, 1985, ASTRON J, V90, P364, DOI 10.1086/113741; DERMOTT SF, 1979, ICARUS, V37, P310, DOI 10.1016/0019-1035(79)90137-4; HUBBARD WB, 1978, ICARUS, V33, P336, DOI 10.1016/0019-1035(78)90153-7; JEFFREYS H, 1962, EARTH; Kaula W. M., 1966, THEORY SATELLITE GEO; Kaula W.M., 1968, INTRO PLANETARY PHYS; Khurana KK, 1997, NATURE, V387, P262, DOI 10.1038/387262a0; MALHOTRA R, 1991, ICARUS, V94, P399, DOI 10.1016/0019-1035(91)90237-N; MOYER TD, 1971, TR321527 JET PROP LA; NULL GW, 1976, ASTRON J, V81, P1153, DOI 10.1086/111999; NULL GW, 1975, SCIENCE, V12, P476; Schubert G, 1996, NATURE, V384, P544, DOI 10.1038/384544a0; SCHUBERT G, 1994, ICARUS, V111, P433, DOI 10.1006/icar.1994.1154; SCHUBERT G, 1986, SATELLITES, P629; TAPLEY BD, 1973, RECENT ADV DYNAMICAL, P396; ZHARKOV VN, 1985, ICARUS, V61, P92, DOI 10.1016/0019-1035(85)90157-5	19	49	52	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 15	1997	387	6630					264	266		10.1038/387264a0	http://dx.doi.org/10.1038/387264a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WZ167	9153389				2022-12-01	WOS:A1997WZ16700046
J	Carandini, M; Ferster, D				Carandini, M; Ferster, D			A tonic hyperpolarization underlying contrast adaptation in cat visual cortex	SCIENCE			English	Article							STRIATE CORTEX; RECEPTIVE-FIELDS; SINGLE CELLS; GAIN-CONTROL; NEURONS; INHIBITION; RESPONSES; EXCITATION	The firing rate responses of neurons in the primary visual cortex grow with stimulus contrast, the variation in the luminance of an image relative to the mean luminance. These responses, however, are reduced after a cell is exposed for prolonged periods to high-contrast visual stimuli, This phenomenon, known as contrast adaptation, occurs in the cortex and is not present at earlier stages of visual processing. To investigate the cellular mechanisms underlying cortical adaptation, intracellular recordings were performed in the visual cortex of cats, and the effects of prolonged visual stimulation were studied. Surprisingly, contrast adaptation barely affected the stimulus-driven modulations in the membrane potential of cortical cells. Moreover, it did not produce sizable changes in membrane resistance. The major effect of adaptation, evident both in the presence and in the absence of a visual stimulus, was a tonic hyperpolarization. Adaptation affects a class of synaptic inputs, most likely excitatory in nature, that exert a tonic influence on cortical cells.	NORTHWESTERN UNIV,DEPT NEUROBIOL & PHYSIOL,EVANSTON,IL 60208	Northwestern University			Carandini, Matteo/C-1922-2008; Carandini, Matteo/ABD-8296-2021	Carandini, Matteo/0000-0003-4880-7682; Carandini, Matteo/0000-0003-4880-7682	NATIONAL EYE INSTITUTE [R01EY004726] Funding Source: NIH RePORTER; NEI NIH HHS [EY04726] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALBRECHT DG, 1982, J NEUROPHYSIOL, V48, P217, DOI 10.1152/jn.1982.48.1.217; ALBRECHT DG, 1984, J PHYSIOL-LONDON, V347, P713, DOI 10.1113/jphysiol.1984.sp015092; Barlow H., 1990, VISION CODING EFFICI; BLAKEMORE C, 1969, J PHYSIOL-LONDON, V203, P237, DOI 10.1113/jphysiol.1969.sp008862; BONDS AB, 1991, VISUAL NEUROSCI, V6, P239, DOI 10.1017/S0952523800006258; CARANDINI M, IN PRESS PHILOS T B; DEALY RS, 1974, J PHYSIOL-LONDON, V241, P261, DOI 10.1113/jphysiol.1974.sp010652; DEBRUYN EJ, 1986, BRAIN RES, V383, P339, DOI 10.1016/0006-8993(86)90036-3; DOUGLAS RJ, 1995, SCIENCE, V269, P981, DOI 10.1126/science.7638624; DOUGLAS RJ, 1988, NATURE, V332, P642, DOI 10.1038/332642a0; FERSTER D, 1988, J NEUROSCI, V8, P1172; FERSTER D, 1992, J NEUROSCI, V12, P1262; HEEGER DJ, 1992, VISUAL NEUROSCI, V9, P181, DOI 10.1017/S0952523800009640; KULIKOWSKI JJ, 1981, J PHYSIOL-LONDON, V318, pP21; MAFFEI L, 1973, SCIENCE, V182, P1036, DOI 10.1126/science.182.4116.1036; MAFFEI L, 1986, J NEUROPHYSIOL, V55, P966, DOI 10.1152/jn.1986.55.5.966; MARLIN S, 1993, J NEUROPHYSIOL, V69, P2209, DOI 10.1152/jn.1993.69.6.2209; McLean J, 1996, VISUAL NEUROSCI, V13, P1069, DOI 10.1017/S0952523800007720; MOVSHON JA, 1978, J PHYSIOL-LONDON, V283, P53, DOI 10.1113/jphysiol.1978.sp012488; MOVSHON JA, 1979, NATURE, V278, P850, DOI 10.1038/278850a0; MOVSHON JA, 1978, J PHYSIOL-LONDON, V283, P79, DOI 10.1113/jphysiol.1978.sp012489; NELSON SB, IN PRESS NEUROBIOLOG; OHZAWA I, 1985, J NEUROPHYSIOL, V54, P651, DOI 10.1152/jn.1985.54.3.651; OHZAWA I, 1982, NATURE, V298, P266, DOI 10.1038/298266a0; SAUL AB, 1989, VISUAL NEUROSCI, V2, P593, DOI 10.1017/S0952523800003527; SAUL AB, 1995, VISUAL NEUROSCI, V12, P191, DOI 10.1017/S0952523800007872; SCHWINDT PC, 1988, J NEUROPHYSIOL, V59, P424, DOI 10.1152/jn.1988.59.2.424; Shou TD, 1996, VISUAL NEUROSCI, V13, P605, DOI 10.1017/S0952523800008518; TODOROV EV, IN PRESS NEUROBIOLOG; VAUTIN RG, 1977, J NEUROPHYSIOL, V40, P1051, DOI 10.1152/jn.1977.40.5.1051; VIDYASAGAR TR, 1990, NEUROSCIENCE, V36, P175, DOI 10.1016/0306-4522(90)90360-G	31	281	287	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 9	1997	276	5314					949	952		10.1126/science.276.5314.949	http://dx.doi.org/10.1126/science.276.5314.949			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WY792	9139658				2022-12-01	WOS:A1997WY79200048
J	RodriguezViciana, P; Warne, PH; Khwaja, A; Marte, BM; Pappin, D; Das, P; Waterfield, MD; Ridley, A; Downward, J				RodriguezViciana, P; Warne, PH; Khwaja, A; Marte, BM; Pappin, D; Das, P; Waterfield, MD; Ridley, A; Downward, J			Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras	CELL			English	Article							EPIDERMAL GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; ACTIVATION; BINDING; RHO; PROTEINS; INDUCTION	The pathways by which mammalian Ras proteins induce cortical actin rearrangement and cause cellular transformation are investigated using partial loss of function mutants of Ras and activated and inhibitory forms of various postulated target enzymes for Ras. Efficient transformation by Ras requires activation of other direct effecters in addition to the MAP kinase kinase kinase Raf and is inhibited by inactivation of the PI 3-kinase pathway. Actin rearrangement correlates with the ability of Ras mutants to activate PI 3-kinase. Inhibition of PI 3-kinase activity blocks Ras induction of membrane ruffling, while activated PI 3-kinase is sufficient to induce membrane ruffling, acting through Rac. The ability of activated Ras to stimulate PI 3-kinase in addition to Raf is therefore important in Ras transformation of mammalian cells and essential in Ras-induced cytoskeletal reorganization.	IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND; LUDWIG INST CANC RES, LONDON W1P 8BT, ENGLAND; UCL, DEPT BIOCHEM, LONDON WC1E 6BT, ENGLAND	Cancer Research UK; Ludwig Institute for Cancer Research; University of London; University College London			Khwaja, Asim/C-1509-2008	Downward, Julian/0000-0002-2331-4729; Ridley, Anne/0000-0001-8186-5708; Pappin, Darryl/0000-0002-8981-8401				BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; CARTER AN, 1992, J BIOL CHEM, V267, P14563; CHANG EC, 1994, CELL, V79, P131, DOI 10.1016/0092-8674(94)90406-5; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Klinghoffer RA, 1996, MOL CELL BIOL, V16, P5905; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; NOBES CD, 1995, J CELL SCI, V108, P225; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RIDLEY AJ, 1995, METHOD ENZYMOL, V256, P313; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; SELF AJ, 1995, METHOD ENZYMOL, V256, P3; SKINNER RH, 1994, ANAL BIOCHEM, P259; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12608; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Virbasius JV, 1996, J BIOL CHEM, V271, P13304, DOI 10.1074/jbc.271.23.13304; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	36	912	924	0	13	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	MAY 2	1997	89	3					457	467		10.1016/S0092-8674(00)80226-3	http://dx.doi.org/10.1016/S0092-8674(00)80226-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WX899	9150145	Bronze			2022-12-01	WOS:A1997WX89900016
J	Cohn, MJ; Patel, K; Krumlauf, R; Wilkinson, DG; Clarke, JDW; Tickle, C				Cohn, MJ; Patel, K; Krumlauf, R; Wilkinson, DG; Clarke, JDW; Tickle, C			Hox9 genes and vertebrate limb specification	NATURE			English	Article							ADDITIONAL LIMB; EXPRESSION; FLANK	Development of paired appendages at appropriate levels along the primary body axis is a hallmark of the body plan of jawed vertebrates. Hox genes are good candidates for encoding position in lateral plate mesoderm along the body axis(1,2) and thus for determining where limbs are formed. Local application of fibroblast growth factors (FGFs) to the anterior prospective flank of a chick embryo induces development of an ectopic wing, and FGF applied to posterior flank induces an ectopic leg(3). If particular combinations of Hox gene expression determine where wings and legs develop, then formation of additional limbs from flank should involve changes in Hox gene expression that reflect the type of limb induced. Here we show that the same population of flank cells can be induced to form either a wing or a leg, and that induction of these ectopic limbs is accompanied by specific changes in expression of three Hox genes in lateral plate mesoderm. This then reproduces, in the flank, expression patterns found at normal Limb levels. Hox gene expression is reprogrammed in lateral plate mesoderm, but is unaffected in paraxial mesoderm. Independent regulation of Hox gene expression in lateral plate mesoderm may have been a key step in the evolution of paired appendages.	UNIV LONDON UNIV COLL,SCH MED,DEPT ANAT & DEV BIOL,LONDON WC1E 6BT,ENGLAND; NATL INST MED RES,DIV DEV NEUROBIOL,LONDON NW7 1AA,ENGLAND	University of London; University College London; UCL Medical School; MRC National Institute for Medical Research			Krumlauf, Robb/AAH-5012-2019; Clarke, Jonathan/C-5347-2009	Krumlauf, Robb/0000-0001-9102-7927; Wilkinson, David/0000-0001-6757-7080	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AGAR WE, 1907, T ROY SOC EDINBURGH, V45, P611; AKAM M, 1994, DEVELOPMENT, P209; CHARITE J, 1994, CELL, V78, P589, DOI 10.1016/0092-8674(94)90524-X; COHN MJ, 1995, CELL, V80, P739, DOI 10.1016/0092-8674(95)90352-6; Crossley PH, 1996, CELL, V84, P127, DOI 10.1016/S0092-8674(00)80999-X; GibsonBrown JJ, 1996, MECH DEVELOP, V56, P93, DOI 10.1016/0925-4773(96)00514-X; GOODRICH ES, 1930, STUDIES STRUCTURE DE; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Lumsden A, 1996, SCIENCE, V274, P1109, DOI 10.1126/science.274.5290.1109; NIETO MA, 1996, METHOD CELL BIOL, V51, P220; OHUCHI H, 1995, BIOCHEM BIOPH RES CO, V209, P809, DOI 10.1006/bbrc.1995.1572; RANCOURT DE, 1995, GENE DEV, V9, P108, DOI 10.1101/gad.9.1.108; SIMON J, 1995, CURR OPIN CELL BIOL, V7, P376, DOI 10.1016/0955-0674(95)80093-X; THOROGOOD P, 1993, NATURE, V364, P196, DOI 10.1038/364196a0; TICKLE C, 1995, CURR OPIN GENET DEV, V5, P478, DOI 10.1016/0959-437X(95)90052-I; Vogel A, 1996, DEVELOPMENT, V122, P1737; WARREN RW, 1994, NATURE, V372, P458, DOI 10.1038/372458a0; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0	18	172	175	1	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 1	1997	387	6628					97	101		10.1038/387097a0	http://dx.doi.org/10.1038/387097a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WW758	9139829				2022-12-01	WOS:A1997WW75800055
J	Nakajima, K; Tatara, K; Nakanishi, N				Nakajima, K; Tatara, K; Nakanishi, N			Assessment of the zinc turbidity test and the use of risk factors in detecting asymptomatic hepatitis C virus carriers: Population based study	BRITISH MEDICAL JOURNAL			English	Article									OSAKA UNIV,SCH MED,DEPT PUBL HLTH,SUITA,OSAKA 565,JAPAN	Osaka University								BRUNO S, 1994, BRIT MED J, V308, P697, DOI 10.1136/bmj.308.6930.697; DIBISCEGLIE AM, 1991, HEPATOLOGY, V14, P969, DOI 10.1016/0270-9139(91)90113-A; FRIED MW, 1995, SEMIN LIVER DIS, V15, P82, DOI 10.1055/s-2007-1007265; POPPER H, 1957, LIVER STRUCTURE FUNC, P323	4	1	1	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 19	1997	314	7088					1169	1169		10.1136/bmj.314.7088.1169	http://dx.doi.org/10.1136/bmj.314.7088.1169			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WV705	9146390	Green Published			2022-12-01	WOS:A1997WV70500024
J	Springer, MS; Cleven, GC; Madsen, O; deJong, WW; Waddell, VG; Amrine, HM; Stanhope, MJ				Springer, MS; Cleven, GC; Madsen, O; deJong, WW; Waddell, VG; Amrine, HM; Stanhope, MJ			Endemic African mammals shake the phylogenetic tree	NATURE			English	Article							SUBSTITUTIONS; EVOLUTION; DNA; RNA	The order Insectivora, including living taxa (lipotyphlans) and archaic fossil forms, is central to the question of higher-level relationships among placental mammals(1). Beginning with Huxley(2), it has been argued that insectivores retain many primitive features and are closer to the ancestral stock of mammals than are other living groups(3). Nevertheless, cladistic analysis suggests that living insectivores, at least, are united by derived anatomical features(4). Here we analyse DNA sequences from three mitochondrial genes and two nuclear genes to examine relationships of insectivores to other mammals. The representative insectivores are not monophyletic in any of our analyses. Rather, golden moles are included in a clade that contains hyraxes, manatees, elephants, elephant shrews and aardvarks. Members of this group are of presumed African origin(5,6). This implies that there was an extensive African radiation from a single common ancestor that gave rise to ecologically divergent adaptive types. 12S ribosomal RNA transversions suggest that the base of this radiation occurred during Africa's window of isolation in the Cretaceous period before land connections were developed with Europe in the early Cenozoic era.	UNIV NIJMEGEN,DEPT BIOCHEM,NL-6500 HB NIJMEGEN,NETHERLANDS; UNIV AMSTERDAM,INST SYSTEMAT & POPULAT BIOL,NL-1090 GT AMSTERDAM,NETHERLANDS; QUEENS UNIV,BELFAST BT9 07BL,ANTRIM,NORTH IRELAND	Radboud University Nijmegen; University of Amsterdam; Queens University Belfast	Springer, MS (corresponding author), UNIV CALIF RIVERSIDE,DEPT BIOL,RIVERSIDE,CA 92521, USA.		Madsen, Ole/E-3730-2012; Klein, Richard G/B-5910-2009	Madsen, Ole/0000-0001-8082-7881; 				Arnason U, 1996, J MOL EVOL, V43, P650, DOI 10.1007/BF02202113; Carroll RL., 1988, VERTEBRATE PALEONTOL; Cope E.D., 1884, AM NAT, V18, P790; COPE E. D., 1884, AM NAT, P892; DEJONG WW, 1981, NATURE, V292, P538, DOI 10.1038/292538a0; DERIJK P, 1994, NUCLEIC ACIDS RES, V22, P3495; FAITH DP, 1991, SYST ZOOL, V40, P366, DOI 10.2307/2992329; Fischer MS, 1993, MAMMAL PHYLOGENY, P217; Gheerbrant E, 1996, NATURE, V383, P68, DOI 10.1038/383068a0; GLOVER TD, 1973, J REPROD FERTIL, V35, P45, DOI 10.1530/jrf.0.0350045; HARTENBERGER JL, 1986, CR ACAD SCI II, V302, P247; HASEGAWA M, 1985, J MOL EVOL, V22, P160, DOI 10.1007/BF02101694; Hedges SB, 1996, NATURE, V381, P226, DOI 10.1038/381226a0; Huxley TH., 1880, P R SOC LOND, V43, P649, DOI DOI 10.1111/J.1469-7998.1869.TB07343.X; KISHINO H, 1989, J MOL EVOL, V29, P170, DOI 10.1007/BF02100115; Lavergne A, 1996, MOL PHYLOGENET EVOL, V6, P245, DOI 10.1006/mpev.1996.0074; Leunissen J. A. M., 1993, MAMMAL PHYLOGENY PLA, V2, P5; LOCKHART PJ, 1994, MOL BIOL EVOL, V11, P605; Madsen O, 1997, MOL BIOL EVOL, V14, P363, DOI 10.1093/oxfordjournals.molbev.a025772; Matthew W. D, 1909, MEM AM MUS NAT HIST, V9, P291; Novacek M.J., 1982, P3; NOVACEK MJ, 1992, NATURE, V356, P121, DOI 10.1038/356121a0; Porter CA, 1996, MOL PHYLOGENET EVOL, V5, P89, DOI 10.1006/mpev.1996.0008; SIBLEY CG, 1988, SCI AM, V254, P82; Springer MS, 1996, J MOL EVOL, V43, P357; SPRINGER MS, 1995, MOL BIOL EVOL, V12, P1138; Stanhope MJ, 1996, J MOL EVOL, V43, P83, DOI 10.1007/BF02337352; Swofford David L., 1996, P407; TAMURA K, 1993, MOL BIOL EVOL, V10, P512, DOI 10.1093/oxfordjournals.molbev.a040023; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; [No title captured]	31	266	282	2	49	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 3	1997	388	6637					61	64		10.1038/40386	http://dx.doi.org/10.1038/40386			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XJ143	9214502	Bronze, Green Submitted			2022-12-01	WOS:A1997XJ14300049
J	Gage, DA; Rhodes, D; Nolte, KD; Hicks, WA; Leustek, T; Cooper, AJL; Hanson, AD				Gage, DA; Rhodes, D; Nolte, KD; Hicks, WA; Leustek, T; Cooper, AJL; Hanson, AD			A new route for synthesis of dimethylsulphoniopropionate in marine algae	NATURE			English	Article							AMINO-ACID-METABOLISM; L-METHIONINE; BIOSYNTHESIS; DIMETHYLSULFONIOPROPIONATE; INTERMEDIATE; PHYTOPLANKTON; ESTERS; DMSP	The 3-dimethylsulphoniopropionate (DMSP) produced by marine algae is the main biogenic precursor of atmospheric dimethylsulphide (DMS)(1-3). This biogenic DMS, formed by bacterial and algal degradation of DMSP4,5, contributes about 1.5 x 10(13) g of sulphur to the atmosphere annually(3), and plays a major part in the global sulphur cycle, in cloud formation and potentially in climate regulation(1,3). Although DMSP biosynthesis has been partially elucidated in a higher plant(6,7), nothing is known about how alg-ae make DMSP except that the whole molecule is derived from methionine(8-12). Here we use in vivo isotope labelling to demonstrate that DMSP synthesis in the green macroalga Enteromorpha intestinalis proceeds by a route entirely distinct from that in higher plants. From methionine, the steps are transamination, reduction and S-methylation to give the novel sulphonium compound 4-dimethylsulphonio-2-hydroxybutyrate (DMSHB), which is oxidatively decarboxylated to DMSP. The key intermediate DMSHB was also identified in three diverse phytoplankton species, indicating that the same pathway operates in other algal classes that are important sources of DMS. The fact that a transamination initiates this pathway could help explain how algal DMSP (and thereby DMS) production is enhanced by nitrogen deficiency(12).	UNIV FLORIDA,DEPT HORT SCI,GAINESVILLE,FL 32611; MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824; PURDUE UNIV,DEPT HORT,W LAFAYETTE,IN 47907; RUTGERS STATE UNIV,CTR AGR MOL BIOL,NEW BRUNSWICK,NJ 08903; CORNELL UNIV,COLL MED,DEPT BIOCHEM,NEW YORK,NY 10021	State University System of Florida; University of Florida; Michigan State University; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Rutgers State University New Brunswick; Cornell University			Cooper, Arthur J.L./H-5171-2016; Rhodes, David/L-4602-2019					Blunden G., 1986, Progress phycol. Res., V4, P39; CHARLSON RJ, 1987, NATURE, V326, P655, DOI 10.1038/326655a0; CHILLEMI R, 1990, J NAT PROD, V53, P87, DOI 10.1021/np50067a011; Christen P, 1985, TRANSAMINASES; DIBNER JJ, 1984, J NUTR, V114, P1716, DOI 10.1093/jn/114.9.1716; Gage DA, 1996, BIOLOGICAL AND ENVIRONMENTAL CHEMISTRY OF DMSP AND RELATED SULFONIUM COMPOUNDS, P29; GOODAY GW, 1970, J MAR BIOL ASSOC UK, V50, P199, DOI 10.1017/S0025315400000710; GREENE RC, 1962, J BIOL CHEM, V237, P2251; GROENE T, 1995, J MARINE SYST, V6, P191, DOI 10.1016/0924-7963(94)00023-5; GUILLARD RR, 1962, CAN J MICROBIOL, V8, P229, DOI 10.1139/m62-029; HANSON AD, 1994, PLANT PHYSIOL, V105, P103, DOI 10.1104/pp.105.1.103; HUANG ZH, 1993, J CHROMATOGR, V635, P271, DOI 10.1016/0021-9673(93)80370-N; JAMES F, 1995, PLANT PHYSIOL, V108, P1439, DOI 10.1104/pp.108.4.1439; JAMES F, 1995, J BIOL CHEM, V270, P22344, DOI 10.1074/jbc.270.38.22344; Keller MD, 1989, ACS SYM SER, P167, DOI 10.1021/bk-1989-0393.ch011; Kirst GO, 1996, BIOLOGICAL AND ENVIRONMENTAL CHEMISTRY OF DMSP AND RELATED SULFONIUM COMPOUNDS, P121; LAVINE TF, 1954, J BIOL CHEM, V207, P107; LEDYARD KM, 1994, MAR ECOL PROG SER, V110, P95, DOI 10.3354/meps110095; LIVESEY G, 1984, TRENDS BIOCHEM SCI, V9, P27, DOI 10.1016/0968-0004(84)90044-6; Malin G, 1996, BIOLOGICAL AND ENVIRONMENTAL CHEMISTRY OF DMSP AND RELATED SULFONIUM COMPOUNDS, P177; MAYER RR, 1990, PLANT PHYSIOL, V94, P796, DOI 10.1104/pp.94.2.796; MIFLIN BJ, 1977, ANNU REV PLANT PHYS, V28, P299, DOI 10.1146/annurev.pp.28.060177.001503; MIZAYAKI HH, 1987, PLANT PHYSIOL, V84, P277; POKORNY M, 1970, PHYTOCHEMISTRY, V9, P2175, DOI 10.1016/S0031-9422(00)85382-0; SCISLOWSKI PWD, 1987, BIOCHEM J, V247, P35, DOI 10.1042/bj2470035; STEFELS J, 1993, MAR ECOL PROG SER, V97, P11, DOI 10.3354/meps097011; Uchida A, 1996, BIOLOGICAL AND ENVIRONMENTAL CHEMISTRY OF DMSP AND RELATED SULFONIUM COMPOUNDS, P97; WALSH CT, 1979, ENZYMATIC REACTION M; WALTERS DS, 1990, PLANT PHYSIOL, V93, P1544, DOI 10.1104/pp.93.4.1544; ZAPPIA V, 1969, J BIOL CHEM, V244, P4499	30	139	152	4	62	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 26	1997	387	6636					891	894		10.1038/43160	http://dx.doi.org/10.1038/43160			4	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XG416	9202120	Bronze			2022-12-01	WOS:A1997XG41600048
J	Cohen, S; Doyle, WJ; Skoner, DP; Rabin, BS; Gwaltney, JM				Cohen, S; Doyle, WJ; Skoner, DP; Rabin, BS; Gwaltney, JM			Social ties and susceptibility to the common cold	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DISEASE; HYPOTHESIS; MORTALITY; INFECTION; NETWORKS; SUPPORT; HEALTH; STRESS	Objective.-To examine the hypothesis that diverse ties to friends, family, work, and community are associated with increased host resistance to infection. Design.-After reporting the extent of participation in 12 types of social ties (eg, spouse, parent, friend, workmate, member of social group), subjects were given nasal drops containing 1 of 2 rhinoviruses and monitored for the development of a common cold. Setting.-Quarantine. Participants.-A total of 276 healthy volunteers, aged 18 to 55 years, neither seropositive for human immunodeficiency virus nor pregnant. Outcome Measures.-Colds (illness in the presence of a verified infection), mucus production, mucociliary clearance function, and amount of viral replication. Results.-In response to both viruses, those with more types of social ties were less susceptible to common colds, produced less mucus, were more effective in ciliary clearance of their nasal passages, and shed less virus. These relationships were unaltered by statistical controls for prechallenge virus-specific antibody, virus type, age, sex, season, body mass index, education, and race. Susceptibility to colds decreased in a dose-response manner with increased diversity of the social network. There was an adjusted relative risk of 4.2 comparing persons with fewest (1 to 3) to those with most (6 or more) types of social ties. Although smoking, poor sleep quality, alcohol abstinence, low dietary intake of vitamin C, elevated catecholamine levels, and being introverted were all associated with greater susceptibility to colds, they could only partially account for the relation between social network diversity and incidence of colds. Conclusions.-More diverse social networks were associated with greater resistance to upper respiratory illness.	CHILDRENS HOSP PITTSBURGH,DEPT OTOLARYNGOL,PITTSBURGH,PA 15213; CHILDRENS HOSP PITTSBURGH,DEPT PEDIAT,PITTSBURGH,PA 15213; UNIV PITTSBURGH,SCH MED,DEPT PATHOL,PITTSBURGH,PA; UNIV VIRGINIA,HLTH SCI CTR,DEPT INTERNAL MED,CHARLOTTESVILLE,VA 22908	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Virginia	Cohen, S (corresponding author), CARNEGIE MELLON UNIV,DEPT PSYCHOL,PITTSBURGH,PA 15213, USA.			Cohen, Sheldon/0000-0003-2248-4600	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH050429] Funding Source: NIH RePORTER; NCRR NIH HHS [NCRR/GCRC 5M01 RR00056] Funding Source: Medline; NIMH NIH HHS [MH00721, MH50429] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x; [Anonymous], 1994, HDB HUMAN STRESS IMM; Baum A.A.G.N., 1995, MEASURING STRESS GUI, P175; BERKMAN LF, 1979, AM J EPIDEMIOL, V109, P186, DOI 10.1093/oxfordjournals.aje.a112674; Berkman LF, 1983, HLTH WAYS LIVING ALA; BLOCK G, 1992, J AM DIET ASSOC, V92, P686; Block G, 1990, Epidemiology, V1, P58, DOI 10.1097/00001648-199001000-00013; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Cohen J., 1983, APPL MULTIPLE REGRES, Vsecond, DOI 10.4324/9780203774441.; COHEN S, 1985, PSYCHOL BULL, V98, P310, DOI 10.1037//0033-2909.98.2.310; COHEN S, 1993, AM J PUBLIC HEALTH, V83, P1277, DOI 10.2105/AJPH.83.9.1277; COHEN S, 1988, HEALTH PSYCHOL, V7, P269, DOI 10.1037/0278-6133.7.3.269; COHEN S, 1991, NEW ENGL J MED, V325, P606, DOI 10.1056/NEJM199108293250903; COHEN S, 1991, LIFE SPAN DEV PSYCHO; Doyle W.J., 1988, AM J RHINOL, V2, P149, DOI [DOI 10.2500/105065888781692961, 10.2500/105065888781692961]; FARR BM, 1990, J INFECT DIS, V162, P1173, DOI 10.1093/infdis/162.5.1173; Felton D., 1991, PSYCHONEUROIMMUNOLOG; FLETCHER MA, 1987, DIAGN CLIN IMMUNOL, V5, P68; Goldberg L.R., 1992, PSYCHOL ASSESSMENT, V4, P26, DOI [10.1037/1040-3590.4.1.26, DOI 10.1037/1040-3590.4.1.26]; Gwaltney J.M., 1989, DIAGNOSTIC PROCEDURE, P579; GWALTNEY JM, 1984, VIRAL INFECT HUMANS; Hosmer DW, 2000, APPL LOGISTIC REGRES, V2nd; HOUSE JS, 1988, SCIENCE, V241, P540, DOI 10.1037/0003-066X.59.8.676; KIECOLTGLASER JK, 1994, HDB HUMAN STRESS IMM, P321; PAFFENBARGER RS, 1993, MED SCI SPORT EXER, V25, P60, DOI 10.1249/00005768-199301000-00010; Stone A. A., 1993, BEHAV MED, V8, P115; THOITS PA, 1983, AM SOCIOL REV, V48, P174, DOI 10.2307/2095103; Uchino BN, 1996, PSYCHOL BULL, V119, P488, DOI 10.1037/0033-2909.119.3.488; VOGT TM, 1992, J CLIN EPIDEMIOL, V45, P659, DOI 10.1016/0895-4356(92)90138-D; WHITESIDE TL, 1990, J CLIN LAB ANAL, V4, P102, DOI 10.1002/jcla.1860040207	30	902	905	3	99	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 25	1997	277	24					1940	1944						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XF087	9200634	Green Submitted			2022-12-01	WOS:A1997XF08700038
J	Chang, HW; Aoki, M; Fruman, D; Auger, KR; Bellacosa, A; Tsichlis, PN; Cantley, LC; Roberts, TM; Vogt, PK				Chang, HW; Aoki, M; Fruman, D; Auger, KR; Bellacosa, A; Tsichlis, PN; Cantley, LC; Roberts, TM; Vogt, PK			Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase	SCIENCE			English	Article							PHOSPHATIDYLINOSITOL KINASE-ACTIVITY; NERVE GROWTH-FACTOR; PROTEIN-KINASE; PHOSPHOINOSITIDE 3-KINASE; AVIAN-SARCOMA; ACTIVATION; ONCOGENE; VIRUS; PROTOONCOGENE; ASSOCIATION	The avian sarcoma virus 16 (ASV 16) is a retrovirus that induces hemangiosarcomas in chickens. Analysis of the ASV 16 genome revealed that it encodes an oncogene that is derived from the cellular gene for the catalytic subunit of phosphoinositide 3-kinase(PI 3-kinase). The gene is referred to as v-p3k, and like its cellular counterpart c-p3k, it is a potent transforming gene in cultured chicken embryo fibroblasts (CEFs). The products of the viral and cellular p3k genes have PI 3-kinase activity. CEFs transformed with either gene showed elevated levels of phosphatidylinositol 3,4-bisphosphate and phosphatidylinositol 3,4,5-trisphosphate and activation of Akt kinase.	Scripps Res Inst, DEPT MOL & EXPT MED, LA JOLLA, CA 92037 USA; BETH ISRAEL DEACONESS MED CTR, DIV SIGNAL TRANSDUCT, BOSTON, MA 02215 USA; DANA FARBER CANC INST, BOSTON, MA 02115 USA; FOX CHASE CANC CTR, PHILADELPHIA, PA 19111 USA	Scripps Research Institute; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Dana-Farber Cancer Institute; Fox Chase Cancer Center			Vogt, Peter K./R-7547-2019; Cantley, Lewis C/D-1800-2014; Aoki, Masahiro/A-5149-2016	Vogt, Peter K./0000-0002-4519-7500; Cantley, Lewis C/0000-0002-1298-7653; Aoki, Masahiro/0000-0003-4316-9490	NCI NIH HHS [CA 42564] Funding Source: Medline; NIGMS NIH HHS [GM 41890, R01 GM041890] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042564] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041890, R37GM041890] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aoki M., UNPUB; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BROWN WJ, 1995, J CELL BIOL, V130, P781, DOI 10.1083/jcb.130.4.781; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FREUND R, 1992, AM J PATHOL, V141, P1409; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; GOUT I, 1992, BIOCHEM J, V288, P395, DOI 10.1042/bj2880395; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; KAPELLER R, 1993, MOL CELL BIOL, V13, P6052, DOI 10.1128/MCB.13.10.6052; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Klippel A, 1996, MOL CELL BIOL, V16, P4117; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; Leevers SJ, 1996, EMBO J, V15, P6584, DOI 10.1002/j.1460-2075.1996.tb01049.x; LI J, 1993, P NATL ACAD SCI USA, V90, P4490, DOI 10.1073/pnas.90.10.4490; NOBES CD, 1995, J CELL SCI, V108, P225; OHMICHI M, 1992, NEURON, V9, P769, DOI 10.1016/0896-6273(92)90039-G; POTTS WM, 1987, J GEN VIROL, V68, P3177, DOI 10.1099/0022-1317-68-12-3177; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; SOUYRI M, 1990, CELL, V63, P1137, DOI 10.1016/0092-8674(90)90410-G; STACK JH, 1994, J BIOL CHEM, V269, P31552; STACK JH, 1993, EMBO J, V12, P2195, DOI 10.1002/j.1460-2075.1993.tb05867.x; TSUCHIE H, 1989, ONCOGENE, V4, P1281; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; Vogt PK, 1969, FUNDAMENTAL TECHNIQU, P198; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; YANO H, 1993, J BIOL CHEM, V268, P25846; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324	36	372	378	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 20	1997	276	5320					1848	1850		10.1126/science.276.5320.1848	http://dx.doi.org/10.1126/science.276.5320.1848			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XF103	9188528				2022-12-01	WOS:A1997XF10300045
J	Chertow, GM				Chertow, GM			Nephrology	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE-RENAL-FAILURE		HARVARD UNIV,SCH MED,BOSTON,MA	Harvard University; Harvard Medical School	Chertow, GM (corresponding author), BRIGHAM & WOMENS HOSP,75 FRANCIS ST,BOSTON,MA 02115, USA.			Chertow, Glenn/0000-0002-7599-0534				*CAN US PER DIAL S, 1996, J AM SOC NEPHROL, V7, P198; Chertow GM, 1996, JAMA-J AM MED ASSOC, V276, P1732, DOI 10.1001/jama.276.21.1732; HAKIM RM, 1994, NEW ENGL J MED, V331, P1338, DOI 10.1056/NEJM199411173312003; KLAHR S, 1994, NEW ENGL J MED, V330, P877, DOI 10.1056/NEJM199403313301301; LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004; Maschio G, 1996, NEW ENGL J MED, V334, P939, DOI 10.1056/NEJM199604113341502; MASSRY SG, 1995, JAMA-J AM MED ASSOC, V273, P1693; SCHIFFL H, 1994, LANCET, V344, P570, DOI 10.1016/S0140-6736(94)91964-X; SCHULMAN G, 1993, KIDNEY INT, V43, pS209; TERASAKI PI, 1995, NEW ENGL J MED, V333, P333, DOI 10.1056/NEJM199508103330601; vanEssen GG, 1996, LANCET, V347, P94, DOI 10.1016/S0140-6736(96)90213-5	11	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	1997	277	23					1872	1873						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD544	9185809				2022-12-01	WOS:A1997XD54400028
J	Negri, ED; Fabbri, S; Bufardeci, E; Baldi, MI; Attardi, DG; Mattoccia, E; TocchiniValentini, GP				Negri, ED; Fabbri, S; Bufardeci, E; Baldi, MI; Attardi, DG; Mattoccia, E; TocchiniValentini, GP			The eucaryal tRNA splicing endonuclease recognizes a tripartite set of RNA elements	CELL			English	Article							INTRON EXCISION REACTION; YEAST TRANSFER RNAPHE; PRE-TRANSFER RNA; XENOPUS-LAEVIS; SUBSTRATE; SITE; POLYMERASE; PRECURSORS; SECONDARY; CLEAVAGE	The tRNA splicing endonuclease cleaves intron-containing tRNA precursors on both sides of the intron, The prevailing belief has been that the enzyme binds only to the mature domain through the invariant bases. We show instead that, for recognition, the endonuclease utilizes distinct sets of structural elements, several of which are within the intron. One subset of recognition elements, localized in the mature domain, is needed for recognition of both cleavage sites, while two other subsets, localized at the exon-intron boundaries, are used for recognition of either one or the other cleavage site. The two cleavage sites are essentially independent: neither is required by the other for cleavage to take place. These results support a two-active-site model for the eucaryal endonuclease.	ENICHEM, INST GUIDO DONEGANI SPA, LAB BIOTECNOL, I-00015 MONTEROTONDO, ROME, ITALY; UNIV CHICAGO, DEPT BIOCHEM & MOL BIOL, CHICAGO, IL 60637 USA	University of Chicago	Negri, ED (corresponding author), CNR, INST CELL BIOL, VIALE MARX 43, I-00137 ROME, ITALY.		Di Nicola Negri, Elisa/G-2251-2014	Di Nicola, Elisa/0000-0003-3659-9708				ABELSON J, 1979, ANNU REV BIOCHEM, V48, P1035, DOI 10.1146/annurev.bi.48.070179.005131; BALDI MI, 1992, SCIENCE, V255, P1404, DOI 10.1126/science.1542788; BALDI MI, 1986, CELL, V47, P965, DOI 10.1016/0092-8674(86)90811-1; BEHLEN LS, 1990, BIOCHEMISTRY-US, V29, P2515, DOI 10.1021/bi00462a013; BUFARDECI E, 1993, EMBO J, V12, P4697, DOI 10.1002/j.1460-2075.1993.tb06158.x; CARRARA G, 1995, P NATL ACAD SCI USA, V92, P2627, DOI 10.1073/pnas.92.7.2627; GANDINIATTARDI D, 1985, EMBO J, V4, P3289; HASELBECK RC, 1993, BIOCHEMISTRY-US, V32, P8575, DOI 10.1021/bi00084a026; KIERZEK R, 1992, NUCLEIC ACIDS RES, V20, P5079, DOI 10.1093/nar/20.19.5079; KIM SH, 1973, SCIENCE, V179, P285, DOI 10.1126/science.179.4070.285; LEE MC, 1985, J BIOL CHEM, V260, P3108; MATTOCCIA E, 1988, CELL, V55, P731, DOI 10.1016/0092-8674(88)90231-0; MIAO F, 1993, J BIOL CHEM, V268, P672; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; NAZARENKO IA, 1994, EMBO J, V13, P2464, DOI 10.1002/j.1460-2075.1994.tb06531.x; OTSUKA A, 1981, MOL CELL BIOL, V1, P269, DOI 10.1128/MCB.1.3.269; PAN T, 1992, NATURE, V358, P560, DOI 10.1038/358560a0; REYES VM, 1987, ANAL BIOCHEM, V166, P90, DOI 10.1016/0003-2697(87)90551-3; REYES VM, 1988, CELL, V55, P719, DOI 10.1016/0092-8674(88)90230-9; SWERDLOW H, 1984, J BIOL CHEM, V259, P5197; TINOCO I, 1973, NATURE-NEW BIOL, V246, P40, DOI 10.1038/newbio246040a0; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; Westaway Shawn K., 1995, P79; WREDE P, 1979, J BIOL CHEM, V254, P9608	24	38	38	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 13	1997	89	6					859	866		10.1016/S0092-8674(00)80271-8	http://dx.doi.org/10.1016/S0092-8674(00)80271-8			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XE357	9200604	Bronze			2022-12-01	WOS:A1997XE35700006
J	Gupta, KJ; Clancy, M				Gupta, KJ; Clancy, M			Discontinuation of cervical spine immobilisation in unconscious patients with trauma in intensive care units - Telephone survey of practice in South and West region	BRITISH MEDICAL JOURNAL			English	Article							RADIOLOGIC EVALUATION; COMPUTED-TOMOGRAPHY; BLUNT TRAUMA; FRACTURES; RADIOGRAPHY; INJURY; LIMITATIONS; DIAGNOSIS; VICTIMS	Objective: To study ho cv the cervical spine is assessed before discontinuation of cervical spine immobilisation in unconscious trauma patients in intensive care units. Design: Telephone interview of consultants responsible for adult intensive care units. Setting: All 25 intensive care units in the South and West region that admit victims of major trauma. Main outcome measures: The clinical and radiological basis on which the decision is made to stop cervical spine immobilisation in unconscious patients Results: in 19 units cervical spine immobilisation was stopped in unconscious patients on the basis of radiology alone, and six units combined radiology with clinical examination after the patient had regained consciousness, Sixteen units relied on a normal lateral radiological view of the cervical spine alone, five required a normal lateral and anteroposterior view, and four required a normal lateral, anteroposterior, and open mouth pig view. Conclusions: There are inconsistencies in the clinical and radiological approach to assessing the cervical spine in unconscious patients with trauma before the removal of immobilisation precautions. There is an overreliance on the lateral cervical spine view alone, which has been shown to be insensitive in this setting.	FRENCHAY HOSP, DEPT ANAESTHESIA, BRISTOL BS16 1LE, AVON, ENGLAND; BRISTOL ROYAL INFIRM & GEN HOSP, DEPT ACCID & EMERGENCY, BRISTOL BS2 8HW, AVON, ENGLAND	Bristol Royal Infirmary								ACHESON MB, 1987, AM J ROENTGENOL, V148, P1179, DOI 10.2214/ajr.148.6.1179; BACHULIS BL, 1987, AM J SURG, V153, P473, DOI 10.1016/0002-9610(87)90796-3; BOROCK EC, 1991, J TRAUMA, V31, P1001, DOI 10.1097/00005373-199107000-00021; *CMA MED DAT, 1996, DIR EM SPEC CAR UN 1; COHN SM, 1991, J TRAUMA, V31, P570, DOI 10.1097/00005373-199104000-00018; DAVIS JW, 1995, J TRAUMA, V39, P435; DAVIS JW, 1993, J TRAUMA, V34, P342, DOI 10.1097/00005373-199303000-00006; GERRELTS BD, 1991, J TRAUMA, V31, P1622, DOI 10.1097/00005373-199112000-00010; GRADY MS, 1986, NEUROSURGERY, V18, P151; HOFFMAN JR, 1992, ANN EMERG MED, V21, P1454, DOI 10.1016/S0196-0644(05)80059-9; MACDONALD RL, 1990, J TRAUMA, V30, P392, DOI 10.1097/00005373-199030040-00004; MIRVIS SE, 1989, RADIOLOGY, V170, P831, DOI 10.1148/radiology.170.3.2492671; Palmer JD, 1996, BRIT MED J, V313, P296, DOI 10.1136/bmj.313.7052.296a; PLAISIER B, 1994, J TRAUMA, V37, P714, DOI 10.1097/00005373-199411000-00004; REID DC, 1987, J TRAUMA, V27, P980, DOI 10.1097/00005373-198709000-00005; ROBERGE RJ, 1988, J TRAUMA, V28, P784, DOI 10.1097/00005373-198806000-00010; ROSEN PB, 1992, ANN EMERG MED, V21, P1189, DOI 10.1016/S0196-0644(05)81744-5; ROSS SE, 1987, J TRAUMA, V27, P1055, DOI 10.1097/00005373-198709000-00017; SCHLEEHAUF K, 1989, ANN EMERG MED, V18, P815, DOI 10.1016/S0196-0644(89)80202-1; STREITWIESER DR, 1983, ANN EMERG MED, V12, P538, DOI 10.1016/S0196-0644(83)80293-5; The American College of Surgeons, 1993, ADV TRAUM LIF SUPP C; WOODRING JH, 1993, J TRAUMA, V34, P32, DOI 10.1097/00005373-199301000-00006; WOODRING JH, 1992, J TRAUMA, V33, P698, DOI 10.1097/00005373-199211000-00019	23	26	26	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 7	1997	314	7095					1652	1655		10.1136/bmj.314.7095.1652	http://dx.doi.org/10.1136/bmj.314.7095.1652			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD874	9180066	Green Published			2022-12-01	WOS:A1997XD87400023
J	Spaulding, CM; Joly, LM; Rosenberg, A; Monchi, M; Weber, SN; Dhainaut, JFA; Carli, P				Spaulding, CM; Joly, LM; Rosenberg, A; Monchi, M; Weber, SN; Dhainaut, JFA; Carli, P			Immediate coronary angiography in survivors of out-of-hospital cardiac arrest	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; UNSTABLE ANGINA; CARDIOPULMONARY-RESUSCITATION; THROMBOLYTIC THERAPY; DEATH; ANGIOPLASTY; THROMBOSIS; MORPHOLOGY	Background The incidence of acute coronary-artery occlusion among patients with sudden cardiac arrest outside of the hospital is unknown, and the role of reperfusion therapy has not been determined. We therefore performed immediate coronary angiography and angioplasty when indicated in survivors of out-of-hospital cardiac arrest. Methods Between September 1994 and August 1996, coronary angiography was performed in 84 consecutive patients between the ages of 30 and 75 years who had no obvious noncardiac cause of cardiac arrest. Results Sixty of the 84 patients had clinically significant coronary disease on angiography, 40 of whom had coronary-artery occlusion (48 percent). Angioplasty was attempted in 37 patients and was technically successful in 28. Clinical and electrocardiographic findings, such as the occurrence of chest pain and the presence of ST-segment elevation, were poor predictors of acute coronary-artery occlusion. The in-hospital survival rate was 38 percent. Multivariate logistic-regression analysis revealed that successful angioplasty was an independent predictor of survival (odds ratio, 5.2; 95 percent confidence interval, 1.1 to 24.5; P=0.04). Conclusions Acute coronary-artery occlusion is frequent in survivors of out-of-hospital cardiac arrest and is predicted poorly by clinical and electrocardiographic findings. Accurate diagnosis by immediate coronary angiography can be followed in suitable candidates by coronary angioplasty, which seems to improve survival. (C) 1997, Massachusetts Medical Society.	UNIV PARIS 05, COCHIN HOSP, DEPT INTENS CARE MED, F-75014 PARIS, FRANCE; SERV AIDE MED URGENTE 75, PARIS, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite	Spaulding, CM (corresponding author), UNIV PARIS 05, COCHIN HOSP, DEPT CARDIOL, 27 RUE FAUBOURG ST JACQUES, F-75014 PARIS, FRANCE.							AMBROSE JA, 1985, J AM COLL CARDIOL, V6, P1233, DOI 10.1016/S0735-1097(85)80207-2; ANDERSON HV, 1993, NEW ENGL J MED, V329, P703; CHESEBRO JH, 1987, CIRCULATION, V76, P142, DOI 10.1161/01.CIR.76.1.142; COBB LA, 1992, CIRCULATION, V85, P98; CROPP GJ, 1960, CIRCULATION, V22, P25, DOI 10.1161/01.CIR.22.1.25; DAVIES MJ, 1992, CIRCULATION, V85, P19; DAVIES MJ, 1984, NEW ENGL J MED, V310, P1137, DOI 10.1056/NEJM198405033101801; DEANTONIO HJ, 1990, PACE, V13, P982, DOI 10.1111/j.1540-8159.1990.tb02144.x; DODGE HT, 1960, AM HEART J, V60, P762, DOI 10.1016/0002-8703(60)90359-8; ELMARAGHI N, 1980, CIRCULATION, V62, P936, DOI 10.1161/01.CIR.62.5.936; FALK E, 1985, CIRCULATION, V71, P699, DOI 10.1161/01.CIR.71.4.699; GORLIN R, 1986, CIRCULATION, V74, P6, DOI 10.1161/01.CIR.74.1.6; GREENE HL, 1990, AM J CARDIOL, V65, pB4; GRINES CL, 1993, NEW ENGL J MED, V328, P673, DOI 10.1056/NEJM199303113281001; Grines CL, 1996, NEW ENGL J MED, V335, P1313; GRUBB NR, 1995, LANCET, V346, P417, DOI 10.1016/S0140-6736(95)92784-0; KAHN JK, 1995, AM J CARDIOL, V75, P1069, DOI 10.1016/S0002-9149(99)80727-9; Lange RA, 1996, NEW ENGL J MED, V335, P1311; LO YSA, 1988, AM HEART J, V115, P781, DOI 10.1016/0002-8703(88)90879-4; MYERBURG RJ, 1980, AM J MED, V68, P568, DOI 10.1016/0002-9343(80)90307-1; RESNEKOV L, 1965, LANCET, V1, P506; SERRUYS PW, 1986, J AM COLL CARDIOL, V7, P729, DOI 10.1016/S0735-1097(86)80330-8; TENAGLIA AN, 1991, AM J CARDIOL, V68, P1015, DOI 10.1016/0002-9149(91)90488-7; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; VANCAMPEN LCMC, 1994, AM J CARDIOL, V73, P953, DOI 10.1016/0002-9149(94)90137-6; WILSON RF, 1986, CIRCULATION, V73, P286, DOI 10.1161/01.CIR.73.2.286	26	681	703	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 5	1997	336	23					1629	1633		10.1056/NEJM199706053362302	http://dx.doi.org/10.1056/NEJM199706053362302			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XC086	9171064				2022-12-01	WOS:A1997XC08600002
J	Belisle, JT; Vissa, VD; Sievert, T; Takayama, K; Brennan, PJ; Besra, GS				Belisle, JT; Vissa, VD; Sievert, T; Takayama, K; Brennan, PJ; Besra, GS			Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis	SCIENCE			English	Article							CYCLOPROPANATED MYCOLIC ACIDS; PROTEINS; IDENTIFICATION; BIOSYNTHESIS; ETHAMBUTOL; SEQUENCE; COMPLEX; TARGET	The dominant exported proteins and protective antigens of Mycobacterium tuberculosis are a triad of related gene products called the antigen 85 (Ag85) complex. Each has also been implicated in disease pathogenesis through its fibronectin-binding capacities, A carboxylesterase domain was found within the amino acid sequences of Ag85A, B, and C, and each protein acted as a mycolyltransferase involved in the final stages of mycobacterial cell wall assembly, as shown by direct enzyme assay and site-directed mutagenesis. Furthermore, the use of an antagonist (6-azido-6-deoxy-alpha,alpha'-trehalose) of this activity demonstrates that these proteins are essential and potential targets for new antimycobacterial drugs.	UNIV WISCONSIN, WILLIAM S MIDDLETON MEM VET HOSP, MYCOBACTERIOL RES LAB, MADISON, WI 53705 USA	University of Wisconsin System; University of Wisconsin Madison; US Department of Veterans Affairs; Veterans Health Administration (VHA); William S Middleton Memorial Veterans Hospital	Belisle, JT (corresponding author), COLORADO STATE UNIV, DEPT MICROBIOL, FT COLLINS, CO 80523 USA.		Belisle, John T/B-8944-2017	Belisle, John T/0000-0002-2539-2798; Besra, Gurdyal/0000-0002-5605-0395	NIAID NIH HHS [AI-18357, AI-38087, AI-35220] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R22AI018357, U19AI038087, R01AI035220, R37AI018357, R01AI018357] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BESRA GS, 1994, P NATL ACAD SCI USA, V91, P12735, DOI 10.1073/pnas.91.26.12735; Blanchard JS, 1996, ANNU REV BIOCHEM, V65, P215, DOI 10.1146/annurev.bi.65.070196.001243; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P63; CHUNG GAC, 1995, ANTIMICROB AGENTS CH, V39, P2235, DOI 10.1128/AAC.39.10.2235; DESSEN A, 1995, SCIENCE, V267, P1638, DOI 10.1126/science.7886450; DOBOS KM, 1995, INFECT IMMUN, V63, P2846, DOI 10.1128/IAI.63.8.2846-2853.1995; DUNBAR BS, 1990, METHOD ENZYMOL, V182, P441; GEORGE KM, 1995, J BIOL CHEM, V270, P27292, DOI 10.1074/jbc.270.45.27292; HANESSIAN S, 1972, J ANTIBIOT, V25, P683, DOI 10.7164/antibiotics.25.683; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; Horton R M, 1993, Methods Mol Biol, V15, P251, DOI 10.1385/0-89603-244-2:251; HORWITZ MA, 1995, P NATL ACAD SCI USA, V92, P1530, DOI 10.1073/pnas.92.5.1530; JOLIFF G, 1992, MOL MICROBIOL, V6, P2349, DOI 10.1111/j.1365-2958.1992.tb01410.x; KAZLAUSKAS RJ, 1994, TRENDS BIOTECHNOL, V12, P464, DOI 10.1016/0167-7799(94)90022-1; KHANOLKARYOUNG S, 1992, INFECT IMMUN, V60, P3925, DOI 10.1128/IAI.60.9.3925-3927.1992; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE RE, 1995, J AM CHEM SOC, V117, P11829, DOI 10.1021/ja00153a002; Liu J, 1996, J BIOL CHEM, V271, P29545, DOI 10.1074/jbc.271.47.29545; Mikusova K, 1996, J BIOL CHEM, V271, P7820, DOI 10.1074/jbc.271.13.7820; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NAGAI S, 1991, INFECT IMMUN, V59, P372, DOI 10.1128/IAI.59.1.372-382.1991; PEAKE P, 1993, INFECT IMMUN, V61, P4834; PHILIPP WJ, 1996, P NATL ACAD SCI USA, V93, P3137; PRICE NC, 1996, PROTEIN LABFAX, P270; QUEMARD A, 1995, BIOCHEMISTRY-US, V34, P8235, DOI 10.1021/bi00026a004; SATHYAMOORTHY N, 1987, J BIOL CHEM, V262, P13417; Slayden RA, 1996, ANTIMICROB AGENTS CH, V40, P2813, DOI 10.1128/AAC.40.12.2813; WIKER HG, 1990, INFECT IMMUN, V58, P272, DOI 10.1128/IAI.58.1.272-274.1990; WIKER HG, 1992, MICROBIOL REV, V56, P66; WOLUCKA BA, 1994, J BIOL CHEM, V269, P23328; YOUNG LJS, 1988, HUM GENET, V79, P137, DOI 10.1007/BF00280552; YUAN Y, 1995, P NATL ACAD SCI USA, V92, P6630, DOI 10.1073/pnas.92.14.6630	32	565	617	0	57	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 30	1997	276	5317					1420	1422		10.1126/science.276.5317.1420	http://dx.doi.org/10.1126/science.276.5317.1420			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XB533	9162010				2022-12-01	WOS:A1997XB53300051
J	Chen, CS; Mrksich, M; Huang, S; Whitesides, GM; Ingber, DE				Chen, CS; Mrksich, M; Huang, S; Whitesides, GM; Ingber, DE			Geometric control of cell life and death	SCIENCE			English	Article							SELF-ASSEMBLED MONOLAYERS; FIBROBLAST GROWTH-FACTOR; EXTRACELLULAR-MATRIX; BASEMENT-MEMBRANE; INTEGRIN ALPHA(V)BETA(3); GENE-EXPRESSION; FOCAL ADHESIONS; BLOOD-VESSELS; ANGIOGENESIS; SHAPE	Human and bovine capillary endothelial cells were switched from growth to apoptosis by using micropatterned substrates that contained extracellular matrix-coated adhesive islands of decreasing size to progressively restrict cell extension. Cell spreading also was varied while maintaining the total cell-matrix contact area constant by changing the spacing between multiple focal adhesion-sized islands. Cell shape was found to govern whether individual cells grow or die, regardless of the type of matrix protein or antibody to integrin used to mediate adhesion. Local geometric control of cell growth and viability may therefore represent a fundamental mechanism for developmental regulation within the tissue microenvironment.	HARVARD UNIV,SCH MED,CHILDRENS HOSP,DEPT SURG,BOSTON,MA 02115; HARVARD UNIV,SCH MED,CHILDRENS HOSP,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University			Ingber, Donald E/AAC-5894-2019; Chen, Christopher S./ABD-8499-2021; Ladoux, Benoit/A-9879-2013; Mrksich, Milan/G-2469-2011	Chen, Christopher S./0000-0003-2445-8449; Mrksich, Milan/0000-0002-4964-796X	NCI NIH HHS [CA55833] Funding Source: Medline; NHLBI NIH HHS [HL47699] Funding Source: Medline; NIGMS NIH HHS [GM30367] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055833] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [S15HL047699] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030367, R37GM030367] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1995, J CLIN INVEST, V96, P1815, DOI 10.1172/JCI118227; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Clark ER, 1939, AM J ANAT, V64, P251, DOI 10.1002/aja.1000640203; Craig SW, 1996, CURR OPIN CELL BIOL, V8, P74, DOI 10.1016/S0955-0674(96)80051-2; Dike LE, 1996, J CELL SCI, V109, P2855; DRAKE CJ, 1995, J CELL SCI, V108, P2655; FALCONE DJ, 1993, J BIOL CHEM, V268, P11951; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; FOLKMAN J, 1988, AM J PATHOL, V130, P393; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; FOLKMAN J, 1975, BIOCHIM BIOPHYS ACTA, V417, P217; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; INGBER D, 1990, NATURE, V348, P555, DOI 10.1038/348555a0; Ingber D. E., 1982, TUMOR INVASION METAS, P335; INGBER DE, 1993, CELL, V75, P1249, DOI 10.1016/0092-8674(93)90612-T; INGBER DE, 1989, J CELL BIOL, V109, P317, DOI 10.1083/jcb.109.1.317; INGBER DE, 1990, P NATL ACAD SCI USA, V87, P3579, DOI 10.1073/pnas.87.9.3579; INGBER DE, 1993, J CELL SCI, V104, P613; INGBER DE, 1986, ENDOCRINOLOGY, V119, P1768, DOI 10.1210/endo-119-4-1768; INGBER DE, 1981, P NATL ACAD SCI-BIOL, V78, P3901, DOI 10.1073/pnas.78.6.3901; INGBER DE, 1997, ANN REV PHYS, V59, P75; INGBER DE, 1985, AM J PATHOL, V12, P248; Ingber DE., 1985, GENE EXPRESSION NORM, P13; INGBER DE, 1989, CELL, V58, P308; KUMAR A, 1994, LANGMUIR, V10, P1498, DOI 10.1021/la00017a030; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; Maniotis AJ, 1997, P NATL ACAD SCI USA, V94, P849, DOI 10.1073/pnas.94.3.849; MCNAMEE HP, 1993, J CELL BIOL, V121, P673, DOI 10.1083/jcb.121.3.673; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; MRKSICH M, 1995, TRENDS BIOTECHNOL, V13, P228, DOI 10.1016/S0167-7799(00)88950-7; OWENS LV, 1995, CANCER RES, V55, P2752; PLOPPER GE, 1995, MOL BIOL CELL, V6, P1349, DOI 10.1091/mbc.6.10.1349; PRIME KL, 1991, SCIENCE, V252, P1164, DOI 10.1126/science.252.5009.1164; RE F, 1994, J CELL BIOL, V127, P537, DOI 10.1083/jcb.127.2.537; ROSKELLEY CD, 1995, CURR OPIN CELL BIOL, V7, P736, DOI 10.1016/0955-0674(95)80117-0; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cb.11.110195.003001; SCHWARTZ MA, 1991, P NATL ACAD SCI USA, V88, P7849, DOI 10.1073/pnas.88.17.7849; SINGHVI R, 1994, SCIENCE, V264, P696, DOI 10.1126/science.8171320; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; Stamenovic D, 1996, J THEOR BIOL, V181, P125, DOI 10.1006/jtbi.1996.0120; STOKER M, 1968, INT J CANCER, V3, P683, DOI 10.1002/ijc.2910030517; Stromblad S, 1996, J CLIN INVEST, V98, P426, DOI 10.1172/JCI118808; SYMPSON CJ, 1994, J CELL BIOL, V125, P681, DOI 10.1083/jcb.125.3.681; TUCKER R W, 1981, Journal of Supramolecular Structure and Cellular Biochemistry, V15, P29, DOI 10.1002/jsscb.1981.380150104; WANG N, 1994, BIOPHYS J, V66, P2181, DOI 10.1016/S0006-3495(94)81014-8; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161; Wang N, 1995, BIOCHEM CELL BIOL, V73, P327, DOI 10.1139/o95-041; WICHA MS, 1980, DEV BIOL, V80, P253, DOI 10.1016/0012-1606(80)90402-9; WITTELSBERGER SC, 1981, CELL, V24, P859, DOI 10.1016/0092-8674(81)90111-2; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161	59	3865	4036	19	800	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 30	1997	276	5317					1425	1428		10.1126/science.276.5317.1425	http://dx.doi.org/10.1126/science.276.5317.1425			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XB533	9162012				2022-12-01	WOS:A1997XB53300053
J	Conrad, MN; Dominguez, AM; Dresser, ME				Conrad, MN; Dominguez, AM; Dresser, ME			Ndj1p, a meiotic telomere protein required for normal chromosome synapsis and segregation in yeast	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; RECOMBINATION; GENE; MINICHROMOSOMES; LOCALIZATION; MEIOSIS	The Saccharomyces cerevisiae gene NDJ1 (nondisjunction) encodes a protein that accumulates at telomeres during meiotic prophase. Deletion of NDJ1 (ndj1 Delta) caused nondisjunction, impaired distributive segregation of linear chromosomes, and disordered the distribution of telomeric Rap1p, but it did not affect distributive segregation of circular plasmids. Induction of meiotic recombination and the extent of crossing-over were largely normal in ndj1 Delta cells, but formation of axial elements and synapsis were delayed. Thus, Ndj1p may stabilize homologous DNA interactions at telomeres, and possibly at other sites, and it is required for a telomere activity in distributive segregation.	OKLAHOMA MED RES FDN,PROGRAM MOL & CELL BIOL,OKLAHOMA CITY,OK 73104	Oklahoma Medical Research Foundation					NIGMS NIH HHS [GM45250] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM045250] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BURNS N, 1994, GENE DEV, V8, P1087, DOI 10.1101/gad.8.9.1087; CLARKE L, 1980, NATURE, V287, P504, DOI 10.1038/287504a0; CONRAD M, UNPUB; DAWSON DS, 1986, SCIENCE, V234, P713, DOI 10.1126/science.3535068; DRESSER ME, 1988, J CELL BIOL, V106, P567, DOI 10.1083/jcb.106.3.567; FLATTERS M, 1993, GENETICS, V134, P423; GOLDWAY M, 1993, GENETICS, V133, P149; Gotta M, 1996, J CELL BIOL, V134, P1349, DOI 10.1083/jcb.134.6.1349; Hawley R.S., 1988, GENETIC RECOMBINATIO, P497; KABACK DB, 1989, CURR GENET, V15, P385, DOI 10.1007/BF00376792; Kirk KE, 1997, SCIENCE, V275, P1478, DOI 10.1126/science.275.5305.1478; KLEIN F, 1992, J CELL BIOL, V117, P935, DOI 10.1083/jcb.117.5.935; LOLDL J, 1994, P NATL ACAD SCI USA, V91, P331; MAGUIRE MP, 1978, EXP CELL RES, V112, P297, DOI 10.1016/0014-4827(78)90213-6; MANN C, 1986, P NATL ACAD SCI USA, V83, P6017, DOI 10.1073/pnas.83.16.6017; Moses M. J., 1968, Annual Review of Genetics, V2, P363, DOI 10.1146/annurev.ge.02.120168.002051; NILSSONTILLGREN T, 1986, CARLSBERG RES COMMUN, V51, P309, DOI 10.1007/BF02907164; PERKINS DD, 1949, GENETICS, V34, P607; SEARS DD, 1994, GENETICS, V138, P1055; SEARS DD, 1992, P NATL ACAD SCI USA, V89, P5296, DOI 10.1073/pnas.89.12.5296; VANDENBOL M, 1995, YEAST, V11, P1069, DOI 10.1002/yea.320111108; WEINER BM, 1994, CELL, V77, P977, DOI 10.1016/0092-8674(94)90438-3; [No title captured]	23	160	164	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 23	1997	276	5316					1252	1255		10.1126/science.276.5316.1252	http://dx.doi.org/10.1126/science.276.5316.1252			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XA497	9157883				2022-12-01	WOS:A1997XA49700042
J	Strandberg, TE; Tilvis, RS; Vuoristo, M; Lindroos, M; Kosunen, TU				Strandberg, TE; Tilvis, RS; Vuoristo, M; Lindroos, M; Kosunen, TU			Prospective study of Helicobacter pylori seropositivity and cardiovascular diseases in a general elderly population	BRITISH MEDICAL JOURNAL			English	Article							HEART-DISEASE; RISK-FACTORS		UNIV HELSINKI,DEPT MED,DIV GERIATR,FIN-00290 HELSINKI,FINLAND; UNIV HELSINKI,DEPT BACTERIOL & IMMUNOL,FIN-00290 HELSINKI,FINLAND; VAASA CENT HOSP,DEPT CARDIOL,VAASA,FINLAND	University of Helsinki; University of Helsinki; Vaasa Central Hospital								KOSUNEN TU, 1989, SCAND J GASTROENTERO, V24, P110, DOI 10.3109/00365528909092247; LINDROOS M, 1993, J AM COLL CARDIOL, V21, P1220, DOI 10.1016/0735-1097(93)90249-Z; MURRAY LJ, 1995, BRIT HEART J, V74, P497; PATEL P, 1995, BRIT MED J, V311, P711, DOI 10.1136/bmj.311.7007.711	4	50	54	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 3	1997	314	7090					1317	1318		10.1136/bmj.314.7090.1317	http://dx.doi.org/10.1136/bmj.314.7090.1317			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WX975	9158467	Green Published			2022-12-01	WOS:A1997WX97500023
J	Volkow, ND; Wang, GJ; Fischman, MW; Foltin, RW; Fowler, JS; Abumrad, NN; Vitkun, S; Logan, J; Gatley, SJ; Pappas, N; Hitzemann, R; Shea, CE				Volkow, ND; Wang, GJ; Fischman, MW; Foltin, RW; Fowler, JS; Abumrad, NN; Vitkun, S; Logan, J; Gatley, SJ; Pappas, N; Hitzemann, R; Shea, CE			Relationship between subjective effects of cocaine and dopamine transporter occupancy	NATURE			English	Article							NUCLEUS-ACCUMBENS; MOLECULAR MECHANISMS; BINDING-SITES; PET; INHIBITORS; INVIVO; HUMANS; DRUGS; BRAIN	Cocaine is believed to work by blocking the dopamine transporter (DAT) and thereby increasing the availability of free dopamine within the brain(1-4). Although this concept is central to current cocaine research and to treatment development, a direct relationship between DAT blockade and the subjective effects of cocaine has not been demonstrated in humans. We have used positron emission tomography to determine what level of DAT occupancy is required to produce a subjective 'high' in human volunteers who regularly abuse cocaine. We report here that intravenous cocaine at doses commonly abused by humans (0.3-0.6 mg kg(-1)) blocked between 60 and 77% of DAT sites in these subjects. The magnitude of the self-reported high was correlated with the degree of DAT occupancy, and at least 47% of the transporters had to be blocked for subjects to perceive cocaine's effects. Furthermore, the time course for the high paralleled that of cocaine concentration within the striatum, a brain region implicated in the control of motivation and reward. This is the first demonstration in humans that the doses used by cocaine abusers lead to significant blockade of DAT, and that this blockade is associated with the subjective effects of cocaine. Although these findings provide justification to target the DAT for medication development they suggest that for drugs to be effective in blocking cocaine's effects they would have to be given at doses that achieve almost complete DAT occupancy.	BROOKHAVEN NATL LAB,DEPT CHEM,UPTON,NY 11973; SUNY STONY BROOK,DEPT PSYCHIAT,STONY BROOK,NY 11794; SUNY STONY BROOK,DEPT ANESTHESIOL,STONY BROOK,NY 11794; COLUMBIA UNIV,DEPT PSYCHIAT,NEW YORK,NY 10032; N SHORE UNIV HOSP,DEPT SURG,MANHASSET,NY 11030	United States Department of Energy (DOE); Brookhaven National Laboratory; State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook; Columbia University; Northwell Health; North Shore University Hospital	Volkow, ND (corresponding author), BROOKHAVEN NATL LAB,DEPT MED,UPTON,NY 11973, USA.							BALSTER RL, 1973, J EXP ANAL BEHAV, V20, P119, DOI 10.1901/jeab.1973.20-119; Fischman M W, 1989, NIDA Res Monogr, V92, P211; FISCHMAN MW, 1991, BRIT J ADDICT, V86, P1563; FOWLER JS, 1989, SYNAPSE, V4, P371, DOI 10.1002/syn.890040412; Gatley SJ, 1996, EUR J PHARMACOL, V296, P145, DOI 10.1016/0014-2999(95)00698-2; GATLEY SJ, 1997, BIOCHEM PHARMACOL, V51, P43; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; IZENWASSER S, 1990, BRAIN RES, V520, P303, DOI 10.1016/0006-8993(90)91719-W; JAVAID JI, 1978, SCIENCE, V202, P227, DOI 10.1126/science.694530; KOOB GF, 1988, SCIENCE, V242, P715, DOI 10.1126/science.2903550; LOGAN J, 1990, J CEREBR BLOOD F MET, V10, P740, DOI 10.1038/jcbfm.1990.127; LOGAN J, 1994, J CEREBR BLOOD F MET, V14, P995, DOI 10.1038/jcbfm.1994.132; MADRAS BK, 1989, J PHARMACOL EXP THER, V251, P131; NESTLER EJ, 1992, J NEUROSCI, V12, P2439; PETTIT HO, 1991, BRAIN RES, V539, P94, DOI 10.1016/0006-8993(91)90690-W; PETTIT HO, 1984, PSYCHOPHARMACOLOGY, V84, P167, DOI 10.1007/BF00427441; POGUN S, 1991, EUR J PHARMACOL, V198, P203; Pontieri FE, 1996, NATURE, V382, P255, DOI 10.1038/382255a0; RITZ MC, 1987, SCIENCE, V237, P1219, DOI 10.1126/science.2820058; ROTHMAN RB, 1990, LIFE SCI, V46, P17; STATHIS M, 1995, PSYCHOPHARMACOLOGY, V119, P376, DOI 10.1007/BF02245852; VERBEY K, 1988, PSYCHIAT ANN, V18, P513; VOLKOW ND, 1995, J NUCL MED, V36, P1289; Volkow ND, 1996, PSYCHOPHARMACOLOGY, V123, P26, DOI 10.1007/BF02246277	24	491	504	0	35	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 24	1997	386	6627					827	830		10.1038/386827a0	http://dx.doi.org/10.1038/386827a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WV706	9126740				2022-12-01	WOS:A1997WV70600053
J	deFonseca, FR; Carrera, MRA; Navarro, M; Koob, GF; Weiss, F				deFonseca, FR; Carrera, MRA; Navarro, M; Koob, GF; Weiss, F			Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal	SCIENCE			English	Article							C-FOS; RAT-BRAIN; PARAVENTRICULAR NUCLEUS; OPIATE WITHDRAWAL; EXPRESSION; STRESS; RECEPTOR; IMMUNOREACTIVITY; MICRODIALYSIS; ANTAGONIST	Corticotropin-releasing factor (CRF) has been implicated in the mediation of the stress-like and negative affective consequences of withdrawal from drugs of abuse, such as alcohol, cocaine, and opiates. This study sought to determine whether brain CRF systems also have a role in cannabinoid dependence. Rats were treated daily for 2 weeks with the potent synthetic cannabinoid HU-210. Withdrawal, induced by the cannabinoid antagonist SR 141716A, was accompanied by a marked elevation in extracellular CRF concentration and a distinct pattern of Fos activation in the central nucleus of the amygdala. Maximal increases in CRF corresponded lo the time when behavioral signs resulting from cannabinoid withdrawal were at a maximum. These data suggest that long-term cannabinoid administration alters CRF function in the limbic system of the brain, in a manner similar to that observed with other drugs of abuse, and also induces neuroadaptive processes that may result in future vulnerability to drug dependence.	Scripps Res Inst, DEPT NEUROPHARMACOL, LA JOLLA, CA 92037 USA	Scripps Research Institute	deFonseca, FR (corresponding author), UNIV COMPLUTENSE MADRID, INST COMPLUTENSE DROGODEPENDENCIAS, DEPT PSICOBIOL, FAC PSICOL, MADRID 28223, SPAIN.		DE FONSECA, FERNANDO RODRIGUEZ/E-9767-2012		NIDA NIH HHS [DA 08426] Funding Source: Medline; NIDDK NIH HHS [DK26741] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK026741] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R03DA008426] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		American Psychiatric Association (Washington), 2000, DSM 4 T DIAGN STAT M; [Anonymous], 1994, SEMIN NEUROSCI; Anthony JC, 1994, EXP CLIN PSYCHOPHARM, V2, P244, DOI 10.1037/1064-1297.2.3.244; ARNOLD FJL, 1992, NEUROSCIENCE, V51, P377, DOI 10.1016/0306-4522(92)90322-S; BECKMANN AM, 1995, NEUROPHARMACOLOGY, V34, P1183, DOI 10.1016/0028-3908(95)00089-O; BULLITT E, 1990, J COMP NEUROL, V296, P517, DOI 10.1002/cne.902960402; CECCATELLI S, 1989, P NATL ACAD SCI USA, V86, P9569, DOI 10.1073/pnas.86.23.9569; DEFONSECA FR, 1995, NEUROENDOCRINOLOGY, V61, P714, DOI 10.1159/000126899; deFonseca FR, 1996, J PHARMACOL EXP THER, V276, P56; DEVANE WA, 1988, MOL PHARMACOL, V34, P605; FISHMAN MW, 1988, RES COMMUN SUBST ABU, V9, P219; HALIKAS JA, 1985, INT J ADDICT, V20, P701, DOI 10.3109/10826088509044290; HAYWARD MD, 1990, BRAIN RES, V525, P256, DOI 10.1016/0006-8993(90)90872-9; HERKENHAM M, 1990, P NATL ACAD SCI USA, V87, P1932, DOI 10.1073/pnas.87.5.1932; HOLLISTER LE, 1986, PHARMACOL REV, V38, P1; HONKANIEMI J, 1992, BRAIN RES, V598, P107, DOI 10.1016/0006-8993(92)90173-7; IMAKI T, 1995, NEUROENDOCRINOLOGY, V61, P445, DOI 10.1159/000126867; KAYMAKCALAN S, 1973, B NARCOTICS, V25, P39; KOOB GF, 1985, FED PROC, V44, P259; Koob GF, 1996, NEURON, V16, P893, DOI 10.1016/S0896-6273(00)80109-9; KOOB GF, 1993, SEMIN NEUROSCI, V5, P351; KUBENA RK, 1971, EUR J PHARMACOL, V14, P89, DOI 10.1016/0014-2999(71)90128-2; LARSEN PJ, 1995, J NEUROSCI, V15, P2609; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MCMILLAN DE, 1971, ANN NY ACAD SCI, V191, P83, DOI 10.1111/j.1749-6632.1971.tb13990.x; MENDELSON JH, 1984, AM J PSYCHIAT, V141, P1289; MENZAGHI F, 1994, NEUROSCI LETT, V168, P139, DOI 10.1016/0304-3940(94)90435-9; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; Navarro M, 1997, NEUROREPORT, V8, P491, DOI 10.1097/00001756-199701200-00023; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; PICH EM, 1995, J NEUROSCI, V15, P5439; PICH EM, 1993, NEUROSCIENCE, V55, P695, DOI 10.1016/0306-4522(93)90435-I; Pope HG, 1996, JAMA-J AM MED ASSOC, V275, P521, DOI 10.1001/jama.275.7.521; RASSNICK S, 1993, BRAIN RES, V605, P25, DOI 10.1016/0006-8993(93)91352-S; RICHTER RM, 1995, NEUROSCI LETT, V187, P169, DOI 10.1016/0304-3940(95)11365-4; RICHTER RP, UNPUB; RINALDICARMONA M, 1994, FEBS LETT, V350, P240, DOI 10.1016/0014-5793(94)00773-X; Rodriguez de Fonseca F., UNPUB; RYABININ AE, 1995, J NEUROSCI, V15, P721; Santucci Vincent, 1996, Life Sciences, V58, P103; STORNETTA RL, 1993, BRAIN RES, V624, P19, DOI 10.1016/0006-8993(93)90055-R; TAKAHASHI LK, 1989, BEHAV NEUROSCI, V103, P648, DOI 10.1037/0735-7044.103.3.648; TSOU K, 1995, EUR J PHARMACOL, V280, pR13; VALE W, 1983, METHOD ENZYMOL, V103, P565; VALE W, 1981, SCIENCE, V213, P1394, DOI 10.1126/science.6267699; VARGAS MA, 1992, ANN NY ACAD SCI, V654, P145, DOI 10.1111/j.1749-6632.1992.tb25963.x; WHANSCHAFFE U, 1993, BRAIN RES, V615, P295; Wiesbeck GA, 1996, ADDICTION, V91, P1469; ZUARDI AW, 1982, PSYCHOPHARMACOLOGY, V76, P245, DOI 10.1007/BF00432554	49	343	351	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 27	1997	276	5321					2050	2054		10.1126/science.276.5321.2050	http://dx.doi.org/10.1126/science.276.5321.2050			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XG748	9197270				2022-12-01	WOS:A1997XG74800068
J	West, JB; Elliott, AR; Guy, HJB; Prisk, GK				West, JB; Elliott, AR; Guy, HJB; Prisk, GK			Pulmonary function in space	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SUSTAINED MICROGRAVITY; LUNG-VOLUMES; BLOOD-FLOW; BREATH WASHOUTS; SHORT PERIODS; GAS-EXCHANGE; SLS-1; INHOMOGENEITY; VENTILATION; INEQUALITY	The lung is exquisitely sensitive to gravity, and so it is of interest to know how its function is altered in the weightlessness of space. Studies on National Aeronautics and Space Administration (NASA) Spacelabs during the last 4 years have provided the first comprehensive data on the extensive changes in pulmonary function that occur in sustained microgravity. Measurements of pulmonary function were made on astronauts during space shuttle flights lasting 9 and 14 days and were compared with extensive ground-based measurements before and after the flights. Compared with preflight measurements, cardiac output increased by 18% during space flight, and stroke volume increased by 46%. Paradoxically, the increase in stroke volume occurred in the face of reductions in central venous pressure and circulating blood volume. Diffusing capacity increased by 28%, and the increase in the diffusing capacity of the alveolar membrane was unexpectedly large based on findings in normal gravity. The change in the alveolar membrane may reflect the effects of uniform filling of the pulmonary capillary bed. Distributions of blood flow and ventilation throughout the lung were more uniform in space, but some unevenness remained, indicating the importance of nongravitational factors. A surprising finding was that airway closing volume was approximately the same in microgravity and in normal gravity, emphasizing the importance of mechanical properties of the airways in determining whether they close. Residual volume was unexpectedly reduced by 18% in microgravity, possibly because of uniform alveolar expansion. The findings indicate that pulmonary function is greatly altered in microgravity, but none of the changes observed so far will apparently limit long-term space flight. In addition, the data help to clarify how gravity affects pulmonary function in the normal gravity environment on Earth.			West, JB (corresponding author), UNIV CALIF SAN DIEGO,DEPT MED,0623A,9500 GILMAN DR,LA JOLLA,CA 92093, USA.							AGOSTONI E, 1964, HDB PHYSL RESP, P00387; BECK KC, 1986, J APPL PHYSIOL, V61, P530, DOI 10.1152/jappl.1986.61.2.530; Buckey JC, 1996, J APPL PHYSIOL, V81, P19, DOI 10.1152/jappl.1996.81.1.19; BUONO MJ, 1983, J APPL PHYSIOL, V54, P1094, DOI 10.1152/jappl.1983.54.4.1094; CRAWFORD ABH, 1985, J APPL PHYSIOL, V59, P838, DOI 10.1152/jappl.1985.59.3.838; EDYVEAN J, 1991, J APPL PHYSIOL, V71, P1956, DOI 10.1152/jappl.1991.71.5.1956; ELLIOTT AR, 1994, J APPL PHYSIOL, V77, P2005, DOI 10.1152/jappl.1994.77.4.2005; Elliott AR, 1996, J APPL PHYSIOL, V81, P33, DOI 10.1152/jappl.1996.81.1.33; ESTENNE M, 1992, J APPL PHYSIOL, V73, P946, DOI 10.1152/jappl.1992.73.3.946; GLAISTER DH, 1973, RESP PHYSIOL, V17, P365, DOI 10.1016/0034-5687(73)90010-8; GLENNY RW, 1990, J APPL PHYSIOL, V69, P532, DOI 10.1152/jappl.1990.69.2.532; GUY HJB, 1994, J APPL PHYSIOL, V76, P1719, DOI 10.1152/jappl.1994.76.4.1719; GUY HJB, 1991, J APPL PHYSIOL, V70, P2587, DOI 10.1152/jappl.1991.70.6.2587; HAKIM TS, 1987, J APPL PHYSIOL, V63, P1114, DOI 10.1152/jappl.1987.63.3.1114; MICHELS DB, 1978, J APPL PHYSIOL, V45, P987, DOI 10.1152/jappl.1978.45.6.987; MICHELS MD, 1979, J APPL PHYSIOL, V47, P851; MILICEMI.J, 1966, J APPL PHYSIOL, V21, P749, DOI 10.1152/jappl.1966.21.3.749; PAIVA M, 1989, J APPL PHYSIOL, V67, P1542, DOI 10.1152/jappl.1989.67.4.1542; PAIVA M, 1981, RESP PHYSIOL, V44, P325, DOI 10.1016/0034-5687(81)90027-X; PERMUTT SOLBERT, 1967, NAT ACAD SCI NAT RES COUNC PUBL, V1485 B, P38; PRISK GK, 1995, J APPL PHYSIOL, V79, P1290, DOI 10.1152/jappl.1995.79.4.1290; PRISK GK, 1994, J APPL PHYSIOL, V76, P1730, DOI 10.1152/jappl.1994.76.4.1730; PRISK GK, 1995, J APPL PHYSIOL, V78, P597, DOI 10.1152/jappl.1995.78.2.597; PRISK GK, 1993, J APPL PHYSIOL, V75, P15, DOI 10.1152/jappl.1993.75.1.15; UDDEN MM, 1995, J LAB CLIN MED, V125, P442; WAGNER P, 1967, J APPL PHYSIOL, V22, P1115, DOI 10.1152/jappl.1967.22.6.1115; WARRELL DA, 1972, J APPL PHYSIOL, V32, P346, DOI 10.1152/jappl.1972.32.3.346; WEST JB, 1972, J APPL PHYSIOL, V32, P357, DOI 10.1152/jappl.1972.32.3.357; WEST JB, 1960, J APPL PHYSIOL, V15, P405, DOI 10.1152/jappl.1960.15.3.405; WEST JB, 1977, REGIONAL DIFFERENCES	30	28	33	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 25	1997	277	24					1957	1961		10.1001/jama.277.24.1957	http://dx.doi.org/10.1001/jama.277.24.1957			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XF087	9200637				2022-12-01	WOS:A1997XF08700041
J	Goldstein, B; Hammond, M				Goldstein, B; Hammond, M			Physical medicine and rehabilitation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									UNIV WASHINGTON,SEATTLE,WA 98195	University of Washington; University of Washington Seattle	Goldstein, B (corresponding author), VA PUGET SOUND HLTH CARE SYST,SEATTLE,WA 98195, USA.							Baker JG, 1996, AM J PHYS MED REHAB, V75, P356, DOI 10.1097/00002060-199609000-00011; BATTERHAUM RW, 1996, ARCH PHS MED REHABIL, V77, P219; Bowling A., 1991, MEASURING HLTH REV Q; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P883, DOI 10.1016/S0003-9993(96)90274-9; Granger C. V., 1996, PHYS MED REHABILITAT, P239; HAMILTON BB, 1994, SCAND J REHABIL MED, V26, P115; HAYS RM, 1994, CHRONIC DIS DISABILI, P215; HEINEMANN AW, 1994, ARCH PHYS MED REHAB, V75, P133; *HLTH INS ASS AM, 1992, RES STAT B HLTH INS, V287; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P223, DOI 10.1016/S0003-9993(96)90102-1; *MED ETH SER, 1995, AM J PHYS MED REHABI, V74, pS3; MULCAHY C, 1994, NATL UNDERWRITE 0509, P17; Rivara JB, 1996, ARCH PHYS MED REHAB, V77, P754, DOI 10.1016/S0003-9993(96)90253-1; Stineman MG, 1996, ARCH PHYS MED REHAB, V77, P1101, DOI 10.1016/S0003-9993(96)90130-6; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103	15	7	7	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	1997	277	23					1891	1892						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD544	9185820				2022-12-01	WOS:A1997XD54400039
J	Gore, JM; Dalen, JE				Gore, JM; Dalen, JE			Cardiovascular disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									UNIV ARIZONA, COLL MED, TUCSON, AZ USA	University of Arizona	Gore, JM (corresponding author), UNIV MASSACHUSETTS, SCH MED, WORCESTER, MA 01605 USA.							Albers GW, 1996, ARCH INTERN MED, V156, P2311, DOI 10.1001/archinte.156.20.2311; Antman EM, 1996, CIRCULATION, V94, P911, DOI 10.1161/01.CIR.94.5.911; Antman EM, 1996, NEW ENGL J MED, V335, P1342, DOI 10.1056/NEJM199610313351802; Blackshear JL, 1996, LANCET, V348, P633; Connors AF, 1996, JAMA-J AM MED ASSOC, V276, P889, DOI 10.1001/jama.276.11.889; Dalen JE, 1996, JAMA-J AM MED ASSOC, V276, P916, DOI 10.1001/jama.276.11.916; Every NR, 1996, NEW ENGL J MED, V335, P1253, DOI 10.1056/NEJM199610243351701; Grines CL, 1996, NEW ENGL J MED, V335, P1313; Hylek EM, 1996, NEW ENGL J MED, V335, P540, DOI 10.1056/NEJM199608223350802; Lange RA, 1996, NEW ENGL J MED, V335, P1311; Ohman EM, 1996, NEW ENGL J MED, V335, P1333, DOI 10.1056/NEJM199610313351801; Rimm EB, 1996, BRIT MED J, V312, P731, DOI 10.1136/bmj.312.7033.731; Topol EJ, 1996, NEW ENGL J MED, V335, P775	13	0	0	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	1997	277	23					1845	1846						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD544	9185793				2022-12-01	WOS:A1997XD54400012
J	Todd, MM				Todd, MM			Anesthesiology	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											Todd, MM (corresponding author), UNIV IOWA, IOWA CITY, IA 52242 USA.							*AM SOC AN, 1995, ANESTHESIOLOGY, V82, P101; [Anonymous], 2005, AM J RESP CRIT CARE, V171, P388, DOI 10.1164/rccm.200405-644ST; Bode RH, 1996, ANESTHESIOLOGY, V84, P3, DOI 10.1097/00000542-199601000-00002; Burkle H, 1996, ANESTH ANALG, V83, P646, DOI 10.1097/00000539-199609000-00038; CAPLAN RA, 1993, ANESTHESIOLOGY, V78, P597; Ferrante FM, 1996, ANESTHESIOLOGY, V84, P1243; Go AS, 1996, ANESTHESIOLOGY, V84, P1, DOI 10.1097/00000542-199601000-00001; Gross JB, 1996, ANESTHESIOLOGY, V84, P459; Kurz A, 1996, NEW ENGL J MED, V334, P1209, DOI 10.1056/NEJM199605093341901; Mangano DT, 1996, NEW ENGL J MED, V335, P1713, DOI 10.1056/NEJM199612053352301; McClure JH, 1996, BRIT J ANAESTH, V76, P300, DOI 10.1093/bja/76.2.300; ROIZEN MF, 1993, ANESTHESIOLOGY, V78, P380; Thys DM, 1996, ANESTHESIOLOGY, V84, P986	13	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	1997	277	23					1842	1843						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD544	9185791				2022-12-01	WOS:A1997XD54400010
J	Dolin, PJ; Faal, H; Johnson, GJ; Minassian, D; Sowa, S; Day, S; Ajewole, J; Mohamed, AA; Foster, A				Dolin, PJ; Faal, H; Johnson, GJ; Minassian, D; Sowa, S; Day, S; Ajewole, J; Mohamed, AA; Foster, A			Reduction of trachoma in a sub-Saharan village in absence of a disease control programme	LANCET			English	Article								Background Trachoma is a leading cause of blindness in the developing world and is most prevalent among people who live in poor rural communities in arid locations. Methods We analysed the results of surveys of trachoma prevalence in Marakissa, a rural village in The Gambia. These surveys were undertaken in 1959, by the Medical Research Council, and in 1987 and 1996 by the Gambian National Eye Care Programme. Findings During this 37-year period, the prevalence of active inflammatory trachoma among children aged 0-9 years fell from 65.7 cases per 100 children in 1959 to 2.4 cases per 100 children in 1996. The prevalence also fell dramatically among people of 10-19 years (52.5 to 1.4 per 100) and among people of 20 years and older (36.7 to 0 cases per 100). Interpretation The dramatic fall in disease occurrence was paralleled by improvements in sanitation, water supply, education, and access to health care in the village. Of particular importance is that the decline in trachoma occurred without any trachoma-specific intervention.	ROYAL VICTORIA HOSP, NATL EYE CARE PROGRAMME, BANJUL, GAMBIA		Dolin, PJ (corresponding author), UCL, INT CTR EYE HLTH, INST OPHTHALMOL, BATH ST, LONDON EC1V 9EL, ENGLAND.			Foster, Allen/0000-0003-2368-4436				COURTRIGHT P, 1991, BRIT J OPHTHALMOL, V75, P322, DOI 10.1136/bjo.75.6.322; FAAL H, 1989, BRIT J OPHTHALMOL, V73, P82, DOI 10.1136/bjo.73.2.82; MABEY DCW, 1991, ANN TROP PAEDIATR, V11, P295, DOI 10.1080/02724936.1991.11747518; MacCallan AF, 1936, TRACHOMA; SOWA S, 1965, MED RES COUNC SPECIA, V308; TAYLOR HR, 1989, ARCH OPHTHALMOL-CHIC, V107, P1821, DOI 10.1001/archopht.1989.01070020903037; THYLEFORS B, 1987, B WORLD HEALTH ORGAN, V65, P477	7	71	71	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 24	1997	349	9064					1511	1512		10.1016/S0140-6736(97)01355-X	http://dx.doi.org/10.1016/S0140-6736(97)01355-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XA901	9167460				2022-12-01	WOS:A1997XA90100010
J	Cusi, D; Barlassina, C; Azzani, T; Casari, G; Citterio, L; Devoto, M; Glorioso, N; Lanzani, C; Manunta, P; Righetti, M; Rivera, R; Stella, P; Troffa, C; Zagato, L; Bianchi, G				Cusi, D; Barlassina, C; Azzani, T; Casari, G; Citterio, L; Devoto, M; Glorioso, N; Lanzani, C; Manunta, P; Righetti, M; Rivera, R; Stella, P; Troffa, C; Zagato, L; Bianchi, G			Polymorphisms of alpha-adducin and salt sensitivity in patients with essential hypertension	LANCET			English	Article							GENETIC DISSECTION; COMPLEX TRAITS; MILAN STRAIN; RATS; LINKAGE; ERYTHROCYTES; MUTATIONS	Background Abnormalities in renal sodium transport may be involved in hypertension. Adducin, an alpha/beta heterodimeric protein found in the renal tubule is thought to regulate ion transport through changes in the actin cytoskeleton. We investigated whether an alpha-adducin polymorphism (Gly 460 Trp) is involved in essential hypertension in two separate populations. Methods Linkage analysis of three DNA markers at different distances from the alpha-adducin locus (20-2500 kb) was done in 137 hypertensive sibling-pairs. 477 hypertensive and 322 normotensive individuals were genotyped for the alpha-adducin polymorphism. The blood-pressure response to acute and chronic changes in sodium balance was studied in hypertensive individuals with and without the 460 Trp alpha-adducin allele. Findings Significant linkage was found for all three markers in the sibling-pair study. The extra shared alleles (9.1%, 6.5%, and 4.7%) and the significance level for linkage (p=0.0006, p=0.0119, and p=0.0211) both decreased with increasing distance from the alpha-adducin locus. There was a significant association between the 460 Trp mutation and hypertension (p=0.0003). In the salt-sensitivity test, to assess the acute blood-pressure response to changes in body sodium in 86 hypertensive patients, the decrease in mean arterial pressure was greater in 65 patients who were heterozygous for the mutant allele (Gly/Trp) than in 21 wild-type homozygotes (Gly/Gly) (mean decrease 15.9 [SE 2.0] vs 7.4 [1.3] mm Hg; p=0.001). Similarly, 21 heterozygous hypertensive patients showed a greater fall in mean arterial pressure in response to 2 months' treatment with hydrochlorothiazide than did 37 wild-type homozygous hypertensive patients (mean decrease 14.7 [2.2] vs 6.8 [1.4] mm Hg; p=0.002). with the mutant allele suggest that alpha-adducin is associated with a salt-sensitive form of essential hypertension. We suggest the alpha-adducin polymorphism may identify hypertensive patients who will benefit from diuretic treatment or manoeuvres to reduce total body sodium.	UNIV MILAN,HOSP SAN RAFFAELE,DIV NEPHROL DIALYSIS & HYPERTENS,I-20132 MILAN,ITALY; UNIV MILAN,POSTGRAD SCH NEPHROL,MILAN,ITALY; PRASSIS SIGMA TAU RES INST,MILAN,ITALY; ROCKEFELLER UNIV,LAB STAT GENET,NEW YORK,NY 10021; IST GIANNINA GASLINI,GENET MOL LAB,I-16148 GENOA,ITALY; UNIV SASSARI,IST CLIN MED,I-07100 SASSARI,ITALY	University of Milan; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Milan; Rockefeller University; University of Genoa; IRCCS Istituto Giannina Gaslini; University of Sassari			Lanzani, Chiara Livia/AAN-2284-2020; Zagato, Laura/AAC-7739-2022; Citterio, Lorena/AAC-1589-2019; Casari, Giorgio/J-3070-2018; Devoto, Marcella/AAP-7595-2021; Manunta, Paolo/ABH-5476-2020	Lanzani, Chiara Livia/0000-0002-5332-4012; Citterio, Lorena/0000-0001-6455-2291; Casari, Giorgio/0000-0002-0115-8980; Manunta, Paolo/0000-0003-3976-9696; DEVOTO, MARCELLA/0000-0002-4431-5114; Barlassina, Cristina/0000-0001-7407-2697; Zagato, Laura/0000-0002-0441-2120; Righetti, Marco/0000-0002-1148-6486; Bianchi, Giuseppe/0000-0002-8365-3618	NHGRI NIH HHS [HG00008] Funding Source: Medline; Telethon [TGM06S01] Funding Source: Medline	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); Telethon(Fondazione Telethon)		Barber B. R., 1994, V16, P316; BIANCHI G, 1983, KIDNEY INT, V23, P870, DOI 10.1038/ki.1983.109; BIANCHI G, 1974, CLIN SCI MOL MED, V47, P435, DOI 10.1042/cs0470435; BIANCHI G, 1994, P NATL ACAD SCI USA, V91, P3999, DOI 10.1073/pnas.91.9.3999; BONNARDEAUX A, 1995, CIRCULATION, V91, P96, DOI 10.1161/01.CIR.91.1.96; CAMUSSI A, 1988, HYPERTENSION, V12, P620, DOI 10.1161/01.HYP.12.6.620; CASARI G, 1995, HYPERTENSION, V25, P320, DOI 10.1161/01.HYP.25.3.320; FERRARI P, 1992, BIOCHIM BIOPHYS ACTA, V1111, P111, DOI 10.1016/0005-2736(92)90280-Y; FERRARI P, 1991, J HYPERTENS, V9, P703, DOI 10.1097/00004872-199108000-00003; Ferrari Patrizia, 1995, P1261; Guidi E, 1996, J AM SOC NEPHROL, V7, P1131; HUGHES CA, 1995, J BIOL CHEM, V270, P18990, DOI 10.1074/jbc.270.32.18990; JEUNEMAITRE X, 1992, CELL, V71, P169, DOI 10.1016/0092-8674(92)90275-H; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; Lifton RP, 1996, SCIENCE, V272, P676, DOI 10.1126/science.272.5262.676; LIN BY, 1995, GENOMICS, V25, P93, DOI 10.1016/0888-7543(95)80113-Z; *LSU MED CTR, 1994, STAT AN GEN EP REL 2; Matsuoka Y, 1996, J BIOL CHEM, V271, P25157, DOI 10.1074/jbc.271.41.25157; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; SALARDI S, 1989, AM J HYPERTENS, V2, P229, DOI 10.1093/ajh/2.4.229; SALVATI P, 1987, J HYPERTENS, V5, P31, DOI 10.1097/00004872-198702000-00005; Sambrook J., 1989, MOL CLONING LAB MANU; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; Soubrier F, 1995, Curr Opin Nephrol Hypertens, V4, P177, DOI 10.1097/00041552-199503000-00011; Swales John D., 1995, P283; Tripodi G, 1996, J CLIN INVEST, V97, P2815, DOI 10.1172/JCI118737; WEINBERGER MH, 1986, HYPERTENSION, V8, P127, DOI 10.1161/01.HYP.8.6_Pt_2.II127; Woolfson RG, 1996, KIDNEY INT, V50, P717, DOI 10.1038/ki.1996.370	30	463	496	0	21	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 10	1997	349	9062					1353	1357		10.1016/S0140-6736(97)01029-5	http://dx.doi.org/10.1016/S0140-6736(97)01029-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WY342	9149697				2022-12-01	WOS:A1997WY34200009
J	Chameides, WL; Saylor, RD; Cowling, EB				Chameides, WL; Saylor, RD; Cowling, EB			Ozone pollution in the rural United States and the new NAAQS	SCIENCE			English	Editorial Material									N CAROLINA STATE UNIV,COLL FOREST RESOURCES,RALEIGH,NC 27695	University of North Carolina; North Carolina State University	Chameides, WL (corresponding author), GEORGIA INST TECHNOL,SCH EARTH & ATMOSPHER SCI,ATLANTA,GA 30332, USA.		Saylor, Rick/D-1252-2014	Saylor, Rick/0000-0003-4835-8290				Bascom R, 1996, AM J RESP CRIT CARE, V153, P477, DOI 10.1164/ajrccm.153.2.8564086; Bascom R, 1996, AM J RESP CRIT CARE, V153, P3, DOI 10.1164/ajrccm.153.1.8542133; Chameides W., 1995, STATE SO OXIDANTS ST; Halpert MS, 1996, B AM METEOROL SOC, V77, pS1, DOI 10.1175/1520-0477-77.5s.S1; LIPPMANN M, 1992, ENV TOXICANTS HUMAN; Seinfeld JH, 1992, RETHINKING OZONE PRO; *US EPA, 1997, FED REG         1213, V61, P65717; *US EPA, 1995, EPA600R95086 NAT EXP; *US EPA, 1996, EPA452R96007 OFF AIR; WOLFF GT, 1996, ENV MANAGER     0927	10	57	58	2	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 9	1997	276	5314					916	916		10.1126/science.276.5314.916	http://dx.doi.org/10.1126/science.276.5314.916			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WY792	9163037				2022-12-01	WOS:A1997WY79200037
J	Hall, DA; Maus, DC; Gerfen, GJ; Inati, SJ; Becerra, LR; Dahlquist, FW; Griffin, RG				Hall, DA; Maus, DC; Gerfen, GJ; Inati, SJ; Becerra, LR; Dahlquist, FW; Griffin, RG			Polarization-enhanced NMR spectroscopy of biomolecules in frozen solution	SCIENCE			English	Article							DYNAMIC NUCLEAR-POLARIZATION; HIGH-RESOLUTION NMR; CROSS POLARIZATION; ROTATING SOLIDS; C-13 NMR; RESONANCE; BLENDS	Large dynamic nuclear polarization signal enhancements (up to a factor of 100) were obtained in the solid-state magic-angle spinning nuclear magnetic resonance (NMR) spectra of arginine and the protein T4 lysozyme in frozen glycerol-water solutions with the use of dynamic nuclear polarization. Polarization was transferred from the unpaired electrons of nitroxide free radicals to nuclear spins through microwave irradiation near the electron paramagnetic resonance frequency. This approach may be a generally applicable signal enhancement scheme for the high-resolution solid-state NMR spectroscopy of biomolecules.	MIT, FRANCIS BITTER NATL MAGNET LAB, CAMBRIDGE, MA 02139 USA; MIT, DEPT CHEM, CAMBRIDGE, MA 02139 USA; MIT, DEPT PHYS, CAMBRIDGE, MA 02139 USA; UNIV OREGON, DEPT CHEM, EUGENE, OR 97403 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); University of Oregon				Maus, Douglas/0000-0002-8195-8637	NCRR NIH HHS [RR-05539, RR-00995] Funding Source: Medline; NIGMS NIH HHS [GM-35382] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000995] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ABRAGAM A, 1961, PRINCIPLES NUCLEAR M; AFEWORKI M, 1992, MACROMOLECULES, V25, P4084, DOI 10.1021/ma00042a006; ANDREW ER, 1958, NATURE, V182, P1659, DOI 10.1038/1821659a0; BECERRA LR, 1993, PHYS REV LETT, V71, P3561, DOI 10.1103/PhysRevLett.71.3561; BECERRA LR, 1995, J MAGN RESON SER A, V117, P28, DOI 10.1006/jmra.1995.9975; BENNETT AE, 1994, NMR-B PR PR, V33, P1; Berliner L.J., 1976, SPIN LABELING THEORY; Bhartia P., 1984, MILLIMETER WAVE ENG; BRUNNER H, 1987, Z NATURFORSCH A, V42, P1456, DOI 10.1515/zna-1987-1217; CAMPBELL GC, 1992, J MAGN RESON, V96, P69, DOI 10.1016/0022-2364(92)90288-I; Douzou P, 1977, CRYOBIOCHEMISTRY INT; GERFEN GJ, 1995, J CHEM PHYS, V102, P9494, DOI 10.1063/1.468818; GRIFFITHS JM, 1993, ANAL CHIM ACTA, V283, P1081, DOI 10.1016/0003-2670(93)80267-O; HACKMANN A, 1988, J MAGN RESON, V79, P148, DOI 10.1016/0022-2364(88)90331-9; HENSTRA A, 1988, J MAGN RESON, V77, P389, DOI 10.1016/0022-2364(88)90190-4; MACHO V, 1983, J MAGN RESON, V52, P450, DOI 10.1016/0022-2364(83)90170-1; MCINTOSH LP, 1990, BIOCHEMISTRY-US, V29, P6341, DOI 10.1021/bi00479a003; Mehring M., 1983, PRINCIPLES HIGH RESO; Meier B. H., 1994, ADV MAGN OPT RESON, V18, P1; Navon G, 1996, SCIENCE, V271, P1848, DOI 10.1126/science.271.5257.1848; PINES A, 1972, J CHEM PHYS, V56, P1776, DOI 10.1063/1.1677439; ROSE DR, 1988, PROTEIN ENG, V2, P277, DOI 10.1093/protein/2.4.277; Schmidt-Rohr K., 2012, MULTIDIMENSIONAL SOL; SINGEL DJ, 1989, J MAGN RESON, V81, P145, DOI 10.1016/0022-2364(89)90273-4; Slichter CP., 1989, PRINCIPLES MAGNETIC; Stejskal E.O., 1994, HIGH RESOLUTION NMR; Tycko R, 1996, J PHYS CHEM-US, V100, P13240, DOI 10.1021/jp953667u; WIND RA, 1985, PROG NUCL MAG RES SP, V17, P33, DOI 10.1016/0079-6565(85)80005-4; WIND RA, 1993, ADV CHEM SER, P3; ZHOU JW, 1994, SOLID STATE NUCL MAG, V3, P339, DOI 10.1016/0926-2040(94)90018-3; ZYSMILICH MG, 1994, J AM CHEM SOC, V116, P8362, DOI 10.1021/ja00097a052; [No title captured]; [No title captured]	33	390	399	2	107	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 9	1997	276	5314					930	932		10.1126/science.276.5314.930	http://dx.doi.org/10.1126/science.276.5314.930			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WY792	9139651				2022-12-01	WOS:A1997WY79200041
J	Reus, VI				Reus, VI			Olanzapine: A novel atypical neuroleptic agent	LANCET			English	Editorial Material											Reus, VI (corresponding author), UNIV CALIF SAN FRANCISCO,LANGLEY PORTER PSYCHIAT INST,SAN FRANCISCO,CA 94143, USA.		reus, victor i/I-7923-2015	reus, victor i/0000-0002-8193-5697				Beasley CM, 1996, NEUROPSYCHOPHARMACOL, V14, P111, DOI 10.1016/0893-133X(95)00069-P; Bymaster FP, 1996, NEUROPSYCHOPHARMACOL, V14, P87, DOI 10.1016/0893-133X(94)00129-N; Meltzer HY, 1996, NEUROPSYCHOPHARMACOL, V14, P83, DOI 10.1016/0893-133X(95)00197-L; Moore NA., 1993, CURR OPIN INVEST DR, V2, P281; Richelson E, 1996, J CLIN PSYCHIAT, V57, P4; Robertson GS, 1996, NEUROPSYCHOPHARMACOL, V14, P105, DOI 10.1016/0893-133X(95)00196-K; SCHMIDT CJ, 1995, LIFE SCI, V56, P2209, DOI 10.1016/0024-3205(95)00210-W; Stockton ME, 1996, NEUROPSYCHOPHARMACOL, V14, P97, DOI 10.1016/0893-133X(94)00130-R; SYBERG S, 1997, NEUROPSYCHOPHARMACOL, V16, P1; TOLLEFSON DG, 1997, AM J PSYCHIAT, V154, P457	10	43	43	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 3	1997	349	9061					1264	1265		10.1016/S0140-6736(97)22018-0	http://dx.doi.org/10.1016/S0140-6736(97)22018-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW899	9142055				2022-12-01	WOS:A1997WW89900002
J	McPherron, AC; Lawler, AM; Lee, SJ				McPherron, AC; Lawler, AM; Lee, SJ			Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member	NATURE			English	Article							CELLS	The transforming growth factor-beta (TGF-beta) superfamily encompasses a large group of growth and differentiation factors playing important roles in regulating embryonic development and in maintaining tissue homeostasis in adult animals(1). Using degenerate polymerase chain reaction, we have identified a new murine TGF-beta family member, growth/differentiation factor-8 (GDF-8), which is expressed specifically in developing and adult skeletal muscle, During early stages of embryogenesis, GDF-8 expression is restricted to the myotome compartment of developing somites. At later stages and in adult animals, GDF-8 is expressed in many different muscles throughout the body, To determine the biological function of GDF-8, we disrupted the GDF-8 gene by gene targeting in mice. GDF-8 null animals are significantly larger than wild-type animals and show a large and widespread increase in skeletal muscle mass. Individual muscles of mutant animals weigh 2-3 times more than those of wild-type animals, and the increase in mass appears to result from a combination of muscle cell hyperplasia and hypertrophy. These results suggest that GDF-8 functions specifically as a negative regulator of skeletal muscle growth.	JOHNS HOPKINS UNIV,SCH MED,DEPT MOL BIOL & GENET,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT OBSTET & GYNECOL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University								BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; FRIEDMAN JM, 1992, CELL, V69, P217, DOI 10.1016/0092-8674(92)90402-X; KNECHT AK, 1995, DEVELOPMENT, V121, P1927; LEE SJ, 1988, J BIOL CHEM, V263, P3521; LESHNER AI, 1972, PHYSIOL BEHAV, V9, P281, DOI 10.1016/0031-9384(72)90251-X; MCPHERRON AC, 1993, J BIOL CHEM, V268, P3444; McPherron AC., 1996, GROWTH FACTORS CYTOK, P357, DOI [10.1016/s1874-5687(96)80016-4, DOI 10.1016/S1874-5687(96)80016-4]; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75	10	2926	3382	18	238	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 1	1997	387	6628					83	90		10.1038/387083a0	http://dx.doi.org/10.1038/387083a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WW758	9139826				2022-12-01	WOS:A1997WW75800052
J	Laufer, E; Dahn, R; Orozco, OE; Yeo, CY; Pisenti, J; Henrique, D; Abbott, UK; Fallon, JF; Tabin, C				Laufer, E; Dahn, R; Orozco, OE; Yeo, CY; Pisenti, J; Henrique, D; Abbott, UK; Fallon, JF; Tabin, C			Expression of radical fringe in limb-bud ectoderm regulates apical ectodermal ridge formation	NATURE			English	Article							PATTERN-FORMATION; WING DEVELOPMENT; VERTEBRATE LIMB; VENTRAL CELLS; CHICK-EMBRYO; MUTANT; DORSAL; DROSOPHILA; INDUCTION; MOUSE	The apical ectodermal ridge of the vertebrate limb bud lies at the junction of the dorsal and ventral ectoderm and directs patterning of the growing limb. Its formation is directed by the boundary between cells that do and cells that do not express the gene Radical fringe. This is similar to the establishment of the margin cells at the Drosophila wing dorsoventral border by fringe. Radical fringe expression in chick-limb dorsal ectoderm is established In part through repression by Engrailed-1 in the ventral ectoderm.	HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; UNIV WISCONSIN,DEPT ANAT,MADISON,WI 53706; LAWRENCE LIVERMORE NATL LAB,DEPT AVIAN SCI,DAVIS,CA 95616; IMPERIAL CANC RES FUND,DEV GENET LAB,LONDON WC2A 3PX,ENGLAND	Harvard University; Harvard Medical School; University of Wisconsin System; University of Wisconsin Madison; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; Cancer Research UK			Henrique, Domingos M/E-5460-2010	Henrique, Domingos M/0000-0001-8869-1894; Yeo, Chang-Yeol/0000-0002-4440-1215; Laufer, Edward/0000-0002-4933-1017				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Ausubel F.M., 1989, SHORT PROTOCOLS MOL; BLAIR SS, 1993, DEVELOPMENT, V119, P339; Brook WJ, 1996, ANNU REV CELL DEV BI, V12, P161, DOI 10.1146/annurev.cellbio.12.1.161; CARRINGTON JL, 1986, DEV BIOL, V116, P130, DOI 10.1016/0012-1606(86)90049-7; CARRINGTON JL, 1988, DEVELOPMENT, V104, P361; CARRINGTON JL, 1984, J EMBRYOL EXP MORPH, V84, P19; Crossley PH, 1996, CELL, V84, P127, DOI 10.1016/S0092-8674(00)80999-X; DAVIS CA, 1991, DEVELOPMENT, V111, P287; DEALY CN, 1993, MECH DEVELOP, V43, P175, DOI 10.1016/0925-4773(93)90034-U; DIAZBENJUMEA FJ, 1993, CELL, V75, P741, DOI 10.1016/0092-8674(93)90494-B; Fallon J F, 1983, Prog Clin Biol Res, V110 Pt A, P33; FRASER RA, 1971, J EXP ZOOL, V176, P237, DOI 10.1002/jez.1401760209; GOETINCK PF, 1964, DEV BIOL, V10, P71, DOI 10.1016/0012-1606(64)90005-3; GRIESHAMMER U, 1997, DEVELOPMENT, V122, P381; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; INGHAM PW, 1994, CURR BIOL, V4, P347, DOI 10.1016/S0960-9822(00)00076-2; IRVINE KD, 1994, CELL, V79, P595, DOI 10.1016/0092-8674(94)90545-2; KIENY M, 1968, ARCH ANAT MICROSC MO, V57, P401; KIENY M, 1960, J EMBRYOL EXP MORPH, V8, P457; Logan C, 1996, CURR BIOL, V6, P1006, DOI 10.1016/S0960-9822(02)00645-0; Loomis CA, 1996, NATURE, V382, P360, DOI 10.1038/382360a0; MEINHARDT H, 1983, J EMBRYOL EXP MORPH, V76, P115; Morgan BA, 1996, METHOD CELL BIOL, V51, P185, DOI 10.1016/S0091-679X(08)60629-9; Myat A, 1996, DEV BIOL, V174, P233, DOI 10.1006/dbio.1996.0069; Noramly S, 1996, DEV BIOL, V179, P339, DOI 10.1006/dbio.1996.0265; PARR BA, 1995, NATURE, V374, P350, DOI 10.1038/374350a0; PARR BA, 1993, DEVELOPMENT, V119, P247; POTTS WM, 1987, J GEN VIROL, V68, P3177, DOI 10.1099/0022-1317-68-12-3177; PRAHLAD KV, 1979, J EXP ZOOL, V209, P427, DOI 10.1002/jez.1402090308; RASER RA, 1971, J EXP ZOOL, V176, P219; RICHMAN JM, 1992, DEV BIOL, V154, P299, DOI 10.1016/0012-1606(92)90069-S; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; RIDDLE RD, 1995, CELL, V83, P631, DOI 10.1016/0092-8674(95)90103-5; RODRIGUEZ CA, UNPUB; Ros MA, 1996, DEVELOPMENT, V122, P2319; ROS MA, 1994, DEV BIOL, V166, P59, DOI 10.1006/dbio.1994.1296; ROSENBLATT LS, 1959, POULTRY SCI, V38, P1242; SAUNDERS JW, 1974, DEV BIOL, V38, P41, DOI 10.1016/0012-1606(74)90257-7; Tanaka M, 1997, DEV BIOL, V182, P191, DOI 10.1006/dbio.1996.8476; TICKLE C, 1995, CURR OPIN GENET DEV, V5, P478, DOI 10.1016/0959-437X(95)90052-I; Vogel A, 1996, DEVELOPMENT, V122, P1737; VOGEL A, 1995, NATURE, V378, P716, DOI 10.1038/378716a0; WALL NA, 1995, MECH DEVELOP, V53, P383, DOI 10.1016/0925-4773(95)00453-X; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; Wu JY, 1996, SCIENCE, V273, P355, DOI 10.1126/science.273.5273.355; Yang XJ, 1996, J NEUROSCI, V16, P6089	47	223	228	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 27	1997	386	6623					366	373		10.1038/386366a0	http://dx.doi.org/10.1038/386366a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WQ170	9121552				2022-12-01	WOS:A1997WQ17000056
J	Bullitt, E; Rout, MP; Kilmartin, JV; Akey, CW				Bullitt, E; Rout, MP; Kilmartin, JV; Akey, CW			The yeast spindle pole body is assembled around a central crystal of Spc42p	CELL			English	Article							CRYO-ELECTRON MICROSCOPY; SACCHAROMYCES-CEREVISIAE; TILT SERIES; HALF-BRIDGE; CELL-CYCLE; PROTEIN; RECONSTRUCTION; PLAQUES; DUPLICATION; CENTROSOMES	The spindle pole body (SPB) is the microtubule organizing center (MTOC) in the yeast Saccharomyces that plays a pivotal role in such diverse processes as mitosis, budding, and mating. We have used cryoelectron microscopy and image processing to study the structure of isolated diploid SPBs. We show that SPBs are present in two lateral-size classes, sharing a similar vertical architecture comprised of six major layers. Tomographic reconstructions of heparin-stripped SPBs reveal a central hexagonally packed layer. Overexpression of Spc42p results in the growth of a similar layer, forming a crystal that encircles the SPB. Hence, the SPB is an MTOC that utilizes crystallographic packing of subunits in its construction.	ROCKEFELLER UNIV,CELL BIOL LAB,NEW YORK,NY 10021; MRC,MOL BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND	Rockefeller University; MRC Laboratory Molecular Biology	Bullitt, E (corresponding author), BOSTON UNIV,SCH MED,DEPT BIOPHYS,BOSTON,MA 02118, USA.		Rout, Michael/Y-7090-2018	Akey, Christopher/0000-0002-3059-3121; Rout, Michael/0000-0003-2010-706X				AKEY CW, 1993, J CELL BIOL, V122, P1, DOI 10.1083/jcb.122.1.1; AKEY CW, 1989, J CELL BIOL, V109, P955, DOI 10.1083/jcb.109.3.955; AKEY CW, 1992, NUCLEAR TRAFFICKING, P31; BAUM P, 1986, P NATL ACAD SCI USA, V83, P5512, DOI 10.1073/pnas.83.15.5512; BYERS B, 1978, J CELL SCI, V30, P331; BYERS B, 1975, J BACTERIOL, V124, P511, DOI 10.1128/JB.124.1.511-523.1975; BYERS B, 1974, COLD SPRING HARB SYM, V38, P123; Byers B, 1981, MOL BIOL YEAST SACCH, P59; DENGLER J, 1989, ULTRAMICROSCOPY, V30, P337, DOI 10.1016/0304-3991(89)90063-6; Donaldson AD, 1996, J CELL BIOL, V132, P887, DOI 10.1083/jcb.132.5.887; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; ERRABOLU R, 1994, J CELL SCI, V107, P9; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; Geissler S, 1996, EMBO J, V15, P3899, DOI 10.1002/j.1460-2075.1996.tb00764.x; GUCKENBERGER R, 1982, ULTRAMICROSCOPY, V9, P167, DOI 10.1016/0304-3991(82)90239-X; Hardt S, 1996, J STRUCT BIOL, V116, P68, DOI 10.1006/jsbi.1996.0012; Kilmartin JV, 1996, EMBO J, V15, P4592, DOI 10.1002/j.1460-2075.1996.tb00837.x; KILMARTIN JV, 1993, J CELL BIOL, V123, P1175, DOI 10.1083/jcb.123.5.1175; KING SM, 1982, J CELL BIOL, V94, P341, DOI 10.1083/jcb.94.2.341; Knop M, 1997, EMBO J, V16, P1550, DOI 10.1093/emboj/16.7.1550; LEE VD, 1993, P NATL ACAD SCI USA, V90, P11039, DOI 10.1073/pnas.90.23.11039; LIU Y, 1995, ULTRAMICROSCOPY, V58, P393, DOI 10.1016/0304-3991(95)00006-M; Marschall LG, 1996, J CELL BIOL, V134, P443, DOI 10.1083/jcb.134.2.443; MOENS PB, 1971, J CELL BIOL, V50, P344, DOI 10.1083/jcb.50.2.344; MORITZ M, 1995, J CELL BIOL, V130, P1149, DOI 10.1083/jcb.130.5.1149; Owen CH, 1996, ULTRAMICROSCOPY, V63, P27, DOI 10.1016/0304-3991(95)00154-9; PETERSON JB, 1972, J CELL BIOL, V53, P837, DOI 10.1083/jcb.53.3.837; PETERSON JB, 1976, J CELL SCI, V22, P219; RADERMACHER M, 1988, J ELECTRON MICR TECH, V9, P359, DOI 10.1002/jemt.1060090405; ROBINOW CF, 1966, J CELL BIOL, V29, P129, DOI 10.1083/jcb.29.1.129; ROSE MD, 1987, CELL, V48, P1047, DOI 10.1016/0092-8674(87)90712-4; ROUT MP, 1991, COLD SH Q B, V56, P687; ROUT MP, 1990, J CELL BIOL, V111, P1913, DOI 10.1083/jcb.111.5.1913; SCHMID MF, 1993, ULTRAMICROSCOPY, V48, P251, DOI 10.1016/0304-3991(93)90099-J; Schroeter JP, 1996, J STRUCT BIOL, V116, P131, DOI 10.1006/jsbi.1996.0021; SPANG A, 1993, J CELL BIOL, V123, P405, DOI 10.1083/jcb.123.2.405; Spang A, 1996, J CELL BIOL, V134, P429, DOI 10.1083/jcb.134.2.429; SPANG A, 1995, J CELL BIOL, V128, P863, DOI 10.1083/jcb.128.5.863; STALLMEYER MJB, 1989, J MOL BIOL, V205, P519, DOI 10.1016/0022-2836(89)90223-4; STEARNS T, 1994, CELL, V76, P623, DOI 10.1016/0092-8674(94)90503-7; TOYOSHIMA C, 1989, ULTRAMICROSCOPY, V30, P439, DOI 10.1016/0304-3991(89)90076-4; WALL JS, 1986, ANNU REV BIOPHYS BIO, V15, P355; WINEY M, 1991, J CELL BIOL, V114, P745, DOI 10.1083/jcb.114.4.745	43	154	154	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 27	1997	89	7					1077	1086		10.1016/S0092-8674(00)80295-0	http://dx.doi.org/10.1016/S0092-8674(00)80295-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XG830	9215630	hybrid			2022-12-01	WOS:A1997XG83000012
J	Casarett, D; Ross, LF				Casarett, D; Ross, LF			Overriding a patient's refusal of treatment after an iatrogenic complication	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							NOT-RESUSCITATE ORDERS; ADVERSE EVENTS; HOSPITALIZED-PATIENTS; PHYSICIANS; ANESTHESIA; SURGERY				Casarett, D (corresponding author), UNIV CHICAGO, CHICAGO, IL 60637 USA.							APPLEGATE WB, 1986, ARCH INTERN MED, V146, P2249, DOI 10.1001/archinte.146.11.2249; BEDELL SE, 1991, JAMA-J AM MED ASSOC, V265, P2815, DOI 10.1001/jama.265.21.2815; BERNAT JL, 1993, SURG NEUROL, V40, P7, DOI 10.1016/0090-3019(93)90161-S; BOSK CL, 1979, FORGIVE REMEMBER; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; BUCHANAN AE, 1989, DECIDING OTHERS ETHI, P104; BURGIO GR, 1994, INT CONGR SER, V1071, P1; CHRISTAKIS NA, 1993, LANCET, V342, P642, DOI 10.1016/0140-6736(93)91759-F; CHRISTENSEN JF, 1992, J GEN INTERN MED, V7, P424, DOI 10.1007/BF02599161; COHEN CB, 1991, NEW ENGL J MED, V325, P1879, DOI 10.1056/NEJM199112263252611; CURTIS JR, 1995, JAMA-J AM MED ASSOC, V273, P124, DOI 10.1001/jama.273.2.124; Engelhardt H. T., 1989, DAXS CASE ESSAYS MED, P79; Feinberg, 1984, HARM OTHERS, VI; Jonsen AR., 1977, PHILOS MED ETHICS IT, P27; LEAPE LL, 1994, JAMA-J AM MED ASSOC, V272, P1851, DOI 10.1001/jama.272.23.1851; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; MACKINNON B, 1988, J MED PHILOS, V13, P313, DOI 10.1093/jmp/13.3.313; Nightingale F., 1863, NOTES ON HOSP; PETERSEN LA, 1994, ANN INTERN MED, V121, P866, DOI 10.7326/0003-4819-121-11-199412010-00008; SCHIMMEL EM, 1964, ANN INTERN MED, V60, P100, DOI 10.7326/0003-4819-60-1-100; STEEL K, 1981, NEW ENGL J MED, V304, P638, DOI 10.1056/NEJM198103123041104; TENO JM, 1995, J GEN INTERN MED, V10, P179, DOI 10.1007/BF02600252; TRUOG RD, 1991, ANESTHESIOLOGY, V74, P606, DOI 10.1097/00000542-199103000-00030; TULSKY JA, 1995, J GEN INTERN MED, V10, P436, DOI 10.1007/BF02599915; 1982, STEDMANS MED DICT	25	38	38	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 26	1997	336	26					1908	1910		10.1056/NEJM199706263362611	http://dx.doi.org/10.1056/NEJM199706263362611			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XF756	9197222				2022-12-01	WOS:A1997XF75600011
J	Schmitz, N; Diehl, V				Schmitz, N; Diehl, V			Carmustine and the lungs	LANCET			English	Editorial Material							BONE-MARROW TRANSPLANTATION; TOXICITY; BCNU		UNIV COLOGNE,DEPT MED,D-50924 COLOGNE,GERMANY	University of Cologne	Schmitz, N (corresponding author), CHRISTIAN ALBRECHTS UNIV KIEL,DEPT INTERNAL MED,GUTENBERGSTR 76-78,D-24098 KIEL,GERMANY.							ARONIN PA, 1980, NEW ENGL J MED, V303, P183, DOI 10.1056/NEJM198007243030403; BEARMAN SI, 1988, J CLIN ONCOL, V6, P1562, DOI 10.1200/JCO.1988.6.10.1562; CLARK JG, 1993, AM REV RESPIR DIS, V147, P1601, DOI 10.1164/ajrccm/147.6_Pt_1.1601; IRIARTE PV, 1966, CANCER, V19, P1187, DOI 10.1002/1097-0142(196609)19:9<1187::AID-CNCR2820190902>3.0.CO;2-T; ODRISCOLL BR, 1990, NEW ENGL J MED, V323, P378, DOI 10.1056/NEJM199008093230604; Rubio C, 1997, BRIT J CANCER, V75, P1044, DOI 10.1038/bjc.1997.178; WHEELER C, 1990, J CLIN ONCOL, V8, P648, DOI 10.1200/JCO.1990.8.4.648	7	14	17	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 14	1997	349	9067					1712	1713		10.1016/S0140-6736(05)62951-0	http://dx.doi.org/10.1016/S0140-6736(05)62951-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XE065	9193378				2022-12-01	WOS:A1997XE06500005
J	Parekh, AB; Fleig, A; Penner, R				Parekh, AB; Fleig, A; Penner, R			The store-operated calcium current I-CRAC: Nonlinear activation by InsP(3) and dissociation from calcium release	CELL			English	Article							HUMAN UMBILICAL VEIN; RBL-2H3 CELLS; INOSITOL TRISPHOSPHATE; ENDOTHELIAL-CELLS; ACINAR-CELLS; CA2+ ENTRY; MAST-CELLS; DEPLETION; RECEPTOR; SIGNALS	Patch-clamp experiments aimed at determining the relationship between intracellular Ca2+ release and activation of store-operated calcium current I-CRAC reveal that both agonist and InsP(3)-mediated activation of I-CRAC are highly nonlinear, occurring over a narrow concentration range. Ca2+ release and Ca2+ influx can be dissociated, as they possess differential sensitivities to InsP(3): low concentrations induce substantial Ca2+ release without any activation of I-CRAC, whereas micromolar concentrations of InsP(3) are required to activate Ca2+ influx. This suggests functionally distinct stores controlling Ca2+ release and influx and enables cells to switch between sources of Ca2+ to fit best their current needs.	MAX PLANCK INST BIOPHYS CHEM, D-37077 GOTTINGEN, GERMANY	Max Planck Society				Fleig, Andrea/0000-0001-8396-7249; Penner, Reinhold/0000-0002-5366-1537				ALI H, 1990, J BIOL CHEM, V265, P745; ALI H, 1994, BIOCHEM J, V304, P431, DOI 10.1042/bj3040431; Berridge Michael J., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P211; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; CHIAVAROLI C, 1994, J BIOL CHEM, V269, P25570; CHIONO M, 1995, J BIOL CHEM, V270, P1149, DOI 10.1074/jbc.270.3.1149; CHOI OH, 1993, J IMMUNOL, V151, P5586; DEMAUREX N, 1992, J BIOL CHEM, V267, P2318; GIOVANNARDI S, 1992, EXP CELL RES, V202, P398, DOI 10.1016/0014-4827(92)90092-M; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; HU YF, 1994, AM J PHYSIOL, V266, pC1736, DOI 10.1152/ajpcell.1994.266.6.C1736; JACOB R, 1990, J PHYSIOL-LONDON, V421, P55, DOI 10.1113/jphysiol.1990.sp017933; LINO M, 1993, EMBO J, V12, P5287, DOI 10.1002/j.1460-2075.1993.tb06224.x; LUCKHOFF A, 1992, NATURE, V355, P356, DOI 10.1038/355356a0; MEYER T, 1990, P NATL ACAD SCI USA, V87, P3841, DOI 10.1073/pnas.87.10.3841; NEHER E, 1988, J PHYSIOL-LONDON, V395, P193, DOI 10.1113/jphysiol.1988.sp016914; NEHER E, 1989, NEUROMUSCULAR JUNCTI, P65; NILIUS B, 1993, PFLUG ARCH EUR J PHY, V424, P285, DOI 10.1007/BF00384354; Parekh AB, 1995, J PHYSIOL-LONDON, V489, P377, DOI 10.1113/jphysiol.1995.sp021058; PAREKH AB, 1995, P NATL ACAD SCI USA, V92, P7907, DOI 10.1073/pnas.92.17.7907; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; Schrenzel J, 1995, BIOPHYS J, V69, P2378, DOI 10.1016/S0006-3495(95)80107-4; Shears Stephen B., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P63; TEPIKIN AV, 1992, J BIOL CHEM, V267, P14073; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; YULE DI, 1991, CELL CALCIUM, V12, P145, DOI 10.1016/0143-4160(91)90016-8; ZWEIFACH A, 1995, J GEN PHYSIOL, V105, P209, DOI 10.1085/jgp.105.2.209	29	198	201	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 13	1997	89	6					973	980		10.1016/S0092-8674(00)80282-2	http://dx.doi.org/10.1016/S0092-8674(00)80282-2			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XE357	9200615	Bronze			2022-12-01	WOS:A1997XE35700017
J	Ikawa, M; Wada, I; Kominami, K; Watanabe, D; Toshimori, K; Nishimune, Y; Okabe, M				Ikawa, M; Wada, I; Kominami, K; Watanabe, D; Toshimori, K; Nishimune, Y; Okabe, M			The putative chaperone calmegin is required for sperm fertility	NATURE			English	Article							ZONA-PELLUCIDA; MOUSE SPERM; ENDOPLASMIC-RETICULUM; EXTRACELLULAR-MATRIX; MOLECULAR-CLONING; BINDING-PROTEIN; CALNEXIN; FERTILIZATION; EGG; MEMBRANE	The proper folding of newly synthesized membrane proteins in the endoplasmic reticulum (ER) is required for the formation of functional mature proteins. Calnexin is a ubiquitous ER chaperone that plays a major role in quality control by retaining incompletely folded or misfolded proteins(1,5). In contrast to other known chaperones such as heat-shock proteins, BiP and calreticulin, calnexin is an integral membrane protein(1,6). Calmegin is a testis-specific ER protein that is homologous to calnexin(7-9). Here we show that calmegin binds to nascent polypeptides during spermatogenesis, and have analysed its physiological function by targeted disruption of its gene. Homozygous-null male mice are nearly sterile even though spermatogenesis is morphologically normal and mating is normal. In vitro, sperm from homozygous-null males do not adhere to the egg extracellular matrix (zona pellucida), and this defect may explain the observed infertility. These results suggest that calmegin functions as a chaperone for one or more sperm surface proteins that mediate the interactions between sperm and egg. The defective zona pellucida-adhesion phenotype of sperm from calmegin-deficient mice is reminiscent of certain cases of unexplained infertility in human males.	OSAKA UNIV,MICROBIAL DIS RES INST,SUITA,OSAKA 565,JAPAN; SAPPORO MED UNIV,DEPT BIOCHEM,SCH MED,SAPPORO,HOKKAIDO 060,JAPAN; MIYAZAKI MED COLL,DEPT ANAT,MIYAZAKI 88916,JAPAN	Osaka University; Sapporo Medical University; University of Miyazaki			ikawa, masahito/A-5315-2009; Okabe, Masaru/B-6917-2015	ikawa, masahito/0000-0001-9859-6217; Okabe, Masaru/0000-0002-0803-9044; Wada, Ikuo/0000-0001-5668-6994				BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BOOKBINDER LH, 1995, SCIENCE, V269, P86, DOI 10.1126/science.7604284; BURKS DJ, 1995, SCIENCE, V269, P83, DOI 10.1126/science.7541556; CHENG A, 1994, J CELL BIOL, V125, P867, DOI 10.1083/jcb.125.4.867; GONG XH, 1995, SCIENCE, V269, P1718, DOI 10.1126/science.7569899; HARDY DM, 1995, J BIOL CHEM, V270, P26025, DOI 10.1074/jbc.270.44.26025; HARDY DM, 1994, J BIOL CHEM, V269, P19000; Herbert Daniel N., 1995, Cell, V81, P425; Hunnicutt GR, 1996, BIOL REPROD, V54, P1343, DOI 10.1095/biolreprod54.6.1343; LIU DY, 1994, HUM REPROD, V9, P489, DOI 10.1093/oxfordjournals.humrep.a138533; LOPEZ LC, 1985, J CELL BIOL, V101, P1501, DOI 10.1083/jcb.101.4.1501; MACKENNA A, 1993, FERTIL STERIL, V59, P405; OHSAKO S, 1994, J BIOL CHEM, V269, P14140; OKABE M, 1988, J REPROD IMMUNOL, V13, P211, DOI 10.1016/0165-0378(88)90002-2; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; RICHARDSON RT, 1994, DEV BIOL, V165, P688, DOI 10.1006/dbio.1994.1285; RUSSELL LD, 1990, HISTOPATHOLOGICAL EV; SALING PM, 1991, BIOL REPROD, V44, P246, DOI 10.1095/biolreprod44.2.246; TANII I, 1994, CELL TISSUE RES, V277, P61, DOI 10.1007/BF00303081; TOSHIMORI K, 1995, MOL REPROD DEV, V42, P72, DOI 10.1002/mrd.1080420110; TOSHIMORI K, 1992, CELL TISSUE RES, V270, P459, DOI 10.1007/BF00645047; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Vassilakos A, 1996, EMBO J, V15, P1495, DOI 10.1002/j.1460-2075.1996.tb00493.x; WADA I, 1994, J BIOL CHEM, V269, P7464; WADA I, 1991, J BIOL CHEM, V266, P19599; WATANABE D, 1994, J BIOL CHEM, V269, P7744; WATANABE D, 1992, MOL REPROD DEV, V33, P307, DOI 10.1002/mrd.1080330312; YAMASAKI N, 1995, MOL REPROD DEV, V40, P48, DOI 10.1002/mrd.1080400107; Yoda Y., 1971, JAPANESE J ANIM REPR, V16, P147, DOI [10.1262/jrd1955.16.147, DOI 10.1262/JRD1955.16.147]	29	221	227	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 5	1997	387	6633					607	611		10.1038/42484	http://dx.doi.org/10.1038/42484			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XC522	9177349				2022-12-01	WOS:A1997XC52200057
J	Rauchschwalbe, R; Mann, NC				Rauchschwalbe, R; Mann, NC			Pediatric window-cord strangulations in the United States, 1981-1995	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACCIDENTAL STRANGULATION; CHILDHOOD; CHILDREN; DEATHS; ASCERTAINMENT; EPIDEMIOLOGY; SUFFOCATION; PREVALENCE; HOMICIDE; INFANTS	Objective.-To document the prevalence of pediatric asphyxial death from window-covering cords in the United States and identify associated risk factors. Design.-Retrospective analysis of existing death certificate and incident files compiled by the US Consumer Product Safety Commission. Setting.-United States, 1981 through 1995. Patients.-Children aged 1 month to 8 years suffering unintentional traumatic asphyxiation from a window-covering cord. Results.-A total of 183 fatal window-cord strangulations were reported for the years 1981 through 1995, representing a mortality rate of 0.14 (95% confidence interval [CI], 0.10-0.18) per 100 000 persons (less than or equal to 3 years old) per year in the United States, Ninety-three percent of victims were 3 years of age or younger. Pull cords on venetian-type horizontal window coverings accounted for 86% of documented injuries. Infant victims were more likely to become entangled while put down for a nap and toddlers were more likely to be suspended by the cord after falling or jumping from a height (P=.002), Window coverings remained anchored and did not undrape when substantial weight was suspended in the draw-cord loop. Conclusions.-Window-covering cords represent a substantial strangulation hazard compared with other potentially harmful household products that were modified based on voluntary standards to mitigate the risk of injury. Product design modifications and parental education will be necessary to avert this type of fatal home injury.	OREGON HLTH SCI UNIV,DEPT EMERGENCY MED,PORTLAND,OR 97201; US CONSUMER PROD SAFETY COMMISS,OFF COMPLIANCE,WASHINGTON,DC; OREGON HLTH SCI UNIV,DEPT EMERGENCY MED,PORTLAND,OR 97201	Oregon Health & Science University; Oregon Health & Science University								*AM NAT STAND I, 1997, AM NAT STAND SAF COR; [Anonymous], 1977, APPL PSYCH MEAS, DOI DOI 10.1177/014662167700100218; *ASTM, 1996, 1996 ANN BOOK ASTM S, P509; BERGESON PS, 1977, PEDIATRICS, V59, P1043; BYARD RW, 1994, ARCH DIS CHILD, V71, P497, DOI 10.1136/adc.71.6.497; CLARK MA, 1993, J FORENSIC SCI, V38, P344; FELDMAN KW, 1980, PEDIATRICS, V65, P1079; HOOK EB, 1993, AM J EPIDEMIOL, V137, P1148, DOI 10.1093/oxfordjournals.aje.a116618; HOOK EB, 1992, AM J EPIDEMIOL, V135, P1060, DOI 10.1093/oxfordjournals.aje.a116400; HORD JD, 1993, AM J DIS CHILD, V147, P1038, DOI 10.1001/archpedi.1993.02160340024006; JASON J, 1983, AM J PUBLIC HEALTH, V73, P195, DOI 10.2105/AJPH.73.2.195; KEMPER M, 1945, J PEDIATR-US, V26, P401, DOI 10.1016/S0022-3476(45)80187-7; KRAUS JF, 1985, PUBLIC HEALTH REP, V100, P231; LAPIDUS GD, 1990, AM J PUBLIC HEALTH, V80, P213, DOI 10.2105/AJPH.80.2.213; LITTLE AS, 1994, AM FAM PHYSICIAN, V49, P335; MOORE L, 1993, AM J FOREN MED PATH, V14, P296, DOI 10.1097/00000433-199312000-00005; NELSON T, 1975, HAZARD ANAL INJURIES, P12; NIXON JW, 1995, ARCH DIS CHILD, V72, P6, DOI 10.1136/adc.72.1.6; *OFF DIS PREV HLTH, 1994, PREV REP; PEARN JH, 1979, PEDIATRICS, V64, P68; SATRAN L, 1981, PEDIATRICS, V68, P422; SHEPHERD RT, 1990, MED SCI LAW, V30, P119, DOI 10.1177/002580249003000207; Sturner W Q, 1976, J Forensic Sci, V21, P483; *US BUR CENS, 1992, P251130 US BUR CENS; *US CONS PROD SAF, 1984, NAT EL INJ SURV SYST; *US CONS PROD SAF, 1994, CONS PROD SAF AL CHI; *US CONS PROD SAF, 1979, 1979 ANN REP 1, P29; *US CONS PROD SAF, 1993, CONS PROD SAF AL WIN; *US CONS PROD SAF, 1986, CONS PROD SAF COMM A; US Department of Health and Human Services, 1980, INT CLASS DIS 9 REV; WALLER JA, 1981, PUBLIC HLTH PREVENTI, P1549; WITTES JT, 1972, BIOMETRICS, V28, P592, DOI 10.2307/2556173; YEE WH, 1990, CAN MED ASSOC J, V142, P436	33	16	16	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 4	1997	277	21					1696	1698		10.1001/jama.277.21.1696	http://dx.doi.org/10.1001/jama.277.21.1696			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XB088	9169896				2022-12-01	WOS:A1997XB08800030
J	Xu, L; Anwyl, R; Rowan, MJ				Xu, L; Anwyl, R; Rowan, MJ			Behavioural stress facilitates the induction of long-term depression in the hippocampus	NATURE			English	Article							POTENTIATED SYNAPTIC RESPONSES; PRIMED BURST POTENTIATION; IN-VIVO; 1-5 HZ; STIMULATION; RAT; DEPOTENTIATION; INHIBITION; ADULT	The induction of activity-dependent persistent increases in synaptic efficacy, such as long-term potentiation (LTP), is inhibited by behavioural stress(1,2). The question arises whether stress also affects the ability to induce persistent decreases in synaptic efficacy, such as long-term depression (LTD)(3-5). We now report that the induction of stable homosynaptic LTD in the CA1 area of the hippocampus of awake adult rats is facilitated, rather than inhibited, by exposure to mild naturalistic stress, The same stress blocked the induction of LTP, The effects of such stress were short lasting: acclimatization to, or removal from, the conditions that facilitated LTD induction led to a rapid loss of the ability to elicit this form of plasticity. The time window in which LTD could be reliably elicited was prolonged by inducing anaesthesia immediately after the stress. These data reveal that even brief exposure to mild stress can produce a striking shift in the susceptibility to synaptic plasticity in the awake animal.	UNIV DUBLIN TRINITY COLL,DEPT PHARMACOL & THERAPEUT,DUBLIN 2,IRELAND; UNIV DUBLIN TRINITY COLL,DEPT PHYSIOL,DUBLIN 2,IRELAND	Trinity College Dublin; Trinity College Dublin			Xu, Lin/T-5531-2017	Xu, Lin/0000-0002-2710-3507; Rowan, Michael Joseph/0000-0002-3867-9536	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BALFOUR DJK, 1979, ARCH INT PHARMACOD T, V237, P67; BARRIONUEVO G, 1980, LIFE SCI, V27, P2385, DOI 10.1016/0024-3205(80)90509-3; Bear MF, 1996, ANNU REV NEUROSCI, V19, P437, DOI 10.1146/annurev.ne.19.030196.002253; BEAR MF, 1995, NEURON, V15, P1, DOI 10.1016/0896-6273(95)90056-X; DIAMOND DM, 1990, PSYCHOBIOLOGY, V18, P273; DIAMOND DM, 1992, HIPPOCAMPUS, V2, P421, DOI 10.1002/hipo.450020409; Doyle C, 1996, J NEUROSCI, V16, P418; Doyle CA, 1997, NEUROSCIENCE, V77, P75, DOI 10.1016/S0306-4522(96)00427-7; DUDEK SM, 1993, J NEUROSCI, V13, P2910; ERRINGTON ML, 1995, J NEUROPHYSIOL, V74, P1793, DOI 10.1152/jn.1995.74.4.1793; Heynen AJ, 1996, NATURE, V381, P163, DOI 10.1038/381163a0; JOELS M, 1995, NEWS PHYSIOL SCI, V10, P71; KERR DS, 1994, PSYCHOBIOLOGY, V22, P123; Kim JJ, 1996, P NATL ACAD SCI USA, V93, P4750, DOI 10.1073/pnas.93.10.4750; LINDEN DJ, 1995, ANNU REV NEUROSCI, V18, P319, DOI 10.1146/annurev.neuro.18.1.319; MANAHANVAUGHAN D, 1994, BRIT J PHARMACOL, V112, P1083, DOI 10.1111/j.1476-5381.1994.tb13194.x; OCONNOR JJ, 1989, EUR J PHARMACOL, V167, P21, DOI 10.1016/0014-2999(89)90743-7; PAVLIDES C, 1995, NEUROSCIENCE, V68, P379, DOI 10.1016/0306-4522(95)94332-S; SHORS TJ, 1989, SCIENCE, V244, P224, DOI 10.1126/science.2704997; STAUBLI U, 1990, BRAIN RES, V513, P113, DOI 10.1016/0006-8993(90)91096-Y; THIELS E, 1994, J NEUROPHYSIOL, V72, P3009, DOI 10.1152/jn.1994.72.6.3009	21	411	436	0	36	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 29	1997	387	6632					497	500		10.1038/387497a0	http://dx.doi.org/10.1038/387497a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XB479	9168111				2022-12-01	WOS:A1997XB47900047
J	Hirano, T; Kobayashi, R; Hirano, M				Hirano, T; Kobayashi, R; Hirano, M			Condensins, chromosome condensation protein complexes containing XCAP-C, XCAP-E and a Xenopus homolog of the Drosophila Barren protein	CELL			English	Article							TOPOISOMERASE-II; MITOTIC CHROMOSOMES; CELL-CYCLE; HISTONE H1; DOSAGE COMPENSATION; SMC FAMILY; EXTRACTS; INVITRO; DEFINES; GENE	We report here purification and characterization of chromosome condensation protein complexes (termed condensins) containing XCAP-C and XCAP-E, two Xenopus members of the SMC family. Sucrose density gradient centrifugation reveals two major forms of condensins. The 8S form is a heterodimer of XCAP-C and XCAP-E, whereas the 13S form contains three additional subunits. One of them is identified as a homolog of the Drosophila Barren protein whose mutation shows a defect in chromosome segregation. Chromosomal targeting of condensins is mitosis-specific and is independent of topoisomerase II alpha. 13S condensin is required for condensation, as demonstrated by immunodepletion and rescue experiments. Our results suggest that the condensin complexes represent the most abundant structural components of mitotic chromosomes and play a central role in driving chromosome condensation.			Hirano, T (corresponding author), COLD SPRING HARBOR LAB,POB 100,COLD SPRING HARBOR,NY 11724, USA.		Hirano, Tatsuya/F-6008-2011	Hirano, Tatsuya/0000-0002-4219-6473	NCI NIH HHS [CA45508] Funding Source: Medline; NIGMS NIH HHS [GM53926] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA045508] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053926] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI Y, 1991, CELL, V64, P137, DOI 10.1016/0092-8674(91)90215-K; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; Bhat MA, 1996, CELL, V87, P1103, DOI 10.1016/S0092-8674(00)81804-8; BRADBURY EM, 1992, BIOESSAYS, V14, P9; CHUANG PT, 1994, CELL, V79, P459, DOI 10.1016/0092-8674(94)90255-0; Chuang PT, 1996, SCIENCE, V274, P1736, DOI 10.1126/science.274.5293.1736; EARNSHAW WC, 1985, J CELL BIOL, V100, P1706, DOI 10.1083/jcb.100.5.1706; EARNSHAW WC, 1994, FASEB J, V8, P947, DOI 10.1096/fasebj.8.12.8088460; GASSER SM, 1986, J MOL BIOL, V188, P613, DOI 10.1016/S0022-2836(86)80010-9; GUO XW, 1995, EMBO J, V14, P976, DOI 10.1002/j.1460-2075.1995.tb07078.x; Harlow E LD, 1988, ANTIBODIES LAB MANUA, V1st; HIRANO T, 1995, TRENDS BIOCHEM SCI, V20, P357, DOI 10.1016/S0968-0004(00)89076-3; HIRANO T, 1991, J CELL BIOL, V115, P1479, DOI 10.1083/jcb.115.6.1479; HIRANO T, 1995, CURR OPIN CELL BIOL, V7, P329, DOI 10.1016/0955-0674(95)80087-5; HIRANO T, 1993, J CELL BIOL, V120, P601, DOI 10.1083/jcb.120.3.601; HIRANO T, 1994, CELL, V79, P449, DOI 10.1016/0092-8674(94)90254-2; JESSBERGER R, 1993, J BIOL CHEM, V268, P15070; Jessberger R, 1996, EMBO J, V15, P4061, DOI 10.1002/j.1460-2075.1996.tb00779.x; Koshland D, 1996, ANNU REV CELL DEV BI, V12, P305, DOI 10.1146/annurev.cellbio.12.1.305; LEHMANN AR, 1995, MOL CELL BIOL, V15, P7067; Lieb JD, 1996, SCIENCE, V274, P1732, DOI 10.1126/science.274.5293.1732; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; Moore JD, 1996, BIOESSAYS, V18, P207, DOI 10.1002/bies.950180308; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; NEWPORT J, 1987, CELL, V48, P219, DOI 10.1016/0092-8674(87)90425-9; OHSUMI K, 1993, SCIENCE, V262, P2033, DOI 10.1126/science.8266099; ROTH SY, 1992, TRENDS BIOCHEM SCI, V17, P93, DOI 10.1016/0968-0004(92)90243-3; SAITOH N, 1995, BIOESSAYS, V17, P759, DOI 10.1002/bies.950170905; SAITOH N, 1994, J CELL BIOL, V127, P303, DOI 10.1083/jcb.127.2.303; SAKA Y, 1994, EMBO J, V13, P4938, DOI 10.1002/j.1460-2075.1994.tb06821.x; SAWIN KE, 1992, J CELL SCI, V101, P303; SHEEHAN MA, 1988, J CELL BIOL, V106, P1, DOI 10.1083/jcb.106.1.1; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; STRUNNIKOV AV, 1993, J CELL BIOL, V123, P1635, DOI 10.1083/jcb.123.6.1635; STRUNNIKOV AV, 1995, GENE DEV, V9, P587, DOI 10.1101/gad.9.5.587; Swedlow JR, 1993, CURR OPIN CELL BIOL, V5, P412, DOI 10.1016/0955-0674(93)90005-B; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; VERNOS I, 1995, CELL, V81, P117, DOI 10.1016/0092-8674(95)90376-3; Walczak CE, 1996, CELL, V84, P37, DOI 10.1016/S0092-8674(00)80991-5; Wolffe A., 1995, CHROMATIN STRUCTURE	40	441	456	1	17	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 16	1997	89	4					511	521		10.1016/S0092-8674(00)80233-0	http://dx.doi.org/10.1016/S0092-8674(00)80233-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WZ323	9160743	Bronze			2022-12-01	WOS:A1997WZ32300005
J	Wilson, M; Daly, M				Wilson, M; Daly, M			Life expectancy, economic inequality, homicide, and reproductive timing in Chicago neighbourhoods	BRITISH MEDICAL JOURNAL			English	Article							TIME PREFERENCE; RATES				Wilson, M (corresponding author), MCMASTER UNIV,DEPT PSYCHOL,HAMILTON,ON L8S 4K1,CANADA.			Daly, Martin/0000-0003-1697-8794				Barkow J.H., 1992, ADAPTED MIND; Charlton BG, 1996, J ROY SOC MED, V89, P3, DOI 10.1177/014107689608900103; DALY M, 1990, HUMAN NATURE, V0001; Daly M., 1988, HOMICIDE; Frank Robert., 1985, CHOOSING RIGHT POND; Geronimus Arline T., 1992, Ethnicity and Disease, V2, P207; Geronimus AT, 1996, HUM NATURE-INT BIOS, V7, P323, DOI 10.1007/BF02732898; Gigerenzer G, 1996, PSYCHOL REV, V103, P650, DOI 10.1037/0033-295X.103.4.650; Gottfredson M.R., 1990, GEN THEORY CRIME, DOI DOI 10.1515/9781503621794; GREEN L, 1994, PSYCHOL SCI, V5, P33, DOI 10.1111/j.1467-9280.1994.tb00610.x; Hagedorn J.M., 1988, PEOPLE FOLKS; HILL EM, IN PRESS HUMAN NATUR; Hsieh C.-C., 1993, CRIMINAL JUSTICE REV, V18, P182, DOI [10.1177/073401689301800203, DOI 10.1177/073401689301800203]; Jankowski MS, 1992, ISLANDS STREET; Kacelnik A, 1996, AM ZOOL, V36, P402; Kaplan GA, 1996, BRIT MED J, V312, P999; Kennedy BP, 1996, BRIT MED J, V312, P1004, DOI 10.1136/bmj.312.7037.1004; KRAHN H, 1986, CRIMINOLOGY, V24, P269, DOI 10.1111/j.1745-9125.1986.tb01496.x; LAWRANCE EC, 1991, J POLIT ECON, V99, P54, DOI 10.1086/261740; Loewenstein G., 1992, CHOICE TIME; Nisbett R.E., 1996, CULTURE HONOR PSYCHO; ROGERS AR, 1994, AM ECON REV, V84, P460; RUBIN PH, 1979, ECON INQ, V18, P585; SCHOEN R, 1978, DEMOGRAPHY, V15, P625, DOI 10.2307/2061212; WALDMAN L, 1993, MY NEIGHBORHOOD WORD; WILKINSON RG, 1992, BRIT MED J, V304, P165, DOI 10.1136/bmj.304.6820.165; Wilkinson RG., 1996, UNHEALTHY SOC AFFLIC; Wilson JI, 1985, CRIME HUMAN NATURE; WILSON M, 1985, ETHOL SOCIOBIOL, V6, P59, DOI 10.1016/0162-3095(85)90041-X; Wilson Margo, 1992, P289; WILSON MI, 1992, CRIMINOLOGY, V30, P189, DOI 10.1111/j.1745-9125.1992.tb01102.x; WILSON WJ, 1987, TRULY DISADVANTAGERE; [No title captured]	33	409	419	0	92	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 26	1997	314	7089					1271	1274		10.1136/bmj.314.7089.1271	http://dx.doi.org/10.1136/bmj.314.7089.1271			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WW718	9154035	Green Published			2022-12-01	WOS:A1997WW71800037
J	Polymeropoulos, MH; Lavedan, C; Leroy, E; Ide, SE; Dehejia, A; Dutra, A; Pike, B; Root, H; Rubenstein, J; Boyer, R; Stenroos, ES; Chandrasekharappa, S; Athanassiadou, A; Papapetropoulos, T; Johnson, WG; Lazzarini, AM; Duvoisin, RC; DiIorio, G; Golbe, LI; Nussbaum, RL				Polymeropoulos, MH; Lavedan, C; Leroy, E; Ide, SE; Dehejia, A; Dutra, A; Pike, B; Root, H; Rubenstein, J; Boyer, R; Stenroos, ES; Chandrasekharappa, S; Athanassiadou, A; Papapetropoulos, T; Johnson, WG; Lazzarini, AM; Duvoisin, RC; DiIorio, G; Golbe, LI; Nussbaum, RL			Mutation in the alpha-synuclein gene identified in families with Parkinson's disease	SCIENCE			English	Article							ALZHEIMERS-DISEASE; CHROMOSOME-1; NUCLEUS	Parkinson Is disease (PD) is a common neurodegenerative disorder with a lifetime incidence of approximately 2 percent. A pattern of familial aggregation has been documented for the disorder, and it was recently reported that a PD susceptibility gene in a large Italian kindred is located on the long arm of human chromosome 4. A mutation was identified in the alpha-synuclein gene, which codes for a presynaptic protein thought to be involved in neuronal plasticity, in the Italian kindred and in three unrelated families of Greek origin with autosomal dominant inheritance for the PD phenotype. This finding of a specific molecular alteration associated with PD will facilitate the detailed understanding of the pathophysiology of the disorder.	NIH,LAB GENE TRANSFER,NATL HUMAN GENOME RES INST,BETHESDA,MD 20892; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,PISCATAWAY,NJ 08854; UNIV NAPLES 2,INST NEUROL SCI,FAC MED,NAPLES,ITALY; UNIV PATRAS,SCH MED,GR-26110 PATRAS,GREECE	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Rutgers State University New Brunswick; Rutgers State University Medical Center; Universita della Campania Vanvitelli; University of Patras	Polymeropoulos, MH (corresponding author), NIH,LAB GENET DIS RES,NATL HUMAN GENOME RES INST,BLDG 10,BETHESDA,MD 20892, USA.		soler, martha maricel m gomez/L-6025-2014	soler, martha maricel m gomez/0000-0002-4412-8108; Polymeropoulos, Mihael/0000-0001-5065-5353				*ALZH DIS COLL GRO, 1995, NAT GENET, V11, P219; CHEN XH, 1995, GENOMICS, V26, P425, DOI 10.1016/0888-7543(95)80237-G; DOTY RL, 1992, ANN NEUROL, V32, P97, DOI 10.1002/ana.410320116; GEORGE JM, 1995, NEURON, V15, P361, DOI 10.1016/0896-6273(95)90040-3; GOLBE LI, 1990, ANN NEUROL, V27, P276, DOI 10.1002/ana.410270309; GOWERS WR, 1893, MANUAL DIS NERVOUS S, P6366; HSIAO K, 1989, NATURE, V338, P342, DOI 10.1038/338342a0; IWAI A, 1995, BIOCHEMISTRY-US, V34, P10139, DOI 10.1021/bi00032a006; Jensen PH, 1997, BIOCHEM J, V323, P539, DOI 10.1042/bj3230539; JENSEN PH, 1995, BIOCHEM J, V315, P91; LAVEDAN C, UNPUB; LAZARRINI AM, 1994, NEUROLOGY, V44, P499; LEROY EM, UNPUB; LEVYLAHAD E, 1995, SCIENCE, V269, P970, DOI 10.1126/science.7638621; MAROTEAUX L, 1988, J NEUROSCI, V8, P2804; MAROTEAUX L, 1991, MOL BRAIN RES, V11, P335, DOI 10.1016/0169-328X(91)90043-W; Parkinson J., 1817, ESSAY SHAKING PALSY; PEARCE RKB, 1995, MOVEMENT DISORD, V10, P283, DOI 10.1002/mds.870100309; PerezTur J, 1995, NEUROREPORT, V7, P297; POLYMEROPOULOS M, UNPUB; Polymeropoulos MH, 1996, SCIENCE, V274, P1197, DOI 10.1126/science.274.5290.1197; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SHITASAKI Y, 1995, CYTOGENET CELL GENET, V71, P54; SORBI S, 1995, LANCET, V346, P439, DOI 10.1016/S0140-6736(95)92809-X; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; WASCO W, 1995, NAT MED, V1, P848, DOI 10.1038/nm0995-848a; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n	28	6096	6332	17	849	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 27	1997	276	5321					2045	2047		10.1126/science.276.5321.2045	http://dx.doi.org/10.1126/science.276.5321.2045			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XG748	9197268	Green Published			2022-12-01	WOS:A1997XG74800066
J	Roberts, RL; Mosch, HU; Fink, GR				Roberts, RL; Mosch, HU; Fink, GR			14-3-3 proteins are essential for RAS/MAPK cascade signaling during pseudohyphal development in S-cerevisiae	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; FILAMENTOUS GROWTH; YEAST; KINASE; 14-3-3-PROTEINS; ACTIVATION; RAS; PATHWAY; RAF-1; IDENTIFICATION	14-3-3 proteins are highly conserved ubiquitous proteins whose explicit functions have remained elusive. Here, we show that the S. cerevisiae 14-3-3 homologs BMH1 and BMH2 are not essential for viability or mating MAPK cascade signaling, but they are essential for pseudohyphal-development MAPK cascade signaling and other processes. Activated alleles of RAS2 and CDC42 induce pseudohyphal development and FG(TyA)-lacZ signaling in Bmh(+) strains but not in ste20 (p65(PAK)) Or bmh1 bmh2 mutant strains. Moreover, Bmh1p and Bmh2p associate with Ste20p in vivo. Three alleles of BMH1 encode proteins defective for FG(TyA)-lacZ signaling and association with Ste20p, yet these alleles complement other 14-3-3 functions. Therefore, the 14-3-3 proteins are specifically required for RAS/MAPK cascade signaling during pseudohyphal development in S. cerevisiae.	UNIV GOTTINGEN, INST MICROBIOL, D-37077 GOTTINGEN, GERMANY	University of Gottingen	Roberts, RL (corresponding author), MIT, WHITEHEAD INST BIOMED RES, DEPT BIOL, CAMBRIDGE, MA 02142 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040266] Funding Source: NIH RePORTER; NIAID NIH HHS [AI07348] Funding Source: Medline; NIGMS NIH HHS [GM40266] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACS P, 1995, BIOCHEM BIOPH RES CO, V216, P103, DOI 10.1006/bbrc.1995.2597; AITKEN A, 1992, TRENDS BIOCHEM SCI, V17, P498, DOI 10.1016/0968-0004(92)90339-B; CAIRNS BR, 1992, GENE DEV, V6, P1305, DOI 10.1101/gad.6.7.1305; CAMERON S, 1988, CELL, V53, P555, DOI 10.1016/0092-8674(88)90572-7; CHAMBERLAIN LH, 1995, J CELL BIOL, V130, P1063, DOI 10.1083/jcb.130.5.1063; Cherry J, 1997, SACCHAROMYCES GENOME; DOLAN JW, 1990, GENE DEV, V4, P492, DOI 10.1101/gad.4.4.492; ESPENSHADE P, 1995, J CELL BIOL, V131, P311, DOI 10.1083/jcb.131.2.311; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; Gavrias V, 1996, MOL MICROBIOL, V19, P1255, DOI 10.1111/j.1365-2958.1996.tb02470.x; GELPERIN D, 1995, P NATL ACAD SCI USA, V92, P11539, DOI 10.1073/pnas.92.25.11539; GIMENO CJ, 1992, CELL, V68, P1077, DOI 10.1016/0092-8674(92)90079-R; GRENSON M, 1966, BIOCHIM BIOPHYS ACTA, V127, P325, DOI 10.1016/0304-4165(66)90387-4; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; ICHIMURA T, 1995, J BIOL CHEM, V270, P28515, DOI 10.1074/jbc.270.48.28515; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; JONES DH, 1995, FEBS LETT, V368, P55, DOI 10.1016/0014-5793(95)00598-4; LALOUX I, 1994, NUCLEIC ACIDS RES, V22, P999, DOI 10.1093/nar/22.6.999; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Leberer E, 1997, EMBO J, V16, P83, DOI 10.1093/emboj/16.1.83; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; LI SF, 1995, EMBO J, V14, P685, DOI 10.1002/j.1460-2075.1995.tb07047.x; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; LIU HP, 1993, SCIENCE, V262, P1741, DOI 10.1126/science.8259520; Madhani HD, 1997, SCIENCE, V275, P1314, DOI 10.1126/science.275.5304.1314; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; Mosch HU, 1997, GENETICS, V145, P671; Mosch HU, 1996, P NATL ACAD SCI USA, V93, P5352, DOI 10.1073/pnas.93.11.5352; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Peter M, 1996, EMBO J, V15, P7046, DOI 10.1002/j.1460-2075.1996.tb01096.x; ROBERTS RL, 1994, GENE DEV, V8, P2974, DOI 10.1101/gad.8.24.2974; SCHLENSTEDT G, 1995, P NATL ACAD SCI USA, V92, P225, DOI 10.1073/pnas.92.1.225; Sherman F., 1986, METHODS YEAST GENETI; Sprague GF, 1992, MOL CELLULAR BIOL YE, V2, P657; SUEN KL, 1995, ONCOGENE, V11, P825; TODA T, 1987, CELL, V50, P277, DOI 10.1016/0092-8674(87)90223-6; TOKER A, 1992, EUR J BIOCHEM, V206, P453, DOI 10.1111/j.1432-1033.1992.tb16946.x; vanHeusden GPH, 1996, FEBS LETT, V391, P252, DOI 10.1016/0014-5793(96)00746-6; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; ZHOU ZQ, 1993, MOL CELL BIOL, V13, P2069, DOI 10.1128/MCB.13.4.2069	43	186	187	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 27	1997	89	7					1055	1065		10.1016/S0092-8674(00)80293-7	http://dx.doi.org/10.1016/S0092-8674(00)80293-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XG830	9215628	Bronze			2022-12-01	WOS:A1997XG83000010
J	Kirkpatrick, DT; Petes, TD				Kirkpatrick, DT; Petes, TD			Repair of DNA loops involves DNA-mismatch and nucleotide-excision repair proteins	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; MEIOTIC RECOMBINATION; YEAST; MUTANTS	A number of enzymes recognize and repair DNA lesions(1). The DNA-mismatch repair system corrects base-base mismatches and small loops, whereas the nucleotide-excision repair systems removes pyrimidine dimers and other helix-distorting lesions. DNA molecules with mismatches or loops can arise as a consequence of heteroduplex formation during meiotic recombination(2). In the yeast Saccharomyces cerevisiae, repair of mismatches results in gene conversion or restoration, and failure to repair the mismatch results in post-meiotic segregation (PMS) (Fig. 1). The ratio of gene-conversion to PMS events reflects the efficiency of DNA repair(3,4). By examining the PMS patterns in yeast strains heterozygous for a mutant allele with a 26-base-pair insertion, we find that the repair of 26-base loops involves Msh2 (a DNA-mismatch repair protein) and Rad1 (a protein required for nucleotide-excision repair).	UNIV N CAROLINA,DEPT BIOL,CURRICULUM GENET & MOL BIOL,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill								ALANI E, 1995, GENE DEV, V9, P234, DOI 10.1101/gad.9.2.234; ALANI E, 1994, GENETICS, V137, P19; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; CARPENTER ATC, 1982, P NATL ACAD SCI-BIOL, V79, P5961, DOI 10.1073/pnas.79.19.5961; DETLOFF P, 1991, MOL CELL BIOL, V11, P737, DOI 10.1128/MCB.11.2.737; DICAPRIO L, 1976, MUTAT RES, V37, P137, DOI 10.1016/0027-5107(76)90061-0; DOWLING EL, 1985, GENETICS, V109, P283; Duckett DR, 1996, P NATL ACAD SCI USA, V93, P6443, DOI 10.1073/pnas.93.13.6443; FOGEL S, 1981, MOL BIOL YEAST SACCH, P289; Friedberg E. C., 1995, DNA REPAIR MUTAGENES, P1; HUANG JC, 1994, P NATL ACAD SCI USA, V91, P12213, DOI 10.1073/pnas.91.25.12213; Johnson RE, 1996, J BIOL CHEM, V271, P7285, DOI 10.1074/jbc.271.13.7285; Marsischky GT, 1996, GENE DEV, V10, P407, DOI 10.1101/gad.10.4.407; Mello JA, 1996, CHEM BIOL, V3, P579, DOI 10.1016/S1074-5521(96)90149-0; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; NAG DK, 1989, NATURE, V340, P318, DOI 10.1038/340318a0; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; REENAN RAG, 1992, GENETICS, V132, P975; RESNICK MA, 1983, GENETICS, V104, P603; Saparbaev M, 1996, GENETICS, V142, P727; SEKELSKY JJ, 1995, GENETICS, V141, P619; Sia EA, 1997, MOL CELL BIOL, V17, P2851, DOI 10.1128/MCB.17.5.2851; STAPLETON A, 1991, GENETICS, V127, P39; Tran HT, 1996, GENETICS, V143, P1579	24	128	130	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 26	1997	387	6636					929	931		10.1038/43225	http://dx.doi.org/10.1038/43225			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XG416	9202128				2022-12-01	WOS:A1997XG41600058
J	Panin, VM; Papayannopoulos, V; Wilson, R; Irvine, KD				Panin, VM; Papayannopoulos, V; Wilson, R; Irvine, KD			Fringe modulates notch ligand interactions	NATURE			English	Article							DROSOPHILA; GENE; EXPRESSION; PROTEIN; DELTA; BOUNDARY; RECEPTOR; SERRATE; ENCODES; MEMBER	Notch family of transmembrane receptor proteins mediate developmental cell-fate decisions(1), and mutations in mammalian Notch genes have been implicated in leukaemia, breast cancer, stroke and dementia(2-4). During wing development in Drosophila, the Notch receptor is activated along the border between dorsal and ventral cells(5-7), leading to the specification of specialized cells that express Wingless (Wg) and organize wing growth and patterning(6,8,9). Three genes, fringe (fng), Serrate (Ser) and Delta (Dl), are involved in the cellular interactions leading to Notch activation(7,9-15). Ser and Dl encode transmembrane ligands for Notch(16,17), whereas fng encodes a pioneer protein(10). We have investigated the relationship between these genes by a combination of expression and coexpression studies in the Drosophila wing, We found that Ser and Dl maintain each other's expression by a positive feedback loop, fng is expressed specifically by dorsal cells and functions to position and restrict this feedback loop to the developing dorsal-ventral boundary, This is achieved by fng through a cell-autonomous mechanism that inhibits a cell's ability to respond to Serrate protein and potentiates its ability to respond to Delta protein.	RUTGERS STATE UNIV,WAKSMAN INST,PISCATAWAY,NJ 08855; RUTGERS STATE UNIV,DEPT MOL BIOL & BIOCHEM,PISCATAWAY,NJ 08855	Rutgers State University New Brunswick; Rutgers State University New Brunswick			Panin, Vlad/G-1583-2016	Panin, Vlad/0000-0001-9126-1481; Papayannopoulos, Venizelos/0000-0002-3741-8190				ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; BRAND AH, 1993, DEVELOPMENT, V118, P401; Couso JP, 1995, CURR BIOL, V5, P1437, DOI 10.1016/S0960-9822(95)00281-8; DECELIS JF, 1994, MECH DEVELOP, V46, P109, DOI 10.1016/0925-4773(94)90080-9; deCelis JF, 1996, DEVELOPMENT, V122, P359; DiazBenjumea FJ, 1995, DEVELOPMENT, V121, P4215; Doherty D, 1996, GENE DEV, V10, P421, DOI 10.1101/gad.10.4.421; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FLEMING RJ, IN PRESS DEVELOPMENT; HINZ U, 1994, CELL, V76, P77, DOI 10.1016/0092-8674(94)90174-0; IRVINE KD, 1994, CELL, V79, P595, DOI 10.1016/0092-8674(94)90545-2; Johnston SH, 1997, DEVELOPMENT, V124, P2245; JONSSON E, 1996, DEV GENES EVOL, V206, P91; Joutel A, 1996, NATURE, V383, P707, DOI 10.1038/383707a0; Kim J, 1996, NATURE, V382, P133, DOI 10.1038/382133a0; KIM J, 1995, CELL, V82, P795, DOI 10.1016/0092-8674(95)90476-X; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; KOPCZYNSKI CC, 1989, DEVELOPMENT, V107, P623; Laufer E, 1997, NATURE, V386, P366, DOI 10.1038/386366a0; Lawrence PA, 1996, CELL, V85, P951, DOI 10.1016/S0092-8674(00)81297-0; MEINHARDT H, 1983, DEV BIOL, V96, P375, DOI 10.1016/0012-1606(83)90175-6; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; ROBBINS J, 1992, J VIROL, V66, P2594, DOI 10.1128/JVI.66.4.2594-2599.1992; RodriguezEsteban C, 1997, NATURE, V386, P360, DOI 10.1038/386360a0; RULIFSON EJ, 1995, DEVELOPMENT, V121, P2813; SPELCHER SA, 1994, DEVELOPMENT, V120, P535; STRUHL G, 1993, CELL, V74, P331, DOI 10.1016/0092-8674(93)90424-O; THOMAS U, 1991, DEVELOPMENT, V111, P749; Wu JY, 1996, SCIENCE, V273, P355, DOI 10.1126/science.273.5273.355; Zecca M, 1996, CELL, V87, P833, DOI 10.1016/S0092-8674(00)81991-1	31	495	500	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 26	1997	387	6636					908	912		10.1038/43191	http://dx.doi.org/10.1038/43191			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XG416	9202123				2022-12-01	WOS:A1997XG41600053
J	Gallagher, RB				Gallagher, RB			Nota bene: Immunology - Population biology of lymphocytes	SCIENCE			English	Editorial Material														Gallagher, Richard/0000-0001-5639-2187				McLean AR, 1997, P NATL ACAD SCI USA, V94, P5792, DOI 10.1073/pnas.94.11.5792; WESTMAN BS, 1982, J NUTR, V112, P562	2	1	1	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 20	1997	276	5320					1817	1817		10.1126/science.276.5320.1817	http://dx.doi.org/10.1126/science.276.5320.1817			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XF103	9206842				2022-12-01	WOS:A1997XF10300034
J	Geppert, M; Goda, Y; Stevens, CF; Sudhof, TC				Geppert, M; Goda, Y; Stevens, CF; Sudhof, TC			The small GTP-binding protein Rab3A regulates a late step in synaptic vesicle fusion	NATURE			English	Article							LONG-TERM POTENTIATION; PAIRED-PULSE FACILITATION; NEUROTRANSMITTER RELEASE; MEMBRANE TRAFFICKING; TRANSMITTER RELEASE; TRANSMISSION; PROBABILITY; INVOLVEMENT; PLASTICITY; EXOCYTOSIS	The Rab family of low-molecular-mass GTP-binding proteins are thought to guide membrane fusion between a transport vesicle and the target membrane, and to determine the specificity of docking(1-3). The docking and fusion of vesicles is, however, a complex multistep reaction, and the precise point at which Rab proteins act in these sequential processes in unknown. In brain, the Rab protein Rab3A is specific to synaptic vesicles, whose exocytosis can be monitored with submillisecond resolution by following synaptic transmission. We have now determined the precise point at which Rab3A acts in the sequence of synaptic vesicle docking and fusion by using electrophysiological analysis of neurotransmitter release in Rab3A-deficient mice. Unexpectedly, the size of the readily releasable pool of vesicles is normal, whereas Ca2+-triggered fusion is altered in the absence of Rab3A in that a more-than-usual number of exocytic events occur within a brief time after arrival of the nerve impulse.	SALK INST BIOL STUDIES,MOL NEUROBIOL LAB,LA JOLLA,CA 92037; SALK INST BIOL STUDIES,HOWARD HUGHES MED INST,LA JOLLA,CA 92037; MAX PLANCK INST EXPT MED,D-37075 GOTTINGEN,GERMANY; UNIV TEXAS,SW MED CTR,DEPT MOL GENET,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235	Salk Institute; Howard Hughes Medical Institute; Salk Institute; Max Planck Society; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Goda, Yukiko/AAR-5641-2020; Goda, Yukiko/A-6576-2016	Goda, Yukiko/0000-0003-0352-9498; Goda, Yukiko/0000-0003-0352-9498				ALLEN C, 1994, P NATL ACAD SCI USA, V91, P10380, DOI 10.1073/pnas.91.22.10380; CLEMENTS JD, 1992, SCIENCE, V258, P1498, DOI 10.1126/science.1359647; GEPPERT M, 1994, NATURE, V369, P493, DOI 10.1038/369493a0; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; HESSLER NA, 1993, NATURE, V366, P569, DOI 10.1038/366569a0; HOLZ RW, 1994, J BIOL CHEM, V269, P10229; HUANG E, UNPUB J NEUROPHYSIOL; HUBBARD JI, 1963, J PHYSIOL-LONDON, V169, P641, DOI 10.1113/jphysiol.1963.sp007286; HUETTNER JE, 1988, P NATL ACAD SCI USA, V85, P1307, DOI 10.1073/pnas.85.4.1307; JOHANNES L, 1994, EMBO J, V13, P2029, DOI 10.1002/j.1460-2075.1994.tb06476.x; KAMIYA H, 1994, NATURE, V371, P603, DOI 10.1038/371603a0; Katz B., 1969, RELEASE NEURAL TRANS; MALLART A, 1968, J PHYSIOL-LONDON, V196, P593, DOI 10.1113/jphysiol.1968.sp008525; MALLART A, 1967, J PHYSIOL-LONDON, V193, P593; MANABE T, 1993, J NEUROPHYSIOL, V70, P1451, DOI 10.1152/jn.1993.70.4.1451; OLVERMAN HJ, 1988, NEUROSCIENCE, V26, P17, DOI 10.1016/0306-4522(88)90124-8; PERKEL DJ, 1993, J PHYSIOL-LONDON, V471, P481, DOI 10.1113/jphysiol.1993.sp019911; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; RAASTAD M, 1992, EUR J NEUROSCI, V4, P113, DOI 10.1111/j.1460-9568.1992.tb00114.x; Rosenmund C, 1996, NEURON, V16, P1197, DOI 10.1016/S0896-6273(00)80146-4; ROSENMUND C, 1993, SCIENCE, V262, P754, DOI 10.1126/science.7901909; Rybin V, 1996, NATURE, V383, P266, DOI 10.1038/383266a0; SCHELLER RH, 1995, NEURON, V14, P893; SCHULZ PE, 1994, J NEUROSCI, V14, P5325; Stahl B, 1996, EMBO J, V15, P1799, DOI 10.1002/j.1460-2075.1996.tb00529.x; STEVENS CF, 1995, P NATL ACAD SCI USA, V92, P846, DOI 10.1073/pnas.92.3.846; STEVENS CF, 1995, NEURON, V14, P795, DOI 10.1016/0896-6273(95)90223-6; STEVENS CF, 1994, NATURE, V371, P704, DOI 10.1038/371704a0; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; TRILLER A, 1982, J NEUROPHYSIOL, V48, P708, DOI 10.1152/jn.1982.48.3.708	30	335	345	0	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 19	1997	387	6635					810	814		10.1038/42954	http://dx.doi.org/10.1038/42954			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XF144	9194562	Bronze			2022-12-01	WOS:A1997XF14400052
J	Lill, NL; Grossman, SR; Ginsberg, D; DeCaprio, J; Livingston, DM				Lill, NL; Grossman, SR; Ginsberg, D; DeCaprio, J; Livingston, DM			Binding and modulation of p53 by p300/CBP coactivators	NATURE			English	Article							CELL-CYCLE; RETINOBLASTOMA PROTEIN; E1A PROTEINS; GENE; SUPPRESSION; INDUCTION; COMPLEXES; REVEALS; GROWTH; FORMS	The adenovirus E1A and SV40 large-T-antigen oncoproteins bind to members of the p300/CBP transcriptional coactivator family. Binding of p300/CBP is implicated in the transforming mechanisms of EIA and T-antigen oncoproteins. A common region of the T antigen is critical for binding both p300/CBP and the tumour suppressor p53 (ref. 1), suggesting a link between the functions of p53 and p300. Here we report that p300/CBP binds to p53 in the absence of viral oncoproteins, and that p300 and p53 colocalize within the nucleus and coexist in a stable DNA-binding complex. Consistent with its ability to bind to p300, E1A disrupted functions mediated by p53. It reduced p53-mediated activation of the p21 and bax promoters, and suppressed p53-induced cell-cycle arrest and apoptosis. We conclude that members of the p300/CBP family are transcriptional adaptors for p53, modulating its checkpoint function in the G1 phase of the cell cycle and its induction of apoptosis. Disruption of p300/p53-dependent growth control may be part of the mechanism by which E1A induces cell transformation. These results help to explain how p53 mediates growth and checkpoint control, and how members of the p300/CBP family affect progression from G1 to the S phase of the cell cycle.	DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School				ginsberg, doron/0000-0002-1257-4920				ABRAHAM SE, 1993, ONCOGENE, V8, P1639; Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAYLEY ST, 1994, INT J ONCOL, V5, P425; CAPOROSSI D, 1990, J GEN VIROL, V71, P801, DOI 10.1099/0022-1317-71-4-801; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Eckner R, 1996, MOL CELL BIOL, V16, P3454; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HOWE JA, 1992, VIROLOGY, V186, P15, DOI 10.1016/0042-6822(92)90057-V; KAHANA JA, 1996, CURRENT PROTOCOLS MO; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; Lill NL, 1997, J VIROL, V71, P129, DOI 10.1128/JVI.71.1.129-137.1997; MIYASHITA T, 1995, CELL, V80, P293; QIN XQ, 1995, MOL CELL BIOL, V15, P742; Somasundaram K, 1997, ONCOGENE, V14, P1047, DOI 10.1038/sj.onc.1201002; Steegenga WT, 1996, MOL CELL BIOL, V16, P2101; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	30	604	618	1	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 19	1997	387	6635					823	827		10.1038/42981	http://dx.doi.org/10.1038/42981			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XF144	9194565	Bronze			2022-12-01	WOS:A1997XF14400055
J	Roach, PL; Clifton, IJ; Hensgens, CMH; Shibata, N; Schofield, CJ; Hajdu, J; Baldwin, JE				Roach, PL; Clifton, IJ; Hensgens, CMH; Shibata, N; Schofield, CJ; Hajdu, J; Baldwin, JE			Structure of isopenicillin N synthase complexed with substrate and the mechanism of penicillin formation	NATURE			English	Article							ACTIVE-SITE; CRYSTAL-STRUCTURE; FACTOR REFINEMENT; BIOSYNTHESIS; ENZYMES	The biosynthesis of penicillin and cephalosporin antibiotics in microorganisms requires the formation of the bicyclic nucleus of penicillin(1). Isopenicillin N synthase (IPNS), a non-haem iron-dependent oxidase, catalyses the reaction of a tripeptide, delta-(L-alpha-aminoadipoyl)-L-cysteinyl-D-valine (ACV), and dioxygen to form isopenicillin N and two water molecules(2). Mechanistic studies suggest the reaction is initiated by ligation of the substrate thiolate to the iron centre, and proceeds through an enzyme-bound monocyclic intermediate(3,4) (Fig. 1), Here we report the crystal structure of IPNS complexed to ferrous iron and ACV, determined to 1.3 Angstrom resolution. Based on the structure, we propose a mechanism for penicillin formation that involves ligation of ACV to the iron centre, creating a vacant iron coordination site into which dioxygen can bind. Subsequently, iron-dioxygen and iron-ore species remove the requisite hydrogens from ACV without the direct assistance of protein residues (Fig. 2). The crystal structure of the complex with the dioxygen analogue, NO and ACV bound to the active-site iron supports this hypothesis.	UNIV OXFORD,DYSON PERRINS LAB,OXFORD OX1 3QY,ENGLAND; UNIV OXFORD,OXFORD CTR MOL SCI,OXFORD OX1 3QY,ENGLAND; UNIV UPPSALA,CTR BIOMED,DEPT BIOCHEM,S-75123 UPPSALA,SWEDEN	University of Oxford; University of Oxford; Uppsala University			Shibata, Norio/A-9628-2008; Roach, Peter/C-6248-2013; Roach, Peter/AAW-7071-2021	Shibata, Norio/0000-0002-3742-4064; Schofield, Christopher/0000-0002-0290-6565				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Baldwin J. E., 1992, CHEM BETA LACTAMS, P1; BALDWIN JE, 1984, J CHEM SOC CHEM COMM, P1225, DOI 10.1039/c39840001225; BALDWIN JE, 1988, NAT PROD REP, V5, P129, DOI 10.1039/np9880500129; Baldwin JE, 1996, TETRAHEDRON, V52, P2537, DOI 10.1016/0040-4020(95)01072-6; BALDWIN JE, 1991, P ROY SOC B-BIOL SCI, V245, P43, DOI 10.1098/rspb.1991.0086; BOROVOK L, 1996, BIOCHEMISTRY-US, V35, P1981; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHEN VJ, 1989, J BIOL CHEM, V264, P21677; Cooper R D, 1993, Bioorg Med Chem, V1, P1, DOI 10.1016/S0968-0896(00)82098-2; Groves John T., 1995, P3; HADFIELD A, 1993, J APPL CRYSTALLOGR, V26, P839, DOI 10.1107/S0021889893005552; HAN S, 1995, SCIENCE, V270, P976, DOI 10.1126/science.270.5238.976; HANAUSKEABEL HM, 1982, J THEOR BIOL, V94, P421, DOI 10.1016/0022-5193(82)90320-4; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KONNERT JH, 1980, ACTA CRYSTALLOGR A, V36, P344, DOI 10.1107/S0567739480000794; LESLIE AGW, 1996, MOSFLM; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; ORVILLE AM, 1992, BIOCHEMISTRY-US, V31, P4602, DOI 10.1021/bi00134a010; OTWINOWSKI Z, 1993, DATA COLLECTION PROC, P55; PANG CP, 1984, BIOCHEM J, V222, P789, DOI 10.1042/bj2220789; PRESCOTT AG, 1993, J EXP BOT, V44, P849, DOI 10.1093/jxb/44.5.849; Que L, 1996, CHEM REV, V96, P2607, DOI 10.1021/cr960039f; RANDALL CR, 1993, BIOCHEMISTRY-US, V32, P6664, DOI 10.1021/bi00077a020; Roach PL, 1996, EUR J BIOCHEM, V242, P736, DOI 10.1111/j.1432-1033.1996.0736r.x; ROACH PL, 1995, NATURE, V375, P700, DOI 10.1038/375700a0; ROWE CJ, 1995, THESIS OXFORD U; Senda T, 1996, J MOL BIOL, V255, P735, DOI 10.1006/jmbi.1996.0060; SHELDRICK GM, 1993, SHELXL93 PROGRAM CRY; SHU LJ, 1995, BIOCHEMISTRY-US, V34, P6649, DOI 10.1021/bi00020a010	30	374	380	0	61	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 19	1997	387	6635					827	830		10.1038/42990	http://dx.doi.org/10.1038/42990			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XF144	9194566	Bronze			2022-12-01	WOS:A1997XF14400056
J	Bartlett, JG				Bartlett, JG			Infectious diseases	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											Bartlett, JG (corresponding author), JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD 21218, USA.							Bloom FE, 1996, SCIENCE, V274, P1987, DOI 10.1126/science.274.5295.1987; Carpenter CCJ, 1996, JAMA-J AM MED ASSOC, V276, P146, DOI 10.1001/jama.276.2.146; *CDC, 1996, MMWR-MORBID MORTAL W, V45, P611; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; EMINI EA, 1996, 11 INT C AIDS VANC B; Fauci AS, 1996, NATURE, V384, P529, DOI 10.1038/384529a0; Fiscus SA, 1996, JAMA-J AM MED ASSOC, V275, P1483, DOI 10.1001/jama.275.19.1483; Foreman KE, 1997, NEW ENGL J MED, V336, P163, DOI 10.1056/NEJM199701163360302; Gorman Christine, 1997, TIME            1230, P56; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Kitahata MM, 1996, NEW ENGL J MED, V334, P701, DOI 10.1056/NEJM199603143341106; Lederberg J, 1996, JAMA-J AM MED ASSOC, V276, P417, DOI 10.1001/jama.276.5.417; Linnen J, 1996, SCIENCE, V271, P505, DOI 10.1126/science.271.5248.505; Lorber B, 1996, ANN INTERN MED, V125, P844, DOI 10.7326/0003-4819-125-10-199611150-00010; MARKOWITZ M, 1996, 11 INT C AIDS VANC B; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; Potter J, 1997, J INFECT DIS, V175, P1, DOI 10.1093/infdis/175.1.1; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9	19	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	1997	277	23					1865	1866		10.1001/jama.277.23.1865	http://dx.doi.org/10.1001/jama.277.23.1865			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD544	9185805				2022-12-01	WOS:A1997XD54400024
J	Mata, J; Nurse, P				Mata, J; Nurse, P			tea1 and the microtubular cytoskeleton are important for generating global spatial order within the fission yeast cell	CELL			English	Article							SCHIZOSACCHAROMYCES-POMBE; GENETIC-ANALYSIS; S-POMBE; PROTEIN; ENCODES; GROWTH; MORPHOGENESIS; ORGANIZATION; CYTOKINESIS; SCRUIN	Fission yeast cells identify and maintain growing regions exactly opposed at the ends of a cylindrical cell. tea1 mutants disrupt this organization, producing bent and T-shaped cells. We have cloned teal and shown that teal is located at the cell poles. Microtubules are continuously required to transfer teal to the cell ends, and teal is located at the ends of microtubules growing toward the cell poles. We suggest that teal acts as an end marker, directing the growth machinery to the cell poles. tea1 is down-regulated in cells treated with pheromone that grow toward a mating partner and no longer maintain their ends exactly opposed. teal may also influence microtubular organization, affecting the maintenance of a single central axis.			Mata, J (corresponding author), IMPERIAL CANC RES FUND, CELL CYCLE LAB, 44 LINCOLNS INN FIELDS, LONDON WC2A 3PX, ENGLAND.			Mata, Juan/0000-0002-5514-3653				ALFA CE, 1983, METHOD CELL BIOL, V37, P201; BALASUBRAMANIAN MK, 1992, NATURE, V360, P84, DOI 10.1038/360084a0; BALASUBRAMANIAN MK, 1994, J CELL BIOL, V125, P1289, DOI 10.1083/jcb.125.6.1289; BORK P, 1994, J MOL BIOL, V236, P1277, DOI 10.1016/0022-2836(94)90056-6; Chang F, 1996, J CELL SCI, V109, P131; EATON S, 1995, CELL, V82, P5, DOI 10.1016/0092-8674(95)90045-4; Eichinger L, 1996, EMBO J, V15, P5547, DOI 10.1002/j.1460-2075.1996.tb00939.x; FORSBURG SL, 1993, NUCLEIC ACIDS RES, V21, P2955, DOI 10.1093/nar/21.12.2955; FUKUI Y, 1986, EMBO J, V5, P1991, DOI 10.1002/j.1460-2075.1986.tb04454.x; Grallert B, 1996, GENE DEV, V10, P2644, DOI 10.1101/gad.10.20.2644; HAGAN IM, 1988, J CELL SCI, V89, P343; HIRAOKA Y, 1984, CELL, V39, P349, DOI 10.1016/0092-8674(84)90013-8; HOHEISEL JD, 1993, CELL, V73, P109, DOI 10.1016/0092-8674(93)90164-L; IMAI Y, 1992, MOL CELL BIOL, V12, P1827, DOI 10.1128/MCB.12.4.1827; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; LEHMANN R, 1995, CELL, V83, P353, DOI 10.1016/0092-8674(95)90111-6; LEUPOLD U, 1987, CURR GENET, V12, P543, DOI 10.1007/BF00419564; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MAEDA T, 1990, P NATL ACAD SCI USA, V87, P7814, DOI 10.1073/pnas.87.20.7814; MARKS J, 1986, J CELL SCI, P229; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MITCHISON JM, 1985, J CELL SCI, V75, P357; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Morgan BA, 1996, P NATL ACAD SCI USA, V93, P2801, DOI 10.1073/pnas.93.7.2801; OHKURA H, 1989, CELL, V57, P997, DOI 10.1016/0092-8674(89)90338-3; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; Roemer T, 1996, TRENDS CELL BIOL, V6, P434, DOI 10.1016/S0962-8924(96)10039-8; SCHMIDT H, 1993, CURR GENET, V24, P271, DOI 10.1007/BF00351803; SNELL V, 1994, EMBO J, V13, P2066, DOI 10.1002/j.1460-2075.1994.tb06481.x; SNELL V, 1993, J CELL SCI DEV S, P289; Stern B, 1997, EMBO J, V16, P534, DOI 10.1093/emboj/16.3.534; TODA T, 1984, CELL, V37, P233, DOI 10.1016/0092-8674(84)90319-2; UMESONO K, 1983, J MOL BIOL, V168, P271, DOI 10.1016/S0022-2836(83)80018-7; VARKEY JP, 1995, GENE DEV, V9, P1074, DOI 10.1101/gad.9.9.1074; VERDE F, 1995, J CELL BIOL, V131, P1529, DOI 10.1083/jcb.131.6.1529; WAY M, 1995, J CELL BIOL, V128, P51, DOI 10.1083/jcb.128.1.51; WILSON AC, 1993, CELL, V74, P115, DOI 10.1016/0092-8674(93)90299-6; WOODS A, 1989, J CELL SCI, V93, P491; XUE FY, 1993, CELL, V72, P681, DOI 10.1016/0092-8674(93)90397-9; Yaffe MP, 1996, P NATL ACAD SCI USA, V93, P11664, DOI 10.1073/pnas.93.21.11664	40	296	303	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 13	1997	89	6					939	949		10.1016/S0092-8674(00)80279-2	http://dx.doi.org/10.1016/S0092-8674(00)80279-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XE357	9200612	Bronze			2022-12-01	WOS:A1997XE35700014
J	Schmidt, G; Sehr, P; Wilm, M; Selzer, J; Mann, M; Aktories, K				Schmidt, G; Sehr, P; Wilm, M; Selzer, J; Mann, M; Aktories, K			Gln 63 of Rho is deamidated by Escherichia coli cytotoxic necrotizing factor-1	NATURE			English	Article							BINDING PROTEIN-RHO; ACTIN STRESS FIBERS; DIFFICILE TOXIN-B; CLOSTRIDIUM-DIFFICILE; GTPASE; MICROINJECTION; INDUCTION; CELLS; RAC	The actin cytoskeleton is regulated by GTP-hydrolysing proteins, the Rho GTPases(1,2), which act as molecular switches in diverse signal-transduction processes(3). Various bacterial toxins can inactivate Rho GTPases by ADP-ribosylation(1) or glucosylation(4). Previous research has identified Rho proteins as putative targets for Escherichia coli cytotoxic necrotizing factors 1 and 2 (CNF1 and 2)(5,6). These toxins induce actin assembly and multinucleation in culture cells. Here we show that treatment of RhoA with CNF1 inhibits the intrinsic GTPase activity of RhoA and completely blocks GTPase activity stimulated by the Rho-GTPase-activating protein (rhoGAP). Analysis by mass spectrometry and amino-acid sequencing of proteolytic peptides derived from CNF1-treated RhoA indicate that CNF1 induces deamidation of a glutamine residue at position 63 (Gln63) to give constitutively active Rho protein.	UNIV FREIBURG,INST PHARMAKOL & TOXIKOL,D-79104 FREIBURG,GERMANY; EUROPEAN MOL BIOL LAB,D-69012 HEIDELBERG,GERMANY	University of Freiburg; European Molecular Biology Laboratory (EMBL)			Mann, Matthias/A-3454-2013; Aktories, Klaus/CAJ-5682-2022	Mann, Matthias/0000-0003-1292-4799; Aktories, Klaus/0000-0002-5397-0436; Sehr, Peter/0000-0002-4348-5066; Wilm, Matthias/0000-0002-5461-6834				AKTORIES K, 1995, METHOD ENZYMOL, V256, P184; CAPRIOLI A, 1983, INFECT IMMUN, V39, P1300, DOI 10.1128/IAI.39.3.1300-1306.1983; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; DERYCKE J, 1990, J CLIN MICROBIOL, V28, P694, DOI 10.1128/JCM.28.4.694-699.1990; DIEKMANN D, 1995, METHOD ENZYMOL, V256, P207; FALBO V, 1993, INFECT IMMUN, V61, P4909, DOI 10.1128/IAI.61.11.4909-4914.1993; FALZANO L, 1993, MOL MICROBIOL, V9, P1247, DOI 10.1111/j.1365-2958.1993.tb01254.x; FIORENTINI C, 1995, INFECT IMMUN, V63, P3936, DOI 10.1128/IAI.63.10.3936-3944.1995; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; HORIGUCHI Y, 1995, J CELL SCI, V108, P3243; JUST I, 1995, J CLIN INVEST, V95, P1026, DOI 10.1172/JCI117747; JUST I, 1994, J BIOL CHEM, V269, P10706; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; LEONARD DA, 1994, BIOCHEMISTRY-US, V33, P12323, DOI 10.1021/bi00206a040; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; MACHESKY IM, 1996, TRENDS CELL BIOL, V6, P304; OSWALD E, 1994, P NATL ACAD SCI USA, V91, P3814, DOI 10.1073/pnas.91.9.3814; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; Renshaw MW, 1996, J BIOL CHEM, V271, P21691, DOI 10.1074/jbc.271.36.21691; RIDLEY AJ, 1995, METHOD ENZYMOL, V256, P313; SCHWEINS T, 1995, NAT STRUCT BIOL, V2, P36, DOI 10.1038/nsb0195-36; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519	22	438	445	1	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 12	1997	387	6634					725	729		10.1038/42735	http://dx.doi.org/10.1038/42735			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XD869	9192900	Bronze			2022-12-01	WOS:A1997XD86900059
J	Inoue, A; Sanes, JR				Inoue, A; Sanes, JR			Lamina-specific connectivity in the brain: Regulation by N-cadherin, neurotrophins, and glycoconjugates	SCIENCE			English	Article							SYNAPSE-SPECIFIC CARBOHYDRATE; CELL-ADHESION MOLECULES; NEURITE OUTGROWTH; VISUAL-CORTEX; OPTIC TECTUM; ACETYLGALACTOSAMINE; EXPRESSION; NEURONS; SURFACE; EVENTS	In the vertebrate brain, neurons grouped in parallel laminae receive distinct sets of synaptic inputs. In the avian optic tectum, arbors and synapses of most retinal axons are confined to 3 of 15 laminae. The adhesion molecule N-cadherin and cell surface glycoconjugates recognized by a plant lectin are selectively associated with these ''retinorecipient'' laminae. The lectin and a monoclonal antibody to N-cadherin perturbed laminar selectivity in distinct fashions. In contrast, neurotrophins increased the complexity of retinal arbors without affecting their laminar distribution. Thus, cell surface molecules and soluble trophic factors may collaborate to shape lamina-specific arbors in the brain, with the former predominantly affecting their position and the latter their size.	WASHINGTON UNIV,SCH MED,DEPT ANAT & NEUROBIOL,ST LOUIS,MO 63110	Washington University (WUSTL)								BAYER SA, 1987, PROG NEUROBIOL, V29, P57, DOI 10.1016/0301-0082(87)90015-3; BIXBY JL, 1990, J CELL BIOL, V110, P1253, DOI 10.1083/jcb.110.4.1253; BOLZ J, 1993, TRENDS NEUROSCI, V16, P310, DOI 10.1016/0166-2236(93)90107-W; Bonhoeffer T, 1996, CURR OPIN NEUROBIOL, V6, P119, DOI 10.1016/S0959-4388(96)80017-1; CABELLI RJ, 1995, SCIENCE, V267, P1662, DOI 10.1126/science.7886458; COHENCORY S, 1994, NEURON, V12, P747, DOI 10.1016/0896-6273(94)90328-X; COHENCORY S, 1995, NATURE, V378, P192, DOI 10.1038/378192a0; DELAROSA EJ, 1994, NEUROSCIENCE, V58, P347, DOI 10.1016/0306-4522(94)90041-8; Doherty Patrick, 1994, Current Opinion in Neurobiology, V4, P49, DOI 10.1016/0959-4388(94)90031-0; Fannon AM, 1996, NEURON, V17, P423, DOI 10.1016/S0896-6273(00)80175-0; FROTSCHER M, 1995, J NEUROBIOL, V26, P350, DOI 10.1002/neu.480260307; Hallbook F, 1996, J COMP NEUROL, V364, P664; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HATTA K, 1986, NATURE, V320, P447, DOI 10.1038/320447a0; Hunt S.P., 1984, P619; ICHIKAWA M, 1994, DEV BRAIN RES, V78, P1, DOI 10.1016/0165-3806(94)90002-7; KARTEN HJ, 1982, CYTOCHEMICAL METHODS, P189; KATZ LC, 1992, ANNU REV NEUROSCI, V15, P31; LEMMON V, 1982, DEV BRAIN RES, V3, P349, DOI 10.1016/0165-3806(82)90003-7; MARTIN PT, 1995, NEURON, V14, P743, DOI 10.1016/0896-6273(95)90218-X; MATSUNAGA M, 1988, NATURE, V334, P62, DOI 10.1038/334062a0; MATSUNAGA M, 1988, NEURON, V1, P289, DOI 10.1016/0896-6273(88)90077-3; NAEGELE JR, 1990, J NEUROSCI, V10, P540; NAKAGAWA F, 1986, J COMP NEUROL, V243, P280, DOI 10.1002/cne.902430210; Prakash N, 1996, NATURE, V381, P702, DOI 10.1038/381702a0; SANES JR, 1982, NATURE, V300, P646, DOI 10.1038/300646a0; Sawai H, 1996, J NEUROSCI, V16, P3887; SCHNELL L, 1994, NATURE, V367, P170, DOI 10.1038/367170a0; Shatz CJ, 1996, P NATL ACAD SCI USA, V93, P602, DOI 10.1073/pnas.93.2.602; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; Uchida N, 1996, J CELL BIOL, V135, P767, DOI 10.1083/jcb.135.3.767; YAMAGATA M, 1995, DEVELOPMENT, V121, P189; YAMAGATA M, 1995, DEVELOPMENT, V121, P3763; YAMAGATA M, 1995, J NEUROSCI, V15, P4556	35	244	246	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 30	1997	276	5317					1428	1431		10.1126/science.276.5317.1428	http://dx.doi.org/10.1126/science.276.5317.1428			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XB533	9162013				2022-12-01	WOS:A1997XB53300054
J	Wu, H; Kwong, PD; Hendrickson, WA				Wu, H; Kwong, PD; Hendrickson, WA			Dimeric association and segmental variability in the structure of human CD4	NATURE			English	Article							IMMUNODEFICIENCY-VIRUS GP120; SIGNAL-TRANSDUCTION; CRYSTAL-STRUCTURE; BINDING; INFECTION; FRAGMENT; HIV; OLIGOMERIZATION; RECEPTORS; DOMAINS	CD4 is a co-receptor in the cellular immune response, It increases the avidity of association between a T cell and an antigen-presenting cell by interacting with non-polymorphic portions of the complex between class II major histocompatibility complex (MHC) and T-cell receptor (TCR) molecules, and it contributes directly to signal transduction through its cytoplasmic association with the lymphocyte kinase Lck (ref. 1). CD4 also serves as the high-affinity receptor for cellular attachment and entry of the human immunodeficiency virus (HIV)(2). The extracellular portion of CD4 comprises four immunoglobulin-like domains (D1-D4), This part of human CD4 (residues 1-369) has been characterized as a recombinant soluble protein (sCD4)(3,4), and crystal structures have been described for the human D1D2 fragment(5,6) and for the rat D3D4 fragment(7). We have now determined the structures of intact sCD4 in three crystal lattices. These structures have a hinge-like variability at the D1D2 to D3D4 junction that might be important in immune recognition and HIV fusion, and a common dimeric association through D4 domains. Dynamic light scattering measurements and chemical crosslinking of sCD4 corroborate dimerization at high protein concentration. We suggest that such dimers may have relevance as mediators of signal transduction in T cells.	COLUMBIA UNIV, DEPT BIOCHEM & MOL BIOPHYS, NEW YORK, NY 10032 USA; COLUMBIA UNIV, HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA	Columbia University; Columbia University; Howard Hughes Medical Institute								BRADY RL, 1993, SCIENCE, V260, P979, DOI 10.1126/science.8493535; BRUNGER AT, 1992, X PLOR SYSTEM XRAY C; DEEN KC, 1988, NATURE, V331, P82, DOI 10.1038/331082a0; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FLEURY S, 1991, CELL, V66, P1037, DOI 10.1016/0092-8674(91)90447-7; Harding S E, 1994, Methods Mol Biol, V22, P97; HEALEY D, 1990, J EXP MED, V172, P1233, DOI 10.1084/jem.172.4.1233; Huang B, 1997, J IMMUNOL, V158, P216; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KONIG R, 1995, J EXP MED, V182, P779, DOI 10.1084/jem.182.3.779; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUPFER A, 1987, P NATL ACAD SCI USA, V84, P5888, DOI 10.1073/pnas.84.16.5888; KWONG PD, 1990, P NATL ACAD SCI USA, V87, P6423, DOI 10.1073/pnas.87.16.6423; KWONG PD, 1994, J APPL CRYSTALLOGR, V27, P504, DOI 10.1107/S0021889893012592; Lapham CK, 1996, SCIENCE, V274, P602, DOI 10.1126/science.274.5287.602; LIFSON JD, 1989, IMMUNOL REV, V109, P93, DOI 10.1111/j.1600-065X.1989.tb00021.x; MOEBIUS U, 1992, P NATL ACAD SCI USA, V89, P12008, DOI 10.1073/pnas.89.24.12008; MOEBIUS U, 1993, P NATL ACAD SCI USA, V90, P8259, DOI 10.1073/pnas.90.17.8259; Moir S, 1996, J VIROL, V70, P8019, DOI 10.1128/JVI.70.11.8019-8028.1996; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; RYU SE, 1994, STRUCTURE, V2, P59, DOI 10.1016/S0969-2126(00)00008-3; SAKIHAMA T, 1995, P NATL ACAD SCI USA, V92, P6444, DOI 10.1073/pnas.92.14.6444; Tong L, 1996, ACTA CRYSTALLOGR A, V52, P782, DOI 10.1107/S010876739600548X; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0	29	234	247	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 29	1997	387	6632					527	530		10.1038/387527a0	http://dx.doi.org/10.1038/387527a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XB479	9168119				2022-12-01	WOS:A1997XB47900055
J	Turkstra, F; Kuijer, PMM; vanBeek, EJR; Brandjes, DPM; tenCate, JW; Buller, HR				Turkstra, F; Kuijer, PMM; vanBeek, EJR; Brandjes, DPM; tenCate, JW; Buller, HR			Diagnostic utility of ultrasonography of leg veins in patients suspected of having pulmonary embolism	ANNALS OF INTERNAL MEDICINE			English	Article						pulmonary embolism; radionuclide imaging; ultrasonography; anticoagulants; thrombophlebitis	PERFUSION LUNG-SCAN; COLOR DOPPLER ULTRASOUND; CLINICAL VALIDITY; D-DIMER; THROMBOSIS; THROMBOEMBOLISM; ANGIOGRAPHY; STRATEGY; COMPLICATIONS; VENOGRAPHY	Background: The standard diagnostic approach in patients suspected of having pulmonary embolism starts with perfusion-ventilation lung scanning. If the resulting scan is not diagnostic, pulmonary angiography should be done. The use of tests for deep venous thrombosis has been advocated as an adjunct to establishing the diagnosis of pulmonary embolism, but no prospective studies have provided adequate information about the value of these tests. Objective: To determine the accuracy and potential clinical utility of compression ultrasonography in the diagnosis of pulmonary embolism. Design: Prospective cohort study with blinded assessment of ultrasonographic results. Setting: Teaching hospital. Patients: 397 consecutive inpatients and outpatients in whom pulmonary embolism was clinically suspected. Measurements: Sensitivity and specificity of compression ultrasonography. Perfusion-ventilation scanning and angiography were the conjoint gold standard for determining the presence or absence of pulmonary embolism. Also calculated were the number of angiograms and lung scans avoided and the number of patients unnecessarily treated when compression ultrasonography was included in the diagnostic strategy. Results: The overall sensitivity of compression ultrasonography for deep venous thrombosis in patients with pulmonary embolism was 29% (95% CI, 22% to 37%); the specificity was 97% (CI, 94% to 99%). Adding ultrasonography to the diagnostic approach before lung scanning would avoid approximately 14% of lung scans and 9% of angiograms but would lead to unnecessary treatment of 13% of patients who have an abnormal ultrasonographic result (2% to 4% of all those receiving anticoagulation). When compression ultrasonography is done only in patients with a nondiagnostic lung scan, 9% of angiographies are prevented at the cost of unnecessarily treating 26% of patients who have an abnormal ultrasonographic result (2% of all patients receiving anticoagulation). Conclusion: The diagnostic value of compression ultrasonography for the detection of deep venous thrombosis in patients suspected of having pulmonary embolism is limited; the gain in diagnostic efficiency obtained through the use of ultrasonography may be offset by a loss in diagnostic accuracy.	UNIV AMSTERDAM, ACAD MED CTR, DEPT INTERNAL MED, NL-1105 AZ AMSTERDAM, NETHERLANDS; UNIV AMSTERDAM, ACAD MED CTR, DEPT RADIOL, NL-1105 AZ AMSTERDAM, NETHERLANDS; SLOTERVAART HOSP, DEPT INTERNAL MED, NL-1066 EC AMSTERDAM, NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Slotervaart Hospital	Turkstra, F (corresponding author), UNIV AMSTERDAM, ACAD MED CTR, CTR THROMBOSIS HAEMOSTASIS & ATHEROSCLEROSIS & IN, MEIBERGDREEF 9, NL-1105 AZ AMSTERDAM, NETHERLANDS.							BARRITT DW, 1960, LANCET, V1, P1309; BEECHAM RP, 1993, AM J ROENTGENOL, V161, P1289, DOI 10.2214/ajr.161.6.8249744; BOUNAMEAUX H, 1991, LANCET, V337, P196, DOI 10.1016/0140-6736(91)92158-X; BRADLEY MJ, 1995, CLIN RADIOL, V50, P232, DOI 10.1016/S0009-9260(05)83476-2; CELI A, 1989, CHEST, V95, P332, DOI 10.1378/chest.95.2.332; Christiansen F, 1996, ACTA RADIOL, V37, P14; DAVIDSON BL, 1992, ANN INTERN MED, V117, P735, DOI 10.7326/0003-4819-117-9-735; FERNANDEZCANTON G, 1994, EUR J RADIOL, V19, P50, DOI 10.1016/0720-048X(94)00569-X; FOURNIER P, 1993, ANN CARDIOL ANGEIOL, V42, P447; GINSBERG JS, 1995, THROMB HAEMOSTASIS, V73, P35; HEIJBOER H, 1993, NEW ENGL J MED, V329, P1365, DOI 10.1056/NEJM199311043291901; HOELLERICH VL, 1986, ARCH INTERN MED, V146, P1699, DOI 10.1001/archinte.146.9.1699; HULL RD, 1985, CHEST, V88, P819, DOI 10.1378/chest.88.6.819; HULL RD, 1994, ARCH INTERN MED, V154, P289, DOI 10.1001/archinte.154.3.289; HULL RD, 1990, CHEST, V97, P23, DOI 10.1378/chest.97.1.23; HULL RD, 1983, ANN INTERN MED, V98, P891, DOI 10.7326/0003-4819-98-6-891; HULL RD, 1995, ARCH INTERN MED, V155, P1845; JONGBLOETS LMM, 1994, LANCET, V343, P1142, DOI 10.1016/S0140-6736(94)90240-2; KRUIT WHJ, 1991, J INTERN MED, V230, P333, DOI 10.1111/j.1365-2796.1991.tb00453.x; LENSING AWA, 1992, THROMB HAEMOSTASIS, V68, P245; LENSING AWA, 1989, NEW ENGL J MED, V320, P342, DOI 10.1056/NEJM198902093200602; LENSING AWA, 1994, HEMOSTASIS THROMBOSI, P1297; MORRELL NW, 1992, BRIT MED J, V304, P1126, DOI 10.1136/bmj.304.6835.1126; MOSER KM, 1990, AM REV RESPIR DIS, V141, P235, DOI 10.1164/ajrccm/141.1.235; REMYJARDIN M, 1992, RADIOLOGY, V185, P381, DOI 10.1148/radiology.185.2.1410342; Rosen MP, 1996, AM J ROENTGENOL, V166, P285, DOI 10.2214/ajr.166.2.8553931; SCHIFF MJ, 1987, ARCH INTERN MED, V147, P505, DOI 10.1001/archinte.147.3.505; SMITH LL, 1994, RADIOLOGY, V191, P143, DOI 10.1148/radiology.191.1.8134561; STEIN PD, 1995, ARCH INTERN MED, V155, P2101, DOI 10.1001/archinte.155.19.2101; STEIN PD, 1992, CIRCULATION, V85, P462, DOI 10.1161/01.CIR.85.2.462; STEIN PD, 1993, CHEST, V103, P1553, DOI 10.1378/chest.103.5.1553; VANBEEK EJR, 1995, CHEST, V108, P170, DOI 10.1378/chest.108.1.170; vanBeek EJR, 1996, EUR RADIOL, V6, P415, DOI 10.1007/BF00182453; VANDERMEER FJM, 1993, ARCH INTERN MED, V153, P1557, DOI 10.1001/archinte.153.13.1557; VREIM CE, 1990, JAMA-J AM MED ASSOC, V263, P2753; WELLS PS, 1995, ANN INTERN MED, V122, P47, DOI 10.7326/0003-4819-122-1-199501010-00008	36	208	213	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1997	126	10					775	+		10.7326/0003-4819-126-10-199705150-00005	http://dx.doi.org/10.7326/0003-4819-126-10-199705150-00005			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WZ823	9148650				2022-12-01	WOS:A1997WZ82300006
J	Tucker, SJ; Gribble, FM; Zhao, C; Trapp, S; Ashcroft, FM				Tucker, SJ; Gribble, FM; Zhao, C; Trapp, S; Ashcroft, FM			Truncation of Kir6.2 produces ATP-sensitive K+ channels in the absence of the sulphonylurea receptor	NATURE			English	Article								ATP-sensitive potassium channels (K-ATP channels) couple cell metabolism to electrical activity and are important in the physiology and pathophysiology of many tissues(1). In pancreatic beta-cells, K-ATP channels Link changes in blood glucose concentration to insulin secretion(2). They are also the target for clinically important drugs such as sulphonylureas, which stimulate secretion, and the K+ channel opener diazoxide, which inhibits insulin release(3,4). Metabolic regulation of K-ATP channels is mediated by changes in intracellular ATP and Mg-ADP levels, which inhibit and activate the channel, respectively(2). The beta-cell K-ATP channel is a complex of two proteins(5,6): an inward-rectifier K+ channel subunit, Kir6.2, and the sulphonylurea receptor, SUR1. We show here that the primary site at which ATP acts to mediate K-ATP channel inhibition is located on Kir6.2, and that SUR1 is required for sensitivity to sulphonylureas and diazoxide and for activation by Mg-ADP.	UNIV OXFORD,PHYSIOL LAB,OXFORD OX1 3PT,ENGLAND	University of Oxford			Tucker, Stephen J./ABE-6741-2020; Trapp, Stefan/D-9240-2011; Tucker, Stephen J./ABE-7468-2020	Tucker, Stephen J./0000-0001-8996-2000; Trapp, Stefan/0000-0003-0665-4948; Tucker, Stephen J./0000-0001-8996-2000; Gribble, Fiona/0000-0002-4232-2898	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Ammala C, 1996, J PHYSIOL-LONDON, V494, P709, DOI 10.1113/jphysiol.1996.sp021526; ANGUILARBRYAN L, 1995, SCIENCE, V268, P423; ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; ASHCROFT FM, 1992, BIOCHIM BIOPHYS ACTA, V175, P45; ASHCROFT SJH, 1990, CELL SIGNAL, V2, P197, DOI 10.1016/0898-6568(90)90048-F; Collins A, 1996, J NEUROSCI, V16, P1; DUNNE MJ, 1993, FRONTIERS INSULIN SE, P153; GRIBBLE EM, 1997, EMBO J, V16, P1145; Gribble FM, 1997, J PHYSIOL-LONDON, V498, P87, DOI 10.1113/jphysiol.1997.sp021843; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cellbio.8.1.67; HILGEMANN DW, 1991, NATURE, V352, P715, DOI 10.1038/352715a0; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; KARSCHIN C, 1996, FEBS LETT, V401, P59; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; McNicholas CM, 1996, AM J PHYSIOL-RENAL, V271, pF275, DOI 10.1152/ajprenal.1996.271.2.F275; Nichols CG, 1996, SCIENCE, V272, P1785, DOI 10.1126/science.272.5269.1785; PROKS P, 1993, PFLUG ARCH EUR J PHY, V424, P63, DOI 10.1007/BF00375103; Sakura H, 1995, FEBS LETT, V377, P338, DOI 10.1016/0014-5793(95)01369-5; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; YAMADA YM, 1997, J PHYSL, V499, P715	22	644	662	0	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 8	1997	387	6629					179	183		10.1038/387179a0	http://dx.doi.org/10.1038/387179a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WX945	9144288				2022-12-01	WOS:A1997WX94500054
J	Clark, S				Clark, S			Dangers of non-sedating antihistamines	LANCET			English	Editorial Material																			0	11	12	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 3	1997	349	9061					1268	1268		10.1016/S0140-6736(05)62504-4	http://dx.doi.org/10.1016/S0140-6736(05)62504-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW899	9142059				2022-12-01	WOS:A1997WW89900006
J	Heinzel, T; Lavinsky, RM; Mullen, TM; Soderstrom, M; Laherty, CD; Torchia, J; Yang, WM; Brard, G; Ngo, SD; Davie, JR; Seto, E; Eisenman, RN; Rose, DW; Glass, CK; Rosenfeld, MG				Heinzel, T; Lavinsky, RM; Mullen, TM; Soderstrom, M; Laherty, CD; Torchia, J; Yang, WM; Brard, G; Ngo, SD; Davie, JR; Seto, E; Eisenman, RN; Rose, DW; Glass, CK; Rosenfeld, MG			A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression	NATURE			English	Article							THYROID-HORMONE RECEPTOR; SACCHAROMYCES-CEREVISIAE; SIN3 GENE; YEAST; ACTIVATION; DOMAIN; MAD; ACETYLATION; HO; DIFFERENTIATION	Transcriptional repression by nuclear receptors has been correlated to binding of the putative co-repressor, N-CoR, A complex has been identified that contains N-CoR, the Mad presumptive co-repressor mSin3, and the histone deacetylase mRPD3, and which is required for both nuclear receptor- and Mad-dependent repression, but not for repression by transcription factors of the ets-domain family, These data predict that the ligand-induced switch of heterodimeric nuclear receptors from repressor to activator functions involves the exchange of complexes containing histone deacetylases with those that have histone acetylase activity.	UNIV CALIF SAN DIEGO,HOWARD HUGHES MED INST,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,GRAD PROGRAM BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,WHITTIER DIABET PROGRAM,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CELLULAR & MOL MED DEPT,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,SCH MED,LA JOLLA,CA 92093; FRED HUTCHINSON CANC RES CTR,DIV BASIC SCI,SEATTLE,WA 98104; UNIV S FLORIDA,DEPT MED MICROBIOL & IMMUNOL,H LEE MOFFIT CANC CTR & RES INST,TAMPA,FL 33612; UNIV MANITOBA,DEPT BIOCHEM & MOL BIOL,WINNIPEG,MB R3E 0W3,CANADA	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Fred Hutchinson Cancer Center; State University System of Florida; University of South Florida; University of Manitoba			Söderström, Mats/C-4005-2009; Glass, Christopher/AAI-3933-2021; Heinzel, Thorsten/B-1013-2015	Söderström, Mats/0000-0003-3927-4394; Glass, Christopher/0000-0003-4344-3592; MULLEN, Tina-Marie/0000-0001-6150-8084; Yang, Wen-Ming/0000-0002-5871-5979; Davie, James/0000-0002-0420-6888				ALMOUZNI G, 1994, DEV BIOL, V165, P654, DOI 10.1006/dbio.1994.1283; Ayer DE, 1996, MOL CELL BIOL, V16, P5772; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; BANIAHMAD A, 1995, MOL CELL BIOL, V15, P76, DOI 10.1128/MCB.15.1.76; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; Gray S, 1996, CURR OPIN CELL BIOL, V8, P358; HannaRose W, 1996, TRENDS GENET, V12, P229, DOI 10.1016/0168-9525(96)10022-6; HENDZEL MJ, 1991, J BIOL CHEM, V266, P21936; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; HURLIN PJ, 1994, COLD SPRING HARB SYM, V59, P109, DOI 10.1101/SQB.1994.059.01.014; JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3; KAMEI Y, 1996, CELL, V85, P1; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; LAHERTY CD, IN PRESS CELL; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; Li W, 1996, BIOCHEM J, V314, P631, DOI 10.1042/bj3140631; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; NASMYTH K, 1987, CELL, V48, P579, DOI 10.1016/0092-8674(87)90236-4; NAWAZ Z, 1994, MOL GEN GENET, V245, P724, DOI 10.1007/BF00297279; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONATE SA, 1995, SCIENCE, V270, P1354; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; Peterson CL, 1996, CURR OPIN GENET DEV, V6, P171, DOI 10.1016/S0959-437X(96)80047-5; ROSE DW, 1992, J CELL BIOL, V119, P1405, DOI 10.1083/jcb.119.6.1405; Roth SY, 1996, CELL, V87, P5, DOI 10.1016/S0092-8674(00)81316-1; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; Seol W, 1996, MOL ENDOCRINOL, V10, P1646, DOI 10.1210/me.10.12.1646; SGOURAS DN, 1995, EMBO J, V14, P4781, DOI 10.1002/j.1460-2075.1995.tb00160.x; STERNBERG PW, 1987, CELL, V48, P567, DOI 10.1016/0092-8674(87)90235-2; Svaren J, 1996, CURR OPIN GENET DEV, V6, P164, DOI 10.1016/S0959-437X(96)80046-3; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; VIDAL M, 1991, MOL CELL BIOL, V11, P6317, DOI 10.1128/MCB.11.12.6317; VIDAL M, 1991, MOL CELL BIOL, V11, P6306, DOI 10.1128/MCB.11.12.6306; WANG HM, 1993, MOL CELL BIOL, V13, P1805, DOI 10.1128/MCB.13.3.1805; WANG HM, 1990, MOL CELL BIOL, V10, P5927, DOI 10.1128/MCB.10.11.5927; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; WONG JM, 1995, GENE DEV, V9, P2696, DOI 10.1101/gad.9.21.2696; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; Zamir I, 1996, MOL CELL BIOL, V16, P5458	51	1069	1117	1	34	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 1	1997	387	6628					43	48		10.1038/387043a0	http://dx.doi.org/10.1038/387043a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WW758	9139820				2022-12-01	WOS:A1997WW75800041
J	Kelsell, DP; Dunlop, J; Stevens, HP; Lench, NJ; Liang, JN; Parry, G; Mueller, RF; Leigh, IM				Kelsell, DP; Dunlop, J; Stevens, HP; Lench, NJ; Liang, JN; Parry, G; Mueller, RF; Leigh, IM			Connexin 26 mutations in hereditary non-syndromic sensorineural deafness	NATURE			English	Article							RECESSIVE DEAFNESS; GENE; EXPRESSION; HOMOLOG	Severe deafness or hearing impairment is the most prevalent inherited sensory disorder, affecting about 1 in 1,000 children(1). Most deafness results from peripheral auditory defects that occur as a consequence of either conductive (outer or middle ear) or sensorineuronal (cochlea) abnormalities. Although a number of mutant genes have been identified that are responsible for syndromic (multiple phenotypic disease) deafness such as Waardenburg syndrome and Usher 1B syndrome(2-4), little is known about the genetic basis of non-syndromic (single phenotypic disease) deafness, Here we study a pedigree containing cases of autosomal dominant deafness and have identified a mutation in the gene encoding the gap-junction protein connexin 26 (Cx26) that segregates with the profound deafness In the family, Cx26 mutations resulting in premature stop codons were also found in three autosomal recessive non-syndromic sensorineuronal deafness pedigrees, genetically linked to chromosome 13q11-12 (DFNB1), where the Cx26 gene is localized. Immunohistochemical staining of human cochlear cells for Cx26 demonstrated high levels of expression. To our knowledge, this is the first nonsyndromic sensorineural autosomal deafness susceptibility gene to be identified, which implicates Cx26 as an important component of the human cochlea.	ST JAMES UNIV HOSP, MOL MED UNIT, LEEDS LS9 7TF, W YORKSHIRE, ENGLAND; UCL, INST LARYNGOL & OTOL, TEMPORAL BONE LAB, LONDON WC1X 8EE, ENGLAND; ST LUKES HOSP, DEPT PAEDIAT, BRADFORD BD5 0NA, W YORKSHIRE, ENGLAND	Saint James's University Hospital; University of Leeds; University of London; University College London	Kelsell, DP (corresponding author), UNIV LONDON QUEEN MARY & WESTFIELD COLL, ST BARTHOLOMEWS & ROYAL LONDON SCH MED & DENT, LONDON E1 2AT, ENGLAND.		Lench, Nicholas/AAB-1791-2021; Kelsell, David P/F-8767-2011	Kelsell, David/0000-0002-9910-7144; Lench, Nicholas/0000-0002-6108-0759	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BERGOFFEN J, 1993, SCIENCE, V262, P2039, DOI 10.1126/science.8266101; BEYER EC, 1993, INT REV CYTOL, V137, P231; BRITZCUNNINGHAM SH, 1995, NEW ENGL J MED, V332, P1323, DOI 10.1056/NEJM199505183322002; Brown KA, 1996, HUM MOL GENET, V5, P169, DOI 10.1093/hmg/5.1.169; CHAIB H, 1994, HUM MOL GENET, V3, P2219, DOI 10.1093/hmg/3.12.2219; Fitzgerald DA, 1996, BRIT J DERMATOL, V134, P939; GOLIGER JA, 1994, DEV DYNAM, V200, P1, DOI 10.1002/aja.1002000102; GUILFORD P, 1994, HUM MOL GENET, V3, P989, DOI 10.1093/hmg/3.6.989; Kibar Z, 1996, HUM MOL GENET, V5, P543, DOI 10.1093/hmg/5.4.543; KIKUCHI T, 1995, ANAT EMBRYOL, V191, P101, DOI 10.1007/BF00186783; Kumar N M, 1992, Semin Cell Biol, V3, P3; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; MARKEY AC, 1992, BRIT J DERMATOL, V126, P154, DOI 10.1111/j.1365-2133.1992.tb07813.x; Mignon C, 1996, CYTOGENET CELL GENET, V72, P185, DOI 10.1159/000134183; MORTON NE, 1991, ANN NY ACAD SCI, V630, P16, DOI 10.1111/j.1749-6632.1991.tb19572.x; Petit C, 1996, NAT GENET, V14, P385, DOI 10.1038/ng1296-385; RISEK B, 1992, DEVELOPMENT, V116, P639; TASSABEHJI M, 1992, NATURE, V355, P635, DOI 10.1038/355635a0; TASSABEHJI M, 1993, NAT GENET, V3, P26, DOI 10.1038/ng0193-26; VERBOV J, 1987, BRIT J DERMATOL, V116, P881, DOI 10.1111/j.1365-2133.1987.tb04914.x; WELL D, 1995, NATURE, V374, P60, DOI 10.1038/374060a0; Yeager M, 1996, CURR OPIN STRUC BIOL, V6, P183, DOI 10.1016/S0959-440X(96)80073-X	22	1117	1214	0	49	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 1	1997	387	6628					80	83		10.1038/387080a0	http://dx.doi.org/10.1038/387080a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WW758	9139825				2022-12-01	WOS:A1997WW75800051
J	Colhoun, H; BenShlomo, Y; Dong, W; Bost, L; Marmot, M				Colhoun, H; BenShlomo, Y; Dong, W; Bost, L; Marmot, M			Ecological analysis of collectivity of alcohol consumption in England: Importance of average drinker	BRITISH MEDICAL JOURNAL			English	Article								Objective: To assess whether the average consumption of alcohol is associated with the prevalence of heavy drinking, problem drinking, and abstention in England. Design: Ecological analysis using data from a cross sectional household based survey of English adults. Subjects: Random sample of 32 333 adults from the English population who participated in the 1993 and 1994 health surveys for England. Main outcome measures: Association, expressed as the correlation coefficient, between the regional mean and median alcohol consumption and the regional prevalence of heavy drinking, problem drinking, and abstention. Results: Mean consumption of alcohol in light to moderate drinkers was strongly positively associated with the prevalence of heavy drinking (r = 0.75 in men and r = 0.62 in women for drinking more than 21 and 14 units per week respectively). A similar association was found between median consumption and prevalence of heavy drinking, Abstention was not significantly associated with mean consumption in drinkers (r = 0.08 for men and r = -0.29 for women). Both the median and mean consumption in drinkers were positively associated with the prevalence of problem drinking as defined by the CAGE questionnaire on alcohol use (r = 0.53 for men and r = 0.42 for women for the association with mean consumption). Conclusion: Factors that increase the average consumption of alcohol in the population may result in an increase in the prevalence of heavy drinking and related problems.	UNIV BRISTOL,DEPT SOCIAL MED,BRISTOL BS8 2PR,AVON,ENGLAND	University of Bristol	Colhoun, H (corresponding author), UNIV LONDON UNIV COLL,DEPT EPIDEMIOL & PUBL HLTH,TORRINGTON PL,LONDON WC1E 6BT,ENGLAND.		Marmot, M G/Y-3920-2019; Ben-Shlomo, Yoav/ABD-2004-2021	Marmot, M G/0000-0002-2431-6419; Ben-Shlomo, Yoav/0000-0001-6648-3007; Colhoun, Helen/0000-0002-8345-3288	Medical Research Council [G8802774] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Bennett N, 1995, HLTH SURVEY ENGLAND; Colhoun H., 1995, HLTH SURVEY ENGLAND; DUFFY JC, 1986, BRIT J ADDICT, V81, P735; Edwards G, 1996, BRIT MED J, V312, P1, DOI 10.1136/bmj.312.7022.1; Edwards G., 1994, ALCOHOL POLICY PUBLI; GODDARD E, 1988, DRINKING ENGLAND WAL; *INT WORK GROUP, 1995, SENS DRINK; Marmot M, 1995, LANCET, V346, P1643, DOI 10.1016/S0140-6736(95)92833-2; MARMOT MG, 1994, BRIT MED J, V303, P565; MAYFIELD D, 1974, AM J PSYCHIAT, V131, P1121; MIDANIK L, 1982, BRIT J ADDICT, V77, P357; Nespor K, 1990, Int J Psychosom, V37, P50; ROSE G, 1990, BRIT MED J, V301, P1031, DOI 10.1136/bmj.301.6759.1031; SKOG OJ, 1985, BRIT J ADDICT, V80, P83; THOMAS M, 1994, GEN HOUSEHOLD SURVEY; WILSON P, 1981, STATISTICIAN, V30, P159, DOI 10.2307/2988046; *WORK GROUP ROYAL, 1995, ALC CARD DIS SENS LI	17	36	37	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 19	1997	314	7088					1164	1168		10.1136/bmj.314.7088.1164	http://dx.doi.org/10.1136/bmj.314.7088.1164			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WV705	9146389	Green Published			2022-12-01	WOS:A1997WV70500023
J	Nightingale, SL				Nightingale, SL			Drug safety information available on the Internet	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	15	15	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 2	1997	278	1					15	15		10.1001/jama.278.1.15	http://dx.doi.org/10.1001/jama.278.1.15			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG387	9207323				2022-12-01	WOS:A1997XG38700010
J	MaierDobersberger, T; Ferenci, P; Polli, C; Balac, P; Dienes, HP; Kaserer, K; Datz, C; Vogel, W; Gangl, A				MaierDobersberger, T; Ferenci, P; Polli, C; Balac, P; Dienes, HP; Kaserer, K; Datz, C; Vogel, W; Gangl, A			Detection of the His1069Gln mutation in Wilson disease by rapid polymerase chain reaction	ANNALS OF INTERNAL MEDICINE			English	Article						hepatolenticular degeneration; polymerase chain reaction; mutation; linkage (genetics); copper	HEPATIC-FAILURE; DIAGNOSIS; GENE	Background: Most known mutations in the gene associated with Wilson disease are rare. Only the His1069Gln mutation is found often in patients of Northern or Eastern European origin. Objective: To examine the frequency of the His1069Gln mutation in Austrian patients with Wilson disease and their families by using a new, rapid polymerase chain reaction (PCR) test. Design: Cross-sectional study. Setting: University medical center. Patients: 83 patients from 72 families and 98 relatives of 11 homozygous index patients. Measurements: Results of a semi-nested PCR-based assay to detect the His1069Gln mutation in Wilson disease, clinical symptoms, and liver histologic findings. Results: 20 patients, including 5 siblings, were homozygous for the His1069Gln mutation. Thirty-three patients, including 4 siblings, were compound heterozygotes. The mutation was not detected in 30 patients, including 2 siblings. Homozygotes were older at onset of symptoms (mean age, 24 +/- 6 years) than compound heterozygotes (17 +/- 6 years [95% CI, 3.3 to 10.7 years]; P = 0.0135) and patients with other mutations (18 +/- 8 years [CI, 1.8 to 10.2 years]; P = 0.117). Homozygotes were more often female (73.3%) than were compound heterozygotes (48% [CI, 0.94% to 2.46%]) and patients with other mutations (50% [CI, 0.91% to 2.37%]) (P = 0.05). Four of 98 asymptomatic relatives of 11 homozygous index patients were also homozygotes. Heterozygosity was confirmed in 46 relatives (19 parents, 11 children, and 16 distant relatives). Conclusion: The His1069Gln mutation was detected in 61% of Austrian patients with Wilson disease. Polymerase chain reaction may be useful for diagnosis and screening of family members of homozygous index patients, even if first-degree relatives are not available for examination.	UNIV VIENNA, DEPT CLIN PATHOL, A-1090 VIENNA, AUSTRIA; UNIV SHEFFIELD, DEPT PAEDIAT, SHEFFIELD S10 2TH, S YORKSHIRE, ENGLAND; UNIV COLOGNE, DEPT PATHOL, D-50931 COLOGNE, GERMANY; LKH SALZBURG, DEPT MED 1, A-5020 SALZBURG, AUSTRIA; UNIV INNSBRUCK, DEPT INTERNAL MED, A-6020 INNSBRUCK, AUSTRIA	University of Vienna; University of Sheffield; University of Cologne; University of Innsbruck	MaierDobersberger, T (corresponding author), UNIV VIENNA, DEPT INTERNAL MED 4, WAEHRINGER GUERTEL 18, A-1090 VIENNA, AUSTRIA.							BERMAN DH, 1991, GASTROENTEROLOGY, V100, P1129, DOI 10.1016/0016-5085(91)90294-U; CZLONKOWSKA A, 1995, Z GASTROENTEROL, V33, P475; DANKS DM, 1990, BRIT MED J, V301, P331, DOI 10.1136/bmj.301.6747.331; FARRER LA, 1991, NEUROLOGY, V41, P992, DOI 10.1212/WNL.41.7.992; FASSMANN H, 1986, MIGRATIONSSTROME INN, P22; FIGUS A, 1995, AM J HUM GENET, V57, P1318; GOODMAN SN, 1994, ANN INTERN MED, V121, P200, DOI 10.7326/0003-4819-121-3-199408010-00008; HOUWEN RHJ, 1995, J MED GENET, V32, P480, DOI 10.1136/jmg.32.6.480; Hubbard R, 1996, NEW ENGL J MED, V334, P1192, DOI 10.1056/NEJM199605023341812; KASAI N, 1992, LAB ANIM SCI, V42, P363; KINGSTON HM, 1986, ANAL CHEM, V58, P2534, DOI 10.1021/ac00125a038; MAIERDOBERSBERGER T, 1995, GASTROENTEROLOGY, V109, P2015, DOI 10.1016/0016-5085(95)90771-8; MCCULLOUGH AJ, 1983, GASTROENTEROLOGY, V84, P161; PETRUKHIN K, 1993, NAT GENET, V5, P338, DOI 10.1038/ng1293-338; PROPST A, 1995, GASTROENTEROLOGY, V108, P885, DOI 10.1016/0016-5085(95)90465-4; ROSS ME, 1985, ANN NEUROL, V17, P411, DOI 10.1002/ana.410170421; Scheinberg IH, 1984, MAJOR PROBLEMS INTER, VXXIII; SCHEUER PJ, 1991, J HEPATOL, V13, P372, DOI 10.1016/0168-8278(91)90084-O; SCHILSKY ML, 1994, HEPATOLOGY, V19, P583, DOI 10.1002/hep.1840190307; STERNLIEB I, 1990, HEPATOLOGY, V12, P1234, DOI 10.1002/hep.1840120526; STRICKLAND GT, 1972, CLIN SCI, V43, P617, DOI 10.1042/cs0430617; THOMAS GR, 1995, NAT GENET, V9, P210, DOI 10.1038/ng0295-210; THOMAS GR, 1995, AM J HUM GENET, V56, P1315; 1995, Z GASTROENTEROL, V33, P472	24	87	94	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1997	127	1					21	+		10.7326/0003-4819-127-1-199707010-00004	http://dx.doi.org/10.7326/0003-4819-127-1-199707010-00004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG914	9214248				2022-12-01	WOS:A1997XG91400003
J	Sikorski, R; Peters, R				Sikorski, R; Peters, R			Xenotransplanters turn xenovirologists	SCIENCE			English	Article																		BENEVISTE RE, 1974, NATURE, V248, P17; COFFIN JM, 1985, RNA TUMOR VIRUSES; MCALLISTER RM, 1972, NATURE-NEW BIOL, V235, P3, DOI 10.1038/newbio235003a0; Patience C, 1997, NAT MED, V3, P282, DOI 10.1038/nm0397-282	4	4	6	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 20	1997	276	5320					1893	1893						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XF103	9206845				2022-12-01	WOS:A1997XF10300059
J	Dover, JS; Arndt, KA				Dover, JS; Arndt, KA			Dermatology	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DOUBLE-BLIND; TERBINAFINE; ONYCHOMYCOSIS; TOENAIL		HARVARD UNIV,SCH MED,BOSTON,MA 02138	Harvard University; Harvard Medical School	Dover, JS (corresponding author), BETH ISRAEL DEACONESS MED CTR,BOSTON,MA 02138, USA.							Beutner KR, 1995, ANTIVIR RES, V28, P281, DOI 10.1016/0166-3542(95)00066-6; BRAUTIGAM M, 1995, BRIT MED J, V311, P919, DOI 10.1136/bmj.311.7010.919; DeDoncker P, 1996, ARCH DERMATOL, V132, P34, DOI 10.1001/archderm.132.1.34; Einarson TR, 1996, PHARMACOECONOMICS, V9, P307, DOI 10.2165/00019053-199609040-00004; ELEWSKI BE, IN PRESS ARCH DERMAT; GUPTA AK, 1994, J AM ACAD DERMATOL, V30, P667; Kost RG, 1996, NEW ENGL J MED, V335, P32, DOI 10.1056/NEJM199607043350107; KUOKKANEN K, 1992, J DERMATOL TREAT, V3, P115; SACHS SL, 1996, JAMA-J AM MED ASSOC, V276, P44; SHEAR NH, 1995, ARCH DERMATOL, V131, P937, DOI 10.1001/archderm.131.8.937; THAKRAY AM, 1996, J INFECT DIS, V173, P291; Tosti A, 1996, J AM ACAD DERMATOL, V34, P595, DOI 10.1016/S0190-9622(96)80057-0; TYRING S, 1995, ANN INTERN MED, V123, P89, DOI 10.7326/0003-4819-123-2-199507150-00002; WATSON A, 1995, J AM ACAD DERMATOL, V33, P775, DOI 10.1016/0190-9622(95)91815-9; WELSBY PD, 1994, J INFECTION, V28, P121, DOI 10.1016/S0163-4453(94)95520-4; Whitley RJ, 1996, ANN INTERN MED, V125, P376, DOI 10.7326/0003-4819-125-5-199609010-00004; 1994, MED LETT DRUGS THER, V36, P97	17	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	1997	277	23					1848	1850						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD544	9185795				2022-12-01	WOS:A1997XD54400014
J	Peterson, WL; Lee, WM				Peterson, WL; Lee, WM			Gastroenterology and hepatology	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEPATITIS; VIRUS				Peterson, WL (corresponding author), UNIV TEXAS,SW MED SCH,DALLAS,TX 75230, USA.							Alter HJ, 1996, NEW ENGL J MED, V334, P1536, DOI 10.1056/NEJM199606063342310; Atherton JC, 1997, GASTROENTEROLOGY, V112, P92, DOI 10.1016/S0016-5085(97)70223-3; BUKH J, 1995, SEMIN LIVER DIS, V15, P41, DOI 10.1055/s-2007-1007262; DIENSTAG JL, 1995, NEW ENGL J MED, V333, P1657, DOI 10.1056/NEJM199512213332501; Enomoto N, 1996, NEW ENGL J MED, V334, P77, DOI 10.1056/NEJM199601113340203; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; Hopkins RJ, 1996, GASTROENTEROLOGY, V110, P1244, DOI 10.1053/gast.1996.v110.pm8613015; Kadakia SC, 1996, GASTROINTEST ENDOSC, V44, P112, DOI 10.1016/S0016-5107(96)70126-8; Kronborg O, 1996, LANCET, V348, P1467, DOI 10.1016/S0140-6736(96)03430-7; Kuipers EJ, 1996, NEW ENGL J MED, V334, P1018, DOI 10.1056/NEJM199604183341603; Lind T, 1996, Helicobacter, V1, P138, DOI 10.1111/j.1523-5378.1996.tb00027.x; Linnen J, 1996, SCIENCE, V271, P505, DOI 10.1126/science.271.5248.505; Parsonnet J, 1996, LANCET, V348, P150, DOI 10.1016/S0140-6736(96)01501-2; Poynard T, 1996, HEPATOLOGY, V24, P778; SIMONS JN, 1995, NAT MED, V1, P564, DOI 10.1038/nm0695-564; US Preventive Services Task Force United States. Office of Disease Prevention Health Promotion, 1996, GUID CLIN PREV SERV, P89; Winawer SJ, 1997, GASTROENTEROLOGY, V112, P594, DOI 10.1053/gast.1997.v112.agast970594	17	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	1997	277	23					1858	1860						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD544	9185801				2022-12-01	WOS:A1997XD54400020
J	Posas, F; Saito, H				Posas, F; Saito, H			Osmotic activation of the HOG MAPK pathway via Ste11p MAPKKK: Scaffold role of Pbs2p MAPKK	SCIENCE			English	Article							PHEROMONE RESPONSE PATHWAY; SACCHAROMYCES-CEREVISIAE; KINASE CASCADE; SIGNAL TRANSDUCTION; PROTEIN-KINASES; YEAST; STE5; PHOSPHORYLATION; COMPONENTS; MITOGEN	Exposure of the yeast Saccharomyces cerevisiae to high extracellular osmolarity induces the Sln1p-Ypd1p-Ssk1p two-component osmosensor to activate a mitogen-activated protein (MAP) kinase cascade composed of the Ssk2p and Ssk22p MAP kinase kinase kinases (MAPKKKs), the Pbs2p MAPKK, and the Hog1p MAPK. A second osmosensor, Sho1p, also activated Pbs2p and Hog1p, but did so through the Ste11p MAPKKK. Although Ste11p also participates in the mating pheromone-responsive MAPK cascade, there was no detectable cross talk between these two pathways. The MAPKK Pbs2p bound to the Sho1p osmosensor, the MAPKKK Ste11p, and the MAPK Hog1p. Thus, Pbs2p may serve as a scaffold protein.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV TUMOR IMMUNOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOL PHARMACOL, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School			Saito, Haruo/AAF-6113-2019; Posas, Francesc/K-1364-2013	Saito, Haruo/0000-0001-7891-1689; Posas, Francesc/0000-0002-4164-7076	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050909] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM50909, GM53415] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTYN J, 1994, MOL CELL BIOL, V14, P4135, DOI 10.1128/MCB.14.6.4135; BOGUSLAWSKI G, 1987, P NATL ACAD SCI USA, V84, P5848, DOI 10.1073/pnas.84.16.5848; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; CAIRNS BR, 1992, GENE DEV, V6, P1305, DOI 10.1101/gad.6.7.1305; CHOI KY, 1994, CELL, V78, P499; CIEJEK E, 1979, CELL, V18, P623, DOI 10.1016/0092-8674(79)90117-X; GARTNER A, 1992, GENE DEV, V6, P1280, DOI 10.1101/gad.6.7.1280; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; KRANZ JE, 1994, GENE DEV, V8, P313, DOI 10.1101/gad.8.3.313; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MAEDA T, 1995, SCIENCE, V269, P554, DOI 10.1126/science.7624781; MANIVASAKAM P, 1995, NUCLEIC ACIDS RES, V23, P2799, DOI 10.1093/nar/23.14.2799; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; MCCAFFREY G, 1987, MOL CELL BIOL, V7, P2680, DOI 10.1128/MCB.7.8.2680; NEIMAN AM, 1994, P NATL ACAD SCI USA, V91, P3398, DOI 10.1073/pnas.91.8.3398; OTA IM, 1993, SCIENCE, V262, P566, DOI 10.1126/science.8211183; Posas F, 1996, CELL, V86, P865, DOI 10.1016/S0092-8674(00)80162-2; POSAS F, UNPUB; PRINTEN JA, 1994, GENETICS, V138, P609; RHODES N, 1990, GENE DEV, V4, P1862, DOI 10.1101/gad.4.11.1862; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPRAGUE GF, 1991, METHOD ENZYMOL, V194, P77; STEVENSON BJ, 1992, GENE DEV, V6, P1293, DOI 10.1101/gad.6.7.1293; WARNER JR, 1991, METHOD ENZYMOL, V194, P423; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; WHITEWAY MS, 1995, SCIENCE, V269, P1572, DOI 10.1126/science.7667635; YOCUM RR, 1984, MOL CELL BIOL, V4, P1985, DOI 10.1128/MCB.4.10.1985	27	451	467	1	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 13	1997	276	5319					1702	1705		10.1126/science.276.5319.1702	http://dx.doi.org/10.1126/science.276.5319.1702			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XD947	9180081				2022-12-01	WOS:A1997XD94700044
J	Maldonado, PE; Godecke, I; Gray, CM; Bonhoeffer, T				Maldonado, PE; Godecke, I; Gray, CM; Bonhoeffer, T			Orientation selectivity in pinwheel centers in cat striate cortex	SCIENCE			English	Article							VISUAL-CORTEX; ORGANIZATION; DOMAINS	In primary visual cortex of higher mammals neurons are grouped according to their orientation preference, forming ''pinwheels'' around ''orientation centers.'' Although the general structure of orientation maps is largely resolved, the microscopic arrangement of neuronal response properties in the orientation centers has remained elusive. The tetrode technique, enabling multiple single-unit recordings, in combination with intrinsic signal imaging was used to reveal the fine-grain structure of orientation maps in these locations. The results show that orientation centers represent locations where orientation columns converge containing normal, sharply tuned neurons of different orientation preference lying in close proximity.	UNIV CALIF DAVIS,SECT NEUROBIOL PHYSIOL & BEHAV,DAVIS,CA 95616; MAX PLANCK INST PSYCHIAT,D-82152 MUNICH,GERMANY	University of California System; University of California Davis; Max Planck Society	Maldonado, PE (corresponding author), UNIV CALIF DAVIS,CTR NEUROSCI,DAVIS,CA 95616, USA.		Maldonado, Pedro/AAH-7670-2019; Bonhoeffer, Tobias/B-9481-2009	Bonhoeffer, Tobias/0000-0001-7897-6634; Maldonado, Pedro/0000-0001-9895-7684				BATSCHELET E, 1991, CIRCULAR STATISTICS; BLASDEL GG, 1986, NATURE, V321, P579, DOI 10.1038/321579a0; BONHOEFFER T, 1993, J NEUROSCI, V13, P4157; BONHOEFFER T, 1991, NATURE, V353, P429, DOI 10.1038/353429a0; Bonhoeffer Tobias, 1996, P55; BRITTEN KH, 1992, J NEUROSCI, V12, P4745; CHAPMAN B, 1991, J NEUROSCI, V11, P1347; Ferster D, 1996, NATURE, V380, P249, DOI 10.1038/380249a0; GILBERT CD, 1989, J NEUROSCI, V9, P2432; Gray CM, 1995, J NEUROSCI METH, V63, P43, DOI 10.1016/0165-0270(95)00085-2; GRINVALD A, 1986, NATURE, V324, P361, DOI 10.1038/324361a0; HENRY GH, 1974, J NEUROPHYSIOL, V37, P1394, DOI 10.1152/jn.1974.37.6.1394; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; HUBEL DH, 1963, J PHYSIOL-LONDON, V165, P559, DOI 10.1113/jphysiol.1963.sp007079; LEE BB, 1977, EXP BRAIN RES, V27, P301; Maldonado PE, 1996, VISUAL NEUROSCI, V13, P509, DOI 10.1017/S095252380000818X; MALONEK D, 1990, SOC NEUR ABSTR, V130, P4; REID RC, 1995, NATURE, V378, P381; Swindale NV, 1996, NETWORK-COMP NEURAL, V7, P161, DOI 10.1088/0954-898X/7/2/002; TSO DY, 1990, SCIENCE, V249, P417, DOI 10.1126/science.2165630; WILSON MA, 1993, SCIENCE, V261, P1055, DOI 10.1126/science.8351520	21	164	167	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 6	1997	276	5318					1551	1555		10.1126/science.276.5318.1551	http://dx.doi.org/10.1126/science.276.5318.1551			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XC701	9171056				2022-12-01	WOS:A1997XC70100039
J	Yokomizo, T; Izumi, T; Chang, K; Takuwa, Y; Shimizu, T				Yokomizo, T; Izumi, T; Chang, K; Takuwa, Y; Shimizu, T			A G-protein-coupled receptor for leukotriene B-4 that mediates chemotaxis	NATURE			English	Article							HUMAN NEUTROPHILS; CLONING; BINDING; ANALOGS; CELLS; ACID	Leukotriene B-4 (LTB4)(1) is a potent chemoattractant that is primarily involved in inflammation, immune responses and host defence against infection(2). LTB4 activates inflammatory cells by binding to its cell-surface receptor (BLTR)(3). LTB4 can also bind and activate the intranuclear transcription factor PPAR alpha, resulting in the activation of genes that terminate inflammatory processess(4). Here we report the cloning of the complementary DNA encoding a cell-surface LTB4 receptor that is highly expressed in human leukocytes. Using a subtraction strategy, we isolated two cDNA clones (HL-1 and HL-5) from retinoic acid-differentiated HL-60 cells. These two clones contain identical open reading frames encoding a protein of 352 amino acids and predicted to contain seven membrane-spanning domains, but different 5'-untranslated regions. Membrane fractions of Cos-7 cells transfected with an expression construct containing the open reading frame of HL-5 showed specific LTB4 binding, with a K-d (0.154 nM) comparable to that observed in retinoic acid-differentiated HL-60 cells. In CHO cells stably expressing this receptor, LTB4 induced increases in intracellular calcium, D-myo-inositol-1,4,5-triphosphate (InsP(3)) accumulation, and inhibition of adenlyl cyclase. Furthermore, CHO cells expressing exogenous BLTR showed marked chemotactic responses towards low concentrations of LTB4 in a pertussis-toxin-sensitive manner. Our findings, together with previous reports(4,5), show that LTB4 is a unique lipid mediator that interacts with both cell-surface and nuclear receptors.	UNIV TOKYO,FAC MED,DEPT BIOCHEM & MOL BIOL,TOKYO 113,JAPAN; UNIV TOKYO,FAC MED,DEPT CARDIOVASC BIOL,TOKYO 113,JAPAN	University of Tokyo; University of Tokyo			Yokomizo, Takehiko/P-5673-2016	Yokomizo, Takehiko/0000-0002-5219-1553				Akbar GKM, 1996, J BIOL CHEM, V271, P18363, DOI 10.1074/jbc.271.31.18363; ALEXANDER SPH, 1997, TRENDS PHARM SCI S, P50; BOMALASKI JS, 1987, PROSTAGLANDINS, V33, P855, DOI 10.1016/0090-6980(87)90114-6; CHANG KG, 1995, J BIOL CHEM, V270, P26152, DOI 10.1074/jbc.270.44.26152; CHEN XS, 1994, NATURE, V372, P179, DOI 10.1038/372179a0; DEGIULIO R, 1993, ANN NY ACAD SCI, V685, P614, DOI 10.1111/j.1749-6632.1993.tb35925.x; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; ERBECK K, 1993, J IMMUNOL, V150, P1913; FIORE S, 1993, BLOOD, V81, P3395; FIORE S, 1994, J EXP MED, V180, P253, DOI 10.1084/jem.180.1.253; FIORE S, 1992, J BIOL CHEM, V267, P16168; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; Gladue RP, 1996, J EXP MED, V183, P1893, DOI 10.1084/jem.183.4.1893; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; Ishii I, 1997, J BIOL CHEM, V272, P7846, DOI 10.1074/jbc.272.12.7846; KINKER JE, 1996, GEN PHARMACOL, V27, P33; KISHIKAWA K, 1992, PROSTAGLANDINS, V44, P261, DOI 10.1016/0090-6980(92)90002-B; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; NG CF, 1991, J IMMUNOL, V147, P3096; Owman C, 1996, GENOMICS, V37, P187, DOI 10.1006/geno.1996.0541; PALMBLAD J, 1994, J IMMUNOL, V152, P262; POWELL WS, 1993, J BIOL CHEM, V268, P9280; Powell WS, 1996, J IMMUNOL, V156, P336; Raport CJ, 1996, J LEUKOCYTE BIOL, V59, P18, DOI 10.1002/jlb.59.1.18; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; TAYLOR BM, 1991, PROSTAG OTH LIPID M, V42, P211, DOI 10.1016/0090-6980(91)90111-R; YASUDA K, 1992, J BIOL CHEM, V267, P20422; YENUSH L, 1994, J BIOL CHEM, V269, P100; Yokomizo T, 1996, J BIOL CHEM, V271, P2844, DOI 10.1074/jbc.271.5.2844	30	807	855	1	26	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 5	1997	387	6633					620	624		10.1038/42506	http://dx.doi.org/10.1038/42506			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XC522	9177352				2022-12-01	WOS:A1997XC52200060
J	Ganot, P; Bortolin, ML; Kiss, T				Ganot, P; Bortolin, ML; Kiss, T			Site-specific pseudouridine formation in preribosomal RNA is guided by small nucleolar RNAs	CELL			English	Article							18S RIBOSOMAL-RNA; SMALL NUCLEAR-RNA; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; PEPTIDYLTRANSFERASE CENTER; YEAST; U3; NUCLEOTIDE; RESIDUES; SNR30	During the nucleolar maturation of eukaryotic ribosomal RNAs, many selected uridines are converted into pseudouridine by a thus far undefined mechanism. The nucleolus contains a large number of small RNAs (snoRNAs) that share two conserved sequence elements, box H and ACA. In this study, we demonstrate that site-specific pseudouridylation of rRNAs relies on short ribosomal signal sequences that are complementary to sequences in box H/ACA snoRNAs. Genetic depletion and reconstitution studies on yeast snR5 and snR36 snoRNAs demonstrate that box H/ACA snoRNAs function as guide RNAs in rRNA pseudouridylation. These results define a novel function for snoRNAs and further reinforce the idea that base pairing is the most common way to obtain specific substrate-''enzyme'' interactions during rRNA maturation.	UNIV TOULOUSE 3, MOL BIOL LAB, CNRS, F-31062 TOULOUSE, FRANCE	Centre National de la Recherche Scientifique (CNRS); Universite de Toulouse; Universite Toulouse III - Paul Sabatier				Bortolin-Cavaille, Marie-Line/0000-0002-6336-4034; Kiss, Tamas/0000-0003-0293-3093				BAKIN A, 1995, NUCLEIC ACIDS RES, V23, P3290, DOI 10.1093/nar/23.16.3290; BAKIN A, 1994, BIOCHEMISTRY-US, V33, P13475, DOI 10.1021/bi00249a036; BAKIN A, 1993, BIOCHEMISTRY-US, V32, P9754, DOI 10.1021/bi00088a030; Balakin AG, 1996, CELL, V86, P823, DOI 10.1016/S0092-8674(00)80156-7; BALAKIN AG, 1993, NUCLEIC ACIDS RES, V21, P5391, DOI 10.1093/nar/21.23.5391; BALLY M, 1988, NUCLEIC ACIDS RES, V16, P5291, DOI 10.1093/nar/16.12.5291; BELTRAME M, 1995, EMBO J, V14, P4350, DOI 10.1002/j.1460-2075.1995.tb00109.x; BONNEAUD N, 1991, YEAST, V7, P609, DOI 10.1002/yea.320070609; Cavaille J, 1996, NATURE, V383, P732, DOI 10.1038/383732a0; DANDEKAR T, 1993, NUCLEIC ACIDS RES, V21, P5386, DOI 10.1093/nar/21.23.5386; EICHLER DC, 1995, PROG NUCL ACID RES M, V49, P179; ENGBERG J, 1990, NUCLEIC ACIDS RES, V18, P6915, DOI 10.1093/nar/18.23.6915; Ganot P, 1997, GENE DEV, V11, P941, DOI 10.1101/gad.11.7.941; GIRARD JP, 1992, EMBO J, V11, P673, DOI 10.1002/j.1460-2075.1992.tb05099.x; Goldwasser E, 1966, Prog Nucleic Acid Res Mol Biol, V5, P399, DOI 10.1016/S0079-6603(08)60241-X; GOODALL GJ, 1990, METHOD ENZYMOL, V181, P148; HADJIOLOV AA, 1985, CELL BIOL MONOGRAPHS; HADJIOLOVA KV, 1994, MOL CELL BIOL, V14, P4044, DOI 10.1128/MCB.14.6.4044; HUGHES JMX, 1991, EMBO J, V10, P4231, DOI 10.1002/j.1460-2075.1991.tb05001.x; KASS S, 1990, CELL, V60, P897, DOI 10.1016/0092-8674(90)90338-F; Kiss T, 1996, MOL CELL BIOL, V16, P1391; KISS T, 1993, EMBO J, V12, P2913, DOI 10.1002/j.1460-2075.1993.tb05953.x; KissLaszlo Z, 1996, CELL, V85, P1077, DOI 10.1016/S0092-8674(00)81308-2; Koonin EV, 1996, NUCLEIC ACIDS RES, V24, P2411, DOI 10.1093/nar/24.12.2411; LANE BG, 1995, BIOCHIMIE, V77, P7, DOI 10.1016/0300-9084(96)88098-9; LI HV, 1990, MOL CELL BIOL, V10, P1145, DOI 10.1128/MCB.10.3.1145; LIANG WQ, 1995, GENE DEV, V9, P2433, DOI 10.1101/gad.9.19.2433; LUBBEN B, 1995, J BIOL CHEM, V270, P11549, DOI 10.1074/jbc.270.19.11549; Maden B E, 1990, Prog Nucleic Acid Res Mol Biol, V39, P241, DOI 10.1016/S0079-6603(08)60629-7; MADEN BEH, 1975, FEBS LETT, V59, P60, DOI 10.1016/0014-5793(75)80341-3; MAXWELL ES, 1995, ANNU REV BIOCHEM, V64, P897, DOI 10.1146/annurev.bi.64.070195.004341; MORRISSEY JP, 1993, MOL CELL BIOL, V13, P2469, DOI 10.1128/MCB.13.4.2469; Nicoloso M, 1996, J MOL BIOL, V260, P178, DOI 10.1006/jmbi.1996.0391; NIELSEN H, 1992, FEBS LETT, V307, P337, DOI 10.1016/0014-5793(92)80708-O; Ofengand J, 1997, J MOL BIOL, V266, P246, DOI 10.1006/jmbi.1996.0737; Ofengand J, 1995, BIOCHEM CELL BIOL, V73, P915, DOI 10.1139/o95-099; PARKER R, 1988, MOL CELL BIOL, V8, P3150, DOI 10.1128/MCB.8.8.3150; PECULIS BA, 1993, CELL, V73, P1233, DOI 10.1016/0092-8674(93)90651-6; RIMOLDI OJ, 1993, MOL CELL BIOL, V13, P4382, DOI 10.1128/MCB.13.7.4382; RUFF EA, 1993, P NATL ACAD SCI USA, V90, P635, DOI 10.1073/pnas.90.2.635; SAMARSKY DA, 1995, NUCLEIC ACIDS RES, V23, P2548, DOI 10.1093/nar/23.13.2548; Sambrook J., 1989, MOL CLONING LAB MANU, V3; SAPONARA AG, 1974, BIOCHIM BIOPHYS ACTA, V349, P61, DOI 10.1016/0005-2787(74)90009-4; SAVINO R, 1990, EMBO J, V9, P2299, DOI 10.1002/j.1460-2075.1990.tb07401.x; SELDEN RF, 1992, CURRENT PROTOCOLS MO; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIRUMCONNOLLY K, 1993, SCIENCE, V262, P1886, DOI 10.1126/science.8266080; SOLLNERWEBB B, 1996, RIBOSOMAL RNA STRUCT, P469; THOMPSON JR, 1988, NUCLEIC ACIDS RES, V16, P5587, DOI 10.1093/nar/16.12.5587; TOLLERVEY D, 1983, CELL, V35, P753, DOI 10.1016/0092-8674(83)90108-3; TOLLERVEY D, 1985, EMBO J, V4, P3873, DOI 10.1002/j.1460-2075.1985.tb04160.x; TOLLERVEY D, 1987, EMBO J, V6, P469, DOI 10.1002/j.1460-2075.1987.tb04777.x; TOLLERVEY D, 1987, EMBO J, V6, P4169, DOI 10.1002/j.1460-2075.1987.tb02763.x; TOLLERVEY D, 1997, IN PRESS CURR OPIN C, V9; TYC K, 1989, EMBO J, V8, P3113, DOI 10.1002/j.1460-2075.1989.tb08463.x; TYCOWSKI KT, 1994, SCIENCE, V266, P1558, DOI 10.1126/science.7985025; Tycowski KT, 1996, P NATL ACAD SCI USA, V93, P14480, DOI 10.1073/pnas.93.25.14480; Tycowski KT, 1996, NATURE, V379, P464, DOI 10.1038/379464a0; TYCOWSKI KT, 1993, GENE DEV, V6, P1120; Venema J, 1995, YEAST, V11, P1629, DOI 10.1002/yea.320111607; WRZESINSKI J, 1995, BIOCHEMISTRY-US, V34, P8904, DOI 10.1021/bi00027a043; WRZESINSKI J, 1995, RNA, V1, P437	62	480	512	2	15	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 30	1997	89	5					799	809		10.1016/S0092-8674(00)80263-9	http://dx.doi.org/10.1016/S0092-8674(00)80263-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XB925	9182768	Bronze			2022-12-01	WOS:A1997XB92500017
J	Churcher, C; Bowman, S; Badcock, K; Bankler, A; Brown, D; Chillingworth, T; Connor, R; Devlin, K; Gentles, S; Hamlin, N; Harris, D; Horsnell, T; Hunt, S; Jagels, K; Jones, M; Lye, G; Moule, S; Odell, C; Pearson, D; Rajandream, M; Rice, P; Rowley, N; Skelton, J; Smith, V; Walsh, S; Whitehead, S; Barrell, B				Churcher, C; Bowman, S; Badcock, K; Bankler, A; Brown, D; Chillingworth, T; Connor, R; Devlin, K; Gentles, S; Hamlin, N; Harris, D; Horsnell, T; Hunt, S; Jagels, K; Jones, M; Lye, G; Moule, S; Odell, C; Pearson, D; Rajandream, M; Rice, P; Rowley, N; Skelton, J; Smith, V; Walsh, S; Whitehead, S; Barrell, B			The nucleotide sequence of Saccharomyces cerevisiae chromosome IX	NATURE			English	Article							DNA-SEQUENCE; PROJECTS; STADEN; GENES	Large-scale systematic sequencing has generally depended on the availability of an ordered library of large-insert bacterial or viral genomic clones for the organism under study. The generation of these large insert libraries, and the location of each clone on a genome map, is a laborious and time-consuming process. In an effort to overcome these problems, several groups have successfully demonstrated the viability of the whole-genome random 'shotgun' method in large-scale sequencing of both viruses and prokaryotes(1-5). Here we report the sequence of Saccharomyces cerevisiae chromosome IX, determined in part by a whole-chromosome 'shotgun', and describe the particular difficulties encountered in the random 'shotgun' sequencing of an entire eukaryotic chromosome. Analysis of this sequence shows that chromosome IX contains 221 open reading frames (ORFs), of which approximately 30% have been sequenced previously. This chromosome shows features typical of a small Saccharomyces cerevisiae chromosome.	SANGER CTR,CAMBRIDGE CB10 1SA,ENGLAND; MRC,MOL BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND	Wellcome Trust Sanger Institute; MRC Laboratory Molecular Biology				Hunt, Sarah/0000-0002-8350-1235	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BUSSEY H, 1995, P NATL ACAD SCI USA, V92, P3809, DOI 10.1073/pnas.92.9.3809; COOPER TG, 1979, GENETICS, V92, P383; CRAXTON M, 1991, Methods (Orlando), V3, P20, DOI 10.1016/S1046-2023(05)80159-8; Davison A J, 1991, DNA Seq, V1, P389, DOI 10.3109/10425179109020794; DEAR S, 1991, NUCLEIC ACIDS RES, V19, P3907, DOI 10.1093/nar/19.14.3907; FITZGERALDHAYES M, 1987, YEAST, V3, P187, DOI 10.1002/yea.320030306; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; HALLORAN N, 1992, METHOD MOL BIOL, V10, P297; Hawkins T., 1992, DNA Sequence, V3, P65, DOI 10.3109/10425179209033998; LOUIS EJ, 1995, BIOCHEMICA, V3, P25; MURAKAMI Y, 1995, NAT GENET, V10, P261, DOI 10.1038/ng0795-261; OLIVER SG, 1992, NATURE, V357, P38, DOI 10.1038/357038a0; Rawlinson WD, 1996, J VIROL, V70, P8833, DOI 10.1128/JVI.70.12.8833-8849.1996; RILES L, 1993, GENETICS, V134, P81; SCHWARTZ DC, 1984, CELL, V37, P67, DOI 10.1016/0092-8674(84)90301-5; SEUFERT W, 1990, NUCLEIC ACIDS RES, V18, P3653, DOI 10.1093/nar/18.12.3653; SHARP PM, 1993, NUCLEIC ACIDS RES, V21, P179, DOI 10.1093/nar/21.2.179; SMITH V, 1993, METHOD ENZYMOL, V218, P173; Staden R, 1994, Methods Mol Biol, V25, P27; Staden R, 1994, Methods Mol Biol, V25, P37; TELFORD EAR, 1992, VIROLOGY, V189, P304, DOI 10.1016/0042-6822(92)90706-U; Termier M, 1996, YEAST, V12, P369, DOI 10.1002/(SICI)1097-0061(19960330)12:4<369::AID-YEA922>3.0.CO;2-#; TUROSCY V, 1984, GENETICS, V108, P827; VAUDIN M, 1995, NUCLEIC ACIDS RES, V23, P670, DOI 10.1093/nar/23.4.670	25	30	284	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 29	1997	387	6632		S			84	87		10.1038/387s084	http://dx.doi.org/10.1038/387s084			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XB546	9169870				2022-12-01	WOS:A1997XB54600010
J	Shafman, T; Khanna, KK; Kedar, P; Spring, K; Kozlov, S; Yen, T; Hobson, K; Gatei, M; Zhang, N; Watters, D; Egerton, M; Shiloh, Y; Kharbanda, S; Kufe, D; Lavin, MF				Shafman, T; Khanna, KK; Kedar, P; Spring, K; Kozlov, S; Yen, T; Hobson, K; Gatei, M; Zhang, N; Watters, D; Egerton, M; Shiloh, Y; Kharbanda, S; Kufe, D; Lavin, MF			Interaction between ATM protein and c-Abl in response to DNA damage	NATURE			English	Article							ATAXIA-TELANGIECTASIA CELLS; IONIZING-RADIATION; TYROSINE KINASE; RADIOSENSITIVITY; INDUCTION; GENE; P53	The gene mutated in the autosomal recessive disorder ataxia telangiectasia (AT), designated ATM (for 'AT mutated'), is a member of a family of phosphatidylinositol-3-kinase-like enzymes that are involved in cell-cycle control, meiotic recombination, telomere length monitoring and DNA-damage response(1-4). Previous results have demonstrated that AT cells are hypersensitive to ionizing radiation(5-7) and are defective at the G1/S checkpoint after radiation damage(8-10). Because cells lacking the protein tyrosine kinase c-Abl are also defective in radiation-induced G1 arrest(11), we investigated the possibility that ATM might interact with c-Abl in response to radiation damage. Here we show that ATM binds c-Abl constitutively in control cells but not in AT cells. Our results demonstrate that the SH3 domain of c-Abl interacts with a DPAPNPPHFP motif (residues 1,373-1,382) of ATM. The results also reveal that radiation-induction of c-Abl tyrosine kinase activity is diminished in AT cells. These findings indicate that ATM is involved in the activation of c-Abl by DNA damage and this interaction may in part mediate radiation-induced G1 arrest.	QUEENSLAND INST MED RES,BRISBANE,QLD 4029,AUSTRALIA; UNIV QUEENSLAND,ROYAL BRISBANE HOSP,DEPT SURG,BRISBANE,QLD 4029,AUSTRALIA; DANA FARBER CANC INST,JOINT CTR RADIAT THERAPY,BOSTON,MA 02115; DANA FARBER CANC INST,DIV CANC PHARMACOL,BOSTON,MA 02115; FOX CHASE CANC CTR,PHILADELPHIA,PA 19111; TEL AVIV UNIV,SACKLER SCH MED,DEPT HUMAN GENET,IL-69978 RAMAT AVIV,ISRAEL	QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; University of Queensland; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Fox Chase Cancer Center; Tel Aviv University; Sackler Faculty of Medicine			Hobson, Keith/Q-9306-2019; Watters, Dianne J/E-6007-2010; Kozlov, Sergei/M-2067-2014; Khanna, Kum Kum/I-1747-2013; Lavin, Martin F/F-5961-2014; Kozlov, Sergei/T-9779-2019	Watters, Dianne J/0000-0002-2555-5825; Kozlov, Sergei/0000-0001-6183-7339; Lavin, Martin F/0000-0002-5940-4769; Yen, Tim/0000-0003-2159-0997; Spring, Kevin/0000-0003-0601-924X; Khanna, Kum Kum/0000-0001-8650-5381				BEAMISH H, 1994, INT J RADIAT BIOL, V65, P175, DOI 10.1080/09553009414550211; CHEN PC, 1975, NATURE, V258, P427; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Gilad S, 1996, HUM MOL GENET, V5, P2033, DOI 10.1093/hmg/5.12.2033; HOULDSWORTH J, 1980, NUCLEIC ACIDS RES, V8, P3709, DOI 10.1093/nar/8.16.3709; JACKSON SP, 1995, CURR BIOL, V5, P1210, DOI 10.1016/S0960-9822(95)00238-7; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KHANNA KK, 1995, ONCOGENE, V11, P609; KHANNA KK, 1993, ONCOGENE, V8, P3307; Kharbanda S, 1996, P NATL ACAD SCI USA, V93, P6898, DOI 10.1073/pnas.93.14.6898; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; LAVIN MF, 1995, TRENDS BIOCHEM SCI, V20, P382, DOI 10.1016/S0968-0004(00)89083-0; PATERSON MC, 1979, CANCER RES, V39, P3725; PAWSON T, 1988, ONCOGENE, V3, P491; PECKER L, 1996, GENOMICS, V35, P39; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; RUDOLPH NS, 1989, MUTAT RES, V211, P31, DOI 10.1016/0027-5107(89)90104-8; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SHAFMAN TD, 1995, CANCER RES, V55, P3242; TAYLOR AM, 1975, NATURE, V274, P484; Telatar M, 1996, AM J HUM GENET, V59, P40; Uziel T, 1996, GENOMICS, V33, P317, DOI 10.1006/geno.1996.0201; Watters D, 1997, ONCOGENE, V14, P1911, DOI 10.1038/sj.onc.1201037; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8; ZHANG N, IN PRESS P NATL ACAD	26	400	414	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 29	1997	387	6632					520	523		10.1038/387520a0	http://dx.doi.org/10.1038/387520a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XB479	9168117				2022-12-01	WOS:A1997XB47900053
J	Deeks, SG; Abrams, DI				Deeks, SG; Abrams, DI			Genotypic-resistance assays and antiretroviral therapy	LANCET			English	Editorial Material							IN-VIVO				Deeks, SG (corresponding author), UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,AIDS PROGRAM,SAN FRANCISCO,CA 94114, USA.							COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0; Jacobsen H, 1996, J INFECT DIS, V173, P1379, DOI 10.1093/infdis/173.6.1379; JAPOUR AJ, 1995, J INFECT DIS, V171, P1172, DOI 10.1093/infdis/171.5.1172; Kozal MJ, 1996, NAT MED, V2, P753, DOI 10.1038/nm0796-753; LARDER BA, 1995, SCIENCE, V269, P696, DOI 10.1126/science.7542804	6	14	14	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 24	1997	349	9064					1489	1490		10.1016/S0140-6736(05)62092-2	http://dx.doi.org/10.1016/S0140-6736(05)62092-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XA901	9167453				2022-12-01	WOS:A1997XA90100003
J	Muers, MF				Muers, MF			Streptokinase for empyema	LANCET			English	Editorial Material							INTRAPLEURAL STREPTOKINASE				Muers, MF (corresponding author), KILLINGBECK HOSP,DEPT MED,LEEDS LS14 6UQ,W YORKSHIRE,ENGLAND.							BERGH NP, 1977, SCAND J THORAC CARD, V11, P265; Davies RJO, 1997, THORAX, V52, P416, DOI 10.1136/thx.52.5.416; Ferguson AD, 1996, QJM-MON J ASSOC PHYS, V89, P285; LAHORRA JM, 1993, AJR, V160, P71; TAYLOR RFH, 1994, THORAX, V49, P856, DOI 10.1136/thx.49.9.856; TILLETT WS, 1949, J CLIN INVEST, V28, P173, DOI 10.1172/JCI102046	6	16	16	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 24	1997	349	9064					1491	1492		10.1016/S0140-6736(05)62094-6	http://dx.doi.org/10.1016/S0140-6736(05)62094-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XA901	9167455				2022-12-01	WOS:A1997XA90100005
J	Charnov, EL				Charnov, EL			Trade-off-invariant rules for evolutionarily stable life histories	NATURE			English	Article							OFFSPRING SIZE	Optimization models have been widely and successfully used in evolutionary ecology to predict the attributes of organisms(1-8). Most such models maximize darwinian fitness in the face of tradeoffs and constraints; the numerical results usually depend on the exact form of the trade-offs or constraints. But not always(9): for example, earlier work(9) predicted that the optimal range in offspring size ought to show a -1 scaling with small litter size, independent of most details of the underlying offspring-survival/offspring-size trade-off relation. Here I report that in nongrowing (stationary), age-structured populations, three major life-history attributes (age at first breeding, size of an offspring in large litters, and reproductive effort) are likely to evolve to equilibrium values that satisfy a universal numerical rule; the underlying trade-off will have a slope of -1 at the optimum, independent of most other aspects of the trade-off. Each of these three attributes can be viewed as an allocation problem between just two alternatives; the trade-off is then between having more of one alternative and less of the other. The slope of the trade-off is simply the slope of the curve of allowed combinations of the two alternatives. The theory predicts that natural selection will push to an equilibrium where the slope is always -1. The economic structure is the same as that which underlies evolution of the sex ratio where the two alternatives are sons and daughters(2,10).			Charnov, EL (corresponding author), UNIV UTAH, DEPT BIOL, SALT LAKE CITY, UT 84112 USA.							Bulmer M. G, 1994, THEORETICAL EVOLUTIO; Charlesworth B., 1994, EVOLUTION AGE STRUCT; CHARNOV E L, 1982; CHARNOV EL, 1991, P NATL ACAD SCI USA, V88, P1134, DOI 10.1073/pnas.88.4.1134; CHARNOV EL, 1995, NATURE, V376, P418, DOI 10.1038/376418a0; Charnov Eric L., 1993, Evolutionary Anthropology, V1, P191, DOI 10.1002/evan.1360010604; Charnov Eric L., 1993, P1; GODFRAY HC, 1994, J PARASITOIDS; LLOYD DG, 1987, AM NAT, V129, P800, DOI 10.1086/284676; MacArthur RH, 1965, THEORETICAL MATH BIO, P388, DOI DOI 10.1038/NATURE04624; Mock D.W., 1997, EVOLUTION SIBLING RI; PARKER GA, 1990, NATURE, V348, P27, DOI 10.1038/348027a0; Seger Jon, 1996, P93; Stearns S.C., 1992, pi; STEARNS SC, 1989, FUNCT ECOL, V3, P259, DOI 10.2307/2389364; WILLIAMS GC, 1966, AM NAT, V100, P687, DOI 10.1086/282461	16	80	82	0	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 22	1997	387	6631					393	394		10.1038/387393a0	http://dx.doi.org/10.1038/387393a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XA496	9163423				2022-12-01	WOS:A1997XA49600058
J	Hakansson, K; Doherty, AJ; Shuman, S; Wigley, DB				Hakansson, K; Doherty, AJ; Shuman, S; Wigley, DB			X-ray crystallography reveals a large conformational change during guanyl transfer by mRNA capping enzymes	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; MUTATIONAL ANALYSIS; COVALENT CATALYSIS; NUCLEOTIDYL TRANSFER; DNA-LIGASE; RNA; GUANYLYLTRANSFERASE; MECHANISM; COMPLEX; MOTIF	We have solved the crystal structure of an mRNA capping enzyme at 2.5 Angstrom resolution. The enzyme comprises two domains with a deep, but narrow, cleft between them. The two molecules in the crystallographic asymmetric unit adopt very different conformations; both contain a bound GTP, but one protein molecule is in an open conformation while the other is in a closed conformation. Only in the closed conformation is the enzyme able to bind manganese ions and undergo catalysis within the crystals to yield the covalent guanylated enzyme intermediate. These structures provide direct evidence for a mechanism that involves a significant conformational change in the enzyme during catalysis.	UNIV OXFORD,MOL BIOPHYS LAB,OXFORD OX1 3QU,ENGLAND; MEM SLOAN KETTERING CANC CTR,PROGRAM MOL BIOL,NEW YORK,NY 10021	University of Oxford; Memorial Sloan Kettering Cancer Center				Doherty, Aidan/0000-0002-6370-1109	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AHOLA T, 1995, P NATL ACAD SCI USA, V92, P507, DOI 10.1073/pnas.92.2.507; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BRUNGER AT, 1989, ACTA CRYSTALLOGR A, V45, P50, DOI 10.1107/S0108767388009195; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CONG PJ, 1995, MOL CELL BIOL, V15, P6222; CONG PJ, 1993, J BIOL CHEM, V268, P7256; Doherty AJ, 1996, NUCLEIC ACIDS RES, V24, P2281, DOI 10.1093/nar/24.12.2281; DOHERTY AJ, 1997, IN PRESS ACTA CRYS D; FRESCO LD, 1994, P NATL ACAD SCI USA, V91, P6624, DOI 10.1073/pnas.91.14.6624; HEAPHY S, 1987, BIOCHEMISTRY-US, V26, P1688, DOI 10.1021/bi00380a030; Ho CK, 1996, J VIROL, V70, P6658, DOI 10.1128/JVI.70.10.6658-6664.1996; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEATHERBARROW RJ, 1985, P NATL ACAD SCI USA, V82, P7840, DOI 10.1073/pnas.82.23.7840; LI Y, 1995, VIROLOGY, V212, P134, DOI 10.1006/viro.1995.1462; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; SCHWER B, 1994, P NATL ACAD SCI USA, V91, P4328, DOI 10.1073/pnas.91.10.4328; Sheldrick G. M., 1991, CRYSTALLOGRAPHIC COM, V5, P145; SHIBAGAKI Y, 1992, J BIOL CHEM, V267, P9521; Shuman S, 1996, STRUCTURE, V4, P653, DOI 10.1016/S0969-2126(96)00070-6; SHUMAN S, 1981, P NATL ACAD SCI-BIOL, V78, P187, DOI 10.1073/pnas.78.1.187; SHUMAN S, 1995, VIROLOGY, V211, P73, DOI 10.1006/viro.1995.1380; SHUMAN S, 1994, P NATL ACAD SCI USA, V91, P12046, DOI 10.1073/pnas.91.25.12046; SHUMAN S, 1995, MOL MICROBIOL, V17, P405, DOI 10.1111/j.1365-2958.1995.mmi_17030405.x; SHUMAN S, 1995, PROG NUCLEIC ACID RE, V50, P101, DOI 10.1016/S0079-6603(08)60812-0; Subramanya HS, 1996, CELL, V85, P607, DOI 10.1016/S0092-8674(00)81260-X; YamadaOkabe T, 1996, MICROBIOL-UK, V142, P2515, DOI 10.1099/00221287-142-9-2515	28	216	218	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 16	1997	89	4					545	553		10.1016/S0092-8674(00)80236-6	http://dx.doi.org/10.1016/S0092-8674(00)80236-6			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WZ323	9160746	Bronze			2022-12-01	WOS:A1997WZ32300008
J	Lauer, SA; Rathod, PK; Ghori, N; Haldar, K				Lauer, SA; Rathod, PK; Ghori, N; Haldar, K			A membrane network for nutrient import in red cells infected with the malaria parasite	SCIENCE			English	Article							PLASMODIUM-FALCIPARUM; ERYTHROCYTES; TRANSPORT; MATURATION; SECRETION; PATHWAYS; CHANNEL; STAGE	The human malaria parasite Plasmodium falciparum exports an interconnected network of tubovesicular membranes (the TVM) that extends from the parasite's vacuolar membrane to the periphery of the red cell. Here it is shown that extracellular solutes such as Lucifer yellow enter the TVM and are delivered to the parasite. Blocking the assembly of the network blocked the delivery of exogenous Lucifer yellow, nucleosides, and amino acids to the parasite without inhibiting secretion of plasmodial; proteins. These data suggest that the NM is a transport network that allows nutrients efficient access to the parasite and could be used to deliver antimalarial drugs directly into the parasite.	STANFORD UNIV, SCH MED, DEPT MICROBIOL & IMMUNOL, STANFORD, CA 94305 USA; CATHOLIC UNIV AMER, INST BIOMOL STUDIES, DEPT BIOL, WASHINGTON, DC 20064 USA	Stanford University; Catholic University of America			Haldar, Kasturi/C-6685-2014		NIAID NIH HHS [AI26912, AI39071, AI26670] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026912, R22AI026670, R01AI026670, R01AI039071, R29AI026912] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CHASIS JA, 1989, BLOOD, V74, P1112, DOI 10.1182/blood.V74.3.1112.1112; CRARY JL, 1992, MOL BIOCHEM PARASIT, V53, P185, DOI 10.1016/0166-6851(92)90020-K; Deitsch KW, 1996, MOL BIOCHEM PARASIT, V76, P1, DOI 10.1016/0166-6851(95)02575-8; DESAI SA, 1993, NATURE, V362, P643, DOI 10.1038/362643a0; ELFORD BC, 1995, BIOCHEM J, V308, P361, DOI 10.1042/bj3080361; ELFORD BC, 1993, PARASITOL TODAY, V9, P80, DOI 10.1016/0169-4758(93)90205-T; ELMENDORF HG, 1994, J CELL BIOL, V124, P449, DOI 10.1083/jcb.124.4.449; ELMENDORF HG, 1992, MOL BIOCHEM PARASIT, V52, P215, DOI 10.1016/0166-6851(92)90054-N; GERO AM, 1988, MOL BIOCHEM PARASIT, V27, P159, DOI 10.1016/0166-6851(88)90035-7; GERO AM, 1994, PARASITOL TODAY, V10, P395, DOI 10.1016/0169-4758(94)90231-3; GRONOWICZ G, 1984, J CELL SCI, V171, P163; HALDAR K, 1992, MOL BIOCHEM PARASIT, V50, P161, DOI 10.1016/0166-6851(92)90253-G; HALDAR K, 1994, PARASITOL TODAY, V10, P393, DOI 10.1016/0169-4758(94)90230-5; HALDAR K, 1989, J CELL BIOL, V108, P2183, DOI 10.1083/jcb.108.6.2183; KIRK K, 1994, J BIOL CHEM, V269, P3339; LAUER SA, 1995, P NATL ACAD SCI USA, V92, P9181, DOI 10.1073/pnas.92.20.9181; POUVELLE B, 1991, NATURE, V353, P73, DOI 10.1038/353073a0; POUVELLE B, 1994, MOL BIOCHEM PARASIT, V66, P83, DOI 10.1016/0166-6851(94)90038-8; RATHOD PK, 1989, ANTIMICROB AGENTS CH, V33, P1090, DOI 10.1128/AAC.33.7.1090; SWEDLOW JR, 1993, CELL, V73, P97, DOI 10.1016/0092-8674(93)90163-K; TARASCHI TF, 1994, PARASITOL TODAY, V10, P399, DOI 10.1016/0169-4758(94)90232-1	21	172	177	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 16	1997	276	5315					1122	1125		10.1126/science.276.5315.1122	http://dx.doi.org/10.1126/science.276.5315.1122			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WZ225	9148808				2022-12-01	WOS:A1997WZ22500047
J	Ringach, DL; Hawken, MJ; Shapley, R				Ringach, DL; Hawken, MJ; Shapley, R			Dynamics of orientation tuning in macaque primary visual cortex	NATURE			English	Article							CAT STRIATE CORTEX; LATERAL INHIBITION; SIMPLE CELLS; SELECTIVITY; ORGANIZATION; DIRECTION; MONKEY; SPECIFICITY; SENSITIVITY; POTENTIALS	Orientation tuning of neurons is one of the chief emergent characteristics of the primary visual cortex, V1 (refs 1, 2). Neurons of the lateral geniculate nucleus, which comprise the thalamic input to V1, are not orientation-tuned, but the majority of VI neurons are quite selective. How orientation tuning arises within V1 is still controversial(1,3-17). To study this problem, we measured how the orientation tuning of neurons evolves with time(18-20) using a new method: reverse correlation in the orientation domain. Orientation tuning develops after a delay of 30-45 milliseconds and persists-for 40-85 ms. Neurons in layers 4C alpha or 4C beta, which receive direct input from the thalamus, show a single orientation preference which remains unchanged throughout the response period. In contrast, the preferred orientations of output layer neurons (in layers 2, 3, 4B, 5 or 6) usually change with time, and in many cases the orientation tuning may have more than one peak This difference in dynamics is accompanied by a change in the sharpness of orientation tuning; cells in the input layers are more broadly tuned than cells in the output layers. Many of these observed properties of output layer neurons cannot be explained by simple feedforward models(1,3-6), whereas they arise naturally in feedback networks(7-17). Our results indicate that V1 is more than a bank of static oriented filters; the dynamics of output layer cells appear to be shaped by intracortical feedback.			Ringach, DL (corresponding author), NYU,CTR NEURAL SCI,4 WASHINGTON PL,NEW YORK,NY 10003, USA.			Shapley, Robert/0000-0003-0099-9849				ANDREWS DP, 1965, NATURE, V205, P1218, DOI 10.1038/2051218a0; BENEVENTO LA, 1972, NATURE-NEW BIOL, V238, P124, DOI 10.1038/newbio238124a0; BENYISHAI R, 1995, P NATL ACAD SCI USA, V92, P3844, DOI 10.1073/pnas.92.9.3844; BLAKEMOR.C, 1970, NATURE, V228, P37, DOI 10.1038/228037a0; BLAKEMORE C, 1972, EXP BRAIN RES, V15, P439; BLASDEL GG, 1984, J NEUROSCI, V4, P880; BONDS AB, 1989, VISUAL NEUROSCI, V2, P41, DOI 10.1017/S0952523800004314; CELEBRINI S, 1993, VISUAL NEUROSCI, V10, P811, DOI 10.1017/S0952523800006052; CHAPMAN B, 1991, J NEUROSCI, V11, P1347; DEBOER E, 1968, IEEE T BIO-MED ENG, VBM15, P169, DOI 10.1109/TBME.1968.4502561; DEVALOIS RL, 1982, VISION RES, V22, P531, DOI 10.1016/0042-6989(82)90112-2; DOUGLAS RJ, 1995, SCIENCE, V269, P981, DOI 10.1126/science.7638624; FERSTER D, 1986, J NEUROSCI, V6, P1284; Ferster D, 1996, NATURE, V380, P249, DOI 10.1038/380249a0; HAWKEN MJ, 1988, J NEUROSCI, V8, P3541; HENRY GH, 1974, J NEUROPHYSIOL, V37, P1394, DOI 10.1152/jn.1974.37.6.1394; HUBEL DH, 1968, J PHYSIOL-LONDON, V195, P215, DOI 10.1113/jphysiol.1968.sp008455; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; LEVENTHAL AG, 1995, J NEUROSCI, V15, P1808, DOI 10.1523/JNEUROSCI.15-03-01808.1995; LUND JS, 1988, ANNU REV NEUROSCI, V11, P253, DOI 10.1146/annurev.ne.11.030188.001345; MORRONE MC, 1982, PROC R SOC SER B-BIO, V216, P335, DOI 10.1098/rspb.1982.0078; NELSON SB, 1991, J NEUROSCI, V11, P344; PEI X, 1994, J NEUROSCI, V14, P7130; REID RC, 1995, NATURE, V378, P281, DOI 10.1038/378281a0; SHEVELEV IA, 1993, NEUROSCIENCE, V56, P865, DOI 10.1016/0306-4522(93)90133-Z; SHEVELEV IA, 1994, NEUROSCIENCE, V61, P965, DOI 10.1016/0306-4522(94)90416-2; SILLITO AM, 1995, NATURE, V378, P492, DOI 10.1038/378492a0; SILLITO AM, 1980, BRAIN RES, V194, P517, DOI 10.1016/0006-8993(80)91234-2; SOMERS DC, 1995, J NEUROSCI, V15, P5448; WORGOTTER F, 1991, J NEUROSCI, V11, P1959	30	420	421	1	40	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 15	1997	387	6630					281	284		10.1038/387281a0	http://dx.doi.org/10.1038/387281a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WZ167	9153392				2022-12-01	WOS:A1997WZ16700052
J	Carter, HB; Epstein, JI; Chan, DW; Fozard, JL; Pearson, JD				Carter, HB; Epstein, JI; Chan, DW; Fozard, JL; Pearson, JD			Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TUMOR VOLUME; MEN; PROGRESSION	Objective.-To evaluate prostate-specific antigen (PSA) testing intervals that maintain the detection of curable cancer and reduce unnecessary testing. Design and Patients.-Historical prospective study of serial PSA measurements at 2- and 4-year intervals from frozen serum samples of 40 men who eventually developed prostate cancer and 272 men without prostate cancer who were participants in a prospective aging study (Gerontology Research Center of the National Institute on Aging, the Baltimore Longitudinal Study of Aging) and the case series of 389 consecutive men treated surgically for nonpalpable prostate cancer. Main Outcome Measures.-Probability of a PSA conversion to 4.1 to 5.0 ng/mL and to greater than 5.0 ng/mL at 2 and 4 years and probability of detecting curable prostate cancer by age and PSA level. Results.-When the pretreatment PSA level was less than or equal to 4.0 ng/mL, nonpalpable prostate cancers were highly likely (34/36, 94%) to be curable (organ-confined or capsular penetration with Gleason score <7 and negative margins), and the majority (25/36, 69%) were small cancers (confined tumor less than or equal to 0.5 cm(3) with no Gleason pattern 4 or 5). When the pretreatment PSA level was greater than 4.0 ng/mL and less than or equal to 5.0 ng/mL, cancers were highly likely to be curable (32/36, 89%), and a minority were small cancers (12/36, 33%), When the pretreatment PSA level was greater than 5.0 ng/mL, 96 (30%) of 317 cancers were noncurable. The PSA conversion (for cancer cases) to a level at which cure is less likely (>5.0 ng/mL) is rare (0%) after 2 or 4 years when the initial PSA is less than 2.0 ng/mL. PSA conversion to a range at which cancers are likely to be curable and less likely to be small (4.1-5.0 ng/mL) is rare after 2 years (0%-4%) when the baseline PSA level is less than 2.0 ng/mL but common when the baseline PSA level is between 2.1 and 3.0 ng/mL (27%) or 3.1 and 4.0 ng/mL (36%). Conclusions.-These data suggest that for men with no cancer suspected on digital rectal examination, a PSA level of 4.0 to 5.0 ng/mL is an acceptable range for maintaining the detection of curable prostate cancer and a 2-year PSA testing interval is not likely to miss a curable prostate cancer when the initial PSA level is less than 2.0 ng/mL. Recognizing that 70% of a screened population between the ages of 50 years and 70 years have PSA levels less than 2.0 ng/mL, elimination of annual PSA testing for these men would result in large health care cost savings.	JOHNS HOPKINS UNIV, JOHNS HOPKINS HOSP,JAMES BUCHANAN BRADY UROL INST, SCH MED,DEPT PATHOL, BALTIMORE, MD 21287 USA; NIA, GERONTOL RES CTR, BALTIMORE, MD 21224 USA; MERCK RES LABS, DEPT EPIDEMIOL, BLUE BELL, PA USA	Johns Hopkins University; Johns Hopkins Medicine; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Merck & Company	Carter, HB (corresponding author), JOHNS HOPKINS UNIV, JOHNS HOPKINS HOSP, JAMES BUCHANAN BRADY UROL INST, SCH MED, DEPT UROL, BALTIMORE, MD 21287 USA.		Fozard, James Leonard/B-3660-2009					CARTER HB, 1995, UROLOGY, V45, P591, DOI 10.1016/S0090-4295(99)80049-1; CARTER HB, 1992, JAMA-J AM MED ASSOC, V267, P2215, DOI 10.1001/jama.267.16.2215; CATALONA WJ, 1993, JAMA-J AM MED ASSOC, V270, P948, DOI 10.1001/jama.270.8.948; Cohen J., 2013, STAT POWER ANAL BEHA, DOI 10.4324/9780203771587; EPSTEIN JI, 1994, JAMA-J AM MED ASSOC, V271, P368, DOI 10.1001/jama.271.5.368; EPSTEIN JI, 1993, CANCER-AM CANCER SOC, V71, P3582, DOI 10.1002/1097-0142(19930601)71:11<3582::AID-CNCR2820711120>3.0.CO;2-Y; EPSTEIN JI, 1993, J UROLOGY, V150, P135, DOI 10.1016/S0022-5347(17)35415-0; Epstein JI, 1996, AM J SURG PATHOL, V20, P286, DOI 10.1097/00000478-199603000-00004; GANN PH, 1995, JAMA-J AM MED ASSOC, V273, P289, DOI 10.1001/jama.273.4.289; Humphrey PA, 1996, J UROLOGY, V155, P816, DOI 10.1016/S0022-5347(01)66316-X; JACOBSEN SJ, 1995, UROLOGY, V45, P447, DOI 10.1016/S0090-4295(99)80014-4; METTLIN C, 1993, CA-CANCER J CLIN, V43, P42, DOI 10.3322/canjclin.43.1.42; OESTERLING JE, 1993, JAMA-J AM MED ASSOC, V270, P860, DOI 10.1001/jama.270.7.860; PARTIN AW, 1989, J UROLOGY, V141, P341, DOI 10.1016/S0022-5347(17)40761-0; Prestigiacomo AF, 1996, J UROLOGY, V155, P1977, DOI 10.1016/S0022-5347(01)66067-1; Shock N, 1984, NIH PUBLICATION; Smith DS, 1996, JAMA-J AM MED ASSOC, V276, P1309, DOI 10.1001/jama.276.16.1309; STAMEY TA, 1993, CANCER, V71, P933, DOI 10.1002/1097-0142(19930201)71:3+<933::AID-CNCR2820711408>3.0.CO;2-L; Stone CJ., 1985, P STAT COMP SECT AM, V1, P45; *US PREV SERV TASK, 1996, GUID CLIN PREV SERV, P119	20	125	128	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 14	1997	277	18					1456	1460		10.1001/jama.277.18.1456	http://dx.doi.org/10.1001/jama.277.18.1456			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WX852	9145718				2022-12-01	WOS:A1997WX85200030
J	Parente, F; Maconi, G; Imbesi, V; Sangaletti, O; Poggio, M; Rossi, E; Duca, P; Porro, GB				Parente, F; Maconi, G; Imbesi, V; Sangaletti, O; Poggio, M; Rossi, E; Duca, P; Porro, GB			Helicobacter pylori infection and coagulation in healthy people	BRITISH MEDICAL JOURNAL			English	Article							CARDIOVASCULAR RISK-FACTORS; CORONARY HEART-DISEASE		UNIV MILAN,L SACCO HOSP,DEPT GASTROENTEROL,I-20157 MILAN,ITALY; UNIV MILAN,L SACCO HOSP,DEPT HAEMATOL,I-20157 MILAN,ITALY; UNIV MILAN,DEPT MED STAT & BIOMETRY,I-20157 MILAN,ITALY	University of Milan; Luigi Sacco Hospital; University of Milan; Luigi Sacco Hospital; University of Milan			Maconi, Giovanni/V-7836-2017; Duca, Piergiorgio/S-7525-2017	Maconi, Giovanni/0000-0003-0810-4026; Duca, Piergiorgio/0000-0003-4499-8805				MANNUCCI PM, 1992, THROMB HAEMOSTASIS, V67, P200; MENDALL MA, 1994, BRIT HEART J, V71, P437; MURRAY LJ, 1995, BRIT HEART J, V74, P497; PATEL P, 1995, BRIT MED J, V311, P711, DOI 10.1136/bmj.311.7007.711; YARNELL JWG, 1991, CIRCULATION, V83, P836, DOI 10.1161/01.CIR.83.3.836	5	35	36	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 3	1997	314	7090					1318	1319		10.1136/bmj.314.7090.1318	http://dx.doi.org/10.1136/bmj.314.7090.1318			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WX975	9158468	Green Submitted, Green Published			2022-12-01	WOS:A1997WX97500024
J	Brzana, RJ; Koch, KL				Brzana, RJ; Koch, KL			Gastroesophageal reflux disease presenting with intractable nausea	ANNALS OF INTERNAL MEDICINE			English	Article							ESOPHAGITIS; DIAGNOSIS; SYMPTOMS; ACID	Background: Typical symptoms of gastroesophageal reflux disease are heartburn and regurgitation. A subset of patients present with atypical symptoms, such as chest pain, cough, wheezing, and hoarseness. Objective: To review the clinical presentation and treatment of patients who presented with nausea as the primary symptom of gastroesophageal reflux disease. Design: Case series. Setting: Outpatient department of a university hospital. Patients: 10 outpatients who had chronic, intractable nausea and had not responded to empirical therapies. Measurements: Patients were evaluated by esophagogastroduodenoscopy, 24-hour esophageal pH studies, gastric-emptying tests, electrogastrography, or a Bernstein test. Results: Abnormal acid reflux was found to be the cause of intractable nausea in all 10 patients. In 5 of the 10 patients, esophagitis was documented by esophagogastroduodenoscopy. Six patients had abnormal results on the 24-hour esophageal pH study. In these 6 patients, 32 of 33 episodes of nausea were accompanied by an episode of acid reflux. One patient had positive results on the Bernstein test. Nausea resolved after treatment with omeprazole in 7 patients, after treatment with cisapride or ranitidine in 2 patients, and after Nissen fundoplication in 1 patient. Conclusions: Intractable nausea is an atypical symptom that can occur in a subset of patients with gastroesophageal reflux disease. A 24-hour esophageal pH study should be considered in patients who have unexplained nausea but normal findings on esophagogastroduodenoscopy, a gastric-emptying test, and electrogastrography. Nausea related to gastroesophageal reflux disease resolves or is markedly reduced with proton-pump inhibitors or promotility drugs.	PENN STATE UNIV, MILTON S HERSHEY MED CTR, DIV GASTROENTEROL, HERSHEY, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health								CLOUD ML, 1991, AM J GASTROENTEROL, V86, P1735; COLLEN MJ, 1987, GASTROENTEROLOGY, V92, P1350; DAVIES HA, 1985, J CLIN GASTROENTEROL, V7, P477, DOI 10.1097/00004836-198512000-00007; DEMEESTER TR, 1980, J THORAC CARDIOV SUR, V79, P656; FITZGERALD JM, 1989, CAN MED ASSOC J, V140, P520; HORROCKS JC, 1978, GUT, V19, P19, DOI 10.1136/gut.19.1.19; JOHNSSON F, 1987, GUT, V28, P1145, DOI 10.1136/gut.28.9.1145; JOHNSSON F, 1987, SCAND J GASTROENTERO, V22, P714, DOI 10.3109/00365528709011148; KLAUSER AG, 1989, AM J GASTROENTEROL, V84, P362; KLAUSER AG, 1990, LANCET, V335, P205, DOI 10.1016/0140-6736(90)90287-F; KOCH KL, 1989, AM J GASTROENTEROL, V84, P1069; Koch KL, 1993, ILLUSTRATED GUIDE GA, P290; ROBERTSON DAF, 1987, GUT, V28, P946, DOI 10.1136/gut.28.8.946; ROKKAS T, 1988, AM J GASTROENTEROL, V83, P629; SCHOFIELD PM, 1989, DIGESTION, V42, P70, DOI 10.1159/000199828; SCHROEDER PL, 1995, ANN INTERN MED, V122, P809, DOI 10.7326/0003-4819-122-11-199506010-00001; SHAY SS, 1992, AM J GASTROENTEROL, V87, P1094; YOU CH, 1980, GASTROENTEROLOGY, V79, P311	18	37	37	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1997	126	9					704	707		10.7326/0003-4819-126-9-199705010-00005	http://dx.doi.org/10.7326/0003-4819-126-9-199705010-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW147	9139556				2022-12-01	WOS:A1997WW14700005
J	Smedley, J; Egger, P; Cooper, C; Coggon, D				Smedley, J; Egger, P; Cooper, C; Coggon, D			Prospective cohort study of predictors of incident low back pain in nurses	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-POPULATION; OCCUPATION; WORKERS; RISK; EPIDEMIOLOGY; INJURIES; HEIGHT	Objective: To assess the impact of handling patients and indicators of individual susceptibility on risk of low back pain in nurses. Design: Prospective cohort study with follow up by repeated self administered questionnaires every three months over two years. Setting: NHS university hospitals trust. Subjects: 961 female nurses who had been free from low back pain for at least one month at the time of completing a baseline questionnaire. Main outcome measures: Incidence of new low back pain during follow up and of pain leading to absence from work. Results: Of 838 women who provided data suitable for analysis, 322 (38%) developed low back pain during follow up (mean 18.6 months), including 93 (11%) whose pain led to absence from work. The strongest predictor of new low back pain was earlier history of the symptom, and risk was particularly high if previous pain had lasted for over a month in total and had occurred within the 12 months before entry to the study (incidence during follow up 66%). Frequent low mood at baseline was strongly associated with subsequent absence from work for back pain (odds ratio 3.4; 95% confidence interval 1.4 to 8.2). After adjustment for earlier history of back pain and other potential confounders, risk was higher in nurses who reported frequent manual transfer of patients between bed and chair, manual repositioning of patients on the bed, and lifting patients in or out of the bath with a hoist. Conclusions: Of the indicators of individual susceptibility that were examined, only history of back trouble was sufficiently predictive to justify selective exclusion of some applicants for nursing posts. The main route to prevention of back disorders among nurses is likely to lie in improved ergonomics.	UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON SO16 6YD,HANTS,ENGLAND	University of Southampton								ALLISON PD, 1988, SOCIOL METHODS RES, V15, P355; ASTRAND NE, 1987, BRIT J IND MED, V44, P327; BATY D, 1987, INT J NURS STUD, V24, P239; BERGQUISTULLMAN M, 1977, ACTA ORTHOP SCAND S, V170, P1; BIERINGSORENSEN F, 1984, SPINE, V9, P106, DOI 10.1097/00007632-198403000-00002; BIERINGSORENSEN F, 1983, SCAND J REHABIL MED, V15, P71; BIGOS SJ, 1991, SPINE, V16, P1, DOI 10.1097/00007632-199101000-00001; BURDORF A, 1991, ERGONOMICS, V34, P909, DOI 10.1080/00140139108964834; Clinical Standards Advisory Group, 1994, EP REV EP COST BACK; CROFT P, 1994, BR J RHEUMATOL S1, V33, P105; DILLANE JB, 1966, BRIT MED J, V2, P82, DOI 10.1136/bmj.2.5505.82; EGGER PJ, 1992, THESIS U SOUTHAMPTON; FRYMOYER JW, 1980, SPINE, V5, P419, DOI 10.1097/00007632-198009000-00005; GYNTELBERG F, 1974, DAN MED B, V21, P109; HARBER P, 1985, J OCCUP ENVIRON MED, V27, P518; HIRSCH C, 1969, CLIN ORTHOPAEDICS, V63, P171; Horal J, 1969, Acta Orthop Scand Suppl, V118, P1; HULT L, 1954, Acta Orthop Scand Suppl, V17, P1; KUH DJL, 1993, BRIT J RHEUMATOL, V32, P911; LLOYD DCEF, 1983, J SOC OCCUP MED, V33, P66; MAGORA A, 1973, SCAND J REHABIL MED, V5, P191; MAGORA A, 1973, SCAND J REHABIL MED, V5, P186; NAGI SZ, 1973, J CHRON DIS, V26, P769, DOI 10.1016/0021-9681(73)90012-X; PUNNETT L, 1991, SCAND J WORK ENV HEA, V17, P337, DOI 10.5271/sjweh.1700; SMEDLEY J, 1995, OCCUP ENVIRON MED, V52, P160, DOI 10.1136/oem.52.3.160; SUADICANI P, 1994, OCCUP MED-OXFORD, V44, P217, DOI 10.1093/occmed/44.4.217; SVENSSON HO, 1989, SPINE, V14, P517, DOI 10.1097/00007632-198905000-00008; UNDEUTSCH K, 1982, SCAND J WORK ENV H S, V1, P92; VENNING PJ, 1987, J OCCUP ENVIRON MED, V29, P820; VIDEMAN T, 1984, SPINE, V9, P400, DOI 10.1097/00007632-198405000-00013; WALSH K, 1992, J EPIDEMIOL COMMUN H, V46, P227, DOI 10.1136/jech.46.3.227; WALSH K, 1991, SCAND J WORK ENV HEA, V17, P420, DOI 10.5271/sjweh.1680; YASSI A, 1995, OCCUP MED-OXFORD, V45, P215, DOI 10.1093/occmed/45.4.215; ZWERLING C, 1993, SPINE, V18, P1242, DOI 10.1097/00007632-199307000-00020	34	189	192	0	21	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 26	1997	314	7089					1225	1228		10.1136/bmj.314.7089.1225	http://dx.doi.org/10.1136/bmj.314.7089.1225			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW718	9154024	Green Published			2022-12-01	WOS:A1997WW71800015
J	Davies, A; Huxley, P				Davies, A; Huxley, P			Survey of general practitioners' opinions on treatment of opiate users	BRITISH MEDICAL JOURNAL			English	Article											Davies, A (corresponding author), UNIV MANCHESTER,SCH PSYCHIAT & BEHAV SCI,MANCHESTER M13 9PL,LANCS,ENGLAND.		Huxley, Peter/AAE-7007-2019					BELL G, 1990, HLTH TRENDS, V2, P56; DONMALL MC, 1993, DRUGLINK, V8, P8; GLANZ A, 1986, BRIT MED J, V293, P486, DOI 10.1136/bmj.293.6545.486; Kirkwood B., 1988, BR K ESSENTIALS MED; *MED WORK GROUP DR, 1994, GUID GOOD CLIN PRACT	5	24	24	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 19	1997	314	7088					1173	1174		10.1136/bmj.314.7088.1173	http://dx.doi.org/10.1136/bmj.314.7088.1173			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WV705	9146392	Green Published			2022-12-01	WOS:A1997WV70500026
J	Forte, P; Copland, M; Smith, LM; Milne, E; Sutherland, J; Benjamin, N				Forte, P; Copland, M; Smith, LM; Milne, E; Sutherland, J; Benjamin, N			Basal nitric oxide synthesis in essential hypertension	LANCET			English	Article							MONOMETHYL-L-ARGININE; NITRATE; THERAPY; AIR	Background There is indirect evidence that nitric oxide (NO) synthesis in vascular endothelium of patients with hypertension is altered. The aim of this study was to estimate more directly NO production in patients with untreated essential hypertension by measurement of synthesis of inorganic nitrate, which is the end product of NO oxidation in humans. Two separate studies were undertaken in patients with hypertension and appropriate healthy controls.(1) Methods In the first study, ten patients and 13 controls were given a diet containing 82 mu moles nitrate per day for 2 days, with urinary and plasma nitrate measurement and 24 h ambulatory blood pressure monitoring on the 2nd day. In the second study, 11 patients and 11 controls were studied in the postabsorptive state; a bolus of 200 mg L-[N-15](2) arginine was administered intravenously over 10 min. 24 h ambulatory blood pressure monitoring was done and complete urine collections were made for the next 36 h. Findings In the first study, 24 h urinary nitrate excretion was lower in the hypertensive patients than in the control group (mean 450 [SEM 37] vs 760 mu moles [77] per 24 h; p<0001). There was an inverse correlation between average mean daytime ambulatory blood pressure and nitrate excretion (p=0.007; r(2)=-0.73). In the second study, mean 36 h urinary N-15 nitrate excretion was significantly lower in the hypertensive than in the control group (1313 [50] vs 2133 [142] pmoles; p<0.001). There was an inverse correlation also between average mean daytime ambulatory blood pressure and 24 h urinary N-15 nitrate excretion expressed per mmole of creatinine (p=0.002, r(2)=-0.59). In addition, total urinary N-15 nitrate excretion in the hypertensive group was significantly higher in women than in men (285 [16] vs 198 [14] mu g N-15 nitrate per kg; p=0.026). Interpretation These data suggest that whole-body NO production in patients with essential hypertension is diminished under basal conditions. The origin of the NO we measured is not known, and we cannot tell whether the impaired synthesis is primary or secondary to a rise in blood pressure.	ST BARTHOLOMEWS & ROYAL SCH MED & DENT,DEPT CLIN PHARMACOL,LONDON EC1M 6BQ,ENGLAND; UNIV ABERDEEN,DEPT MED & THERAPEUT,ABERDEEN,SCOTLAND; ROWETT RES INST,ABERDEEN,SCOTLAND	University of London; Queen Mary University London; University of Aberdeen; University of Aberdeen								ARCHER S, 1993, FASEB J, V7, P349, DOI 10.1096/fasebj.7.2.8440411; BROOKS PD, 1989, SOIL SCI SOC AM J, V53, P1707, DOI 10.2136/sssaj1989.03615995005300060016x; CALVER A, 1992, J HYPERTENS, V10, P1025; CHOWIENCZYK PJ, 1993, BRIT J PHARMACOL, V110, P736, DOI 10.1111/j.1476-5381.1993.tb13873.x; CHOWIENCZYK PJ, 1994, J HYPERTENS, V12, P1322; COCKCROFT JR, 1994, NEW ENGL J MED, V330, P1036, DOI 10.1056/NEJM199404143301502; Crcager MA, 1992, J VASC RES, V29, P97; DUFF F, 1953, J PHYSIOL-LONDON, V120, P160, DOI 10.1113/jphysiol.1953.sp004883; GIBALDI M, 1982, PHARMACOKINETICS DRU, V1; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; HAUCK R. D., 1958, SOIL SCI, V86, P287, DOI 10.1097/00010694-195811000-00011; HIBBS JB, 1992, J CLIN INVEST, V89, P867, DOI 10.1172/JCI115666; HIRATA Y, 1985, BIOCHEM BIOPH RES CO, V128, P538, DOI 10.1016/0006-291X(85)90080-4; HISHIKAWA K, 1994, HYPERTENSION, V24, P386; Jilma B, 1996, LIFE SCI, V58, P469, DOI 10.1016/0024-3205(95)02311-9; Jungersten L, 1996, CLIN PHYSIOL, V16, P369, DOI 10.1111/j.1475-097X.1996.tb00726.x; LYONS D, 1994, J HYPERTENS, V12, P1047; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; *NAT AC SCI COMM N, 1981, HLTH EFFECTS NITRATE; PANZA JA, 1993, J AM COLL CARDIOL, V21, P1145, DOI 10.1016/0735-1097(93)90238-V; SCHILLING J, 1994, EUR RESPIR J, V7, P467, DOI 10.1183/09031936.94.07030467; Taddei S, 1996, CIRCULATION, V94, P1298, DOI 10.1161/01.CIR.94.6.1298; TAKAHASHI H, 1992, J CARDIOVASC PHARM, V20, pS214, DOI 10.1097/00005344-199204002-00061; TESCH JW, 1976, J CHROMATOGR, V126, P743, DOI 10.1016/S0021-9673(01)84117-0; VALLANCE P, 1992, J CARDIOVASC PHARM, V20, pS60, DOI 10.1097/00005344-199204002-00018; VALLANCE P, 1995, LANCET, V346, P153, DOI 10.1016/S0140-6736(95)91211-8; VALLANCE P, 1989, LANCET, V2, P997; WENNMALM A, 1993, CIRC RES, V73, P1121, DOI 10.1161/01.RES.73.6.1121; WESTFELT UN, 1995, BRIT J PHARMACOL, V114, P1621, DOI 10.1111/j.1476-5381.1995.tb14948.x; Winquist R J, 1984, J Hypertens, V2, P541, DOI 10.1097/00004872-198410000-00015	30	316	332	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 22	1997	349	9055					837	842		10.1016/S0140-6736(96)07631-3	http://dx.doi.org/10.1016/S0140-6736(96)07631-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WP403	9121259				2022-12-01	WOS:A1997WP40300012
J	Lecuit, T; Cohen, SM				Lecuit, T; Cohen, SM			Proximal-distal axis formation in the Drosophila leg	NATURE			English	Article							PROTEIN-KINASE-A; LIMB DEVELOPMENT; IMAGINAL DISKS; SIGNAL-TRANSDUCTION; MORPHOGEN GRADIENT; WING DEVELOPMENT; VENTRAL CELLS; FEEDBACK LOOP; HEDGEHOG; GENE	Limb development requires the formation of a proximal-distal axis perpendicular to the main anterior-posterior and dorsal-ventral body axes. The secreted signalling proteins Decapentaplegic and Wingless act in a concentration-dependent manner to organize the proximal-distal axis. Discrete domains of proximal-distal gene expression are defined by different thresholds of Decapentaplegic and Wingless activities. Subsequent modulation of the relative sires of these domains by growth of the leg is required to form the mature pattern.	EUROPEAN MOL BIOL LAB,D-69117 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			Cohen, Stephen M/G-9930-2011	Cohen, Stephen M/0000-0003-2858-9163				BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; Brook WJ, 1996, ANNU REV CELL DEV BI, V12, P161, DOI 10.1146/annurev.cellbio.12.1.161; BROOK WJ, 1996, SCIENCE, V273, P1371; CAMPBELL G, 1993, CELL, V74, P1113, DOI 10.1016/0092-8674(93)90732-6; COHEN SM, 1989, NATURE, V338, P432, DOI 10.1038/338432a0; COHN MJ, 1995, CELL, V80, P739, DOI 10.1016/0092-8674(95)90352-6; COUSO JP, 1993, SCIENCE, V259, P484, DOI 10.1126/science.8424170; Crossley PH, 1996, CELL, V84, P127, DOI 10.1016/S0092-8674(00)80999-X; DiazBenjumea FJ, 1995, DEVELOPMENT, V121, P4215; DIAZBENJUMEA FJ, 1994, NATURE, V372, P175, DOI 10.1038/372175a0; DIAZBENJUMEA FJ, 1993, CELL, V75, P741, DOI 10.1016/0092-8674(93)90494-B; GURDON JB, 1995, NATURE, V376, P520, DOI 10.1038/376520a0; GURDON JB, 1994, NATURE, V371, P487, DOI 10.1038/371487a0; HELD LI, 1994, ROUX ARCH DEV BIOL, V203, P310, DOI 10.1007/BF00457802; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; IRVINE KD, 1994, CELL, V79, P595, DOI 10.1016/0092-8674(94)90545-2; Jiang J, 1996, CELL, V86, P401, DOI 10.1016/S0092-8674(00)80113-0; JIANG J, 1995, CELL, V80, P563, DOI 10.1016/0092-8674(95)90510-3; KIM J, 1995, CELL, V82, P795, DOI 10.1016/0092-8674(95)90476-X; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; Lawrence PA, 1996, CELL, V85, P951, DOI 10.1016/S0092-8674(00)81297-0; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; LEPAGE T, 1995, NATURE, V373, P711, DOI 10.1038/373711a0; LI W, 1995, CELL, V80, P553, DOI 10.1016/0092-8674(95)90509-X; MARDON G, 1994, DEVELOPMENT, V120, P3473; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; Neumann CJ, 1996, DEVELOPMENT, V122, P3477; Neumann CJ, 1997, DEVELOPMENT, V124, P871; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; PAN DJ, 1995, CELL, V80, P543, DOI 10.1016/0092-8674(95)90508-1; PANGANIBAN G, 1995, SCIENCE, V270, P1363, DOI 10.1126/science.270.5240.1363; PARR BA, 1995, NATURE, V374, P350, DOI 10.1038/374350a0; Penton A, 1996, NATURE, V382, P162, DOI 10.1038/382162a0; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8; RUEL L, 1993, EMBO J, V12, P1657, DOI 10.1002/j.1460-2075.1993.tb05811.x; Singer MA, 1997, DEVELOPMENT, V124, P79; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; Theisen H, 1996, DEVELOPMENT, V122, P3939; VACHON G, 1992, CELL, V71, P437, DOI 10.1016/0092-8674(92)90513-C; Wiersdorff V, 1996, DEVELOPMENT, V122, P2153; WILLIAMS JA, 1994, NATURE, V368, P299, DOI 10.1038/368299a0; YANG YZ, 1995, CELL, V80, P939, DOI 10.1016/0092-8674(95)90297-X; Zecca M, 1996, CELL, V87, P833, DOI 10.1016/S0092-8674(00)81991-1; ZECCA M, 1995, DEVELOPMENT, V121, P2265	46	308	311	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 10	1997	388	6638					139	145		10.1038/40563	http://dx.doi.org/10.1038/40563			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK109	9217152	Bronze			2022-12-01	WOS:A1997XK10900040
J	Kondo, H; Rabouille, C; Newman, R; Levine, TP; Pappin, D; Freemont, P; Warren, G				Kondo, H; Rabouille, C; Newman, R; Levine, TP; Pappin, D; Freemont, P; Warren, G			p47 is a cofactor for p97-mediated membrane fusion	NATURE			English	Article							MITOTIC GOLGI FRAGMENTS; VESICLE FUSION; CELL-CYCLE; YEAST; IDENTIFICATION; PROTEINS; HOMOLOGY; ATPASE; STACKS; FAMILY	At least two distinct ATPases, NSF and p97, are known to be involved in the heterotypic fusion of transport vesicles with their target membranes and the homotypic fusion of membrane compartments(1). The NSF-mediated fusion pathway is the best characterized, many of the components having been identified and their functions analysed(2-7). In contrast, none of the accessory proteins for the p97-mediated fusion pathway has been identified(8-10). Now we have identified the first such component, a protein of relative molecular mass 47,000 (p47), which forms a tight, stoichiometric complex with cytosolic p97 (one trimer of p47 per hexamer of p97). It is essential for the p97-mediated regrowth of Golgi cisternae from mitotic Golgi fragments, a process restricted to animal cells(11). As a homologue of p47 exists in budding yeast, this indicates that it might also be involved in other membrane fusion reactions catalysed by p97, such as karyogamy(10).	IMPERIAL CANC RES FUND,CELL BIOL LAB,LONDON WC2A 3PX,ENGLAND; IMPERIAL CANC RES FUND,PROT STRUCT LAB,LONDON WC2A 3PX,ENGLAND; IMPERIAL CANC RES FUND,PROT SEQUENCING LAB,LONDON WC2A 3PX,ENGLAND; MRC,MOL BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND	Cancer Research UK; Cancer Research UK; Cancer Research UK; MRC Laboratory Molecular Biology				Levine, Timothy/0000-0002-7231-0775; Pappin, Darryl/0000-0002-8981-8401				ACHARYA U, 1995, CELL, V82, P895, DOI 10.1016/0092-8674(95)90269-4; CONFALONIERI F, 1994, J MOL BIOL, V235, P396, DOI 10.1016/S0022-2836(05)80047-6; COULL JM, 1991, ANAL BIOCHEM, V194, P110, DOI 10.1016/0003-2697(91)90157-O; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; FROHLICH KU, 1991, J CELL BIOL, V114, P443, DOI 10.1083/jcb.114.3.443; HUNT DF, 1986, P NATL ACAD SCI USA, V83, P6233, DOI 10.1073/pnas.83.17.6233; LATTERICH M, 1995, CELL, V82, P885, DOI 10.1016/0092-8674(95)90268-6; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; PETERS JM, 1990, EMBO J, V9, P1757, DOI 10.1002/j.1460-2075.1990.tb08300.x; PETERS JM, 1992, J MOL BIOL, V223, P557, DOI 10.1016/0022-2836(92)90670-F; Pfeffer SR, 1996, ANNU REV CELL DEV BI, V12, P441, DOI 10.1146/annurev.cellbio.12.1.441; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; RABOUILLE C, 1995, J CELL BIOL, V129, P605, DOI 10.1083/jcb.129.3.605; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Saxton WO, 1996, J STRUCT BIOL, V116, P230, DOI 10.1006/jsbi.1996.0035; SCHERENS B, 1993, YEAST, V9, P1355, DOI 10.1002/yea.320091210; Schiavo Giampietro, 1994, Seminars in Cell Biology, V5, P221, DOI 10.1006/scel.1994.1028; SUTTON A, 1991, COLD SPRING HARB SYM, V56, P75; SUTTON CW, 1995, ELECTROPHORESIS, V16, P308, DOI 10.1002/elps.1150160151; Tu JL, 1996, MOL CELL BIOL, V16, P4199; WARREN G, 1993, ANNU REV BIOCHEM, V62, P323, DOI 10.1146/annurev.bi.62.070193.001543; ZHANG SR, 1995, MOL CELL BIOL, V15, P2037	24	350	360	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 3	1997	388	6637					75	78		10.1038/40411	http://dx.doi.org/10.1038/40411			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XJ143	9214505	Bronze			2022-12-01	WOS:A1997XJ14300053
J	Sibon, OCM; Stevenson, VA; Theurkauf, WE				Sibon, OCM; Stevenson, VA; Theurkauf, WE			DNA-replication checkpoint control at the Drosophila midblastula transition	NATURE			English	Article							CELL-CYCLE CONTROL; MITOTIC-CYCLES; EMBRYOS; XENOPUS; EMBRYOGENESIS; BLASTODERM; BEHAVIOR; NUCLEAR	Embryogenesis is typically initiated by a series of rapid mitotic divisions that are under maternal genetic control(1). The switch to zygotic control of embryogenesis at the midblastula transition is accompanied by significant increases in cell-cycle length and gene transcription, and changes in embryo morphology(2,3). Here we show that mutations in the grapes (grp) checkpoint 1 kinase homologue(4) in Drosophila block the morphological and biochemical changes that accompany the midblastula transition, lead to a continuation of the maternal cell-cycle programme, and disrupt DNA-replication checkpoint control of cell-cycle progression. The timing of the midblastula transition is controlled by the ratio of nuclei to cytoplasm (the nucleocytoplasmic ratio), suggesting that this developmental transition is triggered by titration of a maternal factor by the increasing mass of nuclear material that accumulates during the rapid embryonic mitoses(5-9). Our observations support a model for cell-cycle control at the midblastula transition in which titration of a maternal component of the DNA-replication machinery slows DNA synthesis and induces a checkpoint-dependent delay in cell-cycle progression(10). This delay may allow both completion of S phase and transcription of genes that initiate the switch to zygotic control of embryogenesis.	SUNY STONY BROOK,DEPT BIOCHEM & CELL BIOL,STONY BROOK,NY 11794; SUNY STONY BROOK,INST CELL & DEV BIOL,STONY BROOK,NY 11794	State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook				Sibon, Ody/0000-0002-6836-6063; Theurkauf, William/0000-0001-7342-1912				BANGA SS, 1986, MUTAT RES, V163, P157, DOI 10.1016/0027-5107(86)90044-8; CAMPBELL SD, 1995, MOL BIOL CELL, V6, P1333, DOI 10.1091/mbc.6.10.1333; CLUTE P, 1995, DEV BIOL, V171, P273, DOI 10.1006/dbio.1995.1280; COOLEY L, 1988, SCIENCE, V239, P1121, DOI 10.1126/science.2830671; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; Edgar BA, 1996, GENE DEV, V10, P1966, DOI 10.1101/gad.10.15.1966; EDGAR BA, 1994, GENE DEV, V8, P440, DOI 10.1101/gad.8.4.440; EDGAR BA, 1986, CELL, V44, P365, DOI 10.1016/0092-8674(86)90771-3; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FOE VE, 1983, J CELL SCI, V61, P31; Foe Victoria E., 1993, P149; FOGARTY P, 1994, DEVELOPMENT, V120, P2131; FOGARTY P, IN PRESS CURR BIOL; Francesconi S, 1997, EMBO J, V16, P1332, DOI 10.1093/emboj/16.6.1332; GILBERT SF, 1991, DEV BIOL, P75; KANE DA, 1993, DEVELOPMENT, V119, P447; KELLOGG DR, 1988, DEVELOPMENT, V103, P675; KLINGLER M, 1993, MECH DEVELOP, V43, P3, DOI 10.1016/0925-4773(93)90019-T; MATTHIES HJ, 1996, J CELL BIOL, V341, P455; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; Pritchard DK, 1996, GENE DEV, V10, P1131, DOI 10.1101/gad.10.9.1131; RAFF JW, 1988, J CELL BIOL, V107, P2009, DOI 10.1083/jcb.107.6.2009; RUDEN DM, 1995, DEVELOPMENT, V121, P63; SHERMOEN AW, 1991, CELL, V67, P303, DOI 10.1016/0092-8674(91)90182-X; SULLIVAN W, 1993, DEVELOPMENT, V118, P1245; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; Theurkauf William E., 1994, V44, P489; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; YASUDA GK, 1991, GENE DEV, V5, P1800, DOI 10.1101/gad.5.10.1800	29	223	224	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 3	1997	388	6637					93	97		10.1038/40439	http://dx.doi.org/10.1038/40439			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XJ143	9214509	Bronze			2022-12-01	WOS:A1997XJ14300057
J	Avantaggiati, ML; Ogryzko, V; Gardner, K; Giordano, A; Levine, AS; Kelly, K				Avantaggiati, ML; Ogryzko, V; Gardner, K; Giordano, A; Levine, AS; Kelly, K			Recruitment of p300/CBP in p53-dependent signal pathways	CELL			English	Article							CELL-PROLIFERATION; P53; TRANSFORMATION; ACTIVATION; MUTANT; BCL-2; CYCLE; GENE	The products of the p53 and CBP/p300 genes have been individually implicated in control of cell growth and regulation of transcription. p53 is known to act as a positive and negative regulator of gene expression. Here we show that p53, in both wild-type and mutant conformation, forms a specific protein complex with p300. However, in its wild-type but not mutant conformation, p53 inhibits a promoter containing the DNA-binding sequences for the transcription factor AP1, in a p300-dependent manner. p300 stimulates the transcriptional activity of p53 on p53-regulated promoters, and it enhances the responsiveness to a physiological upstream modulator of p53 function, ionizing radiation. A dominant negative form of p300 prevents transcriptional activation by p53, and it counteracts p53-mediated G1 arrest and apoptosis. The data implicate p300 as an important component of p53-signaling, thus providing new insight into the mechanisms of cellular proliferation.	NCI,PATHOL LAB,BETHESDA,MD 20892; NICHHD,LAB MOL GROWTH REGULAT,NIH,BETHESDA,MD 20892; NICHHD,SECT DNA REPLICAT REPAIR & MUTAGENESIS,NIH,BETHESDA,MD 20892; THOMAS JEFFERSON UNIV,SBARRO INST CANC RES & MOL MED,PHILADELPHIA,PA 19107	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Jefferson University			Ogryzko, Vasily/M-6665-2015; Giordano, Antonio/F-1927-2010	Ogryzko, Vasily/0000-0002-8548-1389; Giordano, Antonio/0000-0002-5959-016X				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Avantaggiati ML, 1996, EMBO J, V15, P2236, DOI 10.1002/j.1460-2075.1996.tb00577.x; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; CHEN KV, 1992, SCIENCE, V255, P459; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; Eckner R, 1996, MOL CELL BIOL, V16, P3454; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; FAN SJ, 1995, CANCER RES, V55, P1649; GIORDANO T, 1991, EXP CELL RES, V192, P193, DOI 10.1016/0014-4827(91)90175-T; HAFFNER R, 1995, CURR OPIN GENET DEV, V5, P84, DOI 10.1016/S0959-437X(95)90058-6; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; Janknecht R, 1996, CURR BIOL, V6, P951, DOI 10.1016/S0960-9822(02)00636-X; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lee JS, 1996, MOL CELL BIOL, V16, P4312; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lill NL, 1997, J VIROL, V71, P129, DOI 10.1128/JVI.71.1.129-137.1997; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; Muraoka M, 1996, ONCOGENE, V12, P1565; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; PURI L, 1997, EMBO J, V16, P369; SHEN YQ, 1994, P NATL ACAD SCI USA, V91, P8940, DOI 10.1073/pnas.91.19.8940; YACIUK P, 1991, MOL CELL BIOL, V11, P5389, DOI 10.1128/MCB.11.11.5389; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009	35	593	607	1	23	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 27	1997	89	7					1175	1184		10.1016/S0092-8674(00)80304-9	http://dx.doi.org/10.1016/S0092-8674(00)80304-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XG830	9215639	Bronze			2022-12-01	WOS:A1997XG83000021
J	AzaBlanc, P; RamirezWeber, FA; Laget, MP; Schwartz, C; Kornberg, TB				AzaBlanc, P; RamirezWeber, FA; Laget, MP; Schwartz, C; Kornberg, TB			Proteolysis that is inhibited by Hedgehog targets Cubitus interruptus protein to the nucleus and converts it to a repressor	CELL			English	Article							DROSOPHILA IMAGINAL DISKS; SIGNAL-TRANSDUCTION; KINASE-A; GENE-EXPRESSION; FUSED GENE; POLARITY; COMPARTMENTS; MELANOGASTER; PATTERN; ENCODES	Cell-cell communication at anterior/posterior compartment borders in Drosophila involves Hedgehog (Hh), a protein secreted by posterior cells, and Cubitus interruptus (Ci), a protein in the Hh response pathway in anterior cells. Although Ci is thought to have roles as a transcription factor repressing hh expression and activating target genes, it localizes in the cytoplasm of anterior cells. We report here the identification of a domain that tethers Ci in the cytoplasm and show that in some anterior cells, Ci is cleaved to generate a form that lacks the tethering domain. This form translocates to the nucleus where it represses hh and other target genes. Hh inhibits proteolysis of Ci, and we suggest that this inhibition leads to the observed patterns of expression of key target genes at the compartment border.			AzaBlanc, P (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.							Akimaru H, 1997, NATURE, V386, P735, DOI 10.1038/386735a0; Alcedo J, 1996, CELL, V86, P221, DOI 10.1016/S0092-8674(00)80094-X; Alexandre C, 1996, GENE DEV, V10, P2003, DOI 10.1101/gad.10.16.2003; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BRAND AH, 1993, DEVELOPMENT, V118, P401; CAPDEVILA J, 1994, EMBO J, V13, P71, DOI 10.1002/j.1460-2075.1994.tb06236.x; Chen Y, 1996, CELL, V87, P553, DOI 10.1016/S0092-8674(00)81374-4; CRICK FHC, 1975, SCIENCE, V189, P340, DOI 10.1126/science.806966; Dominguez M, 1996, SCIENCE, V272, P1621, DOI 10.1126/science.272.5268.1621; EATON S, 1990, GENE DEV, V4, P1068, DOI 10.1101/gad.4.6.1068; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FELSENFELD AL, 1995, DEVELOPMENT, V121, P1; Harlow E LD, 1988, ANTIBODIES LAB MANUA, V1st; HEBERLEIN U, 1995, CELL, V81, P987, DOI 10.1016/S0092-8674(05)80003-0; Hepker J, 1997, DEVELOPMENT, V124, P549; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; JIANG J, 1995, CELL, V80, P563, DOI 10.1016/0092-8674(95)90510-3; Johnson RL, 1995, DEVELOPMENT, V121, P4161; KALDERON D, 1988, GENE DEV, V2, P1539, DOI 10.1101/gad.2.12a.1539; KANG G, 1997, NAT GENET, V15, P266; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; KINZLER KW, 1987, SCIENCE, V236, P70, DOI 10.1126/science.3563490; LAWRENCE PA, 1976, DEV BIOL, V50, P321, DOI 10.1016/0012-1606(76)90155-X; LEPAGE T, 1995, NATURE, V373, P711, DOI 10.1038/373711a0; LI W, 1995, CELL, V80, P553, DOI 10.1016/0092-8674(95)90509-X; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; MOTZNY CK, 1995, MECH DEVELOP, V52, P137, DOI 10.1016/0925-4773(95)00397-J; ORENIC TV, 1990, GENE DEV, V4, P1053, DOI 10.1101/gad.4.6.1053; PAN DJ, 1995, CELL, V80, P543, DOI 10.1016/0092-8674(95)90508-1; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; PHAM A, 1995, GENETICS, V140, P587; PHILLIPS RG, 1990, DEVELOPMENT, V110, P105; PREAT T, 1990, NATURE, V347, P87, DOI 10.1038/347087a0; RAFTERY LA, 1991, DEVELOPMENT, V113, P27; Rizzuto R, 1996, CURR BIOL, V6, P183, DOI 10.1016/S0960-9822(02)00451-7; ROBBINS DJ, 1997, IN PRESS CELL; RUPPERT JM, 1990, MOL CELL BIOL, V10, P5408, DOI 10.1128/MCB.10.10.5408; SanchezHerrero E, 1996, MECH DEVELOP, V55, P159, DOI 10.1016/0925-4773(96)00498-4; SANICOLA M, 1995, GENETICS, V139, P754; SCHWARTZ C, 1995, DEVELOPMENT, V121, P1626; SISSON JC, 1997, IN PRESS CELL; SLUSARSKI DC, 1995, GENETICS, V139, P229; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; TABATA T, 1995, DEVELOPMENT, V121, P3359; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; THEROND P, 1993, MECH DEVELOP, V44, P65, DOI 10.1016/0925-4773(93)90017-R; Therond PP, 1996, P NATL ACAD SCI USA, V93, P4224, DOI 10.1073/pnas.93.9.4224; VANLEEUWEN F, 1994, NATURE, V368, P342, DOI 10.1038/368342a0; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; ZARKOWER D, 1992, CELL, V70, P237, DOI 10.1016/0092-8674(92)90099-X; ZECCA M, 1995, DEVELOPMENT, V121, P2265	53	537	554	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 27	1997	89	7					1043	1053		10.1016/S0092-8674(00)80292-5	http://dx.doi.org/10.1016/S0092-8674(00)80292-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XG830	9215627	Bronze			2022-12-01	WOS:A1997XG83000009
J	Gruer, L; Wilson, P; Scott, R; Elliott, L; Macleod, J; Harden, K; Forrester, E; Hinshelwood, S; McNulty, H; Silk, P				Gruer, L; Wilson, P; Scott, R; Elliott, L; Macleod, J; Harden, K; Forrester, E; Hinshelwood, S; McNulty, H; Silk, P			General practitioner centred scheme for treatment of opiate dependent drug injectors in Glasgow	BMJ-BRITISH MEDICAL JOURNAL			English	Article							METHADONE-MAINTENANCE; USERS		UNIV GLASGOW, DEPT GEN PRACTICE, WOODSIDE HLTH CTR, GLASGOW G20 7LR, LANARK, SCOTLAND; RUCHILL HOSP, PROBLEM SERV, GLASGOW G20 9NB, LANARK, SCOTLAND; UNIV DUNDEE, NINEWELLS HOSP, SCH NURSING & MIDWIFERY, DUNDEE DD1 9SY, SCOTLAND; LOCAL MED COMM, GLASGOW G4 9JT, LANARK, SCOTLAND; GLASGOW ROYAL INFIRM, PRESCRIBING ADVISERS DEPT, GLASGOW G4 0SF, LANARK, SCOTLAND; GREATER GLASGOW HLTH BOARD, GLASGOW G1 1ET, LANARK, SCOTLAND; GLASGOW CITY COUNCIL, DEPT SOCIAL WORK, COMMUNITY CARE SERV, GLASGOW G2 4PF, LANARK, SCOTLAND	University of Glasgow; University of Dundee; University of Glasgow	Gruer, L (corresponding author), RUCHILL HOSP, HIV & ADDICT RESOURCE CTR, GLASGOW G20 9NB, LANARK, SCOTLAND.		Wilson, Philip/V-6519-2019	Wilson, Philip/0000-0002-4123-8248; Gruer, Laurence/0000-0002-1089-2896				ABED RT, 1990, BRIT J ADDICT, V85, P131; *ADV COUNC MIS DRU, 1993, AIDS DRUG MIS UPD RE; Ball J. C., 1991, EFFECTIVENESS METHAD; Bell J, 1996, ADDICT RES, V3, P315, DOI 10.3109/16066359609005245; BURY J, 1995, INT J DRUG POLICY, V6, P267; Cairns A, 1996, BMJ-BRIT MED J, V313, P264, DOI 10.1136/bmj.313.7052.264; CLANZ A, 1986, BRIT MED J, V293, P543; COHEN J, 1992, BRIT MED J, V304, P1158, DOI 10.1136/bmj.304.6835.1158; DARKE S, 1992, BR J ADDICT, V87, P593; FARRELL M, 1994, BMJ-BRIT MED J, V309, P997, DOI 10.1136/bmj.309.6960.997; FRISCHER M, 1993, AM J EPIDEMIOL, V138, P170, DOI 10.1093/oxfordjournals.aje.a116843; FRISCHER M, 1993, J EPIDEMIOL COMMUN H, V47, P59, DOI 10.1136/jech.47.1.59; GREENWOOD J, 1992, BRIT J ADDICT, V87, P567; GREENWOOD J, 1990, BRIT MED J, V300, P587, DOI 10.1136/bmj.300.6724.587; GREENWOOD J, 1996, PSYCHIAT B, V20, P8; Gruer L, 1997, BRIT MED J, V314, P1691, DOI 10.1136/bmj.314.7095.1691; GRUER L, 1993, DRUG MISUSE HLTH GLA; *I STUD DRUG DEP, 1997, DRUG US BRIT 1996; MCLELLAN AT, 1993, JAMA-J AM MED ASSOC, V269, P1953, DOI 10.1001/jama.269.15.1953; *MIN DRUGS TASK FO, 1994, SCOTL M CHALL; PLATT JJ, 1995, HEROIN ADDICTION THE, V3; *SCOTT CTR INF ENV, 1995, HIV AIDS SURV SCOTL; SCOTT RA, 1994, BRIT MED J, V308, P1438, DOI 10.1136/bmj.308.6941.1438; SCOTT RTA, 1995, BMJ-BRIT MED J, V310, P464, DOI 10.1136/bmj.310.6977.464c; Strang J, 1996, BMJ-BRIT MED J, V313, P270, DOI 10.1136/bmj.313.7052.270; *TASK FORC REV SER, 1996, REP; WILSON P, 1994, BRIT MED J, V309, P641, DOI 10.1136/bmj.309.6955.641	27	61	62	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 14	1997	314	7096					1730	1735		10.1136/bmj.314.7096.1730	http://dx.doi.org/10.1136/bmj.314.7096.1730			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XE909	9202504	Green Published			2022-12-01	WOS:A1997XE90900026
J	Wedemayer, GJ; Patten, PA; Wang, LH; Schultz, PG; Stevens, RC				Wedemayer, GJ; Patten, PA; Wang, LH; Schultz, PG; Stevens, RC			Structural insights into the evolution of an antibody combining site	SCIENCE			English	Article							ESCHERICHIA-COLI; CATALYTIC ANTIBODIES; ANTIGEN INTERACTIONS; DIVERSITY; BINDING; RECOGNITION; GENERATION; EXPRESSION; FRAGMENTS; SEGMENTS	The crystal structures of a germline antibody Fab fragment and its complex with hapten have been solved at 2.1 Angstrom resolution. These structures are compared with the corresponding crystal structures of the affinity-matured antibody, 48G7, which has a 30,000 times higher affinity for hapten as a result of nine replacement somatic mutations. Significant changes in the configuration of the combining site occur upon binding of hapten to the germline antibody, whereas hapten binds to the mature antibody by a lock-and-key fit mechanism. The reorganization of the combining site that was nucleated by hapten binding is further optimized by somatic mutations that occur up to 15 Angstrom from bound hapten. These results suggest that the binding potential of the primary antibody repertoire may be significantly expanded by the ability of germline antibodies to adopt more than one combining-site configuration, with both antigen binding and somatic mutation stabilizing the configuration with optimal hapten complementarity.	UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720; UNIV CALIF LAWRENCE LIVERMORE NATL LAB,LIVERMORE,CA 94550; HOWARD HUGHES MED INST,SEATTLE,WA	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System; Howard Hughes Medical Institute			Stevens, Raymond/K-7272-2015	Stevens, Raymond/0000-0002-4522-8725	NIAID NIH HHS [R01 AI39089] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039089] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALFTHAN K, 1993, GENE, V128, P203, DOI 10.1016/0378-1119(93)90564-J; Breinl F., 1930, Z PHYSL CHEM, V192, P45; BRUNGER AT, 1996, XPLOR 3 8; BURLEY SK, 1985, SCIENCE, V229, P23, DOI 10.1126/science.3892686; BURNET FM, 1959, CLONAL SELECTION THE, P53; CARTER P, 1992, BIO-TECHNOL, V10, P163, DOI 10.1038/nbt0292-163; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; CHOTHIA C, 1992, J MOL BIOL, V227, P799, DOI 10.1016/0022-2836(92)90224-8; Crameri A, 1996, NAT BIOTECHNOL, V14, P315, DOI 10.1038/nbt0396-315; DAVIES DR, 1993, ACCOUNTS CHEM RES, V26, P421, DOI 10.1021/ar00032a005; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.biochem.59.1.439; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DOUGHERTY DA, 1990, SCIENCE, V250, P1558, DOI 10.1126/science.2274786; DUENAS M, 1995, GENE, V158, P61, DOI 10.1016/0378-1119(95)00077-J; Fisher E., 1894, BER DTSCH CHEM GES, V27, P2985, DOI [10.1002/cber.18940270364, DOI 10.1002/CBER.18940270364]; FOOTE J, 1994, P NATL ACAD SCI USA, V91, P10370, DOI 10.1073/pnas.91.22.10370; FOUGEREAU M, 1988, IMMUNOL REV, V105, P69, DOI 10.1111/j.1600-065X.1988.tb00766.x; FRENCH DL, 1989, SCIENCE, V244, P1152, DOI 10.1126/science.2658060; GHOSH S, 1986, IMMUNOL TODAY, V7, P217, DOI 10.1016/0167-5699(86)90108-8; HARTMAN AB, 1989, MOL IMMUNOL, V26, P359, DOI 10.1016/0161-5890(89)90125-9; HAUROWTIZ F, 1967, COLD SPRING HARB SYM, P559; HsiehWilson LC, 1996, P NATL ACAD SCI USA, V93, P5363, DOI 10.1073/pnas.93.11.5363; HSIEHWILSON LC, 1996, ACCOUNTS CHEM RES, V29, P391; HURLE MR, 1994, P NATL ACAD SCI USA, V91, P5446, DOI 10.1073/pnas.91.12.5446; JACOBS JW, 1989, THESIS U CALIFORNIA; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JONES TA, 1993, O COMPUTER GRAPHICS; KABAT EA, 1991, J IMMUNOL, V147, P1709; KOSHLAND DE, 1994, ANGEW CHEM INT EDIT, V33, P2375; Laskowski R. A., 1993, J APPL CRYSTALLOGR, V26, P282; LEDERBERG J, 1959, SCIENCE, V129, P1649, DOI 10.1126/science.129.3364.1649; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.immunol.12.1.117; MARIUZZA RA, 1993, CURR OPIN IMMUNOL, V5, P50, DOI 10.1016/0952-7915(93)90080-C; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OTWINOWSKI Z, UNPUB; Patten PA, 1996, SCIENCE, V271, P1086, DOI 10.1126/science.271.5252.1086; Pauling L, 1940, J AM CHEM SOC, V62, P2643, DOI 10.1021/ja01867a018; POLLACK SJ, 1986, SCIENCE, V234, P1570, DOI 10.1126/science.3787262; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; ROMESBERG FE, UNPUB; SCHULTZ PG, 1993, ACCOUNTS CHEM RES, V26, P391, DOI 10.1021/ar00032a001; SCHULTZ PG, 1995, SCIENCE, V269, P1835, DOI 10.1126/science.7569920; STANFIELD RL, 1993, STRUCTURE, V1, P83, DOI 10.1016/0969-2126(93)90024-B; Stevens RC, 1996, ISR J CHEM, V36, P121; STRONG RK, 1991, BIOCHEMISTRY-US, V30, P3749, DOI 10.1021/bi00229a023; TALMAGE DW, 1959, SCIENCE, V129, P1649; Tomlinson IM, 1996, J MOL BIOL, V256, P813, DOI 10.1006/jmbi.1996.0127; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; TRAMONTANO A, 1986, SCIENCE, V234, P1566, DOI 10.1126/science.3787261; ULRICH H, UNPUB; ULRICH HD, 1995, P NATL ACAD SCI USA, V92, P11907, DOI 10.1073/pnas.92.25.11907; WEBSTER DM, 1994, CURR OPIN STRUC BIOL, V4, P123, DOI 10.1016/S0959-440X(94)90070-1; Wedemayer GJ, 1997, J MOL BIOL, V268, P390, DOI 10.1006/jmbi.1997.0974; WILMOT CM, 1988, J MOL BIOL, V203, P221, DOI 10.1016/0022-2836(88)90103-9; WILSON IA, 1994, CURR OPIN STRUC BIOL, V4, P857, DOI 10.1016/0959-440X(94)90267-4; YASUI H, 1994, FEBS LETT, V353, P143, DOI 10.1016/0014-5793(94)01027-7	56	466	502	0	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 13	1997	276	5319					1665	1669		10.1126/science.276.5319.1665	http://dx.doi.org/10.1126/science.276.5319.1665			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XD947	9180069				2022-12-01	WOS:A1997XD94700032
J	Magid, DJ; Koepsell, TD; Every, NR; Martin, JS; Siscovick, DS; Wagner, EH; Weaver, WD				Magid, DJ; Koepsell, TD; Every, NR; Martin, JS; Siscovick, DS; Wagner, EH; Weaver, WD			Absence of association between insurance copayments and delays in seeking emergency care among patients with myocardial infarction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RANDOMIZED CONTROLLED TRIAL; MEDIA CAMPAIGN; THROMBOLYTIC THERAPY; HEALTH-INSURANCE; PUBLIC-EDUCATION; CHEST PAIN; TIMES; DEFIBRILLATION; SYMPTOMS	Background The requirement of copayments for emergency care is thought to control costs by reducing ''inappropriate'' visits to the emergency department. However, requiring copayments may lead to adverse outcomes if patients delay seeking care for emergency conditions. To determine whether such requirements are associated with delays in seeking care, we examined the length of time from the onset of symptoms to arrival at the hospital among patients with myocardial infarction who did or did not have required insurance copayments. Methods All patients were enrolled in a single health maintenance organization (HMO) and presented with myocardial infarction at 1 of 19 hospitals in King County, Washington, from 1989 through 1994. There were 602 patients whose health insurance required a copayment for emergency department care (range, $25 to $100) and 729 patients with no copayment requirement. Data on the time to presentation were obtained from a review of ambulance and hospital records. Results The median length of time from the onset of symptoms to arrival at the hospital, as adjusted for age, sex, and race, was 135 minutes for the copayment group and 137 minutes for the group with no copayment (95 percent confidence interval for the difference, -19 to +16 minutes). There was no significant association between the presence or absence of a copayment requirement and the time to arrival at the hospital after adjustment for calendar year, income, educational level, cardiac history, or clinical symptoms. Since some patients may be unaware of their copayment requirement, we performed a subgroup analysis of data on patients who had a previous visit to the emergency department with the same copayment status - that is, of patients who were likely to know about their copayment. This analysis also showed no significant association between the requirement for a copayment and delays in seeking treatment. Conclusions For privately insured patients in this HMO, the requirement of modest, fixed copayments for emergency services did not lead to delays in seeking treatment for myocardial infarction. (C) 1997, Massachusetts Medical Society.	UNIV COLORADO, HLTH SCI CTR, DEPT PREVENT MED & BIOMETR, DENVER, CO 80262 USA; UNIV COLORADO, HLTH SCI CTR, DIV EMERGENCY MED, DENVER, CO USA; UNIV WASHINGTON, ROBERT WOOD JOHNSON CLIN SCHOLARS PROGRAM, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT EPIDEMIOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT HLTH SERV, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT MED, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT CARDIOL, SEATTLE, WA 98195 USA; VET AFFAIRS MED CTR, NW HLTH SERV RES & DEV FIELD PROGRAM, SEATTLE, WA 98108 USA; GRP HLTH COOPERAT PUGET SOUND, CTR HLTH STUDIES, SEATTLE, WA 98101 USA; HENRY FORD HLTH SYST, DIV CARDIOVASC MED, DETROIT, MI USA; HENRY FORD HLTH SYST, INST HEART & VASC, DETROIT, MI USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); Group Health Cooperative; Henry Ford Health System; Henry Ford Hospital; Henry Ford Health System; Henry Ford Hospital	Magid, DJ (corresponding author), COLORADO PERMANENTE MED GRP, CLIN RES UNIT, 10350 E DAKOTA AVE, DENVER, CO 80231 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038454] Funding Source: NIH RePORTER; AHRQ HHS [HS0836] Funding Source: Medline; NHLBI NIH HHS [R01-HL38454] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1988, Lancet, V1, P545; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; BLOHM M, 1991, HEART LUNG, V20, P661; BROOK RH, 1983, NEW ENGL J MED, V309, P1426, DOI 10.1056/NEJM198312083092305; CHERKIN DC, 1992, SOC SCI MED, V34, P33, DOI 10.1016/0277-9536(92)90064-W; CHERKIN DC, 1989, MED CARE, V27, P1036, DOI 10.1097/00005650-198911000-00005; HERLITZ J, 1991, CARDIOLOGY, V79, P127, DOI 10.1159/000174870; HERLITZ J, 1989, AM J CARDIOL, V64, P90, DOI 10.1016/0002-9149(89)90659-0; HO MT, 1989, ANN EMERG MED, V18, P727, DOI 10.1016/S0196-0644(89)80004-6; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KOREN G, 1985, NEW ENGL J MED, V313, P1384, DOI 10.1056/NEJM198511283132204; LIBERTHSON RR, 1974, NEW ENGL J MED, V291, P317, DOI 10.1056/NEJM197408152910701; LOHR KN, 1986, MED CARE, V24, pUS1; MANNING WG, 1987, AM ECON REV, V77, P251; MITIC WR, 1984, CAN J PUBLIC HEALTH, V75, P414; MOSES HW, 1991, AM J CARDIOL, V68, P249, DOI 10.1016/0002-9149(91)90753-8; NEWHOUSE JP, 1981, NEW ENGL J MED, V305, P1501, DOI 10.1056/NEJM198112173052504; OGRADY KF, 1985, NEW ENGL J MED, V313, P484, DOI 10.1056/NEJM198508223130806; RASELL ME, 1995, NEW ENGL J MED, V332, P1164, DOI 10.1056/NEJM199504273321711; Selby JV, 1996, NEW ENGL J MED, V334, P635, DOI 10.1056/NEJM199603073341006; SHAPIRO MF, 1986, ANN INTERN MED, V104, P246, DOI 10.7326/0003-4819-104-2-246; SHEEHAN FH, 1987, J AM COLL CARDIOL, V9, P937, DOI 10.1016/S0735-1097(87)80252-8; SISCOVICK DS, 1993, ANN EMERG MED, V22, P92, DOI 10.1016/S0196-0644(05)80258-6; STULTS KR, 1984, NEW ENGL J MED, V310, P219, DOI 10.1056/NEJM198401263100403; WEAVER WD, 1990, J AM COLL CARDIOL, V15, P925, DOI 10.1016/0735-1097(90)90218-E; WEAVER WD, 1993, JAMA-J AM MED ASSOC, V270, P1211, DOI 10.1001/jama.270.10.1211; WILCOX RG, 1988, LANCET, V2, P525	28	45	46	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 12	1997	336	24					1722	1729		10.1056/NEJM199706123362406	http://dx.doi.org/10.1056/NEJM199706123362406			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XD543	9180090				2022-12-01	WOS:A1997XD54300006
J	Side, L; Taylor, B; Cayouette, M; Conner, E; Thomspon, P; Luce, M; Shannon, K				Side, L; Taylor, B; Cayouette, M; Conner, E; Thomspon, P; Luce, M; Shannon, K			Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TUMOR-SUPPRESSOR GENE; VONRECKLINGHAUSEN NEUROFIBROMATOSIS; MOLECULAR ANALYSIS; MUTATIONS; PROTEINS; RAS; DISEASE; IDENTIFICATION; RETINOBLASTOMA; NEUROBLASTOMA	Background The risk of malignant myeloid disorders in young children with neurofibromatosis type 1 is 200 to 500 times the normal risk. The gene for neurofibromatosis type 1 (NF1) encodes neurofibromin, a protein that negatively regulates signals transduced by Ras proteins. Genetic and biochemical data support the hypothesis that NF1 functions as a tumor-suppressor gene in immature myeloid cells, but inactivation of both NF1 alleles has not been demonstrated in leukemic cells from patients with neurofibromatosis type 1. Methods Using an in vitro transcription and translation system, we screened bone marrow samples from 18 children with neurofibromatosis type 1 and myeloid disorders for NF1 mutations that cause a truncated protein. Mutations were confirmed by direct sequencing of genomic DNA from the patients, and from their affected parents, in cases of familial neurofibromatosis type 1. Results Specimens from 9 of the 18 children contained abnormal peptide fragments, and truncating mutations of the NF1 gene were found in specimens from 8 of these children. The normal NF1 allele was absent in bone marrow samples from five of the eight children. We detected the same mutation in DNA from the affected parent of each child with familial neurofibromatosis type 1. Conclusions Both alleles of the NF1 gene are inactivated in leukemic cells in some patients with neurofibromatosis type 1. NF1 appears to function as a tumor-suppressor gene in immature myeloid. (C) 1997, Massachusetts Medical Society.	UNIV CALIF SAN FRANCISCO,DEPT PEDIAT,SAN FRANCISCO,CA 94143; ROCHE BIOMED LABS,RES TRIANGLE PK,NC	University of California System; University of California San Francisco			Side, Lucy/A-6990-2011		NATIONAL CANCER INSTITUTE [R01CA072614] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001271] Funding Source: NIH RePORTER; NCI NIH HHS [CA72614] Funding Source: Medline; NCRR NIH HHS [RR01271-13S1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ANDERSEN LB, 1993, MOL CELL BIOL, V13, P487, DOI 10.1128/MCB.13.1.487; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; Binnie CG, 1997, MUTAT RES-GEN TOX EN, V388, P21, DOI 10.1016/S1383-5718(96)00104-0; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Bollag G, 1996, NAT GENET, V12, P144, DOI 10.1038/ng0296-144; BOS JL, 1990, CANCER RES, V50, P1352; BOS JL, 1989, CANCER RES, V49, P4682; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRANNAN CI, 1994, GENE DEV, V8, P2792; BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019; CASTROMALASPINA H, 1984, CANCER, V54, P675, DOI 10.1002/1097-0142(1984)54:4<675::AID-CNCR2820540415>3.0.CO;2-Q; CHEN F, 1995, HUM MUTAT, V5, P66, DOI 10.1002/humu.1380050109; COLMAN SD, 1995, NAT GENET, V11, P90, DOI 10.1038/ng0995-90; CROSSEY PA, 1994, HUM MOL GENET, V3, P1303; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; DRYJA TP, 1993, AM J HUM GENET, V52, P1122; EASTON DF, 1993, AM J HUM GENET, V53, P305; Emanuel PD, 1996, MOL MED TODAY, V2, P468, DOI 10.1016/1357-4310(96)10044-7; FitzGerald MG, 1996, NEW ENGL J MED, V334, P143, DOI 10.1056/NEJM199601183340302; GADNER H, 1992, HEMATOL ONCOL CLIN N, V6, P655, DOI 10.1016/S0889-8588(18)30334-4; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; GLOVER TW, 1991, GENE CHROMOSOME CANC, V3, P62, DOI 10.1002/gcc.2870030111; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HEIM RA, 1994, NAT GENET, V8, P218, DOI 10.1038/ng1194-218; HEIM RA, 1995, HUM MOL GENET, V4, P975, DOI 10.1093/hmg/4.6.975; JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353; JENSEN S, 1995, CANCER, V76, P674, DOI 10.1002/1097-0142(19950815)76:4<674::AID-CNCR2820760421>3.0.CO;2-4; JOHNSON MR, 1993, P NATL ACAD SCI USA, V90, P5539, DOI 10.1073/pnas.90.12.5539; KALRA R, 1994, BLOOD, V84, P3435; KOHL NE, 1995, NAT MED, V1, P792, DOI 10.1038/nm0895-792; Largaespada DA, 1996, NAT GENET, V12, P137, DOI 10.1038/ng0296-137; LEGIUS E, 1993, NAT GENET, V3, P122, DOI 10.1038/ng0293-122; LI Y, 1995, GENOMICS, V25, P9, DOI 10.1016/0888-7543(95)80104-T; Maris JM, 1997, CANCER-AM CANCER SOC, V79, P1438, DOI 10.1002/(SICI)1097-0142(19970401)79:7<1438::AID-CNCR22>3.3.CO;2-A; MENON AG, 1990, P NATL ACAD SCI USA, V87, P5435, DOI 10.1073/pnas.87.14.5435; Miles DK, 1996, BLOOD, V88, P4314; PASSMORE SJ, 1995, BLOOD, V85, P1742, DOI 10.1182/blood.V85.7.1742.bloodjournal8571742; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; Purandare SM, 1995, GENOMICS, V30, P476, DOI 10.1006/geno.1995.1268; Riccardi VM., 1993, PLASTIC RECONST SURG, V91, P561, DOI [10.1097/00006534-199303000-00029, DOI 10.1097/00006534-199303000-00029]; Rodenhuis S, 1992, Semin Cancer Biol, V3, P241; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; Sawada S, 1996, NAT GENET, V14, P110, DOI 10.1038/ng0996-110; SHANNON KM, 1992, BLOOD, V79, P1311; SHANNON KM, 1994, NEW ENGL J MED, V330, P597, DOI 10.1056/NEJM199403033300903; SKUSE GR, 1989, GENE CHROMOSOME CANC, V1, P36, DOI 10.1002/gcc.2870010107; STILLER CA, 1994, BRIT J CANCER, V70, P969, DOI 10.1038/bjc.1994.431; THE I, 1993, NAT GENET, V3, P62, DOI 10.1038/ng0193-62; UPADHYAYA M, 1994, HUM MUTAT, V4, P83, DOI 10.1002/humu.1380040202; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; XU W, 1992, GENE CHROMOSOME CANC, V4, P337, DOI 10.1002/gcc.2870040411	53	212	213	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 12	1997	336	24					1713	1720		10.1056/NEJM199706123362404	http://dx.doi.org/10.1056/NEJM199706123362404			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD543	9180088				2022-12-01	WOS:A1997XD54300004
J	Torchia, J; Rose, DW; Inostroza, J; Kamei, Y; Westin, S; Glass, CK; Rosenfeld, MG				Torchia, J; Rose, DW; Inostroza, J; Kamei, Y; Westin, S; Glass, CK; Rosenfeld, MG			The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function	NATURE			English	Article							THYROID-HORMONE RECEPTOR; RETINOIC ACID; ESTROGEN-RECEPTOR; CRYSTAL-STRUCTURE; DOMAIN; COACTIVATOR; PROTEINS; AF-2	The functionally conserved proteins CBP and p300 act in conjunction with other factors to activate transcription of DNA. A new factor, p/CIP, has been discovered that is present in the cell as a complex with CEP and is required for transcriptional activity of nuclear receptors and other CBP/p300-dependent transcription factors. The highly related nuclear-receptor co-activator protein NCoA-1 is also specifically required for ligand-dependent activation of genes by nuclear receptors, p/CIP, NCoA-1 and CBP all contain related leucine-rich charged helical interaction motifs that ape required for receptor-specific mechanisms of gene activation, and allow the selective inhibition of distinct signal-transduction pathways.	UNIV CALIF SAN DIEGO, HOWARD HUGHES MED INST, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, WHITTIER DIABET PROGRAM, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, CELLULAR & MOL MED SCH, LA JOLLA, CA 92093 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego			Glass, Christopher/AAI-3933-2021	Glass, Christopher/0000-0003-4344-3592				ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; AUSUBEL EM, 1994, CURRENT PROTOCOLS MO; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Bisotto S, 1996, J BIOL CHEM, V271, P17746, DOI 10.1074/jbc.271.30.17746; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; GEOURJON C, 1994, PROTEIN ENG, V7, P157, DOI 10.1093/protein/7.2.157; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; KAMEI Y, 1996, CELL, V85, P1; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; Nakajima T, 1997, GENE DEV, V11, P738, DOI 10.1101/gad.11.6.738; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Oliner JD, 1996, GENE DEV, V10, P2903, DOI 10.1101/gad.10.22.2903; ONATE SA, 1995, SCIENCE, V270, P1354; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; ROSE DW, 1992, J CELL BIOL, V119, P1405, DOI 10.1083/jcb.119.6.1405; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Swope DL, 1996, J BIOL CHEM, V271, P28138, DOI 10.1074/jbc.271.45.28138; TONE Y, 1994, J BIOL CHEM, V269, P31157; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092	46	1092	1132	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 12	1997	387	6634					677	684		10.1038/42652	http://dx.doi.org/10.1038/42652			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XD869	9192892	Bronze			2022-12-01	WOS:A1997XD86900045
J	Batavia, AI				Batavia, AI			Disability and physician-assisted suicide	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CARE				Batavia, AI (corresponding author), MCDERMOTT WILL & EMERY,MIAMI,FL 33131, USA.							Angell M, 1996, NEW ENGL J MED, V335, P1676, DOI 10.1056/NEJM199611283352209; BATAVIA AI, 1991, J HEALTH POLIT POLIC, V16, P523, DOI 10.1215/03616878-16-3-523; BATAVIA AI, 1993, HEALTH AFFAIR, V12, P40, DOI 10.1377/hlthaff.12.1.40; BATAVIA AI, 1990, M HLTH CARE NEEDS PH; BOWE F, 1980, REHABILITATING AM; Breitbart W, 1996, AM J PSYCHIAT, V153, P238; CORBET B, 1997, NEW MOBILITY     APR, P48; DEJONG G, 1979, ARCH PHYS MED REHAB, V60, P435; Gallagher H.G., 1995, TRUST BETRAYED PATIE; NAGLER M, 1993, PERSPECTIVES DISABIL; *NAT COUNC HAND, 1986, THRESH IND; PFLUEGER SS, 1977, INDEPENDENT LIVING; TINDALL B, 1993, J ACQ IMMUN DEF SYND, V6, P1069; vanderWal G, 1996, NEW ENGL J MED, V335, P1706; VNADERMAAS PJ, 1996, NEW ENGL J MED, V335, P1699; WEST J, 1991, AM DISABILITES ACT P	16	19	20	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 5	1997	336	23					1671	1673		10.1056/NEJM199706053362310	http://dx.doi.org/10.1056/NEJM199706053362310			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XC086	9171072				2022-12-01	WOS:A1997XC08600010
J	Taylor, SS; McKeon, F				Taylor, SS; McKeon, F			Kinetochore localization of murine Bub1 is required for normal mitotic timing and checkpoint response to spindle damage	CELL			English	Article							CELL-CYCLE CHECKPOINTS; SACCHAROMYCES-CEREVISIAE; MAMMALIAN-CELLS; PROTEIN-KINASE; BUDDING YEAST; ANAPHASE; MITOSIS; PHOSPHOEPITOPE; PROGRESSION; EXPRESSION	The mitotic checkpoint ensures proper chromosome segregation by delaying anaphase until chromosomes are aligned on the spindle. Following prolonged spindle damage, however, cells eventually exit mitosis and undergo apoptosis. We show here that a murine homolog of the yeast mitotic checkpoint gene BUB1 localizes to the kinetochore during mitosis. By expressing a dominant-negative mutant, we show that mBub1 is not only required for the checkpoint response to spindle damage, but acts in the timing of a normal mitosis. In addition, when mBub1 function is compromised, cells escape apoptosis and continue cell cycle progression, despite leaving mitosis with a disrupted spindle. These data demonstrate a role for kinetochore-associated mBub1 in regulating exit from mitosis, and suggest functional links between the mitotic checkpoint and subsequent apoptotic events in G1.	HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School			Taylor, Stephen/GZL-6499-2022; Pillay, Nischalan/F-9536-2012	Taylor, Stephen/0000-0003-4621-9326	NIGMS NIH HHS [GM52027] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANDREASSEN PR, 1994, J CELL BIOL, V127, P789, DOI 10.1083/jcb.127.3.789; CAMPBELL MS, 1995, J CELL BIOL, V129, P1195, DOI 10.1083/jcb.129.5.1195; Chen RH, 1996, SCIENCE, V274, P242, DOI 10.1126/science.274.5285.242; DAVIS FM, 1983, P NATL ACAD SCI USA, V80, P2962; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; GORBSKY GJ, 1995, TRENDS CELL BIOL, V5, P143, DOI 10.1016/S0962-8924(00)88968-0; GORBSKY GJ, 1993, J CELL BIOL, V122, P1311, DOI 10.1083/jcb.122.6.1311; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HARDWICK KG, 1995, J CELL BIOL, V131, P709, DOI 10.1083/jcb.131.3.709; Hardwick KG, 1996, SCIENCE, V273, P953, DOI 10.1126/science.273.5277.953; Harlow E LD, 1988, ANTIBODIES LAB MANUA, V1st; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; IMIGER S, 1995, CELL, V81, P269; KERR SM, 1994, MAMM GENOME, V5, P557, DOI 10.1007/BF00354930; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; KUNG AL, 1990, P NATL ACAD SCI USA, V87, P9553, DOI 10.1073/pnas.87.24.9553; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; LI XT, 1995, NATURE, V373, P630, DOI 10.1038/373630a0; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; MCINTOSH JR, 1991, COLD SH Q B, V56, P613; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; Minshull J, 1996, CURR BIOL, V6, P1609, DOI 10.1016/S0960-9822(02)70784-7; MOROI Y, 1980, P NATL ACAD SCI-BIOL, V77, P1627, DOI 10.1073/pnas.77.3.1627; MURRAY A, 1994, CURR OPIN CELL BIOL, V6, P872, DOI 10.1016/0955-0674(94)90059-0; MURRAY AW, 1995, CURR OPIN GENET DEV, V5, P5, DOI 10.1016/S0959-437X(95)90046-2; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; NICKLAS RB, 1995, J CELL BIOL, V130, P929, DOI 10.1083/jcb.130.4.929; Nicklas RB, 1997, SCIENCE, V275, P632, DOI 10.1126/science.275.5300.632; Pangilinan F, 1996, MOL BIOL CELL, V7, P1195, DOI 10.1091/mbc.7.8.1195; RIEDER CL, 1994, J CELL BIOL, V127, P1301, DOI 10.1083/jcb.127.5.1301; RIEDER CL, 1995, J CELL BIOL, V130, P941, DOI 10.1083/jcb.130.4.941; ROBERTS BT, 1994, MOL CELL BIOL, V14, P8282, DOI 10.1128/MCB.14.12.8282; Rudner AD, 1996, CURR OPIN CELL BIOL, V8, P773, DOI 10.1016/S0955-0674(96)80077-9; Sambrook J., 1989, MOL CLONING LAB MANU, V3; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4; Wang YC, 1997, MOL CELL BIOL, V17, P620, DOI 10.1128/MCB.17.2.620; WANG YC, 1995, MOL CELL BIOL, V15, P6838; Weiss E, 1996, J CELL BIOL, V132, P111, DOI 10.1083/jcb.132.1.111; Wells WAE, 1996, J CELL BIOL, V133, P75, DOI 10.1083/jcb.133.1.75; Wells WAE, 1996, TRENDS CELL BIOL, V6, P228, DOI 10.1016/0962-8924(96)10018-0; Zachariae W, 1996, MOL BIOL CELL, V7, P791, DOI 10.1091/mbc.7.5.791	48	482	499	0	9	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 30	1997	89	5					727	735		10.1016/S0092-8674(00)80255-X	http://dx.doi.org/10.1016/S0092-8674(00)80255-X			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XB925	9182760	Bronze			2022-12-01	WOS:A1997XB92500009
J	Philippsen, P; Kleine, K; Pohlmann, R; Dusterhoft, A; Hamberg, K; Hegemann, JH; Obermaier, B; Urrestarazu, LA; Aert, R; Albermann, K; Altmann, R; Andre, B; Baladron, V; Ballesta, JPG; Becam, AM; Beinhauer, J; Boskovic, J; Buitrago, MJ; Bussereau, F; Coster, F; Crouzet, M; DAngelo, M; DalPero, F; DeAntoni, A; DelRey, F; Doignon, F; Domdey, H; Dubois, E; Fiedler, T; Fleig, U; Floeth, M; Fritz, C; Gaillardin, C; GarciaCantalejo, JM; Glansdorff, NN; Goffeau, A; Gueldener, U; Herbert, C; Heumann, K; HeussNeitzel, D; Hilbert, H; Hinni, K; Houssaini, II; Jacquet, M; Jimenez, A; Jonniaux, JL; Karpfinger, L; Lanfranchi, G; Lepingle, A; Levesque, H; Lyck, R; Maftahi, M; Mallet, L; Maurer, KCT; Messenguy, F; Mewes, HW; Mostl, D; Nasr, F; Nicaud, JM; Niedenthal, RK; Pandolfo, D; Pierard, A; Piravandi, E; Planta, RJ; Pohl, TM; Purnelle, B; Rebischung, C; Remacha, M; Revuelta, JL; Rinke, M; Saiz, JE; Sartorello, F; Scherens, B; SenGupta, M; SolerMira, A; Urbanus, JHM; Valle, G; VanDyck, L; Verhasselt, P; Vierendeels, F; Vissers, S; Voet, M; Volckaert, G; Wach, A; Wambutt, R; Wedler, H; Zollner, A; Hani, J				Philippsen, P; Kleine, K; Pohlmann, R; Dusterhoft, A; Hamberg, K; Hegemann, JH; Obermaier, B; Urrestarazu, LA; Aert, R; Albermann, K; Altmann, R; Andre, B; Baladron, V; Ballesta, JPG; Becam, AM; Beinhauer, J; Boskovic, J; Buitrago, MJ; Bussereau, F; Coster, F; Crouzet, M; DAngelo, M; DalPero, F; DeAntoni, A; DelRey, F; Doignon, F; Domdey, H; Dubois, E; Fiedler, T; Fleig, U; Floeth, M; Fritz, C; Gaillardin, C; GarciaCantalejo, JM; Glansdorff, NN; Goffeau, A; Gueldener, U; Herbert, C; Heumann, K; HeussNeitzel, D; Hilbert, H; Hinni, K; Houssaini, II; Jacquet, M; Jimenez, A; Jonniaux, JL; Karpfinger, L; Lanfranchi, G; Lepingle, A; Levesque, H; Lyck, R; Maftahi, M; Mallet, L; Maurer, KCT; Messenguy, F; Mewes, HW; Mostl, D; Nasr, F; Nicaud, JM; Niedenthal, RK; Pandolfo, D; Pierard, A; Piravandi, E; Planta, RJ; Pohl, TM; Purnelle, B; Rebischung, C; Remacha, M; Revuelta, JL; Rinke, M; Saiz, JE; Sartorello, F; Scherens, B; SenGupta, M; SolerMira, A; Urbanus, JHM; Valle, G; VanDyck, L; Verhasselt, P; Vierendeels, F; Vissers, S; Voet, M; Volckaert, G; Wach, A; Wambutt, R; Wedler, H; Zollner, A; Hani, J			The nucleotide sequence of Saccharomyces cerevisiae chromosome XIV and its evolutionary implications	NATURE			English	Article							OPEN READING FRAMES; KB DNA SEGMENT; LEFT ARM; PHYSICAL MAPS; YEAST; GENE; PROTEIN; FRAGMENT; HOMOLOG; CENTROMERE	In 1992 we started assembling an ordered library of cosmid clones from chromosome XIV of the yeast Saccharomyces cerevisiae. At that time, only 49 genes were known to be located on this chromosome(1) and we estimated that 80% to 90% of its genes were yet to be discovered. In 1993, a team of 20 European laboratories began the systematic sequence analysis of chromosome XIV. The completed and intensively checked final sequence of 784,328 base pairs was released in April, 1996 (ref. 2), Substantial parts had been published before(3-22) or had previously been made available on request. The sequence contained 419 known or presumptive protein-coding genes, including two pseudogenes and three retrotransposons, 14 tRNA genes, and three small nuclear RNA genes. For 116 (30%) protein-coding sequences, one or more structural homologues were identified elsewhere in the yeast genome. Half of them belong to duplicated groups of 6-14 loosely linked genes, in most cases with conserved gene order and orientation (relaxed interchromosomal synteny). We have considered the possible evolutionary origins of this unexpected feature of yeast genome organization.	UNIV GIESSEN, INST MIKRO & MOL BIOL, D-35392 GIESSEN, GERMANY; MAX PLANCK INST BIOCHEM, MARTINSRIEDER INST PROT SEQUENZEN, D-82152 MARTINSRIED, GERMANY; QIAGEN GMBH, D-40724 HILDEN, GERMANY; LMU MUNCHEN, GENZENTRUM, MOL BIOL LAB, D-811377 MUNICH, GERMANY; MEDIGENE GMBH, D-82152 MARTINSRIED, GERMANY; FREE UNIV BRUSSELS, B-1050 BRUSSELS, BELGIUM; KATHOLIEKE UNIV LEUVEN, LAB GENE TECHNOL, B-3001 LOUVAIN, BELGIUM; UNIV SALAMANCA, DEPT GENET & MICROBIOL, E-37007 SALAMANCA, SPAIN; CSIC, CTR BIOL MOL, E-28049 MADRID, SPAIN; UNIV AUTONOMA MADRID, E-28049 MADRID, SPAIN; UNIV PARIS 06, CTR GENET MOL, CNRS LAB, F-91198 GIF SUR YVETTE, FRANCE; UNIV PARIS 11, INST GENET & MICROBIOL, LAB INFORMAT GENET & DEV, F-91405 ORSAY, FRANCE; UNIV CATHOLIQUE LOUVAIN, UNITE BIOCHIM PHYSIOL, B-1348 LOUVAIN, BELGIUM; UNIV BORDEAUX 2, LBMS, CNR, UPR 9026, F-33076 BORDEAUX, FRANCE; UNIV PADUA, DEPT BIOL, CRIBI BIOTECHNOL CTR, I-35121 PADUA, ITALY; CERIA COOVI, B-1070 BRUSSELS, BELGIUM; INST NATL AGRON PARIS GRIGNON, LAB GENET MOL & CELLULAIRE, CTR BIOTECHNOL AGROIND, F-78850 THIVERVAL GRIGNON, FRANCE; VRIJE UNIV AMSTERDAM, BIOCENTRUM AMSTERDAM, IMBW, DEPT BIOCHEM & MOL BIOL, NL-1081 HV AMSTERDAM, NETHERLANDS; GATC GESELL ANAL TECH & CONSULTING MBH, D-78467 CONSTANCE, GERMANY; AGON GMBH, D-12489 BERLIN, GERMANY	Justus Liebig University Giessen; Max Planck Society; QIAGEN GmbH; University of Munich; Universite Libre de Bruxelles; Vrije Universiteit Brussel; KU Leuven; University of Salamanca; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Autonomous University of Madrid; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay; Universite Catholique Louvain; UDICE-French Research Universities; Universite de Bordeaux; University of Padua; AgroParisTech; University of Amsterdam; Vrije Universiteit Amsterdam	Philippsen, P (corresponding author), UNIV BASEL, BIOZENTRUM, INST APPL MICROBIOL, KLINGELBERGSTR 70, CH-4056 BASEL, SWITZERLAND.		NICAUD, Jean-marc/ABA-9076-2021; Güldener, Ulrich/G-5227-2012; Baladron, Victoriano/L-1758-2014; boskovic, jasminka/L-5117-2018; André, Bruno/D-1725-2010; Nicaud, jean marc/G-4204-2016; del Rey, Francisco/L-7132-2014; Remacha, Miguel/G-1250-2016; DOIGNON, François/AAX-8788-2020; Revuelta, Jose Luis/ABG-1502-2020; Revuelta, Jose L/C-2324-2012; Mewes, Hans-Werner/A-8204-2019	Güldener, Ulrich/0000-0001-5052-8610; Baladron, Victoriano/0000-0003-4574-8760; boskovic, jasminka/0000-0001-6135-0686; Nicaud, jean marc/0000-0002-6679-972X; del Rey, Francisco/0000-0002-6517-7400; DOIGNON, François/0000-0002-9007-2408; Revuelta, Jose Luis/0000-0001-7838-5308; Revuelta, Jose L/0000-0001-7838-5308; Buitrago, Maria Jose/0000-0003-1878-6067; De Antoni, Anna/0000-0003-4908-1684; Mewes, Hans-Werner/0000-0002-9713-6398; Lyck, Ruth/0000-0002-6479-4837; VALLE, GIORGIO/0000-0003-4377-5685; Garcia-Cantalejo, Jesus/0000-0001-6465-1273				BERGEZ P, 1995, YEAST, V11, P967, DOI 10.1002/yea.320111008; CHAN CSM, 1983, CELL, V33, P563, DOI 10.1016/0092-8674(83)90437-3; COSTER F, 1995, YEAST, V11, P85, DOI 10.1002/yea.320110111; Friedman KL, 1996, GENE DEV, V10, P1595, DOI 10.1101/gad.10.13.1595; Garcia-Cantalejo Jesus Manuel, 1996, Yeast, V12, P599, DOI 10.1002/(SICI)1097-0061(199605)12:6<599::AID-YEA938>3.0.CO;2-9; Garrels JI, 1996, NUCLEIC ACIDS RES, V24, P46, DOI 10.1093/nar/24.1.46; HAMBERG K, 1993, THESIS U GIESSEN; JOHNSTON M, 1994, SCIENCE, V265, P2077, DOI 10.1126/science.8091229; JONNIAUX JL, 1994, YEAST, V10, P1639, DOI 10.1002/yea.320101213; KALOGEROPOULOS A, 1995, YEAST, V11, P555, DOI 10.1002/yea.320110605; KICK CT, 1995, YEAST, V11, P1303; LALO D, 1993, CR ACAD SCI III-VIE, V316, P367; Levesque H, 1996, YEAST, V12, P289, DOI 10.1002/(SICI)1097-0061(19960315)12:3<289::AID-YEA909>3.0.CO;2-M; LOGGHE M, 1994, YEAST, V10, P1093, DOI 10.1002/yea.320100811; LOUIS EJ, 1995, GENETICS, V139, P125; Louis EJ, 1995, YEAST, V11, P1553, DOI 10.1002/yea.320111604; MAFTAHI M, 1995, YEAST, V11, P1077, DOI 10.1002/yea.320111109; MAFTAHI M, 1995, YEAST, V11, P567, DOI 10.1002/yea.320110606; MALLET L, 1995, YEAST, V11, P1195, DOI 10.1002/yea.320111210; MAURER KCT, 1995, YEAST, V11, P1303, DOI 10.1002/yea.320111311; MELNICK L, 1993, J MOL BIOL, V233, P372, DOI 10.1006/jmbi.1993.1518; MORTIMER RK, 1992, YEAST, V8, P817, DOI 10.1002/yea.320081002; NASR E, 1996, YEAST, V12, P169; Nasr F, 1996, YEAST, V12, P493, DOI 10.1002/(SICI)1097-0061(199604)12:5<493::AID-YEA929>3.0.CO;2-W; Pandolfo D, 1996, YEAST, V12, P1071; Pohlmann R, 1996, YEAST, V12, P391; POHLMANN R, 1995, YEAST, V11, P634; RILES L, 1993, GENETICS, V134, P81; RODRIGUEZMEDINA JR, 1994, MOL GEN GENET, V243, P532, DOI 10.1007/BF00284201; Saiz JE, 1996, YEAST, V12, P403, DOI 10.1002/(SICI)1097-0061(19960330)12:4<403::AID-YEA923>3.0.CO;2-H; SenGupta M, 1996, YEAST, V12, P505, DOI 10.1002/(SICI)1097-0061(199604)12:5<505::AID-YEA932>3.0.CO;2-F; SolerMira A, 1996, YEAST, V12, P485, DOI 10.1002/(SICI)1097-0061(199604)12:5<485::AID-YEA928>3.0.CO;2-U; STEENSMA HY, 1989, CURR GENET, V16, P131; STOLER S, 1995, GENE DEV, V9, P573, DOI 10.1101/gad.9.5.573; STUCKA R, 1994, MOL GENETICS YEAST P, P49; THIERRY A, 1995, YEAST, V11, P121, DOI 10.1002/yea.320110204; TUGENDREICH S, 1994, HUM MOL GENET, V3, P1509, DOI 10.1093/hmg/3.suppl_1.1509; TUGENDREICH S, 1993, P NATL ACAD SCI USA, V90, P10031, DOI 10.1073/pnas.90.21.10031; VANDYCK L, 1995, YEAST, V11, P987, DOI 10.1002/yea.320111010; VERHASSELT P, 1994, YEAST, V10, P1355, DOI 10.1002/yea.320101013; VERHASSELT P, 1994, YEAST, V10, P945, DOI 10.1002/yea.320100709; VOLLRATH D, 1988, P NATL ACAD SCI USA, V85, P6027, DOI 10.1073/pnas.85.16.6027; WOLFE KH, 1994, YEAST, V10, P41	43	54	501	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 29	1997	387	6632		S			93	98		10.1038/387s093	http://dx.doi.org/10.1038/387s093			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XB546	9169873				2022-12-01	WOS:A1997XB54600013
J	Splawski, I; Timothy, KW; Vincent, GM; Atkinson, DL; Keating, MT				Splawski, I; Timothy, KW; Vincent, GM; Atkinson, DL; Keating, MT			Molecular basis of the long-QT syndrome associated with deafness	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INHERITED CARDIAC-ARRHYTHMIA; LINKAGE ANALYSIS; MUTATIONS; GENE; CHILD		UNIV UTAH, HOWARD HUGHES MED INST, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, ECCLES INST HUMAN GENET, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, DIV CARDIOL, SALT LAKE CITY, UT 84112 USA; LATTER DAY ST HOSP, DEPT MED, SALT LAKE CITY, UT 84143 USA	Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000064] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL053773] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR00064] Funding Source: Medline; NHLBI NIH HHS [R01 HL48074, HL53773] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; FRASER GR, 1964, Q J MED, V33, P361; Friedmann I, 1966, J Laryngol Otol, V80, P451, DOI 10.1017/S002221510006552X; HOLLAND JJ, 1993, ANAESTHESIA, V48, P149; JEFFERY S, 1992, LANCET, V339, P255, DOI 10.1016/0140-6736(92)90071-A; JERVELL A, 1966, AM HEART J, V72, P582, DOI 10.1016/0002-8703(66)90340-1; JERVELL A, 1957, AM HEART J, V54, P59, DOI 10.1016/0002-8703(57)90079-0; JIANG CA, 1994, NAT GENET, V8, P141, DOI 10.1038/ng1094-141; KEATING M, 1991, AM J HUM GENET, V49, P1335; KEATING M, 1992, CIRCULATION, V85, P1973, DOI 10.1161/01.CIR.85.6.1973; KEATING M, 1991, SCIENCE, V252, P704, DOI 10.1126/science.1673802; LATHROP GM, 1985, AM J HUM GENET, V37, P482; MOSS AJ, 1991, CIRCULATION, V84, P1136, DOI 10.1161/01.CIR.84.3.1136; MOSS AJ, 1985, CIRCULATION, V71, P17, DOI 10.1161/01.CIR.71.1.17; Neyroud N, 1997, NAT GENET, V15, P186, DOI 10.1038/ng0297-186; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; ROMANO C, 1963, Clin Pediatr (Bologna), V45, P656; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; SCHOTT JJ, 1995, AM J HUM GENET, V57, P1114; Tesson F, 1996, J MOL CELL CARDIOL, V28, P2051, DOI 10.1006/jmcc.1996.0198; TILL JA, 1988, AM J CARDIOL, V62, P1319, DOI 10.1016/0002-9149(88)90289-5; Vetter DE, 1996, NEURON, V17, P1251, DOI 10.1016/S0896-6273(00)80255-X; VINCENT GM, 1992, NEW ENGL J MED, V327, P846, DOI 10.1056/NEJM199209173271204; WANG Q, 1995, CELL, V80, P805, DOI 10.1016/0092-8674(95)90359-3; WANG Q, 1995, HUM MOL GENET, V4, P1603, DOI 10.1093/hmg/4.9.1603; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17; WARD O C, 1964, J Ir Med Assoc, V54, P103	28	230	239	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 29	1997	336	22					1562	1567		10.1056/NEJM199705293362204	http://dx.doi.org/10.1056/NEJM199705293362204			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XB087	9164812				2022-12-01	WOS:A1997XB08700004
J	Porkka-Heiskanen, T; Strecker, RE; Thakkar, M; Bjorkum, AA; Greene, RW; McCarley, RW				Porkka-Heiskanen, T; Strecker, RE; Thakkar, M; Bjorkum, AA; Greene, RW; McCarley, RW			Adenosine: A mediator of the sleep-inducing effects of prolonged wakefulness	SCIENCE			English	Article							ENDOGENOUS ADENOSINE; CEREBRAL-CORTEX; RAT-BRAIN; CAFFEINE; INHIBITION; METABOLISM; EEG; DERIVATIVES; ALERTNESS; NEURONS	Both subjective and electroencephalographic arousal diminish as a function of the duration of prior wakefulness. Data reported here suggest that the major criteria for a neural sleep factor mediating the somnogenic effects of prolonged wakefulness are satisfied by adenosine, a neuromodulator whose extracellular concentration increases with brain metabolism and which, in vitro, inhibits basal forebrain cholinergic neurons. In vivo microdialysis measurements in freely behaving cats showed that adenosine extracellular concentrations in the basal forebrain cholinergic region increased during spontaneous wakefulness as contrasted with slow wave sleep; exhibited progressive increases during sustained, prolonged wakefulness; and declined slowly during recovery sleep. Furthermore, the sleep-wakefulness profile occurring after prolonged wakefulness was mimicked by increased extracellular adenosine induced by microdialysis perfusion of an adenosine transport inhibitor in the cholinergic basal forebrain but not by perfusion in a control noncholinergic region.	HARVARD UNIV, SCH MED, DEPT PSYCHIAT, VAMC, BROCKTON, MA 02401 USA; UNIV HELSINKI, INST BIOMED, HELSINKI, FINLAND	Harvard University; University of Helsinki			Shenton, Martha/V-8780-2019; McCarley, Robert W/N-5562-2014	McCarley, Robert W/0000-0001-5705-7495; Thakkar, Mahesh/0000-0001-6876-9850	NIMH NIH HHS [R37 MH39,683, R01 MH039683] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH039683, R01MH039683] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BENINGTON JH, 1995, PROG NEUROBIOL, V45, P347, DOI 10.1016/0301-0082(94)00057-O; Berman AL, 1982, THALAMUS BASAL TELEN; BERNE M, 1982, CEREBRAL HYPOXIA PAT, P82; Borbely A A, 1982, Hum Neurobiol, V1, P195; Brundege JM, 1996, J NEUROSCI, V16, P5603; CRAIG CG, 1993, J NEUROCHEM, V60, P1073, DOI 10.1111/j.1471-4159.1993.tb03256.x; CRAIG CG, 1992, J PHARMACOL EXP THER, V260, P1278; DESANCHEZ VC, 1993, BRAIN RES, V612, P115, DOI 10.1016/0006-8993(93)91651-8; DUNWIDDIE TV, 1981, N-S ARCH PHARMACOL, V316, P326, DOI 10.1007/BF00501365; FEINBERG I, 1985, ELECTROEN CLIN NEURO, V61, P134, DOI 10.1016/0013-4694(85)91051-X; FINDLEY LJ, 1988, J APPL PHYSIOL, V64, P556, DOI 10.1152/jappl.1988.64.2.556; GEREAU RW, 1994, NEURON, V12, P1121, DOI 10.1016/0896-6273(94)90319-0; GREENE RW, 1985, BRIT J PHARMACOL, V85, P163, DOI 10.1111/j.1476-5381.1985.tb08843.x; GU JG, 1992, J NEUROCHEM, V58, P1699, DOI 10.1111/j.1471-4159.1992.tb10043.x; HAAS HL, 1988, N-S ARCH PHARMACOL, V337, P561; HAAS HL, 1987, NEUR ABSTR, V13, P155; Huston JP, 1996, NEUROSCIENCE, V73, P99, DOI 10.1016/0306-4522(96)00021-8; JONES BE, 1993, PROG BRAIN RES, V98, P61; KRUEGER JM, IN PRESS SLEEP SLEEP; LANDOLT HP, 1995, NEUROPSYCHOPHARMACOL, V12, P229, DOI 10.1038/sj.npp.1380255; MADSEN PL, 1991, J APPL PHYSIOL, V70, P2597, DOI 10.1152/jappl.1991.70.6.2597; MAQUET P, 1992, BRAIN RES, V571, P149, DOI 10.1016/0006-8993(92)90522-B; MCILWAIN H, 1985, NEUROCHEM INT, V7, P103, DOI 10.1016/0197-0186(85)90014-2; PADUA R, 1990, J NEUROCHEM, V54, P1169, DOI 10.1111/j.1471-4159.1990.tb01945.x; PENETAR D, 1993, PSYCHOPHARMACOLOGY, V112, P359, DOI 10.1007/BF02244933; PORTAS CM, IN PRESS NEUROSCIENC; PULL I, 1972, BIOCHEM J, V126, P965, DOI 10.1042/bj1260965; RADULOVACKI M, 1985, Reviews in Clinical and Basic Pharmacology, V5, P327; RAINNIE DG, 1994, SCIENCE, V263, P689, DOI 10.1126/science.8303279; ROSENBERG PA, 1994, J NEUROSCI, V14, P2953; SANDERSON G, 1996, PFLUEGERS ARCH EUR J, V406, P25; SCHRADER J, 1980, PFLUG ARCH EUR J PHY, V387, P245, DOI 10.1007/BF00580977; Schwierin B, 1996, EUR J PHARMACOL, V300, P163, DOI 10.1016/0014-2999(96)00021-0; Shiromani PJ, 1996, MOL BRAIN RES, V38, P77, DOI 10.1016/0169-328X(95)00325-M; STENIADE M, 1996, SCIENCE, V272, P225; STENIADE M, 1990, J NEUROSCI, V10, P2541; Ursin R., 1981, MANUAL STANDARDIZED; VANWYLEN DGL, 1986, J CEREBR BLOOD F MET, V6, P522, DOI 10.1038/jcbfm.1986.97; WINN HR, 1980, CIRC RES, V47, P568, DOI 10.1161/01.RES.47.4.568; WORLEY PF, 1987, P NATL ACAD SCI USA, V84, P3467, DOI 10.1073/pnas.84.10.3467; WU PH, 1984, GEN PHARMACOL, V15, P251, DOI 10.1016/0306-3623(84)90169-1; ZWYGHUIZENDOORENBOS A, 1990, PSYCHOPHARMACOLOGY, V100, P36, DOI 10.1007/BF02245786	42	754	778	1	86	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 23	1997	276	5316					1265	1268		10.1126/science.276.5316.1265	http://dx.doi.org/10.1126/science.276.5316.1265			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XA497	9157887	Green Accepted, Green Submitted			2022-12-01	WOS:A1997XA49700046
J	Hassig, CA; Fleischer, TC; Billin, AN; Schreiber, SL; Ayer, DE				Hassig, CA; Fleischer, TC; Billin, AN; Schreiber, SL; Ayer, DE			Histone deacetylase activity is required for full transcriptional repression by mSin3A	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; MYC-MAX; NEGATIVE REGULATOR; SODIUM-BUTYRATE; YEAST; PROTEIN; ACTIVATION; DIFFERENTIATION; ACETYLATION; NUCLEOSOME	Members of the Mad family of bHLH-Zip proteins heterodimerize with Max to repress transcription in a sequence-specific manner. Transcriptional repression by Mad:Max heterodimers is mediated by ternary complex formation with either of the corepressors mSin3A or mSin3B. We report here that mSin3A is an in vivo component of large, heterogeneous multiprotein complexes and is tightly and specifically associated with at least seven polypeptides. Two of the mSin3A-associated proteins, p50 and p55, are highly related to the histone deacetylase HDAC1. The mSin3A immunecomplexes possess histone deacetylase activity that is sensitive to the specific deacetylase inhibitor trapoxin. mSin3A-targeted repression of a reporter gene is reduced by trapoxin treatment, suggesting that histone deacetylation mediates transcriptional repression through Mad-Max-mSin3A multimeric complexes.	UNIV UTAH,HUNTSMAN CANC INST,DEPT ONCOL SCI,DIV MOL BIOL & GENET,SALT LAKE CITY,UT 84112; HARVARD UNIV,HOWARD HUGHES MED INST,DEPT CHEM & BIOL CHEM,CAMBRIDGE,MA 02138; HARVARD UNIV,HOWARD HUGHES MED INST,DEPT MOL & CELLULAR BIOL,CAMBRIDGE,MA 02138	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Harvard University; Howard Hughes Medical Institute; Harvard University; Howard Hughes Medical Institute				Ayer, Donald/0000-0002-5595-3269; Fleischer, Tracey C/0000-0002-7141-4265; Billin, Andrew/0000-0001-7752-0934	NIGMS NIH HHS [GM38617] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; Ayer DE, 1996, MOL CELL BIOL, V16, P5772; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; BEMARDS R, 1995, CURR BIOL, V5, P859; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; BRESNICK EH, 1990, P NATL ACAD SCI USA, V87, P3977, DOI 10.1073/pnas.87.10.3977; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; DeRubertis F, 1996, NATURE, V384, P589; DURRIN LK, 1991, CELL, V65, P1023, DOI 10.1016/0092-8674(91)90554-C; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; JOHNSTON LA, 1992, MOL CELL BIOL, V12, P5123, DOI 10.1128/MCB.12.11.5123; Kasten MM, 1996, MOL CELL BIOL, V16, P4215; KOSKINEN PJ, 1995, CELL GROWTH DIFFER, V6, P623; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; LOIDL P, 1994, CHROMOSOMA, V103, P441; MARCUS GA, 1994, EMBO J, V13, P4807, DOI 10.1002/j.1460-2075.1994.tb06806.x; MCKNIGHT GS, 1980, CELL, V22, P469; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Parthun MR, 1996, CELL, V87, P85, DOI 10.1016/S0092-8674(00)81325-2; QIAN YW, 1993, NATURE, V364, P648, DOI 10.1038/364648a0; Roussel MF, 1996, MOL CELL BIOL, V16, P2796; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; STERNECK E, 1992, MOL CELL BIOL, V12, P1728, DOI 10.1128/MCB.12.4.1728; STILLMAN DJ, 1994, GENETICS, V136, P781; SUSSEL L, 1995, GENETICS, V141, P873; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Taunton J, 1996, J AM CHEM SOC, V118, P10412, DOI 10.1021/ja9615841; TURNER BM, 1992, CELL, V69, P375, DOI 10.1016/0092-8674(92)90417-B; TURNER BM, 1993, CELL, V75, P5, DOI 10.1016/0092-8674(93)90673-E; Tyler JK, 1996, MOL CELL BIOL, V16, P6149; Verreault A, 1996, CELL, V87, P95, DOI 10.1016/S0092-8674(00)81326-4; VetteseDadey M, 1996, EMBO J, V15, P2508, DOI 10.1002/j.1460-2075.1996.tb00608.x; VIDAL M, 1991, MOL CELL BIOL, V11, P6317, DOI 10.1128/MCB.11.12.6317; WANG HM, 1994, MOL GEN GENET, V245, P675, DOI 10.1007/BF00297274; WANG HM, 1990, MOL CELL BIOL, V10, P5927, DOI 10.1128/MCB.10.11.5927; Wolffe AP, 1996, SCIENCE, V272, P371, DOI 10.1126/science.272.5260.371; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; YOSHIMOTO H, 1992, MOL GEN GENET, V233, P327, DOI 10.1007/BF00587597; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	43	653	677	0	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 2	1997	89	3					341	347		10.1016/S0092-8674(00)80214-7	http://dx.doi.org/10.1016/S0092-8674(00)80214-7			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WX899	9150133	Bronze			2022-12-01	WOS:A1997WX89900004
J	Yoo, CJ; Wolin, SL				Yoo, CJ; Wolin, SL			The yeast la protein is required for the 3' endonucleolytic cleavage that matures tRNA precursors	CELL			English	Article							RNA POLYMERASE-III; SUPPRESSOR TRANSFER-RNA; LUPUS ANTIGEN-LA; SACCHAROMYCES-CEREVISIAE; INTERVENING SEQUENCE; TRANSCRIPTION; AUTOANTIGEN; EXPRESSION; GENES; ASSOCIATION	Although the La autoantigen binds to the 3' ends of all nascent polymerase III transcripts, its function in vivo has long been unclear. Although S. cerevisiae cells lacking the La protein homolog Lhp1p are viable, cells containing a mutation that disrupts the anticodon stem of tRNAS(CGA)(Ser) require Lhp1p for growth. We demonstrate that for the wild-type pre-tRNAS(CGA)(Ser) and other pretRNAs, Lhp1p is required for the normal endonucleolytic removal of the 3' trailer sequence. In cells lacking Lhp1p, the 3' trailer is removed by exonuclease(s). Although maturation of the mutant pre-tRNA(CGA)(Ser) requires Lhp1p, introduction of a second mutation that restores base pairing eliminates the requirement. We propose that binding by Lhp1p stabilizes pre-tRNAs in conformations that allow the 3' endonucleolytic cleavage to occur.	YALE UNIV, SCH MED, HOWARD HUGHES MED INST, NEW HAVEN, CT 06510 USA	Howard Hughes Medical Institute; Yale University	Yoo, CJ (corresponding author), YALE UNIV, SCH MED, DEPT CELL BIOL, NEW HAVEN, CT 06510 USA.		Wolin, Sandra/H-2333-2016	Wolin, Sandra/0000-0001-6730-0399	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM048410] Funding Source: NIH RePORTER; NIGMS NIH HHS [R29-GM48410] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altman Sidney, 1995, P67; BARRELL BG, 1971, PROCEDURES NUCL ACID, P751; BOELENS WC, 1995, RNA, V1, P273; BRANCH AD, 1989, METHOD ENZYMOL, V180, P130; CHAMBERS JC, 1988, J BIOL CHEM, V263, P18043; CHAMBERS JC, 1983, J BIOL CHEM, V258, P1438; ETCHEVERRY T, 1979, CELL, V18, P11, DOI 10.1016/0092-8674(79)90349-0; ETCHEVERRY T, 1982, J MOL BIOL, V158, P599, DOI 10.1016/0022-2836(82)90251-0; EVANS CF, 1990, METHOD ENZYMOL, V181, P439; FURTER R, 1992, BIOCHEMISTRY-US, V31, P10817, DOI 10.1021/bi00159a024; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; GOFF CG, 1984, GENE, V27, P35, DOI 10.1016/0378-1119(84)90236-1; GOTTLIEB E, 1989, EMBO J, V8, P851, DOI 10.1002/j.1460-2075.1989.tb03446.x; Grimm C, 1997, EMBO J, V16, P793, DOI 10.1093/emboj/16.4.793; HENDRICK JP, 1981, MOL CELL BIOL, V1, P1138, DOI 10.1128/MCB.1.12.1138; HOLTZMAN DA, 1993, J CELL BIOL, V122, P635, DOI 10.1083/jcb.122.3.635; Li ZW, 1996, CELL, V86, P503, DOI 10.1016/S0092-8674(00)80123-3; LINMARQ N, 1995, J MOL BIOL, V245, P81, DOI 10.1006/jmbi.1994.0008; Maraia RJ, 1996, P NATL ACAD SCI USA, V93, P3383, DOI 10.1073/pnas.93.8.3383; McBratney S, 1996, MOL CELL BIOL, V16, P3523; MEEROVITCH K, 1993, J VIROL, V67, P3798, DOI 10.1128/JVI.67.7.3798-3807.1993; NICHOLS M, 1990, METHOD ENZYMOL, V181, P377; OCONNOR JP, 1991, MOL CELL BIOL, V11, P425, DOI 10.1128/MCB.11.1.425; OLSON MV, 1981, NATURE, V291, P464, DOI 10.1038/291464a0; PEARSON D, 1985, MOL CELL BIOL, V5, P808, DOI 10.1128/MCB.5.4.808; Peek R, 1996, EUR J BIOCHEM, V236, P649, DOI 10.1111/j.1432-1033.1996.0649d.x; RINKE J, 1985, NUCLEIC ACIDS RES, V13, P2617, DOI 10.1093/nar/13.7.2617; RINKE J, 1982, CELL, V29, P149, DOI 10.1016/0092-8674(82)90099-X; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; SCHERLY D, 1993, J MOL BIOL, V231, P196, DOI 10.1006/jmbi.1993.1275; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Simons FHM, 1996, RNA, V2, P264; STEFANO JE, 1984, CELL, V36, P145, DOI 10.1016/0092-8674(84)90083-7; TARN WY, 1995, RNA, V1, P644; VALENZUELA P, 1978, P NATL ACAD SCI USA, V75, P190, DOI 10.1073/pnas.75.1.190; YOO CJ, 1994, MOL CELL BIOL, V14, P5412, DOI 10.1128/MCB.14.8.5412; Yu W, 1996, MOL CELL BIOL, V16, P2464	38	220	224	1	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 2	1997	89	3					393	402		10.1016/S0092-8674(00)80220-2	http://dx.doi.org/10.1016/S0092-8674(00)80220-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WX899	9150139	hybrid			2022-12-01	WOS:A1997WX89900010
J	Bujalska, IJ; Kumar, S; Stewart, PM				Bujalska, IJ; Kumar, S; Stewart, PM			Does central obesity reflect ''Cushing's disease of the omentum''?	LANCET			English	Article							BODY-FAT DISTRIBUTION; 11-BETA-HYDROXYSTEROID DEHYDROGENASE; TISSUE DISTRIBUTION; ADIPOSE-TISSUE; CELLS; GLUCOCORTICOIDS; LOCALIZATION; HEPATOCYTES; ISOFORM; ENZYME	Background Central obesity results in a cluster of metabolic abnormalities contributing to premature death. Glucocorticoids regulate adipose-tissue differentiation, function, and distribution, and in excess, cause central obesity. Glucocorticoid hormone action is, in part, controlled by two isoforms of the enzyme 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD) which interconverts hormonally active cortisol to inactive cortisone. We studied cortisol metabolism within different adipose tissue depots. Methods We analysed expression and activity of the two isoforms (1 and 2) of 11 beta-HSD in cultured omental and subcutaneous adipose stromal cells from 16 patients undergoing elective abdominal surgery. Findings Only the type 1 isoform (11 beta-HSD1) was expressed in adipose stromal cells. The predominant activity was oxo-reductase (conversion of cortisone to cortisol greater than cortisol to cortisone) and was higher in omental than subcutaneous fat (cortisone to cortisol, median 57.6 pmol mg(-1) h(-1) [95% CI 25.8-112.9] vs 0 pmol mg(-1) h(-1) [0-0.6], p < 0.001). 11 beta-HSD1 oxo-reductase activity was further increased (127.5 pmol mg(-1) h(-1) [82.1-209], p < 0.05) when omental adipose stromal cells were treated with cortisol and insulin. Interpretation Adipose stromal cells from omental fat, but not subcutaneous fat, can generate active cortisol from inactive cortisone through the expression of 11 beta-HSD1. The expression of this enzyme is increased further after exposure to cortisol and insulin. In vivo, such a mechanism would ensure a constant exposure of glucocorticoid specifically to omental adipose tissue, suggesting that central obesity may reflect ''Cushing's disease of the omentum''.	UNIV BIRMINGHAM,QUEEN ELIZABETH HOSP,DEPT MED,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND	University of Birmingham			kumar, sudhesh/D-6945-2013	kumar, sudhesh/0000-0003-4326-5941				ALBISTON AL, 1994, MOL CELL ENDOCRINOL, V105, pR11, DOI 10.1016/0303-7207(94)90176-7; BJORNTORP P, 1991, DIABETES CARE, V14, P1132, DOI 10.2337/diacare.14.12.1132; BRONNEGARD M, 1995, J CLIN ENDOCR METAB, V80, P3608, DOI 10.1210/jc.80.12.3608; BRONNEGARD M, 1990, ENDOCRINOLOGY, V127, P1689; DAROMINT C, 1994, ENDOCRINOLOGY, V135, P2030; DUNKELMAN SS, 1964, J CLIN ENDOCR METAB, V24, P832, DOI 10.1210/jcem-24-9-832; EDWARDS C R W, 1985, Journal of Endocrinology, V104, P53; EDWARDS CRW, 1988, LANCET, V2, P836; FRIED SK, 1993, J CLIN INVEST, V92, P2191, DOI 10.1172/JCI116821; GLASS AR, 1981, METABOLISM, V30, P89, DOI 10.1016/0026-0495(81)90224-9; HAUNER H, 1989, J CLIN INVEST, V84, P1663, DOI 10.1172/JCI114345; JAMIESON PM, 1995, ENDOCRINOLOGY, V136, P4754, DOI 10.1210/en.136.11.4754; MARTIN P, 1992, METABOLISM, V41, P882; MAYOSMITH W, 1989, RADIOLOGY, V170, P515, DOI 10.1148/radiology.170.2.2911678; MUNE T, 1995, NAT GENET, V10, P394, DOI 10.1038/ng0895-394; PASQUALI R, 1993, J CLIN ENDOCR METAB, V77, P341, DOI 10.1210/jc.77.2.341; REBUFFESCRIVE M, 1988, J CLIN ENDOCR METAB, V67, P1122, DOI 10.1210/jcem-67-6-1122; SIMPSON ER, 1989, ENDOCR REV, V10, P136, DOI 10.1210/edrv-10-2-136; Stewart PM, 1996, LANCET, V347, P88, DOI 10.1016/S0140-6736(96)90211-1; STEWART PM, 1994, J CLIN ENDOCR METAB, V79, P480, DOI 10.1210/jc.79.2.480; Stewart PM, 1996, CLIN ENDOCRINOL, V44, P493, DOI 10.1046/j.1365-2265.1996.716535.x; TANNIN GM, 1991, J BIOL CHEM, V266, P16653; WHORWOOD CB, 1995, MOL CELL ENDOCRINOL, V110, pR7, DOI 10.1016/0303-7207(95)03546-J; ZHAO Y, 1995, MOL ENDOCRINOL, V9, P340, DOI 10.1210/me.9.3.340	24	608	639	0	15	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 26	1997	349	9060					1210	1213		10.1016/S0140-6736(96)11222-8	http://dx.doi.org/10.1016/S0140-6736(96)11222-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW717	9130942				2022-12-01	WOS:A1997WW71700010
J	Ghayur, T; Banerjee, S; Hugunin, M; Butler, D; Herzog, L; Carter, A; Quintal, L; Sekut, L; Talanian, R; Paskind, M; Wong, W; Kamen, R; Tracey, D; Allen, H				Ghayur, T; Banerjee, S; Hugunin, M; Butler, D; Herzog, L; Carter, A; Quintal, L; Sekut, L; Talanian, R; Paskind, M; Wong, W; Kamen, R; Tracey, D; Allen, H			Caspase-1 processes IFN-gamma-inducing factor and regulates LPS-induced IFN-gamma production	NATURE			English	Article							INTERLEUKIN-1-BETA CONVERTING-ENZYME; INTERFERON-GAMMA; ENDOTOXIC-SHOCK; MICE DEFICIENT; CELLS; IL-1-BETA; APOPTOSIS; PATHOGENS; CYTOKINE; PROTEASE	Interferon-gamma-inducing factor (IGIF, interleukin-18) is a recently described cytokine that shares structural features with the interleukin-1 (IL-1) family of proteins and functional properties with IL-12(1-4). Like IL-12, IGIF is a potent inducer of interferon (IFN)-gamma from T cells and natural killer cells(1-3,5,6). IGIF is synthesized as a biologically inactive precursor molecule (proIGIF). The cellular production of IL-1 beta, a cytokine implicated in a variety of inflammatory diseases, requires cleavage of its precursor (proIL-1 beta) at an Asp-X site by interleukin-1 beta-converting enzyme(7,8) (ICE, recently termed caspase-1(9)), The Asp-X sequence at the putative processing site in proIGIF(2,3) suggests that a protease such as caspase-1 might be involved in the maturation of IGIF(4). Here we demonstrate that caspase-1 processes proIGIF and pron-1 beta with equivalent efficiencies in vitro. A selective caspase-1 inhibitor blocks both lipopolysaccharide-induced IL-1 beta and IFN-gamma production from human mononuclear cells. Furthermore, caspase-1-deficient mice are defective in lipopolysaccharide-induced IFN-gamma production, Our results thus implicate caspase-1 in the physiological production of IGIF and demonstrate that it plays a critical role in the regulation of multiple proinflammatory cytokines. Specific caspase-1 inhibitors would provide a new class of antiinflammatory drugs with multipotent action.			Ghayur, T (corresponding author), BASF BIORES CORP,100 RES DR,WORCESTER,MA 01605, USA.							Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Bazan JF, 1996, NATURE, V379, P591, DOI 10.1038/379591a0; CAMPBELL IL, 1991, J CLIN INVEST, V87, P739, DOI 10.1172/JCI115055; DANDREA A, 1993, J EXP MED, V178, P1041, DOI 10.1084/jem.178.3.1041; FLETCHER DS, 1995, J INTERF CYTOK RES, V15, P243, DOI 10.1089/jir.1995.15.243; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; Gu Y, 1997, SCIENCE, V275, P206, DOI 10.1126/science.275.5297.206; Hugunin M, 1996, J BIOL CHEM, V271, P3517, DOI 10.1074/jbc.271.7.3517; HUNTER CA, 1995, J IMMUNOL, V155, P4347; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; LOCKSLEY RM, 1993, P NATL ACAD SCI USA, V90, P5879, DOI 10.1073/pnas.90.13.5879; Magram J, 1996, IMMUNITY, V4, P471, DOI 10.1016/S1074-7613(00)80413-6; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Micallef MJ, 1996, EUR J IMMUNOL, V26, P1647, DOI 10.1002/eji.1830260736; NAKAMURA K, 1993, INFECT IMMUN, V61, P64, DOI 10.1128/IAI.61.1.64-70.1993; NEURATH MF, 1995, J EXP MED, V182, P1281, DOI 10.1084/jem.182.5.1281; OKAMURA H, 1995, INFECT IMMUN, V63, P3966, DOI 10.1128/IAI.63.10.3966-3972.1995; OKAMURA H, 1995, NATURE, V378, P88, DOI 10.1038/378088a0; Patel T, 1996, FASEB J, V10, P587, DOI 10.1096/fasebj.10.5.8621058; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Ushio S, 1996, J IMMUNOL, V156, P4274	25	1014	1064	1	49	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 10	1997	386	6625					619	623		10.1038/386619a0	http://dx.doi.org/10.1038/386619a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WT273	9121587				2022-12-01	WOS:A1997WT27300062
J	Mesecar, AD; Stoddard, BL; Koshland, DE				Mesecar, AD; Stoddard, BL; Koshland, DE			Orbital steering in the catalytic power of enzymes: Small structural changes with large catalytic consequences	SCIENCE			English	Article							DEPENDENT ISOCITRATE DEHYDROGENASE; NICOTINAMIDE ADENINE-DINUCLEOTIDE; LIVER DIHYDROFOLATE-REDUCTASE; HYDRIDE-DONATION REACTION; TRANSITION-STATE; PIG-HEART; CRYSTAL-STRUCTURES; SUBSTRATE BINDING; GLUTATHIONE-REDUCTASE; STO-3G CALCULATIONS	Small structural perturbations in the enzyme isocitrate dehydrogenase (IDH) were made in order to evaluate the contribution of precise substrate alignment to the catalytic power of an enzyme. The reaction trajectory of IDH was modified (i) after the adenine moiety of nicotinamide adenine dinucleotide phosphate was changed to hypoxanthine (the 6-amino was changed to 6-hydroxyl), and (ii) by replacing Mg2+, which has six coordinating ligands, with Ca2+, which has eight coordinating ligands. Both changes make large (10(-3) to 10(-5)) changes in the reaction velocity but only small changes in the orientation of the substrates (both distance and angle) as revealed by cryocrystallographic trapping of active IDH complexes. The results provide evidence that orbital overlap produced by optimal orientation of reacting orbitals plays a major quantitative role in the catalytic power of enzymes.	LAWRENCE BERKELEY NATL LAB,CTR ADV MAT,BERKELEY,CA; FRED HUTCHINSON CANC RES CTR,PROGRAM STRUCT BIOL,DIV BASIC SCI,SEATTLE,WA 98104	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; Fred Hutchinson Cancer Center	Mesecar, AD (corresponding author), UNIV CALIF BERKELEY,DEPT MOL & CELL BIOL,229 STANLEY HALL,BERKELEY,CA 94720, USA.			Mesecar, Andrew/0000-0002-1241-2577	NIGMS NIH HHS [GM49857] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049857] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMARSSON O, 1993, J AM CHEM SOC, V115, P2125, DOI 10.1021/ja00059a005; BAJORATH J, 1989, NATURE, V337, P481, DOI 10.1038/337481a0; BARTUNIK HD, 1992, PHILOS T ROY SOC A, V340, P209, DOI 10.1098/rsta.1992.0061; Bodor N., 1990, THEOCHEM, V65, P315, DOI 10.1016/0166-1280(90)85146-E; BOLDUC JM, 1995, SCIENCE, V268, P1312, DOI 10.1126/science.7761851; BROWN KA, 1992, FARADAY DISCUSS, V93, P217, DOI 10.1039/fd9929300217; BRUICE TC, 1960, J AM CHEM SOC, V82, P5858, DOI 10.1021/ja01507a023; BRUICE TC, 1976, ANNU REV BIOCHEM, V45, P331, DOI 10.1146/annurev.bi.45.070176.001555; BRUNGER AT, 1992, X PLOR VERSION 3 1; BYSTROFF C, 1990, BIOCHEMISTRY-US, V29, P3263, DOI 10.1021/bi00465a018; CHRISTIANSON DW, 1986, P NATL ACAD SCI USA, V83, P7568, DOI 10.1073/pnas.83.20.7568; COLMAN RF, 1972, J BIOL CHEM, V247, P215; CUMMINS PL, 1990, J COMPUT CHEM, V11, P791, DOI 10.1002/jcc.540110703; DAFFORN A, 1971, P NATL ACAD SCI USA, V68, P2463, DOI 10.1073/pnas.68.10.2463; DEAN AM, 1993, BIOCHEMISTRY-US, V32, P9302, DOI 10.1021/bi00087a007; DING XC, 1994, BIOCHEMISTRY-US, V33, P9285, DOI 10.1021/bi00197a032; DONKERSLOOT MCA, 1981, J AM CHEM SOC, V103, P6549, DOI 10.1021/ja00412a002; DONKERSLOOT MCA, 1981, J AM CHEM SOC, V103, P6554, DOI 10.1021/ja00412a003; EHRLICH RS, 1989, BIOCHEMISTRY-US, V28, P2058, DOI 10.1021/bi00431a014; EHRLICH RS, 1995, BBA-PROTEIN STRUCT M, V1246, P135, DOI 10.1016/0167-4838(94)00192-J; GLUSKER JP, 1991, ADV PROTEIN CHEM, V42, P1; GROS P, 1992, PROTEINS, V12, P63, DOI 10.1002/prot.340120108; Hackney D. D., 1990, ENZYMES, P1; HALL MD, 1993, J MOL BIOL, V232, P213, DOI 10.1006/jmbi.1993.1377; HARRISON DH, 1994, BIOCHEMISTRY-US, V33, P2011, DOI 10.1021/bi00174a006; HUHTA DW, 1992, ACTA CHEM SCAND, P778; HURLEY JH, 1989, P NATL ACAD SCI USA, V86, P8635, DOI 10.1073/pnas.86.22.8635; Hurley JH, 1996, BIOCHEMISTRY-US, V35, P5670, DOI 10.1021/bi953001q; HURLEY JH, 1991, BIOCHEMISTRY-US, V30, P8671, DOI 10.1021/bi00099a026; HURLEY JH, 1990, SCIENCE, V249, P1012, DOI 10.1126/science.2204109; KARPLUS PA, 1989, J MOL BIOL, V210, P163, DOI 10.1016/0022-2836(89)90298-2; KATI WM, 1992, BIOCHEMISTRY-US, V31, P7356, DOI 10.1021/bi00147a021; KOSHLAND DE, 1968, ANNU REV BIOCHEM, V37, P359, DOI 10.1146/annurev.bi.37.070168.002043; KOSHLAND DE, 1962, J THEOR BIOL, V2, P75, DOI 10.1016/0022-5193(62)90037-1; MCPHALEN CA, 1991, ADV PROTEIN CHEM, V42, P77; MCTIGUE MA, 1992, BIOCHEMISTRY-US, V31, P7264, DOI 10.1021/bi00147a009; MCTIGUE MA, 1993, BIOCHEMISTRY-US, V32, P6855, DOI 10.1021/bi00078a008; MENGER FM, 1985, ACCOUNTS CHEM RES, V18, P128, DOI 10.1021/ar00113a001; MENGER FM, 1993, ACCOUNTS CHEM RES, V26, P206, DOI 10.1021/ar00028a011; NAVEZA J, 1994, ACTA CRYSTALLOGR A, V50, P157; NORTHROP DB, 1974, J BIOL CHEM, V249, P2928; OTWINOWSKI Z, P CCP4 STUD WEEK DAT; PAGE MI, 1972, J AM CHEM SOC, V94, P8828, DOI 10.1021/ja00780a031; Perutz M. F., 1990, MECH COOPERATIVITY; RAMASWAMY S, 1994, BIOCHEMISTRY-US, V33, P5230, DOI 10.1021/bi00183a028; SCHLICHTING I, 1994, NATURE, V371, P808, DOI 10.1038/371808a0; SCHREINER S, 1976, J AM CHEM SOC, V98, P4770; SHERROD MJ, 1989, J AM CHEM SOC, V111, P2611, DOI 10.1021/ja00189a040; SHERROD MJ, 1990, TETRAHEDRON LETT, V31, P459, DOI 10.1016/0040-4039(90)87007-M; Stoddard BL, 1996, NAT STRUCT BIOL, V3, P590, DOI 10.1038/nsb0796-590; STODDARD BL, 1993, BIOCHEMISTRY-US, V32, P9317, DOI 10.1021/bi00087a009; STORM DR, 1970, P NATL ACAD SCI USA, V66, P445, DOI 10.1073/pnas.66.2.445; Stryer L., 1988, BIOCHEMISTRY-US, P375; SUSTMANN R, 1989, ANGEW CHEM INT EDIT, V28, P1023, DOI 10.1002/anie.198910231; Tanaka N, 1996, BIOCHEMISTRY-US, V35, P7715, DOI 10.1021/bi951904d; Tanaka N, 1996, STRUCTURE, V4, P33, DOI 10.1016/S0969-2126(96)00007-X; Thoden JB, 1996, PROTEIN SCI, V5, P2149, DOI 10.1002/pro.5560051102; WARSHEL A, 1991, COMPUTER MODELING CH; WILLIAMS IH, 1990, J AM CHEM SOC, V112, P530, DOI 10.1021/ja00158a009; WU YD, 1991, J AM CHEM SOC, V113, P2353, DOI 10.1021/ja00007a002; WU YD, 1987, J AM CHEM SOC, V109, P2226, DOI 10.1021/ja00241a074	61	198	205	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 11	1997	277	5323					202	206		10.1126/science.277.5323.202	http://dx.doi.org/10.1126/science.277.5323.202			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK418	9211842				2022-12-01	WOS:A1997XK41800034
J	Russell, RM				Russell, RM			Nutrition	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											Russell, RM (corresponding author), TUFTS UNIV, JEAN MAYER USDA HUMAN NUTR RES CTR AGING, BOSTON, MA 02111 USA.							Abenhaim L, 1996, NEW ENGL J MED, V335, P609, DOI 10.1056/NEJM199608293350901; ANDERSON JW, 1995, NEW ENGL J MED, V333, P276, DOI 10.1056/NEJM199508033330502; ATKINSON RL, 1994, AM J CLIN NUTR, V60, P153, DOI 10.1093/ajcn/60.2.153; Blackburn H, 1996, NEW ENGL J MED, V334, P984, DOI 10.1056/NEJM199604113341511; Centers for Disease Control and Prevention (CDC), 1993, MMWR Morb Mortal Wkly Rep, V42, P669; DIXON ZR, 1994, FREE RADICAL BIO MED, V17, P537, DOI 10.1016/0891-5849(94)90093-0; GOLDSTEIN DJ, 1994, AM J CLIN NUTR, V60, P647, DOI 10.1093/ajcn/60.5.647; Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802; POWELL KE, 1987, ANNU REV PUBL HEALTH, V8, P253, DOI 10.1146/annurev.publhealth.8.1.253; Rimm EB, 1996, ANN INTERN MED, V125, P384, DOI 10.7326/0003-4819-125-5-199609010-00005; ROLLS BJ, 1992, AM J CLIN NUTR, V56, P84, DOI 10.1093/ajcn/56.1.84; SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413; SHELOV SP, 1995, PEDIATRICS, V96, P786	15	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	1997	277	23					1876	1878						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD544	9185812				2022-12-01	WOS:A1997XD54400031
J	Sulmasy, DP; Lynn, J				Sulmasy, DP; Lynn, J			End-of-life care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											Sulmasy, DP (corresponding author), GEORGETOWN UNIV, MED CTR, WASHINGTON, DC 20007 USA.							Allen JP, 1996, JAMA-J AM MED ASSOC, V275, P474; *AMA POLL, 1997, AM MED NEWS     0113, V40, P56; American Board of Internal Medicine, 1996, CAR DYING ID PROM PH; Bachman JG, 1996, NEW ENGL J MED, V334, P303, DOI 10.1056/NEJM199602013340506; Back AL, 1996, JAMA-J AM MED ASSOC, V275, P919, DOI 10.1001/jama.275.12.919; BACON F, 1905, PHILOS WORKS F BACON, V2, P487; BLENDON RJ, 1992, JAMA-J AM MED ASSOC, V267, P2658, DOI 10.1001/jama.267.19.2658; Cassel CK, 1996, NEW ENGL J MED, V335, P1232, DOI 10.1056/NEJM199610173351612; COVINSKY KE, 1994, JAMA-J AM MED ASSOC, V272, P1839, DOI 10.1001/jama.272.23.1839; ENDE J, 1997, GRADUATE ED INTERNAL; JONES WHS, 1992, HIPPOCRATES, V2, P193; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Lee MA, 1996, ANN INTERN MED, V124, P267, DOI 10.7326/0003-4819-124-2-199601150-00014; Lynn J, 1996, NEW ENGL J MED, V335, P201, DOI 10.1056/NEJM199607183350311; Lynn J, 1997, J AM GERIATR SOC, V45, P489, DOI 10.1111/j.1532-5415.1997.tb05176.x; The SUPPORT Principal Investigators, 1995, J AMER MED ASSOC, V274, P1591; *US BUR CENS, 1995, STAT ABSTR US, P86; VITEZ M, 1997, PHILADELPHIA IN 0108, P3; VONROENN JH, 1993, ANN INTERN MED, V119, P121, DOI 10.7326/0003-4819-119-2-199307150-00005; 1996, C ED PHYS DYING APR	20	9	9	1	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	1997	277	23					1854	1855						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD544	9185798				2022-12-01	WOS:A1997XD54400017
J	Lazazzera, BA; Solomon, JM; Grossman, AD				Lazazzera, BA; Solomon, JM; Grossman, AD			An exported peptide functions intracellularly to contribute to cell density signaling in B-subtilis	CELL			English	Article							CONTROL GENE-EXPRESSION; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; TRANSPORT-SYSTEM; STREPTOCOCCUS-PNEUMONIAE; TRANSCRIPTION FACTOR; TRANSDUCTION SYSTEM; SPORULATION; COMPETENCE; COMA	Competence development and sporulation in B. subtilis are partly controlled by peptides that accumulate in culture medium as cells grow to high density. We constructed two genes that encode mature forms of two different signaling molecules, the PhrA peptide that stimulates sporulation, and CSF, the competence- and sporulation-stimulating factor. Both pentapeptides are normally produced by secretion and processing of precursor molecules. The mature pentapeptides were functional when expressed inside the cell, indicating that they normally need to be imported to function. Furthermore, at physiological concentrations (10 nM), CSF was transported into the cell by the oligopeptide permease encoded by spoOK (opp). CSF was shown to have at least three different targets corresponding to its three activities: stimulating competence gene expression at low concentrations, and inhibiting competence gene expression and stimulating sporulation at high concentrations.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050895] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM50895] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alloing G, 1996, MOL MICROBIOL, V21, P471; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BERGER EA, 1974, J BIOL CHEM, V249, P7747; CANGELOSI GA, 1990, P NATL ACAD SCI USA, V87, P6708, DOI 10.1073/pnas.87.17.6708; CARTER HL, 1991, GENE, V96, P101; COX GB, 1988, J BACTERIOL, V170, P2283, DOI 10.1128/jb.170.5.2283-2286.1988; DONOVAN W, 1987, J MOL BIOL, V196, P1, DOI 10.1016/0022-2836(87)90506-7; FERRARI FA, 1983, J BACTERIOL, V154, P1513, DOI 10.1128/JB.154.3.1513-1515.1983; Fuqua C, 1996, ANNU REV MICROBIOL, V50, P727, DOI 10.1146/annurev.micro.50.1.727; Grossman AD, 1995, ANNU REV GENET, V29, P477, DOI 10.1146/annurev.ge.29.120195.002401; GROSSMAN AD, 1988, GENETICS BIOTECHNOLO, V2, P175; HAGEN DC, 1978, DEV BIOL, V64, P284, DOI 10.1016/0012-1606(78)90079-9; HAHN J, 1994, J BACTERIOL, V176, P5753, DOI 10.1128/JB.176.18.5753-5761.1994; Harwood C.R., 1990, MOL BIOL METHODS BAC; Havarstein LS, 1996, MOL MICROBIOL, V21, P863, DOI 10.1046/j.1365-2958.1996.521416.x; HAVARSTEIN LS, 1995, P NATL ACAD SCI USA, V92, P11140, DOI 10.1073/pnas.92.24.11140; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cellbio.8.1.67; HOCH JA, 1993, ANNU REV MICROBIOL, V47, P441, DOI 10.1146/annurev.micro.47.1.441; Hoch JA, 1995, 2 COMPONENT SIGNAL T; IRETON K, 1993, GENE DEV, V7, P283, DOI 10.1101/gad.7.2.283; JAACKS KJ, 1989, J BACTERIOL, V171, P4121, DOI 10.1128/JB.171.8.4121-4129.1989; Ji GY, 1995, P NATL ACAD SCI USA, V92, P12055, DOI 10.1073/pnas.92.26.12055; KOIDE A, 1994, MOL MICROBIOL, V13, P417, DOI 10.1111/j.1365-2958.1994.tb00436.x; KURJAN J, 1992, ANNU REV BIOCHEM, V61, P1097; Leonard BAB, 1996, P NATL ACAD SCI USA, V93, P260, DOI 10.1073/pnas.93.1.260; MAGNUSON R, 1994, CELL, V77, P207, DOI 10.1016/0092-8674(94)90313-1; MANSON MD, 1986, NATURE, V321, P253, DOI 10.1038/321253a0; MATHIOPOULOS C, 1991, MOL MICROBIOL, V5, P1903, DOI 10.1111/j.1365-2958.1991.tb00814.x; Miller JH., 1972, EXPT MOL GENETICS; MITANI T, 1977, BIOCHEM BIOPH RES CO, V77, P1118, DOI 10.1016/S0006-291X(77)80094-6; MOYE HA, 1979, ANAL LETT, V12, P25; MUELLER JP, 1992, J BACTERIOL, V174, P4361, DOI 10.1128/JB.174.13.4361-4373.1992; MUELLER JP, 1992, J BACTERIOL, V174, P4374, DOI 10.1128/JB.174.13.4374-4383.1992; NAKANO MM, 1989, J BACTERIOL, V171, P5347, DOI 10.1128/jb.171.10.5347-5353.1989; NAKANO MM, 1991, J BACTERIOL, V173, P5487, DOI 10.1128/jb.173.17.5487-5493.1991; NAKANO MM, 1991, J BACTERIOL, V173, P7269, DOI 10.1128/jb.173.22.7269-7274.1991; Nodwell JR, 1996, MOL MICROBIOL, V22, P881, DOI 10.1046/j.1365-2958.1996.01540.x; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; PARMES JR, 1973, J BIOL CHEM, V248, P4429; PEARCE BJ, 1994, MOL MICROBIOL, V12, P881, DOI 10.1111/j.1365-2958.1994.tb01076.x; Perego M, 1996, P NATL ACAD SCI USA, V93, P1549, DOI 10.1073/pnas.93.4.1549; Perego M, 1996, MOL MICROBIOL, V19, P1151, DOI 10.1111/j.1365-2958.1996.tb02460.x; PEREGO M, 1991, MOL MICROBIOL, V5, P173, DOI 10.1111/j.1365-2958.1991.tb01838.x; PEREGO M, 1994, CELL, V79, P1047, DOI 10.1016/0092-8674(94)90035-3; Pestova EV, 1996, MOL MICROBIOL, V21, P853, DOI 10.1046/j.1365-2958.1996.501417.x; ROGGIANI M, 1993, J BACTERIOL, V175, P3182, DOI 10.1128/JB.175.10.3182-3187.1993; RUDNER DZ, 1991, J BACTERIOL, V173, P1388, DOI 10.1128/jb.173.4.1388-1398.1991; SANDMAN K, 1987, GENETICS, V117, P603; SOLOMON JM, 1995, GENE DEV, V9, P547, DOI 10.1101/gad.9.5.547; Solomon JM, 1996, GENE DEV, V10, P2014, DOI 10.1101/gad.10.16.2014; Solomon JM, 1996, TRENDS GENET, V12, P150, DOI 10.1016/0168-9525(96)10014-7; Stragier P, 1996, ANNU REV GENET, V30, P297, DOI 10.1146/annurev.genet.30.1.297; STRAGIER P, 1988, CELL, V52, P697, DOI 10.1016/0092-8674(88)90407-2; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; WANNER BL, 1993, J CELL BIOCHEM, V51, P47, DOI 10.1002/jcb.240510110; WEINRAUCH Y, 1989, J BACTERIOL, V171, P5362, DOI 10.1128/jb.171.10.5362-5375.1989; WEINRAUCH Y, 1990, GENE DEV, V4, P860, DOI 10.1101/gad.4.5.860; YANSURA DG, 1984, P NATL ACAD SCI-BIOL, V81, P439, DOI 10.1073/pnas.81.2.439	59	191	197	1	21	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 13	1997	89	6					917	925		10.1016/S0092-8674(00)80277-9	http://dx.doi.org/10.1016/S0092-8674(00)80277-9			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XE357	9200610	Bronze, Green Published			2022-12-01	WOS:A1997XE35700012
J	Webster, NR				Webster, NR			Ventilation in the prone position	LANCET			English	Editorial Material											Webster, NR (corresponding author), UNIV ABERDEEN,ABERDEEN AB25 2ZD,SCOTLAND.							AMIS TC, 1984, RESP PHYSIOL, V56, P145, DOI 10.1016/0034-5687(84)90100-2; BECK KC, 1992, J APPL PHYSIOL, V72, P2292, DOI 10.1152/jappl.1992.72.6.2292; BRYAN AC, 1974, AM REV RESPIR DIS, V110, P143; Chatte G, 1997, AM J RESP CRIT CARE, V155, P473, DOI 10.1164/ajrccm.155.2.9032181; DOUGLAS WW, 1977, AM REV RESPIR DIS, V115, P559; Fridrich P, 1996, ANESTH ANALG, V83, P1206, DOI 10.1097/00000539-199612000-00013; GATTINONI L, 1991, ANESTHESIOLOGY, V74, P15, DOI 10.1097/00000542-199101000-00004; KRAYER S, 1989, ANESTHESIOLOGY, V70, P891, DOI 10.1097/00000542-198906000-00002; LAMM WJE, 1994, AM J RESP CRIT CARE, V150, P184, DOI 10.1164/ajrccm.150.1.8025748; LANGER M, 1988, CHEST, V94, P103, DOI 10.1378/chest.94.1.103; PAPPERT D, 1994, CHEST, V106, P1511, DOI 10.1378/chest.106.5.1511; PIEHL MA, 1976, CRIT CARE MED, V4, P13, DOI 10.1097/00003246-197601000-00003; WEINER CM, 1990, J APPL PHYSIOL, V68, P1386	13	10	10	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 7	1997	349	9066					1638	1639		10.1016/S0140-6736(05)62630-X	http://dx.doi.org/10.1016/S0140-6736(05)62630-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD100	9186378				2022-12-01	WOS:A1997XD10000004
J	Ferveur, JF; Savarit, F; OKane, CJ; Sureau, G; Greenspan, RJ; Jallon, JM				Ferveur, JF; Savarit, F; OKane, CJ; Sureau, G; Greenspan, RJ; Jallon, JM			Genetic feminization of pheromones and its behavioral consequences in Drosophila males	SCIENCE			English	Article							MELANOGASTER; HYDROCARBONS; BIOSYNTHESIS; RECOGNITION; COURTSHIP; ENOCYTES; DIPTERA; LOCUS	Pheromones are intraspecific chemical signals important for mate attraction and discrimination, In the fruit fly Drosophila melanogaster, hydrocarbons on the cuticular surface of the animal are sexually dimorphic in both their occurrence and their effects: Female-specific molecules stimulate male sexual excitation, whereas the predominant male-specific molecule tends to inhibit male excitation, Complete feminization of the pheromone mixture produced by males was induced by targeted expression of the transformer gene in adult oenocytes (subcuticular abdominal cells) or by ubiquitous expression during early imaginal life. The resulting flies generally exhibited male heterosexual orientation but elicited homosexual courtship from other males.	UNIV CAMBRIDGE, DEPT GENET, CAMBRIDGE CB2 3EH, ENGLAND; NYU, DEPT BIOL, NEW YORK, NY 10003 USA; NYU, CTR NEURAL SCI, NEW YORK, NY 10003 USA	University of Cambridge; New York University; New York University	Ferveur, JF (corresponding author), UNIV PARIS 11, CNRS, UNITE RECH ASSOCIEE 1491, BATIMENT 446, F-91405 ORSAY, FRANCE.		O'Kane, Cahir/Q-6681-2019	O'Kane, Cahir/0000-0002-3488-2078	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANTONY C, 1985, J CHEM ECOL, V11, P1617, DOI 10.1007/BF01012116; ANTONY C, 1981, CR ACAD SCI III-VIE, V292, P239; Bell WJ, 1984, CHEM ECOLOGY INSECTS; BRAND AH, 1993, DEVELOPMENT, V118, P401; COBB M, 1990, ANIM BEHAV, V39, P1058, DOI 10.1016/S0003-3472(05)80778-X; Cobb M, 1995, BEHAV PROCESS, V35, P35, DOI 10.1016/0376-6357(95)00052-6; Coyne JA, 1996, GENETICS, V143, P353; COYNE JA, 1994, SCIENCE, V265, P1461, DOI 10.1126/science.8073292; COYNE JA, 1995, P NATL ACAD SCI USA, V92, P9505, DOI 10.1073/pnas.92.21.9505; DIEHL PA, 1975, J INSECT PHYSIOL, V21, P1237, DOI 10.1016/0022-1910(75)90093-1; FERVEUR JF, 1995, SCIENCE, V267, P902, DOI 10.1126/science.7846534; Ferveur JF, 1996, GENET RES, V67, P211, DOI 10.1017/S0016672300033693; Ferveur JF, 1996, P ROY SOC B-BIOL SCI, V263, P967, DOI 10.1098/rspb.1996.0143; Ferveur JF, 1996, GENETICA, V97, P73, DOI 10.1007/BF00132583; GREIG S, 1993, NATURE, V362, P630, DOI 10.1038/362630a0; HALL JC, 1994, SCIENCE, V264, P1702, DOI 10.1126/science.8209251; ISMAIL MT, 1983, J INSECT PHYSIOL, V29, P221, DOI 10.1016/0022-1910(83)90088-4; Ito H, 1996, P NATL ACAD SCI USA, V93, P9687, DOI 10.1073/pnas.93.18.9687; Jallon J.-M., 1986, Advances in Invertebrate Reproduction, V4, P445; JALLON JM, 1988, GENET RES, V51, P17, DOI 10.1017/S0016672300023892; JALLON JM, 1984, BEHAV GENET, V14, P441, DOI 10.1007/BF01065444; JALLON JM, 1981, CR ACAD SCI III-VIE, V292, P1147; JALLON JM, 1979, BEHAV GENET, V8, P487; JOHNSON MB, 1985, J MORPHOL, V184, P51, DOI 10.1002/jmor.1051840106; Miller A., 1950, BIOL DROSOPHILA, P420; ODELL KMC, 1995, NEURON, V15, P55, DOI 10.1016/0896-6273(95)90064-0; OKANE CJ, 1987, P NATL ACAD SCI USA, V84, P9123, DOI 10.1073/pnas.84.24.9123; ROMER F, 1991, RECENT ADV COMP ARTH, P542; Ryner LC, 1996, CELL, V87, P1079, DOI 10.1016/S0092-8674(00)81802-4; SAVARIT F, UNPUB; SCOTT D, 1988, ANIM BEHAV, V36, P1164, DOI 10.1016/S0003-3472(88)80075-7; VAZ AH, 1989, ARCH INSECT BIOCHEM, V12, P173, DOI 10.1002/arch.940120305; WICKER C, 1995, EUR J ENTOMOL, V92, P197; WIGGLESWORTH V B, 1970, Tissue and Cell, V2, P155, DOI 10.1016/S0040-8166(70)80013-1; YONG TPC, 1986, CR ACAD SCI III-VIE, V303, P197	37	172	172	1	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 6	1997	276	5318					1555	1558		10.1126/science.276.5318.1555	http://dx.doi.org/10.1126/science.276.5318.1555			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XC701	9171057				2022-12-01	WOS:A1997XC70100040
J	Pan, Y; Lloyd, C; Zhou, H; Dolich, S; Deeds, J; Gonzalo, JA; Vath, J; Gosselin, M; Ma, JY; Dussault, B; Woolf, E; Alperin, G; Culpepper, J; GutierrezRamos, JC; Gearing, D				Pan, Y; Lloyd, C; Zhou, H; Dolich, S; Deeds, J; Gonzalo, JA; Vath, J; Gosselin, M; Ma, JY; Dussault, B; Woolf, E; Alperin, G; Culpepper, J; GutierrezRamos, JC; Gearing, D			Neurotactin, a membrane-anchored chemokine upregulated in brain inflammation	NATURE			English	Article							MOLECULAR-CLONING; RECEPTOR-BINDING; CC-CHEMOKINES; GROWTH-FACTOR; INTERLEUKIN-8; CLEAVAGE; CELL; TRANSMEMBRANE; LYMPHOTACTIN; LEUKOCYTES	Chemokines are small secreted proteins that stimulate the directional migration of leukocytes and mediate inflammation(1-4). During screening of a murine choroid plexus complementary DNA library, we identified a new chemokine, designated neurotactin. Unlike other chemokines, neurotactin has a unique cysteine pattern, Cys-X-X-X-Cys, and is predicted to be a type 1 membrane protein. Full-length recombinant neurotactin is localized on the surface of transfected 293 cells. Recombinant neurotactin containing the chemokine domain is chemotactic for neutrophils both in vitro and in vivo. Neurotactin messenger RNA is predominantly expressed in normal murine brain and its protein expression in activated brain microglia is upregulated in mice with experimental autoimmune encephalomyelitis, as well as in mice treated with lipopolysaccharide. Distinct from all other chemokine genes, the neurotactin gene is localized to human chromosome 16q. Consequently we propose that neurotactin represents a new delta-chemokine family and that it may play a role in brain inflammation processes.			Pan, Y (corresponding author), MILLENNIUM PHARMACEUT INC,640 MEM DR,CAMBRIDGE,MA 02139, USA.			Lloyd, Clare/0000-0001-8977-6726	Wellcome Trust [087618] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BAGGIOLINI M, 1994, IMMUNOL TODAY, V15, P127, DOI 10.1016/0167-5699(94)90156-2; BALDWIN ET, 1991, P NATL ACAD SCI USA, V88, P502, DOI 10.1073/pnas.88.2.502; BOSENBERG MW, 1992, CELL, V71, P1157, DOI 10.1016/S0092-8674(05)80064-9; BRANNAN CI, 1991, P NATL ACAD SCI USA, V88, P4671, DOI 10.1073/pnas.88.11.4671; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; COWEN DS, 1989, J CLIN INVEST, V83, P1651, DOI 10.1172/JCI114064; FALK W, 1980, J IMMUNOL METHODS, V33; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; GEHRMANN J, 1995, BRAIN RES REV, V20, P269, DOI 10.1016/0165-0173(94)00015-H; GISH W, 1993, NAT GENET, V3, P266, DOI 10.1038/ng0393-266; HEBERT CA, 1991, J BIOL CHEM, V266, P18989; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; KELNER GS, 1994, SCIENCE, V266, P1395, DOI 10.1126/science.7973732; KENNEDY J, 1995, J IMMUNOL, V155, P203; KOCHANEK PM, 1992, STROKE, V23, P1367, DOI 10.1161/01.STR.23.9.1367; KUCHROO VK, 1995, CELL, V80, P707, DOI 10.1016/0092-8674(95)90349-6; LAFAILLE JJ, 1994, CELL, V78, P399, DOI 10.1016/0092-8674(94)90419-7; LARSEN CG, 1989, SCIENCE, V243, P1464, DOI 10.1126/science.2648569; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; MOSER B, 1990, J EXP MED, V171, P1797, DOI 10.1084/jem.171.5.1797; NELSON RM, 1993, J CLIN INVEST, V91, P1157, DOI 10.1172/JCI116275; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; SCHALL TJ, 1994, CURR OPIN IMMUNOL, V6, P865, DOI 10.1016/0952-7915(94)90006-X; SHIROZU M, 1995, GENOMICS, V28, P495, DOI 10.1006/geno.1995.1180; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WITT DP, 1994, CURR BIOL, V4, P394, DOI 10.1016/S0960-9822(00)00088-9; YOSHIDA T, 1995, FEBS LETT, V360, P155, DOI 10.1016/0014-5793(95)00093-O	31	542	556	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 5	1997	387	6633					611	617		10.1038/42491	http://dx.doi.org/10.1038/42491			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XC522	9177350				2022-12-01	WOS:A1997XC52200058
J	Stack, LB				Stack, LB			Latrodectus mactans	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Stack, LB (corresponding author), VANDERBILT UNIV,MED CTR,NASHVILLE,TN 37232, USA.								0	2	20	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 5	1997	336	23					1649	1649		10.1056/NEJM199706053362305	http://dx.doi.org/10.1056/NEJM199706053362305			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XC086	9171067				2022-12-01	WOS:A1997XC08600005
J	Pfeffer, LM; Mullersman, JE; Pfeffer, SR; Murti, A; Shi, W; Yang, CH				Pfeffer, LM; Mullersman, JE; Pfeffer, SR; Murti, A; Shi, W; Yang, CH			STAT3 as an adapter to couple phosphatidylinositol 3-kinase to the IFNAR1 chain of the type I interferon receptor	SCIENCE			English	Article							PROTEIN-KINASE-C; TYROSINE PHOSPHORYLATION; TRANSCRIPTION FACTOR; ALPHA/BETA RECEPTOR; EXPRESSION; ACTIVATION; CLONING; SUBUNIT; CELLS; COMPLEX	STAT (signal transducers and activators of transcription) proteins undergo cytokine-dependent phosphorylation on serine and tyrosine, STAT3, a transcription factor for acute phase response genes, was found to act as an adapter molecule in signal transduction from the type I interferon receptor. STAT3 bound to a conserved sequence in the cytoplasmic tail of the IFNAR1 chain of the receptor and underwent interferon-dependent tyrosine phosphorylation. The p85 regulatory subunit of phosphatidylinositol S-kinase, which activates a series of serine kinases, bound to phosphorylated STAT3 and subsequently underwent tyrosine phosphorylation, Thus, STAT3 acts as an adapter to couple another signaling pathway to the interferon receptor.			Pfeffer, LM (corresponding author), UNIV TENNESSEE, HLTH SCI CTR, DEPT PATHOL, MEMPHIS, TN 38163 USA.			Pfeffer, Lawrence/0000-0003-2809-1234				BRANCA AA, 1982, J BIOL CHEM, V257, P13291; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; COLAMONICI O, 1994, MOL CELL BIOL, V14, P8133, DOI 10.1128/MCB.14.12.8133; COLAMONICI OR, 1994, J BIOL CHEM, V269, P9598; CONSTANTINESCU SN, 1995, P NATL ACAD SCI USA, V92, P10487, DOI 10.1073/pnas.92.23.10487; CONSTANTINESCU SN, 1994, P NATL ACAD SCI USA, V91, P9602, DOI 10.1073/pnas.91.20.9602; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DOMANSKI P, 1995, J BIOL CHEM, V270, P21606, DOI 10.1074/jbc.270.37.21606; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FRIEDMAN RL, 1985, NATURE, V314, P637, DOI 10.1038/314637a0; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; Goldman LA, 1996, BIOTECHNIQUES, V21, P1013; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; LARNER AC, 1986, J BIOL CHEM, V261, P453; MULLERSMAN JE, 1995, TRENDS BIOCHEM SCI, V20, P55, DOI 10.1016/S0968-0004(00)88956-2; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; PFEFFER LM, 1990, P NATL ACAD SCI USA, V87, P6537, DOI 10.1073/pnas.87.17.6537; PFEFFER LM, 1991, P NATL ACAD SCI USA, V88, P7988, DOI 10.1073/pnas.88.18.7988; REICH NC, 1990, P NATL ACAD SCI USA, V87, P8761, DOI 10.1073/pnas.87.22.8761; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; TOKER A, 1994, J BIOL CHEM, V269, P32358; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Yan H, 1996, MOL CELL BIOL, V16, P2074; Yang C. C., UNPUB; Yang CH, 1996, J BIOL CHEM, V271, P8057, DOI 10.1074/jbc.271.14.8057; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	30	224	228	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 30	1997	276	5317					1418	1420		10.1126/science.276.5317.1418	http://dx.doi.org/10.1126/science.276.5317.1418			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XB533	9162009				2022-12-01	WOS:A1997XB53300050
J	Johnston, M; Hillier, L; Riles, L; Albermann, K; Andre, B; Ansorge, W; Benes, V; Bruckner, M; Delius, H; Dubois, E; Dusterhoft, A; Entian, KD; Floeth, M; Goffeau, A; Hebling, U; Heumann, K; HeussNeitzel, D; Hilbert, H; Hilger, F; Kleine, K; Kotter, P; Louis, EJ; Messenguy, F; Mewes, HW; Miosga, T; Mostl, D; MullerAuer, S; Nentwich, U; Obermaier, B; Piravandi, E; Pohl, TM; Portetelle, D; Purnelle, B; Rechmann, S; Rieger, M; Rinke, M; Rose, M; Scharfe, M; Scherens, B; Scholler, P; Schwager, C; Schwarz, S; Underwood, AP; Urrestarazu, LA; Vandenbol, M; Verhasselt, P; Vierendeels, F; Voet, M; Volckaert, G; Voss, H; Wambutt, R; Wedler, E; Wedler, H; Zimmermann, FK; Zollner, A; Hani, J; Hoheisel, JD				Johnston, M; Hillier, L; Riles, L; Albermann, K; Andre, B; Ansorge, W; Benes, V; Bruckner, M; Delius, H; Dubois, E; Dusterhoft, A; Entian, KD; Floeth, M; Goffeau, A; Hebling, U; Heumann, K; HeussNeitzel, D; Hilbert, H; Hilger, F; Kleine, K; Kotter, P; Louis, EJ; Messenguy, F; Mewes, HW; Miosga, T; Mostl, D; MullerAuer, S; Nentwich, U; Obermaier, B; Piravandi, E; Pohl, TM; Portetelle, D; Purnelle, B; Rechmann, S; Rieger, M; Rinke, M; Rose, M; Scharfe, M; Scherens, B; Scholler, P; Schwager, C; Schwarz, S; Underwood, AP; Urrestarazu, LA; Vandenbol, M; Verhasselt, P; Vierendeels, F; Voet, M; Volckaert, G; Voss, H; Wambutt, R; Wedler, E; Wedler, H; Zimmermann, FK; Zollner, A; Hani, J; Hoheisel, JD			The nucleotide sequence of Saccharomyces cerevisiae chromosome XII	NATURE			English	Article							RIBOSOMAL-RNA GENES; COMPLETE DNA-SEQUENCE; SIZE-VARIATION; YEAST; RESOLUTION	The yeast Saccharomyces cerevisiae is the pre-eminent organism for the study of basic functions of eukaryotic cells(1). All of the genes of this simple eukaryotic cell have recently been revealed by an international collaborative effort to determine the complete DNA sequence of its nuclear genome. Here we describe some of the features of chromosome XII.	MAX PLANCK INST BIOCHEM, MARTINSRIEDER INST PROT SEQUENZEN, D-82152 MARTINSRIED, GERMANY; FREE UNIV BRUSSELS, LAB PHYSIOL CELLULAIRE & GENET LEVURES, B-1050 BRUSSELS, BELGIUM; EUROPEAN MOL BIOL LAB, D-69117 HEIDELBERG, GERMANY; GENOTYPE, D-69434 HIRSCHHORN, GERMANY; DEUTSCH KREBSFORSCHUNGSZENTRUM, D-69120 HEIDELBERG, GERMANY; FREE UNIV BRUSSELS, MICROBIOL LAB, B-1070 BRUSSELS, BELGIUM; QIAGEN GMBH, D-40724 HILDEN, GERMANY; UNIV FRANKFURT, INST MIKROBIOL, D-60439 FRANKFURT, GERMANY; UNIV CATHOLIQUE LOUVAIN, FAC SCI AGRON, UNITE BIOCHIM PHYSIOL, B-1348 LOUVAIN, BELGIUM; FAC UNIV SCI AGRON, UNITE MICROBIOL, B-5030 GEMBLOUX, BELGIUM; JOHN RADCLIFFE HOSP, INST MOL MED, DEPT YEAST GENET, OXFORD OX3 9DU, ENGLAND; CERIA COOVI, RES INST, B-1070 BRUSSELS, BELGIUM; INST MIKROBIOL & GENET, D-64287 DARMSTADT, GERMANY; MEDIGENE GMBH, D-82152 MARTINSRIED, GERMANY; GATC GESELL ANAL TECH & CONSULTING MBH, D-78467 CONSTANCE, GERMANY; AGON GMBH, D-12489 BERLIN, GERMANY; FREE UNIV BRUSSELS VIB, DEPT MICROBIOL, B-1070 BRUSSELS, BELGIUM; KATHOLIEKE UNIV LEUVEN, LAB GENE TECHNOL, B-3001 LOUVAIN, BELGIUM; DEUTSCH KREBSFORSCHUNGSZENTRUM, D-69120 HEIDELBERG, GERMANY	Max Planck Society; Universite Libre de Bruxelles; Vrije Universiteit Brussel; European Molecular Biology Laboratory (EMBL); Helmholtz Association; German Cancer Research Center (DKFZ); Universite Libre de Bruxelles; Vrije Universiteit Brussel; QIAGEN GmbH; Goethe University Frankfurt; Universite Catholique Louvain; University of Liege; University of Oxford; Technical University of Darmstadt; Flanders Institute for Biotechnology (VIB); Vrije Universiteit Brussel; KU Leuven; Helmholtz Association; German Cancer Research Center (DKFZ)	Johnston, M (corresponding author), WASHINGTON UNIV, SCH MED, DEPT GENET, GENOME SEQUENCING CTR, 630 EUCLID AVE, ST LOUIS, MO 63110 USA.		Ansorge, Wilhelm/AAN-8780-2020; Wilson, Richard K./AAF-4139-2019; Louis, Edward/B-7920-2008; Johnston, Mark/K-3543-2019; Johnston, Mark/R-6156-2019; Entian, Karl-Dieter/D-3080-2011; André, Bruno/D-1725-2010; Mewes, Hans-Werner/A-8204-2019	Wilson, Richard K./0000-0002-1992-1358; Louis, Edward/0000-0003-1157-3608; Johnston, Mark/0000-0002-4932-7229; Benes, Vladimir/0000-0002-0352-2547; Underwood, Anthony/0000-0002-8547-4277; Mewes, Hans-Werner/0000-0002-9713-6398	NHGRI NIH HHS [P01 HG000956] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); Wellcome Trust(Wellcome TrustEuropean Commission)		CHINDAMPORN A, 1993, J GEN MICROBIOL, V139, P1409, DOI 10.1099/00221287-139-7-1409; DUJON B, 1994, NATURE, V369, P371, DOI 10.1038/369371a0; FELDMANN H, 1994, EMBO J, V13, P5795, DOI 10.1002/j.1460-2075.1994.tb06923.x; Galibert F, 1996, EMBO J, V15, P2031, DOI 10.1002/j.1460-2075.1996.tb00557.x; JOHNSTON M, 1994, SCIENCE, V265, P2077, DOI 10.1126/science.8091229; JONES EW, 1991, MOL CELLULAR BIOL YE, V1; KIM KW, 1988, J BIOL CHEM, V263, P11948; LOUIS EJ, 1995, GENETICS, V139, P125; LOUIS EJ, 1995, BIOCHEMICA, V3, P25; MCMAHON ME, 1984, NUCLEIC ACIDS RES, V12, P8001, DOI 10.1093/nar/12.21.8001; OLSON MV, 1991, MOL CELLULAR BIOL YE, V1, P1; PASERO P, 1993, MOL GEN GENET, V236, P448, DOI 10.1007/BF00277147; PIPER PW, 1984, NUCLEIC ACIDS RES, V12, P4083, DOI 10.1093/nar/12.10.4083; RILES L, 1993, GENETICS, V134, P81; RODRIGUEZMEDINA JR, 1994, MOL GEN GENET, V243, P532, DOI 10.1007/BF00284201; RUSTCHENKO EP, 1994, YEAST, V10, P1157, DOI 10.1002/yea.320100904; SCHOLLER P, 1995, NUCLEIC ACIDS RES, V23, P3842, DOI 10.1093/nar/23.19.3842; SCHOLLER P, 1995, YEAST, V11, P659, DOI 10.1002/yea.320110706; SHARP PM, 1993, NUCLEIC ACIDS RES, V21, P179, DOI 10.1093/nar/21.2.179; SHARP PM, 1987, NUCLEIC ACIDS RES, V15, P1281, DOI 10.1093/nar/15.3.1281; VASSAROTTI A, 1995, J BIOTECHNOL, V41, P131, DOI 10.1016/0168-1656(95)00066-Y; VISWANATHAN M, 1994, GENE, V148, P149, DOI 10.1016/0378-1119(94)90249-6; ZAMB TJ, 1982, CELL, V28, P355, DOI 10.1016/0092-8674(82)90353-1	23	91	696	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 29	1997	387	6632		S			87	90		10.1038/387s087	http://dx.doi.org/10.1038/387s087			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XB546	9169871				2022-12-01	WOS:A1997XB54600011
J	Misteli, T; Caceres, JF; Spector, DL				Misteli, T; Caceres, JF; Spector, DL			The dynamics of a pre-mRNA splicing factor in living cells	NATURE			English	Article							NASCENT TRANSCRIPTS; PROTEIN; REGULATORS; EXPRESSION; INHIBITION; NUCLEUS	Pre-mRNA splicing is a predominantly co-transcriptional event which involves a large number of essential splicing factors(1,2). Within the mammalian cell nucleus, most splicing factors are concentrated in 20-40 distinct domains called speckles(3). The function of speckles and the organization of cellular transcription and pre-mRNA splicing in vivo are not well understood. We have investigated the dynamic properties of splicing factors in nuclei of living cells. Here we show that speckles are highly dynamic structures that respond specifically to activation of nearby genes. These dynamic events are dependent on RNA polymerase II transcription, and are sensitive to inhibitors of protein kinases and Ser/Thr phosphatases. When single genes are transcriptionally activated in living cells, splicing factors leave speckles in peripheral extensions and accumulate at the new sites of transcription, We conclude that one function of speckles is to supply splicing factors to active genes. Our observations demonstrate that the interphase nucleus is far more dynamic in nature than previously assumed.	COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	Cold Spring Harbor Laboratory			Caceres, Javier F/D-5260-2013	Caceres, Javier F/0000-0001-8025-6169	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042694] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM042694] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BADBOIS DM, 1992, BIOCHEM BIOPH RES CO, V184, P80; BEYER AL, 1988, GENE DEV, V2, P754, DOI 10.1101/gad.2.6.754; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BOOM R, 1986, J VIROL, V58, P851, DOI 10.1128/JVI.58.3.851-859.1986; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; Colwill K, 1996, EMBO J, V15, P265, DOI 10.1002/j.1460-2075.1996.tb00357.x; DIRKS RW, 1997, J CELL SCI, V110, P505; Fakan Stanislav, 1994, Trends in Cell Biology, V4, P86, DOI 10.1016/0962-8924(94)90180-5; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; GUI JF, 1994, NATURE, V369, P678, DOI 10.1038/369678a0; HABETS WJ, 1989, J IMMUNOL, V143, P2560; HELFMAN DM, 1988, GENE DEV, V2, P1627, DOI 10.1101/gad.2.12a.1627; Huang S, 1996, J CELL BIOL, V133, P719, DOI 10.1083/jcb.133.4.719; JIMINEZGARCIA LF, 1993, CELL, V73, P47; Kim E, 1997, J CELL BIOL, V136, P19, DOI 10.1083/jcb.136.1.19; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; LINDELL TJ, 1970, SCIENCE, V170, P447, DOI 10.1126/science.170.3956.447; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; MERMOUD JE, 1994, EMBO J, V13, P5679, DOI 10.1002/j.1460-2075.1994.tb06906.x; Misteli T, 1996, MOL BIOL CELL, V7, P1559, DOI 10.1091/mbc.7.10.1559; Misteli T, 1997, TRENDS CELL BIOL, V7, P135, DOI 10.1016/S0962-8924(96)20043-1; MOENS U, 1990, J GEN VIROL, V71, P1461, DOI 10.1099/0022-1317-71-7-1461; Moore M., 1993, RNA WORLD, P303; Mortillaro MJ, 1996, P NATL ACAD SCI USA, V93, P8253, DOI 10.1073/pnas.93.16.8253; POMBO A, 1994, EMBO J, V13, P5075, DOI 10.1002/j.1460-2075.1994.tb06837.x; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; SPECTOR DL, 1993, ANNU REV CELL BIOL, V9, P265, DOI 10.1146/annurev.cb.09.110193.001405; Xing YG, 1995, J CELL BIOL, V131, P1635, DOI 10.1083/jcb.131.6.1635	29	507	519	2	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 29	1997	387	6632					523	527		10.1038/387523a0	http://dx.doi.org/10.1038/387523a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XB479	9168118				2022-12-01	WOS:A1997XB47900054
J	Jiang, XQ; Payne, MA; Cao, ZH; Foster, SB; Feix, JB; Newton, SMC; Klebba, PE				Jiang, XQ; Payne, MA; Cao, ZH; Foster, SB; Feix, JB; Newton, SMC; Klebba, PE			Ligand-specific opening of a gated-porin channel in the outer membrane of living bacteria	SCIENCE			English	Article							FERRIC ENTEROBACTIN RECEPTOR; MICROBIAL IRON TRANSPORT; ESCHERICHIA-COLI K-12; CELL-ENVELOPE; SPIN-LABEL; BACTERIORHODOPSIN MUTANTS; PROTEIN; SIDEROPHORE; TONB; TRANSLOCATION	Ligand-gated membrane channels selectively facilitate the entry of iron into prokaryotic cells. The essential role of iron in metabolism makes its acquisition a determinant of bacterial pathogenesis and a target for therapeutic strategies. In Gram-negative bacteria, TonB-dependent outer membrane proteins form energized, gated pores that bind iron chelates (siderophores) and internalize them. The time-resolved operation of the Escherichia coli ferric enterobactin receptor FepA was observed in vivo with electron spin resonance spectroscopy by monitoring the mobility of covalently bound nitroxide spin labels. A ligand-binding surface loop of FepA, which normally closes its transmembrane channel, exhibited energy-dependent structural changes during iron and toxin (colicin) transport. These changes were not merely associated with ligand binding, but occurred during ligand uptake through the outer membrane bilayer. The results demonstrate by a physical method that gated-porin channels open and close during membrane transport in vivo.	UNIV OKLAHOMA,DEPT CHEM & BIOCHEM,NORMAN,OK 73019; MED COLL WISCONSIN,ESR CTR,BIOPHYS RES INST,MILWAUKEE,WI 53226; UNIV FED SAO PAULO,DEPT MICROBIOL,SAO PAULO,BRAZIL	University of Oklahoma System; University of Oklahoma - Norman; Medical College of Wisconsin; Universidade Federal de Sao Paulo (UNIFESP)					NIGMS NIH HHS [GM53836, GM51339] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053836, R01GM051339] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTENBACH C, 1990, SCIENCE, V248, P1088, DOI 10.1126/science.2160734; ALTENBACH C, 1989, BIOCHEMISTRY-US, V28, P7806, DOI 10.1021/bi00445a042; Aprison MH, 1996, J NEUROSCI RES, V43, P127; BATY D, 1990, BIOCHIMIE, V72, P123, DOI 10.1016/0300-9084(90)90137-6; BENEDETTI H, 1992, EMBO J, V11, P441, DOI 10.1002/j.1460-2075.1992.tb05073.x; BENEDETTI H, 1991, J MOL BIOL, V217, P429, DOI 10.1016/0022-2836(91)90747-T; BENEDETTI H, 1989, J GEN MICROBIOL, V135, P3413; BERLINER LJ, 1983, ANN NY ACAD SCI, V414, P153, DOI 10.1111/j.1749-6632.1983.tb31681.x; BERLINER LJ, 1989, SPIN LABELING THEORY, V8; BRAUN V, 1980, J BACTERIOL, V142, P162, DOI 10.1128/JB.142.1.162-168.1980; BRAUN V, 1991, BIOL MET, V4, P14, DOI 10.1007/BF01135552; BROCHU A, 1992, ANTIMICROB AGENTS CH, V36, P2166, DOI 10.1128/AAC.36.10.2166; Burnashev N, 1996, CURR OPIN NEUROBIOL, V6, P311, DOI 10.1016/S0959-4388(96)80113-9; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; DIMASI DR, 1973, J BACTERIOL, V115, P56; EICHLER DC, 1985, BIOCHEMISTRY-US, V24, P1181, DOI 10.1021/bi00326a019; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P8812, DOI 10.1021/bi00027a033; FARAHBAKHSH ZT, 1993, SCIENCE, V262, P1416, DOI 10.1126/science.8248781; GUERINOT ML, 1994, ANNU REV MICROBIOL, V48, P743, DOI 10.1146/annurev.micro.48.1.743; GUTERMAN SK, 1973, J BACTERIOL, V114, P1217, DOI 10.1128/JB.114.3.1217-1224.1973; HANNAVY K, 1990, J MOL BIOL, V216, P897, DOI 10.1016/S0022-2836(99)80009-6; HUBBELL WL, 1994, CURR OPIN STRUC BIOL, V4, P566, DOI 10.1016/S0959-440X(94)90219-4; Jentsch TJ, 1996, CURR OPIN NEUROBIOL, V6, P303, DOI 10.1016/S0959-4388(96)80112-7; JIANG XPC, UNPUB; Johnston GAR, 1996, TRENDS PHARMACOL SCI, V17, P319, DOI 10.1016/S0165-6147(96)10038-9; KADNER RJ, 1990, MOL MICROBIOL, V4, P2027, DOI 10.1111/j.1365-2958.1990.tb00562.x; KILLMANN H, 1993, EMBO J, V12, P3007, DOI 10.1002/j.1460-2075.1993.tb05969.x; KLEBBA PE, 1993, J BIOENERG BIOMEMBR, V25, P603; KLUG CS, 1995, BIOCHEMISTRY-US, V34, P14230, DOI 10.1021/bi00043a030; LAZDUNSKI CJ, 1995, MOL MICROBIOL, V16, P1059, DOI 10.1111/j.1365-2958.1995.tb02331.x; LIU J, 1993, P NATL ACAD SCI USA, V90, P10653, DOI 10.1073/pnas.90.22.10653; LIU J, 1994, BIOCHEMISTRY-US, V33, P13274, DOI 10.1021/bi00249a014; MASON RP, 1977, BIOCHEMISTRY-US, V16, P1196, DOI 10.1021/bi00625a026; MILLER MJ, 1991, BIOL MET, V4, P62, DOI 10.1007/BF01135559; Molday RS, 1996, CURR OPIN NEUROBIOL, V6, P445, DOI 10.1016/S0959-4388(96)80048-1; MURPHY CK, 1990, J BACTERIOL, V172, P2736, DOI 10.1128/jb.172.5.2736-2746.1990; NEILANDS JB, 1982, ANNU REV MICROBIOL, V36, P285, DOI 10.1146/annurev.mi.36.100182.001441; NEILANDS JB, 1995, J BIOL CHEM, V270, P26723, DOI 10.1074/jbc.270.45.26723; Newton S. L., UNPUB; Newton SMC, 1997, P NATL ACAD SCI USA, V94, P4560, DOI 10.1073/pnas.94.9.4560; NIKAIDO H, 1981, J GEN PHYSIOL, V77, P121, DOI 10.1085/jgp.77.2.121; NIKAIDO H, 1983, J BACTERIOL, V153, P241, DOI 10.1128/JB.153.1.241-252.1983; NIKAIDO H, 1992, SCIENCE, V258, P936, DOI 10.1126/science.1279804; POSTLE K, 1990, MOL MICROBIOL, V4, P2019, DOI 10.1111/j.1365-2958.1990.tb00561.x; PUGSLEY AP, 1976, J BACTERIOL, V126, P1052, DOI 10.1128/JB.126.3.1052-1062.1976; Rathouz MM, 1996, MOL NEUROBIOL, V12, P117, DOI 10.1007/BF02740649; ROOF SK, 1991, J BACTERIOL, V173, P5554, DOI 10.1128/jb.173.17.5554-5557.1991; RUTZ JM, 1992, SCIENCE, V258, P471, DOI 10.1126/science.1411544; RUTZ JM, 1991, J BACTERIOL, V173, P5694; SCHIRMER T, 1995, SCIENCE, V267, P512, DOI 10.1126/science.7824948; SHIN YK, 1993, SCIENCE, V259, P960, DOI 10.1126/science.8382373; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; WAYNE R, 1975, J BACTERIOL, V121, P497, DOI 10.1128/JB.121.2.497-503.1975; WAYNE R, 1976, J BACTERIOL, V126, P7, DOI 10.1128/JB.126.1.7-12.1976; WEISS MS, 1990, FEBS LETT, V267, P268, DOI 10.1016/0014-5793(90)80942-C; WEISS MS, 1991, SCIENCE, V254, P1627, DOI 10.1126/science.1721242; WILLIAMS PH, 1979, INFECT IMMUN, V26, P925, DOI 10.1128/IAI.26.3.925-932.1979; WISNER M, 1997, NATURE, V385, P481; WOLF MK, 1986, J GEN MICROBIOL, V132, P2949	59	88	93	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 23	1997	276	5316					1261	1264		10.1126/science.276.5316.1261	http://dx.doi.org/10.1126/science.276.5316.1261			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XA497	9157886				2022-12-01	WOS:A1997XA49700045
J	Marr, MT; Roberts, JW				Marr, MT; Roberts, JW			Promoter recognition as measured by binding of polymerase to nontemplate strand oligonucleotide	SCIENCE			English	Article							COLI RNA-POLYMERASE; ESCHERICHIA-COLI; TRANSCRIPTION INITIATION; DNA; CHROMATOGRAPHY; SPECIFICITY; SUBUNIT	In transcription initiation, the DNA strands must be separated to expose the template to RNA polymerase. As the closed initiation complex is converted to an open one, specific protein-DNA interactions involving bases of the nontemplate strand form and stabilize the promoter complex in the region of unwinding. Specific interaction between RNA polymerase and the promoter in Escherichia coli was detected and quantified as the binding affinity of nontemplate oligonucleotide sequences. The RNA polymerase subunit sigma factor 70 contacted the bases of the nontemplate DNA strand through its conserved region 2; a mutation that affected promoter function altered the binding affinity of the oligonucleotide to the enzyme.			Marr, MT (corresponding author), CORNELL UNIV, BIOCHEM MOL & CELL BIOL SECT, BIOTECHNOL BLDG, ITHACA, NY 14853 USA.							BUCKLE M, 1991, NUCLEIC ACIDS RES, V19, P833, DOI 10.1093/nar/19.4.833; Burgess R.R., 1987, RNA POLYM REGULATION, P3; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; CHAMBERLIN MJ, 1974, ANNU REV BIOCHEM, V43, P721, DOI 10.1146/annurev.bi.43.070174.003445; DEHASETH PL, 1995, MOL MICROBIOL, V16, P817, DOI 10.1111/j.1365-2958.1995.tb02309.x; DOMBROSKI AJ, 1992, CELL, V70, P501, DOI 10.1016/0092-8674(92)90174-B; HAGER DA, 1990, BIOCHEMISTRY-US, V29, P7890, DOI 10.1021/bi00486a016; HAWLEY DK, 1983, NUCLEIC ACIDS RES, V11, P2237, DOI 10.1093/nar/11.8.2237; LONETTO M, 1992, J BACTERIOL, V174, P3843, DOI 10.1128/jb.174.12.3843-3849.1992; Malhotra A, 1996, CELL, V87, P127, DOI 10.1016/S0092-8674(00)81329-X; Nudler E, 1996, SCIENCE, V273, P211, DOI 10.1126/science.273.5272.211; Ring BZ, 1996, CELL, V86, P485, DOI 10.1016/S0092-8674(00)80121-X; Roberts CW, 1996, CELL, V86, P495; ROSS W, 1993, SCIENCE, V262, P1407, DOI 10.1126/science.8248780; Sambrook J., 1989, MOL CLONING LAB MANU, V3; SCHICKOR P, 1990, EMBO J, V9, P2215, DOI 10.1002/j.1460-2075.1990.tb07391.x; Severinova E, 1996, J MOL BIOL, V263, P637, DOI 10.1006/jmbi.1996.0604; SIEBENLIST U, 1980, CELL, V20, P269, DOI 10.1016/0092-8674(80)90613-3; SIEGELE DA, 1989, J MOL BIOL, V206, P591, DOI 10.1016/0022-2836(89)90568-8; STEFANO JE, 1982, P NATL ACAD SCI-BIOL, V79, P1069, DOI 10.1073/pnas.79.4.1069; VONHIPPE PH, 1972, ANNU REV BIOCHEM, V41, P231, DOI 10.1146/annurev.bi.41.070172.001311; WALDBURGER C, 1990, J MOL BIOL, V215, P267, DOI 10.1016/S0022-2836(05)80345-6; ZUBER P, 1989, J MOL BIOL, V206, P605, DOI 10.1016/0022-2836(89)90569-X	23	148	150	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 23	1997	276	5316					1258	1260		10.1126/science.276.5316.1258	http://dx.doi.org/10.1126/science.276.5316.1258			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XA497	9157885				2022-12-01	WOS:A1997XA49700044
J	Zhang, L; Zhou, W; Velculescu, VE; Kern, SE; Hruban, RH; Hamilton, SR; Vogelstein, B; Kinzler, KW				Zhang, L; Zhou, W; Velculescu, VE; Kern, SE; Hruban, RH; Hamilton, SR; Vogelstein, B; Kinzler, KW			Gene expression profiles in normal and cancer cells	SCIENCE			English	Article							3 ABUNDANCE CLASSES; MESSENGER-RNA; RIBOSOMAL-PROTEIN; COLON-CARCINOMA; HUMAN GUANYLIN; GROWTH; DIFFERENTIATION; PATTERNS; TUMORS	As a step toward understanding the complex differences between normal and cancer cells in humans, gene expression patterns were examined in gastrointestinal tumors. More than 300,000 transcripts derived from at least 45,000 different genes were analyzed. Although extensive similarity was noted between the expression profiles, more than 500 transcripts that were expressed at significantly different levels in normal and neoplastic cells were identified. These data provide insight into the extent of expression differences underlying malignancy and reveal genes that may prove useful as diagnostic or prognostic markers.	JOHNS HOPKINS UNIV,SCH MED,CTR ONCOL,HOWARD HUGHES MED INST,BALTIMORE,MD 21231; JOHNS HOPKINS UNIV,SCH MED,PROGRAM HUMAN GENET & MOL BIOL,BALTIMORE,MD 21231; JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21231	Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University			Velculescu, Victor/ABF-4846-2020; Zhang, Lin/A-7389-2009	Velculescu, Victor/0000-0003-1195-438X; Zhang, Lin/0000-0003-0018-3903	NATIONAL CANCER INSTITUTE [P50CA062924, R37CA057345, R01CA057345] Funding Source: NIH RePORTER; NCI NIH HHS [CA57345, CA62924] Funding Source: Medline; NIGMS NIH HHS [GM07309] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS MD, 1995, NATURE, V377, P3; BARNARD GF, 1992, CANCER RES, V52, P3067; BARNARD GF, 1993, CANCER RES, V53, P4048; BISHOP JO, 1974, NATURE, V250, P199, DOI 10.1038/250199a0; CHAN WY, 1989, BIOCHEMISTRY-US, V28, P1033, DOI 10.1021/bi00429a017; CHIAO PJ, 1992, MOL CARCINOGEN, V5, P219, DOI 10.1002/mc.2940050309; DENIS MG, 1993, INT J CANCER, V55, P275, DOI 10.1002/ijc.2910550218; DeRisi J, 1996, NAT GENET, V14, P457; DESAUVAGE FJ, 1992, P NATL ACAD SCI USA, V89, P9089, DOI 10.1073/pnas.89.19.9089; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FRIGERIO JM, 1995, HUM MOL GENET, V4, P37, DOI 10.1093/hmg/4.1.37; Gress TM, 1996, ONCOGENE, V13, P1819; HASTIE ND, 1976, CELL, V9, P761, DOI 10.1016/0092-8674(76)90139-2; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; KONDOH N, 1992, CANCER RES, V52, P791; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LAMBERT S, 1990, INT J CANCER, V46, P405, DOI 10.1002/ijc.2910460313; LEWIN B, 1980, GENE EXPRESSION, V2; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; MEDINA D, 1993, CANCER RES, V53, P668; MILLER AD, 1984, CELL, V36, P51; MOLL R, 1993, DIFFERENTIATION, V53, P75, DOI 10.1111/j.1432-0436.1993.tb00648.x; Okubo K, 1994, DNA Res, V1, P37, DOI 10.1093/dnares/1.1.37; Owens AH, 1982, TUMOR CELL HETEROGEN; RUBIN DC, 1989, P NATL ACAD SCI USA, V86, P1278, DOI 10.1073/pnas.86.4.1278; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; SCHWEINFEST CW, 1993, P NATL ACAD SCI USA, V90, P4166, DOI 10.1073/pnas.90.9.4166; SOWDEN J, 1993, DIFFERENTIATION, V53, P67, DOI 10.1111/j.1432-0436.1993.tb00647.x; TANAKA M, 1995, CANCER RES, V55, P3228; TRICOLI JV, 1986, CANCER RES, V46, P6169; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Velculescu VE, 1997, CELL, V88, P243, DOI 10.1016/S0092-8674(00)81845-0; WIEGAND RC, 1992, FEBS LETT, V311, P150, DOI 10.1016/0014-5793(92)81387-2	34	1186	1330	1	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 23	1997	276	5316					1268	1272		10.1126/science.276.5316.1268	http://dx.doi.org/10.1126/science.276.5316.1268			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XA497	9157888				2022-12-01	WOS:A1997XA49700047
J	Marin, M; Karis, A; Visser, P; Grosveld, F; Philipsen, S				Marin, M; Karis, A; Visser, P; Grosveld, F; Philipsen, S			Transcription factor Sp1 is essential for early embryonic development but dispensable for cell growth and differentiation	CELL			English	Article							BOX-BINDING-PROTEINS; A-I-GENE; SYNERGISTIC ACTIVATION; TRANSGENIC MICE; CONTROL REGION; DNA-BINDING; GLOBIN GENE; CPG ISLAND; APRT GENE; EXPRESSION	Transcription factor Sp1 has been implicated in the expression of many genes. Moreover, it has been suggested that Sp1 is linked to the maintenance of methylation-free CpG islands, the cell cycle, and the formation of active chromatin structures. We have inactivated the mouse Sp1 gene. Sp1(-/-) embryos are retarded in development, show a broad range of abnormalities, and die around day 11 of gestation. In Sp1(-/-) embryos, the expression of many putative target genes, including cell cycle-regulated genes, is not affected, CpG islands remain methylation free, and active chromatin is formed at the globin loci. However, the expression of the methyl-CpG-binding protein MeCP2 is greatly reduced in Sp1(-/-) embryos. MeCP2 is thought to be required for the maintenance of differentiated cells. We suggest that Sp1 is an important regulator of this process.	ERASMUS UNIV ROTTERDAM,DEPT CELL BIOL,NL-3000 DR ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam				Philipsen, Sjaak/0000-0002-3690-1201				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Birnbaum MJ, 1995, BIOCHEMISTRY-US, V34, P16503, DOI 10.1021/bi00050a034; BONNEROT C, 1993, METHOD ENZYMOL, V225, P451; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; Chestier A, 1992, DNA Seq, V2, P325, DOI 10.3109/10425179209030966; COOPER DN, 1983, NUCLEIC ACIDS RES, V11, P647, DOI 10.1093/nar/11.3.647; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; Crossley M, 1996, MOL CELL BIOL, V16, P1695; DYNAN WS, 1983, CELL, V32, P669, DOI 10.1016/0092-8674(83)90053-3; Ellis J, 1996, EMBO J, V15, P562, DOI 10.1002/j.1460-2075.1996.tb00388.x; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; GURTNER GC, 1995, GENE DEV, V9, P1, DOI 10.1101/gad.9.1.1; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HORNSTRA IK, 1992, MOL CELL BIOL, V12, P5345, DOI 10.1128/MCB.12.12.5345; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JONGSTRA J, 1984, NATURE, V307, P708, DOI 10.1038/307708a0; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; KAFRI T, 1992, GENE DEV, V6, P705, DOI 10.1101/gad.6.5.705; KARISEDER J, 1996, MOL CELL BIOL, V16, P1659; KILBY NJ, 1993, TRENDS GENET, V9, P413, DOI 10.1016/0168-9525(93)90104-P; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KOIVISTO UM, 1994, P NATL ACAD SCI USA, V91, P10526, DOI 10.1073/pnas.91.22.10526; LAMONFAVA S, 1992, J LIPID RES, V33, P831; LETOVSKY J, 1989, NUCLEIC ACIDS RES, V17, P2639, DOI 10.1093/nar/17.7.2639; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; Lin SY, 1996, MOL CELL BIOL, V16, P1668; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; MOUNTFORD P, 1994, P NATL ACAD SCI USA, V91, P4303, DOI 10.1073/pnas.91.10.4303; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; PERKINS AC, 1995, NATURE, V375, P318; PHILIPSEN S, 1993, EMBO J, V12, P1077, DOI 10.1002/j.1460-2075.1993.tb05749.x; PHILIPSEN S, 1990, EMBO J, V9, P2159, DOI 10.1002/j.1460-2075.1990.tb07385.x; PTASHNE M, 1986, NATURE, V322, P697, DOI 10.1038/322697a0; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SHAO ZH, 1995, ONCOGENE, V10, P221; SHE BR, 1995, GENE, V159, P175, DOI 10.1016/0378-1119(95)00024-Z; SHEMER R, 1991, P NATL ACAD SCI USA, V88, P11300, DOI 10.1073/pnas.88.24.11300; SU W, 1991, GENE DEV, V5, P820, DOI 10.1101/gad.5.5.820; Tate P, 1996, NAT GENET, V12, P205, DOI 10.1038/ng0296-205; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; WALL L, 1988, GENE DEV, V2, P1089, DOI 10.1101/gad.2.9.1089; Wijgerde M, 1996, GENE DEV, V10, P2894, DOI 10.1101/gad.10.22.2894; YU CY, 1991, J BIOL CHEM, V266, P8907; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595	54	450	459	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 16	1997	89	4					619	628		10.1016/S0092-8674(00)80243-3	http://dx.doi.org/10.1016/S0092-8674(00)80243-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WZ323	9160753	Green Published, Bronze			2022-12-01	WOS:A1997WZ32300015
J	Heriche, JK; Lebrin, F; Rabilloud, T; Leroy, D; Chambaz, EM; Goldberg, Y				Heriche, JK; Lebrin, F; Rabilloud, T; Leroy, D; Chambaz, EM; Goldberg, Y			Regulation of protein phosphatase 2A by direct interaction with casein kinase 2 alpha	SCIENCE			English	Article							II ALPHA-SUBUNIT; MAP KINASE; BETA-SUBUNIT; PHOSPHORYLATION; ANTIGEN; ENZYME; GROWTH; CELLS; SITE	Timely deactivation of kinase cascades is crucial to the normal control of cell signaling and is partly accomplished by protein phosphatase 2A (PP2A). The catalytic (alpha) subunit of the serine-threonine kinase casein kinase 2 (CK2) bound to PP2A in vitro and in mitogen-starved cells; binding required the integrity of a sequence motif common to CK2 alpha and SV40 small t antigen. Overexpression of CK2 alpha resulted in deactivation of mitogen-activated protein kinase kinase (MEK) and suppression of cell growth. Moreover, CK2 alpha inhibited the transforming activity of oncogenic Ras, but not that of constitutively activated MEK. Thus, CK2 alpha may regulate the deactivation of the mitogen-activated protein kinase pathway.	COMMISS ENERGIE ATOM,DEPT BIOL MOL & STRUCT,LAB BIOCHIM REGULAT CELLULAIRES ENDOCRINES,F-38054 GRENOBLE 9,FRANCE; INSERM,U244,F-38054 GRENOBLE 9,FRANCE; COMMISS ENERGIE ATOM,DEPT BIOL MOL & STRUCT,LAB BIOENERGET CELLULAIRE & PATHOL,F-38054 GRENOBLE 9,FRANCE	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); CEA				lebrin, franck/0000-0002-1650-6757; Heriche, Jean-Karim/0000-0001-6867-9425; Goldberg, Yves/0000-0001-7446-8595				ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; COLLEY S, 1994, CELL, V77, P841; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; FILHOL O, 1990, BIOCHEMISTRY-US, V29, P9928, DOI 10.1021/bi00494a025; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HANNA DE, 1995, J BIOL CHEM, V270, P25905, DOI 10.1074/jbc.270.43.25905; HELLERHARRISON RA, 1991, J BIOL CHEM, V266, P14435; HERICHE JK, UNPUB; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Kelliher MA, 1996, EMBO J, V15, P5160, DOI 10.1002/j.1460-2075.1996.tb00900.x; Krehan A, 1996, BIOCHEMISTRY-US, V35, P4966, DOI 10.1021/bi951989i; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MIKAELIAN I, 1992, NUCLEIC ACIDS RES, V20, P376, DOI 10.1093/nar/20.2.376; PAGES G, 1994, EMBO J, V13, P3003, DOI 10.1002/j.1460-2075.1994.tb06599.x; PEPPERKOK R, 1991, EXP CELL RES, V197, P245, DOI 10.1016/0014-4827(91)90429-X; RABILLOUD T, 1994, ELECTROPHORESIS, V15, P1552, DOI 10.1002/elps.11501501223; ROUSSOU I, 1994, MOL CELL BIOL, V14, P576, DOI 10.1128/MCB.14.1.576; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; SNELL V, 1994, EMBO J, V13, P2066, DOI 10.1002/j.1460-2075.1994.tb06481.x; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; STIGARE J, 1993, MOL CELL BIOCHEM, V129, P77, DOI 10.1007/BF00926578; ULUG ET, 1992, J VIROL, V66, P1458, DOI 10.1128/JVI.66.3.1458-1467.1992	25	247	251	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 9	1997	276	5314					952	955		10.1126/science.276.5314.952	http://dx.doi.org/10.1126/science.276.5314.952			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WY792	9139659				2022-12-01	WOS:A1997WY79200049
J	Deshpande, PP; Danishefsky, SJ				Deshpande, PP; Danishefsky, SJ			Total synthesis of the potential anticancer vaccine KH-1 adenocarcinoma antigen	NATURE			English	Article							SIALYL-LEWIS-X; LEY; OLIGOSACCHARIDES; GLYCOSYLATION; CANCER; III3FUCV3FUCVI2FUCNLC6; FUCOLIPIDS; ANTIBODY; GLYCALS	Human tumours are often marked by the expression of unusual carbohydrate structural motifs(1-3). These carbohydrate domains are manifested as cell-surface bound glycolipids or glycoproteins(4). This raises the possibility of using cell-free equivalents of these domain compounds, obtained by total synthesis with a view towards triggering some level of immune response. In fact, the serum of mice immunized with fully synthetic compounds(5-7) that mimic cell-surface tumour antigens has already been shown to recognize pertinent human cancer cell lines(8). Further advances in this field depend critically on the availability of these tumour-associated carbohydrate antigens which cannot be readily isolated from natural sources in sufficient quantities. Here we present the successful total synthesis of an adenocarcinoma antigen, KH-1, and of a bioconjugatable analogue which can bind to a carrier protein. These results illustrate the capabilities of oligosaccharide synthesis for reconstructing the challenging structural motifs characteristic of carbohydrate antigens, and thereby open up near possibilities for the development of anticancer vaccines.	SLOAN KETTERING INST CANC RES,BIOORGAN CHEM LAB,NEW YORK,NY 10021; COLUMBIA UNIV,DEPT CHEM,NEW YORK,NY 10027	Memorial Sloan Kettering Cancer Center; Columbia University								BILODEAU MT, 1995, J AM CHEM SOC, V117, P7840, DOI 10.1021/ja00134a043; BLACKBURNE ID, 1976, AUST J CHEM, V29, P381, DOI 10.1071/CH9760381; DANISHEFSKY SJ, 1992, J AM CHEM SOC, V114, P8329, DOI 10.1021/ja00047a077; DANISHEFSKY SJ, 1995, J AM CHEM SOC, V117, P5701, DOI 10.1021/ja00126a011; DANISHEFSKY SJ, 1995, J AM CHEM SOC, V117, P1940, DOI 10.1021/ja00112a007; Danishefsky SJ, 1996, ANGEW CHEM INT EDIT, V35, P1380, DOI 10.1002/anie.199613801; FEIZI T, 1985, CANCER SURV, V4, P245; FUGEDI P, 1987, GLYCOCONJUGATE J, V4, P97, DOI 10.1007/BF01049447; GERVAY J, 1993, J ORG CHEM, V58, P5465, DOI 10.1021/jo00072a031; GRIFFITH DA, 1990, J AM CHEM SOC, V112, P5811, DOI 10.1021/ja00171a021; HAKOMORI S, 1985, CANCER RES, V45, P2405; HAKOMORI SI, 1991, CANCER CELL-MON REV, V3, P461; HELLAND AC, 1992, J CARBOHYD CHEM, V11, P77, DOI 10.1080/07328309208016143; Hummel G, 1997, TETRAHEDRON LETT, V38, P1173, DOI 10.1016/S0040-4039(97)00006-3; JEFFREY PD, 1995, NAT STRUCT BIOL, V2, P466, DOI 10.1038/nsb0695-466; KAIZU T, 1986, J BIOL CHEM, V261, P1254; KAMEYAMA A, 1991, J CARBOHYD CHEM, V10, P549, DOI 10.1080/07328309108543931; KIM IJ, 1995, J ORG CHEM, V60, P7716, DOI 10.1021/jo00129a004; KIM YS, 1986, CANCER RES, V46, P5985; KONDO T, 1996, CHEM LETT, V5, P337; Lloyd K. O., 1991, CANCER BIOL, V2, P421; LONN H, 1987, J CARBOHYD CHEM, V6, P301, DOI 10.1080/07328308708058879; NUDELMAN E, 1986, J BIOL CHEM, V261, P1247; Park TK, 1996, J AM CHEM SOC, V118, P11488, DOI 10.1021/ja962048b; Ragupathi G, 1997, ANGEW CHEM INT EDIT, V36, P125, DOI 10.1002/anie.199701251; WILDMULLER R, 1994, TETRAHEDR LETT, V35, P7927	26	68	80	2	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 8	1997	387	6629					164	166		10.1038/387164a0	http://dx.doi.org/10.1038/387164a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WX945	9144285				2022-12-01	WOS:A1997WX94500049
J	Crowcroft, NS; Strachan, DP				Crowcroft, NS; Strachan, DP			The social origins of infantile colic: Questionnaire study covering 76747 infants	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DEATH; RISK	Objective: To describe risk factors for infantile colic. Design: Questionnaire administered by health visitors. Settings: Sheffield. Subjects: Mothers of 76 747 infants born between 1 August 1975 and 31 May 1988, interviewed when the infant was 1 month old. Main outcome measures: Reporting of infantile colic and its duration; weight of infant, feeding, state of the home, socioeconomic characteristics of the parents, parents' age, and mother's parity. Results: The odds of reporting infantile colic were increased with breast feeding (odds ratio of breast v bottle feeding 1.35 (95% confidence interval 1.28 to 1.43)), increasing parental age, lower parity, increasing parental age at leaving full time education, and more affluent homes and districts of residence. In a logistic regression analysis, mother's age and parity and socioeconomic factors remained the most important risk factors for the reporting of infantile colic (each P < 0.005), and the effect of breast feeding was attenuated (odds ratio of breast v bottle feeding 1.09 (1.02 to 1.15)). Conclusion: At a population level, dietary factors contribute little to mothers' reporting of infantile colic, and dietary change should not be the primary intervention.	UNIV LONDON ST GEORGES HOSP, SCH MED, DEPT PUBL HLTH SCI, LONDON SW17 0RE, ENGLAND	St Georges University London								Altman DG, 1991, PRACTICAL STAT MED R; BARR RG, 1990, INF MENTAL HLTH J, V11, P340, DOI 10.1002/1097-0355(199024)11:4<340::AID-IMHJ2280110405>3.0.CO;2-9; CARPENTER RG, 1983, LANCET, V1, P723; CARPENTER RG, 1977, ARCH DIS CHILD, V52, P606, DOI 10.1136/adc.52.8.606; FRANCIS B, 1993, GLIM SYSTEM RELEAS 4; HIDE DW, 1982, ARCH DIS CHILD, V57, P559, DOI 10.1136/adc.57.7.559; JAMESROBERTS IS, 1991, ARCH DIS CHILD, V66, P653, DOI 10.1136/adc.66.5.653; Keefe MR, 1996, NURS RES, V45, P4, DOI 10.1097/00006199-199601000-00002; LESTER BM, 1990, INF MENTAL HLTH J, V11, P321, DOI 10.1002/1097-0355(199024)11:4<321::AID-IMHJ2280110403>3.0.CO;2-E; LEWIS M, 1972, MERRILL-PALMER Q BEH, V18, P95; MILLER AR, 1991, PEDIATR CLIN N AM, V38, P1407; PHILLIPS AN, 1992, STAT MED, V11, P953, DOI 10.1002/sim.4780110712; RAUTAVA P, 1993, BRIT MED J, V307, P600, DOI 10.1136/bmj.307.6904.600; *SAS, 1990, LANG PROC; SHAW C, 1977, CHILD CARE HLTH DEV, V3, P1, DOI 10.1111/j.1365-2214.1977.tb00021.x; SLOMAN J, 1990, CHILD PSYCHIAT HUM D, V21, P25, DOI 10.1007/BF00709925; STACEY TE, 1995, NATL R D PROGR RES M; STAHLBERG MR, 1984, EUR J PEDIATR, V143, P108; WESSEL MA, 1954, PEDIATRICS, V14, P421	19	43	46	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 3	1997	314	7090					1325	1328		10.1136/bmj.314.7090.1325	http://dx.doi.org/10.1136/bmj.314.7090.1325			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WX975	9158470	Green Published			2022-12-01	WOS:A1997WX97500027
J	Poynard, T; Bedossa, P; Opolon, P				Poynard, T; Bedossa, P; Opolon, P			Natural history of liver fibrosis progression in patients with chronic hepatitis C	LANCET			English	Article							NON-B-HEPATITIS; NON-A; POSTTRANSFUSION HEPATITIS; ALPHA-INTERFERON; FOLLOW-UP; TRANSFUSION; TRIAL	Background Our aim was to assess the natural history of liver fibrosis progression in hepatitis C and the factors associated with this progression. Methods We recruited 2235 patients from the Observatoire de l'Hepatite C (OBSVIRC) population, the Cohorte Hepatite C Pitie-Salpetriere (DOSVIRC) population, and the original METAVIR population. All the patients had a biopsy sample compatible with chronic hepatitis C as assessed by the METAVIR scoring system (grades the stage of fibrosis on a five-point scale, FO=no fibrosis, F4=cirrhosis, and histological activity on a four-point scale, AO=no activity, A3=severe activity). No patient had received interferon treatment before the liver biopsy sample was obtained, We assessed the effect of nine factors on fibrosis progression: age at biopsy; estimated duration of infection; sex; age at infection; alcohol consumption; hepatitis C virus C (HCV) genotype; HCV viraemia; cause of infection; and histological activity grade. We defined fibrosis progression per year as the ratio between fibrosis stage in METAVIR units and the duration of infection (1 unit=one stage, 4 units=cirrhosis). Findings The median rate of fibrosis progression per year was 0.133 fibrosis unit (95% CI 0.125-0.143), which was similar to the estimates from previous studies (0.146 to 0.154). Three independent factors were associated with an increased rate of fibrosis progression: age at infection older than 40 years, daily alcohol consumption of 50 g or more, and male sex. There was no association between fibrosis progression and HCV genotype. The median estimated duration of infection for progression to cirrhosis was 30 years (28-32), ranging from 13 years in men infected after the age of 40 to 42 years in women who did not drink alcohol and were infected before the age of 40. Without treatment, 377 (33%) patients had an expected median time to cirrhosis of less than 20 years, and 356 (31%) will never progress to cirrhosis or will not progress for at least 50 years. Interpretation The host factors of ageing, alcohol consumption, and male sex have a stronger association with fibrosis progression than virological factors in HCV infection.	HOP BICETRE,SERV ANAT PATHOL,LE KREMLIN BICETR,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP	Poynard, T (corresponding author), GRP HOSP PITIE SALPETRIERE,SERV HEPATO GASTROENTEROL,URA CNRS 1484,F-75651 PARIS 13,FRANCE.		Yang, Chen/G-1379-2010; Poynard, Thierry/C-1355-2010	Poynard, Thierry/0000-0002-3726-7230; Bedossa, Pierre/0000-0002-8487-7322; Poynard, Thierry/0000-0002-2050-640X				ALTER MJ, 1995, SEMIN LIVER DIS, V15, P5, DOI 10.1055/s-2007-1007259; Bedossa P, 1996, HEPATOLOGY, V24, P289, DOI 10.1002/hep.510240201; CAMPS J, 1993, J HEPATOL, V17, P390, DOI 10.1016/S0168-8278(05)80223-5; CROWE J, 1995, GASTROENTEROLOGY, V108, pA1054, DOI 10.1016/0016-5085(95)28518-0; Delladetsima JK, 1996, J HEPATOL, V24, P27, DOI 10.1016/S0168-8278(96)80182-6; DESMET VJ, 1994, HEPATOLOGY, V19, P1513, DOI 10.1016/0270-9139(94)90250-X; DIBISCEGLIE AM, 1991, HEPATOLOGY, V14, P969, DOI 10.1016/0270-9139(91)90113-A; Dusheiko GM, 1995, HEPATOLOGY, V22, P1863, DOI 10.1016/0270-9139(95)90216-3; GENESCA J, 1991, SEMIN LIVER DIS, V11, P147, DOI 10.1055/s-2008-1040432; GOMEZRUBIO M, 1990, J HEPATOL, V11, pS63, DOI 10.1016/0168-8278(90)90166-O; KIYOSAWA K, 1990, HEPATOLOGY, V12, P671, DOI 10.1002/hep.1840120409; Kobayashi M, 1996, HEPATOLOGY, V23, P695, DOI 10.1002/hep.510230406; Koff RS, 1995, HEPATOLOGY, V22, P1880; LUDWIG J, 1993, GASTROENTEROLOGY, V105, P274, DOI 10.1016/0016-5085(93)90037-D; *METAVIR COOP GROU, 1994, HEPATOLOGY, V20, P15; *OBS NAT HEP C GRO, 1995, GASTROENTEROL CLIN B, V19, P81; POYNARD T, 1995, NEW ENGL J MED, V332, P1457, DOI 10.1056/NEJM199506013322201; Poynard T, 1996, HEPATOLOGY, V24, P778; SAEZROYUELA F, 1991, HEPATOLOGY, V13, P327, DOI 10.1002/hep.1840130220; TAKAHASHI M, 1993, AM J GASTROENTEROL, V88, P240; TONG MJ, 1995, NEW ENGL J MED, V332, P1463, DOI 10.1056/NEJM199506013322202; TREMOLADA F, 1992, J HEPATOL, V16, P273, DOI 10.1016/S0168-8278(05)80657-9; Yano M, 1996, HEPATOLOGY, V23, P1334, DOI 10.1002/hep.510230607	23	2410	2504	1	94	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 22	1997	349	9055					825	832		10.1016/S0140-6736(96)07642-8	http://dx.doi.org/10.1016/S0140-6736(96)07642-8			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WP403	9121257				2022-12-01	WOS:A1997WP40300010
J	Deresiewicz, RL; Thaler, SJ; Hsu, LG; Zamani, AA				Deresiewicz, RL; Thaler, SJ; Hsu, LG; Zamani, AA			Clinical and neuroradiographic manifestations of Eastern equine encephalitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HERPES-SIMPLEX ENCEPHALITIS; CREUTZFELDT-JAKOB-DISEASE; MUMPS ENCEPHALITIS; MRI; CT; ABNORMALITIES; BRAIN	Background Eastern equine encephalitis occurs principally along the east and Gulf coasts of the United States. Recognition of the neuroradiographic manifestations of eastern equine encephalitis could hasten the diagnosis of the illness and speed the response to index cases. Methods We reviewed all cases of eastern equine encephalitis reported in the United States between 1988 and 1994. The records of 36 patients were studied, along with 57 computed tomographic (CT) scans and 23 magnetic resonance imaging (MRI) scans from 33 patients. Results The mortality rate was 36 percent, and 35 percent of the survivors were moderately or severely disabled. Neuroradiographic abnormalities were common and best visualized by MRI. Among the patients for whom MRI scans were available, the results were abnormal for all eight comatose patients as well as for all three noncomatose patients who subsequently became comatose. The CT results were abnormal in 21 of 32 patients with readable scans. The abnormal findings included focal lesions in the basal ganglia (found in 71 percent of patients on MRI and in 56 percent on CT), thalami (found in 71 percent on MRI and in 25 percent on CT), and brain stem (found in 43 percent on MRI and in 9 percent on CT). Cortical lesions, meningeal enhancement, and periventricular white-matter changes were less common. The presence of large radiographic lesions did not predict a poor outcome, but either high cerebrospinal fluid white-cell counts or severe hyponatremia did. Conclusions Eastern equine encephalitis produces focal radiographic signs. The characteristic early involvement of the basal ganglia and thalami distinguishes this illness from herpes simplex encephalitis. MRI is a sensitive technique to identify the characteristic early adiographic manifestations of this viral encephalitis. (C) 1997, Massachusetts Medical Society.	BRIGHAM & WOMENS HOSP,DIV INFECT DIS,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Deresiewicz, RL (corresponding author), BRIGHAM & WOMENS HOSP,CHANNING LAB,DEPT MED,181 LONGWOOD AVE,BOSTON,MA 02115, USA.							AICARDI J, 1985, DEV MED CHILD NEUROL, V27, P249; *CAS REC MASS GEN, 1984, NEW ENGL J MED, V311, P1559; DAVENPORT DS, 1982, ARCH NEUROL-CHICAGO, V39, P322, DOI 10.1001/archneur.1982.00510170064029; DEMAEREL P, 1992, NEURORADIOLOGY, V34, P490, DOI 10.1007/BF00598957; DENT J H, 1955, Bull Tulane Univ Med Fac, V14, P85; DIROCCO A, 1993, NEURORADIOLOGY, V35, P584, DOI 10.1007/BF00588398; Farber S, 1940, J AMER MED ASSOC, V114, P1725; FEEMSTER RF, 1957, NEW ENGL J MED, V257, P701, DOI 10.1056/NEJM195710102571504; Feemster RF, 1938, AM J PUBLIC HEALTH N, V28, P1403, DOI 10.2105/AJPH.28.12.1403; FERNANDEZ RJ, 1982, NEUROLOGY, V32, pA178; Fothergill LD, 1938, NEW ENGL J MED, V219, P411, DOI 10.1056/NEJM193809222191201; FUJII Y, 1992, PEDIATR NEUROL, V8, P133, DOI 10.1016/0887-8994(92)90035-W; GASECKI AP, 1991, EUR NEUROL, V31, P372, DOI 10.1159/000116696; GERTZ HJ, 1988, NEUROLOGY, V38, P1481, DOI 10.1212/WNL.38.9.1481; GOLDFIEL.M, 1968, AM J EPIDEMIOL, V87, P1; GRIFFITH JF, 1983, MED CLIN N AM, V67, P991, DOI 10.1016/S0025-7125(16)31163-4; HAUSER GEORGE H., 1948, NEW ORLEANS MED AND SURG JOUR, V100, P551; Hindmarsh T, 1986, Acta Radiol Suppl, V369, P192; ISSELBACHER KJ, 1994, HARRIONS PRINCIPLES; JORDAN RA, 1965, AM J TROP MED HYG, V14, P470, DOI 10.4269/ajtmh.1965.14.470; KIM JH, 1985, AM J CLIN PATHOL, V84, P223, DOI 10.1093/ajcp/84.2.223; LAVOIE SR, 1993, SOUTHERN MED J, V86, P812, DOI 10.1097/00007611-199307000-00019; LEHEUP BP, 1987, REV NEUROL, V143, P301; LETSON GW, 1993, AM J TROP MED HYG, V49, P677, DOI 10.4269/ajtmh.1993.49.677; MCGOWAN JE, 1973, AM J EPIDEMIOL, V97, P199, DOI 10.1093/oxfordjournals.aje.a121500; MONATH TP, 1979, B WORLD HEALTH ORGAN, V57, P513; MORSE RP, 1992, PEDIATR NEUROL, V8, P473, DOI 10.1016/0887-8994(92)90013-O; OCHI J, 1986, COMPUT RADIOL, V10, P137, DOI 10.1016/0730-4862(86)90058-2; PETERS ACB, 1979, NEUROLOGY, V29, P676, DOI 10.1212/WNL.29.5.676; PILIERO PJ, 1994, CLIN INFECT DIS, V18, P985, DOI 10.1093/clinids/18.6.985; PROTHEROE SM, 1991, ARCH DIS CHILD, V66, P702, DOI 10.1136/adc.66.6.702; PRZELOMSKI MM, 1988, NEUROLOGY, V38, P736, DOI 10.1212/WNL.38.5.736; SHOJI H, 1989, J NEUROL, V236, P255, DOI 10.1007/BF00314452; TARR RW, 1987, PEDIATR RADIOL, V17, P59, DOI 10.1007/BF02386597; Tsai T F, 1991, Infect Dis Clin North Am, V5, P73; 1990, MMWR MORB MORTAL WKL, V39; 1995, MMWR-MORBID MORTAL W, V44, P641	37	211	217	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 26	1997	336	26					1867	1874		10.1056/NEJM199706263362604	http://dx.doi.org/10.1056/NEJM199706263362604			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XF756	9197215				2022-12-01	WOS:A1997XF75600004
J	Jankun, J; Selman, SH; Swiercz, R; SkrzypczakJankun, E				Jankun, J; Selman, SH; Swiercz, R; SkrzypczakJankun, E			Why drinking green tea could prevent cancer	NATURE			English	Letter									MED COLL OHIO, DEPT PHYSIOL & MOL MED, TOLEDO, OH 43699 USA; UNIV TOLEDO, DEPT CHEM, TOLEDO, OH 43606 USA	University System of Ohio; University of Toledo	Jankun, J (corresponding author), MED COLL OHIO, DEPT UROL, TOLEDO, OH 43699 USA.			Jankun, Jerzy/0000-0003-2354-4046				ACHBAROU A, 1994, CANCER RES, V54, P2372; FUJIKI H, 1992, PREV MED, V21, P503, DOI 10.1016/0091-7435(92)90057-O; HARVEY SR, 1988, CLIN EXP METASTAS, V6, P431, DOI 10.1007/BF01784375; Jankun J, 1997, CANCER RES, V57, P559; SPRAGGON G, 1995, STRUCTURE, V3, P681, DOI 10.1016/S0969-2126(01)00203-9; STONER GD, 1995, J CELL BIOCHEM, P169; YANG CS, 1993, J NATL CANCER I, V85, P1038, DOI 10.1093/jnci/85.13.1038	7	611	670	1	89	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 5	1997	387	6633					561	561		10.1038/42381	http://dx.doi.org/10.1038/42381			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XC522	9177339				2022-12-01	WOS:A1997XC52200033
J	Molloy, AM; Daly, S; Mills, JL; Kirke, PN; Whitehead, AS; Ramsbottom, D; Conley, MR; Weir, DG; Scott, JM				Molloy, AM; Daly, S; Mills, JL; Kirke, PN; Whitehead, AS; Ramsbottom, D; Conley, MR; Weir, DG; Scott, JM			Thermolabile variant of 5,10-methylenetetrahydrofolate reductase associated with low red-cell folates: Implications for folate intake recommendations	LANCET			English	Article							CORONARY-ARTERY DISEASE; NEURAL-TUBE DEFECTS; METHYLENETETRAHYDROFOLATE REDUCTASE; RISK FACTOR; VASCULAR-DISEASE; DEFICIENCY	Background The dietary reference values for folate, as for other nutrients, are targeted to the general and supposedly normal population, not people with special needs, such as those with genetic or metabolic abnormalities or diseases. However, 5-15% of general populations are homozygous for a thermolabile variant of 5,10-methylenetetrahydrofolate reductase (C677T) which causes mild hyperhomocysteinaemia and is positively associated with the development of vascular disease and the risk of neural-tube defects. If tissue-folate status is compromised in large sectors of the population by this or other genetic variants, the present dietary reference Values may need to be changed. Methods We identified the C677T genotype and measured red-cell folate concentrations in two groups of healthy women (pregnant, 242, not pregnant, 318). We then analysed the effect of genotype on red-cell folates, which are a reliable marker for tissue folate stores. Findings In the pregnant group there were 20 TT homozygotes, 114 wild-type CC homozygotes, and 108 CT heterozygotes. In the non-pregnant group, the numbers were 41, 148, and 129. In both pregnant and non-pregnant groups, red-cell folate was significantly lower among TT homozygous than CC homozygous women (mean 252 [95% CI 202-317] vs 347 [321-372] mu g/L, p=0.002 for pregnant women; 284 [250-327] vs 347 [342-372] mu g/L, p=0.01 for non-pregnant women). Plasma folate was also significantly lower in TT homozygous than in CC homozygous women in the pregnant group (p=0.009) but not in the non-pregnant group. Interpretation These results suggest that a substantial minority of people in general populatgions may have increased folate needs. Future studies may show the presence of other common genetic variants that interact with particular nutrients and place doubts on the validity of assuming ''normality'' for nutrient requirements in any general population.	UNIV DUBLIN TRINITY COLL,DEPT BIOCHEM,DUBLIN 2,IRELAND; UNIV DUBLIN TRINITY COLL,DEPT CLIN MED,DUBLIN 2,IRELAND; UNIV DUBLIN TRINITY COLL,DEPT GENET,DUBLIN 2,IRELAND; UNIV DUBLIN TRINITY COLL,INST BIOTECHNOL,DUBLIN 2,IRELAND; COOMBE WOMENS HOSP,DUBLIN,IRELAND; HLTH RES BOARD,DUBLIN,IRELAND; NICHHD,BETHESDA,MD 20892	Trinity College Dublin; Trinity College Dublin; Trinity College Dublin; Trinity College Dublin; Trinity College Dublin; Health Research Board - Ireland; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)				Molloy, Anne/0000-0002-1688-9049; Mills, James/0000-0003-4496-332X				BAUMGARTNER ER, 1985, PEDIATR RES, V19, P1288, DOI 10.1203/00006450-198512000-00017; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; Chanarin I, 1990, MEGALOBLASTIC ANAEMI; DALY LE, 1995, JAMA-J AM MED ASSOC, V274, P1698, DOI 10.1001/jama.274.21.1698; deFranchis R, 1995, LANCET, V346, P1703, DOI 10.1016/S0140-6736(95)92865-0; ENGBERSEN AMT, 1995, AM J HUM GENET, V56, P142; FROSST P, 1995, NAT GENET, V10, P111, DOI 10.1038/ng0595-111; Jacques PF, 1996, CIRCULATION, V93, P7, DOI 10.1161/01.CIR.93.1.7; KANG SS, 1988, AM J HUM GENET, V43, P414; KANG SS, 1991, AM J HUM GENET, V48, P536; KANG SS, 1993, CIRCULATION, V88, P1463, DOI 10.1161/01.CIR.88.4.1463; KIRKE PN, 1993, Q J MED, V86, P703; Kirke PN, 1996, LANCET, V348, P1037, DOI 10.1016/S0140-6736(05)64971-9; Kluijtmans LAJ, 1996, AM J HUM GENET, V58, P35; OBROIN S, 1992, J CLIN PATHOL, V45, P344, DOI 10.1136/jcp.45.4.344; ROSENBLATT DS, 1979, J CLIN INVEST, V63, P1019, DOI 10.1172/JCI109370; SMITH CAD, 1992, LANCET, V339, P1375, DOI 10.1016/0140-6736(92)91196-F; VANDERPUT NMJ, 1995, LANCET, V346, P1070, DOI 10.1016/S0140-6736(95)91743-8; VISY JM, 1991, NEUROLOGY, V41, P1313, DOI 10.1212/WNL.41.8.1313; WHITEHEAD AS, 1995, QJM-MON J ASSOC PHYS, V88, P763	20	267	270	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 31	1997	349	9065					1591	1593		10.1016/S0140-6736(96)12049-3	http://dx.doi.org/10.1016/S0140-6736(96)12049-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XB673	9174561				2022-12-01	WOS:A1997XB67300010
J	Keatinge, WR; Donaldson, GC; Bucher, K; Jendritsky, G; Cordioli, E; Martinelli, M; Dardanoni, L; Katsouyanni, K; Kunst, AE; Mackenbach, JP; McDonald, C; Nayha, S; Vuori, I				Keatinge, WR; Donaldson, GC; Bucher, K; Jendritsky, G; Cordioli, E; Martinelli, M; Dardanoni, L; Katsouyanni, K; Kunst, AE; Mackenbach, JP; McDonald, C; Nayha, S; Vuori, I			Cold exposure and winter mortality from ischaemic heart disease, cerebrovascular disease, respiratory disease, and all causes in warm and cold regions of Europe	LANCET			English	Article							ELDERLY PEOPLE; CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; PLASMA-FIBRINOGEN; BODY-TEMPERATURE; BLOOD-PRESSURE; VITAMIN-C; CORONARY; DEATH; NETHERLANDS	Background Differences in baseline mortality, age structure, and influenza epidemics confound comparisons of cold-related increases in mortality between regions with different climates. The Eurowinter study aimed to assess whether increases in mortality per 1 degrees C fall in temperature differ in various European regions and to relate any differences to usual winter climate and measures to protect against cold. Methods Percentage increases in deaths per day per 1 degrees C fall in temperature below 18 degrees C (indices of cold-related mortality) were estimated by generalised linear modelling. We assessed protective factors by surveys and adjusted by regression to 7 degrees C outdoor temperature. Cause-specific data gathered from 1988 to 1992 were analysed by multiple regression for men and women aged 50-59 and 65-74 in north Finland, south Finland, Baden-Wurttemburg, the Netherlands, London, and north Italy (24 groups). We used a similar method to analyse 1992 data in Athens and Palermo. Findings The percentage increases in all-cause mortality per 1 degrees C fall in temperature below 18 degrees C were greater in warmer regions than in colder regions (eg, Athens 2.15% [95% CI 1.20-3.10] vs south Finland 0.27% [0.15-0.40]). At an outdoor temperature of 7 degrees C, the mean living-room temperature was 19.2 degrees C in Athens and 21.7 degrees C in south Finland; 13% and 72% of people in these regions, respectively, wore hats when outdoors at 7 degrees C. Multiple regression analyses (with allowance for sex and age, in the six regions with full data) showed that high indices of cold-related mortality were associated with high mean winter temperatures, low living-room temperatures, limited bedroom heating, low proportions of people wearing hats, gloves, and anoraks, and inactivity and shivering when outdoors at 7 degrees C (p<0.01 for all-cause mortality and respiratory mortality; p>0.05 for mortality from ischaemic heart disease and cerebrovascular disease). Interpretation Mortality increased to a greater extent with given fall of temperature in regions with warm winters, in populations with cooler homes, and among people who wore fewer clothes and were less active outdoors.	DEUTSCH WETTERDRENST,FREIBERG,GERMANY; UNIV BOLOGNA,I-40126 BOLOGNA,ITALY; UNIV PALERMO,I-90133 PALERMO,ITALY; UNIV ATHENS,SCH MED,GR-10679 ATHENS,GREECE; ERASMUS UNIV ROTTERDAM,ROTTERDAM,NETHERLANDS; MCDONALD RES,LONDON,ENGLAND; REG INST OCCUPAT HLTH,OULU,FINLAND; IKK INST HLTH PROMOT RES,TAMPERE,FINLAND	University of Bologna; University of Palermo; Athens Medical School; National & Kapodistrian University of Athens; Erasmus University Rotterdam	Keatinge, WR (corresponding author), UNIV LONDON QUEEN MARY & WESTFIELD COLL,DEPT PHYSIOL,MILE END RD,LONDON E1 4NS,ENGLAND.		Katsouyanni, Klea/D-4856-2014; Donaldson, Gavin/M-7992-2017	Katsouyanni, Klea/0000-0002-0132-9575; Kunst, Anton/0000-0002-3313-5273				BAINTON D, 1978, INT J EPIDEMIOL, V7, P231, DOI 10.1093/ije/7.3.231; BIEMOND BJ, 1995, CLIN SCI, V88, P587, DOI 10.1042/cs0880587; BULL G M, 1978, Age and Ageing, V7, P210, DOI 10.1093/ageing/7.4.210; CLEVELAND WS, 1993, VISUALISING DATA, P94; COLLINS KJ, 1985, CLIN SCI, V69, P465, DOI 10.1042/cs0690465; DONALDSON GC, IN PRESS J EPIDEMIOL; FARB A, 1995, CIRCULATION, V92, P1701, DOI 10.1161/01.CIR.92.7.1701; GALE CR, 1995, BRIT MED J, V310, P1563, DOI 10.1136/bmj.310.6994.1563; GRAY PG, 1950, J ROY STAT SOC A STA, V113, P150, DOI 10.2307/2981039; HANDLEY BA, 1995, J APPL BACTERIOL, V79, P368, DOI 10.1111/j.1365-2672.1995.tb03150.x; HAYWARD MG, 1981, J PHYSIOL-LONDON, V320, P229, DOI 10.1113/jphysiol.1981.sp013946; Imai Y, 1996, CLIN SCI, V90, P55, DOI 10.1042/cs0900055; KATSOUYANNI K, 1996, J EPIDEMIOL S1, V50, P512; KEATINGE WR, 1984, BMJ-BRIT MED J, V289, P1405, DOI 10.1136/bmj.289.6456.1405; KEATINGE WR, 1986, BRIT MED J, V293, P732, DOI 10.1136/bmj.293.6549.732-a; KHAW KT, 1995, BRIT MED J, V310, P1559, DOI 10.1136/bmj.310.6994.1559; KUNST AE, 1993, AM J EPIDEMIOL, V137, P331, DOI 10.1093/oxfordjournals.aje.a116680; LOVETT AA, 1986, SOC SCI MED, V23, P935, DOI 10.1016/0277-9536(86)90251-0; MACKENBACH JP, 1993, J EPIDEMIOL COMMUN H, V47, P121, DOI 10.1136/jech.47.2.121; MCKEE CM, 1989, EUR J EPIDEMIOL, V5, P178, DOI 10.1007/BF00156826; MILLQVIST E, 1987, EUR J RESPIR DIS, V71, P444; MUDGE GH, 1976, NEW ENGL J MED, V295, P1333, DOI 10.1056/NEJM197612092952401; NEILD PJ, 1994, CLIN SCI, V86, P43, DOI 10.1042/cs0860043; OPHIR D, 1987, AM J OTOLARYNG, V3, P149; SPODICK DH, 1984, AM J CARDIOL, V53, P481, DOI 10.1016/0002-9149(84)90016-X; TYRRELL D, 1989, BRIT MED J, V298, P1280, DOI 10.1136/bmj.298.6683.1280; WOODHOUSE PR, 1993, J HYPERTENS, V11, P1267; WOODHOUSE PR, 1994, LANCET, V343, P435, DOI 10.1016/S0140-6736(94)92689-1	28	699	728	1	75	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 10	1997	349	9062					1341	1346						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WY342	9149695				2022-12-01	WOS:A1997WY34200007
J	Nightingale, SL				Nightingale, SL			Treatment IND for drug used in advanced reproductive technology	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,MAIL CODE HFI-40,ROCKVILLE,MD 20857, USA.								0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 7	1997	277	17					1343	1343		10.1001/jama.277.17.1343	http://dx.doi.org/10.1001/jama.277.17.1343			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW261	9134926				2022-12-01	WOS:A1997WW26100005
J	Cork, LC; Clarkson, TB; Jacoby, RO; Gaertner, DJ; Leary, SL; Linn, JM; Pakes, SP; Ringler, DH; Strandberg, JD; Swindle, MM				Cork, LC; Clarkson, TB; Jacoby, RO; Gaertner, DJ; Leary, SL; Linn, JM; Pakes, SP; Ringler, DH; Strandberg, JD; Swindle, MM			The costs of animal research: Origins and options	SCIENCE			English	Editorial Material									WAKE FOREST UNIV,BOWMAN GRAY SCH MED,WINSTON SALEM,NC 27103; YALE UNIV,COMPARAT MED SECT,NEW HAVEN,CT 06511; YALE UNIV,ANIM RESORCES CTR,NEW HAVEN,CT 06511; YESHIVA UNIV,ALBERT EINSTEIN COLL MED,INST ANIM STUDIES,DEPT MICROBIOL & IMMUNOL,NEW YORK,NY 10033; WASHINGTON UNIV,SCH MED,ST LOUIS,MO 63130; UNIV PENN,LAB ANIM RESOURCES,PHILADELPHIA,PA 19104; UNIV TEXAS,SW MED CTR,DIV COMPARAT MED,DALLAS,TX 75235; UNIV MICHIGAN,SCH MED,UNIT LAB ANIM MED,ANN ARBOR,MI 48109; JOHNS HOPKINS UNIV,SCH MED,DIV COMPARAT MED,BALTIMORE,MD 21205; MED UNIV S CAROLINA,LAB ANIM RESOURCES,CHARLESTON,SC 29425; MED UNIV S CAROLINA,DEPT COMPARAT MED,CHARLESTON,SC 29425	Wake Forest University; Wake Forest Baptist Medical Center; Yale University; Yale University; Yeshiva University; Washington University (WUSTL); University of Pennsylvania; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Michigan System; University of Michigan; Johns Hopkins University; Medical University of South Carolina; Medical University of South Carolina	Cork, LC (corresponding author), STANFORD UNIV,SCH MED,DEPT COMPARAT MED,STANFORD,CA 94305, USA.							1997, FED REGISTER, V60, P7107	1	18	18	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 2	1997	276	5313					758	759		10.1126/science.276.5313.758	http://dx.doi.org/10.1126/science.276.5313.758			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WW900	9157554				2022-12-01	WOS:A1997WW90000046
J	Kennedy, BK; Gotta, M; Sinclair, DA; Mills, K; McNabb, DS; Murthy, M; Pak, SM; Laroche, T; Gasser, SM; Guarente, L				Kennedy, BK; Gotta, M; Sinclair, DA; Mills, K; McNabb, DS; Murthy, M; Pak, SM; Laroche, T; Gasser, SM; Guarente, L			Redistribution of silencing proteins from telomeres to the nucleolus is associated with extension of life span in S-cerevisiae	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; BINDING-PROTEIN; TOPOISOMERASE-II; YEAST TELOMERES; GENE; DNA; RAP1; TRANSCRIPTION; INTERACTS; RNA	A prior genetic study indicated that activity of Sir silencing proteins at a hypothetical AGE locus is essential for long life span. In this model, the SIR4-42 mutation would direct the Sir protein complex to the AGE locus, giving rise to a long life span. We show by indirect immunofluorescence that Sir3p and Sir4p are redirected to the nucleolus in the SIR4-42 mutant. Furthermore, this relocalization is dependent on both UTH4 a novel yeast gene that extends life span, and its homologue YGL023. Strikingly, the Sir complex is relocalized from telomeres to the nucleolus in old wild-type cells. We propose that the rDNA is the AGE locus and that nucleolar function is compromised in old yeast cells in a way that may be mitigated by targeting of Sir proteins to the nucleolus.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; SWISS INST EXPT CANC RES,CH-1066 EPALINGES,SWITZERLAND	Massachusetts Institute of Technology (MIT); Swiss Institute Experimental Cancer Research				Kennedy, Brian/0000-0002-5754-1874; Sinclair, David/0000-0002-9936-436X; Gasser, Susan/0000-0003-3610-9123; Gotta, Monica/0000-0002-4336-7860	NATIONAL INSTITUTE ON AGING [R01AG011119, R37AG011119] Funding Source: NIH RePORTER; NIA NIH HHS [AG11119] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; BARKER DD, 1992, GENE DEV, V6, P2312, DOI 10.1101/gad.6.12a.2312; BECKER DM, 1991, P NATL ACAD SCI USA, V88, P1968, DOI 10.1073/pnas.88.5.1968; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BOWMAN PD, 1976, EXP CELL RES, V101, P434, DOI 10.1016/0014-4827(76)90399-2; Bryk M, 1997, GENE DEV, V11, P255, DOI 10.1101/gad.11.2.255; CHACONAS G, 1973, J NEUROCHEM, V21, P1466; CHEN WN, 1991, YEAST, V7, P309, DOI 10.1002/yea.320070314; COCKELL M, 1995, J CELL BIOL, V129, P909, DOI 10.1083/jcb.129.4.909; COGLIEVINA M, 1995, YEAST, V11, P767, DOI 10.1002/yea.320110808; CONRAD MN, 1990, CELL, V63, P739, DOI 10.1016/0092-8674(90)90140-A; EPSTEIN CJ, 1966, MEDICINE, V45, P177, DOI 10.1097/00005792-196605000-00001; FINCH CE, 1990, LONGEVITY SENSCENCE; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; Gompertz B., 1825, PHILOS T ROY SOC LON, V115, P513, DOI [10.1098/rspl.1815.0271, DOI 10.1098/RSTL.1825.0026]; GOTTA M, 1997, IN PRESS EMBO J; GOTTLIEB S, 1989, CELL, V56, P771, DOI 10.1016/0092-8674(89)90681-8; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; HARTWELL LH, 1977, J CELL BIOL, V75, P4222; HENRIQUEZ R, 1990, J BIOL CHEM, V265, P2209; IVY JM, 1986, MOL CELL BIOL, V6, P688, DOI 10.1128/MCB.6.2.688; JOHNSON R, 1972, NATURE, V240, P512; KENNEDY BK, 1994, J CELL BIOL, V127, P1985, DOI 10.1083/jcb.127.6.1985; KENNEDY BK, 1995, CELL, V80, P485, DOI 10.1016/0092-8674(95)90499-9; KIKUCHI Y, 1994, MOL GEN GENET, V245, P107, DOI 10.1007/BF00279756; KLAR AJS, 1981, NATURE, V289, P239, DOI 10.1038/289239a0; KLEIN F, 1992, J CELL BIOL, V117, P935, DOI 10.1083/jcb.117.5.935; LONGTINE MS, 1989, CURR GENET, V16, P225, DOI 10.1007/BF00422108; MACDONALD PM, 1992, DEVELOPMENT, V114, P221; MAHONEY DJ, 1989, MOL CELL BIOL, V9, P4621, DOI 10.1128/MCB.9.11.4621; Maillet L, 1996, GENE DEV, V10, P1796, DOI 10.1101/gad.10.14.1796; Marcand S, 1996, GENE DEV, V10, P1297, DOI 10.1101/gad.10.11.1297; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MORETTI P, 1994, GENE DEV, V8, P2257, DOI 10.1101/gad.8.19.2257; MORTIMER RK, 1959, NATURE, V183, P1751, DOI 10.1038/1831751a0; MULLER I, 1985, A VAN LEEUW J MICROB, V51, P1, DOI 10.1007/BF00444223; MURATA Y, 1995, CELL, V80, P747, DOI 10.1016/0092-8674(95)90353-4; PALLADINO F, 1993, CELL, V75, P543, DOI 10.1016/0092-8674(93)90388-7; PETERSON CRD, 1984, ARCH GERONTOL GERIAT, V3, P115, DOI 10.1016/0167-4943(84)90004-9; PILLUS L, 1989, CELL, V59, P637, DOI 10.1016/0092-8674(89)90009-3; POHLEY HJ, 1987, MECH AGEING DEV, V38, P231, DOI 10.1016/0047-6374(87)90092-3; RATH PC, 1989, FEBS LETT, V244, P193, DOI 10.1016/0014-5793(89)81191-3; RINE J, 1987, GENETICS, V116, P9; SHERMAN F, 1979, METHODS YEAST GENETI; SHORE D, 1987, CELL, V51, P721, DOI 10.1016/0092-8674(87)90095-X; SIKORSKI RS, 1989, GENETICS, V122, P19; Smeal T, 1996, CELL, V84, P633, DOI 10.1016/S0092-8674(00)81038-7; Smith JS, 1997, GENE DEV, V11, P241, DOI 10.1101/gad.11.2.241; STREHLER BL, 1986, EXP GERONTOL, V21, P283, DOI 10.1016/0531-5565(86)90038-0; SWISSHELM K, 1990, MUTAT RES, V237, P131, DOI 10.1016/0921-8734(90)90019-N; TOLLERVEY D, 1993, CELL, V72, P443, DOI 10.1016/0092-8674(93)90120-F; Triolo T, 1996, NATURE, V381, P251, DOI 10.1038/381251a0; WAREHAM KA, 1987, NATURE, V327, P725, DOI 10.1038/327725a0; WATT PM, 1995, CELL, V81, P253, DOI 10.1016/0092-8674(95)90335-6; WILSON V L, 1983, Science (Washington D C), V220, P1055, DOI 10.1126/science.6844925; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	58	310	331	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 2	1997	89	3					381	391		10.1016/S0092-8674(00)80219-6	http://dx.doi.org/10.1016/S0092-8674(00)80219-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WX899	9150138	Bronze			2022-12-01	WOS:A1997WX89900009
J	Nakamura, N; Lowe, M; Levine, TP; Rabouille, C; Warren, G				Nakamura, N; Lowe, M; Levine, TP; Rabouille, C; Warren, G			The vesicle docking protein p115 binds GM130, a cis-Golgi matrix protein, in a mitotically regulated manner	CELL			English	Article							ENDOPLASMIC-RETICULUM; TRANSPORT; STACK	The docking of transport vesicles with their target membrane is thought to be mediated by p115. We show here that GM130, a cis-Golgi matrix protein, interacts specifically with p115 and so could provide a membrane docking site. Deletion analysis showed that the N-terminus binds to p115, whereas the C-terminus binds to Golgi membranes. Mitotic phosphorylation of GM130 or a peptide derived from the N-terminus prevented binding to p115. The peptide also inhibited the NSF- but not the p97-dependent reassembly of Golgi cisternae from mitotic fragments, unless it was mitotically phosphorylated. Together, these data provide a molecular explanation for the COPI-mediated fragmentation of the Golgi apparatus at the onset of mitosis.	IMPERIAL CANC RES FUND, CELL BIOL LAB, LONDON WC2A 3PX, ENGLAND	Cancer Research UK			Nakamura, Nobuhiro/F-7811-2011	Nakamura, Nobuhiro/0000-0002-8836-6714; Levine, Timothy/0000-0002-7231-0775	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARROSO M, 1995, P NATL ACAD SCI USA, V92, P527, DOI 10.1073/pnas.92.2.527; Bednarek SY, 1996, TRENDS CELL BIOL, V6, P468, DOI 10.1016/0962-8924(96)84943-9; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; Levine TP, 1996, J BIOL CHEM, V271, P17304, DOI 10.1074/jbc.271.29.17304; Lupashin VV, 1996, J CELL BIOL, V132, P277, DOI 10.1083/jcb.132.3.277; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; Meijer L, 1996, TRENDS CELL BIOL, V6, P393, DOI 10.1016/0962-8924(96)10034-9; MOERSCHELL RP, 1990, J BIOL CHEM, V265, P19638; NAKAJIMA H, 1991, J CELL BIOL, V113, P245, DOI 10.1083/jcb.113.2.245; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Sapperstein SK, 1996, J CELL BIOL, V132, P755, DOI 10.1083/jcb.132.5.755; SAPPERSTEIN SK, 1995, P NATL ACAD SCI USA, V92, P522, DOI 10.1073/pnas.92.2.522; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SLUSAREWICZ P, 1994, J CELL BIOL, V124, P405, DOI 10.1083/jcb.124.4.405; STUART RA, 1993, J BIOL CHEM, V268, P4050; WARREN G, 1993, ANNU REV BIOCHEM, V62, P323, DOI 10.1146/annurev.bi.62.070193.001543; WARREN G, 1995, TRENDS CELL BIOL, V5, P413, DOI 10.1016/S0962-8924(00)89094-7; WATERS MG, 1992, J CELL BIOL, V118, P1015, DOI 10.1083/jcb.118.5.1015; Yamakawa H, 1996, J STRUCT BIOL, V116, P356, DOI 10.1006/jsbi.1996.0053; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	24	334	342	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 2	1997	89	3					445	455		10.1016/S0092-8674(00)80225-1	http://dx.doi.org/10.1016/S0092-8674(00)80225-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WX899	9150144	Bronze			2022-12-01	WOS:A1997WX89900015
J	Lalioti, MD; Scott, HS; Buresi, C; Rossier, C; Bottani, A; Morris, MA; Malafosse, A; Antonarakis, SE				Lalioti, MD; Scott, HS; Buresi, C; Rossier, C; Bottani, A; Morris, MA; Malafosse, A; Antonarakis, SE			Dodecamer repeat expansion in cystatin B gene in progressive myoclonus epilepsy	NATURE			English	Article							FRAGILE-X-SYNDROME; MYOTONIC-DYSTROPHY; MESSENGER-RNA; PROTEIN; EXPRESSION; FMR-1	Progressive myaclonus epilepsy of the Unverricht-Lundborg type (EPM1; MIM 254800) is an autosomal recessive disorder with onset between 6 and 13 years followed by variable progression to mental deterioration and cerebellar ataxia(1). It is a rare disorder but more common in Finland (1 in 20,000) and the western Mediterranean(1,2). Two point mutations in the cysteine proteinase inhibitor gene cystatin B (CSTB), proved that this gene is responsible for EPM1 (ref. 3). An extensive search in the CSTB gene revealed mutations accounting only for 14% of the 58 unrelated EPM1 alleles studied(4). Here we report that the majority of EPM1 alleles contain expansions of a dodecamer (12-mer) repeat located about 70 nucleotides upstream of the transcription start site nearest to the 5' end of the CSTB gene. Normal alleles contain 2 or 3 copies of this repeat whereas mutant alleles contain more than 60 such repeats and have reduced levels of CSTB messenger RNA in brood but not in cell lines. 'Premutation' CSTB alleles with 12-17 repeats show marked instability when transmitted to off-spring.	HOSP BELLE IDEE,DEPT GENET & MICROBIOL,LAB HUMAN MOL GENET,CH-1211 GENEVA,SWITZERLAND; UNIV GENEVA,SCH MED,CH-1211 GENEVA 4,SWITZERLAND; CANTONAL HOSP GENEVA,CH-1211 GENEVA,SWITZERLAND; HOSP BELLE IDEE,DIV NEUROPSYCHIAT,CH-1211 GENEVA,SWITZERLAND	University of Geneva; University of Geneva; University of Geneva; University of Geneva			Scott, Hamish/B-2122-2009; Antonarakis, Stylianos E/N-8866-2014	Scott, Hamish/0000-0002-5813-631X; Antonarakis, Stylianos E/0000-0001-8907-5823				Ashley CT, 1995, ANNU REV GENET, V29, P703, DOI 10.1146/annurev.ge.29.120195.003415; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; DAUSSET J, 1990, GENOMICS, V6, P575, DOI 10.1016/0888-7543(90)90491-C; FU YH, 1993, SCIENCE, V260, P235, DOI 10.1126/science.8469976; Gecz J, 1996, NAT GENET, V13, P105, DOI 10.1038/ng0596-105; GENTON P, 1990, ACTA NEUROL SCAND, V81, P8; Gu YH, 1996, NAT GENET, V13, P109, DOI 10.1038/ng0596-109; KNIGHT SJL, 1993, CELL, V74, P127, DOI 10.1016/0092-8674(93)90300-F; LABAUGE P, IN PRESS ANN NEUROL; Lafreniere RG, 1997, NAT GENET, V15, P298, DOI 10.1038/ng0397-298; Lalioti MD, 1997, AM J HUM GENET, V60, P342; LEHESJOKI AE, 1993, HUM MOL GENET, V2, P1229, DOI 10.1093/hmg/2.8.1229; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; Mach B, 1996, ANNU REV IMMUNOL, V14, P301, DOI 10.1146/annurev.immunol.14.1.301; NORIO R, 1979, CLIN GENET, V15, P82; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; Paulson HL, 1996, ANNU REV NEUROSCI, V19, P79; Pennacchio LA, 1996, SCIENCE, V271, P1731, DOI 10.1126/science.271.5256.1731; Pennacchio LA, 1996, GENOME RES, V6, P1103, DOI 10.1101/gr.6.11.1103; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; RAWLINGS ND, 1994, METHOD ENZYMOL, V244, P461; RICHARDS RI, 1992, CELL, V70, P709, DOI 10.1016/0092-8674(92)90302-S; SABOURI LA, 1993, NAT GENET, V4, P233, DOI 10.1038/ng0793-233; Takahashi A, 1996, CURR OPIN GENET DEV, V6, P50, DOI 10.1016/S0959-437X(96)90010-6; TALBOT CC, 1995, HUM MOL GENET, V4, P1193, DOI 10.1093/hmg/4.7.1193; TURK V, 1991, FEBS LETT, V285, P213, DOI 10.1016/0014-5793(91)80804-C; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; YOUSSOUFIAN H, 1993, MOL CELL BIOL, V13, P98, DOI 10.1128/MCB.13.1.98; Yu S, 1997, CELL, V88, P367, DOI 10.1016/S0092-8674(00)81875-9	30	260	268	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 24	1997	386	6627					847	851		10.1038/386847a0	http://dx.doi.org/10.1038/386847a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WV706	9126745				2022-12-01	WOS:A1997WV70600058
J	Volkow, ND; Wang, GJ; Fowler, JS; Logan, J; Gatley, SJ; Hitzemann, R; Chen, AD; Dewey, SL; Pappas, N				Volkow, ND; Wang, GJ; Fowler, JS; Logan, J; Gatley, SJ; Hitzemann, R; Chen, AD; Dewey, SL; Pappas, N			Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects	NATURE			English	Article							HUMAN BRAIN; C-11 RACLOPRIDE; THALAMIC NUCLEUS; FRONTAL-LOBE; BINDING; PET; DRUGS; ADDICTION; RECEPTORS; ABUSERS	Cocaine blocks the reuptake of dopamine, a neurotransmitter involved in the control of movement, cognition, motivation and reward. This leads to an increase in extracellular dopamine; the reinforcing effect of cocaine is associated with elevated dopamine levels in the nucleus accumbens(1,2). But addiction to cocaine involves other effects, such as craving, loss of control and compulsive drug intake; the role of the dopamine system in these effects is less well-understood. We therefore used positron emission tomography (PET) to compare the responses of cocaine addicts and normal controls to intravenous methylphenidate, a drug that, like cocaine, causes an increase in synaptic dopamine(3). Addicts showed reduced dopamine release in the striatum, the brain region where the nucleus accumbens is located, and also had a reduced 'high' relative to controls. In contrast, addicts showed an increased response to methylphenidate in the thalamus (a region that conveys sensory input to the cortex). This thalamic response was associated with cocaine craving and was not seen in control subjects. Thus, our findings challenge the notion that addiction involves an enhanced striatal dopamine response to cocaine and/or an enhanced induction of euphoria. Moreover, they suggest a participation of thalamic dopamine pathways in cocaine addiction, a possibility that merits further investigation.	BROOKHAVEN NATL LAB, DEPT CHEM, UPTON, NY 11973 USA; SUNY STONY BROOK, DEPT PSYCHIAT, STONY BROOK, NY 11794 USA	United States Department of Energy (DOE); Brookhaven National Laboratory; State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook	Volkow, ND (corresponding author), BROOKHAVEN NATL LAB, DEPT MED, UPTON, NY 11973 USA.		anand, amit/A-7222-2009					BERGMAN J, 1989, J PHARMACOL EXP THER, V251, P150; BROWN EE, 1992, J NEUROSCI, V12, P4112; DACKIS CA, 1985, NEUROSCI BIOBEHAV R, V9, P469, DOI 10.1016/0149-7634(85)90022-3; DEWEY SL, 1993, SYNAPSE, V13, P350, DOI 10.1002/syn.890130407; DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274; GAWIN FH, 1986, ARCH GEN PSYCHIAT, V43, P107; Gifford AN, 1996, SYNAPSE, V22, P232, DOI 10.1002/(SICI)1098-2396(199603)22:3<232::AID-SYN5>3.0.CO;2-D; GROENEWEGEN HJ, 1988, NEUROSCIENCE, V24, P379, DOI 10.1016/0306-4522(88)90339-9; INSEL TR, 1992, ARCH GEN PSYCHIAT, V49, P739; KOLB B, 1977, PHYSIOL BEHAV, V18, P237, DOI 10.1016/0031-9384(77)90128-7; KOOB GF, 1988, SCIENCE, V242, P715, DOI 10.1126/science.2903550; LOGAN J, 1990, J CEREBR BLOOD F MET, V10, P740, DOI 10.1038/jcbfm.1990.127; LOGAN J, 1994, J CEREBR BLOOD F MET, V14, P995, DOI 10.1038/jcbfm.1994.132; MADRAS BK, 1994, SYNAPSE, V18, P261, DOI 10.1002/syn.890180311; MCALONAN GM, 1993, NEUROSCIENCE, V52, P605, DOI 10.1016/0306-4522(93)90410-H; Modell J G, 1990, J Neuropsychiatry Clin Neurosci, V2, P123; NAUTA WJH, 1971, J PSYCHIAT RES, V8, P167, DOI 10.1016/0022-3956(71)90017-3; Pontieri FE, 1996, NATURE, V382, P255, DOI 10.1038/382255a0; ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P; SEEMAN P, 1989, SYNAPSE, V3, P96, DOI 10.1002/syn.890030113; SHYU BC, 1992, BRAIN RES, V572, P216, DOI 10.1016/0006-8993(92)90472-L; VOLKOW ND, 1993, J NUCL MED, V34, P609; VOLKOW ND, 1994, SYNAPSE, V16, P255, DOI 10.1002/syn.890160402; Volkow ND, 1996, J NUCL MED, V37, P1242; VOLKOW ND, 1993, SYNAPSE, V14, P169, DOI 10.1002/syn.890140210; VOLKOW ND, 1995, ARCH GEN PSYCHIAT, V52, P456; Wang GJ, 1997, EUR ADDICT RES, V3, P49, DOI 10.1159/000259147; WANG GJ, 1993, SYNAPSE, V15, P246, DOI 10.1002/syn.890150311; WANG GJ, 1995, LIFE SCI, V57, P187; YOUSEF KA, 1995, SYNAPSE, V19, P14, DOI 10.1002/syn.890190103	30	647	656	1	44	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 24	1997	386	6627					830	833		10.1038/386830a0	http://dx.doi.org/10.1038/386830a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WV706	9126741				2022-12-01	WOS:A1997WV70600054
J	Bergerat, A; deMassy, B; Gadelle, D; Varoutas, PC; Nicolas, A; Forterre, P				Bergerat, A; deMassy, B; Gadelle, D; Varoutas, PC; Nicolas, A; Forterre, P			An atypical topoisomerase II from archaea with implications for meiotic recombination	NATURE			English	Article							DOUBLE-STRAND BREAKS; SACCHAROMYCES-CEREVISIAE; INITIATION SITE; DNA GYRASE; MEIOSIS; YEAST; PROTEIN; SEQUENCE; MUTANTS	Type II topoisomerases help regulate DNA topology during transcription, replication and recombination by catalysing DNA strand transfer through transient double-stranded breaks(1). All type II topoisomerases described so far are members of a single protein family(2). We have cloned and sequenced the genes encoding the A and B subunits of topoisomerase II from the archaeon Sulfolobus shibatae. This enzyme is the first of a new family. It has no similarity with other type II topoisomerases, except for three motifs in the B subunit probably involved in ATP binding and hydrolysis. We also found these motifs in proteins of the Hsp90(3) and MutL(4) families. The A subunit has similarities with four proteins of unknown function. One of them, the Saccharomyces cerevisiae Spo11(5) protein, is required for the initiation of meiotic recombination. Mutagenesis, performed on SPO11, of the single tyrosine conserved between the five homologues shows that this amino acid is essential for Spo11 activity. By analogy with the mechanism of action of known type II topoisomerases, we suggest that Spell catalyses the formation of double-strand breaks that initiate meiotic recombination in S. cervisiae.	UNIV PARIS 11,CNRS,URA 1354,INST GENET & MICROBIOL,F-91405 ORSAY,FRANCE; INST CURIE,SECT RECH,CNRS,UMR 144,F-75248 PARIS 05,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Universite Paris Cite				Varoutas, Paul-Christophe/0000-0001-9127-4418				ALANI E, 1990, CELL, V61, P419, DOI 10.1016/0092-8674(90)90524-I; Aronshtam A, 1996, NUCLEIC ACIDS RES, V24, P2498, DOI 10.1093/nar/24.13.2498; ATCHESON CL, 1987, P NATL ACAD SCI USA, V84, P8035, DOI 10.1073/pnas.84.22.8035; ATCHESON CL, 1993, CURR OPIN GENET DEV, V3, P736, DOI 10.1016/S0959-437X(05)80092-9; BERGERAT A, 1994, J BIOL CHEM, V269, P27663; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; Caron Paul R., 1994, V29B, P271; DEMASSY B, 1995, EMBO J, V14, P4589, DOI 10.1002/j.1460-2075.1995.tb00138.x; DEMASSY B, 1994, P NATL ACAD SCI USA, V91, P11929, DOI 10.1073/pnas.91.25.11929; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; GUPTA RS, 1995, MOL BIOL EVOL, V12, P1063; HOMES ML, 1991, J BACTERIOL, V173, P3807; JACKSON AP, 1993, P NATL ACAD SCI USA, V90, P11232, DOI 10.1073/pnas.90.23.11232; Keeney S, 1997, CELL, V88, P375, DOI 10.1016/S0092-8674(00)81876-0; KEENEY S, 1995, P NATL ACAD SCI USA, V92, P11274, DOI 10.1073/pnas.92.24.11274; LIN YK, 1994, GENETICS, V136, P769; LIU JH, 1995, EMBO J, V14, P4599, DOI 10.1002/j.1460-2075.1995.tb00139.x; LOIDL J, 1994, J CELL BIOL, V125, P1191, DOI 10.1083/jcb.125.6.1191; LOUVION EL, 1996, P NATL ACAD SCI USA, V93, P13937; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; SZENTGYORGYI C, 1995, MOL CELL BIOL, V15, P6754; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; WOESE CR, 1977, P NATL ACAD SCI USA, V74, P5088, DOI 10.1073/pnas.74.11.5088	28	686	719	0	43	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 27	1997	386	6623					414	417		10.1038/386414a0	http://dx.doi.org/10.1038/386414a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WQ170	9121560				2022-12-01	WOS:A1997WQ17000069
